Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer

Abstract
Described herein are genes whose expression are up-regulated or down-regulated in ovarian cancer. Related methods and compositions that can be used for diagnosis and treatment of ovarian cancer are disclosed. Also described herein are methods that can be used to identify modulators of ovarian cancer.
Description


FIELD OF THE INVENTION

[0002] The invention relates to the identification of nucleic acid and protein expression profiles and nucleic acids, products, and antibodies thereto that are involved in ovarian cancer; and to the use of such expression profiles and compositions in the diagnosis, prognosis, and therapy of ovarian cancer. The invention further relates to methods for identifying and using agents and/or targets that inhibit ovarian cancer.



BACKGROUND OF THE INVENTION

[0003] Ovarian cancer is the sixth most common cancer in women, accounting for 6% of all female cancers. It ranks fifth as the cause of cancer death in women. The American Cancer Society predicts that there will be about 23,100 new cases of ovarian cancer in this country in the year 2000 and about 14,000 women will die of the disease. Because many ovarian cancers cannot be detected early in their development, they account for a disproportionate number of fatal cancers, being responsible for almost half the deaths from cancer of the female genital tract; more deaths than any other reproductive organ cancer.


[0004] Most patients with epithelial ovarian cancer, the predominant form, are asymptomatic in early-stage disease and usually present with stage III or IV disease. Their five-year survival is less than 25%, with lower survival among African-American women. The minority of patients discovered with early-stage disease have a five-year survival rate of 80%-90%. See, Parker, et. al.. (1997) “Cancer Statistics, 1997”CA Cancer J. Clin. 47:5-27.


[0005] In the absence of a family history of ovarian cancer, lifetime risk of ovarian cancer is 1/70. Risk factors include familial cancer syndromes (risk of up to 82% by age 70 in women with hereditary breast/ovarian syndrome); family history (1.4% lifetime risk with no affected relatives, 5% with one affected relative, 7% with two affected relatives; Kerlikowske, et.al. (1992) Obstet. Gynecol. 80:700-707); nulliparity; advancing age; obesity; personal history of breast, endometrial, or colorectal cancer; fewer pregnancies; or older age (>35 years) at first pregnancy. However, 95% of all ovarian cancers occur in women without risk factors. Use of hormonal contraceptives, oophorectomy, and tubal sterilization reduce risk of ovarian cancer (Kerlikowske, et. al. (1992) Obstet. Gynecol. 80:700-707; Grimes (1992) Am J. Obstet. Gynecol. 166:1950-1954; Hankinson, et. al. (1993) JAMA 270:2813-2818); however, even bilateral oophorectomy may not be completely effective in preventing ovarian cancer.


[0006] Treatment of ovarian cancer consists largely of surgical oophorectomy, anti-hormone therapy, and/or chemotherapy. Although many ovarian cancer patients are effectively treated, the current therapies can all induce serious side effects which diminish quality of life. Deciding on a particular course of treatment is typically based on a variety of prognostic parameters and markers (Fitzgibbons, et al. (2000) Arch. Pathol. Lab. Med. 124:966-978; Hamilton and Piccart (2000) Ann. Oncol. 11:647-663), including genetic predisposition markers BRCA-1 and BRCA-2 (Robson (2000) J. Clin. Oncol. 18:113sup-118sup).


[0007] The identification of novel therapeutic targets and diagnostic markers is essential for improving the current treatment of ovarian cancer patients. Recent advances in molecular medicine have increased the interest in tumor-specific cell surface antigens that could serve as targets for various immunotherapeutic or small molecule strategies. Antigens suitable for immunotherapeutic strategies should be highly expressed in cancer tissues and ideally not expressed in normal adult tissues. Expression in tissues that are dispensable for life, however, may be tolerated. Examples of such antigens include Her2/neu and the B-cell antigen CD20. Humanized monoclonal antibodies directed to Her2/neu (Hercepting/trastuzumab) are currently in use for the treatment of metastatic breast cancer. Ross and Fletcher (1998) Stem Cells 16:413-428. Similarly, anti-CD20 monoclonal antibodies (Rituxin®/rituximab) are used to effectively treat non-Hodgkin's lymphoma. Maloney, et al. (1997) Blood 90:2188-2195; Leget and Czuczman (1998) Curr. Opin. Oncol. 10:548-551.


[0008] Potential immunotherapeutic targets have been identified for ovarian cancer. One such target is polymorphic epithelial mucin (MUC1). MUC1 is a transmembrane protein, present at the apical surface of glandular epithelial cells. It is often overexpressed in ovarian cancer, and typically exhibits an altered glycosylation pattern, resulting in an antigenically distinct molecule, and is in early clinical trials as a vaccine target. Gilewski, et al. (2000) Clin. Cancer Res. 6:1693-1701; Scholl, et al. (2000) J. Immunother. 23:570-580. The tumor-expressed protein is often cleaved into the circulation, where it is detectable as the tumor marker, CA 15-3. See, e.g., Bon, et al. (1997) Clin. Chem. 43:585-593. However, many patients have tumors that express neither HER2 nor MUC-1; therefore, it is clear that other targets need to be identified to manage localized and metastatic disease.


[0009] Mutations in both BRCA1 and BRCA2 are associated with increased susceptibility to ovarian cancer. Mutations in BRCA1 occur in approximately 5 percent (95 percent confidence interval, 3 to 8 percent) of women in whom ovarian cancer is diagnosed before the age of 70 years. See Stratton, et al. (1997) N.E.J. Med. 336:1125-1130. And, in BRCA1 gene carriers, the risk for developing ovarian cancer is 0.63. See Easton (1995) Am. J. Hum. Genet. 56:267-xxx; and Elit (2001) Can. Fam. Physician 47:778-84.


[0010] Other biochemical markers such as CA125 have been reported to be associated with ovarian cancer, but they are not absolute indicators of disease. Although roughly 85% of women with clinically apparent ovarian cancer have increased levels of CA125, CA125 is also increased during the first trimester of pregnancy, during menstruation, in the presence of non-cancerous illnesses, and in cancers of other sites.


[0011] While industry and academia have identified novel gene sequences, there has not been an equal effort exerted to identify the function of these novel sequences. The elucidation of a role for novel proteins and compounds in disease states for identification of therapeutic targets and diagnostic markers is essential for improving the current treatment of ovarian cancer patients. Accordingly, provided herein are molecular targets for therapeutic intervention in ovarian and other cancers. Additionally, provided herein are methods that can be used in diagnosis and prognosis of ovarian cancer. Further provided are methods that can be used to screen candidate bioactive agents for the ability to modulate ovarian cancer.



SUMMARY OF THE INVENTION

[0012] The present invention therefore provides nucleotide sequences of genes that are up- and down-regulated in ovarian cancer cells. Such genes are useful for diagnostic purposes, and also as targets for screening for therapeutic compounds that modulate ovarian cancer, such as hormones or antibodies. The methods of detecting nucleic acids of the invention or their encoded proteins can be used for many purposes, e.g., early detection of ovarian cancers, monitoring and early detection of relapse following treatment, monitoring response to therapy, selecting patients for postoperative chemotherapy or radiation therapy, selecting therapy, determining tumor prognosis, treatment, or response to treatment (of primary or metastatic tumors), and early detection of pre-cancerous lesions. Other aspects of the invention will become apparent to the skilled artisan by the following description of the invention.


[0013] In one aspect, the present invention provides a method of detecting an ovarian cancer-associated transcript in a cell from a patient, the method comprising contacting a biological sample from the patient with a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-20.


[0014] In one embodiment, the present invention provides a method of determining the level of an ovarian cancer associated transcript in a cell from a patient.


[0015] In one embodiment, the present invention provides a method of detecting an ovarian cancer-associated transcript in a cell from a patient, the method comprising contacting a biological sample from the patient with a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-20.


[0016] In one embodiment, the polynucleotide selectively hybridizes to a sequence at least 95% identical to a sequence as shown in Tables 1-20.


[0017] In one embodiment, the biological sample is a tissue sample. In another embodiment, the biological sample comprises isolated nucleic acids, e.g., mRNA.


[0018] In one embodiment, the polynucleotide is labeled, e.g., with a fluorescent label.


[0019] In one embodiment, the polynucleotide is immobilized on a solid surface.


[0020] In one embodiment, the patient is undergoing a therapeutic regimen to treat ovarian cancer. In another embodiment, the patient is suspected of having metastatic ovarian cancer.


[0021] In one embodiment, the patient is a human.


[0022] In one embodiment, the ovarian cancer associated transcript is mRNA.


[0023] In one embodiment, the method further comprises the step of amplifying nucleic acids before the step of contacting the biological sample with the polynucleotide.


[0024] In another aspect, the present invention provides a method of monitoring the efficacy of a therapeutic treatment of ovarian cancer, the method comprising the steps of: (i) providing a biological sample from a patient undergoing the therapeutic treatment; and (ii) determining the level of an ovarian cancer-associated transcript in the biological sample by contacting the biological sample with a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-20, thereby monitoring the efficacy of the therapy. In a further embodiment, the patient has metastatic ovarian cancer. In a further embodiment, the patient has a drug resistant form of ovarian cancer.


[0025] In one embodiment, the method further comprises the step of: (iii) comparing the level of the ovarian cancer-associated transcript to a level of the ovarian cancer-associated transcript in a biological sample from the patient prior to, or earlier in, the therapeutic treatment.


[0026] Additionally, provided herein is a method of evaluating the effect of a candidate ovarian cancer drug comprising administering the drug to a patient and removing a cell sample from the patient. The expression profile of the cell is then determined. This method may further comprise comparing the expression profile to an expression profile of a healthy individual. In a preferred embodiment, said expression profile includes a gene of Tables 1-20.


[0027] In one aspect, the present invention provides an isolated nucleic acid molecule consisting of a polynucleotide sequence as shown in Tables 1-20.


[0028] In one embodiment, an expression vector or cell comprises the isolated nucleic acid.


[0029] In one aspect, the present invention provides an isolated polypeptide which is encoded by a nucleic acid molecule having polynucleotide sequence as shown in Tables 1-20.


[0030] In another aspect, the present invention provides an antibody that specifically binds to an isolated polypeptide which is encoded by a nucleic acid molecule having polynucleotide sequence as shown in Tables 1-20.


[0031] In one embodiment, the antibody is conjugated to an effector component, e.g., a fluorescent label, a radioisotope or a cytotoxic chemical.


[0032] In one embodiment, the antibody is an antibody fragment. In another embodiment, the antibody is humanized.


[0033] In one aspect, the present invention provides a method of detecting an ovarian cancer cell in a biological sample from a patient, the method comprising contacting the biological sample with an antibody as described herein.


[0034] In another aspect, the present invention provides a method of detecting antibodies specific to ovarian cancer in a patient, the method comprising contacting a biological sample from the patient with a polypeptide encoded by a nucleic acid comprising a sequence from Tables 1-20.


[0035] In another aspect, the present invention provides a method for identifying a compound that modulates an ovarian cancer-associated polypeptide, the method comprising the steps of: (i) contacting the compound with an ovarian cancer-associated polypeptide, the polypeptide encoded by a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-20; and (ii) determining the functional effect of the compound upon the polypeptide.


[0036] In one embodiment, the functional effect is a physical effect, an enzymatic effect, or a chemical effect.


[0037] In one embodiment, the polypeptide is expressed in a eukaryotic host cell or cell membrane. In another embodiment, the polypeptide is recombinant.


[0038] In one embodiment, the functional effect is determined by measuring ligand binding to the polypeptide.


[0039] In another aspect, the present invention provides a method of inhibiting proliferation of an ovarian cancer-associated cell to treat ovarian cancer in a patient, the method comprising the step of administering to the subject a therapeutically effective amount of a compound identified as described herein.


[0040] In one embodiment, the compound is an antibody. In another aspect, the present invention provides a drug screening assay comprising the steps of: (i) administering a test compound to a mammal having ovarian cancer or to a cell sample isolated from; (ii) comparing the level of gene expression of a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-20 in a treated cell or mammal with the level of gene expression of the polynucleotide in a control cell sample or mammal, wherein a test compound that modulates the level of expression of the polynucleotide is a candidate for the treatment of ovarian cancer.


[0041] In one embodiment, the control is a mammal with ovarian cancer or a cell sample that has not been treated with the test compound. In another embodiment, the control is a normal cell or mammal, or is non-malignant tissue.


[0042] In one embodiment, the test compound is administered in varying amounts or concentrations. In another embodiment, the test compound is administered for varying time periods. In another embodiment, the comparison can occur after addition or removal of the drug candidate.


[0043] In one embodiment, the levels of a plurality of polynucleotides that selectively hybridize to a sequence at least 80% identical to a sequence as shown in Tables 1-20 are individually compared to their respective levels in a control cell sample or mammal. In a preferred embodiment the plurality of polynucleotides is from three to ten.


[0044] In another aspect, the present invention provides a method for treating a mammal having ovarian cancer comprising administering a compound identified by the assay described herein. In another aspect, the present invention provides a pharmaceutical composition for treating a mammal having ovarian cancer, the composition comprising a compound identified by the assay described herein and a physiologically acceptable excipient.


[0045] In one aspect, the present invention provides a method of screening drug candidates by providing a cell expressing a gene that is up- and down-regulated as in an ovarian cancer. In one embodiment, a gene is selected from Tables 1-20. The method further includes adding a drug candidate to the cell and determining the effect of the drug candidate on the expression of the expression profile gene.


[0046] In one embodiment, the method of screening drug candidates includes comparing the level of expression in the absence of the drug candidate to the level of expression in the presence of the drug candidate, wherein the concentration of the drug candidate can vary when present, and wherein the comparison can occur after addition or removal of the drug candidate. In a preferred embodiment, the cell expresses at least two expression profile genes. The profile genes may show an increase or decrease.


[0047] Also provided is a method of evaluating the effect of a candidate ovarian cancer drug comprising administering the drug to a transgenic animal expressing or over-expressing the ovarian cancer modulatory protein, or an animal lacking the ovarian cancer modulatory protein, for example as a result of a gene knockout.


[0048] Moreover, provided herein is a biochip comprising one or more nucleic acid segments of Tables 1-20, wherein the biochip comprises fewer than 1000 nucleic acid probes. Preferably, at least two nucleic acid segments are included. More preferably, at least three nucleic acid segments are included.


[0049] Furthermore, a method of diagnosing a disorder associated with ovarian cancer is provided. The method comprises determining the expression of a gene of Tables 1-20 in a first tissue type of a first individual, and comparing the distribution to the expression of the gene from a second normal tissue type from the first individual or a second unaffected individual. A difference in the expression indicates that the first individual has a disorder associated with ovarian cancer.


[0050] In a further embodiment, the biochip also includes a polynucleotide sequence of a gene that is not up- and down-regulated in ovarian cancer.


[0051] In one embodiment a method for screening for a bioactive agent capable of interfering with the binding of an ovarian cancer modulating protein (ovarian cancer modulatory protein) or a fragment thereof and an antibody which binds to said ovarian cancer modulatory protein or fragment thereof. In a preferred embodiment, the method comprises combining an ovarian cancer modulatory protein or fragment thereof, a candidate bioactive agent and an antibody which binds to said ovarian cancer modulatory protein or fragment thereof. The method further includes determining the binding of said ovarian cancer modulatory protein or fragment thereof and said antibody. Wherein there is a change in binding, an agent is identified as an interfering agent. The interfering agent can be an agonist or an antagonist. Preferably, the agent inhibits ovarian cancer.


[0052] Also provided herein are methods of eliciting an immune response in an individual. In one embodiment a method provided herein comprises administering to an individual a composition comprising an ovarian cancer modulating protein, or a fragment thereof. In another embodiment, the protein is encoded by a nucleic acid selected from those of Tables 1-20.


[0053] Further provided herein are compositions capable of eliciting an immune response in an individual. In one embodiment, a composition provided herein comprises an ovarian cancer modulating protein, preferably encoded by a nucleic acid of Table 1-20 or a fragment thereof, and a pharmaceutically acceptable carrier. In another embodiment, said composition comprises a nucleic acid comprising a sequence encoding an ovarian cancer modulating protein, preferably selected from the nucleic acids of Tables 1-20, and a pharmaceutically acceptable carrier.


[0054] Also provided are methods of neutralizing the effect of an ovarian cancer protein, or a fragment thereof, comprising contacting an agent specific for said protein with said protein in an amount sufficient to effect neutralization. In another embodiment, the protein is encoded by a nucleic acid selected from those of Tables 1-20.


[0055] In another aspect of the invention, a method of treating an individual for ovarian cancer is provided. In one embodiment, the method comprises administering to said individual an inhibitor of an ovarian cancer modulating protein. In another embodiment, the method comprises administering to a patient having ovarian cancer an antibody to an ovarian cancer modulating protein conjugated to a therapeutic moiety. Such a therapeutic moiety can be a cytotoxic agent or a radioisotope.



DETAILED DESCRIPTION OF THE INVENTION

[0056] In accordance with the objects outlined above, the present invention provides novel methods for diagnosis and prognosis evaluation for ovarian cancer (OC), including metastatic ovarian cancer, as well as methods for screening for compositions which modulate ovarian cancer. Also provided are methods for treating ovarian cancer and related conditions, e.g., ovarian carcinoma (e.g., epithelial (including malignant serous tumors, malignant mucinous tumors, and malignant endometrioid tumors), germ cell (including teratomas, choriocarcinomas, polyembryomas, embryonal carcinoma, endodermal sinus tumor, dysgerminoma, and gonadoblastoma), and stromal carcinomas (e.g., granulosal stromal cell tumors)), fallopian tube carcinoma, and peritoneal carcinoma.


[0057] Tables 1-20 provide unigene cluster identification numbers for the nucleotide sequence of genes that exhibit increased or decreased expression in ovarian cancer samples. Tables 1-20 also provide an exemplar accession number that provides a nucleotide sequence that is part of the unigene cluster.


[0058] Definitions


[0059] The term “ovarian cancer protein” or “ovarian cancer polynucleotide” or “ovarian cancer-associated transcript” refers to nucleic acid and polypeptide polymorphic variants, alleles, mutants, and interspecies homologues that: (1) have a nucleotide sequence that has greater than about 60% nucleotide sequence identity, 65%, 70%, 75%, 80%, 85%, 90%, preferably 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or greater nucleotide sequence identity, preferably over a region of over a region of at least about 25, 50, 100, 200, 500, 1000, or more nucleotides, to a nucleotide sequence of or associated with a gene of Tables 1-20; (2) bind to antibodies, e.g., polyclonal antibodies, raised against an immunogen comprising an amino acid sequence encoded by a nucleotide sequence of or associated with a gene of Tables 1-20, and conservatively modified variants thereof; (3) specifically hybridize under stringent hybridization conditions to a nucleic acid sequence, or the complement thereof of Tables 1-20 and conservatively modified variants thereof; or (4) have an amino acid sequence that has greater than about 60% amino acid sequence identity, 65%, 70%, 75%, 80%, 85%, 90%, preferably 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% greater amino sequence identity, preferably over a region of over a region of at least about 25, 50, 100, 200, 500, 1000, or more amino acid, to an amino acid sequence encoded by a nucleotide sequence of or associated with a gene of Tables 1-20. A polynucleotide or polypeptide sequence is typically from a mammal including, but not limited to, primate, e.g., human; rodent, e.g., rat, mouse, hamster; cow, pig, horse, sheep, or other mammal. An “ovarian cancer polypeptide” and an “ovarian cancer polynucleotide,” include both naturally occurring or recombinant forms.


[0060] A “full length” ovarian cancer protein or nucleic acid refers to an ovarian cancer polypeptide or polynucleotide sequence, or a variant thereof, that contains all of the elements normally contained in one or more naturally occurring, wild type ovarian cancer polynucleotide or polypeptide sequences. The “full length” may be prior to, or after, various stages of post-translation processing or splicing, including alternative splicing.


[0061] “Biological sample” as used herein is a sample of biological tissue or fluid that contains nucleic acids or polypeptides, e.g., of an ovarian cancer protein, polynucleotide or transcript. Such samples include, but are not limited to, tissue isolated from primates, e.g., humans, or rodents, e.g., mice, and rats. Biological samples may also include sections of tissues such as biopsy and autopsy samples, frozen sections taken for histologic purposes, blood, plasma, serum, sputum, stool, tears, mucus, hair, skin, etc. Biological samples also include explants and primary and/or transformed cell cultures derived from patient tissues. A biological sample is typically obtained from a eukaryotic organism, most preferably a mammal such as a primate e.g., chimpanzee or human; cow; dog; cat; a rodent, e.g., guinea pig, rat, mouse; rabbit; or a bird; reptile; or fish. Livestock and domestic animals are of particular interest.


[0062] “Providing a biological sample” means to obtain a biological sample for use in methods described in this invention. Most often, this will be done by removing a sample of cells from an animal, but can also be accomplished by using previously isolated cells (e.g., isolated by another person, at another time, and/or for another purpose), or by performing the methods of the invention in vivo. Archival tissues, having treatment or outcome history, will be particularly useful.


[0063] The terms “identical” or percent “identity,” in the context of two or more nucleic acids or polypeptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same (e.g., about 60% identity, preferably 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or higher identity over a specified region, when compared and aligned for maximum correspondence over a comparison window or designated region) as measured using a BLAST or BLAST 2.0 sequence comparison algorithms with default parameters described below, or by manual alignment and visual inspection (see, e.g., NCBI web site http://www.ncbi.nlm.nih.gov/BLAST/or the like). Such sequences are then said to be “substantially identical.” This definition also refers to, or may be applied to, the compliment of a test sequence. The definition also includes sequences that have deletions and/or additions, as well as those that have substitutions, as well as naturally occurring, e.g., polymorphic or allelic variants, and man-made variants. As described below, the preferred algorithms can account for gaps and the like. Preferably, identity exists over a region that is at least about 25 amino acids or nucleotides in length, or more preferably over a region that is 50-100 amino acids or nucleotides in length.


[0064] For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Preferably, default program parameters can be used, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters.


[0065] A “comparison window”, as used herein, includes reference to a segment of one of the number of contiguous positions selected from the group consisting typically of from 20 to 600, usually about 50 to about 200, more usually about 100 to about 150 in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Methods of alignment of sequences for comparison are well-known in the art. Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith and Waterman (1981) Adv. Appl. Math. 2:482-489, by the homology alignment algorithm of Needleman and Wunsch (1970) J. Mol. Biol. 48:443-453, by the search for similarity method of Pearson and Lipman (1988) Proc. Nat'l. Acad. Sci. USA 85:2444-2448, by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.), or by manual alignment and visual inspection (see, e.g., Ausubel, et al. (eds. 1995 and supplements) Current Protocols in Molecular Biology Lippincott.


[0066] Preferred examples of algorithms that are suitable for determining percent sequence identity and sequence similarity include the BLAST and BLAST 2.0 algorithms, which are described in Altschul, et al. (1977) Nuc. Acids Res. 25:3389-3402 and Altschul, et al. (1990) J. Mol. Biol. 215:403-410. BLAST and BLAST 2.0 are used, with the parameters described herein, to determine percent sequence identity for the nucleic acids and proteins of the invention. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/). This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul, et al., supra). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, e.g., for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always>0) and N (penalty score for mismatching residues; always<0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, an expectation (E) of 10, M=5, N=−4 and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a word length of 3, and expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff and Henikoff(1989) Proc. Nat'l Acad. Sci. USA 89:10915-919) alignments (B) of 50, expectation (E) of 10, M=5, N=−4, and a comparison of both strands.


[0067] The BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin and Altschul (1993) Proc. Nat'l Acad. Sci. USA 90:5873-5887). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.2, more preferably less than about 0.01, and most preferably less than about 0.001. Log values may be large negative numbers, e.g., 5, 10, 20, 30, 40, 40, 70, 90, 110, 150, 170, etc.


[0068] An indication that two nucleic acid sequences or polypeptides are substantially identical is that the polypeptide encoded by the first nucleic acid is immunologically cross reactive with the antibodies raised against the polypeptide encoded by the second nucleic acid, as described below. Thus, a polypeptide is typically substantially identical to a second polypeptide, e.g., where the two peptides differ only by conservative substitutions. Another indication that two nucleic acid sequences are substantially identical is that the two molecules or their complements hybridize to each other under stringent conditions, as described below. Yet another indication that two nucleic acid sequences are substantially identical is that the same primers can be used to amplify the sequences.


[0069] A “host cell” is a naturally occurring cell or a transformed cell that contains an expression vector and supports the replication or expression of the expression vector. Host cells may be cultured cells, explants, cells in vivo, and the like. Host cells may be prokaryotic cells such as E. coli, or eukaryotic cells such as yeast, insect, amphibian, or mammalian cells, such as CHO, HeLa, and the like (see, e.g., the American Type Culture Collection catalog or web site, www.atcc.org).


[0070] The terms “isolated,” “purified,” or “biologically pure” refer to material that is substantially or essentially free from components that normally accompany it as found in its native state. Purity and homogeneity are typically determined using analytical chemistry techniques such as polyacrylamide gel electrophoresis or high performance liquid chromatography. A protein or nucleic acid that is the predominant species present in a preparation is substantially purified. In particular, an isolated nucleic acid is separated from some open reading frames that naturally flank the gene and encode proteins other than protein encoded by the gene. The term “purified” in some embodiments denotes that a nucleic acid or protein gives rise to essentially one band in an electrophoretic gel. Preferably, it means that the nucleic acid or protein is at least 85% pure, more preferably at least 95% pure, and most preferably at least 99% pure. “Purify” or “purification” in other embodiments means removing at least one contaminant from the composition to be purified. In this sense, purification does not require that the purified compound be homogenous, e.g., 100% pure.


[0071] The terms “polypeptide,” “peptide” and “protein” are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers, those containing modified residues, and non-naturally occurring amino acid polymers.


[0072] The term “amino acid” refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function similarly to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, γ-carboxyglutamate, and O-phosphoserine. Amino acid analogs refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, e.g., an a carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs may have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. Amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions similarly to a naturally occurring amino acid.


[0073] Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes.


[0074] “Conservatively modified variants” applies to both amino acid and nucleic acid sequences. With respect to particular nucleic acid sequences, conservatively modified variants refers to those nucleic acids which encode identical or essentially identical amino acid sequences, or where the nucleic acid does not encode an amino acid sequence, to essentially identical or associated, e.g., naturally contiguous, sequences. Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode most proteins. For instance, the codons GCA, GCC, GCG, and GCU all encode the amino acid alanine. Thus, at every position where an alanine is specified by a codon, the codon can be altered to another of the corresponding codons described without altering the encoded polypeptide. Such nucleic acid variations are “silent variations,” which are one species of conservatively modified variations. Every nucleic acid sequence herein which encodes a polypeptide also describes silent variations of the nucleic acid. In certain contexts each codon in a nucleic acid (except AUG, which is ordinarily the only codon for methionine, and TGG, which is ordinarily the only codon for tryptophan) can be modified to yield a functionally identical molecule. Accordingly, a silent variation of a nucleic acid which encodes a polypeptide is implicit in a described sequence with respect to the expression product, but not necessarily with respect to actual probe sequences.


[0075] As to amino acid sequences, one of skill will recognize that individual substitutions, deletions, or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters, adds, or deletes a single amino acid or a small percentage of amino acids in the encoded sequence is a “conservatively modified variant” where the alteration results in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art. Such conservatively modified variants are in addition to and do not exclude polymorphic variants, interspecies homologs, and alleles of the invention. Typically conservative substitutions for one another: 1) Alanine (A), Glycine (G); 2) Aspartic acid (D), Glutamic acid (E); 3) Asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (K); 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W); 7) Serine (S), Threonine (T); and 8) Cysteine (C), Methionine (M) (see, e.g., Creighton (1984) Proteins Freeman).


[0076] Macromolecular structures such as polypeptide structures can be described in terms of various levels of organization. For a general discussion of this organization, see, e.g., Alberts, et al. (2001) Molecular Biology of the Cell (4th ed.) Garland Pub.; and Cantor and Schimmel (1980) Biophysical Chemistry Part I: The Conformation of Biological Macromolecules Freeman. “Primary structure” refers to the amino acid sequence of a particular peptide. “Secondary structure” refers to locally ordered, three dimensional structures within a polypeptide. These structures are commonly known as domains. Domains are portions of a polypeptide that often form a compact unit of the polypeptide and are typically 25 to approximately 500 amino acids long. Typical domains are made up of sections of lesser organization such as stretches of β-sheet and α-helices. “Tertiary structure” refers to the complete three dimensional structure of a polypeptide monomer. “Quaternary structure” refers to the three dimensional structure formed, usually by the non-covalent association of independent tertiary units. Anisotropic terms are also known as energy terms.


[0077] “Nucleic acid” or “oligonucleotide” or “polynucleotide” or grammatical equivalents used herein means at least two nucleotides covalently linked together. Oligonucleotides are typically from about 5, 6, 7, 8, 9, 10, 12, 15, 25, 30, 40, 50, or more nucleotides in length, up to about 100 nucleotides in length. Nucleic acids and polynucleotides are a polymers of any length, including longer lengths, e.g., 200, 300, 500, 1000, 2000, 3000, 5000, 7000, 10,000, etc. A nucleic acid of the present invention will generally contain phosphodiester bonds, although in some cases, nucleic acid analogs are included that may have at least one different linkage, e.g., phosphoramidate, phosphorothioate, phosphorodithioate, or O-methylphosphoroamidite linkages (see Eckstein (1992) Oligonucleotides and Analogues: A Practical Approach Oxford University Press); and peptide nucleic acid backbones and linkages. Other analog nucleic acids include those with positive backbones; non-ionic backbones, and non-ribose backbones, including those described in U.S. Pat. Nos. 5,235,033 and 5,034,506, and Chapters 6 and 7 of Sanghvi and Cook (eds. 1994) Carbohydrate Modifications in Antisense Research ASC Symposium Series 580. Nucleic acids containing one or more carbocyclic sugars are also included within one definition of nucleic acids. Modifications of the ribose-phosphate backbone may be done for a variety of reasons, e.g., to increase the stability and half-life of such molecules in physiological environments or as probes on a biochip. Mixtures of naturally occurring nucleic acids and analogs can be made; alternatively, mixtures of different nucleic acid analogs, and mixtures of naturally occurring nucleic acids and analogs may be made.


[0078] A variety of references disclose such nucleic acid analogs, including, e.g., phosphoramidate (Beaucage, et al. (1993) Tetrahedron 49:1925-1963 and references therein; Letsinger (1970) J. Org. Chem. 35:3800-3803; Sprinzl, et al. (1977) Eur. J. Biochem. 81:579-589; Letsinger, et al. (1986) Nucl. Acids Res. 14:3487-499; Sawai, et al. (1984) Chem. Lett. 805, Letsinger, et al. (1988) J. Am. Chem. Soc. 110:4470-4471; and Pauwels, et al. (1986), Chemica Scripta 26:141-149), phosphorothioate (Mag, et al. (1991) Nucl. Acids Res. 19:1437-441; and U.S. Pat. No. 5,644,048), phosphorodithioate (Brill, et al. (1989) J. Am. Chem. Soc. 111:2321-2322), O-methylphophoroamidite linkages (see Eckstein (1992) Oligonucleotides and Analogues: A Practical Approach Oxford Univ. Press), and peptide nucleic acid backbones and linkages (see Egholm (1992) J. Am. Chem. Soc. 114:1895-897; Meier, et al. (1992) Angew. Chem. Int. Ed. Engl. 31:1008-1010; Nielsen (1993) Nature, 365:566-568; Carlsson, et al. (1996) Nature 380:207, each of which is incorporated by reference). Other analog nucleic acids include those with positive backbones (Denpcy, et al. (1995) Proc. Nat'l Acad. Sci. USA 92:6097-101; non-ionic backbones (U.S. Pat. Nos. 5,386,023, 5,637,684, 5,602,240, 5,216,141 and 4,469,863; Kiedrowshi, et al. (1991) Angew. Chem. Intl. Ed. English 30:423-426; Letsinger, et al. (1988) J. Am. Chem. Soc. 110:4470-4471; Jung, et al. (1994) Nucleoside and Nucleotide 13:1597; Chapters 2 and 3, in Sanghvi and Cook (eds. 1994) Carbohydrate Modifications in Antisense Research ASC Symposium Series 580; Mesmaeker, et al. (1994) Bioorganic and Medicinal Chem. Lett. 4:395-398; Jeffs, et al. (1994) J. Biomolecular NMR 34:17-xx; Horn, et al. (1996) Tetrahedron Lett. 37:743-xxx) and non-ribose backbones, including those described in U.S. Pat. Nos. 5,235,033 and 5,034,506, and Chapters 6 and 7, in Sanghvi and Cook (eds. 1994) Carbohydrate Modifications in Antisense Research ASC Symposium Series 580. Nucleic acids containing one or more carbocyclic sugars are also included within one definition of nucleic acids (see Jenkins, et al. (1995) Chem. Soc. Rev. pp 169-176). Several nucleic acid analogs are described in Rawls (p. 35 Jun. 2, 1997) C&E News. Each of these references is hereby expressly incorporated by reference.


[0079] Particularly preferred are peptide nucleic acids (PNA) which includes peptide nucleic acid analogs. These backbones are substantially non-ionic under neutral conditions, in contrast to the highly charged phosphodiester backbone of naturally occurring nucleic acids. This results in two advantages. First, the PNA backbone exhibits improved hybridization kinetics. PNAs have larger changes in the melting temperature (Tm) for mismatched versus perfectly matched base pairs. DNA and RNA typically exhibit a 2-4° C. drop in Tm for an internal mismatch. With the non-ionic PNA backbone, the drop is closer to 7-9° C. Similarly, due to their non-ionic nature, hybridization of the bases attached to these backbones is relatively insensitive to salt concentration. In addition, PNAs are not degraded by cellular enzymes, and thus can be more stable.


[0080] The nucleic acids may be single stranded or double stranded, as specified, or contain portions of both double stranded or single stranded sequence. As will be appreciated by those in the art, the depiction of a single strand also defines the sequence of the complementary strand; thus the sequences described herein also provide the complement of the sequence. The nucleic acid may be DNA, both genomic and cDNA, RNA, or a hybrid, where the nucleic acid may contain combinations of deoxyribo- and ribo-nucleotides, and combinations of bases, including uracil, adenine, thymine, cytosine, guanine, inosine, xanthine hypoxanthine, isocytosine, isoguanine, etc. “Transcript” typically refers to a naturally occurring RNA, e.g., a pre-mRNA, hnRNA, or mRNA. As used herein, the term “nucleoside” includes nucleotides and nucleoside and nucleotide analogs, and modified nucleosides such as amino modified nucleosides. In addition, “nucleoside” includes non-naturally occurring analog structures. Thus, e.g., the individual units of a peptide nucleic acid, each containing a base, are referred to herein as a nucleoside.


[0081] A “label” or a “detectable moiety” is a composition detectable by spectroscopic, photochemical, biochemical, immunochemical, chemical, or other physical means. For example, useful labels include 32P, fluorescent dyes, electron-dense reagents, enzymes (e.g., as commonly used in an ELISA), biotin, digoxigenin, or haptens and proteins or other entities which can be made detectable, e.g., by incorporating a radiolabel into the peptide or used to detect antibodies specifically reactive with the peptide. The labels may be incorporated into the ovarian cancer nucleic acids, proteins and antibodies at any position. Any method known in the art for conjugating the antibody to the label may be employed, including those methods described by Hunter, et al. (1962) Nature 144:945-xxx; David, et al. (1974) Biochemistry 13:1014-1021; Pain, et al. (1981) J. Immunol. Meth. 40:219-230; and Nygren (1982) J. Histochem. and Cytochem. 30:407-412.


[0082] An “effector” or “effector moiety” or “effector component” is a molecule that is bound (or linked, or conjugated), either covalently, through a linker or a chemical bond, or non-covalently, through ionic, van der Waals, electrostatic, or hydrogen bonds, to an antibody. The “effector” can be a variety of molecules including, e.g., detection moieties including radioactive compounds, fluorescent compounds, an enzyme or substrate, tags such as epitope tags, a toxin; activatable moieties, a chemotherapeutic agent; a lipase; an antibiotic; or a radioisotope emitting “hard” e.g., beta radiation.


[0083] A “labeled nucleic acid probe or oligonucleotide” is one that is bound, either covalently, through a linker or a chemical bond, or non-covalently, through ionic, van der Waals, electrostatic, or hydrogen bonds to a label such that the presence of the probe may be detected by detecting the presence of the label bound to the probe. Alternatively, method using high affinity interactions may achieve the same results where one of a pair of binding partners binds to the other, e.g., biotin, streptavidin.


[0084] As used herein a “nucleic acid probe or oligonucleotide” is a nucleic acid capable of binding to a target nucleic acid of complementary sequence through one or more types of chemical bonds, usually through complementary base pairing, usually through hydrogen bond formation. As used herein, a probe may include natural (e.g., A, G, C, or T) or modified bases (7-deazaguanosine, inosine, etc.). In addition, the bases in a probe may be joined by a linkage other than a phosphodiester bond, so long as it does not functionally interfere with hybridization. Thus, e.g., probes may be peptide nucleic acids in which the constituent bases are joined by peptide bonds rather than phosphodiester linkages. Probes may bind target sequences lacking complete complementarity with the probe sequence depending upon the stringency of the hybridization conditions. The probes are preferably directly labeled, e.g., with isotopes, chromophores, lumiphores, chromogens, or indirectly labeled such as with biotin to which a streptavidin complex may later bind. By assaying for the presence or absence of the probe, one can detect the presence or absence of the select sequence or subsequence. Diagnosis or prognosis may be based at the genomic level, or at the level of RNA or protein expression.


[0085] The term “recombinant” when used with reference, e.g., to a cell, or nucleic acid, protein, or vector, indicates that the cell, nucleic acid, protein or vector, has been modified by the introduction of a heterologous nucleic acid or protein or the alteration of a native nucleic acid or protein, or that the cell is derived from a cell so modified. Thus, e.g., recombinant cells express genes that are not found within the native (non-recombinant) form of the cell or express native genes that are otherwise abnormally expressed, under expressed or not expressed at all. By the term “recombinant nucleic acid” herein is meant nucleic acid, originally formed in vitro, in general, by the manipulation of nucleic acid, e.g., using polymerases and endonucleases, in a form not normally found in nature. In this manner, operably linkage of different sequences is achieved. Thus an isolated nucleic acid, in a linear form, or an expression vector formed in vitro by ligating DNA molecules that are not normally joined, are both considered recombinant for the purposes of this invention. It is understood that once a recombinant nucleic acid is made and reintroduced into a host cell or organism, it will replicate non-recombinantly, e.g., using the in vivo cellular machinery of the host cell rather than in vitro manipulations; however, such nucleic acids, once produced recombinantly, although subsequently replicated non-recombinantly, are still considered recombinant for the purposes of the invention. Similarly, a “recombinant protein” is a protein made using recombinant techniques, e.g., through the expression of a recombinant nucleic acid as depicted above.


[0086] The term “heterologous” when used with reference to portions of a nucleic acid indicates that the nucleic acid comprises two or more subsequences that are not normally found in the same relationship to each other in nature. For instance, the nucleic acid is typically recombinantly produced, having two or more sequences, e.g., from unrelated genes arranged to make a new functional nucleic acid, e.g., a promoter from one source and a coding region from another source. Similarly, a heterologous protein will often refer to two or more subsequences that are not found in the same relationship to each other in nature (e.g., a fusion protein).


[0087] A “promoter” is defined as an array of nucleic acid control sequences that direct transcription of a nucleic acid. As used herein, a promoter includes necessary nucleic acid sequences near the start site of transcription, such as, in the case of a polymerase II type promoter, a TATA element. A promoter also optionally includes distal enhancer or repressor elements, which can be located as much as several thousand base pairs from the start site of transcription. A “constitutive” promoter is a promoter that is active under most environmental and developmental conditions. An “inducible” promoter is a promoter that is active under environmental or developmental regulation. The term “operably linked” refers to a functional linkage between a nucleic acid expression control sequence (such as a promoter, or array of transcription factor binding sites) and a second nucleic acid sequence, e.g., wherein the expression control sequence directs transcription of the nucleic acid corresponding to the second sequence.


[0088] An “expression vector” is a nucleic acid construct, generated recombinantly or synthetically, with a series of specified nucleic acid elements that permit transcription of a particular nucleic acid in a host cell. The expression vector can be part of a plasmid, virus, or nucleic acid fragment. Typically, the expression vector includes a nucleic acid to be transcribed operably linked to a promoter.


[0089] The phrase “selectively (or specifically) hybridizes to” refers to the binding, duplexing, or hybridizing of a molecule only to a particular nucleotide sequence under stringent hybridization conditions when that sequence is present in a complex mixture (e.g., total cellular or library DNA or RNA).


[0090] The phrase “stringent hybridization conditions” refers to conditions under which a probe will hybridize to its target subsequence, typically in a complex mixture of nucleic acids, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures. An extensive guide to the hybridization of nucleic acids is found in “Overview of principles of hybridization and the strategy of nucleic acid assays” in Tijssen (1993) Hybridization with Nucleic Probes (Laboratory Techniques in Biochemistry and Molecular Biology) (vol. 24) Elsevier. Generally, stringent conditions are selected to be about 5-10° C. lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength pH. The Tm is the temperature (under defined ionic strength, pH, and nucleic concentration) at which 50% of the probes complementary to the target hybridize to the target sequence at equilibrium (as the target sequences are present in excess, at Tm, 50% of the probes are occupied at equilibrium). Stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30° C. for short probes (e.g., 10 to 50 nucleotides) and at least about 60° C. for long probes (e.g., greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. For selective or specific hybridization, a positive signal is typically at least two times background, preferably 10 times background hybridization. Exemplary stringent hybridization conditions can be as following: 50% formamide, 5×SSC, and 1% SDS, incubating at 42° C., or, 5×SSC, 1% SDS, incubating at 65° C., with wash in 0.2×SSC, and 0.1% SDS at 65° C. For PCR, a temperature of about 36° C. is typical for low stringency amplification, although annealing temperatures may vary between about 32-48° C. depending on primer length. For high stringency PCR amplification, a temperature of about 62° C. is typical, although high stringency annealing temperatures can range from about 50° C. to about 65° C., depending on the primer length and specificity. Typical cycle conditions for both high and low stringency amplifications include a denaturation phase of 90-95° C. for 30-120 sec, an annealing phase lasting 30-120 sec, and an extension phase of about 72° C. for 1-2 min. Protocols and guidelines for low and high stringency amplification reactions are available, e.g., in Innis, et al. (1990) PCR Protocols: A Guide to Methods and Applications Academic Press, N.Y.


[0091] Nucleic acids that do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides which they encode are substantially identical. This occurs, e.g., when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code. In such cases, the nucleic acids typically hybridize under moderately stringent hybridization conditions. Exemplary “moderately stringent hybridization conditions” include a hybridization in a buffer of 40% formamide, 1 M NaCl, 1% SDS at 37° C., and a wash in 1×SSC at 45° C. A positive hybridization is at least twice background. Alternative hybridization and wash conditions can be utilized to provide conditions of similar stringency. Additional guidelines for determining hybridization parameters are provided, e.g., Ausubel, et al. (ed. 1991 and supplements) Current Protocols in Molecular Biology Lippincott.


[0092] The phrase “functional effects” in the context of assays for testing compounds that modulate activity of an ovarian cancer protein includes the determination of a parameter that is indirectly or directly under the influence of the ovarian cancer protein or nucleic acid, e.g., a functional, physical, physiological, or chemical effect, such as the ability to decrease ovarian cancer. It includes ligand binding activity; cell growth on soft agar; anchorage dependence; contact inhibition and density limitation of growth; cellular proliferation; cellular transformation; growth factor or serum dependence; tumor specific marker levels; invasiveness into Matrigel; tumor growth and metastasis in vivo; mRNA and protein expression in cells undergoing metastasis, and other characteristics of ovarian cancer cells. “Functional effects” include in vitro, in vivo, and ex vivo activities.


[0093] By “determining the functional effect” is meant assaying for a compound that increases or decreases a parameter that is indirectly or directly under the influence of an ovarian cancer protein sequence, e.g., functional, enzymatic, physical, physiological, and chemical effects. Such functional effects can be measured by any means known to those skilled in the art, e.g., changes in spectroscopic characteristics (e.g., fluorescence, absorbance, refractive index), hydrodynamic (e.g., shape), chromatographic, or solubility properties for the protein, measuring inducible markers or transcriptional activation of the ovarian cancer protein; measuring binding activity or binding assays, e.g., binding to antibodies or other ligands, and measuring cellular proliferation. Determination of the functional effect of a compound on ovarian cancer can also be performed using ovarian cancer assays known to those of skill in the art such as an in vitro assays, e.g., cell growth on soft agar; anchorage dependence; contact inhibition and density limitation of growth; cellular proliferation; cellular transformation; growth factor or serum dependence; tumor specific marker levels; invasiveness into Matrigel; tumor growth and metastasis in vivo; mRNA and protein expression in cells undergoing metastasis, and other characteristics of ovarian cancer cells. The functional effects can be evaluated by means known to those skilled in the art, e.g., microscopy for quantitative or qualitative measures of alterations in morphological features, measurement of changes in RNA or protein levels for ovarian cancer-associated sequences, measurement of RNA stability, or identification of downstream or reporter gene expression (CAT, luciferase, β-gal, GFP, and the like), e.g., via chemiluminescence, fluorescence, colorimetric reactions, antibody binding, inducible markers, and ligand binding assays.


[0094] “Inhibitors”, “activators”, and “modulators” of ovarian cancer polynucleotide and polypeptide sequences are used to refer to activating, inhibitory, or modulating molecules or compounds identified using in vitro and in vivo assays of ovarian cancer polynucleotide and polypeptide sequences. Inhibitors are compounds that, e.g., bind to, partially or totally block activity, decrease, prevent, delay activation, inactivate, desensitize, or down regulate the activity or expression of ovarian cancer proteins, e.g., antagonists. Antisense or inhibitory nucleic acids may inhibit expression and subsequent function of the protein. “Activators” are compounds that increase, open, activate, facilitate, enhance activation, sensitize, agonize, or up regulate ovarian cancer protein activity. Inhibitors, activators, or modulators also include genetically modified versions of ovarian cancer proteins, e.g., versions with altered activity, as well as naturally occurring and synthetic ligands, antagonists, agonists, antibodies, small chemical molecules, and the like. Assays for inhibitors and activators include, e.g., expressing the ovarian cancer protein in vitro, in cells, or cell membranes, applying putative modulator compounds, and then determining the functional effects on activity, as described above. Activators and inhibitors of ovarian cancer can also be identified by incubating ovarian cancer cells with the test compound and determining increases or decreases in the expression of one or more ovarian cancer proteins, e.g., 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 40, 50, or more ovarian cancer proteins, such as ovarian cancer proteins encoded by the sequences set out in Tables 1-20.


[0095] Samples or assays comprising ovarian cancer proteins that are treated with a potential activator, inhibitor, or modulator are compared to control samples without the inhibitor, activator, or modulator to examine the extent of inhibition. Control samples (untreated with inhibitors) are assigned a relative protein activity value of 100%. Inhibition of a polypeptide is achieved when the activity value relative to the control is about 80%, preferably 50%, more preferably 25% or less. Activation of an ovarian cancer polypeptide is achieved when the activity value relative to the control (untreated with activators) is 110%, more preferably 150%, more preferably 200-500% (e.g., 2-5 fold higher relative to the control), more preferably 1000-3000% higher.


[0096] The phrase “changes in cell growth” refers to a change in cell growth and proliferation characteristics in vitro or in vivo, e.g., cell viability, formation of foci, anchorage independence, semi-solid or soft agar growth, change in contact inhibition or density limitation of growth, loss of growth factor or serum requirements, change in cell morphology, gain or loss of immortalization, gain or loss of tumor specific markers, ability to form or suppress tumors when injected into suitable animal hosts, and/or immortalization of the cell. See, e.g., pp. 231-241 in Freshney (1994) Culture of Animal Cells: A Manual of Basic Technique (3d ed.) Wiley-Liss.


[0097] “Tumor cell” refers to pre-cancerous, cancerous, and normal cells in a tumor.


[0098] “Cancer cells,” “transformed” cells or “transformation” in tissue culture, refers to spontaneous or induced phenotypic changes that do not necessarily involve the uptake of new genetic material. Although transformation can arise from infection with a transforming virus and incorporation of new genomic DNA, or uptake of exogenous DNA, it can also arise spontaneously or following exposure to a carcinogen, thereby mutating an endogenous gene. Transformation is typically associated with phenotypic changes, such as immortalization of cells, aberrant growth control, non-morphological changes, and/or malignancy. See, Freshney (1994) Culture of Animal Cells.


[0099] “Antibody” refers to a polypeptide comprising a framework region from an immunoglobulin gene or fragments thereof that specifically binds and recognizes an antigen. The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon, and mu constant region genes, as well as the myriad immunoglobulin variable region genes. Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD, and IgE, respectively. Typically, the antigen-binding region of an antibody or its functional equivalent will be most critical in specificity and affinity of binding. See, e.g., Paul (ed. 1999) Fundamental Immunology (4th ed.) Raven.


[0100] An exemplary immunoglobulin (antibody) structural unit comprises a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one “light” (about 25 kD) and one “heavy” chain (about 50-70 kD). The N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The terms variable light chain (VL) and variable heavy chain (VH) refer to these light and heavy chains respectively.


[0101] Antibodies exist, e.g., as intact immunoglobulins or as a number of well-characterized fragments produced by digestion with various peptidases. Thus, e.g., pepsin digests an antibody below the disulfide linkages in the hinge region to produce F(ab)′2, a dimer of Fab which itself is a light chain joined to VH-CH1 by a disulfide bond. The F(ab)′2 may be reduced under mild conditions to break the disulfide linkage in the hinge region, thereby converting the F(ab)′2 dimer into an Fab′ monomer. The Fab′0 monomer is essentially Fab with part of the hinge region. See Paul (ed. 1999) Fundamental immunology (4th ed.) Raven. While various antibody fragments are defined in terms of the digestion of an intact antibody, one of skill will appreciate that such fragments may be synthesized de novo either chemically or by using recombinant DNA methodology. Thus, the term antibody, as used herein, also includes antibody fragments either produced by the modification of whole antibodies, or those synthesized de novo using recombinant DNA methodologies (e.g., single chain Fv) or those identified using phage display libraries. See, e.g., McCafferty, et al. (1990) Nature 348:552-554.


[0102] For preparation of antibodies, e.g., recombinant, monoclonal, or polyclonal antibodies, many techniques known in the art can be used (see, e.g., Kohler and Milstein (1975) Nature 256:495-497; Kozbor, et al. (1983) Immunology Today 4:72; Cole, et al., pp. 77-96 in Reisfeld and Sell (1985) Monoclonal Antibodies and Cancer Therapy Liss; Coligan (1991) Current Protocols in Immunology Lippincott; Harlow and Lane (1988) Antibodies: A Laboratory Manual CSH Press; and Goding (1986) Monoclonal Antibodies: Principles and Practice (2d ed.) Academic Press. Techniques for the production of single chain antibodies (U.S. Pat. No. 4,946,778) can be adapted to produce antibodies to polypeptides of this invention. Transgenic mice, or other organisms, e.g., other mammals, may be used to express humanized antibodies. Alternatively, phage display technology can be used to identify antibodies and heteromeric Fab fragments that specifically bind to selected antigens. See, e.g., McCafferty, et al. (1990) Nature 348:552-554; and Marks, et al. (1992) Biotechnology 10:779-783.


[0103] A “chimeric antibody” is an antibody molecule in which (a) the constant region, or a portion thereof, is altered, replaced or exchanged so that the antigen binding site (variable region) is linked to a constant region of a different or altered class, effector function and/or species, or an entirely different molecule which confers new properties to the chimeric antibody, e.g., an enzyme, toxin, hormone, growth factor, drug, etc.; or (b) the variable region, or a portion thereof, is altered, replaced or exchanged with a variable region having a different or altered antigen specificity.


[0104] Identification of Ovarian Cancer-Associated Sequences


[0105] In one aspect, the expression levels of genes are determined in different patient samples for which diagnosis information is desired, to provide expression profiles. An expression profile of a particular sample is essentially a “fingerprint” of the state of the sample; while two states may have any particular gene similarly expressed, the evaluation of a number of genes simultaneously allows the generation of a gene expression profile that is characteristic of the state of the cell. That is, normal tissue (e.g., normal ovarian or other tissue) may be distinguished from cancerous or metastatic cancerous tissue of the ovarian, or ovarian cancer tissue or metastatic ovarian cancerous tissue can be compared with tissue samples of ovarian and other tissues from surviving cancer patients. By comparing expression profiles of tissue in known different ovarian cancer states, information regarding which genes are important (including both up- and down-regulation of genes) in each of these states is obtained. Molecular profiling may distinguish subtypes of a currently collective disease designation, e.g., different forms of a cancer.


[0106] The identification of sequences that are differentially expressed in ovarian cancer versus non-ovarian cancer tissue allows the use of this information in a number of ways. For example, a particular treatment regime may be evaluated: does a chemotherapeutic drug act to down-regulate ovarian cancer, and thus tumor growth or recurrence, in a particular patient. Alternatively, does existing treatment induce expression of a target. Similarly, diagnosis and treatment outcomes may be done or confirmed by comparing patient samples with the known expression profiles. Metastatic tissue can also be analyzed to determine the stage of ovarian cancer in the tissue or origin of the primary tumor. Furthermore, these gene expression profiles (or individual genes) allow screening of drug candidates with an eye to mimicking or altering a particular expression profile; e.g., screening can be done for drugs that suppress the ovarian cancer expression profile. This may be done by making biochips comprising sets of the important ovarian cancer genes, which can then be used in these screens. These methods can also be based on evaluating protein expression; that is, protein expression levels of the ovarian cancer proteins can be evaluated for diagnostic purposes or to screen candidate agents. In addition, the ovarian cancer nucleic acid sequences can be administered for gene therapy purposes, including the administration of antisense or RNAi nucleic acids, or the ovarian cancer proteins (including antibodies and other modulators thereof) administered as therapeutic drugs.


[0107] Thus the present invention provides nucleic acid and protein sequences that are differentially expressed in ovarian cancer relative to normal tissues and/or non-malignant tissues, herein termed “ovarian cancer sequences.” As outlined below, ovarian cancer sequences include those that are up-regulated (e.g., expressed at a higher level) in ovarian cancer, as well as those that are down-regulated (e.g., expressed at a lower level). In a preferred embodiment, the ovarian cancer sequences are from humans; however, as will be appreciated by those in the art, ovarian cancer sequences from other organisms may be useful in animal models of disease and drug evaluation; thus, other ovarian cancer sequences are provided, from vertebrates, including mammals, including rodents (rats, mice, hamsters, guinea pigs, etc.), primates, farm animals (including sheep, goats, pigs, cows, horses, etc.) and pets (e.g., dogs, cats, etc.). Ovarian cancer sequences, e.g., counterpart genes, from other organisms may be obtained using the techniques outlined below.


[0108] Ovarian cancer sequences can include both nucleic acid and amino acid sequences. Ovarian cancer nucleic acid sequences are useful in a variety of applications, including diagnostic applications, which will detect naturally occurring nucleic acids. Screening applications; e.g., biochips comprising nucleic acid probes or PCR microtiter plates with selected probes to the ovarian cancer sequences, are also provided.


[0109] An ovarian cancer sequence can be initially identified by substantial nucleic acid and/or amino acid sequence homology to the ovarian cancer sequences outlined herein. Such homology can be based upon the overall nucleic acid or amino acid sequence, and is generally determined as outlined below, using either homology programs or hybridization conditions.


[0110] For identifying ovarian cancer-associated sequences, the ovarian cancer screen typically includes comparing genes identified in different tissues, e.g., normal and cancerous tissues, or tumor tissue samples from patients who have metastatic disease vs. non metastatic tissue. Other suitable tissue comparisons include comparing ovarian cancer samples with metastatic cancer samples from other cancers, such as lung, ovarian, gastrointestinal cancers, etc. Samples of different stages of ovarian cancer, e.g., survivor tissue, drug resistant states, and tissue undergoing metastasis, are applied to biochips comprising nucleic acid probes. The samples are first microdissected, if applicable, and treated for the preparation of mRNA. Suitable biochips are commercially available, e.g., from Affymetrix. Gene expression profiles as described herein are generated and the data analyzed.


[0111] In one embodiment, the genes showing changes in expression as between normal and disease states are compared to genes expressed in other normal tissues, preferably normal ovarian, but also including, and not limited to, lung, heart, brain, liver, ovarian, kidney, muscle, colon, small intestine, large intestine, spleen, bone, and/or placenta. In a preferred embodiment, those genes identified during the ovarian cancer screen that are expressed in any significant amount in other tissues are removed from the profile, although in some embodiments, expression in non-essential tissues may be tolerated. That is, when screening for drugs, it is usually preferable that the target be disease specific, to minimize possible side effects by interaction with target present in other organs.


[0112] In a preferred embodiment, ovarian cancer sequences are those that are up-regulated in ovarian cancer; that is, the expression of these genes is higher in the ovarian cancer tissue as compared to non-cancerous tissue. “Up-regulation” as used herein often means at least about a two-fold change, preferably at least about a three fold change, with at least about five-fold or higher being preferred. Other embodiments are directed to sequences up regulated in non-malignant conditions relative to normal.


[0113] Unigene cluster identification numbers and accession numbers herein refer to the GenBank sequence database and the sequences of the accession numbers are hereby expressly incorporated by reference. GenBank is known in the art, see, e.g., Benson, et al. (1998) i Nucl. Acids Res. 26:1-7; and http://www.ncbi.nlm.nih.gov/. Sequences are also available in other databases, e.g., European Molecular Biology Laboratory (EMBL) and DNA Database of Japan (DDBJ). In some situations, the sequences may be derived from assembly of available sequences or be predicted from genomic DNA using exon prediction algorithms, e.g., FGENESH. See Salamov and Solovyev (2000) Genome Res. 10:516-522. In other situations, sequences have been derived from cloning and sequencing of isolated nucleic acids.


[0114] In another preferred embodiment, ovarian cancer sequences are those that are down-regulated in ovarian cancer; that is, the expression of these genes is lower in ovarian cancer tissue as compared to non-cancerous tissue. “Down-regulation” as used herein often means at least about a two-fold change, preferably at least about a three-fold change, with at least about five-fold or higher being preferred.


[0115] Informatics


[0116] The ability to identify genes that are over or under expressed in ovarian cancer can additionally provide high-resolution, high-sensitivity datasets which can be used in the areas of diagnostics, therapeutics, drug development, pharmacogenetics, protein structure, biosensor development, and other related areas. Expression profiles can be used in diagnostic or prognostic evaluation of patients with ovarian cancer. Subeellular toxicological information can be generated to better direct drug structure and activity correlation (see Anderson (Jun. 11-12, 1998) Pharmaceutical Proteomics: Targets, Mechanism, and Function, paper presented at the IBC Proteomics conference, Coronado, Calif.) or in a biological sensor device to predict the likely toxicological effect of chemical exposures and likely tolerable exposure thresholds (see U.S. Pat. No. 5,811,231). Similar advantages accrue from datasets relevant to other biomolecules and bioactive agents (e.g., nucleic acids, saccharides, lipids, drugs, and the like).


[0117] Thus, in another embodiment, the present invention provides a database that includes at least one set of assay data. The data contained in the database is acquired, e.g., using array analysis either singly or in a library format. The database can be in a form in which data can be maintained and transmitted, but is preferably an electronic database, and can be maintained on any electronic device allowing for the storage of and access to the database, such as a personal computer, but is preferably distributed on a wide area network, such as the World Wide Web.


[0118] The focus of the present section on databases that include peptide sequence data is for clarity of illustration only. It will be apparent to those of skill in the art that similar databases can be assembled for any assay data acquired using an assay of the invention.


[0119] The compositions and methods for identifying and/or quantitating the relative and/or absolute abundance of a variety of molecular and macromolecular species from a biological sample undergoing ovarian cancer, e.g., the identification of ovarian cancer-associated sequences described herein, provide an abundance of information which can be correlated with pathological conditions, predisposition to disease, drug testing, therapeutic monitoring, gene-disease causal linkages, identification of correlates of immunity and physiological status, and outcome data, among others. Although data generated from the assays of the invention is suited for manual review and analysis, in a preferred embodiment, data processing using high-speed computers is utilized.


[0120] An array of methods for indexing and retrieving biomolecular information is known in the art. For example, U.S. Pat. Nos. 6,023,659 and 5,966,712 disclose a relational database system for storing biomolecular sequence information in a manner that allows sequences to be catalogued and searched according to one or more protein function hierarchies. U.S. Pat. No. 5,953,727 discloses a relational database having sequence records containing information in a format that allows a collection of partial-length DNA sequences to be catalogued and searched according to association with one or more sequencing projects for obtaining full-length sequences from the collection of partial length sequences. U.S. Pat. No. 5,706,498 discloses a gene database retrieval system for making a retrieval of a gene sequence similar to a sequence data item in a gene database based on the degree of similarity between a key sequence and a target sequence. U.S. Pat. No. 5,538,897 discloses a method using mass spectroscopy fragmentation patterns of peptides to identify amino acid sequences in computer databases by comparison of predicted mass spectra with experimentally-derived mass spectra using a closeness-of-fit measure. U.S. Pat. No. 5,926,818 discloses a multi-dimensional database comprising a functionality for multi-dimensional data analysis described as on-line analytical processing (OLAP), which entails the consolidation of projected and actual data according to more than one consolidation path or dimension. U.S. Pat. No. 5,295,261 reports a hybrid database structure in which the fields of each database record are divided into two classes, navigational and informational data, with navigational fields stored in a hierarchical topological map which can be viewed as a tree structure or as the merger of two or more such tree structures.


[0121] Fundamentals of bioinformatics are provided, e.g., in Mount, et al. (2001) Bioinformatics: Sequence and Genome Analysis CSH Press, NY; Durbin, et al. (eds. 1999) Biological Sequence Analysis: Probabilistic Models of Proteins and Nucleic Acids Cambridge Univ. Press; Baxevanis and Oeullette (eds. 1998) Bioinformatics: A Practical Guide to the Analysis of Genes and Proteins (2d ed.) Wiley-Liss; Rashidi and Buehler (1999) Bioinformatics: Basic Applications in Biological Science and Medicine CRC Press; Setubal, et al. (eds 1997) Introduction to Computational Molecular Biology Brooks/Cole; Misener and Krawetz (eds. 2000) Bioinformatics: Methods and Protocols Humana Press; Higgins and Taylor (eds. 2000) Bioinformatics: Sequence, Structure, and Databanks: A Practical Approach Oxford Univ. Press; Brown (2001) Bioinformatics: A Biologist's Guide to Biocomputing and the Internet Eaton Pub.; Han and Kamber (2000) Data Mining: Concepts and Techniques Kaufmann Pub.; and Waterman (1995) Introduction to Computational Biology: Maps, Sequences, and Genomes Chap and Hall.


[0122] The present invention provides a computer database comprising a computer and software for storing in computer-retrievable form assay data records cross-tabulated, e.g., with data specifying the source of the target-containing sample from which each sequence specificity record was obtained.


[0123] In an exemplary embodiment, at least one of the sources of target-containing sample is from a control tissue sample known to be free of pathological disorders. In a variation, at least one of the sources is a known pathological tissue specimen, e.g., a neoplastic lesion or another tissue specimen to be analyzed for ovarian cancer. In another variation, assay records cross-tabulate one or more of the following parameters for a target species in a sample: (1) a unique identification code, which can include, e.g., a target molecular structure and/or characteristic separation coordinate (e.g., electrophoretic or genomic position coordinates); (2) sample source; and (3) absolute and/or relative quantity of target species present in the sample.


[0124] The invention also provides for the storage and retrieval of a collection of target data in a computer data storage apparatus, which can include magnetic disks, optical disks, magneto-optical disks, DRAM, SRAM, SGRAM, SDRAM, RDRAM, DDR RAM, magnetic bubble memory devices, and other data storage devices, including CPU registers and on-CPU data storage arrays. Typically, the target data records are stored as a bit pattern in an array of magnetic domains on a magnetizable medium or as an array of charge states or transistor gate states, such as an array of cells in a DRAM device (e.g., each cell comprised of a transistor and a charge storage area, which may be on the transistor). In one embodiment, the invention provides such storage devices, and computer systems built therewith, comprising a bit pattern encoding a protein expression fingerprint record comprising unique identifiers for at least 10 target data records cross-tabulated with target source.


[0125] When the target is a peptide or nucleic acid, the invention preferably provides a method for identifying related peptide or nucleic acid sequences, comprising performing a computerized comparison between a peptide or nucleic acid sequence assay record stored in or retrieved from a computer storage device or database and at least one other sequence. The comparison can include a sequence analysis or comparison algorithm or computer program embodiment thereof (e.g., FASTA, TFASTA, GAP, BESTFIT) and/or the comparison may be of the relative amount of a peptide or nucleic acid sequence in a pool of sequences determined from a polypeptide or nucleic acid sample of a specimen.


[0126] The invention also preferably provides a magnetic disk, such as an IBM-compatible (DOS, Windows, Windows95/98/2000, Windows NT, OS/2) or other format (e.g., Linux, SunOS, Solaris, AIX, SCO Unix, VMS, MV, Macintosh, etc.) floppy diskette or hard (fixed, Winchester) disk drive, comprising a bit pattern encoding data from an assay of the invention in a file format suitable for retrieval and processing in a computerized sequence analysis, comparison, or relative quantitation method.


[0127] The invention also provides a network, comprising a plurality of computing devices linked via a data link, such as an Ethernet cable (coax or 10BaseT), telephone line, ISDN line, wireless network, optical fiber, or other suitable signal transmission medium, whereby at least one network device (e.g., computer, disk array, etc.) comprises a pattern of magnetic domains (e.g., magnetic disk) and/or charge domains (e.g., an array of DRAM cells) composing a bit pattern encoding data acquired from an assay of the invention.


[0128] The invention also provides a method for transmitting assay data that includes generating an electronic signal on an electronic communications device, such as a modem, ISDN terminal adapter, DSL, cable modem, ATM switch, or the like, wherein the signal includes (in native or encrypted format) a bit pattern encoding data from an assay or a database comprising a plurality of assay results obtained by the method of the invention.


[0129] In a preferred embodiment, the invention provides a computer system for comparing a query target to a database containing an array of data structures, such as an assay result obtained by the method of the invention, and ranking database targets based on the degree of identity and gap weight to the target data. A central processor is preferably initialized to load and execute the computer program for alignment and/or comparison of the assay results. Data for a query target is entered into the central processor via an I/O device. Execution of the computer program results in the central processor retrieving the assay data from the data file, which comprises a binary description of an assay result.


[0130] The target data or record and the computer program can be transferred to secondary memory, which is typically random access memory (e.g., DRAM, SRAM, SGRAM, or SDRAM). Targets are ranked according to the degree of correspondence between a selected assay characteristic (e.g., binding to a selected affinity moiety) and the same characteristic of the query target and results are output via an I/O device. For example, a central processor can be a conventional computer (e.g., Intel Pentium, PowerPC, Alpha, PA-8000, SPARC, MIPS 4400, MIPS 10000, VAX, etc.); a program can be a commercial or public domain molecular biology software package (e.g., UWGCG Sequence Analysis Software, Darwin); a data file can be an optical or magnetic disk, a data server, a memory device (e.g., DRAM, SRAM, SGRAM, SDRAM, EPROM, bubble memory, flash memory, etc.); an I/O device can be a terminal comprising a video display and a keyboard, a modem, an ISDN terminal adapter, an Ethernet port, a punched card reader, a magnetic strip reader, or other suitable I/O device.


[0131] The invention also preferably provides the use of a computer system, e.g., which typically comprises one or more of: (1) a computer; (2) a stored bit pattern encoding a collection of peptide sequence specificity records obtained by methods of the inventions, which may be stored in the computer; (3) a comparison target, such as a query target; and (4) a program for alignment and comparison, typically with rank-ordering of comparison results on the basis of computed similarity values.


[0132] Characteristics of Ovarian Cancer-Associated Proteins


[0133] Ovarian cancer proteins of the present invention may be categorized as secreted proteins, transmembrane proteins, or intracellular proteins. In one embodiment, the ovarian cancer protein is an intracellular protein. Intracellular proteins may be found in the cytoplasm and/or in the nucleus. Intracellular proteins are involved in all aspects of cellular function and replication (including, e.g., signaling pathways); aberrant expression of such proteins often results in unregulated or disregulated cellular processes. See, e.g., Alberts, et al. (eds. 1994) Molecular Biology of the Cell (3d ed.) Garland. For example, many intracellular proteins have enzymatic activity such as protein kinase activity, protein phosphatase activity, protease activity, nucleotide cyclase activity, polymerase activity, and the like. Intracellular proteins can also serve as docking proteins that are involved in organizing complexes of proteins, or targeting proteins to various subcellular localizations, and are often involved in maintaining the structural integrity of organelles.


[0134] An increasingly appreciated concept in characterizing proteins is the presence in the proteins of one or more structural motifs for which defined functions have been attributed. In addition to the highly conserved sequences found in the enzymatic domain of proteins, highly conserved sequences have been identified in proteins that are involved in protein-protein interaction. For example, Src-homology-2 (SH2) domains bind tyrosine-phosphorylated targets in a sequence dependent manner. PTB domains, which are distinct from SH2 domains, also bind tyrosine phosphorylated targets. SH3 domains bind to proline-rich targets. In addition, PH domains, tetratricopeptide repeats and WD domains to name only a few, have been shown to mediate protein-protein interactions. Some of these may also be involved in binding to phospholipids or other second messengers. As will be appreciated by one of ordinary skill in the art, these motifs can be identified on the basis of amino acid sequence; thus, an analysis of the sequence of proteins may provide insight into both the enzymatic potential of the molecule and/or molecules with which the protein may associate. One useful database is Pfam (protein families), which is a large collection of multiple sequence alignments and hidden Markov models covering many common protein domains. Versions are available via the internet from Washington University in St. Louis, the Sanger Center in England, and the Karolinska Institute in Sweden. See, e.g., Bateman, et al. (2000) Nuc. Acids Res. 28:263-266; Sonnhammer, et al. (1997) Proteins 28:405-420; Bateman, et al. (1999) Nuc. Acids Res. 27:260-262; and Sonnhammer, et al. (1998) Nuc. Acids Res. 26:320-322.


[0135] In another preferred embodiment, the ovarian cancer sequences are transmembrane proteins. Transmembrane proteins are molecules that span a phospholipid bilayer of a cell. They may have an intracellular domain, an extracellular domain, or both. The intracellular domains of such proteins may have a number of functions including those already described for intracellular proteins. For example, the intracellular domain may have enzymatic activity and/or may serve as a binding site for additional proteins. Frequently the intracellular domain of transmembrane proteins serves both roles. For example certain receptor tyrosine kinases have both protein kinase activity and SH2 domains. In addition, autophosphorylation of tyrosines on the receptor molecule itself, creates binding sites for additional SH2 domain containing proteins.


[0136] Transmembrane proteins may contain from one to many transmembrane domains. For example, receptor tyrosine kinases, certain cytokine receptors, receptor guanylyl cyclases and receptor serine/threonine protein kinases contain a single transmembrane domain. However, various other proteins including channels and adenylyl cyclases contain numerous transmembrane domains. Many important cell surface receptors such as G protein coupled receptors (GPCRs) are classified as “seven transmembrane domain” proteins, as they contain 7 membrane spanning regions. Characteristics of transmembrane domains include approximately 17 consecutive hydrophobic amino acids that may be followed by charged amino acids. Therefore, upon analysis of the amino acid sequence of a particular protein, the localization and number of transmembrane domains within the protein may be predicted (see, e.g., PSORT web site http://psort.nibb.ac.jp/). Important transmembrane protein receptors include, but are not limited to the insulin receptor, insulin-like growth factor receptor, human growth hormone receptor, glucose transporters, transferrin receptor, epidermal growth factor receptor, low density lipoprotein receptor, epidermal growth factor receptor, leptin receptor, interleukin receptors, e.g., IL-1 receptor, IL-2 receptor, etc.


[0137] The extracellular domains of transmembrane proteins are diverse; however, conserved motifs are found repeatedly among various extracellular domains. Conserved structure and/or functions have been ascribed to different extracellular motifs. Many extracellular domains are involved in binding to other molecules. In one aspect, extracellular domains are found on receptors. Factors that bind the receptor domain include circulating ligands, which may be peptides, proteins, or small molecules such as adenosine and the like. For example, growth factors such as EGF, FGF, and PDGF are circulating growth factors that bind to their cognate receptors to initiate a variety of cellular responses. Other factors include cytokines, mitogenic factors, neurotrophic factors and the like. Extracellular domains also bind to cell-associated molecules, or may be processed or shed to the blood stream. In this respect, they can mediate cell-cell interactions. Cell-associated ligands can be tethered to the cell, e.g., via a glycosylphosphatidylinositol (GPI) anchor, or may themselves be transmembrane proteins. Extracellular domains also associate with the extracellular matrix and contribute to the maintenance of the cell structure.


[0138] Ovarian cancer proteins that are transmembrane are particularly preferred in the present invention as they are readily accessible targets for immunotherapeutics, as are described herein. In addition, as outlined below, transmembrane proteins can be also useful in imaging modalities. Antibodies may be used to label such readily accessible proteins in situ. Alternatively, antibodies can also label intracellular proteins, in which case samples are typically permeablized to provide access to intracellular proteins. In addition, some membrane proteins can be processed to release a soluble protein, or to expose a residual fragment. Released soluble proteins may be useful diagnostic markers, processed residual protein fragments may be useful ovarian markers of disease.


[0139] It will also be appreciated by those in the art that a transmembrane protein can be made soluble by removing transmembrane sequences, e.g., through recombinant methods. Furthermore, transmembrane proteins that have been made soluble can be made to be secreted through recombinant means by adding an appropriate signal sequence.


[0140] In another embodiment, the ovarian cancer proteins are secreted proteins; the secretion of which can be either constitutive or regulated. These proteins may have a signal peptide or signal sequence that targets the molecule to the secretory pathway. Secreted proteins are involved in numerous physiological events; e.g., if circulating, they often serve to transmit signals to various other cell types. The secreted protein may function in an autocrine manner (acting on the cell that secreted the factor), a paracrine manner (acting on cells in close proximity to the cell that secreted the factor), an endocrine manner (acting on cells at a distance, e.g., secretion into the blood stream), or exocrine (secretion, e.g., through a duct or to an adjacent epithelial surface as sweat glands, sebaceous glands, pancreatic ducts, lacrimal glands, mammary glands, wax producing glands of the ear, etc.). Thus, secreted molecules often find use in modulating or altering numerous aspects of physiology. Ovarian cancer proteins that are secreted proteins are particularly preferred as good diagnostic markers, e.g., for blood, plasma, serum, or stool tests. Those which are enzymes may be antibody or small molecule therapeutic targets. Others may be useful as vaccine targets, e.g., via CTL mechanisms, as protein or DNA vaccines.


[0141] Use of Ovarian Cancer Nucleic Acids


[0142] As described above, ovarian cancer sequence is initially identified by substantial nucleic acid and/or amino acid sequence homology or linkage to the ovarian cancer sequences outlined herein. Such homology can be based upon the overall nucleic acid or amino acid sequence, and is generally determined as outlined below, using either homology programs or hybridization conditions. Typically, linked sequences on a mRNA are found on the same molecule.


[0143] The ovarian cancer nucleic acid sequences of the invention, e.g., in Table 1-20, can be fragments of larger genes, e.g., they are nucleic acid segments. “Genes” in this context includes coding regions, non-coding regions, and mixtures of coding and non-coding regions. Accordingly, as will be appreciated by those in the art, using the sequences provided herein, extended sequences, in either direction, of the ovarian cancer genes can be obtained, using techniques well known in the art for cloning either longer sequences or the full length sequences; see Ausubel, et al., supra. Much can be done by informatics and many sequences can be clustered to include multiple sequences corresponding to a single gene, e.g., systems such as UniGene (see, http://www.ncbi.nlm.nih.gov/UniGene/).


[0144] Once the ovarian cancer nucleic acid is identified, it can be cloned and, if necessary, its constituent parts recombined to form the entire ovarian cancer nucleic acid coding regions or the entire mRNA sequence. Once isolated from its natural source, e.g., contained within a plasmid or other vector or excised as a linear nucleic acid segment, the recombinant ovarian cancer nucleic acid can be further-used as a probe to identify and isolate other ovarian cancer nucleic acids, e.g., extended coding regions. It can also be used as a “precursor” nucleic acid to make modified or variant ovarian cancer nucleic acids and proteins.


[0145] The ovarian cancer nucleic acids of the present invention are useful in several ways. In a first embodiment, nucleic acid probes to the ovarian cancer nucleic acids are made and attached to biochips to be used in screening and diagnostic methods, as outlined below, or for administration, e.g., for gene therapy, vaccine, RNAi, and/or antisense applications. Alternatively, the ovarian cancer nucleic acids that include coding regions of ovarian cancer proteins can be put into expression vectors for the expression of ovarian cancer proteins, again for screening purposes or for administration to a patient.


[0146] In a preferred embodiment, nucleic acid probes to ovarian cancer nucleic acids (both the nucleic acid sequences outlined in the figures and/or the complements thereof) are made. The nucleic acid probes attached to the biochip are designed to be substantially complementary to the ovarian cancer nucleic acids, e.g., the target sequence (either the target sequence of the sample or to other probe sequences, e.g., in sandwich assays), such that hybridization of the target sequence and the probes of the present invention occurs. As outlined below, this complementarity need not be perfect; there may be any number of base pair mismatches which will interfere with hybridization between the target sequence and the single stranded nucleic acids of the present invention. However, if the number of mutations is so great that no hybridization can occur under even the least stringent of hybridization conditions, the sequence is not a complementary target sequence. Thus, by “substantially complementary” herein is meant that the probes are sufficiently complementary to the target sequences to hybridize under normal reaction conditions, particularly high stringency conditions, as outlined herein.


[0147] A nucleic acid probe is generally single stranded but can be partially single and partially double stranded. The strandedness of the probe is dictated by the structure, composition, and properties of the target sequence. In general, the nucleic acid probes range from about 8 to about 100 bases long, with from about 10 to about 80 bases being preferred, and from about 30 to about 50 bases being particularly preferred. That is, generally whole genes are not used. In some embodiments, much longer nucleic acids can be used, up to hundreds of bases.


[0148] In a preferred embodiment, more than one probe per sequence is used, with either overlapping probes or probes to different sections of the target being used. That is, two, three, four or more probes, with three being preferred, are used to build in a redundancy for a particular target. The probes can be overlapping (e.g., have some sequence in common), or separate. In some cases, PCR primers may be used to amplify signal for higher sensitivity.


[0149] As will be appreciated by those in the art, nucleic acids can be attached or immobilized to a solid support in a wide variety of ways. By “immobilized” and grammatical equivalents herein is meant the association or binding between the nucleic acid probe and the solid support is sufficient to be stable under the conditions of binding, washing, analysis, and removal as outlined below. The binding can typically be covalent or non-covalent. By “non-covalent binding” and grammatical equivalents herein is meant one or more of electrostatic, hydrophilic, and hydrophobic interactions. Included in non-covalent binding is the covalent attachment of a molecule, such as, streptavidin to the support and the non-covalent binding of the biotinylated probe to the streptavidin. By “covalent binding” and grammatical equivalents herein is meant that the two moieties, the solid support and the probe, are attached by at least one bond, including sigma bonds, pi bonds and coordination bonds. Covalent bonds can be formed directly between the probe and the solid support or can be formed by a cross linker or by inclusion of a specific reactive group on either the solid support or the probe or both molecules. Immobilization may also involve a combination of covalent and non-covalent interactions.


[0150] In general, the probes are attached to the biochip in a wide variety of ways, as will be appreciated by those in the art. As described herein, the nucleic acids can either be synthesized first, with subsequent attachment to the biochip, or can be directly synthesized on the biochip.


[0151] The biochip comprises a suitable solid substrate. By “substrate” or “solid support” or other grammatical equivalents herein is meant a material that can be modified to contain discrete individual sites appropriate for the attachment or association of the nucleic acid probes and is amenable to at least one detection method. As will be appreciated by those in the art, the number of possible substrates are very large, and include, but are not limited to, glass and modified or functionalized glass, plastics (including acrylics, polystyrene and copolymers of styrene and other materials, polypropylene, polyethylene, polybutylene, polyurethanes, TeflonJ, etc.), polysaccharides, nylon or nitrocellulose, resins, silica or silica-based materials including silicon and modified silicon, carbon, metals, inorganic glasses, plastics, etc. In general, the substrates allow optical detection and do not appreciably fluoresce. See, e.g., WO0055627 Reusable Low Fluorescent Plastic Biochip.


[0152] Generally the substrate is planar, although as will be appreciated by those in the art, other configurations of substrates may be used as well. For example, the probes may be placed on the inside surface of a tube, for flow-through sample analysis to minimize sample volume. Similarly, the substrate may be flexible, such as a flexible foam, including closed cell foams made of particular plastics.


[0153] In a preferred embodiment, the surface of the biochip and the probe may be derivatized with chemical functional groups for subsequent attachment of the two. Thus, e.g., the biochip is derivatized with a chemical functional group including, but not limited to, amino groups, carboxyl groups, oxo groups and thiol groups, with amino groups being particularly preferred. Using these functional groups, the probes can be attached using functional groups on the probes. For example, nucleic acids containing amino groups can be attached to surfaces comprising amino groups, e.g., using linkers as are known in the art; e.g., homo-or hetero-bifunctional linkers as are well known (see 1994 Pierce Chemical Company catalog, technical section on cross-linkers, pages 155-200). In addition, in some cases, additional linkers, such as alkyl groups (including substituted and heteroalkyl groups) may be used.


[0154] In this embodiment, oligonucleotides are synthesized as is known in the art, and then attached to the surface of the solid support. As will be appreciated by those skilled in the art, either the 5′ or 3′ terminus may be attached to the solid support, or attachment may be via an internal nucleoside.


[0155] In another embodiment, the immobilization to the solid support may be very strong, yet non-covalent. For example, biotinylated oligonucleotides can be made, which bind to surfaces covalently coated with streptavidin, resulting in attachment.


[0156] Alternatively, the oligonucleotides may be synthesized on the surface, as is known in the art. For example, photoactivation techniques utilizing photopolymerization compounds and techniques are used. In a preferred embodiment, the nucleic acids can be synthesized in situ, using well known photolithographic techniques, such as those described in WO 95/25116; WO 95/35505; U.S. Pat. Nos. 5,700,637 and 5,445,934; and references cited within, all of which are expressly incorporated by reference; these methods of attachment form the basis of the Affymetrix GeneChip™ technology.


[0157] Often, amplification-based assays are performed to measure the expression level of ovarian cancer-associated sequences. These assays are typically performed in conjunction with reverse transcription. In such assays, an ovarian cancer-associated nucleic acid sequence acts as a template in an amplification reaction (e.g., Polymerase Chain Reaction, or PCR). In a quantitative amplification, the amount of amplification product will be proportional to the amount of template in the original sample. Comparison to appropriate controls provides a measure of the amount of ovarian cancer-associated RNA. Methods of quantitative amplification are well known to those of skill in the art. Detailed protocols for quantitative PCR are available. See, e.g., Innis, et al.(1990) PCR Protocols: A Guide to Methods and Applications Academic Press.


[0158] In some embodiments, a TaqMan based assay is used to measure expression. TaqMan based assays use a fluorogenic oligonucleotide probe that contains a 5′ fluorescent dye and a 3′0 quenching agent. The probe hybridizes to a PCR product, but cannot itself be extended due to a blocking agent at the 3′0 end. When the PCR product is amplified in subsequent cycles, the 5′ nuclease activity of the polymerase, e.g., AmpliTaq, results in the cleavage of the TaqMan probe. This cleavage separates the 5′ fluorescent dye and the 3′ quenching agent, thereby resulting in an increase in fluorescence as a function of amplification (see, e.g., literature provided by Perkin-Elmer, e.g., www2.perkin-elmer.com).


[0159] Other suitable amplification methods include, but are not limited to, ligase chain reaction (LCR; see Wu and Wallace (1989) Genomics 4:560-569; Landegren, et al. (1988) Science 241:1077-1980; and Barringer, et al. (1990) Gene 89:117-122), transcription amplification (Kwoh, et al. (1989) Proc. Nat'l Acad. Sci. USA 86:1173-1177), self-sustained sequence replication (Guatelli, et al. (1990) Proc. Nat'l Acad. Sci. USA 87:1874-1878), dot PCR, linker adapter PCR, etc.


[0160] Expression of Ovarian Cancer Proteins from Nucleic Acids


[0161] In a preferred embodiment, ovarian cancer nucleic acids, e.g., encoding ovarian cancer proteins are used to make a variety of expression vectors to express ovarian cancer proteins which can then be used in screening assays, as described below. Expression vectors and recombinant DNA technology are well known and are used to express proteins. See, e.g., Ausubel, supra; and Fernandez and Hoeffler (eds. 1999) Gene Expression Systems Academic Press. The expression vectors may be either self-replicating extrachromosomal vectors or vectors which integrate into a host genome. Generally, these expression vectors include transcriptional and translational regulatory nucleic acid operably linked to the nucleic acid encoding the ovarian cancer protein. The term “control sequences” refers to DNA sequences used for the expression of an operably linked coding sequence in a particular host organism. Control sequences that are suitable for prokaryotes, e.g., include a promoter, optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.


[0162] Nucleic acid is “operably linked” when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a pre-sequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a pre-protein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation; and two sequences may be operably linked when they are physically part of the same polymer. Generally, “operably linked” means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is typically accomplished by ligation at convenient restriction sites. If such sites do not exist, synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice. Transcriptional and translational regulatory nucleic acid will generally be appropriate to the host cell used to express the ovarian cancer protein. Numerous types of appropriate expression vectors, and suitable regulatory sequences are known in the art for a variety of host cells.


[0163] In general, transcriptional and translational regulatory sequences may include, but are not limited to, promoter sequences, ribosomal binding sites, transcriptional start and stop sequences, translational start and stop sequences, and enhancer or activator sequences. In a preferred embodiment, the regulatory sequences include a promoter and transcriptional start and stop sequences.


[0164] Promoter sequences typically encode constitutive or inducible promoters. The promoters may be naturally occurring promoters or hybrid promoters. Hybrid promoters, which combine elements of more than one promoter, are also known in the art, and are useful in the present invention.


[0165] In addition, an expression vector may comprise additional elements. For example, the expression vector may have two replication systems, thus allowing it to be maintained in two organisms, e.g., in mammalian or insect cells for expression and in a procaryotic host for cloning and amplification. Furthermore, for integrating expression vectors, the expression vector contains at least one sequence homologous to the host cell genome, and preferably two homologous sequences which flank the expression construct. The integrating vector may be directed to a specific locus in the host cell by selecting the appropriate homologous sequence for inclusion in the vector. Constructs for integrating vectors are available. See, e.g., Fernandez and Hoeffler, supra.


[0166] In addition, in a preferred embodiment, the expression vector contains a selectable marker gene to allow the selection of transformed host cells. Selection genes are well known in the art and will vary with the host cell used.


[0167] The ovarian cancer proteins of the present invention are produced by culturing a host cell transformed with an expression vector containing nucleic acid encoding an ovarian cancer protein, under the appropriate conditions to induce or cause expression of the ovarian cancer protein. Conditions appropriate for ovarian cancer protein expression will vary with the choice of the expression vector and the host cell, and will be easily ascertained by one skilled in the art through routine experimentation or optimization. For example, the use of constitutive promoters in the expression vector will require optimizing the growth and proliferation of the host cell, while the use of an inducible promoter requires the appropriate growth conditions for induction. In addition, in some embodiments, the timing of the harvest is important. For example, the baculovirus systems used in insect cell expression are lytic viruses, and thus harvest time selection can be crucial for product yield.


[0168] Appropriate host cells include yeast, bacteria, archaebacteria, fungi, and insect and animal cells, including mammalian cells. Of particular interest are Saccharomyces cerevisiae and other yeasts, E. coli, Bacillus subtilis, Sf9 cells, C129 cells, 293 cells, Neurospora, BHK, CHO, COS, HeLa cells, HUVEC (human umbilical vein endothelial cells), THP1 cells (a macrophage cell line) and various other human cells and cell lines.


[0169] In a preferred embodiment, the ovarian cancer proteins are expressed in mammalian cells. Mammalian expression systems are also known in the art, and include retroviral and adenoviral systems. One expression vector system is a retroviral vector system such as is generally described in PCT/US97/01019 and PCT/US97/01048, both of which are hereby expressly incorporated by reference. Of particular use as mammalian promoters are the promoters from mammalian viral genes, since the viral genes are often highly expressed and have a broad host range. Examples include the SV40 early promoter, mouse mammary tumor virus LTR promoter, adenovirus major late promoter, herpes simplex virus promoter, and the CMV promoter. See, e.g., Fernandez and Hoeffler, supra. Typically, transcription termination and polyadenylation sequences recognized by mammalian cells are regulatory regions located 3′ to the translation stop codon and thus, together with the promoter elements, flank the coding sequence. Examples of transcription terminator and polyadenylation signals include those derived form SV40.


[0170] The methods of introducing exogenous nucleic acid into mammalian hosts, as well as other hosts, is well known in the art, and will vary with the host cell used. Techniques include dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, viral infection, encapsulation of the polynucleotide(s) in liposomes, and direct microinjection of the DNA into nuclei.


[0171] In a preferred embodiment, ovarian cancer proteins are expressed in bacterial systems. Bacterial expression systems are well known in the art. Promoters from bacteriophage may also be used and are known in the art. In addition, synthetic promoters and hybrid promoters are also useful; e.g., the tac promoter is a hybrid of the trp and lac promoter sequences. Furthermore, a bacterial promoter can include naturally occurring promoters of non-bacterial origin that have the ability to bind bacterial RNA polymerase and initiate transcription. In addition to a functioning promoter sequence, an efficient ribosome binding site is desirable. The expression vector may also include a signal peptide sequence that provides for secretion of the ovarian cancer protein in bacteria. The protein is either secreted into the growth media (gram-positive bacteria) or into the periplasmic space, located between the inner and outer membrane of the cell (gram-negative bacteria). The bacterial expression vector may also include a selectable marker gene to allow for the selection of bacterial strains that have been transformed. Suitable selection genes include genes which render the bacteria resistant to drugs such as ampicillin, chloramphenicol, erythromycin, kanamycin, neomycin, and tetracycline. Selectable markers also include biosynthetic genes, such as those in the histidine, tryptophan, and leucine biosynthetic pathways. These components are assembled into expression vectors. Expression vectors for bacteria are well known in the art, and include vectors for Bacillus subtilis, E. coli, Streptococcus cremoris, and Streptococcus lividans, among others. See Fernandez and Hoeffler, supra. The bacterial expression vectors are transformed into bacterial host cells using techniques well known in the art, such as calcium chloride treatment, electroporation, and others.


[0172] In one embodiment, ovarian cancer proteins are produced in insect cells. Expression vectors for the transformation of insect cells, and in particular, baculovirus-based expression vectors, are well known in the art.


[0173] In a preferred embodiment, an ovarian cancer protein is produced in yeast cells. Yeast expression systems are well known in the art, and include expression vectors for Saccharomyces cerevisiae, Candida albicans and C. maltosa, Hansenula polymorpha, Kluyveromyces fragilis and K. lactis, Pichia guillerimondii and P. pastoris, Schizosaccharomyces pombe, and Yarrowia lipolytica.


[0174] The ovarian cancer protein may also be made as a fusion protein, using techniques well known in the art. Thus, e.g., for the creation of monoclonal antibodies, if the desired epitope is small, the ovarian cancer protein may be fused to a carrier protein to form an immunogen. Alternatively, the ovarian cancer protein may be made as a fusion protein to increase expression, or for other reasons. For example, when the ovarian cancer protein is an ovarian cancer peptide, the nucleic acid encoding the peptide may be linked to other nucleic acid for expression purposes.


[0175] In a preferred embodiment, the ovarian cancer protein is purified or isolated after expression. Ovarian cancer proteins may be isolated or purified in a variety of ways known to those skilled in the art depending on what other components are present in the sample. Standard purification methods include electrophoretic, molecular, immunological and chromatographic techniques, including ion exchange, hydrophobic, affinity, and reverse-phase HPLC chromatography, and chromatofocusing. For example, the ovarian cancer protein may be purified using a standard anti-ovarian cancer protein antibody column. Ultrafiltration and diafiltration techniques, in conjunction with protein concentration, are also useful. For general guidance in suitable purification techniques, see Scopes (1982) Protein Purification Springer-Verlag. The degree of purification necessary will vary depending on the use of the ovarian cancer protein. In some instances no purification will be necessary.


[0176] Once expressed and purified if necessary, the ovarian cancer proteins and nucleic acids are useful in a number of applications. They may be used as immunoselection reagents, as vaccine reagents, as screening agents, etc.


[0177] Variants of Ovarian Cancer Proteins


[0178] In one embodiment, the ovarian cancer proteins are derivative or variant ovarian cancer proteins as compared to the wild-type sequence. That is, as outlined more fully below, the derivative ovarian cancer peptide will often contain at least one amino acid substitution, deletion or insertion, with amino acid substitutions being particularly preferred. The amino acid substitution, insertion, or deletion may occur at most any residue within the ovarian cancer peptide.


[0179] Also included within one embodiment of ovarian cancer proteins of the present invention are amino acid sequence variants. These variants typically fall into one or more of three classes: substitutional, insertional or deletional variants. These variants ordinarily are prepared by site specific mutagenesis of nucleotides in the DNA encoding the ovarian cancer protein, using cassette or PCR mutagenesis or other techniques well known in the art, to produce DNA encoding the variant, and thereafter expressing the DNA in recombinant cell culture as outlined above. However, variant ovarian cancer protein fragments having up to about 100-150 residues may be prepared by in vitro synthesis using established techniques. Amino acid sequence variants are characterized by the predetermined nature of the variation, a feature that sets them apart from naturally occurring allelic or interspecies variation of the ovarian cancer protein amino acid sequence. The variants typically exhibit the same qualitative biological activity as the naturally occurring analogue, although variants can also be selected which have modified characteristics as will be more fully outlined below.


[0180] While the site or region for introducing an amino acid sequence variation is predetermined, the mutation per se need not be predetermined. For example, in order to optimize the performance of a mutation at a given site, random mutagenesis may be conducted at the target codon or region and the expressed ovarian cancer variants screened for the optimal combination of desired activity. Techniques for making substitution mutations at predetermined sites in DNA having a known sequence are well known, e.g., M13 primer mutagenesis and PCR mutagenesis. Screening of the mutants is done using assays of ovarian cancer protein activities.


[0181] Amino acid substitutions are typically of single residues; insertions usually will be on the order of from about 1 to 20 amino acids, although considerably larger insertions may be tolerated. Deletions range from about 1 to about 20 residues, although in some cases deletions may be much larger.


[0182] Substitutions, deletions, insertions or any combination thereof may be used to arrive at a final derivative. Generally these changes are done on a few amino acids to minimize the alteration of the molecule. However, larger changes may be tolerated in certain circumstances. When small alterations in the characteristics of the ovarian cancer protein are desired, substitutions are generally made in accordance with the amino acid substitution relationships provided in the definition section.


[0183] The variants typically exhibit the same qualitative biological activity and will elicit the same immune response as the naturally-occurring analog, although variants also are selected to modify the characteristics of the ovarian cancer proteins as needed. Alternatively, the variant may be designed such that the biological activity of the ovarian cancer protein is altered. For example, glycosylation sites may be altered or removed.


[0184] Substantial changes in function or immunological identity are made by selecting substitutions that are less conservative than those described above. For example, substitutions may be made which more significantly affect: the structure of the polypeptide backbone in the area of the alteration, for example the alpha-helical or beta-sheet structure; the charge or hydrophobicity of the molecule at the target site; or the bulk of the side chain. The substitutions which in general are expected to produce the greatest changes in the polypeptide's properties are those in which (a) a hydrophilic residue, e.g., serine or threonine is substituted for (or by) a hydrophobic residue, e.g., leucine, isoleucine, phenylalanine, valine, or alanine; (b) a cysteine or proline is substituted for (or by) any other residue; (c) a residue having an electropositive side chain, e.g., lysine, arginine, or histidine, is substituted for (or by) an electronegative residue, e.g., glutamic or aspartic acid; (d) a residue having a bulky side chain, e.g., phenylalanine, is substituted for (or by) one not having a side chain, e.g., glycine; or (e) a proline residue is incorporated or substituted, which changes the degree of rotational freedom of the peptidyl bond.


[0185] Covalent modifications of ovarian cancer polypeptides are included within the scope of this invention. One type of covalent modification includes reacting targeted amino acid residues of an ovarian cancer polypeptide with an organic derivatizing agent that is capable of reacting with selected side chains or the N-or C-terminal residues of an ovarian cancer polypeptide. Derivatization with bifunctional agents is useful, for instance, for crosslinking ovarian cancer polypeptides to a water-insoluble support matrix or surface for use in the method for purifying anti-ovarian cancer polypeptide antibodies or screening assays, as is more fully described below. Commonly used crosslinking agents include, e.g., 1,1-bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, e.g., esters with 4-azidosalicylic acid, homobifunctional imidoesters, including disuccinimidyl esters such as 3,3′-dithiobis(succinimidylpropionate), bifunctional maleimides such as bis-N-maleimido-1,8-octane and agents such as methyl-3-((p-azidophenyl)dithio)propioimidate.


[0186] Other modifications include deamidation of glutamine and asparagine residues to the corresponding glutamic and aspartic acid residues, respectively, hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of serine, threonine, or tyrosine residues, methylation of the amino groups of the lysine, arginine, and histidine side chains (e.g., pp. 79-86, Creighton (1983) Proteins: Structure and Molecular Properties Freeman), acetylation of the N-terminal amine, and amidation of a C-terminal carboxyl group.


[0187] Another type of covalent modification of the ovarian cancer polypeptide included within the scope of this invention comprises altering the native glycosylation pattern of the polypeptide. “Altering the native glycosylation pattern” is intended for purposes herein to mean deleting one or more carbohydrate moieties found in native sequence ovarian cancer polypeptide, and/or adding one or more glycosylation sites that are not present in the native sequence ovarian cancer polypeptide. Glycosylation patterns can be altered in many ways. For example the use of different cell types to express ovarian cancer-associated sequences can result in different glycosylation patterns.


[0188] Addition of glycosylation sites to ovarian cancer polypeptides may also be accomplished by altering the amino acid sequence thereof. The alteration may be made, e.g., by the addition of, or substitution by, one or more serine or threonine residues to the native sequence ovarian cancer polypeptide (for O-linked glycosylation sites). The ovarian cancer amino acid sequence may optionally be altered through changes at the DNA level, particularly by mutating the DNA encoding the ovarian cancer polypeptide at pre-selected bases such that codons are generated that will translate into the desired amino acids.


[0189] Another means of increasing the number of carbohydrate moieties on the ovarian cancer polypeptide is by chemical or enzymatic coupling of glycosides to the polypeptide. See, e.g., WO 87/05330, and pp. 259-306 in Aplin and Wriston (1981) CRC Crit. Rev. Biochem. CRC Press.


[0190] Removal of carbohydrate moieties present on the ovarian cancer polypeptide may be accomplished chemically or enzymatically or by mutational substitution of codons encoding for amino acid residues that serve as targets for glycosylation. Chemical deglycosylation techniques are applicable. See, e.g., Sojar and Bahl (1987) Arch. Biochem. Biophys. 259:52-57; and Edge, et al. (1981) Anal. Biochem. 118:131-137. Enzymatic cleavage of carbohydrate moieties on polypeptides can be achieved by the use of a variety of endo-and exo-glycosidases. See, e.g., Thotakura, et al. (1987) Meth. Enzymol., 138:350-359.


[0191] Another type of covalent modification of ovarian cancer comprises linking the ovarian cancer polypeptide to one of a variety of non-proteinaceous polymers, e.g., polyethylene glycol, polypropylene glycol, or polyoxyalkylene. See, e.g., U.S. Pat. Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192; or 4,179,337.


[0192] Ovarian cancer polypeptides of the present invention may also be modified in a way to form chimeric molecules, e.g., comprising an ovarian cancer polypeptide fused to another heterologous polypeptide or amino acid sequence. In one embodiment, such a chimeric molecule comprises a fusion of an ovarian cancer polypeptide with a tag polypeptide which provides an epitope to which an anti-tag antibody can selectively bind. The epitope tag is generally placed at the amino-or carboxyl-terminus of the ovarian cancer polypeptide. The presence of such epitope-tagged forms of an ovarian cancer polypeptide can be detected using an antibody against the tag polypeptide. Also, provision of the epitope tag enables the ovarian cancer polypeptide to be readily purified by affinity purification using an anti-tag antibody or another type of affinity matrix that binds to the epitope tag. In an alternative embodiment, the chimeric molecule may comprise a fusion of an ovarian cancer polypeptide with an immunoglobulin or a particular region of an immunoglobulin. For a bivalent form of the chimeric molecule, such a fusion could be to the Fc region of an IgG molecule.


[0193] Various tag polypeptides and their respective antibodies are well known in the art. Examples include poly-histidine (poly-his) or poly-histidine-glycine (poly-his-gly) tags; His6 and metal chelation tags, the flu HA tag polypeptide and its antibody 12CA5 (Field, et al. (1988) Mol. Cell. Biol. 8:2159-2165); the c-myc tag and the 8F9, 3C7, 6E10, G4, B7, and 9E10 antibodies thereto (Evan, et al. (1985) Mol. Cell. Biol. 5:3610-3616); and the Herpes Simplex virus glycoprotein D (gD) tag and its antibody (Paborsky, et al. (1990) Protein Engineering 3:547-553). Other tag polypeptides include, e.g., the Flag-peptide (Hopp, et al. (1988) BioTechnology 6:1204-1210); the KT3 epitope peptide (Martin, et al. (1992) Science 255:192-194); tubulin epitope peptide (Skinner, et al. (1991) J. Biol. Chem. 266:15163-15166); and the T7 gene 10 protein peptide tag (Lutz-Freyermuth et al. (1990) Proc. Nat'l Acad. Sci. USA 87:6393-6397).


[0194] Also included are other ovarian cancer proteins of the ovarian cancer family, and ovarian cancer proteins from other organisms, which are cloned and expressed as outlined below. Thus, probe or degenerate polymerase chain reaction (PCR) primer sequences may be used to find other related ovarian cancer proteins from humans or other organisms. As will be appreciated by those in the art, particularly useful probe and/or PCR primer sequences include the unique areas of the ovarian cancer nucleic acid sequence. As is generally known in the art, preferred PCR primers are from about 15 to about 35 nucleotides in length, with from about 20 to about 30 being preferred, and may contain inosine as needed. The conditions for the PCR reaction are well known in the art (e.g., Innis, PCR Protocols, supra).


[0195] Antibodies to Ovarian Cancer Proteins


[0196] In a preferred embodiment, when the ovarian cancer protein is to be used to generate antibodies, e.g., for immunotherapy or immunodiagnosis, the ovarian cancer protein should share at least one epitope or determinant with the full length protein. By “epitope” or “determinant” herein is typically meant a portion of a protein which will generate and/or bind an antibody or T-cell receptor in the context of MHC. Thus, in most instances, antibodies made to a smaller ovarian cancer protein will be able to bind to the full-length protein, particularly linear epitopes. In a preferred embodiment, the epitope is unique; that is, antibodies generated to a unique epitope show little or no cross-reactivity.


[0197] Methods of preparing polyclonal antibodies are known to the skilled artisan (e.g., Coligan, supra; and Harlow and Lane, supra). Polyclonal antibodies can be raised in a mammal, e.g., by one or more injections of an immunizing agent and, if desired, an adjuvant. Typically, the immunizing agent and/or adjuvant will be injected in the mammal by multiple subcutaneous or intraperitoneal injections. The immunizing agent may include a protein encoded by a nucleic acid of the figures or fragment thereof or a fusion protein thereof. It may be useful to conjugate the immunizing agent to a protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. Examples of adjuvants which may be employed include Freund's complete adjuvant and MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate). The immunization protocol may be selected by one skilled in the art without undue experimentation.


[0198] The antibodies may, alternatively, be monoclonal antibodies. Monoclonal antibodies may be prepared using hybridoma methods, such as those described by Kohler and Milstein (1975) Nature 256:495-497. In a hybridoma method, a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes may be immunized in vitro. The immunizing agent will typically include a polypeptide encoded by a nucleic acid of Tables 1-20 or fragment thereof, or a fusion protein thereof. Generally, either peripheral blood lymphocytes (“PBLs”) are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (e.g., pp. 59-103 in Goding (1986) Monoclonal Antibodies: Principles and Practice Academic Press). Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells may be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine (“HAT medium”), which substances prevent the growth of HGPRT-deficient cells.


[0199] In one embodiment, the antibodies are bispecific antibodies. Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens or that have binding specificities for two epitopes on the same antigen. In one embodiment, one of the binding specificities is for a protein encoded by a nucleic acid Table 1-20 or a fragment thereof, the other one is for any other antigen, and preferably for a cell-surface protein or receptor or receptor subunit, preferably one that is tumor specific. Alternatively, tetramer-type technology may create multivalent reagents.


[0200] In a preferred embodiment, the antibodies to ovarian cancer protein are capable of reducing or eliminating a biological function of an ovarian cancer protein, as is described below. That is, the addition of anti-ovarian cancer protein antibodies (either polyclonal or preferably monoclonal) to ovarian cancer tissue (or cells containing ovarian cancer) may reduce or eliminate the ovarian cancer. Generally, at least a 25% decrease in activity, growth, size or the like is preferred, with at least about 50% being particularly preferred and about a 95-100% decrease being especially preferred.


[0201] In a preferred embodiment the antibodies to the ovarian cancer proteins are humanized antibodies (e.g., Xenerex Biosciences; Medarex, Inc.; Abgenix, Inc.; Protein Design Labs, Inc.) Humanized forms of non-human (e.g., murine) antibodies are chimeric molecules of immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab′, F(ab′)2 or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. Humanized antibodies include human immunoglobulins (recipient antibody) in which residues from a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity. In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the framework (FR) regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. Humanization can be essentially performed following the method of Winter and co-workers, e.g., by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. See, e.g., Jones, et al. (1986) Nature 321:522-525; Riechmann, et al. (1988) Nature 332:323-329; Presta (1992) Curr. Op. Struct. Biol. 2:593-596; and Verhoeyen, et al. (1988) Science 239:1534-1536). Accordingly, such humanized antibodies are chimeric antibodies (U.S. Pat. No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species.


[0202] Human antibodies can also be produced using various techniques known in the art, including phage display libraries (see, e.g., Hoogenboom and Winter (1991) J. Mol. Biol. 227:381-388; and Marks, et al. (1991) J. Mol. Biol. 222:581-597) or human monoclonal antibodies (see, e.g., p. 77, Cole, et al. in Reisfeld and Sell (1985) Monoclonal Antibodies and Cancer Therapy Liss; and Boerner, et al. (1991) J. Immunol. 147:86-95). Similarly, human antibodies can be made by introducing of human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. See, e.g., U.S. Pat. Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016; Marks, et al. (1992) Bio/Technology 10:779-783; Lonberg, et al. (1994) Nature 368:856-859; Morrison (1994) Nature 368:812-13; Neuberger (1996) Nature Biotechnology 14:826 commenting on Fishwild, et al. (1996) Nature Biotechnology 14:845-51; and Lonberg and Huszar (1995) Intern. Rev. Immunol. 13:65-93.


[0203] By immunotherapy is meant treatment of ovarian cancer, e.g., with an antibody raised against ovarian cancer proteins. As used herein, immunotherapy can be passive or active. Passive immunotherapy as defined herein is the passive transfer of antibody to a recipient (patient). Active immunization is the induction of antibody and/or T-cell responses in a recipient (patient). Induction of an immune response is the result of providing the recipient with an antigen to which antibodies are raised. The antigen may be provided by injecting a polypeptide against which antibodies are desired to be raised into a recipient, or contacting the recipient with a nucleic acid capable of expressing the antigen and under conditions for expression of the antigen, leading to an immune response.


[0204] In a preferred embodiment the ovarian cancer proteins against which antibodies are raised are secreted proteins as described above. Without being bound by theory, antibodies used for treatment, bind and prevent the secreted protein from binding to its receptor, thereby inactivating the secreted ovarian cancer protein.


[0205] In another preferred embodiment, the ovarian cancer protein to which antibodies are raised is a transmembrane protein. Without being bound by theory, antibodies used for treatment, bind the extracellular domain of the ovarian cancer protein and prevent it from binding to other proteins, such as circulating ligands or cell-associated molecules. The antibody may cause down-regulation of the transmembrane ovarian cancer protein. As will be appreciated by one of ordinary skill in the art, the antibody may be a competitive, non-competitive or uncompetitive inhibitor of protein binding to the extracellular domain of the ovarian cancer protein. The antibody is also an antagonist of the ovarian cancer protein. Further, the antibody prevents activation of the transmembrane ovarian cancer protein. In one aspect, when the antibody prevents the binding of other molecules to the ovarian cancer protein, the antibody prevents growth of the cell. The antibody may also be used to target or sensitize the cell to cytotoxic agents, including, but not limited to TNF-α, TNF-β, IL-1, INF-γ, and IL-2, or chemotherapeutic agents including 5FU, vinblastine, actinomycin D, cisplatin, methotrexate, and the like. In some instances the antibody belongs to a sub-type that activates serum complement when complexed with the transmembrane protein thereby mediating cytotoxicity or antigen-dependent cytotoxicity (ADCC). Thus, ovarian cancer is treated by administering to a patient antibodies directed against the transmembrane ovarian cancer protein. Antibody-labeling may activate a co-toxin, localize a toxin payload, or otherwise provide means to locally ablate cells.


[0206] In another preferred embodiment, the antibody is conjugated to an effector moiety. The effector moiety can be any number of molecules, including labeling moieties such as radioactive labels or fluorescent labels, or can be a therapeutic moiety. In one aspect the therapeutic moiety is a small molecule that modulates the activity of the ovarian cancer protein. In another aspect the therapeutic moiety modulates the activity of molecules associated with or in close proximity to the ovarian cancer protein. The therapeutic moiety may inhibit enzymatic activity such as protease or collagenase or protein kinase activity associated with ovarian cancer.


[0207] In a preferred embodiment, the therapeutic moiety can also be a cytotoxic agent. In this method, targeting the cytotoxic agent to ovarian cancer tissue or cells, results in a reduction in the number of afflicted cells, thereby reducing symptoms associated with ovarian cancer. Cytotoxic agents are numerous and varied and include, but are not limited to, cytotoxic drugs or toxins or active fragments of such toxins. Suitable toxins and their corresponding fragments include diphtheria A chain, exotoxin A chain, ricin A chain, abrin A chain, curcin, crotin, phenomycin, enomycin and the like. Cytotoxic agents also include radiochemicals made by conjugating radioisotopes to antibodies raised against ovarian cancer proteins, or binding of a radionuclide to a chelating agent that has been covalently attached to the antibody. Targeting the therapeutic moiety to transmembrane ovarian cancer proteins not only serves to increase the local concentration of therapeutic moiety in the ovarian cancer afflicted area, but also serves to reduce deleterious side effects that may be associated with the untargeted therapeutic moiety.


[0208] In another preferred embodiment, the ovarian cancer protein against which the antibodies are raised is an intracellular protein. In this case, the antibody may be conjugated to a protein which facilitates entry into the cell. In one case, the antibody enters the cell by endocytosis. In another embodiment, a nucleic acid encoding the antibody is administered to the individual or cell. Moreover, wherein the ovarian cancer protein can be targeted within a cell, e.g., the nucleus, an antibody thereto contains a signal for that target localization, e.g., a nuclear localization signal.


[0209] The ovarian cancer antibodies of the invention specifically bind to ovarian cancer proteins. By “specifically bind” herein is meant that the antibodies bind to the protein with a Kd of at least about 0.1 mM, more usually at least about 1 μM, preferably at least about 0.1 μM or better, and most preferably, 0.01 μM or better. Selectivity of binding is also important.


[0210] Detection of Ovarian Cancer Sequence for Diagnostic and Therapeutic Applications


[0211] In one aspect, the RNA expression levels of genes are determined for different cellular states in the ovarian cancer phenotype. Expression levels of genes in normal tissue (e.g., not undergoing ovarian cancer) and in ovarian cancer tissue (and in some cases, for varying severities of ovarian cancer that relate to prognosis, as outlined below, or in non-malignant disease are evaluated to provide expression profiles. An expression profile of a particular cell state or point of development is essentially a “fingerprint” of the state of the cell. While two states may have any particular gene similarly expressed, the evaluation of a number of genes simultaneously allows the generation of a gene expression profile that is reflective of the state of the cell. By comparing expression profiles of cells in different states, information regarding which genes are important (including both up- and down-regulation of genes) in each of these states is obtained. Then, diagnosis may be performed or confirmed to determine whether a tissue sample has the gene expression profile of normal or cancerous tissue. This will provide for molecular diagnosis of related conditions.


[0212] “Differential expression,” or grammatical equivalents as used herein, refers to qualitative or quantitative differences in the temporal and/or cellular gene expression patterns within and among cells and tissue. Thus, a differentially expressed gene can qualitatively have its expression altered, including an activation or inactivation, in, e.g., normal versus ovarian cancer tissue. Genes may be turned on or turned off in a particular state, relative to another state thus permitting comparison of two or more states. A qualitatively regulated gene will exhibit an expression pattern within a state or cell type which is detectable by standard techniques. Some genes will be expressed in one state or cell type, but not in both. Alternatively, the difference in expression may be quantitative, e.g., in that expression is modulated, either up-regulated, resulting in an increased amount of transcript, or down-regulated, resulting in a decreased amount of transcript. The degree to which expression differs need only be large enough to quantify via standard characterization techniques as outlined below, such as by use of Affymetrix GeneChip™ expression arrays. See, e.g., Lockhart (1996) Nature Biotechnology 14:1675-1680. Other techniques include, but are not limited to, quantitative reverse transcriptase PCR, northern analysis, and RNase protection. As outlined above, preferably the change in expression (e.g., up-regulation or down-regulation) is at least about 50%, more preferably at least about 100%, more preferably at least about 150%, more preferably at least about 200%, with from 300 to at least 1000% being especially preferred.


[0213] Evaluation may be at the gene transcript, or the protein level. The amount of gene expression may be monitored using nucleic acid probes to the DNA or RNA equivalent of the gene transcript, and the quantification of gene expression levels, or, alternatively, the final gene product itself (protein) can be monitored, e.g., with antibodies to the ovarian cancer protein and standard immunoassays (ELISAs, etc.) or other techniques, including mass spectroscopy assays, 2D gel electrophoresis assays, etc. Proteins corresponding to ovarian cancer genes, e.g., those identified as being important in an ovarian cancer or disease phenotype, can be evaluated in an ovarian disease diagnostic test. In a preferred embodiment, gene expression monitoring is performed simultaneously on a number of genes. Multiple protein expression monitoring can be performed, or on an individual basis.


[0214] In this embodiment, the ovarian cancer nucleic acid probes are attached to biochips as outlined herein for the detection and quantification of ovarian cancer sequences in a particular sample. The assays are further described below in the example. PCR techniques can be used to provide greater sensitivity.


[0215] In a preferred embodiment nucleic acids encoding the ovarian cancer protein are detected. Although DNA or RNA encoding the ovarian cancer protein may be detected, of particular interest are methods wherein an mRNA encoding an ovarian cancer protein is detected. Probes to detect mRNA can be a nucleotide/deoxynucleotide probe that is complementary to and hybridizes with the mRNA and includes, but is not limited to, oligonucleotides, cDNA or RNA. Probes also should contain a detectable label, as defined herein. In one method the mRNA is detected after immobilizing the nucleic acid to be examined on a solid support such as nylon membranes and hybridizing the probe with the sample. Following washing to remove the non-specifically bound probe, the label is detected. In another method detection of the mRNA is performed in situ. In this method permeabilized cells or tissue samples are contacted with a detectably labeled nucleic acid probe for sufficient time to allow the probe to hybridize with the target mRNA. Following washing to remove the non-specifically bound probe, the label is detected. For example a digoxygenin labeled riboprobe (RNA probe) that is complementary to the mRNA encoding an ovarian cancer protein is detected by binding the digoxygenin with an anti-digoxygenin secondary antibody and developed with nitro blue tetrazolium and 5-bromo-4-chloro-3-indoyl phosphate.


[0216] In a preferred embodiment, various proteins from the three classes of proteins as described herein (secreted, transmembrane or intracellular proteins) are used in diagnostic assays. The ovarian cancer proteins, antibodies, nucleic acids, modified proteins and cells containing ovarian cancer sequences are used in diagnostic assays. This can be performed on an individual gene or corresponding polypeptide level. In a preferred embodiment, the expression profiles are used, preferably in conjunction with high throughput screening techniques to allow monitoring for expression profile genes and/or corresponding polypeptides.


[0217] As described and defined herein, ovarian cancer proteins, including intracellular, transmembrane, or secreted proteins, find use as prognostic or diagnostic markers of ovarian disease. Detection of these proteins in putative ovarian cancer tissue allows for detection, diagnosis, or prognosis of ovarian disease, and for selection of therapeutic strategy. In one embodiment, antibodies are used to detect ovarian cancer proteins. A preferred method separates proteins from a sample by electrophoresis on a gel (typically a denaturing and reducing protein gel, but may be another type of gel, including isoelectric focusing gels and the like). Following separation of proteins, the ovarian cancer protein is detected, e.g., by immunoblotting with antibodies raised against the ovarian cancer protein. Methods of immunoblotting are well known to those of ordinary skill in the art.


[0218] In another preferred method, antibodies to the ovarian cancer protein find use in in situ imaging techniques, e.g., in histology. See, e.g., Asai (ed. 1993) Methods in Cell Biology: Antibodies in Cell Biology (vol. 37) Academic Press. Cells are contacted with from one to many antibodies to the ovarian cancer protein(s). Following washing to remove non-specific antibody binding, the presence of the antibody or antibodies is detected. In one embodiment the antibody is detected by incubating with a secondary antibody that contains a detectable label. In another method the primary antibody to the ovarian cancer protein(s) contains a detectable label, e.g., an enzyme marker that can act on a substrate. In another preferred embodiment each one of multiple primary antibodies contains a distinct and detectable label. This method finds particular use in simultaneous screening for a plurality of ovarian cancer proteins. As will be appreciated by one of ordinary skill in the art, many other histological imaging techniques are also provided by the invention.


[0219] In a preferred embodiment the label is detected in a fluorometer which has the ability to detect and distinguish emissions of different wavelengths. In addition, a fluorescence activated cell sorter (FACS) can be used in the method.


[0220] In another preferred embodiment, antibodies find use in diagnosing ovarian cancer from blood, serum, plasma, stool, and other samples. Such samples, therefore, are useful as samples to be probed or tested for the presence of ovarian cancer proteins. Antibodies can be used to detect an ovarian cancer protein by previously described immunoassay techniques including ELISA, immunoblotting (western blotting), immunoprecipitation, BIACORE technology, and the like. Conversely, the presence of antibodies may indicate an immune response against an endogenous ovarian cancer protein.


[0221] In a preferred embodiment, in situ hybridization of labeled ovarian cancer nucleic acid probes to tissue arrays is done. For example, arrays of tissue samples, including ovarian cancer tissue and/or normal tissue, are made. In situ hybridization (see, e.g., Ausubel, supra) is then performed. When comparing the fingerprints between an individual and a standard, the skilled artisan can make a diagnosis, a prognosis, or a prediction based on the findings. It is further understood that the genes which indicate the diagnosis may differ from those which indicate the prognosis and molecular profiling of the condition of the cells may lead to distinctions between responsive or refractory conditions or may be predictive of outcomes.


[0222] In a preferred embodiment, the ovarian cancer proteins, antibodies, nucleic acids, modified proteins and cells containing ovarian cancer sequences are used in prognosis assays. As above, gene expression profiles can be generated that correlate to ovarian cancer, clinical, pathological, or other information, in terms of long term prognosis. Again, this may be done on either a protein or gene level, with the use of a plurality of genes being preferred. As above, ovarian cancer probes may be attached to biochips for the detection and quantification of ovarian cancer sequences in a tissue or patient. The assays proceed as outlined above for diagnosis. PCR method may provide more sensitive and accurate quantification.


[0223] Assays for Therapeutic Compounds


[0224] In a preferred embodiment members of the proteins, nucleic acids, and antibodies as described herein are used in drug screening assays. The ovarian cancer proteins, antibodies, nucleic acids, modified proteins and cells containing ovarian cancer sequences are used in drug screening assays or by evaluating the effect of drug candidates on a “gene expression profile” or expression profile of polypeptides. In a preferred embodiment, the expression profiles are used, preferably in conjunction with high throughput screening techniques to allow monitoring for expression profile genes after treatment with a candidate agent. See, e.g., Zlokarnik, et al. (1998) Science 279:84-88; and Heid (1996) Genome Res. 6:986-994.


[0225] In a preferred embodiment, the ovarian cancer proteins, antibodies, nucleic acids, modified proteins and cells containing the native or modified ovarian cancer proteins are used in screening assays. That is, the present invention provides novel methods for screening for compositions which modulate the ovarian cancer phenotype or an identified physiological function of an ovarian cancer protein. As above, this can be done on an individual gene level or by evaluating the effect of drug candidates on a “gene expression profile”. In a preferred embodiment, the expression profiles are used, preferably in conjunction with high throughput screening techniques to allow monitoring for expression profile genes after treatment with a candidate agent. See, e.g., Zlokarnik, supra.


[0226] Having identified the differentially expressed genes herein, a variety of assays may be executed. In a preferred embodiment, assays may be run on an individual gene or protein level. That is, having identified a particular gene as up regulated in ovarian cancer, test compounds can be screened for the ability to modulate gene expression or for binding to the ovarian cancer protein. “Modulation” thus includes both an increase and a decrease in gene expression. The preferred amount of modulation will depend on the original change of the gene expression in normal versus tissue undergoing ovarian cancer, with changes of at least 10%, preferably 50%, more preferably 100-300%, and in some embodiments 300-1000% or greater. Thus, if a gene exhibits a 4-fold increase in ovarian cancer tissue compared to normal tissue, a decrease of about four-fold is often desired; similarly, a 10-fold decrease in ovarian cancer tissue compared to normal tissue often provides a target value of a 10-fold increase in expression to be induced by the test compound.


[0227] The amount of gene expression may be monitored using nucleic acid probes and the quantification of gene expression levels, or, alternatively, the gene product itself can be monitored, e.g., through the use of antibodies to the ovarian cancer protein and standard immunoassays. Proteomics and separation techniques may also allow quantification of expression.


[0228] In a preferred embodiment, gene expression or protein monitoring of a number of entities, e.g., an expression profile, is monitored simultaneously. Such profiles will typically involve a plurality of those entities described herein.


[0229] In this embodiment, the ovarian cancer nucleic acid probes are attached to biochips as outlined herein for the detection and quantification of ovarian cancer sequences in a particular cell. Alternatively, PCR may be used. Thus, a series, e.g., of microtiter plate, may be used with dispensed primers in desired wells. A PCR reaction can then be performed and analyzed for each well.


[0230] Expression monitoring can be performed to identify compounds that modify the expression of one or more ovarian cancer-associated sequences, e.g., a polynucleotide sequence set out inTables 1-20. Generally, in a preferred embodiment, a test modulator is added to the cells prior to analysis. Moreover, screens are also provided to identify agents that modulate ovarian cancer, modulate ovarian cancer proteins, bind to an ovarian cancer protein, or interfere with the binding of an ovarian cancer protein and an antibody or other binding partner.


[0231] The term “test compound” or “drug candidate” or “modulator” or grammatical equivalents as used herein describes any molecule, e.g., protein, oligopeptide, small organic molecule, polysaccharide, polynucleotide, etc., to be tested for the capacity to directly or indirectly alter the ovarian cancer phenotype or the expression of an ovarian cancer sequence, e.g., a nucleic acid or protein sequence. In preferred embodiments, modulators alter expression profiles, or expression profile nucleic acids or proteins provided herein. In one embodiment, the modulator suppresses an ovarian cancer phenotype, e.g., to a normal or non-malignant tissue fingerprint. In another embodiment, a modulator induced an ovarian cancer phenotype. Generally, a plurality of assay mixtures are run in parallel with different agent concentrations to obtain a differential response to the various concentrations. Typically, one of these concentrations serves as a negative control, e.g., at zero concentration or below the level of detection.


[0232] Drug candidates encompass numerous chemical classes, though typically they are organic molecules, preferably small organic compounds having a molecular weight of more than 100 and less than about 2,500 daltons. Preferred small molecules are less than 2000, or less than 1500 or less than 1000 or less than 500 D. Candidate agents comprise functional groups necessary for structural interaction with proteins, particularly hydrogen bonding, and typically include at least an amine, carbonyl, hydroxyl or carboxyl group, preferably at least two of the functional chemical groups. The candidate agents often comprise cyclical carbon or heterocyclic structures and/or aromatic or polyaromatic structures substituted with one or more of the above functional groups. Candidate agents are also found among biomolecules including peptides, saccharides, fatty acids, steroids, purines, pyrimidines, derivatives, structural analogs or combinations thereof. Particularly preferred are peptides.


[0233] In one aspect, a modulator will neutralize the effect of an ovarian cancer protein. By “neutralize” is meant that activity of a protein is inhibited or blocked and the consequent effect on the cell.


[0234] In certain embodiments, combinatorial libraries of potential modulators will be screened for an ability to bind to an ovarian cancer polypeptide or to modulate activity. Conventionally, new chemical entities with useful properties are generated by identifying a chemical compound (called a “lead compound”) with some desirable property or activity, e.g., inhibiting activity, creating variants of the lead compound, and evaluating the property and activity of those variant compounds. Often, high throughput screening (HTS) methods are employed for such an analysis.


[0235] In one preferred embodiment, high throughput screening methods involve providing a library containing a large number of potential therapeutic compounds (candidate compounds). Such “combinatorial chemical libraries” are then screened in one or more assays to identify those library members (particular chemical species or subclasses) that display a desired characteristic activity. The compounds thus identified can serve as conventional “lead compounds” or can themselves be used as potential or actual therapeutics.


[0236] A combinatorial chemical library is a collection of diverse chemical compounds generated by either chemical synthesis or biological synthesis by combining a number of chemical “building blocks” such as reagents. For example, a linear combinatorial chemical library, such as a polypeptide (e.g., mutein) library, is formed by combining a set of chemical building blocks called amino acids in every possible way for a given compound length (e.g., the number of amino acids in a polypeptide compound). Millions of chemical compounds can be synthesized through such combinatorial mixing of chemical building blocks. See, e.g., Gallop, et al. (1994) J. Med. Chem. 37:1233-1251.


[0237] Preparation and screening of combinatorial chemical libraries is well known to those of skill in the art. Such combinatorial chemical libraries include, but are not limited to, peptide libraries (see, e.g., U.S. Pat. No. 5,010,175; Furka (1991) Pept. Prot. Res. 37:487-493; and Houghton, et al. (1991) Nature 354:84-88), peptoids (PCT Publication No WO 91/19735), encoded peptides (PCT Publication WO 93/20242), random bio-oligomers (PCT Publication WO 92/00091), benzodiazepines (U.S. Pat. No. 5,288,514), diversomers such as hydantoins, benzodiazepines and dipeptides (Hobbs, et al. (1993) Proc. Nat'l Acad. Sci. USA 90:6909-913), vinylogous polypeptides (Hagihara, et al. (1992) J. Amer. Chem. Soc. 114:6568-570), non-peptidal peptidomimetics with a Beta-D-Glucose scaffolding (Hirschmann, et al. (1992) J. Amer. Chem. Soc. 114:9217-218), analogous organic syntheses of small compound libraries (Chen, et al. (1994) J. Amer. Chem. Soc. 116:2661-662), oligocarbamates (Cho, et al. (1993) Science 261:1303-305), and/or peptidyl phosphonates (Campbell, et al.(1994) J. Org. Chem. 59:658-xxx). See, generally, Gordon, et al. (1994) J. Med. Chem. 37:1385-401, nucleic acid libraries (see, e.g., Stratagene, Corp.), peptide nucleic acid libraries (see, e.g., U.S. Pat. No .5,539,083), antibody libraries (see, e.g., Vaughn, et al.(1996) Nature Biotechnology 14:309-314; and PCT/US96/10287), carbohydrate libraries (see, e.g., Liang, et al. (1996) Science 274:1520-1522; and U.S. Pat. No. 5,593,853), and small organic molecule libraries (see, e.g., benzodiazepines, page 33, Baum (Jan. 18, 1993) C&E News;isoprenoids, U.S. Pat. No. 5,569,588; thiazolidinones and metathiazanones, U.S. Pat. No. 5,549,974; pyrrolidines, U.S. Pat. Nos. 5,525,735 and 5,519,134; morpholino compounds, U.S. Pat. No. 5,506,337; benzodiazepines, U.S. Pat. No. 5,288,514; and the like).


[0238] Devices for the preparation of combinatorial libraries are commercially available. See, e.g., 357 MPS, 390 MPS, Advanced Chem Tech, Louisville Ky.; Symphony, Rainin, Woburn, Mass.; 433A Applied Biosystems, Foster City, Calif.; 9050 Plus, Millipore, Bedford, Mass.


[0239] A number of well known robotic systems have also been developed for solution phase chemistries. These systems include automated workstations like the automated synthesis apparatus developed by Takeda Chemical Industries, LTD. (Osaka, Japan) and many robotic systems utilizing robotic arms (Zymate II, Zymark Corporation, Hopkinton, Mass.; Orca, Hewlett-Packard, Palo Alto, Calif.), which mimic the manual synthetic operations performed by a chemist. Any of the above devices are suitable for use with the present invention. The nature and implementation of modifications to these devices (if any) so that they can operate as discussed herein will be apparent to persons skilled in the relevant art. In addition, numerous combinatorial libraries are themselves commercially available (see, e.g., ComGenex, Princeton, N.J.; Asinex, Moscow, RU; Tripos, Inc., St. Louis, Mo.; ChemStar, Ltd, Moscow, RU; 3D Pharmaceuticals, Exton, Pa.; Martek Biosciences, Columbia, Md.; etc.).


[0240] The assays to identify modulators are amenable to high throughput screening. Preferred assays thus detect enhancement or inhibition of ovarian cancer gene transcription, inhibition or enhancement of polypeptide expression, and inhibition or enhancement of polypeptide activity.


[0241] High throughput assays for the presence, absence, quantification, or other properties of particular nucleic acids or protein products are well known to those of skill in the art. Similarly, binding assays and reporter gene assays are similarly well known. Thus, e.g., U.S. Pat. No. 5,559,410 discloses high throughput screening methods for proteins, U.S. Pat. No. 5,585,639 discloses high throughput screening methods for nucleic acid binding (e.g., in arrays), while U.S. Pat. Nos. 5,576,220 and 5,541,061 disclose high throughput methods of screening for ligand/antibody binding.


[0242] In addition, high throughput screening systems are commercially available (see, e.g., Zymark Corp., Hopkinton, Mass.; Air Technical Industries, Mentor, Ohio; Beckman Instruments, Inc. Fullerton, Calif.; Precision Systems, Inc., Natick, Mass., etc.). These systems typically automate entire procedures, including all sample and reagent pipetting, liquid dispensing, timed incubations, and final readings of the microplate in detector(s) appropriate for the assay. These configurable systems provide high throughput and rapid start up as well as a high degree of flexibility and customization. The manufacturers of such systems provide detailed protocols for various high throughput systems. Thus, e.g., Zymark Corp. provides technical bulletins describing screening systems for detecting the modulation of gene transcription, ligand binding, and the like.


[0243] In one embodiment, modulators are proteins, often naturally occurring proteins or fragments of naturally occurring proteins. Thus, e.g., cellular extracts containing proteins, or random or directed digests of proteinaceous cellular extracts, may be used. In this way libraries of proteins may be made for screening in the methods of the invention. Particularly preferred in this embodiment are libraries of bacterial, fungal, viral, and mammalian proteins, with the latter being preferred, and human proteins being especially preferred. Particularly useful test compound will be directed to the class of proteins to which the target belongs, e.g., substrates for enzymes or ligands and receptors.


[0244] In a preferred embodiment, modulators are peptides of from about 5 to about 30 amino acids, with from about 5 to about 20 amino acids being preferred, and from about 7 to about 15 being particularly preferred. The peptides may be digests of naturally occurring proteins as is outlined above, random peptides, or “biased” random peptides. By “randomized” or grammatical equivalents herein is meant that each nucleic acid and peptide consists of essentially random nucleotides and amino acids, respectively. Since generally these random peptides (or nucleic acids, discussed below) are chemically synthesized, they may incorporate any nucleotide or amino acid at any position. The synthetic process can be designed to generate randomized proteins or nucleic acids, to allow the formation of all or most of the possible combinations over the length of the sequence, thus forming a library of randomized candidate bioactive proteinaceous agents.


[0245] In one embodiment, the library is fully randomized, with no sequence preferences or constants at any position. In a preferred embodiment, the library is biased. That is, some positions within the sequence are either held constant, or are selected from a limited number of possibilities. For example, in a preferred embodiment, the nucleotides or amino acid residues are randomized within a defined class, e.g., of hydrophobic amino acids, hydrophilic residues, sterically biased (either small or large) residues, towards the creation of nucleic acid binding domains, the creation of cysteines, for cross-linking, prolines for SH-3 domains, serines, threonines, tyrosines or histidines for phosphorylation sites, etc., or to purines, etc.


[0246] Modulators of ovarian cancer can also be nucleic acids, as defined above.


[0247] As described above generally for proteins, nucleic acid modulating agents may be naturally occurring nucleic acids, random nucleic acids, or “biased” random nucleic acids. For example, digests of procaryotic or eucaryotic genomes may be used as is outlined above for proteins.


[0248] In a preferred embodiment, the candidate compounds are organic chemical moieties, a wide variety of which are available in the literature.


[0249] After the candidate agent has been added and the cells allowed to incubate for some period of time, the sample containing a target sequence to be analyzed is added to the biochip. If required, the target sequence is prepared using known techniques. For example, the sample may be treated to lyse the cells, using known lysis buffers, electroporation, etc., with purification and/or amplification such as PCR performed as appropriate. For example, an in vitro transcription with labels covalently attached to the nucleotides is performed. Generally, the nucleic acids are labeled with biotin-FITC or PE, or with cy3 or cy5.


[0250] In a preferred embodiment, the target sequence is labeled with, e.g., a fluorescent, a chemiluminescent, a chemical, or a radioactive signal, to provide a means of detecting the target sequence's specific binding to a probe. The label also can be an enzyme, such as, alkaline phosphatase or horseradish peroxidase, which when provided with an appropriate substrate produces a product that can be detected. Alternatively, the label can be a labeled compound or small molecule, such as an enzyme inhibitor, that binds but is not catalyzed or altered by the enzyme. The label also can be a moiety or compound, such as, an epitope tag or biotin which specifically binds to streptavidin. For the example of biotin, the streptavidin is labeled as described above, thereby, providing a detectable signal for the bound target sequence. Unbound labeled streptavidin is typically removed prior to analysis.


[0251] As will be appreciated by those in the art, these assays can be direct hybridization assays or can comprise “sandwich assays”, which include the use of multiple probes, as is generally outlined in U.S. Pat. Nos. 5,681,702; 5,597,909; 5,545,730; 5,594,117; 5,591,584; 5,571,670; 5,580,731; 5,571,670; 5,591,584; 5,624,802; 5,635,352; 5,594,118; 5,359,100; 5,124,246; and 5,681,697, each of which is hereby incorporated by reference. In this embodiment, in general, the target nucleic acid is prepared as outlined above, and then added to the biochip comprising a plurality of nucleic acid probes, under conditions that allow the formation of a hybridization complex.


[0252] A variety of hybridization conditions may be used in the present invention, including high, moderate and low stringency conditions as outlined above. The assays are generally run under stringency conditions which allows formation of the label probe hybridization complex only in the presence of target. Stringency can be controlled by altering a step parameter that is a thermodynamic variable, including, but not limited to, temperature, formamide concentration, salt concentration, chaotropic salt concentration pH, organic solvent concentration, etc.


[0253] These parameters may also be used to control non-specific binding, as is generally outlined in U.S. Pat. No. 5,681,697. Thus it may be desirable to perform certain steps at higher stringency conditions to reduce non-specific binding.


[0254] The reactions outlined herein may be accomplished in a variety of ways. Components of the reaction may be added simultaneously, or sequentially, in different orders, with preferred embodiments outlined below. In addition, the reaction may include a variety of other reagents. These include salts, buffers, neutral proteins, e.g., albumin, detergents, etc. which may be used to facilitate optimal hybridization and detection, and/or reduce non-specific or background interactions. Reagents that otherwise improve the efficiency of the assay, such as protease inhibitors, nuclease inhibitors, anti-microbial agents, etc., may also be used as appropriate, depending on the sample preparation methods and purity of the target.


[0255] The assay data are analyzed to determine the expression levels, and changes in expression levels as between states, of individual genes, forming a gene expression profile.


[0256] Screens are performed to identify modulators of the ovarian cancer phenotype. In one embodiment, screening is performed to identify modulators that can induce or suppress a particular expression profile, thus preferably generating the associated phenotype. In another embodiment, e.g., for diagnostic applications, having identified differentially expressed genes important in a particular state, screens can be performed to identify modulators that alter expression of individual genes. In an another embodiment, screening is performed to identify modulators that alter a biological function of the expression product of a differentially expressed gene. Again, having identified the importance of a gene in a particular state, screens are performed to identify agents that bind and/or modulate the biological activity of the gene product.


[0257] In addition screens can be done for genes that are induced in response to a candidate agent. After identifying a modulator based upon its ability to suppress an ovarian cancer expression pattern leading to a normal expression pattern, or to modulate a single ovarian cancer gene expression profile so as to mimic the expression of the gene from normal tissue, a screen as described above can be performed to identify genes that are specifically modulated in response to the agent. Comparing expression profiles between normal tissue and agent treated ovarian cancer tissue reveals genes that are not expressed in normal tissue or ovarian cancer tissue, but are expressed in agent treated tissue. These agent-specific sequences can be identified and used by methods described herein for ovarian cancer genes or proteins. In particular these sequences and the proteins they encode find use in marking or identifying agent treated cells. In addition, antibodies can be raised against the agent induced proteins and used to target novel therapeutics to the treated ovarian cancer tissue sample.


[0258] Thus, in one embodiment, a test compound is administered to a population of ovarian cancer cells, that have an associated ovarian cancer expression profile. By “administration” or “contacting” herein is meant that the candidate agent is added to the cells in such a manner as to allow the agent to act upon the cell, whether by uptake and intracellular action, or by action at the cell surface. In some embodiments, nucleic acid encoding a proteinaceous candidate agent (e.g., a peptide) may be put into a viral construct such as an adenoviral or retroviral construct, and added to the cell, such that expression of the peptide agent is accomplished, e.g., PCT US97/01019. Regulatable gene therapy systems can also be used.


[0259] Once the test compound has been administered to the cells, the cells can be washed if desired and are allowed to incubate under preferably physiological conditions for some period of time. The cells are then harvested and a new gene expression profile is generated, as outlined herein.


[0260] Thus, e.g., ovarian cancer or non-malignant tissue may be screened for agents that modulate, e.g., induce or suppress the ovarian cancer phenotype. A change in at least one gene, preferably many, of the expression profile indicates that the agent has an effect on ovarian cancer activity. By defining such a signature for the ovarian cancer phenotype, screens for new drugs that alter the phenotype can be devised. With this approach, the drug target need not be known and need not be represented in the original expression screening platform, nor does the level of transcript for the target protein need to change.


[0261] In a preferred embodiment, as outlined above, screens may be done on individual genes and gene products (proteins). That is, having identified a particular differentially expressed gene as important in a particular state, screening of modulators of either the expression of the gene or the gene product itself can be done. The gene products of differentially expressed genes are sometimes referred to herein as “ovarian cancer proteins” or a “ovarian cancer modulatory protein”. The ovarian cancer modulatory protein may be a fragment, or alternatively, be the full length protein to the fragment encoded by the nucleic acids of the Tables. Preferably, the ovarian cancer modulatory protein is a fragment. In a preferred embodiment, the ovarian cancer amino acid sequence which is used to determine sequence identity or similarity is encoded by a nucleic acid of the Tables. In another embodiment, the sequences are naturally occurring allelic variants of a protein encoded by a nucleic acid of the Tables. In another embodiment, the sequences are sequence variants as further described herein.


[0262] Preferably, the ovarian cancer modulatory protein is a fragment of approximately 14 to 24 amino acids long. More preferably the fragment is a soluble fragment. Preferably, the fragment includes a non-transmembrane region. In a preferred embodiment, the fragment has an N-terminal Cys to aid in solubility. In another embodiment, the C-terminus of the fragment is kept as a free acid and the N-terminus is a free amine to aid in coupling, e.g., to cysteine. Or, the ovarian cancer proteins are conjugated to an immunogenic agent, e.g., to BSA.


[0263] Measurements of ovarian cancer polypeptide activity, or of ovarian cancer or the ovarian cancer phenotype can be performed using a variety of assays. For example, the effects of the test compounds upon the function of the ovarian cancer polypeptides can be measured by examining parameters described above. A suitable physiological change that affects activity can be used to assess the influence of a test compound on the polypeptides of this invention. When the functional consequences are determined using intact cells or animals, one can also measure a variety of effects such as, in the case of ovarian cancer associated with tumors, tumor growth, tumor metastasis, neovascularization, hormone release, transcriptional changes to both known and uncharacterized genetic markers (e.g., northern blots), changes in cell metabolism such as cell growth or pH changes, and changes in intracellular second messengers such as cGMP. In the assays of the invention, mammalian ovarian cancer polypeptide is typically used, e.g., mouse, preferably human.


[0264] Assays to identify compounds with modulating activity can be performed in vitro. For example, an ovarian cancer polypeptide is first contacted with a potential modulator and incubated for a suitable amount of time, e.g., from 0.5 to 48 hours. In one embodiment, the ovarian cancer polypeptide levels are determined in vitro by measuring the level of protein or mRNA. The level of protein is measured using immunoassays such as western blotting, ELISA and the like with an antibody that selectively binds to the ovarian cancer polypeptide or a fragment thereof. For measurement of mRNA, amplification, e.g., using PCR, LCR, or hybridization assays, e.g., northern hybridization, RNAse protection, dot blotting, are preferred. The level of protein or mRNA is detected using directly or indirectly labeled detection agents, e.g., fluorescently or radioactively labeled nucleic acids, radioactively or enzymatically labeled antibodies, and the like, as described herein.


[0265] Alternatively, a reporter gene system can be devised using the ovarian cancer protein promoter operably linked to a reporter gene such as luciferase, green fluorescent protein, CAT, or β-gal. The reporter construct is typically transfected into a cell. After treatment with a potential modulator, the amount of reporter gene transcription, translation, or activity is measured according to standard techniques known to those of skill in the art.


[0266] In a preferred embodiment, as outlined above, screens may be done on individual genes and gene products (proteins). That is, having identified a particular differentially expressed gene as important in a particular state, screening of modulators of the expression of the gene or the gene product itself can be done. The gene products of differentially expressed genes are sometimes referred to herein as “ovarian cancer proteins.” The ovarian cancer protein may be a fragment, or alternatively, be the full length protein to a fragment shown herein.


[0267] In one embodiment, screening for modulators of expression of specific genes is performed. Typically, the expression of only one or a few genes are evaluated. In another embodiment, screens are designed to first find compounds that bind to differentially expressed proteins. These compounds are then evaluated for the ability to modulate differentially expressed activity. Moreover, once initial candidate compounds are identified, variants can be further screened to better evaluate structure activity relationships.


[0268] In a preferred embodiment, binding assays are done. In general, purified or isolated gene product is used; that is, the gene products of one or more differentially expressed nucleic acids are made. For example, antibodies are generated to the protein gene products, and standard immunoassays are run to determine the amount of protein present. Alternatively, cells comprising the ovarian cancer proteins can be used in the assays.


[0269] Thus, in a preferred embodiment, the methods comprise combining an ovarian cancer protein and a candidate compound, and determining the binding of the compound to the ovarian cancer protein. Preferred embodiments utilize the human ovarian cancer protein, although other mammalian proteins, e.g., counterparts, may also be used, e.g., for the development of animal models of human disease. In some embodiments, as outlined herein, variant or derivative ovarian cancer proteins may be used.


[0270] Generally, in a preferred embodiment of the methods herein, the ovarian cancer protein or the candidate agent is non-diffusably bound to an insoluble support having isolated sample receiving areas (e.g., a microtiter plate, an array, etc.). The insoluble supports may be made of any composition to which the compositions can be bound, is readily separated from soluble material, and is otherwise compatible with the overall method of screening. The surface of such supports may be solid or porous and of any convenient shape. Examples of suitable insoluble supports include microtiter plates, arrays, membranes and beads. These are typically made of glass, plastic (e.g., polystyrene), polysaccharides, nylon or nitrocellulose, teflon™, etc. Microtiter plates and arrays are especially convenient because a large number of assays can be carried out simultaneously, using small amounts of reagents and samples. The particular manner of binding of the composition is not crucial so long as it is compatible with the reagents and overall methods of the invention, maintains the activity of the composition and is non-diffusible. Preferred methods of binding include the use of antibodies (which do not sterically block either the ligand binding site or activation sequence when the protein is bound to the support), direct binding to “sticky” or ionic supports, chemical crosslinking, the synthesis of the protein or agent on the surface, etc. Following binding of the protein or agent, excess unbound material is removed by washing. The sample receiving areas may then be blocked through incubation with bovine serum albumin (BSA), casein or other innocuous protein or other moiety.


[0271] In a preferred embodiment, the ovarian cancer protein is bound to the support, and a test compound is added to the assay. Alternatively, the candidate agent is bound to the support and the ovarian cancer protein is added. Novel binding agents include specific antibodies, non-natural binding agents identified in screens of chemical libraries, peptide analogs, etc. Of particular interest are screening assays for agents that have a low toxicity for human cells. A wide variety of assays may be used for this purpose, including labeled in vitro protein-protein binding assays, electrophoretic mobility shift assays, immunoassays for protein binding, functional assays (phosphorylation assays, etc.) and the like.


[0272] The determination of the binding of the test modulating compound to the ovarian cancer protein may be done in a number of ways. In a preferred embodiment, the compound is labeled, and binding determined directly, e.g., by attaching all or a portion of the ovarian cancer protein to a solid support, adding a labeled candidate agent (e.g., a fluorescent label), washing off excess reagent, and determining whether the label is present on the solid support. Various blocking and washing steps may be utilized as appropriate.


[0273] In some embodiments, only one of the components is labeled, e.g., the proteins (or proteinaceous candidate compounds) can be labeled. Alternatively, more than one component can be labeled with different labels, e.g., 125I for the proteins and a fluorophor for the compound. Proximity reagents, e.g., quenching or energy transfer reagents are also useful.


[0274] In one embodiment, the binding of the test compound is determined by competitive binding assay. The competitor is a binding moiety known to bind to the target molecule (e.g., an ovarian cancer protein), such as an antibody, peptide, binding partner, ligand, etc. Under certain circumstances, there may be competitive binding between the compound and the binding moiety, with the binding moiety displacing the compound. In one embodiment, the test compound is labeled. Either the compound, or the competitor, or both, is added first to the protein for a time sufficient to allow binding, if present. Incubations may be performed at a temperature which facilitates optimal activity, typically 4-40° C. Incubation periods are typically optimized, e.g., to facilitate rapid high throughput screening. Typically between 0.1 and 1 hr will be sufficient. Excess reagent is generally removed or washed away. The second component is then added, and the presence or absence of the labeled component is followed, to indicate binding.


[0275] In a preferred embodiment, the competitor is added first, followed by the test compound. Displacement of the competitor is an indication that the test compound is binding to the ovarian cancer protein and thus is capable of binding to, and potentially modulating, the activity of the ovarian cancer protein. In this embodiment, either component can be labeled. Thus, e.g., if the competitor is labeled, the presence of label in the wash solution indicates displacement by the agent. Alternatively, if the test compound is labeled, the presence of the label on the support indicates displacement.


[0276] In an alternative embodiment, the test compound is added first, with incubation and washing, followed by the competitor. The absence of binding by the competitor may indicate that the test compound is bound to the ovarian cancer protein with a higher affinity. Thus, if the test compound is labeled, the presence of the label on the support, coupled with a lack of competitor binding, may indicate that the test compound is capable of binding to the ovarian cancer protein.


[0277] In a preferred embodiment, the methods comprise differential screening to identity agents that are capable of modulating the activity of the ovarian cancer proteins. In this embodiment, the methods comprise combining an ovarian cancer protein and a competitor in a first sample. A second sample comprises a test compound, an ovarian cancer protein, and a competitor. The binding of the competitor is determined for both samples, and a change, or difference in binding between the two samples indicates the presence of an agent capable of binding to the ovarian cancer protein and potentially modulating its activity. That is, if the binding of the competitor is different in the second sample relative to the first sample, the agent is capable of binding to the ovarian cancer protein.


[0278] Alternatively, differential screening is used to identify drug candidates that bind to the native ovarian cancer protein, but cannot bind to modified ovarian cancer proteins. The structure of the ovarian cancer protein may be modeled, and used in rational drug design to synthesize agents that interact with that site. Drug candidates that affect the activity of an ovarian cancer protein are also identified by screening drugs for the ability to either enhance or reduce the activity of the protein.


[0279] Positive controls and negative controls may be used in the assays. Preferably control and test samples are performed in at least triplicate to obtain statistically significant results. Incubation of all samples is for a time sufficient for the binding of the agent to the protein. Following incubation, samples are washed free of non-specifically bound material and the amount of bound, generally labeled agent determined. For example, where a radiolabel is employed, the samples may be counted in a scintillation counter to determine the amount of bound compound.


[0280] A variety of other reagents may be included in the screening assays. These include reagents like salts, neutral proteins, e.g., albumin, detergents, etc. which may be used to facilitate optimal protein-protein binding and/or reduce non-specific or background interactions. Also reagents that otherwise improve the efficiency of the assay, such as protease inhibitors, nuclease inhibitors, anti-microbial agents, etc., may be used. The mixture of components may be added in an order that provides for the requisite binding.


[0281] In a preferred embodiment, the invention provides methods for screening for a compound capable of modulating the activity of an ovarian cancer protein. The methods comprise adding a test compound, as defined above, to a cell comprising ovarian cancer proteins. Preferred cell types include almost any cell. The cells contain a recombinant nucleic acid that encodes an ovarian cancer protein. In a preferred embodiment, a library of candidate agents are tested on a plurality of cells.


[0282] In one aspect, the assays are evaluated in the presence or absence or previous or subsequent exposure of physiological signals, e.g., hormones, antibodies, peptides, antigens, cytokines, growth factors, action potentials, pharmacological agents including chemotherapeutics, radiation, carcinogenics, or other cells (e.g., cell-cell contacts). In another example, the determinations are determined at different stages of the cell cycle process.


[0283] In this way, compounds that modulate ovarian cancer agents are identified. Compounds with pharmacological activity are able to enhance or interfere with the activity of the ovarian cancer protein. Once identified, similar structures are evaluated to identify critical structural feature of the compound.


[0284] In one embodiment, a method of inhibiting ovarian cancer cell division is provided. The method comprises administration of an ovarian cancer inhibitor. In another embodiment, a method of inhibiting ovarian cancer is provided. The method comprises administration of an ovarian cancer inhibitor. In a further embodiment, methods of treating cells or individuals with ovarian cancer are provided. The method comprises administration of an ovarian cancer inhibitor.


[0285] In one embodiment, an ovarian cancer inhibitor is an antibody as discussed above. In another embodiment, the ovarian cancer inhibitor is an antisense or RNAi molecule.


[0286] A variety of cell viability, growth, proliferation, and metastasis assays are known to those of skill in the art, as described below.


[0287] Soft Agar Growth or Colony Formation in Suspension


[0288] Normal cells require a solid substrate to attach and grow. When the cells are transformed, they lose this phenotype and grow detached from the substrate. For example, transformed cells can grow in stirred suspension culture or suspended in semi-solid media, such as semi-solid or soft agar. The transformed cells, when transfected with tumor suppressor genes, regenerate normal phenotype and require a solid substrate to attach and grow. Soft agar growth or colony formation in suspension assays can be used to identify modulators of ovarian cancer sequences, which when expressed in host cells, inhibit abnormal cellular proliferation and transformation. A therapeutic compound would reduce or eliminate the host cells' ability to grow in stirred suspension culture or suspended in semi-solid media, such as semi-solid or soft.


[0289] Techniques for soft agar growth or colony formation in suspension assays are described in Freshney (1994) Culture of Animal Cells: A Manual of Basic Technique (3d ed.) Wiley-Liss, herein incorporated by reference. See also, the methods section of Garkavtsev, et al. (1996), supra, herein incorporated by reference.


[0290] Contact Inhibition and Density Limitation of Growth


[0291] Normal cells typically grow in a flat and organized pattern in a petri dish until they touch other cells. When the cells touch one another, they are contact inhibited and stop growing. When cells are transformed, however, the cells are not contact inhibited and continue to grow to high densities in disorganized foci. Thus, the transformed cells grow to a higher saturation density than normal cells. This can be detected morphologically by the formation of a disoriented monolayer of cells or rounded cells in foci within the regular pattern of normal surrounding cells. Alternatively, labeling index with (3H)-thymidine at saturation density can be used to measure density limitation of growth. See, e.g., Freshney (1994), supra. The transformed cells, when transfected with tumor suppressor genes, regenerate a normal phenotype and become contact inhibited and would grow to a lower density.


[0292] In this assay, labeling index with (3H)-thymidine at saturation density is a preferred method of measuring density limitation of growth. Transformed host cells are transfected with an ovarian cancer-associated sequence and are grown for 24 hr at saturation density in non-limiting medium conditions. The percentage of cells labeling with (3H)-thymidine is determined autoradiographically. See, e.g., Freshney (1994), supra.


[0293] Growth Factor or Serum Dependence


[0294] Transformed cells typically have a lower serum dependence than their normal counterparts. See, e.g., Temin (1966) J. Nat'l Cancer Inst. 37:167-175; Eagle, et al. (1970) J. Exp. Med. 131:836-879; and Freshney, supra. This is in part due to release of various growth factors by the transformed cells. Growth factor or serum dependence of transformed host cells can be compared with that of control.


[0295] Tumor Specific Markers Levels


[0296] Tumor cells release an increased amount of certain factors (hereinafter “tumor specific markers”) than their normal counterparts. For example, plasminogen activator (PA) is released from human glioma at a higher level than from normal brain cells (see, e.g., Gullino, pp. 178-184 “Angiogenesis, tumor vascularization, and potential interference with tumor growth” in Mihich (ed. 1985) Biological Responses in Cancer Plenum. Similarly, tumor angiogenesis factor (TAF) is released at a higher level in tumor cells than their normal counterparts. See, e.g., Folkman (1992) Sem Cancer Biol. 3:89-96.


[0297] Various techniques which measure the release of these factors are described in Freshney (1994), supra. Also, see, Unkeless, et al. (1974) J. Biol. Chem. 249:4295-4305; Strickland and Beers (1976) J. Biol. Chem. 251:5694-5702; Whur, et al. (1980) Br. J. Cancer 42:305-312; Gullino, pp. 178-184 “Angiogenesis, tumor vascularization, and potential interference with tumor growth” in Mihich (ed. 1985) Biological Responses in Cancer Plenum; and Freshney (1985) Anticancer Res. 5:111-130.


[0298] Invasiveness into Matrigel


[0299] The degree of invasiveness into Matrigel or some other extracellular matrix constituent can be used as an assay to identify compounds that modulate ovarian cancer-associated sequences. Tumor cells exhibit a good correlation between malignancy and invasiveness of cells into Matrigel or some other extracellular matrix constituent. In this assay, tumorigenic cells are typically used as host cells. Expression of a tumor suppressor gene in these host cells would decrease invasiveness of the host cells.


[0300] Alternatively, the level of invasion of host cells can be measured by using filters coated with Matrigel or some other extracellular matrix constituent. Penetration into the gel, or through to the distal side of the filter, is rated as invasiveness, and rated histologically by number of cells and distance moved, or by pre-labeling the cells with 125I and counting the radioactivity on the distal side of the filter or bottom of the dish. See, e.g., Freshney (1984), supra.


[0301] Tumor Growth in Vivo


[0302] Effects of ovarian cancer-associated sequences on cell growth can be tested in transgenic or immune-suppressed mice. Knock-out transgenic mice can be made, in which the ovarian cancer gene is disrupted or in which an ovarian cancer gene is inserted. Knock-out transgenic mice can be made by insertion of a marker gene or other heterologous gene into the endogenous ovarian cancer gene site in the mouse genome via homologous recombination. Such mice can also be made by substituting the endogenous ovarian cancer gene with a mutated version of the ovarian cancer gene, or by mutating the endogenous ovarian cancer gene, e.g., by exposure to carcinogens.


[0303] A DNA construct is introduced into the nuclei of embryonic stem cells. Cells containing the newly engineered genetic lesion are injected into a host mouse embryo, which is re-implanted into a recipient female. Some of these embryos develop into chimeric mice that possess germ cells partially derived from the mutant cell line. By breeding the chimeric mice it is possible to obtain a new line of mice containing the introduced genetic lesion. See, e.g., Capecchi, et al. (1989) Science 244:1288-1292. Chimeric targeted mice can be derived according to Hogan, et al. (1988) Manipulating the Mouse Embryo: A Laboratory Manual CSH Press; and Robertson (ed. 1987) Teratocarcinomas and Embryonic Stem Cells: A Practical Approach IRL Press, Washington, D.C.


[0304] Alternatively, various immune-suppressed or immune-deficient host animals can be used. For example, genetically athymic “nude” mouse (see, e.g., Giovanella, et al. (1974) J. Nat'l Cancer Inst. 52:921-930), a SCID mouse, a thymectomized mouse, or an irradiated mouse (see, e.g., Bradley, et al. (1978) Br. J. Cancer 38:263-272; Selby, et al. (1980) Br. J. Cancer 41:52-61) can be used as a host. Transplantable tumor cells (typically about 106 cells) injected into isogenic hosts will produce invasive tumors in a high proportions of cases, while normal cells of similar origin will not. In hosts which developed invasive tumors, cells expressing an ovarian cancer-associated sequences are injected subcutaneously. After a suitable length of time, preferably 4-8 weeks, tumor growth is measured (e.g., by volume or by its two largest dimensions) and compared to the control. Tumors that have statistically significant reduction (using, e.g., Student's T test) are said to have inhibited growth.


[0305] Polynucleotide Modulators of Ovarian Cancer


[0306] Antisense and RNAi Polynucleotides


[0307] In certain embodiments, the activity of an ovarian cancer-associated protein is down-regulated, or entirely inhibited, by the use of antisense polynucleotide, e.g., a nucleic acid complementary to, and which can preferably hybridize specifically to, a coding mRNA nucleic acid sequence, e.g., an ovarian cancer protein mRNA, or a subsequence thereof. Binding of the antisense polynucleotide to the mRNA reduces the translation and/or stability of the mRNA.


[0308] In the context of this invention, antisense polynucleotides can comprise naturally-occurring nucleotides, or synthetic species formed from naturally-occurring subunits or their close homologs. Antisense polynucleotides may also have altered sugar moieties or inter-sugar linkages. Exemplary among these are the phosphorothioate and other sulfur containing species which are known for use in the art. Analogs are comprehended by this invention so long as they function effectively to hybridize with the ovarian cancer protein mRNA. See, e.g., Isis Pharmaceuticals, Carlsbad, Calif.; Sequitor, Inc., Natick, Mass.


[0309] Such antisense polynucleotides can readily be synthesized using recombinant means, or can be synthesized in vitro. Equipment for such synthesis is sold by several vendors, including Applied Biosystems. The preparation of other oligonucleotides such as phosphorothioates and alkylated derivatives is also well known to those of skill in the art.


[0310] Antisense molecules as used herein include antisense or sense oligonucleotides. Sense oligonucleotides can, e.g., be employed to block transcription by binding to the antisense strand. The antisense and sense oligonucleotide comprise a single-stranded nucleic acid sequence (either RNA or DNA) capable of binding to target mRNA (sense) or DNA (antisense) sequences for ovarian cancer molecules. A preferred antisense molecule is for an ovarian cancer sequences in Tables 1-20, or for a ligand or activator thereof. Antisense or sense oligonucleotides, according to the present invention, comprise a fragment generally at least about 14 nucleotides, preferably from about 14 to 30 nucleotides. An antisense or a sense oligonucleotide can be developed based upon a cDNA sequence encoding a given protein. See, e.g., Stein and Cohen (1988) Cancer Res. 48:2659-2668; and van der Krol, et al. (1988) BioTechniques 6:958-976.


[0311] RNA interference is a mechanism to suppress gene expression in a sequence specific manner. See, e.g., Brumelkamp, et al. (2002) Sciencexpress (Mar. 21, 2002); Sharp (1999) Genes Dev. 13:139-141; and Cathew (2001) Curr. Op. Cell Biol. 13:244-248. In mammalian cells, short, e.g., 21 nt, double stranded small interfering RNAs (siRNA) have been shown to be effective at inducing an RNAi response. See, e.g., Elbashir, et al. (2001) Nature 411:494-498. The mechanism may be used to down-regulate expression levels of identified genes, e.g., treatment of or validation of relevance to disease.


[0312] Ribozymes


[0313] In addition to antisense polynucleotides, ribozymes can be used to target and inhibit transcription of ovarian cancer-associated nucleotide sequences. A ribozyme is an RNA molecule that catalytically cleaves other RNA molecules. Different kinds of ribozymes have been described, including group I ribozymes, hammerhead ribozymes, hairpin ribozymes, RNase P, and axhead ribozymes (see, e.g., Castanotto, et al. (1994) Adv. Pharmacol. 25: 289-317 for a general review of the properties of different ribozymes).


[0314] The general features of hairpin ribozymes are described, e.g., in Hampel, et al. (1990) Nucl. Acids Res. 18:299-304; European Patent Publication No. 0 360 257; U.S. Pat. No. 5,254,678. Methods of preparing them are well known to those of skill in the art. See, e.g., WO 94/26877; Ojwang, et al. (1993) Proc. Nat'l Acad. Sci. USA 90:6340-6344; Yamada, et al. (1994) Hum. Gene Ther. 1:39-45; Leavitt, et al. (1995) Proc. Nat'l Acad. Sci. USA 92:699-703; Leavitt, et al. (1994) Hum. Gene Ther. 5:1151-120; and Yamada, et al. (1994) Virology 205:121-126.


[0315] Polynucleotide modulators of ovarian cancer may be introduced into a cell containing the target nucleotide sequence by formation of a conjugate with a ligand binding molecule, as described in WO 91/04753. Suitable ligand binding molecules include, but are not limited to, cell surface receptors, growth factors, other cytokines, or other ligands that bind to cell surface receptors. Preferably, conjugation of the ligand binding molecule does not substantially interfere with the ability of the ligand binding molecule to bind to its corresponding molecule or receptor, or block entry of the sense or antisense oligonucleotide or its conjugated version into the cell. Alternatively, a polynucleotide modulator of ovarian cancer may be introduced into a cell containing the target nucleic acid sequence, e.g., by formation of an polynucleotide-lipid complex, as described in WO 90/10448. It is understood that the use of antisense molecules or knock out and knock in models may also be used in screening assays as discussed above, in addition to methods of treatment.


[0316] Thus, in one embodiment, methods of modulating ovarian cancer in cells or organisms are provided. In one embodiment, the methods comprise administering to a cell an anti-ovarian cancer antibody that reduces or eliminates the biological activity of an endogenous ovarian cancer protein. Alternatively, the methods comprise administering to a cell or organism a recombinant nucleic acid encoding an ovarian cancer protein. This may be accomplished in any number of ways. In a preferred embodiment, e.g., when the ovarian cancer sequence is down-regulated in ovarian cancer, such state may be reversed by increasing the amount of ovarian cancer gene product in the cell. This can be accomplished, e.g., by over-expressing the endogenous ovarian cancer gene or administering a gene encoding the ovarian cancer sequence, using known gene-therapy techniques, e.g. In a preferred embodiment, the gene therapy techniques include the incorporation of the exogenous gene using enhanced homologous recombination (EHR), e.g., as described in PCT/US93/03868, hereby incorporated by reference in its entirety. Alternatively, e.g., when the ovarian cancer sequence is up-regulated in ovarian cancer, the activity of the endogenous ovarian cancer gene is decreased, e.g., by the administration of an ovarian cancer antisense or RNAi nucleic acid.


[0317] In one embodiment, the ovarian cancer proteins of the present invention may be used to generate polyclonal and monoclonal antibodies to ovarian cancer proteins. Similarly, the ovarian cancer proteins can be coupled, using standard technology, to affinity chromatography columns. These columns may then be used to purify ovarian cancer antibodies usefuil for production, diagnostic, or therapeutic purposes. In a preferred embodiment, the antibodies are generated to epitopes unique to an ovarian cancer protein; that is, the antibodies show little or no cross-reactivity to other proteins. The ovarian cancer antibodies may be coupled to standard affinity chromatography columns and used to purify ovarian cancer proteins. The antibodies may also be used as blocking polypeptides, as outlined above, since they will specifically bind to the ovarian cancer protein.


[0318] Methods of Identifying Variant Ovarian Cancer-Associated Sequences


[0319] Without being bound by theory, expression of various ovarian cancer sequences is correlated with ovarian cancer. Accordingly, disorders based on mutant or variant ovarian cancer genes may be determined. In one embodiment, the invention provides methods for identifying cells containing variant ovarian cancer genes, e.g., determining all or part of the sequence of at least one endogenous ovarian cancer genes in a cell. This may be accomplished using any number of sequencing techniques. In a preferred embodiment, the invention provides methods of identifying the ovarian cancer genotype of an individual, e.g., determining all or part of the sequence of at least one ovarian cancer gene of the individual. This is generally done in at least one tissue of the individual, and may include the evaluation of a number of tissues or different samples of the same tissue. The method may include comparing the sequence of the sequenced ovarian cancer gene to a known ovarian cancer gene, e.g., a wild-type gene.


[0320] The sequence of all or part of the ovarian cancer gene can then be compared to the sequence of a known ovarian cancer gene to determine if any differences exist. This can be done using any number of known homology programs, such as Bestfit, etc. In a preferred embodiment, the presence of a difference in the sequence between the ovarian cancer gene of the patient and the known ovarian cancer gene correlates with a disease state or a propensity for a disease state, as outlined herein.


[0321] In a preferred embodiment, the ovarian cancer genes are used as probes to determine the number of copies of the ovarian cancer gene in the genome.


[0322] In another preferred embodiment, the ovarian cancer genes are used as probes to determine the chromosomal localization of the ovarian cancer genes. Information such as chromosomal localization finds use in providing a diagnosis or prognosis in particular when chromosomal abnormalities such as translocations, and the like are identified in the ovarian cancer gene locus.


[0323] Administration of Pharmaceutical and Vaccine Compositions


[0324] In one embodiment, a therapeutically effective dose of an ovarian cancer protein or modulator thereof, is administered to a patient. By “therapeutically effective dose” herein is meant a dose that produces effects for which it is administered. The exact dose will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques. See, e.g., Ansel, et al. (1999) Pharmaceutical Dosage Forms and Drug Delivery Systems Lippincott; Lieberman. (1992) Pharmaceutical Dosage Forms (vols. 1-3) Dekker, ISBN 0824770846, 082476918X, 0824712692, 0824716981; Lloyd (1999) The Art, Science and Technology of Pharmaceutical Compounding Amer. Pharmaceutical Assn.; and Pickar (1999) Dosage Calculations Thomson. Adjustments for ovarian cancer degradation, systemic versus localized delivery, and rate of new protease synthesis, as well as the age, body weight, general health, sex, diet, time of administration, drug interaction, and the severity of the condition may be necessary, and will be ascertainable with routine experimentation by those skilled in the art. U.S. patent application Ser. No. 09/687,576, further discloses the use of compositions and methods of diagnosis and treatment in ovarian cancer is hereby expressly incorporated by reference.


[0325] A “patient” for the purposes of the present invention includes both humans and other animals, particularly mammals. Thus the methods are applicable to both human therapy and veterinary applications. In the preferred embodiment the patient is a mammal, preferably a primate, and in the most preferred embodiment the patient is human.


[0326] The administration of the ovarian cancer proteins and modulators thereof of the present invention can be done in a variety of ways as discussed above, including, but not limited to, orally, subcutaneously, intravenously, intra-nasally, transdermally, intraperitoneally, intramuscularly, intrapulmonary, vaginally, rectally, or intraocularly. In some instances, e.g., in the treatment of wounds and inflammation, the ovarian cancer proteins and modulators may be directly applied as a solution or spray.


[0327] The pharmaceutical compositions of the present invention comprise an ovarian cancer protein in a form suitable for administration to a patient. In the preferred embodiment, the pharmaceutical compositions are in a water soluble form, such as being present as pharmaceutically acceptable salts, which is meant to include both acid and base addition salts. “Pharmaceutically acceptable acid addition salt” refers to those salts that retain the biological effectiveness of the free bases and that are not biologically or otherwise undesirable, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like. “Pharmaceutically acceptable base addition salts” include those derived from inorganic bases such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Particularly preferred are the ammonium, potassium, sodium, calcium, and magnesium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine.


[0328] The pharmaceutical compositions may also include one or more of the following: carrier proteins such as serum albumin; buffers; fillers such as microcrystalline cellulose, lactose, corn and other starches; binding agents; sweeteners and other flavoring agents; coloring agents; and polyethylene glycol.


[0329] The pharmaceutical compositions can be administered in a variety of unit dosage forms depending upon the method of administration. For example, unit dosage forms suitable for oral administration include, but are not limited to, powder, tablets, pills, capsules, and lozenges. It is recognized that ovarian cancer protein modulators (e.g., antibodies, antisense constructs, ribozymes, small organic molecules, etc.) when administered orally, should be protected from digestion. This is typically accomplished either by complexing the molecule(s) with a composition to render it resistant to acidic and enzymatic hydrolysis, or by packaging the molecule(s) in an appropriately resistant carrier, such as a liposome or a protection barrier. Means of protecting agents from digestion are well known in the art.


[0330] The compositions for administration will commonly comprise an ovarian cancer protein modulator dissolved in a pharmaceutically acceptable carrier, preferably an aqueous carrier. A variety of aqueous carriers can be used, e.g., buffered saline and the like. These solutions are sterile and generally free of undesirable matter. These compositions may be sterilized by conventional, well known sterilization techniques. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents and the like, e.g., sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate and the like. The concentration of active agent in these formulations can vary widely, and will be selected primarily based on fluid volumes, viscosities, body weight, and the like in accordance with the particular mode of administration selected and the patient's needs. See, e.g., Remington's Pharmaceutical Science (15th ed., 1980) and Hardman and Limbird (eds. 2001) Goodman and Gillman: The Pharmacological Basis of Therapeutics (10th ed.) McGraw-Hill. Thus, a typical pharmaceutical composition for intravenous administration would be about 0.1 to 10 mg per patient per day. Dosages from 0.1 up to about 100 mg per patient per day may be used, particularly when the drug is administered to a secluded site and not into the blood stream, such as into a body cavity or into a lumen of an organ. Substantially higher dosages are possible in topical administration. Actual methods for preparing parenterally administrable compositions are readily available.


[0331] The compositions containing modulators of ovarian cancer proteins can be administered for therapeutic or prophylactic treatments. In therapeutic applications, compositions are administered to a patient suffering from a disease (e.g., a cancer) in an amount sufficient to cure or at least partially arrest the disease and/or its complications. An amount adequate to accomplish this is defined as a “therapeutically effective dose.” Amounts effective for this use will depend upon the severity of the disease and the general state of the patient's health. Single or multiple administrations of the compositions may be administered depending on the dosage and frequency as required and tolerated by the patient. In any event, the composition should provide a sufficient quantity of the agents of this invention to effectively treat the patient. An amount of modulator that is capable of preventing or slowing the development of cancer in a mammal is referred to as a “prophylactically effective dose.” The particular dose required for a prophylactic treatment will depend upon the medical condition and history of the mammal, the particular cancer being prevented, as well as other factors such as age, weight, gender, administration route, efficiency, etc. Such prophylactic treatments may be used, e.g., in a mammal who has previously had cancer to prevent a recurrence of the cancer, or in a mammal who is suspected of having a significant likelihood of developing cancer based, e.g., in part, upon gene expression profiles. Vaccine strategies may be used, in either a DNA vaccine form, or protein vaccine.


[0332] It will be appreciated that the present ovarian cancer protein-modulating compounds can be administered alone or in combination with additional ovarian cancer modulating compounds or with other therapeutic agent, e.g., other anti-cancer agents or treatments.


[0333] In numerous embodiments, one or more nucleic acids, e.g., polynucleotides comprising nucleic acid sequences set forth in Tables 1-20, such as RNAi, antisense polynucleotides or ribozymes, will be introduced into cells, in vitro or in vivo. The present invention provides methods, reagents, vectors, and cells useful for expression of ovarian cancer-associated polypeptides and nucleic acids using in vitro (cell-free), ex vivo or in vivo (cell or organism-based) recombinant expression systems.


[0334] The particular procedure used to introduce the nucleic acids into a host cell for expression of a protein or nucleic acid is application specific. Many procedures for introducing foreign nucleotide sequences into host cells may be used. These include the use of calcium phosphate transfection, spheroplasts, electroporation, liposomes, microinjection, plasma vectors, viral vectors and any of the other well known methods for introducing cloned genomic DNA, cDNA, synthetic DNA or other foreign genetic material into a host cell. See, e.g., Berger and Kimmel (1987) Guide to Molecular Cloning Techniques from Methods in Enzymology (vol. 152) Academic Press; Ausubel, et al. (eds. 1999 and supplements) Current Protocols Lippincott; and Sambrook, et al. (2001) Molecular Cloning: A Laboratory Manual (3d ed., Vol. 1-3) CSH Press.


[0335] In a preferred embodiment, ovarian cancer proteins and modulators are administered as therapeutic agents, and can be formulated as outlined above. Similarly, ovarian cancer genes (including both the full-length sequence, partial sequences, or regulatory sequences of the ovarian cancer coding regions) can be administered in a gene therapy application. These ovarian cancer genes can include antisense applications, either as gene therapy (e.g., for incorporation into the genome) or as antisense compositions, as will be appreciated by those in the art.


[0336] Ovarian cancer polypeptides and polynucleotides can also be administered as vaccine compositions to stimulate HTL, CTL, and antibody responses. Such vaccine compositions can include, e.g., lipidated peptides (see, e.g., Vitiello, et al. (1995) J. Clin. Invest. 95:341-349), peptide compositions encapsulated in poly(D,L-lactide-co-glycolide, “PLG”) microspheres (see, e.g., Eldridge, et al. (1991) Molec. Immunol. 28:287-294; Alonso, et al. (1994) Vaccine 12:299-306; Jones, et al. (1995) Vaccine 13:675-681), peptide compositions contained in immune stimulating complexes (ISCOMS; see, e.g., Takahashi, et al. (1990) Nature 344:873-875; Hu, et al. (1998) Clin. Exp. Immunol. 113:235-243), multiple antigen peptide systems (MAPs; see, e.g., Tam (1988) Proc. Nat'l Acad. Sci. USA 85:5409-5413; Tam (1996) J. Immunol. Methods 196:17-32), peptides formulated as multivalent peptides; peptides for use in ballistic delivery systems, typically crystallized peptides, viral delivery vectors (Perkus, et al., p. 379, in Kaufinann (ed. 1996) Concepts in Vaccine Development de Gruyter; Chakrabarti, et al. (1986) Nature 320:535-537; Hu, et al. (1986) Nature 320:537-540; Kieny, et al. (1986) AIDS Bio/Technology 4:790-795; Top, et al. (1971) J. Infect. Dis. 124:148-154; Chanda, et al. (1990) Virology 175:535-547), particles of viral or synthetic origin (see, e.g., Kofler, et al. (1996) J. Immunol. Methods 192:25-35; Eldridge, et al. (1993) Sem. Hematol. 30:16-24; Falo, et al. (1995) Nature Med. 7:649-653), adjuvants (Warren, et al. (1986) Ann. Rev. Immunol. 4:369-388; Gupta, et al. (1993) Vaccine 11:293-306), liposomes (Reddy, et al.(1992) J. Immunol. 148:1585-1589; Rock (1996) Immunol. Today 17:131-137), or, naked or particle absorbed cDNA (Ulmer, et al. (1993) Science 259:1745-1749; Robinson, et al. (1993) Vaccine 11:957-960; Shiver, et al., p. 423, in Kaufmann (ed. 1996) Concepts in Vaccine Development de Gruyter; Cease and Berzofsky (1994) Ann. Rev. Immunol. 12:923-989; and Eldridge, et al. (1993) Sem. Hematol. 30:16-24). Toxin-targeted delivery technologies, also known as receptor mediated targeting, such as those of Avant Immunotherupeutics, Inc. (Needham, Mass.) may also be used.


[0337] Vaccine compositions often include adjuvants. Many adjuvants contain a substance designed to protect the antigen from rapid catabolism, such as aluminum hydroxide or mineral oil, and a stimulator of immune responses, such as lipid A, Bortadella pertussis, or Mycobacterium tuberculosis derived proteins. Certain adjuvants are commercially available as, e.g., Freund's Incomplete Adjuvant and Complete Adjuvant (Difco Laboratories, Detroit, Mich.); Merck Adjuvant 65 (Merck and Company, Inc., Rahway, N.J.); AS-2 (SmithKline Beecham, Philadelphia, Pa.); aluminum salts such as aluminum hydroxide gel (alum) or aluminum phosphate; salts of calcium, iron or zinc; an insoluble suspension of acylated tyrosine; acylated sugars; cationically or anionically derivatized polysaccharides; polyphosphazenes; biodegradable microspheres; monophosphoryl lipid A and quil A. Cytokines, such as GM-CSF, interleukin-2, -7, -12, and other like growth factors, may also be used as adjuvants.


[0338] Vaccines can be administered as nucleic acid compositions wherein DNA or RNA encoding one or more of the polypeptides, or a fragment thereof, is administered to a patient. See, e.g., Wolff et. al. (1990) Science 247:1465-1468; U.S. Pat. Nos. 5,580,859; 5,589,466; 5,804,566; 5,739,118; 5,736,524; 5,679,647; and WO 98/04720. Examples of DNA-based delivery technologies include “naked DNA”, facilitated (bupivicaine, polymers, peptide-mediated) delivery, cationic lipid complexes, and particle-mediated (“gene gun”) or pressure-mediated delivery (see, e.g., U.S. Pat. No. 5,922,687).


[0339] For therapeutic or prophylactic immunization purposes, the peptides of the invention can be expressed by viral or bacterial vectors. Examples of expression vectors include attenuated viral hosts, such as vaccinia or fowlpox. This approach involves the use of vaccinia virus, e.g., as a vector to express nucleotide sequences that encode ovarian cancer polypeptides or polypeptide fragments. Upon introduction into a host, the recombinant vaccinia virus expresses the immunogenic peptide, and thereby elicits an immune response. Vaccinia vectors and methods useful in immunization protocols are described in, e.g., U.S. Pat. No. 4,722,848. Another vector is BCG (Bacille Calmette Guerin). BCG vectors are described in Stover, et al. (1991) Nature 351:456-460. A wide variety of other vectors useful for therapeutic administration or immunization e.g., adeno and adeno-associated virus vectors, retroviral vectors, Salmonella typhi vectors, detoxified anthrax toxin vectors, and the like, will be apparent. See, e.g., Shata, et al. (2000) Mol. Med. Today 6:66-71; Shedlock, et al. (2000) J. Leukoc. Biol. 68:793-806; and Hipp, et al. (2000) In Vivo 14:571-85.


[0340] Methods for the use of genes as DNA vaccines are well known, and include placing an ovarian cancer gene or portion of an ovarian cancer gene under the control of a regulatable promoter or a tissue-specific promoter for expression in an ovarian cancer patient. The ovarian cancer gene used for DNA vaccines can encode full-length ovarian cancer proteins, but more preferably encodes portions of the ovarian cancer proteins including peptides derived from the ovarian cancer protein. In one embodiment, a patient is immunized with a DNA vaccine comprising a plurality of nucleotide sequences derived from an ovarian cancer gene. For example, ovarian cancer-associated genes or sequence encoding subfragments of an ovarian cancer protein are introduced into expression vectors and tested for their immunogenicity in the context of Class I MHC and an ability to generate cytotoxic T cell responses. This procedure provides for production of cytotoxic T cell responses against cells which present antigen, including intracellular epitopes.


[0341] In a preferred embodiment, the DNA vaccines include a gene encoding an adjuvant molecule with the DNA vaccine. Such adjuvant molecules include cytokines that increase the immunogenic response to the ovarian cancer polypeptide encoded by the DNA vaccine. Additional or alternative adjuvants are available.


[0342] In another preferred embodiment ovarian cancer genes find use in generating animal models of ovarian cancer. When the ovarian cancer gene identified is repressed or diminished in cancer tissue, gene therapy technology, e.g., wherein antisense RNA directed to the ovarian cancer gene will also diminish or repress expression of the gene. Animal models of ovarian cancer find use in screening for modulators of an ovarian cancer-associated sequence or modulators of ovarian cancer. Similarly, transgenic animal technology including gene knockout technology, e.g., as a result of homologous recombination with an appropriate gene targeting vector, will result in the absence or increased expression of the ovarian cancer protein. When desired, tissue-specific expression or knockout of the ovarian cancer protein may be necessary.


[0343] It is also possible that the ovarian cancer protein is overexpressed in ovarian cancer. As such, transgenic animals can be generated that overexpress the ovarian cancer protein. Depending on the desired expression level, promoters of various strengths can be employed to express the transgene. Also, the number of copies of the integrated transgene can be determined and compared for a determination of the expression level of the transgene. Animals generated by such methods find use as animal models of ovarian cancer and are additionally useful in screening for modulators to treat ovarian cancer.


[0344] Kits for Use in Diagnostic and/or Prognostic Applications


[0345] For use in diagnostic, research, and therapeutic applications suggested above, kits are also provided by the invention. In the diagnostic and research applications such kits may include any or all of the following: assay reagents, buffers, ovarian cancer-specific nucleic acids or antibodies, hybridization probes and/or primers, siRNA or antisense polynucleotides, ribozymes, dominant negative ovarian cancer polypeptides or polynucleotides, small molecules inhibitors of ovarian cancer-associated sequences etc. A therapeutic product may include sterile saline or another pharmaceutically acceptable emulsion and suspension base.


[0346] In addition, the kits may include instructional materials containing directions (e.g., protocols) for the practice of the methods of this invention. While the instructional materials typically comprise written or printed materials they are not limited to such. Any medium capable of storing such instructions and communicating them to an end user is contemplated by this invention. Such media include, but are not limited to electronic storage media (e.g., magnetic discs, tapes, cartridges, chips), optical media (e.g., CD ROM), and the like. Such media may include addresses to internet sites that provide such instructional materials.


[0347] The present invention also provides for kits for screening for modulators of ovarian cancer-associated sequences. Such kits can be prepared from readily available materials and reagents. For example, such kits can comprise one or more of the following materials: an ovarian cancer-associated polypeptide or polynucleotide, reaction tubes, and instructions for testing ovarian cancer-associated activity. Optionally, the kit contains biologically active ovarian cancer protein. A wide variety of kits and components can be prepared according to the present invention, depending upon the intended user of the kit and the particular needs of the user. Diagnosis would typically involve evaluation of a plurality of genes or products. The genes will be selected based on correlations with important parameters in disease which may be identified in historical or outcome data.







EXAMPLES


Example 1


Gene Chip Analysis

[0348] Molecular profiles of various normal and cancerous tissues were determined and analyzed using gene chips. RNA was isolated and gene chip analysis was performed as described (Glynne, et al. (2000) Nature 403:672-676; Zhao, et al. (2000) Genes Dev. 14:981-993).


[0349] TABLE 1A lists about 1119 genes up-regulated in ovarian cancer compared to normal adult tissues These were selected from 59000 probesets on the Affymetrix/Eos Hu03 GeneChip array such that the rato of “average” ovarian cancer to “average” normal adult tissues was greater than or equal to 5.0. The “average” ovarian cancer level was set to the second-highest value amongst five ovarian cancers. The “average” normal adult tissue level was set to the 85th percentile amongst various non-malignant tissues
1TABLE 1AABOUT 1119 UP-REGULATED OVARIAN CANCER GENESPkeyEx Accn NoUG IDTitleratio423634AW959908Hs. 1690heparin-binding growth factor binding protein65.7423017AW178761Hs. 227948“serine (or cysteine) proteinase inhibitor, clade B(ovalbumi63.6432938T27013Hs. 3132steroidogenic acute regulatory protein58.3445810AW265700Hs. 155660ESTs35.9431938AA938471Hs. 115242developmentally regulated GTP-binding protein 132.0407112AA070801Hs. 51615“ESTs, Weakly similar to ALU7_HUMAN ALU SUBFAM31.3425650NM_001944Hs. 1925desmoglein 3 (pemphigus vulgaris antigen)30.0402075predicted exon27.9400301X03635Hs. 1657estrogen receptor 126.4402639predicted exon25.3421948L42583Hs. 111758keratin 6A24.7414540BE379050“gb: 601236655F1 NIH_MGC_44 Homo sapiens cDNA clon24.6418994AA296520Hs. 89546selectin E (endothelial adhesion molecule 1)24.5401575predicted exon23.6457024AA397546Hs. 119151ESTs23.2440684AI253123Hs. 127356“ESTs, Highly similar to NEST_HUMAN NESTI [H. sapien23.1459006AW298631Hs. 27721hypothetical protein FLJ2035322.8400964predicted exon22.5402421predicted exon20.9437329AA811977Hs. 291761ESTs20.8414605BE390440“gb: 601283601F1 NIH_MGC_44 Homo sapiens cDNA clon20.7411004AW813242“gb: MR3-ST0191-020200-207-g10 ST0191 Homo sapiens20.4401283predicted exon20.3440633AI140686Hs. 263320ESTs19.9445603H08345Hs. 106234ESTs19.7403786predicted exon19.7436508AW604381Hs. 121121ESTs19.6459390BE385725“gb: 601276347F1 NIH_MGC_20 Homo sapiens cDNA clon19.2421823N40850Hs. 28625ESTs19.0417366BE185289Hs. 1076small proline-rich protein 1B (cornifin)18.9422525AA758797Hs. 192807ESTs18.5458121S42416Hs. 74647Human T-cell receptor active alpha-chain mRNA from JM c18.3430520NM_016190Hs. 242057chromosome 1 open reading frame 1018.1450192AA263143Hs. 24596RAD51-interacting protein18.0416839H94900Hs. 17882ESTs17.9440788AI806594Hs. 128577ESTs17.9451072AA013451Hs. 117929ESTs17.7402203predicted exon17.3417611AW993983“gb: RC1-BN0035-130400-013-a04 BN0035 Homo sapiens17.3438658AI222068Hs. 123571ESTs17.3403747predicted exon17.2444958AW292643Hs. 167047ESTs17.2404097predicted exon17.1459375BE251770“gb: 601112470F1 NIH_MGC_16 Homo sapiens cDNA clon16.9443198AI039813gb: ox49d06.x1 Soares_total_fetus_Nb2HF8_9w Homo sapi16.9441557AW452647Hs. 270482ESTs16.9433871W02410Hs. 205555ESTs16.8429163AA884766gb: am20a10.s1 Soares_NFL_T_GBC_S1 Homo sapiens cD16.7443406AI056238Hs. 143316ESTs16.7400613predicted exon16.6448372AW445166Hs. 170802ESTs16.5410929H47233Hs. 30643ESTs16.5445887AI263105Hs. 145597ESTs16.1422036AA302647Hs. 271891ESTs16.0404767predicted exon15.9420831AA280824Hs. 190035ESTs15.8405196predicted exon15.8452947AW130413“gb: xf50f04.x1 NCI_CGAP_Gas4 Homo sapiens cDNA clo15.8429538BE182592Hs. 139322small proline-rich protein 315.8435313AI769400Hs. 189729ESTs15.7449635AI989942Hs. 232150ESTs15.6424098AF077374Hs. 139322small proline-rich protein 315.4411660AW855718“gb: RC1-CT0279-070100-021-a06 CT0279 Homo sapiens c15.4442653BE269247Hs. 170226Homo sapiens clone 23579 mRNA sequence15.4443534AI076123gb: oy92e04.x1 Soares_fetal_liver_spleen_1NFLS_S1 Homo15.4458012AI424899Hs. 188211ESTs15.3441018AI809587Hs. 148782ESTs15.1425972BE391563Hs. 165433“ESTs, Highly similar to T17342 hypothetical protein DKFZ15.1418092R45154Hs. 106604ESTs15.1410909AW898161Hs. 53112“ESTs, Weakly similar to ALU8_HUMAN ALU SUBFAM15.1458234BE551408Hs. 127196ESTs15.0434208T92641Hs. 127648hypothetical protein PRO217615.0403177predicted exon15.0423725AJ403108Hs. 132127hypothetical protein LOC5782214.9425090AA350552“gb: EST57886 Infant brain Homo sapiens cDNA 5′ end, mR14.7409723AW885757Hs. 257862ESTs14.6423735AA330259“gb: EST33963 Embryo, 12 week II Homo sapiens cDNA 5′14.6444266AI424984Hs. 125465ESTs14.5443341AW631480Hs. 8688ESTs14.4457336AW969657Hs. 291029ESTs14.4440500AA972165Hs. 150308ESTs14.4446292AF081497Hs. 279682Rh type C glycoprotein14.3438086AA336519Hs. 301167Homo sapiens cDNA FLJ21545 fis, clone COL06195”14.3434715BE005346Hs. 116410ESTs14.2409387AW384900Hs. 123526ESTs14.2409272AB014569Hs. 52526KIAA0669 gene product14.2454913AW841462“gb: RC6-CN0014-080300-012-B09 CN0014 Homo sapiens14.0439846T63959Hs. 228320Homo sapiens cDNA FLJ23537 fis, clone LNG07690”14.0409695AA296961“gb: EST112514 Adrenal gland tumor Homo sapiens cDNA13.9422897AA679784Hs. 4290ESTs13.9404664predicted exon13.9458829AI557388“gb: PT2 1_6_G03 r tumor2 Homo sapiens cDNA 3′, mRNA13.8407327AA487182Hs. 269414ESTs13.8455435AW939445“gb: QV1-DT0072-310100-056-b07 DT0072 Homo sapiens13.7449327AI638743Hs. 224672ESTs13.7411693AW857271“gb: CM0-CT0307-210100-158-g09 CT0307 Homo sapiens13.7407463AJ272034“gb: Homo sapiens mRNA for putative capacitative calcium c13.6446767AI380107Hs. 158954ESTs13.6433040H70423Hs. 300511ESTs13.5435209AW027809Hs. 187698“ESTs, Highly similar to cytomegalovirus partial fusion rece13.5441459AI919142Hs. 214233ESTs13.5401269predicted exon13.4438663AI199575Hs. 153070ESTs13.4426698AA394104Hs. 97489ESTs13.4423637AL137279Hs. 130187Homo sapiens mRNA, cDNA DKFZp434O1214 (from clon13.2448543AW897741Hs. 21380Homo sapiens mRNA; cDNA DKFZp586P1124 (from clon13.2456714AW897265“gb: CM0-NN0057-150400-335-a04 NN0057 Homo sapiens13.2458356AI024855Hs. 131575ESTs13.2431822AA516049“gb: ng65d01.s1 NCI_CGAP _Lip2 Homo sapiens cDNA clo13.1454822AW833793“gb: QV4-TT0008-130100-080-a06 TT0008 Homo sapiens c13.1453358AI990738Hs. 240066ESTs13.1435542AA687376Hs. 269533ESTs13.1421286AA806584Hs. 187895ESTs13.0452799AI948829Hs. 213786ESTs13.0444355BE383686Hs. 191621ESTs13.0444271AW452569Hs. 149804ESTs12.9443860AW866632“gb: QV4-SN0024-210400-181-g04 SN0024 Homo sapiens12.9428719AA358193Hs. 193128hypothetical protein FLJ1080512.9418282AA215535Hs. 98133ESTs12.8437308AA749417Hs. 292353ESTs12.7400584predicted exon12.7426306AA447310Hs. 164059Homo sapiens cDNA FLJ13338 fis, clone OVARC10018812.7448466AI522109Hs. 171066ESTs12.7402738predicted exon12.7451531AA018311Hs. 114762ESTs12.6435243AW292886Hs. 261373adenosine A2b receptor pseudogene12.6431725X65724Hs. 2839Norrie disease (pseudoglioma)12.6425108AI000489Hs. 96967ESTs12.5422330D30783Hs. 115263epiregulin12.5432949AA570749Hs. 298866ESTs12.5417009AA191719Hs. 171872DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 8 (RNA12.4456378AA843387Hs. 87279ESTs12.4432966AA650114“gb: ns92h09.s1 NCI_CGAP_Pr3 Homo sapiens cDNA clon12.4440571AA904461Hs. 130798ESTs12.3411178AW820852“gb: RC2-ST0301-120200-011-f12 ST0301 Homo sapiens c12.3445934AF131737Hs. 13475hypothetical protein12.3433917AI809325Hs. 122814Human DNA sequence from clone RP5-1028D15 on chrom12.2402018predicted exon12.2424101AA335394“gb: EST39787 Epididymus Homo sapiens cDNA 5' end, mR12.2448533AL119710Hs. 21365nucleosome assembly protein 1-like 312.1458154AW816379“gb: QV4-ST0234-181199-035-g01 ST0234 Homo sapiens c12.1440919AW291274Hs. 262826ESTs12.0415747AA381209“gb: EST94257 Activated T-cells I Homo sapiens cDNA 5' e12.0411748AW859920“gb: QV1-CT0364-260100-052-g05 CT0364 Homo sapiens12.0452975M85521Hs. 69469dendritic cell protein12.0427276AA400269Hs. 49598ESTs12.0454315AW373564Hs. 251928nuclear pore complex interacting protein12.0450786H86632Hs. 33654ESTs12.0402578predicted exon11.9459591AL037185gb: DKFZp564A1169_r1 564 (synonym hfbr2) Homo sapie11.9433449AW772282“gb: hn71b05.x1 NCI_CGAP_Kid11 Homo sapiens cDNA c11.9429108AA890521Hs. 126035ESTs11.8454556AW807073“gb: MR4-ST0062-031199-018-d06 ST0062 Homo sapiens11.7443613AI079356gb: oz39b09.s1 Soares_NhHMPu_S1 Homo sapiens cDNA c11.7400385NM_020389Hs. 283104putative capacitative calcium channel11.6411725AW858396“gb: CM0-CT0341-181299-130-c06 CT0341 Homo sapiens11.5455174AI694575Hs. 147801ESTs11.5412402AW984788“gb: RC1-HN0015-120400-021-c07 HN0015 Homo sapiens11.5434205AF119861Hs. 283032hypothetical protein PRO201511.5450496AW449251Hs. 257131ESTs11.5411149N68715Hs. 269128ESTs11.5414210BE383592“gb: 601297871F1 NIH_MGC_19 Homo sapiens cDNA clon11.4409994D86864Hs. 57735acetyl LDL receptor; SREC11.3453845AL157568gb: DKFZp761F0816_r1 761 (synonym hamy2) Homo sapi11.3404849predicted exon11.3442824BE178065Hs. 144081ESTs11.3428548AA430058Hs. 98649EST11.3434804AA649530“gb: ns44f05.s1 NCI_CGAP_Alv1 Homo sapiens cDNA clo11.3430486BE062109Hs. 241551“chloride channel, calcium activated, family member 2”11.3400174predicted exon11.2424324AA346316“gb: EST52440 Greater omentum tumor Homo sapiens cDN11.2447724AW298375Hs. 24477ESTs11.2457028AW449838Hs. 97562ESTs11.2429900AA460421Hs. 30875ESTs11.2452240AI591147Hs. 61232ESTs11.2458067AA393603Hs. 36752Homo sapiens cDNA FLJ22834 fis, clone KAIA4314”11.1402222predicted exon11.1446745AW118189Hs. 156400ESTs11.1453060AW294092Hs. 21594ESTs11.1443482AW188093Hs. 250385ESTs11.1436843AA824588“gb: oc83d02.s1 NCI_CGAP_GCB1 Homo sapiens cDNA c11.0416320H47867Hs. 34024ESTs11.0435772AA700019Hs. 132992“ATP-binding cassette, sub-family G (WHITE), member 5 (11.0451542AA018365Hs. 32713ESTs11.0408522AI541214Hs. 46320“Small proline-rich protein SPRK [human, odontogenic kera11.0414712N88858.compHs. 77039ribosomal protein S3A10.9411940AW876686“gb: CM4-PT0031-180200-507-e05 PT0031 Homo sapiens c10.9408733AW264812Hs. 254290ESTs10.9452030AL137578Hs. 27607Homo sapiens mRNA; cDNA DKFZp564N2464 (from clon10.9458175AW296024Hs. 150434ESTs10.9400612predicted exon10.9440159AI637599Hs. 126127ESTs10.8429443AB028967Hs. 202687“potassium voltage-gated channel, Shal-related subfamily, m10.8416319AI815601Hs. 79197“CD83 antigen (activated B lymphocytes, immunoglobulin s10.8405783predicted exon10.7405708predicted exon10.7433266AI863224Hs. 288677Homo sapiens cDNA FLJ13872 fis, clone THYRO10013210.6456900AA355442Hs. 169054ESTs10.6432408N39127Hs. 76391“myxovirus (influenza) resistance 1, homolog of murine (int10.6451702AW665452Hs. 246503ESTs10.6418179X51630Hs. 1145Wilms tumor 110.6408987H85615gb: yt03f11.r1 Soares retina N2b5HR Homo sapiens cDNA10.6405285predicted exon10.5419276BE165909Hs. 134682Homo sapiens cDNA FLJ23161 fis, clone LNG09730”10.5407287AI678812Hs. 201658“ESTs, Weakly similar to ALU4_HUMAN ALU SUBFAM10.5403065predicted exon10.5414195BE263293“gb: 601144881F2 NIH_MGC_19 Homo sapiens cDNA clon10.4454258AI457286Hs. 143979“ESTs, Weakly similar to KIAA1276 protein [H. sapiens]”10.4412951BE018611Hs. 251946Homo sapiens cDNA FLJ23107 fis, clone LNG07738”10.4428888AA437010Hs. 266584ESTs10.4440834AA907027Hs. 128606ESTs10.4437096AA744406“gb: ny51h02.s1 NCI_CGAP_Pr18 Homo sapiens cDNA clo10.4400135predicted exon10.4447849AI538147Hs. 164277ESTs10.3400593predicted exon10.3427469AA403084Hs. 269347ESTs10.3402794predicted exon10.2452743AW965082Hs. 61455ESTs10.2448983AI611654Hs. 224908ESTs10.2422696AF242524Hs. 26323hypothetical nuclear factor SBBI2210.2428949AA442153Hs. 104744“ESTs, Weakly similar to AF208855_1 BM-013 [H. sapiens]10.2409191AW818390“gb: RC1-ST0278-160200-014-d10 ST0278 Homo sapiens c10.2428493AK001745Hs. 184028hypothetical protein FLJ1088310.2406076AL390179Hs. 137011Homo sapiens mRNA: cDNA DKFZp547P134 (from clone10.2410626BE407727“gb: 601299771F1 NIH_MGC_21 Homo sapiens cDNA clon10.1445835AW290999Hs. 145534chromosome 21 open reading frame 2310.1452507AI904646“gb: QV-BT065-020399-103 BT065 Homo sapiens cDNA, m10.1433297AV658581Hs. 282633ESTs10.1426724AA383623Hs. 293616ESTs10.0436659AI217900Hs. 144464ESTs10.0405675predicted exon10.0413466BE141737Hs. 254105“enolase 1, (alpha)”10.0447198D61523Hs. 283435ESTs10.0403306NM_006825Hs. 74368“transmembrane protein (63 kD), endoplasmic reticulum/Go10.0413544BE147225“gb: PM2-HT0225-031299-003-f11 HT0225 Homo sapiens9.9437094AW103746Hs. 136907ESTs9.9401497predicted exon9.9416203H27794Hs. 269055ESTs9.9426882AA393108Hs. 97365ESTs9.9454874AW836407“gb: PM3-LT0031-301299-002-b09 LT0031 Homo sapiens9.9406702Z20656Hs. 276432“myosin, heavy polypeptide 6, cardiac muscle, alpha (cardio9.9404952predicted exon9.9430691C14187Hs. 103538ESTs9.9444518AI160278Hs. 146884ESTs9.8416665H72974gb: yu28a10.s1 Soares fetal liver spleen 1NFLS Homo sapie9.8438691AA906288Hs. 212184ESTs9.8405636predicted exon9.8437242AA747538Hs. 187942ESTs9.8425627AF019612Hs. 297007ESTs9.8452226AA024898Hs. 296002ESTs9.8418986AI123555Hs. 81796ESTs9.8441139AW449009Hs. 126647ESTs9.7427244AA402400Hs. 178045ESTs9.7423756AA828125“gb: od71a09 s1 NCI_CGAP_Ov2 Homo sapiens cDNA clo9.7457940AL360159Hs. 30445Homo sapiens mRNA full length insert cDNA close EURO9.6443526AW792804Hs. 134002ESTs9.6440576AW449775Hs. 126008ESTs9.6419088AI538323Hs. 77496small nuclear ribonucleoprotein polypeptide G9.6454707AW814989“gb: MR1-ST0206-170400-024-g05 ST0206 Homo sapiens9.6446252AI283125Hs. 150009ESTs9.6434374AA631439“gb: np85d02.s1 NCI_CGAP_Thy1 Homo sapiens cDNA cl9.6403093predicted exon9.6454633AW811380“gb: IL3-ST0143-290999-019-D05 ST0143 Homo sapiens c9.6407291AA001464gb: ze45b01.r1 Soares retina N2b4HR Homo sapiens cDNA9.5455203AW865450“gb: PM4-SN0020-010400-008-b09 SN0020 Homo sapiens9.5403647predicted exon9.5401530predicted exon9.5414281BE269751Hs. 288995hypothetical protein FLJ208139.5411057AW815098“gb: QV4-ST0212-091199-023-f10 ST0212 Homo sapiens c9.5415953H14425Hs. 27947ESTs9.5450174T82121Hs. 177285ESTs9.5422949AA319435“gb: EST21657 Adrenal gland tumor Homo sapiens cDNA 59.5402112R58624Hs. 2186eukaryotic translation elongation factor 1 gamma9.5457886AA742279Hs. 293346ESTs9.4458145AI239457Hs. 130794ESTs9.4452332AW014859Hs. 101657ESTs9.4434950AW974892“gb: EST386997 MAGE resequences, MAGN Homo sapien9.3409601AF237621Hs. 80828keratin 1 (epidermolytic hyperkeratosis)9.3419968X04430Hs. 93913“interleukin 6 (interferon, beta 2)”9.3436211AK001581Hs. 80961“polymerase (DNA directed), gamma”9.3428412AA428240Hs. 126083ESTs9.3449441AI656040Hs. 196532ESTs9.3458771AW295151Hs. 163612ESTs9.3458543AA213403Hs. 257542ESTs9.3414257AI828600Hs. 21124“ESTs, Weakly similar to ALU8_HUMAN ALU SUBFAM9.3442826AI018777Hs. 131241ESTs9.3446740AI611635Hs. 192605ESTs9.2408938AA059013Hs. 22607ESTs9.2434157AI538316Hs. 158451ESTs9.2408774AW270899Hs. 254569ESTs9.2424268AA397653Hs. 144339Human DNA sequence from clone 495O10 on chromosome9.2415715F30364“gb: HSPD20786 HM3 Homo sapiens cDNA clone s4000099.1405277predicted exon9.1412167AW897230“gb: CM0-NN0057-150400-335-a11 NN0057 Homo sapiens9.1442771AW409808Hs. 101550ESTs9.1404898predicted exon9.1401230predicted exon9.1400623predicted exon9.1418808AI821836Hs. 10359ESTs9.1436396AI683487Hs. 299112Homo sapiens cDNA FLJ11441 fis, clone HEMBA1001329.1440466AA885871Hs. 135727ESTs9.0437568AI954795Hs. 156135ESTs9.0405382predicted exon9.0435673AF202961Hs. 284200Homo sapiens uncharacterized gastric protein ZG12P mRN9.0405848predicted exon9.0437229AW976005“gb: EST388114 MAGE resequences, MAGN Homo sapien9.0417728AW138437Hs. 24790KIAA1573 protein9.0454597AW809648“gb: MR4-ST0124-261099-015-d01 ST0124 Homo sapiens9.0427093AA398118Hs. 97579ESTs9.0408000L11690Hs. 620bullous pemphigoid antigen 1 (230/240 kD)9.0440556AW206958Hs. 125968ESTs9.0400163predicted exon8.9420120AL049610Hs. 95243transcription elongation factor A (SII)-like 18.9417549AA203651gb: zx58f10.r1 Soares_fetal_liver_spleen_1NFLS_S1 Homo8.9406163predicted exon8.9437918AI761449Hs. 121629ESTs8.9449419R34910Hs. 119172ESTs8.9434683AW298724Hs. 202639ESTs8.9418432M14156Hs. 85112insulin-like growth factor 1 (somatomedia C)8.9454590AW809762Hs. 222056Homo sapiens cDNA FLJ11572 fis, clone HEMBA1003378.8454574AW809109“gb: MR4-ST0117-070100-027-a04 ST0117 Homo sapiens c8.8441433AA933809Hs. 42746ESTs8.8416858AW979294Hs. 85634ESTs8.8421978AJ243662Hs. 110196NICE-1 protein8.8451528AA018297Hs. 35493ESTs8.8408751N91553Hs. 258343ESTs8.7401862predicted exon8.7417344AW997313“gb: RC2-BN0048-250400-018-f12 BN0048 Homo sapiens8.7454455AW752710“gb: IL3-CT0219-281099-024-A03 CT0219 Homo sapiens c8.7455592BE008002“gb: QV0-BN0147-290400-214-h04 BN0147 Homo sapiens8.7417650T05870Hs. 100640ESTs8.7456309AA225423“gb: nc24a12.r1 NCI_CGAP_Pr1 Homo sapiens cDNA clon8.7432030AI908400Hs. 143789ESTs8.7421492BE176990Hs. 104916hypothetical protein FLJ219408.7402576predicted exon8.7426874N67325Hs. 247132ESTs8.7403334predicted axon8.7408562AI436323Hs. 31141Homo sapiens mRNA for KIAA1568 protein, partial cds”8.7439443AF086261Hs. 127892ESTs8.7428600AW863261Hs. 15036“ESTs, Highly similar to AF161358_1 HSPC095 [H. sapiens8.7414539BE379046“gb: 601236646F1 NIH_MGC_44 Homo sapiens cDNA clon8.8432527AW975028Hs. 102754ESTs8.6403273predicted exon8.6452077BE144949“gb: RC2-HT0187-041099-011-d12 HT0187 Homo sapiens8.6444598AI288830Hs. 149924ESTs8.6434066AF116649Hs. 283944Homo sapiens PRO0566 mRNA, complete cds”8.6429643AA455889Hs. 187548ESTs8.6432340AA534222gb: nj21d02.s1 NCI_CGAP_AA1 Homo sapiens cDNA clon8.6446142AI754693Hs. 145968ESTs8.6417412X16896Hs. 82112“interleukin 1 receptor, type I”8.6416913AW934714“gb: RC1-DT0001-031299-011-a11 DT0001 Homo sapiens8.5451318AA029888Hs. 95071ESTs8.5405547predicted exon8.5423843AA332652gb: EST36627 Embryo, 8 week I Homo sapiens cDNA 5' en8.5454145AA046872Hs. 62798ESTs8.4401200predicted exon8.4404166predicted exon8.4412761AW995092“gb: QV0-BN0041-030300-145-a10 BN0041 Homs sapiens8.4412333AW937485“gb: QV3-DT0044-221299-045-b09 DT0044 Homo sapiens8.4455092BE152428“gb: CM0-HT0323-151299-126-b04 HT0323 Homo sapiens8.4419281H96452Hs. 42189ESTs8.4446171AI374927“gb: ta66c04.x1 Soares_total_fetus_Nb2HF8_9w Homo sapie8.3437362AL359561Hs. 16493hypothetical protein DKFZp762N23168.3402631predicted exon8.3458573AV653838Hs. 295131ESTs8.3439185AF087976Hs. 233343ESTs8.3445881AI263029Hs. 210689ESTs8.3449737A1668581Hs. 246316ESTs8.3401830AJ004832Hs. 5038neuropathy target esterase8.3421991NM_014918Hs. 110488KIAA0990 protein8.3416996W91892Hs. 59609ESTs8.2443626AI540644Hs. 138479“ESTs, Moderately similar to ALU7_HUMAN ALU SUBF8.2407471D55644gb: Human spleen PABL (pseudoautosomal boundary-like se8.2402664predicted exon8.2417682W69561gb: zd47a08.r1 Soares_fetal_heart_NbHH19W Homo sapien8.2424983AI742434Hs. 169911ESTs8.2434353AA630863Hs. 131375“ESTs, Weakly similar to ALUB_HUMAN !!!! ALU CLAS8.2453448AL036710Hs. 209527ESTs8.2455121BE156459“gb: QV0-HT0368-040100-082-f06 HT0368 Homo sapiens8.2404270predicted exon8.1438297AW515196Hs. 258238“ESTs, Moderately similar to ALU1_HUMAN ALU SUBF8.1418122R42778Hs. 22217ESTs8.1419929U90268Hs. 93810cerebral cavernous malformations 18.1400925predicted exon8.1403350predicted exon8.1426116AA868729Hs. 144694ESTs8.1441518AW161697Hs. 294150ESTs8.1421888AA299780Hs. 121036ESTs8.1402745predicted exon8.1462071predicted exon8.1444781NM_014400Hs. 11950GPI-anchored metastasis-associated protein homolog8.0430372AI206173Hs. 211375ESTs8.0449867AI672379Hs. 73919“clathrin, light polypeptide (Lcb)”8.0422174AL049325Hs. 112493Homo sapiens mRNA, cDNA DKFZp564D036 (from clone8.0413382BE090689“gb: RC1-BT0720-280300-011-f08 BT0720 Homo sapiens c8.0456502AI798611Hs. 157277ESTs8.0405336predicted exon8.0405917predicted exon8.0436007AI247716Hs. 232168ESTs8.0439192AW970536Hs. 105413ESTs8.0437724AW444628Hs. 184323ESTs8.0452755AW138937Hs. 213436ESTs8.0401781predicted exon7.9406057predicted exon7.9406289AW068311Hs. 82582“integrin, beta-like 1 (with EGF-like repeat domains)”7.9421459Ai821539Hs. 97249ESTs7.9448251BE280486Hs. 84045Homo sapiens cDNA FLJ11979 fis, clone HEMBB1001287.9429125AA446854Hs. 271004ESTs7.9440154BE077129Hs. 126119Homo sapiens cDNA FLJ13273 fis, clone OVARC1001017.9413233AW578713Hs. 47534“ESTs, Weakly similar to ORF YKL201c [S. cerenisiae]”7.9438268AA782163Hs. 293502ESTs7.9452466N84635Hs. 29664Human DNA sequence from clone 682J15 on chromosome 67.9441194BE274581“gb: 601.120870F1 NIH_LMGC_20 Homo sapiens cDNA clon7.9425292NM_005824Hs. 15554537 kDa leucine-rich repeat (LRR) protein7.9445090AW205208Hs. 147293ESTs7.9431292AA370141Hs. 251453Human DNA sequence from clone 967N21 on chromosome7.9414266BE267834“gb: 601 124428F1 NIH_MGC_8 Homo sapiens cDNA clone7.8407839AA045144Hs. 161566ESTs7.8456101AA159478gb: zo74d06 s1 Stratagene pancreas (937208) Homo sapiens7.8455853BE147225“gb: PM2-HT0225-031299-003-f11 HT0225 Homo sapiens7.8414995C18200gb: C18200 Human placenta cDNA (TFujiwara) Homo sapie7.8447247AW369351Hs. 287955Homo sapiens cDNA FLJ13090 fis, clone NT2RP30021427.8416151T26661“gb: AB6SC7R Infant brain, LLNL array of Dr M. Soares 17.8446435AW206737Hs. 253582ESTs7.8403698predicted exon7.8424914AA348410Hs. 119065ESTs7.8409731AA125985Hs. 56145“thymosin, beta, identified in neuroblastoma cells”7.8401604predicted exon7.8413025AA805265Hs. 291646ESTs7.8405896predicted exon7.8454505AW801365“gb: IL5-UM0067-240300-050-a01 UM0067 Homo sapiens7.7448283AI340402Hs. 182979nbosomal protein L127.7434098AA625499“gb: af69g08.r1 Soares_NhHMPu_S1 Homo sapiens cDNA7.7431673AW971302Hs. 293233ESTs7.7421029AW057782Hs. 293053ESTs7.7408391AW859276“gb: MR1-CT0352-240200-105-d02 CT0352 Homo sapiens7.7422529AW015128Hs. 256703ESTs7.7454389AW752571“gb: IL3-CT0213-170100-055-F02 CT0213 Homo sapien c7.7427821AA470158Hs. 98202ESTs7.7434657AA641876Hs. 191840ESTs7.7445628AI344166Hs. 155743ESTs7.7424672AA347923“gb: EST54302 Fetal heart II Homo sapiens cDNA 5' end, m7.7439232N48590Hs. 46693ESTs7.7441417AI733297Hs. 144474ESTs7.7453596AA441838Hs. 62905ESTs7.7430440X52599Hs. 2561“nerve growth factor, beta polypeptide”7.7413306AW303544Hs. 118654ESTs7.7400968predicted exon7.7446726AW300144Hs. 209209Homo sapiens cDNA FLJ11629 fin, clone HEMBA1004247.7427504AA776743Hs. 191589ESTs7.7405621predicted exon7.6414127AI431863Hs. 135270ESTs7.6409866AW502152gb: UI-HF-BR0p-air-f-11-0-UI.r1 NIH_MGC_52 Homo sap7.6446232AI281848Hs. 165547ESTs7.6403568predicted exon7.6451458AI797558Hs. 270820ESTs7.6439157AA912737Hs. 20160ESTs7.6401793predicted exon7.6429839AI190291Hs. 112143ESTs7.6445672AI907438Hs. 282862ESTs7.6449444AW818436Hs. 23590“solute corrier family 16 (monocarboxylic acid transporters)7.6447499AW262580Hs. 147674KIAA1621 protein7.6421773W69233Hs. 112457ESTs7.6439706AW872527Hs. 59761ESTs7.5432189AA527941“gb: nh30c04 s1 NCI_CGAP_Pr3 Homo sapiens cDNA clon7.5402050predicted exon7.5429687AI675749Hs. 211608nucleoporin 153kD7.5423193R07299Hs. 254637Homo sapiens cDNA FLJ13502 fis, clone PLACE 10046367.5416548H62953gb: yr47t06.r1 Soares fetal liver spleen 1NFLS Homo sapien7.5443236AI079496Hs. 134169ESTs7.5436053AI057224Hs. 15443ESTs7.4437191NM_006846Hs. 5476“senne protease inhibitor, Kazal type, 5”7.4451829AW964081Hs. 247377ESTs7.4443151AI827193Hs. 132714ESTs7.4452055AI377431Hs. 293772ESTs7.4445265AI218295Hs. 144942ESTs7.4401032predicted exon7.4448184BE541249Hs. 109697ESTs7.4414608T95945gb: ye42e02.r1 Soares fetal liver spleen 1NFLS Homo sapine7.4418540AI821597Hs. 90877“ESTs, Weakly similar to ALU1_HUMAN ALU SUBFAM7.4410449AW748954Hs. 18192Ser/Arg-related nuclear matrix protein (plenty of prolines 17.4435568AA688048Hs. 294080ESTs7.4459160AI904723“gb: CM-BT066-120299-092 BT066 Homo sapiens cDNA,7.4419753N42531gb: yy11c 2.r1 Soares melunocyte 2NbHM Homo sapiens cD7.4432383AK000144Hs. 274449Homo sapiens cDNA FLJ20137 fis, clone C0L07137”7.4404893predicted xeon7.4425349AA425234Hs. 79886ribose 5-phosphate isomerase A (ribose 5-phosphate epimer7.4413864BE175582“gb: RCS-HT0580-100500-022-C01 HT0580 Homo sapiens7.3426871AA393041Hs. 216493ESTs7.3415613R20233gb: yg18h11.r1 Soares infant brain 1NlB Homo sapiens cDN7.3427025AA397589Hs. 97523ESTs7.3444683AI375101Hs. 158721“ESTs, Weakly similar to ALU1_HUMAN ALU SUBFAM7.3447700AI420183Hs. 171077“ESTs, Weakly similar to similar to serine/threoninse kinase7.3412740AW993984“gb: RC1-BN0035-130400-013-a05 BN0035 Homo sapiens7.3416642T96118Hs. 226313“ESTs, Weakly similar to ALU1_HUMAN ALU SUBFAM7.3416506H59879Hs. 237306ESTs7.3426130AA853282gb: NHTBCae04f07.r1 Normal Human Trahecular Bone Cell7.3407392AB032369“gb: Home sapiens MIST mRNA, partial cds”7.3432365AK001106Hs. 274419hypothetical protein FLJ102447.3451221AI949701Hs. 210589ESTs7.3443161AI038316gb: ox48c08.x1 Soares_total_fetus_Nb2HF8_9W Homo sapie7.3418186BE541042Hs. 23240Homo sapiens cDNA FLJ13496 fis, clone PLACE10044717.3439152H65014gb: yu66t10.r1 Weizmann Olfactory Epithulium Homo sapie7.2459534BE386808Hs. 147905ESTs7.2443326BE156494Hs. 188478ESTs7.2417351T90278Hs. 15049ESTs7.2454182AW177335“gb: CM1-CT0129-180899-006-b08 C10129 Homo sapiens7.240298predicted exon7.2458562N34128Hs. 145268ESTs7.2407021U52077“gb: Humun manner1 transposase gene, complete consensus7.2449276AW241510Hs. 252713ESTs7.2418251AA832123Hs. 177723ESTs7.2420788AA937957Hs. 193367ESTs7.2401881predicted xeon7.2456436AA251079Hs. 158386ESTs7.2413425F20956“gb: HSPD05390 HM3 Homo sapiens cDNA clone 032-X4-7.2448966AW372914Hs. 287462Homo sapiens cDNA FLJ11875 fis, clone HEMBA1007077.2429340N35938Hs. 199429Homo sapiens mRNA, cDNA DKFZp434M2216 (from clon7.2406053predicted exon7.2405851predicted exon7.2431009BE149762Hs. 248213“gap lunction protein, beta 6 (connexin 30)”7.2426662AA879474Hs. 122710ESTs7.2408536AW381532Hs. 135188ESTs7.1455013BE073250“gb: MR0-BT0551-060300-102-e05 BT0551 Homo sapiens7 .1428910W03667Hs. 193792ESTs7.1424634NM_003613Hs. 151407“cartilage intermediate layer protein, nucleotide pyrophosph7.1449794AW444502HS.256982“ESTs, Highly similar to AE116865 1 hedgehog-interacting7.1423410AF058989Hs. 128231“G antigen, family B, 1 (prostate associated)”7.1445460AI797473Hs. 209468ESTs7.1447285AI371849Hs. 200696“ATPase, Class VI, type 11C”7.1419750AL079741Hs. 183114Homo sapiens cDNA FLJ14236 fis, clone NT2RP40005157.1438986AF085888Hs. 269307ESTs7.1420757X78592Hs. 99915androgen receptor (dihydrofestostemse receptor, testicular7.1432479AL042844Hs. 275675katanin p80 (WD40-containing) subunit B 17.1449733R74546Hs. 29438Homo sapiens cDNA FLJ12094 fis, clone HEMBB1002607.1437846AA773866Hs. 244569ESTs7.1454934AW846080“gb: MR3-CT0176-081099-002-b09 CT0176 Homo sapiens7.1421929AA300543Hs. 247360ESTs7.1401780predicted exon7.0448106AI800470Hs. 171941ESTs7.0448835BE277929Hs. 11081“ESTs, Weakly similar to S57447 HPBRII-7 protein [H. sap7.0400842predicted exon7.0429364AA451797Hs. 201202“ESTs, Moderately similar to Pre-Pol-dUTPase polyprolein7.0454963AW847647“gb: IL3-CT0213-280100-056-A06 CT0213 Homo sapiens c7.0423891AK002042Hs. 134795Homo sapiens cDNA FLJ11180 fis, clone PLACE10074527.0467506U71600“gb: Human zinc finger protein zfp31 (zf31) mRNA, partial7.0413802AW964490Hs. 32241ESTs7.0440051BE559980“gb: 601345293F1 NIH_MGC_8 Homo sapiens cDNA clone7.0446283AI948801Hs. 171073ESTs7.0419236AA330447Hs. 135159“Home sapiens cDNA FLJ11481 fis, clone HEMBA1001807.0405472predicted exon7.0435024AI863518Hs. 127743“ESTs, Weakly similar to V-ATPase G-subunit like protein7.0453969AW090783Hs. 301731“Home sapiens cDNA FLJ11738 fie, clone HEMBA1005477.0404992predicted exon7.0428129AI244311Hs. 26912ESTs7.0414315Z24878“gb: HSB65D052 STRATACENE Human skeletal muscle cD7.0400491H25530Hs. 50868“solute carrier family 22 (organic cation transporter), memb6.9459275AI808913Hs. 118321ESTs6.9450853AA479629Hs. 44243ESTs6.9457460AI143312Hs. 164004ESTs6.9434168AI204525Hs. 116156ESTs6.9445153AI214671“gb: qm32d02.x1 NCI_CGAP_Lu5 Homo sapiens cDNA clo6.9450028AI912012Hs. 200737ESTs6.9414954D81402gb: HUM162A03B Human fetal brain (TFujiwara) Homo sa6.9459478AW195566Hs. 253182ESTs6.9426269H15302Hs. 168950Homo sapiens mRNA, cDNA DKFZp566A1046 (from clon6.9401050predicted exon6.9447588AI394154Hs. 279659“ESTs, Weakly similar to unknown protein [H. sapiens]”6.9449002AI620018Hs. 117461ESTs6.9452759AW590773Hs. 258996ESTs6.9443220R85304Hs. 132032Homo sapiens cDNA FLJ11683 fis, clone HEMBA1004906.9400749predicted exon6.8406277predicted exon6.8433785BE044593Hs. 112704ESTs6.8434129AI807757Hs. 221041ESTs6.8453369BE551550Hs. 232630ESTs6.8411722AW875942“gb: CM1-PT0013-131299-067-b10 PT0013 Homo sapiens6.8455152AW858621“gb: CM0-CT0342-021299-115-f04 CT0342 Homo sapiens6.8412670AA115456gb: zkB9b05.r1 Soares_pregnant_uterus_NbHPU Homo sapi6.8419054N40340Hs. 191510“ESTs, Weakly similar to ORF2 [M. muscular]”6.8421316AA287203Hs. 251397SMA56.8432363AA534489gb: nf76g11 .s1 NCI_CGAP_Co3 Homo sapiens cDNA clone6.8458603AW103046Hs. 6162KIAA0771 protein6.8439527AW298119Hs. 202536ESTs6.8408920AL120071Hs. 48998fibronectin leucine rich trasamembrane protein 26.8439127AW978465Hs. 292368ESTs6.8434890AF161345Hs. 283930“Hamo sapiens HSPC082 mRNA, partial cds”6.8429413NM_014058Hs. 201877DESC1 protein6.7407788BE514982Hs. 38991S100 calcium-binding protein A26.7447252R90916gb:yn01e10.r1 Soares adult brain N2b4HB55Y Homo sapien6.7455851BE146879“gb: QV4-HT0222-261099-014-c11 HT0222 Homo sapiens6.7439509AF086332Hs. 58314ESTs6.7418858AW961605Hs. 21145Homo sapiens cDNA FLJ22489 fis, clone HRC10951”6.7419323AI092379Hs. 135275ESTs6.7415317Z43388Hs. 5570hypathehcal protein FLJ100066.7418654AA226334Hs. 154291ESTs6.7407413AF067801“gb: Homo sapiens HDCGC21P mRNA, complete cds.”6.7439694AA843915Hs. 54707ESTs6.7451191N67900Hs. 118446ESTs6.7454006U12775Hs. 37006agouti (mouse)-signaling protein6.7443657R14973gb: yf42f10.s1 Soares fetal liver spleen 1NFLS Homo sapien6.7455879BE153275“gb: PM0-HT0335-180400-008-e11 HT0335 Homo sapiens6.7451368BE242152Hs. 288417protein serine threonine kinase Clk46.7453509AL040021gb: DKFZp434N1812_r1 434 (synonym htes3) Homo sapie6.7420892AW975076Hs. 172589nuclear phosphoprotein similar to S. cerevisine PWP16.7423372AI246375Hs. 154458ESTs6.7450316W84446Hs. 17850ESTs6.7447795AW295151Hs. 163612ESTs6.7413252BE074910“gb: RC5-5T0580-170300-021-F12 BT0580 Homo sapiens6.7405771predicted exon6.6411483AW848115“gb: IL3-CT0214-301299-048-C09 CT0214 Homo sapiens c6.6420271AI954365Hs. 42892ESTs6.6431948AA917706Hs. 194616ESTs6.6409629AW449589Hs. 279724ESTs6.6458841W28965gb: 54d10 Human retran cDNA randomly primed sublibrary6.6416565AW000960Hs. 44970ESTs6.6409097AA677927Hs. 144269ESTs6.6441832AI018249Hs. 128062ESTs6.6457285AI038858Hs. 228780“ESTs, Highly similar to AF199597_1 A-type potassium cha6.6406504predicted exon6.6414606BE387771“gb: 601283251F1 NIH_MGC_44 Homo sapiens cDNA clon6.6452956AW003578Hs. 231872ESTs6.6410743AA089474Hs. 272153ESTs6.6404599predicted exon6.6423575C8863Hs. 163443Homo sapiens cDNA FLJ11576 fis, clone HEMBA1003546.6443027AI027847Hs. 253550ESTs6.6458663AV658444Hs. 280776Homo sapiens cDNA FLJ13684 fis, clone PLACE20000216.6431277AA501806Hs. 249965ESTs6.6445232BE294357“gb: 601172878F1 NIH_MGC_17 Homo sapiens cDNA clon6.6459170AI905518“gb: RC-8T091-210199-098 BT091 Homo sapiens cDNA, m6.6437876AA770151Hs. 126424ESTs6.6406752AI285598Hs. 217493annexin A26.6401245predicted exon6.6446102AW168067Hs. 252956ESTs6.5446989AK001898Hs. 16740hypathetical protein FLJ110366.5421160AL080215Hs. 102301Homo sapiens mRNA; cDNA DKFZp586J0323 (from clone6.5458831H71739Hs. 200227ESTs6.5408914AW450309gb: UI-H-B13-akz-g-08-0-UI s1 NCI_CGAP_Sub5 Homo sa6.5411018AW813428“gb: MR3-ST0192-010200-210-c05 ST0192 Homo sapiens c6.5436562H71937Hs. 169756“complement component 1, s subcamponent6.5457620AA602711“gb: np03h06 s1 NCI_CGAP_Pr2 Homo sapiens cDNA clon6.5438647AA813118Hs. 163230ESTs6.5439570T79925Hs. 269165ESTs6.5419273BE271180Hs. 293490ESTs6.5443745AB039670Hs. 9728ALEX1 protein6.5431029BE392725Hs. 248571Homo sapiens PAC clone RP5-1163J12 from 7q21.2-q31.16.5458695AV660159Hs. 282284ESTs6.5410966AW812088“gb: RC4-ST0173-191099-032-a07 ST0173 Homo sapiens c6.4417135AA422067Hs. 50547ESTs6.4416441BE407197“gb: 601301552F1 NIH_MGC_21 Homo sapiens cDNA clon6.4413702BE170313“gb: QV4-HT0536-040500-193-g02 HT0536 Homs sapiens6.4452563AI907552“gb: RC-BT147-120499-044 BT147 Homo sapiens cDNA, m6.4408956AK001868Hs. 295306“ESTs, Highly similar to unnamed protein product [H. sapien6.4406349predicted exon6.4425420BE536911Hs. 234545“ESTs, Weakly similar to AF155135_1 novel retinal pigmen6.4459430AW662886gb: hi82h11.x1 Soares_NFL_T_GBC_S1 Homo sapiens cDN6.4425733F13287Hs. 159388Homs sapiens clone 23578 mRNA sequence6.4458678AI306162Hs. 170938“ESTs, Weakly similar to KIAA0705 protein [H. sapiens6.4429695AA835714Hs. 293556ESTs6.4426872AA410446Hs. 112011ESTs, Weakly similar to unknown [H. sapiens]”6.4437152AL050027gb: Homo sapiens mRNA, cDNA DKFZp566C0324 (from c6.4440517AW139632Hs. 132246ESTs6.4450877AI799608Hs. 29178ESTs6.4410664NM_006033Hs. 65370“lipase, endothelial”6.4405793predicted exon6.4418709AA227394gb: zr17c10.r1 Stratagene NT2 neuronal precursor 937230 H.6.4428684AA431792Hs. 44784ESTs6.4448516AW898595“gb: RC1-NN0073-260400-011-g09 NN0073 Homo sapiens6.4400983predicted exon6.3422365AF035537Hs. 115521“REV3 (yeast homolog)-like, catalytic subunit of DNA poly6.3425612BE004257gb: CM0-BN0103-180300-296-c04 BN0103 Homo sapiens6.3401521predicted exon6.3430290AI734110Hs. 136355ESTs6.3414931AK000342Hs. 77646Homo sapiens mRNA; cDNA DKFZp761M0223 (from clon6.3437939AW298600Hs. 141840“ESTs, Weakly similar to S59501 interferon receptor JFNA6.3451842AI820539Hs. 267087“ESTs, Moderately similar to ALU4_HUMAN ALU SUBF6.3405810predicted exon6.3443747AV646352“gb: AV646352 GLC Homo sapiens cDNA clone GLCAME6.3427287NM_014903Hs. 174188KIAA0938 protein6.3413521BE145814“gb: MR0-HT0208-101299-202-a04 HT0208 Homo sapiens6.3429090AW820278Hs. 99066ESTs6.3451488H22999Hs. 208846ESTs6.3455713BE069891“gb: QV4-BT0401-201299-064-b01 BT0401 Homo sapiens6.3452161R43077Hs. 221747ESTs6.3428647AA830050Hs. 124344ESTs6.3445063AI246275Hs. 149196ESTs6.3456671AB011142Hs. 114293KIAA0570 gene product6.3401508predicted exon6.3412677AW029608Hs. 17384ESTs6.3441720AI346487Hs. 28739ESTs6.3418051AW192535Hs. 19479ESTs6.3438014N71183Hs. 121806Homo sapiens cDNA FLJ1I971 fis, clone HEMSBB1001206.3432101AI918950Hs. 11092Homo sapiens cDNA FLJ14290 fis, clone PLACE10067956.3421032AW293133Hs. 101340ESTs6.3436532AA721522gb: nv54h12.r1 NCL_CGAP_Ew1 Homo sapiens cDNA clo6.3431318AA502700Hs. 293147ESTs6.3413470N20934gb: yx5Ac11 s1 Soares melanocyte 2NbHM Homo sapiens c6.3402425predicted exon6.3455993BE179085“gb: RC0-HT0613-140300-021-d06 HT0613 Homo sapiens6.3400160predicted exon6.3413795AL040178Hs. 142003ESTs6.2405071predicted exon6.2403741predicted exon6.2432489AI804855Hs. 207530ESTs6.2402296predicted exon6.2446091AW022192Hs. 200197ESTs6.2444788AI871122Hs. 202821ESTs6.2404972predicted exoc6.2400227predicted exon6.2433804AI936561Hs. 112740ESTs6.2448807AI571940Hs. 7549ESTs6.2404340predicted exon6.2424032AB014523Hs. 151406KIAA0623 gene product6.2449547H93543Hs. 117963ESTs6.2406945K01383Hs. 203967metallothionein 1A (functional)6.2433663AF083131Hs. 229535CATX-15 protein6.2407809AW082279Hs. 244106ESTs6.2418342BE002723Hs. 293504ESTs, Moderately similar to ALU1_HUMAN ALU SU8F6.2438007AA133008Hs. 158675ribosomal protein L146.2410536N39533gb: yv27d04.s1 Soares fetal liver spleen 1NFLS Homs sapie6.2448005AW207437Hs. 170378ESTs6.2414083AL121282Hs. 257786ESTs6.2405362predicted exon6.2410102AW248508Hs. 279727Homo sapiens cDNA FLJ14035 fis, clone HEMBA1004636.2457868AW975133gb: EST387239 MAGE resequences, MAGN Homo sapies6.2407395AF005082“gb: Homo sapiens skin-specific protein (xp33) mRNA, part6.2443603BE502601Hs. 134289“ESTs, Weakly similar to KIAA1063 protein [H. sapiens]”6.2430051AA464611Hs. 52515transducin (beta)-like 26.1434569AI311295Hs. 58609ESTs6.1430481AA479678Hs. 203269ESTs, Moderately similar to ALU8_HUMAN ALU SUBF6.1402859predicted exon6.1401260predicted exon6.1406544predicted eson6.1428446AI024600Hs. 98612ESTs6.1412246AI160873Hs. 69233“ESTs, Weakly similar to KIAA1064 protein [H. sapiens]”6.1400420AJ277247Hs. 287369interleukin 226.1455662BE065387gb: RC1-BT0314-030500-016-d03 BT0314 Homo sapiens6.1428613AB037749Hs. 186928KIM1328 protein6.1443267AW450630Hs. 133851ESTs6.1433405AW157566Hs. 156892ESTs6.1416795AI497778Hs. 168053ESTs, Highly similar to AF227948_1 HBV pX associated p6.1435706W31254Hs. 7045GL004 protein6.1450769AA057418Hs. 33654ESTs6.1427174AA398848Hs. 97541ESTs6.1425389AW974499Hs. 192183ESTs6.1416675H73802Hs. 35381ESTs6.1432749NM_014438Hs. 278909Interleukin-1 Superfamily e6.1401809predicted exon6.1403041predicted exon6.0408523AW833259gb: RC2-TT0007-131099-011-c01 TT0007 Homo sapiens c6.0416515N91716Hs. 194140ESTs6.0452591BE173164Hs. 1516insulin-like growth factor-binding protein 46.0437146AA730977gb: nw55f05 s1 NCI_CGAP_Ew1 Homo sapiens cDNA clo6.0450094AI174947Hs. 295789Homo sapiens mRNA, cDNA DKFZpS64D1164 (from clon6.0402529predicted exon6.0430706NM_003540Hs. 247816“H4 histone family, member C”6.0459186AI908287gb: RC-BT168-020499-035 BT168 Homo sapiens cDNA, m6.0452158AI699120Hs. 61198ESTs6.0411237AW833676gb: QV4-TT0008-181199-038-h04 TT0008 Homo sapiens6.0400441AA15530Hs. 99879B-cell growth factor 1 (12 kD)6.0439398AA284267Hs. 221504ESTs6.0440862H39048Hs. 127432ESTs6.0415451H19415Hs. 268720“ESTs, Moderately similar to ALU1_HUMAN ALU SUBF6.0459587AA031956gb: zk15e04 s1 Soares_pregnant_utems_NbHPU Homo sapi6.0456072H54381gb: yq89a03 s1 Soares fetal liver spleen 1NFLS Homo sapie6.0409954AW512770Hs. 266457ESTs6.0443488AI073495Hs. 133912“ESTs, Weakly similar to methyl-CpG binding domain-coat6.0430825AI734186Hs. 185105ESTs6.0454466AA984138Hs. 279895Homo sapiens mRNA for KIAA1578 protein, partial cds”6.0456506AA278277Hs. 194212ESTs6.0449228AJ403107Hs. 148590“ESTs, Weakly similar to AF208846_1 BM-004 [H. sapiens]6.0457727AW974687gb: EST386776 MAGE resequences, MAGM Homos sapien6.0442440BE464435Hs. 146180“ESTs, Weakly similar to non-receptor protein tyrosine kina5.9455110BE154505gb: PM0-HT0343-281299-003-e06 HT0343 Homo sapiens5.9402790predicted exon5.9409982BE005839gb: RC2-BN0120-250400-012-f03 BN0120 Homo sapiens5.9427635BE397988Hs. 179982tumor protein p53-binding protein5.9408948AW296713Hs. 221441ESTs5.9402046predicted exon5.9416438R89238Hs. 34262ESTs5.9403083predicted exon5.9402481predicted exon5.9409867AW502161gb: UI-HF-BR0p-ajr-g-12-0-UI.r1 NIH_MGC_52 Homo sap5.9420362U79734Hs. 97206huntingtin interacting protein 15.9421375AA489200Hs. 100595“ESTs, Moderately similar to ALU1_HUMAN ALU SUBF5.9437630AI252782Hs. 153029ESTs5.9443500AV646388Hs. 137071ESTs5.9448995AI613276Hs. 5662“guanine nucleotide binding protein (G protein), beta polyp5.9438214H06076Hs. 26320TRABID protein5.9428046AW812795Hs. 155381“ESTs, Moderately similar to I38022 hypothetical protein [H.5.9431941AK000106Hs. 272227Homo sapiens cDNA FLJ20099 fis, clone COL04544”5.9403356predicted exon5.9439031AF075079gb: Homo sapiens full length insert cDNA YQ80A085.9430032AW936136Hs. 99610ESTs5.9423457F08208Hs. 155606paired mesoderm homeo box 15.9422158L10343Hs. 112341“protease inhibitor 3, skin-derived (SKALP)”5.9406592predicted exon5.9418636AW749855“gb: QV4-BT0534-281299-053-c05 BT0534 Homo sapiens5.8429399AA452244Hs. 16727ESTs5.8408590AW238162Hs. 253873ESTs5.8422168AA586894Hs. 112408S100 calcium-binding protein A7 (psonasin 1)5.8417421AL138201Hs. 82120“nuclear receptor subfamily 4, group A, member 2”5.8401129predicted exon5.8434745AW974445Hs. 185155“ESTs, Weakly similar to HuEMAP [H. sapiens]”5.8402800predicted exon5.8436185AW753380Hs. 49753Homo sapiens mRNA for KIAA1561 protein, partial cds”5.8419519AI198719Hs. 176376ESTs5.8452542AW812256“gb: RC0-ST0174-191099-031-a07 ST0174 Homo sapiens c5.8427166AA431576Hs. 155658ESTs5.8416168H23687gb: yn72d12.r1 Soares adult brain N2b5HB55Y Homo sapie5.8431467N71831Hs. 256398Homo sapiens mRNA, cDNA DKFZp434E0528 (from clon5.8421558AB011125Hs. 105749KIAA0553 protein5.8458055AW979121Hs. 131375“ESTs, Weakly similar to ALUB_HUMAN !!!! ALU CLAS5.8418345AJ001696Hs. 241407“serine (or cysteine) proteinase inhibitor, clade B (ovalbumi5.8426544AA492325gb: ng81b11.s1 NCI_CGAP_Pr6 Homo sapiens cDNA clone5.8433544AI793211Hs. 165372“ESTs, Moderately similar to ALU1_HUMAN ALU SUBF5.8442007AA301116Hs. 142838Homo sapiens cDNA FLJ23444 fis, clone HSI01343”5.8443422R10288Hs. 301529ESTs5.8434311BE543469Hs. 266263Homo sapiens cDNA FLJ14115 fis, clone MAMMA100175.8424966AU077312Hs. 153985“solute carrier family 7 (cationic amino acid transporter, y+5.8441744AA960922Hs. 200938ESTs5.8413101BE065215“gb: RC1-BT0314-310300-015-f01 BT0314 Homo sapiens c5.7445687W80382Hs. 149297ESTs5.7441369AA931535gb: oo55a04 s1 NCI_CGAP_Lu5 Homo sapiens cDNA clon5.7414428BE296906Hs. 182625VAMP (vesicle-associated membrane protein)-associated pr5.7431211M86849Hs. 5566“gap junction protein, beta 2, 26 kD (connexin 26)”5.7411541W03940gb: za62b02.r1 Soares fetal liver spleen 1NFLS Homo sapien5.7448612AI696363Hs. 171285ESTs5.7419118AA234223Hs. 139204ESTs5.7406322predicted exon5.7454690AW854639“gb: MR1-CT0258-140100-203-d10 CT0258 Homo sapiens5.7450313AI038989Hs. 24809hypothetical protein FLJ108265.7416292AA179233Hs. 42390nasopharyngeal carcinoma susceptibility protein5.7449309AW589823Hs. 224189ESTs5.7408418AW963897Hs. 44743KIAA1435 protein5.7416100H18700Hs. 268799ESTs5.7437845AA769578Hs. 90488ESTs5.7443345AI052508Hs. 164482“ESTs, Weakly similar to contains similarity to TPR domain5.7418407AL044818Hs. 84928“nuclear transcription factor Y, beta”5.7434557AW855466Hs. 271866“ESTs, Weakly similar to ALU1_HUMAN ALU SUBFAM5.7431688AA513906“gb: ng67c08.s1 NCI_CGAP_Lip2 Homo sapiens cDNA clo5.7437641AA811452Hs. 291911ESTs5.7409319AW752736Hs. 33565ESTs5.7403967AF030107Hs. 17165regulator of G-protein signalling 135.7445189AI936450Hs. 147482ESTs5.7414418H62943Hs. 154188ESTs5.7446563BE326588Hs. 141454ESTs5.7446075AW451457Hs. 279179ESTs5.7428068AW016437Hs. 233462ESTs5.7438425AW292922Hs. 293170ESTs5.7415532R14780Hs. 12826ESTs5.7441442AL043282Hs. 131824ESTs5.7443380AI792478Hs. 135377ESTs5.7445527W39694Hs. 83286ESTs5.7414376BE393856Hs. 66915“ESTs, Weakly similar to 16.7 Kd protein [H. sapiens]”5.7457960AA771881Hs. 298149ESTs5.6453293AA382267Hs. 10653ESTs5.6452503AB000509Hs. 29736TNF receptor-associated factor 55.6405227predicted exon5.6442257AW503831gb: UI-HF-BN0-alb-b-05-0-UI.r1 NIH_MGC_50 Homo sap5.6463403predicted exon5.6454377AA076811gb: 7B03C12 Chromosome 7 Fetal Brain cDNA Library Hom5.6438656H85310Hs. 209456“ESTs, Weakly similar to NG22 [H. sapiens]”5.6419936AI792788“gb: ol91d05.y5 NCI_CGAP_Kid5 Homo sapiens cDNA clo5.6437267AW511443Hs. 258110ESTs5.6430563AA481269Hs. 178381ESTs5.6444835AI198994Hs. 158479ESTs5.6444902AJ132099Hs. 12114vanin 15.6451800AW977435Hs. 31890ESTs5.6465465predicted exon5.6463891predicted exon5.6425557AI694300Hs. 46730ESTs5.6432162AA584062Hs. 272798hypothetical protein FLJ204135.6450152AI138635Hs. 22968ESTs5.6410053AW579707Hs. 59332ESTs5.6421285NM_000102Hs. 1363“cytochrome P450, subfamily XVII (steroid 17-alpha-hydro5.6425264AA353953Hs. 20369“ESTs, Weakly similar to gonadotropin inducible transcript5.6418844M62982Hs. 1200arachidonate 12-lipoxygenase5.6429616AI982722Hs. 120845ESTs5.6423528AB011137Hs. 129740KIAA0565 gene product5.6403089predicted exon5.6414373AW162907Hs. 75969proline-rich protein with nuclear targeting signal5.6403687predicted exon5.6417079U65590Hs. 81134interleukin 1 receptor antagonist5.5432501BE546532Hs. 287329Fas binding protein 15.5403691predicted exon5.5409545BE296182“gb: 601177324F1 NIH_MGC_17 Homo sapiens cDNA clon5.5435990AI015862Hs. 131793ESTs5.5444409AI792140Hs. 49265ESTs5.5435478AA682622gb: zj20f09.s1 Soares_fetal_liver_spleen_1NFLS_S1 Homo5.5439981AI348408Hs. 124675“ESTs, Weakly similar to unnamed protein product [H. sapie5.5433644AW342028Hs. 256112ESTs5.5441541AA938663Hs. 199828ESTs5.5400709predicted exon5.5407615AW753085“gb: PM1-CT0247-151299-005-a03 CT0247 Homo sapiens5.5424153AA451737Hs. 141496MAGE-like 25.5452465AA610211Hs. 34244ESTs5.5406030predicted exon5.5431071AA491379“gb: aa65f05.r1 NCI_CGAP_GCB1 Homo sapiens cDNA cl5.5418086AA211791Hs. 269666Homo sapiens cDNA FLJ13415 fis, clone PLACE10017995.5453034BE246010Hs. 184109ribosomal protein L37a5.5412953Z45794Hs. 238809ESTs5.5425351AI206234Hs. 155924cAMP responsive element modulator5.5406149predicted exon5.5416533BE244053Hs. 79362retinoblastoma-like 2 (p130)5.5458378AI040535Hs. 150524ESTs5.5401213predicted exon5.5405904predicted exon5.5445132Z44811gb: HSC29G031 normalized infant brain cDNA Homo sapie5.5405138predicted exon5.5442238AW135374Hs. 270949ESTs5.5416852AF283776Hs. 80285Homo sapiens mRNA, cDNA DKFZp586C1723 (from clon5.5448691AA481119Hs. 283558hypothetical protein PRO18555.5452242R50956Hs. 59503“ESTs, Weakly similar to AF157318_1 AD-017 protein [H. s5.5456994AA383623Hs. 293616ESTs5.5440913AI267491Hs. 160593ESTs5.5435380AA679001Hs. 192221ESTs5.5450375AA009647Hs. 8850a disintegrin and metalloproteinase domain 12 (meltrin alph5.5414035Y00630Hs. 75716“serine (or cysteine) proteinase inhibitor, clade B (ovalbumi5.4459084H01699Hs. 27289CGI-125 protein5.4405867predicted exon5.4414093BE544867“gb: 601078872F1 NIH_MGC_12 Homo sapiens cDNA clon5.4447306AI373163Hs. 170333ESTs5.4413083BE064528“gb: RC4-BT0311-250200-014-h06 BT0311 Homo sapiens5.4404828predicted exon5.4402543predicted exon5.4421988AW450481Hs. 161333ESTs5.4413404BE503463Hs. 297431ESTs5.4459043AI806444Hs. 208113“ESTs, Weakly similar to N-WASP [H. sapiens]”5.4404410predicted exon5.4430264AA470519“gb: nc71f10.s1 NCI_CGAP_Pr1 Homo sapiens cDNA clon5.4431499NM_001514Hs. 258561general transcription factor IIB5.4412566AW962574“gb: EST374647 MAGE resequences, MAGG Homo sapien5.4454239BE176420Hs. 8177ESTs5.4458163AA884304Hs. 131163ESTs5.4446205AW172662Hs. 149479ESTs5.4455275AW977806“gb: EST389810 MAGE resequences, MAGO Homo sapien5.4415579AA165232Hs. 222069ESTs5.4423200AA323073Hs. 289083ESTs5.4440052AI633744Hs. 195648ESTs5.4424717H03754Hs. 152213“wingless-type MMTV integration site family, member 5A”5.4420111AA255652gb: zs21h11.r1 NCI_CGAP_GCB1 Homo sapiens cDNA clo5.4432140AK000404Hs. 272688hypothetical protein FLJ203975.4414904AA157881Hs. 143056ESTs5.4409479BE163800Hs. 136912ESTs5.4404727predicted exon5.4446011AI623778Hs. 145809ESTs5.4456083U46922Hs. 77252fragile histidine triad gene5.4424834AK001432Hs. 153408Homo sapiens cDNA FLJ10570 fis, clone NT2RP20031175.4425071NM_013989Hs. 154424“deiodinase, iodothyronine, type II”5.4426065N32049gb: yw96g08.s1 Soares_placenta_8to9weeks_2NbHP8to9W5.4415602F12920Hs. 165575ESTs5.4432839AA579465Hs. 287332ESTs5.4416879H98899Hs. 42599ESTs5.4456088BE177320Hs. 156148Homo sapiens cDNA FLJ23082 fis, clone LNG06451”5.4423175W27595Hs. 18653ESTs5.4424585AA464840gb: zx43h11.r1 Soares_total_fetus_Nb2HF8_9w Homo sapie5.3452281T93500Hs. 28792Homo sapiens cDNA FLJ11041 fis, clone PLACE10044055.3424323AA338791Hs. 146763nascent-polypeptide-associated complex alpha polypeptide5.3426701AI968103Hs. 209461Homo sapiens cDNA FLJ12836 fis, clone NT2RP20032065.3447645AW897321Hs. 159699ESTs5.3402974predicted exon5.3436607AW661783Hs. 211061ESTs5.3428873AI701609Hs. 98908ESTs5.3405454predicted exon5.3431867AA523660Hs. 191727ESTs5.3442768AL048534Hs. 48458“ESTs, Weakly similar to ALU8_HUMAN ALU SUBFAM5.3424085NM_002914Hs. 139226replication factor C (activator 1) 2 (40 kD)5.3435098AF174394Hs. 177461Homo sapiens apoptotic-related protein PCAR mRNA, par5.3421284U62435Hs. 103128“cholinergic receptor, nicotinic, alpha polypeptide 6”5.3435711AF226667Hs. 58553CTP synthase II5.3405292predicted exon5.3410123T16981Hs. 21963ESTs5.3435435T89473Hs. 192328ESTs5.3417071N58820Hs. 275133ESTs5.3438958H50167Hs. 33113ESTs5.3457405AA504860gb: ab03a10.s1 Stratagene fetal retina 937202 Homo sapiens5.3413642BE154837“gb: PM1-HT0345-121199-001-c08 HT0345 Homo sapiens5.3433868AA612960gb: nq38g06.s1 NCI_CGAP_Co10 Homo sapiens cDNA clo5.3444461R53734Hs. 25978ESTs5.3427088AA398085Hs. 142390ESTs5.3451307AW293207Hs. 211516ESTs5.3403831predicted exon5.3402892predicted exon5.3433420AI674093Hs. 293961ESTs5.3455759BE080469“gb: QV1-BT0630-280200-086-d06 BT0630 Homo sapiens5.3411379AI816344Hs. 12554“ESTs, Weakly similar to Nacleosome Assembly Protein 1-5.3428483AI908539Hs. 184592KIAA0344 gene product5.3429208AA447990Hs. 190478ESTs5.3447572AI631546Hs. 159732ESTs5.3434896AW022054Hs. 136591ESTs5.3417616R07728Hs. 268668ESTs5.3411805AW864183“gb: PM0-SN0014-260400-002-d02 SN0014 Homo sapiens5.3419000T79855Hs. 268592ESTs5.3413488BE144017Hs. 184693“transcription elongation factor B (SIII), polypeptide 1 (15 k5.3400975predicted exon5.3407453AJ132087gb: Homo sapiens mRNA for axonemal dynein heavy chain (5.3430757AI458623“gb: tk04g09.x1 NCI_CGAP_Lu24 Homo sapiens cDNA clo5.3417793AW405434Hs. 82575small nuclear ribonucleoprotein polypeptide B”5.2401877AB011094Hs. 129892KIAA0522 protein5.2457122AI026157Hs. 33728“ESTs, Weakly similar to ALU1_HUMAN ALU SUBFAM5.2410706AI732404Hs. 68846ESTs5.2435807AI033299Hs. 113614ESTs5.2428398AI249368Hs. 98558ESTs5.2401088predicted exon5.2414501N43991Hs. 171984ESTs5.2419083AI479560Hs. 98613Homo sapiens cDNA FLJ12292 fis, clone MAMMA100185.2421107AA283822Hs. 55606“ESTs, Weakly similar to ZN91_HUMAN ZINC FINGER P5.2411489AW848346“gb: IL3-CT0214-150200-076-F03 CT0214 Homo sapiens c5.2419249X14767Hs. 89768“gamma-aminobutyric acid (GABA) A receptor, beta 1”5.2430082AW514083Hs. 190135ESTs5.2425698NM_016112Hs. 159241polycystic kidney disease 2-like 15.2451686AA059246Hs. 110293ESTs5.2453867AI929383Hs. 108196HSPC037 protein5.2419985H66373Hs. 15973“ESTs, Highly similar to bA393J16.3 [H. sapiens]”5.2426650AA382814“gb: EST96097 Testis I Homo sapiens cDNA 5' end, mRNA5.2424115AA335497Hs. 293965ESTs5.2405576predicted exon5.2409584AA076010gb: zm89f12.s1 Stratagene ovarian cancer (937219) Homo sa5.2454423AW603985Hs. 179662nucleosome assembly protein 1-like 15.2417173U61397Hs. 81424ubiquitin-like 1 (sentrin)5.2439155H81076Hs. 269001ESTs5.2432267AK000872Hs. 274227Homo sapiens cDNA FLJ10010 fis, clone HEMBA1000305.2459024AA020799Hs. 179825RAN binding protein 2-like 15.2404088predicted exon5.2403525predicted exon5.2445882AI948717Hs. 225155“ESTs, Weakly similar to PSF_HUMAN PTB-ASSOCIATE5.2448257AW772070Hs. 253146ESTs5.2410500R09442gb: yf26c09.r1 Soares fetal liver spleen 1NFLS Homo sapien5.2456084AA155859Hs. 79708ESTs5.2410523BE143839“gb: MR0-HT0164-151299-012-d03 HT0164 Homo sapiens5.2434623AB023163Hs. 4014KIAA0946 protein; Huntingtin interacting protein H.5.2454484AW795196Hs. 215857nng finger protein 145.2402131predicted exon5.2438913AI380429Hs. 172445ESTs5.2402628predicted exon5.1415973R24707Hs. 260201ESTs5.1455640BE064059“gb: QV3-BT0296-010300-111-e04 BT0296 Homo sapiens5.1442750AI016803Hs. 131096ESTs5.1404638predicted exon5.1431117AF003522Hs. 250500delta (Drosophila)-like 15.1428819AL135623Hs. 193914KIAA0575 gene product5.1439519AA837118Hs. 118366ESTs5.1427335AA448542Hs. 251677G antigen 7B5.1416450AA180467Hs. 142556ESTs5.1440876AW613524Hs. 279570ESTs5.1414584BE409585“gb: 601301836F1 NIH_MGC_21 Homo sapiens cDNA clon5.1443175N57863gb: yv60c02.s1 Soares fetal liver spleen 1NFLS Homo sapie5.1408968AI652236Hs. 49376hypothetical protein FLJ206445.1415654AW968363“gb: EST380439 MAGE resequences, MAGJ Homo sapiens5.1440559AW629054Hs. 125976ESTs, Weakly similar to metalloprotease/disintegrin/cystei5.1421236AI287622Hs. 151956ESTs5.1416258N45661Hs. 275131ESTs5.1405982predicted exon5.1406589predicted exon5.1412458AW953229Hs. 169142ESTs5.1435693AI033134Hs. 119887ESTs5.1449182AW292381Hs. 224150ESTs5.1403963predicted exon5.1440830AI733112Hs. 176101ESTs5.1415412F08049Hs. 52132ESTs5.1442832AW206560Hs. 253569ESTs5.1445359AI808725Hs. 147783ESTs5.1412088AI689496Hs. 108932ESTs5.1428785AI015953Hs. 125265ESTs5.1430163X66610Hs. 234748“enolase alpha, lung-specific”5.1455441AW945964“gb: QV0-ET0001-050500-228-e09 ET0001 Homo sapiens c5.1400304AF005082Hs. 113261Homo sapiens skin-specific protein (xp33) mRNA, partial5.1403944predicted exon5.1457069BE159191Hs. 114318“ESTs, Weakly similar to ORF1 [H. sapiens]”5.1414125BE253197“gb: 601116804F1 NIH_MGC_16 Homo sapiens cDNA clon5.1448566AW291319Hs. 194574ESTs5.1457948AI498640Hs. 159354ESTs5.1438240N92638Hs. 124004ESTs5.1404070predicted exon5.1402709predicted exon5.1416425BE077308“gb: RC1-BT0606-060200-012-h12 BT0606 Homo sapiens5.0407173T64349gb: yc10d08.s1 Stratagene lung (937210) Homo sapiens cDN5.0452502AI904296“gb: PM-BT046-220199-286_1 BT046 Homo sapiens cDNA5.0446657AI335191Hs. 260702“ESTs, Moderately similar to ALU7_HUMAN ALU SUBF5.0459124AW301478Hs. 299178ESTs5.0409940BE548143“gb: 601073109F1 NIH_MGC_12 Homo sapiens cDNA clon5.0443547AW271273Hs. 23767Homo sapiens cDNA FLJ12666 fis, clone NT2RM4002255.0447452BE618258Hs. 102480ESTs5.0414327BE408145Hs. 185254“ESTs, Moderately similar to NAC-1 protein [R.norvegicus]5.0416155AI807264Hs. 205442“ESTs, Weakly similar to AF117610_1 inner centromere pro5.0408081AW451597Hs. 167409ESTs5.0426834AI091533Hs. 135167ESTs5.0433368AW877277“gb: MR4-PT0051-150200-001-d03 PT0051 Homo sapiens5.0433098AW190593Hs. 151143ESTs5.0439721W92142Hs. 271963“ESTs, Weakly similar to ALU5_HUMAN ALU SUBFAM5.0441818AI630451Hs. 7976KIAA0332 protein5.0458804AL157625gb: DKFZp761L2016_r1 761 (synonym hamy2) Homo sapi5.0411905BE265067“gb: 601193893F1 NIH_MGC_7 Homo sapiens cDNA clone5.0434248AA628151Hs. 187783ESTs5.0423967AW296756Hs. 11641Homo sapiens cDNA FLJ21432 fis, clone COL04219”5.0456212N51636gb: yy87b01.s1 Soares_multiple_sclerosis_2NbHMSP Homo5.0442914AW188551Hs. 99519Homo sapiens cDNA FLJ14007 fis, clone Y79AA10024075.0436084AK000185“gb: Homo sapiens cDNA FLJ20178 fis, clone COL09990”5.0449252AW594482Hs. 253315ESTs5.0454653AW812227“gb: RC2-ST0173-201099-011-g09 ST0173 Homo sapiens c5.0414699AI815523Hs. 76930“synuclein, alpha (non A4 component of amyloid precursor)5.0443335T89697Hs. 16645ESTs5.0448419AL080072Hs. 21195Homo sapiens mRNA; cDNA DKFZp564M0616 (from clon5.0425574AA359663“gb: EST68717 Fetal lung II Homo sapiens cDNA 5' end, mR5.0435174AA687378Hs. 194624ESTs5.0429548AW138872Hs. 135288ESTs5.0450613AI702055“gb: tq20g10.x1 NCI_CGAP_Ut1 Homo sapiens cDNA clon5.0400432AX015809Hs. 287767Sequence 8 from Patent WO99502855.0421751AW813731Hs. 159153ESTs5.0405800predicted exon5.0429430AI381837Hs. 155335ESTs5.0439518W76326gb: zd60d04.r1 Soares_fetal_heart_NbHH19W Homo sapien5.0430884AF053748Hs. 248114glial cell derived neurotrophic factor5.0452741BE392914Hs. 30503Homo sapiens cDNA FLJ11344 fis, clone PLACE10108705.0441001AW137017Hs. 126373Human DNA sequence from clone RP5-1184F4 on chromos5.0438490AW593272Hs. 26261ESTs5.0408170AW204516Hs. 31835ESTs5.0449104R08702gb: yf24c06.r1 Soares fetal liver spleen 1NFLS Homo sapien5.0Pkey: Primekey Ex. Accn No: Exemplar Accession UG ID: Unigene ID Title: UG title ratio: ration tumor vs normal tissues


[0350]

2







TABLE 1B








Pkey
CAT Number
Accession

















407615
1005404_1
AW753085 AW753082 AW054744 AW753107 AW753087


408391
1055687_1
AW859276 AW859274 AW190959 T91463


408523
1063925_1
AW833259 AW833273 AW206846


408914
1089828_1
AW450309


408987
109306_1
H85615 H86300 H86263 H86282 AA059278 H86304


409191
1107176_1
AW818390 AW818237 AW858911 AW858977 BE072544 W26498


409545
1138823_1
BE296182 AW629821


409584
114165_1
AA076010 AA076009 AI094314


409695
114876_1
AA296961 AA296889 AA076945 AA077528 AA077497


409866
1156522_1
AW502152 H41202 H29772


409867
1156530_1
AW502161 AW502587 AW502345


409940
1160994_1
BE548143 AW511659


409982
1165022_1
BE005839 BE005619 AW516815


410500
1206323_1
R09442 AW846115 AW846108 AW751967 AW846083 AW846087 AW846090


410523
1207041_1
BE143839 AW752787 AW752795 BE143584 N71805


410536
1207322_1
N39533 AW753094 AW753093


410626
1212621_−1
BE407727


410966
1228071_1
AW812088 AW812105 AW812082


411004
1228975_1
AW813242 BE146089 AW813195 AW813173 AW813206 BE145953 BE146212 AW813196 AW854582




AW813241 BE061582


411018
1229132_1
AW813428 AW813444 AW813367 AW813368 AW813429 AW813424


411057
1230493_1
AW815098 BE154843 BE154831


411178
1234752_1
AW820852 AW820773 AW821088


411237
1236377_1
AW833676 AW833814 AW833798 AW833677 AW833449 AW833630 AW833626 AW833444 AW833366




AW833791 AW833659 AW833432 AW833534 AW833556 AW833553


411483
1247172_1
AW848115 AW848127 AW887028 AW887117


411489
1247360_1
AW848346 AW848760 AW848340 AW848818 AW849043 AW849061


411541
1249044_1
W03940 T98335 AW850705


411660
1253078_1
AW855718 AW855740 AW855748


411693
1254206_1
AW857271 AW857308 AW857296 AW857258


411722
1254914_1
AW875942 AW858234 AW875938 AW875941 AW858235 AW875958


411725
1255047_1
AW858396 AW858505 AW858476 AW861971 AW858556 AW861908 AW858514 AW858601 AW861909




AW858434 AW858400 AW858405 AW858393


411748
1256178_1
AW859920 BE079582 AW997112


411805
1259273_1
AW864183 AW864181 AW864135 AW864198


411905
1265181_1
BE265067 BE264978 AW875420


411940
1266262_1
AW876686 AW876717 AW877215 AW876691 AW876722 AW877218 AW876694 AW876725


412167
1280605_1
AW897230 AW897252 AW897244 AW897231 AW897263


412333
1289037_1
AW937485 AW937589 AW937658 AW937654 AW937492


412402
1292917_1
AW984788 AW984816 AW984811 AW984807 AW984819 AW984790 AW984782 AW984784 AW984780 AW984814




AW984795 AW984793 AW984789 AW984823 AW948021 AW984802 AW984800 AW984799 AW984825 AW984792




AW984821 AW984820 AW984808 AW984809 AW984812 AW984801 AW984813 AW984778 AW984804 AW984798




AW948017 AW984827


412566
1306469_1
AW962574 BE073261


412670
131990_1
AA115456 AW978117 AA814593


412740
1324538_1
AW993984 AW994001 AW994002


412761
1325424_1
AW995092 AW995095 AW995103


413083
1348639_1
BE064528 BE064589 BE064561


413101
1349154_1
BE065215 BE155544 BE155541 BE155540 BE155542 BE155543


413252
1355877_1
BE074910 BE074913 BE074911 BE074903 BE074892 BE074935


413382
1365954_1
BE090689 BE090685 BE090697 BE090680 BE090691 BE090696 BE090698 BE090686


413425
136885_1
F20956 AA129374 AA133740 AW819878


413470
1371600_1
N20934 BE141875 BE141877


413521
1374612_1
BE145814 BE145830 BE145884 BE145823 BE145905 BE145883 BE145833 BE145889 BE145834


413544
1375671_1
BE147225 BE147205 BE147234


413642
1381386_1
BE154837 BE154879 BE154850 BE154877 BE154835 BE154849 BE154902 BE154905 BE154867 BE154901




BE154904 BE154899


413702
1383899_1
BE170313 BE158339 BE158290


413864
1395788_1
BE175582 BE175514 BE175505 BE175591 BE175530


414093
1416417_1
BE544867 BE247720


414125
1419230_1
BE253197 BE259456 BE254462


414195
1424854_−3
BE263293


414210
1426051_1
BE383592 BE261671


414266
1430984_1
BE267834 BE514180 BE514096


414315
143512_1
Z24878 AA494098 F13654 AA494040 AA143127


414539
1460320_1
BE379046 BE395459


414540
1460324_−1
BE379050


414584
1464068_−1
BE409585


414605
1465790_−1
BE390440


414606
1465801_1
BE387771 BE387954 BE389705


414808
1492624_1
T95945 R98276 BE539541


414954
1509857_1
D81402 C15494 D61078 D61313 D80399 D81520


414995
1511736_1
C18200 D78681 T82025


415613
1540602_1
R20233 F12901 T74740


415654
154135_1
AW968363 AA465492 R34539 AA165411


415715
1548818_1
F30364 F36559 T15435


415747
155189_1
AA381209 AA381245 AA167683


416151
1573926_1
T26661 Z44135 H23016


416168
1574545_1
H23687 H46460 H40239


416425
159388_1
BE077308 AL043350 AW962170 AA180251 AA325287


416441
159480_1
BE407197 AA182474 AA180369 BE275628 BE276131


416548
1600181_1
H62953 N76608 N72413


416665
1607797_1
H72974 W28967


416913
163001_1
AW934714 BE161007 BE162500 AW749902 AW749864 BE162498 BE161005 AA190449 AW513465




BE161006 BE162499


417344
166827_1
AW997313 AA195805


417549
168700_1
AA203651 R89136


417611
168900_1
AW993983 AW994798 AW993990 AW993999 AW993989 AA204755


417682
1692759_1
W69561 R08486 R87183


418636
177402_1
AW749855 AA225995 AW750208 AW750206


418709
178363_1
AA227394 AA641866 AW750732


419753
187763_1
N42531 W25700 AA249574 AA569553


419936
189181_1
AI792788 BE142230 AA252019


420111
190755_1
AA255652 AA280911 AW967920 AA262684


422949
223184_1
AA319435 N56456 AA319377 AW961532 T48452 AA894424


423735
231498_1
AA330259 AA661806 AA502431 AW974633 AA649496


423756
231725_1
AA828125 AA834883 AA330555


423843
232510_1
AA332652 AA331633 AW999369 AW902993 BE170475 AA378845 AW964175 AI475221


424101
235398_1
AA335394 AA335535 AA335244 AW966148


424324
238127_1
AA346316 BE160193 AA338802 AW954536


424585
241151_1
AA464840 AA343628


424872
244505_1
AA347923 AA347928 AW961769


425090
246649_1
AA350552 R21667 AW953258


425574
253317_1
AA359663 AA359654 AW963124


425612
253969_1
BE004257 AW811190 AA360576 BE172402 BE181703


426065
260276_1
N32049 R34821 R78237


426130
261414_1
AA853282 BE255688 AA370481


426544
268987_1
AA492325 AA503675 AA381181


426650
270283_1
AA382814 AA402411 AA412355


429163
300543_1
AA884766 AW974271 AA592975 AA447312


430264
315008_1
AA470519 BE303010 BE302954 BE384120


430757
322947_1
AI458623 AA639708 AA485409 R22065 AA485570


431071
327550_1
AA491379 H86020 AW969148


431688
336609_1
AA513906 AA847734 AI357044


431822
338082_1
AA516049 AW004922


432189
342819_1
AA527941 AI810608 AI620190 AA635266


432340
345248_1
AA534222 AA632632 T81234


432363
345469_1
AA534489 AW970240 AW970323


432966
356839_1
AA650114 AW974148 AA572946


433368
364276_1
AW877277 AW811294


433449
366532_1
AW772282 AA592974


433868
375629_1
AA612960 AI934769 T12348


434098
380006_1
AA625499 AA625269 AA625184


434374
384889_1
AA631439 AI086355 AI082577


434804
393481_1
AA649530 AA659316 H464973


434950
396061_1
AW974892 AA654375


435478
406683_1
AA682622 BE141696


436084
41437_1
AK000185 AW841262


436532
421802_1
AA721522 AW975443 T93070


436843
427748_1
AA824588 AA732269 AW977148


437096
433006_1
AA744406 AA745347 AA745535


437146
43371_1
AA730977 AI261584 AA334473 Z43283 AW875861 AW938044 BE150701 AW936262




AA306862 BE565575 BE567380 AA728920 AA167612 AI239729 AI251752 AA485791 BE568425 AW962958


437152
43386_1
AL050027 BE089051


437229
434947_1
AW976005 AW419264 AA747275 AA810377


439031
46798_1
AF075079 H48601 H48795


439152
46920_1
H65014 AF086007 H65015


439518
47334_1
W76326 AF086341 W72300


440051
48426_2
BE559980 BE397203 BE268207 BE559764 BE267725 BE513654 BE267742 BE268219 BE267665 BE561356


441194
51193_1
BE274581 BE275382 AA703515 BE166690


441369
515636_1
AA931535 AI458601 Z44913


442257
53699_1
AW503831 AW503317 BE565665


443161
561305_1
AI038316 AI344631 AI261653


443175
561882_1
N57863 AI038952 W90167 N64103


443198
562655_1
AI039813 AI684642 Z40121 AI951414 BE501049


443534
572957_1
AI076123 AI244834 AI695239


443613
575391_1
AI079356 W23287


443657
576685_1
R14973 R14967 AI081006


443747
57918_1
AV646352 AV652121 AV652008


443860
583216_1
AW866632 AI089351 D61942


445132
63111_1
Z44811 R13709 AV652749 AW814906 AA084016


445153
631644_1
AI214671 Z45244 H24136 R25934


445232
633433_1
BE294357 N36568 AI217006


446171
664826_1
AI374927 AI278380 AI301383


447252
714160_1
R90916 AL120023 R18429 Z42095 AI369730 R90824


448516
766241_1
AW898595 AW898588 AW898590 AW898663 AW898592 AI525093


449104
798149_1
R08702 R09864 AI630313


450613
840016_1
AI702055 R89204 R86260


452077
897051_1
BE144949 BE144991 BE144990 AI832199


452502
919733_1
AI904296 BE007223 R30687


452507
919998_1
AI904646 BE179494 BE179421


452542
921410_1
AW812256 AW812257 AI906423 AI906422


452563
922265_1
AI907552 C03707 C02870


452947
939810_1
AW130413 AI932362


453509
969632_1
AL040021 AL040037


453845
983027_1
AL157568


454182
1049569_1
AW177335 AW177352 AW177340 AW177378 AW177339 AW177388 AW177393


454377
114761_1
AA076811 AW814764


454389
115682_1
AW752571 AW847602 AA077979


454455
1206965_1
AW752710 BE180336 BE180186


454505
1219564_1
AW801365 AW801435 AW801372


454556
1223878_1
AW807073 AW807055 AW807067 AW807276 AW807030 AW807363 AW845892




AW807091 AW807275 AW807284 AW807287 AW845891 AW807195 AW807271


454574
1225636_1
AW809109 AW809112 AW809122 AW809126 AW809128 AW809133 AW809131 AW809113 AW809111 AW809132


454597
1226059_1
AW809648 AW809704 AW809643 AW809653 AW809709 AW809949 AW809939 AW810010 AW809705 AW809950




AW809822 AW809667 AW810093 AW810076 AW809673 AA810349 AW809895


454633
1227504_1
AW811380 AW811385


454653
1228081_1
AW812227 AW812294 AW812092


454690
1229106_1
AW854639 AW854719 AW854718 BE145880 AW854692 BE145866 AW816154 AW854698 AW854654 AW813335




AW854699


454707
1230250_1
AW814989 AW814852 AW814808


454822
1236369_1
AW833793 AW833799 AW833346 AW833371 AW833795 AW833562 AW833667 AW833377


454874
1238494_1
AW836407 BE175600 BE175579


454913
1242238_1
AW841462 BE156657 BE156668 BE092475


454934
1245577_1
AW846080 AW846074 AW846118 AW846130


454963
1246752_1
AW847647 AW847659 AW847656 AW847653 AW847717 AW847786


455013
1248899_1
BE073250 BE073378 BE073379 AW850533 AW850529


455092
1252971_1
BE152428 AW855572 AW855607


455110
1253955_1
BE154505 BE154462 BE154454 BE154460 BE154489 BE154496 AW856909 BE154497 BE154565 BE154572




BE154500 BE154472


455121
1254339_1
BE156459 BE156469 BE156468 AW857447


455152
1255227_1
AW858621 AW937120


455203
1259973_1
AW865450 AW865119 AW865452 AW865461 AW865325 AW865114 AW865116 AW865321 AW865590 AW865390


455275
1272255_1
AW977806 AW887923 AW886321


455435
1290546_1
AW939445 AW939465 AW939604 AW939531 AW939530 AW939993


455441
1291505_1
AW945964 AW946020 AW946034 AW946027 AW946041 AW946044 AW946033 AW946024 AW946021 AW946029




AW946015 AW946016 AW946039 AW946045 AW946028 AW946036


455592
1335196_1
BE008002 BE007997 BE007998 BE008000


455640
1348141_1
BE064059 BE063903 BE063838 BE063863 BE064056 BE063974 BE063904 BE063898 BE063896 BE063906 BE063980


455662
1349206_1
BE065387 BE065310 BE065391


455713
1352512_1
BE069891 BE158893 BE069898 BE158900


455759
1359316_1
BE080469 BE080474 BE080477 BE080546 BE080545


455851
1375451_1
BE146879 BE146914 BE146918


455853
1375671_1
BE147225 BE147205 BE147234


455879
1380017_1
BE153275 BE153189 BE153329 BE153022 BE153030 BE152974


455993
1398665_1
BE179085 BE179084 BE179086 BE179264


456072
1470256_1
H54381 H54463 BE393262


456101
151654_1
AA159478 AW901089 AA160437 AW593155


456212
1655565_1
N51636 T51874 T51829


456309
177026_1
AA225423 AA225369 BE144153 AW801549


456714
221500_1
AW897265 AW897274 AL119504 AW897275 AW897270 AW897312 AW897318 AW897317 AA317240 AW961361




T06241 AA326794 AL138130 AW407975 AW999277


457405
333127_1
AA504860 AA504911


457620
371514_1
AA602711 BE078290


457727
393566_1
AW974687 AA649656 AA652145


457868
426095_1
AW975133 AA729943 AA805813


458154
491768_1
AW816379 AA888282 AA879046 AA879195


458804
75803_1
AL157625 N72696 BE622492


458829
773443_1
AI557388 BE158936


458841
784186_1
W28965 W28971


459160
920051_1
AI904723 AI904725 AI904729 AI904722 AI904758 AI904736


459170
920646_1
AI905518 AI905516 AI905457 AI905515 AW176013 AW176037


459186
922888_1
AI908287 BE064074 BE068820 BE068823 BE068822 BE068826






Pkey Unique Eos probeset identifier number




CAT number Gene cluster number




Accession Genbank accession numbers








[0351]

3








TABLE 1C








Pkey
Ref
Strand
Nt_position


















400584
9887612
Minus
18398-18573


400593
9887642
Minus
25013-25127


400612
9929646
Minus
151513-151662


400613
9864507
Plus
92278-92472


400623
7228177
Plus
74195-74335, 74653-74827


400709
7249204
Plus
153075-154680


400749
7331445
Minus
9162-9293


400842
1927146
Plus
90462-90673


400925
7651921
Plus
38183-38391, 43900-44086


400964
7139719
Minus
155282-155403


400968
7923967
Plus
19938-20043


400975
7139779
Minus
108473-108847


400983
8081198
Plus
107903-108832


401032
8117525
Minus
68451-68555


401050
8117628
Minus
78449-79425


401088
8492704
Plus
194659-195179


401129
8699792
Minus
62022-62242, 62326-62451,





62543-62710, 63072-63167


401200
9743387
Minus
111586-111806, 114791-114916,





115419-115583, 116351-116446,





116847-116907, 122853-123067,





124982-125407


401213
9858408
Plus
98243-98380, 98489-98619


401230
9929527
Minus
33835-34006, 34539-34592,





36461-36745, 48925-49098,





52604-52758


401245
4827300
Minus
59373-59531


401260
8076883
Minus
86008-86355


401269
8954206
Plus
2259-2591


461283
9800093
Minus
47256-47456


401497
7381770
Plus
92607-92813


401508
7534110
Minus
110779-110983


401521
7705251
Plus
9127-9234


401530
7770649
Plus
41468-42406


401575
7229804
Minus
76253-76364


401604
7689963
Minus
119835-120185


401780
7249190
Minus
28397-28617, 28920-29045





29135-29296, 29411-29567,





29705-29787, 30224-30573


401781
7249190
Minus
83215-83435, 83531-83656,





83740-83901, 84237-84393,





84955-85037, 86290-86814


401793
7263888
Minus
102945-103083


401809
7342191
Minus
107548-108298


401862
7770606
Minus
55839-55993, 59145-59293


401881
8122429
Minus
148470-148651, 153418-153618,





154282-154438


402018
7528100
Plus
168728-168859


402046
8072415
Plus
166394-166556, 168167-168395


402050
8076908
Minus
130105-130227


402071
8117361
Plus
85924-86039


402075
8117407
Plus
121907-122035, 122804-122921,





124019-124161, 124455-124610,





125672-126076


402131
7704961
Minus
33114-33209, 33498-33678


402203
8576119
Minus
8124-8285


402222
9958106
Plus
3261-3834, 3939-4269


402296
6598824
Plus
22587-23723


402298
6598824
Plus
36758-37953


402421
9796341
Minus
48609-46662, 46758-46811,





86293-86346, 89776-89829,





90048-90101, 102817-102924


402425
9796347
Minus
50224-50395


402481
9797406
Plus
87891-88991


402529
7630937
Minus
165-917


402543
9838066
Minus
89684-90893


402576
7230225
Minus
1867-2247


402578
9884928
Plus
66350-66496


402628
9931216
Plus
31753-31966


402631
9931231
Minus
115658-116580


402639
9958129
Minus
20167-22383


402664
8077024
Plus
70318-70846


402709
8901246
Minus
56847-57055


402738
7331557
Minus
8725-8859


402745
9212200
Minus
76516-76690


402790
4835258
Minus
147744-147861


402794
6136940
Minus
131034-131794


402800
6010175
Plus
43921-44049, 46181-46273


402859
9588237
Minus
69821-75323


402892
8086844
Minus
194384-194645


402974
9663349
Plus
124035-124321


403041
3171152
Plus
70527-71019


403065
8954197
Minus
71615-71773, 73930-74144


403083
8954241
Plus
163070-163351


403089
8954241
Plus
171964-172239


403093
8954241
Plus
177083-177373, 177464-177751


403177
9838213
Minus
142560-142726


403273
8018055
Plus
133809-134099


403334
8568877
Minus
137205-137350


403350
8569775
Minus
135374-135523


403356
8569930
Plus
92839-93036


403403
9438460
Plus
21240-21399


403525
7960440
Plus
152431-153243


403568
8101145
Minus
85509-85658


403647
8699843
Minus
35849-36204


403687
7387384
Plus
9009-9534


403691
7387384
Minus
88280-88463


403698
4263532
Plus
10464-10907


403741
7630932
Minus
2833-3468


403747
7658395
Minus
20493-20621


403786
8083636
Minus
73028-73217


403831
7249249
Minus
61468-61575


403891
7331467
Minus
191508-193220


403944
7711864
Minus
129213-129415


403963
8568150
Plus
149466-149665


404070
2996642
Plus
7210-7414, 10043-10195


404088
9958257
Plus
184131-184295


404097
7770701
Plus
55512-55781


404166
7596822
Plus
86147-86509


404270
9828129
Minus
3649-3750, 4161-4306,





5962-6049, 6849-6965


404340
7630856
Plus
10898-11506


404410
7342122
Plus
49052-49176, 56177-56273,





59384-59488


404599
8705107
Plus
110443-110733


404638
9796751
Minus
99433-99528, 100035-100161


404664
9797142
Minus
104257-105215


404727
8081050
Plus
115534-115747


404767
7882827
Minus
23244-23759


404828
6580415
Minus
26291-27253


404849
7706886
Plus
144843-144964, 149848-150121


404893
6850447
Plus
65083-65223


404898
7331420
Minus
177015-177328


404952
7382669
Minus
136326-136618


404972
3213020
Plus
48711-49524


404992
4662677
Minus
106104-106199, 111659-111781


405071
7708797
Minus
11115-11552


405138
8576241
Plus
90303-90516


405196
7230083
Minus
135716-135851


405227
6731245
Minus
22550-22802


405277
3980473
Plus
23471-23572


405285
6139075
Minus
55744-55903, 57080-57170,





61478-61560


405292
3845420
Plus
33227-33442


405336
6094635
Plus
33267-33563


405362
2337862
Minus
105008-105142, 105980-106091,





140445-140556, 142519-142641


405382
6552767
Plus
31923-32311


405454
7656675
Plus
133807-134053


405465
7767904
Plus
8935-9073, 12242-12367,





13364-13506, 14965-15493


405472
8439781
Plus
106297-106447, 108462-108596


405547
1054740
Plus
124361-124520, 124914-125050


405576
4003382
Plus
84000-85009


405621
5523811
Plus
59362-59607


405636
5123990
Plus
56384-56587


405675
4557087
Plus
70304-70630


405708
4156182
Plus
55030-55604


405771
7018349
Plus
91191-91254, 91510-91589


405783
5738434
Minus
27238-27885


405793
1405887
Minus
89197-89453


405800
2791346
Plus
19271-19813


405810
4938307
Minus
64543-64966


405848
7651809
Minus
28135-28244


405851
6164995
Minus
26407-27151


405867
6758731
Minus
74553-75173


405896
6758795
Plus
57311-57874


405904
7705118
Minus
16375-16584


405917
7712162
Minus
106829-107213


405982
8247790
Minus
36028-36408


406030
8312328
Minus
96123-96547


406053
6758997
Plus
30921-31532


406057
6691254
Minus
20830-21222


406149
7144791
Minus
44464-45164


406163
7158901
Plus
66690-66835


406277
5686030
Minus
4759-5490


406322
9212102
Minus
130230-130418


406349
9256007
Minus
21251-21526


406504
7711360
Minus
107068-107277


406544
7711508
Plus
46576-40757


406589
8224211
Plus
38806-38989


406592
4567182
Plus
352560-352963






Pkey Unique number corresponding to an Eos probeset




Ref: Sequence source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. “Dunham I et al.” refers to the publication entitled “The DNA sequence of human chromosome 22” Dunham, et al. (1999) Nature 402: 489-495




Strand Indicates DNA strand trom which exons were predicted




Nt_position Indicates nucleotide positions of predicted exons








[0352] TABLE 2A lists about 187 genes up-regulated in ovarian cancer compared to normal adult tissues that are likely to be extracellular or cell-surface proteins. These were selected as for Table 1A, except that the ratio was greater than or equal to 2.5, and the predicted protein contained a PFAM domain that is indicative of extracelluar localization (e.g. ig, fn3, egf, 7tm domains)
4TABLE 2AABOUT 187 UP-REGULATED OVARIAN CANCER GENESENCODING EXTRACELLULAR/CELL SURFACE PROTEINSPkeyEx Accn NoUG IDTitlePFAM domainratio423017AW178761Hs 227948senne (or cysteine) proteinase inhibitoserpin63.6431938AA938471Hs 115242developmentally regulated GTP-bindiSCP32.0425650NM_001944Hs 1925desmoglein 3 (pemphigus vulgaris antcadherin30.0418994AA296520Hs. 89546selectin E (endothelial adhesion molecEGF, lectin_c, sushi24.5452947AW130413gb: xf50f04.x1 NCI_CGAP_Gas4 Homalpha-amylase15.8418092R45154Hs 106604ESTspkinase, Activin_recp15.1431725X65724Hs. 2839Nome disease (pseudoglioma)Cys_knot12.6422330D30783Hs 115263epiregulinEGF12.5446745AW118189Hs 156400ESTsvwa11.1416319AI815601Hs 79197CD83 antigen (activated B lymphocytig10.8432408N39127Hs 76391myxovirus (influenza) resistance 1, hoion_trans, K_tetra10.6405285predicted exonA2M, A2M_N10.5405636predicted exonEGF; Idl_recept_a, Idl_recept_b9.8403093predicted exonfn39.6446740AI611635Hs 192605ESTsRYDR_ITPR9.2405547predicted exonABC_tran, ABC_membrane8.5412333AW937485gb: QV3-DT0044-221299-045-b09 DT7tm_f8.4404270predicted exonSCP8.1402745predicted exonEGF, Idl_recept_b, thyroglobulin_18.1452755AW134937Hs. 213436ESTscystatin8.0421459AI821539Hs 97249ESTsdisintegrin, Reprolysin7.9416151T26661gb: AB65C7R Infant brain, LLNL arralaminin_G; EGF7.8446232AI281848Hs 165547ESts7tm_37.6431009BE149762Hs 248213gap junction protein, beta 6 (connexinconnexin7.2424634NM_003613Hs 151407cartilage intermediate layer protein, nig, tsp_17.1400749predicted exonfn3, Idl_recept_a, Idl_recept_b6.8419054N40340Hs 191510ESTs, Weakly similar to ORF2 (M mig; SPRY6.8459170AI905518gb RC-BT091-210199-098 BT091 HoABC_tran; ABC_membrane6.6416441BE407197gb 601301552F1 NIH_MGC_21 HomSDF6.4410664NM_006033Hs 65370lipase, endothelialRibosomal_L226.4402425predicted exonion_trans6.3415451H19415Hs 268720ESTs, Moderately similar to ALU1_HEphrin6.0403083predicted exonfn35.9448995AI613276Hs 5662guanine nucleotide binding protein (GSDF5.9418345AJ001696Hs 241407serine (or cysteine) proteinase inhibitoserpin5.8424966AU077312Hs 153985solute carrier family 7 (cationic aminoaa_permeases5.8431211M86849Hs. 5566gap junction protein, beta 2, 26 kD (coconnexin5.7430563AA481269Hs 178381ESTsABC_tran, ABC_membrane5.6450152AI138635Hs 22968ESTsig, pkinase5.6418844M62982Hs 1200arachidonate 12-lipoxygenaselipoxygenase, PLAT5.6403089predicted exonfn35.6403687predicted exontsp_1; Reprolysin5.6403691predicted exontsp_1; Reprolysin5.5414035Y00630Hs 75716serine (or cysteine) proteinase inhibitoserpin5.4421284U62435Hs 103128cholinergic receptor, nicotinic, alpha pneur_chan5.3435435T89473Hs 1932328ESTsliphase, PLAT5.3457122AI026157Hs. 33728ESTs, Weakly similar to ALU1_HUMlipoxygenase; PLAT5.2419249X14767Hs. 89768gamma-aminobutyric acid (GABA) Aneur_chan5.2425698NM_016112Hs 159241polycystic kidney disease 2-like 1ion_trans5.2431117AF003522Hs 250500delta (Drosophila)-like 1EGF, DSL5.1457948AI498640Hs. 159354ESTsG-alpha; arf5.1435174AA687378Hs 194624ESTsSPRY5.0408170AW204516Hs 31835ESTsarf; ras5.0434351AW974991Hs. 191852ESTs, Weakly similar to ALU1_HUMarf; ras4.9430708U78308Hs 278485olfactory receptor, family 1, subfamily7tm_14.8422597BE245909Hs 118634ATP-binding cassette, sub-family B (MABC_tra; ABC_membane4.8405545predicted exonABC_tran; ABC_membrane4.8426471M22440Hs. 170009transforming growth factor, alphaEGF4.7409632W74001Hs 55279serine (or cysteine) proteinase inhibitoserpin4.7420206M91463Hs 95958solute carrier family 2 (facilitated glucsugar_tr4.6415138C18356Hs 78045tissue factor pathway inhibitor 2Kunitz_BPTI, G-gamma4.6424402M63108Hs. 1769futeinizing hormone/chonogonadotrop7tm_14.5436480AJ271643Hs. 87469putative acid-sensing ion channelASC4.5430226BE245562Hs 2551adrenergic, beta-2-, receptor, surface7tm_14.4436126AW449757Hs 163036ESTsSNF4.4406812AF000575Hs 67846leukocyte immunoglobulin-like recepig4.4409385AA071267gb: zm61g01.r1 Stratagene fibroblast (TIMP4.3449184AW296295Hs. 196491ESTsTNFR_c64.3410555U92649Hs 64311a disintegrin and metalloproteinase dodisintegrin, Reprolysin4.3422389AF240635Hs. 115897profocadherin 12cadherin4.3405281predicted exonA2M, A2M_N4.3413548BE147555Hs 288541Homo sapiens mRNA for KIAA1558EGF, Idl_recept_a, Idl_recept_b4.3449535W15267Hs 23672low density lipoprotein receptor-relateIdl_recept_a, EGF, Idl_recept_b4.3425864U56420Hs 159903olfactory receptor, family 5, subfamily7tm_14.3410611AW954134Hs 20924KIAA1628 proteinPeptidase_S94.2430686NM_001942Hs 2633desmoglein 1cadherin, Cadherin_C_term4.1418693AI750878Hs 87409thrombospondin 1vwc, TSPN4.0445924AI264671Hs 164166ESTssugar_tr3.9457148AF091035Hs 184627KIAA0118 proteinarf; ras3.9428568AC004755Hs 184922one cut domain, family member 3E1-E2_ATPase3.9412170D16532Hs 73729very low density lipoprotein receptorEGF, Idl_recept_a; Idl_recept_b3.8442566R37337Hs 12111ESTsank, death, RHD, TIG3.8403763predicted exon7tm_13.8403074predicted exonfn33.8413605BE152644gb CM1-HT0329-250200-128-f09 HTalpha-amylase3.8442295AI827248Hs 224398Homo sapiens cDNA FLJ11469 fis, cCollagen, COLFI3.7403661predicted exon7tm_3, ANF_receptor3.7407305AA715284gb: nv35f03.r1 NCI_CGAP_Br5 Hompkinase, Sema; Pfexin_repeat, TIG3.7457353X65633Hs 248144melanocortin 2 receptor (adrenocortic7tm_13.7431176AI026984Hs. 293662ESTslaminin_EGF; laminin_B3.6436233AI742878Hs. 124116ESTsig3.6431808M30703Hs 270833amphiregulin (schwannoma-derived gEGF3.6445798NM_012421Hs 13321rearranged L-myc fusion sequencezf-C2H23.6400380NM_018485Hs 283079G protein-coupled receptor C5L27tm_13.6453893NM_000835Hs 36451glutamate receptor, ionotropic, N-metlig_chan3.5409402AF208234Hs. 695cystatin B (stefin B)cystatin3.5421166AA305407Hs 102308potassium inwardly-rectifying channeIRK3.5445575Z25368Hs 172004titinfn33.5428957NM_003881Hs 194679WNT1 inducible signaling pathway ptsp_1, vwc, IGFBP3.5403909NM_016255Hs 95260Homo sapiens mRNA; cDNA DKFZpNa_H_Exchanger3.5403077predicted exonfn33.5455612BE042896Hs 274848ESTsABC_tran, ABC_membrane3.5424091AF235097Hs 139263calcium channel, voltage-dependent, aion_trans3.5403956W28077Hs 79389nel (chicken)-like 2cadherin, Cadherin_C_term3.4457470AB040973Hs 272385protein-coupled receptor 727tm_13.4401522N47812Hs 81360CGI-35 proteindisintegrin; Reprolysin3.4404886predicted exonion_trans3.4437692AA176959Hs 172004titinfn33.4407944R34008Hs. 239727desmocollin 2cadherin3.4407393AB038237gb Homo sapiens mRNA for G protei7tm_13.3436936AL134451Hs 197478ESTsEGF, laminin_G3.3423309BE006775Hs 126782sushi-repeat proteinsushi, HYR3.3402172predicted exonig3.3447420AI378628gb tc72g07.x1 Soares_NhHMPu_S1 Hank; pkinase, death3.3438901AF085834Hs 29036ESTssushi3.3424362AL137646Hs 146001Homo sapiens mRNA, cDNA DKFZptrypsin, sushi, CUB3.3430453BE387060Hs. 3903Cdc42 effector protein 4, binder of Rhfn33.3416631H69466gb yr88f07 r1 Soares fetal liver spleenIdl_recept_a; MACPF3.3453174AI633529Hs 135238ESTa7tm_13.3433848AF095719Hs 93764carboxypeptidase A3Zn_carbOpept, Propep_M143.2408546W49512Hs 46348bradykinin receptor B17tm_13.2423573AA328504gb EST31993 Embryo, 12 week I Hom7tm_13.2458662AI823410Hs. 169149karyophenn alpha 1 (importin alpha 57tm_3, ANF_receptor3.2433430AI863735Hs 186755ESTsthyroglobulin_1, IGFBP3.2438850R33727Hs 24688ESTank; pkinase, death3.2420783AI659838Hs 99923lectin, galactoside-binding, soluble, 7Gal-bind_lectin3.2409968U56102Hs 57699adhesion glycoproteinig3.1430630AW269920Hs 2621cystatin A (stefin A)7tm_3, ANF_receptor3.1420737L08096Hs 99899tumor necrosis factor (ligand) superfaTNF3.1422279H69644Hs 114231C-type lectin-like receptor-2lectin_c3.1400289X07820Hs. 2258matrix metalloproteinase 10 (stromelyhemopexin, Peptidase_M103.1412597AU077051Hs 74561alpha-2-macroglobulinA2M, A2M_N3.1453420AJ003459gb: AJ003459 Setected chromosome 2IRK3.1404243predicted exonzf-C3HC4, SPRY; zf-B_box3.1449987AW079749Hs 184719ESTs, Weakly similar to AF116721 1ABC_tran; ABC_membrane3.1422471AA311027Hs. 271894ESTsig3.0400464predicted exonPeptidase_S93.0458713BE044496Hs 282707ESTsEGF3.0421340F07783Hs 1369decay accelerating factor for complemsushi3.0449523NM_000579Hs 54443chemokine (C-C motif) receptor 57tm_13.0400704predicted exonlig_chan, ANF_receptor3.0416239AL038450Hs 48948ESTsE1-E2_ATPase; Hydrolase3.0433664AW292176Hs 245834ESTsRicin_B_lectin3.0423994X01057Hs. 1724interleukin 2 receptor, alpharrm2.9447726AL137638Hs 19368Homo sapiens mRNA, cDNA DKFZpvwa2.9425483AF231022Hs 301273Homo sapiens protocadherin Fat 2 (FAEGF; cadherin, laminin_G2.9423513AF035960Hs 129719transglutaminase 5Transglut_core; Transglutamin_N2.9401537predicted exonig, pkinase, LRRNT; LRRCT2.9405790predicted exonSema; Plexin_repeat; TIG2.9422669H12402Hs. 119122ribosomal protein L13aarf; ras; Ribosomal_S172.9430793M83181Hs. 2479405-hydroxytryptamine (serotonin) recep7tm_12.9403411predicted exonABC_tran, ABC_membrane2.8428188M98447Hs. 22transglutaminase 1 (K polypeptide epTransglutamin_N; Transglut_core2.8414482S57498Hs 76252endothelin receptor type A7tm_12.8427223BE208189Hs 174031cytochrome c oxidase subunit VIbCOX6B2.8404187predicted exonig2.8443537D13305Hs. 203cholecystokinin B receptor7tm_12.8428701NM_013276Hs 190207carbohydrate kinase-likevwa; integrin_A, P2X_receptor2.7411213AA676939Hs 69285neuropilin 1CUB; MAM, F5_F8_type_C2.7453999BE328153Hs 240087ESTskazal2.7401244predicted exonvwa, vwd, TIL2.7458930NM_003612Hs 24640sema domain, immunoglobulin domaiSema2.7434411AA632649Hs 201372ESTssushi2.7400421AF263537Hs 287370fibroblast growth factor 23FGF2.7448999AF179274Hs 22791transmembrane protein with EGF-likekazal2.7417350U50928Hs 82001polycystic kidney disease 2 (autosomaion_trans2.6419452U33635Hs 90572PTK7 protein tyrosine kinase 7pkinase, ig2.6401657predicted exon7tm_12.6456711AA033699Hs 83938ESTs, Moderately similar to MASP-2sushi, trypsin, CUB2.6432042AW971345Hs 292715ESTssugar_tr2.6433138AB029496Hs 59729semaphonn sem2ig, Sema2.6452530AI905518gb RC-BT091-210199-098 BT091 HoABC_tran, ABC_membrane2.6426418M90464Hs 169825collagen, type IV, alpha 5 (Alport synCollagen, C42.6403796predicted exoncadherin2.6431728NM_007351Hs 268107multimerinEGF; C1q2.6441595AW206035Hs. 192123ESTssugar_tr2.6445537AJ245671Hs. 12844EGF-like-domain, multiple 6EGF, MAM2.6447197R36075gb yh88b01.s1 Soares placenta Nb2HSDF2.5428765X54150Hs 193122Fc fragment of IgA, receptor forig2.5450245AA007536Hs 271767ESTs, Moderately similar to ALU1_Hig2.5416429H54658Hs 268942ESTsE1-E2_ATPase, Hydrolase2.5417067AJ001417Hs. 81086solute carrier family 22 (extraneuronasugar_tr2.5433182AB039920Hs 127821BWRT proteinion_trans2.5403092predicted exonfn32.5406850A1624300Hs 172928collagen, type I, alpha 1vwc, Collagen, COLFI2.5438698AW297855Hs. 125815ESTslipoxygenase, PLAT2.5456815NM_013348Hs 144011potassium inwardly-rectifying channeIRK2.5Pkey: Primekey Ex. Accn Exemplar Accession UG ID. UniGene ID Title. Unigene Title PFAM domains ratio: tumor vs normal tissues


[0353]

5







TABLE 2B








Pkey
CAT Number
Accession

















409385
112523_1
AA071267 T65940 T64515 AA071334


412333
1289037_1
AW937485 AW937589 AW937658




AW937654 AW937492


413605
1379792_1
BE152644 BE152712 BE152668




BE152659 BE152810 BE152811 BE152816




BE152643 BE152706 BE152656 BE152660




BE152715 BE152662 BE152669 BE152661




BE152672 BE152653 BE152716 BE152651




BE152767 BE152677 BE152652 BE152714




BE152708 BE152665 BE152679 BE152771




BE152775 BE152666 BE152768 BE152813




BE152664 BE152676 BE152681 BE152709




BE152667 BE152814 BE152808 BE152711




BE152707 BE152815 BE152678 BE152673




BE152782 BE152671 BE152682 BE152760




BE152809 BE152778 BE152780 BE152762




BE152776 BE152781 BE152774 BE152763




BE152769


416151
1573926_1
T26661 Z44135 H23016


416441
159480_1
BE407197 AA182474 AA180369 BE275628




BE276131


416631
1605019_1
H69466 H93884 N59684


423573
229714_1
AA328504 AA327783 AW962370


447197
711623_1
R36075 AI366546 R36167


447420
721207_1
AI378628 N32350 H85772


452530
920646_1
AI905518 AI905516 AI905457 AI905515




AW176013 AW176037


452947
939810_1
AW130413 AI932362


453420
966433_1
AJ003459 AJ003461


459170
920646_1
AI905518 AI905516 AI905457 AI905515




AW176013 AW176037






Pkey: Unique Eos probeset identifier number




CAT number: Gene cluster number




Accession: Genbank accession numbers








[0354]

6








TABLE 2C








Pkey
Ref
Strand
Nt_position


















400464
9929670
Plus
22074-22214


400704
8118864
Minus
63110-63241


400749
7331445
Minus
9162-9293


401244
4827300
Minus
55359-56376


401537
7960358
Minus
186786-187029, 190607-190779,





198218-198348


401657
9100664
Minus
7312-8163


402172
8575911
Minus
143378-143671


402425
9796347
Minus
50224-50395


402745
9212200
Minus
76516-76690


403074
8954241
Plus
143375-143561


403077
8954241
Plus
146923-147222, 147326-147628


403083
8954241
Plus
163070-163351


403089
8954241
Plus
171964-172239


403092
8954241
Plus
174720-175016, 175104-175406,





175508-175813


403093
8954241
Plus
177083-177373, 177464-177751


403411
9438635
Minus
104247-104420


403661
8705027
Minus
30268-30482


403687
7387384
Plus
9009-9534


403691
7387384
Minus
88280-88463


403763
7229888
Minus
43575-43887


403796
8099896
Minus
75073-77664


404187
4481839
Plus
7644-7991


404243
5672609
Plus
74695-75123


404270
9828129
Minus
3649-3750, 4161-4306, 5962-6049,





6849-6965


404886
4884062
Plus
30058-30596


405281
6139075
Minus
34202-34351, 35194-35336,





45412-45475, 45731-45958,





47296-47457, 49549-49658,





49790-49904, 50231-50342,





53583-53667, 54111-54279


405285
6139075
Minus
55744-55903, 57080-57170,





61478-61560


405545
1054740
Plus
118677-118807, 119091-119296,





121626-121823


405547
1054740
Plus
124361-124520, 124914-125050


405636
5123990
Plus
56384-56587


405790
1203968
Plus
136364-136509, 136579-136699,





136805-136941






Pkey: Unique number corresponding to an Eos probeset




Ref Sequence source The 7 digit numbers in this column are Genbank Identifier (Gt) numbers “Dunham I. et al” refers to the publication entitled “The DNA sequence of human chromosome 22” Dunham, et al (1999) Nature 402: 489-495




Strand Indicates DNA strand from which exons were predicted




Nt_position Indicates nucleotide positions of predicted exons








[0355] TABLE 3A lists about 1643 genes up-regulated in ovarian cancer compared to normal ovaries These were selected as for Table 1A, except that the ration was greater than or equal to 15, and the denominator was the arithmetic mean value for various non-malignant ovary specimens obtained
7TABLE 3AABOUT 1643 UP-REGULATED GENES, OVARIAN CANCER VERSUS NORMAL OVARYPkeyEx Accn No.UG IDTitleratio420859AW468397Hs. 100000S100 calcium-binding protein A8 (calgranulin A)219.9422166W72424Hs. 112405S100 calcium-binding protein A9 (calgranulin B)180.2422158L10343Hs. 112341protease inhibitor 3, skin-derived (SKALP)165.0424799BE550723Hs. 153179fatty acid binding protein 5 (psoriasis-associated)161.5442402NM_000954Hs. 8272prostaglandin D2 synthase (21 kD, brain)150.2408522AI541214Hs. 46320Small proline-rich protein SPRK [human, odontogenic k149.5431369BE184455Hs. 251754secretory leukocyte protease inhibitor (antileukoprotein144.9430520NM_016190Hs. 242057chromosome 1 open reading frame 10136.6428471X57348Hs. 184510stratifin129.5421978AJ243662Hs. 110196NICE-1 protein108.7437191NM_006846Hs. 5476serine protease inhibitor, Kazal type, 5106.2407788BE514982Hs. 38991S100 calcium-binding protein A2105.5441565AW953575Hs. 169902solute carrier family 2 (facilitated glucose transporter),103.6431211M86849Hs. 5566gap junction protein, beta 2, 26 kD (connexin 26)102.1419329AY007220Hs. 288998S100-type calcium binding protein A1495.3430572U33114Hs. 245188tissue inhibitor of metalloproteinase 3 (Sorsby fundus d87.0417079U65590Hs. 81134interleukin 1 receptor antagonist86.1412636NM_004415Hs. 74316desmoplakin (DPI, DPII)85.0417515L24203Hs. 82237ataxia-telangiectasia group D-associated protein84.8426295AW367283Hs. 75839zinc finger protein 6 (CMPX1)84.5452669AA216363Hs. 262958ESTs, Weakly similar to alternatively spliced product u84.4406711N25514Hs. 77385myosin, light polypeptide 6, alkali, smooth muscle and n83.8406712M31212Hs. 77385myosin, light polypeptide 6, alkali, smooth muscle and n81.0432680T47364Hs. 278613interferon, alpha-inducible protein 2781.0416889AW250318Hs. 80395mal, T-cell differentiation protein77.8409453AI885516Hs. 95612ESTs75.3424670W61215Hs. 116651epithelial V-like antigen 167.5417130AW276858Hs. 81256S100 calcium-binding protein A4 (calcium protein, calv67.0423634AW959908Hs. 1690heparin-binding growth factor binding protein65.7442379NM_004613Hs. 8265transglutaminase 2 (C polypeptide, protein-glutamine-g64.7456898NM_001928Hs. 155597D component of complement (adipsin)64.6423017AW178761Hs. 227948serine (or cysteine) proteinase inhibitor, clade B (ovalbu63.6447990BE048821Hs. 20144small inducible cytokine subfamily A (Cys-Cys), memb60.7424362AL137646Hs. 146001Homo sapiens mRNA, cDNA DKFZp586F0824 (from60.3414438AI879277Hs. 76136thioredoxin59.9420136AW801090Hs. 195851actin, alpha 2, smooth muscle, aorta58.9433336AF017986Hs. 31386ESTs, Highly similar to JE0174 frizzled protein-2 [H. sa58.8403741predicted exon57.0430637BE160081Hs. 256290S100 calcium-binding protein A11 (calgizzarin)56.1424098AF077374Hs. 139322small proline-rich protein 355.8441591AF055992Hs. 183Duffy blood group55.6426521AF161445Hs. 170219hypothetical protein55.5406713U02629Hs. 77385myosin, light polypeptide 6, alkali, smooth muscle and n55.3406725D51245Hs. 288061actin, beta54.1422168AA586894Hs. 112408S100 calcium-binding protein A7 (psoriasin 1)54.1406755N80129Hs. 94360metallothionein 1L54.0425593AA278921Hs. 1908proteoglycan 1, secretory granule53.3442257AW503831gb: UI-HF-BN0-alb-b-05-0-UI.r1 NIH_MGC_50 Homo53.1421957AW068637Hs. 109857hypothetical protein DKFZp434H082052.3447526AL048753Hs. 340small inducible cytokine A2 (monocyte chemotactic pro51.2406722H27498Hs. 283305Homo sapiens SNC73 protein (SNC73) mRNA, comple51.0427223BE208189Hs. 174031cytochrome c oxidase subunit VIb51.0414420AA043424Hs. 76095immediate early response 350.9417259AW903838Hs. 81800chondroitin sulfate proteoglycan 2 (versican)50.3414191AW250089Hs. 75807PDZ and LIM domain 1 (elfin)49.5436906H95990Hs. 181244major histocompatibility complex, class I, A49.0408000L11690Hs. 620bullous pemphigoid antigen 1 (230/240 kD)49.0414035Y00630Hs. 75716serine (or cysteine) proteinase inhibitor, clade B (ovalbu48.8432706NM_013230Hs. 286124CD24 antigen (small cell lung carcinoma cluster 4 antig48.8421948L42583Hs. 111758keratin 6A48.7414662AL036058Hs. 76807major histocompatibility complex, class II, DR alpha48.5425071NM_013989Hs. 154424deiodinase, iodothyronine, type II48.5404767predicted exon48.4418327U70370Hs. 84136paired-like homeodomain transcription factor 148.2436729BE621807Hs. 3337transmembrane 4 superfamily member 147.7414183AW957446Hs. 301711ESTs47.2400163predicted exon47.0433423BE407127Hs. 8997heat shock 70 kD protein 1A46.9423457F08208Hs. 155606paired mesoderm homeo box 146.6414085AA114016Hs. 75746aldehyde dehydrogenase 646.0423189M59371Hs. 171596EphA245.6438240N92638Hs. 124004ESTs45.5417366BE185289Hs. 1076small proline-rich protein 1B (cornifin)45.3412774AA120865Hs. 23136ESTs45.1407242M18728gb: Human nonspecific crossreacting antigen mRNA, co44.8431292AA370141Hs. 251453Human DNA sequence from clone 967N21 on chromos44.8403695predicted exon43.5417365D50683Hs. 82028transforming growth factor, beta receptor II (70-80 kD)43.4432331W37862Hs. 274368Homo sapiens mRNA, cDNA DKFZp586I1524 (from c43.4424479AF064238Hs. 149098smoothelin43.3444726NM_006147Hs. 11801interferon regulatory factor 643.2432314AA533447Hs. 285173ESTs43.2429500X78565Hs. 289114hexabrachion (tenascin C, cytotactin)43.1441406Z45957Hs. 7837Homo sapiens cDNA FLJ10457 fis, clone NT2RP100142.7412969AI373162Hs. 75103tyrosine 3-monooxygenase/tryptophan 5-monooxygenas42.6423720AL044191Hs. 23388Homo sapiens cDNA FLJ21310 fis, clone COL0216042.5400111predicted exon42.4407207T03651Hs. 179661tubulin, beta polypeptide42.4417164AA338283Hs. 81361heterogeneous nuclear ribonucleoprotein A/B42.2424971AA479005Hs. 154036tumor suppressing subtransferable candidate 341.9439394AA149250Hs. 56105ESTs, Weakly similar to WDNM RAT WDNM1 PROT41.9406657AI678644Hs. 277477major histocompatibility complex, class I, C41.8451092AI207256Hs. 13766Homo sapiens mRNA for FLJ00074 protein, partial cds41.6412596AA161219Hs. 799diphtheria toxin receptor (heparin-binding epidermal gro41.6422103AA984330Hs. 111676protein kinase H11, small stress protein-like protein HS41.5428785AI015953Hs. 125265ESTs41.3450988BE618571Hs. 429ATP synthase, H+ transporting, mitochondrial F0 comp41.0414622AI752666Hs. 76669nicotinamide N-methyltransferase40.8405022predicted exon40.8408221AA912183Hs. 47447ESTs40.8446500U78093Hs. 15154sushi-repeat-containing protein, X chromosome40.7421416BE302950Hs. 104125adenylyl cyclase-associated protein40.6412247AF022375Hs. 73793vascular endothelial growth factor40.5410541AA065003Hs. 64179hypothetical protein40.5406658AI920965Hs. 77961major histocompatibility complex, class I, B40.0420225AW243046Hs. 94789ESTs40.0406825AI982529Hs. 84298CD74 antigen (invariant polypeptide of major histocom39.4443623AA345519Hs. 9641complement component 1, q subcomponent, alpha poly39.4404201AF059566Hs. 103983solute carrier family 5 (sodium iodide symporter), mem39.3405138predicted exon39.1408733AW264812Hs. 254290ESTs39.0414044BE614194Hs. 75721profilin 138.9430152AB001325Hs. 234642aquaporin 338.8428121AB006622Hs. 182536Homo sapiens cDNA FLJ21370 fis, clone COL0309238.8434311BE543469Hs. 266263Homo sapiens cDNA FLJ14115 fis, clone MAMMA1038.7406140predicted exon38.5432918AF077200Hs. 279813hypothetical protein38.4420107AL043980Hs. 7886pellino (Drosophila) homolog 138.4427693BE546832Hs. 180370cofilin 1 (non-muscle)38.1448835BE277929Hs. 11081ESTs, Weakly similar to S57447 HPBRII-7 protein [H.38.1432374W68815Hs. 301885Homo sapiens cDNA FLJ11346 fis, clone PLACE101037.9428383BE616599Hs. 184029hypothetical protein DKFZp761A05237.7436258AW867491Hs. 107125ESTs, Weakly similar to S57447 HPBRII-7 protein [H.37.7420798W93774Hs. 99936keratin 10 (epidermolytic hyperkeratosis; keratosis palm37.7400327M18679Hs. 247942Human variant 5S rRNA-like gene and ORF, complete37.6401781predicted exon37.6448257AW772070Hs. 253146ESTs37.3428415AA337211Hs. 184222Down syndrome critical region gene 137.2424206NM_003734Hs. 198241amine oxidase, copper containing 3 (vascular adhesion p37.2406812AF000575Hs. 67846leukocyte immunoglobulin-like receptor, subfamily B (37.2425882U83115Hs. 161002absent in melanoma 137.2432501BE546532Hs. 287329Fas binding protein 137.1421786AI188653Hs. 21351ESTs37.1427981BE275986Hs. 181311asparaginyl-tRNA synthetase37.0410143AA188169Hs. 288819Homo sapiens cDNA FLJ21022 fis, clone CAE0638336.8451328AW853606Hs. 109012ESTs36.7414135NM_004419Hs. 2128dual specificity phosphatase 536.7414602AW630088Hs. 76550Homo sapiens mRNA; cDNA DKFZp564B1264 (from36.7401785predicted exon36.5411469T09997Hs. 70327cysteine-rich protein 236.2419693AA133749Hs. 92323FXYD domain-containing ion transport regulator 336.1417039AA302180Hs. 80986ATP synthase, H+ transporting, mitochondrial F0 comp36.1406718AA505525Hs. 169476glyceraldehyde-3-phosphate dehydrogenase36.0402543predicted exon36.0408669AI493591Hs. 78146platelet/endothelial cell adhesion molecule (CD31 antig35.9414987AA524394Hs. 165544ESTs35.9445810AW265700Hs. 155660ESTs35.9406653AA574074Hs. 77961major histocompatibility complex, class I, B35.7407498U28131gb: Human HMGI-C chimeric transcript mRNA, partial35.6412524AA417813Hs. 11177ESTs35.5401521predicted exon35.4408948AW296713Hs. 221441ESTs35.1406728AI986345Hs. 183704ubiquitin C34.9440669AI206964gb: qr30g06.x1 NCI_CGAP_GC6 Homo sapiens cDNA34.8422658AF231981Hs. 250175homolog of yeast long chain polyunsaturated fatty acid34.8452924AW580939Hs. 97199complement component C1q receptor34.7428600AW863261Hs. 15036ESTs, Highly similar to AF161358 1 HSPC095 [H. sapi34.7409828AW501137gb: UI-HF-BP0p-ait-e-12-0-UI.r1 NIH_MGC_51 Homo34.5459390BE385725gb: 601276347F1 NIH_MGC_20 Homo sapiens cDNA34.5445055BE512856Hs. 109051glycoprotein, synaptic 234.3411789AF245505Hs. 72157Homo sapiens adlican mRNA, complete cds34.3410626BE407727gb: 601299771F1 NIH_MGC_21 Homo sapiens cDNA34.2410706AI732404Hs. 68846ESTs34.2419273BE271180Hs. 293490ESTs34.2407839AA045144Hs. 161566ESTs34.0444286AI625304Hs. 190312ESTs34.0449226AB002365Hs. 23311KIAA0367 protein34.0414290AI568801Hs. 71721ESTs33.9401245predicted exon33.9425222M85430Hs. 155191villin 2 (ezrin)33.8409950R42678Hs. 301669KIAA0564 protein33.8437201F29279Hs. 177486amyloid beta (A4) precursor protein (protease nexin-II,33.7406566AF088886Hs. 11590cathepsin F33.7405071predicted exon33.7455426AW937792gb: QV3-DT0045-140200-082-b07 DT0045 Homo sapi33.6415160T82802gb: yd38a04.r1 Soares fetal liver spleen 1NFLS Homo s33.5424995Z45023gb: HSC2FA041 normalized infant brain cDNA Homo s33.5453870AW385001Hs. 8042Homo sapiens cDNA FLJ23173 fis, clone LNG1001933.5433470AW960564Hs. 3337transmembrane 4 superfamily member 133.4428188M98447Hs. 22transglutaminase 1 (K polypeptide epidermal type I, pro33.3417409BE272506Hs. 82109syndecan 133.3425389AW974499Hs. 192183ESTs33.3434658AI624436Hs. 194488ESTs33.2456562AA306049Hs. 102669DKFZP434O125 protein33.1447111AI017574Hs. 17409cysteine-rich protein 1 (intestinal)33.0432360BE045243Hs. 274416NADH dehydrogenase (ubiquinone) 1 alpha subcomple32.9424125M31669Hs. 1735inhibin, beta B (activin AB beta polypeptide)32.7419968X04430Hs. 93913interleukin 6 (interferon, beta 2)32.7429415NM_002593Hs. 202097procollagen C-endopeptidase enhancer32.6451541BE279383Hs. 26557plakophilin 332.6424499N90344Hs. 149436kinesin family member 5B32.4402144predicted exon32.4422511AU076442Hs. 117938collagen, type XVII, alpha 132.4400231predicted exon32.3437712X04588Hs. 85844neurotrophic tyrosine kinase, receptor, type 132.3417433BE270266Hs. 821285T4 oncofetal trophoblast glycoprotein32.2419659AB023206Hs. 92186Leman coiled-coil protein32.0428582BE336699Hs. 185055BENE protein32.0421401AW410478Hs. 104019transforming, acidic coiled-coil containing protein 332.0414064BE245289Hs. 16165expressed in activated T/LAK lymphocytes32.0431938AA938471Hs. 115242developmentally regulated GTP-binding protein 132.0411930F06485gb: HSC19G051 normalized infant brain cDNA Homo s31.9428150AW950547Hs. 182684cytochrome c oxidase subunit VIIa polypeptide 2 (liver)31.8401887predicted exon31.8412570AA033517Hs. 74047electron-transfer-flavoprotein, beta polypeptide31.7422738X80915Hs. 1573growth differentiation factor 5 (cartilage-derived morph31.6453092X64838Hs. 31638restin (Reed-Steinberg cell-expressed intermediate filam31.5413924AL119964Hs. 75616KIAA0018 gene product31.4420231R06866Hs. 19813ESTs31.3434715BE005346Hs. 116410ESTs31.3422831R02504gb: ye86f06.r1 Soares fetal liver spleen 1NFLS Homo sa31.2416854H40164Hs. 80296Purkinje cell protein 431.2422976AU076657Hs. 1600sec61 homolog31.1426356BE536836gb: 601064837F1 NIH_MGC_10 Homo sapiens cDNA31.0433935AF112208Hs. 4416313 kDa differentiation-associated protein30.8430040AW503115Hs. 227823pM5 protein30.8406340AA299679Hs. 180370cofilin 1 (non-muscle)30.8426050AF017307Hs. 166096E74-like factor 3 (ets domain transcription factor, epith30.7425105BE280066Hs. 24956hypothetical protein FLJ2205630.7402066predicted exon30.7429538BE182592Hs. 139322small proline-rich protein 330.6418371M13560Hs. 84298CD74 antigen (invariant polypeptide of major histocom30.4421251Z28913Hs. 102948enigma (LIM domain protein)30.3456084AA155859Hs. 79708ESTs30.3402023predicted exon30.3404356predicted exon30.2415973R24707Hs. 260201ESTs30.2445983AI269107Hs. 132219ESTs30.1450440AB024334Hs. 25001tyrosine 3-monooxygenase/tryptophan 5-monooxygenas30.1458789AL157468Hs. 20157Homo sapiens cDNA FLJ20848 fis, clone ADKA0173230.1400842predicted exon30.1406828AA419202Hs. 84298CD74 antigen (invariant polypeptide of major histocom30.0423267AL137416Hs. 126177Homo sapiens mRNA; cDNA DKFZp434O192 (from c30.0451383AW239364Hs. 20242hypothetical protein FLJ1278830.0437042AK000702Hs. 5420hypothetical protein FLJ2069530.0459399BE407712gb: 601299745F1 NIH_MGC_21 Homo sapiens cDNA30.0425650NM_001944Hs. 1925desmoglein 3 (pemphigus vulgaris antigen)30.0416511NM_006762Hs. 79356Lysosomal-associated multispanning membrane protein29.9431009BE149762Hs. 248213gap junction protein, beta 6 (connexin 30)29.7436651BE045962Hs. 275998ESTs29.6419766BE243101Hs. 22391chromosome 20open reading frame 329.5420747BE294407Hs. 99910phosphofructokinase, platelet29.5436895AF037335Hs. 5338carbonic anhydrase XII29.5412765AK000620Hs. 74571ADP-ribosylation factor 129.4419223X60111Hs. 1244CD9 antigen (p24)29.4413796AW408094Hs. 75545interleukin 4 receptor29.4447795AW295151Hs. 163612ESTs29.4431103M57399Hs. 44pleiotrophin (heparin binding growth factor 8, neurite g29.4415314N88802Hs. 5422glycoprotein M6B29.3428411AW291464Hs. 10338ESTs29.3430580AA806105Hs. 140immunoglobulin heavy constant gamma 3 (Gm marker)29.3430451AA836472Hs. 249982cathepsin B29.2453949AU077146Hs. 36927heat shock 105 kD29.2413859AW992356Hs. 8364pyruvate dehydrogenase kinase, isoenzyme 429.2407845AL036518Hs. 118598ESTs29.1453500AI478427Hs. 43125ESTs29.1456054BE313241gb: 601151545F1 NIH_MGC_19 Homo sapiens cDNA29.0453467AI535997Hs. 30089ESTs29.0411794AL118577Hs. 75658phosphorylase, glycogen, brain28.9421773W69233Hs. 112457ESTs28.9423621BE002904gb: QV4-BN0090-070400-163-c07 BN0090 Homo sapi28.8408935BE539706Hs. 285363ESTs28.8450847NM_003155Hs. 25590stanniocalcin 128.8431243U46455Hs. 252189syndecan 4 (amphiglycan, ryudocan)28.7423225AA852604Hs. 125359Thy-1 cell surface antigen28.7433469F12741gb: HSC3DG061 normalized infant brain cDNA Homo28.7405783predicted exon28.7417308H60720Hs. 81892KIAA0101 gene product28.7400749predicted exon28.7413442BE140643gb: RC0-HT0015-310599-016 HT0015 Homo sapiens c28.6404828predicted exon28.6407453AJ132087gb: Homo sapiens mRNA for axonemal dynein heavy ch28.6418529AW005695Hs. 250897TRK-fused gene (NOTE non-standard symbol and nam28.6413787AI352558Hs. 75544tyrosine 3-monooxygenase/tryptophan 5-monooxygenas28.5450690AA296696Hs. 25334FXYD domain-containing ion transport regulator 528.5402430predicted exon28.4413929BE501689Hs. 75617collagen, type IV, alpha 228.2423803NM_005709Hs. 132945PDZ-73 protein28.2406086predicted exon28.2416585X54162Hs. 79386leiomodin 1 (smooth muscle)28.2417055N39489Hs. 7258Homo sapiens cDNA FLJ22021 fis, clone HEP0825328.1449184AW296295Hs. 196491ESTs28.1446542NM_004281Hs. 15259BCL2-associated athanogene 328.1412793AW997986gb: RC1-BN0056-230200-021-e11 BN0056 Homo sapie28.0452818W21909Hs. 8372ubiquinol-cytochrome c reductase (6.4 kD) subunit28.0402869predicted exon27.9436810AA353044Hs. 5321ARP3 (actin-related protein 3, yeast) homolog27.9402075predicted exon27.9410480R97457Hs. 63984cadherin 13, H-cadherin (heart)27.8406690M29540Hs. 220529carcinoembryonic antigen-related cell adhesion molecul27.8439766AB033492Hs. 301241Homo sapiens mRNA, cDNA DKFZp586A0424 (from27.7424482BE268621Hs. 149155voltage-dependent anion channel 127.6420737L08096Hs. 99899tumor necrosis factor (ligand) superfamily, member 727.6414663BE396326gb: 601289258F1 NIH_MGC_8 Homo sapiens cDNA c27.6409703NM_006187Hs. 560092′-5′oligoadenylate synthetase 327.6446108AL036596Hs. 102773ESTs27.5428144BE269243Hs. 182625VAMP (vesicle-associated membrane protein)-associate27.5445688AI248205Hs. 153244ESTs27.5405411predicted exon27.5410275U85658Hs. 61796transcription factor AP-2 gamma (activating enhancer-b27.5424675NM_005512Hs. 151641glycoprotein A repetitions predominant27.3450455AL117424Hs. 25035chloride intracellular channel 427.3414855AA156986Hs. 104640HIV-1 inducer of short transcripts binding protein27.2433578BE336886Hs. 3416adipose differentiation-related protein27.2401994predicted exon27.2445033AV652402Hs. 155145ESTs27.2402277predicted exon27.1428106BE620016Hs. 182470PTD010 protein27.1448625AW970786Hs. 178470Homo sapiens cDNA FLJ22662 fis, clone HSI0808027.1422587AI879352Hs. 118625hexokinase 127.0457204BE264152Hs. 221994ESTs27.0444094AI695764Hs. 202394ESTs27.0414053BE391635Hs. 75725transgelin 226.9430511BE018156Hs. 2575calpain 1, (mu/l) large subunit26.9434039L32977Hs. 3712ubiquinol-cytochrome c reductase, Rieske iron-sulfur po26.9424939AK000059Hs. 153881Homo sapiens NY-REN-62 antigen mRNA, partial cds26.9414539BE379046gb: 601236646F1 NIH_MGC_44 Homo sapiens cDNA26.9404675predicted exon26.8401597AA172106Hs. 110950Rag C protein26.8401405predicted exon26.8411541W03940gb: za62b02.r1 Soares fetal liver spleen 1NFLS Homo sa26.8412025AI827451Hs. 24143ESTs26.7414276BE297862gb: 601174780F1 NIH_MGC_17 Homo sapiens cDNA26.7444065AW449415Hs. 10260Homo sapiens cDNA FLJ11341 fis, clone PLACE101026.7447981R53772Hs. 8929hypothetical protein FLJ1136226.7410677NM_003278Hs. 65424tetranectin (plasminogen-binding protein)26.5400982predicted exon26.5452933AW391423Hs. 288555Homo sapiens cDNA FLJ22425 fis, clone HRC0868626.5407233X16354Hs. 50964carcinoembryonic antigen-related cell adhesion molecul26.4430127AA219498Hs. 233952proteasome (prosome, macropain) subunit, alpha type, 726.3448218AI188489gb: qd09b12x1 Soares_placenta_8to9weeks_2NbHP8to26.3413511AI627178Hs. 75412Arginine-rich protein26.2459511AI142379gb: qg64c01.r1 Soares_testis_NHT Homo sapiens cDNA26.2410668BE379794Hs. 65403hypothetical protein26.2458662AI823410Hs. 169149karyophenn alpha 1 (importin alpha 5)26.2451219AA054209Hs. 167904ESTs26.2448939BE267795Hs. 22595hypothetical protein FLJ1063726.2400800Y10262Hs. 46925eyes absent (Drosophila) homolog 326.2446342BE298665Hs. 14846Homo sapiens mRNA; cDNA DKFZp564D016 (from c26.2421177AW070211Hs. 102415Homo sapiens mRNA; cDNA DKFZp586N0121 (from26.1433848AF095719Hs. 93764carboxypeptidase A326.1448497BE613269Hs. 21893ESTs, Weakly similar to glycerol 3-phosphate permease26.1415279F04237Hs. 1447glial fibrillary acidic protein26.0419323AI092379Hs. 135275ESTs26.0430265L36033Hs. 237356stromal cell-derived factor 125.9437679NM_014214Hs. 5753inositol(myo)-1(or 4)-monophosphatase 225.9425535AB007937Hs. 158287KIAA0468 gene product25.8412923AA179922Hs. 75056adaptor-related protein complex 3, delta 1 subunit25.8447980AI703397Hs. 202355ESTs25.8419118AA234223Hs. 139204ESTs25.8421224AW402154Hs. 125812ESTs25.8414890BE281095Hs. 77573undine phosphorylase25.8447330BE279949Hs. 18141ladinin 125.7405610predicted exon25.7447604AW089933Hs. 293674ESTs25.7445677H96577Hs. 6838ras homolog gene family, member E25.7456088BE177320Hs. 156148Homo sapiens cDNA FLJ23082 fis, clone LNG0645125.7417120N79687Hs. 46616ESTs25.6405194predicted exon25.6410687U24389Hs. 65436lysyl oxidase-like 125.6421888AA299780Hs. 121036ESTs25.6420459AF016045Hs. 97905ovo (Drosophila) homolog-like 125.5416323N72630Hs. 33981Homo sapiens genomic DNA, chromosome 21q, section25.5446292AF081497Hs. 279682Rh type C glycoprotein25.5416274AW160404Hs. 79126guanine nucleotide binding protein 1025.5430028BE564110Hs. 227750NADH dehydrogenase (ubiquinone) 1 beta subcomplex25.5438450AI050866Hs. 65853nodal, mouse, homolog25.5400215predicted exon25.4430014H59354Hs. 182485actinin, alpha 425.4453582AW854339Hs. 33476hypothetical protein FLJ1193725.4405867predicted exon25.4459170AI905518gb: RC-BT091-210199-098 BT091 Homo sapiens cDNA25.4407944R34008Hs. 239727desmocollin 225.4415748D90086Hs. 979pyruvate dehydrogenase (lipoamide) beta25.3423287H38340gb: yp70h07.r1 Soares adult brain N2b4HB55Y Homo s25.3450944AA554989Hs. 209061sudD (suppressor of bimD6, Aspergillus nidulans) Homo25.3432906BE265489Hs. 3123lethal giant larvae (Drosophila) homolog 225.3400104predicted exon25.3449019AI949095Hs. 67776ESTs, Weakly similar to ALU7_HUMAN ALU SUBFA25.3406897M57417gb: Homo sapiens mucin (mucin) mRNA, partial cds25.3402639predicted exon25.3447147AA910353Hs. 292815ESTs25.3453379AA035261Hs. 61753ESTs25.3414217AI309298Hs. 279898Homo sapiens cDNA: FLJ23165 fis, clone LNG0984625.3430223NM_002514Hs. 235935nephroblastoma overexpressed gene25.3406685M18728gb: Human nonspecific crossreacting antigen mRNA, co25.3444747AW450407Hs. 257291ESTs, Weakly similar to PSS8_HUMAN PROSTASIN25.2417883R22519Hs. 23398ESTs25.2430235BE268048Hs. 236494RAB10, member RAS oncogene family25.2459001AI761313Hs. 204605ESTs25.2434368AW519020Hs. 212640Homo sapiens cDNA FLJ13265 fis, clone OVARC100025.2415917Z43912gb: HSC1OA111 normalized infant brain cDNA Homo25.2444409AI792140Hs. 49265ESTs25.2428578BE391797Hs. 82148hypothetical protein25.1433417AA587773Hs. 136494ESTs25.1426372BE304680Hs. 169531DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 2125.1402131predicted exon25.1450545AW135582Hs. 201767ESTs25.0434162AI221214Hs. 116136ESTs25.0406571predicted exon24.9427600AW630918Hs. 179774proteasome (prosome, macropain) activator subunit 2 (P24.9409402AF208234Hs. 695cystatin B (stefin B)24.9400135predicted exon24.9428403AI393048Hs. 239894leucine rich repeat (in FLII) interacting protein 124.9403223predicted exon24.8435236T03890Hs. 157208ESTs, Highly similar to Arx homeoprotein [M. musculu24.8457439AW410408Hs. 271167L-pipecolic acid oxidase24.8448667Z78394Hs. 4896Homo sapiens cDNA; FLJ22046 fis, clone HEP0927624.8440605Z40094Hs. 185698ESTs24.8426724AA383623Hs. 293616ESTs24.8403359predicted exon24.7442826AI018777Hs. 131241ESTs24.7411503AW190338Hs. 28029purinergic receptor P2X, ligand-gated ion channel, 424.6414540BE379050gb: 601236655F1 NIH_MGC_44 Homo sapiens cDNA24.6421595AB014520Hs. 105958Homo sapiens cDNA: FLJ22735 fis, clone HUV0018024.5438802AA825976Hs. 136954ESTs24.5400491H25530Hs. 50868solute carrier family 22 (organic cation transporter), me24.5418994AA296520Hs. 89546selectin E (endothelial adhesion molecule 1)24.5426383BE537380gb: 601064570F1 NIH_MGC_10 Homo sapiens cDNA24.4418408AA219321Hs. 173294ESTs24.4416186W87575Hs. 269177ESTs24.4416908AA333990Hs. 80424coagulation factor XIII, A1 polypeptide24.4453857AL080235Hs. 35861DKFZP586E1621 protein24.4439706AW872527Hs. 59761ESTs24.4441619NM_014056Hs. 7917DKFZP564K247 protein24.4417198F11533Hs. 81634ATP synthase, H+ transporting, mitochondrial F0 comp24.3433662W07162Hs. 150826CATX-8 protein24.3453986M13232Hs. 36989coagulation factor VII (serum prothrombin conversion a24.3457123AA770021Hs. 16332ESTs24.3433864AA931550Hs. 192785ESTs24.3409865AW502208gb: UI-HF-BR0p-aju-e-09-0-UI_r1 NIH_MGC_52 Hom24.3448175BE296174Hs. 225160Homo sapiens cDNA FLJ13102 fis, clone NT2RP300224.3406277predicted exon24.3451957AI796320Hs. 10299Homo sapiens cDNA FLJ13545 fis, clone PLACE100624.3408802AL048269Hs. 288544Homo sapiens cDNA FLJ20882 fis, clone ADKA032024.2401757predicted exon24.2444751AI207406Hs. 11866hypothetical protein PRO119724.2408647AW245831gb: 2822937.5prime NIH_MGC_7 Homo sapiens cDNA24.2418870AF147204Hs. 89414chemokine (C-X-C motif), receptor 4 (fusin)24.2436913AA789074Hs. 187478ESTs24.2434745AW974445Hs. 185155ESTs, Weakly similar to HuEMAP [H. sapiens]24.2451743AW074266Hs. 23071ESTs24.2421853AL117472Hs. 108924DKFZP586P1422 protein24.2407926AW956382Hs. 59771ESTs24.1413973BE279858Hs. 128417Homo sapiens cDNA FLJ14009 fis, clone Y79AA100224.1439078AF085936gb: Homo sapiens full length insert cDNA clone YR58F24.1401913predicted exon24.1435138BE314734gb: 601152976F1 NIH_MGC_19 Homo sapiens cDNA24.1405311predicted exon24.0413127BE066529Hs. 83484SRY (sex determining region Y)-box 424.0430793M83181Hs. 2479405-hydroxytryptamine (serotonin) receptor 1A24.0434445AI349306Hs. 11782ESTs24.0418166AI754416Hs. 260024Cdc42 effector protein 324.0431971BE274907Hs. 77385myosin, light polypeptide 6, alkali, smooth muscle and n23.9401167predicted exon23.9454163AW175997gb: QV0-BT0078-190899-005-E02 BT0078 Homo sapi23.9403306NM_006825Hs. 74368transmembrane protein (63 kD), endoplasmic reticulum/23.9410627AA181339Hs. 929myosin, heavy polypeptide 7, cardiac muscle, beta23.9450796NM_001988Hs. 25482envoplakin23.8442199BE277633Hs. 286027etoposide-induced mRNA23.8402699predicted exon23.8426143BE379836Hs. 167106proteasome (prosome, macropain) subunit, alpha type, 323.8437592NM_003851Hs. 5710cellular repressor of E1A-stimulated genes23.8433598AI762836Hs. 271433ESTs, Moderately similar to ALU2_HUMAN ALU SU23.8401088predicted exon23.8445924AI264671Hs. 164166ESTs23.8420902AA742277gb: ny28e09.s1 NCI_CGAP_GCB1 Homo sapiens cDN23.8426369AF134157Hs. 169487Kreisler (mouse) maf-related leucine zipper homolog23.8458698AW452189Hs. 257528ESTs23.7422048NM_012445Hs. 288126spondin 2, estracellular matrix protein23.7413460R61610Hs. 21527ESTs, Weakly similar to KIAA0918 protein [H. sapiens23.6401575predicted exon23.6431822AA516049gb: ng65d01.s1 NCI_CGAP_Lip2 Hamo sapiens cDNA23.6427276A4400269Hs. 49598ESTs23.6417069AA442192Hs. 81097cytochrome c oxidase subunit VIII23.5400161predicted exon23.5417190NM_001359Hs. 815482,4-dienoyl CoA reductase 1, mitochondrial23.5443667AI129066Hs. 135457ESTs23.5413544BE147225gb: PM2-HT0225-031299-003-f11 HT0225 Homo sapie23.5400685predicted exon23.5422090W05345Hs. 293884ESTs23.4432517AF275816Hs. 283096PR domain containing 923.4405307predicted exon23.4416328H48389Hs. 268886ESTs23.4427174AA398848Hs. 97541ESTs23.4426148AI751071Hs. 167135Homo sapiens cDNA FLJ10728 fis, clone NT2RP300123.3452544AW851888gb: QV0-CT0225-131099-034-d05 CT0225 Homo sapie23.3404890predicted exon23.3408725AA131539Hs. 15669ESTs23.3428362AA426555Hs. 169333ESTs23.3425349AA425234Hs. 79886nbose 5-phosphate isomerase A (ribose 5-phosphate ep23.3422440NM_004812Hs. 116724aldo-keto reductase family 1, member B11 (aldose redu23.3410962BE273749Hs. 752FK506-binding protein 1A (12 kD)23.2411796AA807197Hs. 6918ESTs23.2458954AW379075Hs. 141742Homo sapiens cDNA FLJ12211 fis, clone MAMMA1023.2408896AI610447Hs. 48778niban protein23.2457024AA397546Hs. 119151ESTs23.2414591AI888490Hs. 55902ESTs23.2437846AA773866Hs. 244569ESTs23.2401220predicted exon23.1421747AI816224Hs. 107747DKFZP566C243 protein23.1452950AA428123Hs. 774517 kD fetal brain protein23.1414327BE408145Hs. 185254ESTs, Moderately similar to NAC-1 protein [norvegic23.1405256predicted exon23.1452416AA026115Hs. 114777ESTs23.1440684AI253123Hs. 127356ESTs, Highly similar to NEST_HUMAN NESTI [H. sap23.1445603H08345Hs. 106234ESTs23.1436306AA805939Hs. 117927ESTs23.1434867AF159442Hs. 103382phospholipid scramblase 323.0404727predicted exon23.0407317AI204033Hs. 271461ESTs, Weakly similar to ALU5_HUMAN ALU SUBFA23.0405580predicted exon23.0437898W81260Hs. 43410ESTs22.9448781AW243419Hs. 254048ESTs22.9457297AW968188Hs. 290999ESTs22.9405545predicted exon22.9431562AI884334Hs. 11637ESTs22.9440703AL137663Hs. 7378Homo sapiens mRNA, cDNA DKFZp434G227 (from c22.9439848AW979249gb: EST391359 MAGE resequences, MAGP Homo sap22.9418149AA811473Hs. 291877ESTs22.9439332AW842747Hs. 293314ESTs, Highly similar to unnamed protein product [H. sa22.8401566predicted exon22.8425078NM_002599Hs. 154437phosphodiesterase 2A, cGMP-stimulated22.8406684X16354Hs. 50964carcinoembryonic antigen-related cell adhesion molecul22.8421651AW860612Hs. 283586ESTs22.8421064AI245432Hs. 101382tumor necrosis factor, alpha-induced protein 222.8441249AA971585Hs. 166250ESTs22.8457624AA809159Hs. 287581Homo sapiens cDNA FLJ13544 fis, clone PLACE100622.8407395AF005082gb: Homo sapiens skin-specific protein (xp33) mRNA, p22.8459006AW298631Hs. 27721hypothetical protein FLJ2035322.8436827H72187Hs. 5322guanine nucleotide binding protein (G protein), gamma22.7418174L20688Hs. 83656Rho GDP dissociation inhibitor (GDI) beta22.7418307U70867Hs. 83974solute carrier family 21 (prostaglandin transporter), mem22.7456035N54956Hs. 271726ESTs22.7457867AA045767Hs. 5300bladder cancer associated protein22.7440401AI126341Hs. 143887ESTs22.7400126predicted exon22.7414931AK000342Hs. 77646Homo sapiens mRNA, cDNA DKFZp761M0223 (from22.7406719AI832962Hs. 169476glyceraldehyde-3-phosphate dehydrogenase22.6439675W95357Hs. 138860Rho GTPase activating protein 122.6456058N94587Hs. 55063ESTs22.6441926AI015051Hs. 130953ESTs22.6428423AU076517Hs. 184276solute carrier family 9 (sodium/hydrogen exchanger), is22.6438518BE561958Hs. 285823immunoglobulin heavy constant mu22.6420674NM_000055Hs. 1327butyrylcholinesterase22.6422160AW582898gb: ia07e04.y1 Human Pancreatic Islets Homo sapiens c22.5412408D51103Hs. 73851ATP synthase, H+ transporting, mitochondrial F0 comp22.5400964predicted exon22.5434360AW015415Hs. 127780ESTs22.5427977AW630727Hs. 181307H3 histone, family 3A22.4450339AI693281Hs. 54547ESTs22.4424059AW451266Hs. 107418ESTs22.4414626BE410589gb: 601303308F1 NIH_MGC_21 Homo sapiens cDNA22.4401991predicted exon22.4419741NM_007019Hs. 93002ubiquitin carrier protein E2-C22.3457952U25750Hs. 210783Human chromosome 17q21 mRNA clone 1046.1-122.3422597BE245909Hs. 118634ATP-binding cassette, sub-family B (MDR/TAP), mem22.3429504X99133Hs. 204238lipocalin 2 (oncogene 24p3)22.3447306AI373163Hs. 170333ESTs22.3424966AU077312Hs. 153985solute carrier family 7 (cationic amino acid transporter,22.3422739H20106Hs. 119591adaptor-related protein complex 2, sigma 1 subunit22.2432504AL121015Hs. 277704oxygen regulated protein (150 kD)22.2423804AW403448Hs. 1706interferon-stimulated transcription factor 3, gamma (48 k22.2404683AI924294Hs. 173259uncharacterized bone marrow protein BM03322.2441624AF220191Hs. 179666uncharacterized hypothalamas protein HSMNP122.2425751T19239Hs. 1940crystallin, alpha B22.2452976R44214Hs. 101189ESTs22.2414642AA150350gb: zl03h01.r1 Soares_pregnant_uterus_NbHPU Homo22.2437452AL390127Hs. 7104Homo sapiens mRNA; cDNA DKFZp761P06121 (from22.2417426NM_002291Hs. 82124laminin, beta 122.2414774X02419Hs. 77274plasminogen activator, urokinase22.1424631AA688021Hs. 179808ESTs22.1413967AW204431Hs. 117853ESTs22.1400174predicted exon22.1431837T79326Hs. 298262ESTs, Weakly similar to dJ88J8.1 [H. sapiens]22.1401628predicted exon22.1418374AJ011916Hs. 84359hypothetical protein22.0429297X82494Hs. 198862fibulin 222.0403508predicted exon22.0432638AI017717Hs. 126525chromosome 21 open reading frame 1522.0407382M503620gb: ne49b08.s1 NCI_CGAP_Co3 Homo sapiens cDNA22.0411492T46848Hs. 70337immunoglobulin superfamily, member 422.0420185AL044056Hs. 158047ESTs22.0409545BE296182gb: 601177324F1 NIH_MGC_17 Homo sapiens cDNA22.0426662AA879474Hs. 122710ESTs22.0424247X14008Hs. 234734lysozyme (renal amyloidosis)22.0443062N77999Hs. 8963Homo sapiens mRNA full length insert cDNA clone EU21.9422447AA310711Hs. 124340ESTs21.9421574AJ000152Hs. 105924defensin, beta 221.9435302AI076259Hs. 190337ESTs21.9414527BE241739Hs. 76359catalase21.9441436AW137772Hs. 185980ESTs21.9454178AW177274gb: CM2-CT0128-230899-005-a02 CT0128 Homo sapie21.8448838BE614761gb: 601281335F1 NIH_MGC_39 Homo sapiens cDNA21.8427889AI400968Hs. 181046dual specificity phosphatase 3 (vaccinia virus phosphat21.8441114AA917466Hs. 126600ESTs21.8451831NM_001674Hs. 460activating transcription factor 321.8405600predicted exon21.8446981AI652743Hs. 197497ESTs21.8432839AA579465Hs. 287332ESTs21.8405208predicted exon21.8435025T08990Hs. 4742anchor attachment protein 1 (Gaa1p, yeast) homolog21.7413976BE295452Hs. 75655procollagen-proline, 2-oxoglutarate 4-dioxygenase (pro21.7423515AA327017Hs. 162204ESTs21.7452329N36626Hs. 29106mitogen-activated protein kinase phosphatase x21.7423050AA320946gb: EST23529 Adipose tissue, brown Homo sapiens cD21.7413679BE156765gb: RC1-HT0370-120100-012-c09 HT0370 Homo sapie21.7442166AW845280Hs. 204723ESTs21.6445585AI243836Hs. 147066ESTs21.6406160predicted exon21.6433025AA374743Hs. 279920tyrosine 3-monooxygenase/tryptophan 5-monooxygenas21.6446598AW250546gb: 2821774.5prime NIH_MGC_7 Homo sapiens cDNA21.6434493AA635305Hs. 121574ESTs21.6429582AI569068Hs. 22247ESTs21.6403796predicted exon21.6405028predicted exon21.6426597AA382250Hs. 145601ESTs21.6437308AA749417Hs. 292353ESTs21.6447384AI377221Hs. 40528ESTs21.6429060AW139155Hs. 194995hypothetical protein DKFZp434O032021.6437068AA743643Hs. 291427ESTs21.6418509AB028624Hs. 85539ATP synthase, H+ transporting, mitochondrial F0 comp21.5432999BE294029Hs. 279903Ras homolog enriched in brain 221.5407663NM_016429Hs. 37482COPZ2 for nonclathrin cost protein zeta-COP21.5446627AI973016Hs. 15725hypothetical protein SBBI4821.5413605BE152644gb: CM1-HT0329-250200-128-f09 HT0329 Homo sapie21.5427286AW732802Hs. 2132epidermal growth factor receptor pathway substrate 821.5405226predicted exon21.4402570predicted exon21.4457960AA771881Hs. 298149ESTs21.4400684predicted exon21.4425943H46986Hs. 31861ESTs21.4434240AF119912Hs. 258119hypothetical protein PRO307321.4448376AI494332Hs. 196963ESTs21.4408089H59799Hs. 42644thioredoxin-like21.4400304AF005082Hs. 113261Homo sapiens skin-specific protein (xp33) mRNA, part21.4412652AI801777Hs. 6774ESTs21.4428373AI751656Hs. 183986poliovirus receptor-related 2 (herpesvirus entry mediato21.3416138C18946Hs. 79026myeloid leukemia factor 221.3425184BE278288Hs. 155048Lutheran blood group (Auberger b antigen included)21.3411028AW813703gb: RC3-ST0197-130100-014-h09 ST0197 Homo sapien21.3417438Z43989Hs. 82141Human clone 23612 mRNA sequence21.3417534NM_004998Hs. 82251myosin IC21.3427767AI879283Hs. 180714cytochrome c oxidase subunit VIa polypeptide 121.2433300AA582307gb: nn49d09.s1 NCI_CGAP_Kid6 Homo sapiens cDNA21.2452061AI074259Hs. 469succinate dehydrogenase complex, subunit A, flavoprot21.2411939AI365585Hs. 146246ESTs21.2435060AI422719Hs. 233349ESTs, Weakly similar to fork head like protein [H. sapie21.2432412AI470549Hs. 162201ESTs21.2407491S82769gb: GABAA receptor gamma 3 subunit [human, fetal bra21.2418960NM_004494Hs. 89525hepatoma-derived growth factor (high-mobility group p21.1426254BE018103Hs. 168541Homo sapiens mRNA full length insert cDNA close EU21.1458188AW297226Hs. 137840ESTs, Moderately similar to SIX1_HUMAN HOMEOB21.1406215predicted exon21.1425461AK000602Hs. 157938hypothetical protein FLJ2059521.1448296BE622756Hs. 10949Homo sapiens cDNA FLJ14162 fis, clone NT2RM400221.1409415AA579258Hs. 6083Homo sapiens cDNA FLJ21028 fis, clone CAE0715521.1408546W49512Hs. 46348bradykinin receptor B121.1450008H52970Hs. 36688WAP four-disulfide core domain 121.1430998AF128847Hs. 204038indolethylamine N-methyltransferase21.1438901AF085834Hs. 29036ESTs21.1440500AA972165Hs. 150308ESTs21.1413101BE065215gb: RC1-BT0314-310300-015-f01 BT0314 Homo sapie21.1447452BE618258Hs. 102480ESTs21.1412446AI768015Hs. 92127ESTs21.1418975T75496Hs. 296980ESTs21.0454961AW847807gb: IL3-CT0213-190200-040-E12 CT0213 Homo sapien21.0401072predicted exon21.0401204predicted exon21.0433626AF078859Hs. 86347hypothetical protein21.0418047R37633Hs. 4847ESTs21.0443380AI792478Hs. 135377ESTs21.0427424AA402453Hs. 113011ESTs21.0433412AV653729Hs. 8185CGI-44 protein, sulfide dehydrogenase like (yeast)21.0422599BE387202Hs. 118638non-metastatic cells 1, protein (NM23A) expressed in20.9435656R93409Hs. 120759ESTs20.9413745AW247252Hs. 75514nucleoside phosphorylase20.9418874T60872gb: yb72h11.s1 Stratagene ovary (937217) Homo sapien20.9452574AF127481Hs. 35093lymphoid blast crisis oncogene20.9400332S66407Hs. 248032FLT420.9402421predicted exon20.9427138N77624Hs. 173717phosphatidic acid phosphatase type 2B20.9432038AA524746Hs. 162110ESTs20.8423711AF059194Hs. 131953v-maf musculoaponeurotic fibrosarcoma (avian) oncoge20.8402297predicted exon20.8405133predicted exon20.8436661AI125270Hs. 128069ESTs, Weakly similar to similar to collagen [C. elegans]20.8437836BE269291Hs. 292458ESTs20.8437329AA811977Hs. 291761ESTs20.8445830H10451Hs. 42656Homo sapiens cDNA FLJ12667 fis, clone NT2RM400220.8406824AW515961Hs. 84298CD74 antigen (invariant polypeptide of major histocom20.7421271AW170057Hs. 133179ESTs20.7400256predicted exon20.7414028AA782576Hs. 4944Homo sapiens cDNA FLJ12783 fis, clone NT2RP200120.7456728AL120077Hs. 122967kelch (Drosophila)-like 2 (Mayven)20.7417707AL035786Hs. 82425actin related protein 2/3 complex, subunit 5(16 kD)20.7438713H16902Hs. 6749ESTs20.7450306AL080080Hs. 24766DKFZP564E1962 protein20.7438898AI819863Hs. 106243ESTs20.7403273predicted exon20.7414605BE390440gb: 601283601F1 NIH_MGC_44 Homo sapiens cDNA20.7401283predicted exon20.7403703predicted exon20.6416969AI815443Hs. 283404organic cation transporter20.6442400AW381148Hs. 3593ESTs20.6447563BE536115Hs. 160983ESTs20.5419754H52299Hs. 75243bromodomain-centaining 220.5408204AA454501Hs. 43666protein tyrosine phosphatase type IVA, member 320.5450507AW295603Hs. 250891ESTs20.5429612AF062649Hs. 252587pituitary tumor-transforming 120.5413758BE162391gb: PM2-HT0451-090100-002-f04 HT0451 Homo sapie20.5432140AK000404Hs. 272688hypothetical protein FLJ2039720.5400642predicted exon20.4431582F07136Hs. 261828G protein-coupled receptor kinase 720.4442724AA355525Hs. 159604cysteinyl-tRNA synthetase20.4417861AA334551Hs. 82767sperm specific antigen 220.4402948predicted exon20.4411004AW813242gb: MR3-ST0191-020200-207-g10 ST0191 Homo sapie20.4435478AA682622gb: zj20f09.s1 Soares_fetal_liver_spleen_1NFLS_S1 Ho20.4447955BE544271Hs. 288390Homo sapiens cDNA FLJ22795 fis, clone KAIA254320.3433592NM_004642Hs. 3436deleted in oral cancer (mouse, homolog) 120.3420865N73241Hs. 100001solute carrier family 17 (sodium phosphate), member 120.3449482AI784266Hs. 28774ESTs20.3400807predicted exon20.3419942U25138Hs. 93841potassium large conductance calcium-activated channel20.3420783AI659838Hs. 99923lectin, galactoside-binding, soluble, 7 (galectin 7)20.3402986BE244588Hs. 6456chaperonin containing TCP1, subunit 2 (beta)20.3451375AI792066Hs. 283902Homo sapiens BAC clone RP11-481J13 from 220.3453586AA248089Hs. 50841ESTs, Weakly similar to tuftelin [M. musculus]20.3433090AI720050Hs. 145362immortalization-upregulated protein20.3425053AF046024Hs. 154320ubiquitin-activating enzyme E1C (homologous to yeast20.3412802U41518Hs. 74602aquaporin 1 (channel-forming integral protein, 28 kD)20.3409738BE222975Hs. 56205insulin induced gene 120.3428245AF151048Hs. 183180hypothetical protein20.2412582BE270631Hs. 74077proteasome (prosome, macropain) subunit, alpha type, 620.2406207predicted exon20.2400931predicted exon20.2410709AL122109Hs. 65735Homo sapiens mRNA; cDNA DKFZp434M1827 (from20.2428438NM_001955Hs. 2271endothelin 120.2446918AL135125Hs. 13913KIAA1577 protein20.2417821BE245149Hs. 82643protein tyrosine kinase 920.2429113D28235Hs. 196384prostaglandin-endoperoxide synthase 2 (prostaglandin G20.2414511AA148725Hs. 12969hypothetical protein20.2451546AF051782Hs. 26584Homo sapiens clone CDABP0038 mRNA sequence20.1441899AI372588Hs. 8022TU3A protein20.1425811AL039104Hs. 159557karyopherin alpha 2 (RAG cohort 1, importin alpha 1)20.1411014AW816072gb: MR3-ST0220-070100-021-h07 ST0220 Homo sapie20.1451400BE160479gb: QV1-HT0413-210200-081-g05 HT0413 Homo sapi20.1459247N46243Hs. 110373ESTs20.1441633AW958544Hs. 112242ESTs20.1427466AA523543Hs. 7678cellular retinoic acid-binding protein 120.0406893M22406gb: Human intestinal mucin mRNA, partial cds, clone SM20.0406268predicted exon20.0403348predicted exon20.0400970predicted exon20.0414045NM_002951Hs. 75722ribophorin II20.0427169AA398823Hs. 97549EST20.0405586predicted exon20.0445834AI913290Hs. 145532ESTs, Weakly similar to Gag polyprotein [M. musculus20.0422525AA758797Hs. 192807ESTs20.0425383D83407Hs. 156007Down syndrome critical region gene 1-like 120.0454590AW809762Hs. 222056Homo sapiens cDNA FLJ11572 fis, clone HEMBA10020.0411529AA430348Hs. 288837Homo sapiens cDNA FLJ12927 fis, clone NT2RP200420.0425397J04088Hs. 156346topoisomerase (DNA) II alpha (170 kD)20.0403234predicted exon19.9427267AI201185Hs. 119164ESTs19.9400203predicted exon19.9449296AL137257Hs. 23458Homo sapiens mRNA, cDNA DKFZp434C1613 (from19.9406704M21665Hs. 929myosin, heavy polypeptide 7, cardiac muscle, beta19.9423083AA321774Hs. 10941ESTs, Weakly similar to IPP1_HUMAN PROTEIN PH19.9422112BE540240Hs. 111783Lsm1 protein19.9413282BE078159gb: CM0-BT0615-140200-175-e06 BT0615 Homo sapie19.9453702AA037637Hs. 42128ESTs19.9403065predicted exon19.9440633AI140686Hs. 263320ESTs19.9456994AA383623Hs. 293616ESTs19.9458260R41782Hs. 22279ESTs19.9452388BE019696Hs. 29287retinoblastoma-binding protein 819.9422278AF072873Hs. 114218frizzled (Drosophila) homolog 619.9441989AA306207Hs. 286241Homo sapiens cDNA FLJ22698 fis, clone HSI1204419.9418758AW959311Hs. 87019ESTs19.9406646M33600Hs. 180255major histocompatibility complex, class II, DR beta 119.8433053BE301909Hs. 279952glutathione S-transferase subunit 13 homolog19.8414194BE175494Hs. 75811N-acylsphingosine amidohydrolase (acid ceramidase)19.8452321AW844498Hs. 289052Homo sapiens LENG8 mRNA, variant C, partial sequen19.8449713AW027025Hs. 239262ESTs19.8458827AW970786Hs. 178470Homo sapiens cDNA FLJ22662 fis, clone HSI0808019.8414092Z14244Hs. 75752cytochrome c oxidase subunit VIIb19.8441730AI243276Hs. 149017ESTs19.8420701N42919Hs. 88630ESTs, Weakly similar to AC007228 1 R31665 2 [H. sap19.8403642predicted exon19.8408987H85615gb: yt03f11.r1 Soares retina N2b5HR Homo sapiens cD19.8446712AW204789Hs. 209828ESTs19.8403286predicted exon19.8434439AI022360Hs. 190583ESTs19.8404067predicted exon19.7455694BE067300gb: PM2-BT0349-161299-001-h10 BT0349 Homo sapie19.7403287predicted exon19.7434633AI189587Hs. 120915ESTs19.7408199AA132637Hs. 15396ESTs19.7420080M94065Hs. 94925dihydroorotate dehydrogenase19.7408852AW291435Hs. 254961ESTs19.7403786predicted exon19.7416839H94900Hs. 17882ESTs19.7434385AA631946Hs. 259580ESTs19.7446845AI343645Hs. 156108ESTs19.7425612BE004257gb: CM0-BN0103-180300-296-c04 BN0103 Homo sapi19.7402520predicted exon19.6436098R20597Hs. 9739ESTs19.6438974AF089816Hs. 6454chromosome 19 open reading frame 319.6447751AA339541Hs. 24956hypothetical protein FLJ2205619.6451310AW250651Hs. 26213ESTs, Moderately similar to dJ447F3 3 [H. sapiens]19.6435961BE293127Hs. 283722GTT1 protein19.6452937BE410390Hs. 288940five-span transmembrane protein M8319.6404850predicted exon19.6438360H74149Hs. 288193hypothetical protein FLJ1037519.6436508AW604381Hs. 121121ESTs19.6430486BE062109Hs. 241551chloride channel, calcium activated, family member 219.6407824AA147884Hs. 9812ESTs19.6406388predicted exon19.6430204AA618335Hs. 146137ESTs, Weakly similar to putative [C. elegans]19.5457560AI801934Hs. 163909ESTs19.5429521BE048708Hs. 50949ESTs19.5429758AW137722Hs. 246804ESTs19.5441473AA934995Hs. 184846ESTs, Weakly similar to R28830 1 [H. sapiens]19.5411724AA770559Hs. 71618polymerase (RNA) II (DNA directed) polypeptide L (719.5450453AA009883Hs. 50186ESTs19.5419687AI638859Hs. 227699ESTs, Weakly similar to Yhr217cp [S. cerevisiae]19.5442162AW294966Hs. 150849ESTs19.5435056AW023337Hs. 5422glycoprotein M6B19.5417412X16896Hs. 82112interleukin 1 receptor, type I19.5413825BE299181Hs. 75564CD151 antigen19.4422687AW068823Hs. 119206insulin-like growth factor binding protein 719.4435551AF212365Hs. 5470IL-17B receptor19.4440069BE617892Hs. 6895actin related protein 2/3 complex, subunit 3 (21 kD)19.4432277AI669790Hs. 161825ESTs19.4428044AA093322Hs. 182225RNA binding motif protein 319.4456064AA256213Hs. 72010ESTs19.4424897D63216Hs. 153684frizzled-related protein19.4424673AA345051Hs. 294092ESTs19.4403852predicted exon19.3405699predicted exon19.3433096AU076803Hs. 282975carboxylesterase 2 (intestine, liver)19.3400344NM_012368Hs. 258574olfactory receptor, family 2, subfamily C, member 119.3417501AL041219Hs. 82222sema domain, immunoglobulin domain (Ig), short basic19.3400449predicted exon19.3453801AL134751Hs. 23450mRNA for FLJ00023 protein19.3435849BE305242Hs. 112442ESTs, Weakly similar to CLDE_HUMAN CLAUDIN-19.3454181AW177377gb: CM4-CT0129-190899-007-e09 CT0129 Homo sapie19.3414807AI738616Hs. 77348hydroxyprostaglandin dehydrogenase 15-(NAD)19.3406326predicted exon19.3421921H83363Hs. 109571translocase of inner mitochondrial membrane 10 (yeast)19.3416700AW498958Hs. 79572cathepsin D (lysosomal aspartyl protease)19.2458857AI627342Hs. 224801ESTs19.2405501predicted exon19.2416601R08652Hs. 20205hemoglobin, beta pseudogene 119.2426600NM_003378Hs. 171014VGF nerve growth factor inducible19.2425590AI954686Hs. 158321beaded filament structural protein 2, phakinin19.2428151AA422028gb: zv26g06.r1 Soares_NhHMPu_S1 Homo sapiens cDN19.2426420BE383808Hs. 169829KIAA1180 protein19.2414428BE296906Hs. 182625VAMP (vesicle-associated membrane protein)-associate19.2404601predicted exon19.2403861predicted exon19.2448363BE174595Hs. 3666-pyruvoyltetrahydroptenn synthase19.2406655M21533Hs. 181244major histocompatibility complex, class I, A19.1435372AA809591Hs. 106486ESTs, Highly similar to CIKG_HUMAN VOLTAGE-G19.1413154BE067870gb: RC0-BT0362-021299-031-b06 BT0362 Homo sapie19.1443021AA368546Hs. 8904Ig superfamily protein19.1412975T70956Hs. 75106clusterin (complement lysis inhibitor, SP-40,40, sulfated19.1412633AF001691Hs. 74304periplakin19.1402071predicted exon19.1410387AI277367Hs. 47094ESTs19.1423961D13666Hs. 136348osteoblast specific factor 2 (fasciclin I-like)19.1407032U73799gb: Human dynactin mRNA, partial cds.19.0404034predicted exon19.0456534X91195Hs. 100623phospholipase C, beta 3, neighbor pseudogene19.0446599Z97832Hs. 15476differentially expressed in FDCP (mouse homolog) 619.0426410BE298446Hs. 180372BCL2-like 119.0419618AA528295gb: nh26e06.s1 NCI_CGAP_Pr3 Homo sapiens cDNA c19.0457632AW292151Hs. 112689ESTs19.0417138AA193646Hs. 65771Homo sapiens chromosome 19, BAC CIT-HSPC_204F19.0417933X02308Hs. 82962thymidylate synthetase19.0458808AW134832Hs. 246295ESTs19.0415860D56051Hs. 78888diazepam binding inhibitor (GABA receptor modulator18.9440919AW291274Hs. 262826ESTs18.9423725AJ403108Hs. 132127hypothetical protein LOC5782218.9401747predicted exon18.9454209AW179083gb: MR4-ST0065-270899-006-A07 ST0065 Homo sapi18.8417661T84155Hs. 15404Homo sapiens cDNA: FLJ21351 fis, clone COL0276218.8426499C14937Hs. 11169Gene 33/Mig-618.8404240predicted exon18.8439718AA307634Hs. 6650vacuolar protein sorting 45B (yeast homolog)18.8401789predicted exon18.8456952AW445081Hs. 301469ESTs18.8439739AI199391Hs. 124464ESTs18.8437974T74445Hs. 5957Homo sapiens clone 24416 mRNA sequence18.8427490Z95152Hs. 178695mitogen-activated protein kinase 1318.8443482AW188093Hs. 250385ESTs18.8411420BE390652gb: 601286820F1 NIH_MGC_44 Homo sapiens cDNA18.8435196F35675Hs. 188128ESTs, Moderately similar to ALUB_HUMAN !!!! ALU18.8417022NM_014737Hs. 80905Ras association (RaIGDS/AF-6) domain family 218.8413531AL036958Hs. 75416DAZ associated protein 218.7428981BE313077Hs. 93135ESTs18.7421598AW630942Hs. 106061RD RNA-binding protein18.7443907AU076484Hs. 9963TYRO protein tyrosine kinase binding protein18.7406754AA477223Hs. 75922brain protein 1318.7400661predicted exon18.7442638AI088742Hs. 134713ESTs18.7434169AA883752Hs. 179724ESTs18.7424126AA335635Hs. 96917ESTs18.7408473BE259039Hs. 129953Ewing sarcoma breakpoint region 118.7401962predicted exon18.7447326AW002252Hs. 201395ESTs18.7459053AI807052Hs. 210361ESTs18.7403362predicted exon18.7427697T18997Hs. 180372BCL2-like 118.7402061H83363Hs. 109571translocase of inner mitochondrial membrane 10 (yeast)18.7433785BE044593Hs. 112704ESTs18.7405423predicted exon18.6429259AA420450Hs. 292911ESTs18.6444071AI627808Hs. 110524ESTs18.6410512AA085603Hs. 250570ESTs18.6440376AI024452Hs. 236816ESTs18.6457353X65633Hs. 248144melanocortin 2 receptor (adrenocorticotropic hormone)18.6432749NM_014438Hs. 278909Interleukin-1 Superfamily e18.6415602F12920Hs. 165575ESTs18.6407891AA486620Hs. 41135endomucin-218.6455910Z43712gb: HSC1JA121 normalized infant brain cDNA Homo s18.6426716NM_006379Hs. 171921sema domain, immunoglobulin domain (Ig), short basic18.6444246H93281Hs. 10710hypothetical protein FLJ2041718.6428125AA393071Hs. 182579leucine aminopeptidase18.6406457predicted exon18.5446625AI333070Hs. 156141ESTs18.5423334AK000906Hs. 127273hypothetical protein FLJ1004418.5423103AA322029gb: EST24685 Cerebellum II Homo sapiens cDNA 5′ en18.5443549T89608Hs. 16601ESTs18.5419299AI311085Hs. 62406Homo sapiens cDNA: FLJ22573 fis, clone HSI0238718.5411942AW877015gb: QV2-PT0010-250300-096-f12 PT0010 Homo sapien18.5442440BE464435Hs. 146180ESTs, Weakly similar to non-receptor protein tyrosine k18.5454574AW809109gb: MR4-ST0117-070100-027-a04 ST0117 Homo sapie18.5454377AA076811gb: 7B03C12 Chromosome 7 Fetal Brain cDNA Library18.5422365AF035537Hs. 115521REV3 (yeast homotog)-like, catalytic subunit of DNA p18.5421733AL119671Hs. 1420fibroblast growth factor receptor 3 (achondroplasia, tha18.5420603AB042636Hs. 4775junctophilin 318.4401373predicted exon18.4402292predicted exon18.4444118AA458542Hs. 10326coatomer protein complex, subunit epsilon18.4408310AW179023gb: PM3-ST0036-170899-001-e08 ST0036 Homo sapie18.4411236AW833752gb: QV4-TT0008-130100-077-b07 TT0008 Homo sapie18.4431405AI470895Hs. 252574ribosomal protein L10a18.4441408AI733249Hs. 126897ESTs18.4453994BE180964Hs. 165590ribosomal protein S1318.4444518AI160278Hs. 146884ESTs18.4402407predicted exon18.4404270predicted exon18.4409103AF251237Hs. 112208XAGE-1 protein18.4415198AW009480Hs. 943natural killer cell transcript 418.3430771BE387244Hs. 2664flavin containing monooxygenase 418.3432636AA340864Hs. 278562claudin 718.3433504NM_014874Hs. 3363KIAA0214 gene product18.3415606W70022gb: zd51e10.r1 Soares_fetal_heart_NbHH19W Homo sa18.3401401BE047878Hs. 99093Homo sapiens chromosome 19, cosmid R2837918.3420758AW297536Hs. 33053ESTs18.3457520AA553495Hs. 162264ESTs18.3432323AK001409Hs. 274356hypothetical protein FLJ1054718.3404750predicted exon18.3450645AL117441Hs. 25264DKFZP434N126 protein18.3445160AI299144Hs. 150797ESTs18.3418461BE242781Hs. 288037Homo sapiens cDNA FLJ12999 fis, clone NT2RP300018.3401809predicted exon18.3458121S42416Hs. 74647Human T-cell receptor active alpha-chain mRNA from18.3435106AA100847Hs. 193380ESTs, Highly similar to AF174600 1 F-box protein Fbx18.3448398AW444655Hs. 170838ESTs18.3428145BE243327Hs. 182626chromosome 22 open reading frame 518.2445302AK001537Hs. 12488hypothetical protein FLJ1067518.2407352H47860gb: yp76h12.r1 Soares fetal liver spleen 1NFLS Homo s18.2413190AA151802Hs. 40368adaptor-related protein complex 1, sigma 2 subunit18.2436371AI821912Hs. 113912ESTs18.2400965predicted exon18.2433427AI816449Hs. 171889cholinephosphotransferase 118.2427504AA776743Hs. 191589ESTs18.2426759AI590401Hs. 21213ESTs18.2423792AW135866Hs. 245854ESTs18.2406826AW516005Hs. 84298CD74 antigen (invariant polypeptide of major histocom18.1406659AA663985Hs. 277477major histocompatibility complex, class I, C18.1437453AI761350Hs. 181391hypothetical protein DKFZp761G211318.1409276AW372097Hs. 278429hepatocellular carcinoma-associated antigen 5918.1449628AI697676Hs. 197713ESTs18.1421043BE379455Hs. 89072ESTs18.1442344AI022925Hs. 301212ESTs18.1448744AL135424Hs. 9469phosphoinositol 3-phosphate binding protein-118.1416062AA724811Hs. 74427p53-induced protein18.1414500W24087Hs. 76285DKFZP564B167 protein18.1427272NM_001096Hs. 174140ATP citrate lyase18.1403964predicted exon18.1433217AB040914Hs. 278628KIAA1481 protein18.1427902AI809202Hs. 208343ESTs, Weakly similar to cerebroside sulfotransferase [H.18.1449586AI863918Hs. 195078ESTs18.1430826U10061Hs. 248019POU domain, class 4, transcription factor 318.1414195BE263293gb: 601144881F2 NIH_MGC_19 Homo sapiens cDNA18.1416305AU076628Hs. 79187coxsackie virus and adenovirus receptor18.1411088BE247593Hs. 145053ESTs18.1419407AW410377Hs. 41502Homo sapiens cDNA FLJ21276 fis, clone COL0182918.1407938AA905097Hs. 85050phospholamban18.1449360AI640623Hs. 252720ESTs18.1417286AA122237Hs. 81874microsomal glutathione S-transferase 218.0405515predicted exon18.0439319AW016401Hs. 233476ESTs18.0419387BE379356Hs. 90107cell membrane glycoprotein, 110000M(r) (surface antig18.0414015AA340987Hs. 75693prolylcarboxypeptidase (angiotensinase C)18.0447778BE620592Hs. 71190ESTs18.0435523T62849Hs. 11090high affinity immunoglobulin epsilon receptor beta sub18.0429230AF088991Hs. 198274NADH dehydrogenase (ubiquinone) 1 beta subcomplex18.0457822AA970001Hs. 150319ESTs18.0442424AI342715Hs. 129569ESTs, Moderately similar to B34087 hypothetical prote18.0418394AF132818Hs. 84728Kruppel-like factor 5 (intestinal)18.0413477AI815825Hs. 48756ESTs, Moderately similar to neuronal-STOP protein [M18.0405277predicted exon18.0450192AA263143Hs. 24596RAD51-interacting protein18.0442191W95186Hs. 8136endothelial PAS domain protein 118.0429490AI971131Hs. 293684ESTs, Weakly similar to alternatively spliced product u18.0406744AA554082Hs. 279860hypothetical protein FLJ2003017.9425205NM_005854Hs. 155106receptor (calcitonin) activity modifying protein 217.9414387AL043148Hs. 186257ESTs17.9411811AW864370gb: PM4-SN0016-100500-004-h09 SN0016 Homo sapie17.9433882U90441Hs. 3622procollagen-proline, 2-oxoglutarate 4-dioxygenase (pro17.9414333BE274897gb: 601122959F1 NIH_MGC_20 Homo sapiens cDNA17.9403747predicted exon17.9435542AA687376Hs. 269533ESTs17.9403093predicted exon17.9412088AI689496Hs. 108932ESTs17.9450506NM_004460Hs. 418fibroblast activation protein, alpha17.9404763predicted exon17.9454633AW811380gb: IL3-ST0143-260999-019-D05 ST0143 Homo sapien17.9440788AI806594Hs. 128577ESTs17.9411800N39342Hs. 5184TH1 drosophila homolog17.9441361BE263308Hs. 7797TERF1 (TRF1)-interacting nuclear factor 217.8422033AW245805Hs. 110903claudin 5 (transmembrane protein deleted in velocardiof17.8405333predicted exon17.8408297R17710Hs. 113314ESTs17.8403036predicted exon17.8417924AU077231Hs. 82932cyclin D1 (PRAD1: parathyroid adenomatosis 1)17.8417091AA193283Hs. 291990ESTs17.8440789AB007857Hs. 7416KIAA0397 gene product17.8438397AA806478Hs. 123206ESTs17.8435948AA702675Hs. 114135ESTs17.8450273AW296454Hs. 24743hypothetical protein FLJ2017117.8435969W85773Hs. 191386ESTs17.8427031AA397601Hs. 125147ESTs17.8454505AW801365gb: IL5-UM0067-240300-050-a01 UM0067 Homo sapi17.8403447predicted exon17.8433297AV658581Hs. 282633ESTs17.8443326BE156494Hs. 188478ESTs17.8448283AI340462Hs. 182979ribosomal protein L1217.8458067AA393603Hs. 36752Homo sapiens cDNA: FLJ22834 fis, clone KAIA431417.8452359BE167229Hs. 29206Homo sapiens close 24659 mRNA sequence17.8434098AA625499gb: af69g08.r1 Soares_NhHMPu_S1 Homo sapiens cDN17.8450911AA011586Hs. 272097ESTs17.7410342R31350Hs. 743Fc fragment of IgE, high affinity I, receptor for, gamma17.7407082Z47055gb: Human partial cDNA sequence, farnesyl pyrophosph17.7415271X94232Hs. 78335microtubule-associated protein, RP/EB family, member17.7417413AA197072Hs. 86092Human DNA sequence from clone RP11-243J16 on chr17.7408937AA210734Hs. 291386ESTs17.7433459AA593498gb: nn27b05.s1 NCI_CGAP_Gas1 Homo sapiens cDNA17.7459536AI254723Hs. 145496ESTs17.7428500AI815395Hs. 184641delta-6 fatty acid desaturase17.7433463R41963Hs. 4197ESTs17.7406537predicted exon17.7410003AA079487gb: zm97f08.s1 Stratagene colon HT29 (937221) Homo17.7440857AA907808Hs. 135556ESTs17.7451072AA013451Hs. 117929ESTs17.7418693AI750878Hs. 87409thrombospondin 117.7443624BE616129Hs. 9651related RAS viral (r-ras) oncogene homolog17.6422626AA344932Hs. 118786metallothionein 2A17.6410756AB037820Hs. 66159KIAA1399 protein17.6436621AI266254Hs. 132929ESTs17.6453317NM_002277Hs. 41696keratin, hair, acidic, 117.6456828AF156889Hs. 148427LIM homeobox protein 317.6421486AW408800Hs. 104859hypothetical protein DKFZp762E131217.6428834AW899713Hs. 10338ESTs17.6451419R36309Hs. 174369EST17.6448413AI745379Hs. 42911ESTs17.6424323AA338791Hs. 146763nascent-polypeptide-associated complex alpha polypept17.6423943AF163570Hs. 135756polymerase (DNA-directed) kappa17.6439423BE536678Hs. 147099ESTs17.6434025AF114264Hs. 216381Homo sapiens clone HH409 unknown mRNA17.6408246N55669Hs. 43946L13 protein17.6441579AW468847Hs. 127194ESTs17.5420867NM_014183Hs. 100002HSPC162 protein17.5453680AL079647Hs. 14485ESTs17.5400202predicted exon17.5410768AF038185Hs. 66187Homo sapiens clone 23700 mRNA sequence17.5409932AI376750Hs. 57600adaptor-related protein complex 1, sigma 1 subunit17.5425563AF084199Hs. 299837ESTs17.5440475AI807671Hs. 128343ESTs17.5452767AW014195Hs. 61472ESTs, Weakly similar to unknown [S. cerevisiae]17.5410570AI133096Hs. 64593ATP synthase, H+ transporting, mitochondrial F1F0, su17.4419600AA448958Hs. 91481NEU1 protein17.4419588AI347205Hs. 91375Human clone 23614 mRNA sequence17.4428975NM_004672Hs. 194694mitogen-activated protein kinase kinase kinase 617.4448928AI350260Hs. 5384Homo sapiens cDNA FLJ11743 fis. clone HEMBA10017.4403924predicted exon17.4419889AA251600gb: zs10d12 r1 NCI_CGAP_GCB1 Homo sapiens cDNA17.4405023AW408800Hs. 104859hypothetical protein DKFZp762E131217.4426065N32049gb: yw96g08.s1 Soares_placenta_8to9weeks_2NbHP8to17.4453199AI336266Hs. 301854Homo sapiens PRO0412 mRNA, complete cds17.4455132AW857955gb: PM0-CT0325-151299-002-A12 CT0325 Homo sapi17.4442932AA457211Hs. 8858bromodomain adjacent to zinc finger domain, 1A17.4432065AA401039Hs. 2903protein phosphatase 4 (formerly X), catalytic subunit17.3444652BE513613Hs. 11538actin related protein 2/3 complex, subunit 1A (41 kD)17.3417935R53697Hs. 170044ESTs17.3430050AA430993Hs. 227913API5-like 117.3446272BE268912Hs. 14601hematopoietic cell-specific Lyn substrate 117.3425996W67330Hs. 81256S100 calcium-binding protein A4 (calcium protein, calv17.3416964D87467Hs. 80620guanine nucleotide exchange factor for Rap1, M-Ras-re17.3437418AI478954Hs. 59459ESTs17.3447255AI884908Hs. 158607ESTs17.3402203predicted exon17.3417611AW993983gb: RC1-BN0035-130400-013-a04 BN0035 Homo sapie17.3426560AA381661Hs. 119878ESTs17.3446163AA026880Hs. 25252Homo sapiens cDNA FLJ13603 fis, clone PLACE101017.3445017AI205493Hs. 176860ESTs17.3438658AI222068Hs. 123571ESTs17.3442238AW135374Hs. 270949ESTs17.3443195BE148235Hs. 193063Homo sapiens cDNA FLJ14201 fis, clone NT2RP300217.3442609AL020996Hs. 8518selenoprotein N17.2416591AA091976Hs. 79387proteasome (prosome, macropain) 26S subunit ATPase17.2403674predicted exon17.2430514AA318501Hs. 241587megakaryocyte-enhanced gene transcript 1 protein17.2411696AW857404gb: CM3-CT0313-291199-046-c11 CT0313 Homo sapie17.2434560R13052Hs. 3964Homo sapiens clone 24877 mRNA sequence17.2422627BE336857Hs. 118787transforming growth factor, beta-induced, 68 kD17.2414364D38521Hs. 75935KIAA0077 protein17.2409119AA531133Hs. 4253G protein-coupled receptor 4417.2425640U34051Hs. 299204ESTs, Highly similar to CD5S_HUMAN CYCLIN-DE17.2436044BE247571Hs. 15627Nit protein 217.2401657predicted exon17.2449763AI822112Hs. 118241ESTs17.2409601AF237621Hs. 80828keratin 1 (epidermolytic hyperkeratosis)17.2449636AI656608Hs. 281328ESTs17.2444958AW292643Hs. 167047ESTs17.2429978AA249027Hs. 241507ribosomal protein S617.2453043AW136440Hs. 224277ESTs17.2458640AI284935gb: qk55g09.x1 NCI_CGAP_Co8 Homo sapiens cDNA17.1456329T41418gb: ph1h3_19/1TV Outward Alu-primed hncDNA librar17.1414839X63692Hs. 77462DNA (cytosine-5-)-methyltransferase 117.1403662predicted exon17.1411651AW855392gb: CM3-CT0275-191099-024-e12 CT0275 Homo sapie17.1404097predicted exon17.1447252R90916gb: yn01e10.r1 Soares adult brain N2b4HB55Y Homo s17.1430024AI808780Hs. 227730integrin, alpha 617.1412828AL133396Hs. 74621prion protein (p27-30) (Creutzfeld-Jakob disease, Gerst17.1444558AW181975Hs. 165892ESTs17.1420869X58964Hs. 123638regulatory factor X, 1 (influences HLA class II expressi17.1448812H30775Hs. 22140BM88 antigen17.0431777AA570296Hs. 105470found in inflammatory zone 117.0422007AI739435Hs. 39168ESTs17.0403051predicted exon17.0402427predicted exon17.0417408F17211Hs. 86092Human DNA sequence from clone RP11-243J16 on chr17.0450598AF151076Hs. 25199hypothetical protein17.0421121AA459028Hs. 86228TRIAD3 protein17.0458488AL040565Hs. 209544ESTs17.0417158AW965223Hs. 110062ESTs, Weakly similar to ACR3_HUMAN 30 KD ADIP17.0439318AW837046Hs. 6527G protein-coupled receptor 5617.0428758AA433988Hs. 98502Homo sapiens cDNA FLJ14303 fis, clone PLACE200017.0447572AI631546Hs. 159732ESTs17.0434434AA633516Hs. 157201ESTs17.0409994D86864Hs. 57735acetyl LDL receptor; SREC17.0408927AW295650Hs. 255453ESTs17.0439093AA534163Hs. 5476serine protease inhibitor, Kazal type, 517.0454466AA984138Hs. 279895Homo sapiens mRNA for KIAA1578 protein, partial cd17.0426996AW968934Hs. 173108Homo sapiens cDNA FLJ21897 fis, clone HEP03447,17.0436659AI217900Hs. 144464ESTs17.0422731AL138411gb: DKFZp434A1229_r1 434 (synonym htes3) Homo s17.0429294AA095971Hs. 198793KIAA0750 gene product17.0432847BE266941Hs. 279554proteasome (prosome, macropain) 26S subunit, non-AT16.9416977AW130242Hs. 293476ESTs16.9406827AA971409Hs. 84298CD74 antigen (invariant polypeptide of major histocom16.9453758U83527gb: HSU83527 Human fetal brain (M Lovett) Homo sap16.9431314AI732204Hs. 105423ESTs16.9423185BE299590Hs. 125078omithine decarboxylase antizyme 116.9435086AW975243Hs. 122596ESTs16.9447383N24231gb: yx22a11.r1 Soares melanocyte 2NbHM Homo sapie16.9456251R13326Hs. 21303ESTs16.9456327H68741Hs. 38774ESTs16.9450594N31036gb: yx51g04.r1 Soares melanocyte 2NbHM Homo sapie16.9428177AA423967Hs. 178113ESTs, Moderately similar to kinesin like protein 9 [M. m16.9453250AI346520Hs. 121619chromosome 11 open reading frame 1516.9418294AF061739Hs. 83954protein associated with PRK116.9446546BE167687Hs. 156628ESTs16.9421100AW351839Hs. 124660Homo sapiens cDNA FLJ21763 fis, clone COLF696716.9455993BE179085gb: RC0-HT0613-140300-021-d06 HT0613 Homo sapie16.9459375BE251770gb: 601112470F1 NIH_MGC_16 Homo sapiens cDNA16.9454803AW860148gb: RC0-CT0379-290100-032-b10 CT0379 Homo sapie16.9445474AI240014Hs. 259558ESTs16.9443198AI039813gb: ox49d06.x1 Soares_total_fetus_Nb2HF8_9w Homo16.9441557AW452647Hs. 270482ESTs16.9420206M91463Hs. 95958solute carrier family 2 (facilitated glucose transporter),16.9442202BE272862Hs. 106534Homo sapiens cDNA: FLJ22625 fis, clone HSI0600916.9416913AW934714gb: RC1-DT0001-031299-011-a11 DT0001 Homo sapie16.9419355AA428520Hs. 90061progesterone binding protein16.9452975M85521Hs. 69469dendritic cell protein16.9432525AI796096Hs. 109414ESTs16.8453718AL119317Hs. 120360phospholipase A2, group VI (cytosolic. calcium-indepe16.8437270R18087Hs. 11282ESTs, Weakly similar to cleft lip and palate transmemb16.8408007AW135965Hs. 246783ESTs16.8450954AI904740Hs. 25691receptor (calcitonin) activity modifying protein 316.8402958predicted exon16.8445656W22050Hs. 21299ESTs, Weakly similar to AF151840_1 CGI-82 protein [H.16.8410684AA088500Hs. 170298ESTs16.8437669AI358105Hs. 123164ESTs, Weakly similar to match to ESTs AA667999 [H.16.8447869AW139113Hs. 164307ESTs16.8458025AI275406gb: ql63c10.x1 Soares_NhHMPu_S1 Homo sapiens cDN16.8445614AV660763Hs. 110675apolipoprotein C-IV16.8454610AW810224gb:MR4-ST0125-021199-017-e07 ST0125 Homo sapie16.8449303AK001495Hs. 23467hypothetical protein FLJ1063316.8422105AI929700Hs. 111680endosulfine alpha16.8444788AI871122Hs. 202821ESTs16.8414057AI815559Hs. 75730signal recognition particle receptor (‘docking protein’)16.8408822AW500715Hs. 57079Homo sapiens cDNA FLJ13267 fis, clone OVARC100016.8433379AA586368Hs. 190232ESTs16.8441552AA937975gb: oc08e12.s1 NCI_CGAP_GCB1 Homo sapiens cDN16.8403582predicted exon16.8433871W02410Hs. 205555ESTs16.8439509AF086332Hs. 58314ESTs16.8431639AK000680Hs. 266175phosphoprotein associated with GEMs16.8430129BE301708Hs. 233955hypothetical protein FLJ2040116.8401465predicted exon16.8448913AA194422Hs. 22564myosin VI16.8410261AF145713Hs. 61490schwannomin interacting protein 116.8421199BE244219Hs. 102497paxillin16.7450489AI697990Hs. 224375ESTs16.7410186AW602528gb: RC5-BT0562-260100-011-A02 BT0562 Homo sapi16.7447224BE617125gb: 601441664F1 NIH_MGC_65 Homo sapiens cDNA16.7403010predicted exon16.7404881predicted exon16.7445572AI243445Hs. 189654ESTs16.7419440AB020689Hs. 90419KIAA0882 protein16.7443406AI056238Hs. 143316ESTs16.7457901AW207023Hs. 250497ESTs, Highly similar to dJ745C22 1 [H. sapiens]16.7448364T08958Hs. 16561HSPC141 protein16.6407239AA076350Hs. 67846leukocyte immunoglobulin-like receptor, subfamily B (16.6401847predicted exon16.6429523AK000788Hs. 205280Homo sapiens cDNA FLJ20781 fis, clone COL0423516.6432845AI989751Hs. 150378ESTs16.6400246predicted exon16.6404971predicted exon16.6422954AW998605Hs. 32399ESTs, Weakly similar to Similar to Ena-VASP like prot16.6415042NM_006759Hs. 77837UDP-glucose pyrophosphorylase 216.6432201AI538613Hs. 135657ESTs16.6456993AL134577Hs. 200302ESTs16.6456525AW468397Hs. 100000S100 calcium-binding protein A8 (calgranulin A)16.6444060AA340277Hs. 10248Homo sapiens cDNA FLJ20167 fis, clone COL0951216.6428928BE409838Hs. 194657cadherin 1, type 1, E-cadherin (epithelial)16.6448199AI953278Hs. 170557ESTs16.6443422R10288Hs. 301529ESTs16.6401117predicted exon16.6400613predicted exon16.6431214AA294921Hs. 250811v-ral simian leukemia viral oncogene homolog B (ras re16.6431649AL133077Hs. 266746Homo sapiens cDNA FLJ22615 fis, clone HSI0511816.5421335X99977Hs. 103505ARS component B16.5427154AL137262Hs. 288991Homo sapiens cDNA FLJ22523 fis, clone HRC1250716.5401010predicted exon16.5436678BE512828Hs. 5273NADH dehydrogenase (ubiquinone) Fe-S protein 3 (30 k16.5401589predicted exon16.5402538predicted exon16.5430478NM_014349Hs. 241535TNF-inducible protein CG12-116.5437623D63880Hs. 5719chromosome condensation-related SMC-associated pro16.5401244predicted exon16.5415167AA160784Hs. 26410ESTs16.5438291BE514605Hs. 289092Homo sapiens cDNA FLJ22380 fis, clone HRC07453,16.5405183predicted exon16.5436480AJ271643Hs. 87469putative acid-sensing ion channel16.5456691AI023428Hs. 205696ESTs16.5418332R34976Hs. 78293ESTs16.5446052AA358760gb: EST67699 Fetal lung II Homo sapiens cDNA 5′ end16.5444859AW449137Hs. 157487ESTs16.5437192AW975786Hs. 75355ubiquitin-conjugating enzyme E2N (homologous to yea16.5400891predicted exon16.5448372AW445166Hs. 170802ESTs16.5425798AA364002gb: EST74529 Pineal gland II Homo sapiens cDNA 5′ en16.5459253AL157476Hs. 32913Homo sapiens mRNA, cDNA DKFZp761C082 (from c16.5420746AW195932Hs. 197488ESTs16.4414717BE271039Hs. 77060proteasome (prosome, macropain) subunit, beta type, 616.4400727predicted exon16.4422691NM_003365Hs. 119251ubiquinol-cytochrome c reductase core protein I16.4405639predicted exon16.4414444BE298594gb: 601119754F1 NIH_MGC_17 Homo sapiens cDNA16.4456146AL034349Hs. 79005protein tyrosine phosphatase, receptor type, K16.4414610BE388044gb: 601283747F1 NIH_MGC_44 Homo sapiens cDNA16.4414267AL078459Hs. 289109dimethylarginine dimethylaminohydrolase 116.4401268predicted exon16.4403613predicted exon16.4414203BE262170gb: 601150419F1 NIH_MGC_19 Homo sapiens cDNA16.4454315AW373564Hs. 251928nuclear pore complex interacting protein16.4452114N22687Hs. 8236ESTs16.4404638predicted exon16.4404600predicted exon16.3448855AF070574Hs. 22316Homo sapiens clone 24819 mRNA sequence16.3406629AW277078Hs. 181165eukaryotic translation elongation factor 1 alpha 116.3450957BE515202Hs. 21497Homo sapiens mRNA for FLJ00042 protein, partial cds16.3449966H60542Hs. 37848ESTs16.3402585predicted exon16.3436008AI078428Hs. 58785ESTs16.3401492predicted exon16.3412288NM_003005Hs. 73800selectin P (granule membrane protein 140 kD, antigen C16.3405088predicted exon16.3437345BE259522Hs. 5556NADH dehydrogenase (ubiquinone) 1, alpha/beta subco16.3432280BE440142Hs. 2943signal recognition particle 19 kD16.3419596BE379320Hs. 91448MKP-1 like protein tyrosine phosphatase16.3428801AW277121Hs. 254881ESTs16.3431394AK000692Hs. 252351HERV-H LTR-associating 216.3452998BE019681Hs. 6019Homo sapiens cDNA: FLJ21288 fis, clone COL0192716.3439938AI147392Hs. 124607ESTs16.3418844M62982Hs. 1200arachidonate 12-lipoxygenase16.3446081AA972412Hs. 13755f-box and WD-40 domain protein 216.3443534AI076123gb: oy92e04.x1 Soares_fetal_liver_spleen_1NFLS_S1 H.16.3459510AA076706gb: 7B01B02 Chromosome 7 Fetal Brain cDNA Library16.3450517AI523755Hs. 59236ESTs, Weakly similar to B35049 ankyrin 1, erythrocyte16.3451938AI354355Hs. 16697down-regulator of transcription 1, TBP-binding (negativ16.3454478AW805749gb: QV1-UM0105-180400-162-f10 UM0105 Homo sap16.2407214AA412048Hs. 279574CGI-39 protein, cell death-regulatory protein GRIM1916.2406580predicted exon16.2409452BE336714Hs. 289271cytochrome c-116.2416841N33878Hs. 249495heterogeneous nuclear ribonucleoprotein A116.2458710AV660856gb: AV660856 GLC Homo sapiens cDNA clone GLCG16.2450657AK001579Hs. 25277hypothetical protein FLJ2106516.2404230predicted exon16.2439471W69839Hs. 58033ESTs16.2400848predicted exon16.2428797AA496205Hs. 193700Homo sapiens mRNA, cDNA DKFZp586I0324 (from c16.2416272AA178882gb: zp38b09.r1 Stratagene muscle 937209 Homo sapiens16.2444465AI206592Hs. 143843ESTs16.2431257AF039597gb: Homo sapiens Ku86 autoantigen related protein 1 (K16.2447775BE179318gb: RC1-HT0615-290300-021-g05 HT0615 Homo sapie16.2403833predicted exon16.2444140AV648089Hs. 282383ESTs16.2446102AW168067Hs. 252956ESTs16.2416475T70298gb: yd26g02.s1 Soares fetal liver spleen 1NFLS Homo s16.2430783AW971248Hs. 291289ESTs, Weakly similar to ALU1_HUMAN ALU SUBFA16.2414070AW963783gb: EST375856 MAGE resequences, MAGH Homo sap16.2444283AI138971Hs. 154636ESTs16.2405599X92715Hs. 3057zinc finger protein 74 (Cos52)16.2409427AW389668gb: RC2-ST0168-071299-013-f06 ST0168 Homo sapien16.2409417AA156247Hs. 295908ESTs, Weakly similar to ALU7_HUMAN ALU SUBFA16.2435380AA679001Hs. 192221ESTs16.2406752AI285598Hs. 217493annexin A216.2406096F12200Hs. 5811chromosome 21 open reading frame 5916.2417551AI816291Hs. 82273hypothetical protein16.2441252AW360901Hs. 183047ESTs, Weakly similar to unnamed protein product [H. s16.2419608AL037237Hs. 91586transmembrane 9 superfamily member 116.1438894AI630819Hs. 300431ESTs16.1451287AK002158Hs. 26194hypothetical protein FLJ1129616.1412499AW956916Hs. 11238KIAA0622 protein, Drosophila “multiple asters” (Mast16.1433355AI808235gb: wf44e01.x1 Soares_NFL_T_GBC_S1 Homo sapien16.1416818AI986408Hs. 204766ESTs, Weakly similar to B48013 proline-rich proteogly16.1438765AI031888Hs. 132594ESTs16.1424470BE244261Hs. 5615nuclear RNA export factor 116.1416194H27114Hs. 301212ESTs16.1446702R44518Hs. 143496ESTs16.1414222AL135173Hs. 878sorbitol dehydrogenase16.1443122AI806656Hs. 209022ESTs, Weakly similar to Pro-Pol-dUTPase polyprotein16.1448648BE614345Hs. 159089ESTs16.1456394W28506gb: 48f1 Human retina cDNA randomly primed sublibra16.1445887AI263105Hs. 145597ESTs16.1412332AW937661Hs. 288324Homo sapiens cDNA FLJ13283 fis, clone OVARC100116.1403912predicted exon16.1441446R66269Hs. 28714ESTs16.1403153predicted exon16.0444907AW772596Hs. 148586ESTs16.0421946R99629Hs. 109773hypothetical protein FLJ2062516.0437513AW410681Hs. 5648proteasome (prosome, macropain) 26S subunit, non-AT16.0407752AA573581Hs. 13328ESTs16.0447953AI804218Hs. 209614Homo sapiens cDNA FLJ22343 fis, clone HRC0604316.0425708AK001342Hs. 14570Homo sapiens cDNA FLJ22530 fis, clone HRC1286616.0421449AA713491Hs. 291501ESTs16.0418323NM_002118Hs. 1162major histocompatibility complex, class II, DM beta16.0447787BE620108gb: 601483015F1 NIH_MGC_69 Homo sapiens cDNA16.0422716AI702835Hs. 124475ESTs16.0443958BE241880Hs. 10029cathepsin C16.0417908AA207221gb: zq55h04.s1 Stratagene neuroepithelium (937231) Ho16.0438542AA810131Hs. 123317ESTs16.0400288X06256Hs. 149609integrin, alpha 5 (fibronectin receptor, alpha polypeptid16.0456825H67220Hs. 146406nitrilase 116.0431360NM_000427Hs. 251680loncrin16.0414266BE267834gb: 601124428F1 NIH_MGC_8 Homo sapiens cDNA c16.0440571AA904461Hs. 130798ESTs16.0426075AW513691Hs. 270149ESTs16.0413488BE144017Hs. 184693transcription elongation factor B (SIII), polypeptide 1 (116.0446767AI380107Hs. 158954ESTs16.0418008W56044Hs. 211556Homo sapiens cDNA FLJ23378 fis, clone HEP1624816.0404239predicted exon16.0458401AW236939Hs. 172154ESTs16.0412955BE241849Hs. 75082ras homolog gene family, member G (rho G)15.9423072AI792946Hs. 123116solute carrier family 12 (sodium/potassium/chloride tran15.9444954AW247076Hs. 12163eukaryotic translation initiation factor 2, subunit 2 (beta15.9449023AI623261Hs. 248875ESTs15.9435729BE048886Hs. 275017EST15.9438575BE304709Hs. 146550myosin, heavy polypeptide 9, non-muscle15.9413047H02209gb: yj38c09.r1 Soares placenta Nb2HP Homo sapiens cD15.9425997AK000086Hs. 165948hypothetical protein FLJ2007915.9446863AW614370Hs. 254620ESTs15.9448564AL044962Hs. 21453Homo sapiens mRNA for inositol 1,4,5-trisphosphate 315.9455640BE064059gb: QV3-BT0296-010300-111-e04 BT0296 Homo sapie15.9404345AA730407Hs. 159156protocadhenn 1115.9418512AW498974Hs. 89981diacylglycerol kinase, zeta (104 kD)15.9411551AW851309gb: IL3-CT0220-170200-067-C11 CT0220 Homo sapien15.9446726AW300144Hs. 209209Homo sapiens cDNA FLJ11629 fis, clone HEMBA10015.9410748BE383816Hs. 136005ESTs, Highly similar to bG115G20 2 [H. sapiens]15.9449618AI076459Hs. 14366Homo sapiens cDNA FLJ12819 fis, clone NT2RP200215.9429697AW296451Hs. 24605ESTs15.9424012AW368377Hs. 137569tumor protein 63 kDa with strong homology to p5315.9403151predicted exon15.8452363AI582743Hs. 94953ESTs, Highly similar to C1QC_HUMAN COMPLEME15.8425971AF135024Hs. 165296kallikrein 1315.8432826X75363Hs. 250770kallikrein 1515.8431972AI805145Hs. 191711ESTs15.8400269predicted exon15.8404703AI904493Hs. 99890polymerase (DNA directed), delta 1, catalytic subunit (115.8449335AW150717Hs. 296176STAT induced STAT inhibitor 315.8418443NM_005239Hs. 85146v-ets avian erythroblastosis virus E26 oncogene homolo15.8445773H73456Hs. 13299Homo sapiens mRNA, cDNA DKFZp761M0111 (from15.8433782AF090945gb: Homo sapiens clone HQ067015.8406473predicted exon15.8420831AA280824Hs. 190035ESTs15.8402939predicted exon15.8405196predicted exon15.8452947AW130413gb: xf50f04.x1 NCI_CGAP_Gas4 Homo sapiens cDNA15.8414170AA335996Hs. 3743matrix metalloproteinase 24 (membrane-inserted)15.8437133AB018319Hs. 5460KIAA0776 protein15.8458356AI024855Hs. 131575ESTs15.8407857AI928445Hs. 92254hypothetical protein FLJ2016315.8405687predicted exon15.8415189L34657Hs. 78146platelet/endothelial cell adhesion molecule (CD31 antig15.8408662AW247699Hs. 105897ESTs15.7448338AI492857gb: th72h08.x1 Soares_NhHMPu_S1 Homo sapiens cDN15.7402694predicted exon15.7430224AW675175Hs. 235975hypothetical protein DKFZp434D041215.7458792N56666gb: yw75e02.r1 Soares_placenta_8to9weeks_2NbHP8to15.7402944predicted exon15.7422675BE018517Hs. 119140eukaryotic translation initiation factor 5A15.7408661AW247625gb: 2820094 5prime NIH_MGC_7 Homo sapiens cDNA15.7423238AA323569Hs. 280482ESTs15.7421517AB018352Hs. 105399KIAA0809 protein15.7429865AB023217Hs. 225968KIAA1000 protein15.7440815AW071945Hs. 7436putative acyltransferase15.7400634predicted exon15.7451034AL050341Hs. 25846zinc metalloproteinase, STE24 (yeast, homolog)15.7457571AI375726Hs. 279918hypothetical protein15.7450105BE281124Hs. 288013similar to yeast BET3 (S. cerevisiae)15.7407464AJ276396gb: Homo sapiens mRNA for matrix extracellular phosp15.7439465AF086285gb: Homo sapiens full length insert cDNA clone ZD47B15.7451837T92157Hs. 16970ESTs15.7435313AI769400Hs. 189729ESTs15.7402738predicted exon15.7432966AA650114gb: ns92h09.s1 NCI_CGAP_Pr3 Homo sapiens cDNA c15.7457666AW470302Hs. 129663ESTs15.7401269predicted exon15.7427509M62505Hs. 2161complement component 5 receptor 1 (C5a ligand)15.7418846AI821602Hs. 115127ESTs15.6448891AI587332Hs. 209115ESTs15.6445930AF055009Hs. 13456Homo sapiens clone 24747 mRNA sequence15.6421254AK001724Hs. 102950coat protein gamma-cop15.6447073AW204821Hs. 157726ESTs15.6445438AB014578Hs. 12707KIAA0678 protein15.6432126AA865239Hs. 55144ESTs15.6424091AF235097Hs. 139263calcium channel, voltage-dependent, alpha 1F subunit15.6440832AI057548Hs. 128224ESTs15.6449228AJ403107Hs. 148590ESTs, Weakly similar to AF208846_1 BM-004 [H. sapie15.6434253AI393345Hs. 116215ESTs15.6459270AL039604gb: DKFZp434E2211_r1 434 (synonym htes3) Homo s15.6454425AW300927Hs. 27192hypothetical protein dJ1057B20 215.6412055AA099907Hs. 271806ESTs15.6400837predicted exon15.6458866BE616694Hs. 288042Homo sapiens cDNA FLJ14299 fis, clone PLACE101015.6417124BE122762Hs. 25338ESTs15.6414376BE393856Hs. 66915ESTs, Weakly similar to 16.7 Kd protein [H. sapiens]15.6418636AW749855gb: QV4-BT0534-281299-053-c05 BT0534 Homo sapie15.6454128AL031259Hs. 41639programmed cell death 215.6441074AW500001Hs. 4783Homo sapiens cDNA. FLJ22035 fis, clone HEP0883815.6451742T77609Hs. 117970ankyrin 2, neuronal15.6403687predicted exon15.6431838AI097229Hs. 217484ESTs15.6402855predicted exon15.6449635AI989942Hs. 232150ESTs15.6434392AW983709Hs. 268051ESTs15.6444301AK000136Hs. 10760hypothetical protein FLJ2012915.6414973C19089gb: C19089 Human placenta cDNA (TFujiwara) Homo15.5428374AW405156Hs. 183994protein phosphatase 1, catalytic subunit, alpha isoform15.5415745AI301107Hs. 150790ESTs15.5432532AW058459Hs. 162246ESTs15.5417112AA193439gb: zr41b09.s1 Soares_NhHMPu_S1 Homo sapiens cDN15.5418101AL047476Hs. 98485gap junction protein, beta 4 (connexin 30.3)15.5453110AW384928Hs. 225160Homo sapiens cDNA FLJ13102 fis, clone NT2RP300215.5458606AJ239397gb: AJ239397 Uni-ZAP XR retinal pigment epithelium H.15.5436989AA741028Hs. 256155ESTs15.5407396AF011757gb: Homo sapiens RAGE binding protein (P12) mRNA,15.5449684AI659166Hs. 207144ESTs15.5454666AW812994gb: RC3-ST0186-230300-019-g02 ST0186 Homo sapien15.5430492U15197Hs. 300803Human histo-blood group ABO protein mRNA, partial15.5439460AA836220Hs. 13774ESTs15.5449231BE410360gb: 601302340F1 NIH_MGC_21 Homo sapiens cDNA15.5453060AW294092Hs. 21594ESTs15.5416961BE391476Hs. 80617ribosomal protein S1615.5439988AA860119Hs. 255976ESTs15.5400917predicted exon15.5424585AA464840gb: zx43h11.r1 Soares_total_fetus_Nb2HF8_9w Homo15.5431029BE392725Hs. 248571Homo sapiens PAC clone RP5-1163J12 from 7q21.2-q315.5441680AW444598Hs. 7940RAP1, GTP-GDP dissociation stimulator 115.5437830AB020658Hs. 5867KIAA0851 protein15.5409479BE163800Hs. 136912ESTs15.5409885AW503068gb: UI-HF-BP0p-aje-g-10-0-UI.r1 NIH_MGC_51 Homo15.4459090AA443323Hs. 107812ESTs, Weakly similar to SPOP [H. sapiens]15.4429324AA488101Hs. 199245inactivation escape 115.4403766predicted exon15.4413970U59309Hs. 75653fumarate hydratase15.4456674BE266120Hs. 269358ESTs15.4417931W95642Hs. 82961trefoil factor 3 (intestinal)15.4430125U46418Hs. 233950serine protease inhibitor, Kunitz type 115.4452154AW953265Hs. 271277hypothetical protein from EUROIMAGE 36366815.4422984W28614Hs. 75984chorionic somatomammotropin hormone 215.4408649BE242232Hs. 26045protein tyrosine phosphatase, receptor type, A15.4417497AW402482Hs. 82212CD53 antigen15.4404666predicted exon15.4456847AI360456Hs. 37776ESTs15.4426995AA400646Hs. 221988ESTs15.4445350AF052112Hs. 12540lysophospholipase I15.4450214BE439763Hs. 227571regulator of G-protein signalling 415.4449733R74546Hs. 29438Homo sapiens cDNA FLJ12094 fis, clone HEMBB10015.4411660AW855718gb: RC1-CT0279-070100-021-a06 CT0279 Homo sapie15.4442653BE269247Hs. 170226Homo sapiens clone 23579 mRNA sequence15.4447552AI394125Hs. 160413ESTs15.4448712W01046Hs. 181634Homo sapiens cDNA FLJ23602 fis, clone LNG1573515.4420180AI004035Hs. 25191ESTs15.4440099AL080058Hs. 6909DKFZP564G202 protein15.4427550BE242818Hs. 179606nuclear RNA helicase, DECD variant of DEAD box fam15.4432894AW167668Hs. 279772brain specific protein15.3412113AW161274Hs. 74427p53-induced protein15.3431614AI189827gb: qd19d07.x1 Soares_placent_8to9weeks_2NbHP8to15.3445870AW410053Hs. 13406syntaxin 1815.3424347AA723883Hs. 145513Homo sapiens mRNA; cDNA DKFZp434L0435 (from15.3425132AW250114gb: 2821134 5prime NIH_MGC_7 Homo sapiens cDNA15.3439756AL359651Hs. 283852Homo sapiens mRNA full length insert cDNA close EU15.3432946U60899Hs. 279854mannosidase, alpha, class 2B, member 115.3406130predicted exon15.3453359AA448787Hs. 24872ESTs, Weakly similar to aortic carboxypeptidase-like p15.3405491predicted exon15.3436481AA379597Hs. 5199HSPC150 protein similar to ubiquitin-conjugating enzy15.3446826AK000626Hs. 16230hypothetical protein FLJ2061915.3441211AW946155Hs. 7750hypothetical protein AL13320615.3418711AW247977Hs. 87595translocase of inner mitochondrial membrane 22 (yeast)15.3457301AA469146gb: nc67e03.s1 NCl_CGAP_Pr1 Homo sapiens cDNA c15.3449999AI679421Hs. 231098ESTs, Highly similar to ALU4_HUMAN ALU SUBFA15.3439090H65724Hs. 271663ESTs15.3416586D44643Hs. 14144secreted modular calcium-binding protein 115.3411940AW876686gb: CM4-PT0031-180200-507-e05 PT0031 Homo sapie15.3407639AW205369Hs. 252936ESTs15.3458012AI424899Hs. 188211ESTs15.3426490NM_001621Hs. 170087aryl hydrocarbon receptor15.3408741M73720Hs. 646carboxypeptidase A3 (mast cell)15.3437371AK000868Hs. 5570hypothetical protein FLJ1000615.3437134AA349944Hs. 42915ARP2 (actin-related protein 2, yeast) homolog15.3441890AI809547Hs. 128075ESTs15.3409442AA310162Hs. 169248cytochrome c15.3407078Z26256gb: H. sapiensisoform 1 gene for L-type calcium channe15.2436553AW407157Hs. 181125immunoglobulin lambda locus15.2443177BE268461Hs. 202benzodiazapine receptor (peripheral)15.2448771BE315511Hs. 296244SNARE protein15.2436837AI968248Hs. 187869ESTs15.2423623AB011117Hs. 129943KIAA0545 protein15.2422651NM_015670Hs. 118926DKFZP586K0919 protein15.2403221AL134878Hs. 119500karyopherin alpha 4 (importin alpha 3)15.2431620AA126109Hs. 2649812′-5′oligoadenylate synthetase 215.2404794NM_000078Hs. 89538cholesteryl ester transfer protein, plasma15.2412944AA384110Hs. 197143ESTs15.2450817N71597Hs. 29698ESTs15.2418666AF001434Hs. 155119EH domain containing 115.2451636AW173270Hs. 140444ESTs15.2426302AA459085Hs. 275163non-metastatic cells 2, protein (NM23B) expressed in15.2454485AW795322gb: PM0-UM0018-120400-002-h01 UM0018 Homo sap15.2440617AA894880Hs. 181181ESTs15.2449718AA459480Hs. 23956hypothetical protein FLJ2050215.2405227predicted exon15.2431006BE152871gb: CM1-HT0333-101299-064-d12 HT0333 Homo sap15.2443476AW068594Hs. 133878ESTs, Weakly similar to AF151889_1 CGl-131 protein15.2438828AL134275Hs. 6434hypothetical protein DKFZp761F201415.2407634AW016569Hs. 301280ESTs, Highly similar to AF241831_1 intracellular hyalu15.2436857AA732647gb: nz89d01.s1 NCl_CGAP_GCB1 Homo sapiens cDN15.2431526Y10129Hs. 258742myosin-binding protein C, cardiac15.1447386NM_006289Hs. 18420KIAA1027 protein15.1436573AA723297Hs. 127138ESTs15.1432858BE618609Hs. 279591Homo sapiens clone 25056 mRNA sequence15.1437352AL353957Hs. 284181hypothetical protein DKFZp434P053115.1413209AW083791Hs. 21263Homo sapiens cDNA FLJ13152 fis, clone NT2RP300315.1407376AA993138Hs. 142287ESTs, Weakly similar to ALUF_HUMAN !!!! ALU CL15.1430475BE387420Hs. 241531peflin15.1446764AW291276Hs. 285532ESTs15.1425868AB017548Hs. 160100Homo sapiens gene for Sepiapterin Reductase, partial c15.1453464AI884911Hs. 32989receptor (calcitonin) activity modifying protein 115.1447246AW449032Hs. 170257ESTs15.1401780predicted exon15.1434063AA018893Hs. 3727unr-interacting protein15.1416114AI695549Hs. 183868glucuronidase, beta15.1441018AI809587Hs. 148782ESTs15.1425972BE391563Hs. 165433ESTs, Highly similar to T17342 hypothetical protein D15.1426062N57014Hs. 44013ESTs15.1451234AI914901Hs. 24052ESTs15.1429565AB020719Hs. 207802KIAA0912 protein15.1418092R45154Hs. 106604ESTs15.1424550AI650541Hs. 115298ESTs15.1425023AW956889Hs. 154210endothelial differentiation, sphingolipid G-protein-coup15.1445213AW204314Hs. 170784ESTs15.1418102R58958Hs. 26608ESTs15.0450082AI908894Hs. 245893ESTs15.0446749NM_016069Hs. 16089CGI-136 protein15.0406124predicted exon15.0457408AL137507Hs. 255348Homo sapiens mRNA; cDNA DKFZp761P211 (from c15.0410051U25773Hs. 218182ESTs, Weakly similar to dJ1042K10 2 [H. sapiens]15.0440965AI523646Hs. 169859ESTs15.0440190AW752597gb: IL3-CT0214-161299-045-B06 CT0214 Homo sapien15.0417437U52682Hs. 82132interferon regulatory factor 415.0454249AW249008gb: 2821048 5prime NIH_MGC_7 Homo sapiens cDNA15.0432276AF163302Hs. 274255somatostatin receptor-interacting protein15.0401116predicted exon15.0423960AA164516Hs. 136309CGI-61 protein15.0451661AB020650Hs. 26777KIAA0843 protein15.0450983AA305384Hs. 25740ERO1 (S. cerevisiae)-like15.0446187AK001241Hs. 14229hypothetical protein FLJ1037915.0404122predicted exon15.0411299BE409857Hs. 69499hypothetical protein15.0403077predicted exon15.0438000AI825880Hs. 5985non-kinase Cdc42 effector protein SPEC215.0447118AB014599Hs. 17411KIAA0699 protein15.0417878U90916Hs. 82845Human clone 23815 mRNA sequence15.0444079H09048Hs. 23606ESTs15.0458234BE551408Hs. 127196ESTs15.0434208T92641Hs. 127648hypothetical protein PRO217615.0423136AW375506Hs. 124147ESTs15.0403177predicted exon15.0448699AI857269Hs. 227351ESTs15.0425248AW957442Hs. 252766ESTs15.0429430AI381837Hs. 155335ESTs15.0Pkey: Primekey Ex Accn: Exemplar Accession UG ID: UniGene ID Title: Unigene Title PFAM: domains ratio: tumor vs. normal tissues


[0356]

8







TABLE 3B








Pkey
CAT Number
Accession







408310
1051011_1
AW179023 AW179010


408647
1071855_1
AW245831 AW273207


408661
1073036_1
AW247625 AW249214


408987
109306_1
H85615 H86300 H86263 H86282 AA059278 H86304


409427
1129667_1
AW389668 AW389657 AW609198 AW389649


409545
1138823_1
BE296182 AW629821


409828
1155571_1
AW501137 AW501295 AW501212


409865
1156518_1
AW502208 AW502366 AW502148


409885
1157385_1
AW503068 AW503789


410003
116761_1
AA079487 AA128547 AA128291 AA079587 AA079600


410186
1182096_1
AW602528 BE073859 Z38412


410626
1212621_−1
BE407727


411004
1228975_1
AW813242 BE146089 AW813195 AW813173 AW813206 BE145953 BE146212 AW813196 AW854582




AW813241 BE061582


411014
1229091_1
AW816072 AW813375 AW813385 AW813372 AW813436 AW816148 AW813475 AW816107 AW813398




AW813479 AW814475 AW813317


411028
1229404_1
AW813703 AW813839


411236
1236374_1
AW833752 AW833633 AW833776 AW833719 AW833362 AW833749


411420
1245222_−1
BE390652


411541
1249044_1
W03940 T98335 AW850705


411551
1249196_1
AW851309 AW850888 AW851419 AW851412 AW851299


411651
1252835_1
AW855392 AW855559 AW855423


411660
1253078_1
AW855718 AW855740 AW855748


411696
1254304_1
AW857404 AW857401 BE144856


411811
1259427_1
AW864370 AW864319 AW864504


411930
1266070_1
F06485 AW876454


411940
1266262_1
AW876686 AW876717 AW877215 AW876691 AW876722 AW877218 AW876694 AW876725


411942
1266449_1
AW877015 AW877133 AW876978 AW877071 AW876988 AW877069 AW877063 AW877013


412793
1327636_−1
AW997986


413047
1346806_1
H02209 BE062154 BE062032


413101
1349154_1
BE065215 BE155544 BE155541 BE155540 BE155542 BE155543


413154
1351077_1
BE067870 BE067866 BE165133 BE165334 BE165329 BE165332


413282
1358147_1
BE078159 BE078276 BE078163 BE078277 BE078279 BE078158


413442
1370508_1
BE140643 BE140645 BE140644 BE140657 BE140660 BE140659 BE140661


413544
1375671_1
BE147225 BE147205 BE147234


413605
1379792_1
BE152644 BE152712 BE152668 BE152659 BE152810 BE152811 BE152816 BE152643 BE152706




BE152656 BE152660 BE152715 BE152662 BE152669 BE152661 BE152672 BE152653




BE152716 BE152651 BE152767 BE152677 BE152652 BE152714 BE152708 BE152665 BE152679




BE152771 BE152775 BE152666 BE152768 BE152813 BE152664 BE152676 BE152681 BE152709




BE152667 BE152814 BE152808 BE152711 BE152707 BE152815 8E152678 BE152673




BE152782 BE152671 BE152682 BE152760 BE152809 BE152778 BE152780 BE152762 BE152776




BE152781 BE152774 BE152763 BE152769


413679
1382784_1
BE156765 BE156770 BE156767 BE156769 BE156803 BE156802 BE156847 BE156853 BE156780




BE156836 BE156792 BE156834 BE156779 BE156789 BE156833 BE156844




BE156831 BE156849 BE156797 BE156784 BE156801 BE156843 BE156793 BE156852


413758
1386900_−1
BE162391


414070
141442_1
AW963783 F36521 F30667 AW753177 AW753195 AW853065 AA135150 AA375028


414195
1424854_−3
BE263293


414203
1425510_2
BE262170 BE382553 BE261026 BE273627


414266
1430984_1
BE267834 BE514180 BE514096


414276
1432115_−1
BE297862


414333
1436492_1
BE274897 BE408199 BE274723


414444
1446827_−1
BE298594


414539
1460320_1
BE379046 BE395459


414540
1460324_−1
BE379050


414605
1465790_−1
BE390440


414610
1466027_1
BE388044 BE391117 BE391530


414626
1467232_1
BE410589 BE390949 BE408297 BE389529


414642
146960_1
AA150350 AA361174 AW959038


414663
1472628_−1
BE396326


414973
1510755_1
C19089 C18814 C16621


415160
1525766_1
T82802 D78670 R08505


415606
1540470_1
W70022 R35201 F12763 T74725 H63485 Z45782 H61126


415917
1561575_1
Z43912 H09194


416272
158407_1
AA178882 AA179898 AA178897


416475
1596398_1
T70298 H58072 R02750


416913
163001_1
AW934714 BE161007 BE162500 AW749902 AW749864 BE162498 BE161005 AA190449




AW513466 BE161006 BE162499


417112
165068_1
AA193439 AA193537 AW814128


417611
168900_1
AW993983 AW994798 AW993990 AW993999 AW993989 AA204755


417908
170764_1
AA207221 BE538271


418636
177402_1
AW749855 AA225995 AW750208 AW750206


418874
1799516_1
T60872 T60906


419618
186533_1
AA528295 AW971284 AA247945


419889
188798_1
AA251600 AA279607


420902
197525_1
AA742277 AW976493 AA281585


422160
212412_1
AW582898 AA305114


422731
220507_1
AL138411 AL138412 AA315860


422831
221879_1
R02504 AA317715 AW961465 AF121172


423050
224288_1
AA320946 H92114 BE144449 BE144438


423103
225019_1
AA322029 BE315237


423287
226793_1
H38340 H39081 AA324112


423621
230314_1
BE002904 H64880 AA328679


424585
241151_1
AA464840 AA343628


424995
245794_1
Z45023 AA349514


425132
247059_1
AW250114 Z43124 AA431421 AI879054 AA351616 AA351035 AL048999


425612
253969_1
BE004257 AW811190 AA360576 BE172402 BE181703


425798
256586_1
AA364002 AI522307


426065
260276_1
N32049 R34821 R78237


426356
265381_1
BE536836 AA376153


426383
266126_1
BE537380 BE255215


428151
287658_1
AA422028 W79191


431006
326833_1
BE152871 BE152870 AA490552


431257
33049_1
AF039597 BE243938


431614
335668_1
AI189827 AW860554 AW860552 AA508543


431822
338082_1
AA516049 AW004922


432966
356839_1
AA650114 AW974148 AA572946


433300
362452_1
AA582307 BE273018


433355
364004_1
AI808235 AI024295 AA584528


433459
366899_1
AA593498 AW749647 AW749630


433469
367263_1
F12741 T75155 AA594014


433782
37414_1
AF090945 AW996754 AI064870


434098
380006_1
AA625499 AA625269 AA625184


435138
401159_1
BE314734 AA666393


435478
406683_1
AA682622 BE141696


436857
428068_1
AA732647 BE008970 BE009028


439078
46841_1
AF085936 H64070 H64017


439465
47272_1
AF086285 W69587 W69421


439848
477806_1
AW979249 D63277 AA846968


440190
488021_1
AW752597 AW848781 AW849062 AW848490 AW752699 AW752604 AW752700


440669
499861_1
AI206964 AI350890 AA902772 AI768881


441552
520138_1
AA937975 F11215 BE005635


442257
53699_1
AW503831 AW503317 BE565665


443198
562655_1
AI039813 AI684642 Z40121 AI951414 BE501049


443534
572957_1
AI076123 AI244834 AI695239


446052
65988_1
AA358760 AA158850 AW062737 AW062738 AV656291


446598
68463_1
AW250546 BE257108 BE251006 BE255957 BE250926 BE513012 AV659318


447224
71279_−1
BE617125


447252
714160_1
R90916 AL120023 R18429 Z42095 AI369730 R90824


447383
71990_1
N24231 BE617964 N36313


447775
73665_1
BE179318 BE620044


447787
73719_1
BE620108 BE312062 AW896316 BE262546


448218
75525_1
AI188409 BE622201


448338
758968_1
AI492857 AW070478 AI885157


448838
78409_4
BE614761 AA263136 W00335 W00327


449231
80303_1
BE410360 AA442408 AA315540


450594
83962_1
N31036 N42915 F07753 AA010329


451400
868459_1
BE160479 BE160478 BE069211 AW861059 AI793147


452544
921467_1
AW851888 AW851889 AW852147


452947
939810_1
AW130413 AI932362


453758
980026_1
U83527 AL120938 U83522


454163
1048369_1
AW175997 AW176000 AW175999 AW175994 AW176004 AW175989


454178
1049458_1
AW177274 AW177249 AW177223 AW177216 AW177233


454181
1049567_1
AW177377 AW177357 AW177359 AW177385 AW177358 AW177395 AW177394 AW177396 AW177383




AW177333 AW177384 AW177382 AW177360 AW177356


454209
1051071_1
AW179083 AW179085 AW179087 AW179081 AW179084 AW179086 AW179082 AW801493 AW801658




AW801714


454249
1073933_1
AW249008 BE295653 BE296765


454377
114761_1
AA076811 AW814764


454478
1214744_1
AW805749 AW805872 AW794466 AW798102 AW796921 AW794538 AW794380


454485
1215381_1
AW795322 AW795308 AW795311 AW795310 AW795314 AW795321


454505
1219564_1
AW801365 AW801435 AW801372


454574
1225636_1
AW809109 AW809112 AW809122 AW809126 AW809128 AW809133 AW809131 AW809113 AW809111




AW809132


454610
1226543_1
AW810224 AW810337 AW810295 AW810333 AW810335 AW810296 AW816053


454633
1227504_1
AW811380 AW811385


454666
1228600_1
AW812994 AW812723 AW812930


454803
1235520_1
AW860148 AW862380 AW821887 AW821863 AW821870 AW821894 AW862351 AW862378


454961
1246745_1
AW847807 AW847935 AW847636


455132
1254686_1
AW857955 AW861636 AW857967 AW857958 AW857943 AW857945 AW857963 AW857968 AW857959




AW857961 AW857956 BE072135 AW857972 BE072137 AW857952




AW857935 AW857940 AW857944 AW857947 AW857934


455426
1289303_1
AW937792 BE072250 BE072251 BE072264


455640
1348141_1
BE064059 BE063903 BE063838 BE063863 BE064056 BE063974 BE063904 BE063898 BE063896 BE063906




BE063980


455694
1350650_1
BE067300 BE067293 BE067279


455910
1382504_1
Z43712 BE156729 BE156538 BE156731 BE156673 BE156539 BE156674 BE156430 BE156672 BE156675




BE156432 BE156541


455993
1398665_1
BE179085 BE179084 BE179086 BE179264


456054
1452761_1
BE313241 BE383148


456329
1789807_1
T41418 T41320 T41379


456394
1843275_−2
W28506


457301
314434 _1
AA469146 AA469396 AA469218 AA469395


458025
46409_1
AI275406 L23206


458606
65568_1
AJ239397 AV655764


458640
670076_1
AI284935 AW409822 BE408182


458710
69727_1
AV660856 BE167375


458792
748294_1
N56666 AI460076


459170
920646_1
AI905518 AI905516 AI905457 AI905515 AW176013 AW176037


459270
969232_1
AL039604 AL039497






Pkey: Unique Eos probeset identifier number




CAT number Gene cluster number




Accession: Genbank accession numbers








[0357]

9








TABLE 3C








Pkey
Ref
Strand
Nt_position







400449
9887692
Minus
50889-51188


400613
9864507
Plus
92278-92472


400634
8567750
Minus
101102-101223, 101886-102018


400642
8117693
Plus
10475-10845


400661
8118474
Plus
84912-85187


400684
8118768
Plus
58189-58323


400685
8118768
Minus
72969-73050, 73713-73800


400727
6705887
Plus
106175-107016


400749
7331445
Minus
9162-9293


400807
8567878
Plus
69375-70295


400837
9188531
Plus
144778-144838, 145582-145670, 146656-146751-147255-147419, 147682-147807


400842
1927148
Plus
90462-90673


400848
1927148
Plus
107149-107339, 110873-111171


400891
9958279
Minus
140073-140427


400917
7283186
Minus
173258-173631


400931
7651921
Minus
142145-142353, 144311-144721


400964
7139719
Minus
155282-155403


400965
7770576
Minus
173043-173564


400970
7960452
Minus
92744-92895


400982
8078794
Minus
119245-119471


401010
8117391
Minus
83967-84180


401072
3687273
Plus
64370-64524


401088
8492704
Plus
194659-195179


401116
9966559
Plus
123579-124447


401117
8570083
Minus
28948-29204


401167
9438381
Plus
18944-19176


401204
9743388
Minus
33694-33872


401220
9929324
Minus
48079-48279


401244
4827300
Minus
55359-56376


401245
4827300
Minus
59373-59531


401268
9797154
Plus
152272-152483, 157312-157418, 158025-158205, 158838-158974, 160716-160952


401269
8954206
Plus
2259-2591


401283
9800093
Minus
47256-47456


401373
7248205
Minus
84211-84336


401405
7768126
Minus
69276-69452, 69548-69958


401465
6682292
Plus
25676-25800


401492
7341778
Plus
171020-171282, 171858-172241


401521
7705251
Plus
9127-9234


401566
8469090
Minus
96277-96420, 96979-97160


401575
7229804
Minus
76253-76364


401589
9966292
Plus
135969-136263


401628
8575954
Minus
210617-210796


401657
9100664
Minus
7312-8163


401747
9789672
Minus





130468-130593, 131097-131258, 131866-131932, 132451-132575, 133580-134011


401757
7239630
Plus
88641-88751


401780
7249190
Minus
28397-28617, 28920-29045, 29135-29296, 29411-29567, 29705-29787, 30224-30573


401781
7249190
Minus
83215-83435, 83531-83656, 83740-83901, 84237-84393, 84955-85037, 86290-86814


401785
7249190
Minus
165776-165996, 166189-166314, 166408-166569, 167112-167268, 167387-167469,





168634-168942


401789
7249213
Minus
70399-70629, 70941-71055


401809
7342191
Minus
107548-108298


401847
7139731
Plus
85447-85593


401887
7229981
Plus
93973-94120


401913
9369520
Minus
33753-33904


401962
3176728
Minus
71433-71648, 76711-76833, 78677-78845, 79585-79763, 82349-82485


401991
4156128
Plus
2398-2513


401994
4153858
Minus
42904-43124, 43211-43336, 44607-44763, 45199-45281, 46337-46732


402023
7528158
Minus
132872-133040


402066
6649269
Plus
135543-136031


402071
8117361
Plus
85924-86039


402075
8117407
Plus
121907-122035, 122804-122921, 124019-124161, 124455-124610, 125672-126076


402131
7704961
Minus
33114-33209, 33496-33678


402144
7242326
Plus
115425-115977


402203
8576119
Minus
8124-8285


402277
2894631
Plus
16980-17152, 17933-18018, 18170-18306


402292
2447220
Plus
33880-34029, 34176-34336, 34953-35103


402297
6598824
Plus
35279-35405, 35573-35659


402407
3962498
Minus
115812-116187


402421
9796341
Minus
46609-46662, 46758-46811, 86293-86346, 89776-89829, 90048-90101, 102817-102924


402427
9796372
Plus
16266-16431


402430
9796372
Minus
62382-62552


402520
7596899
Minus
171761-171996


402538
9801137
Minus
96314-96539


402543
9838066
Minus
89684-90893


402570
9884747
Minus
12649-12866


402585
9908890
Minus
174893-175050, 183210-183435


402639
9958129
Minus
20167-22383


402694
8569867
Plus
2218-2440


402699
8570304
Minus
182773-182883, 184551-184732


402738
7331557
Minus
8725-8859


402855
9662953
Minus
59763-59909


402869
6434643
Minus
138639-139335


402939
9187334
Minus
18329-18535


402944
9368423
Plus
110411-110716, 111173-111640


402948
9368458
Minus
143456-143626, 143808-143935


402958
9368493
Plus
13324-13507


403010
3132346
Plus
78385-79052


403036
3132360
Plus
66545-66712


403051
4827080
Minus
5269-5411


403065
8954197
Minus
71615-71773, 73930-74144


403077
8954241
Plus
146923-147222, 147326-147628


403093
8954241
Plus
177083-177373, 177464-177751


403151
7407965
Minus
14055-14264


403153
9799871
Minus
42232-43389


403177
9838213
Minus
142560-142726


403223
7630969
Plus
81529-81692


403234
7637801
Plus
180641-180822


403273
8018055
Plus
133809-134099


403286
8080320
Plus
118369-118872


403287
8080320
Minus
126097-126411


403348
7239527
Plus
13809-13968


403359
8570207
Minus
108939-109229


403362
8571772
Plus
64099-64260


403447
9837821
Minus
159072-159387


403508
7630896
Plus
5570-5719


403582
8101186
Plus
18308-18458


403613
8493504
Plus
81290-81465


403642
8699671
Plus
7062-7311


403662
5823349
Plus
58627-59062, 59222-59548


403674
7321642
Plus
104988-105623, 107394-107590


403687
7387384
Plus
9009-9534


403695
3046276
Plus
168272-168514


403703
4966380
Plus
83681-84042


403741
7630932
Minus
2833-3468


403747
7658395
Minus
20493-20621


403766
7229888
Plus
136283-136830


403786
8083636
Minus
73028-73217


403796
8099896
Minus
75073-77664


403833
887461
Plus
13522-13664


403852
7708872
Minus
124007-124202


403861
7708966
Plus
58363-58649


403912
7710730
Minus
72000-72290, 72431-72700, 72929-73199


403924
7711688
Minus
89369-89592


403964
7596976
Plus
178174-178300


404034
8567760
Minus
44635-47010


404067
3282162
Plus
1415-2071


404097
7770701
Plus
55512-55781


404122
9796270
Plus
90540-92977


404230
7981448
Minus
92934-93093


404239
5002624
Plus
94841-95095


404240
5002624
Minus
116132-116407, 116653-116922


404270
9828129
Minus
3649-3750, 4161-4306, 5962-6049, 6849-6965


404356
7630858
Minus
126433-126623


404600
8705107
Plus
118354-118444, 118649-118792


404601
8705107
Plus
128449-128693, 129085-129249, 130525-130733


404638
9796751
Minus
99433-99528, 100035-100161


404666
7272179
Minus
18677-18993


404675
9797204
Minus
48532-48645, 49808-49975, 51088-51369, 54944-55063


404727
8081050
Plus
115534-115747


404750
7596836
Plus
181879-182198


404763
7882612
Plus
50981-51392


404767
7882827
Minus
23244-23759


404828
6580415
Minus
26291-27253


404850
5420148
Minus
35145-35413, 40635-41062


404881
5931510
Minus
36360-36608


404890
7329390
Plus
101280-101408


404971
3212939
Minus
74585-75532


405022
7330304
Plus
217163-217439


405028
7533974
Minus
110588-110847, 110933-111115


405071
7708797
Minus
11115-11552


405088
8072518
Minus
115690-117621


405133
8516055
Minus
28127-28288


405138
8576241
Plus
90303-90516


405183
7209940
Plus
12335-12653


405194
7230072
Plus
190465-190645, 193346-193610


405196
7230083
Minus
135716-135851


405208
7230142
Plus
8068-8214


405226
7248966
Plus
53547-54128


405227
6731245
Minus
22550-22802


405256
7329310
Plus
26070-26309


405277
3980473
Plus
23471-23572


405307
3638954
Plus
39195-39429


405311
3638954
Plus
46313-46496


405333
3165399
Plus
149905-150215


405411
3451356
Minus
17503-17778, 18021-18290


405423
4753276
Plus
6162-6983


405491
5801645
Plus
81857-82045


405501
9211311
Minus
49085-49400, 49565-49679, 50117-50262


405515
9454624
Plus
37329-37469


405545
1054740
Plus
118677-118807, 119091-119296, 121626-121823


405580
4512267
Plus
169232-169647


405586
5002511
Plus
38810-39017


405600
5923640
Plus
26662-27225


405610
5757553
Minus
71907-72080


405639
5091650
Plus
211184-211350


405687
6249668
Minus
54787-54891, 55844-55917


405699
4165331
Plus
100727-100859


405783
5738434
Minus
27238-27885


405867
6758731
Minus
74553-75173


406086
7107817
Plus
9418-9573


406124
9149714
Minus
1331-1774


406130
9161404
Minus
32394-32498


406140
9168231
Minus
49887-50219


406160
7144945
Plus
55498-56268


406207
5923650
Minus
162607-162800


406215
7342161
Plus
310-432


406268
6682695
Minus
6605-7072


406277
5686030
Minus
4759-5490


406326
9212385
Plus
84508-84655


406388
9256205
Plus
85153-85277


406457
9755793
Plus
44966-45406


406473
9795566
Minus
109669-109931


406537
7711478
Plus
32904-33017


406571
7711622
Minus
65634-65912, 66116-66596


406580
7711838
Minus
96654-97640






Pkey Unique number corresponding to an Eos probeset




Ref Sequence source The 7 digit numbers in this column are Genbank Identifier (GI) numbers, “Dunham I et al.” refers to the publication entitled “The DNA sequence of human chromosome 22” Dunham, et al. (1999) Nature 402: 489-495




Strand: Indicates DNA strand from which exons were predicted




Nt_position Indicates nucleotide positions of predicted exons








[0358] TABLE 4A lists about 131 genes up-regulated in ovarian cancer compared to normal ovaries that are likely to be extracellalar or cell-surface proteins These were selected for Table 3A, except that the ratio was greater than or equal to 10, and the predicted protein contained a PFAM domain that is indictive of extracellular localization
10TABLE 4AABOUT131 UP-REGULATED GENES ENCODING EXTRACELLULAR/CELLSURFACE PROTEINS, OVARIAN CANCER VERSUS NORMAL OVARYPkeyEx. AccnUG IDTitlePFAMratio403077predicted exonfn315.0426535AU077012Hs. 288582ESTs, Weakly similar to ubiquitous TPKunitz_BPTI14.9403089predicted exonfn314.9457148AF091035Hs 184627KIAA0118 proteinarf; ras14.8431176AI026984Hs 293662ESTslaminin_EGF; laminin_B,14.8434293NM_004445Hs. 3796EphB6fn3, pkinase, EPH_lbd14.8408482NM_000676Hs 45743adenosine A2b receptor7tm_114.6428695AI355647Hs 189999punnergic receptor (family A group 5)7tm_114.5426125X87241Hs. 166994FAT tumor suppressor (Drosophila) hoEGF14.4423732AF058056Hs 132183solute carrier family 16 (monocarboxysugar_tr, MCT14.3422125NM_003459Hs 111967solute carrier family 30 (zinc transporteCation_efflux14.2407483NM_012368(NONE)7tm_114.2446689AW594695Hs 167046ESTs7tm_114.1410184AW503667Hs 59545ring finger protein 15zf-C3HC4; SPRY, zf-B_box14.0423217NM_000094Hs 1640collagen, type VII, alpha 1 (epidermolyfn3, vwa14.0405448AI015709Hs. 172089Homo sapiens mRNA, cDNA DKFZp5trypsin, sushi, CUB14.0450684AA872605Hs. 25333interleukin 1 receptor, type IIig14.0406692L36607gb Homo sapiens (clone 22) pregnancyig13.9425549U64863Hs 158297programmed cell death 1ig13.8452755AW138937Hs 213436ESTscystatin13.8427637AK000816Hs 179986flotillin 1Band_713.7424591R55704Hs. 150968hypocretin (orexin) receptor 17tm_113.7405024predicted exonTGF-beta, TGFb_propeptide13.7405285predicted exonA2M, A2M_N13.7412116AW402166Hs. 784Epstein-Barr virus induced gene 2 (lym7tm_113.7420256U84722Hs 76206cadherin 5, type 2, VE-cadherin (vascucadherin, Cadherin_C_term13.6420511AF052692Hs 98485gap junction protein, beta 4 (connexin 3connexin13.5448638R17122Hs 21639nuclear protein, marker for differentiatig13.4431117AF003522Hs 250500delta (Drosophila)-like 1EGF, DSL13.4439285AL133916Hs 298998ESTsig, pkinase, LRRNT, LRRCT13.4424283AA338246Hs 301678ESTsE1-E2_ATPase, Hydrolase13.3436233AI742878Hs 124116ESTsig13.3443859NM_013409Hs. 9914follistatinkazal13.2410016AA297977Hs 57907small inducible cytokine subfamily A (IL813.2414020NM_002984Hs 75703small inducible cytokine A4 (homologoIL813.2400242predicted exonEphrin13.0429057AF156557Hs 194816stomatin-like protein 1Band_7, SCP212.9438294AI693753Hs. 143004ESTsE1-E2_ATPase; Hydrolase12.9458493AV649408Hs 282418ESTsRYDR_ITPR12.8444181AB033063Hs 10491KIAA1237 proteinfn3, ig, PH, RhoGEF12.8422357AF016272Hs 115418cadherin 16, KSP-cadherincadherin12.7409632W74001Hs. 55279serine (or cysteine) proteinase inhibiterserpin12.7407000U12139gb Human alpha1(XI) collagen (COL1TSPN, Collagen:COLFI12.6417064W02903Hs 15440ESTslectin_c12.6439389AA318940Hs 56004ESTshemopexin, Peptidase_M1012.6407786AA687538Hs 38972tetraspan 1transmembrane412.5410498AA355749gb EST64459 Jurkat T-cells VI Homoaa_permeases12.5422487AJ010901Hs. 198267mucin 4, tracheobronchialvwd12.5422330D30783Hs 115263epiregulinEGF12.5402425predicted exonion_trans12.4414875H42679Hs 77522major histocompatibility complex, clasig12.2424239AA67439Hs 143526dopamine receptor D57tm_112.2442622NM_000435Hs 8546Notch (Drosophila) homolog 3EGF, ank, notch12.2405368predicted exon7tm_112.2402406predicted exonGal-bind_lectin12.1426514BE616633Hs 301122bone morphogenetic protein 7 (osteogeTGF-beta, TGFb_propeptide12.1406811U82979Hs 67846leukocyte immunoglobulin-like receptoig12.0416441BE407197gb: 601301552F1 NIH_MGC_21 HomoSDF12.0433221AB040917Hs 97860KIAA1484 proteinfn3, ig, LRRCT11.9442915AA852875Hs 8850a disintegrin and metalloproteinase domdisintegrin, Reprolysin; 11.9423613AF036035Hs 129910hyaluronoglucosaminidase 3ig, Sema, Acetyltransf11.9411213AA676939Hs 69285neuropilin 1CUB, MAM, F5_F8_type_C11.9425483AF231022Hs 301273Homo sapiens protocadherin Fat 2 (FAEGF; cadherin, laminin_G11.8421258AA286731gb: zs53d08 r1 NCI_CGAP_GCB1 Hom7tm_311.8423795AW849759gb: IL3-CT0216-240200-077-C04 CT0arf, ras11.7422424AI186431Hs 116577prostate differentiation factorTGF-beta11.7443296AI765286gb: wi73b05 x1 NCI_CGAP_Kid12 Hoig11.7448999AF179274Hs. 22791transmembrane protein with EGF-likekazal11.7414878AA341040Hs 77541ADP-ribosylation factor 5arf, ras11.5429344R94038Hs 199538inhibin, beta CTGF-beta11.5402114predicted exonlaminin_EGF, laminin_G11.5419216AU076718Hs 164021small inducible cytokine subfamily B (IL811.5430263D12614Hs 36lyphotoxin alpha (TNF superfamily, mTNF11.4400464predicted exonPeptidase_S911.4456841AA875863Hs 152345poliovirus receptor-related 1 (herpesvirig11.4409420Z15008Hs 54451laminin, gamma 2 (nicein (100 kD), kalluminin_EGF, laminin_B11.4418043AW377752Hs 83341H sapiens mRNA for tyrosine kinase refn3; ig, pkinase11.3426523S68616Hs 170222solute carrier family 9 (sodium/hydrogNa_H_Exchanger11.3446051BE048061Hs 153315ESTsReprolysin; disintegrin11.3439710AF086543gb Homo sapiens full length insert cDNXlink11.3416602NM_006159Hs 79389nel (chicken)-like 2vwc, TSPN11.3418299AA279530Hs 83968integrin, beta 2 (antigen CD18 (p95), lyintegrin_B11.3425721AC002115Hs. 159309uroplakin 1Atransmembrane4; COX6B; Ets11.2409757NM_001898Hs 123114cystatin SNcystatin11.2430630AW269920Hs 2621cystatin A (stefin A)7tm_3, ANF_receptor11.2429630M85289Hs 211573heparan sulfate proteoglycan 2 (perlecalaminin_EGF, ig, Idl_recept_a11.1427289AI097346Hs. 174203solute carrier family 1 (glutamate/neutrSDF11.1401248AB028989Hs 88500mitogen-activated protein kinase 8 intevwa, vwd, TIL11.1412627BE391959Hs 74276chloride intracellular channel 1G-patch, ig, MutS_C11.1420104U09825Hs 1287zinc finger protein 173zf-C3HC4, SPRY, zf-B_box11.1405275AB028989Hs 88500mitogen-activated protein kinase 8 intevwa, vwd; TIL11.1425864U56420Hs. 159903olfactory receptor, family 5, subfamily7tm_111.1446745AW118189Hs. 156400ESTsvwa11.1441834AL138034Hs 7979KIAA0736 gene productsugar_tr11.0450986BE241845Hs 25744Novel human gene mapping to chomosPH, RhoGAP, Gal-bind_lectin11.0416118N52773Hs 167721ESTshemopexin; Peptidase_M1011.0443071AL080021Hs. 8986complement component 1, q subcompoC1q, Collagen10.9431247AL021578Hs 278489matrilin 4EGF, vwa10.9431449M55994Hs 256278tumor necrosis factor receptor superfamTNFR_c610.9457044373899Hs. 2131arginine vasopressin receptor 1A7tm_110.9416319AI815601Hs 79197CD83 antigen (activated B lymphocyteig10.8402172predicted exonig10.7424218AF031824Hs 143212cystatin F (leukocystatin)cystatin10.6409208Y00093Hs 51077integrin, alpha X (antigen CD11C (p15vwa10.6426330M77235Hs. 169331sodium channel, voltage-gated, type V,ion_trans; IQ10.6439758AA845235Hs. 124470ESTstransmembrane410.6412429AV650262Hs 75765GRO2 oncogeneIL810.6449987AW079749Hs 184719ESTs, Weakly similar to AF116721 11ABC_tran, ABC_membrane10.6432408N39127Hs 76391myxovirus (influenza) resistance 1, homion_trans, K_tetra10.6406672M26041Hs 198253major histocompatibility complex, clasig, MHC_II_alpha10.5419749X73608Hs 93029sparc/osteonectin, cwcv and kazal-likekazal, thyroglobulin_110.5419086NM_000216Hs. 89591Kallmann syndrome 1 sequencefn3; wap10.5425009X58288Hs 154151protein tyrosine phosphatase, receptor tfn3, ig; Y_phosphatase, MAM10.5423869BE409301Hs. 134012C1q-related factorGTP_EFTU, EFG_C10.4430209AF177941Hs. 235368Pro-(alpha)3(V) collagenCollagen; COLFI; TSPN10.4400834predicted exonIRK10.4442941AU076728Hs 8867cysteine-rich, angiogenic inducer, 61Cys_knot, tsp_1, vwc, IGFBP10.4403691predicted exontsp_1, Reprolysin10.4430776AJ011021Hs 247905potassium voltage-gated channel, subfaion_trans10.3432342AL036128Hs. 274404plasminogen activator, tissueEGF, fn1; kringle; trypsin10.3413731BE243845Hs 75511connective tissue growth factorCys_knot, top_1, vwc10.3423309BE006775Hs 126782sushi-repeat proteinsushi, HYR10.3431728NM_007351Hs 268107multimennEGF, C1q10.3450245AA007536Hs 271767ESTs, Moderately similar to ALU1_HUig10.2446983AA157484Hs. 97199complement component C1q receptorEGF; Xlink10.2414320U13616Hs. 75893ankyrin 3, node of Ranvier (ankynn G)death, ank; ZU510.1400253predicted exon7tm_110.0406694M94891Hs 225932pregnancy specific beta-1-glycoproteinig10.0418793AW382987Hs. 88474prostaglandin-endoperoxide synthase 1EGF10.0410664NM_006033Hs 65370lipase, endothelialRibosomal_L2210.0427274NM_005211Hs 174142colony stimulating factor 1 receptor, fopkinase, ig10.0Pkey: Pnmekey Ex. Accn: Exemplar Accession UG ID UniGene ID Title: Unigene Title PFAM domains ratio: tumor vs normal ovary


[0359]

11







TABLE 4B








Pkey:
CAT Number
Accession







410498
120611_1
AA355749 AA085520 AW966333 AA340319




BE170938


416441
159480_1
BE407197 AA182474 AA180369 BE275628




BE276131


421258
200725_1
AA286731 AA287621 AW188228 AW137774


423795
232093_1
AW849759 AW849758 T89549 AA331069


439710
47550_1
AF086543 W96291 W96225


443296
56539_2
AI765286 AW297086 BE568658






Pkey: Unique Eos probeset identifier number




CAT number: Gene cluster number




Accession Genbank accession numbers








[0360]

12








TABLE 4C








Pkey
Ref
Strand
Nt_position







400464
9929670
Plus
22074-22214


400834
8705192
Plus
121963-122288


402114
8318586
Plus
71578-71715


402172
8575911
Minus
143378-143671


402406
3970929
Plus
10872-11123, 12932-13048


402425
9796347
Minus
50224-50395


403077
8954241
Plus
146923-147222, 147326-147628


403089
8954241
Plus
171964-172239


403691
7387384
Minus
88280-88463


405024
7107727
Plus
88500-88697


405285
6139075
Minus
55744-55903, 57080-57170,





61478-61560


405368
2104517
Plus
46055-47188






Pkey: Unique number corresponding to an Eos probeset




Ref: Sequence source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers “Dunham I. et. al” refers to the publication entitled “The DNA sequence of human chromosome 22” Dunham, et. al (1999) Nature 402: 489-495




Strand: Indicates DNA strand from which exons were predicted




Nt_position: Indicates nucleotide positions of predicted exons








[0361] TABLE 5A lists about 685 genes down-regulated in ovarian cancer compared to normal ovaries These were selected as for Table 3A, except that the numerator and denominator were switched, and the ratio was greater than or equal to 3.0 (i e 3 fold down-regulated in tumor vs normal ovary)
13TABLE 5A685 DOWN-REGULATED GENES, OVARIAN CANCER VERSUS NORMAL OVARYPkeyEx. AccnUG IDTitleratio421013M62397Hs. 1345mutated in colorectal cancers14.8439360AA448488Hs. 55346ESTs, Weakly similar to Z141_HUMAN ZINC FINGE12.8407644D16815Hs. 37288nuclear receptor subfamily 1, group D, member 212.6424851AA676441Hs. 119059ESTs11.6455056AW853057gb: RC1-CT0249-170200-025-h04 CT0249 Homo sapie11.5420727H75701Hs. 99886complement component 4-binding protein, beta11.3451617C01056Hs. 168000ESTs10.0401308predicted exon9.9440987AA911705Hs. 130229ESTs9.7409725T40760Hs. 90459EST9.7415752BE314524Hs. 78776putative transmembrane protein9.7437690AA804362Hs. 180544ESTs9.6437787AI908263Hs. 291625ESTs9.5459054AW798466Hs. 823962′,5′-oligoadenylate syathetase 19.2435330R16769Hs. 185689ESTs9.2436642AA724430Hs. 127960ESTs9.1453752AL120800gb: DKFZp762E152_r1 762 (synonym: hmel2) Homo sa9.1451683AI808964Hs. 207673ESTs9.1401464AF039241Hs. 9028histone deacetylase 59.0436812AW298067gb: UI-H-BW0-ajp-g-09-0-UI.s1 NCI_CGAP_Sub6 Hom8.7410758BE535988gb: 601062418F1 NIH_MGC_10 Homo sapiens cDNA8.7412637AA115097Hs. 261313ESTs8.4419166AA234638Hs. 293584ESTs8.3423739AA398155Hs. 97600ESTs8.1413813M96956Hs. 75561teratocarcinoma-derived growth factor 18.1416211R14625gb: yg45c03.r1 Soares infant brain 1 NIB Homo sapiens8.0443131AI033833Hs. 132689ESTs7.9415866T10115Hs. 92423KIAA1566 protein7.9410130AI912097Hs. 163208ESTs7.9439426AI131502Hs. 143135ESTs, Weakly similar to FAFY_HUMAN PROBABLE7.8408141U69205Hs. 45152ESTs, Moderately similar to neurogenic basic-helix-loop7.7419015T79262Hs. 14463ESTs7.6441573BE563966Hs. 6529ESTs7.5419386AA236867Hs. 143868ESTs7.5430562D78260Hs. 285097ESTs7.5434738AA836265gb: od17e02.s1 NCI_CGAP_CGB1 Homo sapiens cDNA7.4403283predicted exon7.4415861Z43123Hs. 144513ESTs7.4412732AW993300gb: RC2-BN0033-180200-015-g06 BN0033 Homo sapie7.4441247AW118681Hs. 128051ESTs7.4482865N57659Hs. 114541ESTs, Weakly similar to neuronal thread protein AD7c-7.3409699BE154650gb: PM3-HT0344-071299-003-c08 HT0344 Homo sapie7.3420352BE258835gb: 601117374F1 NIH_MGC_16 Homo sapiens cDNA7.3421418AA806639gb: ob88g05.s1 NCI_CGAP_GCB1 Homo sapiens cDN7.2413597AW302885Hs. 117183ESTs7.2454102AW752363gb: RC0-CT0201-270999-011-f03 CT0201 Homa sapien7.1445487AI806287Hs. 201217ESTs7.1457604AI004397Hs. 130558ESTs, Weakly similar to similar to O-sialoglycoprotein7.1400942predicted exon6.9407596R86913gb: yq30f05.r1 Soares fetal liver spleen 1NFLS Homo sa6.9422046AI638562gb: ts50a10.x1 NCI_CGAP_Ut1 Homo sapiens cDNA c6.9441284AA927676Hs. 196542ESTs6.9446224AW450551Hs. 13308ESTs6.9424943AU077260Hs. 153924death-associated protein kinase 16.9453967AW009077Hs. 232947ESTs6.9448683AA167642Hs. 14632ESTs6.8431877AA521204Hs. 105507ESTs6.8411337AW837349gb: QV2-LT0038-270300-108-d12 LT0038 Homo sapie6.8410596AA374186gb: EST86290 HSC172 cells I Homo sapiens cDNA 5′ e6.8417762AA205976gb: zq48a10.r1 Stratagene hNT neuron (937233) Homo6.7406364predicted exon6.7452238F01811Hs. 187931ESTs, Moderately similar to S22703 voltage-gated pota6.7415288R15794Hs. 141027ESTs, Weskly similar to ALU1_HUMAN ALU SUBFA6.7407437AF220264gb: Homo sapiens MOST-1 mRNA, complete cds6.7439126AF085984gb: Homo sapiens full length insert cDNA close YT99F6.6452453AI902519gb: QV-BT009-101198-051 BT009 Homo sapiens cDNA6.6431800AW452768Hs. 162045ESTs6.5426380AI291267Hs. 149990ESTs, Weakly similar to unnamed protein product [H sa6.5449529AI990559Hs. 232033ESTs6.4437755AW204256Hs. 291887ESTs6.4448307AI480289Hs. 211026ESTs6.4439586AA922936Hs. 110039ESTs6.4420051N35696Hs. 44745ESTs6.4425806AI522299Hs. 173369ESTs6.4433923AI823453Hs. 146625ESTs6.4408159H63977Hs. 118526ESTs6.3434844AF157116Hs. 301355hypothetical protein LOC567576.3430197AA468888Hs. 187697ESTs, Weakly similar to ALU5_HUMAN ALU SUBFA6.3440332AI218517Hs. 188051ESTs6.3450061AI797034Hs. 201115ESTs6.3454994AW850176gb: IL3-CT0219-271099-022-H04 CT0219 Homo sapien6.3402105predicted exon6.3409090W56067Hs. 103105ESTs6.2405752predicted exon6.2408074R20723Hs. 124764ESTs6.2459200Y09306Hs. 30148homeodomain-interacting protein kinase 36.1416310T81421Hs. 221396ESTs6.1421976AL138443Hs. 23450mRNA for FLJ00023 protein6.1429755NM_001364Hs. 215839discs, large (Drosophila) homolog 2 (chapsyn-110)6.0448732BE614063gb: 601503993F1 NIH_MGC_71 Homo sapiens cDNA6.0453909AW004045Hs. 203365ESTs6.0431178AA493884Hs. 218008Homo sapiens cDNA FLJ21440 fis, clone COL043896.0449671AW959755Hs. 288896Homo sapiens cDNA FLJ12977 fis, clone NT2RP200626.0421349W01715Hs. 102958ESTs, Weakly similar to Lpg6p [S. cerevisiae]6.0453282AK000043Hs. 32922hypothetical protein FLJ200365.9420618AA278781Hs. 280698ESTs5.9412480BE142364gb: CM0-HT0143-270999-062-d12 HT0143 Homo sapi5.9449858AW205979Hs. 196065ESTs5.9429884AL049925Hs. 225984DKFZP547G0910 protein5.9416453H56968Hs. 114593ESTs5.9459497AA825742Hs. 87517ESTs5.9433773AA759293Hs. 112692ESTs5.9458942AA009647Hs. 8850a disintegrin and metalloproteinase domain 12 (meltrin a5.9436054AI076262Hs. 119813ESTs5.9410495N95428gb: zb80d09.s1 Soares_senescent_fibroblasts_NbHSF H5.8403277predicted exon5.8444302AI140115Hs. 225130ESTs5.8439834AI754576Hs. 124523ESTs5.8404020predicted exon5.8454338AW381251Hs. 1050pleckatrin homology, Sec7 and coiled/coil domains 1(cy5.7430922AW373747Hs. 183337ESTs5.7420289N55394Hs. 963988-oxoguanine DNA glycosylase5.7428498AA429575Hs. 243032ESTs5.7445597H65649gb: yr72d10.r1 Soares fetal liver spleen 1NFLS Homo sa5.7411543AW851248gb: IL3-CT0220-160200-066-F01 CT0220 Homo sapien5.7408354AI382803Hs. 159235ESTs5.7444431AW513324Hs. 42280ESTs5.7406605predicted exon5.7405541AF039241Hs. 9028histone deacetylase 55.6458090AI282149Hs. 56213ESTs, Highly similar to FXD3_HUMAN FORKHEAD5.6454529Z45439Hs. 270425ESTs5.6445832AI261545gb: qz30a07.x1 NCI_CGAP_Kid11 Homo sapiens cDNA5.6441223AI475067Hs. 132499ESTs5.6432552AI537170Hs. 173725ESTs, Weakly similar to ALU8_HUMAN ALU SUBFA5.6443650AI698330Hs. 151444ESTs5.6403714predicted exon5.6444165AL137443Hs. 10441hypothetical protein FLJ112365.6458914BE327696Hs. 280922ESTs5.6420620AA278807Hs. 173343ESTs5.5458228AA934995Hs. 184846ESTs, Weakly similar to R28830 1 [H. sapiens]5.5448067R68568Hs. 183373src homology 3 domain-containing protein HIP-555.5427000AI187420Hs. 145221ESTs5.5452351AA025647gb: ze85d01.r1 Soares_fetal_heart_NbHH19W Homo sa5.5459359N99545gb: za40a05.r1 Soares fetal liver spleen 1 NFLS Homo sa5.5408385AF055634Hs. 44553unc5 (C. elegans homolog) c5.5450938AW753734Hs. 277215ESTs5.5431888H99557Hs. 2864early endosome antigen 1, 162 kD5.4459418W96550Hs. 26418ESTs5.4416718R83017Hs. 204828ESTs5.4413236H16442Hs. 127376KIAA0266 gene product5.4439063AF085922Hs. 113968ESTs5.4446361AI291234Hs. 282241ESTs5.4458253AW296952Hs. 196802ESTs5.4433682AA642418Hs. 17381ESTs5.4455790BE090690gb: RC1-BT0720-280300-011-g02 BT0720 Homo sapie5.4445755AW294870Hs. 223672ESTs5.3436513AJ278110Hs. 125507DEAD-box protein5.3416671N94087Hs. 26073ESTs, Moderately similar to HG14_HUMAN NONHIS5.3440231AW015420Hs. 163323ESTs5.3429866AA460104Hs. 99540ESTs5.3437779AA345232Hs. 21227ESTs5.3424029AB014594Hs. 137579KIAA0694 gene product5.3425614AI334963Hs. 156256ESTs5.3430653AW902062Hs. 30280ESTs5.2408855T83061Hs. 279604desmin5.2410454AW749041gb: RC3-BT0319-100100-012-c05 BT0319 Homo sapie5.2438116AI904105Hs. 122016ESTs5.2409138W73159Hs. 58290ESTs5.2423047NM_005323Hs. 123064Hi histone family, member T (testis-specific)5.2440212AW300959Hs. 126216ESTs, Weakly similar to good similarity to E coli hypo5.2404108predicted exon5.2456253T12198gb: A568F Heart Homo sapiens cDNA clone A588, mRN5.2409365AA702376Hs. 226440Homo sapiens close 24881 mRNA sequence5.1444013T08531Hs. 44404hypothetical protein PRO14885.1454071AI041793Hs. 42502ESTs5.1419761M17373Hs. 93177interferon, beta 1, fibroblast5.1451250AA491275Hs. 236940Homo sapiens cDNA FLJ12542 fis, clone NT2RM40005.1405290predicted exon5.1454487AW796342gb: PM2-UM0027-230200-002-h02 UM0027 Homo sap5.1444131AI806600Hs. 207119EST, Weakly similar to intrinsic factor-B12 receptor pr5.1441679BE502267Hs. 65996ESTs5.1450077AA523752Hs. 120855ESTs5.1421209AJ010230Hs. 102576ret finger protein-like 1 antisense5.1445140AI650599Hs. 197913ESTs5.1421126M74587Hs. 102122insulin-like growth factor binding protein 15.1447037AI357568Hs. 157612ESTs5.1407168R45175gb: yg40f01.s1 Soares infant brain 1NIB Homo sapiens5.0436196AK001084gb: Homo sapiens cDNA FLJ110222 fin, clone HEMBB15.0442772AW503680Hs. 300513ESTs, Weakly similar to T15B7 2 [C. elegans]5.0444138AI701572Hs. 151153ESTs5.0458589AV654623Hs. 288141Homo sapiens cDNA FLJ13016 fis, clone NT2RP300065.0451640AA195601Hs. 26771Human DNA sequence from clone 747H23 on chromos5.0441318AI078234Hs. 176130ESTs5.0407490S79281gb: pancreatic ribonuclease [human, mRNA Recombinan4.9438224AA933999gb: on91f04.s1 Soares_NFL_T_GBC_S1 Homo sapiens4.9451638AW798466Hs. 823962′,5′-oligoadenylate synthetase 14.9457356AA489621Hs. 191670ESTs4.9430679R44428Hs. 22801ESTs4.9445747AI820863Hs. 145328ESTs, Weakly similar to ALU1_HUMAN ALU SUBFA4.9409036T88693Hs. 226410ESTs4.9433382T64293Hs. 291453ESTs4.9401287predicted exon4.9424188AW954552Hs. 142634zinc finger protein4.9404868predicted exon4.9410152AW593104Hs. 23681ESTs4.9444997AI204451Hs. 146196ESTs4.9431075BE267477gb: 601189542F2 NIH_MGC_7 Homo sapiens cDNA cl4.8429033NM_007374Hs. 194756sine oculis homeobox (Drosophila) homolog 64.8414337BE386606gb: 601273980F1 NIH_MGC_20 Homo sapiens cDNA4.8410336BE391510Hs. 18498Homo sapiens cDNA FLJ12277 fis, clone MAMMA104.8445283AW515763Hs. 246872ESTs4.8434792AA649253Hs. 132458ESTs4.8433403AF040247gb: Homo sapiens erythroid differentiation-related factor4.8454940AW846202gb: QV0-CT0179-011299-061-f10 CT0179 Homo sapie4.8455534AW991925gb: PM3-BN0011-130100-002-b07 BN0011 Homo sapi4.8416437N48990Hs. 37204ESTs4.8433767AA609245gb: af13a11.s1 Soares_testis_NHT Homo sapiens cDNA4.8434977AI734233Hs. 226142ESTs, Weakly similar to ALU7_HUMAN ALU SUBFA4.8416192NM_005036Hs. 998peroxisome proliferative activated receptor, alpha4.8459218AA812633Hs. 10845ESTs4.8402109predicted exon4.8444490AI151080Hs. 146830ESTs4.8432632AW973801Hs. 134656ESTs4.8438683AA813982Hs. 291842ESTs4.8404044predicted exon4.8449862AI672277Hs. 199475ESTs4.8419002T78625Hs. 268594ESTs4.7425582AL157686Hs. 293737ESTs4.7416086H18252Hs. 227263ESTs4.7441133AA918191Hs. 194457ESTs4.7446323AI288274Hs. 149868ESTs4.7440347AI125590Hs. 142864ESTs4.7439481AF086294Hs. 125844ESTs4.6456388W28557gb: 48d8 Human retina cDNA randomly primed sublibra4.6441864R34177Hs. 181315ESTs, Moderately similar to ALU4_HUMAN ALU SU4.6445910R93483Hs. 260273ESTs4.6403531predicted exon4.6429773AI332482Hs. 218791proteoglycan 4, (megakaryocyte stimulating factor, artic4.6422563BE299342Hs. 19348Homo sapiens cDNA FLJ13119 fis, clone NT2RP300264.6422890Z43784Hs. 78713solute carrier family 25 (mitochondrial carrier; phospha4.6453663AL048807Hs. 180714cytochrome c oxidase subunit VIa polypeptide 14.6447839N72050Hs. 164144ESTs4.5415612F12893Hs. 13301ESTs4.5433371T25451gb: PTHI188 HTCDL1 Homo sapiens cDNA 5′/3′ simila4.5410667AW936099gb: QV0-DT0020-210100-095-d04 DT0020 Homo sapie4.5410890AW809575gb: MR4-ST0121-060200-002-a12 ST0121 Homo sapie4.5404451predicted exon4.5441705AI087052Hs. 55993ESTs4.5439597W79579Hs. 58552ESTs4.5407825NM_006152Hs. 40202lymphoid-restricted membrane protein4.5423073BE252922Hs. 123119MAD (mothers against decapentaplegic, Drosophila) ho4.5456278BE300369Hs. 42643ESTs, Weakly similar to KIAA1016 protein [H. sapiens4.5424719H90452gb: yv01c03.r1 Soares fetal liver spleen 1NFLS Homo sa4.5439542AW297571Hs. 17646ESTs4.5444433AV649844Hs. 282436ESTs4.5438831BE263273Hs. 301128ESTs4.5410065AW812744gb: RC3-ST0186-181099-012-c09 ST0186 Homo sapien4.5453895AA039843Hs. 61948ESTs4.5458250AI807339Hs. 152174ESTs, Weakly similar to Z140_HUMAN ZINC FINGE4.5423403AA325483gb: EST28475 Cerebellem II Homo sapiens cDNA 5′ en4.5454679AW813110gb: CM4-ST0189-051099-021-f05 ST0189 Homo sapien4.5445368AI221631Hs. 166788ESTs4.5401004predicted exon4.5425837AF007567Hs. 159609insulin receptor substrate 44.5420497AW206285Hs. 253548ESTs4.5449438AA927317Hs. 176719ESTs4.5429409AI694817Hs. 155980ESTs4.5447959AI452784Hs. 270270ESTs4.4407340AA810168Hs. 232119ESTs4.4424326NM_014479Hs. 145296disintegrin protease4.4443479AF027219Hs. 9443zinc finger protein 2024.4443246T75157Hs. 285516ESTs, Weakly similar to hypothetical protein [H. sapien4.4414475BE302955Hs. 119598ribosomal protein L34.4432075AW972934gb: EST385030 MAGE resequences, MAGM Homo sap4.4417906R24769Hs. 23725ESTs4.4406518W28077Hs. 79389nel (chicken)-like 24.4441460AI962478Hs. 226804ESTs, Moderately similar to ALUC_HUMAN !!!! ALU4.4450549T49427Hs. 181244major histocompatibility complex, class I, A4.4426528AA380828gb: EST93827 Activated T-cells VII Homo sapiens cDN4.4430535AW968485gb: EST380561 MAGE resequences, MAGJ Homo sapi4.4408479BE047329Hs. 144483ESTs4.3448636AI557139Hs. 129179Homo sapiens cDNA FLJ13581 fis, clone PLACE100904.3411280N50617gb: yy89h02.r1 Soares_multiple_sclerosis_2NbHMSP H4.3440790AW593050Hs. 128580ESTs4.3458301AF003834gb: AF003834 Clontech HI1149x Homo sapiens cDNA4.3442277AW448914Hs. 202391ESTs4.3449463AI657038Hs. 196109ESTs4.3433426H69125Hs. 133525ESTs4.3410782AW504860Hs. 288836Homo sapiens cDNA FLJ12673 fis, clone NT2RM40024.3423040AA320749Hs. 209464KIAA1604 protein4.3432430AW079984Hs. 262480ESTs4.3432072N62937Hs. 269109ESTs4.3452213AL110237Hs. 28425Homo sapiens mRNA, cDNA DKFZp566D224 (from c4.3403635predicted exon4.3441919AI553802Hs. 128121ESTs4.3416717H79559Hs. 297726ESTs4.3430995NM_005092Hs. 248197tumor necrosis factor (ligand) superfamily, member 184.2429269AA449013Hs. 99203ESTs4.2415840R15955Hs. 21758ESTs4.2451300AA017066Hs. 237686EST4.2445366AI221511Hs. 298662ESTs4.2424194BE245833Hs. 169854hypothetical protein SP1924.2459105NM_014517Hs. 28423upstream binding protein 1 (LBP-1a)4.2455387BE069037gb: QV3-BT0379-161299-040-e12 BT0379 Homo sapie4.2410507AA355288Hs. 271408ESTs4.2453823AL137967gb: DKFZp761D2315_r1 761 (synonym hamy2) Homo4.2450966AA017245Hs. 32794ESTs4.2432694AW991585Hs. 276755ESTs, Weakly similar to F53B1.2 [C. elegans]4.2455108AW856866gb: RC0-CT0299-291199-031-G02 CT0299 Homo sapie4.2443609AV650231Hs. 282941ESTs4.2427469AA403084Hs. 269347ESTs4.2417178N51636gb: yy87b01.s1 Soares_multiple_sclerosis_2NbHMSP H4.2439751AA196090Hs. 50794Homo sapiens mRNA full length insert cDNA clone EU4.2431982AW419296Hs. 105754ESTs4.1442641AI890955Hs. 262983ESTs4.1422128AW881145gb: QV0-OT0033-010400-182-a07 OT0033 Homo sapie4.1449156AF103907Hs. 171353prostate cancer antigen 34.1419668AI033098Hs. 132777ESTs4.1418236AW994005Hs. 172572hypothetical protein FLJ200934.1432663AI984317Hs. 122589ESTs4.1448313BE622486Hs. 121688Homo sapiens cDNA FLJ13463 fis, clone PLACE100344.1411279AW884776gb: QV4-OT0067-010300-121-d01 OT0067 Homo sapie4.1440652AI216751Hs. 143977ESTs4.1416608R11499Hs. 189716ESTs4.1420405AA743396Hs. 189023ESTs4.1405717predicted exon4.1435267N23797Hs. 110114ESTs4.1412228AW503785Hs. 73792complement component (3d/Epstein Barr virus) recepto4.1403560AI929721Hs. 5120dynein, cytoplasmic, light polypeptide4.1449162AI632740Hs. 10476ESTs4.1459157AI904385gb: CM-BT054-080399-054 BT054 Homo sapiens cDN4.1432474AA584042gb: nn65e09.s1 NCI_CGAP_Lar1 Homo sapiens cDNA4.1455388AW936234gb: QV0-DT002-090200-106-g05 DT0020 Homo sapie4.0426456AA580748Hs. 130658ESTs4.0438597AA811662Hs. 171497ESTs4.0437934AW880871Hs. 77496small nuclear ribonucleoprotein polypeptide G4.0459385BE380047gb: 601159362F2 NIH_MGC_53 Homo sapiens cDNA4.0436404AW968556Hs. 137240Homo sapiens mRNA for partial 3′UTR, sequence 24.0457740AW500458gb: UI-HF-BN0-akb-d-07-0-UI.r1 NIH_MGC_50 Homo4.0437385AA757055Hs. 164060ESTs4.0444530AV650124Hs. 282435ESTs4.0408066AA046914gb: zf47h10.r1 Soares retina N2b4HR Homo sapiens cD4.0411256AW834039gb: QV0-TT0010-091199-053-e09 TT001 Homo sapie4.0433582BE548749Hs. 148016ESTs4.0438637BE500941Hs. 126730ESTs, Weakly similar to KIAA1214 protein [H. sapiens4.0414571BE410746Hs. 22868protein tyrosine phosphatase, non-receptor type 114.0446190AI279299Hs. 256564ESTs4.0443542AI927065Hs. 146040ESTs4.0430444AW296421Hs. 121035ESTs4.0454573BE146471gb: QV0-HT0216-011199-043-c09 HT0216 Homo sapie4.0409846AW501748gb: UI-HF-BR0p-ajm-b-12-0-UI.r1 NIH_MGC_52 Hom4.0456141AI751357Hs. 288741Homo sapiens cDNA: FLJ22256 fis, clone HRC028604.0456140AA169515Hs. 6006ESTs4.0441685AI459261Hs. 144481ESTs4.0416677T83470gb: yd46g06.r1 Soares fetal liver spleen 1NFLS Homo s4.0401740predicted exon4.0420122AA255714Hs. 284153Fanconi anemia, complementation group A4.0442594AW272467Hs. 254655Untitled3.9426294AA374185gb: EST86289 HSC172 cells I Homo sapiens cDNA 5′ e3.9411922AW876260gb: PM4-PT0019-131299-006-E04 PT0019 Homo sapie3.9452320AA042873Hs. 160412ESTs3.9431644AW972822Hs. 169248cytochrome c3.9409892AW956113gb: EST368183 MAGE resequences, MAGD Homo sap3.9418132T92670Hs. 117421ESTs3.9414372AA143654gb: zo65a02.r1 Stratagene pancreas (937208) Homo sap3.9400196predicted exon3.9416900M59964Hs. 1048KIT ligand3.9445444AA380876Hs. 270pleckstrin homology, Sec7 and coiled/coil domains, bind3.9435957N39015Hs. 190368ESTs3.9442299AW467791Hs. 155561ESTs3.9419499AA808136Hs. 177698ESTs3.9438403AA806607Hs. 292206ESTs3.9449386AA001308Hs. 193213ESTs3.9443283BE568610gb: 601342622F1 NIH_MGC_53 Homo sapiens cDNA3.9406481predicted exon3.9453530AW021633gb: df26c02.y1 Morton Fetal Cochlea Homo sapiens cDN3.9415558AA885143Hs. 125719ESTs3.9416874H98752Hs. 42568ESTs3.9454885AW836922gb: QV1-LT0036-150200-074-h06 LT0036 Homo sapie3.9419896Z99362gb: HSZ99362 DKFZphamy1 Homo sapiens cDNA clon3.9440962AI989961Hs. 233477ESTs, Moderately similar to A Chain A, Secypa Compl3.9419401AW804663gb: QV4-UM0094-160300-135-d06 UM0094 Homo sap3.9406562predicted exon3.8405690BE409855Hs. 808heterogeneous nuclear ribonucleoprotein F3.8435282AA677428Hs. 189731ESTs3.8402451predicted exon3.8451577N69101Hs. 32703ESTs3.8457141AA521410Hs. 41371ESTs3.8407817H92553Hs. 40400ESTs3.8412613AA653507Hs. 285711Homo sapiens cDNA FLJ13089 fis, clone NT2RP300213.8418355L42563Hs. 1165ATPase, H+/K+ transporting, nongastric, alpha polypep3.8446357AW161533Hs. 300866ESTs3.8407448AJ001865gb: Homo sapiens mRNA, partial cDNA sequence for h3.8456383AI148037gb: qg61e01.r1 Soares_testis_NHT Homo sapiens cDNA3.8444651W58469Hs. 103120ESTs3.8455067AW854538gb: RC3-CT0255-200100-024-b02 CT0255 Homo sapie3.8442657BE502631Hs. 130645ESTs3.8429142AA835639Hs. 104972ESTs3.8429274AI379772Hs. 99206ESTs3.8437774AW978199Hs. 291648ESTs3.8427737AA435988Hs. 178066ESTs, Weakly similar to AF068289 5 HDCME31 P [H. s3.8405671predicted exon3.8413627BE182082Hs. 246973ESTs3.8438858R37529Hs. 269924ESTs3.8416612H70565gb: yr97c04.r1 Soares fetal liver spleen 1NFLS Homo sa3.8423045AW967472Hs. 301511ESTs, Highly similar to KPT2_HUMAN SERINE/THR3.8453361AA035197Hs. 107375ESTs3.7437243AA747549Hs. 259122ESTs3.7437987AW450202Hs. 122963ESTs3.7408781BE148621Hs. 254602ESTs3.7455895BE154837gb: PM1-HT0345-121199-001-c08 HT0345 Homo sapie3.7431492AW612343gb: hg97c10.x1 NCI_CGAP_Kid11 Homo sapiens cDN3.7413247AW963969gb: EST376042 MAGE resequences, MAGH Homo sap3.7422866NM_002410Hs. 121502mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetyl-g3.7431828AA572994gb: nm33f12.s1 NCI_CGAP_Lip2 Homo sapiens cDNA3.7438872R64197Hs. 23589ESTs3.7438673AI824717Hs. 123443ESTs3.7416624H69044gb: yr77h05.s1 Soares fetal liver spleen 1NFLS Homo sa3.7401963predicted exon3.7402867predicted exon3.7408315AW179148gb: MR4-ST0067-200899-002-B07 ST0067 Homo sapie3.7418320D86981Hs. 84084amyloid beta precursor protein (cytoplasmic tail)-bindin3.7447199AI939421Hs. 160900ESTs3.7422590AA312758Hs. 193945Homo sapiens cDNA FLJ13962 fis, clone Y79AA100123.7451996AW514021Hs. 245510ESTs3.7412463AW953444Hs. 78672laminin, alpha 43.7440928AL046575Hs. 130198ESTs3.7441951W31002Hs. 128195ESTs3.7440705AA904244Hs. 153205ESTs3.7434231AF119901Hs. 250568hypothetical protein PRO28313.7411039AL135674Hs. 163348ESTs3.7413137BE066915gb: PM0-BT0340-231199-001-b07 BT0340 Homo sapie3.7417970AA309234Hs. 57760Homo sapiens cDNA: FLJ23119 fis, clone LNG079783.7439786AV652707Hs. 33756Homo sapiens mRNA full length insert cDNA clone EU3.7459595AL040421gb: DKFZp434B0714_r1 434 (synonym htes3) Homo s3.7443601AI078554Hs. 15682ESTs3.7404041predicted exon3.6406122predicted exon3.6404582predicted exon3.6455786BE090077gb: RC6-BT0710-300300-021-F02 BT0710 Homo sapie3.6411899AA370573gb: EST82238 Prostate gland I Homo sapiens cDNA 5′ e3.6426758AL036430Hs. 197772ESTs3.6421776AW301994Hs. 108183candidate tumor suppressor p33 ING1 homolog3.6430169AA468531Hs. 189047ESTs3.6407695AI808007Hs. 66450ESTs3.6454564AW807573gb: MR1-ST0088-021299-004-g01 ST0088 Homo sapie3.6425902X52509Hs. 161640tyrosine aminotransferase3.6439328W07411Hs. 118212ESTs, Moderately similar to ALU3_HUMAN_ALU SU3.6429066AA868555Hs. 178222ESTs3.6428690AI948490Hs. 98765ESTs3.6437302AA837146Hs. 180275ESTs3.6443973AI580083Hs. 176154ESTs3.6453993AW615224Hs. 252839ESTs3.6413623AA825721Hs. 246973ESTs3.6409196NM_001874Hs. 169765carboxypeptidase M3.6424916AW867440Hs. 23096ESTs3.6424769H06469Hs. 142653ret finger protein3.6400080predicted exon3.6421521AI638760Hs. 161795ESTs3.6405549predicted exon3.6446114AI275715Hs. 145926ESTs3.6441392AW451831Hs. 222119ESTs, Weakly similar to K1CQ_HUMAN KERATIN, T3.6424025AI701852Hs. 301296ESTs3.5448527AI525606gb: PT1 3_03_G05 r tumor 1 Homo sapiens cDNA 5′, mR3.5437063AA351109Hs. 5437Tax1 (human T-cell leukemia virus type I) binding prot3.5449880AI673006Hs. 231948ESTs, Weakly similar to ALUB_HUMAN !!!! ALU CL3.5449311AI657014gb: tt49a12.x1 NCI_CGAP_GC6 Homo sapiens cDNA c3.5442999AW662889Hs. 132395ESTs3.5416238W90448gb: zh78c08.s1 Soares_fetal_liver_spleen_1NFLS_S1 H3.5423209BE278528Hs. 106823H. sapiens gene from PAC 426I6, similar to syntaxin 73.5409854AW501833gb: UI-HF-BR0p-ajo-d-01-0-UI.r1 NIH_MGC_52 Hom3.5414941C14865Hs. 182159ESTs3.5456337AW751661Hs. 65919ESTs3.5415296F05086gb: HSC01A011 normalized infant brain cDNA Homo s3.5423338AB007961Hs. 127338KIAA0492 protein3.5415618F12954gb: HSC3GG091 normalized infant brain cDNA Homo s3.5405583predicted exon3.5435601AF217509Hs. 283077centrosomal P4 1-associated protein, uncharacterized bo3.5450867AA011454Hs. 245122ESTs3.5431339AA506294Hs. 257266ESTs3.5441969AI733386Hs. 129194ESTs, Weakly similar to ALU1_HUMAN_ALU SUBFA3.5431343AW970603Hs. 300941Homo sapiens cDNA FLJ11661 fis, clone HEMBA1003.5434317AI674095Hs. 116323ESTs3.5414741R51321Hs. 25780Homo sapiens cDNA FLJ12252 fis, clone MAMMA103.5439707AW297702Hs. 102915ESTs3.5443178AI631241Hs. 47312ESTs3.5400397AJ270770Hs. 154485transcription factor 7-like 2 (T-cell specific, HMG-box)3.5455887BE154173gb: PM1-HT0340-201299-004-f12 HT0340 Homo sapie3.5434362W27081Hs. 295446ESTs3.5409211AA078835gb: zm94h04.s1 Stratagene colon HT29 (937221) Homo3.5414390BE281040gb: 601156234F1 NIH_MGC_21 Homo sapiens cDNA3.5457142AI924353Hs. 290969EST3.5423006U29700Hs. 123014anti-Mullerian hormone receptor, type II3.5453363AI989776Hs. 232623ESTs3.5418913BE046745gb: hn39b06.x1 NCI_CGAP_RDF2 Homo sapiens cDN3.4440016AW118114Hs. 137057ESTs3.4405096predicted exon3.4435072AW592176Hs. 116932ESTs3.4438535L09078gb: Homo sapiens mRNA fragment3.4424001W67883Hs. 137476KIAA1051 protein3.4428361NM_015905Hs. 183858transcriptional intermediary factor 13.4410587AA370706Hs. 11252ESTs, Weakly similar to Weak similarity with the Ysy63.4454543AW806895gb: QV4-ST0023-160400-172-c06 ST0023 Homo sapien3.4419515S81944Hs. 90791gamma-aminobutyric acid (GABA) A receptor, alpha 63.4410280AA083558Hs. 261286ESTs3.4425714AW963278gb: EST375351 MAGE resequences, MAGH Homo sap3.4416895AW961600gb: EST373672 MAGE resequences, MAGG Homo sap3.4427935AW503687Hs. 119424ESTs, Weakly similar to unnamed protein product [H. sa3.4411673BE064863gb: RC1-BT0313-110300-015-f06 BT0313 Homo sapien3.4453339AW992599Hs. 252797ESTs3.4424696BE439547Hs. 151903Homo sapiens clone 24706 mRNA sequence3.4436242AK002187gb: Homo sapiens cDNA FLJ11325 fis, clone PLACE103.4442837AI022082Hs. 50492ESTs3.4452807AA028933Hs. 162434ESTs3.4418110R43523Hs. 217754Homo sapiens cDNA FLJ22202 fis, clone HRC013333.4433936AI208072Hs. 123459ESTs3.4458177AI744995Hs. 267072ESTs, Moderately similar to ALU4_HUMAN ALU SU3.4401896predicted exon3.4406237predicted exon3.4457688AL110157Hs. 3843Homo sapiens mRNA, cDNA DKFZp586F2224 (from3.4456914AW363582Hs. 75323prohibitin3.4421916R34441Hs. 101007Homo sapiens cDNA FLJ23546 fis, clone LNG083613.4419321N48146Hs. 269069ESTs3.4447876AV654978Hs. 19904cystathionase (cystathionine gamma-lyase)3.4406197predicted exon3.4443005AI027184Hs. 200918ESTs3.4450078AI681743gb: tx38g10.x1 NCI_CGAP_Lu24 Homo sapiens cDNA3.4431301AA502384Hs. 151529ESTs3.4430202T85775gb: yd60g02.r1 Soares fetal liver spleen 1NFLS Homo s3.4428559H24338Hs. 27041ESTs3.4455731BE072188gb: QV4-BT0536-211299-055-b09 BT0536 Homo sapie3.4420735AW297440Hs. 88653ESTs3.4430881NM_000809Hs. 248112gamma-aminobutyric acid (GABA) A receptor, alpha 43.3405836predicted exon3.3449178AI633748Hs. 197597ESTs3.3453265U61232Hs. 32675tubulin-specific chaperone e3.3430700AA768902Hs. 247812H2A histone family, member K, pseudogene3.3424496AI733451Hs. 129212ESTs3.3446963AI862668Hs. 176333ESTs3.3422879AI241409Hs. 188092ESTs3.3419831AW448930Hs. 5415ESTs3.3449570AA001793gb: zh86c06.r1 Soares_fetal_liver_spleen_1NFLS_S1 H3.3406255predicted exon3.3412319AW936903gb: RC1-DT0029-030200-012-d02 DT0029 Homo sapie3.3401350predicted exon3.3439098AF085955gb: Homo sapiens full length insert cDNA clone YR86G3.3450589AI701505Hs. 202526ESTs3.3430749AJ242956Hs. 25960v-myc avian myelocytomatosis viral related oncogene, n3.3430689AI695595Hs. 293219ESTs3.3454753AW819212gb: CM1-ST0283-071299-061-c07 ST0283 Homo sapie3.3444479AA194980Hs. 30818Homo sapiens cDNA FLJ13681 fis, clone PLACE200003.3413516BE145907gb: MR0-HT0208-221299-204-e12 HT0208 Homo sapie3.3425541AA359119gb: EST68172 Fetal lung II Homo sapiens cDNA 5′ end,3.3457107AA418246Hs. 185796ESTs, Weakly similar to b34I8 1 [H. sapiens]3.3421480NM_016158Hs. 104671erythrocyte transmembrane protein3.3444289BE267060Hs. 76391myxovirus (influenza) resistance 1, homolog of murine3.3417725R25257Hs. 21503ESTs3.3453631AL046418gb: DKFZp434N247_r1 434 (synonym htes3) Homo sa3.3450692H50603Hs. 94037hypothetical protein FLJ230533.3413357W47611gb: zc35e06.r1 Soares_senescent_fibroblasts_NbHSF H3.3415327H22769Hs. 1861membrane protein, palmitoylated 1 (55 kD)3.3457569AW970021Hs. 291120ESTs, Weakly similar to ALU8_HUMAN ALU SUBFA3.3448601R61666Hs. 293690ESTs3.3436526AW993633Hs. 287681Homo sapiens cDNA: FLJ21685 fis, clone COL093723.3440589BE397763Hs. 194478Homo sapiens mRNA, cDNA DKFZp434O1572 (from3.3418768T39310Hs. 1139cold shock domain protein A3.3426768AW303337Hs. 270411ESTs3.3400394AF040257Hs. 283818Homo sapiens TNF receptor homolog mRNA, partial cd3.3433565AA599763Hs. 112520ESTs3.3424093AA335025gb: EST39621 Epididymus Homo sapiens cDNA 5′ end,3.3449552AA001742Hs. 83722ESTs3.3431892AA521315Hs. 194424ESTs3.3405512predicted exon3.3446990AI354717Hs. 223908ESTs3.3457729AI821863Hs. 293467ESTs, Weakly similar to ALU7_HUMAN ALU SUBFA3.2417333AL157545Hs. 42179bromodomain and PHD finger containing, 33.2456420AW401361Hs. 91773protein phosphatase 2 (formerly 2A), catalytic subunit,3.2403497predicted exon3.2427145R52635Hs. 25935ESTs3.2406454predicted exon3.2441033BE562555gb: 601335867F1 NIH_MGC_44 Homo sapiens cDNA3.2408444AW661839Hs. 253204ESTs3.2434739AA804487Hs. 144130ESTs3.2437060AA745591Hs. 292063ESTs3.2423092BE274837Hs. 123637putative homeodomain transcription factor3.2424695U58331Hs. 151899sarcoglycan, delta (35 kD dystrophin-associated glycopr3.2443362AI053464Hs. 166505ESTs3.2437500AL390150gb: Homo sapiens mRNA; cDNA DKFZp547L156 (from3.2425458H89317Hs. 182889ESTs3.2439171AA831133Hs. 294128ESTs3.2407647AW860158gb: RC0-CT0379-290100-032-b04 CT0379 Homo sapie3.2435608AW183971Hs. 250896ESTs3.2426743AA383833Hs. 245022ESTs3.2457525AW973800gb: EST385901 MAGE resequences, MAGM Homo sap3.2413800AI129238Hs. 192235ESTs3.2414193BE260069gb: 601150964F1 NIH_MGC_19 Homo sapiens cDNA3.2455565BE000537gb: RC3-BN0072-240200-011-d07 BN0072 Homo sapie3.2410061T91029Hs. 15069ESTs3.2450666T99968Hs. 18799ESTs3.2458529AV652120Hs. 213232ESTs3.2424751AA769482Hs. 296320ESTs3.2442225AI306597Hs. 129192ESTs3.2410990AW812929gb: RC3-ST0186-250200-018-c05 ST0186 Homo sapien3.2435644AA700867Hs. 269659ESTs3.2405347predicted exon3.2441202AI632143Hs. 135853ESTs3.2446694AV659942Hs. 258132ESTs3.2454652AW812088gb: RC4-ST0173-191099-032-a07 ST0173 Homo sapien3.2418985AI042330Hs. 87128ESTs, Weakly similar to similar to YBS4 YEAST [C. el3.2430118AI377255Hs. 183287ESTs3.2430691C14187Hs. 103538ESTs3.2416313H47206Hs. 194109ESTs, Weakly similar to ALUB_HUMAN !!!! ALU CL3.2446122AI362790Hs. 181801ESTs3.2453725W28543gb: 48c5 Human retina cDNA randomly primed sublibra3.2453954AW118336Hs. 75251DEAD/H (Asp-Glu-Ala-Asp/His) box binding protein 13.2428166AA423849Hs. 79530M5-14 protein3.2447506R78778Hs. 29808Homo sapiens cDNA FLJ21122 fis, clone CAS059173.2401871predicted exon3.2442160AI337127Hs. 156325ESTs3.2404708predicted exon3.1412588AW993055Hs. 44024ESTs3.1431976AA719001Hs. 291065ESTs3.1408884AW891024Hs. 281172ESTs3.1433811AW975015Hs. 123138ESTs3.1431691AI208511Hs. 292510ESTs3.1418719AW975590Hs. 161707ESTs3.1431740N75450Hs. 183412ESTs, Moderately similar to AF116721 67 PRO1777 [H.3.1435699AI911488Hs. 213724ESTs3.1459344AW499533Hs. 257976ESTs3.1431729AW004714Hs. 162033ESTs3.1436771AW975687Hs. 292979ESTs3.1434480AW956268Hs. 59395Homo sapiens clone IMAGE 112574 mRNA sequence3.1459547AI400579Hs. 225186EST3.1427962AA946582Hs. 133546Homo sapiens cDNA FLJ21120 fis, clone CAS056913.1403743predicted exon3.1413560BE148411gb: MR0-HT0241-131299-002-f04 HT0241 Homo sapie3.1454372H96643Hs. 283565FOS-like antigen-13.1450018AA421642Hs. 24309hypothetical protein FLJ111063.1428839AI767756Hs. 82302ESTs3.1407110AA018042Hs. 95078ESTs3.1436133T77531Hs. 191124ESTs3.1418872R94785Hs. 270263ESTs3.1404418predicted exon3.1446877AI559472Hs. 270720ESTs3.1429053AA443967Hs. 194114ESTs3.1425189H16622gb: ym26c07.r1 Soares infant brain 1NIB Homo sapiens3.1404134predicted exon3.1441404AI638880Hs. 126895ESTs3.1400076predicted exon3.1411876AW961336Hs. 69705ESTs, Weakly similar to KIAA0443 [H. sapiens]3.1451048AA013349Hs. 60602ESTs3.1447021AI356564Hs. 161406ESTs3.1404083predicted exon3.0415833H05175Hs. 107510ESTs3.0402142predicted exon3.0415820R53720Hs. 189745ESTs3.0441140AW016534Hs. 226994ESTs3.0449376AA001278Hs. 59905ESTs3.0457593AI738815Hs. 117323ESTs3.0411542AW850767gb: IL3-CT0220-031199-025-A05 CT0220 Homo sapien3.0403375predicted exon3.0449561AI022240Hs. 17924ESTs3.0406241predicted exon3.0420306AA258318Hs. 219226ESTs3.0413161BE068130gb: CM2-BT0368-171299-056-a01 BT0368 Homo sapie3.0448221BE622615gb: 601440775T1 NIH_MGC_72 Homo sapiens cDNA3.0415920Z45684gb: HSCZRD121 normalized infant brain cDNA Homo3.0459135AI902802gb: RC-BT015-311298-026 BT015 Homo sapiens cDNA3.0425357AA355842gb: EST64303 Jurkat T-cells VI Homo sapiens cDNA 5′3.0454724AA091228gb: cchn2152 seq F Human fetal heart, Lambda ZAP Ex3.0429395AK002071Hs. 201624hypothetical protein FLJ112093.0427607AA406119Hs. 270479ESTs3.0443598AW499970Hs. 14822ESTs3.0437948AA772920gb: ae73c09.s1 Stratagene schizo brain S11 Homo sapien3.0418105AW937488Hs. 178000ESTs3.0426763AL042262Hs. 172101Human DNA sequence from clone RP1-202121 on chro3.0403473predicted exon3.0427501AI369280Hs. 131743ESTs3.0453246NM_000933Hs. 32539KIAA1264 protein3.0404587M99587Hs. 104134homeo box (H6 family) 13.0433964AW241987Hs. 197025ESTs3.0453472AL037925gb: DKFZp564MO37_r1 564 (synonym: hfbr2) Homo sa3.0433183AF231338Hs. 222024transcription factor BMAL23.0435899W89093Hs. 189914ESTs3.0425626AI537536Hs. 173519ESTs3.0428931AA994979Hs. 98967ATPase, H(+)-transporting, lysosomal, noncatalytic acc3.0426593AW958560gb: EST370630 MAGE resequences, MAGE Homo sapi3.0431899AA521381Hs. 187726ESTs3.0422406AF025441Hs. 116206Opa-interacting proteins 53.0448178AI479482Hs. 170789ESTs3.0404227predicted exon3.0440575AA889870Hs. 126006ESTs3.0431198AL047634Hs. 231913ESTs3.0434221AF119885Hs. 283040hypothetical protein PRO25433.0459459AA460445gb: zx66h11.r1 Soares_total_fetus_Nb2HF8_9w Homo3.0Pkey: Primekey Ex. Accn: Exemplar Accession UG ID: UniGene ID Title: UniGene Title ratio: ration normal ovary vs tumor


[0362]

14







TABLE 5B








Pkey
CAT Number
Accession







407596
1003489_1
R86913 R86901 H25352 R01370 H43764 AW044451 W21298


407647
1007366_1
AW860158 AW862385 AW860159 AW862386 AW862341 AW821869 AW821893 AW062660 AW062656


408066
103649_1
AA046914 AA057231 H38371


408315
1051132_1
AW179148 AW179150


409211
110906_1
AA078835 AA079319 AA078816 AA079026 AA122167 A111933 AA068989 AA084691 AA068999 AA069038




AA069225 AA650522


409699
1149033_1
BE154650 BE154785 AW468343 BE154816 BE154667


409846
1156150_1
AW501748 AW502972 AW502513


409854
1156229_1
AW501833 AW502145 AW502581


409892
1157859_1
AW956113 AW503580


410065
1174258_1
AW812744 AW581974 AW812725


410454
1204154_1
AW749041 BE066025 H85202


410495
1205826_1
N95428 W24040 AW751366 H81987


410596
121053_1
AA374186 AW963684 AA086107 AI491986


410667
1214679_1
AW936099 AW936243 AW936097 BE162104 BE162109 AW794263


410758
1219899_1
BE535988 AW801777


410890
1226008_1
AW809575 BE090626 BE090617 AW936551 AW936552 AW936530 AW936550 AW936481


410990
1228649_1
AW812929 AW812779 AW813088


411256
1236790_1
AW834039 AW834040 AW834047 AW845410 BE003128 AW852479


411279
1237516_1
AW884776 AW935737 AW835261 AW835247 AW835246 AW835263 AW835240 AW835258


411280
1237585_1
N50617 N47321 R54159 AW860545 AW835317


411337
1239217_1
AW837349 AW837355 AW882717


411542
1249095_1
AW850767 AW851180 AW851359 AW851223 AW851360 AW851222 AW851108


411543
1249127_1
AW851248 AW851425 AW850805 AW851021 AW850905


411673
1253737_1
BE064863 BE153698 AW856751 BE153820 BE064737 BE153674 BE064730 BE065062 BE153536




AW856622 BE155079 BE064651 BE153665 BE064650 BE064691


411899
126497_1
AA370573 BE160501 BE160500 BE160498 BE160502 BE160497 N72424 AA096462


411922
1265825_1
AW876260 AW876269 AW876340 AW876146 AW876323 AW876320 AW876171 AW876421




AW876227 AW876243


412319
1288602_1
AW936903 AW936907 AW936908 AW936914


412480
129929_1
BE142364 BE142341 AA112025


412732
1323951_1
AW993300 N23107 R22345


413137
1350383_1
BE066915 BE066942


413161
1351262_1
BE068130 BE068135 BE068134 BE068183 BE068184 BE068094


413247
135544_1
AW963969 AW963971 AA127651 AA376726


413357
1364165_1
W47611 BE087851


413516
1374595_1
BE145907 BE145796 BE145803 BE145851 BE145923 BE145812 BE145809 BE145852 BE145856


413560
1376621_1
BE148411 BE148415 H59098


414193
1424706_−2
BE260069


414337
1436706_1
BE386606 BE275195 BE274984


414372
143909_1
AA143654 AW753140 AA213770 AW970865 AA569075 AA492132


414390
1441570_−1
BE281040


415296
1533528_1
F05086 F05091 R17158


415618
1540651_1
F12954 H10624 R11948 R56523 T75190


415920
1561733_1
Z45684 H09361 R53285


416211
1578993_1
R14625 R17952 H29120 R14650


416238
1580451_1
W90448 H30749


416612
1603885_1
H70565 N77403 H67949


416624
1604694_1
H69044 T47567 H75691 T50292


416677
1608621_1
T83470 T84283 H74054


416895
162874_1
AW961600 AA190217 AA321260


417178
1655565_1
N51636 T51874 T51829


417762
169750_1
AA205976 AA205930


418913
180520_1
BE046745 AI074878 AI817476 AW572513 AA447586 H28330 AA232486 AA365704 BE271167


419401
184454_1
AW804663 AW805017 AA236969


419896
1888662_1
Z99362 Z99363


420352
192979_1
BE258835 AW968316 AA258918 AW843305 R14744 AI580388 BE071923 R36280


421418
202288_1
AA806639 AA291008 AA836274 AW978806


422046
210744_1
AI638562 T16929 H13401 F07773 R55836


422128
211994_1
AW881145 AA490718 M85637 AA304575 T06067 AA331991


423403
227942_1
AA325483 AW962169 AW962660


424093
235233_1
AA335025 AA335496 AW966145


424719
242889_1
H90452 AA345767 AW964302 H90399


425189
247825_1
H16622 R17322 AA351959


425357
250578_−1
AA355842


425541
252945_1
AA359119 AW963014 D79884


425714
255333_1
AW963278 AA362266 AA362267


426294
263994_1
AA374185 AW956180 H38344


426528
268722_1
AA380828 AW963760 AA380805 AA380830


426593
269748_1
AW958560 AA382199 AW444933


430202
314322_1
T85775 AW968345 AA468998


430535
319643_1
AW968485 AW968670 AA480922 BE350425


431075
327638_1
BE267477 AA491488 AW836723


431492
333930_1
AW612343 AA922558 AA505925 AA927038 AW972537 AI693564


431828
338201_1
AA572994 AA516249 AA702595


432075
341066_1
AW972934 AA525260 AA525266 AA835021 BE000149 BE000148


432474
348197_1
AA584042 AW973273 AA548798


433371
364430_1
T25451 AA585296 AA585305


433403
36534_−1
AF040247


433767
374014_1
AA609245 AA724581 AW241989 AI377274 T47300


434738
392562_1
AA836265 AA648266 AW974440


436196
41562_1
AK001084 AA078092 AA829049


436242
41641_1
AK002187 R66351


436812
427323_1
AW298067 AA731645 AA810101 AW194180 AI690673 AW978773


437500
43772_1
AL390150 AW959182 AA358923


437948
445966_1
AA772920 D59870 D61151 AI591331


438224
452656_1
AA933999 AA781181


438535
45946_1
L09078 L03145 L09094 L09098 L03165 L09102


439098
46859_1
AF085955 H69158 H69081


439126
46887_1
AF085984 H95905 H95906


441033
50807_−1
BE562555


443283
56492_−1
BE568610


445597
644513_1
H65649 AW753545 AI244270


445832
651925_1
AI261545 N59134 AW875371 AW875247


448221
75534_−1
BE622615


448527
766707_1
AI525606 BE549857


448732
77773_−1
BE614063


449311
804513_1
AI657014 AW594035 AI657036 AI638390


449570
81018_1
AA001793 AA001871


450078
823882_1
AI681743 AW897287 AW897205 AW897284


452351
91233_1
AA025647 R45716 AW753786


452453
918300_1
AI902519 AI902518 AI902516


453472
968371_1
AL037925 AL037931 AL037957


453530
97021_1
AW021633 AA036730 AI866854


453631
975024_1
AL046418 N52738 R33840


453725
978760_1
W28543 AL119531


453752
979899_1
AL120800 BE378580


453823
982526_1
AL137967 BE064160 BE064186


454102
1011603_1
AW752363 BE147120 N22640


454487
1216101_1
AW796342 AW796356 BE161430


454543
1223775_1
AW806895 AW866476 AW866465 AW866535 AW866623


454564
1224407_1
AW807573 AW807566 AW807572


454673
1225624_1
BE146471 AW833743 AW833609 AW821469 AW821488 AW821541 AW821531 AW821513




AW821549 AW821384 AW821625 AW821577 AW821547 AW834577


454052
1228071_1
AW812088 AW812105 AW812082


454679
1228929_1
AW813110 AW813113


454724
123128_1
AA091228 H71860 H71073


454753
233576_1
AW819212 AW819170 BE158474 AW819172 AW819213 AW819200 AW819256 AW819254




AW819178 AW819214 AW819215 AW819233 AW819171


454885
1238874_1
AW836922 AW876719 AW876688 AW836919 AW836997 AW836908 AW836912 AW836993


454940
1245640_1
AW846202 AW846174 AW846532 AW846181 AW846458 AW846206 AW846432 AW846553




AW846533 AW846197 AW846198 AW846189 AW846469 AW846530 AW846560 AW846536




AW846472 AW846470 AW846466 AW846192 AW846479 AW846260 AW846204 AW846139




AW846187 AW846353 AW846462 AW846151 AW846549 AW846538 AW846527 AW846567 AW846531


454994
1248637_1
AW850176 AW850513 AW850412 AW850451


455056
1250934_1
AW853057 AW853039 AW853042 AW853050 AW853114 AW853105 AW853102 AW853111




AW853121 AW853109 AW853126


455067
1252050_1
AW854538 AW854418 AW854412


455108
1253916_1
AW856866 AW856858 AW856856


455387
1287871_1
BE069037 AW936025 BE069178 AW936034


455388
1287904_1
AW936234 AW936074 AW936181 AW936179 AW936217 AW936077 AW936227 AW936191


455534
1322942_1
AW991925 AW991919


455565
1329591_1
BE000537 BE180584 BE180540 BE180542 BE180546


455731
1353872_1
BE072188 BE072299 BE072269 BE072317 BE072238


455786
1365510_1
BE090077 BE090079


455790
1365950_1
BE090690 BE090688 BE090681 BE090693 BE090675


455887
1380836_1
BE154173 BE154098 BE154096


455895
1381386_1
BE154837 BE154879 BE154850 BE154877 BE154835 BE154849 BE154902 BE154905 BE154867




BE154901 BE154904 BE154899


456253
1699178_1
T12198 T19684 T11583 R15526 R15585 R45876 R15562


456383
184252_1
AI148037 AA287178 AA236756


456388
1842839_−1
W28557


457525
351732_1
AW973800 AA557589 AA559886


457740
39528_1
AW500458 AW160900 AF161362 AF150327 AW578393 AW360921 AW360920 AW360902 AW360890




AW732529


458301
543058_1
AF003834 W36292


459135
918516_1
AI902802 AI902783 AI902800


459157
919804_2
AI904385 AI904382






Pkey: Unique Eos probeset idenitifier number




CAT number: Gene cluster number




Accession: Genbank accession number








[0363]

15








TABLE 5C








Pkey
Ref
Strand
Nt_position







400942
7656749
Minus
91593-91757, 92720-92843, 93962-94079, 94824-94997


401004
7229982
Plus
62580-62772


401287
9801612
Minus
42287-42431


401308
9212516
Plus
169019-169649


401350
9931226
Plus
14471-14623


401740
2982169
Plus
148357-148484, 148591-148690


401871
8079355
Minus
58158-59585


401896
8569194
Plus
115129-115294


401963
3126783
Plus
51382-51521


402105
8131588
Minus
22856-24055


402109
8131678
Minus
171722-171859, 173197-173303


402142
7704985
Minus
29932-30698


402451
9796677
Minus
48137-48343


402867
5596716
Plus
52806-53106, 53500-53818


403277
8072597
Minus
27494-27642


403283
8076905
Minus
71124-71996


403375
9255944
Minus
92554-92795


403473
9945095
Minus
54241-54437


403497
6067111
Plus
7221-7441


403531
8076842
Minus
75903-76134


403635
6862664
Minus
157028-157145, 161725-161900


403714
7210030
Minus
145556-145873


403743
7652003
Minus
136463-136646


404020
8655966
Minus
174449-174663


404041
8886967
Minus
1334-1503, 2483-2685, 5230-5337, 19656-19804


404044
9558573
Minus
225757-225939


404083
9944029
Minus
16650-17082


404108
8247074
Minus
63603-64942


404134
6981900
Minus
40633-40911


404227
7838233
Minus
93110-93259


404418
7382420
Minus
153339-153481, 155099-155294


404451
7638438
Minus
105191-105622


404582
9739220
Plus
53230-53424


404708
9800828
Plus
77522-77658


404868
9454593
Plus
39954-40430


405096
8072599
Plus
140844-140897, 148510-148581


405290
3900849
Minus
79582-79765


405347
2979602
Minus
977-1116


405512
9454624
Plus
17802-17966, 18573-18697


405549
1552494
Plus
10876-11048


405583
4512287
Plus
56211-56353


405671
2565031
Plus
25805-26923


405717
9588573
Plus
11275-11973


405752
9212305
Plus
91392-91528


405836
5686282
Minus
5031-5217


406122
9144087
Minus
30940-31386


406197
7289992
Minus
47520-47961


406237
7417725
Plus
30032-30501


406241
7417725
Minus
34951-35752


406255
7417729
Plus
2959-3200


406364
9256114
Minus
50715-50833


406454
9588380
Minus
91746-91958


406481
9864741
Minus
91439-91579


406562
7711584
Plus
37316-37426


406605
8272666
Minus
23275-23493, 23723-23903






Pkey: Unique number corresponding to an Eon probeset




Ref: Sequence source. The 7 digit numbers in this column are Genbank Identifier (Gi) numbers. “Dunham I et at,” refers to the publication entitled “The DNA sequence of human chromosome 22“ Dunham, et al, (1999) Nature 402: 489-495




Strand: Indicates DNA strand from which exons were predicted




Nt_position: Indicates nucteobde positions of predicted exons








[0364] TABLE 6A lists about 68 genes highly down-regulated in ovarian cancer compared to normal ovaries These were selected as for Table 5A, except the “average” ovarian cancer level was set to the maximum value amongst various ovarian cancers and the “average” normal ovary level was set to the minimum value from various non-malignant ovary specimens, and the ratio was greater than or equal to 2 5 (i e 2 5-fold down-regulated in the highest tumor vs. the lowest normal ovary) This has the overall effect of increasing stringency, and reducing the number of false-positives
16TABLE 6AABOUT 68 HIGHLY DOWN-REGULATED GENES,OVARIAN CANCER VERSUS NORMAL OVARYPkeyEx. AccnUG IDTitleratio42485144676441Hs. 119059ESTs7.9437690AA804362Hs. 180544ESTs4.7433682AA642418Hs. 17381ESTs4.1407437AF220264gb: Homo sapiens MOST-1 mRNA, complete cds4.1437787AI908263Hs. 291625ESTs4.0453282AK000043Hs. 32922hypothetical protein FLJ200364.0440987AA911705Hs. 130229ESTs3.8443131AI033833Hs. 132689ESTs3.8431075BE267477gb: 601189542F2 NIH_MGC_7 Homo sapiens cDNA clo3.6412637AA115097Hs. 261313ESTs3.6408141U69205Hs. 45152ESTs, Moderately similar to neurogenic basic-helix-loop3.5420122AA255714Hs. 284153Fanconi anemia, complementatian group A3.5430653AW902062Hs. 30280ESTs3.4401308predicted exon3.4410758BE535988gb: 601062418F1 NIH_MGC_10 Homo sapiens cDNA c3.4421418AA806639gb: ob88g05.s1 NCI_CGAP_GCB1 Homo sapiens cDNA3.4450061AI797034Hs. 201115ESTs3.3409725T40760Hs. 90459EST3.343473844836265gb: od17e02.s1 NCI_CGAP_GCB1 Homo sapiens cDNA3.3431644AW972822Hs. 169248cytochrome c3.3450938AW753734Hs. 277215ESTs3.2420497AW206285Hs. 253548ESTs3.2439426AI131502Hs. 143135ESTs, Weakly similar to FAFY_HUMAN PROBABLE C3.2407596R86913gb: yq30f05.r1 Soares fetal liver spleen 1NFLS Homo sap3.2448683AA167642Hs. 14632ESTs3.2431982AW419296Hs. 105754ESTs3.1452320AA042873Hs. 160412ESTs3.1419401AW804663gb: QV4-UM0094-160300-135-d06 UM0094 Homo sapim3.1402105predicted exon3.1444997AI204451Hs. 146196ESTs3.1403283predicted exon3.0455388AW936234gb: QV0-DT0020-090200-106-g05 DT0020 Homo sapie3.0428559H24338Hs. 27041ESTs2.9419002T78625Hs. 268594ESTs2.9404868predicted exon2.9409090W56067Hs. 103105ESTs2.9406605predicted exon2.9441202AI632143Hs. 135853ESTs2.8422046AI638562gb: ts50a10.x1 NCI_CGAP_Ut1 Homo sapiens cDNA cl2.8442865N57659Hs. 114541ESTs, Weakly similar to neuronal thread protein AD7c-N2.8444431AW513324Hs. 42280ESTs2.8426294AA374185gb: EST86289 HSC172 cells I Homo sapiens cDNA 5′ en2.8412480BE142364gb: CM0-HT0143-270999-062-d12 HT0143 Homo sapie2.8449858AW205979Hs. 196065ESTs2.8401464AF039241Hs. 9028histone deacetylase 52.7439126AF085984gb: Homo sapiens full length insert cDNA clone YT99F02.7403277predicted exon2.7450078AI681743gb: tx38g10.x1 NCI_CGAP_Lu24 Homo sapiens cDNA2.7458090AI282149Hs. 56213ESTs, Highly similar to FXD3_HUMAN FORKHEAD D2.7420620AA278807Hs. 173343ESTs2.7459054AW798466Hs. 823962′, 5′-oligoadenylate synthetase 12.6421379Y15221Hs. 103982small inducible cytokine subfamily B (Cys-X-Cys), mem2.6454338AW381251Hs. 1050pleckstnn homology, Sec7 and coiled/coil domains 1(cyt2.6454529Z45439Hs. 270425ESTs2.6446877AI559472Hs. 270720ESTs2.6412588AW993055Hs. 44024ESTs2.6449862AI672277Hs. 199475ESTs2.6446694AV659942Hs. 258132ESTs2.6424029AB014594Hs. 137579KIAA0694 gene product2.6454102AW752363gb: RC0-CT0201-270999-011-f03 CT0201 Homo sapien2.6430922AW373747Hs. 183337ESTs2.6420289N55394Hs. 963988-oxoguanine DNA glycosylase2.6410495N95428gb: zb80d09.s1 Soares_senescent_fibroblasts_NbHSF Ho2.5412319AW936903gb: RC1-DT0029-030200-012-d02 DT0029 Homo sapien2.5409699BE154650gb: PM3-HT0344-071299-003-c08 HT0344 Homo sapien2.5445832AI261545gb: qz30a07.x1 NCI_CGAP_Kid11 Homo sapiens cDNA2.5429755NM_001364Hs. 215839discs, large (Drosophila) homolog 2 (chapsyn-110)2.5445755AW294870Hs. 223672ESTs2.5Pkey: Primekey Ex. Accn: Exemplar Accession UG ID: UniGene ID Title: UniGene Title ratio: ration of normal ovary vs. tumor


[0365]

17







TABLE 6B








Pkey
CAT Number
Accession







407596
1003489_1
R86913 R86901 H25352 R01370




H43764 AW044451 W21298


409699
1149033_1
BE154650 BE154785 AW468343 BE154816




BE154667


410495
1205826_1
N95428 W24040 AW751366 H81987


410758
1219899_1
BE535988 AW801777


412319
1288602_1
AW936903 AW936907 AW936908




AW936914


412480
129929_1
BE142364 BE142341 AA112025


419401
184454_1
AW804663 AW805017 AA236969


421418
202288_1
AA806639 AA291008 AA836274 AW978806


422046
210744_1
AI638562 T16929 H13401 F07773 R55836


426294
263994_1
AA374185 AW956180 H38344


431075
327638_1
BE267477 AA491488 AW836723


434738
392562_1
AA836265 AA648266 AW974440


439126
46887_1
AF085984 H95905 H95906


445832
651925_1
AI261545 N59134 AW875371 AW875247


450078
823882_1
AI681743 AW897287 AW897205 AW897284


454102
1011603_1
AW752363 BE147120 N22640


455388
1287904_1
AW936234 AW936074 AW936181




AW936179 AW936217 AW936077




AW936227 AW936191






Pkey: Unique Eos probeset identifier number




CAT number Gene cluster number




Accession: Genbank accession numbers








[0366]

18








TABLE 6C








Pkey
Ref
Strand
Nt_position







481308
9212516
Plus
169019-169649


402105
8131588
Minus
22856-24055


483277
8072597
Minus
27494-27642


483283
8076905
Minus
71124-71996


484868
9454593
Plus
39954-40430


406605
8272666
Minus
23275-23493, 23723-23903






Pkey: Unique number corresponding to an Eos probeset




Ref: Sequence source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. “Dunham I et al” refers to the publication entitled “The DNA sequence of human chromosome 22” Dunham, et al (1999) Nature 402: 489-495




Strand: Indicates DNA strand from which exons were predicted




Nt_position: Indicates nucleotide positions of predicted exons








[0367] Table 7A lists about 770 genes up-regulated in ovarian cancer compared to normal adult tissues These were selected from 35403 probesets on the Affymetrix/Eos-Hu01 GeneChip array such that the ratio of “average” ovarian cancer to “average” normal adult tissues was greater than or equal to 2 5 The “average” ovarian cancer level was set to the 2nd highest amongst various ovarian cancers. The “average” normal adult tissue level was set to the 7th highest amongst various non-malignant tissues In order to remove gene-specific background levels of non-specific hybridization, the 15th percentile value amongst the non-malignant tissues was subtracted from both the numerator and the denominator before the ratio was evaluated
19TABLE 7AABOUT 770 UP-REGULATED GENES, OVARIAN CANCER VERSUS NORMAL ADULT TISSUESPkeyEx. AccnUG IDTitleratio109680F09255Hs 4993ESTs23.2119743W70242Hs.58086ESTs22.0132528AA283006Hs 50758chromosome-associated polypeptide C22.0129571X51630Hs 1145Wilms tumor 120.0102151U17280Hs 3132steroidogenic acute regulatory protein19.6130941D49394Hs 21425-hydroxytryptamine (serotonin) receptor 3A17.5132624AA164819Hs 53631ESTs15.9102610U65011Hs 30743preferentially expressed antigen in melanoma15.4101249L33881Hs.1904protein kinase C, iota14.5122802AA460530Hs 256579ESTs14.5135242M74093Hs 9700cyclin E113.8101804M86699Hs.169840TTK protein kinase12.2123005AA479726Hs 105577ESTs12.0114965AA250737Hs 72472ESTs11.5115536AA347193Hs 62180ESTs11.4132191AA449431Hs.158688KIAA0741 gene product10.9121853AA425887Hs.98502ESTs10.9115881AA435577Hs 184942G protein-coupled receptor 6410.8119780W72967Hs 191381ESTs, Weakly similar to hypothetical protein10.5104301D45332Hs.6783ESTs10.3132632N59764Hs 5398guanine-monophosphate synthetase10.1105298AA233459Hs.26369ESTs9.7108857AA133250Hs 62180ESTs9.1113168T53592Hs 161586EST9.0115892AA435946Hs 50831ESTs8.9125666AA199856Hs.118811ESTs8.9102200U21551Hs 157205branched chain aminotransferase 1, cytosolic8.8108055AA043562Hs 62637ESTs8.6132572AA448297Hs.237825signal recognition particle 72 kD8.6115909AA436666Hs 59761ESTs8.5109166AA179845Hs 73625RAB6 interacting, kinesin-like (rabkinesin6)8.3121779AA422036Hs 98367ESTs8.3102915X07820Hs.2258matrix metalloproteinase 10 (stromelysin 2)8.0105317AA233926Hs.23635ESTs7.8125250W87465Hs 222926ESTs, Weakly similar to D2092 2 [C. elegans]7.8126960AA317900Hs.161756ESTs7.8122969AA478539Hs 104336ESTs7.7130376R40873Hs 155174KlAA0432 gene product7.7123339AA504253Hs 101515ESTs7.7134972M19720Hs 169252Human L-myc protein gene, complete cds7.6111234N69287Hs.21943ESTs, Weakly similar to ORF YGL221c [S.cerevi7.5123689AA609556Hs 256562ESTs7.5123494AA599786Hs 112110ESTs7.4131985AA434329Hs 36563ESTs7.4106738AA470145Hs.25130ESTs7.4108768AA127741Hs 61345ESTs7.3106474AA450212Hs 42484Homo sapiens mRNA, cDNA DKFZp564C053 (from cl7.2123308AA496211Hs 103538ESTs7.2106124AA423987Hs.7567ESTs7.2111345N89820Hs.14559ESTs7.1105200AA195399Hs 24641ESTs7.1116416AA609219Hs 39982ESTs7.1118846N80567Hs 50895ESTs7.1133434AA278852Hs 250786ESTs7.1120472AA251875Hs 104472ESTs, Weakly similar to Gag-Pol polyprotein [6.9115291AA279943Hs.122579ESTs6.9111185N67551Hs 12844EGF-like-domain, multiple 66.9108778AA128548Hs 90847general transcription factor IIIC, polypeptid6.9132939U76189Hs 61152exostoses (multiple)-like 26.9134520N21407Hs 257325ESTs6.9114724AA131701Hs 256287ESTs, Highly similar to SPERM SURFACE PROTEIN6.8116296AA489033Hs 62601mRNA, cDNA DKFZp586K1318 (from c6.8102136U15552Hs 85769acidic 82 kDa protein mRNA6.7132725L41887Hs 184167splicing factor, arginine/serine-rich 7 (35 kD6.5109648F04600Hs 7154ESTs6.4116401AA599963Hs 59698ESTs6.4127563AI367707Hs.150587ESTs6.4104252AF002246Hs.210863cell adhesion molecule with homology to L1CAM6.4120438AA243441Hs.99488ESTs, Weakly similar to ORF YKR074w [S.cerevi6.2131978D80008Hs 36232KIAA0186 gene product6.2134621L02547Hs.172865cleavage stimulation factor, 3′ pre-RNA; subu6.2120571AA280738Hs 128679ESTs6.2102627U66561Hs 158174zinc finger protein 184 (Kruppel-like)6.1100661HG2874-HT3018Ribosomal Protein L39 Homolog6.1118204N59859Hs 48443ESTs6.0131386AA096412Hs 173135dual-specificity tyrosine-(Y)-phosphorylation6.0129097S50223HKR-T1=Kruppel-like zinc finger protein [huma5.9131228AA279157Hs.24485chondroitin sulfate proteoglycan 6 (bamacan)5.9106369AA443828Hs 25324ESTs5.9108255AA063157Hs 172608ESTs5.8125370AA256743Hs 151791KIAA0092 gene product5.8130010N52966Hs 142838ESTs5.8131945M87339Hs 35120replication factor C (activator 1) 4 (37 kD)5.7116238AA479362Hs.47144DKFZP586N0819 protein5.7102221U24576LIM domain only 45.6130757R00641Hs.18925ESTs, Weakly similar to cDNA EST yk339a7 5 co5.6131278U81523Hs.25195endometrial bleeding associated factor (left-5.6101383M14113Hs 79345coagulation factor VIIIc, procoagulant compon5.5131836AA610086Hs 32990DKFZP566F084 protein5.5129628U26727Hs 1174cyclin-dependent kinase inhibitor 2A (melanoma5.5106523AA453441Hs 31511ESTs5.5111772R28287Hs 237146ESTs5.5101255L34600Hs.149894mitochondrial translational initiation factor5.5106895AA489665Hs.25245ESTs5.5104943AA065217Hs 169674ESTs5.5129229AA211941Hs 109643polyadenylate binding protein-interacting pro5.4102305U33286Hs 90073chromosome segregation 1 (yeast homolog)-like5.4106553AA454967Hs 5887ESTs; Highly similar to RNA binding motif pro5.4112305R54822Hs.26244ESTs5.3123972C14782Hs 70337immunoglobulin superfamily; member 45.3102676U72514Hs 12045putative protein5.3106459AA449741Hs 4029glioma-amplified sequence-415.2107865AA025104Hs 61252ESTs5.2121121AA399371Hs 189095ESTs, Weakly similar to zinc finger protein S5.2127162N76398Hs 21187ESTs5.2131646AA171895Hs 30057clone 24749 and 24750 mRNA seque5.2121770AA421714Hs 11469KIAA0896 protein5.2122512AA449311Hs.98658budding uninhibited by benzimidazoles 1 (yeas5.1105870AA399623Hs 23505ESTs5.1100341D63506Hs 8813syntaxin binding protein 35.1116848H65187Hs 39001ESTs5.1120821AA347419Hs 96870mRNA full length insert cDNA clo5.1130690AA084286Hs.139033paternally expressed gene 35.1122661AA454936Hs 245541ESTs5.1123169AA488892Hs 104472ESTs, Weakly similar to Gag-Pol polyprotein [5.1108810AA130596Hs.71331ESTs; Weakly similar to POTENT HEAT-STABLE PR5.0110799N26101Hs 7838Human nng zinc-finger protein (ZNF127-Xp) ge5.0120619AA284372Hs 111471ESTs5.0122792AA460225Hs.99519ESTs5.0129912AA047344Hs 107213ESTs, Highly similar to NY-REN-6 antigen [H.s5.0102823U90914Hs 5057carboxypeptidase D4.9129890M13699Hs 111461ceruloplasmin (ferroxidase)4.9101084L05425autoantigen mRNA, complete cds4.9134859D87716Hs 90315KIAA0007 protein4.9115955AA446121Hs.44198BAC clone RG054D04 from 7q314.9105516AA257971Hs 21214ESTs4.9114932AA242751Hs 16218KIAA0903 protein4.9106672AA461300Hs 30643ESTs4.8106126AA424006Hs 22972ESTs, Moderately similar to H5AR [M. musculus]4.8110695H93463Hs 124777ESTs4.8102025U03911Hs.78934matS (E. coli) homolog 2 (colon cancer, nonpo4.8133282U52960Hs 250855SRB7 (suppressor of RNA polymerase B; yeast)4.8119708W67810Hs 57904mago-nashi (Drosophila) homolog, proliferatio4.7120695AA291468ESTs4.7128651AA446990Hs.103135ESTs4.7103152X66533Hs 77890guanylate cyclase 1, soluble, beta 34.7108699AA121514Hs 70832ESTs4.7115094AA255921Hs 88095ESTs4.7121429AA406293Hs 193498ESTs4.7123203AA489671Hs 89709glutamate-cysteine ligase (gamma-glutamylcyst4.7126802AA947601Hs.97056ESTs4.7130527C17384Hs.184227F-box protein 214.7134470X54942Hs 83758CDC28 protein kinase 24.7100449D87470Hs 75400KIAA0280 protein4.7110970N51374Hs 96870mRNA full length insert cDNA clo4.7115901AA436403Hs 86909ESTs; Moderately similar to Frizzled-6 [H.sap4.7109799F10770Hs.180378clone 669 unknown mRNA, complete4.6116195AA465148Hs.72402ESTs4.6132122U65092Hs 40403Cbp/p300-interacting transactivator, with Glu4.6108990AA152296Hs 72045ESTs4.6109055AA160529Hs 48524ESTs4.6115937AA443269Hs 30991KIAA0957 protein4.6133520X74331Hs 74519primase, polypeptide 2A (58 kD)4.6131200AA609427Hs.210706ESTs, Moderately similar to !!!! ALU SUBFAMIL4.6121369AA405657Hs 128791Human DNA sequence from clone 967N21 on chrom4.5132880AA444369Hs 177537ESTs4.5127386AI457411Hs 106728ESTs4.5120067W93592Hs.47343ESTs4.5122986AA479063Hs 102947ESTs4.5135286AA401269Hs 97849ESTs4.5130155L33404Hs 151254kallikrein 7 (chymotryptic, stratum corneum)4.5106103AA421104Hs 12094ESTs4.5102654U68494Hs.24385Human hbc647 mRNA sequence4.4107876AA025315Hs 61184Novel human gene mapping to chomosome X4.4109454AA232255Hs 46912ESTs4.4125960D63307Hs.145968ESTs4.4126892AI160190Hs 76127hect (homologous to the E6-AP (UBE3A) carboxy4.4100269D38550Hs.1189E2F transcription factor 34.4134161U97188Hs 79440IGF-II mRNA-binding protein 34.3100502HG1496-HT1496Adrenal-Specific Protein Pg24.3105542AA261858Hs 8241ESTs, Weakly similar to heat shock protein hs4.3109787F10610Hs 34853inhibitor of DNA binding 4, dominant negative4.3110759N21671Hs.19025ESTs4.3129970AA478975Hs 200434ESTs4.3134666AA482319Hs 8752putative type II membrane protein4.3117693N40939Hs.44162ESTs, Weakly similar to cDNA EST yk342h125 c4.3111008N53388Hs 7222ESTs4.3120977AA398155Hs 97600ESTs4.2105808AA393808Hs 21490KIAA0438 gene product4.2121381AA405747Hs.97865ESTs, Weakly similar to WASP-family protein [4.2100893HG4557-HT4962Small Nuclear Ribonucleoprotein U1, 1snrp4.2107176AA621762Hs 7576ESTs4.2118976N93629Hs 93391ESTs4.2130703N63295Hs 18103ESTs4.2106540AA454607Hs 38114ESTs, Weakly similar to coded for by C.elega4.2119367T78324Hs.90905ESTs4.2133633D21262Hs 75337nucleolar phosphoprotein p1304.2105520AA258068Hs 33085WD repeat domain 34.2114264Z40074Hs 27595ESTs4.1131046X02530Hs 2248IP10; small inducible cytokine subfamily B (4.1105220AA210695Hs 17212ESTs4.1103111X63187Hs 2719epididymis-specific, whey-acidic protein type4.1125640R37700Hs 208261ESTs4.1110561H59617Hs 5199ESTs, Weakly similar to UBIQUITIN-CONJUGATING4.1118092N54915Hs.82719mRNA, cDNA DKFZp586F1822 (from c4.1134891F03517Hs 90787ESTs4.1112364R59312Hs 197642ESTs, Weakly similar to DNA-DIRECTED RNA POLY4.1120699AA291716Hs 97258ESTs4.1106272AA432074Hs 32538ESTs4.1112041R43300Hs.22929ESTs4.1131689AA599653Hs.30696transcription factor-like 5 (basic helix-loop4.1116134AA460246Hs 50441ESTs, Highly similar to CGI-04 protein [H.sap4.1107638AA009528Hs 42743ESTs, Weakly similar to predicted using Genef4.0131941D62657Hs 35086ubiquitin-specific protease 14.0106154AA425304Hs 6994ESTs4.0105546AA262032Hs.26089ESTs, Weakly similar to 62D9 a [D.melanogaste4.0106319AA436606Hs.7392ESTs, Weakly similar to Gu protein [H. sapiens4.0121816AA424814Hs 187509ESTs4.0122851AA463627Hs.99598ESTs4.0123337AA504153Hs 132797ESTs, Weakly similar to ORF YGL050w [S.cerevi4.0128643N40212Hs 102958ESTs4.0129011S72869Hs 107932DNA segment, single copy, probe pH4 (transfor4.0130895AA609828Hs.21015ESTs, Highly similar to tetracycline transpor4.0132323AA436102Hs 256559ESTs4.0134255J05032Hs 80758aspartyl-tRNA synthetase4.0102827U91327Hs 6456chaperonin containing TCP1; subunit 2 (beta)4.0102123U14518Hs 1594centromere protein A (17 kD)4.0102813U90651Hs 151461embryonic ectoderm development protein3.9113970W86748Hs.8109ESTs3.9107145AA621108Hs.173001ESTs3.9114212Z39338Hs 21201DKFZP566B0846 protein3.9106614AA458934Hs 179912ESTs3.9132742AA490862Hs 55901ESTs; Weakly similar to C43H8 1 [C. elegans]3.9120948AA397822Hs.104650ESTs, Highly similar to similar to mago nashi3.9129337R63542Hs 110488KIAA0990 protein3.9103835AA172215Hs 93748ESTs, Moderately similar to TRANSCRIPTION FAC3.9133330U42360Hs 71119Putative prostate cancer tumor suppressor3.9133928N34096Hs.7766ubiquitin-conjugating enzyme E2E 1 (homologou3.9133640D83004Hs.75355ubiquitin-conjugating enzyme E2N (homologous3.9133350AA135468Hs 71573ESTs3.9115623AA401475Hs 39733postsynaptic protein CRIPT3.9101973S82597Hs 80120UDP-N-acetyl-alpha-D-galactosamine polypeptid3.9102669U71207Hs 29279eyes absent (Drosophila) homolog 23.9134248AA292677Hs.80624ESTs3.9102380U40434Hs.155981mesothelin3.9116157AA461063Hs 44298ESTs; Highly similar to HSPC011 [H. sapiens]3.8106691AA463453Hs 23259ESTs, Weakly similar to ACTIN, CYTOPLASMIC 23.8115844AA430124Hs 234607ESTs3.8107159AA621340Hs 10600ESTs, Weakly similar to ORF YKR081c [S.cerevi3.8106498AA452141Hs 7171ESTs3.8134405J04177Hs 82772collagen, type XI, alpha 13.8106260AA431448Hs 5250ESTs; Weakly similar to BACR37P7 g [D.melanog3.8109864H02554Hs.30323ESTs3.8124648N91948Hs 125034ESTs3.8134719L07515Hs 89232chromobox homolog 5 (Drosophila HP1 alpha)3.8113702T97307Hs 161720ESTs; Moderately similar to !!!! ALU SUBFAMIL3.8128639N91246Hs.102897ESTs3.8111299N73808Hs 24936ESTs3.7129351AA167268Hs 62349Human ras inhibitor mRNA, 3′end3.7119741W70205Hs 43670kinesin family member 3A3.7105012AA116036Hs.9329chromosome 20 open reading frame 13.7128734AA343629Hs 104570kallikrein 8 (neuropsin/ovasin)3.7130567L07493Hs 1608replication protein A3 (14 kD)3.7114253Z39909Hs 14831ESTs3.7103169X68560Hs 44450Sp3 transcription factor3.7111269N70711Hs 18885ESTs; Highly similar to CGI-116 protein [H.sa3.7112876T03488Hs 4842ESTs3.7118261N62780Hs.94122ESTs3.7130385AA126474Hs 155223stanniocalcin 23.7129300C20976Hs 110165ESTs, Highly similar to ribosomal protein L263.7134388M15841Hs 82575small nuclear ribonucleoprotein polypeptide B3.7106968AA504631Hs 26813ESTs; Weakly similar to hypothetical 43.2 kDa3.7100906HG4716-HT5158Guanosine 5′-Monaphosphate Synthase3.7100418D86978Hs 84790KIAA0225 protein3.7101484M24594Hs 20315Interferon-induced protein 563.7102547U57911Hs.46638chromosome 11 open reading frame 83.7103587Z29083Hs 821285T4 oncofetal trophoblast glycoprotein3.7130600AA478601Hs 258737ESTs3.7128733AA328993Hs 104558ESTs3.7134375AA412720Hs.82389ESTs, Highly similar to CGI-118 protein [H.sa3.7134098X06323Hs 79086ribosomal protein; mitochondrial, L33.6101188L20320Hs 184298cyclin-dependent kinase 7 (homolog of Xenopus3.6132149T10822Hs 4095ESTs3.6116200AA465358Hs 118793ESTs; Highly similar to p621 [H. sapiens]3.6121920AA428300Hs.161841ESTs3.6128609AA234365Hs 102456survival of motor neuron protein interacting3.6101078L04510Hs 792ADP-ribosylation factor domain protein 1, 64 k3.6108693AA121289Hs 49597ESTs; Highly similar to retinoic acid-induced3.6109139AA176121Hs 59757zinc finger protein 2813.6111870R37778Hs 18685ESTs, Weakly similar to hypothetical protein3.6113848W60080Hs 27099DKFZP564J0863 protein3.6127947AI432475Hs 146327ESTs3.6128056AI379480Hs.125449ESTs, Weakly similar to MaxiK channel beta 23.6129914U22377Hs 13321rearranged L-myc fusion sequence3.6132148AA283988Hs 4094ESTs3.6134644S83308Hs 87224SRY (sex-determining region Y)-box 53.6115047AA252627Hs 22554homeo box B53.6102398U42359Human N33 protein form 1 (N33) gene, exon 1 a3.6127479AA513722Hs 179729collagen; type X, alpha 1 (Schmid metaphyseal3.6105545AA262030Hs 5152ESTs, Weakly similar to katanin p80 subunit [3.6101483M24486Hs.76768procollagen-proline, 2-oxoglutarate 4-dioxyge3.6105709AA291268Hs 26761DKFZP586L0724 protein3.6122636AA454103Hs 110031ESTs3.6124792R44357Hs 132784ESTs; Weakly similar to cDNA EST EMBL T014213.6103621Z47727Hs.150675polymerase (RNA) II (DNA directed) polypeptid3.5105427AA251330Hs 28248ESTs3.5121553AA412488Hs 48820ESTs3.5115167AA258421Hs 43728hypothetical protein3.5134570U66615Hs.172280SWI/SNF related; matrix associated, actin dep3.5110787N24716Hs 12244ESTs, Weakly similar to C44B9 1 [C. elegans]3.5131621U77665Hs 139120ribonuclease P (30 kD)3.5132813N72116Hs 57435solute carrier family 11 (proton-coupled diva3.5116370AA521256Hs.236204ESTs; Moderately similar to NUCLEAR PORE COMP3.5131965W90146Hs 35962ESTs3.5115221AA262942Hs 79741ESTs3.5116093AA456020Hs 50848ESTs, Weakly similar to KIAA0862 protein [H.s3.5123507AA600176Hs 112345ESTs3.5129801F11087Hs 239666ESTs3.5115084AA255566Hs.42484mRNA, cDNA DKFZp564C053 (from cl3.5123442AA598803Hs 111496ESTs3.5115061AA253217Hs 41271ESTs3.5100146D13645Hs 2471KIAA0020 gene product3.5115140AA258030Hs.55356ESTs, Weakly similar to supported by GENSCAN3.5115360AA281950Hs 5057carboxypeptidase D3.5130261D83767Hs 153678reproduction 83.4100824HG4058-HT4328Oncogene Aml1-Evi-1, Fusion Activated3.4102287U31814Hs 3352histone deacetylase 23.4102788U86602Hs 74407nucleolar protein p403.4118836N79820Hs 50854ESTs3.4102423U44754Hs.179312small nuclear RNA activating complex, polypep3.4106300AA435840Hs 19114high-mobility group (nonhistone chromosomal)3.4106156AA425354Hs 4210ESTs3.4106483AA451676Hs 30299IGF-II mRNA-binding protein 23.4107868AA025234Hs.61260ESTs3.4108187AA056538Hs 27842ESTs, Weakly similar to similar to 1-acyl-gly3.4116123AA459282Hs 43756ESTs3.4119501W37721Hs 151363ESTs3.4129121AA127459Hs.108788ESTs, Weakly similar to zeste [D. melanogaster3.4131638D87120Hs.29882predicted osteoblast protein3.4132962N34893Hs 6153ESTs, Highly similar to CGI-48 protein [H.sap3.4133767D63875Hs 173288KIAA0155 gene product3.4111823R35253Hs 24944ESTs3.4134372D63877Hs 82324KIAA0157 protein3.4130938AA013250Hs.21398ESTs, Moderately similar to PUTATIVE GLUCOSAM3.4115169AA258427Hs 58427ESTs3.4123978C20653Hs 170278ESTs3.4108807AA129968Hs.49376ESTs, Weakly similar to PROTEIN PHOSPHATASE P3.4132581R42266Hs 52256ESTs, Weakly similar to beta-TrCP protein E3R3.4134654W23625Hs 8739ESTs; Weakly similar to ORF YGR200c [S.cerevi3.4105730AA292701Hs 5364DKFZP564I052 protein3.4111295N73275Hs.21275ESTs, Weakly similar to ubiquitin-conjugating3.3102009U02680Hs 82643protein tyrosine kinase 93.3114161Z38904Hs 22385ESTs, Weakly similar to KIAA0970 protein [H.s3.3130604X03635Hs 1657estrogen receptor 13.3100103AF007875Hs 5085dolichyl-phosphate mannosyltransferase polype3.3121748AA421171Hs 234545ESTs3.3106698AA463745Hs 29403ESTs, Weakly similar to PROBABLE ATP-DEPENDEN3.3134353S77154Hs.82120nuclear receptor subfamily 4, group A; member3.3134154AA211320Hs.79404neuron-specific protein3.3133142F03321Hs 65874ESTs3.3124461N50641Hs 80285mRNA, cDNA DKFZp586C1723 (from c3.3104903AA055534Hs 124134ESTs3.3106772AA478106Hs.12692ESTs, Weakly similar to protein phosphatase-13.3109704F09687Hs 12876ESTs3.3111131N64267Hs 10177ESTs3.3115019AA251906Hs.48473ESTs3.3116019AA450312Hs 237480mRNA, cDNA DKFZp434E102 (from cl3.3118528N67889Hs 49397ESTs3.3124027F03625Hs 107537ESTs3.3131699R68657Hs.90421ESTs; Moderately similar to !!!! ALU SUBFAMIL3.3111044N55443Hs.23625ESTs3.3103768AA089997Hs 180320ESTs, Weakly similar to GOLGI 4-TRANSMEMBRANE3.3131882N49091Hs 3385ESTs, Highly similar to CGI-134 protein [H.sa3.3123673AA609471Hs 112712ESTs3.3132936AB002305Hs 6111KIAA0307 gene product3.3103023X53793Hs.117950multifunctional polypeptide similar to SAICAR3.3120572AA280794Hs 258787ESTs3.3132384AA479933Hs 46967Human DNA sequence from clone 167A19 on chrom3.3105658AA282914Hs 10176ESTs3.2105086AA147719Hs.159441ESTs3.2118695N71781Hs 50081mRNA full length insert cDNA clo3.2112092R44538Hs 140889ESTs3.2125154W38419Hs.24936ESTs3.2108040AA041551Hs 48644ESTs3.2133453M68941Hs 73826protein tyrosine phosphatase; non-receptor ty3.2124006D60302Hs 108977ESTs3.2116083AA455653Hs 44581ESTs; Weakly similar to HEAT SHOCK 70 KD PROT3.2106753AA476944Hs 7331ESTs3.2102621U66075Hs 50924GATA-binding protein 63.2103330X85373Hs.77496small nuclear ribonucleoprotein polypeptide G3.2128926AA481403Hs.107213ESTs, Highly similar to NY-REN-6 antigen [H.s3.2101167L15309Hs 193677zinc finger protein 141 (clone pHZ-44)3.2104055AA393755Hs 117211ESTs, Highly similar to CGI-62 protein [H.sap3.2112917T10196Hs 4263ESTs, Weakly similar to/prediction3.2120358AA213459Hs 100932transcription factor 173.2121857AA426017Hs.62694ESTs, Highly similar to DNA-REPAIR PROTEIN CO3.2122124AA434257Hs 186679ESTs; Moderately similar to !!!! ALU SUBFAMIL3.2132231H99131Hs 42635ESTs3.2134272X76040Hs 223014protease; serine, 153.2115860AA431719Hs.61809ESTs3.2115278AA279757Hs.67466ESTs, Weakly similar to BACN32G11 d [D.melano3.2134125R38102Hs 50421KIAA0203 gene product3.2129160AA131252Hs 109007ESTs3.2121710AA419011Hs 96744DKFZP586D0823 protein3.2102242U27185Hs 32943retinoic acid receptor responder (tazarotene3.2104956AA074880Hs 120915ESTs, Weakly similar to hypothetical protein3.2113047T25867Hs.7549ESTs3.2115017AA251880Hs 179982tumor protein p53-binding protein3.2133780M14219Hs 76152decorin3.1129453AA421213Hs 111632Lsm3 protein3.1130353X86018Hs 172210MUF1 protein3.1106036AA412505Hs.10653ESTs3.1102234U26312Hs 8123chromobox homolog 3 (Drosophila HP1 gamma)3.1106133AA424346Hs 107573sialyltransferase3.1116803H47357ESTs, Moderately similar to weak similarity t3.1106721AA465194Hs 6670ESTs3.1107115AA610108Hs 27693ESTs; Highly similar to CGI-124 protein [H.sa3.1133228N90029Hs 6831clone 1400 unknown protein mRNA;3.1104733AA019498Hs.23071ESTs3.1103879AA228148Hs 50252ESTs, Weakly similar to putative [C. elegans]3.1103038X54941Hs 77550CDC28 protein kinase 13.1135154AA126433Hs.173242sorting nexin 43.1114860AA235112Hs 106227ESTs, Moderately similar to similar to murine3.1102437U46569Hs 221986aquaporin 53.1100352D64159mRNA for 3-7 gene product parti3.1103631Z48570H. sapiens Sp17 gene3.1104238AB002364Hs.27916a disintegrin-like and metalloprotease (repro3.1108613AA100967Hs 69165ESTs3.1115915AA436884Hs 48926ESTs3.1120640AA286945Hs 163933ESTs3.1124068H03099Hs 101619ESTs3.1130375U91931Hs.155172adaptor-related protein complex 3, beta 1 sub3.1131632AA443671Hs.29826ESTs3.1131523H88801Hs 201676M phase phosphoprotein 10 (U3 small nucleolar3.1115827AA427890Hs 44426ESTs; Weakly similar to PHOSPHOLIPID HYDROPER3.1108828AA131584Hs.71435DKFZP564O0463 protein3.1112198R49483Hs 22159ESTs, Weakly similar to ZINC FINGER PROTEIN H3.1123960AA621785Hs 170008methylmalonate-semialdehyde dehydrogenase3.1131538Z29331Hs.28505ubiquitin-conjugating enzyme E2H (homologous3.1105616AA280670Hs 24968ESTs3.1101228L27706Hs 82916chaperonin containing TCP1; subunit 6A (zeta3.1100280D42085Hs 155314KIAA0095 gene product3.1132744X54326Hs 55921glutamyl-prolyl-tRNA synthetase3.1103105X61970Hs.76913proteasome (prosome; macropain) subunit, alph3.1106984AA521201Hs.7129ESTs3.1105127AA158132Hs 11817ESTs; Weakly similar to contains similarity t3.1102302U33052Hs 69171protein kinase C-like 23.1117708N45114Hs 46476ESTs3.1111314N74574Hs 33922H. sapiens novel gene from PAC 117P20; chromos3.0132902AA490969Hs 168147ESTs3.0130356X84373Hs.155017nuclear receptor interacting protein 13.0128420AI088155Hs 14146ESTs, Weakly similar to unknown [H. sapiens]3.0108746AA126974Hs 43388ESTs3.0127236AI341818Hs 98658budding uninhibited by beazimidazoles 1 (yeas3.0114208Z39301Hs.7859ESTs3.0107071AA609053Hs 35198ESTs3.0104957AA074919Hs 10026ESTs; Weakly similar to ORF YJL063c [S.cerevi3.0124073H05394Hs.127376KIAA0266 gene product3.0130869AA128100Hs 2057uridine monophosphate synthetase (orotate pho3.0101232L28997Hs 242894ADP-ribosylation factor-like 13.0104276C02193Hs 85222ESTs, Weakly similar to R27090_2 [H. sapiens]3.0126160N90960Hs 247277ESTs, Weakly similar to transformation-relate3.0128584M11433Hs.101850retinol-binding protein 1, cellular3.0100405D86425Hs 82733nidogen 23.0101335L49054t(3;5)(q25 1, p34) fusion gene NP3.0108761AA127514Hs 61603ESTs3.0111346N89829Hs.13259ESTs3.0114988AA251089Hs 94576ESTs; Weakly similar to phosducin; retinal [H3.0116008AA449338Hs.48589ESTs; Weakly similar to finger protein HZF6;3.0116545D20313Hs 74899ESTs3.0117873N49967Hs 46624ESTs3.0121463AA411745Hs.239681ESTs, Weakly similar to KIAA0554 protein [H.s3.0128625AA242816Hs 102652ESTs, Weakly similar to KIAA0437 [H. sapiens]3.0131185M25753Hs 23960cyclin B13.0134380D38073Hs 179565minichromosome maintenance deficient (S cere3.0105740AA293206Hs 10852ESTs3.0130919AA291710Hs 21276collagen; type IV; alpha 3 (Goodpasture antig3.0134423W96151Hs.83006ESTs, Highly similar to CGI-139 protein [H.sa3.0104896AA054228Hs.23165ESTs3.0134407X72964Hs 82794caltractin (20 kD calcium-binding protein)3.0106378AA445994Hs 21331ESTs3.0112283R53545Hs 20952clone 24411 mRNA sequence3.0109018AA156960Hs 114992ESTs3.0114239Z39742Hs 222478ESTs3.0114969AA250775Hs.87747ESTs3.0116408AA608752Hs 71969mRNA, cDNA DKFZp564P0823 (from c3.0115286AA279803Hs 82204ESTs2.9105809AA393827Hs 20104ESTs2.9113811W44928Hs 4878ESTs2.9107248D59894Hs.34782ESTs2.9134489U09284Hs 112378LIM and senescent cell antigen-like domains 12.9134064D87685Hs 78893KIAA0244 protein2.9127370AI024352Hs.70337immunoglobulin superfamily, member 42.9113277T65797Hs 11774protein (peptidyl-prolyl cis/trans isomerase)2.9132783N74897Hs 5683DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide2.9109010AA156460Hs 44229dual specificity phosphatase 122.9130095F01831Hs.14838ESTs2.9106618AA459249Hs 8715ESTs, Weakly similar to Similarity with snail2.9103427X97303H. sapiens mRNA for Ptg-12 protein2.9133980D00760Hs 181309proteasome (prosome, macropain) subunit; alph2.9111353N90430Hs.6616ESTs2.9105344AA235303Hs 8645ESTs2.9134498M63180Hs 84131threonyl-tRNA synthetase2.9117910N50828Hs 12940zinc-fingers and homeoboxes 12.9118903N90774Hs 132207ESTs; Moderately similar to !!!! ALU SUBFAMIL2.9121713AA419198Hs 105577ESTs2.9129080H19307Hs.108507ESTs2.9129404AA172056Hs.111128ESTs2.9129457X55330Hs 207776aspartylglucosaminidase2.9130352D87450Hs 154978KIAA0261 protein2.9133415X69699Hs.73149paired box gene 82.9120649AA287115Hs.99697ESTs2.9131257AA256042Hs 24908ESTs2.9134480AA024664Hs 83916NADH dehydrogenase (ubiquinone) 1 alpha subco2.9116734F13789Hs 93796DKFZP586D2223 protein2.9105028AA126719Hs.25282ESTs2.9114986AA251010Hs 87807ESTs2.9105651AA282481Hs 18439ESTs2.9101714M68874Human phosphatidylcholine 2-acylhydrolase (cP2.9123398AA521265Hs 105514ESTs2.9106007AA411462Hs 11042ESTs; Weakly similar to veli 1 [H. sapiens]2.9109450AA232183Hs 173042ESTs, Weakly similar to !!!! ALU SUBFAMILY J2.9104685AA010530Hs.9599Human BAC clone GS025M02 from 7q21-q222.9108677AA115629Hs 118531ESTs2.9116028AA452112Hs.42644thioredoxin-like2.9105404AA243303Hs 21187ESTs2.9132365AA598694Hs 46541PAC clone DJ0894A10 from 7q32-q32.9119638W52480Hs 56148ESTs, Moderately similar to NY-REN-58 antigen2.9124637N80716Hs.75798Human DNA sequence from clone 1183I21 on chro2.9130588AA287735Hs 16411Human DNA sequence from clone 1189B24 on chro2.9105640AA281623Hs 7525ESTs, Weakly similar to KIAA0742 protein [H.s2.9131818Z39297Hs 3281neuronal pentraxin II2.9119298T23820Hs.155478cyclin T22.9128742D00763Hs 251531proteasome (prosome; macropain) subunit, alph2.9115089AA255876Hs 86919ESTs, Weakly similar to !!!! ALU SUBFAMILY J2.9100468D89289Hs 118722fucosyltransferase 8 (alpha (1:6) fucosyltran2.8132920L06133Hs 606ATPase; Cu++ transporting, alpha polypeptide2.8113490T88700Hs 173374ESTs2.8133451Y00764Hs.73818ubiquinol-cytochrome c reductase hinge protei2.8128770H98645Hs 143460protein kinase C; nu2.8129122N62515Hs 108790ESTs2.8104827AA035630Hs 8551PRP4/STK/WD splicing factor2.8111348N90041Hs 9585ESTs2.8130987R45698Hs.21893ESTs, Weakly similar to cAMP inducible 2 prot2.8102139U15932Hs 2128dual specificity phosphatase 52.8114902AA236359Hs 39504ESTs2.8106094AA419461Hs 18127ESTs2.8126438N93125Hs 137300ESTs2.8107129AA620553Hs.4756flap structure-specific endonuclease 12.8104491N71513Hs 39328ESTs2.8105043AA132239Hs 11810ESTs, Weakly similar to CD4 2 [C. elegans]2.8106855AA486182Hs 17975ESTs2.8109695F09530Hs 180591ESTs; Weakly similar to R06F6 5b [C. elegans]2.8120455AA251083Hs 104347ESTs2.8130861N23393Hs.20509ESTs2.8131649AA481254Hs 30120ESTs2.8128517AA280617Hs 100861ESTs, Weakly similar to p60 katanin [H.sapien2.8100486HG1112-HT1112Ras-Like Protein Tc42.8116729F13700Hs.115823ribonuclease P, 40 kD subunit2.8101851M94250Hs 82045midkine (neurite growth-promoting factor 2)2.8115465AA286941Hs 43691ESTs2.8100137D13627Hs 15071chaperonin containing TCP1, subunit 8 (theta)2.8125837H05323Hs.146401endothelial monocyte-activating polypeptide2.8131562U90551Hs 28777H2A histone family; member L2.8129445AA306121Hs 111515ESTs, Weakly similar to predicted using Genef2.8129239D31544Hs.109701ESTs; Moderately similar to weak similarity t2.8106507AA452584Hs.91585protein phosphatase 1, regulatory (inhibitor)2.8101664M60752Hs 121017H2A histone family; member A2.8129426AA412087Hs 168272EST, Highly similar to protein inhibitor of a2.8103437X98260Hs 82254M-phase phosphoprotein 112.8129821F11019Hs 12696cortactin SH3 domain-binding protein2.8130160Z39228Hs 151344UDP-Gal.betaGlcNAc beta 1;3-galactosyltransfe2.8104257AF006265Hs.9222estrogen receptor-binding fragment-associated2.8116204AA465701Hs 108646ESTs2.8125914AA262925Hs 180034cleavage stimulation factor: 3′ pre-RNA, subu2.8131510AA207114Hs 27842ESTs, Weakly similar to similar to 1-acyl-gly2.8106291AA435551Hs 30824ESTs2.8122761AA459296Hs 105039ESTs; Weakly similar to !!!! ALU SUBFAMILY J2.8107056AA600310Hs.18720programmed cell death 8 (apoptosis-inducing f2.8108535AA084505Hs.226440clone 24881 mRNA sequence2.8116226AA478729Hs 76450ESTs2.8120266AA173939Hs 193902ESTs, Weakly similar to inner centromere prot2.8128654H20689Hs 103180actin-like 62.8116726F13681Hs.42309ESTs2.7132640U33821Tax1 (human T-cell leukemia virus type I) bin2.7133273AA147725Hs 69469dendritic cell protein2.7108846AA132983Hs 44155DKFZP586G1517 protein2.7105621AA280865Hs 6375mRNA; cDNA DKFZp564K0222 (from c2.7129164AA282183Hs 109045ESTs2.7133618U78524Hs.75251DEAD/H (Asp-Glu-Ala-Asp/His) box binding prot2.7120521AA258785Hs 107476ATP synthase, H− transporting, mitochondrial2.7116429AA609710Hs 82837Human chromosome 3p21.1 gene sequence2.7110984N52006Hs 80120UDP-N-acetyl-alpha-D-galactosamine polypeptid2.7100372D79997Hs 184339KIAA0175 gene product2.7125134W19228Hs 100748ESTs2.7129254AA453624Hs.1098deoxynucleotidyltransferase, terminal2.7102339U37022Hs 95577cyclin-dependent kinase 42.7106589AA456646Hs 28661ESTs2.7119118R44122Hs 42743ESTs, Weakly similar to predicted using Genef2.7105973AA406320Hs 21201DKFZP566B0846 protein2.7106317AA436568Hs.172140ESTs2.7115551AA365527Hs 177861ESTs, Highly similar to CGI-110 protein [H.sa2.7103789AA096178Hs 70337immunoglobulin superfamily; member 42.7105079AA143190Hs 12677ESTs; Highly similar to CGI-147 protein [H.sa2.7109299AA205649Hs.86371zinc finger protein 2542.7122089AA432136Hs 98682ESTs2.7129108L20321Hs 1087serine/threonine kinase 22.7129385D82675Hs 110950clone 25007 mRNA sequence2.7131412U34044Hs 124027SELENOPHOSPHATE SYNTHETASE, Human selenium d2.7104052AA393164Hs 97644mammaglobin 22.7116254AA481146Hs.41086ESTs, Weakly similar to OXYSTEROL-BINDING PRO2.7106878AA488872Hs.12314mRNA, cDNA DKFZp586C1019 (from c2.7114652AA101416Hs 107149ESTs, Weakly similar to PTB-ASSOCIATED SPLICI2.7106831AA482014Hs 29463centrin, EF-hand protein; 3 (CDC31 yeast homo2.7101445M21259Hs 1066small nuclear ribonucleoprotein polypeptide E2.7124428N36881Hs.82202ribosomal protein L172.7114471AA028074Hs 103387ESTs2.7102051U07550Hs 1197heat shock 10 kD protein 1 (chaperonin 10)2.7106916AA490814Hs.24170ESTs; Weakly similar to ribosomal S1 protein2.7116142AA460649Hs 39457ESTs2.7109912H05509Hs 24639ESTs2.7103193X70476Hs.75724coatomer protein complex, subunit beta 2 (bet2.7102046U07151Hs 182215ADP-ribosylation factor-like 32.7104567R64534Hs 101469ESTs2.7112996T23539Hs 7165zinc finger protein 2592.7118138N57773Hs 93560ESTs, Weakly similar to trg [R.norvegicus]2.7123095AA485724Hs 192119ESTs2.7124315H94892Hs 6906v-ral simian leukemia viral oncogene homolog2.7124447N48000Hs.140945mRNA, cDNA DKFZp586L141 (from cl2.7132834H77546Hs 57898ESTs, Highly similar to NY-REN-49 antigen [H2.7107529Y12065Hs 5092nucleolar protein (KKE/D repeat)2.7130648AA075427Hs.17296ESTs, Weakly similar to /prediction2.7106685AA461551Hs 16251ESTs; Highly similar to 73 kDA subunit of cle2.6133848AA093287Hs 76728ESTs2.6134880AA092376Hs 9060615 kDa selenoprotein2.6128871AA400271Hs 106778mRNA for putative Ca2+ transport2.6106846AA485223Hs 34892ESTs2.6119892W84548Hs.94896ESTs2.6132309AA460917Hs 2780Jun D proto-oncogene2.6132923U21858Hs 60679TATA box binding protein (TBP)-associated fac2.6114365Z41688Hs 18653ESTs2.6114162Z38909Hs 22265ESTs2.6133370AA156897Hs 72157DKFZP56411922 protein2.6106818AA480890Hs 3542ESTs2.6133501W16684Hs 74284ESTs; Moderately similar to Similar to S cere2.6100530HG1869-HT1904Male Enhanced Antigen2.6130553AA430032Hs 252587pituitary tumor-transforming 12.6108917AA137078Hs 173648ESTs2.6122249AA436679Hs 258543ESTs, Highly similar to CGI-07 protein [H.sap2.6119598W45531Hs.94642ESTs2.6119902W84865Hs 40094Human DNA sequence from clone 167A19 on chrom2.6133272AA465016Hs 69423kallikrein 102.6132575AA045365Hs 5188ESTs; Weakly similar to 60S RIBOSOMAL PROTEIN2.6130459AA460264Hs.155983KIAA0677 gene product2.6133083N70633Hs 6456chaperonin containing TCP1, subunit 2 (beta)2.6131130T19399Hs 23255nucteoporin 155 kD2.6112043R43317Hs 26312glioma amplified on chromosome 1 protein (leu2.6116146AA460701Hs 193200ESTs2.6122378AA446100Hs 103617ESTs2.6103134X65724Hs 2839Norrie disease (pseudoglioma)2.6133395AA491296Hs 72805ESTs2.6115652AA405098Hs.38178ESTs2.6104975AA086071Hs 50758chromosome-associated polypeptide C2.6134691M59979Hs 88474prostaglandin-endoperoxide synthase 1 (prosta2.6112869T03313Hs 4747dyskeratosis congenita 1; dyskerin2.6100092AF000231Hs.75618RAB11A, member RAS oncogene family2.6102635U66838Hs 79378cyclin A12.6104490N71503Hs 43087ESTs; Weakly similar to dysferlin [H. sapiens]2.6106813AA479922Hs.181022ESTs2.6106872AA487907Hs 18282ESTs, Highly similar to unknown [H. sapiens]2.6107022AA599041Hs 28866programmed cell death 102.6107113AA610073Hs 23900ESTs; Weakly similar to oligophrenin-1 like p2.6113281T66300Hs.112356mRNA for lipoyltransferase; comp2.6115586AA399218Hs 92423ESTs2.6115779AA424183Hs 70945ESTs2.6122895AA469946Hs 105325ESTs2.6124726R15740Hs.104576carbohydrate (keratan sulfate Gal-6) sulfotra2.6129775R94659Hs 12420ESTs2.6131991AA251909Hs 36708budding uninhibited by benzimidazoles 1 (yeas2.6132518D57975Hs 5064ESTs2.6134612AA451712Hs.171581ESTs, Highly similar to ubiquitin C-terminal2.6130313AA620323Hs 154320ubiquitin-activating enzyme E1C (homologous t2.6131971R70167Hs 3611ESTs2.6133175AA134767Hs 66666ESTs2.6102083U10323Hs 75117interleukin enhancer binding factor 2, 45 kD2.6125670AI432621Hs.82685CD47 antigen (Rh-related antigen; integrin-as2.6121822AA425107Hs 97016ESTs; Moderately similar to SH3 domain-bindin2.6106719AA465171Hs 236844ESTs2.6130029AA236412Hs 236510ESTs; Moderately similar to PFT27 [M. musculus2.6124328H97781Hs.14415ESTs, Highly similar to CGI-108 protein [H.sa2.6105387AA236951Hs.108636chromosome 1 open reading frame 92.6103073X59417Hs 74077proteasome (prosome; macropain) subunit; alph2.6116294AA489000Hs 93748ESTs, Moderately similar to TRANSCRIPTION FAC2.6135339D59269Hs.127842mRNA full length insert cDNA clo2.6125390H95094Hs.75187translocase of outer mitochondrial membrane 22.6102504U52077Hs 247948Human mariner1 transposase gene, complete con2.6131076H44386Hs 22666ESTs2.6114096Z38342Hs 27007chromosome condensation 1-like2.6120402AA234339Hs 50282GTP-binding protein ragB2.6102125U14550Hs 107573sialyltransferase2.6134653AA452818Hs.87385ESTs2.6101959S80343Hs 180832arginyl-tRNA synthetase2.6116766H13260Hs 95097ESTs2.6104954AA074514Hs 26213ESTs, Weakly similar to protein [H. sapiens]2.5108771AA127924Hs 71034ESTs2.5116439AA610068Hs.43913PIBF1 gene product2.5133859U86782Hs 17876126S proteasome-associated pad1 homolog2.5132792AA401903Hs 242985hemoglobin, gamma G2.5129620AA010686Hs 239720ESTs; Weakly similar to KIAA0691 protein [H. s2.5120296AA191353Hs.22385ESTs, Weakly similar to KIAA0970 protein [H. s2.5115615AA401186Hs 48617ESTs2.5102983X17620Hs 118638non-metastatic cells 1; protein (NM23A) expre2.5106288AA435536Hs 24336ESTs2.5107444W28391Hs.5181proliferation-associated 2G4, 38 kD2.5104525R16007Hs.75355ubiquitin-conjugating enzyme E2N (homologous2.5128917AA204876Hs 206097oncogene TC212.5102299U32907Hs 15554537 kDa leucine-rich repeat (LRR) protein2.5115363AA282071Hs 152759activator of S phase kinase2.5130399AA449417Hs 155356mRNA for putative glucosyltransf2.5130752D50927Hs.18895tousled-like kinase 12.5132724AA417962Hs 55498geranylgeranyl diphosphate synthase 12.5106743AA476352Hs 21938ESTs, Weakly similar to KIAA0704 protein [H.s2.5128949AA190993Hs 8850a disintegrin and metalloproteinase domain 122.5125685AI040346Hs.4943hepatocellular carcinoma associated protein,2.5105826AA398243Hs 21806ESTs; Moderately similar to similar to NEDD-42.5110841N31610Hs 18645ESTs, Weakly similar to partial CDS [C.elegan2.5111987R42036Hs 6763KIAA0942 protein2.5132669AA188378Hs 54602ESTs; Weakly similar to 60S RIBOSOMAL PROTEIN2.5100398D84557Hs.155462minichromosome maintenance deficient (mis5; S2.5130800AA223386Hs 19574ESTs; Weakly similar to katanin p80 subunit [2.5114481AA033562Hs 151572ESTs2.5113404T82323Hs 70337immunoglobulin superfamily, member 42.5100260D38491Hs 174135KIAA0117 protein2.5103563Z22534Hs.150402activin A receptor, type I2.5104573R68952Hs.29780ESTs2.5105025AA126336Hs 22744ESTs, Weakly similar to ZINC FINGER PROTEIN 12.5105524AA258158Hs.22153ESTs; Weakly similar to KIAA0352 [H. sapiens]2.5106157AA425367Hs 32094ESTs2.5107243D59489Hs 34727ESTs2.5109920H05733Hs 30558ESTs2.5109981H09552Hs 26090ESTs, Weakly similar to T20B12 1 [C. elegans]2.5114518AA046407Hs 106469suppressor of var1 (S cerevisiae) 3-like 12.5114768AA149007Hs.182339Ets homologous factor2.5118906N91000Hs 94433ESTs2.5119025N98926Hs 55209ESTs, Weakly similar to DMR-N9 PROTEIN [H.sap2.5131712N29502Hs 30991KIAA0957 protein2.5132233X04706Hs.93574homeo box D32.5132740AA227751Hs 55896ESTs2.5115239AA278650Hs 73291ESTs, Weakly similar to similar to the beta t2.5128820F10338Hs.106309Friend of GATA22.5124049F10523Hs 74519primase, polypeptide 2A (58 kD)2.5128781X85372Hs 105465small neclear ribonucleoprotein polypeptide F2.5121361AA405494Hs 183052ESTs2.5134133X93920Hs 180383dual specificity phosphatase 62.5102502U51678Hs.78050small acidic protein2.5115875AA433943Hs.43946ESTs, Weakly similar to Weak similarity to Ye2.5132874AA425776Hs 58609ESTs2.5109646F04543Hs 5028DKFZP564O0423 protein2.5111197N68093Hs 22909ESTs2.5102968X16396Hs 154672methylese tetrahydrofolate dehydrogenase (NAD2.5124911R88992Hs 123645ESTs2.5106628AA459657Hs 12311close 23570 mRNA sequence2.5116988H82527ys69e12.s1 Soares retina N2b4HR Homo sapiens2.5131075Y00757Hs 2265secretory granule; neuroendocrine protein 1 (2.5133578X78627Hs 75066translin2.5100420D86983Hs.118893p53-responsive gene 22.5130743W87710Hs 18724Homo sapiens mRNA, cDNA DKFZp564F093 (from cl2.5122465AA448164Hs 99153ESTs, Highly similar to CGI-73 protein [H.sap2.5115117AA256492Hs 49007poly(A) polymerase2.5124582N68477Hs 108408ESTs; Highly similar to CGI-78 protein [H.sap2.5104771AA025911Hs.24994ESTs; Highly similar to CGI-53 protein [H.sap2.5108059AA043944Hs 62663ESTs2.5105628AA281251Hs 35696ESTs, Weakly similar to putative zinc finger2.5109261AA195255Hs 61779ESTs2.5119789W73140Hs 50915kallikrein 52.5130512AA045304Hs 181271ESTs; Highly similar to CGI-120 protein [H.Sa2.5134402U25165Hs.82712fragile X mental retardation, autosomal homol2.5104769AA025887Hs 114774ESTs, Weakly similar to !!!! ALU SUBFAMILY J2.5125787AA744748Hs 29403ESTs, Weakly similar to PROBABLE ATP-DEPENDEN2.5131775AA459555Hs 31921KIAA0648 protein2.5Pkey: Primekey Ex. Accn. Exemplar Accession UG ID UniGene ID Title: UniGene Title ratio: ration tumor vs normal tissues


[0368]

20







TABLE 7B








Pkey
CAT Number
Accession







101335
46413_1
L49054 N87447 AA248791 AA452193 AI015525 AI762070 AA781526




AW183498 AA625682 AI268713 AA400391 AI193725 AW590304




W56360 AA936067 AI990398 AA406183 AA628888 AA844206 AA621117




AI141092 AI808150 BE379750 AI351482 AA093527 AA405119




AA400562 AW368723 AA463811 AW242927 R50034 W56334 F21257




AA164314 BE074125 AA470924 AI307439 W16738 AA026647




T35999 T19178 AA164313 AI744010 AI015466 AI014921


100906
4312_1
AU076916 BE298110 AW239395 AW672700 NM_003875 U10860 AW651755




BE297958 C03806 AI795876 AA644165 T36030 AW392852




AA446421 AW881866 AI469428 BE548103 T96204 R94457 N78225




AI564549 AW004984 AW780423 AW675448 AW087890 AA971454




AA305698 AA879433 AA535069 AI394371 AA928053 AI378367




N59764 AI364000 AI431285 T81090 AW674657 AW674987 AA897396




AW673412 BE063175 AW674408 AI202011 R00723 AI753769 AI460161




AW079585 AW275744 AI873729 D25791 BE537646 T81139




R00722


102221
3861_1
NM_006769 U24576 AW161961 AW160473




AW160465 AW160472 AW161069 AI824831 AW162635 AI990356 AW162477 AW162571




AI520836 AW162352 AW162351 AW162752 AI962216 AI537346 AA853902




H17667 BE045346 BE559802 BE255391 AA985217 AA235051




AI129757 AW366451 T34489 D56106 D56351 AI936579 AW023219 AW889335




AW889120 AW889232 AW889175 BE093702 AW889349




AA147546 AI952998 AA912579 AI143356 AW902211 R64717 AW157236




AI815242 D45274 AW263991 AA442920 AA129965 AL035713




AI923255 AI949082 AI142826 AI684160 AI701987 AI678954 AI827349




BE463635 AW628092 AW302281 AA493203 BE348856 BE536419




AW193969 AW673561 AW592609 AI224044 H43943 AA091912 R49632 R48353




AI568409 R48256 AI198046 H27986 H43899 AI678759




AI680310 AI624220 H17052 AA156410 N56062 AI699430 AA664529 T09406




T10459 AA627506 AI379584 N83831 N88633 AW022651




AA971281 AA248036 AI039197 AI914689 AA973825 AL047305 AA129966




AI798369 AW264348 AI445879 AI658759 N67924 AI933507




AI216121 AI333174 T10972 AI375028 AI186756 AI273778 AA610487




AI797946 AA853903 AA903939 AI338587 AI278494 AW627595




AA904019


101714
30725_1
M68874 AL022147 M72393 AL049797 BE439441 T27650 AI766240 AW150345




AW778943 AI627464 BE439479 AA587049 AI277900




AI984983 AI630935


116803
55078_4
H47357 W33034 H55976 H55975 R67830 AA527091 F24482 AW841585 R66514


116988
185904_1
AW953679 AW953680 AA244436 H82527 AA361046 AA244483 H82526


132640
179_1
AW162087 AA224538 AA471218 AA088655 AA375275 BE440052




AF090891 AA324435 AF063549 AI10675 AA322223 AW953306




AA233590 AW949864 AW949859 AA383721 AA081878 U33821




NM_006024 AA350900 AA081588 AI148087 AF268075 AA088185




AI142478 AA081824 AI887930 AA070570 BE185248 AI459825




BE257794 AA420459 AA420859 AA777997 AA081219 AW815721




AW854758 AA157932 BE018208 AW378974 AL041212 AI247564




AW581897 AI002897 BE543242 AI811690 AW852076 AW852270




AA360969 AA094943 AA090680 AW601554 AA099673 AA662226




AA356814 AA330174 AA187544 C02751 AA315460 BE168358




AW080447 AI813764 AI624222 AW156901 AI954032 AW473780




AI861975 AA173643 AW511541 AI951492 BE301686 AA669760




BE182212 AA081009 T69431 AI186207 AA604124 AA707346




AA173953 AI016700 AI125916 AA358962 AI673719 T90593 T90497 T10776




AW513002 AW304292 AA724885 AW474759 AI811621 AW068925




AA666305 AI580161 AI128023 AW471151 AA534849 AA666358




AI078833 AI139223 AI244874 AI381658 AW263441 AI432440




AW802882 N66401 A224251 AI167469 AI141060 AA099214 AI537130




AL120428 AA948655 D53110 AA076099 AA938617 AA826543 AI357914




AA565098 AA807994 AI288812 AA632832 AA157933 AA639802




AA634268 AA282337 AA551431 AA557374 AA256923 AA872943




AA009665 H89626 AA810386 T92925 T36145 AA632190 AA130436




AI686635 AA130437 AW392904 AW392839 AW392848 AW392836




AA729737 AA070450 AW392890 W04825 AA771848 AA084634




AA481985 AI263840 AI801006 AA235380 AI954229 AI559330




AI208724 AA887638 T25894 AA041269 W44443 AI581770 W46171




AA878485 W46535 AA197336 AA894945 AA394224 AI766834 AI582590




AI033007 AA481889 AW190598 AW392855 R27279 AA398137




AI248407 AI241386 AI991753 AI826585 AA865699 AI096806




AI833030 AA041279 AW888745 AI703279 N70572 AI912553 BE549931




AI240422 AW376187 AW591692 AA975905 AW614967 AA009666 W44332




AA664659 T06561 BE468150 AI650695 AA587920 AI473310




AI032991 AA256499 AW104241 BE163782 AI984973 BE163613 AI263906




AA628191 AA282072 BE163769 BE163775 AI492939 AI473315




D56907 AA587930 H89480 AI362373 AA598483 D56595 AI167590 C16223




AI935415 D62555 D62884 D63130 AI760286 AI650286




AW173598 AI499145 AI122566 AW903408 AI810569 AA854936 BE049510




D62065 D61900 D62101 R27475 AI469835 AI669086 N80399




N48922 N48746 AA481381 R22858 H13912 AC004549 AW602500 AW768788


103427
43892_1
BE514383 AA071273 AW247987 AW673286 BE312102 AW749824




BE071985 AW577383 BE071945 BE072005 AW577355 BE071965




AW239231 BE072000 BE071960 AW577360 AW749830 AW373020




X97303 AW999522 BE000192 BE562219 BE266655 BE264970


103631
152_34
R64730 AF214731 T19173 BE258318 AF161446 BE542228 BE383856




BE206748 BE543260 AA640735 AA788907 BE251313 BE221852




AW855357 AA224407 AW855346 BE150454 AW070651 BE326867




AW051698 AI829278 AI470927 AW855345 AI804942 AI971004




BE046620 AI863664 AA808492 AI915971 BE046949 AW590711




AI468066 BE409685 AA332653 BE385394 AA852623 BE255591




BE254968 AA211871 BE255493 BE257727 BE255389 BE257491




BE262528 BE261296 BE313277 BE261714 BE314316 Z28434 AA315545




BE008562 BE012093 BE161393 T31969 AA305848 AW955238




BE619156 AI191748 AA323396 AW361760 AA216118 BE264939 AA325954




AW580281 AA302597 AW888908 AW888893 BE312970 AA134402




H52679 AA478191 T34090 AW961505 Z24771 AA179552 R57244




BE315207 AW583121 AI372747 T33143 AW377460 T33141 R14922




AW352414 H93249 AW405576 T33102 R89545 N46625 H08434




BE165062 AW367891 H93121 H47325 T30931 AW402852 H47410




Z20368 T18928 T30758 H93254 AW389725 R96628 AI372407 R88995




AI815980 AW157278 AW607664 AW163288 AA133492 AA099328




AA157348 AI816063 AW449556 AA157252 AW608980 H66576




AW821127 T32030 AW856058 AA032188 Z42120 R18582 AW402392




BE408021 AA280989 AA039427 AA035354 AW328008 T94186




R97481 AA181444 AA774697 BE613141 AW630221 H13066 AI124578




AW754481 BE262112 AW839942 H60108 AW364002 AW363800




BE547161 BE082634 AA642471 BE619719 BE082719 W28879 AW794944




C01685 AI291127 AW166099 AI936102 AI478929 R70284




AA872914 W31065 N54216 AI568741 H56262 NM_017425




Z48570 AI831777 T75007 AA354867 AA427988 AI922844 AA733170




AW821145 BE081547 AW881571 AW881573 AW055249 AA204724 AI417415




AI127303 AI355013 AI039527 AW593259 AA576745




AI457317 AW593236 H93126 BE396072 AL134941 AW629175 AI424011




AA115732 AA179986 AI334944 AW367922 AW152304 AA806752




AI312418 AW935023 BE301136 AA032258 AI829922 AI372406 BE177074




AW513743 AI151526 AA975643 AA478034 AI814920 AW080063




AI032624 BE177107 AA319768 AW935098 AI017620 AA974477 D51441




C14225 AL043583 D80145 AI690771 AW009711 AW881570




AI220431 N51090 AI143003 AA961480 AA039351 AI094885 AI096520




AA179553 AA593974 AI373929 AA677252 AA687374 AA886867




AA312863 AI150654 AI138450 AA133209 H99368 AI565632 AW070496




AI539748 H59455 AI811537 H52680 T74907 AI499657 R96670




AA854796 AA427863 AA224345 AA889899 AI347782 AA931056 AI076059




AI360841 AI797975 AI362268 AI200968 BE350785 R97433




N98499 AA134403 AA035355 AW263162 AI369607 D80144 AI376627




AI520801 AA365942 AI707705 AI123495 T33101 H08716 AA804238




AA922201 AA723522 AW183592 AI445884 F34614 AW022342 AA363998




AA568793 AA152475 D31233 AA852622 AA099862 AI129147




AA922699 AA782664 T33142 T30009 T32913 AI676138 AI914657 N34899




AI372746 AI265911 AI352444 AA443158 AA910603 AI420273




AA868050 AI277700 C14224 AW082087 R41447 Z38385 AI911845 AI961888




R91976 F04560 AA661955 AI857675 AA369666 AA424207




N79953 AA382958 AA894626 AI884964 AA846989 AA215454 AI742580




AI339437 AI806879 AI091373 AA782558 AI026868 AW590904




AW204599 BE348235 AI819318 AA122324 AA939221 AW139711 AA131608




AW613548 AA122286 AI309179 AA437247 AW339322




AI671306 AW439848 AA131701 AI078075 N64624 AA812881 AI140547


129097
25953_1
BE243933 AA355449 T29766 F08396 N83324 NM_006963 S50223




AI207648 AA258092 AA113952 AI311718 AI128612 AW607449 M77172




AI951311 X52346 AA903307 AI569810 N55421 W77876 R37223




R83788 AA031666 H47092 AA133451 AA311095 AA906963 H87667




N56058 AA393593 W24864 H10710 F06925 F07239 AW386140




AA325018 AA235950 AW373176 N57158 AA258093 N39467 R21609




BE089979 R34173 AW889005 AA745644 AI693852 AA424914




AA744771 W72632 AI291213 AA524318 AI472134 AI911230 AA528418




AA115745 AA775720 AI671134 AA975044 AW298117 AA321015




N26288 AW952194 AI743379 AI204233 AI801026 AA830690 AI146980




AW104611 AI338576 R21507 AI367623 BE244484 AI269308 AA031667




AI884346 AA731989 AA988943 AA235951 AA807887 AA642645




AI246489 N29739 AI216718 AI383349 AI038618 AI351476 AA806031




AI914178 H10711 AI095573 H89220 AW470854 AA729015 R83353




AA782239 R34295 H87165 AW419059 AI653689 Z40349 H89114




AW074506 AA397785 AA888377 AI911228 F03193 AI468783 AA702615




AI830829 AA748323 R37224 AA424915 AA731647 H47183


120695
9683_3
AA976503 AI917802 AA953664 AA404613 AA428771 BE280542 AW194691 AI927301




AI740458 AI796100 AI935603 AW052210 AA970201




AI633384 AA425910 AI017004 AI241295 AA402816 AA291468


100352
37786_1
AL133887 D64159 AF112218 AI766633 AL039303 AL133888 BE620604




AW976259 AW262792 AW591383 AI365413 N36652 AA807027




AI472041 BE620065


101084
13883_1
AW409934 AW245855 AU077157 AW163245 AW161434 AW250083 AA316055




BE621134 AA171883 BE272494 L05425 BE250310




NM_013285 BE311494 AA858436 AA308223 AW362598 AA373618 BE394454




AA126101 AA581348 AA303227 AA058438 AA126544




AL135350 AW996947 AA403201 AA446682 W79685 AW246249 AW577783




AW002316 AA320025 AW753913 AI798554 AW070650




BE250413 AW250835 BE076336 AI925558 AI907634 AW804193




AW804270 AA902387 AW804232 AW804255 AW607751 AI909114




AW157242 AA934590 AI628921 AI470650 AW409935 AW172793




AA401208 AW162279 AA888018 BE206452 AI826742 AA857353




AA483614 AA126418 AA722289 AA780182 AW768894 AW183614




AW156969 AI244063 AA863491 AI376281 AA582490 AA846248




AI474094 AW246802 AA446557 AA126000 AI699045 AI702310




AI253092 AA171554 AA831455 AW118384 AI954511 AI760439 AI867001




AA493881 W81287 AA515590 AA659297 AA635139 AA659293




AA766044 AA196109 N32569 AI907635


100502
26409_1
U15979 X17544 W52755 NM_003836 Z12172 AW370136 BE262564 T49116




AA333753 BE262238 BE313737 H38153 AW583056 R28890




BE259532 D16897 AA885610 AA911293 AA319627 R94472




R29022 AA443405 R96397 W04904 W01746 W01204 N74203 N58621




AA701996 AW418723 N53220 AA602813 AA576129 AA593786




AA911577 AA575957 AI149135 AW573058 AA772985 AI188918 AI372065




AA575838 W60010 AI004576 AI131265 AA319845 T50070 AI335742




AA235245 W32706 AA447372 R96355 N59573 AA904616 AI291224




BE467454 T49117 AI268620 AA928248 AA449494 AA318817 T49929




R94473 H38154 AI076649 AW935307 AW605112 AW935433




AW935342 AW935310 AW935345 AI298308 AW935395 AW935384




AI184857 AA319871 T29465 C21134 Z19785 AA329107 T52079




AW935346 C06234 AI951555 T49928 AA371745 AA369296 AA346673




R82547 T50006


102398
entrez_U42359
U42359






Pkey: Unique Eos probeset identifier number




CAT number: Gene cluster number




Accession Genbank accession numbers








[0369] TABLE 8A lists about 54 genes up-regulated in ovarian cancer compared to normal adult tissues These were selected from 35403 probesets on the Affymetrix/Eos-Hu01 GeneChip array such that the ratio of “average” ovarian cancer to “average” normal adult tissues was greater than or equal to 4.0 The “average” ovarian cancer level was set to the 3rd highest amongst various ovarian cancers. The “average” normal adult tissue level was set to the 4th highest amongst various non-malignant tissues. In order to remove gene-specific background levels of non-specific hybridization, the 15th percentile value amongst the non-malignant tissues was subtracted from both the numerator and the denominator before the ratio was evaluated
21TABLE 8AABOUT 54 UP-REGULATED GENES, OVARIANCANCER VERSUS NORMAL ADULT TISSUESPkeyEx. AccnUG IDTitleratio130941D49394Hs 21425-hydroxytryptamine (serotonin) receptor 3A12.1101249L33881Hs 1904protein kinase C, iota11.8132528AA283006Hs 50758chromosome-associated polypeptide C11.5102610U65011Hs.30743preferentially expressed antigen in melanoma11.0115536AA347193Hs 62180ESTs10.0129571X51630Hs 1145Wilms tumor 19.3105298AA233459Hs 26369ESTs7.8121779AA422036Hs 98367ESTs7.3104301D45332Hs 6783ESTs6.9132191AA449431Hs 158688KIAA0741 gene product6.7102136U15552Hs 85769acidic 82 kDa protein mRNA6.6101804M86699Hs.169840TTK protein kinase6.5132572AA448297Hs 237825signal recognition particle 72 kD5.9106738AA470145Hs 25130ESTs5.8108857AA133250Hs.62180ESTs5.8115291AA279943Hs 122579ESTs5.8132632N59764Hs 5398guanine-monophosphate synthetase5.8116401AA599963Hs.59698ESTs5.7132725L41887Hs 184167splicing factor, arginine/senne-nch 7 (35 kD5.7129097S50223HKR-T1=Kruppel-like zinc finger protein [huma5.6134520N21407Hs 257325ESTs5.5108778AA128548Hs.90847general transcription factor IIIC, polypeptid5.4131228AA279157Hs 24485chondroitin sulfate proteoglycan 6 (bamacan)5.2116238AA479362Hs 47144DKFZP586N0819 protein5.2108055AA043562Hs 62637ESTs5.1132939U76189Hs 61152exostoses (multiple)-like 25.1115909AA436666Hs 59761ESTs5.0120438AA243441Hs 99488ESTs; Weakly similar to ORF YKR074w [S.cerevi5.0123494AA599786Hs.112110ESTs5.0109648F04600Hs 7154ESTs4.9132624AA164819Hs 53631ESTs4.9111234N69287Hs 21943ESTs; Weakly similar to ORF YGL221c [S.cerevi4.9135242M74093Hs.9700cyclin E14.9123005AA479726Hs 105577ESTs4.8116296AA489033Hs 62601Homo sapiens mRNA; cDNA DKFZp586K1318 (from c4.7100661HG2874-HT3018Ribosomal Protein L39 Homolog4.6111345N89820Hs.14559ESTs4.6102627U66561Hs 158174zinc finger protein 184 (Kruppel-like)4.5106459AA449741Hs.4029glioma-amplified sequence-414.5102305U33286Hs 90073chromosome segregation 1 (yeast homolog)-like4.5129229AA211941Hs 109643polyadenylate binding protein-interacting pro4.5130376R40873Hs 155174KIAA0432 gene product4.4120619AA284372Hs 111471ESTs4.4122802AA460530Hs 256579ESTs4.4116416AA609219Hs.39982ESTs4.3115094AA255921Hs 88095ESTs4.2126802A4947601Hs 97056ESTs4.2126892AI160190Hs.76127hect (homologous to the E6-AP (UBE3A) carboxy4.2105516AA257971Hs 21214ESTs4.1131985AA434329Hs 36563ESTs4.1114965AA250737Hs.72472ESTs4.0120821AA347419Hs 96870Homo sapiens mRNA full length insert cDNA clo4.0134621L02547Hs 172865cleavage stimulation factor, 3′ pre-RNA, subu4.0134161U97188Hs 79440IGF-II mRNA-binding protein 34.0Pkey: Primekey Ex. Accn Exemplar Accession UG ID UniGene ID Title: UniGene Title ratio: ration tumor vs normal tissues


[0370]

22







TABLE 8B








Pkey
CAT Number
Accession







101249
2520_1
L18964 NM_002740 L33881 AA095249 BE080871 AW605320




M85571 AA179776 AA160650 AW117327 BE467131 AW088338 AW937631




AW087514 AI480090 AI873147 T57875 AI217404 AA827196 AI279471




AA969093 AA815168 AA988896 AI754623 T28044 AW950302




AW950294 AI032193 AI953696 AI630583 AA062633 BE541355




AA180493 AW015748 AA255651


100661
23182_1
BE623001 L05096 AA383604 AW966416 N53295 AA460213 AW571519 AA603655


116401
95855_1
AW893940 AW978851 AA034240 AI686323 AI767653 AA829515 AA053933




AA737691 W92607 AW261869 AA835698 AA447216 AI623248




Z21891 AA835700 AA599963 T20152 AA533167


116416
373989_1
AW753676 R11789 AW001886 AA609219 AW780420 AI860557 AI280331




AI334300 AI288870 AA669343 N29918 BE537790 AA934687




H79075 N42970 R63752


132191
54683_4
AA507576 AI610269 AI380079 R40309 AI203932 AI342128




AI342578 R43110 AW583269 AI375234 AI092708 R52802 AI1028462 AI016062




AI189144 AI016691 W45515 AA551452 AA449431 T10046 AA424059 N62822




AW197701 AA465242 AI418989 AI942433 AI891115 BE302316




AI743979 AI283341 AW340338 AA774643 AW104778 AI078020




N21487 H97562 AA970063 BE327945 F03880 F03885 AA970699 AI298468




AI380330 AI247787 AA770467 AI200154 AI089863 AI089890 AI695738




W88524 AI471010 AA700191 AA778937 BE440182 R79225 AA338236




AA548984 AA907692 N21250 AW904736 AI909337 AA987772 AW959228




AI149372 N29644 AI039967 AA677529 AI694291 R85811 N28672




AA465598 AA321185 AW130492 AI824479 AI682992


130941
2774_1
NM_000869 D49394 BE252349 AW249320 AW249140 AW250535




S82612 AJ003079 AJ005205 AW178407 AA811360 AW976407 AW976408




AW248903 AA731733 AA804189 AA703169 AI435492 AI076288




AA912176 AW248713 AA743457 R08170 C06167 R02351


115909
47548_1
AW872527 AA453863 AA442475 AF086541




AA365801 AI692575 AW131631 AA732993 W96131 AA436666 AA453779 AA365504 AW959717




AA975337 AA365503 AI632902 AA659686 AA665087 C00396 AA988869


108778
18565_1
AF133123 NM_012086 AA128292 S81493 AL137453 BE614053




AA307628 BE009521 BE085659 BE085542 BE085598 AL120654 R13165




AA429306 R13465 R55236 AW994182 W00838 AW994417 AW994404 AW994426




AW994321 AA516147 AA345603 AW953009 BE315104




AI126654 AA626457 AA291327 H67983 H66271 H67976 AW270955




AA758221 AI023487 AI921811 AI953370 AF085850 R70992 N25129




AW295143 AI433661 AW608361 AA873402 AI217453 AI953358




AA262143 AA928495 AI475268 AI167211 AW385961 AA259045 AI762630




AA428238 AI001932 AI735550 AI951370 AA766807 S81492 AA918976




AI040967 R70939 AA469065 T70340 AA477615 AA478070 AI017743




AI608833 AI635824 AI186039 AA741312 AI040184 H67656 AA258221




AA731316 AI381293 AW298473 R55237 R37375 AI768014 AA128548




AI206773 AI879827 R64193


102136
17647_1
AA300576 U15552 NM_014597 AA223318 AA171806 BE269461




AW578439 AW604388 AW953513 AA772816 AW604383 AW577851




BE169672 AW117711 AW366303 AW366302 AW366308 AW366304




AW366300 AI908432 AW591937 AI358420 AW272622 C75067 AI926471




AW002266 BE064947 BE064722 T10372 AW838681 AI811119 AW262098




AA588547 AI916666 AI440083 AI078150 F24260 AA512919




AI953413 AI064798 AI420425 AA191324 BE503222 AI632721 AA180035




AA558329 W44843 T10610 W38442 BE542869 AI125024 BE279566




AW747936 AI589491 AA559096 AI090265 AA548959 AA223220 AW515936




AW368395 AW368407 BE540776 AI039762 AI584020 AA171691


108857
61_1
AK001468 AA190315 AA374980 AW961179 AA307782 AA315295 AA347194




AW953073 AW368190 AW368192 AA280772 AA251247 N85676




AI215522 AI216389 N87835 R12261 R57094 AI660045




AA347193 R16712 AW119006 N55905 N87768 AW900167 AI341261 AI818674 D20285




AI475165 AA300756 R40626 AI122827 AA133250 AI952488




AA970372 AA889845 AW069517 AI524385 AA190314 AI673359 AA971105




AI351088 AI872789 AI919056 AI611216 AK001472 BE568761 AA581004


102305
18424_1
AL043202 U33286 NM_001316 AF053641 AL048759 N99830 AA263091 AW408174




N90467 R84306 AA317882 BE613644 AA307378 T10722




AA207207 AA315560 AA113938 AW386317 AW386316 L44546




AW386335 AA243317 AA713588 AA192541 AA649035 BE300737 AW752491




AW902334 AW993922 BE003403 AA251521 AA382754 AA339152 AA382619




H58600 H67810 T70379 T82109 D81644 D60375 H59003




BE075732 AA471242 H17790 F11801 T84903 R78076 BE614356 R16380




R16395 AA876127 W95535 AA164768 AI279876 H02142 C18698




AA365866 AW954410 AI539769 T39128 AL121103 AA192466 AA213367




AI963800 BE090601 Z20096 BE566508 AI969470 BE044090 T65536




AA837311 AA075484 AA075621 AA778294 AA587266 T69722 AA446118




X85624 AI334209 AI587101 AI281280 AA568602 AA946837 C75603




AA236997 AA459274 AI150191 AA165156 AI198839 AA789258 AI139373




AA236574 AI127770 AA678954 AI140786 AA113939 AI187231




AI754062 AI753243 AA934719 AW439362 H02038 C17463 AI400951




AA227539 N66040 R89384 AA872668 AI344110 W95420 AA164700




C05669 BE094097 AI826398 H58956 T17222 AW139044 AI271344




T16445 R42323 C75565 AA165228 AI025443 AA165229 C21496 AI826239




AI868711 AA582354 AA524392 R01549 R01641 Z21083 AA528463 T39127




AA989472 F09450 AA084485 BE004378 AW974353 AA137250




AI278406 AW609291 AA137249 AA142866 AA639198 AW609271




AW149760 AI025112 AA236620 AA937248 U90736 AW005487 AW674427




BE397971 AW609285 T65602 T99684 T97378 AW609366 T85647 AI572235




T99083 AA199583 AW303874 T35523 AA586445 Z39669




AA459503 N95643 AW821210 AW813461 AW582064 AW609293 AW609320




AW609270 AW582085 AW582071 AW609318 AW813451




AW813456 AW582079 AW609276 AW609280 AW609290 AW582101




AW582102 AW609263 AW609317 AW609256 AW609305 AW582063




F06655 AW605343 AA446426 BE090595 AW969578 T79852 AI082505




N63239 AI973168 AI086182 AA846711 AI874213 AA730605 AI927257




AA912624 D60376 T10180 AA705847 AI018123 AA493197 T67083




R77739 AA953087 R00885 AI370606 R01642 AA862914 N57843




AW023353 H77483 H68082 R42337 H58601 T97267


109648
708849_1
H17800 AI362549 AI671064 T23526 F03426 F04694 F04600 AI635856 Z38715




F02039 AW022635


132528
11027_8
T78736 AA284422 AA283006


101804
26687_1
M86699 NM_003318 AL133475 AA122377 Z21415 R57092 AA806569




AA811904 BE538323 R41558 AA421620 AI337292 AA470077




AW795371 AA543024 AI677941 AI472200 AI215042 AA732384




AA837143 AA804229 AI907533 AI742701 AA121159 AI973225 AI620839


132572
31281_1
AI929659 AA227827 AF069765 AW408768 NM_006947 AF077019 AA220974 H07969




C14621 D52294 BE512960 BE614138 BE258539




BE251981 AA355433 AA481126 AW403053 BE542282 AI929818 AL120605




AW753079 AW391834 BE018603 BE395262 W21406 AW663259




AW975690 W93905 W96519 AI863832 AA443177 AA730942 T99558




T86581 W19444 N55583 AI701020 AI928986 AI857864 AI590849




AW081819 AA714970 AI122630 W04887 AW662427 AA602680 W93645




AA582946 AW008812 AA311187 AA463631 AI421918 AI400518




AI921404 AA143770 AA587675 BE302192 AA813080 AI493386




AW327435 AW340871 AI143616 AA687231 AA218961 AI362249 AI378345




N74716 AW969249 AA468581 AA516399 AI274726 AI131244 AI572604




AI929236 AW327971 R65637 N90309 H07877 W96486 AI358806




T90801 AI383246 AI740957 T86758 AI471248 AI864233 AA910590




AI079094 AW805781 AA709025 AW196707 AW327436 AI903790




AI873956 T99348 AI924643 AW103910 AI802993 AI080390 T99098




D19794 AW327972 AI935904 AI288575 AW360875 AA779784 N93574




AW769295 W32639 AA363094 N89012 W39751 AI291329 AI291371




AA829411 AI985219 AI422775 AA918940 AA363108 AA192633




AF086131 AA373679 AA165043 AA355705 AI243507 AI027796 AA573461




AA757260 AI370979 AA574149 AA558276 N70650 AI478948




R35393 AA448435 AA334659 AW879356 AA436527 AW972044




W25165 AA521219 AI094141 AI302096 AW578551 AW578534 AW390535




AI131472 N50381 AA736938 AI089112 AA863053 AI359793




AA962268 T27353 D82590 AA448297 AI277168 AI368457 AA872737 AA330346




AA308346 AA342341 AA355159 T85701 BE162893 T99703


131985
113870_1
AA503020 AI858190 AI686571 AW615203 AW073686 AW172459 AI828762




AW150534 AI859795 AA411046 AI539195 AA404609 AI638559




AA434329 AA171844 AI684143 AA953518 AW470108 AI870700




AA706376 AI539668 AI683712 AA075579 AI682137 AA291512 AA554431




H51315 AA404225 AA075632 AA172293 H51911


132624
42095_1
AA326108 W74020 AW612698 AI750909 AA487800 AJ270695 AA044941 H20708




AA296750 AA018401 AA378581 AW964159 AA018887




R68533 AA525338 AA526640 H84308 AA278942 AA164818




AA847110 T82335 N25519 AA021474 N31381 N36297 AA838191 AA318932




AA961206 N41430 N41439 AW630477 W37595 BE394538




AA365256 N47771 N34873 AA988105 AI242138 AW148523 AI978761 N50882




AA527448 AW086200 AI750910 N50868 AA709437 N51946




AI222179 AA732883 H96742 AW615360 N53720 W37490 R87362 AA613273




H98999 AI469022 AI368442 AI460122 N20486 N24087 AA164819 N24878




AW471270 AW590458 R68240 AA594434 N20400 AI419626




AW500664 AI033658 AA593215 AA907408 AA713508 AI422627 H85551




AA923571 D62680 AW627456 H96206 AA016289 AA485896 N25691


132632
4312_1
AU076916 BE298110 AW239395 AW672700 NM_003875 U10860 AW651755




BE297958 C03806 AI795876 AA644165 T36030 AW392852




AA446421 AW881866 AI469428 BE548103 T96204 R94457




N78225 AI564549 AW004984 AW780423 AW675448 AW087890 AA971454




AA305698 AA879433 AA535069 AI394371 AA928053 AI378367




N59764 AI364000 AI431285 T81090 AW674657 AW674987 AA897396




AW673412 BE063175 AW674408 AI202011 R00723 AI753769 AI460161




AW079585 AW275744 AI873729 D25791 BE537646 T81139 R00722


102610
9336_1
U65011 NM_006115 AW182053 BE383930 BE407839 BE409930 BE408826




AW370292 AA312859 AA136204 AW365852 AW365735




BE622732 AW939295 AA781195 AI017284 AW375329 AW375366 AW178384




AW178333 AW178424 AW365726 AF025440 AW172852




AI570998 AW117792 AI885499 BE465516 BE207427 AW130942 AW513316




AW770892 BE207426 AW173563 AW168292 AW173565




AI810101 AI744983 AI861974 BE207404 AI744982




AI613210 AW591505 AW169285 AI521444 AI745044 AI627904 AI690634 AI289305




AA861253 AI612799 BE207425 AI149694 AA902662 AI082468




AI014752 AA613844 AA725693 AA136089 AI290092 AA565489 AI689083




AI859014 AW051225 AA665758 AA496991 AA564738 T19428




AI567170 AW166726 AW084200 AW188723 AA617626 AI918664 AW381473




AW381543 AA598817 AW088942 AW050423 AI362502 AI680308




AI687500 BE327836 D20455 BE410282 BE254766 BE256014 AA357423




BE618208 AA489577 AW182114 BE379147


102627
25245_1
AL021918 AA160639 U66561 AA321623 U52098 AL119453 AA455712 N80080




N46550 W07223 N75923 W05057 AI811577 AA455657




AI275409 AI139121 AI927568 AI927562 AI139471 AA160473




N78795 AI719983 AI718928 AA723097 AI335776 N39140 N59184 AI587600




AI864812 AA732097 N74667 AA832398 H89600 D19825 AI554833


132725
29101_1
NM_006276 NM_006276 L41887 L22253 BE379909 BE567870 BE274265




BE539518 AW239523 AW239271 AI093618 BE504485 AA580279




AA494481 BE440161 AW780428 BE543960 D55986 AA852399




AI630020 W77996 AA278193 R10505 AI963201 AI739336 BE174301




AA662222 AA664912 AA244152 AW611553 BE503285 AA211023




AA383016 AI698174 AW195381 AA948229 AI768495 AI690437 N30025




AI718952 AI953572 BE464509 AA777315 AI337221 AW070910




AI953848 AW674561 H54177 AW510890 AW078699 AI436178 AA630759




BE502074 AA278769 AI499038 AW469072 AA778071 AW236753 AI933033




AI690458 AI276691 AW768235 AI952118 AA425156 AA610579




W73953 AA244153 W86034 AI948872 AI952678 AW087811 AI333591




AI869883 AI926911 W48865 AL048024 AA214485 AI972522 AI151368




W48738 AA214467 AA334640 AI678170 AA927525 AA581588 W96283




AA365470 AI471919 AW611488 AA211834 AI365198 AI698365




AW002238 AA507624 W96150 AA446490 AL048025 AA852400 AA362221




AI338376 R35083 AA290812 R10397 AA975988 AW236462 Z43032




H16969 F13487 D19858 AA452207 BE085942 AA344396 AW949533




AA279472 AW902406 AW070440 BE395195 H00835 AA300750




AA729303 AA420591 AA385025 AA420542 R69155 AA420592




AA281747 N88502 AI458206 AI700996 AW418607 AW341202 AI825692




W00640 AA214405 AA044744 AI950617 BE467493 AW474113 AA446310




BE328705 AI911573 AW243968 AI628622 AW173020 AW079958




AI140387 AW051969 AW299438 AI127170 AW769164 AI422435




AI307116 BE549519 AI371116 AA281748 AA701073 AA679948 BE551197




N50345 AW338776 BE326601 AI142892 AW470687 AI989568 AA911241




AW294822 AI174414 AA804366 AI004725 AW271994 AI559313




AI270102 AI351542 AW768904 AA765964 AI961708 AI149231




AA995907 AI094280 AI185753 H01219 AW768846 AA747500 AA970106




AI601238 AA513452 AW612802 BE075163 R39171 AI565328 AI375559




F10356 AA284625 BE241509 AI702889 AW193010 AA649847




AW439150 AA721407 AA810333 AA706384 AI049887 BE569015




BE622280 BE566618 AW967342 R69269


111234
83711_2
AA902656 AI185915 R43705 H15150 H09794 AA832464 AI697438 AI354538 AI436354 AA948272




AA928143 AI091263 R41658 AI352580




AI122948 AA946670 AI340088 AI275007 N70255 AA721176 AI934162




AA827098 AA935934 AA827088 AI081207 AA992399 AW130757




AI805667 AA035556 AI379266 AI093901 AI095234 AA909079




AA516079 AI572357 AA205969 AI432383 AA905290 AW628920 AW182996




AI266084 N49879 AW024457 AI246246 AI934031 AI369270 AI003836




AA010063 AA494361 AI284151 AI919536 N34884 N69287 AW510465




AI358609 AW081421 AA706205 AI085317 AI140633 AI347104 AA602547




AI686707 AA872686 AA694028 AI094546 Z40832 AI382838




AA610132 AA501433 H84120 AI140722 AW674839 BE503822 AW663895




BE327472 AW393494 AI340087 W04189 AW393499 H56506




BE089878 BE301950 AI025475 AA724446 BE275324 H15210 AW957667


134161
16074_1
AA634543 AI682259 AF117108 BE396917 NM_006547 U97188 U76705 BE560799




BE396918 BE269531 BE560268 BE560346 AA836048




AL023775 BE545535 AA427803 C18804 D58801 AA303353 U46218 BE539704




AA187966 AA252545 AA261821 D63197 AI824109 AI088047




AI424833 AI807368 AI250857 AA741476 AI146832 AA169615




AI809821 AI274288 AW136704 AI206172 AA917039 AA243584 AI808611




AW674709 AA935733 AW450092 AA905172 AA471196 AA302256 AW673348




AI352044 AW511295 AA247134 W81035 AA722962 AW662471




R64432 AW044616 AI086619 AW628546 AW043682 AA425750 AI743038




AI368723 AA187143 AI376987 AI803976 AI275537 AW471358




AW104877 AA195464 W81072 AW197351 AA932674 AI393420 AI434998




R63822 AW085083 AI240272 W87006 AA011347 H58428 AI497895




R23223


132939
11857_1
AB009284 AF000416 AA022636 BE082610 AW367997 AA491410 AA337477 AA336421




W38526 AA625283 AA773685 AA490078 T66134




AA847838 AA022647 AW054726 AI918001 AA431966 AI263596 AI804298




AW469314 U76189 AA779001 AA625945 AL042357 AI674730




AA410350 AK001450 AV654353 AA058443 D81618 AA853665 W31930




AA334445 AW955767 N47777 AA883784 AA428916 AI652062




AA329703 AI417923 AI435031 AA708791 AI989636 AI220345 AI239913




AI220102 AI435875 AI076731 AI377049 AI039173 AW972638 N90076




AW263652 BE440048 BE440013 AA577463 AI038774 AW204992 AA846580




AA501952 AA342058 AA508525 D61670 W31725 AI689499




AI955969 AA526628 AI282717 T66198


111345
6692_1
AW263155 AA314512 AW408152 AA360413 BE206274 AK001402 AA307665 AW954678




W39078 AW369236 AW369115 AW369096




AW753235 AW369072 AW361194 AW369125 AW364187 H94225 T79502




AA131908 BE071359 AW368503 AW801517 AW801322 AI674163




AA861077 AI738568 AI830199 AW118577 AI478895 AI688497 H92996




AW083479 AW970625 AW613124 AI632234 AI654210 AI696847




AI923423 AA131909 AA806630 AA806158 AW592520 R96509 AA813923




AA502823 AW467889 AA960972 AA994566 AI280346 AA884588




AA653563 AI200023 N89820 AW768792 C00145 R96554 T79416


104301
145380_1
AA768491 AA476251 AA809748 AI186268 AA621244 AI379029 BE550341




AA651915 AI216376 AI215585 AI471780 AA772159 AW181980




AI151169 AA759270 AI675769 AI018776 AA757335 AA148511




AI138378 AA504167 AI420617 AW261930 AW872797 N51769 AW614403




AI860533 AW573108 N64830 AI693732 AI436159 BE501089 AI436163




AA971485 AI269364 AI935358 AI222050 AW303978 AW573247




AI871154 T16758 AI765893 AW969016 AA744720 BE094085




AA743769 AI476407 AA156619 AI768535 R81435 D45332 N75682 N51177




AW207406 AA425184 R20997 AA504168 Z43298


134520
13358_3
BE091005 BE541579 AW387738 AW386083 H13769 AW377820 AW369180




AW753239 AW672695 BE379572 AW021732 AW891450




AW891416 BE091358 N50375 BE091354 BE091365 BE091361




BE091363 BE091350 AA353863 AA845510 N21407 AW770981 AI361577




AA526557 AA525443 AW893622 AA630898 AI418983 BE172016




AA550754 AA664574 C16147 AA355902 AW958586 N51590 C20995




BE544186 AI337578 AA090549 AI807374 AW450654 BE067578




AA446781 AA447058 T10807 AA457082 AI267703 AI880220 BE568979




AW380506 BE150744 AW380468 AW380546 BE150713 D60029 H88099




BE546301 BE150731 AW368467 BE091348


135242
5782_1
AI583187 M73812 AW339829 M74093 BE252510 BE252518 BE536901 U40788




W95578 BE018493 BE544205 N83637 AI671049 AW439693




AW300786 AW374970 AA592960 AI215885 AI215884 BE302101




AI186210 AW771831 T54213 AW452924 AA834019 W95471 AA628312




AW304866 AA570076 AI559873 T54121


134621
27351_1
AA037145 L02547 NM_001324 AW411516 AA314711 AA143605 BE394455 AA325731




AA093227 AA083307 BE299438 BE295669 AA370886




AA338272 AA166862 BE304837 BE298306 R60507 AW238966




N72750 AW505406 AW994153 AA309742 AA309929 BE090721 AW904189




AW904214 AA363564 R94127 AA352101 R28249 AA206337 AW577208




AA385473 AA355463 AA400696 AA075587 W72815 AA554033




AA075530 AA620555 AA554034 T27804 AW950014 AI570740




AI268538 AA704423 AW411517 AI278646 AW339924 AI668917 AI796034




AA994601 R94082 AW027137 AA400652 AW299746 W72816 AA988494




AA146582 AW087489 AA992763 AW516454 AA992759 AW270444




AA227188 AI208929 AA167720 AI052527 AA865660 AA569368




AI888464 AI670003 AA827620 AA507543 AI888385 R88418 AW959083




AI341077 AI825719 BE552285 AA738076 AW085903 R28242


126802
116467_4
AW805510 AW805503 AW805500 AW805819 AW517040 AW473670 AW516701 T30141




AA894497 BE349504 AI272007 AI985274 BE501962




AW102975 AI801727 AW197918 T24046 AA947601 AW900958


126892
38252_1
AF121856 BE242657 U83194 AA226732 AI160190 AA948725 AI079958 AW513369




W39443 AW408479 W06854 AA094683 AI985095




AA316647 H96313 N78438 R81582 H95034 R79674 AA488552




W25292 W31697 W19918 T30640 R08686 H78637 AA165100 Z41909




AA165080 R34212 AA150886 T82168 N77082 W56864 R19848




AA888217 AA314539 AW750293 N62714 R58039 AA845453 N63268 W03474




N41923 AI264123 AI808533 AA824288 AW198143 N99916 AA902465




AA775397 AA772387 AI567675 AA227473 AI082614 R58334 N78878




R34329 AW438902 AA164685 AA558790 AI590102 AA863422 BE002625




AA934039 AI298102 W15351 H93997 AA725325 BE180993 W05350




AI510771 W06941 AA488414 R79863 N91264 R76884 AA312948




T71267 AW959659 AI086695 N90421 AI278098 AA164538 AI300271




AA854381 R81331 AA700449 H06174 AW518427 AA876634 AA150778




N32393 H78585 T85364 BE002808 AW663196 N90337 BE252097




T71401 H06438 N40268 N31015 R77046 T99588 T85462 W25298




T59815 H09416 T85403 W32150 N79109 R78812


105298
8689_1
BE387790 BE276849 BE246825 BE246900 AA380487 AA332996 AW408727 AK000294




AI636887 AW197272 AW590657 AW594006 AI768979




AI751632 AA580098 AA313261 AA300475 AA133237 AA233499




BE242126 BE242597 BE242254 AA314374 AW961210 AW939345 AA173535




AA305779 R99373 AA128304 AA447246 AA476365 T34973 BE264878




N25149 Z24939 BE263038 AA128317 Z46082 H23504 AW378551




AA088533 AA442625 H15235 H79172 AA344697 AA344742 AL040280




BE173256 BE173129 T59749 AA088410 BE242311 AA173576




AA455337 AA129715 AA582953 AW612637 AA917038 AW340019 AW006315




AW593024 H05915 AW294592 AI146814 AW195659 AW440271




AI209090 AI288689 H98630 H15174 AI214454 AI569471 AA085808




AW188361 AI751631 AW440477 AW300860 AA516088 AI365108




AI305805 AI264064 AI246276 AA442611 AA807059 AA233459




AA875987 AI374653 AA972665 AA947515 AA436867 AI216423 AI657181




AI680306 AA436854 AI537153 AA883723 Z28659 AA705973 Z40741




AA463884 AI216025 AI564986 AA476316 AI432566 AI571662 AA447126




AW293675 AI675617 AW009004 H23498


120438
166102_1
AW015242 AA831493 AI292346 AI076966 AI191561 AA243441 AI183309 AA252613




AI038422 AI306531 AW051480 AI348605 AA195119




AI817119 AI091896 AA738440 AA195013 AA976687 AA459659




AI246250 BE219252 AI703457 AA243291 AA243401 AA989100 AA931640




AA459782


105516
9334_1
AK001269 AL354613 AA147472 AA490803 BE207628 AW816113 AA085574 AW503392




AA299910 AW750305 BE079539 BE079484




BE512838 AK001593 AW968772 AW967440 AW206280




AA251270 AI627886 AA303599 AA147473 BE206616 AA490611 AA715039




AW590866 AW590447 AI864512 AA204731 AA894490 BE001136




AA612785 AA237035 AA149960 Z44257 R12986 AA448446 AI734041




AA422167 BE220551 R66041 R32927 R32942 AA258773 AW386142




R53730 N54624 AW880296 AA253485 AW954441 H98989 AW614348




AI654838 AA779793 AW237213 N66635 AI186812 AA947479




BE158011 AI859480 AW805579 N52010 AA806305 AI628445 AW270990




AA778165 AA149949 AI650728 AA749108 AA687257 AI261661




AA747442 AA481351 AA206339 AA903407 AW473306 AI688930 AA262281




AA448310 AA748820 AI347430 BE465692 R32839 AW510564 AA436408




AA257971 AA253362 AA938330 AA513150 AA976840 AA687117




AI281547 AA046243 R32825 AI631554 AW139818 AI244536




R52946 AW235443 R40183 AA299909 AA811958 AI302918 Z40213 BE158047




BE158060 AA767245 AW748159 AW500735 AA094074


129097
25953_1
BE243933 AA355449 T29766 F08396 N83324 NM_006963 S50223 AI207648




AA258092 AA113952 AI311718 AI128612 AW607449 M77172




A1951311 X52346 AA903307 AI569810 N55421 W77876 R37223




R83788 AA031666 H47092 AA133451 AA311095 AA906963 H87667 N56058




AA393593 W24864 H10710 F06925 F07239 AW386140 AA325018




AA235950 AW373176 N57158 AA258093 N39467 R21609 BE089979




R34173 AW889005 AA745644 AI693852 AA424914 AA744771 W72632




AI291213 AA524318 AI472134 AI911230 AA528418 AA115745




AA775720 AI671134 AA975044 AW298117 AA321015 N26288 AW952194




AI743379 AI204233 AI801026 AA830690 AI146980 AW104611




AI338576 R21507 AI367623 BE244484 AI269308 AA031667




AI884346 AA731989 AA988943 AA235951 AA807887 AA642645 AI246489




N29739 AI216718 AI383349 AI038618 AI351476 AA806031




AI914178 H10711 AI095573 H89220 AW470854 AA729015 R83353 AA782239




R34295 H87165 AW419059 AI653689 Z40349 H89114 AW074506




AA397785 AA888377 AI911228 F03193 AI468783 AA702615 AI830829




AA748323 R37224 AA424915 AA731647 H47183


120619
169895_1
AW965339 AL045632 AA333229 AI806195 AA284372 AA206108 AA682533 AW449514




AA804785 AI215473 AI357263 AI651208 A1651753


129229
20927_1
AF013758 NM_006451 AI538709 AA209236 AA300293 AA367274




AA126598 AA324825 AW955225 F11436 AW374740 AW374714 AW374774




AW751514 W74780 AI909015 AW997079 AW997067 AW379344




AW363397 W38589 AA043823 BE169280 AI909016 AW994851 AI740638




AW148560 AW368339 AI858333 AA314718 AW954872 AW468734 AI681980




AW519045 AW055171 AA579286 AW069164 AW615004




AA345052 AI446735 AI142106 AA662683 AW002813 AI418280




AW613203 AI613333 AI354480 AI929755 AI146977 W74674 AW799610




AI798529 AI589422 AA043957 AI223043 AA157016 AI446759 D56729




AI587471 F30716 AA812125 AI537301 AA653347 D11966 AI434383




AA598533 AI287254 AW139140 AW051033 AA601911 AI702506 AA737460




T30221 AI129081 N90213 AA805225 AI798518 BE001071 T10841




W20199 AW664594 AW195667 D60123 D61496 AW468018 AI720097




N90553 AA829375 AW513266 H92758 AA585324 C14767 AI922391




D60124 D60666 AW071558 BE044120 AA728821 AA211941


120821
19274_2
Y19062 NM_014393 AW296801 AK001576 AL079288 W16667 Z45664 AI768561




AL079286 R12736 AW080147 AW136530 AI202958




AW241579 R21013 AA347419 AI929333 AW196689 AI040867




F13437 AA918240 AI869798 AI365176 AW440030 AW440072 N80892




AW242030 Z44807 R12417 AA436784 AA442041 AA046503 AL157526




AI929265 AA055542 AA045462 AA683542 N51374 AW193508




A1873524 AW473151 AW004719 AI810504 AI581093 AA493977




Z40600 F04553 R46130 F09321


106459
3897_1
AA789081 AW408328 NM_006530 U61384 AA449641 AW138216 AA448598




AJ245746 AI365301 N44728 AA255743 AA360783 BE550380




AW593925 AI962309 AA322097 AW964625 AI695988 AW672827




BE543256 AK001413 AW603395 AA651700 AA449053 AA465540




AW083185 T62128 Z78373 AW673713 AW468061 BE350755




AW673958 AW675504 AA995709 AW574841 AA835883 AI248439 AA548364




T62072 N33193 AA814046 AI376210 AI340020 AA449766




AA703407 AA427613 AI470108 AI298757 AA507602 AI658941 AA449478




AA633165 AA449741 AA831821 AA903673 AA682588 AW673075


115094
190995_1
AA255920 AI817197 AA255921 AI612925 AW874669 AA493440


129571
1726_1
X51630 M80232 X61631 S75264 AA172249 AA134066 AA130278 AA130187 AA130291




AA031554 AI246677 Z21455 AI745434 AW273544




AW088613 AW471307 AI745483 AI399854 AI683952




AA031555 AA298075 AI935945 T29809 AA172099 AA356120


121779
287665_1
AW513143 AA422036 AI821669




AW514232 AA477828 AW772009 AW439799 AW089884


106738
174703_1
AW149266 R49246 AW237401 AA938113 AW665871 AI969698 AI950812 AW874276




AI571939 AA741222 AI869822 AW104061 AI569994




AW972559 AA506012 AI553704 AA470145 AI332421




AA218990 AW131361 AI709076 AW392488 AW392477 AI970981 AW392476 D61949




H44981 BE172698


123005
75629_1
AW369771 AW748174 AA290801 AA419198 AA044331 AA127909 AW995442 AI480343




AA044582 AW956159 AA373451 AA127965




AL134913 AW994956 BE622314 BE006298 BE006312




BE006305 BE006317 BE006303 AA043906 AA234175 AA479726


108055
100690_1
AJ404672 AJ289819 AW976000




AA043561 AW450885 AW452879 AA043562 AA788832 AI564338




AI564330 AI368875 AA643607 AA994375




AA810342 AI367704


115291
22325_1
BE545072 AI540751 AA301103 AI916675 N85422 BE563965 AA327978 AI816094




AK001515 BE501319 AA279943 BE138895 AA343765




AW963051 AW082308 AI823992 AI653752 AI589007




AI816135 AI566535 BE501307 AW272765 AW242239 AA766315 AI014927 AA578848




AI354483 AI476548 AI038579 AA973322 AA992180 AW472921




BE504789 AI392988 AA506076 AA769228 AI370562 AL137710 BE005656




AW965920


130376
24827_−4
R40873


115536
61_1
AK001468 AA190315 AA374980 AW961179 AA307782 AA315295 AA347194




AW953073 AW368190 AW368192 AA280772 AA251247 N85676




AI215522 AI216389 N87835 R12261 R57094 AI660045 AA347193




R16712 AW119006 N55905 N87768 AW900167 AI341261 AI818674 D20285




A1475165 AA300756 R40626 AI122827 AA133250 AI952488 AA970372




AA889845 AW069517 AI524385 AA190314 AI673359 AA971105




AI351088 AI872789 AI919056 AI611216 AK001472 BE568761 AA581004


114965
153955_1
AI733881 AA165164 AI826437 AI972791 AA165165 BE219575 AI732586




AI821571 AA250737 AW136875 AI984273 AI249271


131228
8262_1
AW207469 AL079814 AA354351 AF020043 AW291396 BE550484 NM_005445 BE046917 AW594249




AI651554 AI631515 AW771344




AI969758 AI699982 AA247175 AI244676 D44780




AW593978 AI638479 AI373676 AW089547 AL121432 AA554698 AI016991 AI087260




AW449939 AF067163 W40482 AW316558 AI537184 AW381979 W40150 AI810562 AA573151




AI630288 AI675561 AI674420 AW840733




AW022653 AA114219 AJ005015 AL046587 AA878141




AW271896 AW085287 AA150465 BE536295 AA463412 BE093222 AA213739




AA485586 AI825913 AA706307 AI337348 R31995 AI819641




R32095 AW976653 AA742375 AA142957 AI808214 AW468303 AI205987




AI206347 AI769095 BE501640 AA113866 AI093931 AI752855 AA612743




AA463411 AA279157 AI123791 AA213570 AI207305 AW627814




R31945 R32040


116238
10772_1
AV660717 NM_015437 AL050285 R95774 AI867094 AA443833 AI367670 AA609046




AI440298 AI613139 AI291826 AW028954 AI123242




AI824715 AW079750 AA479362 AW150151 AI952267




AA814094 AI168431 AI566595 AI521422 AI920793 AW051241 N70051 AI689429




A1783813 AI769315 AI743691 AI915645 AA479473 C21435




N50944 N50902 AW978102 H23837 BE087538 AA316516


122802
287993_1
AI687303 AW571681 Al554465 AI684252 AI581056 AA604098 AI628160 AI859843




AA424021 AA460530 BE042778 AW273200 AW273223




AW167288 AW083347 AI654306 AW517496 AW104706 AW273214




BE139512 AW189487 AW130822 AW167419 AI289485 AW150010




H88004 AI743745 AW088710


123494
21202_1
AW179019 AW179011 AFl35I60 NM_014050 AF078860 BE018005 AK000285




AF151038 BE245156 AW179007 AA345114 BE619758




BE619209 W25509 AA314339 AA336674 AA337956 AW954843




AW390412 N46796 AA316235 AA314286 R15686 BE535633 N57134 N46483




AW368462 AA923517 AA665223 AI418513 AA837523 AI359320 AI309273




AI522278 N40939 AA904977 AA938272 N30240 AA887965




AI671972 AI028109 AA094652 AA883262 AA887781 AI744447 AW592944




AI077790 AW860883 AW148667 N89861 AA557195 AI191824




AI433166 AI719760 AA453089 AA630656 AA300976 AA639620 AW675033




AA284393 AW886987 AI476335 AI332939 BE301513 AA452920




AW674302 AI925483 AW170412 AI698717 AI375985 BE220535 AI688151




AW514809 AW062346 AA599786 BE350848 AI560848 AI023075




AA864875 AA166871 AI807947 AW514579 AI978602 AI860340 AA830886




AI374788 AI283592 AA683152 AA743159 AI379932 AI432056




AI128904 AW150433 N38909


116296
11967_2
AW149502 Z43342 AW002826 AL049382 AA442545 AW971471 BE220243 AW968952 AA043607




AW299245 AA659892 AI038768 H26330




BE463534 AI628252 AA836139 AI277291 AA489033




AA741239 AI209064 AI300253 AI275761 Z39417 C01835






Pkey Unique Eos probeset identifier number




CAT number Gene cluster number




Accession Genbank accession numbers








[0371] Table 9A lists about 382 genes up-regulated in ovarian cancer compared to normal ovaries These were selected from 35403 probesets on the Affymetrix/Eos-Hu01 GeneChip array such that the ratio of “average” ovarian cancer to “average” normal adult ovaries was greater than or equal to 10 The “average” ovarian cancer level was set to the 2nd highest amongst various ovarian cancers. The “average” normal adult ovaries level was set to the arithmetic mean amongst various non-malignant ovaries In order to remove gene-specific background levels of non-specific hybridization, the 15th percentile value amongst the non-malignant tissues (see Table 7A) was subtracted from both the numerator and the denominator before the ratio was evaluated
23TABLE 9A382 UP-REGULATED GENES, OVARIAN CANCER VERSUS NORMAL OVARYPkeyEx AccnUG IDTitleratio134454L33930Hs 173996CD24 antigen (small cell lung carcinoma clust86.2102927X12876Hs.65114keratin 1884.7115909AA436666Hs 59761ESTs72.3123169AA488892Hs 104472ESTs, Weakly similar to Gag-Pol polyprotein [66.8115674AA406542Hs 71520ESTs65.4102193U20758Hs.313secreted phosphoprotein 1 (osteopontin, bone63.1101839M93036Hs 692membrane component; chromosomal 4, surface ma56.8115221AA262942Hs 79741ESTs56.1108059AA043944Hs 62663ESTs52.3121853AA425887Hs.98502ESTs47.8133504W95070Hs 74316desmoplakin (DPI, DPII)47.0103546Z14244Hs 75752cytochrome c oxidase subunit VIIb46.5100147D13666Hs 136348osteoblast specific factor 2 (fasciclin I-lik45.5102979X17042Hs.1908proteoglycan 1; secretory granule44.6130967AA134138Hs.182579Homo sapiens leucine aminopeptidase mRNA, com44.5102009U02680Hs 82643protein tyrosine kinase 940.4126960AA317900Hs 161756ESTs39.6103111X63187Hs 2719epididymis-specific, whey-acidic protein type39.1133829AA453783Hs 76550Homo sapiens mRNA, cDNA DKFZp564B1264 (from c39.0111223N68921Hs 34806ESTs, Weakly similar to neogenin [H. sapiens]38.9102803U89916Hs.26126claudin 1038.8104943AA065217Hs 169674ESTs38.7106605AA457718Hs 21103Homo sapiens mRNA, cDNA DKFZp564B076 (from cl38.4120655AA287347Hs 238205ESTs38.1102968X16396Hs.154672methylene tetrahydrofolate dehydrogenase (NAD36.3104052AA393164Hs.97644mammaglobin 236.0109166AA179845Hs 73625RAB6 interacting, kinesin-like (rabkinesin6)35.9101332L47276Homo sapiens (cell line HL-6) alpha topoisome35.0106167AA425906Hs 7956ESTs34.5101042J05428Hs.10319UDP glycosyltransferase 2 family, polypeptide34.3125852H09290Hs 76550Homo sapiens mRNA; cDNA DKFZp564B1264 (from c33.7101201L22524Hs 2256matrix metalloproteinase 7 (matrilysin, uten32.3126410R51912Hs 12409somatostatin32.1134326U16306Hs 81800chondroitin sulfate proteoglycan 2 (versican)32.0125739AA428557Hs 92137v-myc avian myelocytomatosis viral oncogene h31.6132254L20826Hs.430plastin 1 (I isoform)31.4112610R79392Hs 23643ESTs30.9101441M21005Hs 100000S100 calcium-binding protein A8 (calgranulin30.6116345AA496981Hs 199067HER3 receptor tyrosine kinase (c-erbB3; ERBB330.1108860AA133334Hs.129911ESTs29.8133859U86782Hs 17876126S proteasome-associated pad1 homolog29.2107295T34527Hs 80120UDP-N-acetyl-alpha-D-galactosamine polypeptid28.9106210AA428239Hs 10338ESTs28.9134711X04011Hs.88974cytochrome b-245; beta polypeptide (chronic g28.0125769AI382972Hs 821285T4 oncofetal trophoblast glycoprotein27.5107222D51235Hs 82689tumor rejection antigen (gp96) 127.4102260U28386Hs 159557karyopherin alpha 2 (RAG cohort 1, importin a26.9134691M59979Hs.88474prostaglandin-endoperoxide synthase 1 (prosta26.8105588AA279215Hs 10867ESTs26.3130718N70196Hs 18376ESTs26.3111185N67551Hs 12844EGF-like-domain, multiple 625.6131965W90146Hs 35962ESTs25.6132903AA235404Hs 5985Homo sapiens clone 25186 mRNA sequence25.6114359Z41589Hs.153483ESTs, Moderately similar to H1 chloride chann25.5101185L19872Hs 170087aryl hydrocarbon receptor25.2128742D00763Hs 251531proteasome (prosome, macropain) subunit, alph25.1116724F13665Hs 65641ESTs24.9111929R40057Hs 112360prominin (mouse)-like 124.9102915X07820Hs.2258matrix metalloproteinase 10 (stromelysin 2)24.8131210AA430047Hs 24248ESTs24.7101714M68874Human phosphatidylcholine 2-acylhydrolase (cP24.6100154D14657Hs 81892KIAA0101 gene product24.6134656X14787Hs 87409thrombospondin 124.3100294D49396Hs.75454antioxidant protein 123.9104080AA402971Hs 57771kallikrein 1123.7107056AA600310Hs 18720programmed cell death 8 (apoptosis-inducing f23.7115697AA411502Hs 63325ESTs, Weakly similar to airway trypsin-like p23.7130350U02020Hs 239138pre-B-cell colony-enhancing factor23.7105870AA399623Hs 23505ESTs23.6118528N67889Hs.49397ESTs23.4105309AA233790Hs 4104ESTs, Weakly similar to cDNA EST yk386g7.5 co23.2109680F09255Hs 4993ESTs23.2131501AA121127Hs 181307H3 histone, family 3A23.2100824HG4058-HT4328Oncogene Aml1-Evi-1, Fusion Activated23.1111890R38678Hs.12365ESTs23.0101543M31166Hs 2050pentaxin-related gene, rapidly induced by IL-22.8102095U11313Hs 75760sterol carrier protein 222.8114988AA251089Hs 94576ESTs, Weakly similar to phosducin, retinal [H22.8120695AA291468ESTs22.8130941D49394Hs 21425-hydroxytryptamine (serotonin) receptor 3A22.8106654AA460449Hs 3784ESTs, Highly similar to phosphoserine aminotr22.7109141AA176428Hs 193380ESTs22.6102345U37283Hs 58882Microfibril-associated glycoprotein-222.6115652AA405098Hs 38178ESTs22.4100103AF007875Hs.5085dolichyl-phosphate mannosyltransferase polype22.3105463AA253370Hs 32646ESTs22.2132624AA164819Hs 53631ESTs22.2119743W70242Hs 58086ESTs22.0132528AA283006Hs 50758chromosome-associated polypeptide C22.0107174AA621714Hs 25338ESTs21.8134495D63477Hs.84087KIAA0143 protein21.8131985AA434329Hs 36563ESTs21.5105832AA398346Hs 21898ESTs21.2126160N90960Hs 247277ESTs, Weakly similar to transformation-relate21.2114846AA234929Hs 44343ESTs20.9109703F09684Hs 24792ESTs; Weakly similar to ORF YOR283w [S.cerevi20.9135154AA126433Hs.173242sorting nexin 420.8131185M25753Hs 23960cyclin B120.7105616AA280670Hs 24968ESTs20.5131148C00038Hs.23579ESTs20.2129337R63542Hs 110488KIAA0990 protein20.2133640D83004Hs 75355ubiquitin-conjugating enzyme E2N (homologous20.1127479AA513722Hs 179729collagen, typo X, alpha 1 (Schmid metaphyseal19.9133711J04130Hs 75703small inducible cytokine A4 (homologous to mo19.8131818Z39297Hs.3281neuronal pentraxin II19.7125303Z39821Hs 107295ESTs19.6109112AA169379Hs 72865ESTs19.5105376AA236559Hs 8768ESTs; Weakly similar to !!!! ALU SUBFAMILY SQ19.2103605Z35402Hs 194657cadherin 1, E-cadherin (epithelial)19.1100661HG2874-HT3018Ribosomal Protein L39 Homolog19.1129571X51630Hs.1145Wilms tumor 119.0115239AA278650Hs 73291ESTs, Weakly similar to similar to the beta t18.9131562U90551Hs 28777H2A histone family, member L18.9131272AA423884Hs 139033paternally expressed gene 318.9130343AA490262Hs.15485ESTs, Weakly similar to APICAL-LIKE PROTEIN [18.8103245X76648Hs 28988glutaredoxin (thioltransferase)18.7101809M86849Homo sapiens connexin 26 (GJB2) mRNA, complet18.6105344AA235303Hs 8645ESTs18.4135225AA455988Hs 9667butyrobetaine (gamma); 2-oxoglutarate dioxyge18.4116786H25836Hs.83429tumor necrosis factor (ligand) superfamily; m18.3131510AA207114Hs.27842ESTs, Weakly similar to similar to 1-acyl-gly18.2124059F13673Hs 99769ESTs18.0103352X89398Hs.78853uracil-DNA glycosylase17.9132742AA490862Hs 55901ESTs, Weakly similar to C43H8 1 [C. elegans]17.9135242M74093Hs 9700cyclin E117.9123494AA599786Hs 112110ESTs17.8129168T90621Hs.109052chromosome 14 open reading frame 217.7128517AA280617Hs 100861ESTs; Weakly similar to p60 katanin [H.sapien17.6130160Z39228Hs 151344UDP-Gal.betaGlcNAc beta 1,3-galactosyltransfe17.6103448X99133Hs 204238lipocalin 2 (oncogene 24p3)17.5119708W67810Hs 57904mago-nashi (Drosophila) homolog, proliferatio17.5122946AA477445Hs 105341ESTs17.5125819AA044840Hs 251871CTP synthase17.5131689AA599653Hs.30696transcription factor-likes 5 (basic helix-loop17.5115061AA253217Hs 41271ESTs17.3113702T97307Hs 161720ESTs; Moderately similar to !!!! ALU SUBFAMIL17.3115291AA279943Hs 122579ESTs17.3102567U59863Hs 146847TRAF family member-associated NFKB activator17.2129229AA211941Hs 109643polyadenylate binding protein-interacting pro17.2129351AA167268Hs 62349Human ras inhibitor mRNA, 3′ end17.2110769N22222yw34b06 s1 Morton Fetal Cochlea Homo sapiens17.1113182T55234Hs 9676Human DNA sequence from clone 30M3 on chromos17.0115892AA435946Hs 50831ESTs17.0123114AA486407Hs 105235ESTs, Moderately similar to KIAA0454 protein17.0123442AA598803Hs 111496ESTs17.0123339AA504253Hs.101515ESTs16.9123689AA609556Hs 256562ESTs16.9131941D62657Hs 35086ubiquitin-specific protease 116.8120649AA287115Hs.99697ESTs16.8102139U15932Hs 2128dual specificity phosphatase 516.8115522AA331393Hs 47378ESTs16.7135243AA215333Hs 97101putative G protein-coupled receptor16.6131257AA256042Hs.24908ESTs16.5109508AA233892Hs 55902ESTs, Weakly similar to !!!! ALU SUBFAMILY SX16.3132701AA279359Hs 55220BCL2-associated athanogene 216.3134449L34155Hs.83450laminin, alpha 3 (nicein (150 kD); kalinin (1616.3126180R18070Hs 3712ubiquinol-cytochrome c reductase, Rieske iron16.3106124AA423987Hs 7567ESTs16.2115363AA282071Hs 152759activator of S phase kinase16.2117588N34895Hs.44648ESTs16.1131245AA620599Hs 24766DKFZP564E1962 protein16.1101674M61916Hs 82124laminin, beta 116.0126819AA305536Hs 161489ESTs16.0134039S78569Hs.78672laminin; alpha 416.0130648AA075427Hs.17296ESTs, Weakly similar to /prediction15.9102823U90914Hs 5057carboxypeptidase D15.8128470AA447504Hs 100261Homo sapiens mRNA, cDNA DKFZp564B222 (from cl15.8115844AA430124Hs 234607ESTs15.7132543AA417152Hs.5101protein regulator of cytokinesis 115.7130155L33404Hs 151254kallikrein 7 (chymotryptic; stratum corneum)15.7101008J04162Hs 763Fc fragment of IgG, low affinity IIIa, recept15.7120472AA251875Hs 104472ESTs; Weakly similar to Gag-Pol polyprotein [15.6116844H64938Hs.38331ESTs15.6106753AA476944Hs 7331ESTs15.6114767AA148885Hs 154443minichromosome maintenance deficient (S cere15.5114768AA149007Hs 182339Ets homologous factor15.5127370AI024352Hs.70337immunoglobulin superfamily, member 415.5101507M27492Hs 82112interleukin 1 receptor, type I15.4102519U52969Hs 80296Purkinje cell protein 415.4102610U65011Hs.30743preferentially expressed antigen in melanoma15.4111244N69556Hs.24724MFH-amplified sequences with leucine-rich tan15.4120404AA234921Hs 96427KIAA1013 protein15.3130455X17059Hs 155956N-acetyltransferase 1 (arylamine N-acetyltran15.2129519AA298786Hs 112242ESTs15.1106553AA454967Hs 5887ESTs; Highly similar to RNA binding motif pro15.0109502AA233837Hs.44755ESTs; Weakly similar to membrane glycoprotein14.9115967AA446887Hs 42911ESTs14.9104636AA004415Hs.106106ESTs14.9134133X93920Hs.180383dual specificity phosphatase 614.9134444X04470Hs.251754secretory leukocyte protease inhibitor (antil14.8132998Y00062Hs 170121protein tyrosine phosphatase, receptor type,14.8131997D82399Hs 136644Homo sapiens clone 23714 mRNA sequence14.6134056R27358Hs 7886ESTs; Weakly similar to Pelle associated prot14.6101249L33881Hs.1904protein kinase C; iota14.5105298AA233459Hs.26369ESTs14.5107119AA620307Hs 27379ESTs14.5115839AA429038Hs 40541ESTs14.5122802AA460530Hs 256579ESTs14.5129896AA043021Hs 13225UDP-Gal: betaGlcNAc beta 1; 4-galactosyltransf14.3130269AA284694Hs.168352nucleoporin-like protein 114.3134374D62633Hs 8236ESTs14.3106370AA443841Hs 18676sprouty (Drosophila) homolog 214.2130919AA291710Hs 21276collagen: type IV, alpha 3 (Goodpasture antig14.1132923U21858Hs 60679TATA box binding protein (TBP)-associated fac14.1107968AA034020Hs 61539ESTs14.1125390H95094Hs 75187translocase of outer mitochondrial membrane 214.1107148AA621131Hs 5889ESTs; Weakly similar to W01A11.2 gene product14.1110788N24730Hs.15420ESTs14.0109481AA233342Hs 90680ESTs, Weakly similar to WD40 protein Ciao 1 [13.9105646AA282147Hs 5888ESTs13.9106030AA412251Hs 12802development and differentiation enhancing fac13.8132618AA253330Hs 5344adaptor-related protein complex 1; gamma 1 su13.7133230S82240Hs 6838ras homolog gene family, member E13.7124803R45480Hs 164866cyclin K13.6121381AA405747Hs.97865ESTs, Weakly similar to WASP-family protein [13.6105200AA195399Hs.24641ESTs13.5105627AA281245Hs 23317ESTs13.5114986AA251010Hs 87807ESTs13.5118036N52844Hs 196008ESTs13.5134672N79749Hs 87627ESTs; Weakly similar to cDNA EST EMBL: T0054213.5110915N46252Hs 29724ESTs13.3117984N51919Hs 47368ESTs13.3132550AA029597Hs 170195bone morphogenetic protein 7 (osteogenic prot13.3124315H94892Hs.6906v-ral simian leukemia viral oncogene homolog13.2102547U57911Hs 46638chromosome 11 open reading frame 813.2125134W19228Hs 100748ESTs13.2111806R33468Hs 24651ESTs13.1106983AA521195Hs.10887similar to lysosome-associated membrane glyco13.0106498AA452141Hs 7171ESTs13.0110787N24716Hs 12244ESTs, Weakly similar to C44B9.1 [C. elegans]13.0122860AA464414Hs 112159ESTs13.0131535AA504642Hs 28436ESTs, Weakly similar to coded for by C. elega13.0116188AA464728Hs 184598ESTs13.0107243D59489Hs 34727ESTs12.9129300C20976Hs.110165ESTs, Highly similar to ribosomal protein L2612.9134487R38185Hs 83954Homo sapiens unknown mRNA12.8102348U37519Hs 87539aldehyde dehydrogenase 812.8131839H80622Hs 33010KIAA0633 protein12.8119620W47620Hs 560092′-5′ oligoadenylate synthetase 312.8120802AA343533Hs 128777ESTs; Weakly similar to predicted using Genef12.7102250U28014Hs 74122caspase 4, apoptosis-related cysteine proteas12.7105539AA258873Hs 25242ESTs12.7114965AA250737Hs.72472ESTs12.7118001N52151Hs 47447ESTs12.7100448D87469Hs 57652EGF-like-domain, multiple 212.6130920D50975Hs 75525calreticulin12.6131075Y00757Hs 2265secretory granule; neuroendocrine protein 1 (12.6105496AA256323Hs 25264DKFZP434N126 protein12.5109235AA193592Hs 42300ESTs; Weakly similar to !!!! ALU SUBFAMILY SQ12.5118215N62195Hs.779103-hydroxy-3-methylglutaryl-Coenzyme A synthas12.5134388M15841Hs 82575small nuclear ribonucleoprotein polypeptide B12.5106897AA489790Hs 167496RAN binding protein 612.4133050S67325Hs 63788propionyl Coenzyme A carboxylase, beta polype12.4109683F09308Hs 27607ESTs12.3121463AA411745Hs.239681ESTs, Weakly similar to KIAA0554 protein [H.s12.3102876X03663Hs 174142colony stimulating factor 1 receptor, formerl12.2101804M86699Hs 169840TTK protein kinase12.2129017H13108Hs 107968ESTs12.1105812AA394126Hs 20814ESTs; Highly similar to CGI-27 protein [H.sap12.1106459AA449741Hs.4029glioma-amplified sequence-4112.0107059AA608545Hs 23044RAD51 (S cerevisiae) homolog (E coli RecA ho12.0107080AA609210Hs 19221ESTs12.0110799N26101Hs 7838Human ring zinc-finger protein (ZNF127-Xp) ge12.0112253R51818Hs.104222Homo sapiens mRNA, cDNA DKFZp566L034 (from cl12.0116760H11054Hs.155342protein kinase C; delta12.0120314AA194166Hs 221040KIAA1038 protein12.0123005AA479726Hs 105577ESTs12.0132572AA448297Hs 237825signal recognition particle 72 kD12.0110561H59617Hs 5199ESTs; Weakly similar to UBIQUITIN-CONJUGATING12.0101923S75256HNL = neutrophil lipocalin [human, ovarian canc11.9134992H05625Hs.92414ESTs11.8105516AA257971Hs.21214ESTs11.8105248AA226968Hs 22826ESTs11.7109130AA172040Hs 20161ESTs, Weakly similar to IgE receptor beta sub11.7115955AA446121Hs 44198Homo sapiens BAC clone RG054D04 from 7q3111.7116135AA460314Hs 94179ESTs11.7116284AA487252Hs 237809ESTs, Weakly similar to hypothetical protein11.7132384AA479933Hs 46967Human DNA sequence from clone 167A19 on chrom11.7134753Y09216Hs 173135dual-specificity tyrosine-(Y)-phosphorylation11.7125136W31479Hs.129051ESTs11.7133928N34096Hs 7766ubiquitin-conjugating enzyme E2E 1 (homologou11.6117395N26330Hs 93701ESTs11.5127007AA299360EST11857 Uterus tumor I Homo sapiens cDNA 5′11.5130567L07493Hs 1608replication protein A3 (14 kD)11.5135073AA452000Hs.94030Homo sapiens mRNA, cDNA DKFZp586E1624 (from c11.5115140AA258030Hs 55356ESTs, Weakly similar to supported by GENSCAN11.411553611347193Hs 62180ESTs11.4133240D31161Hs 68613ESTs11.3106521AA453431Hs 14732malic enzyme 1, NADP(+)-dependent cytosolic11.3107674AA011027Hs.41143KIAA0581 protein11.3114149Z38814Hs 27196ESTs11.3132478H20906Hs 49500KIAA0746 protein11.2104252AF002246Hs 210863cell adhesion molecule with homology to L1CAM11.2102436U46499Hs.790microsomal glutathione S-transferase 111.2106726AA465339Hs 7141ESTs11.2100116D00654Hs 77443actin, gamma 2, smooth muscle, enteric11.2110970N51374Hs 96870Homo sapiens mRNA full length insert cDNA clo11.2130417U58522Hs.155485huntingtin-interacting protein 211.2132906AA142857Hs.234896ESTs, Highly similar to geminin [H. sapiens]11.2107853AA024427Hs 59461DKFZP434C245 protein11.2103467Y00451Hs 78712aminolevulinate; delta-; synthase 111.1100438D87448Hs 91417topoisomerase (DNA) II binding protein11.1102654U68494Hs 24385Human hbc647 mRNA sequence11.1103172X68742Hs 116774integrin; alpha 111.1106856AA486183Hs.15839ESTs, Weakly similar to similar to oxysterol-11.1108255AA063157Hs.172608ESTs11.1124308H93575Hs.227146Homo sapiens mRNA, cDNA DKFZp564J142 (from cl11.1129057X62466Hs 214742CDW52 antigen (CAMPATH-1 antigen)11.1128845AA455658Hs 10649basement membrane-induced gene11.1129025AA420992Hs.103441ESTs; Weakly similar to testicular tektin B1-11.0107638AA009528Hs 42743ESTs; Weakly similar to predicted using Genef11.0134480AA024664Hs 83916NADH dehydrogenase (ubiquinone) 1 alpha subco11.0115262AA279112Hs 88594ESTs11.0102580U60808Hs.152981CDP-diacylglycerol synthase (phosphatidate cy10.9106614AA458934Hs.179912ESTs10.9107115AA610108Hs 27693ESTs, Highly similar to CGI-124 protein [H.sa10.9115764AA421562Hs 91011anterior gradient 2 (Xenepus laevis) homolog10.9121770AA421714Hs 11469KIAA0896 protein10.9132191AA449431Hs 158688KIAA0741 gene product10.9133214Y10659Hs 250911interleukin 13 receptor, alpha 110.9133914N32811Hs.77542ESTs10.8101973S82597Hs 80120UDP-N-acetyl-alpha-D-galactosamine: polypeptid10.8102669U71207Hs 29279eyes absent (Drosophila) homolog 210.8104147AA451992Hs 226799ESTs, Highly similar to HSPC039 protein [H.sa10.8106474AA450212Hs 42484Homo sapiens mRNA, cDNA DKFZp564C053 (from cl10.8115881AA435577Hs.184942G protein-coupled receptor 6410.8129950M31516Hs.1369decay accelerating factor for complement (CD510.8132783N74897Hs 5683DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide10.8133784AA214305Hs 76173ESTs10.8134248AA292677Hs 80624ESTs10.8105565AA278302Hs 18349ESTs, Weakly similar to partial CDS [C.elegan10.8127999AA837495Hs 69851ESTs; Weakly similar to Wiskott-Aldrich syndr10.8108040AA041551Hs.48644ESTs10.7130367Z38501Hs 8768ESTs, Weakly similar to !!!! ALU SUBFAMILY SQ10.7108539AA084677Hs 54558ESTs, Weakly similar to protein B [H. sapiens]10.7111345N89820Hs 14559ESTs10.7115583AA398913Hs 45231LDOC1 protein10.7128965T17440Hs 107418ESTs10.7101396M15796Hs 78996proliferating cell nuclear antigen10.6132164U84573Hs 41270procollagen-lysine, 2-oxoglutarate 5-dioxygen10.6101275L37936Hs 3273Ts translation elongation factor, mitochondn10.6104660AA007160Hs.14846Homo sapiens mRNA, cDNA DKFZp564D016 (from cl10.6108609AA100694Hs.69499Human DNA sequence from BAC 15E1 on chromosom10.6112041R43300Hs 22929ESTs10.6114208Z39301Hs.7859ESTs10.6118537N67974Hs 75431fibrinogen, gamma polypeptide10.6106919AA490885Hs 21766ESTs10.6115984AA447687Hs.91109ESTs10.6105538AA258860Hs 32597ring finger protein (C3H2C3 type) 610.6102200U21551Hs 157205branched chain aminotransferase 1, cytosolic10.5116710F10577Hs.70312ESTs10.5119780W72967Hs 191381ESTs, Weakly similar to hypothetical protein10.5112996T23539Hs 7165zinc finger protein 25910.5103029X54489Hs 789GRO1 oncogene (melanoma growth stimulating ac10.5101255L34600Hs 149894mitochondrial translational initiation factor10.4107032AA599472Hs.247309succinate-CoA ligase, GDP-foming; beta subun10.4125617AI287461Hs 164950ESTs10.4131475Z39053Hs 27263ESTs10.4132073N67408Hs 38516ESTs10.4101469M22877Hs 169248Human somatic cytochrome c (HCS) gene, comple10.3102437U46569Hs 221986aquaporin 510.3104301D45332Hs 6783ESTs10.3127236AI341818Hs.98658budding uninhibited by benzimidazoles 1 (yeas10.3101465M22612Hs 241395protease, serine; 1 (trypsin 1)10.3113805W42957Hs 250617ESTs10.2133536Y00264Hs 177486amyloid beta (A4) precursor protein (protease10.2109799F10770Hs.180378Homo sapiens clone 669 unknown mRNA, complete10.2113523T90037Hs 16686ESTs10.2116195AA465148Hs 72402ESTs10.2134542X57025Hs 85112insulin-like growth factor 1 (somatomedin C)10.2125298Z39255Hs.235350YDD19 protein10.2119367T78324Hs 90905ESTs10.2134470X54942Hs 83758CDC28 protein kinase 210.2134288AA430008Hs 8117ESTs10.1105127AA158132Hs 11817ESTs, Weakly similar to contains similarity t10.1110627H70485Hs 35225ESTs; Weakly similar to MBNL protein [H.sapie10.1115188AA261819Hs.88367ESTs10.1132632N59764Hs 5398guanine-monophosphate synthetase10.1124049F10523Hs 74519primase, polypeptide 2A (58 kD)10.1100079AB002365Hs 23311KIAA0367 protein10.0113987W87494Hs 9641ESTs; Moderately similar to COMPLEMENT C1Q SU10.0117280N22107Hs 172241ESTs10.0Pkey: Primekey Ex. Accn: Exemplar Accession UG ID: UniGene ID Title: UniGene title ratio: ratio tumor vs normal tissues


[0372]

24







TABLE 9B








Pkey
CAT Number
Accession







100661
23182_1
BE623001 L05096 AA383604 AW966416 N53295 AA460213




AW571519 AA603655


101332
25130_1
J04088 NM_001067 AF071747 AJ011741 N85424 AL042407 AA218572 BE296748




BE083981 AL040877 AW499918 AW675045 H17813




BE081283 AA670403 AW504327 BE094229 AA104024




AI471482 AI970337 AA737616 AI827444 AW003286 AI742333 AI344044




AI765634 AI948838 AW235336 AW172827 AA095289 BE046383




AI734240 W16699 AI660329 AI289433 AA933778 AW469242 AA468838




AA806983 AA625873 W78031 BE206307 AA550803 AI743147 AI990075




AA948274 AA129533 AI635399 AA605313 AI624669 AW594319




AI221834 AI337434 AA307706 BE550282 AI760467 AI630636




AI221521 AW674314 AW078889 AI933732 AI686969 AI186928 AW074595




AI127486 AL079644 AI910815 H17814 AA310903 AW137854 T19279




AA026682 AA306035 AW383390 AW383389 AW383422 AW383427




AW383395 H09977 AA306247 AA352501 AW403639 F05421 AA224473




AA305321 H93904 AA089612 AW391543 AW402915 AW173382




AW402701 AW403113 R94438 N73126 H93466 AA090928 AA095051




T29025 AW951071 L47277 L47276 AI375913 BE384156 W24652




AA746288 AA568223 BE090591 H93033 N57027 AA504348 AA327653




AW959913 N53767 AA843715 AI453437 AW263710 AI076594




AA583483 AW873194 AW575166 AI128799 AI803319 AL042776 AW07431




AI887722 AI032284 AA447521 AI123885 N29334 AI354911




AW090687 AA236763 AA435535 AA236910 AA047124 AA236734 AW514610




H93467 AA962007 AI446783 AA127259 AI613495




AI686720 AI587374 AA936731 AA702453 AI859757 AA216786




AI251819 AI469227 AA806022 AI092324 N71868 AA968782 AA236919




AA809450 AA227220 AA765284 AI192007 AA768810 AA805794




AA729280 AA806238 AW768817 N71879 AI050686 AA505822




AA668974 AI688160 BE045915 AW466315 AA731314 AA649568




AA834316 AW591901 AW063876 AW294770 AI300266 AI336094




AI560380 AA721755 H09978 D20305 D29155 AW821790 BE150864




F01675 AI457474 AW466316 AA550969 AA630788


100824
5_36
AI393237 AI521317 AI761348 AF025841 D43968 AW994987 L34598




AF025841 D89789 D89788 D89790 AW998932 AI971742 AI310238




X90976 AW139668 AW674280 AI365552 AA877452 AV657554




C75229 AA376077 AI798056 AW609213 W25586 H30149 BE075089




BE075190 AW580858 H99598 AA425238 AA133916 AW363478




BE158121 BE158127 AW467960 BE158135 BE158126 BE158145




N92860 AA847246 AI961688 AI361423 AA878154 AA043767




AI863712 AI559226 AW339007 AI371266 AI368901 AA046624 AA134739




AW449154 AA130232 AI458720 AA962511 AI700627 R70437




AW004008 AA045229 AI671572 H99599 AA043768 AI685454 AI871685




N29937 X90977 AA524240 AI142114 AI825750 AI567805 AI631365




AI347893 AA134740 F20669 AA046707 AW793216 AW963298




AW959380 AA363265 AI784593 AI268201 R69451 AV657618 AI695588


101714
30725_1
M68874 AL022147 M72393 AL049797 BE439441 T27650 AI766240 AW150345




AW778943 AI627464 BE439479 AA587049 AI277900




AI984983 AI630935


101809
32963_1
M86849 AA315280 NM_004004 AA315269 BE142653 AA461400




AW802042 BE152893 AW383155 AA490688 AW117930 AW384563




AW384544 AW384566 AW378307 AW378323 AW839085 AA257102




AW378317 AW276060 AW271245 AW378298 AW384497 AI598114




AW264544 AI018136 AW021810 AA961504 AW086214 AW771489




AW192483 AI290266 AW192488 AW384490 AW007451 AW890895




AA554460 AA613715 AW020066 AI783695 AI589498 AI917637




AW264471 AW384491 AI816732 AW368530 AW368521 AW368463




AA461087 AI341438 AI970613 AI040737 AI418400 AA947181




AA962716 AI280695 AW769275 AW023591 AI160977 AA055400 N71882




AA490466 AW243772 AW316636 AI076554 AW511702 N69323 H88912




AA257017 AI952506 H88913 AI912481 AA600714 BE465701




N64149 C00523 N64240 AA677120


101923
30543_1
X99133 X83006 W38398 AA401137 AA298242 AA366738 AA308126 AW583781




AA298668 AW845024 BE140204 AW845005 U47734




AA837575 NM_005564 AA329732 AA421943 BE171567 S75256




AI750047 AI762213 AA100735 AW612993 AI474120 AW062884




AI940001 AW062852 AW062899 BE182639 AW778875 AA528093




AW517424 AI939989 AA076188 BE182636 AA169569 AA167439




AI283967 AA167783 AA076140 AI749649 AA166792 AI708618




AA400973 AA514773 AA514789 AA164458 AA167440 AA074845




AA421944 AA514874 AA079557 AA102361 AA587027 AA642930




AA878029 AA164459 AW176400 AW475086 AA857522 AA148193




AA838234 AA593897 AI284506 AW193324 AA148194 AW583341




AI669077 AW264913 AA074902 AI680515 AA169874 AA169614




AA079651 AW591737 AW190644 AA076565 AA662747 AA075896




AA535642 N27757 AI306666 AA074727 N79823 AA524360 AI826800




AA173827 BE140374 BE004062 AW265060 BE184103 AI199258




AA857853 AA299459 AA837890 AI626104 AA503624 BE183618




BE183717 AA573267 AI833071 AW270590 AA506601 BE004010




AA837854 AI675895 AI810491 AI184883 AW664712 AA076046




AA515574 AW352267 AI797418 AA172395 AI749194 AI559933




AA502597 AA321220 AI866124 AI695633 AA494293 AW085635




AA165649 AA165663


127007
19921_1
AB037771 BE005079 AA394189 AW959650 AA299360 AA398081 W37627 AW750817




AW630138 AI522058 BE326323 AA374890




AW418534 AW997510 AW995214 AW959649 AA504426 D79223




D79621 AI276062 AI973155 AA653470 AA337887 AI382521 AW084427




D57078 W37628 AI610506 Z30230 AI567034 AA766091 H25097




H25078 AW991507 AA319736


110769
229824_1
BE000831 AA541787 AW173038 AA327931 AW117510 AW664665 AI066624 AI478955




AI863075 AI073744 AA490170 R46651 AI075653




F02865 N22222 AW972956


120695
9683_3
AA976503 AI917802 AA953664 AA404613 AA428771 BE280542 AW194691 AI927301




AI740458 AI796100 AI935603 AW052210




AA970201 AI633384 AA425910 AI017004




AI241295 AA402816 AA291468






Pkey. Unique Eos probeset identifier number




CAT number Gene cluster number




Accession Genbank accession numbers








[0373] Table 10A lists about 733 genes up-regulated in ovarian cancer compared to normal adult tissues These were selected from These were selected from 59680 probesets on the Affymetrix/Eos-Hu03 GeneChip array such that the ratio of “average” ovarian cancer to “average” normal adult tissues was greater than or equal to 3 0 The “average” ovarian cancer level was set to the about the 80th percentile amongst various ovarian cancers The “average” normal adult tissue level was set to the 90th percentile value amongst various non-malignant tissues In order to remove gene-specific background levels of non-specific hybridization, the 15th percentile value amongst the non malignant tissues was subtracted from both the numerator and the denominator before the ratio was evaluated.
25TABLE 10AABOUT 733 UP-REGULATED GENES, OVARIANCANCER VERSUS NORMAL ADULT TISSUESPkeyEx AccnUG IDTitleratio432938T27013Hs 3132steroidogenic acute regulatory protein56.1418179X51630Hs.1145Wilms tumor 133.5400292AA250737Hs 72472BMPR-lb, bone morphogenetic protein receptor30.0452838U65011Hs 30743Preferentially expressed antigen in melanoma29.5415511AI732617Hs 182362ESTs28.1422956BE545072Hs.122579ESTs28.1410929H47233Hs 30643ESTs27.4400289X07820Hs 2258Matrix Metalloproteinase 10 (Stromolysin 2)25.2449034AI624049Hs 277523gb: ts41a09x1 NCI_CGAP_Ut1 Homo sapiens cDNA23.7427585D31152Hs.179729collagen, type X, alpha 1 (Schmid metaphyseal22.7428392H10233Hs 2265secretory granule, neuroendocrine protein 121.9448243AW369771Hs 77496ESTs21.3430691C14187Hs 103538ESTs21.2444783AK001468Hs 62180ESTs20.8407638AJ404672Hs 288693EST20.1423739AA398155Hs.97600ESTs19.7436982A8018305Hs 5378spondin 1, (f-spondin) extracellular matrix p19.0451110AI955040Hs 301584ESTs18.8426427M86699Hs 169840TTK protein kinase18.7428227AA321649Hs 2248INTERFERON-GAMMA INDUCED18.3419854AW664873Hs.87836Homo sapiens PAC clone RP5-1087M19 from 7q1118.3439706AW872527Hs 59761ESTs18.3428579NM_005756Hs 184942G protein-coupled receptor 6417.4410247AF181721Hs.61345RU2S17.0428153AW513143Hs.98367hypothetical protein FLJ22252 similar to SRY-16.9415076NM_000857Hs 77890guanylate cyclase 1, soluble, beta 316.6416209AA236776Hs 79078MAD2 (mitotic arrest deficient, yeast, homolo16.6424905NM_002497Hs 153704NIMA (never in mitosis gene a)-related kinase16.2423685BE350494Hs 49753Homo sapiens mRNA for KIAA1561 protein, parti15.9428187AI687303Hs 285529ESTs15.9438817AI023799Hs 163242ESTs15.9424906AI566086Hs.153716Homo sapiens mRNA for Hmob33 protein, 3′ untr15.9407721Y12735Hs 38018dual-specificity tyrosine-(Y)-phosphorylation15.7412723AA648459Hs 179912ESTs15.3424717H03754Hs 152213wingless-type MMTV integration site family, m15.2443646AI085198Hs 298699ESTs15.1424345AK001380Hs 145479Homo sapiens cDNA FLJ10518 fis, clone NT2RP2014.8428976AL037824Hs 194695ras homolog gene family, member 114.6418738AW388633Hs 6682solute carrier family 7, member 1114.3428479Y00272Hs 184572cell division cycle 2, G1 to S and G2 to M14.2436209AW850417Hs 254020ESTs, Moderately similar to unnamed protein p14.1427356AW023482Hs 97849ESTs13.9418601AA279490Hs 86368calmegin13.8416661AA634543Hs 79440IGF-II mRNA-binding protein 313.7428532AF157326Hs 184786TBP-interacting protein13.6402408013.6447350AI375572Hs 172634ESTs, HER4 (c-erb-B4)13.4451807W52854Hs 27099DKFZP564J0863 protein13.4423575C18863Hs 163443ESTs13.2443211AI128388Hs.143655ESTs13.2437872AK002015Hs 5887RNA binding motif protein 713.0451659BE379761Hs 14248ESTs, Weakly similar to ALU8_HUMAN ALU SUBFAM12.7452904AL157581Hs 30957Homo sapiens mRNA, cDNA DKFZp434E0626 (from c12.7442655AW027457Hs.30323ESTs12.5452096BE394901Hs 226785ESTs12.4414972BE263782Hs.77695KIAA0008 gene product12.3435039AW043921Hs 130526ESTs12.3447033AI357412Hs 157601EST —not in UniGene12.3433764AW753676Hs 39982ESTs12.2442611BE077155Hs.177537ESTs12.0408562AI436323Hs 31141Homo sapiens mRNA for KIAA1568 protein, parti11.9427344NM_000869Hs 21425-hydroxytryptamine (serotonin) receptor 3A11.8421478AI683243Hs 97258ESTs11.8426635BE395109Hs 129327ESTs11.8415989AI267700Hs 111128ESTs11.7433159AB035898Hs.150587kinesin-like protein 211.5452249BE394412Hs.61252ESTs11.4418506AA084248Hs 85339G protein-coupled receptor 3911.3442353BE379594Hs.49136ESTs11.3447700AI420183Hs 171077ESTs, Weakly similar to similar to serine/thr11.3450480X82125Hs 25040zinc finger protein 23911.3425176AW015644Hs 301430ESTs, Moderately similar to TEF1_HUMAN TRANSC11.2435496AW840171Hs.265398ESTs, Weakly similar to transformation-relate11.2433133AB027249Hs 104741PDZ-binding kinase; T-cell originated protein11.1445258AI635931Hs 147613ESTs11.1432677NM_004482Hs 278611UDP-N-acetyl-alpha-D-galactosamine polypeptid11.0429782NM_005754Hs 220689Ras-GTPase-activating protein SH3-domain-bind10.9404567010.8423811AW299598Hs 50895homeo box C410.7452891N75582Hs 212875ESTs, Weakly similar to KIAA0357 [H. sapiens]10.6441627AA947552Hs 58086ESTs10.3443555N71710Hs 21398ESTs, Moderately similar to GNPI_HUMAN GLUCOS10.3412140AA219691Hs.73625RAB6 interacting, kinesin-like (rabkinesin6)10.2427469AA403084Hs 269347ESTs10.1415227AW821113Hs 72402ESTs10.1445413AA151342Hs 12677CGI-147 protein10.0425734AF056209Hs 159396peptidylglycine alpha-amidating monooxygenase10.0421451AA291377Hs 50831ESTs10.0410044BE566742Hs.58169highly expressed in cancer, rich in leucine h9.8427878C05766Hs 181022CGI-07 protein9.7408460AA054726Hs 285574ESTs9.7422972N59319Hs 145404ESTs9.7443715AI583187Hs 9700cyclin E19.7440901AA909358Hs.128612ESTs9.6453160AI263307Hs 146228ESTs9.6415211R64730.compHs.155986ESTs; Highly similar to SPERM SURFACE PROTEIN9.5425282AW163518Hs.155485huntingtin interacting protein 29.540025009.5410568AW162948Hs 64542pre-mRNA cleavage factor Im (68 kD)9.3442957AI949952Hs 49397ESTs9.3453922AF053306Hs 36708budding uninhibited by benzimidazoles 1 (yeas9.3434401AI864131Hs 71119Putative prostate cancer tumor suppressor9.2453628AW243307Hs.170187ESTs9.1452055AI377431Hs.293772ESTs9.1424086AI351010Hs 102267lysyl oxidase9.1442875BE623003Hs 23625Homo sapiens clone TCCCTA00142 mRNA sequence9.1416208AW291168Hs 41295ESTs9.0407168R45175Hs 117183gb: yg40f01 s1 Soares infant brain 1NIB Homo s9.0445537AJ245671Hs 12844EGF-like-domain, multiple 68.9409269AA576953Hs 22972Homo sapiens cDNA FLJ13352 fis, clone OVARC108.9433527AW235613Hs 133020ESTs8.9409928AL137163Hs.57549hypothetical protein dJ473B48.8423020AA383092Hs 1608replication protein A3 (14 kD)8.7425665AK001050Hs 159066ESTs8.6443204AW205878Hs 29643Homo sapiens cDNA FLJ13103 fis, clone NT2RP308.6449433AI672096Hs 9012ESTs8.6453878AW964440Hs 19025ESTs8.6450505NM_004572Hs.25051plakophilin 28.6407001U12471Hs.247954Human thrombospondin-1 gene, partial cds8.5414315Z24878gb: HSB65D052 STRATAGENE Human skeletal muscle8.5425492AL021918Hs 158174zinc finger protein 184 (Kruppel-like)8.5435181AA669339Hs 28838KIAA1571 protein8.5436396AI683487Hs 299112Homo sapiens cDNA FLJ11441 fis, clone HEMBA108.5418384AW149266Hs 25130ESTs8.4453370AI470523Hs 182356ESTs, Moderately similar to translation initi8.4409041AB033025Hs 50081KIAA1199 protein8.4447078AW885727Hs 301570ESTs8.4448674W31178Hs 154140ESTs8.3433393AF038564Hs 98074atrophin-1 interacting protein 48.3433496AF064254Hs 49765VERY-LONG-CHAIN ACYL-COA SYNTHETASE8.3421155H87879Hs 102267lysyl oxidase8.2438394BE379623Hs.27693CGI-124 protein8.2400298AA032279Hs 61635STEAP18.1409092AI735283Hs 172608ESTs8.1440250AA876179Hs 134650ESTs8.1409143AW025980Hs 138965ESTs8.1407771AL138272Hs 62713ESTs8.1419088AI538323Hs.77496ESTs8.1431725X65724Hs 2839Norrie disease (pseudoglioma)7.9431750AA514986Hs 283705ESTs7.9435635AF220050Hs 181385uncharacterized hematopoietic stem/progenitor7.9441826AW503603Hs.129915phosphotriesterase related7.9417728AW138437Hs 24790KIAA1573 protein7.8418845AA852985Hs 89232chromobox homolog 5 (Drosophila HP1 alpha)7.8421039NM_003478Hs 101299cullin 57.8446999AA151520Hs.279525hypothetical protein PRO26057.8429609AF002246Hs 210863cell adhesion molecule with homology to L1CAM7.8415139AW975942Hs 48524ESTs7.7450192AA263143Hs.24596RAD51-interacting protein7.7423992AW898292Hs.137206Homo sapiens mRNA; cDNA DKFZp564H1663 (from c7.7436211AK001581Hs 80961polymerase (DNA directed), gamma7.7450101AV649989Hs 24385Human hbc647 mRNA sequence7.5426921AA037145Hs 172865cleavage stimulation factor, 3′ pre-RNA, subu7.5433330AW207084Hs.132816ESTs7.5439759AL359055Hs 67709Homo sapiens mRNA full length insert cDNA clo7.5427660AI741320Hs 114121Homo sapiens cDNA FLJ23228 fis, clone CAE0667.5422095AI868872Hs 288966ceruloplasmin (ferroxidase)7.5436476AA326108Hs 53631ESTs7.5412170D16532Hs.73729very low density lipoprotein receptor7.4428954AF100781Hs 194678WNT1 inducible signaling pathway protein 37.4450221AA328102Hs 24641cytoskeleton associated protein 27.4439262AA832333Hs 124399ESTs7.4435420AI928513Hs 59203ESTs7.3422892AA988176Hs.121553hypothetical protein FLJ206417.3457030AI301740Hs 173381dihydropyrimidinase-like 27.3411571AA122393Hs.70811hypothetical protein FLJ205167.2409916BE313625Hs.57435solute carrier family 11 (proton-coupled diva7.2418007M13509Hs 83169Matrix metalloprotease 1 (interstitial collag7.2420900AL045633Hs 44269ESTs7.2424001W67883Hs 137476KIAA1051 protein7.2400301X03635Hs 1657Estrogen receptor 17.140023807.1413573AI733859Hs 149089ESTs7.1428071AF212848Hs 182339transcription factor ESE-3B7.1447164AF026941Hs 17518Homo sapiens cig5 mRNA, partial sequence7.1453062AW207538Hs 61603ESTs7.1456965AW131888Hs 172792ESTs, Weakly similar to hypothetical protein7.1442500AI819068Hs 209122ESTs7.1446142AI754693Hs 145968ESTs7.0417791AW965339Hs.111471ESTs7.0418524AA300576Hs 85769acidic 82 kDa protein mRNA7.0451797AW663858Hs 56120ESTs7.0452909NM_015368Hs 30985pannexin 17.0453616NM_003462Hs.33846dynein, axonemal, light intermediate polypept7.0436281AW411194Hs 120051ESTs7.0449897AW819642Hs 24135transmembrane protein vezatin, hypothetical p6.9414142AW368397Hs 150042ESTs6.9448776BE302464Hs 30057transporter similar to yeast MRS26.9419423D26488Hs 90315KIAA0007 protein6.9420908AL049974Hs.100261Homo sapiens mRNA, cDNA DKFZp564B222 (from cl6.8452971AI873878Hs 91789ESTs6.8413597AW302885Hs 117183ESTs6.8415138C18356Hs 78045tissue factor pathway inhibitor 2 TFPI26.8437478AL390172Hs 118811ESTs6.7425292NM_005824Hs.15554537 kDa leucine-rich repeat (LRR) protein6.7421184NM_003616Hs 102456survival of motor neuron protein interacting6.7410227AB009284Hs 61152exostoses (multiple)-like 26.6446608N75217Hs 257846ESTs6.6438167R28363Hs 24286ESTs6.6445459AI478629Hs 158465ESTs6.6452291AF015592Hs 28853CDC7 (cell division cycle 7, S. cerevisiae, h6.6410011AB020641Hs.57856PFTAIRE protein kinase 16.6410292AA843087Hs 124194ESTs6.5415716N59294Hs 301141Homo sapiens cDNA FLJ11689 fis, clone HEMBA106.5424770AA425562gb: zw46e05 r1 Soares_total_fetus_Nb2HF8_9w Ho6.5438122AI620270Hs 129837ESTs6.5439820AL360204Hs 283853Homo sapiens mRNA full length insert cDNA clo6.5444743AA045648Hs 11817nudix (nucleoside diphosphate linked moiety X6.5450638AK001826Hs.25245hypothetical protein FLJ112696.5418203X54942Hs 83758CDC28 protein kinase 26.5439901N73885Hs 124169ESTs6.5428758AA433988Hs 98502Homo sapiens cDNA FLJ14303 fis, clone PLACE206.440455206.440459906.4419503AA243642Hs.137422ESTs6.4420149AA255920Hs 88095ESTs6.4440411N30256Hs 156971ESTs, Weakly similar to Weak similarity with6.4449108AI140683Hs.98328ESTs6.4452097AB002364Hs 27916ADAM-TS3, a disintegrin-like and metallopr6.4453619H87648Hs 33922H. sapiens novel gene from PAC 117P20, chromos6.4410273BE326877Hs 281523ESTs6.3434486AA678816Hs 117142ESTs6.3454036AA374756Hs 93560ESTs, Weakly similar to unnamed protein produ6.340338106.2421308AA687322Hs 192843ESTs6.2419346AI830417gb: wh94d12x1 NCI_CGAP_CLL1 Homo sapiens cDNA6.2446140AA356170Hs 26750Homo sapiens cDNA FLJ21908 fis, clone HEP0386.2453047AW023798Hs 286025ESTs6.2442573H93366Hs.7567Branched chain aminotransferase 1, cytosolic,6.1410102AW248508Hs 279727ESTs,6.1410004AI298027Hs 299115ESTs6.1413335AI613318Hs 48442ESTs6.1424945AI221919Hs 173438hypothetical protein FLJ105826.1427510Z47542Hs 179312small nuclear RNA activating complex, polypep6.1451229AW967707Hs 48473ESTs6.1452641AW952893Hs.237825signal recognition particle 72 kD6.1433172AB037841Hs 102652hypothetical protein ASH16.1425465L18964Hs 1904protein kinase C, iota6.1437117AL049256Hs 122593ESTs6.0423440R25234Hs 143434contactin 16.0430510AW162916Hs.241576hypothetical protein PRO25776.0433252AB040957Hs 151343KIAA1524 protein6.0434699AA643687Hs 149425Homo sapiens cDNA FLJ11980 fis, clone HEMBB106.0436954AA740151Hs.130425ESTs5.9436032AA150797Hs 109276latexin protein5.9424590AW966399Hs 46821hypothetical protein FLJ200865.9444078BE246919Hs 10290U5 snRNP-specific 40 kDa protein (hPrp8-bindi5.9418379AA218940Hs 137516fidgetin-like 15.9438081H49546Hs.298964ESTs5.8443270NM_004272Hs 9192Homer, neuronal immediate early gene, 1B5.8450459AI697193Hs 299254ESTs5.8433612AF078164Hs 61188Homo sapiens Ku70-binding protein (KUB3) mRNA5.8449048Z45051Hs 22920similar to S68401 (cattle) glucose induced ge5.8417251AW015242Hs 99488ESTs, Weakly similar to ORF YKR074w [S.cerevi5.7429181AW979104Hs 294009ESTs5.7454933BE141714gb: QV0-HT0101-061099-032-c04 HT0101 Homo sapi5.7456553AA721325Hs 189058ESTs, Weakly similar to cAMP-regulated guanin5.7430371D87466Hs.240112KIAA0276 protein5.7425371D49441Hs 155981mesothelin5.7424513BE385864Hs 149894mitochondrial translational initiation factor5.6432015AL157504Hs.159115ESTs5.6438109AI076621Hs 71367ESTs, Moderately similar to ALU7_HUMAN ALU SU5.6407137T97307Hs 199067v-erb-b2 avian erythroblastic leukemia viral5.6407945X69208Hs 606ATPase, Cu++ transporting, alpha polypeptide5.6416565AW000960Hs 44970ESTs5.6417830AW504786Hs.132808epithelial cell transforming sequence 2 oncog5.5419752AA249573Hs.152618ESTs5.5422093AF151852Hs.111449CGI-94 protein5.5424583AF017445Hs 150926fucose-1-phosphate guanylyltransferase5.5430388AA356923Hs 240770nuclear cap binding protein subunit 2, 20 kD5.5452534AW083022Hs 149425Homo sapiens cDNA FLJ11980 fis, clone HEMBB105.5453279AW893940Hs 59698ESTs5.5424188AW954552Hs.142634zinc finger protein5.5453884AA355925Hs 36232KIAA0186 gene product5.5424641AB001106Hs 151413glia maturation factor, beta5.5444478W07318Hs.240M-phase phosphoprotein 15.5427975AI536065Hs 122460ESTs5.5424620AA101043Hs 151254kallikrein 7 (chymotryptic, stratum comeum)5.5442914AW188551Hs 99519Homo sapiens cDNA FLJ14007 fis, clone Y79AA105.5417995AW974175Hs.188751ESTs5.4418946AI798841Hs.132103ESTs5.4419963AA743276Hs 301052ESTs5.4420362U79734Hs 97206huntingtin interacting protein 15.4422670AA371612Hs 115351ESTs5.4432837AA310693Hs 279512HSPC072 protein5.4447020T27308Hs 16986hypothetical protein FLJ110465.4458027L49054Hs.85195ESTs, Highly similar to t(3,5)(q25 1, p34) fus5.4425217AU076696Hs 155174CDC5 (cell division cycle 5, S pombe, homolo5.4422938NM_001809Hs 1594centromere protein A (17 kD)5.4450434AA166950Hs.18645ESTs, Weakly similar to partial CDS [C.elegan5.4438279AA805166Hs 165165ESTs, Moderately similar to ALU8_HUMAN ALU SU5.4413384NM_000401Hs 75334exostoses (multiple) 25.3420328Y19062Hs 96870staufen (Drosophila, RNA-binding protein) hom5.3436586AI308862Hs.167028ESTs5.3435793AB037734Hs 4993ESTs5.3422306BE044325Hs 227280Homo sapiens mRNA for Lsm5 protein5.3425154NM_001851Hs 154850collagen, type IX, alpha 15.2453293AA382267Hs 10653ESTs5.2429944R13949Hs 226440Homo sapiens clone 24881 mRNA sequence5.2434891AA814309Hs.123583ESTs5.2415263AA948033Hs 130853ESTs5.2409506NM_006153Hs 54589NCK adaptor protein 15.2412848AA121514Hs 70832ESTs5.2421246AW582962Hs 300961ESTs, Highly similar to AF151805 1 CGI-47 pro5.2431548AI834273Hs 9711Homo sapiens cDNA FLJ13018 fis, clone NT2RP305.2412719AW016610Hs 129911ESTs5.2411945AL033527Hs.92137v-myc avian myelocytomatosis viral oncogene h5.1424078AB006625Hs 139033paternally expressed gene 35.1433558AA833757Hs 201769ESTs5.1434265AA846811Hs.130554Homo sapiens cDNA FLJ23089 fis, clone LNG0705.1453911AW503857Hs 4007Sarcolemmal-associated protein5.1415539AI733881Hs 72472BMPR-lb, bone morphogenetic protein receptor5.1442717R88362Hs 180591ESTs, Weakly similar to R06F6.5b [C. elegans]5.1432358AI093491Hs 72830ESTs5.0409731AA125985Hs 56145thymosin, beta, identified in neuroblastoma c5.0419699AA248998Hs 31246ESTs5.0420313AB023230Hs 96427KIAA1013 protein5.0422505AL120862Hs 124165ESTs, (HSA)PAP protein (programmed cell deat5.0425733F13287Hs 159388Homo sapiens clone 23578 mRNA sequence5.0434160BE551196Hs.114275ESTs5.0435094AI560129Hs.277523EST5.0436812AW298067gb: UI-H-BW0-ajp-g-09-0-UI s1 NCI_CGAP_Sub6 Ho5.0432415T16971Hs 289014ESTs4.940611704.9438018AK001160Hs 5999hypothetical protein FLJ102984.9447505AL049266Hs 18724Homo sapiens mRNA, cDNA DKFZp564F093 (from cl4.9448621AI097144Hs.5250ESTs, Weakly similar to BACR37P7 g [D.melanog4.9453001AW131636Hs 191260ESTs4.9410561BE540255Hs 6994Homo sapiens cDNA FLJ22044 fis, clone HEP0914.9418811AK001407Hs 88663hypothetical protein FLJ105454.9436754AI061288Hs.133437ESTs, Moderately similar to gonadotropin indu4.8437212AI765021Hs 210775ESTs4.8447312AI434345Hs 36908activating transcription factor 14.8409732NM_016122Hs 56148NY-REN-58 antigen4.8434690AI867679Hs.148410ESTs4.8444172BE147740Hs 104558ESTs4.8424539L02911Hs 150402activin A receptor, type I4.8418677S83308Hs 87224SRY (sex determining region Y)-box 54.8406076AL390179Hs 137011Homo sapiens mRNA, cDNA DKFZp547P134 (from cl4.8420179N74530Hs 21168ESTs4.7450375AA009647Hs.8850a disintegrin and metalloproteinase domain 124.7419247S65791Hs.89764fragile X mental retardation 14.7420850BE139590Hs 122406ESTs4.7425420BE536911Hs 234545ESTs4.7428664AK001666Hs 189095similar to SALL1 (sal (Drosophila)-like4.7419131AA406293Hs.301622ESTs4.7422278AF072873Hs 114218ESTs4.7451684AF216751Hs 26813CDA144.6400296AA305627Hs.139336ATP-binding cassette, sub-family C (CFTR/MRP)4.6408425AW058674Hs 44787Homo sapiens mRNA, cDNA DKFZp434O0227 (from c4.6417168AL133117Hs 81376Homo sapiens mRNA; cDNA DKFZp586L1121 (from c4.6429486AF155827Hs 203963hypothetical protein FLJ103394.6442917AA314907Hs.85950ESTs4.6443268AI800271Hs 129445hypothetical protein FLJ124964.6452795AW392555Hs 18878hypothetical protein FLJ216204.6457300AW297436Hs 158849Homo sapiens cDNA FLJ21663 fis, clone COL0884.6459551AI472808gb: tj70e07.x1 Soares_NSF_F8_9W_OT_PA_P_S1 Hom4.6421977W94197Hs.110165ribosomal protein L26 homolog4.6429441AJ224172Hs 204096lipophilin B (uteroglobin family member), pro4.6449722BE280074Hs 23960cyclin B14.6431689AA305688Hs 267695UDP-Gal betaGlcNAc beta 1,3-galactosyltransfe4.5425178H16097Hs 161027ESTs4.5429597NM_003816Hs 2442a disintegrin and metalloproteinase domain 94.5436556AI364997Hs 7572ESTs4.540053404.5417845AL117461Hs 82719Homo sapiens mRNA, cDNA DKFZp586F1822 (from c4.5423123NM_012247Hs 124027SELENOPHOSPHATE SYNTHETASE, Human selenium d4.5448305AA625207Hs.264915Homo sapiens cDNA FLJ12908 fis, clone NT2RP204.5441006AW605267Hs.7627CGI-60 protein4.5414569AF109298Hs 118258Prostate cancer associated protein 14.5447924AI817226Hs 170337ESTs4.5425506NM_003666Hs 158205basic leucine zipper nuclear factor 1 (JEM-1)4.5411630U42349Hs 71119Putative prostate cancer tumor suppressor4.4432842AW674093Hs.279525hypothetical protein PRO26054.4413472BE242870Hs.75379solute carrier family 1 (glial high affinity4.4414699AI815523Hs 76930synuclein, alpha (non A4 component of amyloid4.4412733AA984472Hs 74554KIAA0080 protein4.4419790U79250Hs 93201glycerol-3-phosphate dehydrogenase 2 (mitocho4.4433377AI752713Hs.43845ESTs4.4449535W15267Hs 23672low density lipoprotein receptor-related prot4.4453900AW003582Hs.226414ESTs, Weakly similar to ALU8_HUMAN ALU SUBFAM4.4443881R64512Hs.237146Homo sapiens cDNA FLJ14234 fis, clone NT2RP404.4423025AA831267Hs 12244Homo sapiens cDNA FLJ23581 fis, clone LNG1364.4408621AI970672Hs 46638chromosome 11 open reading frame 8, fetal br4.3416241N52639Hs 32683ESTs4.3432005AA524190Hs 120777ESTs, Weakly similar to ELL2_HUMAN RNA POLYME4.3435532AW291488Hs.117305ESTs4.3451813NM_016117Hs 27182phospholipase A2-activating protein4.3454193BE141183gb: MR0-HT0071-191199-001-b04 HT0071 Homo sapi4.3418478U38945Hs 1174cyclin-dependent kinase inhibitor 2A (melanom4.340606904.3419465AW500239Hs 21187Homo sapiens cDNA FLJ23068 fis, clone LNG0554.3418413R95735Hs.117753ESTs, Weakly similar to antigen of the monocl4.3452028AK001859Hs 27595hypothetical protein FLJ109974.3418693AI750878Hs 87409thrombospondin 14.3410361BE391804Hs.62661guanylate binding protein 1, interferon-induc4.2409763AL043212gb: DKFZp434H0623_r1 434 (synonym htes3) Homo4.2455601AI368680Hs 816SRY (sex determining region Y)-box 2, partial4.2408908BE296227Hs 48915serine/threonine kinase 154.2413582AW295647Hs 71331Homo sapiens cDNA FLJ21971 fis, clone HEP0574.2423248AA380177Hs.125845ribulose-5-phosphate-3-epimerase4.2425024R39235Hs 12407ESTs4.2447153AA805202Hs 173912eukaryotic translation initiation factor 4A,4.2447406BE618060Hs 282882ESTs4.2449347AV649748Hs.295901ESTs4.2414279AW021691Hs 3804DKFZP564C1940 protein4.2428856AA436735Hs 183171Homo sapiens cDNA FLJ22002 fis, clone HEP0664.2407872AB039723Hs.40735frizzled (Drosophila) homolog 34.2421502AF111856Hs 105039solute carner family 34 (sodium phosphate),4.2436406AW105723Hs 125346ESTs4.2438209AL120659Hs 6111KIAA0307 gene product4.2443653AA137043Hs.9663programmed cell death 6-interacting protein4.1454556AW807073gb: MR4-ST0062-031199-018-d06 ST0062 Homo sapi4.1424834AK001432Hs 153408Homo sapiens cDNA FLJ10570 fis, clone NT2RP204.1412593Y07558Hs 74088early growth response 34.1416566NM_003914Hs 79378cyclin A14.1426342AF093419Hs 169378multiple PDZ domain protein4.1428417AK001699Hs.184227F-box only protein 214.1429317AA831552Hs 268016solute carrier family 5 (inositol transporter4.1446880AI811807Hs.108646Homo sapiens cDNA FLJ12534 fis, clone NT2RM404.1422988AW673847Hs.97321ESTs4.0434657AA641876Hs.191840ESTs4.0412494AL133900Hs 792ADP-ribosylation factor domain protein 1, 64 k4.0443271BE568568Hs 195704ESTs4.0421437AW821252Hs 104336ESTs4.040164404.040509504.0418417R77182gb: yi65e02 r1 Soares placenta Nb2HP Homo sapi4.0420807AA280627Hs 57846ESTs4.0429529AA454190Hs 193811ESTs, Moderately similar to reduced expressio4.0457726AI217477Hs 194591ESTs4.0431130NM_006103Hs 2719epididymis-specific, whey-acidic protein type4.0453403BE466639Hs 61779Homo sapiens cDNA FLJ13591 fis, clone PLACE104.0442768AL048534Hs 48458ESTs, Weakly similar to ALU8_HUMAN ALU SUBFAM4.0413430R22479Hs 24650Homo sapiens cDNA FLJ13047 fis, clone NT2RP304.0424081NM_006413Hs 139120ribonuclease P (30 kD)4.0425692D90041Hs.155956NAT1; arylamine N-acetyltransferase4.0407792AI077715Hs 39384putative secreted ligand homologous to fjx14.0408353BE439838Hs 44298hypothetical protein4.0421175AI879099Hs.102397GIOT-3 for gonadotropin inducible transcripti3.9420324AF163474Hs 96744DKFZP586D0823 protein, Prostate androgen-regu3.9417531NM_003157Hs 1087serine/threonine kinase 23.9458924BE242158Hs 24427DKFZP566O1646 protein3.940019503.940148003.9410360AW663690gb: hj21g03 x1 NCI_CGAP_Li8 Homo sapiens cDNA3.9410908AA121686Hs 10592ESTs3.9420159AI572490Hs 99785ESTs3.9422805AA436989Hs 121017H2A histone family, member A3.9424639AI917494Hs.131329ESTs3.9428555NM_002214Hs.184908integrin, beta 83.9431699NM_001173Hs 267831Homo sapiens cDNA FLJ12952 fis, clone NT2RP203.9433703AA210863Hs 3532nemo-like kinase3.9437144AL049466Hs 7859ESTs3.9452728AI915676Hs.239708ESTs3.9430447W17064Hs 241451SWI/SNF related, matrix associated, action dep3.9440594AW445167Hs 126036ESTs3.9408938AA059013Hs 22607ESTs3.9427051BE178110Hs.173374ESTs3.9447568AF155655Hs.18885CGI-116 protein3.9457211AW972565Hs 32399ESTs, Weakly similar to Similar to Ena-VASP I3.9443475AI066470Hs 134482ESTs3.9433447U29195Hs 3281neuronal pentraxin II3.9428093AW594506Hs 104830ESTs3.8437938AI950087ESTs; Weakly similar to Gag-Pol polyprotein [3.8408829NM_006042Hs 48384heparan sulfate (glucosamine) 3-O-sulfotransf3.8429250H56585Hs.198308tryptophan rich basic protein3.8441859AW194364Hs 128022ESTs, Weakly similar to FIG1 MOUSE FIG-1 PROT3.8437700AA766060Hs 122848ESTs3.8439560BE565647Hs 74899hypothetical protein FLJ128203.8409564AA045857Hs.54943fracture callus 1 (rat) homolog3.8429474AA453441Hs 31511ESTs3.8431965BE175190gb: QV2-HT0577-010500-165-g04 HT0577 Homo sapi3.8454018AW016892Hs.241652ESTs3.8426320W47595Hs 169300transforming growth factor, beta 23.8439635AA477288Hs 94891Homo sapiens cDNA FLJ22729 fis, clone HSI1563.8417517AF001176Hs 82238POP4 (processing of precursor, S cerevisiae3.8446402AI681145Hs 160724ESTs3.8450236AW162998Hs 24684KIAA1376 protein3.8410804U64820Hs 66521Machado-Joseph disease (spinocerebellar ataxi3.840026803.8418217AI910647Hs.13442ESTs3.8421928AF013758Hs 109643polyadenylate binding protein-interacting pro3.8417300AI765227Hs 55610solute carner family 30 (zinc transporter),3.8414136AA812434Hs 178227ESTs3.8453945NM_005171Hs 36908activating transcription factor 13.740024003.7407877AW016811Hs 234478Homo sapiens cDNA FLJ22648 fis, clone HSI0733.7450581AF081513Hs.25195endometrial bleeding associated factor (left-3.7418223NM_014733Hs 83790KIAA0305 gene product3.7411704AI499220Hs 71573hypothetical protein FLJ100743.7432712AB016247Hs 288031sterol-C5-desaturase (fungal ERG3, delta-5-de3.7422809AK001379Hs.121028hypothetical protein FLJ105493.740282003.7408090BE173621Hs 292478ESTs3.7416421AA134006Hs 79306eukaryotic translation initiation factor 4E3.7418282AA215535Hs 98133ESTs3.7418454AA315308gb: EST187095 Colon carcinoma (HCC) cell line3.7418668AW407987Hs 87150Human clone A9A2BR11 (CAC)n/(GTG)n repeat-con3.7422290AA495854Hs.48827hypothetical protein FLJ120853.7432824AK001783Hs 279012hypothetical protein FLJ109213.7439907AA853978Hs 124577ESTs3.7447479AB037834Hs 18685Homo sapiens mRNA for KIAA1413 protein, parti3.7451073AI758905Hs 206063ESTs3.7450377AB033091Hs 24936ESTs3.7414343AL036166Hs 75914coated vesicle membrane protein3.7448807AI571940Hs 7549ESTs3.7442821BE391929Hs 8752Putative type II membrane protein3.7426300U15979Hs.169228delta-like homolog (Drosophila)3.7418068AW971155Hs.293902ESTs, Weakly similar to prolyl 4-bydroxylase3.7411263BE297802Hs 69360kinesin-like 6 (mitotic centromere-associated3.7443054AI745185Hs 8939yes-associated protein 65 kDa3.7421154AA284333Hs 287631Homo sapiens cDNA FLJ14269 fis, clone PLACE103.7411402BE297855Hs.69855NRAS-related gene3.7450447AF212223Hs 25010hypothetical protein P15-23.6414706AW340125Hs 76989KIAA0097 gene product3.6434228Z42047Hs 283978ESTs, KIAA0738 gene product3.6434164AW207019Hs 148135ESTs3.6409533AW969543Hs 2129mitogen-activated protein kinase kinase kinas3.640222203.640491503.640499603.6411560AW851186gb: IL3-CT0220-150200-071-H05 CT0220 Homo sapi3.6419750AL079741Hs 183114Homo sapiens cDNA FLJ14236 fis, clone NT2RP403.6426010AA136563Hs 1975Homo sapiens cDNA FLJ21007 fis, clone CAE0383.6427038NM_014633Hs.173288KIAA0155 gene product3.6439255BE164500gb: RC4-HT0469-230300-014-e10 HT0469 Homo sapi3.6458242BE299588Hs 28465Homo sapiens cDNA FLJ21869 fis, clone HEP0243.6415115AA214228Hs.127751hypothetical protein3.6453468W00712Hs 32990DKF7P566F084 protein3.6441205AW137827Hs 176904ESTs3.6452693T79153Hs 48589zinc finger protein 2283.6417389BE260964Hs 82045Midkine (neunte growth-promoting factor 2)3.6448105AW591433Hs.170675ESTs, Weakly similar to TMS2_HUMAN TRANSMEMBR3.6451522BE565817Hs 26498hypothetical protein FLJ216573.6440048AA897461Hs 158469ESTs, Weakly similar to envelope protein [H.s3.5419359AL043202Hs 90073chromosome segregation 1 (yeast homolog)-like3.5452030AL137578Hs 27607Homo sapiens mRNA, cDNA DKFZp564N2464 (from c3.540066603.5422646H87863Hs.151360ESTs3.5407846AA426202Hs 40403Cbp/p300-interacting transactivator, with Glu3.5408730AV660717Hs.47144DKFZP586N0819 protein3.540151703.5413775AW409934Hs 75528nucleolar GTPase3.5417177NM_004458Hs 81452fatty-acid-Coenzyme A ligase, long-chain 43.5427943AW959075gb: EST371145 MAGE resequences, MAGE Homo sapi3.5439107AL046134Hs 27895ESTs3.5447268AI370413Hs.36563Homo sapiens cDNA FLJ22418 fis, clone HRC0853.5412604AW976324Hs 47144DKFZP586N0819 protein3.5427134AA398409Hs 173561EST3.5430273AI311127Hs 125522ESTs3.5436671AW137159Hs 146151ESTs3.5433037NM_014158Hs 279938HSPC067 protein3.5453745AA952989Hs 63908Homo sapiens HSPC316 mRNA, partial cds3.5400531AF151064Hs 36069hypothetical protein3.5433345AI681545Hs 152982EST cluster (not in UniGene)3.4406400AA343629Hs 104570kallikrein 8 (neuropain/ovasin)3.4407596R86913gb: yq30f05 r1 Soares fetal liver spleen 1NFLS3.4453779N35187Hs 43388ESTs3.4444858AI199738Hs 208275ESTs, Weakly similar to unnamed protein product3.4447688N87079Hs 19236NADH dehydrogenase (ubiquinone) 1 beta subcom3.4424856AA347746Hs 9521ESTs, Weakly similar to KIAA1015 protein [H.s3.4407864AF069291Hs 40539chromosome 8 open reading frame 13.440410803.440372903.440423203.4423687AA329633Hs.133011ESTs, Highly similar to Z117_HUMAN ZINC FINGE3.4428372AK000684Hs 183887hypothetical protein FLJ221043.4439741BE379646Hs 6904Homo sapiens mRNA full length insert cDNA clo3.4441447AA934077Hs 126980ESTs3.4448358R44433Hs.106614Human DNA sequence from clone RP4-534K7 on ch3.4450926AI744361Hs 205591ESTs, Weakly similar to zinc finger protein P3.4458477NM_000314Hs 10712phosphatase and tensin homolog (mutated in mu3.4421379Y15221Hs 103982small inducible cytokine subfamily B (Cys-X-C3.4452822X85689Hs 288617Homo sapiens cDNA FLJ22621 fis, clone HSI0563.4441111AI806867Hs.126594ESTs3.4447519U46258Hs.23448ESTs3.4446913AA430650Hs 16529transmembrane 4 superfamily member (tetraspan3.4449581AI989517Hs 181605ESTs3.4456132BE219771Hs 237146Homo sapiens cDNA FLJ14234 fis, clone NT2RP403.4448186AA262105Hs 4094Homo sapiens cDNA FLJ14208 fis, clone NT2RP303.4422611AA158177Hs 118722fucosyltransferase 8 (alpha (1,6) fucosyltran3.4441433AA933809Hs.42746ESTs3.4417837AL079905Hs 1103transforming growth factor, beta 13.4450516AA902656Hs 21943NIF3 (Ngg1 interacting factor 3, S pombe homo3.4407796AA195509Hs 272239lymphocyte activation-associated protein3.3419200AW966405Hs 288856prefoldin 53.3423161AL049227Hs 124776Homo sapiens mRNA, cDNA DKFZp564N1116 (from c3.3445679AI343868Hs 58800Homo sapiens cDNA FLJ12488 fis, clone NT2RM203.3435014BE560898Hs 10026ribosomal protein L17 isolog3.3446619AU076643Hs.313secreted phosphoprotein 1 (osteoporitin, bone3.3439170AA332365Hs 165539ESTs3.3429830AI537278Hs 225841DKFZP434D193 protein3.3428943AW086180Hs 37636ESTs, Weakly similar to KIAA1392 protein [H.s3.3445817NM_003642Hs 13340histone acetyltransferase 13.3408805H69912Hs.48269vaccinia related kinase 13.3441134W29092Hs 7678cellular retinoic acid-binding protein 13.3408532AI453137Hs 63176ESTs3.3409517X90780Hs 54668troponin I, cardiac3.3414304AI621276Hs 165998DKEZP564M2423 protein3.3436427AI344378Hs 143399ESTs3.3436662AI582393Hs 126695ESTs3.3440304BE159984Hs.125395ESTs3.3447385F12863gb: HSC3FE081 normalized infant brain cDNA Hom3.3451177AI969716Hs 13034ESTs3.3428949AA442153Hs 104744ESTs, Weakly similar to AF208855 1 BM-013 [H3.3451743AW074266Hs 23071ESTs3.3421515Y11339Hs 105352GalNAc alpha-2, 6-sialyltransferase I, long f3.3446351AW444551Hs.258532ESTs3.3435102AW899053Hs 76917F-box only protein 83.3418216AA662240Hs 283099AF15q14 protein3.340150803.3437108AA434054Hs 80624Homo sapiens cDNA FLJ23442 fis, clone HSI0093.3416530U62801Hs 79361kallikrein 6 (neurosis, zyme)3.3443171BE281128Hs 9030TONDU3.3458627AW088642Hs.97984ESTs; Weakly similar to WASP-family protein [3.3412078X69699Hs 73149paired box gene 83.3414080AA135257Hs 47783ESTs, Weakly similar to T12540 hypothetical p3.340119703.3422134AW179019Hs.112110ESTs3.3409044AI129586Hs 33033ESTs3.3416198H27332Hs 99598ESTs3.2436481AA379597Hs 5199HSPC150 protein similar to ubiquitin-conjugat3.2436525AA721428Hs 26145Homo sapiens cDNA FLJ14127 fis, clone MAMMA103.2409142AL136877Hs.50758chromosome-associated polypeptide C3.2428819AL135623Hs.193914KIAA0575 gene product3.2428728NM_016625Hs 191381ESTs, Weakly similar to hypothetical protein3.2421261AA600853Hs 98133ESTs3.2446219AI287344Hs 149827ESTs3.2457574H88717Hs 27774ESTs, Highly similar to AF161349 I HSPC086 [H3.2409172Z99399Hs.118145ESTs3.2419388T67012Hs 75323prohibitin3.2434187AA627098Hs 99103ESTs, Weakly similar to I38428 T-complex prot3.2445060AA830811Hs.88808ESTs3.2448254AI829900Hs 22929ESTs3.2452943BE247449Hs 31082hypothetical protein FLJ105253.2411393AW797437Hs 69771B-factor, properdin3.2453775NM_002916Hs.35120replication factor C (activator 1) 4 (37 kD)3.2408418AW963897Hs 44743KIAA1435 protein3.2442025AW887434Hs 11810ESTs, Weakly similar to CD4 [C. elegans]3.2417006AW673606Hs 80758aspartyl-tRNA synthetase3.2407881AW072003Hs 40968heparan sulfate (glucosamine) 3-O-solfotransf3.2444755AA431791Hs 183001ESTs3.240282903.2451593AF151879Hs 26706CGI-121 protein3.2419926AW900992Hs 93796DKFZP586D2223 protein3.2434551BE387162Hs.280858ESTs, Highly similar to XPB_HUMAN DNA-REPAIR3.2445929AI089660Hs 7838makorin, ring finger protein, 13.2409365AA702376Hs 226440Homo sapiens clone 24881 mRNA sequence3.2418836AI655499Hs 61712ESTs3.2441020W79283Hs 35962ESTs3.1422363T55979Hs 115474replication factor C (activator 1) 3 (38 kD)3.1413010AA393273Hs.75133transcription factor 6-like 1 (mitochondrial3.1452092BE245374Hs.27842hypothetical protein FLJ112103.1410486AW235094Hs.193424ESTs, Weakly similar to KIAA1064 protein [H.s3.1434540NM_016045Hs 5184TH1 drosophila homolog3.1409178BE393948Hs.50915kallikrein 53.1439480AL038511Hs 125316ESTs3.1417848AA206581Hs 39457ESTs3.1446293AI420213Hs 149722ESTs3.1408108AI580492Hs 42743hypothetical protein3.1415947U04045Hs 78934mutS (E coli) homolog 2 (colon cancer, nonpo3.1410519AW612264Hs.131705ESTs3.1421987AI133161Hs 286131CGI-101 protein3.1440046AW402306Hs 6877hypothetical protein FLJ104833.1453931AL121278Hs 25144ESTs3.1454423AW603985Hs 179662nucleosome assembly protein 1-like 13.1459089F13036Hs 27373Homo sapiens mRNA; cDNA DKFZp564O1763 (from c3.1418735N48769Hs 44609ESTs3.1414245BE148072Hs 75850WAS protein family, member 13.1410909AW898161Hs.53112ESTs, Weakly similar to ALU8_HUMAN ALU SUBFAM3.1434926BE543269Hs 50252Homo sapiens HSPC283 mRNA, partial cds3.1409239AA740875Hs 44307ESTs3.1429017AA463605Hs 238995ESTs3.1447072D61594Hs.17279tyrosylprotein sulfotransferase 13.1426514BE616633Hs 301122bone morphogenetic protein 7 (osteogenic prot3.1448133AA723157Hs 73769folate receptor 1 (adult)3.1418792AB037805Hs.88442KIAA1384 protein3.1427528AU077143Hs 179565minichromosome maintenance deficient (S.cere3.140207703.1440671AW297920Hs 130054ESTs3.1419890X17360Hs 278255homeo box D43.1406687M31126Hs 272620pregnancy specific beta-1-glycoprotein 93.1409151AA306105Hs.50785SEC22, vesicle trafficking protein (S.cerevi3.1431221AA449015Hs.286145SRB7 (suppressor of RNA polymerase B, yeast)3.1443584AI807036Hs 101619ESTs3.1445525BE149866Hs 14831ESTs3.1410441BE298210gb: 601118016F1 NIH_MGC_17 Homo sapiens cDNA c3.1422634NM_016010Hs.118821CGI-62 protein3.0420022AA256253Hs 120817ESTs453912AL121031Hs 32556KIAA0379 protein3.0456844AI264155Hs.152981CDP-diacylglycerol synthase (phosphatidate cy3.0414941C14865Hs 182159ESTs3.0407807AL031427Hs 40094Haman DNA sequence from clone 167A19 on chrom3.0414725AA769791Hs.120355Homo sapiens cDNA FLJ13148 fis, clone NT2RP303.0444420AI148157Hs 146766ESTs3.0431742NM_016652Hs 268281CGI-201 protein3.0412519AA196241Hs 73980troponin T1, skeletal, slow3.0418348AI537167Hs 96322Homo sapiens cDNA FLJ23560 fis, clone LNG0983.0444261AA298958Hs.10724MD5023 protein3.0457465AW301344Hs 195969ESTs3.0443933AI091631Hs 135501Homo sapiens two pore potassium channel KT3 33.0442150AI368158Hs.128864ESTs3.0414883AA926960Hs.77550CDC28 protein kinase 13.0442879AF032922Hs 8813syntaxin binding protein 33.0437949U78519Hs 41654ESTs3.040351503.040386403.0407785AW207285Hs 98279ESTs3.0426199AA371865Hs 97090ESTs3.0426324AW291787Hs 200933ESTs3.0427738NM_000318Hs.180612peroxisomal membrane protein 3 (35 kD, Zellweg3.0427837U87309Hs 180941vacuolar protein sorting 41 (yeast homolog)3.0439430AF124250Hs 6564breast cancer anti-estrogen resistance 33.0442039AW276240Hs.128352ESTs, Weakly similar to p80 [R.norvegicus]3.0446978NM_001938Hs 16697down-regulator of transcription 1, TBP-bindin3.0452431U88879Hs 29499toll-like receptor 33.0452841T17431Hs 65412DEAD/H (Asp-Gla-Ata-Asp/His) box polypeptide3.0432114AL036021Hs 225597ESTs3.0445640AW969626Hs.31704ESTs, Weakly similar to KIAA0227 [H. sapiens]3.0442607AA507576Hs 288361KIAA0741 gene product3.0453920AI133148Hs 36602I factor (complement)3.0430000AW205931Hs.99598ESTs3.0429164AI688663Hs.116586ESTs3.0453331AI240665Hs 8895ESTs3.0448663BE614599Hs 108823H. sapiens gene from PAC 42616, similar to syn3.0425776U25128Hs 159499parathyroid hormone receptor 23.040171403.040090303.0428428AL037544Hs 184298cyclin-dependent kinase 7 (homolog of Xenopus3.0443761AI525743Hs 160603ESTs3.0451640AA195601Hs 26771Human DNA sequence from close 747H23 on chrom3.0442580AI733682Hs 130239ESTs3.0Pkey: Primekey Es Accn: Exemplar Accession UG ID: UniGene ID Title: UniGene title ration: ratio tumor vs normal tissues


[0374]

26







TABLE 10B








Pkey
CAT Number
Accession







407596
1003489_1
R86913 R86901 H25352 R01370 H43764 AW044451 W21298


409763
115392_1
AL043212 AA077575 AA077655 R19502 BE545457 AI638421 R14093


410360
1197225_−2
AW663690


410441
120358_1
BE298210 AI672315 AW086489 BE298417 AA455921 AA902537 BE327124 R14963 AA085210




AW274273 AI333584 AI369742 AI039658 AI885095 AI476470 AI287650 AI885299 AI985381 AW592624




AW340136 AI266556 AA456390 AI310815 AA484951


411560
1249443_1
AW851186 AW996967 BE143456


414315
143512_1
Z24878 AA494098 F13654 AA494040 AA143127


418417
1750818_1
R77182 R77197 R80484


418454
175699_1
AA315308 AA223392 BE538098 BE087173


419346
184129_1
AI830417 AA236612


424770
243504_1
AA425562 AI880208 AA346646 N22655 AW811775 AW811786


427943
284802_1
AW959075 W06838 AA417863


431965
33959_2
BE175190 BE003348


436812
427323_1
AW298067 AA731645 AA810101 AW194180 AI690673 AW978773


437938
44573_2
AI950087 N70208 R97040 N36809 AI308119 AW967677 N35320 AI251473 H59397 AW971573 R97278




W01059 AW967671 AA908598 AA251875 AI820501 AI820532 W87891 T85904 U71456 T82391 BE328571 T75102




R34725 AA884922 BE328517 AI219788 AA884444 N92578 F13493 AA927794 AI560251 AW874068




AL134043 AW235363 AA663345 AW008282 AA488964 AA283144 AI890387 AI950344




AI741346 AI689062 AA282915 AW102898 AI872193 AI763273 AW173586 AW150329 AI653832 AI762688 AA988777




AA488892 AI356394 AW103813 AI539642 AA642789 AA856975 AW505512 AI961530 AW629970 BE612881 AW276997




AW513601 AW512843 AA044209 AW856538 AA180009 AA337499




AW961101 AA251669 AA251874 AI819225 AW205862 AI683338 AI858509 AW276905 AI633006 AA972584




AA908741 AW072629 AW513996 AA293273 AA969759 N75628 N22388 H84729 H60052 T92487 AI022058




AA780419 AA551005 W80701 AW613456 AI373032 AI564269




F00531 H83488 W37181 W78802 R66056 AI002839 R67840 AA300207 AW959581 T63226 F04005


439255
470321_1
BE164500 AA832198 BE164502


447385
719912_1
F12863 AI377223 T75099


454193
1050256_1
BE141183 AW178167 AW178162 AW178166 AW178172 AW845893 AW178159




AW178222 AW178213 AW178215 AW178090 AW178091 AW178161 AW178207 AW178210 AW178214




AW178212 BE140918 BE140917 AW178135 AW178205 AW178209 AW178223 AW178220




AW178206 AW178203 AW178165 AW178168 AW178160 AW178136 AW845878 AW178131




AW178138 AW178105 AW845894 AW178129 AW845810 AW845828 AW178216 AW178112




AW178211 AW178224 BE140915 AW178221 AW178130 AW178134 AW178096 AW178108




AW178133 AW178164 AW178218 AW178171 AW178157 AW178158 AW178103 BE141189




AW178170 AW845816 BE141586 AW178156 AW178104 AW178163 AW178093




AW178208 AW178137 AW178140 AW178219 BE141592 AW845901 BE141580 AW178155 BE141598




BE140957


454556
1223878_1
AW807073 AW807055 AW807067 AW807276 AW807030 AW807363




AW845892 AW807091 AW807275 AW807284 AW807287 AW845891 AW807195 AW807271


454933
1245515_1
BE141714 AW845993 AW845989






Pkey: Unique Eos probeset identifier number




CAT number: Gene cluster number




Accession: Genbank accession numbers








[0375]

27








TABLE 10C








Pkey
Ref
Strand
Nt_position







400534
6981826
Minus
278637-279292


400666
8118496
Plus
17982-18115, 20297-20456


400903
2911732
Plus
59112-59228


401197
9719705
Plus
176341-176452


401480
7321503
Plus
166120-166347, 166451-166557, 169651-169832


401508
7534110
Minus
110779-110983


401517
7677912
Plus
29278-29770


401644
8576138
Plus
82655-83959


401714
6715702
Plus
96484-96681


402077
8117414
Plus
65014-65195


402222
9958106
Plus
3261-3834, 3939-4269


402408
9796239
Minus
110326-110491


402820
6456853
Minus
82274-82443


402829
8918414
Plus
101532-101852, 102006-102263


403381
9438267
Minus
26009-26178


403515
7656757
Minus
173358-179553


403729
7543752
Minus
37662-37909


403864
7709019
Minus
51753-51890, 79290-79445


404108
8247074
Minus
63603-64942


404232
8218045
Minus
71800-71956


404552
7243881
Plus
19854-20010


404567
7249169
Minus
101320-101501


404599
8705107
Plus
110443-110733


404915
7341766
Minus
100915-101087


404996
6007890
Plus
37999-38145, 38652-38998, 39727-39872, 40557-40674, 42351-42450


405095
8072599
Plus
138877-139066


406069
9117732
Plus
68880-69374


406117
9142932
Plus
54304-54584






Pkey: Unique number corresponding to an Eos probeset




Ref: Sequence source The 7 digit numbers in this column are Genbank Identifier (GI) numbers “Dunham I et al.” refers to the publication entitled “The DNA sequence of human chromosome 22” Dunham, et al. (1999) Nature 402: 489-495




Strand: Indicates DNA strand from which exons were predicted




Nt_position: Indicates nucleotide positions of predicted exons








[0376] Table 11A lists about 222 genes up-regulated in ovarian cancer compared to normal adult tissues that are likely to encode extracellular or cell-surface proteins These were selected as for Table 10A, except that the ratio was greater than or equal to 2 0, and the predicted protein contained a structural domain that is indicative of extracellular localization (e g ig, fn3, egf, 7tm domains, signal sequences, transmembrane domains) Predicted protein domains are noted
28TABLE 11AABOUT 222 UP-REGULATED GENES ENCODING EXTRACELLULAR/CELLSURFACE PROTEINS, OVARIAN CANCER VERSUS NORMAL ADULT TISSUESPkeyEx AccnUG IDTitlePFAM domainsratio400292AA250737Hs 72472BMPR-lb, bone morphogenetic propkinase, Activin_recp30.0400289X07820Hs 2258Matrix Metalloproteinase 10 (StromSS, hemepexin, Peptidas25.2427585D31152Hs 179729collagen, type X, alpha 1 (Schmid mC1q, Collagen22.7436982AB018305Hs 5378spondin 1, (f-spondin) extracellular mtsp_119.0428579NM_005756Hs. 184942G protein-coupled receptor 64TM17.4443646AI085198Hs 298699ESTsTSPN, vwc, tsp_1, EGF15.1436209AW850417Hs 254020ESTs, Moderately similar to unnameTM14.1418601AA279490Hs 86368calmeginSS, calreticulin13.8428532AF157326Hs. 184786TBP-interacting proteinTM13.6427344NM_000869Hs 21425-hydroxytryptamine (serotonin) recTM, neur_chan11.8432677NM_004482Hs 278611UDP-N-acetyl-alpha-D-galactosaminTM, Glycos_transf_2, Ri11.0404567NM_015902Hs 278428progestin induced protein (DD5)TM, HECT, zf-UBR110.8445537AJ245671Hs. 12844EGF-like-domain, multiple 6SS, MAM, EGF8.9409928AL137163Hs. 57549hypothetical protein dJ473B4TM, MSP_domain8.8407001U12471Hs 247954Human thrombospondin-1 gene, parTSPN, vwc, tsp_1, EGF8.5453370AI470523Hs 182356ESTs, Moderately similar to translatABC_tran, ABC_membr8.4400298AA032279Hs 61635STEAP1TM8.1431725X65724Hs. 2839Norrie disease (pseudoglioma)SS, Cys_knot7.9429609AF002246Hs. 210863cell adhesion molecule with homoloTM, fn3, ig7.8412170D16532Hs 73729very low density lipoprotein receptoTM, Idl_recept_a, ldl_rec7.4428954AF100781Hs 194678WNT1 inducible signaling pathwaySS, IGFBP, Cys_knot, tsp7.4418007M13509Hs 83169Matrix metalloprotease 1 (interstitiaSS, hemopexin, Peptidas7.2424001W67883Hs 137476KIAA1051 proteinPep_M128_propep, Rep7.2456965AW131888Hs 172792ESTs, Weakly similar to hypotheticaTM7.1446142AI754693Hs. 145968ESTsCadherin_C_term, cadhe7.0415138C18356Hs 78045tissue factor pathway inhibitor 2 TFPKunitz_BPTI, G-gamma6.8438167R28363Hs 24286ESTs7tm_16.6452097AB002364Hs 27916ADAM-TS3, a disintegrin-like andPep_M12B_propep, Rep6.4449048Z45051Hs 22920similar to S68401 (cattle) glucose inSS5.8425371D49441Hs 155981mesothelinSS5.7407945X69208Hs 606ATPase, Cu++ transporting, alpha pTM, E1-E2_ATPase, Hy5.6424620AA101043Hs. 151254kallikrein 7 (chymotryptic, stratum cSS, trypsin5.5420362U79734Hs 97206huntingtin interacting protein 1TM, ENTH, I_LWEQ5.4413384NM_000401Hs 75334exoatoses (multiple) 2TM5.3425154NM_001851Hs 154850collagen, type IX, alpha 1Collagen, TSPN5.2411945AL033527Hs 92137v-myc avian myelocytomatosis viralTGF-beta, TGFb_propep5.1415539AI733881Hs. 72472BMPR-lb, bone morphogenetic propkinase, Activin_recp5.1438018AK001160Hs 5999hypothetical protein FLJ10298TM4.9424539L02911Hs 150402activin A receptor, type IActivin_recp, pkinase4.8450375AA009647Hs 8850a disintegrin and metalloproteinase ddisintegrin, Reprolysin, P4.7451684AF216751Hs 26813CDA14TM4.6400296AA305627Hs. 139336ATP-binding cassette, sub-family CTM, ABC_tran ABC_m4.6429597NM_003816Hs 2442a disintegrin and metalloproteinase dTM4.5400534AP000541predicted exonsTM, KRAB, zf-C2H24.5425506NM_003666Hs 158205basic leucine zipper nuclear factor 1TM, Folate_carrier4.5413472BE242870Hs. 75379solute carrier family 1 (glial high affTM, SDF4.4449535W15267Hs 23672low density lipoprotein receptor-relaSS, Idl_recept_b, dl_rece4.4452028AK001859Hs 27595hypothetical protein FLJ10997Zn_carbOpept, Propep_M4.3418693AI750878Hs 87409thrombospondin 1EGF, TSPN, tsp_1, tsp_3,4.3410361BE391804Hs 62661guanylate binding protein 1, interferTM, GBP4.2407872AB039723Hs. 40735frizzled (Drosophila) homolog 3Frizzled, Fz, 7tm_24.2421502AF111856Hs 105039solute carrier family 34 (sodium phoTM, Na_Pi_cotrans4.2412494AL133900Hs 792ADP_ribosylation factor domain proarf, zf-B_box, zf-C3HC44.0405095NM_014479Hs 145296disintegrin proteaseReprolysin, disintegrin4.0431130NM_006103Hs 2719epididymis-specific, whey-acidic proSS, wap4.0407792AI077715Hs 39384putative secreted ligand homologonsSS4.0408829NM_006042Hs 48384heparan sulfate (glucosamine) 3-O-sTM3.8450581AF081513Hs. 25195endometrial bleeding associated factSS, TGF-beta, TGFb_pro3.7432712AB016247Hs 288031sterol-C5-desaturase (fungal ERG3,TM, Sterol_desat3.7450447AF212223Hs 25010hypothetical protein P15-2TM, ANF_receptor, guan3.6414706AW340125Hs 76989KIAA0097 gene productTM3.6417389BE260964Hs. 82045Midkine (neurite growth-promotingTM, PTN_MK3.6400666X07820Hs 2258Matrix Metalloproteinase 10 (StromSS, hemopexin, Peptidas3.5406400AA343629Hs. 104570kallikrein 8 (neuropsin/ovasin)SS, trypsin3.4407864AF069291Hs 40539chromosome 8 open reading frame 1TM, FHA, BRCT3.4452822XB5689Hs. 288617Homo sapiens cDNA. FLJ2621 fis,EGF, fn3, pkinase3.4446913AA430650Hs 16529transmembrane 4 superfamily membTM, transmembrane43.4422611AA158177Hs 118722fucosyltransferase 8 (alpha.(1,6) fucSS3.4423161AL049227Hs. 124776Homo sapiens mRNA, cDNA DKFZcadherin, Cadherin_C_te3.3435102AW899053Hs. 76917F-box only protein 8TM, Sec73.3416530U62801Hs 79361kallikrein 6 (nenrosin, zyme)SS, TM, trypsin3.3401197predicted exonsarf, Ets3.3436525AA721428Hs 26145Homo sapiens cDNA FLJ14127 fis,TM3.2452943BE247449Hs 31082hypothetical protein FLJ10525TM3.2411393AW797437Hs. 69771B-factor, properdinSS, sushi, trypsin, vwa, fib3.2407881AW072003Hs 40968heparan sulfate (glucosamine) 3-O-sSS3.2418836AI655499Hs. 161712ESTspkinase, Activin_recp3.2409178BE393948Hs 50915kallikreinSS, trypsin3.1421987AI133161Hs 286131CGI-101 proteinTM3.1447072D61594Hs 17279tyrosylprotein sulfotransferase 1SS3.1426514BE616633Hs 301122bone morphogenetic protein 7 (osteoSS, TGFb_propeptide, T3.1448133AA723157Hs. 73769folate receptor 1 (adult)TM3.1406687M31126Hs 272620pregnancy specitic beta-1-glycoprotSS, Peptidase_M10, hem3.1456844AI264155Hs 152981CDP-diacylglycerol synthase (phospTM, Cyhdylyltrans3.0414725AA769791Hs. 120355Homo sapiens cDNA FLJ13148 fis,SPRY, 7tm_13.0407785AW207285Hs 98279ESTsSema, ig3.0427738NM_000318Hs 180612peroxisomal membrane protein 3 (35TM, zf-C3HC43.0452431U88879Hs 29499toll-like receptor 3TM, TIR, LRRCT3.0453920AI133148Hs. 36602I factor (complement)Idl_recept_a, trypsin, SRC3.0453331AI240665Hs 8895ESTsdisintegrin, Reprolysin, P3.0425776U25128Hs 159499parathyroid hormone receptor 2TM, 7tm_23.0428428AL037544Hs 184298cyclin-dependent kinase 7 (homologTM, pkinase3.0407910AA650274Hs 41296fibronectin leucine rich transmembraTM, LRRCT, LRRNT, LR2.9408380AF123050Hs 44532diubiquitinTM, ubiquitin, 7tm_3, AN2.9407783AW996872Hs. 172028a disintegrin and metalloproteinase ddisintegrin, Reprolysin2.9420757X78592Hs 99915androgen receptor (dihydrotestosteroTM, Androgen_recep, ho2.9424406D54120Hs 146409wingless-type MMTV integration sitcadherin, Cadherin_C_te2.9428549AA430064Hs 220929ESTs, Moderately similar to ARF-faarf2.9419452U33635Hs. 90572PTK7 protein tyrosine kinase 7TM, pkinase, ig2.9452281T93500Hs 28792ESTsTGFb_propeptide, TGF-2.9420440NM_002407Hs 97644mammaglobin 2SS, Uteroglobin2.9418848AI820961Hs. 193465ESTspkinase, Activin_recp2.9421991NM_014918Hs 110488KIAA0990 proteinSS2.9433190M26901Hs 3210reninSS, asp2.9424538NM_005095Hs 150390zinc finger protein 262TM2.8433002AF048730Hs. 279906cyclin T1SS2.8444342NM_014398Hs. 10887similar to lysosome-associated memTM, Lamp2.8430598AK001764Hs. 247112hypothetical protein FLJ10902TM2.8428450NM_014791Hs 184339KIAA0175 gene productTM, pkinase, KA12.8450171AL133661Hs 24583hypothetical protein DKFZp434C03TM2.8423554M90516Hs 1674glutamine-fructose-6-phosphate tranTM, GATase 2, SIS2.8430016NM_004736Hs 227656xenotropic and polytropic retrovirusTM2.8417866AW067903Hs 82772collagen, type XI, alpha 1Collagen, COLF1, TSPN2.8424894H83520Hs. 153678reproduction 8SS, UBX2.8430651AA961694Hs 105187kinesin protein 9 geneSS2.7414853U31116Hs 77501sarcoglycan, beta (43kD dystrophin-TM2.7448595AB014544Hs. 21572KIAA0644 gene productTM, LRRCT, LRR2.7452835AK001269Hs 30738ESTsTM2.7403019AA834626Hs 66718RAD54 (S. cerevisiae)-likeSS, Anti_proliferat2.7420281AI623693Hs 191533ESTsCation_efflux2.7434815AF155582Hs. 46744core 1 UDP-galactose N-acetylgalactSS2.6432201AI538613Hs 135657TMPRSS3a mRNA for serine proteatrefoil, trypsin2.6430450R23553Hs 241489hypothetical proteinSS2.6448402BE244226Hs 21094RAB18, member RAS oncogene famras, arf2.6421802BE261458Hs 108408CGI-78 proteinTM2.6452355N54926Hs 29202G protein-coupled receptor 34TM, 7tm_12.6417742R64719gb EST22d11 WATM1 Homo sapieank, deatti, RHD, TIG2.6451346NM_006338Hs. 26312glioma amplified on chromosome 1TM, ig, LRR, LRRNT, LR2.6433147AF091434Hs 43080platelet derived growth factor CTM, PDGF, CUB2.6420079NM_014051Hs 94896PTD011 proteinSS, TM,2.6419918X80700Hs 93728pre-B-cell leukemia transcription fachomeobox, ig, Acyltransf2.5432350NM_005865Hs. 274407protease, serine, 16 (thymus)SS2.5406671AA129547Hs 285754met proto-oncogene (hepatocyte gropkinase, Sema, Plexin_re2.5417412X16896Hs 82112interleukin 1 receptor, type ISS, TIR, ig2.5422530AW972300Hs. 118110bone marrow stromal cell antigen 2TM2.5433929AI375499Hs 27379ESTsEGF, ldl_recept_a, ldl_re2.5443562AF118838Hs 9599solute carrier family 25, member 13TM, mito_carr2.5414386X00442Hs 75990haptoglobinsushi, trypsin2.5417576AA339449Hs 82285phosphoribosylglycinamide fomyltrAIRS, formyl_transf, GA2.5449207AL044222Hs 23255nucleoporin 155kDTM2.5416107AA173846Hs. 79015antigen identified by monoclonal antTM, ig2.4421750AK000768Hs. 107872hypothetical protein FLJ20761TM, PH2.4414812X72755Hs 77367monokine induced by gamma interfeSS, IL82.4406137R42764Hs 3248mutS (E. coli) homolog 6TM MutS_C, MutS_N, P2.4450710AW953381Hs 18627ESTs, Weakly similar to G01447 GPTM2.4430291AV660345Hs 238126CGI-49 proteinTM2.4425184BE278288Hs 155048Lutheran blood group (Auberger b aig2.4451418BE387790Hs. 26369ESTsTM2.4412277BE277592Hs 73799guanine nucleotide binding protein (TM, G-alpha2.4413719BE439580Hs 75498small inducible cytokine subfamily ASS, IL82.4451806NM_003729Hs. 27076RNA 3′-terminal phosphate cyclaseTM, RCT2.3416224NM_002902Hs 79088reticulocalbin 2, EF-hand calcium brSS, efhand2.3452268NM_003512Hs 28777H2A histone family, member Lhistone, Calc_CGRP_IA42.3451668Z43948Hs 26789ASPIC (acidic secreted protein in caSS, TM,2.3400880M84349Hs. 119663CD59 antigenSS, UPAR_LY62.3421340F07783Hs 1369decay accelerating factor for compleSS, sushi2.3443986AI381750Hs 283437HTGN29 proteinTM2.3443037AW500305Hs. 8906syntaxin 7TM, Syntaxin2.3440516S42303Hs 161cadherin 2, type 1, N-cadherin (neurHNH, cadherin, Cadherin2.3404877AI394145Hs 18048melanoma antigen MAGE-10TM, MAGE2.3440704M69241Hs 162insulin-like growth factor binding prSS, thyroglobulin_1, IGF2.3437952D63209Hs. 5944solute carrier family 11 (proton-coupTM2.3418624AI734080Hs 104211ESTsSema, ig2.2410434AF051152Hs 63668toll-like receptor 2SS, TIR, LRRCT, LRR2.2424687J05070Hs 151738matrix metalloproteinase 9 (gelatinaSS, fn2, hemopexin, Pepti2.2431457NM_012211Hs. 256297integrin, alpha 11TM, FG-GAP, vwa2.2407907AI752235Hs. 41270procollagen-lysine, 2-oxoglutarate 5SS, Lyayl_hydro2.2400898AF220030Hs 125300Homo sapiens tripartite motif proteinSPRY, 7tm_12.2400303AA242758Hs 79136Human breast cancer, estrogen regulSS, TM,2.2411789AF245505Hs 72157Homo sapiens mRNA: cDNA DKFZig, LRRCT2.2414809AI434699Hs 77356transferrin receptor (p90, CD71)TM, PA, Ribosomal_S22.2401131NM_001651Hs 298023Homo sapiens aquaponn 5 (AQP5),TM, MIP2.2400277Y00281Hs. 2280Human mRNA for nbophorin ITM2.1409317U20165Hs 53250bone morphogenetic protein receptoTM, pkinase2.1409956AW103364Hs 727H sapiens activin beta-A subunit (exTGP-beta, TGFb_propep2.1451253H48299Hs 26126claudin 10TM, PMP22_Claudin2.1429638AI916662Hs. 211577Kinectin 1 (kinesin receptor)TM2.1409267NM_012453Hs 52515transducin (beta)-like 2TM, WD402.1418414J04977Hs 84981X-ray repair complementing defectivSS2.1449057AB037784Hs 22941ESTsTM2.1417666AI345001Hs. 82380menage a trois 1 (CAK assembly faczf-C3HC42.1428485NM_002950Hs 2280ribophorin ITM2.1445798NM_012421Hs 13321rearranged L-myc fusion sequenceTM, zf-C2H22.1430057AW450303Hs 2534bone morphogenetic protein receptoTM, Activin_recp, pkina2.1425189H16622gb ym26c07 r1 Soares infant brain 1RasGEF, PH, fibrinogen2.1413063AL035737Hs 75184chitinase 3-like 1 (cartilage glycoproSS, Glyco_hydro_182.1421343BE246444Hs. 283685hypothetical protein FLJ20396TM2.1425627AF019612Hs 297007ESTsTM, Peptidase_M502.1426261AW242243Hs 168670peroxisomal farnesylated proteinE1-E2_ATPase, Cation2.1431638NM_000916Hs 2820oxytocin receptorTM, 7tm_12.1456546AI690321Hs. 203845ESTs, Weakly similar to TWIK-relaTM2.1421685AF189723Hs 106778calcium transport ATPase ATP2C1TM, E1-E2_ATPase, Hy2.1424099AF071202Hs. 139336ATP-binding cassette, sub-family CTM, ABC_tran, ABC_m2.1424800AL035588Hs 153203MyoD family inhibitorTM2.1410007AW950887Hs 57813zinc nbbon domain containing, 1TFIIS2.1436135D85390Hs 5057carboxypeptidase DSS, Zn_carbOpept2.1420633NM_014581Hs 99526odorant-binding protein 2BTM, lipocalin2.1420162BE378432Hs. 95577cyclin-dependent kinase 4pkinase, ank, ArfGap, PH2.1426156BE244537Hs 167382natriuretic peptide receptor A/guanyTM, ANF_receptor, guan2.0442711AF151073Hs 8645hypothetical proteinTM2.0411872AW327356Hs 90918chromosome 11 open reading frameTM2.0427801AW979155Hs 234433hypothetical protein PRO1068TM, Aa_trans2.0430268AK000737Hs 237480hypothetical protein FLJ20730TM2.0431183NM_006855Hs 250696KDEL (Lys-Asp-Glu-Leu) endoplasTM, ER_lumen_recept, I2.0431846BE019924Hs. 271580Uroplakin 1BTM, transmembrane42.0404210U02478Hs. 100469Human AF-6 mRNATM, RA, DIL, PDZ, FHA2.0435640AF220053Hs 54960uncharacterized hematopeietic stem/TM, SET, zf-CXXC, PHD2.0447906AL050062Hs. 19999DKFZP566K023 proteinSS2.0412666AL080116Hs. 74420origin recognition complex, subunitTM2.0417181L10123Hs 1071surfactant protein A binding proteinTM2.0423945AA410943Hs 72472BMPR-Ib: bone morphogenetic proTM, pkinase, Activin_rec2.0411773NM_006799Hs 72026protease, serine, 21 (testisin)SS, trypsin2.0448350L14561Hs 78546Homo sapiens clone 24411 mRNA sTM, E1-E2_ATPase, Hy2.0401093AI955244Hs. 121520HYPOTHETICAL 16 4 kDa PROTETM, LRRCT2.0415664NM_004939Hs 78580DEAD/H (Asp-Glu-Ala-Asp/His) boDEAD, helicase_C, SPRY2.0448165NM_005591Hs 202379meiotic recombination (S cerevisiaeDNA_repair, Glyco_tran2.0416391AI878927Hs 79284mesoderm specific transcript (mouseTM, abhydrolase2.0422926NM_016102Hs 121748ring finger protein 16SPRY, zf-C3HC4 zf-B2.0446849AU076617Hs. 16251cleavage and polyadenylation specifTM2.0427617D42063Hs. 179825RAN binding protein 2-like 1TM, Ran_BP1, zf-RanBP2.0411678AI907114Hs 71465squalene epoxidaseTM, Monooxygenase2.0432554AI479813Hs 278411NCK-associated protein 1TM2.0Pkey: Primekey Ex. Accn Exemplar Accession UG ID: UniGene ID Title: UniGene title PFAM domains. predicted protein structural domains ratio: ratio tumor vs normal tissue


[0377]

29







TABLE 11B








Pkey
CAT Number
Accession







417742
1696282_1
R64719 Z44680 R12451


425189
247825_1
H16622 R17322 AA351959






Pkey: Unique Eos probeset identifier number




CAT number Gene cluster number




Accession Genbank accession numbers








[0378]

30










TABLE 11C











Pkey
Ref
Strand
Nt_position









400534
6981826
Minus
278637-279292



401197
9719705
Plus
176341-176452








Pkey: Unique number corresponding to an Eos probeset





Ref: Sequence source The 7 digit numbers in this column are Genbank Identifier (GI) numbers. “Dunham I. et al.” refers to the publication entitled “The DNA sequence of human chromosome 22” Dunham I et al. (1999) Nature 402: 489-495.





Strand Indicates DNA strand from which exons were predicted.





Nt_position Indicates nucleotide positions of predicted exons.








[0379] Table 12A lists about 57 genes up-regulated in ovarian cancer compared to normal adult tissues that are likely to encode either enzymes or proteins amenable to modulation by small molecules These were selected as for Table 10A, except that the ratio was greater than or equal to 2 0, and the predicted protein contained a structural domain that is indicative of enzymatic function or of being modulated by small molecules (e g, pkinase, peptidase, isomerase, transporters) Predicted protein domains are noted.
31TABLE 12AABOUT 57 UP-REGULATED GENES ENCODING EXTRACELLULAR/CELLSURFACE PROTEINS, OVARIAN CANCER VERSUS NORMAL ADULT TISSUESPkeyEx AccnUG IDTitlePFAM domainsratio400292AA250737Hs 72472BMPR-Ib, bone morphogenetic propkinase, Activin_recp30.0400289X07820Hs 2258Matrix Metalloproteinase 10 (StromSS,, Peptidase_M1025.2426427M86699Hs. 169840TTK protein kinasepkinase18.7424905NM_002497Hs. 153704NIMA (never in mitosis gene a)-relapkinase16.2433159AB035898Hs 150587kinesin-like protein 2kinesin11.5453370AI470523Hs 182356ESTs, Moderately similar to translatABC_tran8.4418007M13509Hs 83169Matrix metalloprotease 1 (interstitiaSS,, Peptidase_M107.2425465L18964Hs. 1904protein kinase C, iotaSki_Sno, pkinase_C6.1409506NM_006153Hs. 54589NCK adaptor protein 1SH2, SH35.2415539AI733881Hs 72472BMPR-Ib, bone morphogenetic propkinase, Activin_recp5.1424539L02911Hs. 150402activin A receptor, type IActivin_recp, pkinase4.8400296AA305627Hs 139336ATP-binding cassette, sub-family CTM, ABC_tran4.6431699NM_001173Hs 267831Homo sapiens cDNA FLJ12952 fis,RhoGAP, FF, ras3.9439560BE565647Hs 74899hypothetical protein FLJ12820C2, PI-PLC-Y, PI-PLC-X3.8450447AF212223Hs. 25010hypothetical protein P15-2ANF_receptor , pkinase3.6400666X07820Hs 2258Matrix Metalloproteinase 10 (StromSS,, Peptidase_M103.5452822X85689Hs 288617Homo sapiens cDNA FLJ22621 fis,EGF, fn3, pkinase3.4416530U62801Hs 79361kallikrein 6 (neurosin, zyme)SS, TM, trypsin3.3411393AW797437Hs 69771B-factor, properdinSS, sushi, trypsin, vwa, fn3,3.2444755AA431791Hs 183001ESTsAAA3.2418836AI655499Hs. 161712ESTspkinase, Activin_recp3.2409178BE393948Hs 50915kallikrein 5SS, trypsin3.1406687M31126Hs 272620pregnancy specific beta-1-glycoprotSS, Peptidase_M10, , ig3.1453920AI133148Hs 36602I factor (complement)Idl_recept_a, trypsin, SRCR3.0404653AA923729Hs. 263220pkinase2.9419452U33635Hs 90572PTK7 protein tyrosine kinase 7TM, pkinase, ig2.9418848AI820961Hs 193465ESTspkinase, Activin_recp2.9428450NM_014791Hs 184339KIAA0175 gene productTM, pkinase, KA12.8401323AL158037predicted exonlactamase_B2.7444798BE242144Hs 12013ATP-binding cassette, sub-family ESH3, pkinase , ABC_tran2.7432201AI538613Hs 135657TMPRSS3a mRNA for serine proteatrefoil, trypsin2.6448402BE244226Hs 21094RAB18, member RAS oncogene famras, arf2.6406671AA129547Hs 285754met proto-oncogene (hepatocyte gropkinase, Sema2.5453448AL036710Hs 209527ESTsCNH, pkinase2.5414386X00442Hs. 75990haptoglobinsushi, trypsin2.5421270H56037Hs 108146ESTsRhoGAP2.4414695BE439915Hs 76913proteasome (prosome, macropain) suproteasome2.4431341AA307211Hs 251531proteasome (prosome, macropain) suproteasome2.4424085NM_002914Hs 139226replication factor C (activator 1) 2 (4AAA, Viral_helicase 12.2424687J05070Hs. 151738matrix metalloproteinase 9 (gelatinaSS, fn2, , Peptidase_M102.2416517AA775987Hs 79357proteasome (prosome, macropain) 26AAA2.2417601NM_014735Hs 82292KIAA0215 gene productPHD2.1400509M97639Hs 155585receptor tyrosine kinase-like orphanpro_isomerase2.1430057AW450303Hs. 2534bone morphogenetic protein receptoActivin_recp, pkinase2.1421841AA908197Hs 108850KIAA0936 proteinTPR, pkinase2.1453078AF053551Hs 31584metaxin 2pro_isomerase2.1424099AF071202Hs 139336ATP-binding cassette; sub-family CTM, ABC_tran2.1411190AA306342Hs 69171protein kinase C-like 2pkinase, pkinase_C, HR12.1407740AA295547Hs 62666ESTsp4502.1420162BE378432Hs 95577cyclin-dependent kinase 4pkinase, ank, ArtGap , ras2.1420490H69894Hs 193041ESTsPI3Ka, PI3_PI4_kinase2.1426156BE244537Hs 167382natnuretic peptide receptor A/guanyTM, ANF_receptor , pkinase2.0423945AA410943Hs. 72472BMPR-Ib, bone merphogenetic proTM, pkinase, Activin_recp2.0411773NM_006799Hs 72026protease, serine, 21 (testisin)SS, trypsin2.0447298BE617527Hs. 180450ribosomal protein S24PI3Ka, P14_kinase2.0427617D42063Hs 179825RAN binding protein 2-like 1TPR, pro_isomerase2.0453546AF042385Hs 33251peptidylprolyl isomerase E (cyclophpro_isomerase, rrm2.0Pkey: Primekey Ex. Accn Exemplar Accession UG ID. UniGene ID Title: UniGene title PFAM domains predicted structural domains ratio: ratio tumor vs normal


[0380]

32










TABLE 12C











Pkey
Ref
Strand
Nt_position









401323
9212516
Plus
213509-214450








Pkey: Unique number corresponding to an Eos probeset





Ref: Sequence source The 7 digit numbers in this column are Genbank Identifier (GI) numbers “Dunham I et al.” refers to the publication entitled “The DNA sequence of human chromosome 22” Dunham, et al. (1999) Nature 402: 489-495





Strand Indicates DNA strand from which exons were predicted





Nt_position Indicates nucleotide positions of predicted exons








[0381] Table 13A lists about 1086 genes up-regulated in ovarian cancer compared to normal ovaries. These were selected as for Table 10A, except that the ratio was greater than or equal to 10, and the denominator was the median value for various non-malignant ovary specimens.
33TABLE 13AAbout 1086 UP-REGULATED GENES, OVARIAN CANCER VERSUS NORMAL OVARYPkeyEx. AccnUG IDTitleratio439706AW872527Hs. 59761ESTs109.2446619AU076643Hs. 313secreted phosphoprotein 1 (osteopontin, bone107.8422095AI868872Hs. 288966ceruloplasmin (ferroxidase)104.4447111AI017574Hs. 17409cysteine-rich protein 1 (intestinal)88.3431130NM_006103Hs. 2719epididymis-specific, whey-acidic protein type82.8431369BE184455Hs. 251754secretory leukocyte protease inhibitor (antil81.9413859AW992356Hs. 8364ESTs73.9446291BE397753Hs. 14623interferon, gamma-inducible protein 3072.7426050AF017307Hs. 166096E74-like factor 3 (ets domain transcription f68.1411469T09997Hs. 70327cysteine-rich protein 266.6429504X99133Hs. 204238lipocalin 2 (oncogene 24p3)65.7416971R34657Hs. 80658uncoupling protein 2 (mitochondrial, proton c64.9450273AW296454Hs. 24743hypothetical protein FLJ2017162.5446441AK001782Hs. 15093hypothetical protein60.7428758AA433988Hs. 98502Homo sapiens cDNA: FLJ14303 fis, clone PLACE2059.7441406Z45957Hs. 7837Homo sapiens cDNA: FLJ10457 fis, clone NT2RP1057.8441859AW194364Hs. 128022ESTs, Weakly similar to FIG1 MOUSE FIG-1 PROT56.7448406AW772298Hs. 21103Homo sapiens mRNA, cDNA DKFZp564B07655.7414602AW630088Hs. 76550Homo sapiens mRNA, cDNA DKFZp564B126455.2418068AW971155Hs. 293902ESTs, Weakly similar to prolyl 4-hydroxylase54.8428330L22524Hs. 2256matrix metalloproteinase 7 (matrilysin, uteri53.4412636NM_004415Hs. 74316desmoplakin (DPI, DPII)51.4430634AI860651Hs. 26685ESTs50.7439318AW837046Hs. 6527G protein-coupled receptor 5650.7417259AW903838Hs. 81800chondroitin sulfate proteoglycan 2 (versican)50.6407786AA687538Hs. 38972tetraspan 150.4426836N41720Hs. 172684vesicle-associated membrane protein 8 (endobr49.7417308H60720Hs. 81892KIAA0101 gene product48.9436876AI124756Hs. 5337isocitrate dehydrogenase 2 (NADP+), mitochond48.4439180AI393742Hs. 199067v-erb-b2 avian erythroblastic leukemia viral47.1428289M26301Hs. 2253complement component 246.3405484046.1425371D49441Hs. 155981mesothelin45.7403912045.0443021AA368546Hs. 8904Ig superfamily protein44.6427697T18997Hs. 180372BCL2-like 144.3428227AA321649Hs. 2248INTERFERON-GAMMA INDUCED PROTEIN44.0404678043.9400289X07820Hs. 2258Matrix Metalloproteinase 10 (Stromolysin 2)43.8451035AU076785Hs. 430plastin 1(I isoform)43.8440848BE314650Hs. 7476ATPase, H+transporting, lysosomal (vacuolar42.8436278BE396290Hs. 5097synaptogyrin 242.4413936AF113676Hs. 75621serine (or cysteine) proteinase inhibitor, cl42.1420859AW468397Hs. 100000S100 calcium-binding protein A8 (calgranulin42.1428411AW291464Hs. 10338ESTs41.8422166W72424Hs. 112405S100 calcium-binding protein A9 (calgranulin41.5412477AA150864Hs. 790microsomal glutathione S-transferase 140.7417130AW276858Hs. 81256S100 calcium-binding protein A4 (calcium prot40.1424673AA345051Hs. 294092ESTs39.8416530U62801Hs. 79361kallikrein 6 (neurosin, zyme)39.7443162T49951Hs. 9029ESTs, Highly similar to KERATIN, TYPE I CYTO39.5413719BE439580Hs. 75498small inducible cytokine subfamily A (Cys-Cys39.3424687J05070Hs. 151738matrix metalloproteinase 9 (gelatinase B, 92 k38.9413063AL035737Hs. 75184chitinase 3-like 1 (cartilage glycoprotein-3938.5429441AJ224172Hs. 204096lipophilin B (uteroglobin family member), pro38.1418526BE019020Hs. 85838solute carner family 16 (monocarboxylic acid37.9415511AI732617Hs. 182362ESTs37.7409453AI885516Hs. 95612ESTs37.7445537AJ245671Hs. 12844EGF-like-domain, multiple 637.3442432BE093589Hs. 38178Homo sapiens cDNA: FLJ23468 fis, clone HSI11637.3408243Y00787Hs. 624interleukin 837.3419092J05581Hs. 89603mucin 1, transmembrane36.7444172BE147740Hs. 104558ESTs36.0412115AK001763Hs. 73239hypothetical protein FLJ1090135.8420440NM_002407Hs. 97644mammaglobin 235.7414386X00442Hs. 75990haptoglobin35.3423225AA852604Hs. 125359Thy-1 cell surface antigen35.1440596H13032Hs. 103378ESTs, Weakly similar to DRR1 [H. sapiens]35.0413278BE563085Hs. 833interferon-stimulated protein, 15 kDa34.9418506AA084248Hs. 85339G protein-coupled receptor 3934.8445919T53519Hs. 290357ESTs34.7416854H40164Hs. 80296Purkinje cell protein 434.4414186U33446Hs. 75799protease, serine, 8 (prostasin)34.2434371AA631362gb: np86b01.s1 NCI_CGAP_Thy1 Homo sapiens cDNA33.9421937AI878857Hs. 109706HN1 protein33.9449722BE280074Hs. 23960cyclin B133.8400965033.7452203X57522Hs. 158164ATP-binding cassette, sub-family B (MDR/TAP),33.5411945AL033527Hs. 92137v-myc avian myelocytomatosis viral oncogene h33.5425811AL039104Hs. 159557karyopherin alpha 2 (RAG cohort 1, importin a33.4408901AK001330Hs. 48855hypothetical protein FLJ1046833.3438461AW075485Hs. 286049phosphoserine aminotransferase33.3422963M79141Hs. 13234ESTs33.3426158NM_001982Hs. 199067v-erb-b2 avian erythroblastic leukemia viral33.2431836AF178532Hs. 271411beta-site APP-cleaving enzyme 232.8421502AF111856Hs. 105039solute carrier family 34 (sodium phosphate),32.5431211M86849Hs. 5566Homo sapiens connexin 26 (GJB2) mRNA, complet32.5436552NM_014038Hs. 5216HSPC028 protein32.5442533AA161224Hs. 8372ubiquinol-cytochrome c reductase (6.4 kD) subu32.5406400AA343629Hs. 104570kallikrein 8 (neuropsin/ovasin)32.4450353AI244661Hs. 103296ESTs32.4422158L10343Hs. 112341protease inhibitor 3, skin-derived (SKALP)32.4433412AV653729Hs. 8185CGI-44 protein, sulfide dehydrogenase like (y32.3441020W79283Hs. 35962ESTs32.2432201AI538613Hs. 135657TMPRSS3a mRNA for serine protease (ECHOS1) (T32.0424125M31669Hs. 1735inhibin, beta B (activin AB beta polypeptide)31.9453309AI791809Hs. 32949defensin, beta 131.8408380AF123050Hs. 44532diubiquitin31.7419329AY007220Hs. 288998S100-type calcium binding protein A1431.6409231AA446644Hs. 692GA733-2; epithelial glycoprotein (EGP) (KSA)31.6423961D13666Hs. 136348Homo sapiens mRNA for osteoblast specific fac31.2413840AI301558Hs. 290801ESTs30.8440943AW082298Hs. 146161ESTs, Weakly similar to KIAA0859 protein [H.s30.8419239AA468183Hs. 184598Homo sapiens cDNA: FLJ23241 fis, clone COL01330.4410132NM_003480Hs. 58882Microfibril-associated glycoprotein-230.2418203X54942Hs. 83758CDC28 protein kinase 230.1412719AW016610Hs. 129911ESTs30.0407862BE548267Hs. 50724Homo sapiens cDNA: FLJ10934 fis, clone OVARC1030.0431563AI027643Hs. 120912ESTs29.9431743AW972642Hs. 293055ESTs29.8443295AI049783Hs. 241284ESTs29.7413745AW247252Hs. 75514nucleoside phosphorylase29.7441028AI333660Hs. 17558ESTs29.6442315AA173992Hs. 7956ESTs29.6452838U65011Hs. 30743Preferentially expressed antigen in melanoma29.5428479Y00272Hs. 184572cell division cycle 2, G1 to S and G2 to M29.5432280BE440142Hs. 2943signal recognition particle 19 kD29.4420158AI791905Hs. 95549hypothetical protein29.3445033AV652402Hs. 155145ESTs29.2452367U71207Hs. 29279eyes absent (Drosophila) homolog 229.1432706NM_013230Hs. 286124CD2429.0422163AF027208Hs. 297332prominin (mouse)-like 128.7447035NM_004753Hs. 17144short-chain dehydrogenase/reductase 128.6443958BE241880Hs. 10029cathepsin C28.2422956BE545072Hs. 122579ESTs28.1450377AB033091Hs. 24936ESTs28.0447471AF039843Hs. 18676sprouty (Drosophila) homolog 228.0444725AW952022Hs. 234174Homo sapiens cDNA: FLJ13819 fis, clone THYRO1027.8430250NM_016929Hs. 283021chloride intracellular channel 527.7416305AU076628Hs. 79187coxsackie virus and adenovirus receptor27.6418174L20688Hs. 83656Rho GDP dissociation inhibitor (GDI) beta27.5417233W25005Hs. 24395small inducible cytokine subfamily B (Cys-X-C27.4417866AW067903Hs. 82772collagen, type XI, alpha 127.3427344NM_000869Hs. 21425-hydroxytryptamine (serotonin) receptor 3A27.2442993BE018682Hs. 44343ESTs27.2407137T97307Hs. 199067v-erb-b2 avian erythroblastic leukemia viral27.0419356AI656166Hs. 7331ESTs27.0433662W07162Hs. 150826CATX-8 protein26.7422576BE548555Hs. 118554CGl-83 protein26.4423271W47225Hs. 126256interleukin 1, beta26.3443715AI583187Hs. 9700cyclin E126.1420816NM_015925Hs. 95697liver-specific bHLH-Zip transcription factor26.0419551AW582256Hs. 91011antenor gradient 2 (Xenepus laevis) homolog25.9443672AA323362Hs. 9667butyrobetaine (gamma), 2-oxoglutarate dioxyge25.8416889AW250318Hs. 80395mal, T-cell differentiation protein25.3408474AA188823Hs. 83196Homo sapiens cDNA: FLJ23597 fis, clone LNG15225.3411825AK000334Hs. 72289hypothetical protein FLJ2032725.3400881025.2440594AW445167Hs. 126036ESTs25.1414586AA306160Hs. 76506lymphocyte cytosolic protein 1 (L-plastin)25.1411925AW014588Hs. 72925chromosome 11 open reading frame 1325.1417869BE076254Hs. 82793proteasome (prosome, macropain) subunit, beta25.0433447U29195Hs. 3281neuronal pentranin II25.0450858C18458Hs. 25597elongation of very long chain fatty acids (FE24.8410619BE512730Hs. 65114keratin 1824.8434094AA305599Hs. 238205hypothetical protein PRO201324.6421924BE514514Hs. 109606coronin, actin-binding protein, 1A24.6446859AI494299Hs. 16297COX17 (yeast) homolog, cytochrome c oxidase a24.5421451AA291377Hs. 50831ESTs24.3433929AI375499Hs. 27379ESTs24.3438930AW843633Hs. 81256S100 calcium-binding protein A4 (calcium prot24.2444212AW503976Hs. 10649basement membrane-induced gene24.2441633AW958544Hs. 112242ESTs24.2441134W29092Hs. 7678cellular retinoic acid-binding protein 124.2417715AW969587Hs. 86366ESTs24.1409361NM_005982Hs. 54416sine oculis homeobon (Drosophila) homolog 124.1416984H38765Hs. 80706diaphorase (NADH/NADPH) (cytochrome b-5 reduc24.1430125U46418Hs. 233950serine protease inhibitor, Kunitz type 123.9434078AW880709Hs. 283683EST23.8408669AI493591Hs. 78146platelet/endothelial cell adhesion molecule (23.8439413AI598252Hs. 37810ESTs23.7449034AI624049Hs. 277523gb: ts41a09 x1 NCI_CGAP_Ut1 Homo sapiens cDNA23.7420344BE463721Hs. 97101Putative G protein-coupled receptor GPCR15023.6431243U46455Hs. 252189syndecan 4 (amphiglycan, ryundocan)23.6417515L24203Hs. 82237ataxia-telangiectasia group D-associated prot23.5451267AI033894Hs. 117865solute carner family 17 (anion/sugar transpo23.4450101AV649989Hs. 24385Human hbc647 mRNA sequence23.4419693AA133749Hs. 92323FXYD domain-containing ion transport regulato23.4431103M57399Hs. 44pleiotrophin (hepann binding growth factor 823.4451110AI955040Hs. 301584ESTS23.3426295AW367283Hs. 75839zinc finger protein 6 (CMPX1)23.2448517AA082750Hs. 42194hypothetical protein FLJ22649 similar to sign23.1424670W61215Hs. 116651epithelial V-like antigen 123.1417847AI521558Hs. 288312Homo sapiens cDNA: FLJ22316 fis, clone HRC05223.1449027AJ271216Hs. 22880dipeptidylpeptidase III23.1424969AW950928Hs. 153998creatine kinase, mitochondrinal 1 (ubiquitous)23.1433159AB035898Hs. 150587kinesin-like protein 223.0411393AW797437Hs. 69771B-factor, properdin23.0434815AF155582Hs. 46744core1 UDP-galactooe N-acetylgalactosamine-alp22.8427585D31152Hs. 179729collagen; type X, alpha 1 (Schmid metaphyseal22.7445721H92136Hs. 13144HSPC160 protein22.6448258BE386983Hs. 85015ESTs, Weakly similar to A4P_HUMAN INTESTINAL22.6456844AI264155Hs. 152981CDP-diacylglycerol synthase (phosphatidate cy22.6452698NM_001295Hs. 301921ESTs22.5418693AI750878Hs. 87409thrombospondin 122.4414880AW247305Hs. 119140eukaryotic translation initiation factor 5A22.4401519022.3402496022.3420324AF163474Hs. 96744DKFZP586D0823 protein, Prostate androgen-regu22.3403022022.2434042AI589941Hs. 8254hypothetical protein PRO089922.1419080AW150835Hs. 18878hypothetical protein FLJ2162022.1406545AB018249Hs. 10458small inducible cytokine subfamily A (Cys-Cys22.1447362AW176120Hs. 9061ESTs22.0429547AW009166Hs. 99376ESTs22.0427954J03060Hs. 247551metaxin 122.0423161AL049227Hs. 124776Homo sapiens mRNA, cDNA DKFZp564N1116 (from c22.0428392H10233Hs. 2265secretory granule, neuroendocrine protein 1 (21.9444107T46839Hs. 10319UDP glycosyltransferase 2 family, polypeptide21.7414421AI521130Hs. 55567ESTs, Weakly similar to LAK-4p [H. sapiens]21.5412589R28660Hs. 24305ESTs21.5446525AW967069Hs. 211556Homo sapiens cDNA: FLJ23378 fis, clone HEP16221.5416847L43821Hs. 80261enhancer of filamentation 1 (cas-like docking21.5436972AA284679Hs. 25640claudin 321.5428698AA852773Hs. 297939ESTs, Weakly similar to neogenin [H. sapiens]21.5421340F07783Hs. 1369decay accelerating factor for complement (CD521.4413966AA133935Hs. 173704ESTs21.4448243AW369771Hs. 77496ESTs21.3421928AF013758Hs. 109643polyadenylate binding protein-interacting pro21.3403399021.3435793AB037734Hs. 4993ESTs21.3432629AW860548Hs. 280658ESTs21.2449057AB037784Hs. 22941ESTs21.1437575AW954355Hs. 36529ESTs21.2401131021.0407207T03651Hs. 179661tubulin, beta polypeptide20.8444783AK001468Hs. 62180ESTs20.8426230AA367019Hs. 241395protease, serine, 1 (trypsin 1)20.8447343AA256641Hs. 236894ESTs, Highly similar to LOW-DENSITY LIPOPROTE20.7409041AB033025Hs. 50081KIAA1199 protein20.6421305BE397354Hs. 289721diptheria toxin resistance protein required f20.6411704AI499220Hs. 71573hypothetical protein FLJ1007420.5417018M16038Hs. 80887v-yes-1 Yamaguchi sarcoma viral related oncog20.5432827Z68128Hs. 3109Rho GTPase activating protein 420.4410174AA306007Hs. 59461DKFZP434C245 protein20.4425184BE278288Hs. 155048Lutheran blood group (Auberger b antigen incl20.4452322BE566343Hs. 28988glutaredoxin (thioltransferase)20.3447526AL048753Hs. 340small inducible cytokine A2 (monocyte chemota20.2447335BE617695Hs. 286192protein phosphatase 1, regulatory (inhibitor)20.2424867AI024860Hs. 153591Not56 (D melanogaster)-like protein20.1410275U85658Hs. 61796transcription factor AP-2 gamma (activating e20.1429083Y09397Hs. 227817BCL2-related protein A120.0410173AA706017Hs. 119944ESTs19.8433047M86135Hs. 279946methionine-tRNA synthetase19.8419088AI538323Hs. 77496ESTs19.7403381019.6409162H25530Hs. 50868solute carrier family 22 (organic cation tran19.5426150NM_003658Hs. 167218BarH-like homeobox 219.4449292AI990292Hs. 225457ESTs19.4425207AB014551Hs. 155120rho/rac guanine nucleotide exchange factor (G19.4419950AK001645Hs. 93871hypothetical protein FLJ1078319.3436481AA379597Hs. 5199HSPC150 protein similar to ubiquitin-conjugat19.3445930AF055009Hs. 13456Homo sapiens clone 24747 mRNA sequence19.2446608N75217Hs. 257846ESTs19.1425222M85430Hs. 155191villin 2 (eznn)19.1428309M97815Hs. 183650cellular retinoic acid-binding protein 219.1420005AW271106Hs. 133294ESTs19.1436982AB018305Hs. 5378spondin 1, (f-spondin) estracellular matrix p19.0407142AA412535Hs. 55235sphingomyelin phosphodiesterase 2, neutral me19.0430122NM_013342Hs. 233765TCF3 (E2A) fusion partner (in childhood Leuke18.9446293AI420213Hs. 149722ESTs18.9444825AW167613Hs. 248mitogen-activated protein kinase kinase kinas18.9407634AW016569Hs. 301280UDP-GlcNAc: betaGal beta-1,3-N-acetylglucosami18.9445200AA084460Hs. 12409somatoatatin18.9418917X02994Hs. 1217adenosine deaminase18.8435777AW419202Hs. 286192protein phosphatase 1, regulatory (inhibitor)18.8431049AA846576Hs. 103267hypothetical protein FLJ22548 similar to gene18.7426427M86699Hs. 169840TTK protein kinase18.7436281AW411194Hs. 120051ESTs18.6425907AA365752Hs. 155965ESTs18.6459720ESTs18.6421242AW161386Hs. 13561ESTs, Weakly similar to dJ37E165 [H. sapiens]18.5457715AA642402Hs. 59142ESTs18.5451668Z43948Hs. 26789ASPIC (acidic secreted protein in cartilage)A18.4437142AI791617Hs. 145068ESTs18.4418588BE387040Hs. 182476ESTs, Weakly similar to similar to alpha/beta18.3433068NM_006456Hs. 288215sialyltransferase18.3419854AW664873Hs. 87836Homo sapiens PAC clone RP5-1087M19 from 7q1118.3444726NM_006147Hs. 11801interferon regulatory factor 618.3423011NM_000683Hs. 299847ESTs, Highly similar to A2AD_HUMAN ALPHA-2C-218.2451428AW083384Hs. 11067ESTs, Weakly similar to K02E10.2 [C. elegans]18.2424865AF011333Hs. 153563lymphocyte antigen 7518.2418742AW451197Hs. 113418ESTs18.1446627AI973016Hs. 15725ESTs; hypothetical protein SBBI4818.1424885AI333771Hs. 82204ESTs18.1402926018.0405452018.0428641AA431367Hs. 234546GMPR2 for guanosine monophosphate reductase $$18.0454390AB020713Hs. 56966KIAA0906 protein18.0441784AI522132Hs. 28700ESTs18.0418758AW959311Hs. 87019ESTs17.9408621AI970672Hs. 46638chromosome 11 open reading frame 8, fetal br17.9426201AW182614Hs. 128499ESTs17.8410442X73424Hs. 63788propionyl Coenzyme A carboxylase, beta polype17.8456423AW748920gb: CM2-BT0306-171199-034-g02 BT0306 Homo sapi17.8422867L32137Hs. 1584cartilage oligomeric matrix protein17.8448110AA626937Hs. 181551ESTs17.7421750AK000768Hs. 107872hypothetical protein FLJ2076117.7405224017.7447630AI660149Hs. 44865lymphoid enhancer-binding factor 117.7407663NM_016429Hs. 37482COPZ2 for nonclathrin coat protein zeta-COP17.7427490Z95152Hs. 178695mitogen-activated protein kinase 1317.6414812X72755Hs. 77367monokine induced by gamma interferon17.6427691AW194426Hs. 20726ESTs17.6420650AA455706Hs. 44581heat shock protein hap70-related protein17.5439841AF038961Hs. 6710mannose-P-dolichol utilization defect 117.5425810AI923627Hs. 31903ESTs17.5425397J04088Hs. 156346topoisomerase (DNA) II alpha (170 kD)17.5456098AW747800Hs. 55016hypothetical protein FLJ2193517.4428579NM_005756Hs. 184942G protein-coupled receptor 6417.4410361BE391804Hs. 62661guanylate binding protein 1, interferon-induc17.4442402NM_000954Hs. 8272prostaglandin D2 synthase (21 kD, brain)17.4411734AW374954Hs. 71779Homo sapiens DNA from chromosome 19, cosmid F17.3405295017.3408340AB037762Hs. 44268myelin gene expression factor 217.3456068AI677897Hs. 76640RGC32 protein17.3448571AA486794Hs. 66915ESTs, Weakly similar to 16.7 Kd protein [H.sap17.2441829AL117482Hs. 7978DKFZP434C131 protein17.2418004U37519Hs. 87539aldehyde dehydrogenase 817.2412078X69699Hs. 73149paired box gene 817.2414658X58528Hs. 76781ATP-binding cassette, sub-family D (ALD), mem17.1418478U38945Hs. 1174cyclin-dependent kinase inhibitor 2A (melanom17.0426805AB032945Hs. 172506myosin VB17.0410247AF181721Hs. 61345RU2S17.0434516AA807814Hs. 70582ESTs, Moderately similar to AF144056 1 apopto16.9428153AW513143Hs. 98367hypothetical protein FLJ22252 similar to SRY-16.9417793AW405434Hs. 82575small nuclear ribonucleoprotein polypeptide B16.9454163AW175997gb: QV0-BT0078-190899-005-E02 BT0078 Homo sapi16.9415402AA164687Hs. 297889ESTs16.9420309AW043637Hs. 21766ESTs16.9419201M22324Hs. 1239alanyl (membrane) aminopeptidase (aminopeptid16.9444391AL137597Hs. 11114hypothetical protein dJ1181N3 116.9457705AW974668gb: EST386757 MAGE resequences, MAGM Homo sapi16.8412723AA648459Hs. 179912ESTs16.8435774R88066Hs. 4992tumor suppressing subtransferable candidate 116.8408753AI337192Hs. 47438SH3 domain binding glutamic acid-rich protein16.8447783AF054178Hs. 19561NADH dehydrogenase (ubiquinone) 1 alpha subco16.8418085R40328Hs. 258822ESTs16.7452472AW957300Hs. 294142ESTs, Weakly similar to SP49_HUMAN SPLICEOSOM16.7409112BE243971Hs. 50649quinone oxidoreductase homolog16.7410250AI082777Hs. 61384KIAA1445 protein16.7446219AI287344Hs. 149827ESTs16.6428928BE409838Hs. 194657cadherin 1, type 1, E-cadherin (epithelial)16.6425812AA364128Hs. 245633ESTs16.6411742AW247593Hs. 71819eukaryotic translation initiation factor 4E b16.6415076NM_000857Hs. 77890guanylate cyclase 1, soluble, beta 316.6416209AA236776Hs. 79078MAD2 (mitotic arrest deficient, yeast, homolo16.6440667BE076969Hs. 7337hypothetical protein FLJ1093616.6430375AW371048Hs. 93758H4 histone family, member H16.6419607R52557Hs. 91579Homo sapiens clone 23783 mRNA sequence16.6410328BE080190Hs. 62275CGI-141 protein16.5405426016.5432636AA340864Hs. 278562claudin 716.5434725AK000796Hs. 4104hypothetical protein16.5414683S78296Hs. 76888internexin neuronal intermediate filament pro16.5429500X78565Hs. 289114hexabrachion (tenascin C, cytotactin)16.5449944AF290512Hs. 58215Homo sapiens rhotekin mRNA, partial cds16.4400666016.4421536BE250690Hs. 105509CTL2 gene16.4436032AA150797Hs. 109276latexin protein16.4418196AI745649Hs. 26549ESTs, Weakly similar to T00066 hypothetical p16.4452323W44356Hs. 292812ESTs, Weakly similar to C43H8 1 [C. elegans]16.4407699AA825974Hs. 32646Homo sapiens cDNA: FLJ21901 fis, clone HEP03416.4414617AI339520Hs. 20524ESTs, Moderately similar to hexokinase I [H.s16.3408204AA454501Hs. 43666protein tyrosine phosphatase type IVA, member16.3452650AW270150Hs. 254516ESTs16.3432906BE265489Hs. 3123lethal giant larvae (Drosophila) homolog 216.3402408016.3408805H69912Hs. 48269vaccinia related kinase 116.3447155AA100605Hs. 121557ESTs, Weakly similar to AF251041 1 SGC32445 p16.3405699016.2406893M22406gb: Human intestinal mucin mRNA, partial cds,16.2418629BE247550Hs. 86859growth factor receptor-bound protein 7 (GRB7)16.2424905NM_002497Hs. 153704NIMA (never in mitosis gene a)-related kinase16.2424243AI949359Hs. 301837ESTs, Highly similar to cis Golgi-localized c16.2418462BE001596Hs. 85266integrin, beta 416.1457205AI905780Hs. 198272NADH dehydrogenase (ubiquinone) 1 beta subcom16.1428188M98447Hs. 22transglutaminase 1 (K polypeptide epidermal t16.1449845AW971183Hs. 60054ESTs16.1406429016.1407375AA091354gb: II0815.seq.F Human fetal heart, Lambda ZAP16.1448377AI494514Hs. 171380ESTs16.1431156NM_002220Hs. 2722inositol 1,4,5-trisphosphate 3-kinase A16.0450043AA885699Hs. 24332CGI-26 protein16.0403121016.0400214015.9453252R02436Hs. 215725ESTs15.9451734NM_006176Hs. 26944neurogranin (protein kinase C substrate, RC3)15.9416855AA188763Hs. 36793Homo sapiens cDNA: FLJ23188 fis, clone LNG12015.9424474AA308883Hs. 148680calcyon, D1 dopamine receptor-interacting pro15.9423685BE350494Hs. 49753Homo sapiens mRNA for KIAA1561 protein, parti15.9428187AI687303Hs. 285529ESTs15.9438817AI023799Hs. 163242ESTs15.9425692D90041Hs. 155956NAT1, arylamine N-acetyltransferase15.9421674T10707Hs. 296355neuronal PAS domain protein 215.9439999AA115811Hs. 6838ras homolog gene family, member E15.9411351W02919Hs. 283476peroxisomal acyl-CoA thioesterase15.9413027NM_002885Hs. 75151RAP1, GTPase activating protein 115.9453884AA355925Hs. 36232KIAA0186 gene product15.8407894AJ278313Hs. 41143phosphoinositide-specific phospholipase C-bet15.8422748AA316266Hs. 129349ESTs15.8414591AI888490Hs. 55902ESTs15.8421877AW250380Hs. 109059mitochondrial ribosomal protein L1215.8404780015.8401192015.8447519U46258Hs. 23448ESTs15.8434262AF121858Hs. 12169sorting nexin 815.7451253H48299Hs. 26126claudin 1015.7435499R89344Hs. 14148ESTs15.7422424AI186431Hs. 116577prostate differentiation factor; placental bo15.7424834AK001432Hs. 153408Homo sapiens cDNA: FLJ10570 fis, clone NT2RP2015.7424562AI420859Hs. 150557basic transcription element binding protein 115.7443247BE614387Hs. 47378ESTs15.7430696AA531276Hs. 59509ESTs15.6437044AL035864Hs. 69517ESTs, highly similar to differentially expres15.6428237AF175206Hs. 183125killer cell lectin-like receptor F115.6440048AA897461Hs. 158469ESTs, Weakly similar to envelope protein [H.s15.6414922D00723Hs. 77631glycine cleavage system protein H (aminomethy15.6422030X51416Hs. 110849estrogen-related receptor alpha15.6408716AI567839Hs. 151714ESTs15.5410258X52638Hs. 7396-phosphofructo-2-kinase/fructose-2,6-biphosp15.5410530M25809Hs. 64173ESTs, Highly similar to VAB1_HUMAN VACUOLAR A15.5447072D61594Hs. 17279tyrosylprotein sulfotransferase 115.5409015BE389387Hs. 49767NADH dehydrogenase (ubiquinone) Fe-S protein15.5447549AI871120Hs. 231265ESTs15.5449704AK000733Hs. 23900GTPase activating protein15.4427337Z46223Hs. 176663Fc fragment of IgG, low affinity Illb, recept15.4421630NM_001956Hs. 1407endothelin 215.4433018AI669760Hs. 188881ESTs15.4422938NM_001809Hs. 1594centromere protein A (17 kD)15.3407014U38268gb: Human cytochrome b pseudogene, partial cds15.2429311AF080157Hs. 198998conserved helix-loop-helix ubiquitous kinase15.2431842NM_005764Hs. 271473epithelial protein up-regulated in carcinoma,15.2406907Z25427gb: H. Sapiens protein-serine/threonine kinase15.2458495AI202029Hs. 148593ESTs15.2420551AL137692Hs. 98790Homo sapiens mRNA, cDNA DKFZp434P182 (from cl15.1448443AW167128Hs. 231934ESTs15.1443646AI085198Hs. 298699ESTs15.1431538AL137547Hs. 259619Homo sapiens mRNA; cDNA DKFZp434B1120 (from c15.1436687AA868643Hs. 120461ESTs15.1420917AW135716Hs. 117330ESTs15.0428575M19684Hs. 184929serine (or cysteine) proteinase inhibitor, cl15.0403482015.0421499AI271438Hs. 105022Homo sapiens PAC clone RP4-701O16 from 7q33-q15.0401047014.9417749U09196Hs. 82520polymerase (DNA-directed), delta 414.9416693AI373204Hs. 79531Homo sapiens TTF-I interacting peptide 20 mRN14.9428474AB023182Hs. 184523KIAA0965 protein14.9428862NM_000346Hs. 2316SRY (sex-determining region Y)-box 9 (campome14.9430271T06199Hs. 237506heat shock cognate 4014.9414328Z21666Hs. 75900aconitase 2, mitochondrial14.9415314N88802Hs. 5422glycoprotein M6B14.8453735AI066629Hs. 125073ESTs14.8424345AK001380Hs. 145479Homo sapiens cDNA: FLJ10518 fis, clone NT2RP2014.8423575C18863Hs. 163443ESTs14.8438081H49546Hs. 298964ESTs14.8403485014.8452114N22687Hs. 8236ESTs14.8426559AB001914Hs. 170414paired basic amino acid cleaving system 414.8412869AA290712Hs. 82407Homo sapiens HSPC296 mRNA, partial cds14.8452101T60298gb: yb87f12.r1 Stratagene liver (937224) Homo14.7420505AW967984Hs. 291612ESTs14.7426125X87241Hs. 166994FAT tumor suppressor (Drosophila) homolog14.7433336AF017986Hs. 31386ESTs; Highly similar to FRIZZLED PROTEIN PRE14.7428977AK001404Hs. 194698cyclin B214.7429785H82114Hs. 301769ESTs14.7402424014.7424971AA479005Hs. 154036tumor suppressing subtransferable candidate 314.7433037NM_014158Hs. 279938HSPC067 protein14.6421670BE207318Hs. 106674BRCA1 associated protein-1 (ubiquitin carboxy14.6438598AI805943Hs. 5723Homo sapiens cDNA: FLJ23439 fis, clone HSI00114.6453370AI470523Hs. 182356ESTs, Moderately similar to translation initi14.6410561BE540255Hs. 6994Homo sapiens cDNA: FLJ22044 fis, clone HEP09114.6402287014.6419741NM_007019Hs. 93002ubiquitin carrier protein E2-C14.6442047AA974598Hs. 150324ESTs14.5428582BE336699Hs. 185055BENE protein14.5440006AK000517Hs. 6844hypothetical protein FLJ2051014.5406851AA609784Hs. 180255major histocompatibility complex, class II, D14.5457316AI123657Hs. 127264ESTs14.5420453AL157500Hs. 97840Homo sapiens mRNA; cDNA DKFZp434G015 (from cl14.5436406AW105723Hs. 125346ESTs14.5420736AI263022Hs. 82204ESTs14.5419743AW408762Hs. 127478ESTs14.5429113D28235Hs. 196384Prostaglandin-endoperoxide synthase 2 (COX-2)14.5450256AA286887Hs. 24724MFH-amplified sequences with leucine-rich tan14.5424906AI566086Hs. 153716Homo sapiens mRNA for Hmob33 protein, 3′ untr14.5427414F11750Hs. 6647Homo sapiens cDNA: FLJ13088 fis, clone NT2RP3014.4419839U24577Hs. 93304phospholipase A2, group VII (platelet-activat14.4418738AW388633Hs. 6682solute carrier family 7, member 1114.3429414AI783656Hs. 202095empty spiracles (Drosophila) homolog 214.3424669AA417181Hs. 120858Homo sapiens cDNA: FLJ13945 fis, clone Y79AA1014.3408989AW361666Hs. 49500KIAA0746 protein14.3406788AI911841Hs. 5184TH1 drosophila homolog14.3417861AA334551Hs. 82767sperm specific antigen 214.3402104014.3416368R88849gb: ym96a06.r1 Soares adult brain N2b4HB55Y Ho14.2405802014.2448357N20169Hs. 108923ESTs14.2444261AA298958Hs. 10724MDS023 protein14.2407846AA426202Hs. 40403Cbp/p300-interacting transactivator, with Glu14.2425163D10040Hs. 154890fatty-acid-Coenzyme A ligase, long-chain 214.1402520014.1429597NM_003816Hs. 2442a disintegrin and metalloproteinase domain 914.1430044AA464510Hs. 152812EST cluster (not in UniGene)14.1429663M68874Hs. 211587Human phosphatidylcholine 2-acylhydrolase (cP14.1427036AA397625Hs. 163913ESTs14.1444381BE387335Hs. 283713ESTs14.1432090AW972855Hs. 292853ESTs14.0406778H06273Hs. 101651Homo sapiens mRNA; cDNA DKFZp434C107 (from cl14.0404961AW972195Hs. 284236aldo-keto reductase family 7, member A3 (afla14.0452313Y00486Hs. 28914adenine phosphoribosyltransferase14.0452355N54926Hs. 29202G protein-coupled receptor 3414.0429942AI338993Hs. 134535ESTs14.0403165013.9442150AI368158Hs. 128864ESTs13.9439709AW401433Hs. 6649hypothetical protein FLJ2012813.9456799AC004923Hs. 135187Homo sapiens clone CDABP0025 mRNA sequence13.9427356AW023482Hs. 97849ESTs13.9448982AI638164Hs. 225520ESTs13.9432025BE407132Hs. 111286hypothetical protein FLJ2251213.8427505AA361562Hs. 17876126S proteasome-associated pad1 homolog13.8402965013.8418601AA279490Hs. 86368calmegin13.8436954AA740151Hs. 130425ESTs13.8405024013.8453976BE463830Hs. 163714ESTs13.8431921N46466Hs. 58879ESTs13.8401735013.8445496AB007860Hs. 12802development and differentiation enhancing fac13.8425007AA456483Hs. 172081phosphodiesterase 4D, cAMP-specific (dunce (D13.7409463AI458165Hs. 17296ESTs13.7430193AI826653Hs. 102928Homo sapiens cDNA: FLJ13479 fis, clone PLACE1013.7458869AI637934Hs. 224978ESTs13.7426769AA075596Hs. 172153glutathione peroxidase 3 (plasma)13.7416661AA634543Hs. 79440IGF-ll mRNA-binding protein 313.7439901N73885Hs. 124169ESTs13.7431374BE258532Hs. 251871CTP synthase13.7432861AA339526Hs. 279593HSPC171 protein13.7441172AI279652Hs. 132879ESTs13.7410001AB041036Hs. 57771kallikrein 11, serine protease (TLSP)13.7430315NM_004293Hs. 239147guanine deaminase13.6422769AA938905Hs. 289112CGI-43 protein13.6402389013.6448977X91809Hs. 22698regulator of G-protein signalling 1913.6459648gb: IL3-CT0220-150200-070-B02 CT0220 Homo sapi13.6452972M31732Hs. 31210B-cell CLL/lymphoma 313.6431441U81961Hs. 2794sodium channel, nonvoltage-gated 1 alpha13.6448585AB020676Hs. 21543KIAA0869 protein13.6428385AF112213Hs. 184062putative Rab5-interacting protein13.6434699AA643687Hs. 149425Homo sapiens cDNA: FLJ11980 fis, clone HEMBB1013.6447238AW451676Hs. 158564ESTs13.6437108AA434054Hs. 80624Homo sapiens cDNA: FLJ23442 fis, clone HSI00913.6425749AW328587Hs. 159448surfeit 213.5425154NM_001851Hs. 154850collagen, type IX, alpha 113.5413753U17760Hs. 301103Laminin, beta 3 (nicein (125 kD), kalinin (14013.5419034NM_002110Hs. 89555hemopoietic cell kinase13.5448361H82028Hs. 238707Homo sapiens cDNA: FLJ22457 fis, clone HRC09913.5412754AW160375Hs. 74565amyloid beta (A4) precursor-like protein 113.5419081AI798863Hs. 87191ESTs13.5407732AW138839Hs. 24210ESTs13.5423329AF054910Hs. 127111tektin 2 (testicular)13.5422627BE336857Hs. 118787transforming growth factor, beta-induced, 68 k13.4439636AF086467gb: Homo sapiens full length insert cDNA clone13.4417605AF006609Hs. 82294regulator of G-protein signalling 313.4445861BE293423Hs. 11809single Ig IL-1R-related molecule13.4447350AI375572Hs. 172634ESTs, HER4 (c-erb-B4)13.4451807W52854Hs. 27099DKFZP564J0863 protein13.4421515Y11339Hs. 105352GalNAc alpha-2, 6-sialyltransferase I, long f13.4422443NM_014707Hs. 116753histone deacetylase 7B13.4412504Z44496Hs. 26039Homo sapiens cDNA: FLJ13937 fis, clone Y79AA1013.4453344BE349075Hs. 44571ESTs13.4402885013.4438712AW978161Hs. 169877ESTs13.4421774AL050374Hs. 108169DKFZP586C1619 protein13.3425638NM_012337Hs. 158450nasopharyngeal epithelium specific protein 113.3401897013.3425601AW629485Hs. 293352ESTs13.3450779AW204145Hs. 156044ESTs13.3444858AI199738Hs. 208275ESTs, Weakly similar to unnamed protein produ13.3442619AA447492Hs. 20183ESTs, Weakly similar to AF164793 1 protein x13.3434263N34895Hs. 44648ESTs13.3426059BE292842Hs. 166120interferon regulatory factor 713.3407467D55638gb: Human B-cell PABL (pseudoautosomal boundar13.3412560R24601Hs. 108300CCR4-NOT transcription complex, subunit 313.2442986AI025990Hs. 285520ESTs13.2420317AB006628Hs. 96485KIAA0290 protein13.2443211AI128388Hs. 143655ESTs13.2434361AF129755Hs. 117772ESTs13.2423493AI815965Hs. 129683ubiquitin-conjugating enzyme E2D 1 (homologou13.2414183AW957446Hs. 301711ESTs13.2447778BE620592Hs. 71190ESTs13.2435106AA100847Hs. 193380ESTs, Highly similar to AF174600 1 F-box prot13.1439490AW249197Hs. 100043ESTs, Weakly similar to PSF_HUMAN PTB-ASSOCIA13.1409606AW444594Hs. 2387transglutaminase 4 (prostate)13.1421308AA687322Hs. 192843ESTs13.1414950C15407gb: C15407 Clontech human aorta polyA+ mRNA (613.1416783AA206186Hs. 79889monocyte to macrophage differentiation-associ13.1415927AL120168Hs. 78919Kell blood group precursor (McLeod phenotype)13.1422605H16646Hs. 118666Human clone 23759 mRNA, partial cds13.0430427AA296701Hs. 241413opticin13.0424620AA101043Hs. 151254kallikrein 7 (chymotryptic; stratum comeum)13.0421693X71490Hs. 106876ATPase, H+ transporting, lysosomal (vacuolar13.0407727AW411148Hs. 38044DKFZP564M082 protein13.0427706AW971225Hs. 293800ESTs, Weakly similar to ALU1_HUMAN ALU SUBFAM13.0406709AI355761Hs. 242463keratin 813.0405353013.0453060AW294092Hs. 21594ESTs13.0459299BE094291Hs. 155651hepatocyte nuclear factor 3, beta13.0447843AW337186Hs. 224891ESTs13.0446576AI659477Hs. 51820ESTs, Moderately similar to ALU7_HUMAN ALU SU13.0449700L02867Hs. 78358ESTs13.0436476AA326108Hs. 53631ESTs13.0432532AW058459Hs. 162246ESTs13.0408405AK001332Hs. 44672hypothetical protein FLJ1047013.0432673AB028859Hs. 278605ER-associated DNAJ, ER-associated Hsp40 co-ch12.9414684AW630023Hs. 768933-hydroxybutyrate dehydrogenase (heart, mitoc12.9447210AF035269Hs. 17752phosphatidylserine-specific phospholipase A1a12.9427923AW274357Hs. 268384Fzr1 protein12.9437395AL365408Hs. 10632hypothetical protein DKFZp762M13612.9441627AA947552Hs. 58086ESTs12.9419084AA496539Hs. 179902transporter-like protein12.9423067AA321355Hs. 285401ESTs12.9423070R55677Hs. 155569ESTs12.8441344BE250144Hs. 41514ESTs12.8423527AI206965Hs. 105861Homo sapiens cDNA: FLJ13824 fis, clone THYRO1012.8417006AW673606Hs. 80758aspartyl-tRNA synthetase12.8453552AL041941Hs. 1547293-phosphoinositide dependent protein kinase-112.8453657W23237Hs. 296162ESTs12.8434414AI798376gb: tr34b07 x1 NCl_CGAP_Ov23 Homo sapiens cDNA12.7456051T85626Hs. 76239hypothetical protein FLJ2060812.7451659BE379761Hs. 14248ESTs, Weakly similar to ALU8_HUMAN ALU SUBFAM12.7418216AA662240Hs. 283099AF15q14 protein12.7423281AJ271684Hs. 126355C-type (calcium dependent, carbohydrate-recog12.7424275AW673173Hs. 144505DKFZP566F0546 protein12.7440062AI350518Hs. 129692ESTs12.7444371BE540274Hs. 239Forkhead box M112.7412520AA442324Hs. 795H2A histone family, member O12.7413349BE086692gb: QV1-BT0678-130400-156-g07 BT0678 Homo sapi12.7414500W24087Hs. 76285DKFZP564B167 protein12.6429261AW176254Hs. 143475ESTs12.6402238012.6400280012.6421246AW582962Hs. 300961ESTs, Highly similar to AF151805 1 CGI-47 pro12.6442029AW956698Hs. 14456neural precursor cell expressed, developmenta12.6435502L13266Hs. 105glutamate receptor, ionotropic, N-methyl D-as12.6409964AW368226Hs. 67928ESTs12.6418793AW382987Hs. 88474prostaglandin-endoperoxide synthase 1 (prosta12.5452117AI421760Hs. 77870Homo sapiens cDNA: FLJ12750 fis, clone NT2RP2012.5448074BE621355Hs. 27160ESTs12.5442655AW027457Hs. 30323ESTs12.5409928AL137163Hs. 57549hypothetical protein dJ473B412.5400240012.5413048M93221Hs. 75182mannose receptor, C type 112.5426215AW963419Hs. 155223ESTs12.5430024AI808780Hs. 227730integrin, alpha 612.5445655AA873830Hs. 167746B cell linker protein12.5419941X98654Hs. 93837phosphatidylinositol transfer protein, membra12.5425280U31519Hs. 1872phosphoenolpyruvate carboxykinase 1 (soluble)12.5427767AI879283Hs. 180714cytochrome c oxidase subunit Via polypeptide12.4450243AW119084Hs. 201037ESTs12.4408930AA146721Hs. 49005hypothetical protein12.4418783T41368gb: ph1d1_19/1TV Outward Alu-primed hncDNA lib12.4452096BE394901Hs. 226785ESTs12.4424513BE385864Hs. 149894mitochondrial translational initiation factor12.4422306BE044325Hs. 227280Homo sapiens mRNA for Lsm5 protein12.4409031AA376836Hs. 76728ESTs12.4435515N40080Hs. 6879DC13 protein12.4429583NM_006412Hs. 2091191-acylglycerol-3-phosphate O-acyltransferase12.3449643R05989Hs. 19603ESTs12.3440313AL050060Hs. 7158DKFZP566H073 protein12.3425593AA278921Hs. 1908proteoglycan 1, secretory granule12.3447357AI375922Hs. 159367ESTs12.3405089012.3414972BE263782Hs. 77695KIAA0008 gene product12.3435039AW043921Hs. 130526ESTs12.3447033AI357412Hs. 157601EST —not in UniGene12.3427521AW973352Hs. 299056ESTs12.3409377AA300274Hs. 115659Homo sapiens cDNA: FLJ23461 fis, clone HSI07712.3400116012.3445806AL137516Hs. 13323hypothetical protein FLJ2205912.2457817AA247751Hs. 79572cathepsin D (lysosomal aspartyl protease)12.2442410AW996503Hs. 197680ESTs12.2445404AI261687Hs. 145541ESTs, Weakly similar to JC4974 sodium iodide12.2403372AW249152Hs. 44017SIR2 (silent mating type information regulati12.2427082AB037858Hs. 173484hypothetical protein FLJ1033712.2433764AW753676Hs. 39982ESTs12.2400268012.2433190M26901Hs. 3210renin12.2444863AW384082Hs. 301323ESTs12.2434779AF153815Hs. 50151potassium inwardly-rectifying channel, subfam12.2451346NM_006338Hs. 26312glioma amplified on chromosome 1 protein (leu12.2430262AA218780Hs. 237323N-acetylglucosamine-phosphate mutase12.2421071AI311238Hs. 104476ESTs12.2426773NM_015556Hs. 172180KIAA0440 protein12.1409178BE393948Hs. 50915kallikrein 512.1400250012.1428450NM_014791Hs. 184339KIAA0175 gene product12.1414531T69387Hs. 76364allograft inflammatory factor 112.1448210AW247775Hs. 7393hypothetical protein from EUROIMAGE 198717012.1440081AA863389Hs. 135643ESTs12.1413179N99692Hs. 75227NADH dehydrogenase (ubiquinone) 1 alpha Subco12.1447551BE066634Hs. 929myosin, heavy polypeptide 7, cardiac muscle,12.1400517AF242388Hs. 149585lengsin12.1401610012.0454381AI935093Hs. 193428ESTs12.0443997AW081465Hs. 299644ESTs12.0402944012.0430637BE160081Hs. 256290S100 calcium-binding protein A11 (calgizzarin12.0415099AI492170Hs. 77917ubiquitin carboxyl-terminal esterase L3 (ubiq12.0445422AV653731Hs. 282829ESTs12.0416667AK000526Hs. 79457hypothetical protein FLJ2051912.0442611BE077155Hs. 177537ESTs12.0443271BE568568Hs. 195704ESTs12.0415120N64464Hs. 34950ESTs12.0439574AI469788Hs. 165190ESTs12.0405804012.0412519AA196241Hs. 73980troponin T1, skeletal, slow12.0414135NM_004419Hs. 2128dual specificity phosphatase 512.0447075AV662037Hs. 124740ESTs12.0416841N33878Hs. 249495heterogeneous nuclear ribonucleoprotein A112.0402943011.9416933BE561850Hs. 80506small nuclear ribonucleoprotein polypeptide A11.9439744AL389994Hs. 301272ESTs, Weakly similar to homologue of Drosphil11.9405762011.9408983NM_000492Hs. 663cystic fibrosis transmembrane conductance reg11.9455102BE005496gb: CM1-BN0117-110400-183-b09 BN0117 Homo sapi11.9402840011.9449183AW445022Hs. 196985Homo sapiens cDNA: FLJ21135 fis, clone CAS07211.9439273AW139099Hs. 269701ESTs11.9450484BE220675gb: ht98f11 x1 NCI_CGAP_Lu24 Homo sapiens cDNA:11.9445431AF137386Hs. 12701plasmolipin11.9401888011.9426037AW160780Hs. 166071cyclin-dependent kinase 511.9416742R38644Hs. 248420ESTs11.9418324AW246273Hs. 84131threonyl-tRNA synthetase11.8412870N22788Hs. 82407Homo sapiens HSPC296 mRNA, partial cds11.8432680T47364Hs. 278613interferon, alpha-inducible protein 2711.8421478AI683243Hs. 97258ESTs11.8426635BE395109Hs. 129327ESTs11.8420523AA262999Hs. 42788ESTs11.8426227U67058Hs. 168102Human proteinase activated receptor-2 mRNA, 311.8416658U03272Hs. 79432fibrillin 2 (congenital contractural arachnod11.8441816AI401807Hs. 149997ESTs11.8424596AB020639Hs. 151017estrogen-related receptor gamma11.8400640011.8448133AA723157Hs. 73769folate receptor 1 (adult)11.8401532011.8400161011.8442556AL137761Hs. 8379Homo sapiens mRNA, cDNA: DKFZp586L2424 (from c11.7451002AA013299Hs. 8018ESTs, Weakly similar to ALU3_HUMAN ALU SUBFAM11.7401879011.7415989AI267700Hs. 111128ESTs11.7416434AW163045Hs. 79334nuclear factor, interleukin 3 regulated11.7410616AW873401Hs. 273599ESTs11.7449239T24653Hs. 23360likely ortholog of yeast ARV111.7447669AL049985Hs. 19180Homo sapiens mRNA; cDNA: DKFZp564E122 (from cl11.7436877AA931484Hs. 121255ESTs, Weakly similar to cDNA: EST EMBL: D6741911.7434560R13052Hs. 3964Homo sapiens clone 24877 mRNA sequence11.7448105AW591433Hs. 170675ESTs, Weakly similar to TMS2_HUMAN TRANSMEMBR11.7400279011.6440497AA887266Hs. 144979ESTs11.6451260AW750773gb: CM0-CN0044-260100-164-h03 CN0044 Homo sapi11.6429175AI953040Hs. 127714ESTs, Moderately similar to SOX30 protein [H.11.6408209NM_004454Hs. 43697ets variant gene 5 (ets-related molecule)11.6428856AA436735Hs. 183171Homo sapiens cDNA: FLJ22002 fis, clone HEP06611.6420153N22120Hs. 75277hypothetical protein FLJ1391011.6428760AI351459Hs. 192398ESTs11.6421401AW410478Hs. 104019transforming, acidic coiled-coil containing p11.6404502011.6430423AI190548Hs. 143479ESTs, Weakly similar to hypothetical protein11.6405192011.6439092AA830149gb: oc44f08 s1 NCI_CGAP_GCB1 Homo sapiens cDNA:11.6401714011.5439335AA742697Hs. 62492ESTs, Weakly similar to S59856 collagen alpha11.5406082S47833Hs. 82927adenosine monophosphate deaminase 2 (isoform11.5401010011.5412140AA219691Hs. 73625RAB6 interacting, kinesin-like (rabkinesin6)11.5409339AB020686Hs. 54037ectonucleotide pyrophosphatase/phosphodiester11.5459684gb: ao86a08 ×1 Schiller meningioma Homo sapien11.5451051BE254309Hs. 125262DKFZP586G1624 protein11.5415323BE269352Hs. 949neutrophil cytosolic factor 2 (65 kD, chronic11.5412153R87934gb: yo47b10.r1 Soares adult brain N2b4HB55Y Ho11.5427256AL042436Hs. 97723ESTs11.5406708AI282759Hs. 242463keratin 811.4457644AA770080Hs. 144962ESTs, Moderately similar to I59365 ubiquitin11.4422848Z25884Hs. 121483chloride channel 1, skeletal muscle (Thomsen11.4424134AF070637Hs. 140950hypothetical protein11.4451931AK000208Hs. 27267Homo sapiens cDNA: FLJ20201 fis, clone COLF12111.4400438AF185611Hs. 115352growth hormone 111.4412994D32257Hs. 75113general transcription factor IIIA11.4408124U89337Hs. 42853cAMP responsive element binding protein-like11.4452249BE394412Hs. 61252ESTs11.4424627AA344555gb: EST50715 Gall bladder I Homo sapiens cDNA:11.4405626011.4436690AA373970Hs. 183096ESTs11.4415862R51034Hs. 144513ESTs11.4406755N80129Hs. 94360metallothionein 1L11.4433657AI244368Hs. 8124PH domain containing protein in retina 111.4429612AF062649Hs. 252587pituitary tumor-transforming 111.4423334AK000906Hs. 127273hypothetical protein FLJ1004411.4433053BE301909Hs. 279952glutathione S-transferase subunit 13 homolog11.4428423AU076517Hs. 184276solute carrier family 9 (sodium/hydrogen exch11.3442353BE379594Hs. 49136ESTs11.3447700AI420183Hs. 171077ESTs, Weakly similar to similar to serine/thr11.3402077011.3409203AA780473Hs. 687cytochrome P450, subfamily IVB, polypeptide 111.3405145011.3428248AI126772Hs. 40479ESTs11.3425508AA991551Hs. 97013ESTs11.3428340AF261088Hs. 154721aconitase 1, soluble11.3431452AI073641Hs. 152372ESTs11.3446651AA393907Hs. 97179ESTs11.3443755C18397Hs. 9730tachykinin 3 (neuromedin K, neurokinin beta)11.3436209AW850417Hs. 254020ESTs, Moderately similar to unnamed protein p11.3401020011.3456724AW247388Hs. 301423calcium binding protein 1 (calbrain)11.2407227H94949Hs. 171955trophinin associated protein (tastin)11.2402066011.2442721AI015892Hs. 101282Homo sapiens mRNA, cDNA: DKFZp434B102 (from cl11.2401025011.2452423AA991724Hs. 180535Homo sapiens cDNA: FLJ22711 fis, clone HSI13311.2431685AW296135Hs. 267659van 3 oncogene11.2425176AW015644Hs. 301430ESTs, Moderately similar to TEF1_HUMAN TRANSC11.2435496AW840171Hs. 265398ESTs, Weakly similar to transformation-relate11.2409079W87707Hs. 82065interleukin 6 signal transducer (gp130, oncos11.2456995T89832Hs. 170278ESTs11.2419223X60111Hs. 1244CD9 antigen (p24)11.2407788BE514982Hs. 38991S100 calcium-binding protein A211.2407604AW191962Hs. 288061actin, beta11.2437929T09353Hs. 106642ESTs, Weakly similar to hypothetical protein11.1415789H01581gb: yj33f08.r1 Soares placenta Nb2HP Homo sapi11.1424447AL137376Hs. 147368Homo sapiens mRNA, cDNA: DKFZp434J0226 (from c11.1436034AF282693Hs. 150185inflammation-related G protein-coupled recept11.1404931011.1445979AI695047Hs. 202395ESTs11.1446733AA863360Hs. 26040ESTs, Highly similar to CYTOCHROME P45 IVA211.1433133AB027249Hs. 104741PDZ-binding kinase; T-cell originated protein11.1445258AI635931Hs. 147613ESTs11.1417251AW015242Hs. 99488ESTs, Weakly similar to ORF YKR074w [S.cerevi11.1421041N36914Hs. 14691ESTs11.1425537AB007913Hs. 158291KIAA0444 protein11.1435763AI243929Hs. 190419ESTs11.1444790AB030506Hs. 11955B9 protein11.1453857AL080235Hs. 35861DKFZP586E1621 protein11.1433882U90441Hs. 3622procollagen-proline, 2-oxoglutarate 4-dioxyge11.1405358011.1435814AW615179Hs. 152870ESTs11.0422809AK001379Hs. 121028hypothetical protein FLJ1054911.0446772AW294404Hs. 144515Homo sapiens cDNA: FLJ11672 fis, clone HEMBA1011.0456694AW016382Hs. 105642Homo sapiens cDNA: FLJ23271 fis, clone HEP00111.0441128AA570256Hs. 54628ESTs11.0432677NM_004482Hs. 278611UDP-N-acetyl-alpha-D-galactosamine polypeptid11.0412576AA447718Hs. 107057ESTs11.0411122F00809Hs. 143696coactivator-associated arginine methyltransfe11.0427225AA432391Hs. 258903Homo sapiens mRNA for KIAA1640 protein, parti11.0426260NM_002541Hs. 168669oxoglutarate dehydrogenase (lipoamide)11.0444652BE513613Hs. 11538actin related protein 2/3 complex, subunit 1A11.0431947AL359613Hs. 49933hypothetical protein DKFZp762D101111.0414432BE378174Hs. 26506Homo sapiens clone CDABP0005 mRNA sequence11.0458627AW088642Hs. 97984ESTs; Weakly similar to WASP-family protein [10.9409142AL136877Hs. 50758chromosome-associated polypeptide C10.9447627AF090922Hs. 285902CGI-113 protein10.9447656NM_003726Hs. 19126src kinase-associated phosphoprotein of 55 kD10.9454227AW963897Hs. 44743KIAA1435 protein10.9402927010.9422380AA309881Hs. 136246ESTs10.9455986BE177736gb: RC1-HT0598-140300-021-g06 HT0598 Homo sapi10.9410962BE273749Hs. 752FK506-binding protein 1A (12 kD)10.9450361BE327108Hs. 202512ESTs10.9457484H57645gb: yr21e01.r1 Soares fetal liver spleen 1NFLS10.9407903AI287341Hs. 154029bHLH factor Hes410.9403398010.9401405010.9445570010.9421240R72730Hs. 29283ESTs, Weakly similar to PLK_HUMAN PROTEOGLYCA10.9403649010.9447824BE620800gb: 601483379T1 NIH_MGC_69 Homo sapiens cDNA: c10.9450935BE514743Hs. 25664tumor suppressor deleted in oral cancer-relat10.9439853AL119566Hs. 6721lysophospholipase-like10.9451852R51928gb: yj71c05.r1 Soares breast 2NbHBst Homo sapi10.9431218NM_002145Hs. 2733homeo box B210.9457794AA689292Hs. 246850ESTs10.9444374AA009841Hs. 11039Homo sapiens cDNA: FLJ12798 fis, clone NT2RP2010.9456566AW235317Hs. 259214ESTs10.8405552010.8439436BE140845Hs. 57868ESTs10.8435310AA705075Hs. 169536Rhesus blood group-associated glycoprotein10.8411125AA151647Hs. 68877cytochrome b-245, alpha polypeptide10.8415807H03139Hs. 24683ESTs10.8409430R21945Hs. 166975splicing factor, arginine/serine-rich 510.8417033H83784Hs. 40532ESTs, Weakly similar to PEBP MOUSE PHOSPHATID10.8418464R87580gb: ym89h07.r1 Soares adult brain N2b4HB55Y Ho10.8404567010.8418384AW149266Hs. 25130ESTs10.8421971U63127Hs. 110121SEC7 homolog10.8428769AW207175Hs. 106771ESTs10.8459104R19238Hs. 282057ESTs10.8410896AW809637gb: MR4-ST0124-261099-015-b07 ST0124 Homo sapi10.8416969AI815443Hs. 283404organic cation transporter10.8408796AA688292Hs. 118553ESTs10.8426298AW965058Hs. 111583ESTs10.8421595AB014520Hs. 105958Homo sapiens cDNA: FLJ22735 fis, clone HUV00110.8408007AW135965Hs. 246783ESTs10.8400167010.7445243AI217439Hs. 109854ESTs, Weakly similar to ALU1_HUMAN ALU SUBFAM10.7421733AL119671Hs. 1420fibroblast growth factor receptor 3 (achondro10.7412241AW948343gb: RC0-MT0015-130400-031-c01 MT0015 Homo sapi10.7425827W28316gb: 45b6 Human retina cDNA: randomly primed sub10.7420255NM_007289Hs. 1298membrane metallo-endopeptidase (neutral endop10.7430891U22492Hs. 248118G protein-coupled receptor 810.7402883010.7423811AW299598Hs. 50895homeo box C410.7447078AW885727Hs. 301570ESTs10.7414343AL036166Hs. 75914coated vesicle membrane protein10.7446913AA430650Hs. 16529transmembrane 4 superfamily member (tetraspan10.7452279AA286844Hs. 61260hypothetical protein FLJ1316410.7401220010.7459259AJ003294gb: AJ003294 Selected chromosome 21 cDNA: libra10.7414171AA360328Hs. 865RAP1A, member of RAS oncogene family10.7448449BE314567Hs. 211440ESTs10.7429670L01087Hs. 211593protein kinase C, theta10.7446759R61463Hs. 16165expressed in activated T/LAK lymphocytes10.7400776010.7428093AW594506Hs. 104830ESTs10.7412801AA121055gb: zm22b01.r1 Stratagene pancreas (937208) Ho10.6440545AW183201Hs. 190559ESTs10.6434540NM_016045Hs. 5184TH1 drosophila homolog10.6414273BE269057gb: 601184231F1 NIH_MGC_8 Homo sapiens cDNA: cl10.6401817010.6410423AW402432Hs. 63489protein tyrosine phosphatase, non-receptor ty10.6430590AW383947Hs. 246381CD68 antigen10.6426680AA320160Hs. 171811adenylate kinase 210.6445413AA151342Hs. 12677CGI-147 protein10.6402947010.6457426AW971119gb: EST383206 MAGE resequences, MAGL Homo sapi10.6424148BE242274Hs. 1741integrin, beta 710.6404944010.6405421010.6416772AI733872Hs. 79769protocadherin 1 (cadherin-like 1)10.6414191AW250089Hs. 75807PDZ and LIM domain 1 (elfin)10.6457588AI571225Hs. 284171KIAA1535 protein10.6406038Y14443Hs. 88219zinc finger protein 20010.6404790010.6418922AW956580Hs. 42699Thrombospondin-1 (Hs. 87409)10.6425940AB023184Hs. 163990KIAA0967 protein10.6448749AW859679Hs. 21902Homo sapiens clone 25237 mRNA sequence10.6418870AF147204Hs. 89414CXCR4, chemokine CXC receptor 4 (fusin)10.5417933X02308Hs. 82962thymidylate synthetase10.5450538AW297396Hs. 227052ESTs10.5427928AA417662Hs. 119217ESTs10.5432721AL121478Hs. 3132steroidogenic acute regulatory protein10.5429267AA299290Hs. 246857ESTs, Highly similar to S71100 protein kinase10.5439190AW978693Hs. 293811ESTs10.5408975AW958693Hs. 49391hypothetical protein LOC5414910.5415130W85893Hs. 249867ESTs10.5425738H29630Hs. 159408Homo sapiens clone 24420 mRNA sequence10.5440232AI766925Hs. 112554ESTs10.5425065AA371906Hs. 294151ESTs, Moderately similar to KIAA0544 protein10.5420829AW665612Hs. 221969ESTs10.5430466AF052573Hs. 241517polymerase (DNA directed), theta10.5407771AL138272Hs. 62713ESTs10.5444611AK002180Hs. 11449DKFZP564O123 protein10.5444665BE613126Hs. 47783ESTs, Weakly similar to T12540 hypothetical p10.5448030N30714Hs. 20161HDCME31P protein10.5438982AW979101Hs. 291980ESTs10.5446224AW450551Hs. 13308ESTs10.5405108010.5438233W52448Hs. 56147ESTs10.5401799010.5454038X06374Hs. 37040platelet-derived growth factor alpha polypept10.5414222AL135173Hs. 878sorbitol dehydrogenase10.5421828AW891965Hs. 289109dimethylarginine dimethylaminohydrolase 110.5422626AA344932Hs. 118786metallothionein 2A10.5449261AI637592Hs. 224958ESTs10.4416218R21499Hs. 23213ESTs10.4457848W26524Hs. 125682ESTs, Weakly similar to D2092.2 [C. elegans]10.4442577AA292998Hs. 163900ESTs10.4406505AF016272Hs. 115418cadherin 16, KSP-cadherin10.4412258AA376768Hs. 288977Homo sapiens cDNA: FLJ22622 fis, clone HSI05610.4429224AI905780Hs. 198272NADH dehydrogenase (ubiquinone) 1 beta subcom10.4447774BE018118Hs. 19554chromosome 1 open reading frame 210.4403914010.4406329010.4402423010.4431986AA536130Hs. 149018ESTs10.4423145BE264548Hs. 222190ESTs, Weakly similar to secretory carrier mem10.4414402BE294186gb: 601172959F1 NIH_MGC_17 Homo sapiens cDNA: c10.4417079U65590Hs. 81134interleukin 1 receptor antagonist10.4426095AI278023Hs. 89986ESTs10.4434577R37316Hs. 179769Homo sapiens cDNA: FLJ22487 fis, clone HRC10910.4442415AI005101Hs. 129550ESTs10.3421506BE302796Hs. 105097thymidine kinase 1, soluble10.3435084D17516Hs. 301607adenylate cyclase activating polypeptide 1 (p10.3431724AA514535Hs. 283704ESTs10.3456798AJ006422Hs. 135183centaurin-alpha10.3417370T28651Hs. 82030tryptophanyl-tRNA synthetase10.3422596AF063611Hs. 1186332′-5′oligoadenylate synthetase-like10.3435226AI248938Hs. 270106ESTs10.3433192AB040880Hs. 225594ESTs, Moderately similar to KIAA1447 protein10.3419879Z17805Hs. 93564Homer, neuronal immediate early gene, 210.3416228AW505190Hs. 79089sema domain, immunoglobulin domain (Ig), tran10.3453403BE466639Hs. 61779Homo sapiens cDNA: FLJ13591 fis, clone PLACE1010.3447906AL050062Hs. 19999DKFZP566K023 protein10.3401782NM_012434Hs. 117865solute carrier family 17 (anion/sugar transpo10.3453927AA082465Hs. 301751ESTs, Weakly similar to/prediction10.3450737AW007152Hs. 203330ESTs10.3421633AF121860Hs. 106260sorting nexin 1010.3409881AF139799Hs. 202830ESTs10.3432883U48936Hs. 3112sodium channel, nonvoltage-gated 1, gamma10.3440099AL080058Hs. 6909DKFZP564G202 protein10.3419024X56411Hs. 1219alcohol dehydrogenase 4 (class II), pi polype10.3401835010.3408896AI610447Hs. 48778niban protein10.3443120AW402677Hs. 290801ESTs10.3400208010.2416908AA333990Hs. 80424coagulation factor XIII, A1 polypeptide10.2400166010.2434642W25739Hs. 135287ESTs10.2424837BE276113Hs. 153436N-acetyltransferase, homolog of S cerevisiae10.2435075R51094Hs. 12400ESTs10.2425912AL137629Hs. 162189serine/threonine kinase with Dbl- and pleckst10.2435080AI831760Hs. 155111ESTs10.2414998NM_002543Hs. 77729oxidised low density lipoprotein (lectin-like10.2410020T86315Hs. 728ribonuclease, RNase A family, 2 (liver, eosin10.2411410R20693Hs. 69954laminin, gamma 310.2450294H42587Hs. 238730ESTs10.2421154AA284333Hs. 287631Homo sapiens cDNA: FLJ14269 fis, clone PLACE1010.2414271AK000275Hs. 75871protein kinase C binding protein 110.2400812010.2425843BE313280Hs. 159627death associated protein 310.2449392Z41698Hs. 26039Homo sapiens cDNA: FLJ13937 fis, clone Y79AA1010.2409089NM_014781Hs. 50421KIAA0203 gene product10.2401383010.2456855AF035528Hs. 153863MAD (mothers against decapentaplegic, Drosoph10.2442912AI088060Hs. 131450ESTs10.2400954D25969Hs. 76325Homo sapiens cDNA: FLJ23125 fis, clone LNG08210.2401029BE382701Hs. 25960v-myc avian myelocytomatosis viral related on10.2416602NM_006159Hs. 79389nel (chicken)-like 210.2421905AI660247Hs. 32699ESTs, Weakly similar to LIV-1 protein [H.sapi10.2405094010.2450832AW970602Hs. 105421ESTs10.2440076R32052Hs. 178617ESTs, Weakly similar to AF151840 1 CGI-82 pro10.2447563BE536115Hs. 160983ESTs10.2421238AB033101Hs. 102796KIAA1275 protein10.2400882010.2415738BE539367Hs. 295953ESTs, Weakly similar to AF220049 1 uncharacte10.1445464AW172389Hs. 249999ESTs10.1459042AW272058Hs. 210338ESTs10.1414469R51952Hs. 32587steriod receptor RNA activator 1 (complexes w10.1434732AI078443gb: oz05g05 x1 Soares_fetal_liver_spleen_1NFLS10.1441030AW204139Hs. 174424ESTs, Weakly similar to p140mDia [M.musculus]10.1446855BE616767Hs. 16269B-cell CLL/lymphoma 7B10.1456785AF151074Hs. 132744hypothetical protein10.1404182010.1410358AW975168Hs. 13337ESTs, Weakly similar to unnamed protein produ10.1430355NM_006219Hs. 239818phosphoinositide-3-kinase, catalytic, beta po10.1442152R39246Hs. 239666Homo sapiens cDNA: FLJ13495 fis, clone PLACE1010.1436354AI879252Hs. 5151Homo sapiens mRNA, cDNA: DKFZp564C2163 (from c10.1426711AA383471Hs. 180669conserved gene amplified in osteosarcoma10.1450599AA460865Hs. 48516ESTs10.1454393BE153288gb: PM0-HT0335-180400-008-c08 HT0335 Homo sapi10.1403383010.1415947U04045Hs. 78934mutS (E. coli) homolog 2 (colon cancer, nonpo10.1411773NM_006799Hs. 72026protease, serine, 21 (testisin)10.1412116AW402166Hs. 784Epstein-Barr virus induced gene 2 (lymphocyte10.1413808J00287Hs. 182183caldesmon 110.0458572AI223423Hs. 292794ESTs10.0403295010.0403910010.0453400AI991901Hs. 82590ESTs, Moderately similar to ALU7_HUMAN ALU SU10.0406502010.0404743010.0412517BE271584gb: 601141065F1 NIH_MGC_9 Homo sapiens cDNA: cl10.0402679010.0455864BE148970gb: CM0-HT0245-031199-085-h05 HT0245 Homo sapi10.0425734AF056209Hs. 159396peptidylglycine alpha-amidating monooxygenase10.0419280W07506Hs. 283725Homo sapiens cDNA: FLJ12627 fis, clone NT2RM4010.0443503AV645438Hs. 282927ESTs10.0423165AI937547Hs. 124915Human DNA sequence from clone 380A1 on chromo10.0450206AI796450Hs. 201600ESTs10.0459052AA298812Hs. 98539ESTs10.0456248AL035786Hs. 82425actin related protein 2/3 complex, subunit 510.0428438NM_001955Hs. 2271Endothelin 110.0456525AW468397Hs. 100000S100 calcium-binding protein A8 (calgranulin10.0426127L36983Hs. 167013dynamin 210.0Pkey: Primekey Ex. Accn Exemplay Accession UG ID. UniGene ID Title: UniGene title ratio: ration tumor vs normal ovary


[0382]

34







TABLE 13B








Pkey
CAT Number
Accession







410896
1226053_1
AW809637 AW809697 AW810554 AW809707 AW809885 AW810000




AW810088 AW809742 AW809816 AW809749 AW809639 AW809722




AW809836 AW809774 AW810023 AW810013 AW809813 AW809660 AW809728 AW809768 AW809951




AW809657 AW809954


412153
1279701_1
R87934 AW898205 AW896020 AW896035


412241
1284681_1
AW948343 AW948341 AW902855 AW984737


412517
130281_1
BE271584 AA112511


412801
132825_1
AA121055 AA330917


413349
1363558_1
BE086692 BE087077 BE087072


414273
1431911_1
BE269057 BE513434 BE396654


414402
1443240_1
BE294186 BE298975


414950
1509777_1
C15407 D81769 D61133


415789
1555357_1
H01581 H12850 R65905 H13053


416368
1591066_1
R88849 R84573 H50890


418464
1759038_−2
R87580


418783
1789791_1
T41368 T41369 T41294


424627
241724_1
AA344555 AA344312 AW963070


425827
256834_1
W28316 W26507 AA364334


434371
384839_1
AA631362 AA631438


434414
38585_1
AI798376 S46400 AW811617 AW811616 W00557 BE142245 AW858232




AW861851 AW858362 AA232351 AA218567 AA055556 AW858231




AW857541 AW814172 H66214 AW814398 AF134164 AA243093 AA173345 AA199942 AA223384




AA227092 AA227080 T12379 AA092174 T61139 AA149776 AA699829 AW879188




AW813567 AW813538 AI267168 AA157718 AA157719 AA100472 AA100774 AA130756 AA157705




AA157730 AA157715 AA053524 AW849581 AW854566 C05254 AW882836 T92637 AW812621




AA206583 AA209204 BE156909 AA226824 AI829309 AW991957 N66951 AA527374 H66215




AA045564 AI694265 H60808 AA149726 AW195620 BE081333 BE073424 AW817662




AW817705 AW817703 AW817659 BE081531 H59570


434732
392447_1
AI078443 AA648102 AI765577 AW974381


439092
468554_1
AA830149 AW978407 M85983 AW503637


439636
47467_1
AF086467 W81444 W81445


447824
73861_−1
BE620800


450484
83645_1
BE220675 AA345621 AA009992


451260
863912_1
AW750773 AI768154


451852
888359_1
R51928 AI820698 R48360 AI820694


452101
898742_1
T60298 AI858257 T69667 T67634 T61224 T71537 T68933


454163
1048369_1
AW175997 AW176000 AW175999 AW175994 AW176004 AW175989


454393
115888_1
BE153288 BE153151 BE152925 AA078302


455102
1253524_1
BE005496 BE005494 AW856324 AW900199


455864
1377038_1
BE148970 BE148975 BE148957 BE148937


455986
1397521_1
BE177736 BE177735 BE177734


456423
187241_1
AW748920 AA487506 AA248914 AA780494


457426
336189_1
AW971119 AA574265 AA513268


457484
342113_1
H57645 T19302 AA527038 Z24851 H93171


457705
389383_1
AW974668 AA661959 AA649572 AA640401 AA640402


459259
966269_1
AJ003294 AJ003315 AJ003293






Pkey: Unique Eos probeset identifier number




CAT number: Gene cluster number




Accession Genbank accession numbers








[0383]

35








TABLE 13C








Pkey
Ref
Strand
Nt_position







400640
8117686
Plus
144324-144429


400666
8118496
Plus
17982-18115, 20297-20456


400776
8131651
Plus
103576-103720


400812
8568711
Plus
71708-72153


400881
2842777
Minus
91446-91603, 92123-92265


400882
2842777
Minus
110431-110708


400965
7770576
Minus
173043-173564


401010
8117391
Minus
83967-84180


401020
8117458
Minus
59085-60227


401025
8117518
Minus
179287-179483, 181044-181166, 181844-182039


401047
6705887
Minus
4804-5035, 5133-5314


401131
8699812
Minus
94802-94987, 95804-95887, 96323-96487, 97596-97826


401192
9719502
Minus
69559-70101


401220
9929324
Minus
48079-48279


401383
6721135
Minus
155543-157381


401405
7768126
Minus
69276-69452, 69548-69958


401519
6649315
Plus
157315-157950


401532
7798785
Plus
124414-124950, 125050-125418


401610
7705041
Minus
18921-19505


401714
6715702
Plus
96484-96681


401735
3252819
Plus
217235-217356, 217621-217873


401799
7331447
Plus
147802-148251


401817
7417850
Minus
45888-46535


401835
7139700
Plus
142257-142742


401879
8099914
Minus
101064-102827


401888
8516069
Minus
189498-190514


401897
8569218
Plus
604-767


402066
6649269
Plus
135543-136031


402077
8117414
Plus
65014-65195


402104
8119072
Plus
122409-122600


402238
7690126
Plus
24726-24880, 26791-27021


402287
4559317
Plus
40811-42447


402389
9885999
Minus
771-972, 1571-1683


402408
9796239
Minus
110326-110491


402423
9796344
Minus
62487-62664


402424
9796344
Minus
64925-65073


402496
9797769
Minus
8615-9103


402520
7596899
Minus
171761-171996


402679
8113438
Plus
132079-132216


402840
9369121
Minus
57118-57306


402883
9926562
Plus
38666-38803, 38885-39019, 39097-39231, 39308-39445


402885
9926751
Plus
71919-72049


402926
8217647
Minus
41261-41443


402927
8217647
Minus
47247-47396


402943
6456831
Plus
38467-39068


402944
9368423
Plus
110411-110716, 111173-111640


402947
9368458
Minus
101629-101991


402965
9581599
Minus
46865-46941, 47032-47148


403022
3132351
Plus
92097-92864


403121
9180223
Plus
4059-4258


403165
9838098
Minus
90595-91848


403295
8096528
Plus
22386-22708


403381
9438267
Minus
26009-26178


403383
9438267
Minus
119837-121197


403398
6862689
Minus
13685-14699


403399
6684178
Plus
61841-62145, 62367-62756


403482
9966050
Plus
196964-197135


403485
9966528
Plus
2888-3001, 3198-3532, 3655-4117


403649
8705159
Minus
27141-27247


403910
7710710
Minus
5761-6188


403912
7710730
Minus
72000-72290, 72431-72700, 72929-73199


403914
7417588
Minus
7431-8472


404182
4775644
Plus
18163-18444


404502
7229863
Minus
56277-56819


404567
7249169
Minus
101320-101501


404678
9797204
Plus
115196-115448


404743
8894169
Minus
120556-120999


404780
9887810
Minus
175708-175871


404790
7230958
Plus
38611-38761


404931
7342203
Plus
44226-44382


404944
6899705
Plus
4256-4581


405024
7107727
Plus
88500-88697


405089
8072523
Plus
103182-103973


405094
8072579
Plus
135587-135758


405108
7107890
Minus
135020-135472


405145
9438278
Plus
37883-38052, 38138-38332


405192
7230070
Plus
115629-116071


405224
6731245
Minus
14413-15979


405295
3818412
Plus
56933-57099


405353
2811095
Plus
118525-118892


405358
2341017
Minus
18016-18315


405421
7243869
Minus
97411-97687


405426
7243900
Minus
37640-37817


405452
7656638
Minus
93876-94275


405484
5922025
Plus
199214-199579, 199672-199920, 200262-200495


405552
1552506
Plus
45199-45647


405570
2808656
Plus
98208-98331


405626
4508116
Minus
89275-89384, 92450-92629, 97091-97279, 98546-98666


405699
4165331
Plus
100727-100859


405762
5931935
Plus
160502-161110


405802
5924004
Minus
27743-28264


405804
7274891
Minus
122557-123551


406329
6982072
Minus
607903-608271


406429
9256476
Minus
83206-83365, 94051-94193


406502
7711350
Minus
63430-63602






Pkey: Unique number corresponding to an Eos probeset




Ref: Sequence source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. “Dunham I et al.” refers to the publication entitled “The DNA sequence of human chromosome 22” Dunham, et al. (1999) Nature 402: 489-495




Strand Indicates DNA strand from which exons were predicted.




Nt_position Indicates nucleotide positions of predicted exons.








[0384] Table 14A lists about 1025 genes up-regulated in ovarian cancer compared to normal adult tissues. Genes associated with ovarian cancer were selected from 53462 probesets such that the ratio of “average” ovarian cancer to “average” normal adult tissue was greater than or equal to 5 0 The “average” ovarian cancer level was set to the 93rd percentile value amongst various ovarian cancer specimens, the “average” normal adult tissue level was set to the 96th percentile value amongst various non-malignant tissues In order to remove gene-specific background levels of non-specific hybridization, the 15th percentile value amongst the non-malignant tissue was subtracted from both the numerator and the denominator before the ratio was evaluated


[0385] Tables 14B-18B show the accession numbers for those Pkey's lacking UnigeneID's for tables 14A-18A For each probeset is listed the gene cluster number from which oligonecleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist Oakland Calif.) Genbank accession numbers for sequences comprising each cluster are listed in the “Accession” column.


[0386] Tables 14C-18B show genomic positioning for those Pkey's lacking Unigene ID's and accession numbers in tables 14A-18A. For each predicted exon is listed genomic sequence source used for prediction Necleotide locations of each predicted exon are also listed
36TABLE 14APkeyExAccnUniGene IDUnigene TitlePred Protein DomR1421296NM_002666Hs 103263perilipinperilipin, SS32.5453028AB006532Hs 31442RecQ protein-like 4DEAD, helicase_C, Fork_head27.6422310AA316622Hs 98370cytochrome P450, subfamily IISSS, TM, pkinase, fn3, ig26.5437897AA770561Hs 146170hypothetical protein FLJ22969SS, TM, zf-DHHC26.3446374AA329256Hs 24756ESTs, Moderately similar to al22.6441021AW578716Hs. 7644H1 histone family, member 222.3409518BE384836Hs 3454KIAA1821 proteinSS21.3413436AF238083Hs 68061sphingosine kinase 1DAGKc21.2424420BE614743Hs 146688prostaglandin E synthaseMAPEG, SS, TM, MAPEG20.7422645L40027Hs. 118890glycogen synthase kinase 3 alppkinase, SS, Ets20.7422098H03117Hs 111497similar to mouse neuronal protTM20.2429556AW139399Hs 98988ESTsSS, pkinase, PMP22_Claudin20.1436485X59135Hs. 156110immunoglobulin kappa constantSS, ig, SS19.9423652AF052122Hs 130712Homo sapiens clone 23929 mRNAABC1, SS, PID, PID19.8431773BE409442Hs 268557pleckstrin homology-like domaiPH, SS, LIM, Troponin19.4422179AF091619Hs 112667dynein, axonemal, intermediateWD40, SS19.3420839AI792682Hs 282960hypothetical protein MGC10870SS, DS, UPF0139, Glyco_hydro18.5441356BE384361Hs. 182885ESTs, Weakly similar to JC5024SS, TM, ank18.5424659AW891298Hs 331601Homo sapiens, Similar to cysteSS, Fork_head18.4439924AI985897Hs. 125293ESTsSS18.1458814AI498957Hs 170861ESTs, Weakly similar to Z195_HSS, TM, Idl_recept_a, Idl_re17.5451643M64437Hs 234799breakpoint cluster regionRhoGEF, RhoGAP, PH, C217.2439108AW163034Hs 6467synaptogynn 3Synaptogynn, SS, TM, PDZ, WD16.9432945AL043683hypothetical protein FLJ10803SS16.8410418D31382Hs 63325transmembrane protease, serineSS, TM, Idl_recept_a, trypsi16.8438424AI912498Hs 25895hypothetical protein FLJ14996SS, TM16.7409435AI810721Hs 95424ESTsSS16.4418969W33191Hs 28907hypothetical protein FLJ20258SH3, SH316.2421612AF161254Hs 1061968D6 antigenIdl_recept_a, SS, TM16.0456177NM_012391Hs 79414prostate epithelium-specific EEts, SAM_PNT15.7414837U24266Hs 77448aldehyde dehydrogenase 4 familaldedh15.6432631H08379Hs 165563hypothetical protein DKFZp434NTM, DnaJ, UBA, ArfGap, homeob15.5454017AW023617Hs. 347130hypothetical protein FLJ22709SS, TM, myosin_head, RA, DAG15.5401278Target ExonBand_4115.4444804AI084452Hs 22158hypothetical protein FLJ21988SS15.4410259AK000337Hs 61485hypothetical proteinGFO_IDH_MocA, GFO_IDH_MocA15.4406620M81105Hs 146550myosin, heavy polypeptide 9, nmyosin_head, Myosin_fail, l15.1423081AF262992Hs 123159sperm associated antigen 4TM14.9421495AI583067Hs 149152ESTs, Weakly similar to RHOP M14.7416893AA455588Hs. 62406hypothetical protein FLJ22573SS, rrm, SS14.7413244AW955951Hs 159265kruppel-related zinc finger prSS, TM, BTB, pep_M12B_propep14.6406901M14624gb: Human 4-beta-galactosyltran14.6416006AA324251Hs. 78950branched chain keto acid dehydE1_dehydrog14.6436186BE390717Hs 5074similar to S pombe dim1DIM1, SS14.5455557AW995839gb QV4-BN0044-110200-108-h07 BMetallophos14.4434518H56995Hs 37372homo sapiens DNA binding peptiSS14.2421489AI922821Hs. 32433ESTsSS, PI-PLC-X, PI-PLC-Y, C214.1444441AW613841Hs 301394hypothetical protein MGC310114.0435017AA336522Hs 12854angiotensin II, type I recepto14.0446572AV659151Hs 282961ESTs13.9434068AA977935Hs 127274ESTsSS13.7432481AW451645Hs. 151504homo sapiens cDNA FLJ11973 fisSS, Collagen, COLF1, TSPN13.7447304Z98883Hs 18079phosphatidylinositol glycan, cSS, Peptidase_C213.6421182AA284855Hs 104480ESTsSS, Topoisomerase_I, TopoiS13.3407767W15398Hs 38628hypothetical proteinSS, zf-CCCH13.3456642AW451623Hs 109752putative c-Myc-responsive13.3437457AA757900Hs. 270823ESTs, Weakly similar to S65657SQS_PSY13.2430178AW449612Hs 152475ESTsSS13.1430399AI916284Hs. 199671ESTsSec7, PH12.9436725BE045223Hs. 136912hypothetical protein MGC1079612.9410219T98226Hs 171952occludinSS, TM, Occludin, BIR12.7442620C00138Hs 8535Homo sapiens mRNA for KIAA1668SS, RNA_pol_K12.7439233AA831893Hs 292767hypothetical protein FLJ23109zf-C3HC4, TM, Sulfate_trans12.7425018BE245277Hs 154196E4F transcription factor 1zf-C2H2, LIM, SS, Exo_endo_p12.6423801NM_015071Hs. 132942GTPase regulator associated wiRhoGAP, SH3, PH12.6417826T85105Hs. 15471ESTsSS, cadherin, Cadherin_C_te12.6409261BE315042Hs 19210hypothetical protein MGC1130812.6420568F09247Hs 247735protocadherin alpha 10cadherin, SS, TM, cadherin12.6411570BE144584Hs 314341ESTs12.5430397AI924533Hs 105607bicarbonate transporter relateHCO3_cotransp, SS, TM12.5423767H18283Hs 132753F-box only protein 2F-box, SS, F-box, HORMA12.4441805AA285136Hs 301914neuronal specific transcriptioLIM, SS, LIM12.3402365Target ExonSS, SS, TM, ig12.2414371AI905865thymosin, beta 4, X chromosomeThymosin12.2446780R31107gb yh61g01 s1 Soares placenta12.1428782X12830Hs. 193400interleukin 6 receptorSS, TM, fn3, ig, SS, TM12.1427695R88483Hs 172862intron of Bicaudal D homolog 112.1400460C11002253* gi|129091|sp|P23267SS, TM, SCAN, zf-C2H2, KRAB12.0407341AA918886Hs 204918ESTs, Weakly similar to ALU8_HSS, TM12.0424049AB014524Hs 138380KIAA0624 proteinSS11.9422872BE326786Hs 187646ESTsTM11.9450800BE395161Hs 1390proteasome (prosome, macropainSS11.8428648AF052728Hs. 188021potassium voltage-gated channecNMP_binding11.7432329NM_002962Hs 2960S100 calcium-binding protein AS_100, efhand, SS, efhand, S11.7417061AI675944Hs 188691Homo sapiens cDNA FLJ12033 fisCTF_NFI11.6451195U10492Hs 438mesenchyme homeo box 1homeobox, SS11.5417595AA424317Hs. 6259KIAA1698 proteinSS, TM, Glyco_hydro_31, Glyc11.5426500NM_014638Hs 170156KIAA0450 gene productSS11.4433124U51712Hs 13775hypothetical protein SMAP3111.4444001AI095087Hs 152299ESTs, Moderately similar to S611.4419298AA853479Hs 89890pyruvate carboxylaseCPSase_L_chain, PYC_OADA, H11.4428593AW207440Hs. 185973degenerative spermatocyte (homSS11.3411408U76666Hs 69949calcium channel, voltage-depenion_trans, SS, TM11.2404438Target Exon11.2427448BE246449Hs 2157Wiskott-Aldrich syndrome (eczeWH1, PBD, WH2, SS11.2406230Target Exon11.2432125AW972667Hs. 183006Homo sapiens cDNA FLJ12300 fisBand_41, ERM11.2408832AW085690Hs 63428ESTs, Weakly similar to Z195_H11.1400206Eos ControlSS, SS, Glyco_tranf_43, COLF11.1450503R35917Hs 301338hypothetical protein FLJ12587SS11.0407605W03512Hs 6479hypothetical protein MGC13272SS, Sema, pkinase, TIG, PSI, e11.0432143AL040183Hs 123484Homo sapiens, clone IMAGE 4178SS, TM, cys_rich_FGFR10.9446839BE091926Hs 16244mitotic spindle coiled-coil reTroponin, SS, glycolytic_en10.8443559AI076765Hs 269899ESTs, Moderately similar to ALSS, TM, BIR, UQ_com10.8411298AW835858gb PM0-LT0017-031299-001-h07 L10.8409557BE182896Hs 211193ESTs10.8435158AW663317Hs 65588DAZ associated protein 1rrm, SS, rrm10.8444410BE387360Hs 33719ESTs, Moderately similar to S6SS10.6428948BE514362FK506-binding protein 3 (25 kD)FKBP, PIP5K10.6424707BE061914Hs. 10844Homo sapiens cDNA FLJ14476 fisSS, SS, TM, Sema10.6416819U77735Hs. 80205pim-2 oncogenepkinase, SS, TM, OTU, K_tetra10.5419341N71463Hs 118888ESTs, Weakly similar to ALU1_HSS, TM, UPF001610.5444359AI697160Hs 143594ESTs, Weakly similar to HS4L_H10.5404333C7001735* gi|7768636|dbj|BAA95vwd10.5401210C12000519 gi|7710046|ref|NP_0510.5457941AI004525Hs 14587ESTs, Weakly similar to AF1518SS, TM, SS, TM10.4401594NM_024817. Homo sapiens hypothe10.3441790AW294909Hs. 132208ESTs10.3444008BE544855Hs 236572ESTs, Weakly similar to SFR4_HSS, SS, SAC3_GANP10.3438185Y19188Hs 320461ESTsSS10.2432031AF039196Hs. 272367hairless protein (putative sinjmjC10.2410471T88872gb yd31a12 s1 Soares fetal liv10.1433573AF234887Hs 57652cadherin, EGF LAG seven-pass GSS, TM, 7tm_2, EGF, cadherin, 10.1417371N74613Hs 269149ESTs10.0428167AA770021Hs 16332ESTsSS, ig, fn310.0419563AA526235Hs. 193162Homo sapiens cDNA FLJ11983 fis10.0412674X04106Hs 74451calpain 4, small subunit (30 K)efhand, SS, CAP_GLY10.0425863U43604Hs. 159901Human unidentified mRNA, parti9.9442739NM_007274Hs 8679cytosolic acyl coenzyme A thioAcyl-CoA_hydro, SS, TM9.9429469AA64590Hs 27glycine dehydrogenase (decarboGDC-P, GDC-P9.9420029BE258876Hs 94446polyamine-modulated factor 1aldo_ket_red, SS, TM, gla9.8445625BE246743hypothetical protein FLJ22635SS, TM9.8435339AI358300ESTsSS, ras9.8407235D20569Hs 169407SAC2 (suppressor of actin mutaSS, TM, Ribosomal_S13, Galac9.8428758AA433988Hs 98502CA125 antigen, mucin 16SS9.8401349inositol polyphosphate-1-phosp9.7437915AI637993Hs 202312Homo sapiens clone N11 NTera2D9.7424511BE300512Hs 193657ESTs, Moderately similar to AL9.7423366Z80345Hs. 127610acyl-Coenzyme A dehydrogenase, Acyl-CoA_dh, Acyl-CoA_dh_M9.7405143NM_013432* homo sapiens nucleaank, SS, TM, CPSF_A9.6427497AW139476Hs. 31240ESTs9.6420423AA827718Hs 88218ESTsSS9.6431512BE270734Hs 2795lactate dehydrogenase AIdh, Idh_C, SS, Idh9.6450052AI681298Hs. 236524ESTszf-C3HC4, zf-B_box9.5412738N34731Hs 74562siah binding protein 1, FBP inhomeohox9.5444202AL031685Hs. 12785KIAA0939 proteinSS, TM, Na_H_Exchanger, ABC29.5451165AI340575Hs 286084MRIP-1 protein9.5411450H49619Hs 127301ESTsSS, pkinase9.5405371NM_005569* Homo sapiens LIM dopkinsoe, LIM, PDZ9.5435782N49433Hs 285737homo sapiens cDNA: FLJ20895 fiSS, G6PD, Glucosamine_iso, G9.5416866AA297356Hs. 80324serine/threonine protein phospMetallophos, Metallophos9.4405474NM_001093* homo sapiens acetylCPSase_L_chain, biotin_lip9.4412837AI922293Hs 58389hypothetical protein MGC40909.3448133AA723157Hs 73769folate receptor 1 (adult)Folate_rec, SS9.3431081AA491594Hs 75813polycystic kidney disease 1 (aSS, TM9.3427640AF058293Hs. 180015D-dopachrome tautomeraseMIF, late_protein_L2, SS, GS9.2427435AW938739Hs 115412hypothetical protein FLJ13881SS9.2407688W25317Hs 37616Human D9 splice variant B mRNA9.2407507U73799gb: Haman dynactin mRNA, partiaSS, TM, HCO3_cotransp, CAP_G9.2400833C11000890 gi|3746443|gb|AAC639SS, TM, 7tm_19.2422064AW452589Hs 335742ESTsTM9.2452434D30934Hs 29549C-type lectin-like receptor-1lectin_c, SS, TM9.2451752AB032997KIAA1171 proteinTBC, SS, TM, pkinase, laminin9.2432931AF174487Hs. 293753Bcl-2-related ovanan killer p9.1407893BE408359Hs 43621Homo sapiens, Similar to hypotSS, SS, arf, ras, fn3, ras9.1427397AI929685Hs 177656calmodulin 1 (phosphorylase kiefhand, RrnaAD, SS, efhand9.1405159ENSP00000243337* CDNA FLJ139849.1422283AW411307Hs 114311CDC45 (cell division cycle 45, CDC459.1407058X94563gb: H. sapiens dbi/acbp gene exoSS9.0448045AJ297436Hs 20166prostate stem cell antigenSS, TM, UPAR_LY6, toxin, SS, T9.0400772NM_003105*: homo sapiens sortilIdl_recept_a, fn3, Idl_rece9.0427315AA179949Hs 175563homo sapiens mRNA, cDNA DKFZp5spectrin, SH3, PN, CH9.0414391BE409872gb: 601299655F1 NIH_MGC_21 Homo9.0447867AI525268Hs 164303ESTsTM9.0422639AI929377Hs 173724creatine kinase, brainATP-gua_Ptrans, ATP-gua_Pt9.0454319AW247736Hs 101617ESTs, Weakly similar to T32527SS8.9428781AF164799Hs. 193384putatatine 28 kDa protein8.9408645AW245738Hs 109274hypothetical protein MGC4365SS, TM8.9429527AA454184Hs 289014ESTs8.9406651AI559224gb tq32c02.x1 NCI_CGAP_Ut1 Hom8.9430893BE502068Hs 282067ESTs8.8414413BE294877gb 601174162F1 NIH_MGC_17 HomoSS8.8413726AJ278465Hs. 75510annexin A11annexin, SS, annexin8.8432211BE274530Hs. 273333hypothetical protein FLJ109868.8421694BE387430Hs 106880bystin-like8.8453683AL079854Hs 118598homo sapiens mRNA for KIAA1878SS8.8456741W37608Hs 184492ESTsSS, pkinase8.7442995AA532511Hs 288455homo sapiens cDNA FLJ23270 fi8.7415898Z43379Hs. 177193gb: HSC1AE111 normalized infant8.7456977AK000252Hs 169758hypothetical protein FLJ202458.7439632AW410714Hs 334437hypothetical protein MGC4248SS, TM, transmembrane48.7431462AW583672Hs. 256311granin-like neuroendocrine pepSS8.7400128Eos ControlTM, E1-E2_ATPase, NMA, Hydro8.7438582AI521310Hs 283365ESTs, Weakly similar to ALU5_HSS8.7450958AL137669Hs 348012homo sapiens mRNA, cDNA DKFZp48.7410855X97795Hs 66718RAD54 (S. cerevisiae)-likeSNF2_N, helicase_C, SS8.7415126D60945gb: HUM141D04B Clontech human fSS, TM8.7418736T18979Hs 87908Snf2-related CBP activator proSS, helicase_C, AT_hook, SS, 8.6431157AI823969Hs 132678ESTsSS, MAPEG, SS, MAPEG8.6418843AJ251016Hs 89230potassium intermediate/small cTM, CaMBD, SK_channel, TM8.6419167AI589535Hs 94875ESTs, Weakly similar to A35363SS8.6432343NM_002960Hs. 2961S100 calcium-binding protein AS_100, SS, efhand, S_100 efh8.6458440AI095468Hs 135254Homo sapiens clone 1 thrombosp8.6407065Y10141gb H. sapiens DAT1 gene, partiaSNF, SS, TM8.6452851AW173191Hs 213117ESTsSS, Sema8.6422418AK001383Hs. 116385hypothetical protein FLJ10521RhoGEF8.6420836AW958453Hs 204959hypothetical protein FLJ14886SS, ras8.6455588AI129903Hs 74669vesicle-associated membrane prsynaptobrevin, SS, TM8.5431974AW972689Hs 200934ESTsbZIP8.5410720AF035154Hs 65756regulator of G-protein signallRGS, G-gamma, DEP, SS, RGS, DI8.5449751AW207115Hs 25555ESTs8.5434030AW162336Hs 3709low molecular mass ubiquinone-SS8.5405557Target ExonEts, SAM_PNT8.5443780NM_012068Hs 9754activating transcription factobZIP, NTP_transf_2, SS, TBC8.5428860U38291Hs 194301microtubule-associated proteinM8.5421901AB014554Hs 109299protein tyrosine phosphatase,SAM, SS, TM, rrm, PDZ8.4401885Target Exonkinesin, SS, TM8.4449382AI650407Hs. 197875ESTsSS, rrm, zt-RanBP8.4432862AW004958Hs. 236720amnionless proteinSS, MATH, zf-TRAF, zf-C3HC48.4441363AW450211Hs 126825ESTs, Weakly similar to A46302SS, TM, HSP20, 7tm_18.4407363AF035032Hs. 181125gb: Homo sapiens clone MCA1L mySS, ig, SS, G_glu_transpept8.4425380AA356389Hs 32148AD-015 proteinSS, TM, LRR, P, Peptidase_S88.4424893AW295112Hs 153648Homo sapiens cDNA FLJ13303 fisSS, SAM, SS, TM, 7tm_18.4424080AW189983Hs. 139119Homo sapiens cDNA FLJ10967 fis8.3439772AL365406Hs. 10268Homo sapiens mRNA full length8.3431765AF124249Hs 268541novel SH2-containing protein 1SH2, SS, TM8.3404365Target ExonSS8.3424310AA338648Hs 50334testes development-related NYDSS, TM8.3401935Target ExonPH8.3434796AA812046ESTsSS, myb_DNA-binding.myb_DN8.3423098AA321980Hs 204682ESTs8.3434552AA639618Hs 325116Homo sapiens, clone MGC: 2962, SS8.2457082AA470687Hs. 104772ESTsSS8.2432603AA554920Hs 105794UDP-glucose: glycoprotein glucoSS, TM8.2402445Target Exonfn3, SS, TM, BNR8.2422078AW872378Hs 120170hypothetical protein FLJ21415SS8.2418361AW505368Hs 12460gb: UI-HF-BN0-alu-d-03-0-UI.r18.2431354BE046956Hs. 251673DNA (cytosine-5-)-methyltransfSS, PWWP, PHD8.2403885Target ExonTM, Sulfate_transp, STAS, HM8.2450029AW073380Hs 267963hypothetical protein FLJ10535SS, Pyridox_oxidase, zf-C2H8.2452512AW363486Hs 337635ESTsSS8.2420138BE268854Hs 177729ESTsSS8.2439788N71241Hs 119275ESTsUQ_con8.2423662AK001035Hs 130881B-cell CLL/lymphoma 11A (zincSS8.2449656AA002008Hs 188633ESTsPIP5K8.1452295BE379936Hs. 28866programmed cell death 10SS, serpin8.1448650AW769385Hs 204891ESTsSS, IL88.1446035NM_006558Hs 13565Sam68-like phosphotyrosine proKH-domain8.1444406AI147237immunoglobulin heavy constantSS8.1437215AL117488Human clone 23564 mRNA sequencSS8.1408891NM_006577Hs 284284ESTs, Highly similar to beta-1SS, TM, DIX, PDZ, DEP, Disheve8.1400409AF153341Homo sapiens winged helix/forkSS8.0443801AW206942Hs 253594intron of trichothinophalangGATA8.0425281AA444390Hs. 155482hydroxyacyl glutathione hydrollactamase_B, SS8.0458216AW024282Hs 104938hypothetical protein MGC159068.0401507C15000810* gi|11131272|sp|P7938.0401180eukaryotic translation elongatSS, TM, ion_trans, IQ8.0454291AW384847Hs 213534ESTs, Weakly similar to MUC2_HSS, XRCC1_N, BRCT, lactamase8.0444014AI095718Hs. 135015ESTs8.0412128AW894709gb CM1-NN0032-020500-212-d05 NSCAN, zf-C2H2, KRAB7.9408363NM_003389Hs 44396coronin, actin-binding proteinWD407.9425694U51333Hs 159237hexokinase 3 (white cell)hexokinase, hexokinase2, he7.9425263NM_001197Hs 155419BCL2-interacting killer (apoptSS, TM, TspQ_MBR7.9447045AW392394sorting nexin 17SS, IF-2B, PP2C7.9457613AA598869Hs 173770ESTs7.9410338W03445Hs 38205gb: za05g11 r1 Soares melanocytpkinase7.9402545Target Exon7.9454246AW245185Hs 6996ESTs7.9410079U94362Hs 58589glycogenin 2Glyco_transf_87.9443678AW009605Hs 231923ESTsSS7.9404676Target Exon7.9406649AI569392gb tn86a02 x1 NCI_CGAP_Ut2 Hom7.9420230AL034344Hs. 284186forkhead box C1Fork_head, SS, Fork_head7.9413534BE146961gb QV4-HT0222-011199-019-b12 HSS, TM7.8444628U01120Hs. 242glucose-6-phosphatase, catalytPAP2, SS, TM7.8410839NM_006849Hs 66581protein disulfide isomerasethiored, Rho_GDI, gntR, SS, T7.8444046AI360834Hs 135094ESTsSS, GTP_EFTU, EFG_C, GTP_EFT7.8439501AF086321Hs 287452Homo sapiens cDNA FLJ11760 fisTM7.8415441R13977Hs 9634ESTs7.8450461BE408081Hs. 46736hypothetical protein FLJ23476SS7.8448993AI471630KIAA0144 gene product7.8400923Target ExonSS, TM, DUF2897.8440546AI491994gb to07g09 x1 NCI_CGAP_Ut2 HomSS, HATPase_c7.8419757AA773820Hs 63970ESTsSS, TM7.8451721NM_006946Hs 26915spectrin, beta, non-erythrocytspectrin, PH, CH, SS, Peptida7.8458834AI566883Hs 196446ESTs7.8422633X56832Hs 118804enolase 3, (beta, muscle)enolase, SS, TM, kinesin, FHA7.7438452AI220911Hs. 288959hypothetical protein FLJ20920SS7.7421445AA913059Hs 104433Homo sapiens, clone IMAGE 4054asp, SS, TM, ion_trans, K_tet7.7434743AI363410ribosomal protein S18SS, TM7.7450635AW403954Hs 25237mesenchymal stem cell protein4HBT7.7442394R62926Hs 285193ESTs7.7434333AA186733Hs 292154stromal cell protein7.7427221L15409Hs. 174007von Hippel-Lindau syndromeVHL, TM7.7429099BE439952Hs 196177phosphorylase kinase, gamma 2pkinase, SS, SNF2_N, helicas7.7444670H58373Hs 332938hypothetical protein MGC5370SS, zf-RanBP, MDM27.7449495AI652833gb: wb22c11.x1 NCI_CGAP_GC6 HomSS7.7444607AW405635Hs 293687ESTsSS, PI-PLC-X, PH, PI-PLC-Y, C7.7449125AI671439Hs 196029Homo sapiens mRNA for KIAA1657TIMP7.7447151AI022813Hs 92679Homo sapiens clone CDABP0014 mSS, TM, LRR, aminotran_1_27.6448626W27670Hs. 55613hypothetical protein FLJ225317.6430432AB037758Hs 241419KIAA1337 proteinTM, Patched, TM7.6401822C17001422: gi|2695866|emb|CAA757.6428909AI190714Hs. 98945ESTs7.6414534BE257293Hs. 76366BCL2-antagonist of cell deathSS, hormone_rec, zf-C47.6421620AA446183Hs 91885ESTs, Weakly similar to I552147.6441650AI261960Hs. 132545ESTsSS, TM, KOW7.6442232AI357813Hs 337460ESTs, Weakly similar to A47582SS, TM, TGFb_propeptide, TGF7.6439539BE348395Hs 121589ESTsSS, Fork_head7.5400286C16000922 gi|7499103|pir||T209TM ABC_tran, ABC_membrane7.5452833BE559681Hs 30736KIAA0124 proteinWD407.5417390AA196552Hs 85852hypothetical protein MGC31697.5427721AI582843Hs. 180455RAD23 (S. cerevisiae) homologubiquitin, UBA, integrin_B, 7.5450716T57758Hs 10255ESTs7.5407435AF211976gb Homo sapiens LENG9 mRNA, pa7.5413956AI821351Hs 193133ESTs, Weakly similar to ALU7_H7.5427899AA829286Hs 332053serum amyloid A1SS, SAA_proteins, SS, SAA_pr7.5406495Target ExonSRCR, TM, Acetyltransf7.5430387AW372884Hs 240770nuclear cap binding protein surrm, SS, TM, rrm7.5408601U47928Hs 86122protein ASS, 7tm_1, SS, ig, WD40, zf-UB7.5424364AW383226Hs 163834ESTs, Weakly similar to G01763SS, ras7.4409832AW963293gb EST375366 MAGE resequences, SS7.4448043AI458653Hs 201881ESTsPHD7.4421148AF008936Hs. 102178syntaxin 16Syntaxin, SS, Peptidase_M177.4420970AA305079Hs 1342cytochrome c oxidase subunit VCOX5B7.4419295BE397712Hs 144027ESTsmyb_DNA-binding, myh_DNA-b7.4448330AL036449ESTs7.4419639AK001502Hs 91753hypothetical protein7.4431488AB037785Hs 257594KIAA1364 proteinSS, CH, LIM, SS7.4456487AF064804suppressor of Ty (S. cerevisiae7.4448615AI910868Hs 212957ESTsSS7.4427433D82070Hs. 177972chromosome 4 open reading framSS, pkinase7.4441076N49809Hs 11197Homo sapiens, clone IMAGE 33437.4452554AW452434Hs 58006ESTs, Weakly similar to ALU5_HSS, PAS, HLH7.4411448AA178955Hs 271439ESTs, Weakly similar to I38022rrm, PDZ7.4442318AI792199ESTsSS, zf-C2H27.4425055AW961959Hs. 96940ESTs7.4412935BE267045Hs 75064tubulin-specific chaperone cSS, TM, transmembrane47.4403748Target ExonTM7.4447282AI989963Hs 197505ESTsTM7.3422305AI928242Hs. 293438ESTs, Highly similar to AF1984SS7.3416472AA180756Hs 340316ESTs, Moderately similar to ALzf-C2H27.3427273AW139032Hs 107376hypothetical protein DKFZp434NSS, SS, TM7.3412265AA101325Hs 86154hypothetical protein FLJ12457UPP_synthetase, HMG14_177.3447859AK002194Hs 19851peroxisomal biogenesis factor7.3432747NM_014404Hs. 278907calcium channel, voltage-depenPMP22_Claudin, SS, TM, PMP227.3406727AI219282Hs 2186eukaryotic translation elongatSS, G-gamma7.3404199ENSP00000211797*: Helicase SK12SS, RasGAP, PH, SS, PHD7.3445434BE391690Hs 9265hypothetical protein FLJ20917SS, PWWP, Exonuclease, lipoc7.2428550AW297880Hs 98661ESTsSS, homeobox, homeobox7.2454718AW815144gb: QV4-ST0212-120100-075-d10 SSS, ATP-synt_ab, ATP-synt_a7.2407686AW901268Hs 126043chromosome 21 open reading fraSS, TM, ISK_Channel7.2418304AA215702gb: zr97g10.r1 NCI_CGAP_GCB1 Hoserpin7.2424263M77640Hs. 1757L1 cell adhesion molecule (hydfn3, ig, IRK, SS, TM, fn3, ig, R7.2407581R48402Hs 173508P3ECSLSS, TM, 7tm_17.2430746AW977370Hs 222012ESTsSS7.2402651NM_000721* Homo sapiens calciuion_trans7.2407323AA181183Hs. 143504gb zp57c02.s1 Stratagene endotSS, Ribosomal_S4e, ubiquiti7.2407619AL050341Hs. 37165collagen, type IX, alpha 2SS, Collagen, SS, Collagen7.2434035AI762074Hs 204769ESTs, Weakly similar to T28770SS, TM7.2400419AF084545TargetEGF, ig, lectin_c, sushi, Xli7.2424241AW995948Hs 182339Homo sapiens pyruvate dehydrogSAM_PNT7.2445837AI261700ESTs7.2427725U66839Hs 180533mitogen-activated protein kinapkinase7.1421879AW959607gb: EST371677 MAGE resequences, 7.1418285H68616Hs 293756ESTsSS, EMP24_GP25L7.1442893H78133gb yu86c11.s1 Soares fetal liv7.1437829AI358522Hs 103834ESTs7.1450873BE464016Hs 238956ESTsSS, zf-C2H2, rrm7.1433396AI742071Hs 133205ESTsSS, TM7.1415595R54144Hs 278707chromosome 21 open reading fraSS7.1436629AA861011Hs 249795ESTsTM7.1414593BE386764gb: 601273249F1 NIH_MGC_20 Homo7.1422765AW409701Hs 1578baculoviral IAP repeat-containBIR, TK, SS, TM7.1419823AW271708Hs. 118918ESTs, Weakly similar to M2OM_HSS, TM7.1405247Target ExonSS7.1455778BE088746gb CM2-BT0693-210300-123-d09 B7.1431005AA490544Hs 127269ESTs, Weakly similar to T02345WD407.1435717AF227905Hs 105794UDP-glucose glycoprotein glucoGlyco_transf_87.1405113Target ExonSS7.1428070T63918Hs 182313retinol-binding protein 2, cellipocalin, lipocalin, WD407.1429029AA443443Hs. 85524for muscle specific ring fingeSS7.1430354AA954810Hs 239784human homolog of Drosophila ScSS, TM, ig7.0412970AB026436Hs. 177534dual specificity phosphatase 1Rhodanese, DSPc, SS, DSPc7.0438701AA937112Hs. 207788ESTsTM, sushi7.0454756AW819273gb: CM2-ST0284-061299-046-a12 S7.0401264C18000090*: gi|6678656|ref|NP_0SS, laminin_Nterm, laminin7.0408080AW149754Hs 248652ESTs, Weakly similar to T00273SS7.0418641BE243136Hs 86947a disintegrin and metalloprotedisintegrin, Reprolysin, Pe7.0431402AA743534Hs. 250861ESTs7.0423790BE152393gb: CM2-HT0323-171199-033-a08 HSS7.0450688AW272352Hs 60450ESTsTM7.0405928Target ExonSS, cystatin, Coprogen_oxid7.0454438AA224053cell division cycle 27SS, TM, SPRY, 7tm_3, _ANF_rece7.0407281AI307226Hs 164421ESTsSS6.9423386AW136098Hs 314081ESTsSS, WD40, EPO_TPO6.9459360BE384526Hs 25734gb 601277913F1 NIH_MGC_20 Homo6.9420187AK001714Hs. 95744hypothetical protein similar tank, TM6.9431549AA507036Hs 170673ESTs6.9423384AL133632Hs 127808Homo sapiens mRNA, cDNA DKFZp46.9454577AW809272gb MR4-ST0118-040100-034-c08_16.9438118AW753311ESTsSS lipocalin6.9416233AA176633gb zp13g01 s1 Stratagene fetal6.9417012N38970Hs 194214ESTs6.9452399BE513301Hs 29344hypothetical protein, clone 24SS, perilipin6.9439963AW247529Hs 6793platelet-activating factor acePAF-AH_Ib, Lipase_GOSL, SS, 6.9418416U11700Hs. 84999ATPase, Cu transporting, betaE1-E2_ATPase, HMA, Hydrolas6.9404956C1003210* gi|6912582|ref|NP_03PI3_PI4_kinase, PI3K_C2 PI6.9451606AA018791Hs 7945AIE-75 binding protein proteinSS6.9438525AW368528Hs 100855ESTsSS6.9400906C18000324* gi|12229928|sp|Q9PTW6.9411411AA345241Hs 55950ESTs, Weakly similar to KlAA13SS6.8406834AI318680gb: ta49g09 x1 NCI_CGAP_Lu25 Ho6.8414629AA345824Hs 76688carboxylesteruse 1 (monocyte/mSS, COesterase, SS, COestera6.8424198AB029010Hs 143026KIAA1087 proteinSS, TM, Na_Ca_Ex, Calx-beta, 6.8445873AA250970Hs. 251946poly(A)-binding protein, cytopSS, PABP, rrm, pkinase, 14-3-6.8439605AF086431Hs 22380ESTsSS, TM6.8432284AA532807Hs 105822ESTsSS, TM, pkinase6.8421904BE143533Hs 109309hypothetical protein FLJ200356.8443136NM_001440Hs 9018exostoses (multiple)-like 3Exostosin, SS, TM6.8421758BE397336Hs 1422Gardner-Rasheed feline sarcomaSH2, SH3, pkinase6.8448148NM_016578Hs 20509HBV pX associated protein-8PHD, Virus_HS, SS, ICln_chan6.8400205NM_006265* Homo sapiens RAD21SS6.8434315AW196608ESTs6.8418184AA367375Homo sapiens cDNA FLJ14015 fis6.8431898AK000020Hs 272018hypothetical protein FLJ200136.7438627AI087335Hs. 123473ESTsTM, Reticulon6.7409649AA159216Hs 55505hypothetical protein FLJ20442Y_phosphatase, DSPc, TM6.7429712AW245825Hs 211914ENSP00000233627* NADH-ubiquinooxidored_q6, SS, TM, rrm6.7456886AW089093Hs 144996ESTs, Weakly similar to I380226.7427461AA531527Hs. 332040hypothetical protein MGC13010SS, TM, ACAT, LRR6.7434000BE002846Hs 112964ESTs6.7432530AF131786Hs 278303Homo sapiens clone 25220 mRNASS, proteasome6.7436141AA970001Hs 150319Homo sapiens, clone IMAGE 3610SS, TM6.7441794AW197794ESTs6.7450287AW291483Hs 255909ESTs6.7441523AW514263ESTs, Weakly similar to ALUF_HSS6.7452798AI918771Hs 257170ESTsSS, TM, TNFR_c66.7451937AF119664Hs 27299transcriptional regulator protSS, integrin_B, fn3, Calx-be6.7421417AA291004Hs 326088ESTs6.7440317BE561888gb 601346093F1 NIH_MGC_8 Homo6.7421321NM_005309Hs. 103502glutamic-pyruvate transaminaseaminotran_2, SS, TM, LRR6.7444904AW452054Hs 161139ESTs6.7449730R72290Hs 117557ESTs, Weakly similar to I38022RasGAP, thyroglobulin_1, Ri6.7450622AI660285Hs. 58210ESTs, Highly similar to |TH4_HSS, TM, vwa6.7425424NM_004954Hs 157199ELKL motif kinasepkinase, KA1, UBA, SS6.7435864AL036499Hs 188491ESTs6.7410397AF217517Hs 63042DKFZp564J157 proteinSS, homeobox, UPF0160, DUF236.7454262AW612232Hs. 254835ESTsSS, TM, voltage_CLC, CBS6.7453023AW028733Hs. 31439serine protease inhibitor, KunKunitz_BPTI, SS, TM, ion_tra6.6419157AA234540Hs 23871ESTspkinase6.6412464T78141Hs 22826ESTs, Weakly similar to I55214SS, cadherin, crystall6.6407332AI801565Hs 200113Homo sapiens cDNA FLJ379 fisSS, adh_short, Transglutami6.6456643AW751497Hs 98370cytochrome P450, subfamily IIS6.6411490R39474gb yh95b09 r1 Soares placentaSS6.6455885BE153524gb PM0-HT0339-241199-002-C03 HSS, pkinase6.6438857AI627912Hs 130783Forssman synthetaseSS, RA, RasGEF, RasGEFN6.6420307AW502869Hs 66219ESTsSS, TM6.6453496AA442103Hs 33084solute carrier family 2 (facilsugar_tr, SS, TM6.6419182AA234822Hs 66147ESTsES, TM, ion_trans, ion_trans6.6406301Target ExonTM6.6433938AF161536Hs 284292ubiquinol-cytochrome c reductaTM6.6448980AL137527Hs 289038hypothetical protein MGC41266.6454095AW178110Hs 191705gb IL3-HT0061-010999-013-H04 HSS, TM, homeobox, trypsin, PD6.6459702AI204995gb an03c03.x1 Stratagene schiz6.6422201NM_001505Hs. 113207G protein-coupled receptor 307tm_1, SS, TM6.6406779AA412048Hs. 279574CGI-39 protein, cell death-regSS, SS6.6404149C6002509*: gi|5031885|ref|NP_00SS, TM, kringle6.6418576AW968159Hs. 302740Epithelial calcium channel 2, SS, TM6.6421363NM_001381Hs 103854docking protein 1, 62 kD (downsPH, IRS, TM, PH, IRS, trypsin, 6.6458919AI681567Hs. 13349KIAA0756 proteinTM6.6427502AI811865Hs 7133Homo sapiens, clone IMAGE 3161SS, TM, ABC_tran, Glyco_tran6.5412289AW935967Hs 170162KIAA1357 proteinSS6.5447105AW377610Hs 11123DKFZP564G092 proteinSS, TM6.5444672Z95636Hs 11669laminin, alpha 5laminin_EGF, laminin_G, EGF6.5429299AI620463Hs 347408hypothetical protein MGC13102SS, TM, gla6.5420003AA256906Hs 111364ESTs, Weakly similar to ubiquiSS, TM6.5431849AI670823Hs. 85573hypothetical protein MGC10911SS, TM6.5430396D49742Hs. 241363hyaluronan-binding protein 2trypsin, kringle, EGF, SS6.5437662AA765387ESTsWD40, RCC1, SPRY6.5436543NM_002212Hs 5215integrin beta 4 binding proteieIF66.5405375CX000741* gi|4885461|ref|NP_00SS, TM6.5430116AA465350Hs. 119400ESTsSS, TM, adh_short6.5406109Target Exon6.5414871BE549179Hs 29008gb 601078714F1 NIH_MGC_12 Homo6.5440656AI979248Hs 148221ESTs6.5438951U51336Hs 6453inositol 1,3,4-triphosphate 5/SS, oxidored_nitro, SS6.5405376Target ExonSS, TM6.5426925NM_001196Hs 315689Homo sapiens cDNA FLJ22373 fiSS6.5400500Target Exon6.5408294BE141732gb QV0-HT0101-061099-032-e07 HAmmonium_transp6.5447904AW206303ESTs6.4439211AI890347Hs 271923Homo sapiens cDNA FLJ22785 fiSS6.4426828NM_000020Hs 172670activin A receptor type II-likpkinase, Activin_recp, SS, T6.4446100AW967109Hs. 13804hypothetical protein dJ462O23SS, TM6.4442146R52599gb: yg81g01 r1 Soares infant brTM6.4425041AI377150Hs 150914ESTsSS6.4457584AA147979Hs 285005mitochondrial import receptorJosephin6.4435449AA682379Hs 303460EST6.4406284Homo sapiens mRNA full length6.4425944AK000664Hs 164256hypothetical protein FLJ206576.4453367AW732847Hs 70573PKCI-1-related HIT proteinSS, TM6.4419725U66048Hs 92683Homo sapiens clone 161455 brea6.4412452AA215731suppression of tumorigenicitySS6.4421273AJ245416Hs 103106U6 snRNA-associated Sm-like prSm, SS, tRNA-synt_1, GST_C, G6.4432746AA564512Hs. 24301polymerase (RNA) II (DNA direcSS, TM, EF1BD6.4429398AA452239KIAA0970 protein6.4404430C8000066*: gi|10432395|emb|CAC1SS6.4427339AI734109Hs 97984SRY (sex determining region Y)6.4436389AI811706CHMP1 5 protein6.4428890AA525226Hs 303293ESTs, Moderately similar to I56.4445333BE537641Hs 44278hypothetical protein FLJ12538SS6.4414756AW451101Hs. 159489ESTs, Moderately similar to JChexokinase2, hexokinase6.4423847U16997Hs 133314RAR-related orphan receptor Chormone_rec, zf-C4, SS, TM, h6.4408493BE206854Hs 46039phosphoglycerate mutase 2 (musPGAM, BRCT, RNA_pol_L6.4439569AW602166Hs 222399CEGP1 proteinCUB, EGF, SS6.4457274AW674193Hs 227152mannan-binding lectin senne pSS, TM, SS, TM, Clathrin_lg_c6.4444550BE250716Hs 87614ESTsSS6.4407198H91679gb yv04a07.s1 Soares fetal livBIR6.4423228AL137491Hs 125511Homo sapiens mRNA, cDNA DKFZp4SS, TM, sushi6.4422682W05238Hs 94316ESTs, Weakly similar to T31613SS, TM, DEAD, helicase_C, Lam6.3447887AA114050Hs. 19949caspase 8, apoptosis-related cICE_p20, DED, ICE_p106.3400137Eos Control6.3408784AW971350Hs 63386ESTsSS6.3435028AW193035Hs 187370ESTs6.3438113AI467908Hs 8882ESTsSS, TM, 7tm_16.3417810D28419Hs 82609hydroxymethylbilane synthasePorphobil_deam6.3436050AI057205Hs 14584ESTs6.3403672C4001244: gi|539933|pir||A61275tubulin, TM6.3448269BE622358Hs. 61260hypothetical protein FLJ131646.3430217N47863Hs 180450ribosomal protein S24Ribosomal_S24e6.3426675AW084791Hs 133122hypothetical protein FLJ14524SS, TM, aminotran_1_26.3423510AB000824Hs. 129712trehalase (brush-border membraTrehalase6.3428573AA430651Hs 209249ESTs6.3457052BE167242Hs 47099hypothetical protein FLJ21212SS6.3445099BE163341gb: QV3-HT0458-230200-099-b01 H6.3450334AF035959Hs 24879phosphatidic acid phosphatasePAP2, SS6.3416000R82342Hs 79856ESTs, Weakly similar to S65657SS, TM, sugar_tr6.3427880AA436011Hs 98187ESTs6.3426722U53823Hs 171952occludinOccludin, SS, TM, BIR6.3452072BE258857Hs 27744RAB3A, member RAS oncogene famras, arf, SS, PDEase6.2431161AA493591gb: nh01a12 s1 NCI_CGAP_Thy1 HoSS6.2413055AV655701Hs 75183cytochrome P450, subfamily IIEp4506.2431250BE264649Hs 251377taxol resistance associated ge6.2406373Target ExonSS, TM, vwa, FG-GAP, integrin6.2403003NM_024944*: Homo sapiens hypothTM6.2437834AA769294gb: nz36g03 s1 NCI_CGAP_GCB1 HoSS6.2406299Target Exon6.2439327AF086141Hs. 50760ESTs, Highly similar to BimL [SS6.2414246BE391090Hs 280278EST6.2427812AA770424Hs 98162ESTsSS6.2420926AA830402Hs 221216ESTsUQ_con6.2443766N91071Hs 109650ESTs6.2431082AA491600gb: ne80a11.s1 NCI_CGAP_Ew1 Hom6.2420530AI218431coagulation factor VIII-associ6.2407360X13075gb Human 2a12 mRNA for kappa-i6.2449008AW578003Hs 22826tropomodulin 3 (ubiquitous)6.2409946AW162263Hs. 312468ESTs, Weakly similar to ALUC_HRasGAP, C2, PH, BTK6.2413272AA127923ESTsSS6.2445050AW205483Hs 147260ESTsSS, trypsin, kringle, fn2, EG6.2458130AA115811Hs 6838ras homolog gene family, memberas, arf6.2449940AW291126Hs. 187520Homo sapiens, clone IMAGE: 3834SS, zf-C2H26.2440390AW207385Hs 36475KIAA0493 protein6.2423106N52572Hs 13702ESTs, Moderately similar to AL6.2402501sperm specific antigen 2ig, MHC_I, SS6.1431470AA832417Hs. 139650ESTsSS, ig, pkinase, LRR, LRRCT6.1416597H66891gb yr71c03 r1 Soares fetal liv6.1412122AW852707G-rich RNA sequence binding faSS, WD406.1415056AB004662Hs 77867adenosine A1 receptor7tm_1, SS, TM6.1400358AF181286Homo sapiens mutant dystrophin6.1405473NM_001093*: Homo sapiens acetylCPSase_L_chain, biotin_lip6.1422625AW504698Hs 155976cullin 4BSS, SS, Cullin, Cullin6.1422262AL022315Hs 113987lectin, galactoside-binding, sGal-bind_lectin6.1401121C12001638* gi|7291960|gb|AAF476.1425188AK002052Hs 155071hypothetical protein FLJ11190TM6.1457216AA452554Hs. 283697ESTs, Weakly similar to A41796bZIP_Maf, SS, P5CR, EF1BD6.1456021BE246628Hs. 250726gb TCBAP1D5030 Pediatric pre-BSS, TM, SS6.1420319AW406289Hs 96593hypothetical proteinras, arf6.1410082AA081594Hs 158311Musashi (Drosophila) homolog 1SS, HECT, phoslip6.1450593AF129085Hs 25197STIP1 homology and U-Box contaTPR, SS, TM, Rhomboid, lactam6.1437050AA766420ESTsSS6.1458835AI868753Hs 76372ESTsSS6.1412777AI335773ESTs6.1454364BE263928Hs 323806gb 601191272F1 NIH_MGC_7 HomoSS, TM6.1448877AI583696Hs 253313ESTs6.1413045X92121Hs 75180protein phosphatase 5, calalytMetallophos, TPR6.1408054AW816490Hs 8102ESTs6.1417852AJ250562Hs. 82749transmembrane 4 superfamily metransmembrane4, SS, TM6.1410445AA199830gb zq75h01 r1 Stratagene hNT n6.1415870H15578Hs 21017ESTs6.1438723M34429gb Human PVT-IGLC fusion prote6.1441307AW071696Hs. 209065hypothetical protein FLJ14225SS, TM6.0406575Target ExonSS, pkinase, pkinase_C, RFX6.0401488Target ExonGlyco_hydro_16.0437650AA814338Hs 292297ESTs6.0439827AA846538Hs 187389ESTspkinase, DAG_PE-bind, PH6.0456373BE247706Hs 89751membrane-spanning 4-domains, sSS, TM6.0454513BE159271Hs 109731gb MR0-HT0407-180100-004-h05 H6.0414944C15044gb: C15044 Clontech human aortaSS, TM6.0451277AK001123Hs 26176hypothetical protein FLJ10261TM, SS, TM, death, DED6.0421190U95031Hs 102482mucin 5, subtype B, tracheobroCys_knot, vwc6.0401215C12000457* gi|7512178|pir||T30trypsin, SS, TM6.0408117AL138255ESTs, Weakly similar to I38022SS, zf-C3HC4, BIR6.0426357AW753757Hs 12396gb RC3-CT0283-271099-021-a08 C6.0418630AI351311Hs 251946poly(A)-binding protein, cytopSS, pkinase6.0400389AL135841olfactory receptor, family 2, 7tm_1, SS, TM, CSD6.0447128AI271898cyclin K6.0431297AA651771Hs 3076ESTs6.0431857W19144Hs 271742ADP-ribosyltransferase (NAD, pPARP, PARP_reg, SS, TM, Pepti6.0430023AA158243Hs 227729FK506-binding protein 2 (13 kD)SS, FKBP, SS, PDGF, C2, PI-PLC6.0453101AW952776Hs. 94943ESTsTM6.0407383AA532576ESTs, Moderately similar to ALSS, Patatin, ank6.0430132AA204686Hs 234149hypothetical protein FLJ20647SS, SS, TM, ig6.0459111AU077013Hs 28757transmembrane 9 superfamily meEMP706.0405770NM_002362 Homo sapiens melanomMAGE6.0415611T26376gb: AB123C11R Infant brain, LLNSS, TM, rrm, sushi6.0453413AJ003294gb: AJ003294 Selected chromosomSS, Folate_carrier6.0424415NM_001975Hs. 146580enolase 2, (gamma, neuronal)enolase, SS, Atrophin-1, Atr5.9426048AI768853Hs 134478ESTsTM5.9435750AB029012Hs 4990KIAA1089 proteinSS, TM5.9439469W69836gb zd48a02 r1 Soares_fetal_heaSS, pkinase, C2, pkinase_C, D5.9445664AW968638Hs. 237691ESTs, Weakly similar to KIAA065.9418830BE513731Hs. 88959hypothetical protein MGC4816TM, CDP-OH_P_transf5.9452113AI859393gb wm11a02.x1 NCI_CGAP_Ut4 Homactin5.9449101AA205847Hs 23016G protein-coupled receptor7tm_1, SS, TM5.9437640AA764893Hs. 272155ESTs, Weakly similar to I380225.9400748NM_022122. Homo sapiens matrixSS, Peptidase_M10, hemopexi5.9442370AI143593Hs 129419ESTs5.9442419AI749893Hs 270532ESTs, Weakly similar to I38022Adaptin_N, Alpha_adaptinC25.9439986AW750272Hs. 128608ESTsSS, TM, ISK_Channel5.9407553Z11168gb: H. sapiens 5HT1A receptor reSS, TM5.9431424AI222969ESTsSS5.9442297NM_006202Hs 89901phosphodiesterase 4A, cAMP-spePDEase5.9457845H93040Hs 297729ESTsSS, TM, WD405.9446912AI347650Hs. 128521ESTs, Moderately similar to ALSS5.9451381BE241831Hs 172330hypothetical protein MGC2705SS, Ribosomal_L28e5.9416024AW886484Hs 343522ATPase, Ca transporting, plasmE1-E2_ATPase, Hydrolase, Ca5.9446329NM_013272Hs 14805solute camer family 21 (orgakazal, OATP_N, OATP_C5.9431321AW136372Hs 1852acid phosphatase, prostateSS, TM, acid_phosphat5.9420039NM_004605Hs 94581sulfotransferase family, cytosSulfotransfer, SS, DAGKc5.9428223AA424313Hs 98402ESTsHECT5.9433333AI016521Hs. 71816v-akt murine thymoma viral onchomeobox, pkinase, PH, pkina5.9450251BE080483gb QV1-BT0630-280200-086-a05 BSS5.9408511AW206404Hs 27268ESTs5.9414348AF041430Hs 75922brain protein I3SS, SH35.9456950AF111170Hs. 306165Homo sapiens 14q32 Jagged2 genSS, TM, DSL5.9412173T71071gb yc50b05.r1 Stratagene liverCPSase_L_chain5.8404001Target Exon5.8445263H57646Hs. 42586KIAA1560 proteinSS5.8441583AI791499Hs 205742ESTs, Weakly similar to ALUA_H5.8430168AW968343DKFZP434I1735 proteinSS, TM, efhand, efhand5.8454682AW816029gb: MR3-ST0220-151299-027-b10 Sfilament5.8453829AL138200gb: DKFZp547N052_r1 547 (synonySS, TM, ATP-synt_C, Galactos5.8437372AA323968Hs 283631hypothetical protein DKFZp547GSS5.8421726AK001237Hs 319088hypothetical protein FLJ10375TM5.8451045AA215672gb zr96e09 s1 NCI_CGAP_GCB1 HoSS, Peptidase_C1, zf-C2H25.8439616BE018635Hs 58582Homo sapiens cDNA FLJ12789 fisSS, TM5.8455679BE066529gb RC3-BT0333-300300-017-a12 BUBX5.8457125AW444451Hs 134812ESTsSS5.8430600AW950967Hs. 274348HLA-B associated transcript-3ubiquitin, SS, TM, G-patch, a5.8421707NM_014921Hs 107054lectomedin-2Latrophilin, OLF, 7tm_2, Gal5.8436127W94824Hs 11565RIKEN cDNA 2010100O12 geneCorona_7, SS, TM5.8414347BE275835gb: 601121639F1 NIH_MGC_20 HomoSS5.8439910H66765Hs 339397ESTsSS5.8410382AW664971Hs 259546ESTsLIM5.8426391AW161050Hs 169611second mitochondria-derived acSS5.8423358AI815474Hs. 343866gb au47f10.y1 Schneider fetalSS5.8440146AW014231Hs 90790Homo sapiens cDNA FLJ22930 fiPeptidase_M15.8402189ENSP00000247423*: D-siglec prec5.8439949AW979197Hs 292073ESTs, Weakly similar to ALU7_H5.8457978AA776638gb ae78g04 s1 Stratagene schizSS, PH, IQ, RasGEF, RasGEFN, R5.8436685W28661Hs 5288Homo sapiens mRNA, cDNA DKFZp4SS, TM, pkinase, Activin_rec5.8411602L01406Hs 767growth hormone releasing hormo7tm_2, HRM5.8433357T05639gb: EST03528 Fetal brain, StratSS5.8404311Target ExonTM5.8428092AW879141ESTsSS, TM5.8452620AA436504Hs 119286ESTsSS5.8401938Target ExonSS, PHD, proteasome5.7407202N58172Hs. 109370ESTsSS, F5_F8_type_C, pkinase, E5.7458882R34993Hs 226666ESTs, Moderately similar to I5SS, CRAL_TRIO, PKI5.7452357AI638176Hs 283865ESTsSS, TM, SS, TM5.7452625AA724771Hs 61425ESTs5.7430281AI878842Hs. 237924CGI-69 proteinmito_carr, SS, TM5.7430490AW902951Hs 301723Homo sapiens cDNA FLJ12974 fisTM5.7450122BE313765Hs 343443ESTs, Weakly similar to I38022SS, TM, Y_phosphatase, LON, A5.7450801AI739013Hs 203348ESTsSS, TM, Hint, HH_signal5.7413413D82520Hs 132390zinc finger protein 36 (KOX 18SS, rrm, DUF1855.7445631AK001822Homo sapiens cDNA FLJ10960 fis5.7419390AI701162Hs. 90207hypothetical protein MGC11138SS, TM, PMP22_Claudin, PMP225.7423139AW402725Hs 288560hypothetical protein FLJ211065.7426221AB007881KIAA0421 proteinPI3_PI4_kinase, FATC, SS, TM5.7443785AW449952Hs 190125basic-helix-loop-helix-PAS pro5.7417900BE250127Hs 82906CDC20 (cell division cycle 20, WD40, SS, TM, fn3, EGF, fn3, ig5.7446596AW204515Hs 156113ESTs, Weakly similar to G010255.7432353NM_016558Hs 274411SCAN domain-containing 1SCAN5.7427625AF008216Hs 285013putative human HLA class II as5.7421543AK000519Hs 105606hypothetical protein FLJ20512TM5.7418087AA961613Hs 127838ESTs5.7432751AF152099Hs 278911interleukin 17CSS5.7433943AA992805Hs. 44865lymphoid enhancer-binding fact5.7414274AW300961Hs 334684Homo sapiens, clone IMAGE 4127SS, Vps26, Acyl-CoA_dh5.7431328AA502999Hs 291591ESTs5.7451481AA300228Hs 295866hypothetical protein DKFZp434N5.7430344AA476827Hs 171012hypothetical protein FLJ22349HLH5.6419516H82550ATP-binding cassette, sub-famiSS, TM, ABC_tran, ABC_membra5.6413564BE260120gb 601146990F1 NIH_MGC_19 Homo5.6415958H10942gb ym06c11 r1 Soares infant brSS, TM5.6401402Target Exon5.6456145BE299427Hs 21446KIAA1716 proteinSS, DIX, PDZ, DEP, Dishevelle5.6431536AL133066Hs. 341906ESTsTM, SAM_decarbox, SS, pkinas5.6456266L29073Hs 198726cold shock domain protein ACSD, homeobox, SS, TM, 7tm_2, 5.6435800AI248285Hs 118348ESTsTM, ECH, chromo5.6449285AI912702Hs. 139135ESTs5.6418256AW845318Hs 12271f-box and leucine-nch repeatSS, SS, TM, HSF_DNA-bind5.6417442AA199940Hs 124039ESTs5.6405931Target Exon5.6455286BE144384gb: MR0-HT0166-191199-004-c11 HSS5.6446931AI348856Hs 21627gb tb05a05 x2 NCI_CGAP_Lu26 Ho5.6446548AI769392Hs 200215ESTsSS, TM, Ribosomal_S25, sugar5.6401984C17000146* gi|2143629|pir||A57pkinase, SS, TM, P2X_recepto5.6404066Target ExonSS, tRNA-synt_2b, HGTP_anti5.6418363AA218628Hs 202977ESTs5.6458198AI286100ESTs5.6432278AL137506Hs. 274256hypothetical protein FLJ23563SS, TM, GNS1_SUR4, SS, TM, Rho5.6432328AI572739Hs 1954716-phosphofructo-2-kinase/fructPGAM, 6PF2K5.6421871AK001416Hs 306122glycoprotein, synaptic 2TM, Steroid_dh, SS5.6415514F11301Hs 138329ESTsSS, TM5.6426208AI370379Hs 132216ESTsSS, TM5.6429367AB007867Hs. 278311plexin B1Sema, PSI, TIG, SS, TM, TIG, Se5.6405939Target Exon5.6457331AV647405Hs 18443aldehyde dehydrogenase 8 familGTP_EFTU5.6438705AI049624Hs 283390ESTs, Weakly similar to 210926SS, E2F_TDP, E2F_TDP5.6428624AI125222Hs 98712hypothetical protein DKFZp434HSS, TM, ras, MSP_domain5.6419389AI074951Hs 319095ESTsSS, DPPIV_N_term5.6447595AW379130Hs. 18953phosphodiesterase 9APDEase5.6408015AW136771Hs 244349epidermal differentiation comp5.6413041BE061580Hs 61622gb MR0-BT0249-091299-201-c07 BSS5.5452849AF044924Hs 30792hook2 proteinbZIP, SS, AhpC-TSA5.5434357AW732284Hs 3828mevalonate (diphospho) decarboGHMP_kinases, SS, TM5.5455274BE151622gb: PM0-HT0302-271099-001-a08 HSS, TM, RNA_pol_L5.5453904AW003821ESTs5.5424624AB032947Hs 151301Ca2+dependent activator proteiFork_head5.5426576AA381720gb EST94853 Activated T-cellsvwa, integrin_A, FG-GAP5.5440682AW362152Hs. 27181nuclear receptor binding facto5.5419125AA642452Hs 130881B-cell CLL/lymphoma 11A (zincSS5.5450207T87615Hs 14716ESTs5.5405211C7000900 gi|4508027|ref|NP_003SS5.5413937H65775Hs 207915ESTs5.5426793X89887Hs 172350HIR (histone cell cycle regulaWD40, Clathrin, Clathrin_pr5.5412091R06185gb: ye94d03 r1 Soares fetal livSS, TM, IBR, IBR5.5446536W74413Hs 15251hypothetical proteinSS5.5451117AA015752Hs 205173ESTs5.5409547AW409885Hs 335877Homo sapiens, clone MGC 4558, TM5.5412673AL042957Hs. 31845ESTs5.5426440BE382756Hs 169902solute carrrier family 2 (facilsugar_tr, SS, TM, sugar_tr5.5449225R39108Hs 6777ESTsSS, TM, Na_sulph_symp5.5403938Target ExonEphrin5.5441197BE244638Hs 166sterol regulatory element bindHLH5.5455604BE011183gb PM3-BN0218-100500-003-d09 B5.5457468AW971345Hs 292715ESTs5.5447677AI419235Hs 344456gb tf21d02.x1 NCI_CGAP_Brn23 HSS, zf-C2H2, SCAN, SCAN, zf-C5.5415473R39986Hs 12778ESTsTM, ion_trans5.5408422AW977031Hs. 143554ESTs, Highly similar to B450365.5442780AI017521ESTsSS, TM, 7tm_15.5451558NM_001089Hs 26630ATP-binding cassette, sub-famiABC_tran, SRP54, SS, TM, ECH5.5439422AW452791Hs 249625ESTsSS, TM5.5423479NM_014326Hs 129208death-associated protein kinaspkinase5.5459558AI539821Hs 298799ESTs, Weakly similar to 210926SS5.5441187AW195237Hs 7734hypothetical protein FLJ22174SS, TM, tubulin5.5420894AA744597Hs 88854ESTsSS, ank5.5404710C9001584: gi|7499208|pir||T20995.5447827U73727Hs 19718protein tyrosine phosphatase, Y_phosphatase, fn3, ig, MAM, 5.5448387AI874402Hs. 292590ESTs5.5419541AW749617Hs 280776tankyrase, TRF1-interacting an5.5449686AW072813Hs 270868ESTs, Moderately similar to AL5.5426315AA854219Hs 348137Homo sapiens, clone IMAGE 3542SS, crystall5.5451312AI769831Hs 337054ESTsSS5.5432538BE258332Hs. 278362male-enhanced antigenSS, TM, AAA, Ribosomal_L25.5446790AW452105ESTsSS, zf-C2H25.5448682T09471Hs 250820hypothetical protein FLJ148275.5425234AW152225Hs 165909ESTs, Weakly similar to I38022SS5.5411219AW832917gb QV2-TT0003-161199-013-h06 T5.5439742AI827721Hs. 284298Homo sapiens mRNA full lengthSS5.5432004BE018302Hs. 2894placental growth factor, vascuPDGF, SS5.5402916ENSP00000202587*: Bicarbonate tHCO3_cotransp, SS5.5405346Rag C proteinRCC15.5415976R43144Hs. 21919ESTsTM5.4435064T70740Hs 31433ESTsSS, MDM25.4440024AA969333Hs 160098ESTs5.4431525AA506656Hs 6185KIAA1557 protein5.4458644AW270149ESTs, Moderately similar to GG5.4410895AW809679gb MR4-ST0124-261099-015-f05 S5.4441350AB020690Hs 7782paraneoplastic antigen MA25.4413034BE392896Hs 129126Homo sapiens, clone MGC. 10992, SS5.4444664N26362Hs. 11615map kinase phosphatase-like prDSPc, Rhodanese, SS, TM5.4443887NM_004729Hs. 9933Ac-like transposable elementzf-BED5.4445871AI702901Hs 145582ESTs, Weakly similar to FOR4 MSS, TM, efhand, efhand5.4411992AW816214Hs 143055ESTsSS, TM5.4458341AW373583Hs. 221994gb QV4-BT0534-281299-053-e08 B5.4451677AA059222Hs 33538ESTs, Weakly similar to oxygen5.4432656NM_000246Hs 3076MHC class II transactivatorLRR5.4417739Z43995gb HSC1QB121 normalized infantSS, ArfGap, vwa, TSPN, fn3, Co5.4424618L29472Hs 1802major histocompatibility complTM, ig, MHC_II_beta, SS, TM, A5.4446847T51454Hs 82845Homo sapiens cDNA FLJ21930 fiSS, TM, BNR, fn3, ldl_recept5.4436094AI798701ESTs5.4433168AI085436gb ow84g06 s1 Soares_fetal_livSS, TM, PID5.4417359T99264Hs 191117ESTs5.4436014AF281134Hs 283741exosome component Rrp46RNase_PH, RNase_PH_C, SS, TG5.4435154AA668764Hs 301637ESTsSS, TM5.4431630NM_002204Hs 265829integrin, alpha 3 (antigen CD4integrin_A, FG-GAP, Rhabd_g5.4444064W85970Hs 16292ESTsSS, TM, Dihydroorotase5.4415970H23333Hs. 29002KIAA1706 protein5.4445303AW362198Hs 12503interleukin 15 receptor, alphaSS, sushi, SS5.4421542AA411607Hs 118964ESTs, Weakly similar to KIAA11SS, SS5.4459704AA719572Hs 274441Homo sapiens mRNA, cDNA DKFZp45.4402285sclerostinSS, TM5.4431543AW969619Hs. 259768adenylate cyclase 1 (brain)TM5.4431534AL137531Hs 258890Homo sapiens mRNA, cDNA DKFZp4SS, TM, ras5.4417516AA203473Hs 81529ESTsTM5.4423233BE048021Hs 11067ESTs, Highly similar to T463955.4420733AW291446Hs 88651ESTsSS5.4404807Target ExonUPF00275.4436483AJ272063Hs 283010vanilloid receptor subtype 1SS, TM, ank, ion_trans, SS, TM5.4425316AA354977Hs. 99010ESTs, Moderately similar to T1SS, pkinase, ig5.4425565AA359485Hs. 173084gb EST68511 Fetal lung II Homo5.4413341H78472Hs 191325ESTs, Weakly similar to T189675.4401203Target Exonfilament5.4422452AL110255Hs. 116808Homo sapiens mRNA, cDNA DKFZp5SS, asp, PGAM5.4436718AW015227Hs 289053hypothetical protein FLJ14733SS, TM5.4428501AL041162Hs 98587ESTsTM5.4439695W28548Hs 285050ESTsTM, ion_trans, K_tetra, Kv2c5.3417514AA203445Hs 325819ESTs5.3441358AW173212ESTs5.3401722Target ExonTM, PLAT, SS5.3408905AV655783Hs 661Target CAT5.3454453AW752781hypothetical protein FLJ126145.3410312AW850953Hs 75350gb IL3-CT0220-150200-068-A11 CVinculin5.3437926BE383605Hs 300816small GTP-binding proteinSS, TM, TPR5.3458682AV659151Hs 282961ESTs5.3411605AW006831ESTsTM, synaptobrevin5.3409164AA706639gb: ag90e09.r1 Stratagene hNT nSS, TM, Hint, HH_signal, tubu5.3438868AW246243Hs 334800hypothetical protein FLJ209745.3439034AF075083gb: Homo sapiens full length infilament, filament5.3411426BE141714gb: QV0-HT0101-061099-032-c04 HSS5.3428186AW504300Hs 295605mannosidase, alpha, class 2A, Glyco_hydro_38, SS, TM, Pept5.3438470AW936329Hs. 227823pM5 proteinSS, TM5.3427789AA412428Hs 48642hypothetical protein FLJ230935.3430230BE257724Hs 236361seb4Drrm, SS, 2-Hacid_DH, WD405.3434314BE392921Hs 3797RAB26, member RAS oncogene farmras, arf, SS5.3428539AW410063Hs 184877solute carrier family 25 (mitomito_carr, SS, TM, profilin, 5.3414927T83587Hs 186476ESTsSS, Sulfatase5.3404596Target ExonSS5.3454151AA047169Hs. 154088hypothetical protein FLJ22756SS, TM, Glycos_transf_45.3431627AW609720HSPC042 protein5.3422379AA932860Hs 133864ESTs5.3426765AA743603Hs 172108nucleoporin 88 kDMAM335.3433325AW206986Hs 143905ESTsSS5.3403128KIAA1033 proteinSS, TM, tubulin, EGF, F5_F8_t5.3447730AI421251Hs 114085Homo sapiens mRNA for KIAA1755SS, Transglutamin_C, Transg5.3405085Target ExonSS, SS, SNF2_N, helicase_C5.3438080AA777381Hs 291530ESTs, Weakly similar to ALUC_H5.3439091AA830144Hs. 135613ESTs, Moderately similar to l3KH-domain5.3427326AI287878gb: qv23f06 x1 NCI_CGAP_Lym6 HoSS, TM, 7tm_1, SS, TM5.3427859AA416856Hs 98170ESTsSS, TM, DUF60, trypsin, CUB, u5.3421779AI879159Hs 108219wingless-type MMTV integrationSS, wnt, SS5.3408270AW177805gb IL3-HT0059-180899-007-B06 H5.3418437AA771738Hs. 348000ESTs, Moderately similar to AL5.3409879BE083422Hs. 56851hypothetical protein MGC2668SS, TM5.3428304AI743177ESTsSS, TM5.3418678NM_001327Hs 167379cancer/testis antigen (NY-ESO-SS, TM, zf-C2H25.3436540BE397032Hs 14468hypothetical protein MGC14226SS, TM5.2437161AA054477Hs 25391ESTsSS, TM5.2400171ENSP00000211797: Helicase SKI2WSS, proteasome5.2431461BE299671Hs. 256310likely ortholog of mouse ZFP285.2402197Target ExonSS, TM, ATP1G1_PLM_MAT8, ig, 5.2449514AW970440Hs 23642protein predicted by clone 236SS, PX, arf, lipocalin, PHD, z5.2442472AW806859gb: MR0-ST0020-081199-004-c03 SSS, TM, lnos-1-P_synth, Occl5.2409679BE250521ras homolog gene family, membeSS, homeobox, CUT5.2439150AF086006gb: Homo sapiens full length inSS5.2412934BE011437gb CM4-BN0220-080500-170-f03 B5.2435186AL119470ESTsSS5.2400668Target ExonCARD, ICE_p20, SS, ICE_p20, I5.2409125R17268Hs 343567axonal transport of synaptic vSS, kinesin, PH, FHA, kinesin5.2445904AW449920Hs 248855ESTsSS, homeobox5.2414567BE281057Hs. 184519hypothetical protein FLJ12949SS, TM, ank, Adap_comp_sub5.2414551AI815639Hs. 76394enoyl Conezyme A hydratase, shECH, Peptidase_U7, SS, TM5.2432872AI908984Hs 279623selenoprotein X, 1DUF25, SS, Ribosomal_L3, PDZ5.2419492AA243547Hs 19447PDZ-LIM protein mystiqueLIM, SS, SH3, Sorb, Metalloph5.2407478L77559gb Homo sapiens DGS-B partial5.2457892AA744389gb ny51e10 s1 NCI_CGAP_Pr18 Ho5.2457228U15177Hs 206984Human cosmid CRI-JC2015 at D106PF2K, PGAM5.2437536X91221Hs 144465ESTsSS, TM, Na_Ca_Ex5.2420285AA258124Hs 293878ESTs, Moderately similar to ZN5.2431275T56571Hs 10041ESTsSS, HLH5.2428021AI022287Hs 111991ESTs, Weakly similar to T33900SS5.2422400AA974434Hs 128353ESTs5.2446442BE221533Hs. 257858ESTs5.2415585R59946Hs 184852KIAA1553 proteinSS5.2438429D16918Hs 12547Homo sapiens cDNA FLJ233888 fiTM5.2401677BAI1-associated protein 3SS, TM, zf-C2H2, kinesin, Vau5.2405637Target Exon5.2450437X13956Hs 24998hypothetical protein MGC10471SS5.2408215BE614290syntaxin 10SS, SS, TM, HLH, TRM, zf-CCCH5.2452666AW194601Hs 13219ESTsPI-PLC-X, PI-PLC-Y, C2, PH5.2401553Target Exon5.2447541AK000288Hs 18800hypothetical protein FLJ20281zf-CCHC5.2453434AJ271378Hs 333243ESTs5.2450351BE547267Hs 59791hypothetical protein MGC13183SS, TM5.2411456AW847588gb IL3-CT0213-161299-038-G09 CSS, TM5.2445634AI624849Hs. 344612ESTs, Weakly similar to NEL1_Hvwd5.2453740AL120295Hs 311809ESTs, Moderately similar to PC5.2426318AA375125Hs 147112Homo sapiens cDNA FLJ22322 fiSS, TM, EPH_Ibd, pkinase, fn35.1416470N90464Hs 303023beta tubulin 1, class VISS, tubulin, SS5.1432022AL162042Hs 272348homo sapiens mRNA, cDNA DKFZp75.1457579AB030816Hs 36761HRAS-like suppressorTM5.1438484AW021671Hs. 293330ESTs, Weakly similar to p40 [H5.1422802NM_004278Hs 27008phosphatidylinositol glycan, cDUF158, ank5.1401724C16001374 gi|6755086|ref|NP_03TM, PLAT, SS5.1438670AI275803Hs 123428ESTs5.1414757U46922Hs. 77252fragile histidine triad geneHIT5.1425098AW295349Hs 8038ESTsSS, TM5.1431896AW297844Hs 101428ESTsSS5.1416732H81066Hs 285017hypothetical protein FLJ21799SS5.1404571NM_015902*: Homo sapiens progesHECT, zf-UBR1, PABP5.1433675AW977653Hs. 75319ribonucleotide reductase M2 poSS5.1426358AA378438gb EST88856 HSC172 cells II HoTM5.1456767AI086412Hs 129064homo sapiens chromosome 19, coSS, TM, trypsin, kringle, UPA5.1412915AW087727Hs 74823NM_004541 Homo sapiens NADH de5.1443553AL040535Hs 9573ATP-binding cassette, sub-famiABC_tran, S55.1415886Z42737gb: HSC0SE081 normalized infantSS5.1401674C16001417*: gi|7500345|pir||T21FAD-oxidase_C, FAD_binding5.1424266AA337810Hs 149152ESTs, Weakly similar to RHOP M5.1455035AW851734gb MR2-CT0222-011199-007-e10 C5.1408567S72921ciliary neurotrophic factorCNTF5.1436616AW799109Hs. 226755ESTs14-3-35.1409078AW327515ESTs5.1447976AW972653Hs 293691ESTs, Highly similar to CR2_HU5.1457720AA992835Hs 186776ESTs5.1400528NM_020975* Homo sapiens ret prcadherin, pkinase, SS5.1407757BE048414Hs 165215hypothetical protein MGC5395SS, EF1G_domain, GST_C, GST5.1452446AA086123Hs 297856ESTsrrm, NTF25.1450807AI739262gb: wi17b08.x1 NCI_CGAP_Co16 Ho5.1432540AI821517Hs 105866ESTsSS, TM5.1449324AI638706ESTs, Weakly similar to A475825.1426434M17755Hs 2041thyroid peroxidaseEGF, sushi, An_peroxidase, p5.1407652W27953Hs 292911ESTs, Highly similar to S60712Troponin5.1443952AI149106ESTsSS, pkinase5.1448869AI792798Hs 12496ESTs, Weakly similar to ALU4_HSS, TM5.1422837U25441Hs 121478dopamine receptor D37tm_1, SS, TM, 7tm_15.1407143C14076Hs. 332329ESTSS, TM5.1442296NM_007275Hs 8186lung cancer candidateSS, TM, Glyco_hydro_56, Glyc5.1407722BE252241Hs 38041pyridoxal (pyridoxine, vitaminpfkB, SS5.1427336NM_005658Hs 2134TNF receptor-associated factorMATH, SS, MATH, A2M_N, A2M, NT5.1447960AW954377Hs. 26412ring finger protein 26SS, TM, Cbl_N, Cbl_N2, Cbl_N35.1400863C11002296.gi|11692557|gb|AAG39SS, TM5.1409034AI684149Hs 172035hypothetical protein similar tSS5.1421696AF035306Hs 106890Homo sapiens clone 23771 mRNA5.1427587BE348244Hs 284239ESTs, Weakly similar to 178885SS, UDPGT5.1407204R41933Hs. 140237ESTs, Weakly similar to ALU1_HSS, histone, histone5.1454219X75042Hs. 44313v-rel avian reticuloendothelioRHD, TIG5.1430513AJ012008Hs 241586G6C proteinSS, TM, GST_C, abhydrolase5.1435902AA701867Hs 297726ESTs5.1442743AI801351Hs 302110ESTs, Weakly similar to MUC2_HSS, fibrinogen, Rhodanese5.1454923AW897236gb CM0-NN0057-150400-335-c06 NSS, Caldesmon5.1440518AA888046Hs 233235ESTsSS, TM5.1448237AI471790Hs 309386ESTsTM, Ribosomal_S75.1428924AI016405Hs 98959ESTs, Weakly similar to JC5314SS, TM, lectin_c5.1412081Z24895Hs 293818gb: HSB67F122 STRATAGENE HumanSS, TM, SQS_PSY, GATA5.1437141BE304917Hs. 31097hypothetical protein FLJ21478SS, TM, Glycos_transf_45.1421658X84048Hs 301760frequenin (Drosophila) homologefhand5.1423467AK000214Hs 129014hypothetical protein FLJ20207SS, TM, GDPD, SS, TM, SH3, PDZ,5.0417151AA194055Hs 293858ESTsPH5.0408307AI761786Hs. 204674ESTsArmadillo_seg5.0404752NM_024778 Homo sapiens hypothe5.0453126AA032155Hs 61622ESTs5.0413983BE348384Hs 279194ESTs5.0405366NM_003371*: Homo sapiens vav 2SS5.0412425AW949156gb QV4-FT0005-110500-205-b06 F5.0437036AI571514Hs. 133022ESTsSS, TM, Glycos_transf_25.0448455AI252625Hs 269860ESTs, Moderately similar to S6SS, TM5.0411413BE379438Hs 211573heparan sulfate proteoglycan 2ig, laminin_B, laminin_EGF,5.0432579AF043244Hs 278439nucleolar protein 3 (apoptosisCARD, SS, HSF_DNA-bind, E2F5.0424874AA347951Homo sapiens cDNA FLJ20812 fisSS5.0408023BE018269Hs 279688ESTs5.0411758AW860667gb QV0-CT0383-210400-204-d03 Chomeobox, homeobox5.0410660AI061118Hs 65328Fanconi anemia, complementatio5.0427411AA402242ESTs5.0437018AA889078ESTsSS, TM, ERG4_ERG245.0427029AA397596ESTsSS, ras5.0452047N35953Hs 43510ESTs, Weakly similar to BOX BSS5.0432093H28383gb yl52c03 r1 Soares breast 3NBand_41, ERM5.0453099H62087Hs 31659thyroid hormone receptor-assocSS5.0441456AI458911Hs. 127765ESTs5.0414356AW505085Hs 335147gb: UI-HF-BN0-als-a-10-0-Ul r1SS, TM5.0434067H18913Hs 124023Homo sapiens cDNA FLJ14218 fis5.0436393AW022213ESTsGalactosyl_T_25.0409227AA806165Hs. 130323Homo sapiens, clone IMAGE 39605.0448680AW245890Hs 21753JM5 proteinWD40, SS, TM, KOW, HLH5.0439343AF086161Hs 114611hypothetical protein FLJ118085.0428079AA421020Hs 208919ESTsSS, TM, trypsin5.0421951BE327432Hs 109804H1 histone family, member X5.0427204AA405404Hs 215725ESTsSS, SS5.0409690W45393Hs. 55888activating transcription facto5.0436574AW293527Hs 126465ESTs5.0457761AW401809Hs 4779KIAA1150 proteinSS, LIM, SS5.0435294T84084Hs 196008Homo sapiens cDNA FLJ11723 fisHMG_box5.0445372N36417Hs 144928ESTsSS, PID, PDZ5.0440511AF132959Hs 7236eNOS interacting proteinSS, TM, MAGE, Ribosomal_S17,5.0424437BE244700Hs 147049cut (Drosophila)-like 1 (CCAATCUT, homeobox, beta-lactama5.0401539NM_002675.Homo sapiens promyelzf-B_box, zf-C3HC4, SS5.0417903NM_002342Hs. 1116lymphotoxin beta receptor (TNFTNFR_c6, SS5.0442451AI498080Hs 129616ESTsSS5.0450536AI699529gb tt17a02 x1 NCI_CGAP_GC6 HomSS, G-alpha, arf5.0425169AW292500Hs 128514ESTsSS5.0435262AA677088ESTs5.0444855BE409261Hs 12084Tu translation elongation factGTP_EFTU GTP_EFTU_D3, GTP5.0433507AI817336Hs 191791ESTspkinase5.0432396AW295956Hs 11900hypothetical protein FLJ14972SS5.0438395AA017514Hs. 6211methyl-CpG binding domain protMBD, zf-CXXC, SS, zf-CXXC5.0446603NM_014835Hs 15519oxysterol-binding protein-relaOxysterol_BP, SS5.0400762Target Exon5.0440133AI056255Hs 133349ESTs5.0445903AI347487Hs. 132781class I cytokine receptorSS, TM, EF1BD5.0412940BE295701Hs 819homo box B7homeobox, SS, homeobox, home5.0419269AA235838gb: zs41b04 s1 Soares_NhHMPu_S1TM5.0Pkey. Unique Eos probeset identifier number ExAccn: Exemplar Accession number, Genbank accession number UnigeneID Unigene number Unigene Title Unigene gene title Pred. Protein Dom Predicted protein domain R1 Ratio of tumor to normal body tissue


[0387]

37







TABLE 14B








Pkey
CAT Numver
Accession







408117
104000_1
AL138255 BE380045 AA047314 D82381 T18585 H64978 T10798


408215
10478_1
BE614290 AA307674 N35629 AA338538 AI193603 AA781096 AI680061 AI613258




AW276647 BE221263 AI348910 AI985031 AI090078 AI359617 AA666391 AI160210 AI446461 AI355345




AI343638 AI343640 AI275091 M78746 AW262795 AW250002 AA503756 AI934519




AW272086 N26520 AA626639


408270
1049980_1
AW177805 AW177895 AW177816 AW177901 BE141597 BE141584




AW177822 AW177818 AW177899


408294
1050553_1
BE141732 U75823 BE141331 AW178416 AW178430 BE141343 BE141298 BE141702 BE141285


408567
10663_1
S72921 NM_000614 X55889 X60542 X60477


409078
1098756_1
AW327515 AW327774 AW327571


409164
110421_1
AA706639 AA064707 AL036920 AI651598


409679
114787_1
BE250521 AA076837 BE249870 AA984291 AW502442 AW501551 AI221491 AA194239 D63046




AA193426 AA773243 AA193293


409832
115564_1
AW963293 AI866310 AA077791 AA362540


410445
120374_2
AA199830 AI143895 AW961629 AA322482


410471
1204721_1
T88872 AW749857


410895
1226051_1
AW809679 AW809678 AW810113 AW810182 AW809900 AW809851 AW810110 AW810228 AW810342




AW810181 AW809632 AW809745 AW810372 AW809681 AW809792 AW809806




AW810452 AW809675 AW809964 AW810033 AW810111 AW809846 AW809847 AW809717


411219
1236055_1
AW832917 AW832913 AW832906 AW832788 AW832915 AW832776


411298
1237955_1
AW835858 AW835836 AW835823 AW835834 AW835831 AW835832 AW835843 AW835816 AW835833




AW835815 AW835849 AW835835 AW835848 AW835851 AW835852 AW835862




AW835855 AW835825 AW835847 AW835838


411426
1245515_1
BE141714 AW845993 AW845989


411456
1246706_1
AW847588 AW847716 AW847664 AW847592


411490
1247426_1
R39474 AW848420 R76943


411605
125123_2
AW006831 AA678298 R12579 W86152 AI123683 AA699780 AI672156 BE092587 AA094230 AI633815




AA526153 W86151


411758
1256751_1
AW860667 AW860665


412091
1276564_1
R06185 AW891805 AW901892 AW901895


412122
127838_2
AW852707 N57282 AA725075 AI703492 AW612137 AI696372 AI879394 AI653605 W26914


412128
1278726_1
AW894709 N78140


412173
1280870_1
T71071 AW902279 AW897608


412425
1293726_1
AW949156 AW949003 AW949008


412452
129707_1
AA215731 N48523 AA307559 AA130794 BE296746 BE378396 AA190411 AI904194 AA311805 AI356291




AA446714 AI818924 AI609152 AW771476 BE298184 AA295023 AA130708 AI078381 AA114156 AI198283 AA215665




AI201085 AI694848 AI077572 AA102778 AW016425 AI923123 AA577072 AI671


412777
132672_1
AI335773 AI288496 AA120880


412934
1337389_1
BE011437 BE011402 BE011395 BE011428 BE011407 BE011421 BE011406


413272
135718_1
AA127923 AA127846 AA534131 N53566 AA533669 AW511251 AI174441 AA127875 AI685293




AA127913 N72525 AW770386 N69010 AW070312 H80275 H80289 AA972923


413534
1375357_1
BE146961 BE146780 BE146788 BE146967 BE146774 BE146963 BE146907


413564
1376722_1
BE260120 BE148538


414347
1437406_1
BE275835 BE390063 BE388764 BE409101


414371
14388_8
AI905865 BE294801 BE562308 BE297957 AW157051 AI815883 AW162529 BE439610 AW157225




AW157210 AW162675 AW161998 AI816168 AW162599 AI816004 AI815820 AW162158




AW162339 M17733 AW157639 AI879416 BE258811 AW157436 AW162433 AW161633 AW162155




AW157410 AW157269 AW162


414391
1441921_1
BE409872 BE281460


414413
1443696_1
BE294877 BE294759


414593
1464909_1
BE386764 BE387560


414944
1509480_1
C15044 D80943 C15696


415126
1523506_1
D60945 D61346 D81568 D80539


415611
1540555_1
T26376 F12852 T75058


415886
1560411_1
Z42737 T08986 H07956


415958
1563222_1
H10942 Z42911 R60453


416233
158010_1
AA176633 AW961842 AA309418


416597
1603081_1
H66891 R98149 H68467


417739
1696198_1
Z43995 R12357 R34740


418184
172744_1
AA367375 AA486701 BE152479 BE152800 AW816961 AA214097


418304
173658_2
AA215702 AA368006 AA215703 BE066555 BE006876


419269
183444_1
AA235838 BE180775


419516
185533_1
H82550 N43802 AA243820 AL040762 N24315 U66692


420530
19446_1
AI218431 AA432232 AW183040 X86012 AA868831 AI191788 AA912999 AI204297 AI205744 AI218259




AA428596 AA993742 AA703660 AI018669 AA879431


421879
208649_1
AW959607 AA299654 AA579966


423790
232031_1
BE152393 AA330984 BE073904


424874
244523_1
AA347951 AI688463 AA883123


426221
26281_1
AB007881 U32581 AW131202 AW995994 W31964 N24261 AI033045 H98694 AW364848 AI222031




AA907216 AI215730 AA776981 AW473826 W31373


426358
265504_1
AA376438 AA376324 AW963848 AW834782


426576
269378_1
AA381720 AA382040 AW963564


427029
274544_1
AA397596 AI198827 AA435832


427326
277229_1
AI287878 AI804160 AA400787


427411
278474_1
AA402242 AA813659 AI150316 AA412054


428092
286920_1
AW879141 AA421182 AI734104 AI733923 AA430600


428304
289603_1
AI743177 AA425743 AI804283 AI743189


428948
29737_1
BE514362 AI879343 BE272870 BE616390 AW163444 AW161588 AW378754 AW238803 BE267205




BE047746 BE207213 BE312782 BE266301 BE266413 BE278348 BE280885 BE278833 BE281417




BE407786 BE378176 BE392818 AW377597 BE395951 BE393978 AW327483 BE394175




BE385795 BE275663 BE3


429398
303954_1
AA452239 AI262173 AI925886 AI469041 H96628 AI768463 AI671422 AI915624 AA766891 AA521087




AA814103 AW993151 AW005927


430168
313927_1
AW968343 AA468507 AI478223 AW513008 AI762122 AI554512 AA862642 AA468976


431082
327710_1
AA491600 AA491645 AI920986


431161
328713_1
AA493591 AA829120 AA533792


431424
333110_1
AI222969 AA806560 AA504839 AA805261


431627
33581_1
AW609720 AW609735 AA082767 N88831 R23418 N55837 BE549484 AW816584 AW816947




AW816897


432093
341283_1
H28383 AW972670 H28359 AA525808


432945
356589_1
AL043683 AA570698 AA907496 AL043682 AW362288


433168
360235_1
AI085436 AA579438 AA579002


433357
36402_1
T05639 AF024702


434315
383402_1
AW196608 AA884617 AA758108 AI126321 AA629291 AW196549 AI208031


434743
3925_1
AI363410 AI356019 H00141 T78748 AL049365 AL079911 AI750972 Z42602 AW452523 AI223826




AA215407 AI633829 AA292122 N42783 AW505595 AF086096 N90340 N63271




AA131836 AW607273 AA527132 T32315 AA421961 T34951 AW966080 M78807 N31947 AA521151




AA278866 AA044784 AA700


434796
393400_1
AA812046 AW974514 AA764999 AA649302


435186
402143_1
AL119470 AA669492 AI628351 AI263835 AL119498


435262
403605_1
AA677088 AI022246 AA677107


435339
404485_1
AI358300 AI762981 AA678073 AA988621


436094
414444_1
AI798701 AW008826 AA704731


436389
41894_1
AI811706 AW297940 AJ227887 AA875850 AA228803 AI610234 AI921618 AI768606 N37039




AA081104 BE172693 D56503 Z28585 T95651 AA292389 AA293502 N28751


436393
41903_1
AW022213 AI274032 AJ227898 AI160412 AI084451


437018
431333_1
AA889078 AA907263 AA742199


437050
432210_1
AA766420 AA743319 AW976442


437215
43473_1
AL117488 AL044479


437662
440374_1
AA765387 AA832241 AI222134 AI216405 AI685043


437834
443674_1
AA769294 AW749299 AW749302 AW749295 AW749304 AW749293 AW749298 AW749294




AW749288 AW749291 AW749297 AW749292 AW749296 AW749289 AW749287 BE535498


438118
450293_1
AW753311 AW663081 AA778411


438723
46392_1
M34429 M34431 M34432 M25802 AW938720


439034
46802_1
AF075083 H52291 H52528


439150
46919_1
AF086006 H64722 H65212 H66282


439469
47274_1
W69836 AF086287 W69657


440317
49187_1
BE561888 BE560615 BE562102


440546
496976_2
AI491994 AW139809 AA889258 AI700895


441358
515468_1
AW173212 AA983948 AI080705 AA931334


441523
519049_1
AW514263 AI567908 AI299828 AI299043 N51706 AA936483


441794
526289_1
AW197794 AW195867 AW197787 AA968466


442146
533972_1
R52599 T65201 F11984 F13186 AA977679 T77028 H12167


442318
538584_1
AI792199 AI733491 AA991378


442472
543371_1
AW806859 AW806852 AF049582


442780
551405_1
AI017521 AI017613 AW511133


442893
553987_1
H78133 H90849 AI023482


443952
586524_1
AI149106 AI500318 AI334156 AI093029 AI765679 AI769652 AI167308 AI128885


444406
605004_1
AI147237 AI800517


445099
629785_1
BE163341 AI207756 BE171477


445625
64558_1
BE246743 AA436942 AW024744 AW242177 AA975476 AW385185 R07536 R73462




AV654529 T57442 AI399986 R50073 R48743 AI769689 AI863005 AA317806 AI678000




AW189963 AI986207 AW471273 R73463 AI335104 AI590161 AI469257 AI954604 H21954 T25141




AA856793 R50074 AI708253 AI2


445631
6457_1
AK001822 AW860325 AA335296 AW965531 AW130957 AW193951 AI347975 AW081323




AW662527 AI343924 AI380749 AA938153 T66966 AI655000 AW418837 AI380485 AA410698




AI520726 BE501355 AI637925 AW779200 AI524755 AW593995 AI336927 AI336928 AI357036




R60592 H19058 R11124 T1


445837
652068_1
AI261700 AI793196 AI469160 AI793007


446780
692897_1
R31107 AI341136 AI653198 H04953


446790
693032_1
AW452105 AI341280 AI917445


447045
70510_1
AW392394 AW579531 AW382131 AA010316 BE146145 AW579562 AW579577




BE146152 BE146040 BE145972 BE146099 AW003280 AA868470 BE146306 T85009 AI087294




BE146299 BE146319 BE146307 W44912 AI703134 AW026017 BE382873 AA903733 AI655933




BE551223 AA847664 AW173582 AW57240


447128
70934_1
AI271898 BE048502 AI452509 AI244810 X84721 AI858001 AI553937 AA149853 H00719




AI765259 AW973696 F25787 F35749 AI568815




AW015380 AA554539 C00201 AA961610 AW059537 R77127


447904
741913_1
AW206303 AW207644 AI765705


448330
758690_1
AL036449 AW016705 AI492482


448993
79225_1
AI471630 BE540637 BE265481 AW407710 BE513882 BE546739 AA053597 BE140503




BE218514 AW956702 AI656234 AI636283 AI567265 AW340858 BE207794 AA053085 R69173




AA292343 AA454908 AA293504 AI659741 AI927478 AA399460 AI760441 AA346416 BE047245




AA730380 AA394063 AA454


449324
804806_1
AI638706 BE550292 R11026


449495
808345_1
AI652833 AI695904 AW888916


450251
829987_1
BE080483 BE080416 AI689298


450536
837848_1
AI699529 BE161564 BE077251


450807
847591_1
AI739262 R28418


451045
85673_1
AA215672 AI696628 AA013335 H86334 AA017006


451752
8835_1
AB032997 N74056 BE467119 AW237035 AI141678 AA934774 AW978722 AI761408 H09497




AI934521 AA716567 H62600 AI479668 Z40632 AA832081 Z44858 H09496 BE395335 AW295901




BE465977 AI621269 BE465983 M79058 H62533 AA325444


452113
899664_1
AI859393 BE177742


453413
966269_1
AJ003294 AJ003315 AJ003293


453829
982731_1
AL138200 T71830 T71828


453904
986581_1
AW003821 AW027475 AW025661


454438
120132_1
AA224053 AA114150 AA214275 AA224027 T58431 AA211908 AA669657 AA199744




AA630511 AA164864 T58463 AA214394 AA161378




AA161386 AA205211 AA167824 AA084940 AA223625 AA191190 AA309486 AW961804


454453
1206827_1
AW752781 BE143749 AW752727 AW752559 AW752578 AW752584 R45742


454577
1225673_1
AW809272 AW809169 AW809179 AW809192 AW809166 AW809172 AW809191 AW809165




AW809197 AW809181 AW809237 AW809226 AW809250 AW809199 AW809259 AW809239




AW809273 AW809270 AW809147 AW809188 AW809245


454682
1228976_1
AW816029 AW813292 AW816156 AW813333 AW816159 AW813302






454718
1230532_1
AW815144 AW815150 AW861007


454756
1233646_1
AW819273 AW819283 AW819287 AW819281 AW819274 AW819282 AW819277 AW819286


454923
1245024_1
AW897236 AW845406


455035
1249762_1
AW851734 AW851676 AW851693 AW851713 AW851722 AW851616 AW851731 AW851618




AW851648 AW852215


455274
1272212_1
BE151622 BE151636 AW885648


455286
1273576_1
BE144384 AW887474 AW887403 BE144386


455557
1325974_1
AW995839 AW995907


455604
1337197_1
BE011183 BE011170 BE011333 BE011188 BE011181 BE011324 BE011161 BE011169


455679
1349914_1
BE066529 BE066274 BE066390 BE066356 BE066419 BE066345 BE066298




BE066292 BE066359


455778
1364506_1
BE088746 BE088802 BE088755 BE088876 BE088947 BE088881 BE088952


455885
1380385_1
BE153524 BE153576 BE153583


456487
19270_1
AF064804 AA320309 N89343 AA564588 AF069734 AA349248 AW964366 T98541




AW511100 T98542 AW070452 AA013172 AI767005 T32140




W05727 T30969 T30970 N74883 AA903211 AI392796 AI434622 AA829283


457892
432926_1
AA744389 AA744270 AA744284 AA744299 AA745380 AA744337 AA846905 AA847698


457978
448900_1
AA776638 BE439540


458198
504834_1
AI286100 AA952934 AA918305


458644
670856_1
AW270149 AW664628 AI285912






Pkey: Unique Eos probeset identifier number




CAT number Gene cluster number




Accession Genbank accession numbers








[0388]

38








TABLE 14C








Pkey
Ref
Strand
Nt_position


















400460
8389428
Plus
35559-36295


400500
9796136
Minus
120238-120495


400528
6981824
Plus
472381-472528, 474170-474277,





475328-475542, 475878-476000


400668
8118719
Plus
121756-122043


400748
8119063
Plus
84237-84398


400762
8131616
Plus
7235-7605


400772
8131629
Minus
34896-35021, 41078-41197


400833
8705148
Minus
187599-188138


400863
9798616
Plus
21575-22330


400906
9966290
Plus
112863-112989, 120162-120286


400923
7637836
Minus
94518-94659


401121
8570296
Plus
57211-57525


401180
9438648
Minus
150981-152128


401203
9743387
Minus
172961-173056, 173868-173928


401210
7712287
Plus
166969-167133, 169760-169877,





171563-171733


401215
9858408
Plus
103739-103919


401264
9797154
Plus
130810-130927, 133367-133504


401278
9799936
Plus
98428-98573


401349
9930791
Plus
72440-73030


401402
7710964
Plus
75730-76077


401488
7341775
Plus
54523-54686, 55364-55451,





55737-55846, 58047-58175,





58261-58356


401507
7534110
Plus
71055-71259


401539
8072433
Minus
62028-62608


401553
8099284
Minus
83990-84161


401594
7230963
Plus
7997-8170


401674
7689903
Plus
138786-138927, 139157-139298,





139440-139599, 139960-140159


401677
9965537
Minus
62856-63086, 63603-63884


401722
7656694
Plus
143861-144054


401724
7656694
Plus
150063-150241


401822
6730824
Plus
88400-89959


401885
8140731
Plus
148234-148321, 150365-150559


401935
3808091
Plus
46329-48473


401938
6102666
Plus
151891-152032


401984
4454511
Plus
103825-104024


402189
8576043
Minus
128318-129601


402197
8576113
Plus
199466-199585


402285
2689079
Minus
92386-92634


402365
9454515
Minus
70928-71185


402445
9796614
Plus
90925-91064, 91172-91331


402501
9797862
Plus
8601-8876


402545
9838114
Minus
48547-48678, 50604-50737,





51384-51467


402651
7960391
Plus
174215-174380


402916
7406502
Minus
361-474, 541-687


403003
5441423
Minus
79403-79560, 79712-80021


403128
7331426
Plus
122884-123018, 123134-123283,





123372-123695, 123779-123940,





124059-124256


403672
7283286
Minus
96600-96881, 96951-97280,





97393-97594


403748
7658423
Minus
129503-130344


403885
7710403
Minus
53259-53524


403938
7711795
Plus
48636-48822


404001
8655948
Minus
137995-138317


404066
3367505
Minus
71040-71288


404149
7534008
Plus
121831-121951, 124044-124150


404199
6010176
Minus
1669-2740


404311
8570412
Minus
149189-149303


404333
9802821
Minus
137948-138024, 138111-138300


404365
9964977
Plus
50151-50319, 50859-51098


404430
7407979
Plus
42921-43109


404438
6984205
Plus
63413-63553


404571
7249169
Minus
112450-112648


404596
9958262
Minus
104807-105043


404676
9797204
Minus
56167-56342, 58066-58189, 58891-





59048, 60452-60628


404710
9801097
Minus
45190-45339, 47509-47622, 48137-





48264, 48805-48946, 50073-50345,





51467-51588


404752
7109522
Minus
120168-120326


404807
4165210
Minus
124246-124422


404956
7387343
Plus
55883-56203


405085
8072509
Minus
44045-44230


405113
8096927
Plus
170073-170894


405143
9438278
Plus
5894-5983, 7355-7427


405159
9966252
Plus
79659-79804


405211
6692345
Minus
31340-32609


405247
7249301
Minus
65578-65778, 68088-68234


405346
2981263
Plus
101982-102171


405366
2182280
Plus
22478-22632


405371
2078469
Minus
47657-47766, 48461-48596


405375
1552539
Plus
11646-12050, 12207-12485


405376
1552533
Plus
28875-29099


405473
8439781
Plus
153074-153343, 154501-154598,





156879-156999, 158863-159051,





159910-160053, 161109-161229,





163035-163131, 165163-165259,





165868-166003, 167375-167552,





169252-169364, 171127-171281


405474
8439781
Plus
172005-172175


405557
1621108
Plus
39883-40047


405637
6289229
Plus
189852-189978


405770
2735037
Plus
61057-62075


405928
7717155
Minus
2923-3209


405931
6758795
Minus
148233-148705


405939
6758795
Plus
170500-170654


406109
9127147
Minus
58328-58485


406230
4760409
Plus
71716-72515


406284
7549620
Plus
74002-74199


406299
5686278
Minus
35655-36119


406301
8575868
Plus
57291-57494


406373
9256130
Plus
188922-189152


406495
7711328
Minus
174661-174978


406575
7711679
Plus
142034-142473






Pkey: Unique number corresponding to an Eos probeset




Ref: Sequence source The 7 digit numbers in this column are Genbank Identifier (GI) numbers “Dunham I et al” refers to the publication entitled “The DNA sequence of human chromosome 22” Dunham, et al. (1999) Nature 402: 489-495




Strand Indicates DNA strand from which exons were predicted




Nt_position Indicates nucleotide positions of predicted exons








[0389] Table 15A lists about 933 genes up-regulated in ovarian cancer compared to normal adult tissues that are likely to encode extracellular or cell-surface proteins These were selected for Table 14A, except that the ratio of “average” ovarian cancer to “average” normal adult tissues was greater than or equal to 3 0, the “average” ovarian cancer level was set to the 96th percentile value amongst various ovarian cancer specimens, the “average” normal adult tissue level was set to the 75th percentile value amongst various non-malignant tissues, the “average” ovarian cancer value was greater than or equal to 400 units (this selects for the most abundant of the up-regulated genes), and the predicted protein contained a structural domain that is indicative of extracellular localization (e g, ig, fn3, efg, 7tm domains, signal sequences, transmembrane domains). Predicted protein domains are noted.
39TABLE 15APkeyExAccnUniGene IDUnigene TitlePred Protein DomR1407223H96850gb: yw03b12 s1 Soares melanocytSS, TM, SS, TM, DDOST_48 kD58.9421296NM_002666Hs 103253perilipinperilipin, SS47.6430281AI878842Hs 237924CGI-69 proteinmito_carr, SS, TM46.7410418D31382Hs 63325transmembrane protease, serineSS, TM, ldl_recepta, trypsi41.0431773BE409442Hs. 268557pleckstrin homology-like domaiPH, SS, LIM, Troponin37.1428758AA433988Hs 98502CA125 antigen, mucin 16SS35.6438424AI912498Hs 25895hypothetcal protein FLJ 14996SS, TM35.3450461BE408081Hs 46736hypothetical protein FLJ23476SS34.4437897AA770561Hs 146170hypothetical protein FLJ22969SS, TM, zf-DHHC33.9452554AW452434Hs. 58006ESTs, Weakly similar to ALU5_HSS, PAS, HLH32.5422310AA316622Hs 98370cytochrome P450, subfamily IISSS, TM, pkinase, fn3, ig30.5452849AF044924Hs 30792hook2 proteinbZIP, SS, AhpC-TSA29.6407722BE252241Hs 38041pyridosal (pyridoxine, vitaminpfkB, SS28.2416819U77735Hs. 80205pim-2 oncogenepkinase, SS, TM, OTU, K_tetra27.9430397AI924533Hs. 105607bicarbonate transporter relateHCO3_cotransp, SS, TM27.7427725U66839Hs 180533mitogen-activated protein kinapkinase27.5454017AW023617Hs 347130bypothetical protein FLJ22709SS, TM, myosin_head, RA, DAG27.2445434BE391690Hs 9265hypothetical protein FLJ20917SS, PWWP, Exonuclease, lipoc26.8452399BE513301Hs. 29344hypothetical protein, clone 24SS, perilipin26.5419451AI907117Hs 90535syntaxin binding protein 2Sec1, SS, TM25.1424420BE614743Hs 146688prostaglandin E synthaseMAPEG, SS, TM, MAPEG25.1407893BE408359Hs 43621Homo sapiens, Similar to hypotSS, SS, arf, ras, fn3, ras25.0412674X04106Hs. 74451calpain 4, small subunit (30 K)efhand, SS, CAP_GLY24.4430023AA158243Hs 227729FK506-binding protein 2 (13 kD)SS, FKBP, SS, PDGF, C2, PI-PLC24.3444672Z95636Hs 11669laminin, alpha 5laminin_EGF, laminin_G, EGF24.0413726AJ278465Hs 75510annexin A11annexin, SS, annexin23.1438951U51336Hs 6453inositol 1,3,4-triphosphate 5/SS, oxidored_nitro, SS23.0429099BE439952Hs. 196177phosphorylase kinase, gamma 2pkinase, SS, SNF2_N, helicas23.0422645L40027Hs 118890glycogen synthase kinase 3 alppkinase, SS, Ets22.4427899AA829286Hs 332053serum amyloid A1SS, SAA_proteins, SS, SAA_pr22.2407117AA146625gb zo71c07.s1 Stratagene pancrSS21.3402916ENSP00000202587*: Bicarbonate tHCO3_cotransp, SS20.8425760D17629Hs 159479galactosamine (N-acetyl)-6-sulSulfatase, SS, TM20.7422098H03117Hs 111497similar to mouse neuronal protTM20.6442232AI357813Hs 337460ESTs, Weakly similar to A47582SS, TM, TGFb_propeptide, TGF20.1453157AF077036Hs 31989DKFZP586G1722 proteinSS, Tropomyosin20.0422179AF091619Hs 112667dynein, axonemal, intermediateWD40, SS20.0419444NM_002496Hs. 90443Target CATfer4, SS, TM, V_ATPase_sub_a19.5416893AA455588Hs. 62406hypothetical protein FLJ22573SS, rrm, SS19.2434030AW162336Hs 3709low molecular mass ubiquinone-SS19.1411813NM_014931Hs 72172KIAA1115 proteinSS, TM, Y_phosphatase18.9422305AI928242Hs 293438ESTs, Highly similar to AF1984SS18.8419167AI589535Hs. 94875ESTs, Weakly similar to A35363SS18.6406663U24683immunoglobulin heavy constantSS18.5429712AW245825Hs 211914ENSP00000233627* NADH-ubiquinooxidored_q6, SS, TM, rrm18.5425848BE242709Hs 159637valyl-tRNA synthetase 2GSt_C, GST_N, Tropomyosin, S18.4447151AI022813Hs 92679Homo sapiens clone CDABP0014 mSS, TM, LRR, aminotran_1_218.4413343BE392026Hs. 334346hypottiehcal protein MGC13045SS, DnaJ18.2450029AW073380Hs 267963hypothetical protein FLJ10535SS, Pyridox_oxidase, zf-C2H17.7427721AI582843Hs 180455RAD23 (S. cerevisiae) homologubiquitin, UBA, integrin_B,17.6443780NM_012068Hs 9754activating transcription factobZIP, NTP_transf_2, SS, TBC17.2421612AF161254Hs. 1061968D6 antigenldl_recept_a, SS, TM17.1444607AW405635Hs 293687ESTsSS, PI-PLC-X, PH, PI-PLC-Y, C16.7406621X57809Hs 181125immunoglobulin lambda locusSS16.6443496AJ006973Hs 9482target of myb1 (chicken) homolVHS, GAT, TM, Heme_oxygenase16.6440104AA132838Hs 239894hypothetical protein MGC2803SS, DS16.3427640AF058293Hs. 180015D-dopachrome tautomeraseMIF, late_protein_L2, SS, GS16.2445625BE246743hypothetical protein FLJ22635SS, TM16.1427461AA531527Hs 332040hypothetical protein MGC13010SS, TM, ACAT, LRR15.9423366Z80345Hs 127610acyl-Coenzyme A dehydrogenase,Acyl-CoA_dh, Acyl-CoA_dh_M15.7409017T86957Hs 272299hypothetical protein RP4-622L5SS, TM15.6428167AA770021Hs. 16332ESTsSS, ig, fn315.5420029BE258876Hs. 94446polyamine-modulated factor 1aldo_ket red, SS, TM, gla15.5400460C11002253*: gi|129091|sp|P23267SS, TM, SCAN, zf-C2H2, KRAB15.4407767W15398Hs. 38628hypothetical proteinSS, zf-CCCH15.4406918M88357gb Homo sapiens DNA-binding przf-C2H2, SS15.4435158AW663317Hs 65588DAZ associated protein 1rrm, SS, rrm15.3407619AL050341Hs 37165collagen, type IX, alpha 2SS, Collagen, SS, Collagen15.3421273AJ245416Hs 103106U6 snRNA-associated Sm-like prSm, SS, tRNA-synt_1, GST_C, G15.1402365Target ExonSS, SS, TM, ig14.9450503R35917Hs 301338hypothetical protein FLJ12587SS14.8427502AI811865Hs 7133Homo sapiens, clone IMAGE 3161SS, TM, ABC_tran, Glyco_tran14.6432872AI908984Hs 279623selenoprotein X, 1DUF25, SS, Ribosomal_L3, PDZ14.5439233AA831893Hs 292767hypothetical protein FLJ23109zf-C3HC4, TM, Sulfate_trans14.5416897M78146Hs 324700hypothetical protein MGC2663SS14.3447304Z98883Hs. 18079phosphatidylinositol glycan, cSS, Peptidase_C214.2431543AW969619Hs 259768adenylate cyclase 1 (brain)TM14.0447544AA401573Hs 288284hypothetical protein FLJ22378SS, TM14.0417595AA424317Hs. 6259KIAA1698 proteinSS, TM, Glyco_hydro_31, Glyc13.8436127W94824Hs 11565RIKEN cDNA 2010100O12 geneCorona_7, SS, TM13.8412623R28898Hs 74170metallothionein 1E (functionalSS, TM, metalthio, DEAD, meta13.7448133AA723157Hs 73769folate receptor 1 (adult)Folate_rec, SS13.5453367AW732847Hs. 70573PKCI-1-related HIT proteinSS, TM13.5431462AW583672Hs 256311granin-like neuroendocrine pepSS13.2408724AI685842Hs 294143ESTs, Weakly similar to T22914SS, pkinase, tubulin13.2423464NM_016240Hs 128856CSR1 proteinCollagen, SS13.1428539AW410063Hs 184877solute carrier family 25 (mitomito_carr, SS, TM, profilin,13.0436014AF281134Hs 283741exosome component Rrp46RNase_PH, RNase_PH_C, SS, TG12.9438857AI627912Hs. 130783Forssman synthetaseSS, RA, RasGEF, RasGEFN12.8444410BE387360Hs 33719ESTs, Moderately similar to S6SS12.8427527AI809057Hs. 153261immunoglobulin heavy constantSS, TM, ig12.6430168AW968343DKFZP43411735 proteinSS, TM, efhand, efhand12.5437543H16443Hs 7117glutamate receptor, ionotropicSS, TM, lig_chan, ANF_recept12.4413711AW291765Hs 75486heat shock transcription factoNA, SS, E2F_TDP12.3422625AW504698Hs. 155976cullin 4BSS, SS, Cullin, Cullin12.2443136NM_001440Hs 9018exostoses (multiple)-like 3Exostosin, SS, TM12.1407143C14076Hs 332329ESTSS, TM12.1424707BE061914Hs. 10844Homo sapiens cDNA FLJ14476 fisSS, SS, TM, Sema12.1425251Z22521Hs 155342protein kinase C, deltapkinase, DAG_PE-bind, pkina12.0427336NM_005658Hs 2134TNF receptor-associated factorMATH, SS, MATH, A2MN, A2M_N, A2M, NT12.0421572AA531607hypothetical protein FLJ22678SS, TM, TGF-beta, ASC12.0447946AI566164Hs 165827ESTsSS, PTN_MK, 7tm_1, DAGKc, DAG11.9425954AK000633Hs. 164476hypothetical protein FLJ20626SCAN, zf-C2H2, KRAB, SS, KRAB11.7427273AW139032Hs 107376hypothetical protein DKFZp434NSS, SS, TM11.7427397AI929685Hs 177656calmodulin 1 (phosphorylase kiefhand, RrnaAD, SS, efhand11.7424415NM_001975Hs 146580enolase 2, (gamma, neuronal)enolase, SS, Atrophin-1, Atr11.7417852AJ250562Hs 82749transmembrane 4 superfamily metransmembrane4, SS, TM11.6447451AI379925Hs 207525ESTsSS, pkinase, PH, pkinase_C11.5410397AF217517Hs. 63042DKFZp564J157 proteinSS, homeobox, UPF0160, DUF2311.4430354AA954810Hs 239784human homolog of Drosophila ScSS, TM, ig11.3419390AI701162Hs 90207hypothetical protein MGC11138SS, TM, PMP22_Claudin, PMP2211.3422682W05238Hs. 94316ESTs, Weakly similar to T31613SS, TM, DEAD, helicase_C, Lam11.3422178AL122083Hs 112645Homo sapiens mRNA; cDNA DKFZp4SS, TM11.2450122BE313765Hs 343443ESTs, Weakly similar to I38022SS, TM, Y_phosphatase, LON, A11.1453968AA847843Hs 62711High mobility group (nonhistonSS, HMG_box11.1444744BE394732Hs. 147562ESTsSS10.9423220BE394920Hs 125262aladinWD40, TM, Activin_recp, pkin10.9417116Z43916Hs 7634hypothetical protein FLJ12287SS, TM, filament, IF_tail10.9406779AA412048Hs 279574CGI-39 protein, cell death-regSS, SS10.8450593AF129085Hs 25197STIP1 homology and U-Box contaTPR, SS, TM, Rhomboid, lactam10.7406837R70292Hs 156110immunoglobulin kappa constantSS10.7452434D30934Hs 29549C-type lectin-like receptor-1lectin_c, SS, TM10.7440150AW975738Hs 7001Homo sapiens, clone IMAGE 3940SS, TM, SS, TM, Peptidase_M2210.6418641BE243136Hs 86947a disintegrin and metalloprotedisintegrin, Reprolysin, Pe10.6414313NM_004371Hs. 75887coatomer protein complex, subuWD4O, SS, WD40, Ribosomal_S210.6420307AW502869Hs 66219ESTsSS, TM10.6414918AI219207Hs 72222hypothetical protein FLJ13459SS, TM, efhand10.6446562BE272686Hs. 15356hypothetical protein FLJ20254hormone, SS, pfkB10.5419846NM_015977Hs 285681Williams-Beuren syndrome chromSS, HLH, SS, TM, WD4O10.4453023AW028733Hs 31439serine protease inhibitor, KunKunitz BPTI, SS, TM, ion_tra10.4438800AB037108Hs 6418seven transmembrane domain orpSS, TM10.3431275T56571Hs. 10041ESTsSS, HLH10.3407241M34516gb Human omega light chain proSS, ig, PH, ig, PH10.3441238AI372555Hs 322456hypothetical protein DKFZp761Dhomeobox, SS, TM, Rho_GDI, th10.3436325AL390088Hs. 7393hypothetical protein from EUROSS, Synapsin_C, SS10.3435605AF151815Hs 4973hypothetical proteinSS, TM, SS, TM, ABC_tran, ABC-10.3444202AL031685Hs 12785KIAA0939 proteinSS, TM, Na_H_Exchanger, ABC210.3425597U28694Hs. 158324chemokine (C-C motif) receptor7tm_110.3415200AL040328Hs. 78202SWI/SNF related, matrix associSNF2_N, helicase_C, bromodo10.2446528AU076640Hs 15243nucleolar protein 1 (120 kD)Nol1 _Nop2_Sun, SS, SNF2_N, h10.2414874D26351Hs 77515inositol 1,4,5-triphosphate reTM, RYDR_ITPR, ion_trans, MI10.2423524AF055989Hs 129738potassium voltage-gated channeion_trans, K_tetra, thaumat10.2434552AA639618Hs. 325116Homo sapiens, clone MGC: 2962,SS10.2406836AW514501Hs 156110immunoglobulin kappa constantSS10.1420233AA256714Hs 194864hypothetical protein FLJ22578SS10.1427458BE208364Hs. 29283ESTs, Weakly similar to LKHU pSS, F5_F8_type_C, EGF, TGT10.1427672AA356615Hs. 336916death-associated protein 6SS, BTB, abhydrolase_2, RasG10.0423218NM_015896Hs 167380BLu proteinzf-MYND, SS, TM, Glyco_hydro10.0403028Target ExonSS, trefoil10.0412790NM_014767Hs. 74583KIAA0275 gene productkazal, thyroglobulin_1, zf-10.0419823AW271708Hs 118918ESTs, Weakly similar to M2OM_HSS, TM10.0433886AA613596Hs 28412ESTsSS9.9428092AW879141ESTsSS, TM9.8450493M93718Hs 166373nitric oxide synthase 3 (endotflavodoxin, FAD_binding, NO9.7420423AA827718Hs 88218ESTsSS9.7452302AF173867Hs 28906glucocorticoid modulatory elemSAND, SS9.7444681AJ243937Hs 288316chromosome 6 open reading framnotch, EGF, ank, GoLoco, SS, T9.7414249AI797994Hs. 279929gp25L2 proteinSS, TM, EMP24_GP25L, SS, TM, G9.6424263M77640Hs 1757L1 cell adhesion molecule (hydfn3, ig, IRK, SS, TM, fn3, ig, R9.6438627AI087335Hs 123473ESTsTM, Reticulon9.6407065Y10141gb H. sapiens DAT1 gene, partiaSNF, SS, TM9.6441307AW071696Hs. 209065hypothetical protein FLJ14225SS, TM9.6409649AA159216Hs. 55505hypothetical protein FLJ20442Y_phosphatase, DSPc, TM9.6424487T08754Hs 6259KIAA1698 proteinSS, SS, TM, Glyco_hydro_31, G9.5444633AF111713Hs 286218junctional adhesion molecule 1ig, SS, TM, HLH9.4427747AW411425Hs 180655serine/threonine kinase 12pkinase, SS, TM, synaptobrev9.4450437X13956Hs. 24998hypothetical protein MGC10471SS9.4415169W42913Hs 78089ATPase, vacuolar, 14 kDATP-synt_F, SS, TM, CH, Filam9.4400201NM_006156*. Homo sapiens neuralubiquitin, SS, TM, Transglut9.4454319AW247736Hs. 101617ESTs, Weakly similar to T32527SS9.4421680AL031186Hs 289106Human DNA sequence from cloneSS, SS, rrm, zf-RanBP, rrm, GA9.4445143U29171Hs 75852casein kinase 1, deltapkinase, SS9.4407507U73799gb Human dynactin mRNA, partiaSS, TM, HCO3_cotransp, CAP_G9.4450883NM_001348Hs 25619death-associated protein kinaspkinase, GTP_EFTU, EFG_C, GT9.4411674AW861123gb RC3-CT0297-120200-014-a05 CSS9.3414625AA335738Hs 76686glutathione peroxidase 1GSHPx, SS, ras, HLH9.3456950AF111170Hs 306165Homo sapiens 14q32 Jagged2 genSS, TM, DSL9.3445333BE537641Hs 44278hypothetical protein FLJ12538SS9.2407204R41933Hs 140237ESTs, Weakly similar to ALU1_HSS, histone, histone9.1412338AA151527Hs 69485hypothetical protein FLJ12436SS, TM, TIG, Sema, PSI9.1439963AW247529Hs. 6793platelet-activating factor acePAF-AH_lb, Lipase_GDSL, SS,9.1412104AW205197Hs. 240951Homo sapiens, Similar to RlKENSS, TM9.1443553AL040535Hs 9573ATP-binding cassette, sub-famiABC_tran, SS9.1448984AW751955Hs 22753hypothetical protein FLJ22318SS9.0418776AI401004Hs 88411lymphocyte antigen 117SS, TNF, TNF9.0418843AJ251016Hs. 89230potassium intermediate/small cTM, CaMBD, SK_channel, TM9.0419244AI436567Hs 89761ATP synthase, H transporting,ATP-synt_DE, SS, rrm, Ephrin8.9451855R54913Hs 175804ESTsSS, TM, vwa8.9424825AF207069Hs 153357procollagen-lysine, 2-oxogluta2OG-Fell_Oxy, Glycos_trans8.9447374AF263462Hs. 18376KIAA1319 proteinSS, Myosin_tail, M8.9430167Y08976Hs 234759FEV proteinEts, SS, crystall8.8409936AK001691Hs 57655hypothetical protein FLJ10829SS, TM8.7437926BE383605Hs 300816small GTP-binding proteinSS, TM, TPR8.7430037BE409649Hs 227789mitogen-activated protein kinapkinase8.7424919BE314461Hs. 153768U3 snoRNP-associated 55-kDa prWD40, SS, KH-domain8.7414534BE257293Hs. 76366BCL2-antagonist of cell deathSS, hormone_rec, zf-C48.7433333AI016521Hs. 71816v-akt murine thymoma viral onchomeobox, pkinase, PH, pkina8.7423228AL137491Hs 125511Homo sapiens mRNA, cDNA DKFZp4SS, TM, sushi8.7419493AF001212Hs 90744proteasome (prosome, macropainPCI, SS, CDK5_activator8.7420160AI492840ESTsSS, TM8.6421871AK001416Hs 306122glycoprotein, synaptic 2TM, Steroid_dh, SS8.6447827U73727Hs 19718protein tyrosine phosphatase,Y_phosphatase, fn3, ig, MAM,8.6417193AI922189Hs 288390hypothetical protein FLJ22795SS8.6418678NM_001327Hs. 167379cancer/testis antigen (NY-ESO-SS, TM, zf-C2H28.5458963AI701393Hs 278728Rad and Gem-related 2 (rat homras, SS, Peptidase_M10, hemo8.5406868AA505445Hs 300697immunoglobulin heavy constantSS, TM, ig8.3434105AW952124Hs 13094presenilins associated rhomboiTM, Rhomboid, SS, TM8.3421726AK001237Hs. 319088hypothetical protein FLJ10375TM8.3421707NM_014921Hs 107054lectomedin-2Latrophilin, OLF, 7tm_2, Gal8.2453898AW003512Hs 232770arachidonate lipoxygenase 3SS, TM, lipoxygenase, PLAT, s8.2456672AK002016Hs 114727Homo sapiens, clone MGC: 16327,SS, PK, PK_C, myosin_head, Rh8.2421592AF009801Hs 105941bagpipe homeobox (Drosophila)homeobox, SS8.2409829M33552Hs 56729lymphocyte-specific protein 1Caldesmon, SS, Ribosomal_S28.1444341AI142027Hs 146650ESTsSS, TM, Reprolysin, Pep_M12B8.0413762AW411479Hs. 848FK506-binding protein 4 (59 kD)FKBP, TPR, SS8.0436685W28661Hs 5288Homo sapiens mRNA, cDNA DKFZp4SS, TM, pkinase, Activin_rec8.0420932AW374605Hs 11607ESTs, Weakly similar to T21697SS, bZIP_Maf8.0431493AI791493Hs 129873ESTs, novel cytochrome P450SS, p450, SS7.9447598AI799968Hs 199630ESTsSS, TM7.9415758BE270465Hs. 78793protein kinase C, zetapkinase, DAG_PE-bind, pkina7.8457022AW377258gb: MR2-CT0222-261099-003-a10 CSS, Ribosomal_L7Ae7.8426440BE382756Hs 169902solute carrier family 2 (facilsugar_tr, SS, TM, sugar_tr7.8432747NM_014404Hs 278907calcium channel, voltage-depenPMP22_Claudin, SS, TM, PMP227.8441084W24563Hs. 9911hypothetical protein FLJ11773SS, TM, hormone_rec, zf-C47.8424443AI751281Hs. 284161hypothetical protein from EUROSS, TM, SS, TM7.7424198AB029010Hs 143026KIAA1087 proteinSS, TM, Na_Ca_Ex, Calx-beta,7.6430513AJ012008Hs 241586G6C proteinSS, TM, GST_C, abhydrotase7.6417900BE250127Hs 82906CDC20 (cell division cycle 20,WD4O, SS, TM, fn3, EGF, fn3, ig7.6432891AF161483Hs 279761HSPC134 proteinSS, TM, ubiquitin, Transglut7.5432234AA531128Hs. 115803ESTsSS7.5453485BE620712Hs 33026hypothetical protein PP2447SS, TM7.5441327AK001706Hs 7778hypothetical protein FLJ10751SS, TM, 7tm_17.5436540BE397032Hs 14468hypothetical protein MGC14226SS, TM7.5418256AW845318Hs. 12271f-box and leucine-rich repeatSS, SS, TM, HSF_DNA-bind7.5457274AW674193Hs 227152mannan-binding lectin serine pSS, TM, SS, TM, Clathrin_lg_c7.5437141BE304917Hs 31097hypothetical protein FLJ21478SS, TM, Glycos_transf_47.5425428AL110261Hs 157211DKFZP586B0621 proteinC1q, Collagen, SS7.4431934AB031481Hs 272214STG proteinSS7.4418349NM_001383Hs 84183diptheria toxin resistance proDiphthamide_syn, SS7.4430600AW950967Hs 274348HLA-B associated transcript-3ubiquitin, SS, TM, G-patch, a7.3421758BE397336Hs. 1422Gardner-Rasheed feline sarcomaSH2, SH3, pkinase7.3412841AI751157Hs 101395hypothetical protein MGC11352SS, TM7.3418313BE244231Hs 84038CGI-06 proteinSS, wap7.3429367AB007867Hs 278311plexin B1Sema, PSI, TIG, SS, TM, TIG, Se7.3418837U48263Hs 89040prepronociceptinOpiods_nenropep, SS7.2423015U18548Hs 123034G protein-coupled receptor 12TM7.2440188AK001812Hs 7036N-Acetylglucosamine kinaseROK, SS, TM7.2421975AW961017Hs 6459hypothetical protein FLJ11856SS, TM, ACAT7.2423858AL137326Hs. 133483Homo sapiens mRNA; cDNA DKFZp4SS, TM7.2446143BE245342Hs 306079sec61 homologsecY, SS, TM7.2417704NM_001747Hs 82422capping protein (actin filamenGelsolin, SS, Gelsolin7.2440869NM_014297Hs 7486protein expressed in thyroidlactamase_B, SS, XRCC1_N, BR7.1435099AC004770Hs 4756flap structure-specific endonuXPG_N, XPG_I, 5_3_exonuclea7.1438856N40027Hs 7473ESTsSS, TM, connexin7.1426268AF083420Hs 168913serine/threonine kinase 24 (Stpkinase, pkinase7.1418373AW750770Hs. 84344CGI-135 proteinSS, TM, PMP22_Claudin, 2OG-F7.1445087AW893449Hs. 12303suppressor of Ty (S.cerevisiaeS1, SH2, Ribosomal_L23, pkin7.1421748NM_014718Hs 107809KIAA0726 gene productcadherin, TM, TPR7.1413837AW163525titin-cap (telethonin)SS, Methyltransf_37.0426691NM_006201Hs 171834PCTAIRE protein kinase 1pkinase, SS, UCH-2, UCH-1, rr7.0409125R17268Hs 343567axonal transport of synaptic vSS, kinesin, PH, FHA, kinesin7.0424251AA677466Hs. 143696coactivator-associated argininSS, SNF2_N, helicase_C, brom7.0431630NM_002204Hs 265829integrin, alpha 3 (antigen CD4integrin_A, FG-GAP, Rhabd_g7.0428156BE269388Hs 182698mitochondrial ribosomal proteinSS7.0459255AI493244Hs 239500hypothetical protein MGC13114SS7.0441323AA928413Hs 159089ESTs, Weakly similar to ALU7_HSS, Peptidase_C1, zf-C2H26.9455928BE170313gb: QV4-HT0536-040500-193-g02 HSS6.9420856BF513294Hs 205736HLA class II region expressedkazal, SS, TM, ig, pkinase6.9421543AK000519Hs. 105606hypothetical protein FLJ20512TM6.9442296NM_007275Hs 8186lung cancer candidateSS, TM, Glyco_hydro_56, Glyc6.9445937AI452943Hs 321231UDP-Gal betaGIcNAc beta 1, 4-gGalactosyl_T_2, SS, TM, tsp6.9439732AW629604Hs 167641hypothetical protein from EUROSS, TM, SS, TM, A2M, A2M_N, NTR6.8429542AF038660Hs 206713UDP-Gal betaGIcNAc beta 1, 4-gGalactosyl_T_2, ig, SS, TM, A6.8420190AI816209Hs. 95867hypothetical protein EST00098SS, dynamin_2, dynamin, PH, G6.8408215BE614290syntaxin 10SS, SS, TM, HLH, TRM, zf-CCCH6.7410277R88621Hs 26249ESTs, Weakly similar to T2D3_HSS, TM, SS6.7419667AU077005Hs 92208a disintegrin and metalloprotedisintegrin, Reprolysin, Pe6.7448677AI560769ESTsSS, TM6.7425228NM_005253Hs 301612FOS-like antigen 2bZIP, SS6.6432538BE258332Hs 278362male-enhanced antigenSS, TM, AAA, Ribosomal_L26.6421864BE387198Hs 108973dolichyl-phosphate mannosyltraSS, TM, SS, TM6.6429962M69113Hs. 226795glutathione S-transferase piGST_C, GST_N, SS, efhand6.6406867AA157857Hs 182265keratin 19filament, bZIP, SS, filament6.6426068AF029778Hs 166154jagged 2DSL, EGF, vwc, granulin, SS, T6.5419344U94905Hs 277445diacylglycerol kinase, zeta (1ank, DAGKa, DAGKc, DAG_PE-bi6.5424681AA054400Hs 151706KIAA0134 gene producthelicase_C, PRK, SS, TM, 7tm6.5417903NM_002342Hs 1116lymphotoxin beta receptor (TNFTNFR_c6, SS6.5423876BE502835Hs 15463Homo sapiens, clone IMAGE 2959SS, efhand6.4433439AA431176Hs. 133230ribosomal protein S15TM, SS, TM, TPR, ras6.4441379AW175787Hs 334841selenium binding protein 1SS, RFX_DNA_binding6.4432968BE614192Hs 279869melanoma-associated antigen reSS, TM, RGS, DIX6.4456863T16837Hs. 4241ESTsfusion_gly, homeobox, TM6.4432269NM_002447Hs 2942macrophage stimulating 1 receppkinase, Sema, PSI, TIG, A4_E6.4425676AW410656Hs 159161Rho GDP dissociation inhibitorRho_GDI, homeobox, SS, Cytid6.4443420P06846Hs. 191208ESTsSS6.4436322AL355092Hs 120243parvin, gammaCH, SS, TM, CTF_NFI6.4440088BE559877Hs 183232hypothetical protein FLJ22638SS, zf-C3HC4, SPRY, zf-B_box6.4447665BE044245Hs 30011hypothetical protein MGC2963SS, TM6.3431785AA292385Hs 268763Breakpoint cluster region protBAF, kazal, TM6.3422714AB018335Hs 119387KIAA0792 gene productDUF221, SS, TM, TGFb_propept6.3434916AF161383Hs. 284207Homo sapiens, Similar to RIKENTM6.3414551AI815639Hs. 76394enoyl Coenzyme A hydratase, shECH, Peptidase_U7, SS, TM6.3413254U40272Hs 75253isocitrate dehydrogenase 3 (NAisodh, SS6.3458367AA088470Hs 83135Homo sapiens, Similar to RIKENSS, tRNA-synt_2d6.3415010NM_004203Hs 77783membrane-associated tyrosine-pkinase, SS, PMP22_Claudin6.3410076T05387Hs 7991ESTsSS6.3412940BE295701Hs. 819homeo box B7homeobox, SS, homeobox, home6.2440042AI073387Hs 133898ESTsSS6.2414023BE243628gb TCBAP1D1053 Pediatric pre-BSS6.2414513AW239400Hs 76297G protein-coupled receptor kinpkinase, RGS, pkinase_C, SS,6.2446662NM_013323Hs 15827sorting nexin 11PX, SS6.2409882AJ243191Hs 56874heat shock 27kD protein familyHSP2O, SS, TMzf-C2H2, BTB, E6.2414576AK000405Hs 76480ubiquitin-like 4ubiquitin, SS, TM, G6PD, G6PD6.2447507H59696Hs. 18747POP7 (processing of precursor,SS, TM, WD40, vwd, MAM, EPO_TP6.2453447AW771318Hs 326586hypothencal protein MGC11134SS, TPR6.1435968AW161481Hs 111577integral membrane protein 3TM6.1424441X14850Hs. 147097H2A histonefamily, member Xhistone, CRED_NFYB_HMF, SS,6.1434558AW264102Hs 39168ESTsSS, TM, LRRCT, LRR6.1434202BE382411Hs 3764guanytate kinase 1Guanylate_kin, CoaE, Viral6.1432183AW151952Hs. 46679hypothetical protein FLJ20739SS6.0444416AW288085Hs 11156hypothetical proteinzf-C3HC4, SpoA, PHD, TM, syna6.0447205BE617015Hs 11006ESTs, Moderately similar to T1SS, TM, LRRCT, Sema6.0407704BE315072Hs 78768malignant cell expression-enhaTM, MBOAT, SS, TM6.0453190AB002354Hs. 32312KIAA0356 gene productPH, PHD, RUN, SS6.0439975AW328081Hs. 6817inosine triphosphatase (nucleoHam 1p_like, SS6.0449514AW970440Hs 23642protein predicted by clone 236SS, PX, arf, lipocalin, PHD, z6.0432805X94630Hs 3107CD97 antigenSS, TM, 7tm_2, GPS, EGF, SS, TM6.0414362AI347934Hs 75932N-ethylmaleimide-sensitive facNSF, SS, TM6.0417483BE549343Hs 82208acyl-Coenzyme A dehydrogenase,Acyl-CoA_dh, Acyl-Cokdh_M6.0427988A44789333Hs. 181349hypothetical protein 628SS, SS6.0423473H49104Hs 129888hypothetical protein FLJ14768zf-C2H2, SS, mm, ENTH6.040677344812424Hs 76067heat shock 27kD protein 1HSP20, SS5.9409938AW974648gb EST386752 MAGE resequences,SS, Adapcomp_sub, GYF5.9424959NM_005781Hs. 153937activated p21cdc42Hs kinasepkinase, SH35.9453082H18835Hs 31608hypothetical protein FLJ20041SS, TM, ion_trans5.9452094AF049105Hs 27910centrosomal protein 2bZIP, 5_3_exonuclease, M, SS5.9451524AK001466Hs 26516hypothetical protein FLJ10604SS, SS, TM, pkinase, pkinase5.9427438AW328515Hs 178011hypothetical protein FLJ20257SS, TM5.9439685AW956781Hs 293937ESTs, Weakly similar to FXD2_HSS, PWWP, TSC225.9440511AF132959Hs. 7236eNOS interacting proteinSS, TM, MAGE, Ribosomal_S17,5.9417334AA337572Hs 157240hypothetical protein MGC4737SS, TM, ion_trans5.9425976C75094Hs 334514NG22 proteinSS, TM, pkinase, SH2, SH3, BNR5.8433173Z35093Hs 3196surfeit 1SURF1, SS, TM, SURF1, SURF45.8437891AW006969Hs 6311hypothetical protein FUJ20859TM, SET5.8410239AI568350Hs 61273hypothetical protein MGC2650SS, ART, TM5.8458060R95860Hs. 293629hypothetical protein MGC3121SS5.8409591AA 532963Hs 9100Homo sapiens cDNA FUJ3100 fisSS, TM, LIM, homeobox5.8409686AK000002Hs 55879Homo sapiens mRNA; cDNA DKFZp4SS, ABC_tran, SS, TM5.8450778U81375Hs. 25450solute camer family 29 (nuclNucleoside _tran, SS, TM, HSP5.8423612NM_002067Hs 1686guanine nucleotide binding proG-alpha, arf, SS, G-alpha5.8422701NM_014699Hs 119273KIAA0296 gene prodectzf-C2H2, GST_C, PHD, SS, TM, H5.8412958BE391579Hs 75087Fas-activated senne/threonineSS, pkinase5.8436957AA902488Hs. 122952ESTsSS, DAGKc, DAGKa, RA, DAG_PE-5.8423158H97991Hs 193313Target CATMoaA_NifB_PqqE, SS, TM5.841478878342Hs 77313cyclin-dependent kinase (CDC2-pkinase5.8420904AL035964Hs 100221nuclear receptor subfamily 1.hormone_rec, zf-C4, SS, DNA5.7410431BE261320Hs 158196transcriptional adaptor 3 (ADApkinase5.7420508AJ270993Hs. 98428homeo box B6homeobox, SS, homeobox, home5.7435593R88872Hs. 4964DKFZP586J1624 proteinHerpes_HEPA, SS5.7433064D79991Hs 30002SH3-containing protein SH3GLB2TM5.7451920AA224483Hs 27239DKFZP586K0S24 proteinSS, TM, SS, TM5.7453054AI878908Hs 31547Target CATSS5.7415117AF120499Hs. 78016polynecleotide kinase 3-phospViral_helicase1, SS, Amino5.7413163Y00815Hs 75216protein tyrosine phosphatase,fn3, ig, Y_pshosphatase, SS, T5.7425246AI085561Hs 155321serum response facter (c-fos sSRF-F, flavodoxin, SS, TM, p5.7433271BE621697Hs 14317nucleotar protein family A, meSS, TM5.7448484BE613340Hs 334725Hemo sapiens, Similar to RIKENTM, SS, TM, Kunitz_BPTI5.7449139BE268315Hs. 23111phenylalanine-tRNA synthetase-neur, SS, zf-C2H2, DNase_II5.7449181X96783Hs 23179synaptotagmin VC2, SS, TM, Y_phosphatase, Tr5.6414457AW514320Hs 76159ATPase, H transporting, lysosoATP-syn_C, SS, TM, pkinase5.6424964AW161271Hs 153961ARP1 (actin-related protein 1,actin, SS5.6415193AL048891Hs 12185hypothetical protein MGC14333SS, TM, aminotran_1_2, LRR5.6407754AA527348Hs 288967Homo sapiens cDNA FLJ14105 fisSS, TM, SS, TM, TSPN, tsp_3, SE5.6413049N_002151Hs. 823hepein (transmembrane proteasetrypsin, SS, TM, ATP1G1_PLM5.6454252H50256Hs. 63236ribosomal protein S15aSS5.6431787AW972024Hs 343661ret finger proteinSS, WD405, pkinase5.6431607A8033097Hs 183669KIAA1271 proteinSS, TM5.6406782AA4430373gb zw20f11.s1 Soares ovary tumSS5.6444364AL137294Hs 10964hypothetical protein FLJ22351SS, TM, pkinase5.6427834AA506101Hs. 285813hypothetical protein FLJ11807SS, TM5.5443759BE390832Hs. 134729FXYD domain-containing ion traSS, TM, ATP1G1_PLM_MAT8, ATP5.5416322BE019494Hs 79217pyrroline-5-carboxylate redectP5CR, Octopine_DH_N, SS, thi5.5406673M34996Hs 198253major histocompatibility complSS, TM, MHC_II_alpha, ig, SS,5.5415351U44755Hs. 78403small nuclear RNA activating cSS, TM, pkinase5.5411030BE387193Hs 678967-60 proteinSS, Collagen, Collagen5.5410653BE383768Hs 6523895 kDa retineblastoma proteinzf-C3HC4, SS, SNF2_N, helica5.5433012NM_004045Hs. 279910ATX1 (antioxidant protein 1, yHMA, SS, TM5.5437741BE561610Hs. 5809putative transmembrane proteinSS, TM, SS, TM, RA, VPS9, SH25.5421883X55079Hs 1437glucosidase, alpha; acid (Pomptrefoil, Glyco_hydro_31, SS5.4427361AW732480Hs 7678cellular retinoic acid-bindingSS, TM, aminotran_1_2, LRR5.4411574BE242842Hs 6780protein tyrosine kinase 9-likecofilin_ADF, SS, TM5.4457313AF047002Hs 241520transcriptional coactivaterSS, rrm, SS, Cytidylyltransf5.4428345AI242431Hs. 118282PAP-1 binding proteinSS, TM5.4434845BE267057Hs 325321hypothetical protein R32184_1SS, TM, CH, calponin, ARID5.4427162AB011133Hs 173864KIAA0561 proteinSS, pkinase, PDZ, SS, SH2, Rhs5.4447402H54520Hs 18490hypothetical protein FLJ20452SS, TM5.4433676AW371389Hs. 250173hypothetical protein FLJ13158SS5.4424373AJ133798Hs. 146219copine VIIC2, SS5.4423402BE167615Hs 141556Homo sapiens cDNA FLJ12976 fisSS5.4409983D50922Hs 57729Kelch like ECH-associated protBTB, Kelch, SS, TM5.4450184W31096Hs 237617Homo sapiens, clone IMAGE 3447SS5.3431629AU077025Hs 265827interferon, alpha-inducible prpkinase, SH2, SH35.3430413AW842182Hs 241392small inducible cytokine A5 (RIL8, SS5.3440333AI378424Hs 288761hypothetical protein FLJ21749SS, TM, IP_trans, pkinase, pk5.3424927AW973666Hs 153850hypothetical protein C321D2 4SS, TM5.3412276BE262621Hs 73798macrophage migration inhibitorMIF, SS, TM, MIF, sugar_tr5.3416181AA174126Hs 332163ESTsSS, TM, GalP_UDP_transf, Gal5.3440609AI287585Hs. 7301G protein pathway suppressor 2SS, Acyl-CoA_dh, Acyl-CoA_d5.3435327BE301871Hs 4867mannosyl (alpha-1, 3-)-glycoproSS, HLH, Myc_N_term, Myc-LZ,5.2421139AW953933Hs. 301372KIAA1552 proteinSS, TM5.2453449W16752Hs 32981sema domain, immunoglobulin doSS, Sema, ig, PSI, SS, TM, G-al5.2414411X54079Hs 76067heat shock 27kD protein 1HSP20, SS5.2440906AW161556Hs 240170hypothetical protein MGC2731SS, TM, Funn-like, pkinase,5.2421899AJ011895Hs 109281Nef-associated factor 1Virus_HS, bZIP, G-gamma, Myo5.2439473AI215529Hs. 144787ESTsSS5.2451585AK001171Hs. 326422hypothetical protein MGC4549SS, Metallophos5.2407191AA608751gb ae56h07 s1 Stratagene lungSS, Peptidase_C15.2427515T79526Hs 179516integral type I proteinEMP24_GP25L, SS5.2405325C14000786* gi|7023514|dbj|BAA9SS5.2434119AF193844Hs 3758COP9 complex subunit 7aSS5.1413052BE249841gb: 600942857F2 NIH_MGC_15 HomoTM, SS, TM5.1445109AF039916Hs 12330ectonucleoside triphosphate diSS, TM, GDA1_CD39, SS, TM, pho5.1409323H28855Hs 53447Homo sapiens mRNA, cDNA DKFZp7TPR, SS, TM, pkinase, ig5.1438707L08239amino acid system N transporteSS, TM, ACAT, MBOAT, SS, TM, TB5.1442599AF078037Hs. 324051RelA-associated inhibitorSH3, ank, SS, TM, HHH, ig5.1420372AW960049Hs 293660Homo sapiens, clone IMAGE 3535SS5.1436576AI458213Hs 77542ESTsSS, TM, 7tm_1, DnaJ5.1439012BE383814Hs 6455RuvB (E. coli homolog)-like 2AAA, DnaB, UPF0079, SS, Cys_k5.1418910Z25821Hs 89466Homo sapiens, Similar to dodecECH, SS, TM, aminotran_3, ABC5.1414849AW372721Hs. 291623ESTs, Weakly similar to unnameTM, pkinase5.1425743BE396495Hs. 159428BCL2-associated X proteinBcl-2, SS, ferntin, Bcl-2, e5.1418231AA326895Hs 83848triosephosphate isomerase 1TIM, SS, TM, zf-UBP, UCH-2, UB5.0419238AW959538Hs 321214hypothetical protein DKFZp564DSS, TM, WH25.0441917AI989925Hs 24891ESTs, Highly similar to unknowSS, TM, Ammonium_transp5.0437617AI026701Hs 5716KIAA0310 gene productSS, zf-C3HC4, Peptidase_M165.0412867AU076861Hs 74637testis enhanced gene transcripUPF005, SS, TM5.0419579W49529Hs. 296200hypothetical protein AF053356MSP_domain, SS, TM, CUB, NTR,5.0425824AI939563Hs 159589ESTs, Moderately similar to RESS, PHD5.0439414NM_001183Hs 6551ATPase, H transporting, lysosoSS, SS, TM, GDI, Sema, TIG, PSI5.0436042AF284422Hs. 119178cation-chloride cotransporter-SS, TM, aa_permeases, SS, TM,5.0410775AB014460Hs 66196nth (E. coli endonuclease III)-HhH-GPD, SS, TM, REJ, PLAT, PK5.0453350AI917771Hs 61790hypothetical protein FLJ23338SS, SS, TM, EMP70, PA28_alpha4.9400300X03363HER2 receptor tyrosine kinasepkinase4.9426811BE259228Hs. 172609nucleobindin 1efhand, SS, TM, GFO_IDH_MocA4.9421179U72664Hs 148495proteasome (prosome, macropainUIM, SS, TM, PMP22_Claudin, P4.9429762AI346255Hs 216354ring finger protein 5SS, zf-C3HC4, Palm_thioest4.9419250AW770185U5 snRNP-specific protein, 116SS, TM, 7tm_1, BAH, zf-CXXC, D4.9426831BE296216Hs 172673S-adensylhomocysteine hydrolaAdoHcyase, SS4.9442103AA333367Hs 8088similar to S. cerevisiae Sec6pSS4.9414820AA371931Hs 77422proteolipid protein 2 (colonicSS4.9426347AA454912Hs. 169407SAC2 (suppressor of actin mutaSS, RasGEF, RA, RasGEFN, horm4.9423880BE278111Hs 134200DKFZP564C186 proteinUPF0120, SS, TM4.9429545AI824164lymphocyte antigen 6 complex,SS, TM4.9443044N28522Hs. 8935quinolinate phosphoribosyltranQRPTase, ORPTase_N, SS, TM4.9417080BE392848Hs 1063small nuclear ribonucleoproteiSS, S10_plectin4.8441455AJ271671Hs 7854zinc/iron regulated transporteZip, SS, TM, Cytidylyltransf4.8410182NM_001983Hs 59544excision repair cross-complemeHHH, SS, SH3, ank4.8456062AI866286Hs. 71962ESTs, Weakly similar to B36298SS4.8439270BE268278Hs 28393hypothetical protein MGC2592SS, TM, HCO3_cotransp4.8408985BE267317Hs 332040hypothetical protein MGC13010SS, TM, ACAT, LRR4.8416976BE243985Hs 80680major vault proteinVault, SS, TM, kinesin, zf-C24.8436057AJ004832Hs 5038neuropathy target esterasecNMP_binding, SS, TM, cNMP_b4.8424501AI470163Hs 323342actin related protein 2/3 compSS, HhH-GPD4.8409214AW405967Hs 333388Homo sapiens, clone IMAGE 3957SS, EF1BD, P5CR4.8432716AI762964Hs. 205180ESTsSS, TM4.8414460L00727Hs. 898dystrophia myotonica-protein kpkinase, SS, WD404.8443329BE262943Hs 9234hypothetical protein MGC1936SS, TM, SS, TM, gpdh, gpdh_C4.7426120AA325243Hs 166887copine IC2, SS, aminotran_54.7405356ENSP00000247029* SEBOXSS, TM, hemopexin, Somatomed4.7437118AB037857Hs 300591CD9 partner 1TM, ig, SS, TM4.7430609AA302921Hs. 247362dimethylarginine dimethylaminoSS, TM, GST_C, abhydrolase4.7447131NM_004585Hs 17466retinoic acid receptor respondSS, TM, pkinase4.7428469BE549205Hs. 184488flotillin 2Band_7, Flotillin, TM4.7405189Target ExonSS4.7404256NM_024018* Homo sapiens butyroSS, TM, SPRY, SPRY, ig4.7457955AI208986Hs 121647ESTsSS, zf-B_box, SPRY, SS, Nol14.7413201BE275378Hs 13972hypothetical protein MGC12972SS, SH2, RhoGAP, SH3, GILT4.7431115AB015427Hs 250493zinc finger protein 219zf-C2H2, SS4.7442414BE408758Hs 8297nbonuclease 6 precursorribonuclease_T2, SS, nbonu4.7418289AW403103Hs 83951Hermansky-Pudlak syndromeSS4.6436730AA045767Hs 5300bladder cancer associated protSS4.6444596BE560662Hs 11417Rab acceptor 1 (prenylated)SS, TM, tig_chan, ANF_recept4.6433019AI208513Hs 279915translocase of inner mitochondzf-Tim 10_DDP, SS4.6431522AI625859Hs 258609protein tyrosine phosphatase,fn3, Y_phosphatase, SS, TM4.6400846sortilin-related receptor, L(DIdl_recept_a, fn3, Idl_rece4.6422154T79045Hs 168812ESTsSS4.6420321D78761Hs 96657hyothetical proteinSS, tsp_1, SS4.6439921AL110209Hs 6770LCAT-like lysophospholipaseSS, LACT, SS, TM, aa_permease4.6427122AW057736Hs 323910HER2 receptor tyrosine kinasepkinase, Funn-like, Recep4.6426899AL043221Hs 172825KIAA1037 proteinWD40, TPR, SS, TM4.6408116AA251393Hs 289052Homo sapiens, Similar to RIKENSS, TM4.6412974R18978Hs. 75105emopamil-binding protein (sterSS, TM, SS, TM, TBC, rrm, FtsJ4.6426510AW861225Hs 110613BANP homolog, SMAR1 HomologTM4.6414702L22005Hs 76932cell division cycle 34UQ_con, SS, trypsin, ig4.6408135AA317248Hs 42957methyltransferase-like 1Methyltransf_4, SS, p450, Ge4.6445637W58459Hs. 8949hypothetical protein MGC4172SS4.6452190H26735Hs 91668Homo sapiens clone PP1498 unknSS4.6409680W31092Hs 55847mitochondnal ribosomal proteiSS, TM, synaptobrevin4.6421140AA298741Hs 102135signal sequence receptor, deltHerpes_UL3, SS, TM, Sema, pki4.6413407AI356293Hs. 75339inositol polyphosphate phosphaSH2, SAM, SS, Folate_rec4.6402463NM_014624: Homo sapiens S 100 caefhand, S_100, SS, efhand, S4.5426402BE387327Hs 80475polymerase (RNA) II (DNA direcSS, PGAM4.5406939M34515gb Human omega light chain proSS, ig, PH4.5417891W79410Hs 82887protein phosphatase 1, regulatSS, TFIIS4.5426207BE390657Hs. 30026HSPC182 proteinSS4.5423664NM_004714Hs. 130988dual-specificity tyrosine-(Y)-pkinase, SS, Fibnllann, CK4.5432562BE531048Hs 278422DKFZP586G1122 proteinzf-C2H2, SS, TM, FG-GAP, inte4.5427391W60675hypothetical protein FLJ10350SS, SS4.5432893NM_016154Hs 279771Homo sapiens clone PP1596 unknras, arf, SS, 2OG-Fell_Oxy, 24.5424954NM_000546Hs. 1846tumor protein p53 (Li-FraumeniP53, SS4.5413815AL046341Hs 75562discoidin domain receptor famiF5_F8_type_C, pkinase, SS, T4.5448963AA459796Hs 331247Homo sapiens, clone IMAGE 3610SS, TM4.5416297AA157634Hs 79172solute carrier family 25 (mitomito_carr, SS4.5421962D82061Hs 288354FabG (beta-ketoacyl-[acyl-carrSS, adh_short, SS, TM, zf-C3H4.5426726AA488915Hs. 171955trophinin associated protein (SS4.5414427L19711Hs 76111dystroglycan 1 (dystrophin-assSS, TM4.5435891AW249394Hs 5002copper chaperone for superoxidsodcu, HMA, SS, TM, spectrin, 4.5453997AW247615Hs 37003v-Ha-ras Harvey rat sarcoma viras, SS4.5449029N28989Hs. 22891solute carrier family 7 (catioaa_permeases, SS, TM, bZIP4.5432078BE314877Hs 24553hypothetical protein FLJ12541SS, TM4.5409650T08490Hs 288969HSCARG proteinSS, SS, WD404.5412833AW960547Hs 298262ribosomal protein S19SS, TM, ig, ITAM, Ribosomal_S4.4424133AA335721Hs 213628ESTsSS, TM4.4414787AL049332Hs 77311BTG family, member 3SS, Anti_proliferat4.4433046AA229553Hs 279945HSPC023 proteinSS4.4417068AA451910Hs. 85852hypothetical protein MGC3169SS, TM4.4414814D14697Hs 77393famesyl diphosphate synthasepolyprenyl_synt, SS, TM4.4418267BE389537Hs 83919glucosidase IGlyco_hydro_63, SS, PH4.4439902AF174499Hs 6764hiotone deacetylase 6Hist_deacetyl, zf-UBP, SS, G4.4448847AI587180Hs 110906Homo sapiens, Similar to RIKENTM, SS4.4452160BE378541cysteine sulfinic acid decarboSS4.4416121X92762Hs 79021tafazzin (cardiomyopathy, dilaAcyltransferase, SS, TM, GDI4.4449717AB040935Hs 23954cerebral cell adhesion molecutSS, SS4.4425069AA687465Hs 298184potassium voltage-gated channeSS, aldo_ket_red4.4413380AI904232Hs. 75323prohibitinBand_7, SS, Band_7, SH34.4452911AA541537Hs 112619metallothionein 1E (functionalSS, SS, TM, Sec14.4436415BE265254Hs 343258proliferation-associated 2G4,Peptidase_M24, SS, TM, Pepti4.4429218AA225065Hs 198269Target CATSS, Nop4.4447987BE621544Hs 157160hypothetical protein MGC2616SS, NDK, LRRNT, LRRCT, LRR4.4407230AA157857Hs. 182265keratin 19filament, bZIP, SS, filament4.3448886AL137291Hs 22451hypothetical protein FLJ10357SS, PH, RhoGEF, SS, rnaseA4.3421178BE267994Hs 102419zinc finger proteinzf-C2H2, SS, TM4.3454031R36772Hs 71941hypothetical protein MGC15677TM4.3450126BE018138Hs. 24447sigma receptor (SR31747 bindinSS, ig, fn34.3446557U68566Hs 15318HS1 binding proteinSS, TM, MIP, UBA4.3413781J05272Hs 850IMP (inosine monophosphate) deIMPDH_C, IMPDH_N, CBS, NPD, S4.3433251AB040955Hs 322735KIAA1522 proteinSS, SS, zf-C3HC4, SPRY4.3420531AI652069Hs. 98614ribosome binding protein 1 (dobZIP, SS4.3432179X75208Hs. 2913EphB3EPH_Ibd, fn3, pkinase, SAM4.3448988Y09763Hs 22785gamma-aminobutync acid (GABA)Neur_chan_LBD, Neur_chan_m4.3426626AI124572Hs 323879inhibitor of kappa light polypzf-C2H2, SS4.3432956AL037895Hs 279861CGI-31 proteinthiored, SS, TM4.3428970BE276891Hs 194691retinoic acid induced 37tm_3, SS, TM4.3428953AA306610Hs 348183turnor necrosis factor receptorTNFR_c6, SS4.2401128C12000644: gi|5729785|ref|NP_00SS4.2446899NM_005397Hs. 16426podocalyxin-likeSS, TM, SS, TM4.2407151H25836Hs 301527ESTs, Moderately similar to unSS, TNF4.2426613U96132Hs. 171280hydroxyacyl-Coenzyme A dehydroadh_short, SS4.2408616R51604Hs 300842KIAA1608 proteinSS, DENN, DENN4.2446616R65964Hs 334873ESTs, Weakly similar to ALU8_HSS, Zn_carbOpept4.2414467AW903820Hs 85752copine IISS4.2455857T70192gb yc18d03.s1 Stratagene lungSS, TM, isodh4.2401751RAN binding protein 3SS, Orexin, SH2, STAT4.2400563Target ExonSS, Pep_M12B_propep4.2430237AI272144Hs 236522DKFZP434P106 proteinabhydrolase, TM4.2406101C11000273* gi|12656107|gb|AAK0SS, TM, 7tm_14.2421661BE281303Hs 299148hypothetical protein FLJ21801SS, VHP4.2444590AA457456hypothetical protein FLJ20435SS4.2408187AF034373Hs 43509ataxin 2 related proteinSS4.2437696Z83844Hs 5790hypothetical protein dJ37E16 5SS, Hydrolase, SS, Gal-bind4.2400278ENSP00000243264: Dolichyl-diphoSS, TM4.2407394AF005081gb Homo sapiens skin-specificSS4.2447407BE387301Hs 18528Sjogren's syndrome nuclear autSS, HLH, ras, GSHPx4.2410237AI750589Hs. 61258argininosuccinate lyaselyase_1, SS4.1415410AF037332Hs. 278569sorting nexin 17PX, fn3, pkinase, SAM, EPH_lb4.1457757AA434109Hs 12271f-box and leucine-rich repeatSS, F-box, SS, TM, HSF_DNA-bi4.1446388AA292979Hs 7788NPD007 proteinSS, TM4.1412825AW167439Hs 190651Homo sapiens cDNA FLJ13625 fisSS4.1439737AI751438Hs 41271Homo sapiens mRNA full lengthSS, C1q, Collagen4.1422256M64673Hs 1499heat shock transcription factoNA, SS, TM, F-box4.1441164AB023180Hs. 7724KIAA0963 proteinhelicase_C, SS, RNA_pol_H4.1401727Target ExonA_deamin, SS4.1411142NM_014256Hs. 69009transmembrane protein 3Galactosyl_T, SS, Ribosomal4.1458176AI961519Hs 140309Homo sapiens, clone IMAGE 3677SS, pkinase, pkinase_C4.1432178BE265369Hs 272814hypothetical protein DKFZp434ESS, serine_carbpept4.1421537BE383488Hs 105547neural proliferation, differenSS, TM, Glyco_hydro_474.1421380D31833Hs. 1372arginine vasopressin receptor7tm_14.1422702AJ011373Hs 119285chromosome 9 open reading framSS, TM, SS, TM4.1434142U47927Hs 3759ubiquitin specific protease 5zf-UBP, UCH-2, UBA, UCH-1, SS4.1423696Z92546Sushi domain (SCR repeat) contSS, TPR, vwd, sushi, Somatome4.1427407BE268649Hs. 177766ADP-ribosyltransferase (NAD; pBRCT, PARP, zf-PARP, PARP_re4.1413749AI929320Hs 75516tyrosine kinase 2pkinase, SS, TM, ig4.1411927BE274009Hs 772glycogen synthase 1 (muscle)Glycos_transf_1, SS4.1433320D60647Hs 250879ESTs, Highly similar to CTXN RSS, TM, rrm4.1433890AF103801Hs 16361hypothetical proteinDAO, SS4.1452603AW410601Hs. 30026HSPC182 proteinSS4.1444496BE302472Hs. 11314DKFZP564N1363 proteinSS, GKAP, Band_414.1422556NM_006245Hs. 118244protein phosphatase 2, regulatB56, SS, TM, Atrophin-1, Exo4.1447347AA570056Hs 122730ESTs, Moderately similar to KITM, SS4.1428284AA535762Hs 183435NM_004545 Homo sapiens NADH deSS, TM, Josephin, UIM, Joseph4.1426551AA381268Hs. 323947ESTsSS, sushi4.0417782T10149Hs 4243hypothetical protein FLJ12650SS, TM4.0443639BE269042Hs 9661proteasome (prosome, macropainproteasome, SS, TM, LACT, try4.0410039AF207989Hs. 58014Homo sapiens, Similar to G proSS, TM, 7tm_3, SS, TM4.0452715Z21093Hs 30352ribosomal protein S6 kinase, 5pkinase4.0442549AI751601Hs 8375TNF receptor-associated factorzf-C3HC4, MATH, zf-TRAF, SS, 4.0430603AA148164Hs 247280HBV associated factorSS, zf-C3HC4, zf-RanBP, pkin4.0427239BE270447ubiquitin carrier proteinUQ_con, SS, TM4.0402665Target ExonSS, TM, ig, DSPc4.0413818BE161405Hs 79hypothetical protein MGC15429SS, KH-domain, WD40, Ribosom4.0406919M88359gb Homo sapiens DNA-binding prSS, rrm4.0412656AF006011Hs 74375dishevelled 1 (homologous to DSS, PDZ, DEP, DIX, Dishevelle4.0437546AW074836Hs 173984T-box 1SS, TM, T-box, GTP_CDC, LRRCT4.0419489AW411280Hs 90693replication initiation regionzf-C2H2, LIM, TM4.0410043D30612Hs 58167zinc finger protein 282zf-C2H2, KRAB, SS, zf-C2H2, K4.0430067U79458Hs 231840WW domain binding protein 2GRAM, SS4.0408449NM_004408Hs 166161dynamin 1PH, GED, dynamin, dynamin_2, 4.0448099BE621839Hs 61976Homo sapiens cDNA FLJ12947 fisSS4.0436656N35568Hs 5245hypothetical protein FLJ20643SS, TM, sugar_tr, PID4.0424512X53002Hs. 149846integrin, beta 5integrin_B, EGF, SS, TM4.0440346AI923985Hs 59621ESTs, Weakly similar to A40815SS, TM, ig, pkinase3.9420065AW140093Hs 129926ESTsSS, TM3.9426636BE242634Hs 2055ubiquitin-activating enzyme E1ThiF, UBACT, SS, pkinase, UCH3.9421579NM_002975Hs. 105927stem cell growth factor; lymphlectin_c, SS, TM3.9427498NM_003926Hs 178728methyl-CpG binding domain protSS, HLH3.9457820AA341497Hs 31408RAR (RAS like GTPASE)SS, TM, Rhomboid3.9439998BE559554Hs 61790hypothetical protein FLJ23338SS, SS, TM, EMP70, PA28_alpha3.9438662AA223599Hs 6351cleavage and polyadenylation szf-CCHC, zf-CCCH, thaumatin3.9414303NM_004427Hs. 165263early development regulator 2SAM, SS3.9435406F26698Hs 4884calcium/calmodulin-dependent ppkinase, SS, hexokinase, hex3.9414168AW793296Hs. 103845ESTs, Moderately similar to l5SS3.9451982F13036Hs 27373Homo sapiens mRNA; cDNA DKFZp5SS3.9418181U37012Hs 83727cleavage and polyadenylation sCPSF_A, SS, TM3.9402793Target ExonSS, TM, cyclin, cyclin_C3.9418681AA287786Hs. 23449insulin receptor tyrosine kinaSS, SH33.9412621L40397Hs 74137transmembrane trafficking protEMP24_GP25L, SS, TM3.9420631AW976530Hs 28355hypothetical protein FLJ22402SS, TM3.9438483AW966735Hs. 321635ESTs, Weakly similar to A46302SS, TM, IP_trans3.9431472AK001023Hs 256549nucleotide binding protein 2 (fer4_NifH, ParA, APS_kinase3.9447800AL080092Hs 19610DKFZP564N1362 proteinSS, TM, SS, TM3.8436686AW450205Hs. 305890BCL2-like 1TM, Bcl-2, 8H43.8408815AW957974Hs 25485hypothetical protein FLJ22341SS, TM3.8441196BE397802Hs 7744NM_007103*. Homo sapiens NADH dComplex1_51K, SNF2_N, helic3.8433030AW068857Hs. 279929gp25L2 proteinSS, TM, EMP24_GP25L, SS, TM, G3.8408721BE515274Hs 47062polymerase (RNA) II (DNA direcRNA_POL_M_15 KD, SS, COX7a3.8435049AL122067Hs 4746hypothetical protein FLJ21324SS, pfkB3.8431347AI133461Hs 251664insulin-like growth factor 2 (SS, Insulin, Insulin3.8450835BE262773Hs. 25584hypothetical protein FLJ10767ArfGap, SS, vwa, TSPN, fn3, Co3.8414134X60188Hs 861mitogen-activated protein kinapkinase, SS, pkinase, T-box3.8418090U57059Hs 83429tumor necrosis factor (ligand)TNF, SS3.8448832AW245212Hs 22199ECSITSS, rrm3.8447256AW593008Hs 6126hypothetical protein dJ1141E15SS, TM, SS, TM3.8448107D45853Hs 20313protein tyrosine kinase 2 betaFocal_AT, pkinase, SS, Pepti3.8426433L38969Hs. 169875thrombospondin 3TSPN, tsp_3, SS, TM, SEA, TSPN3.8431626AL035681Hs. 265327hypothetical protein DKFZp761ISS3.8430956AI183529Hs 2706glutathione peroxidase 4 (phosGSHPx, SS, TM, ABC_tran3.8450998BE387614Hs 25797splicing factor 3b, subunit 4, SS, TM, sugar_tr, histone3.8434899BE613631Hs. 283565FOS-like antigen-1bZIP, SS, bZIP, cofilin_ADF, 3.8444734NM_001360Hs 118067-dehydrocholesterol reductaseERG4 _ERG24, SS, TM3.8411090BE165650Hs. 339697VPS28 proteinSS, TM, CPSF_A3.8452135AI492175Hs. 21446KIAA1716 proteinSS, DIX, PDZ, DEP, Dishevelle3.8421339AA070224Hs 103561SRp25 nuclear proteinSS3.7406535Target ExonSS, TM, Ribosomal_S19e, ig, l3.7447281AA017018Hs 18021hypothetical protein FLJ20446SS, SS, Tektin, Piwi, PAZ3.7433126AB021262Hs 99816beta-catenin-interacting proteSS, TM3.7425215AF030291Hs. 155165zinc finger protein-like 1PHD, SS, TM, DnaJ, ERG4_ERG243.7420536AL117455Hs 275438histone deacetylase 7AHist_deacetyl, SS, Hist_dea3.7417998AW967420gb EST379495 MAGE resequences, SS, TM3.7430890X54232Hs 2699glypican 1Glypican, SS3.7427863AF189712Hs 181002MLL septin-like fusionSS, GTP_CDC, SS, TM3.7448606BE613362Homo sapiens ubiquitin conjugaSS, TM3.7421961AB032993Hs. 109929likely homolog of rat GRIP-assTM, K_tetra, ion_trans, HLH, 3.7410293AK000047Hs. 61960hypothetical proteinK_tetra, SS3.7425233Z17861Hs 155218E1B-55kDa-associated protein 5SPRY, SAP, SS, TM, SPRY, SAP, p3.7423683BE388699Hs 4188hypothetical protein MGC10812SS, Peptidase_C15, TGF-beta3.7415697AI365603Hs 78605DKFZP566I1024 proteinSS, cpn60_TCP13.7415825Y18024Hs. 78877inositol 1,4,5-trisphosphate 3SS3.7418052AA350659Hs 83347angio-associated, migratory ceWD40, Bacterial_PQQ, TM, UPF3.7444706AK000398Hs 11747hypothetical protein FLJ20391SS, SS, TM3.7407381AA420659Hs 183110ESTs, Weakly similar to ALUC_HSS, TM3.7423432BE252996Hs. 44067ESTsTM3.7444982AK002182Hs 12211GDP-fucose transporter 1SS, TM, DUF6, SS, TM3.7407777AA161071Hs 71465squalene epoxidaseSS, TM, Monooxygenase3.7422715AA332178Hs 119403hexosaminidase A (alpha polypeGlyco_hydro_20, Glyco_hydr3.7422609Z46023Hs 118721sialidase 1 (lysosomal sialidaSS, TM, BNR, SS, TM, SET, HSP703.7414732AW410976Hs 77152minichromosome maintenance defMCM, RIP, SS, zf-C2H2, KRAB3.7452579AA131657Hs 23830ESTsSS, CN_hydrolase3.7419032W81330Hs. 58643ESTs, Highly similar to JAK3BSS, pkinase, SH2, Insulin, pk3.6411165NM_000169Hs 69089galactosidase, alphaMelibrase, Ribosomal_L44, z3.6444000AI095034Hs 135528ESTsSS, HLH3.6441174BE312775Hs 294005Homo sapiens, clone IMAGE.3050SS, TM3.6429491NM_012111Hs. 204041chromosome 14 open reading fraSS3.6438433AB018274Hs 6214KI440731 proteinSS3.6425162BE514851Hs 154886choline kinase-likeCarn_acyltransf, Choline_k3.6429671BE379335Hs 211594proteasome (prosome, macropainAAA, NB-ARC, TM3.6421018AI569028Hs 129888hypothetical protein FLJ14768zf-C2H2, SS, rrm, ENTH3.6433604NM_013442Hs 3439stomatin-like 2Band_7, SS, TM, AAA cdc48_N, 3.6451544AK000429Hs 26570hypothetical protein FLJ20422SS, TM, COX3, SS, TM, SRF-TF3.6444369AV649296Hs 282793ESTsSS3.6406660X65371Hs. 172550polypyrimidine tract binding prrm, beta-tactamase, SS, try3.6456503AW977779Hs 194613ESTsSS, TM, bromodomain, abhydro3.6451711AK000461Hs 26890cat eye syndrome chromosome reSS, SS, TM, A_deaminase3.6425394AA356730Hs 323949kangai 1 (suppression of tumorSS, TM, transmembrane43.6428011BE387514Hs 181418KIAA0152 gene productAcyl-CoA_dh, SS, efhand3.6407627AI419020Hs 62620chromosome 6 open reading framSS3.6436437F12200Hs. 5811chromosome 21 open reading fraSS, Syja_N, Exo_endo_phos3.6419418X75621Hs 90303tuberous sclerosis 2Rap_GAP, Tuberin, Peptidase3.6440300N39760Hs 8859Homo sapiens, Similar to RIKENSS3.6448136AA036680Hs 20447protein kinase related to S cpkinase, PBD3.6435977AL138079Hs 5012brain-specific membrane-anchorSS, TM, SS, TM, ubiquitin, Rib3.6419095AA234009Hs. 188715ESTspkinase, PH, pkinase_C3.6447267AL360143Hs 17936DKFZP434H132 proteinSS3.6418054NM_002318Hs 83354lysyl oxidase-like 2SRCR, Lysyl_oxidase, SS, TM, 3.6444354AA847582Hs 10927hypothetical protein R33729_1SS3.6429098AF030249Hs 196176enoyl Coenzyme A hydratase 1, ECH, Herpes_V23, SS, Gal-bin3.6430622BE616971Hs. 247478Homo sapiens, Similar to DNA sG-patch, SS, TM, ubiquitin, a3.6440675AW005054Hs. 47883ESTs, Weakly similar to KCC1_Hpkinase3.6409678NM_005632Hs 55836small optic lobes (Drosophila)TM, Peptidase_C23.6413097BE383876Hs 75196ankyrin repeat-containing protank, SET, SS, TM, pkinase, SH23.6427579AA366143Hs 179669hypothetical protein FLJ20637HECT, SS, HECT3.6409154U72882Hs 50842interferon-induced protein 35SS, ras, Ribosomal_L27e, KOW3.5448528BE613248Hs 172084Homo sapiens, clone IMAGE 3627SS, PID, SH23.5444426AL121105Hs 11170RNA binding motif protein 14mm, SS, spectrin, PH, rrm, so3.5409297R34662Hs. 53066hsp70-interacting proteinSS3.5441138T56785Hs 10101hypothetical protein FLJ12875SS3.5435169AF148509Hs 279881mannosidase, alpha, class 1B, TM, Glyco_hydro_473.5422575AK000546Hs 118552hypothetical protein FLJ20539TM, SS, TM, SRCR, Glyco_trans3.5403325C2000428* gi|7705383|ref|NP_05SS3.5437895AB014568Hs. 5898KIAA0668 proteinTM, UL21, Lipoprotein_6, GBP3.5449030AI365582Hs. 57100Homo sapiens mRNA for FLJ00016SS, Synuclein3.5426542AF190746Hs 170310cat eye syndrome chromosome reA_deaminase, SS, TM, Hydrola3.5439873BE159253Hs 300638ESTsSS3.5428950BE311879Hs 194673phosphoprotein enriched in astDED, SS, TM, Calsequestrin3.5421564AB007864Hs. 105850KIAA0404 proteinSS3.5441094U33819Hs. 7647MYC-associated zinc finger proSS, zf-C2H2, LIM, PHD, TFIIS, 3.5450007BE270693Hs 24301polymerase (RNA) II (DNA direcNA, SS3.5422898AL043101Hs 127401DKFZP434A163 protein, selectivSS, TM3.5444914AA046947Hs 12142WD repeat domain 13WD40, SS, TBC, rrm3.5420178D50550Hs. 95659lethal giant larvae (DrosophilWD40, SS, TM3.5418984AA421401ribosomal protein L18SS, TM3.5414166AW888941Hs 75789N-myc downstream regulatedNdr, abhydrolase, SS3.5409944BE297925Hs 57687four and a half LIM domains 3LIM, SS3.5421458NM_003654Hs 104576carbohydrate (keratan sulfateSS3.5423599AI805664Hs 31731peroxiredoxin 5AhpC-TSA, SS, hormone_rec, z3.5427715BE245274Hs. 180428KIAA1181 proteinTM, SS, TM, KOW3.5405496Target ExonSS, tubulin, SS3.5417911AA333387Hs 82916chaperonin containing TCP1, sucpn60_TCP1, SS, cpn60_TCP13.5433620AA604520Hs 269468ESTs, Moderately similar to ALSS, UCH-2, UCH-13.5430053AF052155Hs 227949SEC13 (S. cerevisiae)-like 1WD40, SS, TM, E1-E2_ATPase, C3.5458687AW024815Hs. 170088GLUT4 enhancer factorSS3.5424679AL117477Hs. 119960DKFZP727G051 proteinchromo, SS3.5417360AW651703Hs 82023hypothetical protein similar tSS, TM, GDA1_CD39, GDA1_CD393.5439641AI251317Hs. 33184ESTsSS, TM, GYF, actin, PA3.5426437BE076537Hs 169895ubiquitin-conjugating enzyme EUQ_con, SS, TM, Armadillo_se3.5427117BE258946Hs 173611Target CATcomplex1_49 Kd, SS, TM, ITAM, 3.4422051AW327546Hs 111024solute carrier family 25 (mitoSS, mito_carr, SS, mito_carr3.4422759AA316582Hs 224571ESTsSS3.4417230U40998Hs. 81728unc119 (C. elegans) homologSS, glycolytic_enzy3.4450158AK001999Hs. 24545hypothetical protein FLJ11137SS, zf-C2H2, SCAN, TFIIS, SS3.4425421L11669Hs 157145tetracycline transporter-likeSS, TM, SS, TM3.4415515F11327Hs 167406gb HSC2VD101 normalized infantSS3.4427868AI360119Hs 181013phosphoglycerate mutase 1 (braPGAM, SS, TM, Idh3.4comp413503BE410228Hs 75410heat shock 70 kD protein 5 (gluSS, HSP70, homeobox, Hydanto3.4413014AW250533Hs. 75139partner of RAC1 (arfaptin 2)SS, hemopexin, Filamin, NHL, 3.4457655AA622968Hs 71574hypothetical protein FLJ14926SS, P5CR, EF1BD3.4419432AK001459Hs 90375hypothetical protein FLJ10597PEP-utilizers, PEP-utilize3.4421066AU076725Hs 101408branched chain aminotransferasaminotran_4, TM3.4428038AW134756Hs. 192477ESTsSS, Exonuclease, zf-C2H23.4430352AW750535Hs 50742Homo sapiens cDNA FLJ23331 fiTM3.4432647AI807481Hs 278581fibroblast growth factor recepig, pkinase, SS, TM, ig, pkina3.4421310AW630087Hs 103315trinucleotide repeat containinTM, zf-C2H2, SS, PHD3.4420999AA338903Hs 100915peroxisomal biogenesis factorSS3.4409561U58048Hs. 183138procollagen (type III) N-endopSS, TM3.4419727AW160796Hs. 92700DKFZP564O243 proteinHerpes_env, SS, TM, Peptidas3.4421267BE314724Hs 103081ribosomal protein S6 kinase, 7pkinase, pkinase_C, SS3.4411501AB002368Hs 70500KIAA0370 proteinSS, TM, SS, TM3.4448741BE614567Hs 19574hypothetical protein MGC5469SS3.4407103AA424881Hs 256301hypothetical protein MGC13170SS, TM, trypsin3.4422808AA449014Hs 121025chromosome 11 open reading fraSS, TM, trypsin, CUB, ubiquit3.4448173N95657Hs 6820ESTs, Moderately similar to YOSS3.4416535H61851gb yr80e10.r1 Soares fetal livSS, TM, homeobox, LIM3.4406656M16714Hs 181392major histocompatibility complMHC_I, ig, SS, TM3.4435669AI867781Hs 31819HT014SS, abhydrolase_23.4411077AW977263Hs 68257general transcription factor lSS, TM, TGF-beta3.4427062AW327785Hs 173421KIAA1564 proteinSS, Peptidase_M243.4421890AW959486Hs 21732ESTsSS, zf-C3HC4, SPRY3.4412968AW500508Hs. 75102alanyl-tRNA synthetaseDHHA1, SS, tRNA-synt_2c, DHH3.4439496BE616501Hs 32343Homo sapiens, Similar to RIKENSS3.4433659AK001301Hs 3487hypothetical protein FLJ10439WD40, SS, TM, Syntaxin, Synta3.3447578AA912347Hs 136585ESTs, Weakly similar to JC5314SS3.3441722AW960504Hs 173103FE65-LIKE 2SS, TM3.3452345AA293279Hs 29173hypothetical protein FLJ20515DSPc, SS, jmjC, F-box3.3451714AK000344Hs 26898hypothetical protein FLJ20337SS, TBC, FHA, zf-C3HC43.3410633BE546789Hs. 346742hypothetical protein MGC3260SS, TM3.3410609BE298441Hs 287361ADP-ribosylation factor relatearf, ras, SS, arf, Stathmin3.3414775AA992036Hs 172702ESTs, Weakly similar to (defliSS, PCI3.3428495NM_013279Hs 184640hypothetical protein MGC10781SS, TM, XPG_N, XPG_I, 5_3_exo3.3429215NM_005341Hs 2364GLI-Kruppel family member HKR3zf-C2H2, BTB, TP2, K_tetra, S3.3446618AL110307Hs. 15591COP9 subunit 6 (MOV34 homolog, Mov34, SS, zf-C2H2, SCAN3.3444868BE560471Hs 12101hypothetical proteinSS, PCI3.3430041AW247237Hs 227835KIAA1049 proteinSS, TM, 7tm_1, tubulin3.3416950AL049798Hs 80552dermatopontinSS3.3431203AW248421Hs. 250758proteasome (prosome, macropainAAA, Sigma54_activat, SS, TP3.3432714Y12059Hs. 278675bromodomain-containing 4bromodomain, SS, TM, SNF2_N,3.3415674BE394784Hs 78596proteasome (prosome, macropainSS, proteasome, SS, TM, Cadhe3.3426152BE299190Hs 167246P450 (cytochrome) oxidoreductaflavodoxin, FAD_binding, SS3.3418440NM_006936Hs. 85119SMT3 (suppressor of mif two 3,ubiquitin, SS, UQ_con3.3410545U32324Hs 64310interleukin 11 receptor, alphaig, fn3, SS, TM, GalP_UDP_tra3.3409428M33680Hs 54457CD81 antigen (target of antiprtransmembrane4, cyclin, SS,3.3443121Z19267Hs 9006VAMP (vesicle-associated membrTM, MSP_domain3.3453856AA804789Hs. 19447PDZ-LIM protein mystiqueLIM, SS, SH3, Sorb3.3430137NM_005456Hs 234249mitogen-activated protein kinaSS, SH3, PID, SS, PID3.3446427AW295863Hs 119632ESTsSS3.3400747Target Exonfn3, ig3.3445580AF167572Hs 12912skb1 (S pombe) homologSS, SS3.3452568AA805634Hs. 300870Homo sapiens mRNA; cDNA DKFZp5SS, rrm, Ephrin, pkinase, ATP3.3418558AW082266Hs 86131Fas (TNFRSF6)-associated via ddeath, DED, SS, TM3.3401655Target ExonSS3.3429460D56263Hs 203238phosphodiesterase 1B, calmodulPDEase, SS, PDEase3.3416448L13210Hs. 79339lectin, galactoside-binding, sSRCR, SS, TM3.3433038AF192559Hs 279939mitochondrial carrier homologTM, mito_carr, TM3.3440251AW796016Hs 332012Homo sapiens, clone IMAGE 3687SS, TM, SS, TM, IRK3.3412922M60721Hs 74870H2 0 (Drosophila)-like homeo bSS, homeobox, SS3.3432941W04803Hs. 279851hypothetical protein FLJ10241SS, RNase_PH, RNase_PH_C3.3441244BE612935Hs 184052PP1201 proteinSS, TM, WD403.3438175AI376727Hs 122110ESTsSS, TM, trypsin, kringle, fn23.3423024AA593731Hs 325823ESTs, Moderately similar to ALSS, TM, CD36, CD363.3430120AW675298Hs 233694hypothetical protein FLJ11350SS3.3419571AW674962Hs. 91146protein kinase D2pkinase, DAG_PE-bind, PH, DC3.3413019BE281604Hs. 75140low density lipoprotein-relateSS3.3400299X07730Hs 171995kallikrein 3, (prostate speciftrypsin, SS, trypsin, trypsi3.3433519BE263901ESTs, Weakly similar to S37431SS, TM3.2434702AL039734Hs 4099nardilysin (N-arginine dibasicPeptidase_M16, HCO3_cotran3.2422242AJ251760Hs 273385guanine nucleotide binding proG-alpha, arf, SS, G-alpha3.2430480AL079399Hs 241543DKFZP586F1524 proteinSS, TM, hemopexin, Somatomed3.2452438BE514230Hs. 29595JM4 proteinSS, TM, KOW, HLH3.2456939AA431633Hs 163867NM_002488*: Homo sapiens NADH dSS, tRNA-synt_2b, WHEP-TRS,3.2421009AL049709Hs 343357Human DNA sequence from cloneTM3.2411969X12458Hs 72980Protein P3SBF, SS, TM, G6PD, G6PD_C, hex3.2409197N54706Hs. 303025chromosome 11 open reading fraSS3.2417896AA379770Hs 82890defender against cell death 1DAD, SS, TM3.2418026BE379727Hs 83213fatty acid binding protein 4,lipocalin, SS, lipocalin3.2409057AA702305Hs 180060ESTsSS, TGFb_propeptide, TGF-be3.2437869W91976Hs. 290834ESTsSS, TM, SH3, zf-C3HC43.2413211AW967107Hs 109274hypothetical protein MGC4365SS, TM3.2425080AI393498inositol 1,4,5-triphosphate reSS, CTF_NFI3.2445363NM_005993Hs 12570tubulin-specific chaperone dATP-synt_B, HEAT_PBS, SS, TM3.2421943BE616520Hs 343912Homo sapiens, Similar to RIKENSS, TM, SS, TM3.2443337Y07604Hs. 9235non-metastatic cells 4, proteiNDK, SS, adh_short, NDK3.2418885D17530Hs 89434drebrin 1cofilin_ADF, SS, cofilin_AD3.2411817BE302900Hs 72241mitogen-activated protein kinapkinase, SS3.2413891BE271020tumor suppressor deleted in orSS, TM3.2449455T60748Hs 278408hypothetical proteinTM3.2419193D29643Hs 34789dolichyl-diphosphooligosaccharSS, TM, DDOST_48 kD, VP7, SS, T3.2406701AA780613Hs 62954ferritin, heavy polypeptide 1SS, TM, UDPGT3.2436467AW450278Hs 91681ESTs, Weakly similar to DCHUOSS, tRNA-synt_1b, tRNA_bind3.2446334U52427Hs. 14839polymerase (RNA) II (DNA direcS1, SS3.2410270AF279142Hs 195727tumor endothelial marker 1 preSS, TM, EGF, lectin_c, sushi,3.2445411AL137255Hs 12646hypothetical protein FLJ22693SS, hormone_rec, zf-CCCH3.2458018AI199575Hs 37716ESTsSS, TM, Oxysterol_BP3.2426530U24578Hs 278625complement component 4ASS, A2M, NTR, A2M_N.prenyltr3.2445604T08566Hs 12956Tax interaction protein 1PDZ, SS, TM, P2X_receptor, FG3.2443402U77846elastin (supravalvular aorticSS, PDZ, LIM, pkinase3.2432416BE410937Hs 2985emerin (Emery-Dreifuss musculaLEM, SS, Ribosomal_L10e, Acy3.2429662AI929701Hs 211586phosphoinositide-3-kinase, regSH2, SH3, RhoGAP, SS, GILT, SH3.2429150AF120103Hs 197366smoothened (Drosophila) homoloSS, TM, Fz, Frizzled, 7tm_2, S3.2427729AB033100Hs 300646KIAA1274 protein (similar to mSS3.2418151AA864238Hs 83583actin related protein 2/3 compRhoGEF, REV, PH, SS, TM, Ribos3.2comp448250NM_016034Hs. 20776mitochondrial ribosomal proteiRibosomal_S2, SS, lipocalin3.2431158AW859138Hs 136280Homo sapiens cDNA: FLJ22288 fiSS, Exonuclease3.2414292BE388407Hs 75875ubiquitin-conjugating enzyme EUQ_con, SS, TM, SAM_PNT3.2406307Target ExonSS, TM, 7tm_2, SS, TM, 7tm_2, G3.2423325R55565Hs. 347286hypothetical protein FLJ22427SS, TM, Surp, ubiquitin, TBC3.2427584BE410293Hs 179718v-myb avian myeloblastosis virNA, SS3.1419069AA233801ESTs, Weakly similar to CA13_HSS3.1431717BE396150Hs 6945mitochondrial ribosomal proteiSS, TM3.1448381D61580Hs 21036Homo sapiens mRNA, cDNA DKFZp4RhoGAP, SS, TM, SET, zf-CXXC,3.1419394AB011124Hs. 90232KIAA0552 gene productSS, ig3.1436240BE388673Hs 5086hypothetical protein MGC10433SS, TM, Ets, COX6B, transmemb3.1413900AW409747Hs 75612stress-induced-phosphoproteinTPR, SS, TM, DnaJ3.1417920S47833Hs. 82927adenosine monophosphate deaminA_deaminase, SS, G-alpha, GS3.1421819NM_013403Hs 108665zinedinWD40, pkinase, pkinase3.1426362BE267158Hs. 169474DKFZP586J0119 proteinIF-2B, SS, PP2C3.1408917AW249025Hs. 7768fibroblast growth factor (acidSS, bZIP, cofilin_ADF, EGF3.1443099AI372836Hs 9003hypothetical protein FLJ13868TM3.1427022AW245839Hs. 173255small nuclear ribonucleoproteirrm, SS, rrm, SH3, ras, 2OG-Fe3.1452711AW967047Hs 293224ESTs, Weakly similar to T00375SS3.1407236W79485Hs 173980nuclear matrix protein NMP200WD40, SS, TM, PTR2, 7tm_13.1452537AW247390Hs 77735hypothetical protein FLJ11618SS, SNF2_N, helicase_C3.1452139AA099969Hs 16331Homo sapiens cDNA: FLJ21482 fiSS3.1447629AF034790Hs 19105translocase of inner mitochondTim17, SS, TM, pkinase, OTU3.1401097C12000858* gi|7363437|ref|NP_0SS, TM, 7tm_1, SS3.1452736C01164Hs 4232Homo sapiens PAC clone RP1-130SS, SS, TM, TBC, Surp, ubiquit3.1435507AI143579Hs 26510vacuolar protein sorting 33B (SS, Sec1, Sec13.1424934U75370Hs 153880polymerase (RNA) mitochondrialPPR, SS, TM, cNMP_binding, RN3.1413245BE244334Hs 75249ADP-ribosylation factor-like 6SS, TM, kazal, Ribosomal_S8,3.1409858NM_006586Hs 56828trinucleotide repeat containinSS, SS, TM, B563.1424582AF026849Hs 150922BCS1 (yeast homolog)-likeAAA, SS, PI-PLC-X, PH, PI-PLC3.1431677AK000496Hs 306989hypothetical protein FLJ20489SS3.1417947AA323563Hs 325309hypothetical protein FLJ14596SS, TM, PTPA3.1409283NM_004860Hs 52788fragile X mental retardation,KH-domain, SS, TM, HMG_box3.1412813AF086947Hs 74617dynactin 1 (p150, Glued (DrosoCAP_GLY, SS3.1456535AA305079Hs 1342cytochrome c oxidase subunit VCOX5B, SS, p450, actin3.1432482L19267Hs. 275924dystrophia myotonica-containinWD40, SS, pkinase, pkinase3.1437256AL137404Hs. 97871Homo sapiens, clone IMAGE 3845TM, SS3.1440191AI990417tubulin, beta 5SS, formiminotr, prenyltran3.0407972AA827639Hs 18587KIAA1588 proteinSS, TM3.0420890AA434058Hs 1000716-phosphogluconolactonaseGlucosamine_iso, SS3.0440060AI696387Hs 126451ESTs, Weakly similar to A46302SS3.0452222AW806287Hs 21432SEX geneSS, TM, Sema, TIG, PSI, GDI3.0401772NM_014520 Homo sapiens MYB binSS3.0453754AW972580Hs 172753ESTsSS, TM, ras, Ribosomal_S19, T3.0423865H05202Hs 133968FGF receptor activating proteiSS, TM3.0450962BE535647Hs 25723Sjogren's syndrome/sclerodermaSS, TM3.0441954AI744935Hs 8047Fanconi anemia, complementatioTPR, SS, TM, AAA, cdc48_N, Ban3.0412787D87452Hs 74579KIAA0263 gene productzf-CCCH, SS, TM, NTP_transfe3.0422034AC006486Hs 333069Ets2 repressor factorEts, SS, pkinase, PAF-AH_lb3.0450788AI738410ESTsSS, TM3.0452511BE408178Hs. 285165Homo sapiens cDNA FLJ20845 fisSS, thiored, P5CR3.0414380BE391815Hs 75981ubiquitin specific protease 14UCH-2, UCH-1, ubiquitin, SS3.0407597AA043925Hs 339352Homo sapiens brother of CDO (BSS, TM, SS, TM3.0434955BE276128Hs 284286mitochondrial ribosomal proteiSS3.0435632AF220049Hs 43549uncharacterized hematopoieticSS, UQ_con3.0432465D56165Hs 275163non-metastatic cells 2, proteiNDK, SS, NDK3.0430526AF181862Hs 242407G protein-coupled receptor, fa7tm_3, homeobox, SS, TM3.0453412AJ003290gb AJ003290 Selected chromosompkinase3.0446456BE613933Hs. 15106chromosome 14 open reading fraUPF0143, SS3.0433180AB038651Hs 31854K562 cell-derived leucine-zippTM, Acetyltransf, TM, Acetyl3.0447322BE617649Hs 77690RAB5B, member RAS oncogene famSS, oxidored_molyb, heme_1,3.0422268N25485Hs. 330310maternal G10 transcriptG10, SS, WD403.0419578AF064853Hs 91299guanine nucleotide binding proWD40, SS, EPO_TPO3.0446929AA076132Hs 9460Homo sapiens mRNA, cDNA DKFZp5SS, TM, WD403.0Pkey: Unique Eos probeset identifier number ExAccn: Exemplar Accession number, Genbank accession number UnigeneID Unigene number Unigene Title Unigene gene title Pred. Protein Dom: Predicted protein domain R1: Ratio of tumor to normal body tissue


[0390]

40







TABLE 15B








Pkey
CAT Number
Accession

















408215
10478_1
BE614290 AA307674 N35629 AA338538 AI193603




AA781096 AI680061 AI613258 AW276647 BE221263 AI348910 AI985031 AI090078




AI359617 AA666391 AI160210 AI446461 AI355345 AI343638 AI343640 AI275091 M78746 AW262795 AW250002




AA503756 AI934519 AW272086 N26520 AA626639


409938
116091_1
AW974648 AA652153 AA649671 AA078582


411674
1253746_1
AW861123 AW861125 AW856717 AW861116 AW856706




AW856788 AW856774 AW856787 AW856780 AW856782 AW856789 AW856772 AW856784 AW856786 AW856776




AW856635 AW856767


413052
1347214_1
BE249841 BE062657 BE062771 BE062636 BE062813




BE062699 BE062895 BE062747 BE062719 BE293541


413837
139363_1
AW163525 AW163255 AW163385 AI929359 BE279279




AA132590 AW157329 AA584408 AW157252 AI692198 AW003514 T24436




AI765658 AW157459 AI810740 AI659582 AI969924 AI929284 AI340993 AI349083 AW299522 AW664650 AW299513




AAI32529 AI340991 AI912836 AI341293 AI650609 AA279


413891
139759_1
BE271020 AI763358 AI925430 AI806151 AW003726 T15590 AA649945




AW129911 AI570748 T57492 AA828002 AW237602 AW003539




AI139045 AI950958 BE042625 AW778973 AI287859 AI983931 AW515101




AW150029 AI358496 AI621173 AA846016 AI470921




AW169748 AI991000 AW513748 AI04058


414023
1410860_1
BE243628 BE246081 BE247016 BE241984 BE241534 BE246091




BE245679 BE243620 BE245998 BE242329 BE241417 BE241457




BE242522 BE241989 BE241464


416535
1599332_1
H61851 H74099 T67099


417998
171375_1
AW967420 AA210915 AA236991 AA210916


418984
181094_1
AA421401 T49326 AA330666 AA328941 W63573 AA758023




AA976306 H52254 AA877107 BE207784 AW664584 AI924890 AA458586




AI422142 AI891097 AI811174 R69866 T49327 AA233722 AA631138 AA910314




AI379416 AI129321 AA861574 AA635649 AI339443




AW009533 AA677036 AA948287 AA62


419069
181650_3
AA233801 BE383487 AA913939 AI632681 AI813277 AI373652




AW134802 AI863574 AW305364 AI858557 AI670746 AI015036 AI935384




AI935317 AW138668 AW204971 AI765223 AA884146 AA973341 AA234062


419250
183289_2
AW770185 AW296271 H11254 AW403510 AI032786 AA767046




AI376115 AI582209 AA460965 AI868663 AI016900 R05715 AI127382




AI660953 AI023644 H00465 AW959578 AA815039 AW292253 R05714 AA815462




AA235654 AA461274 W24933 AA300091 H00515


420160
191054_1
AI492840 AI287657 AA255989 AI698206 AI468558


421572
204022_1
AA531607 AI565370 AI376907 AI811618 AW138145




AW139465 AA421658 AA293069 AW118141 AI214980 AW663502 AI343486




AI553789 AA650416 AI498947


423696
23112_1
Z92546 AA330586 AI570568 AW341487 AI827050 AW298668




AI792189 AI015693 AI733599 AI572251 AI672488 AW193262 AI244716




AI864375 AI206100 AA912444 AI269365 AI640254 AW772466 AI867336




AA627604 H16914 AA358477 AA338009


425080
246559_1
AI393498 R42314 AI088818 AI696468 AI418641




AA573152 F08817 AI910796 AW338984 R39024 AA729145 BE245956 AI093722




AA541730 F09835 AI242755 AA350447 AA865667 T93903 AW081029 AA493711




AA650030 N35995 N21491 T57002 Z25379 AI906851


427239
27647_1
BE270447 AW409921 BE207288 BE207170 D56355




BE263223 BE408171 BE262243 BE392439 BE292738 BE261776 BE314300 BE267719 BE268715 BE513876 BE295291




BE297066 AA210923 BE407519




H51344 BE622905 AW248281 AW250313 T19021 AA355115 AA316879 BE269633 BE621936 AA290724


427391
27815_1
W60675 AK001212 AA155752 AA878366 AA090872




AB033013 AW249107 AA031890 AA112820 AW366388 N55156 AA326756




AW952294 AA180820 C03570 C04358 W60676 AW248674 AA034989 AA044781




AA074274 H26212 AI800572 AI127583 AI951785 AA856557 AI571746 H23835 AI589543 AI215670


428092
286920_1
AW879141 AA421182 AI734104 AI733923 AA430600


429545
305902_1
AI824164 AI676005 AW129612 AI825903 AA773987




AI823645 AI823860 AA456229 AI824295 AA454622 AI264049 AI090237 AI669787




AI804012 AI306153 W96164 AI298273 AW884073 AW883986


430168
313927_1
AW968343 AA468507 AI478223 AW513008 AI762122 AI554512 AA862642 AA468976


433519
368801_2
BE263901 AA596086 AI190276 AI094806 AI831250 AI572668 AW204652 AI660600 AI922941 R49621


438707
46360_1
L08239 BE618914 AW385394 AW385398 AW385401 AI922683 AA907337




AA160504 AA928142 AA601969 AA010594 BE618528 AA160591


440191
48804_3
AI990417 AI304400 AI193071 AI742483 AW003408 AW131566 AI400201




AI656740 AI309186 AW665173 AW204722 AI215122 AI200785




BE467373 AI147599 AI215120 AI076110 AI803429 AI262491 AI808243 AI281007




AW135212 AW205103 AI754349 AI004801 AI051273




AW768918 AW103289 AI4


443402
5681_1
U77846 AA479373 AA346348 AA348194 M26867 AA728901 AA715367




AA377787 R64236 AI752721 R77311 AA339685 BE074254




AW938712 AW068444 AA330624 AA347098 AA327507 AW391973 AA495763




AA479278 AW605018 T19644 AI204484 AW834745




AW081309 AW090002 AI095659 AI131556 AI56


444590
6116_1
AA457456 AA907921 AI567715 AA579472 T64216 AA373128 F35533




AA722113 T64403 AA653738 F28806 AA595689 AA047537




AA022499 AW440532 F36782 AI554180 AI183767 AI806052 AA160379 AA481678




AI185031 AI148988 AI174482 AA868833 AI674395




AA481440 AI914985 AI698771 AA44


445625
64558_1
BE246743 AA436942 AW024744 AW242177 AA975476 AW385185




R07536 R73462 AV654529 T57442 AI399986 R50073 R48743




AI769689 AI863005 AA317806 AI678000 AW189963 AI986207 AW471273 R73463




AI335104 AI590161 AI469257 AI954604 H21954




T25141 AA856793 R50074 AI708253 AI2


448606
77159_1
BE613362 AA447862 H72036 AA393664 AI681334 AW139128




AA932579 AI302241 AI936800 AW960628 AI492148 C06192 AA336107 AA808008 AW615212 BE297403




BE298978 AI187207 AA928695 AI620631 AA938128 AI346527 AI040261 AA808401 AW130326 AI440313 AA868693




AI653329 AI33246


448677
775217_1
AI560769 AI857497 AW151454


450788
846840_1
AI738410 AW016905 AI971725


452160
901991_1
BE378541 AI863051


453412
966264_1
AJ003290 AJ003288 AW276947


455857
1376021_1
T70192 BE147696


455928
1383899_1
BE170313 BE158339 BE158290


457022
274445_1
AW377258 BE067468 BE067511 BE067515 BE067467 BE067514 AA397442






Pkey: Unique Eos probeset identifier number




CAT number Gene cluster number




Accession Genbank accession numbers








[0391]

41








TABLE 15C








Pkey
Ref
Strand
Nt_position


















400460
8389428
Plus
35559-36295


400563
9844011
Plus
81941-82434


400747
7329330
Minus
71249-71441


400846
9188605
Plus
39310-39474


401097
9965518
Minus
60356-61096


401128
8699792
Plus
37349-37885


401655
9099093
Plus
79556-80132


401727
8134856
Plus
54342-54482


401751
9828651
Plus
139165-139322


401772
9966243
Plus
183917-184042


402365
9454515
Minus
70928-71185


402463
9796896
Minus
8818-8952


402665
8077033
Minus
11824-12090, 14290-14544


402793
6136940
Minus
69012-69165


402916
7406502
Minus
361-474, 541-687


403028
7670577
Minus
114150-114272


403325
8440025
Minus
109763-109926


404256
9367203
Plus
146931-147796


405189
7229907
Minus
168236-168795


405325
6094661
Minus
25818-26380


405356
2155224
Plus
36116-36276


405496
8468968
Plus
147706-148062


406101
9124019
Plus
125325-125831


406307
8576099
Plus
95473-95585, 98900-99180


406535
7711477
Plus
83135-83362






Pkey: Unique number corresponding to an Eos probeset




Ref: Sequence source The 7 digit numbers in this column are Genbank Identifier (GI) numbers. “Dunham I. et al.” refers to the publication entitled “The DNA sequence of human chromosome 22” Dunham, et al (1999) Nature 402: 489-495.




Strand Indicates DNA strand from which exons were predicted.




Nt_position Indicates nucleotide positions of predicted exons.








[0392] Table 16A lists about 811 genes up-regulated in ovarian cancer compared to normal adult tissues that are likely to encode extracellular or cell-surface proteins These were selected as for Table 14A, except that the ratio of “average” ovarian cancer to “average” normal adult tissues was greater than or equal to 4.0, the “average” ovarian cancer level was set to the 96th percentile value amongst various ovarian cancer specimens, the “average” normal adult tissue level was set to the 75th percentile value amongst various non-malignant tissues, the “average” ovarian cancer value was greater than or equal to 80 units, and the predicted protein contained a structural domain that is indicative of enzymatic function or of transducing an intracellular signal, or of being modulatable by small molecules (e g , pkinase, peptidase, phosphatase, or ion_transporter) Predicted protein domains are noted
42TABLE 16APkeyExAccnUniGene IDUnigene TitlePred. Protein Dom.R1407223H96850gb yw03b12 s1 Soares melanocyt58.9430281AI878842Hs 237924CGI-69 proteinmito_carr46.7410418D31382Hs 63325transmembrane protease, serineIdl_recept_a, trypsin41.0431773BE409442Hs.268557pleckstrin homology-like domaiPH37.1438424AI912498Hs.25895hypothetical protein FLJ1499635.3418969W33191Hs 28907hypothetical protein FLJ20258SH335.2453028AB006532Hs 31442RecQ protein-like 4DEAD, helicase_C28.2407722BE252241Hs 38041pyridoxal (pyridoxine, vitaminpfkB28.2451721NM_006946Hs 26915spectrin, beta, non-erythrocytspectrin, PH, CH27.9416819U77735Hs 80205pim-2 oncogenepkinase27.9430397AI924533Hs 105607bicarbonate transporter relateHCO3_cotransp27.7450334AF035959Hs 24879phosphatidic acid phosphatasePAP226.7418945BE246762Hs 89499arachidonate 5-lipoxygenaselipoxygenase, PLAT25.3424420BE614743Hs.146688prostaglandin E synthaseMAPEG25.1412674X04106Hs 74451calpain 4, small subunit (30 K)efhand24.4430023AA158243Hs 227729FK506-binding protein 2 (13 kD)FKBP24.3444672Z95636Hs 11669laminin, alpha 5laminin_EGF, laminin_G, EGF24.0413726AJ278465Hs 75510annexin A11annexin23.1438951U51336Hs 6453inositol 1,3,4-triphosphate 5/oxidored_nitro23.0429099BE439952Hs.196177phosphorylase kinase, gamma 2pkinase23.0431765AF124249Hs 268541novel SH2-containing protein 1SH222.4422645L40027Hs 118890glycogen synthase kinase 3 alppkinase22.4413436AF238083Hs 68061sphingosine kinase 1DAGKc22.3422639AI929377Hs 173724creatine kinase, brainATP-gua_Ptrans, ATP-gua_Pt21.5429869AI907018Hs.15977Target CAT21.3418891NM_002419Hs 89449mitogen-activated protein kinaSH3, pkinase, pyridoxal_deC21.1419138U48508Hs 89631ryanodine receptor 1 (skeletalRYDR_ITPR, RyR, SPRY, ion_tr21.0432866BE395875Hs 279609mitochondrial carner homologmito_carr20.9452875BE275760Hs 30928DNA segment on chromosome 19 (Euk_porin20.8426997BE620738Hs 173125peptidylprolyl isomerase F (cypro_isomerase20.8402916ENSP00000202587* Bicarbonate tHCO3_cotransp20.8425760D17629Hs.159479galactosamine (N-acetyl)-6-sulSulfatase20.7400419AF084545TargetEGF, ig, lectin_c, sushi, Xli20.0419444NM_002496Hs 90443Target CATfer419.5459133U40343Hs 29656cyclin-dependent kinase inhibiank19.2447595AW379130Hs 18953phosphodiesterase 9APDEase19.2422708AB017430Hs.119324kinesin-like 4kinesin, homeobox19.0414837U24266Hs.77448aldehyde dehydrogenase 4 familaldedh18.8429712AW245825Hs.211914ENSP00000233627* NADH-ubiquinooxidored_q618.5425848BE242709Hs 159637valyl-tRNA synthetase 2GST_C, GST_N, Tropomyosin18.4451643M64437Hs 234799breakpoint cluster regionRhoGEF, RhoGAP, PH, C218.1447859AK002194Hs 19851peroxisomal biogenesis factor17.5426457AW894667Hs 169965chimerin (chimaerin) 1DAG_PE-bind, RhoGAP17.3421612AF161254Hs.1061968D6 antigenIdl_recept_a17.1421363NM_001381Hs 103854docking protein 1, 62 kD (downsPH, IRS16.9442739NM_007274Hs 8679cytosolic acyl coenzyme A thioAcyl-CoA_hydro16.8420568F09247Hs 247735protocadherin alpha 10cadherin16.8421445AA913059Hs.104433Homo sapiens, clone IMAGE 4054asp16.8425424NM_004954Hs 157199ELKL motif kinasepkinase, KA1, UBA16.7446329NM_013272Hs 14805solute carrier family 21 (orgakazal, OATP_N, OATP_C16.5406620M81105Hs 146550myosin, heavy polypeptide 9, nmyosin_head, Myosin_tail, I16.4429109AL008637Hs 196352neutrophil cytosolic factor 4PX, SH3, OPR16.3429183AB014604Hs 197955KIAA0704 proteinPH, Oxysterol_BP16.2444664N26362Hs 11615map kinase phosphatase-like prDSPc, Rhodanese16.2427640AF058293Hs.180015D-dopachrome tautomeraseMIF, late_protein_L216.2425123AW205274Hs.154695phosphomannomutase 2PMM16.0416006AA324251Hs 78950branched chain keto acid dehydE1_dehydrog15.8412942AL120344Hs 75074mitogen-activated protein kinapkinase15.8423366Z80345Hs.127610acyl-Coenzyme A dehydrogenase,Acyl-CoA_dh, Acyl-CoA_dh_M15.7426391AW161050Hs 169611second mitochondna-derived ac15.7424568AF005418Hs 150595cytochrome P450, subfamily XXVp45015.5420029BE258876Hs 94446polyamine-modulated factor 1aldo_ket_red15.5433573AF234887Hs 57652cadherin, EGF LAG seven-pass G7tm_2, EGF, cadherin, lamini15.4407619AL050341Hs 37165collagen, type IX, alpha 2Collagen15.3427326AI287878gb qv23f06x1 NCl_CGAP_Lym6 Ho7tm_115.2442620C00138Hs 8535Homo sapiens mRNA for KIAA166815.1458130AA115811Hs.6838ras homolog gene family, memberas, arf15.0449936AA938293Hs 60088hypothetical protein MGC1131415.0409230AA852431Hs 51299NM_021074 Homo sapiens NADH decomplex1_24 kD14.7423801NM_015071Hs.132942GTPase regulator associated WIRhoGAP, SH3, PH14.0419639AK001502Hs 91753hypothetical protein13.6419298AA853479Hs 89890pyruvate carboxylaseCPSase_L_chain, PYC_OADA, H43.6426108AA622037Hs 166468programmed cell death 5DUF12213.5448133AA723157Hs 73769folate receptor 1 (adult)Folate_rec13.5418736T18979Hs 87908Snf2-related CBP activator prohelicase_C, AT_hook13.5436543NM_002212Hs.5215integrin beta 4 binding proteielF613.3431515NM_012152Hs 258583endothetial differentiation, I7tm_113.3429469M64590Hs 27glycine dehydrogenase (decarboGDC-P13.2431462AW583672Hs 256311granin-like neuroendocrine pep13.2444855BE409261Hs 12084Tu translation elongation factGTR_EFTU, GTP_EFTU_D3, GTP13.2423464NM_016240Hs 128856CSR1 proteinCollagen13.1450787AB006190Hs 25475aquaporin 7MIP13.0428539AW410063Hs 184877solute carrier family 25 (mitomito_carr13.0436014AF281134Hs 283741exosome component Rrp46RNaae_PH, RNase_PH_C12.9416866AA297356Hs.80324serine/threonine protein phospMetallophos12.9433867AK000596Hs 3618hippocalcin-like 1efhand12.9411408U76666Hs 69949calcium channel, voltage-depenion_trans12.8432329NM_002962Hs 2960S100 calcium-binding protein AS_100, efhand12.7447887AA114050Hs.19949caspase 8, apoptosis-related cICE_p20, DED, ICE_p1012.7427448BE246449Hs 2157Wiskott-Aldrich syndrome (eczeWH1, PBD, WH212.7428820AA436187Hs 172631integrin, alpha M (complementFG-GAP12.7446603NM_014835Hs 15519oxysterol-binding protein-relaOxysterol_BP12.6422633X56832Hs 118804enolase 3, (beta, muscle)enolase12.6446839BE091926Hs.16244mitotic spindle coiled-coil reTroponin12.6414757U46922Hs.77252fragile histidine triad geneHIT12.5428593AW207440Hs 185973degenerative spermatocyte (hom12.5432370AA308334Hs 274424N-acetylneuraminic acid phosphAntifreeze, NeuB12.5401542C15001413* gi|10645199|ref|NP12.4428782X12830Hs.193400interleukin 6 receptorfri3, ig12.3425999AW513051Hs 332981ESTs, Weakly similar to I38022FAD_binding_212.3422301AI752163Hs 114599collagen, type VIII, alpha 1C1q, Collagen12.2410720AF035154Hs 65756regulator of G-protein signallRGS, G-gamma, DEP12.2407143C14076Hs.332329EST12.1421321NM_005309Hs 103502glutamic-pyruvate transaminaseaminotran_1_212.1425251Z22521Hs 155342protein kinase C, deltapkinase, DAG_PE-bind, pkina12.0431354BE046956Hs 251673DNA (cytoaine-5-)-methyltransfPWWP, PHD12.0420421AF281133Hs 343589exosome component Rrp41RNase_PH, RNase_PH_C12.0416714AF283770Hs 79630CD79A antigen (immunoglobulin-ig, ITAM, Zn_clus12.0427336NM_005658Hs 2134TNF receptor-associated factorMATH12.0409799D11928Hs.76845phosphoserine phosphatase-likeHydrolase11.9436319H90727Hs 5123inorganic pyrophosphatasePyrophosphatase11.9400748NM_022122 Homo sapiens matrix11.9428948BE514362FK506-binding protein 3 (25 kD)FKBP, PIP5K11.8401215C12000457* gi|7512178|pir||T30trypsin11.7401281DKFZP586N2124 protein11.7427397AI929685Hs 177656calmodulin 1 (phosphorylase kiefhand, RrnaAD11.7453496AA442103Hs 33084solute carrier family 2 (facilsugar_tr11.7409608AF231023Hs.55173cadherin, EGF LAG seven-pass G7tm_2, cadherin, GPS, lamini11.7424415NM_001975Hs 146580enolase 2, (gamma, neuronal)enolase11.7447495AW401864Hs 18720programmed cell death 8 (apoptpyr_redox11.6426928AF037062Hs 172914retinol dehydrogenase 5(11-ciadh_short11.6405371NM_005569* Homo sapiens LIM dopkinase, LIM, PDZ11.5416282R86664Hs 167257brain link protein-1Xlink11.4452295BE379936Hs 28866programmed cell death 1011.4430390AB023186Hs 241161KIAA0969 proteinPH11.4430594AK000790Hs 246885hypothetical protein FLJ20783PH11.2443814BE281240Hs 9857carbonyl reductase11.2440242AW295871glucose transporter protein 1011.1447365BE383676Hs 334Rho guanine nucleotide exchangSH3, PH, RhoGEF11.1400843NM_003105*: Homo sapiens sortilldl_recept_a, fn3, ldl_rece11.1422418AK001383Hs 116385hypothetical protein FLJ10521RhoGEF11.0400232NM_001895* Homo sapiens caseinpkinase10.9426828NM_000020Hs 172670activin A receptor type II-likpkinase, Activin_recp10.9431157AI823969Hs 132678ESTsMAPEG10.8422616BE300330Hs 118725selenophosphate synthetase 2AIRS, AIRS_C10.8406779AA412048Hs 279574CGI-39 protein, cell death-reg10.8400389AL135841olfactory receptor, family 2,7tm_110.8402207Target ExonA2M_N, A2M10.8435615Y15065Hs 4975potassium vollage-gated charineion_trans, KCNQ1_channel10.8452434D30934Hs 29549C-type lectin-like receptor-1lectin_c10.7402053C11001722*: gi|11436283|ref|XP10.7418641BE243136Hs 86947a disintegrin and metalloprotedisintegrin, Reprolysin, Pe10.6431512BE270734Hs 2795lactate dehydrogenase Aldh, ldh_C10.6403213NM_019595 Homo sapiens interseSH3, efhand, C2, PH, RhoGEF10.6412158BE241740Hs.785integrin, alpha 2b (platelet gFG-GAP, integrin_A10.6423673BE003054Hs 1695matrix metalloproteinase 12 (mPeptidase_M10, hemopexin10.6403949C10000813*: gi|5453992|ref|NP_010.6457670AF119666Hs 23449insulin receptor tyrosine kinaSH310.5418416U11700Hs.84999ATPase, Cu transporting, betaE1-E2_ATPase, HMA, Hydrolas10.4419594AA013051Hs.91417topoisomerase (DNA) II bindingBRCT10.4422765AW409701Hs 1578baculoviral IAP repeat-containBIR, TK10.4453023AW028733Hs 31439serine protease inhibitor, KunKunitz_BPTI10.4425694U51333Hs 159237hexokinase 3 (white cell)hexokinase, hexokinase210.4438800AB037108Hs.6418seven transmembrane domain orp10.3402478Target ExonCarn_acyltransf10.3444202AL031685Hs.12785KIAA0939 proteinNa_H_Exchanger, ABC2_membr10.3425597U28694Hs 158324chemokine (C-C motif) receptor7tm_110.3413431AW246428Hs.75355ubiquitin-conjugating enzyme EUQ_con10.2415200AL040328Hs 78202SWI/SNF related, matrix associSNF2_N, helicase_C, bromodo10.2414874D26351Hs 77515inositol 1,4,5-triphosphate reRYDR_ITPR, ion_trans, MIR10.2423524AF055989Hs 129738potassium voltage-gated channeion_trans, K_tetra, thaumat10.2457558AF083955Hs.279852G protein-coupled receptor7tm_1, globin10.2445629AI245701Hs 193326fibroblast growth factor recep10.1434314BE392921Hs 3797RAB26, member RAS oncogene famras, arf10.1402497C1001261*: gi|2695979|emb|CAA7010.1449853AF006823Hs 24040potassium channel, subfamily Kion_trans10.0427672AA356615Hs 336916death-associated protein 610.0412048AW866863Hs 73090nuclear factor ot kappa lightRHD, TIG, ank, death10.0410079U94362Hs.58589glycogenin 2Glyco_transf_810.0420319AW406289Hs 96593hypothetical proteinras, art10.0420332NM_001756Hs 1305serine (or cysteine) proteinasserpin9.9405474NM_001093*: Homo sapiens acetylCPSase_L_chain, biotin_lip9.9401507C15000810*: gi|11131272|sp|P7939.9431434BE267696Hs.254105enolase 1, (alpha)enolase9.9447232AW499834Hs 327interleukin 10 receptor, alpha9.8432343NM_002960Hs 2961S100 calcium-binding protein AS_1009.8408931AA251995Hs 334648poly(A) polymerase alphaNTP_transf_29.8421542AA411607Hs.118964ESTs, Weakly similar to KIAA119.8430323U40714Hs 239307tyrosyl-tRNA synthetaseDUF1019.8412270AC005262Hs 73797guanine nucleotide binding proG-alpha, arf9.7424649BE242035Hs 151461embryonic ectoderm developmentWD409.7400772NM_003105*: Homo sapiens sortilIdl_recept_a, fn3, Idl_rece9.7450493M93718Hs 166373nitric oxide synthase 3 (endotflavodoxin, FAD_binding, NO9.7401510NM_017434 Homo sapiens dual oxethand, Ferric_reduct9.7404596Target Exon9.7451367AA923729Hs 26322cell cycle related kinasepkinase9.7417810D28419Hs 82609hydroxymethylbilane synthasePorphobil_deam9.6432855AF017988Hs.279565secreted frizzled-related protFz, NTR9.6424263M77640Hs 1757L1 cell adhesion molecule (hydfn3, ig, IRK9.6430398AF105202Hs 241376potassium voltage-gated channeion_trans, KCNQ1_channel9.6424339BE257148endoglycanMCM9.6429257AW163799Hs 1983652,3-bisphosphoglycerate mutasePGAM9.6407065Y10141gb.H. sapiens DAT1 gene, partiaSNF9.6433938AF161536Hs 284292ubiquinol-cytochrome c reducta9.6409649AA159216Hs 55505hypothetical protein FLJ20442Y_phosphatase, DSPc9.6404968C4001170: gi|6863176|gb|AAF30409.5400833C11000890: gi|3746443|gb|AAC6397tm_19.5410191AI609645NM_021075*: Homo sapiens NADH d9.5444633AF111713Hs 286218junctional adhesion molecule 1ig9.4427747AW411425Hs 180655serine/threonine kinase 12pkinase9.4415169W42913Hs 78089ATPase, vacuolar, 14 kDATP-synt_F9.4432579AF043244Hs 278439nucleolar protein 3 (apoptosisCARD9.4422328X60459Hs 1513interferon (alpha, beta and om9.4445143U29171Hs.75852casein kinase 1, deltapkinase9.4450883NM_001348Hs 25619death-associated protein kinaspkinase9.4414625AA335738Hs 76686glutathione peroxidase 1GSHPx9.3401935Target ExonPH9.3418329AW247430Hs 84152cystathionine-beta-synthasePALP, CBS9.3425242D13635Hs 155287KIAA0010 gene productHECT, IQ9.3400404AF161221kallikrein 14trypsin9.2442332AI693251Hs.8248Target CATfer2, molybdopterin, bac_dn9.2431534AL137531Hs 258890Homo sapiens mRNA; cDNA DKFZp49.2402823C1002456*: gi|9930918|emb|CAC059.1404527peptide YY, 2 (seminalplasmin)GDA1_CD399.1439963AW247529Hs 6793platelet-activating factor acePAF-AH_lb, Lipase_GDSL9.1412970AB026436Hs.177534dual specificity phosphatase 1Rhodanese, DSPc9.1443553AL040535Hs 9573ATP-binding cassette, sub-famiABC_tran9.1400933NM_004347 Homo sapiens caspaseICE_p20, ICE_p10, CARD9.0403268NM_002210*: Homo sapiens integrFG-GAP9.0446673NM_016361Hs 15871LPAP for lysophosphatidic acidacid_phosphat9.0422531AW967280Hs 293894ESTs, Weakly similar to HERC2pkinase9.0421658X84048Hs.301760frequenin (Drosophila) homologethand9.0401885Target Exonkinesin9.0402651NM_000721*: Homo sapiens calciuion_trans9.0457432NM_005136Hs.268538potassium voltage-gated channeISK_Channel9.0433146AB033002Hs 21413solute carrier family 12, (pot9.0420090AA220238Hs 94986ribonuclease P (38 kD)Ribosomal_L7Ae9.0425281AA444390Hs 155482hydroxyacyl glutathione hydrollactamase_B9.0410855X97795Hs.66718RAD54 (S.cerevisiae)-likeSNF2_N, helicase_C9.0407986U32659Hs.41724interleukin 17 (cytotoxic T-ly9.0431131N84730Hs 250616isocitrate dehydrogenase 3 (NAisodh9.0422802NM_004278Hs.27008phosphatidylinositol glycan, cDUF1589.0447958AW796524Hs.68644Homo sapiens microsomal signal9.0438080AA777381Hs 291530ESTs, Weakly similar to ALUC_H9.0418843AJ251016Hs 89230potassium intermediate/small cCaMBD, SK_channel9.0419244AI436567Hs 89761ATP synthase, H transporting,ATP-synt_DE8.9404676Target Exon8.9428744BE267033Hs.192853ubiquitin-conjugating enzyme EUQ_con8.9421474U76362Hs 104637solute carrier family 1 (glutaSDF8.9419056M89957Hs 89575CD79B antigen (immunoglobulin-ig, ITAM8.9424825AF207069Hs 153357procollagen-lysine, 2-oxogluta2OG-Fell_Oxy, Glycos_trans8.9444628U01120Hs 242glucose-6-phosphatase, catalytPAP28.9404199ENSP00000211797*: Helicase SKI2RasGAP, PH8.9428826AL048842Hs 194019attractinlectin_c, CUB, Kelch, PSI, EG8.9410681AW246890Hs 65425calbiridin 1, (28 kD)ethanol8.8415056AB004662Hs 77867adenosine A1 receptor7tm_18.8400471Target Exon8.8406591NM_003888* Homo sapiens retinaaldedh8.8425427AI652662Hs 157205branched chain aminotransferasaminotran_48.8410839NM_006849Hs.66581protein disulfide isomerasethiored, Rho_GDI, gntR8.7430037BE409649Hs 227789mitogen-activated protein kinapkinase8.7450848AI677994Hs 428fms-related tyrosine kinase 3flt3_lig8.7414534BE257293Hs 76366BCL2-antagonist of cell death8.7401454NM_014226*: Homo sapiens renalpkinase8.7408493BE206854Hs 46039phosphoglycerate mutase 2 (musPGAM8.7433333AI016521Hs.71816v-akt murine thymoma viral onchomeobox, pkinase, PH, pkina8.7430432AB037758Hs.241419KIAA1337 proteinPatched8.7406128NM_002920* Homo sapiens regulaOest_recep, zf-C4, hormone8.7419493AF001212Hs 90744proteasome (prosome, macropainPCI8.7439569AW602166Hs 222399CEGP1 proteinCUB, EGF8.6401134C12001198 gi|3183183|sp|Q92142biopterin_H8.6442286W31847Hs 50335cytochrome P450 monooxygenase8.6428376AF119665Hs 184011pyrophosphatase (inorganic)Pyrophosphatase8.6433494AB029396beta-1,3-glucuronyltransferaseGlyco_tranf_438.6427001NM_006482Hs 173135dual-specificity tyrosine-(Y)-pkinase8.6437278AA748017Hs.290145ESTscNMP_binding8.6414463T69078Hs 76177alpha-1-microglobulin/bikuninlipocalin, Kunitz_BPTI8.6421871AK001416Hs 306122glycoprotein, synaptic 2Steroid_dh8.6447827U73727Hs 19718protein tyrosine phosphatase,Y_phosphatase, fn3, ig, MAM8.6403379Target ExonDNA_pol_A8.6446872X97058Hs.16362pynmidinergic receptor P2Y, G7tm_18.6432857NM_016103Hs 279582GTP-binding protein Saraarf, ras8.5420970AA305079Hs 1342cytochrome c oxidase subunit VCOX5B8.5427221L15409Hs 174007von Hippel-Lindau syndromeVHL8.5402209Target ExonA2M_N, A2M8.5400518C10002057* gi|3211705|gb|AAC218.5425606U52112Hs 158331renin-binding protein8.5437965AA843222Hs 193534ESTs, Moderately similar to ALRasGEF8.5433392AF038535Hs 127588synaptotagmin VIIC28.5402191NM_021733* Homo sapiens testis8.5458963AI701393Hs 278728Rad and Gem-related 2 (rat homras8.5431857W19144Hs 271742ADP-ribosyltransferase (NAD, pPARP, PARP_reg8.5457579AB030816Hs.36761HRAS-like suppressor8.5409656NM_005133Hs 288626RCE1, prenyl protein proteaseAbi8.5456373BE247706Hs 89751membrane-spanning 4-domains, s8.4432499BE276633RAB6B, member RAS oncogene famras, art8.4400565Target Exon8.4401960Target ExonBranch8.3432545X52486Hs 3041uracil-DNA glycosylase 2cyclin8.3445303AW362198Hs 12503interleukin 15 receptor, alphasushi8.3404528peptide YY, 2 (seminalplasmin)GDA1_CD398.3428542D79989KIAA0167 gene productank, PH, ArfGap, ras8.3406868AA505445Hs 300697immunoglobulin heavy constant8.3405473NM_001093* Homo sapiens acetylCPSase_L_chain, biotin_lip8.3408601U47928Hs 86122protein A7tm_18.3415008NM_002777Hs.928proteinase 3 (serine proteinastrypsin8.3430258AU076644Hs 236963protein phosphatase 2A, regula8.3436483AJ272063Hs 283010vanilloid receptor subtype 1ank, ion_trans8.3459302NM_002314Hs 36566LIM domain kinase 18.3437644AA748575Hs.136748lectin-like NK cell receptorlectin_c8.3421707NM_014921Hs.107054lectomedin-2Latrophilin, OLF, 7tm_2, Gal8.2414629AA345824Hs 76688carboxylesterase 1 (monocyte/mCOesterase8.2453898AW003512Hs 232770arachidonate lipoxygenase 38.2424053AF057036Hs.138520collagen-like tail subunit (siCollagen8.2457398BE258532Hs 251871CTP synthaseGATase8.2421504AW402997Hs 105052adaptor protein with pleckstnSH2, PH8.1406495Target ExonSRCR8.1453610AW368882Hs 33818RecQ protein-like 5DEAD, helicase_C8.1424880NM_000328Hs 153614retinitis pigmentosa GTPase reRCC18.1423847U16997Hs 133314RAR-related orphan receptor Chormone_rec, zf-C48.1409829M33552Hs.56729lymphocyte-specific protein 1Caldesmon8.1401180eukaryotic translation elongation_trans, IQ8.1452072BE258857Hs 27744RAB3A, member RAS oncogene famras, arf8.1426484AA379658Hs 272759KIAA1457 proteinIP_trans8.1402453C1002496 gi|7363439|ref|NP_0397tm_18.1457310W28363Hs.239752nuclear receptor subfamily 2,8.1422069AJ010063Hs 343603titin-cap (telethonin)globin, cNMP_binding, pkina8.1400275NM_006513* Homo sapiens seryl-NA8.0434357AW732284Hs 3828mevalonate (diphospho) decarboGHMP_kinases8.0430299W28673Hs 106747senne carboxypeptidase 1 prec8.0413762AW411479Hs 848FK06-binding protein 4 (59 kD)FKBP, TPR8.0402393ENSP00000085284* CDNA FLJ20404RhoGEF, PH8.0429252NM_004658Hs 198312RAS protein activator like 1 (C2, PH, RasGAP, BTK8.0456181L36463Hs 1030ras inhibitorRA, SH2, VPS97.9431493Al791493Hs.129873ESTs, novel cytochrome P450p4507.9451558NM_001089Hs 26630ATP-binding cassette, sub-famiABC_tran, SRP547.8415758BE270465Hs 78793protein kinase C, zetapkinase, DAG_PE-bind, pkina7.8419270NM_005232Hs 89839EphA1EPH_Ibd, pkinase, SAM, fn37.8422837U25441Hs 121478dopamine receptor D37tm_17.8401118Target Exonpkinase7.8426440BE382756Hs 169902solute carner family 2 (facilsugar_tr7.8418635L11329Hs 1183dual specificity phosphatase 2DSPc, Rhodanese, Y_phosphat7.8432747NM_014404Hs 278907calcium channel, voltage-depenPMP22_Claudin7.8403672C4001244 gi|539933|pir||A61275tubulin7.8437806Al424921Hs.122487ESTs, Weakly similar to A54854RasGAP7.7456890U48213Hs 155402D site of albumin promoter (alDAGKc, bZIP7.7424107AB014606Hs 139648kinesin family member 1Ckinesin, FHA7.7452695AW780199Hs 30327mitogen-activated protein kina7.7433262Al571225Hs 2484171KIAA1535 proteincNMP_binding, ion_ion_trans7.7424198AB029010Hs 143026KIAA1087 proteinNa_Ca_Ex, Calx-beta7.6406496Target ExonSRCR7.6425423NM_005897Hs.157180intracisternal A particle-promBTB, Kelch7.6402211KIAA0430 gene production_trans, K_tetra7.6408710Y10256Hs.47007mitogen-activated protein kinapkinase, SAM_decarbox7.5457615W56321Hs 111460calcium/calmodulin-dependent ppkinase7.5402760NM021797* Homo sapiens eosinoGlyco_hydro_18, CBM_147.5425428AL110261Hs 157211DKFZP586B0621 proteinC1q, Collagen7.4423579NM_004121Hs 1675gamma-glutamyltransferase-likeG_glu_transpept7.4413104L42374Hs.75199protein phosphatase 2, regulatB567.4419660BE280337Hs.194693solute carner family 7 (catioaa_permeases7.4424774BE244179Hs.153022TATA box binding protein (TBP)7.4402632Target ExonFz, knngle, ig7.4444159AF116846Hs 10431dead nnger (Drosophila)-likeARID, SNF7.4405714ENSP00000221137: Olfactory rece7tm_17.3442732AA257161Hs 8658hypothetical protein DKFZp434EEGF, laminin_EGF, Xlink, S_m7.3421758BE397336Hs 1422Gardner-Rasheed feline sarcomaSH2, SH3, pkinase7.3415995NM_004573phospholipase C, beta 2PI-PLC-X, PI-PLC-Y, C27.3405137Target Exon7.3402460C1001261* gi|2695979|emb|CAA707.3431398BE616547Hs 2785keratin 17filament7.3429592AB029041Hs 209646KIAA1118 proteinTroponin7.3429225BE250337Hs 198273Target CAT7.2423015U18548Hs 123034G protein-coupled receptor 127.2454373NM_005133Hs.288626RCE1, prenyl protein proteaseAbi7.2440188AK001812Hs.7036N-Acetylglucosamine kinaseROK7.2432920U37689Hs 3128polymerase (RNA) II (DNA direc7.2446143BE245342Hs 306079sec61 homologsecY7.2422201NM_001505Hs.113207G protein-coupled receptor 307tm_17.2440869NM_014297Hs.7486protein expressed in thyroidlactamase_B7.1435099AC004770Hs 4756flap structure-specific endonuXPG_N, XPG_I, 5_3_exonuclea7.1437161AA054477Hs 25391ESTs7.1429683AF148213Hs.211604adisintegrin-like and metallotsp_1, Reprolysin, Pep_M12B7.1426268AF083420Hs 168913serine/threonine kinase 24 (Stpkinase7.1445087AW893449Hs 12303suppreosor of Ty (S. cerevisiaeS1, SH2, Ribosomal_L23, pkin7.1416377AA179930Hs 293867caspase recruitment domain pro7.1421748NM_014718Hs.107809KIAA0726 gene productcadherin7.1426691NM_006201Hs 171834PCTAIRE protein kinase 1pkinase7.0428599AB033078Hs 186613sphingosine-1-phosphate lyasepyndoxal_deC7.0411898BE409714Hs 44856hypothetical protein FLJ121167.0427010AW138332muscle RAS oncogene homologras7.0457305BE268048Hs 236494RAB10, member RAS oncogene famras, arf7.0431630NM_002204Hs 265829integrin, alpha 3 (antigen CD4integrin_A, FG-GAP, Rhabd_g7.0457764AW028284Hs 4815nudix (nucleoside diphosphateNUDIX6.9435575AF213457Hs 44234triggering receptor expressedig6.9456488AW015098Hs 301946ESTs, Weakly similar to T308676.9428761AF236119Hs 193076GRB2-related adaptor protein 2SH2,5H36.9430396D49742Hs 241363hyaluronan-binding protein 2trypsin, knngle, EGF6.9422066AW249275Hs 343521malate dehydrogenase 2, NAD (mIdh, Idh_C, adh_short, Semia6.9445937AI452943Hs 321231UDP-Gal betaGlcNAc beta 1,4-gGalactosyl_T_26.9457499AA953015Hs 274370hypothetical protein FLJ20260PH6.8400845NM_003105*: Homo sapiens sortilIdl_recept_a, fn3, Idl_rece6.8416931D45371Hs.80485adipose most abundant gene traC1q, Collagen6.8414915NM_002462Hs.76391myxovirus (influenza) resistandynamin_2, dynamin, GED6.8432990AL036071Hs 279899tumor necrosis factor receptorTNFR_c66.8458128W32474Hs.301746RAP2A, member of RAS oncogeneras, arf, 1dh6.8429542AF038660Hs 206713UDP-Gal: betaGlcNAc beta 1,4-gGalactosyl_T_2, ig6.8401488Target ExonGlyco_hydro_16.7456243AI345001Hs 82380menage a trois 1 (CAK assemblyzf-C3HC46.7424321W74048Hs.1765lymphocyte-specific protein tySH2, SH3, pkinase6.7405187NM_014272. Homo sapiens a disinReprolysin, tsp_1, Pep_M12B6.7413055AV655701Hs 75183cytochrome P450, subfamily IIEp4506.7448496BE379077Hs 130849ESTs, Weakly similar to I38022NADHdh_26.7419667AU077005Hs 92208a disintegrin and metalloprotedisintegrin, Reprolysin, Pe6.7417103Z33905Hs.81218hypothetical protein MGC3597TPR, zf-C3HC4, PHD6.7407687AK002011Hs.37558hypothetical protein FLJ11149FAD_Synth6.7456469NM_005109Hs 95220oxidative-stress responsive 1zf-C2H2, pkinase6.7449546W86248Hs 58819ESTshexokinase6.6428926NM_001702Hs 194654brain-specific angiogenesis in7tm_2, tsp_1, GPS, HRM6.6404953C1002000* gi|12735712|ref|XP_06.6449401AL135401Hs.23557serologically defined colon capro_isomerase6.6429962M69113Hs 226795glutathione S-transferase piGST_C, GST_N6.6421547AA489908Hs 1390proteasome (prosome, macropainClathrin_lg_ch, proteasome6.6430035NM_003463Hs 227777protein tyrosine phosphatase tY_phosphatase, DSPc6.6406867AA157857Hs.182265keratin 19filament, bZIP6.6404946Target Exon3Beta_HSD6.5435213AA092510Hs 5985non-kinase Cdc42 effector prot6.5411201T74588Hs 8509ESTs, Weakly similar to C3HU cA2M_N, A2M6.5419344U94905Hs 277445diacylglycerol kinase, zeta (1ank, DAGKa, DAGKc, DAG_PE-bi6.5426194T50872Hs 2001thromboxane A synthase 1 (platp4506.5424681AA054400Hs.151706KIAA0134 gene producthelicase_C, PRK6.5417903NM_002342Hs.1116lymphotoxin beta receptor (TNFTNFR_c66.5408905AV655783Hs 661Target CAT6.5438646AI973076Hs 231958matrix metalloproteinase 286.5431530X61615Hs 2798leukemia inhibitory factor recfn36.5428883AA436959Hs 258802ATPase, (Na)/K transporting, bNa_K-ATPase6.5404757Target Exon6.4406370interleukin 11trypsin6.4443611NM_014397Hs 9625NIMA (never in mitosis gene a)pkinase6.4424008R02740Hs 137555putative chemokine receptor; G7tm_16.4444912AW247380Hs 12124putative prostate cancer suscelactamase_B6.4454460X66945Hs 748fibroblast growth factor recepig, pkinase6.4432269NM_002447Hs 2942macrophage stimulating 1 receppkinase, Sema, PSI, TIG, A4_E6.4458718AI359476Hs 157699ESTs6.4405282Target ExonCache6.4447245AK001713Hs 17860hypothetical protein FLJ10851E1_dehydrog6.3442297NM_006202Hs 89901phosphodiesterase 4A, cAMP-spePDEase6.3400894C11000129 gi|9938014|ref|NP_067tm_16.3440446NM_013385Hs 7189pleckstrin homology, Sec7 andPH, Sec76.3430886L36149Hs 248116chemokine (C motif) XC recepto7tm_16.3451394NM_003595Hs.26350tyrosylprotein sulfotransferasSulfotransfer6.3436523BE612990Hs 5212single-strand selective monofu6.3422714AB018335Hs 119387KIAA0792 gene productDUF2216.3408924AW295606Hs 236131homeodomain-interacting protei6.3414551AI815639Hs.76394enoyl Coenzyme A hydratase, shECH, Peptidase_U76.3413254U40272Hs 75253isocitrate dehydrogenase 3 (NAisodh6.3415010NM_004203Hs 77783membrane-associated tyrosine-pkinase6.3449761AB009698Hs 23965solute carrier family 22 (orgasugar_tr6.3432221M21191Hs 273415aldolase A, fructose-bisphosphglycolytic_enzy, Adeno_E36.3414513AW239400Hs.76297G protein-coupled receptor kinpkinase, RGS, pkinase_C6.2458516BE010749Hs 255097ESTs6.2417985AA187545Hs 83114crystallin, zeta (quinone reduadh_zinc6.2447507H59696Hs 18747POP7 (processing of precursor,6.2418322AA284166Hs 84113cyclin-dependent kinase inhibiY_phosphatase, DSPc6.2428443BE618106Hs 184326CDC10 (cell division cycle 10,GTP_CDC, M6.2423229AC003965Hs 125532protease, serine, 26trypsin6.2408903BE244377Hs.48876farnesyl-diphosphate farnesyltSQS_PSY, dsrm, z-alpha6.2426176AB000462Hs 167679SH3-domain binding protein 2PH, SH26.1421395D90084Hs 1023pyruvate dehydrogenase (lipoamE1_dehydrog6.1430517S80071Hs 241597solute carrier family 6 (neuroSNF6.1435906AI686379Hs 110796SAR1 proteinarf, ras6.1402758C1001899*: gi|12722636|ref|XP_0Glyco_hydro_186.1434202BE382411Hs 3764guanylate kinase 1Guanylate_kin, CoaE, Viral6.1402115NM_021624 Homo sapiens histami7tm_16.1407601AC002300Hs.37129sodium channel, nonvoltage-gatASC6.1404679Target Exon6.0450739AI732707ESTs, Weakly similar to ALU7_HV1R6.0439888AB040949Hs 6733pancreas-enriched phospholipasC2, PI-PLC-Y, PI-PLC-X, RasG6.0415742BE410243Hs.78769thimet oligopeptidase 1Peptidase_M36.0453190AB002354Hs 32312KIAA0356 gene productPH, PHD, RUN6.0439975AW328081Hs 6817inosine triphosphatase (nucleoHam1p_like6.0412800AW950852Hs 74598polymerase (DNA directed), delhomeobox6.0432805X94630Hs 3107CD97 antigen7tm_2, GPS, EGF6.0418964T74640gb: yc57c12 r1 Stratagene liverA2M_N, A2M6.0417483BE549343Hs.82208acyl-Coenzyme A dehydrogenase,Acyl-CoA_dh, Acyl-CoA_dh_M6.0419755H18444Hs.134846BAI1-associated protein 3C26.0457276AF235097Hs.227583Homo sapiens chromosome X map6.0423908AJ006422Hs 135183centaurin-alphaPH, ArfGap6.0432118N98718gb yy65g02 r1 Soares_multiple5.9427334R44789Hs 33191Homo sapiens, Similar to trans5.9424959NM_005781Hs 153937activated p21cdc42Hs kinasepkinase, SH35.9453082H18835Hs 31608hypothetical protein FLJ20041ion_trans5.9421168AF182277Hs.330780cytochrome P450, subfamily IIBp4505.9422287F16365Hs 114346cytochrome c oxidase subunit VCOX7a, Phage_G5.9401736C16000492* gi|3127193|gb|AAD05AMP-binding5.9434755AA648502ESTs5.9414962AF273304Hs 235376XPMC2 proteinExonuclease5.8407338AA773213gb ab66f10 s1 Stratagene lungig5.8448426BE018315Hs 280776tankyrase, TRF1-interacting an5.8409686AK000002Hs.55879Homo sapiens mRNA, cDNA DKFZp4ABC_tran5.8450778U81375Hs 25450solute carrier family 29 (nuclNucleoside_tran5.8423612NM_002067Hs 1686guanine nucleotide binding proG-alpha, arf5.8430845AF024690Hs 248056G protein-coupled receptor 437tm_15.8424741AF051941Hs 343824nucleoside diphosphate kinaseNDK5.8412958BE391579Hs.75087Fas-activafed serine/threonine5.8415701NM_003878Hs 78619gamma-glutamyl hydrolase (conjGATase5.8423158H97991Hs 193313Target CATMoaA_NifB_PqqE5.8414788X78342Hs 77313cyclin-dependent kinase (CDC2-pkinase5.8412915AW087727Hs 74823NM_004541. Homo sapiens NADH de5.7420904AL035964Hs.100221nuclear receptor subfamily 1,hormone rec, zf-C45.7415503U36601Hs.78473N-deacetylase/N-sulfotransferaSulfotransfer5.7433074AL045019Hs 323462Homo sapiens cDNA FLJ11214 fisDEAD, helicase_C, dsrm, Vira5.7409124AW292809Hs 50727N-acetylglucosaminidase, alpha5.7428270BE501549Hs 107040ESTs5.7435114AA775483Hs.288936mitochondrial ribosomal proteiODC_AZ5.7425211M18667Hs 1867progastricsin (pepsinogen C)asp5.7453054AI878908Hs 31547Target CAT5.7420730NM_002691Hs 99890polymerase (DNA directed), delICL5.7415117AF120499Hs 78016polynucleotide kinase 3′-phospViral_helicase 15.7400985Target Exon5.7413163Y00815Hs.75216protein tyrosine phosphatase,fn3, ig, Y_phosphatase5.7413858NM_001610Hs 75589acid phosphatase 2, lysosomalacid_phosphat5.7457308AI416988Hs 238272inositol 1,4,5-triphosphate reion_trans, RYDR_ITPR, MIR5.7400551C10001991*.gi|6624920|emb|CAB6SRCR5.7433472AI541246Hs 3343phosphoglycerate dehydrogenase2-Hacid_DH, 2-Hacid_DH_C, M5.7409531BE384319Hs 54702xylosylprotein beta1,4-galactoGalactosyl_T_25.7449139BE268315Hs 23111phenylalanine-tRNA synthetase-neur5.7450207T87615Hs 14716ESTs5.7400266NM_002858* Homo sapiens ATP-biABC_tran5.6430713AA351647Hs.2642eukaryotic translation elongatGTP_EFTU, GTP_EFTU_D3, GTP5.6420911U77413Hs 100293O-linked N-acetylglucosamine (TPR5.6405683Target Exon5.6449181X96783Hs 23179synaptotagmin VC25.6414457AW514320Hs 76159ATPase, H transporting, lysosoATP-synt_C5.6415193AL048891Hs 12185hypothetical protein MGC143335.6434883AW381538Hs.19807hypothetical protein MGC129595.6433135AA443873Hs 110477dolichyl-phosphate mannosyltra5.6413049NM_002151Hs 823hepsin (tranamembrane proteasetrypsin5.6420899NM_001629Hs 100194arachidonate 5-lipoxygenase-acMAPEG5.6423397NM_001838Hs.1652chemokine (C-C motif) receptor7tm_15.5443759BE390832Hs 134729FXYD domain-containing ion tra5.5454112NM_000885Hs 40034integrin, alpha 4 (antigen CD4integrin_A, FG-GAP5.5405594NM_021949 Homo sapiens ATPaseE1-E2_ATPase, Hydrolase5.5416322BE019494Hs 79217pyrroline-5-carboxylate reductP5CR, Octopine_DH_N5.5446755AW451473Hs 16134serine/threonine kinase 10pkinase, TYA5.5411030BE387193Hs 678967-60 protein5.5431498AK001777Hs 258551aspartyl aminopeptidasePeptidase_M185.5433012NM_004045Hs 279910ATX1 (antioxidant protein 1, yHMA5.5414907X90725Hs.77597polo (Drosophia)-like kinasepkinase, POLO_box5.5424572M19650Hs 929092′,3′-cyclic nucleotide 3′pho5.5406617Target Exonefhand, Ferric_reduct5.5421883X55079Hs 1437glucosidase, alpha, acid (Pomptrefoil, Glyco_hydro_315.4419525T79257Hs 1259asialoglycoprotein receptor 2lectin_c5.4448093AW977382Hs 158982,4-dienoyl CoA reductase 2, padh_short5.4411574BE242842Hs 6780protein tyrosine kisase 9-likecofilin_ADF5.4406432CD1E antigen, e polypeptideSulfotransfer5.4428921Z43809Hs.194638polymerase (RNA) II (DNA direc5.4430337M36707Hs 239600calmodulin-like 3efhand5.4427162AB011133Hs 173864KIAA0561 proteinpkinase, PDZ5.4414216D86970Hs 75822TGFB1-induced anti-apoptotic foxidored_q4, myosin_head, b5.4422083NM_001141Hs 111256arachidonate 15-lipoxygenase,lipoxygenase, PLAT5.4424373AJ133798Hs 146219copine VIIC25.4449405AA001350gb zh83h05 r1 Soares_fetal_livmito_carr5.4409983D50922Hs.57729Kelch-like ECH-associated protBTB, Kelch5.4455818AI733747Hs 71174interleukin 21 receptor5.4424357AW961058Hs 44856hypothetical protein FLJ121165.4423606AB011094Hs.129892KIAA0522 proteinPH, bZIP, IQ, Sec75.3432311BE083080Hs.274323similar to sialyltransferase 7Glyco_transf_295.3450080AB037831Hs 24372ESTs, Weakly similar to dJ207HDEAD, GSPII_E5.3423778Y09267Hs.132821flavin containing monooxygenasFMO-like, pyr_redox5.3402338Target Exonp4505.3412276BE262621Hs 73798macrophage migration inhibitorMIF5.3437967BE277414Hs.5947mel transforming oncogene (derras, art5.3424766BE388855Hs.152978proteaseome (prosome, macroparPA28_alpha, PA28_beta5.3447766NM_016011Hs 19513CGI-63 proteinadh_zinc5.3453660X98507Hs 286226myosin ICmyosin_head, IQ5.2435327BE301871Hs 4867mannosyl (alpha-1,3-)-glycoproHLH, Myc_N_term, Myc-LZ5.2432336NM_002759Hs 274382protein kinase, interferon-inddsrm, pkinase5.2445139AB037848Hs 12365synaptotagmin XIIIC25.2429214AB012722Hs 198256kinesin-like 3kinesin5.2432462AK000013Hs.274701thymidine kinase 2, mitochondrdNK5.2424387AI739312Hs 284163ANKHZN protein5.2405697gb Human homeobox-like mRNA5.2450321Y16521Hs 24812CDP-diacylglycerol synthase (pCytidylyltrans, Adeno_VII5.1412939AW411491Hs.75069eukaryotic translation elongatSHMT5.1445109AF039916Hs 12330ectonucleoside triphosphate diGDA1_CD395.1419073AW372170Hs 183918Homo sapiens cDNA FLJ12797 fisig, tsp_1, ZU55.1409958NM_001523Hs.57697hyaluronan synthase 1Glycos_transf_25.1442599AF078037Hs 324051ReIA-associated inhibitorSH3, ank5.1424305BE386095Hs 112272histone deacetylase 8Hist_deacetyl5.1427247AW504221Hs.174103integrin, alpha L (antigen CD1vwa, integrin_A, FG-GAP5.1429061Y14039Hs.195175CASP8 and FADD-like apoptosisDED, ICE_p205.1420849X52221Hs.99987excision repair cross-compleme5.1453337R73417Hs.25391gb yj92g12 r1 Soares breast 2NGSPII_III5.1418910Z25821Hs 89466Homo sapiens, Similar to dodecECH5.1425771BE561776Hs 159494Bruton agammaglobulinemia tyroSH2, SH3, pkinase, PH, BTK5.1405202NM_021734* Homo sapiens deoxynmito_carr5.1451452BE560065Hs.26433dolichyl-phosphate (UDP-N-acetGlycos_transf_45.0418231AA326895Hs 83848triosephosphate isomerase 1TIM5.0425165NM_014434Hs 154899Target CAT5.0407876NM_004519Hs 40866potassium voltage-gated channeion_trans, KCNQ1_channel5.0417831H16423Hs.82685CD47 antigen (Rh-related antigig5.0404716NM_007313*: Homo sapiens v-ablSH2, SH3, pkinase5.0405020Target Exon7tm_15.0426236NM_004798Hs 168212kinesin family member 3Bkinesin5.0433178AB038269Hs.253706cysteinyl leukotriene CysLT2r7tm_15.0422340AW296219Hs 115325RAB7, member RAS oncogene famiarf, ras5.0439414NM_001183Hs 6551ATPase, H transporting, lysoso5.0425846AA102174Hs 159629myosin IXBmyosin_head, DAG_PE-bind, I5.0413599AJ006239Hs 75438quinoid dihydropteridine reducadh_short5.0424168L29277Hs 321677signal transducer and activatoSH2, STAT, STAT_bind, STAT_p5.0436042AF284422Hs 119178cation-chlonde cotransporter-aa_permeases5.0410775AB014460Hs.66196nth (E coli endonuclease III)-HhH-GPD5.0428734BE303044Hs 192023eukaryotic translation initiatWD405.0420340NM_000734Hs 97087CD3Z antigen, zeta polypeptideITAM4.9433075NM_002959sortilin 1BNR4.9400300X03363HER2 receptor tyrosine kinasepkinase4.9426811BE259228Hs 172609nucleobindin 1efhand4.9401577NM_000761: Homo sapiens cytochrp4504.9409637AA323948Hs 55407Homo sapiens mRNA, cDNA DKFZp4Collagen4.9426831BE296216Hs.172673S-adenosylhomocysteine hydrolaAdoHcyase4.9430904U65402Hs 248124G protein-coupled receptor 317tm_14.9423552AF107028Hs 129783sodium channel, voltage-gated,ig, Adeno_E3_CR24.9421487AF027406Hs 104865serine/threonine kinase 23pkinase4.9402183NM_004491* Homo sapiens glucocFF4.9456748AW137749Hs.125902ubiquitin specific protease 2UCH-1, UCH-24.9424771BE397151Hs.153003serine/threonine kinase 16pkinase4.9406441Target ExonAa_trans4.9437053AU077018Hs 3235keratin 4filament, bZIP, Tropomyosin4.9443044N28522Hs 8935quinolinate phosphoribosyltranQRPTase, QRPTase_N4.9431204F28841Hs 250760cytochrome c oxidase subunit VdUTPase, COX6A, ras, ATP-syn4.9456417L36531Hs.91296integrin, alpha 8integrin_A, FG-GAP4.8436735L48489mannosyl (beta-1,4-)-glycoprot4.8441455AJ271671Hs.7854zinc/iron regulated transporteZip4.8446948BE409053Hs.299629peroxisomal long-chain acyl-co4.8451564AU076698Hs 132760hypothetical protein MGC15729sugar_tr, Condensation4.8403771NM_003061: Homo sapiens slit (DEGF, laminin_G, LRR, LRRNT, L4.8403248ESTs, Weakly similar to I78885SLT4.8410214L29555Hs 301698sialyltransferase 4A (beta-galGlyco_transf_294.8407047X65965gb H. sapiens SOD-2 gene for masodfe4.8422668AF199364Hs.119120E3 ubiquitin ligase SMURF1C2, WW, HECT4.8436057AJ004832Hs 5038neuropathy target esterasecNMP_binding4.8431262NM_006672Hs 251395solute carrier family 22 (orgasugar_tr4.8406625Y13647Hs 119597stearoyl-CoA desaturase (deltaFA_desaturase4.8428659U66579Hs 188859G protein-coupled receptor 204.8432716AI762964Hs 205180ESTs4.8414460L00727Hs 898dystrophia myotonica-protein kpkinase4.8400287S39329Hs 181350kallikrein 2, prostatictrypsin4.8428946D42046Hs 194665DNA2 (DNA replication helicaseUvrD-helicase, Viral_helic4.7420028AB014680Hs.8786carbohydrate (N-acetylglucosamSulfotransfer4.7402912Target Exonpkinase4.7443329BE262943Hs.9234hypothetical protein MGC19364.7426120AA325243Hs 166887copine IC24.7430609AA302921Hs 247362dimethylarginine dimethylamino4.7451320AW118072diacylglycerol kinase, zeta (1zf-C2H2, BAR, SH34.7447131NM_004585Hs 17466retinoic acid receptor respond4.7431222X56777Hs 273790zona pellucida glycoprotein 3Azona_pellucida4.7406458C14000133* gi|1082739|pir||C44proteasome4.7427804AL049654Hs 180871protein kinase C, alpha bindinPDZ4.7450748AI733093Hs.247686ESTs7tm_14.7422937U03270Hs 122511centrin, EF-hand protein, 1efhand4.7407978AW385129Hs 41717phosphodiesterase 1A, calmodulPDEase4.7428773BE6256238Hs 193163bridging integrator 1SH3, BAR4.7456444AA884517Hs.31856ESTs, Weakly simitar to KIAA144.7405574Target Exonpkinase4.7442414BE408758Hs 8297ribonuclease 6 precursorribonuclease_T24.7418289AW403103Hs 83951Hermansky-Pudlak syndrome4.6421601AI660190Hs 106070cyclin-dependent kinase inhibtCDI4.6422795AB033109Hs 120866KIAA1283 proteinkazal, A2M, A2M_N4.6433019AI208513Hs 279915transfocase of inner mitochondzf-Tim10_DDP4.6431522AI625859Hs.258609protein tyrosine phosphatase,fn3, Y_phosphatase4.6400846sortilin-related receptor, L(DIdl_recept_a, fn3, Idl_rece4.6456881AW028302Hs 155079protein phosphatase 2, regulatB564.6418172X61157Hs 83636adrenergic, beta, receptor kinpkinase, PH, RGS4.6408433AW162931Hs 45002ras-related C3 botulinum toxinras4.6439921AL110209Hs.6770LCAT-like lysophospholipaseLACT4.6427122AW057736Hs 323910HER2 receptor tyrosine kinasepkinase, Furin-like, Recep4.6427945AW137156Hs 181202hypothetical protein FLJ10038Collagen4.6451777U09210Hs 459solute carrier family 18 (vesisugar_tr4.6429938BE296804Hs.226377phosphate cytidylyltransferaseCytidylyltransf, COX6C4.6412974R18978Hs 75105emopamil-binding protein (ster4.6414702L22005Hs 76932cell division cycle 34UQ_con4.6425795AJ000479Hs 159543endothelial differentiation, G7tm,_14.6422454U49070Hs.161362protein (peptidyl-prolyl cis/tRotamase, WW4.6408135AA317248Hs.42957methyltransferase-like 1Methyltransf_44.6457388AF035300Hs 264157cadherin-like 22cadherin, Cadherin_C_term4.6421140AA298741Hs 102135signal sequence receptor, deltHerpes_UL34.6434834AF156774Hs 3240201-acylglycerol-3-phosphate O-aAcyltransferase4.6413407AI356293Hs.75339inositol polyphosphate phosphaSH2, SAM4.6402463NM_014624 Homo sapiens S100 caefhand, S_1004.5417891W79410Hs 82887protein phosphatase 1, regulat4.5421681AA384922Hs 195175CASP8 and FADD-like apoptosisICE_p20, DED4.5426516BE262660Hs.170197glutamic-oxaloacetic transaminaminotran_1_24.5418963BE304571Hs 89529aldo-keto reductase family 1,aldo_ket_red4.5423664NM_004714Hs 130988dual-specificity tyrosine-(Y)-pkinase4.5427681AB018263Hs 180338tumor necrosis factor receptorTNFR_c6, death, PH, Xlink, Rh4.5432893NM_016154Hs.279771Homo sapiens clone PP1596 unknras, arf4.5413815AL046341Hs 75562dincoidin domain receptor famiF5_F8_type_C, pkinase4.5405546NM_018833* Homo sapiens transpABC_membrane, ABC_tran4.5416297AA157634Hs 79172solute carrier family 25 (mitomito_carr4.5421962D82061Hs 288354FabG (beta-ketoacyl-[acyl-carradh_short4.5415341R00602gb: ye74c04 r1 Soares fetal livpkinase4.5456668W81526Hs 118329ESTs, Moderately similar to GANeur_chan_LBD, Neur_chan_m4.5456652AW327546Hs.111024solute carrier family 25 (mitomito_carr4.5407863AA317089Hs 597glutamic-oxaloacetic transaminaminotran_1_24.5435891AW249394Hs 5002copper chaperone for superoxidsodcu, HMA4.5453997AW247615Hs 37003v-Ha-ras Harvey rat sarcoma viras4.5449029N28989Hs 22891solute carrier family 7 (catioaa_permeases4.5424829NM_002507Hs 1827nerve growth factor receptor (death, TNFR_c64.5429362T25833Hs 200478ubiquitin-conjugating enzyme EUQ_con4.5429133N31854Hs 197116solute carrier family 7 (catioaa_permeases4.5426079D31220Hs.166168peter pan (Drosophila) homolog7tm_14.4414814D14697Hs.77393farnesyl diphosphate synthasepelyprenyl_synt4.4433261AB040967Hs 112034KIAA1534 proteinPH, Oxysterol_BP4.4402915ENSP00000202587* Bicarbonate tHCO3_cotransp4.4418267BE389537Hs 83919glucosidase IGlyco_hydro_634.4430716BE387257Hs 247831Homo sapiens, Similar to myosiefhand4.4420874X66357Hs 336478cyclin-dependent kinase 3pkinase4.4439902AF174499Hs.6764histone deacetylane 6Hist_deacetyl, zf-UBP4.4400223Eos controlSkp14.4450611NM_004405Hs 419distal-less homeo box 2homeobox4.4412965L06419Hs 75093procollagen-lysine, 2-oxogluta2OG-Fell_Oxy4.4435564AF210652Hs.166145(3)-deoxyribonucleotidase (dN4.4416121X92762Hs 79021tafazzin (cardiomyopathy, dilaAcyltranferase4.4423323AI951628Hs 127007potassium channel, subfamily Kion_trans4.4448191NM_005881Hs.20644branched chain alpha-ketoacidHATPase_c4.4456217BE253181Hs 81687non-metastatic cells 3, proteiNDK, Arten_glycop4.4436415BE265254Hs 343258proliferation-associated 2G4,Peptidase_M244.4429218AA225065Hs 198269Target CAT4.4407433AF209923gb: Homo sapiens orphan G-prote7tm_34.4425955T96509Hs.248549ESTs, Moderately similar to S64.4407230AA157857Hs.182265keratin 19filament, bZIP4.3410197NM_005518Hs.598893-hydroxy-3-methylglutaryl-CoeHMG_CoA_synt4.3416409R61573Hs 79300ubiquitin-conjugating enzyme EUQ_con4.3447957NM_014821Hs 20126KIAA0317 gene productFilamin, HECT4.3421771NM_001224Hs.108131caspase 2, apoptosis-related cICE_p20, CARD, ICE_p104.3448886AL137291Hs 22451hypothetical protein FLJ10357PH, RhoGEF4.3414821M63835Hs 77424Fc fragment of IgG, high affinig4.3431096AA324358Hs 249227Homo sapiens DNA, cosmid clone4.3429892NM_003803Hs.2504myomesin 1 (skelemin) (185 kD)ig, fn34.3450126BE018138Hs.24447sigma receptor (SR31747 bindin4.3413781J05272Hs.850IMP (inosine monophosphate) deIMPDH_C, IMPDH_N, CBS, NPD4.3406530NM_005546* Homo sapiens IL2-inSH2, SH3, pkinase, PH, BTK4.3428363AK000284Hs 183860hypothetical protein FLJ20277GNT-I4.3413954AL037111Hs 75641galactose-1-phosphate uridylylGaIP_UDP_transf, GaIP_UDP4.3432179X75208Hs.2913EphB3EPH_Ibd, fn3, pkinase, SAM4.3456529AF014643Hs 100072connexin46.6connexin4.3448988Y09763Hs 22785gamma-aminobutyric acid (GABA)Neur_chan_LBD, Neur_chan_m4.3426626AI124572Hs.323879inhibitor of kappa light polypzf-C2H24.3432956AL037895Hs 279861CGI-31 proteinthiored4.3428970BE276891Hs 194691retinoic acid induced 37tm_34.3428953AA306610Hs.348183tumor necrosis factor receptorTNFR_c64.2423922AK001663Hs 135458muscle-specific beta 1 integri4.2426613U96132Hs 171280hydroxyacyl-Coenzyme A dehydroadh_short4.2426566AF131836Hs 170453tropomodulinTropomodulin, pkinase4.2425179AJ224442Hs.155020putative methyltransferase4.2412715NM_000947Hs 74519primase, polypeptide 2A (58 kD)4.2459298R86701gb: ym86d09.r1 Soares adult bra4.2404879NM_030807 Homo sapiens glucose4.2400836Target ExonApolipoprotein4.2430940Z25470Hs 248145melanocortin 5 receptor4.2400563Target ExonPep_M12B_propep4.2430237AI272144Hs 236522DKFZP434P106 proteinabhydrolase4.2425175AF020202Hs.155001UNC13 (C. elegans)-likeDAG_PE-bind, C24.2409067BE260459Hs 50267putative GTP-binding proteinsras4.2419982AA252544Hs 55610solute carrier family 30 (zinc4.2428394AU076472Hs.184141glutaryl-Coenzyme A dehydrogenAcyl-CoA_dh, Acyl-CoA_dh_M4.2437696Z83844Hs 5790hypothetical protein dJ37E16 5Hydrolase4.2454034NM_000691Hs 575aldehyde dehydrogenase 3 familaldedh4.2410237AI750589Hs 61258argininosuccinate lyaselyase_14.1451478NM_012331Hs.26458methionine sulfoxide reductasePMSR4.1415410AF037332Hs.278569sorting nexin 17PX, fn3, pkinase, SAM, EPH_lb4.1406538Target Exontrypsin4.1424349AF141289Hs 145550solute carrier family 7 (catioaa_permeases4.1441164AB023180Hs 7724KIAA0963 proteinhelicase_C4.1421318U63973Hs 103501rhodopsin kinasepkinase, pkinase_C, RGS4.1439340AB032436Hs 6535brain-specific Na-dependent insugar_tr, BT14.1417447N73703Hs.293267ESTsGlyco_hydro_314.1409693AA010233Hs 55921glutamyl-prolyl-tRNA synthetasWHEP-TRS, GST_C, HGTP_antic4.1403655NM_003071. Homo sapiens SWI/SNFSNF2_N, helicase_C, zt-C3HC4.1411142NM_014256Hs.69009transmembrane protein 3Galactosy_T4.1437016AU076916Hs 5398guanine monphosphate synthetasGMP_synt_C, GATase4.1422699BE410590Hs 119257ems1 sequence (mammary tumor aSH3, HS1_rep4.1427202BE272922Hs.173936interleukin 10 receptor, betaTissue_fac4.1421380D31833Hs 1372arginine vasopressin receptor7tm_14.1434142U47927Hs 3759ubiquitin specific protease 5zf-UBP, UCH-2, UBA, UCH-14.1427407BE268649Hs 177766ADP-ribosyltransferase (NAD, pBRCT, PARP, zf-PARP, PARP_re4.1413749AI929320Hs 75516tyrosine kinase 2pkinase4.1411927BE274009Hs.772glycogen synthase 1 (muscle)Glycos_transf_14.1419726U50330Hs.1274bone morphogenetic protein 1EGF, CUB, Astacin4.1423814AF105020Hs 132989putative protein O-mannosyltraPMT, MIR4.1451355NM_004197Hs 444serine/threonine kinase 194.1422556NM_006245Hs 118244protein phosphatase 2, regulatB564.1428284AA535762Hs 183435NM_004545 Homo sapiens NADH de4.1431968AF117222Hs 272261UDP-Gal betaGlcNAc beta 1,3-gaGalactosyl_T4.0443639BE269042Hs 9661proteasome (prosome, macropainproteasome4.0410039AF207989Hs 58014Homo sapiens, Similar to G pro7tm_34.0431066AF026273Hs 249175interleukin-1 receptor-associapkinaae, death4.0452715Z21093Hs 30352ribosomal protein S6 kinase, 5pkinaae4.0403692NM_007037* Hams sapiens a disiReprotysin, tsp_1, Pep_M12B4.0442549AI751601Hs 8375TNF receptor-associated factorzf-C3HC4, MATH, zf-TRAF4.0427239BE270447ubiquitin carrier proteinUQ_con4.0451125AA015779Hs 226923ESTsY_phosphatase4.0425081X74794Hs 154443minichromosome maintenance defMCM4.0402171Target ExonC24.0402665Target Exon4.0420148U34227Hs.95361myosin VIIA (Usher syndrome 1 Bmyosin_head, IQ, MyTH4, SH3,4.0412187U68487Hs 737395-hydroxytryptamine (serotonin7tm_14.0412656AF006011Hs 74375dishevelled 1 (homologous to DPDZ, DEP, DIX, Dishevelled4.0425786U35234Hs 159534protein tyrosine phosphatase,fn3, ig, Y_phosphatase, DSPc4.0424288AW137198Hs 278682Phosphatidylglycerophosphate S4.0452230AW135360Hs 224170ESTspkinase4.0408449NM_004408Hs.166161dynamin 1PH, GED, dynamin, dynamin_24.0423883AF250238Hs.134514ATP-binding cassette, sub-famiABC_tran, photoRC, SRP54, Ca4.0422676D28481Hs 1570histamine receptor H17tm_14.0458639BE247683Hs 14611dual specificity phosphatase 1DSPc4.0400726C13000717* gi|129376|sp|P26196DEAD, helicase_C4.0405370NM_005569* Homo sapiens LIM dopkinase, LIM, PDZ4.0413654AA331881Hs.75454peroxiredoxin 3AhpC-TSA4.0432917NM_014125Hs 241517PRO0327 protein4.0448362AA641767Hs 21015hypothetical protein DKFZp564Lsugar_tr4.0424512X53002Hs 149846integrin, beta 5integrin_B, EGF4.0Pkey: Unique Eos probeset identifier number ExAccn: Exemplar Accession number, Genbank accession number UnigeneID: Unigene number Unigene Title: Unigene gene title Pred. Protein Dom.: Predicted protein domain R1: Ratio of tumor to normal body tissue


[0393]

43







TABLE 16B








Pkey
CAT Number
Accession

















410191
11824_1
AI609645 AI818201 AA948024 AI278970 AA688086 AA858279




F21973 W95840 AW969644 X99726 AA431579 AA970887 AI885085




AI767835 BE566516 AA725824 AI000871 AW242322 AW007204 W68289 AA431450




AW466973 BE222544 AA483454 AI968050 W95975




AI381017 AA776726 AI040976 AA89


415341
1534442_1
R00602 Z42921 F06132


415995
1564_1
NM_004573 M95678 BE242666 AW504110 AW408049 AW402206 AA774879




AW630959 AI439623 AI933994 AW751282 AW374413




AA578823 H18054 AA310466 F12578 T74300 AA353176 AW950138




AW950600 AA912021 AI524064 AW183098 AI416986 AW769231




AI767111 AA293723 AI422290 AA465038 A


418964
1809680_1
T74640 T74649


424339
23827_1
BE257148 BE312111 AF219137 NM_015720 BE313658 BE382652 BE252205 BE251553




F12128 T66208 BE255806 BE254484 AA324163




H07952 AL134164 AI867802 AI204971 AI282924 AW192547 AI652760 AI266471 AI083778


427010
27436_1
AW138332 AW207450 AW138931 AW136963 NM_012219 AF043938 AA931386




AI084600 AA975999 BE551105 AA450260 AI080368




AA324154 AF022080 BE009901 AL118847 W44458 AI765270




AA453121 AI148638 AI373696 AA324153 BE174809 AA350765


427239
27647_1
BE270447 AW409921 BE207288 BE207170 D56355 BE263223 BE408171 BE262243




BE392439 BE292738 BE261776 BE314300 BE267719




BE268715 BE513876 BE295291 BE297066 AA210923 BE407519 H51344 BE622905




AW248281 AW250313 T19021 AA355115 AA316879




BE269633 BE621936 AA290724


427326
277229_1
AI287878 AI804160 AA400787


428542
29266_1
D79989 NM_014770 U81031 AA352392 AA984512 H38328 AL120358 AL134787 AL134589




AI637763 AI671506 AA526909 AI651627




AW243560 AA939069


428948
29737_1
BE514362 AI879343 BE272870 BE616390 AW163444 AW161588 AW378754




AW238803 BE267205 BE047746 BE207213 BE312782




BE266301 BE266413 BE278348 BE280885 BE278833 BE281417 BE407786 BE378176




BE392818 AW377597 BE395951 BE393978




AW327483 BE394175 BE385795 BE275663 BE3


432118
341702_−1
N98718


432499
34857_1
BE276633 NM_016577 AF166492 BE276152 AF091031 AA908607




U66623 AI570393 AA682567 AW593957 AI148105 AW002431 AI637463




AI767195 AA339439 R13005 R23431 AW961068 AA233819 AA224118 R19618 AI890314 Z46184


433075
35820_1
NM_002959 X98248 AA233278 AA846376 AI470560




AI470533 BE327147 AW291971 AA017125 AI198417 AI365213 AI168442 AI337018




AI475049 H85459 AA969895 AA888000 AA418326 AA418378 N71981




AL043634 AA426361 AA418275 AA232975 AL036861 BE277220




BE387505 N99710 AW375004 A


433494
3679_1
AB029396 T04934 R21715 R19005 H11563 H14256 R46605 Z40857 BE218899




AI457785 BE550988 AI693847 AA961017 H40944 M78617




H38447 N80090 BE549719 BE550952 AW005546 AI332686 AI928848 N49234 R44075




AI694943 AI858538 AI290722 BE550759 R43116




H40212 H40089 AA018091


434755
392764_1
AA648502 AA814365 AW976711 AA746117


436735
425_1
L48489 AL022312 D13789 AI761974 AW173260 AW271715 AA837437




AI075278 AI367012 AI953032 AI571173 H44868 AA743691 H47026




AA837368 AA829826 AA713585 AW502618 AW500856 AW501353 AW499765




AA339125 H19141 H29645 R18883 AW450375 AA326081




AW406015 BE263659 N52684 A


440242
489536_1
AW295871 AI005144 AA909877 T52634 AI239684 AA875959




BE171353 AI767633 AW510907 AI742007


449405
80651_1
AA001350 AA203114 H83070 R00660


450739
844917_1
AI732707 AI742120


451320
86576_1
AW118072 AI631982 T15734 AA224195 AI701458 W20198 F26326 AA890570 N90552




AW071907 AI671352 AI375892 T03517 R88265




AI124088 AA224388 AI084316 AI354686 T33652 AI140719 AI720211 T03490




AI372637 T15415 AW205836 AA630384 T03515 T33230




AA017131 AA443303 T33623


459298
983107_1
R86701 R84600 AL157655






Pkey: Unique Eos probeset identifier number




CAT number Gene cluster number




Accession Genbank accession numbers








[0394]

44








TABLE 16C








Pkey
Ref
Strand
Nt_position


















400471
9931670
Minus
105629-105760


400518
9796703
Plus
37240-37774


400551
9801071
Minus
40629-40934


400563
9844011
Plus
81941-82434


400565
9863505
Minus
93178-93429


400726
8118950
Plus
51524-51786


400748
8119063
Plus
84237-84398


400772
8131629
Minus
34896-35021, 41078-41197


400833
8705148
Minus
187599-188138


400836
8954179
Plus
677-1188


400843
9188605
Plus
5863-5970, 7653-7784, 8892-9023, 9673-9807, 10634-10789, 15254-15403, 23827-23958


400845
9188605
Plus
34428-34612


400846
9188605
Plus
39310-39474


400894
9958307
Minus
84607-85554


400933
7651935
Minus
105330-105503


400985
8085497
Minus
5856-6006, 6236-6402


401118
9966714
Minus
111939-112126


401134
7210005
Plus
51210-51406


401180
9438648
Minus
150981-152128


401215
9858408
Plus
103739-103919


401281
9800073
Minus
13622-15130


401454
9186923
Minus
114659-114832


401488
7341775
Plus
54523-54686, 55364-55451, 55737-55846, 58047-58175, 58261-58356


401507
7534110
Plus
71055-71259


401510
7622346
Minus
46835-47126


401542
8072607
Minus
87695-87840


401577
9280797
Minus
139377-139674, 141195-141281, 142217-142340


401736
3219338
Plus
1771-1894


401885
8140731
Plus
148234-148321, 150365-150559


401935
3808091
Plus
46329-46473


401960
3249127
Minus
87589-88081


402053
8083229
Plus
62703-63179


402115
8547592
Minus
101750-102018


402171
8575908
Minus
79357-79514, 83258-83476


402183
7658390
Minus
100618-104298


402191
8576073
Minus
69410-69583


402207
8576119
Plus
41683-41851


402209
8576119
Minus
53315-53472


402211
7689783
Minus
67414-68229


402338
6957691
Minus
36915-37250


402393
9929688
Plus
19813-20084, 20163-20263


402453
7534025
Plus
41-631


402460
9796884
Minus
108901-109254, 110246-110581, 113613-113960


402463
9796896
Minus
8818-8952


402478
9797301
Minus
106204-106535


402497
9797775
Plus
98984-99452


402632
9931268
Plus
101166-101419


402651
7960391
Plus
174215-174380


402665
8077033
Minus
11824-12090, 14290-14544


402758
9213869
Plus
87638-87924


402760
9213869
Plus
136829-136952, 137336-137521


402823
8217451
Plus
57916-58170, 58475-58759, 59580-59867


402912
7263904
Plus
145965-146257, 150876-151368


402915
7406502
Minus
140-276


402916
7406502
Minus
361-474, 541-687


403213
7630897
Minus
162572-162739, 164442-164540


403248
7656833
Minus
167439-167606


403268
7230852
Minus
73832-73962


403379
9438244
Minus
117348-117560


403655
8736093
Plus
65668-65859


403672
7283286
Minus
96600-96881, 96951-97280, 97393-97594


403692
7387384
Minus
93803-93938


403771
7770492
Plus
112901-113045


403949
7711972
Minus
1731-1941


404199
6010176
Minus
1669-2740


404527
8152087
Plus
127737-127796, 128080-128210, 129888-130054, 132545-132869


404528
8152087
Plus
135325-135486


404596
9958262
Minus
104807-105043


404676
9797204
Minus
56167-56342, 58066-58189, 58891-59048, 60452-60628


404679
9797204
Plus
125964-126092, 126691-127011, 127774-127893


404716
9838068
Minus
123145-123417


404757
7706327
Plus
100933-101083, 101580-101782


404879
5103013
Plus
78346-78473, 78693-78893


404946
7382189
Plus
134445-134750


404953
7387324
Plus
16588-17031


404968
6899755
Plus
39287-39606


405020
7137674
Plus
106606-107309


405137
8570507
Plus
158969-159423


405187
7229826
Plus
117025-117170, 118567-118736


405202
7230116
Plus
40209-40429


405282
3810573
Minus
10482-10689


405370
2078469
Minus
38980-39111


405371
2078469
Minus
47657-47766, 48461-48596


405473
8439781
Plus
153074-153343, 154501-154598, 156879-156999, 158863-159051, 159910-160053,





161109-161229, 163035-163131,





165163-165259, 165868-166003, 167375-167552, 169252-169364, 171127-171281


405474
8439781
Plus
172005-172175


405546
1054740
Plus
124010-124183


405574
3820491
Minus
33200-33646


405594
6960456
Plus
161628-161734, 162823-163014, 164439-164652


405683
4508157
Minus
21701-21844


405697
4309923
Minus
56765-57010, 57696-58016


405714
4156179
Minus
42789-43553


406128
9159110
Plus
50425-50876


406370
9256130
Plus
125320-125482


406432
9256504
Plus
3804-3930, 4026-4120, 4929-5109


406441
9280715
Plus
26200-26458


406458
9756020
Plus
145874-146911


406495
7711328
Minus
174661-174978


406496
7711328
Minus
178947-179264, 181779-182087


406530
7711474
Minus
11703-11860, 14711-14829,





14920-14984, 16232-16448, 16916-17087


406538
7711478
Plus
35196-35367, 38229-38476, 40080-40216, 43522-43840


406591
8224230
Minus
2117-2257, 2436-2540


406617
8439858
Plus
36430-36552






Pkey: Unique number corresponding to an Eos probeset




Ref: Sequence source The 7 digit numbers in this column are Genbank Identifier (GI) numbers “Dunham I et al.” refers to the publication entitled “The DNA sequence of human chromosome 22” Dunham, et al (1999) Nature 402: 489-495




Strand Indicates DNA strand from which exons were predicted




Nt_position Indicates nucleotide positions of predicted exons








[0395] Table 17A lists about 779 genes up-regulated in ovarian cancer compared to non-malignant adult ovaries These were selected as for Table 14A, except that the ratio of “average ” ovarian cancer to “average” normal ovaries was greater than or equal to 4.0, the “average” ovarian cancer level was set to the 93rd percentile value amongst various ovarian cancer specimens, the “average” normal adult tissue level was set to the 93rd percentile value amongst various non-malignant adult ovaries, the “average” ovarian cancer value was greater than or equal to 200 units
45TABLE 17APkeyExAccnUniGene IDUnigene TitlePred Protein Dom.R1421296NM_002666Hs 103253perilipinperilipin, SS37.8437897AA770561Hs.146170hypothetical protein FLJ22969SS, TM, zf-DHHC29.2453028AB006532Hs 31442RecQ protein-like 4DEAD, helicase_C, Fork_head27.6441021AW578716Hs.7644H1 histone family, member 227.2422310AA316622Hs.98370cytochrome P450, subfamily IISSS, TM, pkinase, fn3, ig26.5454017AW023617Hs 347130hypothetical protein FLJ22709SS, TM, myosin_head, RA, DAG25.9438424AI912498Hs 25895hypothetical protein FLJ14996SS, TM25.8435017AA336522Hs 12854angiotensin II, type I recepto25.0409518BE384836Hs 3454KIAA1821 proteinSS23.3410418D31382Hs 63325transmembrane protease, serineSS, TM, Idl_recept_a, trypsi22.8439924AI985897Hs.125293ESTsSS22.7446374AA329256Hs.24756ESTs, Moderately similar to al22.6431773BE409442Hs 268557pleckstrin homology-like domaiPH, SS, LIM, Troponin21.4420839AI792682Hs.282960hypothetical protein MGC10870SS, DS, UPF0139, Glyco_hydro21.4413436AF238083Hs 68061sphingosine kinase 1DAGKc21.2424420BE614743Hs 146688prostaglandin E synthaseMAPEG, SS, TM, MAPEG20.7422645L40027Hs 118890glycogen synthase kinase 3 alppkinase, SS, Ets20.7436725BE045223Hs.136912hypothetical protein MGC1079620.4422098H03117Hs.111497similar to mouse neuronal protTM20.2429556AW139399Hs 98988ESTsSS, pkinase, PMP22_Claudin20.1434068AA977935Hs 127274ESTsSS20.0423767H18283Hs 132753F-box only protein 2F-box, SS, F-box, HORMA19.9423652AF052122Hs 130712Homo sapiens clone 23929 mRNAABC1, SS, PID, PID19.8422179AF091619Hs 112667dynein, axonemal, intermediateWD40, SS19.3441356BE384361Hs.182885ESTs, Weakly similar to JC5024SS, TM, ank18.5418969W33191Hs.28907hypothetical protein FLJ20258SH3, SH317.2432631H08379Hs 165563hypothetical protein DKFZp434NTM, DnaJ, UBA, ArfGap, homeob17.2439108AW163034Hs 6467synaptogyrin 3Synaptogyrin, SS, TM, PDZ, WD17.2451643M64437Hs.234799breakpoint cluster regionRhoGEF, RhoGAP, PH, C217.2434518H56995Hs 37372Homo sapiens DNA binding peptiSS16.9413244AW955951Hs 159265kruppel-related zinc finger prSS, TM, BTB, Pep_M12B_propep16.3456642AW451623Hs.109752putative c-Myc-responsive16.2421612AF161254Hs 1061968D6 antigenIdl_recept_a, SS, TM16.0456177NM_012391Hs.79414prostate epithelium-specific EEts, SAM_PNT15.7409261BE315042Hs 19210hypothetical protein MGC1130815.6414837U24266Hs 77448aldehyde dehydrogenase 4 familaldedh15.6401278Target ExonBand_4115.4444804AI084452Hs 22158hypothetical protein FLJ21988SS15.4406620M81105Hs 146550myosin, heavy polypeptide 9, nmyosin_head, Myosin_tail, l15.1421495AI583067Hs 149152ESTs, Weakly similar to RHOP M15.0416893AA455588Hs.62406hypothetical protein FLJ22573SS, rrm, SS15.0442620C00138Hs 8535Homo sapiens mRNA for KIAA1668SS, RNA_pol_K14.9406901M14624gb: Human 4-beta-galactosyltran14.6416006AA324251Hs 78950branched chain keto acid dehydE1_dehydrog14.6455557AW995839gb QV4-BN0044-110200-108-h07 BMetallophos14.4416819U77735Hs 80205pim-2 oncogenepkinase, SS, TM, OTU, K_tetra14.3444441AW613841Hs 301394hypothetical protein MGC310114.0406918M88357gb Homo sapiens DNA-binding przf-C2H2, SS14.0407605W03512Hs 6479hypothetical protein MGC13272SS, Sema, pkinase, TIG, PSI, e13.6447304Z98883Hs 18079phosphatidylinositol glycan, cSS, Peptidase_C213.6402365Target ExonSS, SS, TM, ig13.4407767W15398Hs.38628hypothetical proteinSS, zf-CCCH13.3432931AF174487Hs.293753Bcl-2-related ovarian killer p12.7439233AA831893Hs 292767hypothetical protein FLJ23109zf-C3HC4, TM, Sulfate_trans12.7423801NM_015071Hs.132942GTPase regulator associated wiRhoGAP, SH3, PH12.6430397AI924533Hs 105607bicarbonate transporter relateHCO3_cotransp, SS, TM12.6411570BE144584Hs 314341ESTs12.5400206Eos ControlSS, SS, Glyco_tranf_43, COLF12.3457941AI004525Hs 14587ESTs, Weakly similar to AF1518SS, TM, SS, TM12.2412674X04106Hs.74451calpain 4, small subunit (30 K)efhand, SS, CAP_GLY12.0400460C11002253*: gi|129091|sp|P23267SS, TM, SCAN, zf-C2H2, KRAB12.0417595AA424317Hs.6259KIAA1698 proteinSS, TM, Glyco_hydro_31, Glyc11.6428758AA433988Hs.98502CA125 antigen; mucin 16SS11.5424707BE061914Hs.10844Homo sapiens cDNA FLJ14476 fisSS, SS, TM, Sema11.5444359AI697160Hs 143594ESTs, Weakly similar to HS4L_H11.5435158AW663317Hs 65588DAZ associated protein 1rrm, SS, rrm11.3407688W25317Hs.37616Human D9 splice variant B mRNA11.3450503R35917Hs 301338hypothetical protein FLJ12587SS11.2427448BE246449Hs.2157Wiskott-Aldrich syndrome (eczeWH1, PBD, WH2, SS11.2406230Target Exon11.2432143AL040183Hs 123484Homo sapiens, clone IMAGE: 4178SS, TM, cys_rich_FGFR11.2433573AF234887Hs.57652cadherin, EGF LAG seven-pass GSS, TM, 7tm_2, EGF, cadherin,11.1413726AJ278465Hs.75510annexin A11annexin, SS, annexin11.1431974AW972689Hs.200934ESTsbZIP11.0428167AA770021Hs.16332ESTsSS, ig, fn311.0450461BE408081Hs.46736hypothetical protein FLJ23476SS10.9412738N34731Hs 74562siah binding protein 1, FBP inhomeobox10.9445434BE391690Hs 9265hypothetical protein FLJ20917SS, PWWP, Exonuclease, lipoc10.9444008BE544855Hs 236572ESTs, Weakly similar to SFR4_HSS, SS, SAC3_GANP10.7444410BE387360Hs 33719ESTs, Moderately similar to S6SS10.6444607AW405635Hs.293687ESTsSS, PI-PLC-X, PH, PI-PLC-Y, C10.6404333C7001735* gi|7768636|dbj|BAA95vwd10.5401210C12000519: gi|7710046|ref|NP_0510.5434743AI363410ribosomal protein S18SS, TM10.4434030AW162336Hs.3709low molecular mass ubiquinone-SS10.4450029AW073380Hs 267963hypothetical protein FLJ10535SS, Pyndox_oxidase, zf-C2H10.4439632AW410714Hs 334437hypothetical protein MGC4248SS, TM, transmembrane410.3438185Y19188Hs 320461ESTsSS10.2432031AF039196Hs.272367hairless protein (putative sinjmjC10.2405371NM_005569* Homo sapiens LIM dopkinase, LIM, PDZ10.1456741W37608Hs 184492ESTsSS, pkinase10.1458130AA115811Hs 6838ras homolog gene family, memberas, arf10.0456977AK000252Hs 169758hypothetical protein FLJ2024510.0420029BE258876Hs 94446polyamine-modulated factor 1aldo_ket_red, SS, TM, gla10.0445625BE246743hypothetical protein FLJ22635SS, TM9.9423366Z80345Hs 127610acyl-Coenzyme A dehydrogenase,Acyl-CoA_dh, Acyl-CoA_dh_M9.8458216AW024282Hs.104938hypothetical protein MGC159069.8451721NM_006946Hs 26915spectrin, beta, non-erythrocytspectrin, PH, CH, SS, Peptida9.7421445AA913059Hs 104433Homo sapiens, clone IMAGE 4054asp, SS, TM, ion_trans, K_tet9.7431354BE046956Hs 251673DNA (cytosine-5-)-methyltransfSS, PWWP, PHD9.7443780NM_012068Hs 9754activating transcription factobZIP, NTP_transf_2, SS, TBC9.7448133AA723157Hs.73769folate receptor 1 (adult)Folate_rec, SS9.7444202AL031685Hs 12785KIAA0939 proteinSS, TM, Na_H_Exchanger, ABC29.7427640AF058293Hs 180015D-dopachrome tautomeraseMIF, late_protein_L2, SS, GS9.6419167AI589535Hs.94875ESTs, Weakly similar to A35363SS9.6424618L29472Hs 1802major histocompatibility complTM, ig, MHC_II_beta, SS, TM, A9.6427497AW139476Hs 31240ESTs9.6420423AA827718Hs 88218ESTsSS9.6414756AW451101Hs 159489ESTs, Moderately similar to JChexokinase2, hexokinase9.6407893BE408359Hs.43621Homo sapiens, Similar to hypotSS, SS, arf, ras, fn3, ras9.5408294BE141732gb QV0-HT0101-061099-032-e07 HAmmonium_transp9.5442232AI357813Hs 337460ESTs, Weakly similar to A47582SS, TM, TGFb_propeptide, TGF9.4416866AA297356Hs 80324serine/threonine protein phospMetallophos, Metallophos9.4419823AW271708Hs 118918ESTs, Weakly similar to M2OM_HSS, TM9.4422625AW504698Hs.155976cullin 4BSS, SS, Cullin, Cullin9.3401264C18000090* gi|6678656|ref|NP_0SS, laminin_Nterm, laminin9.3407507U73799gb Human dynactin mRNA, partiaSS, TM, HCO3_cotransp, CAP_G9.2400833C11000890: gi|3746443|gb|AAC639SS, TM, 7tm_19.2422064AW452589Hs 335742ESTsTM9.2452434D30934Hs.29549C-type lectin-like receptor-1lectin_c, SS, TM9.2421363NM_001381Hs 103854docking protein 1, 62 kD (downsPH, IRS, TM, PH, IRS, trypsin,9.1427397AI929685Hs 177656calmodulin 1 (phosphorylase kiefhand, RrnaAD, SS, efhand9.1431462AW583672Hs.256311granin-like neuroendocrine pepSS9.0434796AA812046ESTsSS, myb_DNA-binding, myb_DN9.0422639AI929377Hs.173724creatine kinase, brainATP-gua_Ptrans, ATP-gua_Pt9.0447867AI525268Hs 164303ESTsTM9.0442472AW806859gb MR0-ST0020-081199-004-c03 SSS, TM, Inos-1-P_synth, Occl8.9455588AI129903Hs 74669vesicle-associated membrane prsynaptobrevin, SS, TM8.9454319AW247736Hs 101617ESTs, Weakly similar to T32527SS8.9429527AA454184Hs 289014ESTs8.9432603AA554920Hs 105794UDP-glucose glycoprotein glucoSS, TM8.9410338W03445Hs 38205gb za05g11.r1 Soares melanocytpkinase8.9452833BE559681Hs 30736KIAA0124 proteinWD408.9407363AF035032Hs 181125gb Homo sapiens clone MCA1L mySS, ig, SS, G_glu_transpept8.8414413BE294877gb: 601174162F1 NIH_MGC_17 HomoSS8.8431765AF124249Hs 268541novel SH2-containing protein 1SH2, SS, TM8.8421694BE387430Hs 106880bystin-like8.8453683AL079854Hs 118598Homo sapiens mRNA for KIAA1878SS8.8418736T18979Hs 87908Snf2-related CBP activator proSS, helicase_C, AT_hook, SS,8.7450958AL137669Hs.348012Homo sapiens mRNA; cDNA DKFZp48.7419725U66048Hs 92683Homo sapiens clone 161455 brea8.7415126D60945gb HUM141D04B Clontech human fSS, TM8.7406301Target ExonTM8.6418843AJ251016Hs 89230potassium intermediate/small cTM, CaMBD, SK_channel, TM8.6433396AI742071Hs.133205ESTsSS, TM8.6434333AA186733Hs.292154stromal cell protein8.6407065Y10141gb: H. sapiens DAT1 gene, partiaSNF, SS, TM8.6452851AW173191Hs 213117ESTsSS, Sema8.6422418AK001383Hs 116385hypothetical protein FLJ10521RhoGEF8.6447859AK002194Hs.19851peroxisomal biogenesis factor8.6420836AW958453Hs 204959hypothetical protein FLJ14886SS, ras8.6429099BE439952Hs 196177phosphorylase kinase, gamma 2pkinase, SS, SNF2_N, helicas8.6419639AK001502Hs 91753hypothetical protein8.6429712AW245825Hs 211914ENSP00000233627* NADH-ubiquinooxidored_q6, SS, TM, rrm8.5452554AW452434Hs 58006ESTs, Weakly similar to ALU5_HSS, PAS, HLH8.5441076N49809Hs.11197Homo sapiens, clone IMAGE 33438.5428860U38291Hs 194301microtubule-associated proteinM8.5421901AB014554Hs 109299protein tyrosine phosphatase,SAM, SS, TM, rrm, PDZ8.4441363AW450211Hs 126825ESTs, Weakly similar to A46302SS, TM, HSP20, 7tm_18.4443801AW206942Hs.253594intron of: trichorhinophalangGATA8.4432862AW004958Hs 236720amnionless proteinSS, MATH, zf-TRAF, zf-C3HC48.4431849AI670823Hs 85573hypothetical protein MGC10911SS, TM8.4423662AK001035Hs 130881B-cell CLL/lymphoma 11A (zincSS8.3404365Target ExonSS8.3425694U51333Hs 159237hexokinase 3 (white cell)hexokinase, hexokinase2, he8.3423098AA321980Hs 204682ESTs8.3434552AA639618Hs 325116Homo sapiens, clone MGC: 2962,SS8.2418361AW505368Hs.12460gb: UI-HF-BN0-alu-d-03-0-Ul r18.2427433D82070Hs 177972chromosome 4 open reading framSS, pkinase8.2420138BE268854Hs 177729ESTsSS8.2426391AW161050Hs 169611second mitochondria-derived acSS8.1457613AA598869Hs 173770ESTs8.1427502AI811865Hs.7133Homo sapiens, clone IMAGE 3161SS, TM, ABC_tran, Glyco_tran8.1437215AL117488Human clone 23564 mRNA sequencSS8.1423384AL133632Hs 127808Homo sapiens mRNA; cDNA DKFZp48.1447151AI022813Hs 92679Homo sapiens clone CDABP0014 mSS, TM, LRR, aminotran_1_28.0431898AK000020Hs.272018hypothetical protein FLJ200138.0454291AW384847Hs 213534ESTs, Weakly similar to MUC2_HSS, XRCC1_N, BRCT, lactamase8.0430354AA954810Hs 239784human homolog of Drosophila ScSS, TM, ig8.0459302NM_002314Hs 36566LIM domain kinase 18.0422765AW409701Hs.1578baculoviral IAP repeat-containBIR, TK, SS, TM8.0425944AK000664Hs.164256hypothetical protein FLJ206577.9450873BE464016Hs 238956ESTsSS, zf-C2H2, rrm7.9454246AW245185Hs 6996ESTs7.9450635AW403954Hs 25237mesenchymal stem cell protein4HBT7.9422305AI928242Hs 293438ESTs, Highly similar to AF1984SS7.9425760D17629Hs 159479galactosamine (N-acetyl)-6-sulSulfatase, SS, TM7.9413534BE146961gb: QV4-HT0222-011199-019-b12 HSS, TM7.8446931AI348856Hs.21627gb: tb02a05.x2 NCI_CGAP_Lu26 Ho7.8421726AK001237Hs 319088hypothetical protein FLJ10375TM7.8427461AA531527Hs 332040hypothetical protein MGC13010SS, TM, ACAT, LRR7.8448993AI471630KIAA0144 gene product7.8443136NM_001440Hs 9018exostoses (multiple)-like 3Exostosin, SS, TM7.8427725U66839Hs 180533mitogen-activated protein kinapkinase7.8400923Target ExonSS, TM, DUF2897.8419757AA773820Hs.63970ESTsSS, TM7.8458834AI566883Hs 196446ESTs7.8427899AA829286Hs 332053serum amyloid A1SS, SAA_proteins, SS, SAA_pr7.7452399BE513301Hs 29344hypothetical protein, clone 24SS, perilipin7.7436543NM_002212Hs 5215integrin beta 4 binding proteielF67.7431811AB040972Hs.301696hypothetical protein FLJ11560SS, TM, Band_7, AAA, cdc48_N,7.7414534BE257293Hs 76366BCL2-antagonist of cell deathSS, hormone_rec, zf-C47.7455885BE153524gb PM0-HT0339-241199-002-C03 HSS, pkinase7.7427721AI582843Hs 180455RAD23 (S. cerevisiae) homologubiquitin, UBA, integrin_B,7.6430432AB037758Hs 241419KIAA1337 proteinTM, Patched, TM7.6427273AW139032Hs.107376hypothetical protein DKFZp434NSS, SS, TM7.6450334AF035959Hs 24879phosphatidic acid phosphatasePAP2, SS7.6413564BE260120gb 601146990F1 NIH_MGC_19 Homo7.6410397AF217517Hs.63042DKFZp564J157 proteinSS, homeobox, UPF0160, DUF237.6439539BE348395Hs 121589ESTsSS, Fork_head7.5400286C16000922 gi|7499103|pir||T209TM, ABC_tran, ABC_membrane7.5416472AA180756Hs 340316ESTs, Moderately similar to ALzf-C2H27.5418641BE243136Hs 86947a disintegrin and metalloprotedisintegrin, Reprolysin, Pe7.5419492AA243547Hs.19447PDZ-LIM protein mystiqueLIM, SS, SH3, Sorb, Metalloph7.5420970AA305079Hs.1342cytochrome c oxidase subunit VCOX5B7.5406495Target ExonSRCR, TM, Acetyltransf7.5448043AI458653Hs 201881ESTsPHD7.4401724C16001374 gi|6755086|ref|NP_03TM, PLAT, SS7.4424263M77640Hs 1757L1 cell adhesion molecule (hydfn3, ig, IRK, SS, TM, fn3, ig, R7.4428092AW879141ESTsSS, TM7.3453023AW028733Hs 31439serine protease inhibitor, KunKunitz_BPTI, SS, TM, ion_tra7.3400137Eos Control7.3436127W94824Hs.11565RIKEN cDNA 2010100O12 geneCorona_7, SS, TM7.3412265AA101325Hs 86154hypothetical protein FLJ12457UPP_synthetase, HMG14_177.3432747NM_014404Hs 278907calcium channel, voltage-depenPMP22_Claudin, SS, TM, PMP227.3448859BE272446Hs.265317hypothetical protein MGC2562SS, TPR7.3407619AL050341Hs 37165collagen, type IX, alpha 2SS, Collagen, SS, Collagen7.3429299AI620463Hs 347408hypothetical protein MGC13102SS, TM, gla7.3401674C16001417* gi|7500345|pir||T21FAD-oxidase_C, FAD_binding7.2412289AW935967Hs 170162KIAA1357 proteinSS7.2424198AB029010Hs.143026KIAA1087 proteinSS, TM, Na_Ca_Ex, Calx-beta,7.2412173T71071gb yc50b05.r1 Stratagene liverCPSase_L_chain7.2438113AI467908Hs.8882ESTsSS, TM, 7tm_17.2429869AI907018Hs 15977Target CATrrm7.2439963AW247529Hs 6793platelet-activating factor acePAF-AH_Ib, Lipase_GDSL, SS,7.2425041AI377150Hs.150914ESTsSS7.2448340AI492910Hs 32362ESTs7.1406779AA412048Hs 279574CGI-39 protein, cell death-regSS, SS7.1431005AA490544Hs 127269ESTs, Weakly similar to T02345WD407.1421273AJ245416Hs 103106U6 snRNA-associated Sm-like prSm, SS, tRNA-synt_1, GST_C, G7.1409649AA159216Hs 55505hypothetical protein FLJ20442Y_phosphatase, DSPc, TM7.0430281AI878842Hs.237924CGI-69 proteinmito_carr, SS, TM7.0444672Z95636Hs.11669laminin, alpha 5laminin_EGF, laminin_G, EGF7.0405928Target ExonSS, cystatin, Coprogen_oxid7.0421321NM_005309Hs 103502glutamic-pyruvate transaminaseaminotran_1_2, SS, TM, LRR6.9439905AW799755Hs 110953retinoic acid induced 1HLH6.9451937AF119664Hs 27299transcriptional regulator protSS, integrin_B, fn3, Calx-be6.9426675AW084791Hs.133122hypothetical protein FLJ14524SS, TM, aminotran_1_26.9438627AI087335Hs 123473ESTsTM, Reticulon6.9438951U51336Hs 6453inositol 1,3,4-triphosphate 5/SS, oxidored_nitro, SS6.8421758BE397336Hs.1422Gardner-Rasheed feline sarcomaSH2, SH3, pkinase6.8423228AL137491Hs 125511Homo sapiens mRNA, cDNA DKFZp4SS, TM, sushi6.8405346Rag C proteinRCC16.8432746AA564512Hs 24301polymerase (RNA) II (DNA direcSS, TM, EF1BD6.8452798AI918771Hs.257170ESTsSS, TM, TNFR_c66.7426315AA854219Hs 348137Homo sapiens, clone IMAGE 3542SS, crystall6.7440317BE561888gb 601346093F1 NIH_MGC_8 Homo6.7438857AI627912Hs 130783Forssman synthetaseSS, RA, RasGEF, RasGEFN6.7452072BE258857Hs 27744RAB3A, member RAS oncogene famras, arf, SS, PDEase6.7433938AF161536Hs 284292ubiquinol-cytochrome c reductaTM6.7423106N52572Hs 13702ESTs, Moderately similar to AL6.7453101AW952776Hs.94943ESTsTM6.7420307AW502869Hs 66219ESTsSS, TM6.7415056AB004662Hs 77867adenosine A1 receptor7tm_1, SS, TM6.7454262AW612232Hs.254835ESTsSS, TM, voltage_CLC, CBS6.7409227AA806165Hs 130323Homo sapiens, clone IMAGE: 39606.6413908BE409966Hs.323813Homo sapiens, clone MGC 2867SS, zf-C2H26.6457274AW674193Hs.227152mannan-binding lectin senne pSS, TM, SS, TM, Clathrin_lg_c6.6419157AA234540Hs 23871ESTspkinase6.6431424AI222969ESTsSS6.6412464T78141Hs 22826ESTs, Weakly similar to I55214SS, cadherin, crystall6.6430168AW968343DKFZP434I1735 proteinSS, TM, efhand, efhand6.6455035AW851734gb MR2-CT0222-011199-007-e10 C6.6422682W05238Hs.94316ESTs, Weakly similar to T31613SS, TM, DEAD, helicase_C, Lam6.6453367AW732847Hs 70573PKCI-1-related HIT proteinSS, TM6.6450593AF129085Hs 25197STIP1 homology and U-Box contaTPR, SS, TM, Rhomboid, lactam6.6420319AW406289Hs 96593hypothetical proteinras.arf6.6431131N84730Hs 250616isocitrate dehydrogenase 3 (NAisodh, isodh6.6431297AA651771Hs 3076ESTs6.6410082AA081594Hs.158311Musashi (Drosophila) homolog 1SS, HECT, phoslip6.5441307AW071696Hs 209065hypothetical protein FLJ14225SS, TM6.5454682AW816029gb: MR3-ST0220-151299-027-b10 Sfilament6.5407299AA460205Hs 289770ESTs, Weakly similar to I380226.5422837U25441Hs.121478dopamine receptor D37tm_1, SS, TM,7tm_16.5407722BE252241Hs 38041pyridoxal (pyridoxine, vitaminpfkB, SS6.4417810D28419Hs 82609hydroxymethylbilane synthasePorphobil_deam6.4445333BE537641Hs 44278hypothetical protein FLJ12538SS6.4402197Target ExonSS, TM, ATP1G1_PLM_MAT8, ig,6.3419390AI701162Hs.90207hypothetical protein MGC11138SS, TM, PMP22_Claudin, PMP226.3447754AW073310Hs.163533intron of HER46.3444664N26362Hs.11615map kinase phosphatase-like prDSPc, Rhodanese, SS, TM6.3421190U95031Hs 102482mucin 5, subtype B, tracheobroCys_knot, vwc6.3432872AI908984Hs 279623selenoprotein X, 1DUF25, SS, Ribosomal_L3, PDZ6.3430023AA158243Hs 227729FK506-binding protein 2 (13 kD)SS, FKBP, SS, PDGF, C2, PI-PLC6.3413343BE392026Hs.334346hypothetical protein MGC13045SS, DnaJ6.2417852AJ250562Hs 82749transmembrane 4 superfamily metransmembrane4, SS, TM6.2403128KIAA1033 proteinSS, TM, tubulin, EGF, F5_F8_t6.2413055AV655701Hs 75183cytochrome P450, subfamily IIEp4506.2427812AA770424Hs 98162ESTsSS6.2457761AW401809Hs 4779KIAA1150 proteinSS, LIM, SS6.2453099H62087Hs 31659thyroid hormone receptor-assocSS6.2426048AI768853Hs 134478ESTsTM6.2407223H96850gb yw03b12 s 1 Soares melanocytSS, TM, SS, TM, DDOST_48 kD6.2445634AI624849Hs 344612ESTs, Weakly similar to NEL1_Hvwd6.2441197BE244638Hs 166sterol regulatory element bindHLH6.1421707NM_014921Hs 107054lectomedin-2Latrophilin, OLF,7tm_2, Gal6.1435750AB029012Hs 4990KIAA1089 proteinSS, TM6.1432353NM_016558Hs 274411SCAN domain-containing 1SCAN6.1427326AI287878gb qv23f06 x1 NCI_CGAP_Lym6 HoSS, TM, 7tm_1, SS, TM6.1447128AI271898cyclin K6.1419444NM_002496Hs 90443Target CATfer4, SS, TM, V_ATPase_sub_a6.1457978AA776638gb ae78g04 s 1 Stratagene schizSS, PH, IQ, RasGEF, RasGEFN, R6.1410445AA199830gb: zq75h01.r1 Stratagene hNT n6.1431857W19144Hs 271742ADP-ribosyltransferase (NAD, pPARP, PARP_reg, SS, TM, Pepti6.1407143C14076Hs 332329ESTSS, TM6.0408724AI685842Hs.294143ESTs, Weakly similar to T22914SS, pkinase, tubulin6.0436685W28661Hs 5288Homo sapiens mRNA; cDNA DKFZp4SS, TM, pkinase, Activin_rec6.0441583AI791499Hs 205742ESTs, Weakly similar to ALUA_H6.0418802AB028989Hs 88500mitogen-activated protein kinaWD40, Pico_P2A, M, SS6.0414927T83587Hs 186476ESTsSS, Sulfatase6.0434314BE392921Hs.3797RAB26, member RAS oncogene famras, arf, SS6.0414157BE297801Hs 103845ESTs, Moderately similar to I5SS6.0424415NM_001975Hs 146580enolase 2, (gamma, neuronal)enolase, SS, Atrophin-1, Atr6.0406487Target ExonSS, TM6.0447365BE383676Hs 334Rho guanine nucleotide exchangSH3, PH, RhoGEF6.0417900BE250127Hs 82906CDC20 (cell division cycle 20,WD40, SS, TM, fn3, EGF, fn3, ig6.0442297NM_006202Hs.89901phosphodiesterase 4A, cAMP-spePDEase5.9426440BE382756Hs 169902solute carrier family 2 (facilsugar_tr, SS, TM, sugar_tr5.9418256AW845318Hs 12271f-box and leucine-rich repeatSS, SS, TM, HSF_DNA-bind5.9431543AW969619Hs 259768adenylate cyclase 1 (brain)TM5.9430344AA476827Hs 171012hypothetical protein FLJ22349HLH5.9428539AW410063Hs.184877solute carrier family 25 (mitomito_carr, SS, TM, profilin,5.9403938Target ExonEphrin5.9456950AF111170Hs 306165Homo sapiens 14q32 Jagged2 genSS, TM, DSL5.9451481AA300228Hs 295866hypothetical protein DKFZp434N5.9434357AW732284Hs 3828mevalonate (diphospho) decarboGHMP_kinases, SS, TM5.9443553AL040535Hs 9573ATP-binding cassette, sub-famiABC_tran, SS5.9433333AI016521Hs 71816v-akt murine thymoma viral onchomeobox, pkinase, PH, pkina5.9430600AW950967Hs 274348HLA-B associated transcript-3ubiquitin, SS, TM, G-patch, a5.9409034AI684149Hs 172035hypothetical protein similar tSS5.9421542AA411607Hs 118964ESTs, Weakly similar to KIAA11SS, SS5.9431534AL137531Hs 258890Homo sapiens mRNA, cDNA DKFZp4SS, TM, ras5.9409608AF231023Hs 55173cadherin, EGF LAG seven-pass GSS, TM, 7tm_2, cadherin, GPS,5.9423464NM_016240Hs.128856CSR1 proteinCollagen, SS5.9422379AA932860Hs.133864ESTs5.8443887NM_004729Hs 9933Ac-like transposable elementzf-BED5.8450122BE313765Hs 343443ESTs, Weakly similar to I38022SS, TM, Y_phosphatase, LON, A5.8404807Target ExonUPF00275.8445303AW362198Hs.12503interleukin 15 receptor, alphaSS, sushi, SS5.8445631AK001822Homo sapiens cDNA FLJ10960 fis5.8412091R06185gb ye94d03 r1 Soares fetal livSS, TM, IBR, IBR5.8446536W74413Hs 15251hypothetical proteinSS5.8432866BE395875Hs 279609mitochondrial carrier homologmito_carr5.8402393ENSP00000085284*.CDNA FLJ20404RhoGEF, PH, SS, zf-CCCH, vwd5.8413041BE061580Hs 61622gb.MR0-BT0249-091299-201-c07 BSS5.8414356AW505085Hs 335147gb.UI-HF-BN0-als-a-10-0-Ul.r1SS, TM5.8402916ENSP00000202587* Bicarbonate tHCO3_cotransp, SS5.7459133U40343Hs.29656cyclin-dependent kinase inhibiank, SS, Adap_comp_sub5.7404757Target ExonTM, zf-C2H25.7409879BE083422Hs 56851hypothetical protein MGC2668SS, TM5.7411219AW832917gb: QV2-TT0003-161199-013-h06 T5.7421871AK001416Hs 306122glycoprotein, synaptic 2TM, Steroid_dh, SS5.7434067H18913Hs.124023Homo sapiens cDNA FLJ14218 fis5.7416759AK000978Hs 79741hypothetical protein FLJ101165.7446562BE272686Hs 15356hypothetical protein FLJ20254hormone, SS, pfkB5.7407117AA146625gb zo71c07 s1 Stratagene pancrSS5.7444855BE409261Hs 12084Tu translation elongation factGTP_EFTU, GTP_EFTU_D3, GTP5.7421543AK000519Hs 105606hypothetical protein FLJ20512TM5.7407757BE048414Hs 165215hypothetical protein MGC5395SS, EF1G_domain, GST_C, GST5.7419125AA642452Hs.130881B-cell CLL/lymphoma 11A (zincSS5.7437141BE304917Hs 31097hypothetical protein FLJ21478SS, TM, Glycos_transf_45.7408905AV655783Hs 661Target CAT5.7450787AB006190Hs 25475aquaporin 7MIP, SS, TM5.7432496D45576Hs.187959ESTs5.7429367AB007867Hs 278311plexin B1Sema, PSI, TIG, SS, TM, TIG, Se5.7422708AB017430Hs.119324kinesin-like 4kinesin, homeobox, SS, TM, zf5.7417442AA199940Hs 124039ESTs5.7432751AF152099Hs.278911interleukin 17CSS5.7432004BE018302Hs.2894placental growth factor, vascuPDGF, SS5.7454151AA047169Hs 154088hypothetical protein FLJ22756SS, TM, Glycos_transf_45.7456145BE299427Hs 21446KIAA1716 proteinSS, DIX, PDZ, DEP, Dishevelle5.6417677NM_016055Hs 82389CGI-118 protein5.6451558NM_001089Hs 26630ATP-binding cassette, sub-famiABC_tran, SRP54, SS, TM, ECH5.6408795AW749126Hs 170345hypothetical protein FLJ13710hormone_rec, zf-C45.6407204R41933Hs.140237ESTs, Weakly similar to ALU1_HSS, histone, histone5.6452849AF044924Hs.30792hook2 proteinbZIP, SS, AhpC-TSA5.6439343AF086161Hs 114611hypothetical protein FLJ118085.6459271AL045934gb: DKFZp434M116_r1 434 (synonySS, PI3_PI4_kinase, PI3Ka5.6401609C16001614: gi|7801278|emb|CAB915.6447827U73727Hs 19718protein tyrosine phosphatase,Y_phosphatase, fn3, ig, MAM,5.6409125R17268Hs 343567axonal transport of synaptic vSS, kinesin, PH, FHA, kinesin5.6450437X13956Hs.24998hypothetical protein MGC10471SS5.6415514F11301Hs 138329ESTsSS, TM5.6437926BE383605Hs 300816small GTP-binding proteinSS, TM, TPR5.6406663U24683immunoglobulin heavy constantSS5.6421678AA419008Hs 106730chromosome 22 open reading fraSS, TM, UBA, Rhomboid, SS, TM5.6422472R59096Hs 279939mitochondrial carrier homologmito_carr5.6414918AI219207Hs 72222hypothetical protein FLJ13459SS, TM, efhand5.6434906BE410573Hs.283636Homo sapiens, clone IMAGE 4053SS, TM, Exo_endo_phos, BNR, A5.6414757U46922Hs 77252fragile histidine triad geneHIT5.6436014AF281134Hs 283741exosome component Rrp46RNase_PH, RNase_PH_C, SS, TG5.6421696AF035306Hs 106890Homo sapiens clone 23771 mRNA5.6408015AW136771Hs.244349epidermal differentiation comp5.6445871AI702901Hs.145582ESTs, Weakly similar to FOR4 MSS, TM, efhand, efhand5.5411813NM_014931Hs 72172KIAA1115 proteinSS, TM, Y_phosphatase5.5425098AW295349Hs 8038ESTsSS, TM5.5429720M79091gb EST01239 Subtracted Hippoca5.5453898AW003512Hs 232770arachidonate lipoxygenase 3SS, TM, lipoxygenase, PLAT, s5.5449225R39108Hs 6777ESTsSS, TM, Na_sulph_symp5.5423233BE048021Hs.11067ESTs, Highly similar to T463955.5432538BE258332Hs 278362male-enhanced antigenSS, TM, AAA, Ribosomal_L25.5408215BE614290syntaxin 10SS, SS, TM, HLH, TRM, zf-CCCH5.5406244Target Exon5.5436041AI803516Hs 272891hippocalcin-like protein 4SS, efhand, TGF-beta, TGFb_p5.5422013N92696Hs 293354ESTsSS, TM5.5442451AI498080Hs.129616ESTsSS5.5427859AA416856Hs 98170ESTsSS, TM, DUF60, trypsin, CUB, u5.5436540BE397032Hs 14468hypothetical protein MGC14226SS, TM5.5427747AW411425Hs 180655serine/threonine kinase 12pkinase, SS, TM, synaptobrev5.4441456AI458911Hs 127765ESTs5.4431630NM_002204Hs.265829integrin, alpha 3 (antigen CD4integrin_A, FG-GAP, Rhabd_g5.4415976R43144Hs 21919ESTsTM5.4447374AF263462Hs 18376KIAA1319 proteinSS, Myosin_tail, M5.4431275T56571Hs 10041ESTsSS, HLH5.4404343C7002191* gi|5053028|gb|AAD388SS, ABC_tran5.4431461BE299671Hs 256310likely ortholog of mouse ZFP285.4421779AI879159Hs 108219wingless-type MMTV integrationSS, wnt, SS5.4418678NM_001327Hs 167379cancer/testis antigen (NY-ESO-SS, TM, zf-C2H25.4457310W28363Hs 239752nuclear receptor subfamily 2,5.3417193AI922189Hs 288390hypothetical protein FLJ22795SS5.3432545X52486Hs.3041uracil-DNA glycosylase 2cyclin, SS, cyclin5.3456573AI279811Homo sapiens, clone IMAGE 39535.3409164AA706639gb ag90e09 r1 Stratagene hNT nSS, TM, Hint, HH_signal, tubu5.3442296NM_007275Hs 8186lung cancer candidateSS, TM, Glyco_hydro_56, Glyc5.3438670AI275803Hs 123428ESTs5.3400257ENSP00000000452 BAD protein (BSS, hormone_rec, zf-C45.3449514AW970440Hs 23642protein predicted by clone 236SS, PX, arf, lipocalin, PHD, z5.3427336NM_005658Hs 2134TNF receptor-associated factorMATH, SS, MATH, A2M_N, A2M, NT5.3414551AI815639Hs 76394enoyl Coenzyme A hydratase, shECH, Peptidase_U7, SS, TM5.3447960AW954377Hs 26412ring finger protein 26SS, TM, Cbl_N, Cbl_N2, Cbl_N35.3430605AJ245433Hs 247323G4 proteinSS, TM, G-patch, ubiquitin, a5.3456849AA622394Hs 153177ribosomal protein S28SS, TM5.2430513AJ012008Hs.241586G6C proteinSS, TM, GST_C, abhydrolase5.2424437BE244700Hs 147049cut (Drosophila)-like 1 (CCAATCUT, homeobox, beta-lactama5.2427815BE072019Hs.12851phosphatidylserine synthase 2SS, TM, 7tm_15.2417903NM_002342Hs.1116lymphotoxin beta receptor (TNFTNFR_c6, SS5.2420476AW575863Hs 136232ESTsSS, HLH5.2409960BE261944hexokinase 1SS, TM5.2436325AL390088Hs.7393hypothetical protein from EUROSS, Synapsin_C, SS5.2444439AI458883Hs 143545hypothetical protein MGC11303SS, TM, PAF-AH_p_II5.2412915AW087727Hs 74823NM_004541: Homo sapiens NADH de5.2418891NM_002419Hs 89449mitogen-activated protein kinaSH3, pkinase, pyridoxal_deC5.2430323U40714Hs 239307tyrosyl-tRNA synthetaseDUF101, SS, tRNA-synt_1b, tR5.2432396AW295956Hs 11900hypothetical protein FLJ14972SS5.2457843AW138211Hs 128746ESTs5.2429252NM_004658Hs 198312RAS protein activator like 1 (C2, PH, RasGAP, BTK, SS, C2, PH5.1429225BE250337Hs 198273Target CATWD405.1412104AW205197Hs 240951Homo sapiens, Similar to RIKENSS, TM5.1449750H28586Hs 32325ESTsSS, ras5.1442725AI935786Hs 131035ESTs, Weakly similar to CA24_HSS, SS, TM, PX, PH, PLDc, arres5.1430390AB023186Hs.241161KIAA0969 proteinPH, SS, TM5.1421658X84048Hs 301760frequenin (Drosophila) homologefhand5.1426928AF037062Hs 172914retinol dehydrogenase 5 (11-ciadh_short, SS, adh_short, TG5.1428924AI016405Hs.98959ESTs, Weakly similar to JC5314SS, TM, lectin_c5.1458876AI650896Hs 195347ESTs5.1402632Target ExonFz, kringle, ig5.1413762AW411479Hs 848FK506-binding protein 4 (59 kD)FKBP, TPR, SS5.1419451AI907117Hs 90535syntaxin binding protein 2Sed1, SS, TM5.1456155R85182Hs 7175ESTs, Weakly similar to AF1568SS5.1422396W21872Hs 7907ESTs, Weakly similar to T194865.1413983BE348384Hs 279194ESTs5.0447598AI799968Hs 199630ESTsSS, TM5.0425858AA364923gb EST75602 Pineal gland II HoSS, TM, Peptidase_M10, fn2, h5.0440511AF132959Hs.7236eNOS interacting proteinSS, TM, MAGE, Ribosomal_S17,5.0452661AW449413Hs 257152ESTs5.0412800AW950852Hs 4598polymerase (DNA directed), delhomeobox, SS, efhand, hexoki5.0446603NM_014835Hs.15519oxysterol-binding protein-relaOxysterol_BP, SS5.0402884ENSP00000164597.PRO0566laminin_Nterm, laminin_Nte5.0448680AW245890Hs 21753JM5 proteinWD40, SS, TM, KOW, HLH5.0431515NM_012152Hs 258583endothelial differentiation, I7tm_15.0427204AA405404Hs 215725ESTsSS, SS5.0425169AW292500Hs 128514ESTsSS5.0412940BE295701Hs 819homeo box B7homeobox, SS, homeobox, home5.0440839AI142078Hs 135562ESTsSS5.0443814BE281240Hs 9857carbonyl reductase5.0434243AA628062Hs.200358ESTs, Moderately similar to ALSS, TM5.0435605AF151815Hs 4973hypothetical proteinSS, TM, SS, TM, ABC_tran, ABC5.0417116Z43916Hs 7634hypothetical protein FLJ12287SS, TM, filament, IF_tail5.0403055C2002219*: gi|12737280|ref|XP_05.0420856BE513294Hs.205736HLA class II region expressedkazal, SS, TM, ig, pkinase4.9405594NM_021949 Homo sapiens ATPase,E1-E2_ATPase, Hydrolase, SS4.9405334Target ExonSS, TM, MIP4.9419493AF001212Hs 90744proteasome (prosome, macropainPCI, SS, CDK5_activator4.9413764BE162704gb PM1-HT0454-301299-001-d08 HSS4.9409169F00991Hs 50889(clone PWHLC2-24) myosin light4.9446933AL137659Hs 297214HSPC141 proteinSS, TM, ank, EGF, notch, MATH,4.9409139AI681917Hs.3321ESTs, Highly similar to IRX1_HSS, homeobox4.9456672AK002016Hs 114727Homo sapiens, clone MGC: 16327,SS, PK, PK_C, myosin_head, Rh4.9420842AI083668Hs 50601hypothetical protein MGC10986SS4.9421909NM_013375Hs 109428TATA-binding protein-binding p4.9419667AU077005Hs 92208a disintegrin and metalloprotedisintegrin, Reprolysin, Pe4.9443496AJ006973Hs.9482target of myb1 (chicken) homolVHS, GAT, TM, Heme_oxygenase4.9400933NM_004347 Homo sapiens caspaseICE_p20, ICE_p10, CARD, SS, l4.9456143H11097Hs 61960hypothetical proteinSS, pkinase4.9427527AI809057Hs.153261immunoglobulin heavy constantSS, TM, ig4.9414265BE410411Hs.75864endoplasmic reticulum glycopro4.9433933AI754389Homo sapiens clone TCCCIA00164SS, TM, SS, TM, SH2, Y_phospha4.9452302AF173867Hs 28906glucocorticoid modulatory elemSAND, SS4.9409938AW974648gb: EST386752 MAGE resequences,SS, Adap_comp_sub, GYF4.8400845NM_003105*: Homo sapiens sortilIdl_recept_a, fn3, Idl_rece4.8425976C75094Hs 334514NG22 proteinSS, TM, pkinase, SH2, SH3, BNR4.8452969W92792Hs 77575hypothetical protein MGC31364.8413163Y00815Hs 75216protein tyrosine phosphatase,fn3, ig, Y_phosphatase, SS, T4.8434962AK001574Hs 4291golgi perepheral membrane prot4.8418572AI751740Hs.86172paired related homeobox proteinhomeobox4.8440869NM_014297Hs 7486protein expressed in thyroidlactamase_B, SS, XRCC1_N, BR4.8453446BE299996gb: 600944574F1 NIH_MGC_17 Homo4.8412159AF286598Hs 9271KIAA1071 proteinbZIP4.8438999AW276811gb xp66c02.x1 NCI_CGAP_Ov39 Ho4.8420233AA256714Hs 194864hypothetical protein FLJ22578SS4.8414576AK000405Hs 76480ubiquitin-like 4ubiquitin, SS, TM, G6PD, G6PD4.8433669AL047879Hs 80475ESTs, Weakly similar to ALU2_HSS, TM, RNA_pol_L, RasGAP, C24.8448984AW751955Hs.22753hypothetical protein FLJ22318SS4.8426912AL043054Hs 256657ESTs, Weakly similar to A46302SS4.8418945BE246762Hs 89499arachidonate 5-lipoxygenaselipoxygenase, PLAT, SS4.8440333AI378424Hs 288761hypothetical protein FLJ21749SS, TM, IP_trans, pkinase, pk4.8425615AF023614Hs 158341transmembrane activator and CATM4.8458040BE280562Hs 287711hypothetical protein FLJ226924.8458367AA088470Hs.83135Homo sapiens, Similar to RIKENSS, tRNA-synt_2d4.8433294AA582082Hs.199410ESTs4.8437671AA536047Hs 9850hypothetical protein MGC18424.8425338H16716Hs 182648Homo sapiens cDNA FLJ14444 fis4.8447946AI566164Hs 165827ESTsSS, PTN_MK, 7tm_1, DAGKc, DAG4.7447205BE617015Hs 11006ESTs, Moderately similar to T1SS, TM, LRRCT, Sema4.7416880H99640Hs.53687EST4.7440150AW975738Hs 7001Homo sapiens, clone IMAGE.3940SS, TM, SS, TM, Peptidase_M224.7426268AF083420Hs 168913serine/threonine kinase 24 (Stpkinase, pkinase4.7429253Y11739Hs 198313winged-helix nudeFork_head, SS, TM, glycolyti4.7450261AA788727Hs 34068ESTs, Weakly similar to A43932SS4.7439246AI498072membrane-associated tyrosine-SS, SS, TM4.7419120BE271922ESTs, Weakly similar to zinc fSS, TM, DENN, Cytidylyltrans4.7416487AW190458Hs 79347KIAA0211 gene productSS, zf-C2H24.7413837AW163525titin-cap (telethonin)SS, Methyltransf_34.7419887AW292562Hs 187628ESTsTM4.7410277R88621Hs 26249ESTs, Weakly similar to T2D3_HSS, TM, SS4.7415169W42913Hs 78089ATPase, vacuolar, 14 kDATP-synt_F, SS, TM, CH, Filam4.7410892AW809762Hs 222056Homo sapiens cDNA FLJ11572 fis4.7407754AA527348Hs 288967Homo sapiens cDNA FLJ14105 fisSS, TM, SS, TM, TSPN, tsp_3, SE4.7409877AW502498Hs.15220zinc finger protein 1064.7431629AU077025Hs 265827interferon, alpha-inducible prpkinase, SH2, SH34.7438800AB037108Hs 6418seven transmembrane domain orpSS, TM4.7420823R96881Hs 63609Hpall tiny fragments locus 9CTM4.7418900BE207357Hs.3454KIAA1821 proteinSS4.7402400Target ExonSS, TM, RNase_HII, bZIP, DUF24.7419625U91616Hs 91640nuclear factor of kappa lightank, SS, TM4.7433319AA583232ESTsSS4.7424959NM_005781Hs.153937activated p21cdc42Hs kinasepkinase, SH34.7432750NM_014440Hs.278910interleukin 1, epsilonIL14.7425954AK000633Hs.164476hypothetical protein FLJ20626SCAN, zf-C2H2, KRAB, SS, KRAB4.7447245AK001713Hs 17860hypothetical protein FLJ10851E1_dehydrog4.7427101R87591Hs.172884ESTsSS, TM4.6447544AA401573Hs 288284hypothetical protein FLJ22378SS, TM4.6400266NM_002858*: Homo sapiens ATP-biABC_tran4.6412841AI751157Hs.101395hypothetical protein MGC11352SS, TM4.6422066AW249275Hs.343521malate dehydrogenase 2, NAD (mIdh, ldh_C, adh_short, Semia4.6414874D26351Hs 77515inositol 1,4,5-triphosphate reTM, RYDR_ITPR, ion_trans, MI4.6418373AW750770Hs 84344CGI-135 proteinSS, TM, PMP22_Claudin, 2OG-F4.6424487T08754Hs 6259KIAA1698 proteinSS, SS, TM, Glyco_hydro_31, G4.6426571AA381642gb: EST94816 Activated T-cells4.6433941AA620612ESTsSS, TM, TNFR_c64.6421717AF230924Hs 107187divalent cation tolerant prote4.6450883NM_001348Hs 25619death-associated protein kinaspkinase, GTP_EFTU, EFG_C, GT4.6427361AW732480Hs 7678cellular retinoic acid-bindingSS, TM, aminotran_1_2, LRR4.6420421AF281133Hs 343589exosome component Rrp41RNase_PH, RNase_PH_C4.6414513AW239400Hs 76297G protein-coupled receptor kinpkinase, RGS, pkinase_C, SS,4.6431498AK001777Hs 258551aspartyl aminopeptidaseSS, Peptidase_M18, SS, TM, Y4.6432593AW301003Hs.51483ESTs, Weakly similar to hypothSS, TM, adh_short4.6404661C9000306* gi|12737280|ref|XP_04.6412790NM_014767Hs 74583KIAA0275 gene productkazal, thyroglobulin_1, zf-4.6456243AI345001Hs.82380menage a trois 1 (CAK assemblyZf-C3HC44.6426222BE391706Hs.168073DKFZP727M231 proteinGSH_synthase4.6439594AI245026Hs.111099hypothetical protein MGC10974CLP_protease4.6409114AA070021gb zm67h03 r1 Stratagene neuro4.6429049AW452125Hs.119273KIAA0296 gene productSS, TM, trypsin4.6424271AI991887Hs 3058825-oxoprolinase (ATP-hydrolysin4.6418741H83265Hs 8881ESTs, Weakly similar to S41044SS, TM, pkinase, Activin_rec4.6450493M93718Hs 166373nitric oxide synthase 3 (endotflavodoxin, FAD_binding, NO4.6433074AL045019Hs 323462Homo sapiens cDNA FLJ11214 fisDEAD, helicase_C, dsrm, Vira4.6444893AW249312Hs.12109WD40 protein Ciao1WD404.6420508AJ270993Hs 98428homeo box B6homeobox, SS, homeobox, home4.6409591AA532963Hs 9100Homo sapiens cDNA FLJ13100 fisSS, TM, LIM, homeobox4.6456181L36463Hs 1030ras inhibitorRA, SH2, VPS9, SS, TM, Nucleos4.6439270BE268278Hs 28393hypothetical protein MGC2592SS, TM, HCO3_cotransp4.6440104AA132838Hs 239894hypothetical protein MGC2803SS, DS4.5423279AW959861Hs 290943ESTsSS4.5445087AW893449Hs.12303suppressor of Ty (S.cerevisiaeS1, SH2, Ribosomal_L23, pkin4.5404036Target ExonSS, TM, cadherin, cadherin4.5431832AW276866Hs 192715ESTsEts, SAM_PNT4.5433886AA613596Hs 28412ESTsSS4.5426735T78716Hs 120446ESTsOxysterol_BP, PH4.5417825AW838994Hs 6363heparan sulfate 6-O-sulfotransSS, TM4.5455600BE061053gb: QV0-BT0041-271099-037-d09 BC44.5423858AL137326Hs 133483Homo sapiens mRNA, cDNA DKFZp4SS, TM4.5421680AL031186Hs 289106Human DNA sequence from cloneSS, SS, rrm, zf-RanBP, rrm, GA4.5408157AA047685Hs 62946ESTspkinase4.5434303AW204058transforming growth factor betSS, TM, SSF, FG-GAP, vwa, inte4.5440745AW303627Hs 143301ESTs4.5419344U94905Hs.277445diacylglycerol kinase, zeta (1ank, DAGKa, DAGKc, DAG_PE-bi4.5447208BE315291Hs.237971hypothetical protein MGC56274.5436163R84938gb yt65f04.r1 Soares retina N24.5456856AK001528Hs 347285Homo sapiens, Similar to DiGeo4.5410817AI262789Hs 93659protein disulfide isomerase reSS, thiored4.5434558AW264102Hs.39168ESTsSS, TM, LRRCT, LRR4.5440548AL117408Hs.7274DKFZP434P1750 protein4.5450200AW975625Hs.173088ESTsZf-UBP, zf-C3HC44.5432434AL161977Hs 2994PCTAIRE protein kinase 3SS, pkinase4.5440042AI073387Hs 133898ESTsSS4.5454328AW372097Hs 278429hepatocellular carcinoma-assoc4.5458196AI802408ubiquitin A-52 residue ribosomSS, TM, fn3, FKBP, TPR4.5433472AI541246Hs 3343phosphoglycerate dehydrogenase2-Hacid_DH, 2-Hacid_DH_C, M4.5408928AW295827Hs 255479hypothetical protein MGC5566A_deaminase, A_deaminase4.5448093AW977382Hs.158982,4-dienoyl CoA reductase 2, padh_short, NDK4.5426272AW450671Hs 189284ESTs4.5453610AW368882Hs 33818RecQ protein-like 5SS, DEAD, helicase_C, SS, DEA4.5441327AK001706Hs.7778hypothetical protein FLJ10751SS, TM, 7tm_14.5424681AA054400Hs 151706KIAA0134 gene producthelicase_C, PRK, SS, TM, 7tm4.5443443AI344042Hs 9347regulator of G-protein signallTM, Na_Pi_cotrans4.5426677AW949856Hs 97165ESTsSS4.5412482AI499930Hs.334885mitochondrial GTP binding protSS4.4425236AW067800Hs.155223stanniocalcin 2Stanniocalcin, SS4.4423229AC003965Hs.125532protease, serine, 26trypsin, SS4.4412338AA151527Hs 69485hypothetical protein FLJ12436SS, TM, TIG, Serina, PSI4.4419395BE268326Hs 902805-aminoimidazole-4-carboxamideAICARFT_IMPCHas, MGS, AICAR4.4442462AF031405gb AF031405 Soares fetal liver4.4439975AW328081Hs 6817inosine triphosphatase (nucleoHam1p_like, SS4.4423876BE502835Hs.15463Homo sapiens, clone IMAGE 2959SS, ethanol4.4423220BE394920Hs.125262aladinWD40, TM, Activin_recp, pkin4.4411574BE242842Hs 6780protein tyrosine kinase 9-likecofilin_ADF, SS, TM4.4448947BE615408Hs 337228ESTs, Weakly similar to AXHU aSS, TM, ig, pkinase4.4407755AI151353Hs.29742Homo sapiens serine palmitoylSS, TM, aminotran_1_24.4414849AW372721Hs.291623ESTs, Weakly similar to unnameTM, pkinase4.4458171AI20016Hs.192090ESTsSS, TM4.4424443AI751281Hs 284161hypothetical protein from EUROSS, TM, SS, TM4.4427002AA524093Hs 23158ESTsSS, zf-C2H24.4404344C7002191* gi|5053028|gb|AAD388SS, ABC_tran4.4427458BE208364Hs 29283ESTs, Weakly similar to LKHU pSS, F5_F8_type_C, EGF, TGT4.4419764BE262524Hs.93183vasodilator-stimulated phosphoWH14.4446872X97058Hs 16362pyrimidinergic receptor P2Y, G7tm_1, SS, TM4.4435615Y15065Hs 4975potassium voltage-gated channeion_trans, KCNQ1_channel4.4403945Target Exon4.3435593R88872Hs.4964DKFZP586J1624 proteinHerpes_HEPA, SS4.3421899AJ011895Hs.109281Nef-associated factor 1Virus_HS, bZIP, G-gamma, Myo4.3425245AI751768Hs 155314KIAA0095 gene productSS, TM4.3423348AA324687gb EST27558 Cerebellum Il HomoSS, TM4.3452105AA022838Hs.6570ESTs, Weakly similar to S10889SS, TM, TBC, rrm4.3431934AB031481Hs 272214STG proteinSS4.3429499AA453809Hs 99350ESTs4.3453485BE620712Hs 33026hypothetical protein PP2447SS, TM4.3459393BE409283Hs 193264hypothetical protein MGC32344.3405364ENSP00000239138* Guanine nucle4.3428345AI242431Hs 118282PAP-1 binding proteinSS, TM4.3435327BE301871Hs 4867mannosyl (alpha-1,3-)-glycoproSS, HLH, Myc_N_term, Myc-LZ,4.3413053AW963263Hs 65377ESTs, Moderately similar to KITM, SS, TM, EF_TS, UBA, transm4.3409983D50922Hs 57729Kelch-like ECH-associated protBTB, Kelch, SS, TM4.3409936AK001691Hs 57655hypothetical protein FLJ10829SS, TM4.3421592AF009801Hs 105941bagpipe homeobox (Drosophila)homeobox, SS4.3424251AA677466Hs 143696coactivator-associated argininSS, SNF2_N, helicase_C, brom4.3414788X78342Hs.77313cyclin-dependent kinase (CDC2-pkinase4.3432805X94630Hs 3107CD97 antigenSS, TM, 7tm_2, GPS, EGF, SS, TM4.3424927AW973666Hs.153850hypothetical protein C321D24SS, TM4.3456863T16837Hs 4241ESTsfusion_gly, homeobox, TM4.3417823R88869Hs.102447TSC-22-likePWWP4.3406621X57809Hs 181125immunoglobulin lambda locusSS4.3431493AI791493Hs.129873ESTs, novel cytochrome P450SS, p450, SS4.3412958BE391579Hs 75087Fas-activated serine/threonineSS, pkinase4.3431658BE409917Hs 266935tRNA selenocysteine associatedrrm, SS, RCC14.3419579W49529Hs 296200hypothetical protein AF053356MSP_domain, SS, TM, CUB, NTR,4.3410076T05387Hs.7991ESTsSS4.2406773AA812424Hs 76067heat shock 27 kD protein 1HSP20, SS4.2424709AL137589Hs 152149hypothetical protein DKFZp434K4.2418419X55039Hs 85004centromere protein B (80 kD)CENP-B, HTH_54.2447377X77343Hs 334334transcription factor AP-2 alphTF_AP-2, TF_AP-24.2416931D45371Hs 80485adipose most abundant gene traC1q, Collagen, SS4.2411674AW861123gb.RC3-CT0297-120200-014-a05 CSS4.2419073AW372170Hs 183918Homo sapiens cDNA FLJ12797 fisSS, ig, tsp_1, ZU5, SS, TM, Nuc4.2406867AA157857Hs 182265keratin 19filament, bZIP, SS, filament4.2432183AW151952Hs.46679hypothetical protein FLJ20739SS4.2418910Z25821Hs 89466Homo sapiens, Similar to dodecECH, SS, TM, aminotran_3, ABC4.2437300AL040504Hs 25063PRO0461 proteinSS, TM, pkinase, cyclin, F-bo4.2426615AA400678Hs 6473gb zu70a11 r1 Soares_testis_NH4.2421453AA234652Hs 104555neuropeptide FF-amide peptideSS, bZIP, zf-C2H2, bZIP, zf-C4.2409616AA076248gb zm18c10 r1 Stratagene pancr4.2444744BE394732Hs.147562ESTsSS4.2412575AA113177gb zm29e05.s1 Stratagene pancrTM, ER_lumen_recept4.2429542AF038660Hs 206713UDP-Gal betaGlcNAc beta 1,4-gGalactosyl_T_2, ig, SS, TM, A4.2435995BE260415Hs 348198hypothetical protein FLJ202624.2451585AK001171Hs 326422hypothetical protein MGC4549SS, Metallophos4.2456153AW972270Hs.144054ESTsSS, TM4.2455340AW901435gb: RC0-NN1012-270300-031-a10 N4.2457268AW272279ESTs, Moderately similar to AL4.2432311BE083080Hs.274323similar to sialyltransferase 7Glyco_transf_294.2409656NM_005133Hs 288626RCE1, prenyl protein proteaseAbi, SS, CPSase_L_chain, HMG4.2424919BE314461Hs 153768U3 snoRNP-associated 55-kDa prWD40, SS, KH-domain4.2416528H65052Hs 337621ESTs4.2415137AI634834Hs.72451Homo sapiens PAC clone RP5-1084.2417334AA337572Hs 157240hypothetical protein MGC4737SS, TM, ion_trans4.2451920AA224483Hs 27239DKFZP586K0524 proteinSS, TM, SS, TM4.2413049NM_002151Hs 823hepsin (transmembrane proteasetrypsin, SS, TM, ATP1G1_PLM4.2458988AW410431Hs 283670CGI-119 protein4.2406964M21305FGENES predicted novel secrete4.2451595AW965569Hs 20996ESTsSS, WD404.2449728AI820751Hs 107635ESTsSS4.1453245T99801Hs 339751ESTsTM, ABC_tran4.1432238AL133057Hs.274135Homo sapiens mRNA; cDNA DKFZp4WD40, LRR4.1430037BE409649Hs 227789mitogen-activated protein kinapkinase4.1442196AI902646Hs 31844hypothetical protein FLJ12586SS, SCAN4.1425251Z22521Hs 155342protein kinase C, deltapkinase, DAG_PE-bind, pkina4.1415014AW954064Hs.24951ESTs4.1440088BE559877Hs 183232hypothetical protein FLJ22638SS, zf-C3HC4, SPRY, zf-B_box4.1418837U48263Hs 89040prepronociceptinOpiods_neuropep, SS4.1410239AI568350Hs 61273hypothetical protein MGC2650SS, ART, TM4.1446975BE246446Hs.16695ubiquitin-activating enzyme E1ThiF, UBACT4.1453968AA847843Hs.62711High mobility group (nonhistonSS, HMG_box4.1448241AW811064gb.MR2-ST0131-211099-008-c06 SSS4.1441455AJ271671Hs.7854zinc/iron regulated transporteZip, SS, TM, Cytidylyltransf4.1450848AI677994Hs 428fms-related tyrosine kinase 3fit3_lig, SS, Ribosomal_L134.1429218AA225065Hs.198269Target CATSS, Nop4.1425437AK000482Hs.181780hypothetical protein FLJ202414.1406613Target ExonSS, pkinase, LRR, LRRCT, Ribo4.1431239AL039971Hs.251216hypothetical protein DKFZp434Aank, WH24.1436057AJ004832Hs.5038neuropathy target esterasecNMP_binding, SS, TM, cNMP_b4.1415193AL048891Hs.12185hypothetical protein MGC14333SS, TM, aminotran_1_2, LRR4.1424619BE387282Hs.207443hypothetical protein MGC108484.1432968BE614192Hs 279869melanoma-associated antigen reSS, TM, RGS, DIX4.1428156BE269388Hs 182698mitochondrial ribosomal proteiSS4.1414084AW168771Hs.71574hypothetical protein FLJ14926SS, P5CR, EFIBD4.1424964AW161271Hs 153961ARP1 (actin-related protein 1,actin, SS4.1431410AW299534Hs.105739ESTs4.1435968AW161481Hs.111577integral membrane protein 3TM4.1432351AI270313Hs 127762hypothetical protein MGC129824.1426120AA325243Hs.166887copine IC2, SS, aminotran_54.1416877BE386266Hs.85658hypothetical protein FLJ234364.1425970AK001500Hs 165186hypothetical protein FLJ13852SS, P5CR, Epimerase, zf-C2H24.1434848BE256304Hs.32148AD-015 proteinSS, TM, SS, TM, LRR, P, Peptida4.1458715AK000973Hs 16725hypothetical protein FLJ10111IBR, zt-C3HC4, SS, TM, IRF, CK4.1435851AA700946ESTs4.1425538BE270918Hs.164026Homo sapiens, clone IMAGE: 3534SS, SNF2_N, helicase_C, brom4.1444416AW288085Hs 11156hypothetical proteinzf-C3HC4, SpoA, PHD, TM, syna4.0426831BE296216Hs.172673S-adenosylhomocysteine hydrolaAdoHcyase, SS4.0444596BE560662Hs 11417Rab acceptor 1 (prenylated)SS, TM, lig_chan, ANF_recept4.0439685AW956781Hs 293937ESTs, Weakly similar to FXD2_HSS, PWWP, TSC224.0447402H54520Hs.18490hypothetical protein FLJ20452SS, TM4.0450184W31096Hs.237617Homo sapiens, clone IMAGE: 3447SS4.0426068AF029778Hs.166154jagged 2DSL, EGF, vwc, granulin, SS, T4.0459255AI93244Hs 239500hypothetical protein MGC13114SS4.0403182Target ExonSS4.0432078BE314877Hs 24553hypothetical protein FLJ12541SS, TM4.0459167BE504370ESTs, Weakly similar to CA13_HSS4.0452747BE153855Hs.61460Ig superfamily receptor LNIRSS, TM, ig, HLH4.0444633AF111713Hs.286218junctional adhesion molecule 1ig, SS, TM, HLH4.0434171BE247688Hs.347349KIAA0948 protein4.0422155AW249152sirtuin (silent mating type inSIR2, HLH, Myc_N_term, Myc-L4.0433262AI571225Hs.284171KIAA1535 proteinSS, TM, cNMP_binding, ion_tr4.0442599AF078037Hs.324051RelA-associated inhibitorSH3, ank, SS, TM, HHH, ig4.0452500AW373011Hs.54558hypothetical protein FLJ222224.0437563AI217204Hs 144968ESTs4.0432234AA531128Hs 115803ESTsSS4.0433135AA443873Hs 110477dolichyl-phosphate mannosyltra4.0447495AW401864Hs 18720programmed cell death 8 (apoptpyr_redox, SS, Ets4.0452857BE072814Hs.258519ESTs, Moderately similar to S6SS4.0427834AA506101Hs 285813hypothetical protein FLJ11807SS, TM4.0418963BE304571Hs 89529aldo-keto reductase family 1,alde_ket_red4.0437340AL353935Hs.135917hypothetical protein DKFZp761DTBC, bZIP, WD40, WD404.0455928BE170313gb QV4-HT0536-040500-193-g02 HSS4.0400607Target ExonSS, homeobox4.0424825AF207069Hs 153357procollagen-lysine, 2-oxogluta2OG-Fell_Oxy, Glycos_trans4.0438143BE500981Hs 269652ESTs4.0433173Z36093Hs.3196surfeit 1SURF1, SS, TM, SURF1, SURF44.0412550R52452Hs 26370gb yg80g07.r1 Soares infant br4.0Pkey: Unique Eos probeset identifier number ExAccn: Exemplar Accession number, Genbank accession number UnigeneID: Unigene number Unigene Title: Unigene gene title Pred. Protein Dom.: Predicted protein domain R1: Ratio of tumor to normal ovaries


[0396]

46







TABLE 17B








Pkey
CAT Number
Accession

















408215
10478_1
BE614290 AA307674 N35629 AA338538 AI193603 AA781096




AI680061 AI613258 AW276647 BE221263 AI348910 AI985031 AI090078




AI359617 AA666391 AI160210 AI446461 AI355345 AI343638 AI343640




AI275091 M78746 AW262795 AW250002 AA503756 AI934519




AW272086 N26520 AA626639


408294
1050553_1
BE141732 U75823 BE141331 AW178416 AW178430




BE141343 BE141298 BE141702 BE141285


409114
110088_1
AA070021 AA126205 AA082771 AA102169 AA083530 AA082183




AA115915 AA085147 AA125905 AA063336 AA079206


409164
110421_1
AA706639 AA064707 AL036920 AI651598


409616
114348_1
AA076248 AA120958 AA122152 AA076249


409938
116091_1
AW974648 AA652153 AA649671 AA078582


409960
116270_1
BE261944 AA715461 AA318136 AA134972 AA319849 W04622 AI291655




AW879092 AA130778 BE314003 AA908246 AW960808 AA385346




AA205977 C02043 AA135057 AA078870 AA377395 AA318795 AA318785 AA319160




BE000960 AW370250 AW370244 T85930 AA759250




AI567682 AA932839 AI056920


410445
120374_2
AA199830 AI143895 AW961629 AA322482


411219
1236055_1
AW832917 AW832913 AW832906 AW832788 AW832915 AW832776


411674
1253746_1
AW861123 AW861125 AW856717 AW861116 AW856706 AW856788




AW856774 AW856787 AW856780 AW856782 AW856789 AW856772




AW856784 AW856786 AW856776 AW856635 AW856767


412091
1276564_1
R06185 AW891805 AW901892 AW901895


412173
1280870_1
T71071 AW902279 AW897608


412575
130769_1
AA113177 AW894515 AA113847


413534
1375357_1
BE146961 BE146780 BE146788 BE146967 BE146774 BE146963 BE146907


413564
1376722_1
BE260120 BE148538


413764
1387163_1
BE162704 BE162705 BE162732 BE162702 BE162694


413837
139363_1
AW163525 AW163255 AW163385 AI929359 BE279279 AA132590 AW157329




AA584408 AW157252 AI692198 AW003514 T24436 AI765658




AW157459 AI810740 AI659582 AI969924 AI929284 AI340993 AI349083 AW299522




AW664650 AW299513 AA132529 AI340991 AI912836




AI341293 AI650609 AA279


414413
1443696_1
BE294877 BE294759


415126
1523506_1
D60945 D61346 D81568 D80539


419120
182026_1
BE271922 N54771 AA234233 AA471354 BE171081 AA253482




AA470113 AA824327 H24470 AW504757 N51688 AI400700 AA578548




AA714130 AA609917 AW780349 AW664465 AW467553 AW571643 AA469943




AW474826 AA767165 AA326817 AA593859 AW952245




AW341739 AA805093 AA779455 AW016655


422155
21235_1
AW249152 AW249153 BE298958 AW192872 AF095714 R05553 AF083107




AF160214 NM_012237 BE258447 BE253088 AA297721 H68948




W39153 AA070372 H14246 AL079367 R24561 AW403997 AA297034 AA297092 F11858




AI372597 AA297787 Z42780 AA297072 T81280




T83544 AA297053 H26063 AA26


423348
227276_1
AA324687 AA325155 AW962038


425858
257265_1
AA364923 AW963483 BE182774 C21461


426571
269283_1
AA381642 AA381664 AW963560 AW949848 AA381728 AA381608


427326
277229_1
AI287878 AI804160 AA400787


428092
286920_1
AW879141 AA421182 AI734104 AI733923 AA430600


429720
308153_1
M79091 AA773950 AA586573 AA457225


430168
313927_1
AW968343 AA468507 AI478223 AW513008 AI762122 AI554512 AA862642 AA468976


431424
333110_1
AI222969 AA806560 AA504839 AA805261


433319
363095_1
AA583232 AA601715


433933
377703_1
AI754389 AW295190 AI056058 AI056059 AI863364 AI863355




AW131720 AI674922 AI949042 AI990060 AI623178 AW469497 AA620354


433941
377883_1
AA620612 AA994983 AA994990


434303
383224_1
AW204058 AI424379 AI669663 AA629077 AW613033


434743
3925_1
AI363410 AI356019 H00141 T78748 AL049365 AL079911 AI750972 Z42602




AW452523 AI223826 AA215407 AI633829 AA292122 N42783




AW505595 AF086096 N90340 N63271 AA131836 AW607273 AA527132 T32315




AA421961 T34951 AW966080 M78807 N31947 AA521151




AA278866 AA044784 AA700


434796
393400_1
AA812046 AW974514 AA764999 AA649302


435851
411522_1
AA700946 AA702712 AA947620


436163
41515_6
R84938 AL047151 AA310309 AW063200 AI569528 AI307823 N49975


437215
43473_1
AL117488 AL044479


438999
467686_1
AW276811 AA829050 AA829190


439246
47021_3
AI498072 AW251083 AA985226 AA852987 AI392809 AA206609 AW190187




AA555262 AF086057 F35814 AW516382 AA377885 N50847




F27148 AA731186 AA417728 AI003145


440317
49187_1
BE561888 BE560615 BE562102


442462
543232_1
AF031405 H73415


442472
543371_1
AW806859 AW806852 AF049582


445625
64558_1
BE246743 AA436942 AW024744 AW242177 AA975476




AW385185 R07536 R73462 AV654529 T57442




AI399986 R50073 R48743 AI769689




AI863005 AA317806 AI678000 AW189963




AI986207 AW471273 R73463 AI335104




AI590161 AI469257 AI954604 H21954 T25141 AA856793




R50074 AI708253 AI2


445631
6457_1
AK001822 AW860325 AA335296




AW965531 AW130957 AW193951 AI347975




AW081323 AW662527 AI343924 AI380749 AA938153 T66966




AI655000 AW418837 AI380485 AA410698 AI520726 BE501355




AI637925 AW779200 AI524755 AW593995 AI336927 AI336928




AI357036 R60592 H19058 R11124 T1


447128
70934_1
AI271898 BE048502 AI452509 AI244810 X84721 AI858001




AI553937 AA149853 H00719 AI765259 AW973696 F25787 F35749 AI568815




AW015380 AA554539 C00201 AA961610 AW059537 R77127


448241
756181_1
AW811064 AW811160 AI478413


448993
79225_1
AI471630 BE540637 BE265481 AW407710 BE513882 BE546739 AA053597 BE140503




BE218514 AW956702 AI656234 AI636283 AI567265




AW340858 BE207794 AA053085 R69173 AA292343 AA454908 AA293504 AI659741




AI927478 AA399460 AI760441 AA346416 BE047245




AA730380 AA394063 AA454


453446
967533_1
BE299996 BE297115 BE270415 BE295214 BE296526


454682
1228976_1
AW816029 AW813292 AW816156 AW813333




AW816159 AW813302 AW813344 AW813172


455035
1249762_1
AW851734 AW851676 AW851693 AW851713 AW851722




AW851616 AW851731 AW851618 AW851648 AW852215


455340
1283604_1
AW901435 BE094527


455557
1325974_1
AW995839 AW995907


455600
1335877_1
BE061053 BE008959 BE008957 BE091618


455885
1380385_1
BE153524 BE153576 BE153583


455928
1383899_1
BE170313 BE158339 BE158290


456573
201205_1
AI279811 AI301071 AI214696 AI279813 AA588460 AA287256 BE171665


457268
310453_1
AW272279 AA461542 AA460615


457978
448900_1
AA776638 BE439540


458196
503719_1
AI802408 AA907424 AI279233 AI302762 N33153 BE045678 AI863332 AW173558 AI302328 Z20793 D25594 BE326823


459167
92053_1
BE504370 AI243453 AI809556 AI702878 AI702163 AI300626 AW072219




AI369492 AI349587 AW779061 W78149 AA055693 AA974162




AI394380 AI830098 AW054857 AI870008 AW207658 AW665508




AW300595 AI192992 AW628019 AI274365 AA906922 N92547




AW054727 AW206667 AW136707 AW13761


459271
969257_1
AL045934 AL039532 H55631






Pkey Unique Eos probeset identifier number




CAT number Gene cluster number




Accession Genbank accession numbers








[0397]

47








TABLE 17C








Pkey
Ref
Strand
Nt_position


















400460
8389428
Plus
35559-36295


400607
9887666
Plus
3112-4159


400833
8705148
Minus
187599-188138


400845
9188605
Plus
34428-34612


400923
7637836
Minus
94518-94659


400933
7651935
Minus
105330-105503


401210
7712287
Plus
166969-167133, 169760-169877, 171563-171733


401264
9797154
Plus
130810-130927, 133367-133504


401278
9799936
Plus
98428-98573


401609
7705041
Minus
9877-11997


401674
7689903
Plus
138786-138927, 139157-139298, 139440-139599, 139960-140159


401724
7656694
Plus
150063-150241


402197
8576113
Plus
199466-199585


402365
9454515
Minus
70928-71185


402393
9929688
Plus
19813-20084, 20163-20263


402400
9945145
Minus
80123-80322


402632
9931268
Plus
101166-101419


402884
9926562
Plus
47980-48191


402916
7406502
Minus
361-474, 541-687


403055
8748904
Minus
109532-110225


403128
7331426
Plus
122884-123018, 123134-123283, 123372-123695, 123779-123940, 124059-124256


403182
9838273
Plus
102163-102345, 102545-102725


403938
7711795
Plus
48636-48822


403945
7711869
Minus
32141-32263


404036
8567760
Minus
65247-67529, 112537-114863


404333
9802821
Minus
137948-138024, 138111-138300


404343
9838093
Plus
122664-122931


404344
9838093
Plus
127865-128384


404365
9964977
Plus
50151-50319, 50859-51098


404661
9797073
Plus
33374-33675, 33769-34008


404757
7706327
Plus
100933-101083, 101580-101782


404807
4165210
Minus
124246-124422


405334
3135285
Plus
139386-139856


405346
2981263
Plus
101982-102171


405364
2281075
Minus
48325-48491, 49136-49252


405371
2078469
Minus
47657-47766, 48461-48596


405594
6960456
Plus
161628-161734, 162823-163014, 164439-164652


405928
7717155
Minus
2923-3209


406230
4760409
Plus
71716-72515


406244
7417725
Plus
39422-39595


406301
8575868
Plus
57291-57494


406487
7711306
Plus
82039-82902


406495
7711328
Minus
174661-174978


406613
2957168
Plus
5029-5147






Pkey Unique number corresponding to an Eos probeset




Ref Sequence source The 7 digit numbers in this column are Genbank Identifier (GI) numbers “Dunham I et al” refers to the publication entitled “The DNA sequence of human chromosome 22” Dunham, et al. (1999) Nature 402: 489-495




Strand Indicates DNA strand from which exons were predicted




Nt_position Indicates nucleotide positions of predicted exons








[0398] Table 18A lists about 117 genes down-regulated in ovarian cancer compared to non-malignant adult ovaries. These were selected as for 17A, except that the numerator was set to the 75th percentile amongst various non-malignant ovary specimens, the denominator was set to the 96th percentile value amongst various ovarian cancers, the numerator was greater than or equal to 75 units, and the ratio was greater than or equal to 2 0(i e, 2-fold downregutation in tumor vs. normal ovaries)
48TABLE 18APkeyEx AccnUG IDTitlePred Protein Dom.R1428232BE272452Hs 183109monoamine oxidase AAmine_oxidase, pyr_redox, F16.9433563AI732637Hs.277901ESTsSS10.8444931AV652066general transcription factor lSS, Glypican8.7451573AW130351ESTsSS8.3429570BE242256Hs 2441KIAA0022 gene productlectin_c, SS, TM7.9453510AI699482Hs 42151ESTsSS7.5410295AA741357nidogen (enactin)SS, EGF, ldl_recept_b, thyro6.9438549BE386801Hs.21858tnnucleotide repeat containinSS, serpin, SS, WD40, FYVE6.5407969AA046217Hs.105370ESTsSS, Pep_M12B_propep, Reprol6.2414541BE293116Hs 76392aldehyde dehydrogenase 1 familaldedh6.0448438BE613081Hs 24654Homo sapiens cDNA FLJ11640 fis5.7441422R43777Hs 21364ESTsSS, TM5.1413391AI223328Hs.75335glycine amidinotransferase (L-Amidinotransf3.9428022Z39686Hs 27865ESTsSS3.6423044AA320829Hs 97266protocadhenn 183.6416039AA376989Hs 78989alcohol dehydrogenase 5 (classadh_zinc, HCV_NS4a, TM, adh3.5452854AA437061Hs.14060prokineticin 1 precursorSS3.4436772AW975688metallothionein 1E (functionalSS, TM,7tm_2, HRM3.2415162AF035718Hs 78061transcription factor 21HLH3.2427794AA709186Hs 99070ESTsSS3.1433072AI928037Hs 158832ESTsSS3.1418318U47732Hs 84072transmembrane 4 superfamily metransmembrane42.9410059NM_007038Hs.58324a disintegnn-like and metalloReprolysin, tsp_1, Pep_M12B2.9431933AI187057Hs 132554ESTsTM, SS, TM2.9420303AA258282Hs 278436KIAA1474 protein2.8438780M64936gb Homo sapiens retinoic acid-2.8427661AA410292Hs 104761ESTsSS, wnt2.8437342AW903297Hs 236438hypothetical protein DKFZp761KSec7, PH2.8453828AW970960Hs 293821ESTsSS, Pep_M12B_propep, Reprol2.7418444AI902899Hs.85155butyrate response factor 1 (EGzf-CCCH, SS2.7453767AB011792Hs 35094extracelluler matrix protein 2vwc, LRR, SS, LRR2.7413624BE177019Hs.75445SPARC-like 1 (mast9, hevin)kazal, SS, kazal2.7413305NM_000426Hs 323511Homo sapiens cDNA FLJ23176 filaminin_B, laminin_EGF, lam2.7414504AW069181Hs 115175stenle-alpha motif and leucinSS, pkinase, SAM2.7439897NM_015310Hs 6763KIAA0942 proteinSec7, PH2.7421639NM_012082Hs.106309Friend of GATA2SS2.7442498U54617Hs.8364Homo sapiens pyruvate dehydrogHATPase_c, HATPase_c2.6410494M36564Hs 64016protein S (alpha)EGF, laminin_G, gla2.6452958AA883929Hs 40527ESTsSS2.6449648AW205607Hs 253499ESTsSS2.5435519AI218950Hs 125461hypothetical protein FLJ11539SS2.5433690AI373949Hs 279610hypothetical protein FLJ10493SS2.5424319AW961026Hs.96752ESTs, Weakly similar to ALU8_H2.5420174AI824144Hs 199749ESTs2.5421709AA159394Hs 107056CED-6 proteinPID, Herpes_UL62.4417622AW298163Hs.82318WAS protein family, member 3WH22.4453655AW960427Hs 342874transforming growth factor, beSS, TM, zona_pellucida2.4408468AI909712phosphatidylinositol transferSS, PX, PH, PLDc, PH, PLDc, PX2.4400829C11000244 gi|11056030|ref|NP_0SS, TM, SS, TFIID_30 kD2.3453125AW779544Hs 115497hypothetical protein FLJ22655ras2.3437862AW978107Hs.5884Homo sapiens mRNA, cDNA DKFZp5HLH2.3425462AI491852Hs.46783Homo sapiens cDNA FLJ22382 fi2.3417094NM_006895Hs 81182histamine N-methyltransferaseAcyl-CoA_dh2.3403247Target Exon2.3441916AA993571ESTs2.3422746NM_004484Hs 119651glypican 3Glypican, SS2.3416777AF146760Hs.79844DKFZP564M1416 proteinSS, GTP_CDC, SS2.3409403AA668224Hs 6634Homo sapiens cDNA FLJ22547 fiSS, TM2.3418956AA234831KIAA0788 proteinSS2.3410073AW408163Hs.58488catenin (cadhenn-associated pVinculin, Stathmin2.3419461AI452601Hs 288869nuclear receptor subfamily 2,hormone_rec, zf-C4, hormone2.3429319AL023754Hs 199068similar to calcium/calmodulinSS, pkinase2.2452123AI267615Hs 38022ESTsSS2.2453305R39224Hs 267997EHM2 gene2.2416157NM_003243Hs.342874transforming growth factor, bezona_pellucida, SS, TM, zona2.2406637U14966Hs.180946ribosomal protein L5Ribosomal_L18p2.2414466AA349211Hs.76205cytochrome P450, subfamily XIAp4502.2408915NM_016651Hs.48950heptacellular carcinoma novelSS2.2420929AI694143Hs 326248programmed cell death 4MA3, LRR2.2456972AI054347Hs 2017ribosomal protein L38SS, TM2.2409549AB029015Hs.54886phospholipase C, epsilon 2C2, PH, PI-PLC-Y, PI-PLC-X2.2410209AI583661Hs 60548hypothetical protein PRO1635SS, TM, Fork_head2.2449500AW956345Hs 12926ESTsSS, TM2.2447806W03616Hs 10432ESTs, Weakly similar to I380222.1441712AW391927Hs.7946KIAA1288 protein2.1445025AI768895Hs 295727ESTs, Weakly similar to ALUB_HSS, BAG, UPF00012.1444161N52543Hs 142940ESTsSS2.1427156BE621719Hs 173802KIAA0603 gene productSS, TM, TBC2.1436995AI160015Hs 125489ESTsSS, TM, RasGEF, actin, RasGEF2.1408443N33937Hs 10336ESTsSS2.1448274AI268097Hs 67317Homo sapiens cDNA FLJ11775 fis2.1426354NM_004010Hs.169470dystrophin (muscular dystrophyZZ, CH, WW, spectrin, bZIP, SS2.1443906AA348031Hs 7913ESTs2.1444815AA151539Hs.1227aminolevulinate, delta-, dehydSS, ALAD2.1420728AA767718Hs 93581hypothetical protein FLJ10512SS, TM, Sema, PSI, ig2.1404245NM_007116*fibrinogen_C, fn3, SS2.1436420AA443966Hs.31595ESTsSS, TM, PMP22_Claudin, SS, TM2.1410066AL117664Hs 58419DKFZP586L2024 protein2.0414476AA301867Hs 76224EGF-containing fibulin-like exEGF, TIL, SS2.0424137AA335769Hs 16262ESTs2.0447659AA017472Hs 107260hypothetical protein DKFZp586HSS2.0444862AI209158Hs.143929ESTsSS, TM2.0426086T94907Hs.188572ESTsPH, CH, spectrin2.0436080AI684710Hs.201645ESTsSS, ATP-synt_C2.0424651AI493206ESTsSS2.0432939AL038924Hs 279849KIAA0438 gene productzf-C3HC4, myosin_head, DIL,2.0449088AI654048Hs 196556ESTsSS, MACPF, sushi, Idl_recept2.0428642NM_014899Hs 10432KIAA0878 proteinBTB, ras2.0419577L36531Hs 91296integrin, alpha 8TM, integrin_A, FG-GAP2.0450435AI695975Hs.201805ESTslaminin_B, laminin_EGF, lam2.0450696AI654223Hs 16026hypothetical protein FLJ23191SS2.0421255BE326214Hs 93813ESTsTM2.0432467T03667Hs.239388Human DNA sequence from cloneSS2.0408654BE018882Hs 46721UCC1 proteinSS, Ependymin, SS2.0412611AA732036Hs 164478hypothetical protein FLJ219392.0453355AW295374Hs 31412myopodin2.0424665AW368576Hs 139851caveolin 2SS, TM, Caveolin, Caveolin2.0458147AW752597gb IL3-CT0214-161299-045-B06 CSS, TM, PMM2.0447566N50432Hs.102648ESTs2.0414496W73853ESTsSS, TM, pkinase, F5_F8_type2.0425618AW119112Hs.9052Homo sapiens cDNA FLJ22042 fiSS, TM2.0415166NM_003652Hs 78068carboxypeptidase ZZn_carbOpept, Fz, Dioxygena2.0422157AW957295Hs 1123186.2 kd proteinSS2.0450253AL133047Hs.24715Homo sapiens mRNA, cDNA DKFZp4SH32.0418919AA232635ESTsSS, DUF252.0444846AI871055Hs 148477ESTsSS, TM2.0418781T41160Hs 8404ESTs2.0Pkey: Unique Eos probeset identifier number Ex Accn: Exemplar Accession number, Genbank accession number UG ID UniGene number Title. UniGene gene title Pred. Protein Dom.: Predicted protein domain R1: Ratio of normal ovaries to tumor


[0399]

49







TABLE 18B








Pkey
CAT Number
Accession

















408468
106033_1
AI909712 AL039752 BE000369 AA376876 N75269 AA345398 AA349053




AW960062 R76169 R70638 AA054770 AI378587




AI338002 AI762398 N47873 AI066549 AI474112 AW450680




AA668668 R76114 AW242828 N58855 AW080313 AI378491




AI807102 AA417043 AI565444 AW263286 AW297099


410295
11922_2
AA741357 AI870000 W75997 H50726 AV658709 AI498817 AL037804




W67847 BE018553 AI033256 N76810 N31548 AI032084




N36278 AW075272 AI032081 R35753 W93372 AA700790




AI903697 N52985 R82468 AW580252 AL036760 AI052219




R36621 W07047 AA088621 AI249109 W68776 W69374 AA15


414496
145392_1
W73853 AA928112 W77887 AW889237 AA148524 AI749182 AI754442




AI338392 AI253102 AI079403 AI370541 AI697341 H97538




AW188021 AI927669 W72716 AI051402 AI188071 AI335900 N21488




AW770478 W92522 AI691028 AI913512 AI144448




W73819 AA604358 N28900 W95221 AI868132 H98


418919
180623_1
AA232635 AI373703 AA233330


418956
180862_1
AA234831 AI700302 AA906216 AA776957 R49415 AI420777 AA666394 AI830619




AA779469 AI972390 N40980 AI094453




AA826397 AA535994 AI868257 AI804295 AA897791 AA232893




AI348680 AI356232 AA235138 F31396 AW079977 H16405


424651
241981_1
AI493206 AA732315 AA344619 AA904035 AW952967 AA488889 AA635644




BE245127 AA669979 AA761874 H28767 AA910081




AA837086 AA766495 W76175 AI521825 AA746092 AA743152 AI478562 H88863


436772
426854_1
AW975688 AA731063 N67084


438780
46501_1
M64936 AI025512 AI382987 BE061777 AA089966 BE169930




T41176 AW594624 BE502415 AA121893 AI269283 T40311




AI684569 AA257011 AI079277 AI241318




BE327710 AW975215 AW896268 AA884990 BE327514


441916
528799_1
AA993571 AA971518 AI937262


444931
62567_1
AV652066 AA459880 T58512 T58561 AI651255 N49838 H87921




AW264447 AA428067 AA364094 AW955685 D62894 AW341452




AA243652 AI984618 AI816803 AI871252 AI376942 AI740496 AA452836




AI277917 AI149141 AA456147 AI784566 AI003975




AI245674 AI433703 AI200208 AI268985 AI38


451573
875588_1
AW130351 AW338699 AI803973


458147
488021_1
AW752597 AW848781 AW849062 AW848490 AW752699 AW752604 AW752700






Pkey Unique Eos probeset identifier number




CAT number Gene cluster number




Accession Genbank accession numbers








[0400]

50








TABLE 18C








Pkey
Ref
Strand
Nt_position


















400829
8570385
Plus
152176-152616


403247
7656833
Minus
76626-77140


404245
7406725
Plus
36019-36282, 37073-37813, 38946-





39314, 40355-40651, 42738-43028,





43391-43696, 45698-46030, 51110-





51415, 52779-53072, 54648-54935,





55201-55509, 55926-56240, 56355-





56672, 57078-57401 , 59966-60262,





62600-62926, 63363-63686,





66693-67025, 68180-68497,





68909-69232, 71372-71695, 720






Pkey: Unique number corresponding to an Eos probeset




Ref Sequence source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers “Dunham I et al.” refers to the publication entitled “The DNA sequence of human chromosome 22” Dunham, et al. (1999) Nature 402: 489-495




Strand Indicates DNA strand from which exons were predicted




Nt_position Indicates nucleotide positions of predicted exons








[0401] Table 19A provides UnigeneID, UnigeneTitle, Pkey, and Exemplar Accession for sequences in Table 20 Information in Table 19A is linked by SEQ ID NO to Table 20
51TABLE 19APkeyExAccnUG IDTitleSEQ ID NO452838U65011Hs 30743preferentially expressed antigen in melaSEQ ID NO: 1-2421478AI683243Hs 97258ESTs, Moderately similar to S29539 ribosSEQ ID NO 3-4436982AB018305Hs. 5378spondin 1, (f-spondin) extracellular matSEQ ID NO 5-6458627AW088642Hs 97984SRY (sex determining region Y)-box 17 (SSEQ ID NO 7-8422956BE545072Hs 122579ECT2 protein (Epithelial cell transformSEQ ID NO: 9-10410102AW248508Hs. 279727ESTs, homologue of PEM-3 [Ciona savignyiSEQ ID NO 11-12428579NM_005756Hs 184942G protein-coupled receptor 64SEQ ID NO 13-22428227AA321649Hs 2248smell inducible cytokine subfamily B (CySEQ ID NO 23-24451110AI955040Hs 265398PAR-6 beta (partitioning defective 6 hSEQ ID NO 25-26428187AI687303Hs 285529G protein-coupled receptor 49SEQ ID NO: 27-28424905NM_002497Hs. 153704NIMA (never in mitosis gene a)-related kSEQ ID NO 29-30433159A8035898Hs 150587kinesin-like protein 2SEQ ID NO: 31-32426427M86699Hs 169840TTK protein kinaseSEQ ID NO: 33-34425371D49441Hs 155981mesothelinSEQ ID NO: 35-38418506AA084248Hs 85339G protein-coupled receptor 39SEQ ID NO: 39-40456546AI690321Hs 203845KCNK15 potassium channel, subfamily K, mSEQ ID NO: 41-42427344NM_000869Hs 21425-hydroxytryptamine (serotonin) receptorSEQ ID NO 43-44445537AJ245671Hs. 12844EGE-like-domain, multiple 6SEQ ID NO 45-46424620AA101043Hs 151254kallikrein 7 (chymotryptic, stratum cornSEQ ID NO 47-48412078X69699Hs 73149paired box gene 8SEQ ID NO 49-52409178BE393948Hs 50915kallikrein 5SEQ ID NO: 53-54448243AW369771integrin, beta 8SEQ ID NO 55-56426514BE616633Hs 170195bone morphogenetic protein 7 (osteogenicSEQ ID NO 57-58419452U33635Hs 90572PTK7 protein tyrosine kinase 7SEQ ID NO 59-60431130NM_006103Hs. 2719HE4, epididymia-specific, whey-acidic prSEQ ID NO 61-62415539AI733881Hs 72472BMP-R1BSEQ ID NO 63-64423961D13666Hs 136348periostin (OSF-2os)SEQ ID NO 65-66417433BE270266Hs 821285T4 oncofetal trophoblast glycoproteinSEQ ID NO 67-68422867L32137Hs 1584cartilage oligomeric matrix protein (pseSEQ ID NO: 69-70409542AA503020Hs 36563hypothetical protein FLJ22418SEQ ID NO 71-72444381BE387335Hs 283713ESTs, Weakly similar to S64054 hypothetiSEQ ID NO 73-74452747BE153855Hs. 61460Ig superfamily receptor LNIRSEQ ID NO 75-76450375AA009647a disintegrin and metalloproteinase domaSEQ ID NO 77-78426215AW963419Hs 155223stanniocalcin 2SEQ ID NO 79-80430044AA464510Hs 152812ESTsSEQ ID NO: 81447033AI357412Hs 157601ESTsSEQ ID NO 82-87410418D31382Hs. 63325transmembrane protease, serine 4SEQ ID NO 88-89411274NM_002776Hs 69423kallikrein 10SEQ ID NO 90-91422260AA315993Hs 105484regenerating gene type IVSEQ ID NO: 92-93409041AB033025Hs. 50081Hypothetical protein, XP_051860 (KIAA119SEQ ID NO 94-95428664AK001666Hs 189095similar to SALL1 (sal (Drosophila)-likeSEQ ID NO 96-97404977Insulin-like growth factor 2 (somatomediSEQ ID NO 98-99427747AW411425Hs 180655serine/threonine kinase 12SEQ ID NO 100-101412140AA219691Hs 73625RAB6 interacting, kinesin-like (rabkinesSEQ ID NO: 102-103431846BE019924Hs 271580uroplakin 1BSEQ ID NO: 104-105425465L18964Hs 1904protein kinase C, iotaSEQ ID NO: 106-107432938T27013Hs 3132steroidogenic acute regulatory proteinSEQ ID NO 108-109421451AA291377Hs. 50831ESTsSEQ ID NO 110-117437478AL390172Hs 317432branched chain aminotransferase 1, cytosSEQ ID NO 116-119411945AL033527Hs 92137L-myc-2 protein (MYCL2)SEQ ID NO 120-121424078AB006625Hs 139033paternally expressed 3SEQ ID NO 122-123406400kallikrein 8 (neuropsin/ovasin) (KLK8)SEQ ID NO: 124-125428450NM_014791Hs 184339KIAA0175 gene productSEQ ID NO 126-127438167R28363Hs 24286chemokine binding protein 2 (CCBP2), mRNSEQ ID NO 126-129416530U62801Hs. 79361kallikrein 6 (neurosin, zyme)SEQ ID NO: 130-131430691C14187Hs 157208anstaless-related homeobox protein ARXSEQ ID NO 132-133408081AW451597Hs 167409intron of basic-helix-loop-helix-PAS proSEQ ID NO 134411773NM_006799Hs 72026protease, serine, 21 (testisin)SEQ ID NO: 135-138407792AI077715Hs. 39384putative secreted ligand homologous to fSEQ ID NO 139-140428093AW594506Hs. 104830ESTsSEQ ID NO 141-144431630NM_002204Hs 265829integrin, alpha 3 (antigen CD49C, alphaSEQ ID NO 145-148421502AF111856Hs 105039solute carrier family 34 (sodiam phosphaSEQ ID NO 149-150431441U81961Hs 2794sodium channel, nonvoltage-gated 1 alphaSEQ ID NO 151-152431369BE184455Hs 251754secretory leukocyte protease inhibitor (SEQ ID NO 153-154436972AA284679Hs 25640claudin 3SEQ ID NO: 155-156429504X99133Hs. 204238lipocalin 2 (oncogene 24p3) (NGAL)SEQ ID NO 157-158410001AB041036Hs 57771kallikrein 11SEQ ID NO 159-160Pkey: Unique Eos probeset identifier number ExAccn Exemplar Accession number, Genbank accession number UG ID: UniGene number Title: UniGene gene title SEQ ID NO: Sequence Identification number for sequences in Table 20


[0402]

52







TABLE 19B











CAT



Pkey
Number
Accession





448243
75629_1
AW369771 AW748174 AA290801 AA419198




AA044331 AA127909 AW995442 AI480343




AA044582 AW956159 AA373451 AA127965




AL134913 AW994956 BE622314 BE006298




BE006312 BE006305 BE006317 BE006303




AA043906 AA234175 AA479726


450375
83327_1
AA009647 AA131254 AA374293 AW954405




H04410 AW606284 AA151166 BE157467




BE157601 H04384 W46291 AW663674 H04021




H01532 AA190993 H03231 H59605 H01642




AA852876 AA113758 AA626915 AA746952




AI161014 AA099554 R69067













Pkey
Unique Eos probeset identifier number



CAT number
Gene cluster number



Accession
Genbank accession numbers











[0403]

53










TABLE 19C













Pkey
Ref
Strand
Nt_position







404977
3738341
Minus
43081-43229



406400
9256298
Plus
1553-1712, 1878-2140,






4252-4385, 5922-6077












Pkey:
Unique number corresponding to an Eos probeset


Ref
Sequence source. The 7 digit numbers in this column



are Genbank Identifier (GI) numbers. “Dunham I et



al.” refers to the publication entitled “The



DNA sequence of human chromosome 22” Dunham, et



al. (1999) Nature 402:489-495


Strand
Indicates DNA strand from which exons were predicted


Nt_position
Indicates nucleotide positions of predicted exons










[0404]

54






TABLE 20










SEQ ID NO: 1 DNA sequence



Nucleic Acid Accession #. NM_006115.1


Coding sequence. 236..1765


1          11         21         31         41         51


|          |          |          |          |          |


GCTTCAGGGT ACAGCTCCCC CGCAGCCAGA AGCCGGGCCT GCAGCCCCTC AGCACCGCTC
60





CGGGACACCC CACCCGCTTC CCAGGCGTGA CCTGTCAACA GCAACTTCCC GGTCTGGTGA
120





ACTCTCTGAG GAAAAACCAT TTTGATTATT ACTCTCAGAC GTGCGTGGCA ACAAGTGACT
180





GAGACCTAGA AATCCAAGCG TTGGAGGTCC TGAGGCCAGC CTAAGTCGCT TCAAAATGGA
240





ACGAAGGCGT TTGTGGGGTT CCATTCAGAG CCGATACATC AGCATGAGTG TGTGGACAAG
300





CCCACGGAGA CTTGTGGAGC TGGCAGGGCA GAGCCTGCTG AAGGATGAGG CCCTGGCCAT
360





TGCCGCCCTG GAGTTGCTGC CCAGGGAGCT CTTCCCGCCA CTCTTCATGG CAGCCTTTGA
420





CGGGAGACAC AGCCAGACCC TGAAGGCAAT GGTGCAGGCC TGGCCCTTCA CCTGCCTCCC
480





TCTGGGAGTG CTGATGAAGG GACAACATCT TCACCTGGAG ACCTTCAAAG CTGTGCTTGA
540





TGGACTTGAT GTGCTCCTTG CCCAGGAGGT TCGCCCCAGG AGGTGGAAAC TTCAAGTGCT
600





GGATTTACGG AAGAACTCTC ATCAGGACTT CTGGACTGTA TGGTCTGGAA ACAGGGCCAG
660





TCTGTACTCA TTTCCAGAGC CAGAAGCAGC TCAGCCCATG ACAAAGAAGC GAAAAGTAGA
720





TGGTTTGAGC ACAGAGGCAG AGCAGCCCTT CATTCCAGTA GAGGTGCTCG TAGACCTGTT
780





CCTCAAGGAA GGTGCCTGTG ATGAATTGTT CTCCTACCTC ATTGAGAAAG TGAAGCGAAA
840





GAAAAATGTA CTACGCCTGT GCTGTAAGAA GCTGAAGATT TTTGCAATGC CCATGCAGGA
900





TATCAAGATG ATCCTGAAAA TGGTGCAGCT GGACTCTATT GAAGATTTGG AAGTGACTTG
960





TACCTGGAAG CTACCCACCT TGGCGAAATT TTCTCCTTAC CTGGGCCAGA TGATTAATCT
1020





GCGTAGACTC CTCCTCTCCC ACATCCATGC ATCTTCCTAC ATTTCCCCGG AGAAGGAAGA
1060





GCAGTATATC GCCCAGTTCA CCTCTCAGTT CCTCAGTCTG CAGTGCCTGC AGGCTCTCTA
1140





TGTGGACTCT TTATTTTTCC TTAGAGGCCG CCTGGATCAG TTGCTCAGGC ACGTGATGAA
1200





CCCCTTGGAA ACCCTCTCAA TAACTAACTG CCGGCTTTCG GAAGGGGATG TGATGCATCT
1260





GTCCCAGAGT CCCAGCGTCA GTCAGCTAAG TGTCCTGAGT CTAAGTGGGG TCATGCTGAC
1320





CGATGTAAGT CCCGAGCCCC TCCAAGCTCT GCTGGAGAGA GCCTCTGCCA CCCTCCAGGA
1380





CCTCGTCTTT GATGAGTGTG GGATCACGGA TGATCAGCTC CTTGCCCTCC TGCCTTCCCT
1440





GAGCCACTGC TCCCAGCTTA CAACCTTAAG CTTCTACGGG AATTCCATCT CCATATCTGC
1500





CTTGCAGAGT CTCCTGCAGC ACCTCATCGG GCTGAGCAAT CTGACCCACG TGCTGTATCC
1560





TGTCCCCCTG GAGAGTTATG AGGACATCCA TGGTACCCTC CACCTGGAGA GGCTTGCCTA
1620





TCTGCATGCC AGGCTCAGGG AGTTGCTGTG TGAGTTGGGG CGGCCCAGCA TGGTCTGGCT
1680





TAGTGCCAAC CCCTGTCCTC ACTGTGGGGA CAGAACCTTC TATGACCCGG AGCCCATCCT
1740





GTGCCCCTGT TTCATGCCTA ACTAGCTGGG TGCACATATC AAATGCTTCA TTCTGCATAC
1800





TTGGACACTA AAGCCAGGAT GTGCATGCAT CTTGAAGCAA CAAAGCAGCC ACAGTTTCAG
1860





ACAAATGTTC AGTGTGAGTG AGGAAAACAT GTTCAGTGAG GAAAAAACAT TCAGACAAAT
1920





GTTCAGTGAG GAAAAAAAGG GGAAGTTGGG GATAGGCAGA TGTTGACTTG AGGAGTTAAT
1980





GTGATCTTTG GGGACATACA TCTTATAGAG TTAGAAATAG AATCTGAATT TCTAAAGGGA
2040





GATTCTGGCT TGGGAAGTAC ATGTAGGAGT TAATCCCTGT GTAGACTGTT GTAAAGAAAC
2100





TGTTGAAAAT AAAGAGAAGC AATGTGAAGC AAAAAAAAAA AAAAAAAA





SEQ ID NO: 2 Protein sequence


Protein Accession #: NP_006106.1


1          11         21         31         41         51


|          |          |          |          |          |


MERRELMGSI QSRYISMSVW TSPRELVELA GQSLLEDEAL AIAALELLPR ELFPPLFMAA
60





FDGRHSQTLK AMVQAWPFTC LPLGVLMKGQ HLHLETFKAV LDGLDVLLAQ EVRPRRWKLQ
120





VLDLRKNSNQ DPWTVWSGNR ASLYSFPEPE AAQPMTKKRK VDGLSTEASQ PFIPVEVLVD
180





LFLKEGACDE LFSYLIEKVK RKKNVLRLCC KKLKIFAMPM QDIKMILKMV QLDSIEDLEV
240





TCTWKLPTLA KESPYLGQMI NLRRLLLSNI HASSYISPEK EEQYIAQFTS QFLSLQCLQA
300





LYVDSLFFLR GRLDQLLRHV MNPLETLSIT NCRLSEGDVN HLSQSPSVSQ LSVLSLSGVM
360





LTDVSPEPLQ ALLERASATL QDLVFDECGI TDDQLLALLP SLSNCSQLTT LSFYGNSISI
420





SALQSLLQHL IGLSNLTKVL YPVPLESYED IHGTLHLERL AYLHARLREL LCELGRPSMV
480





WLSANPCPHC GDRTFYDPEP ILCPCFMPN





SEQ ID NO: 3 DNA sequence


Nucleic Acid Accession #. Eos sequence


Coding sequence: 264..782


1          11         21         31         41         51


|          |          |          |          |          |


CCCTGCTCCA GTCACACCCG GAAGCTGACT GGTCCACGCA CAGCTGAAGC ATGAGGAAAC
60





TCATCGCGGG ACTAATTTTC CTTAAAATTT AGACTTGCAC AGTAAGGACT TCAACTGACC
120





TTCCTCAGAC TGAGAACTGT TTCCAGTATA TACATCAAGT CACTGAGATC TCCAGCACCC
180





TGCCGGTGGC ACTACTGAGA GACGAGGTGC CAGGGTGGTT CCTGAAAGTG CCTGAGCCCC
240





AACTTATCAG CAAGGAGCTC ATCATGCTGA CAGAAGTCAT GGAGGTCTGG CATGGCTTAG
300





TGATCGCGGT GGTGTCCCTC TTCCTGCAGG CCTGCTTCCT CACCGCCATC AACTACCTGC
360





TCAGCAGGCA CATGGCCCAC AAGAGTGAAC AGATACTGAA AGCGGCCAGT CTCCAGGTTC
420





CCAGGCCCAG CCCTGGCCAC CATCATCCAC CTGCTGTCAA AGAGATGAAG GAGACTCAGA
480





CAGAGAGAGA CATCCCAATG TCTGATTCCC TTTACAGGCA TGACAGCGAC ACACCCTCAG
540





ATAGCTTGGA TAGCTCCTGC AGTTCGCCTC CTGCCTGCCA GGCCACAGAG GATGTGGATT
600





ACACACAAGT CGTCTTTTCT GACCCTGGAG AACTAAAAAA TGACTCCCCG CTGGACTATG
660





AGAACATAAA GGAAATCACA GATTATGTCA ATGTCAATCC AGAAAGACAC AAGCCCAGTT
720





TCTGGTATTT TGTCAACCCT GCTCTGTCTG AGCCAGCGGA ATATGATCAA GTGGCCATGT
780





GAATTCCAAA TATTTTTAAT GGGGTCCAGT TCTCTATGGA TTCTTACATT TAATTTGTAG
840





GGAAATGCCA TTTTTCCCCC TTAAACAAGG CATGGGGCTC ACAAGTCTAT GGAGACAGGC
900





CAAAAAGAAT GTGGAGAAGA AAACTGATAA ATACACAGAG GTCCTCAAGA CCCATGGACT
960





CCTGGTCTGT ACCCAAAAAA GCTGTTCGTT CCTCAAAAAC AAAAACAAGG CTTGGCTGGG
1020





AAAACAGGCC AATGCCCCGG CAAGAAAGGT TGAGATCAGA TGTTAGGAAG AACTTTCAGG
1080





TAAAGTATGA GAACTATGGA GTCCATCAGC AGAGATAGTA GTGAAGTCTC TCCCCAGGGA
1140





AAATTTTAAA AAGGTTGAAT CAGCTGTTGT AGAGTTCTAT TTGGCAATCT CATGGTTAAA
1200





TGACTTCCCT TTGAGCTCTT TAATTATTGG CAATAAACAA CTTCTTTAAA AGTTTTAAAT
1260





AAAATAGCAA CCACCACCA





SEQ ID NO: 4 Protein sequence


Protein Accession #: Eos sequence


1          11         21         31         41         51


|          |          |          |          |          |


MLTEVMEVWH GLVIAVVSLF LQACFLTAIN YLLSRHMAHK SEQILKAASL QVPRPSPGHH
60





HPPAVKENKE TQTERDIPMS DSLYRHDSDT PSDSLDSSCS SPPACQATED VDYTQVVFSD
120





PGELKNDSPL DYENIKEITD YVNVNPERHK PSFWYFVNPA LSEPAEYDQV AM





SEQ ID NO: 5 DNA sequence


Nucleic Acid Accession #: AB051390


Coding sequence. 34..2457


1          11         21         31         41         51


|          |          |          |          |          |


AGCGGCCGCG GCACAAAGTT GGGGGCCGCG AAGATGAGGC TGTCCCCGGC GCCCCTGAAG
60





CTGAGCCGGA CTCCGGCACT GCTGGCCCTG GCGCTGCCCC TGGCCGCGGC GCTGGCCTTC
120





TCCGACGAGA CCCTGGACAA AGTGCCCAAG TCAGAGGGCT ACTGCAGCCG TATCCTGCGC
180





GCCCAGGGCA CGCGGCGCGA GGGCTACACC GAGTTCAGCC TCCGCGTGGA GGGCGACCCC
240





GACTTCTACA AGCCGGGAAC CAGCTACCGC GTAACACTTT CAGCTGCTCC TCCCTCCTAC
300





TTCAGAGGAT TCACATTAAT TGCCCTCAGA GAGAACAGAG AGGGTGATAA GGAAGAAGAC
360





CATGCTGGGA CCTTCCAGAT CATAGACGAA GAAGAAACTC AGTTTATGAG CAATTGCCCT
420





GTTGCAGTCA CTGAAAGCAC TCCACGGAGG AGGACCCGGA TCCAGGTGTT TTGGATAGCA
480





CCACCAGCGG GAACAGGCTG CGTGATTCTG AAGGCCAGCA TCGTACAAAA ACGCATTATT
540





TATTTTCAAG ATGAGGGCTC TCTGACCAAG AAACTTTGTG AACAAGATTC CACATTTGAT
600





GGGGTGACTG ACAAACCCAT CTTAGACTGC TGTGCCTGCG GAACTGCCAA GTACAGACTC
660





ACATTTTATG GGAATTGGTC CGAGAAGACA CACCCAAAGG ATTACCCTCG TCGGGCCAAC
720





CACTGGTCTG CGATCATCGG AGGATCCCAC TCCAAGAATT ATGTACTGTG GGAATATGGA
780





GGATATGCCA GCGAAGGCGT CAAACAAGTT GCAGAATTGG GCTCACCCGT GAAAATGGAG
840





GAAGAAATTC GACAACAGAG TGATGAGGTC CTCACCGTCA TCAAAGCCAA AGCCCAATGG
900





CCAGCCTGGC AGCCTCTCAA CGTGAGAGGA GCACCTTCAG CTGAATTTTC CGTGGACAGA
960





ACGCGCCATT TAATGTCCTT CCTGACCATG ATGGGCCCTA GTCCCGACTG GAACGTAGGC
1020





TTATCTGCAG AAGATCTGTG CACCAAGGAA TGTGGCTGGG TCCAGAAGGT GGTGCAAGAC
1080





CTGATTCCCT GGGACGCTGG CACCGACAGC GGGGTGACCT ATGAGTCACC CAACAAACCC
1140





ACCATTCCCC AGGAGAAAAT CCGGCCCCTG ACCACCCTGG ACCATCCTCA GAGTCCTTTC
1200





TATGACCCAG AGGGTGGGTC CATCACTCAA GTACCCAGAG TTGTCATCGA GAGAATCGCA
1260





CGGAAGGGTG AACAATGCAA TATTGTACCT GACAATGTCG ATGATATTGT AGCTGACCTG
1320





GCTCCAGAAG AGAAAGATGA AGATGACACC CCTGAAACCT GCATCTACTC CAACTGGTCC
1380





CCATGGTCCG CCTGCAGCTC CTCCACCTGT GACAAAGGCA AGAGGATGCG ACAGCGCATG
1440





CTGAAAGCAC AGCTGGACCT CAGCGTCCCC TGCCCTGACA CCCAGGACTT CCAGCCCTGC
1500





ATGGGCCCTG GCTGCAGTGA CGAAGACGGC TCCACCTGCA CCATGTCCGA GTGGATCACC
1560





TGGTCGCCCT GCAGCATCTC CTGCGGCATG GGCATGAGGT CCCGGGAGAG GTATGTGAAG
1620





CAGTTCCCGG AGGACGGCTC CCTGTGCACG CTGCCCACTG AGGAAACGGA GAAGTGCACG
1680





GTCAACGAGG AGTGCTCTCC CAGCAGCTGC CTGATGACCG AGTGGGGCGA GTCGGACGAG
1740





TGCAGCGCCA CCTGCGGCAT GGGCATGAAG AAGCGGCACC GCATCATCAA GATGAACCCC
1800





GCAGATGGCT CCATGTGCAA AGCCGAGACA TCACAGGCAG AGAAGTGCAT GATGCCAGAG
1860





TGCCACACCA TCCCATGCTT GCTGTCCCCA TGGTCCGAGT GGAGTGACTG CACCGTGACC
1920





TGCGGGAAGG GCATGCGAAC CCGACAGCGG ATGCTCAAGT CTCTGGCAGA ACTTGGAGAC
1980





TGCAATGAGG ATCTGGAGCA GGTGGAGAAG TGCATGCTCC CTGAATGCCC CATTGACTGT
2040





GAGCTCACCG AGTGGTCCCA GTGGTCGGAA TGTAACAAGT CATGTGGGAA AGGCCACGTG
2100





ATTCGAACCC GGATGATCCA AATGGAGCCT CAGTTTGGAG GTGCACCCTG CCCAGAGACT
2160





GTGCAGCGAA AAAAGTGCCG CATCCGAAAA TGCCTTCGAA ATCCATCCAT CCAAAAGCTA
2220





CGCTGGAGGG AGGCCCGAGA GAGCCGGCGG AGTGAGCAGC TGAAGGAAGA GTCTGAAGGG
2280





GAGCAGTTCC CAGGTTGTAG GATGCGCCCA TGGACGGCCT GGTCAGAATG CACCAAACTG
2340





TGCGGAGGTG GAATTCAGGA ACGTTACATG ACTGTAAAGA AGAGATTCAA AAGCTCCCAG
2400





TTTACCAGCT GCAAAGACAA GAAGGAGATC AGAGCATGCA ATGTTCATCC TTGTTAGCAA
2460





GGGTACGAGT TCCCCAGGGC TGCACTCTAG ATTCCAGAGT CACCAATGGC TGGATTATTT
2520





GCTTGTTTAA GACAATTTAA ATTGTGTACG CTAGTTTTCA TTTTTGCAGT GTGGTTCGCC
2580





CAGTAGTCTT GTGGATGCCA GAGACATCCT TTCTGAATAC TTCTTGATGG GTACAGGCTG
2640





AGTGGGGCGC CCTCACCTCC AGCCAGCCTC TTCCTGCAGA GGAGTAGTGT CAGCCACCTT
2700





GTACTAAGCT GAAACATGTC CCTCTGGAGC TTCCACCTGG CCAGGGAGGA CGGAGACTTT
2760





GACCTACTCC ACATGGAGAG GCAACCATGT CTGGAAGTGA CTATGCCTGA GTCCCAGGGT
2820





GCGGCAGGTA GGAAACATTC ACAGATGAAG ACAGCAGATT CCCCACATTC TCATCTTTGG
2880





CCTGTTCAAT GAAACCATTG TTTGCCCATC TCTTCTTAGT GGAACTTTAG GTCTCTTTTC
2940





AAGTCTCCTC AGTCATCAAT AGTTCCTGGG GAAAAACAGA GCTGGTAGAC TTGAACAGGA
3000





GCATTGATGT TGGGTGGCTT TTGTTCTTTC ACTGAGAAAT TCGGAATACA TTTGTCTCAC
3060





CCCTGATATT GGTTCCTGAT GCCCCCCCAA CAAAAATAAA TAAATAAATT ATGGCTGCTT
3120





TATTTAAATA TAAGGTAGCT AGTTTTTACA CCTGAGATAA ATAATAAGCT TAGAGTGTAT
3180





TTTTCCCTTG CTTTTGGGGG TTCAGAGGAG TATGTACAAT TCTTCTGGGA AGCCAGCCTT
3240





CTGAACTTTT TGGTACTAAA TCCTTATTGG AACCAAGACA AAGGAAGCAA AATTGGTCTC
3300





TTTAGAGACC AATTTGCCTA AATTTTAAAA TCTTCCTACA CACATCTAGA CGTTCAAGTT
3360





TGCAAATCAG TTTTTAGCAA GAAAACATTT TTGCTATACA AACATTTTGC TAAGTCTGCC
3420





CAAAGCCCCC CCAATGCATT CCTTCAACAA AATACAATCT CTGTACTTTA AAGTTATTTT
3480





AGTCATGAAA TTTTATATGC AGAGAGAAAA AGTTACCGAG ACAGAAAACA AATCTAAGGG
3540





AAAGGAATAT TATGGGATTA AGCTGAGCAA GCAATTCTGG TGGAAAGTCA AACCTGTCAG
3600





TGCTCCACAC CAGGGCTGTG GTCCTCCCAG ACATGCATAG GAATGGCCAC AGGTTTACAC
3660





TGCCTTCCCA GCAATTATAA GCACACCAGA TTCAGGGAGA CTGACCACCA AGGGATAGTG
3720





TAAAAGGACA TTTTCTCAGT TGGGTCCATC AGCAGTTTTT CTTCCTGCAT TTATTGTTCA
3780





AAACTATTGT TTCATTTCTT CTTTTATAGG CCTTATTACT GCTTAATCCA AATGTGTACC
3840





ATTGGTGAGA CACATACAAT GCTCTGAATA CACTACGAAT TTGTATTAAA CACATCAGAA
3900





TATTTCCAAA TACAACATAG TATAGTCCTG AATATGTACT TTTAACACAA GAGAGACTAT
3960





TCAATAAAAA CTCACTGGGT CTTTCATGTC TTTAAGCTAA GTAAGTGTTC AGAAGGTTCT
4020





TTTTTATATT GTCCTCCACC TCCATCATTT TCAATAAAAG ATAGGGCTTT TGCTCCCTTG
4080





TTCTTGGAGG GACCATTATT ACATCTCTGA ACTACCTTTG TATCCAACAT GTTTTAAATC
4140





CTTAAATGAA TTGCTTTCTC CCAAAAAAAG CACAATATAA AGAAACACAA GATTTAATTA
4200





TTTTTCTACT TGGGGGGAAA AAAGTCCTCA TGTAGAAGCA CCCACTTTTG CAATGTTGTT
4260





CTAAGCTATC TATCTAACTC TCAGCCCATG ATAAAGTTCC TTAAGCTGGT GATTCCTAAT
4320





CAAGGACAAG CCACCCTAGT GTCTCATGTT TGTATTTGGT CCCAGTTGGG TACATTTTAA
4390





AATCCTGATT TTGGAGACTT AAAACCAGGT TAATGGCTAA GAATGGGTAA CATGACTCTT
4440





GTTGGATTGT TATTTTTTGT TTGCAATGGG GAATTTATAA GAAGCATCAA GTCTCTTTCT
4500





TACCAAAGTC TTGTTAGGTG GTTTATAGTT CTTTTGGCTA ACAAATCATT TTGGAAATAA
4560





AGATTTTTTA CTACAAAAAT G





SEQ ID NO: 6 Protein sequence


Protein Accession #: BAB18461


1          11         21         31         41         51


|          |          |          |          |          |


MRLSPAPLKL SRTPALLALA LPLAAALAFS DETLDKVPKS EGYCSRILRA QGTRREGYTE
60





FSLRVEGDPD FYKPGTSYRV TLSAAPPSYF RGFTLIALRE NREGDKEEDH AGTFQIIDEE
120





ETQFMSNCPV AVTESTPRRR TRIQVFWIAP PAGTGCVILK ASIVQKRIIY FQDEGSLTKK
180





LCEQDSTFDG VTDKPILDCC ACGTAKYRLT FYGNWSEKTH PKDYPRRANH WSAIIGGSHS
240





KNYVLWEYGG YASEGVKQVA ELGSPVKMEE EIRQQSDEVL TVIKAKAQWP AWQPLNVRAA
300





PSAEFSVDRT RHLMSFLTMM GPSPDWNVGL SAEDLCTKEC GWVQKVVQDL IPWDAGTDSG
360





VTYESPNKPT IPQERIRPLT SLDNPQSPFY DPEGGSITQV ARVVIERIAR KGEQCNIVPD
420





NVDDIVADLA PEEKDEDDTP ETCIYSNWSP WSACSSSTCD KGKRMRQRML KAQLDLSVPC
480





PDTQDFQPCM GPGCSDEDGS TCTNSEWITW SPCSISCGMG MRSRERYVKQ FPEDGSVCTL
540





PTEETEKCTV NEECSPSSCL MTEWGEWDEC SATCGMGMKK RHRMIKMNPA DGSMCKAETS
600





QAEKCMMPEC HTIPCLLSPW SEWSDCSVTC GKGMRTRQRM LKSLAELGDC NEDLEQVEKC
660





MLPECPIDCE LTEWSQWSEC NKSCGKGHVI RTRMIQMEPQ FGGAPCPETV QRKKCRIRKC
720





LRNPSIQKLR WREARESRRS EQLKEESEGE QFPGCRMRPN TAWSECTKLC GGGIQERYMT
780





VKKRFKSSQF TSCKDKKEIR ACNVHPC





SEQ ID NO: 7 DNA sequence


Nucleic Acid Accession #: NM_022454


Coding sequence: 205..1449


1         11         21         31         41         51


|          |          |          |          |          |


GCAGTGTCAC TAGGCCGGCT GGGGGCCCTG GGTACGCTGT AGACCAGACC GCGACAGGCC
60





AGAACACGGG CGGCGGCTTC GGGCCGGGAG ACCCGCGCAG CCCTCGGGGC ATCTCAGTGC
120





CTCATTCCCC ACCCCCTCCC CCGGGTCGGG GGAGGCGGCG CGTCCGGCGG AGGGTTGAGG
180





GGAGCGGGGC AGGCCTGGAG CGCCATGAGC AGCCCGGATG CGGGATACGC CAGTGACGAC
240





CAGAGCCAGA CCCAGAGCGC GCTGCCCGCG GTGATGGCCG GGCTGGGCCC CTGCCCCTGG
300





GCCGAGTCGC TGAGCCCCAT CGGGGACATG AAGGTGAAGG GCGAGGCGCC GGCGAACAGC
360





GGAGCACCGG CCGGGGCCGC GGGCCGAGCC AAGGGCGAGT CCCGTATCCG GCGGCCGATG
420





AACGCTTTCA TGGTGTGGGC TAAGGACGAG CGCAAGCGGC TGGCGCAGCA GAATCCAGAC
480





CTGCACAACG CCGAGTTGAG CAAGATGCTG GGCAAGTCGT GGAAGGCGCT GACGCTGGCG
540





GAGAAGCGGC CCTTCGTGGA GGAGGCAGAG CGGCTGCGCG TGCAGCACAT GCAGGACCAC
600





CCCAACTACA AGTACCGGCC GCGGCGGCGC AAGCAGGTGA AGCGGCTGAA GCGGGTGGAG
660





GGCGGCTTCC TGCACGGCCT CGCTGAGCCG CAGGCGGCCG CGCTGGGCCC CGAGGGCGGC
720





CGCGTGGCCA TGGACGGCCT GGGCCTCCAG TTCCCCGAGC AGGGCTTCCC CGCCGGCCCG
780





CCGCTGCTGC CTCCGCACAT GGGCGGCCAC TACCGCGACT GCCAGAGTCT GGGCGCGCCT
840





CCGCTCGACG GCTACCCGTT GCCCACGCCC GACACGTCCC CGCTGGACGG CGTGGACCCC
900





GACCCGGCTT TCTTCGCCGC CCCGATGCCC GGGGACTGCC CGGCGGCCGG CACCTACAGC
960





TACGCGCAGG TCTCGGACTA CGCTGGCCCC CCGGAGCCTC CCGCCGGTCC CATGCACCCC
1020





CGACTCGGCC CAGAGCCCGC GGGTCCCTCG ATTCCGGGCC TCCTGGCGCC ACCCAGCGCC
1080





CTTCACGTGT ACTACGGCGC GATGGGCTCG CCCGGGGCGG GCGGCGGGCG CGGCTTCCAG
1140





ATGCAGCCGC AACACCAGCA CCAGCACCAG CACCAGCACC ACCCCCCGGG CCCCGGACAG
1200





CCGTCGCCCC CTCCGGAGGC ACTGCCCTGC CGGGACGGCA CGGACCCCAG TCAGCCCGCC
1260





GAGCTCCTCG GGGAGGTGGA CCGCACGGAA TTTGAACAGT ATCTGCACTT CGTGTGCAAG
1320





CCTGAGATGG GCCTCCCCTA CCAGGGGCAT GACTCCGGTG TGAATCTCCC CGACAGCCAC
1380





GGGGCCATTT CCTCGGTGGT GTCCGACGCC AGCTCCGCGG TATATTACTG CAACTATCCT
1440





GACGTGTGAC AGGTCCCTGA TCCGCCCCAG CCTGCAGGCC AGAAGCAGTG TTACACACTT
1500





CCTGGAGGAG CTAAGGAAAT CCTCAGACTC CTGGGTTTTT GTTGTTGCTG TTGTTGTTTT
1560





TTAAAAGGTG TGTTGGCATA TAATTTATGG TAATTTATTT TGTCTGCCAC TTGAACAGTT
1620





TGGGGGGGTG AGGTTTCATT TAAAATTTGT TCAGAGATTT GTTTCCCACA GTTGGATTGT
1680





CAAAACCCTA TTTCCAAGTT CAAGTTAACT AGCTTTGAAT GTGTCCCAAA ACAGCTTCCT
1740





CCATTTCCTG AAAGTTTATT GATCAAAGAA ATGTTGTCCT GGGTGTGTTT TTTCAATCTT
1800





CTAAAAAATA AAATCTGGAA TCCTGAAAAA AAAAAAAAAA AAAAAAAAAA AAA





SEQ ID NO: 8 Protein sequence


Protein Accession #: NP_071899


1          11         21         31         41         51


|          |          |          |          |          |


MSSPDAGYAS DDQSQTQSAL PAVMADLGPC PWAESLSPIG DMRVKGEAPA NSGAPAGAAG
60





RAKGESRIRR PMNAFMTWAK DERKRLAQQN PDLHNAELSK MLGKSWKALT LAEKRPFVEE
120





AERLRVQHMQ DHPNYKYRPR RRKQVKRLKR VEGGFLHGLA EPQAAALGPE GGRVANDGLG
180





LQFPEQGFPA GPPLLPPHMG GHYRDCQSLG APPLDGYPLP TPDTSPLDGV DPDPAFFAAP
240





MPGDCPAAGT YSYAQVSDYA GPPEPPAGPM HPRLGPEPAG PSIPGLLAPP SALHVYYGAM
300





GSPGAGGGRG FQMQPQHQHQ HQHQHHPPGP GQPSPPPEAL PCRDGTDPSQ PAELLGEVDR
360





TEFEQYLHFV CKPEMGLPYQ GHDSGVNLPD SHGAISSVVS DASSAVYYCN YPDV





SEQ ID NO. 9 DNA sequence


Nucleic Acid Accession #: NM_018098


Coding sequence: 112..2856


1          11         21         31         41         51


|          |         |          |          |          |


AAGCTTGCGG CCGCCGGCGA GGAATGGCGG TATTTGTGAG AGGAGTCGGC GTTTGAAGAG
60





GTGGAACTCC TAGGGCTTTT TTGAGAGTGC TGATTTAGAA GAATACAAAT CATGGCTGAA
120





AATAGTGTAT TAACATCCAC TACTGGGAGG ACTAGCTTGG CAGACTCTTC CATTTTTGAT
180





TCTAAAGTTA CTGAGATTTC CAAGGAAAAC TTACTTATTG GATCTACTTC ATATGTAGAA
240





GAAGAGATGC CTCAGATTGA AACAAGAGTG ATATTGGTTC AAGAAGCTGG AAAACAAGAA
300





GAACTTATAA AAGCCTTAAA GACTATTAAA ATAATGGAAG TCCCTGTTAT AAAGATAAAA
360





GAAAGTTGTC CTGGAAAATC GGATGARAAA TTAATAAAAA GTGTTATTAA TATGGACATT
420





AAAGTGGGCT CTGTAAAGAT GGAGTCAGTG GAAGAATTTG AAGGTTTGGA TTCTYCGGAA
480





TTKGAAAATG TATTTKKAGK CACGGACTTT CAGGATTCTG TCTTTAATGA CCTCTACAAG
540





GCTGATTGTA GAGTTATTGG ACCACCAGTT GTATTAAATT GTTCACAAAA AGGAGAGCCT
600





TTGCCATTTT CATGTCGCCC GTTGTATTGT ACAAGTATGA TGAATCTAGT ACTATGCTTT
660





ACTGGATTTA GGAAAAAAGA AGAACTAGTC AGGTTGGTGA CATTGGTCCA TCACATGGGT
720





GGAGTTATTC GAAAAGACTT TAATTCAAAA GTTACACATT TGGTGGCAAA TTGTACACAA
780





GGAGAAAAAT TCAGGGTTGC TGTGAGTCTA GGTACTCCAA TTATGAAGCC AGAATGGATT
840





TATAAAGCTT GGGAAAGGCG GAATGAACAG GATTTCTATG CAGCAGTTGA TGACTTTAGA
900





AATGAATTTA AAGTTCCTCC ATTTCAAGAT TGTATTTTAA GTTTCCTGGG ATTTTCAGAT
960





GAAGAGAAAA CCAATATGGA AGAAATGACT GAAATGCAAG GAGGTAAATA TTTACCGCTT
1020





GGAGATGAAA GATGCACTCA CCTTGTAGTT GAAGAGAATA TAGTAAAAGA TCTTCCCTTT
1080





GAACCTTCAA AGAAACTTTA TGTTGTCAAG CAAGAGTGGT TCTGGGGAAG CATTCAAATG
1140





GATGCCCGAG CTGGAGAAAC TATGTATTTA TATGAAAAGG CAAATACTCC TGAGCTCAAG
1200





AAATCAGTGT CAATGCTTTC TCTAAATACC CCTAACAGCA ATCGCAAACG ACGTCGTTTA
1260





AAACAAACAC TTGCTCAGCT TTCAAGAGAG ACAGACGTGT CACCATTTCC ACCCCGTAAG
1320





CGCCCATCAG CTGAGCATTC CCTTTCCATA GGGTCACTCC TAGATATCTC CAACACACCA
1380





GAGTCTAGCA TTAACTATGG AGACACCCCA AAGTCTTGTA CTAAGTCTTC TAAAAGCTCC
1440





ACTCCAGTTC CTTCAAAGCA GTCAGCAAGG TGGCAAGTTG CAAAAGAGCT TTATCAAACT
1500





GAAAGTAATT ATGTTAATAT ATTGGCAACA ATTATTCAGT TATTTCAAGT ACCATTGGAA
1560





GAGGAAGGAC AACGTGGTGG ACCTATCCTT GCACCAGAGG AGATTAAGAC TATTTTTGGT
1620





AGCATCCCAG ATATCTTTGA TGTACACACT AAGATAAAGG ATGATCTTGA AGACCTTATA
1680





GTTAATTGGG ATGAGAGCAA AAGCATTGGT GACATTTTTC TGAAATATTC AAAAGATTTG
1740





GTAAAAACCT ACCCTCCCTT TGTAAACTTC TTTGAAATGA GCAAGGAAAC AATTATTAAA
1800





TGTGAAAAAC AGAAACCAAG ATTTCATGCT TTTCTCAAGA TAAACCAAGC AAAACCAGAA
1860





TGTGGACGGC AGAGCCTTGT TGAACTTCTT ATCCGACCAG TACAGAGGTT ACCCAGTGTT
1920





GCATTACTTT TAAATGATCT TAAGAAGCAT ACAGCTGATG AAAATCCAGA CAAAAGCACT
1980





TTAGAAAAAG CTATTGGATC ACTGAAGGAA GTAATGACGC ATATTAATGA GGATAAGAGA
2040





AAAACAGAAG CTCAAAAGCA AATTTTTGAT GTTGTTTATG AAGTAGATGG ATGCCCAGCT
2100





AATCTTTTAT CTTCTCACCG AAGCTTAGTA CAGCGGGTTG AAACAATTTC TCTAGGTGAG
2160





CACCCCTGTG ACAGAGGAGA ACAAGTAACT CTCTTCCTCT TCAATGATTG CCTAGAGATA
2220





GCAAGAAAAC GGCACAAGGT TATTGGCACT TTTAGGAGTC CTCATGGCCA AACCCGACCC
2280





CCAGCTTCTC TTAAGCATAT TCACCTAATG CCTCTTTCTC AGATTAAGAA GGTATTGGAC
2340





ATAAGAGAGA CAGAAGATTG CCATAATGCT TTTGCCTTGC TTGTGAGGCC ACCAACAGAG
2400





CAGGCAAATG TGCTACTCAG TTTCCAGATG ACATCAGATG AACTTCCAAA AGAAAACTGG
2460





CTAAAGATGC TGTGTCGACA TGTAGCTAAC ACCATTTGTA AAGCAGATGC TGAGAATCTT
2520





ATTTATACTG CTGATCCAGA ATCCTTTGAA GTAAATACAA AAGATATGGA CAGTACATTG
2580





AGTAGAGCAT CAAGAGCAAT AAAAAAGACT TCAAAAAAGG TTACAAGAGC ATTCTCTTTC
2640





TCCAAAACTC CAAAAAGAGC TCTTCGAAGG GCTCTTATGA CATCCCACGG CTCAGTGGAG
2700





GGAAGAAGTC CTTCCAGCAA TGATAAGCAT GTAATGAGTC GTCTTTCTAG CACATCATCA
2760





TTAGCAGGTA TCCCTTCTCC CTCCCTTGTC AGCCTTCCTT CCTTCTTTGA AAGGAGAAGT
2820





CATACGTTAA GTAGATCTAC AACTCATTTG ATATGAAGCG TTACCAAAAT CTTAAATTAT
2880





AGAAATGTAT AGACACCTCA TACTCAAATA AGAAACTGAC TTAAATGGTA CTTGTAATTA
2940





GCACTTGGTG AAAGCTGGAA GGAAGATAAA TAACACTAAA CTATGCTATT TGATTTTTCT
3000





TCTTGAAAGA GTAAGGTTTA CCTGTTACAT TTTCAAGTTA ATTCATGTAA AAAATGATAG
3060





TGATTTTGAT GTAATTTATC TCTTGTTTGA ATCTGTCATT CAAAGGCCAA TAATTTAAGT
3120





TGCTATCAGC TGATATTAGT AGCTTTGCAA CCCTGATAGA GTAAATAAAT TTTATGGGCG
3180





GGTGCCAAAT ACTGCTGTGA ATCTATTTGT ATAGTATCCA TGAATGAATT TATGGAAATA
3240





GATATTTGTG CAGCTCAATT TATGCAGAGA TTAAATGACA TCATAATACT GGATGAAAAC
3300





TTGCATAGAA TTCTGATTAA ATAGTGGGTC TGTTTCACAT GTGCAGTTTG AAGTATTTAA
3360





ATAACCACTC CTTTCACAGT TTATTTTCTT CTCAAGCGTT TTCAAGATCT AGCATGTGGA
3420





TTTTAAAAGA TTTGCCCTCA TTAACAAGAA TAACATTTAA AGGAGATTGT TTCAAAATAT
3480





TTTTGCAAAT TGAGATAAGG ACAGAAAGAT TGAGAAACAT TGTATATTTT GCAAAAACAA
3540





GATGTTTGTA GCTGTTTCAG AGAGAGTACG GTATATTTAT GGTAATTTTA TCCACTAGCA
3600





AATCTTGATT TAGTTTGATA GTGTGTGGAA TTTTATTTTG AAGGATAAGA CCATGGGAAA
3660





ATTGTGGTAA AGACTGTTTG TACCCTTCAT GAAATAATTC TGAAGTTGCC ATCAGTTTTA
3720





CTAATCTTCT GTGAAATGCA TAGATATGCG CATGTTCAAC TTTTTATTGT GGTCTTATAA
3780





TTAAATGTAA AATTGAAAAT TCATTTGCTG TTTCAAAGTG TGATATCTTT CACAATAGCC
3840





TTTTTATAGT CAGTAATTCA GAATAATCAA GTTCATATGG ATAAATGCAT TTTTATTTCC
3900





TATTTCTTTA GGGAGTGCTA CAAATGTTTG TCACTTAAAT TTCAAGTTTC TGTTTTAATA
3960





GTTAACTGAC TATAGATTGT TTTCTATGCC ATGTATGTGC CACTTCTGAG AGTAGTAAAT
4020





GACTCTTTGC TACATTTTAA AAGCAATTGT ATTAGTAAGA ACTTTGTAAA TAAATACCTA
4080





AAACCCAAAA AAAAAAAAAA AAAAA





SEQ ID NO: 10 Protein sequence


Protein Accession #: Q9H8V3


1          11         21         31         41         51


|          |          |          |          |          |


MAENSVLTST TGRTSLADSS IFDSKVTEIS KENLLIGSTS YVEEEMPQIE TRVILVQEAG
60





KQEELTKALK DIKVGFVKME SVEEFEGLDS PEFSNVFVVT DFQDSVFNDL YKADCRVIGP
120





PVVLNCSQKG EPLPFSCRPL YCTSMMNLVL CFTGFRKKEE LVRLVTLVHH MGGVIRKDFN
180





SKVTHLVANC TQGEKFRVAV SLGTPIMKPE WIYKAWERRN EQDFYAAVDD FRNEFKVPPF
240





QDCIFSFLGF SDEEKTNMEE MTEMQGGKYL PLGDERCTHL VVEENIVKDL PFEPSKKLYV
300





VKQEWFWGSI QMDARAGETM YLYEKANTPE LKKSVSMLSL NTPNSNRKRR RLKETLAQLS
360





RDTDVSPFPP RKRPSAEHSL SIGSLLDISN TPESSINYGD TPKSCTKSSK SSTPVPSKQS
420





ARWQVAKELY QTESNYVNIL ATIIQLFQVP LEEEGQRGGP ILAPEEIKTI FGSIPDIFDV
480





HTKIKDDLED LIVNWDESKS IGDIFLKYSK DLVKTYPPFV NFFEMSKETI IKCEKQKPRF
540





HAFLKINQAK PECGRQSLVE LLIRPVQRLP SVALLLNDLK KHTADENPDK STLEKAIGSL
600





KEVMTHINED KRKTEAQKQI FDVVYEVDGC PANLLSSHRS LVQRVETISL GEHPCDRGEQ
660





VTLFLFNDCL EIARKRHEVI GTFRSPHGQT RPPASLKHIH LMPLSQIKRV LDIRETEDCH
720





NAFALLVRPP TEQANVLLSF QMTSDELPKE NWLKMLCRHV ANTICKADAE NLIYTADPES
780





FEVNTKDMDS TLSRASRAIK KTSKKVTRAF SFSKTPKRAL RRALMTSHGS VEGRSPSSND
840





KHVMSRLSST SSLAGIPSPS LVSLPSFFER RSHTLSRSTT HLI





SEQ ID NO: 11 DNA sequence


Nucleic Acid Accession #: XM_044166


Coding sequence: 1..1576


1          11         21         31         41         51


|          |          |          |          |          |


CTTTTGTTTC GCCATGCCTA GTCTAGTGGT ATCTGGAATA ATGGAAAGAA ATGGGGGCTT
60





TGGAGAACTA GGATGTTTCG GGGGAAGCGC TAAGGACCGA GGGCTGCTGG AACACGAGCG
120





CGCCCTTCAG CTGGCTCTCG ATCAACTCTG CCTCCTGGGT TTGGGGGAGC CCCCCGCCCC
180





CAGGGCGGGC CAGGACGGGG GAGGTGGGGG GGGCGGCGCC CCCGCGCAGC CGACAGCCCC
240





CCCGCAGCCG GCGCCGCCGC CGCCGCCCGC GGCCCCCCCG GCCGCCCCGA CGACGGCCCC
300





CGCAGCGCAG ACGCCCCAGC CCCCCACCGC CCCCAAAGGG GCGAGCGACG CCAAGCTCTG
360





CGCTCTCTAC AAAGAGGCCG AGCTGCGCCT GAAGGGCAGC AGCAACACCA CGGAGTGTGT
420





TCCCGTGCCC ACCTCCGAGC ACGTGGCCGA GATCGTGGGC AGGCAAGGCT GCAAGATTAA
480





GGCCTTGAGG GCCAAGACCA ACACCTACAT CAAGACACCG GTGAGGGGCG AGGAACCAGT
540





GTTCATGGTG ACAGGGCGAC GGGAGGACGT GGCCACAGCC CGGCGGGAAA TCATCTCAGC
600





AGCGGAGCAC TTCTCCATGA TCCGTCCCTC CCGCAACAAG TCAGGCGCCG CCTTTGGTGT
660





GGCTCCTGCT CTGCCCGGCC AGGTGACCAT CCGTGTGCGG GTGCCCTACC GCGTGGTGGG
720





GCTGGTGGTG GGCCCCAAAG GGGCAACCAT CAAGCGCATC CAGCAGCAAA CCAACACATA
780





CATTATCACA CCAAGCCGTG ACCGCGACCC CGTGTTCGAG ATCACGGGTG CCCCAGGCAA
840





CGTGGAGCGT GCGCGCGAGG AGATCGACAC GCACATCGCG GTGCGCACTG GCAAGATCCT
900





CGAGTACAAC AATGAAAACG ACTTCCTGGC GGGGAGCCCC GACGCAGCAA TCGATAGCCG
960





CTACTCCGAC GCCTGGCGGG TGCACCAGCC CGGCTGCAAG CCCCTCTCCA CCTTCCGGCA
1020





GAACAGCCTG GGCTGCATCG GCGAGTGCGG AGTGGACTCT GGCTTTGAGG CCCCACGCCT
1080





GGGTGAGCAG GGCGGGGACT TTGGCTACGG CGGGTACCTC TTTCCGGGCT ATGGCGTGGG
1140





CAAGCAGGAT GTGTACTACG GCGTGGCCGA GACTAGCCCC CCGCTGTGGG CGGGCCAGGA
1200





GAACGCCACG CCCACCTCCG TGCTCTTCTC CTCTGCCTCC TCCTCCTCCT CCTCTTCCGC
1280





CAAGGCCCGC GCTGGGCCCC CGGGCGCACA CCGCTCCCCT GCCACTTCCG CGGGACCCGA
1320





GCTGGCCGGA CTCCCGAGGC GCCCCCCGGG AGAGCCGCTC CAGGGCTTCT CTAAACTTGG
1380





TGGGGGCGGC CTGCGGAGCC CCGGCGGCGG GCGGGATTGC ATGGTCTGCT TTGAGAGCGA
1440





AGTGACTGCC GCCCTTGTGC CCTGCGGACA CAACCTGTTC TGCATGGAGT GTGCAGTACG
1500





CATCTGCGAG AGGACGGACC CAGAGTGTCC CGTCTGCCAC ATCACAGCCA CGCAAGCCAT
1560





CCGAATATTC TCCTAAGCCC CGTGCCCCAT GCCTCCGGGG CCCACTCCAC TGGGCCCACC
1620





CTGGACCTGT TTTCCACTAA AGCCTTTTGG AAAGCGGTGA TTTGAGGGGC AAGGTGCTTA
1680





GAGATACTCG CTCGCTGGGG AAGGGGGGAG GGAGGCAGTG GTGGCTGGAG GGTGCGCCAC
1740





TTTCAGAGCC TCTGGTCACC CTGTCCTGGA AAGATTGGGA GGGGGCCAGA CTGAAAATTT
1800





TACTAGAGTT ACAACTCTGA TACCTCAACA CACCCTTAAA TCTGGAAGCA GCTAAGAGAA
1860





ACTTTTGTTT TGCCAGAGGT GGCCACTAAG GCATTCTGAC GCCCTCTGCC CACCTCCCCC
1920





GCTGTGTGTC ACTCCACCCC TTCTTCCGAG GAGGGGGTGG GTAAAAGGGA GAGGGAGAAT
1980





TACCACCTGT ATCTAGAGGT GCTCTTTGCA ATCCCTAAGC CCTCTGGTCC TGACCTCCGA
2040





CCTCCCAGCT CTGTCTTGTT CCTTGTCTTT GTCTTTCTTC CCTTCCCCCT GCCCCTGCCC
2100





CTACCAGCCC AGCTTTGGGG ACACCATCCT TCTGGGGAGA AGTAGGGGGA GGAATATTTG
2160





GATGGTCCCT CCATTCCTCT TCAGGCATCT GGAGGCCCTC TCCCCCACTC CTCCAAAGAA
2220





ACATCTCAAA TTATTGATGG AATGTATCCC CATTCTCAGT GAAAATGTGA GGAGGGGACT
2280





AATACTGGGG TAAAGGGTCA AACCCCCACC TTCATCACTA TGGGCATTAT ATTTAGGGAG
2340





TAGTTCTTGG GCTGGATTTT CTGGTTGTGG AAGTGGGGGC GCCAGAGTAG TGTGTCTGCT
2400





ATTTAAAGGA GCAGGAAAGG GCGTGAGGCA GGAGGAGAGA CTGGTGGAGG GAAGAGCTGC
2460





TCCTCCCATG CAGTGCCCGA CTCCCTGCAC CCCTCTCAAC CTGACCTGAA CCTTTATTGA
2520





ATCCTTATTA GCTTGAATCC TTATTAGCTT GAATCCTCCA TGCAAATCAT GGAGTCTGTG
2580





TCCCACCTGA TGTGGTTGAG GAGAAGCCAG GTCTTCAAAG AGGGGTCAGC CTGGGGCAAA
2640





GCAGGACTGG GGGGAGGTGG GCAGCAGGGC CTATTCTGAG AATCACATAT TGTTACAGGC
2700





CTTGCACCCC CTTTGCTGCT TCCCTCCTGC TCATTTGGGG CTGCCACCAG CTCTCCACCC
2760





TCCTGGTTCC GCTGGCCGGG CCAAGAGAGG ATGGAGGGAT GGGAGTCCCA GGAGATCCTT
2820





GTAAATAGTG GGGTGGGACT GTTCTGAGTG ATCACCCGAG CACTTAAAGC TCCAGAGTCC
2880





CATTCTTCCT GGATGGAGCA GGTGGAGGTG CAGAGGGGAT TTCCTCCTCT CCTTCCTCCT
2940





GTCGAGAATT AACACCTCTC CACAGCCTTC CCCTCCAGAA CACCAGCCAG GGAGGGGTGG
3000





GGAAGGAGGT CACAGCCAAG AAAACTGCCC TGTGACGACT TCCCTCCTTC CCGCCTATGT
3060





GAGCCATCCT GAGATGTCTG TACAATAGAA ACCAAACCAA ATGGGCACCC TCGGTTGCCG
3120





GGGGGCAGGT GGGGAGGGGG GTGGGAAGAA GGGATGTCTG TCTGTCGTCC CCCTCCCCCT
3180





CTCCACTCTT TACCCACAAA GGCAGAAGAC TGTTACACTA GGGGGCTCAG CAAATTCAAT
3240





CCCACCCTTA CCAATTGAGC CAAACCTAGA AACAAACACA AAACACGAAT AGTGAGAGAC
3300





AAAATAGAGG AGAGAAAGAG AGCATGAGAG GGAGCGAGAC AGGCGACCAA CACAGAGGAG
3360





AGAAAACAAA AATAGCAAAA AAAAAAAAAA AAAGCAGTTC TTTATAATTT AATATTCTAT
3420





TTTAATAAAG GCGTTTATTA CCATATAAAT GTAGCAAAGA ACCTGGGCTA ATATGAA





SEQ ID NO: 12 Protein sequence


Protein Accession #: XP_044166


1          11         21         31         41         51


|          |          |          |          |          |


FCFANPSLVV SCIMERNGGF GELGCPGGSA KDRGLLEDER ALQLALDQLC LLGLGEPPAP
60





RACEDGGGGG GGAPAQPTAP PQPAPPPPPA APPAAPTTAP AAQTPQPPTA PKGASDAKLC
120





ALYKEAELRL KGSSNTTECV PVPTSENVAE IVGRQGCKIK ALRAKTNTYI KTPVRGEEPV
180





FMVTGRREDV ATARREIISA AEHFSMIRAS RNKSGAAFGV APALPGQVTI RVRVPYRVVG
240





LVVGPKGATI KRIQQQTNTY IITPSRDRDP VFEITGAPGN VERAREEIET HIAVRTGKIL
300





EYNNENDFLA GSPDAAIDSR YSDAWRVHQP GCKPLSTFRQ NSLGCIGECG VDSGFEAPEL
360





GEQGGDFGYG GYLFPGYGVG KQDVYYGVAE TSPPLWAGQE NATPTSVLFS SASSSSSSSA
420





KARAGPPGAH RSPATSAGPE LAGLPRRPPG EPLQGFSKLG GGGLRSPGGG RDCNVCFESE
480





VTAALVPCGN NLFCMECAVR ICERTDPECP VCNITATQAI RIFS





SEQ ID NO: 13 DNA sequence


Nucleic Acid Accession #: Eos sequence


Coding sequence: 1..2982


1          11         21         31         41         51


|          |          |          |          |          |


ATGGTTTTCT CTGTCAGGCA GTGTGGCCAT GTTGGCAGAA CTGAAGAAGT TTTACTGACG
60





TTCAAGATAT TCCTTGTCAT CATTTGTCTT CATGTCGTTC TGGTAACATC CCTGGAAGAA
120





GATACTGATA ATTCCAGTTT GTCACCACCA GCTGATGTTA CTTTAAGCTT ACTCCCTTCA
180





AACGAAACAG AAAAAACTAA AATCACTATA GTAAAAACCT TCAATGCTTC AGGCGTCAAA
240





CCCCAGAGAA ATATCTGCAA TTTGTCATCT ATTTGCAATG ACTCAGCATT TTTTAGAGGT
300





GAGATCATGT TTCAATATGA TAAAGAAAGC ACTGTTCCCC AGAATCAACA TATAACGAAT
360





GGCACCTTAA CTGGAGTCCT GTCTCTAAGT GAATTAAAAC GCTCAGAGCT CAACAAAACC
420





CTGCAAACCC TAAGTGAGAC TTACTTTATA ATGTGTGCTA CAGCAGAGGC CCAAAGCACA
480





TTAAATTGTA CATTCACAAT AAAACTGAAT AATACAATGA ATGCATGTGC TGTAATAGCT
540





GCTTTGGAAA GAGTAAAGAT TCGACCAATG GAACACTGCT GCTGTTCTGT CAGGATACCC
600





TGCCCTTCCT CCCCAGAAGA GTTGGAAAAG CTTCAGTGTG ACCTGCAGGA TCCCATTGTC
660





TGTCTTGCTG ACCATCCACG TGGCCCACCA TTTTCTTCCA GCCAATCCAT CCCAGTGGTG
720





CCTCGGGCCA CTGTGCTTTC CCAGGTCCCC AAAGCTACCT CTTTTGCTGA GCCTCCAGAT
780





TATTCACCTG TGACCCACAA TGTTCCCTCT CCAATAGGGG AGATTCAACC CCTTTCACCC
840





CAGCCTTCAG CTCCCATAGC TTCCAGCCCT GCCATTGACA TGCCCCCACA GTCTGAAACG
900





ATCTCTTCCC CTATGCCCCA AACCCATGTC TCCGGCACCC CACCTCCTGT GAAAGCCTCA
960





TTTTCCTCTC CCACCGTGTC TGCCCCTGCG AATGTCAACA CTACCAGCGC ACCTCCTGTC
1020





CAGACAGACA TCGTCAACAC CAGCAGTATT TCTGATCTTG AGAACCAAGT GTTGCAGATG
1080





GAGAAGGCTC TGTCCTTGGG CAGCCTGGAG CCTAACCTCG CAGGAGAAAT GATCAACCAA
1140





GTCAGCAGAC TCCTTCATTC CCCGCCTGAC ATGCTGGCCC CTCTGGCTCA AAGATTGCTG
1200





AAAGTAGTGG ATGACATTGG CCTACAGCTG AACTTTTCAA ACACGACTAT AAGTCTAACC
1260





TCCCCTTCTT TGGCTCTGGC TGTGATCAGA GTGAATGCCA GTAGTTTCAA CACAACTACC
1320





TTTGTGGCCC AAGACCCTGC AAATCTTCAG GTTTCTCTGG AAACCCAAGC TCCTGAGAAC
1380





AGTATTGGCA CAATTACTCT TCCTTCATCG CTGATGAATA ATTTACCAGC TCATGACATG
1440





GAGCTAGCTT CCAGGGTTCA GTTCAATTTT TTTGAAACAC CTGCTTTGTT TCAGGATCCT
1500





TCCCTGGAGA ACCTCTCTCT GATCAGCTAC GTCATATCAT CGAGTGTTGC AAACCTGACC
1560





GTCAGGAACT TGACAAGAAA CGTGACAGTC ACATTAAAGC ACATCAACCC GAGCCAGGAT
1620





GAGTTAACAG TGAGATGTGT ATTTTGGGAC TTGGGCAGAA ATGGTGGCAG AGGAGGCTGG
1680





TCAGACAATG GCTGCTCTGT CAAAGACAGG AGATTGARTG AAACCATCTG TACCTGTAGC
1740





CATCTAACAA GCTTCGGCGT TCTGCTGGAC CTATCTAGGA CATCTGTGCT GCCTGCTCAA
1800





ATGATGGCTC TGACGTTCAT TACATATATT GGTTGTGGGC TTTCATCAAT TTTTCTGTCA
1860





GTGACTCTTG TAACCTACAT AGCTTTTGAA AAGATCCGGA GGGATTACCC TTCCAAAATC
1920





CTCATCCAGC TGTGTGCTGC TCTGCTTCTG CTGAACCTGG TCTTCCTCCT GGACTCGTGG
1960





ATTGCTCTGT ATAAGATGCA AGGCCTCTGC ATCTCAGTGG CTGTATTTCT TCATTATTTT
2040





CTCTTGGTCT CATTCACATG GATGGGCCTA GAAGCATTCC ATATGTACCT GGCCCTTGTC
2100





AAAGTATTTA ATACTTACAT CCGAAAATAC ATCCTTAAAT TCTGCATTGT CGGTTGGGGG
2160





GTACCAGCTG TGGTTGTGAC CATCATCCTG ACTATATCCC CAGATAACTA TGGGCTTGGA
2220





TCCTATGGGA AATTCCCCAA TGGTTCACCG GATGACTTCT GCTGGATCAA CAACAATGCA
2280





GTATTCTACA TTACGGTGGT GGGATATTTC TGTGTGATAT TTTTGCTGAA CGTCAGCATG
2340





TTCATTGTGG TCCTGGTTCA GCTCTGTCGA ATTAAAAAGA AGAAGCAACT GGGAGCCCAG
2400





CGAAAAACCA GTATTCAAGA CCTCAGGAGT ATCGCTGGCC TTACATTTTT ACTGGGAATA
2460





ACTTGGGGCT TTGCCTTCTT TGCCTGGGGA CCAGTTAACG TGACCTTCAT GTATCTGTTT
2520





GCCATCTTTA ATACCTTACA AGGATTTTTC ATATTCATCT TTTACTGTGT GGCCAAAGAA
2580





AATGTCAGGA AGCAATGGAG GCGGTATCTT TGTTGTGGAA AGTTACGGCT GGCTGAAAAT
2640





TCTGACTGGA GTAAAACTGC TACTAATGGT TTAAAGAAGC AGACTGTAAA CCAAGGAGTG
2700





TCCAGCTCTT CAAATTCCTT ACAGTCAAGC AGTAACTCCA CTAACTCCAC CACACTGCTA
2760





GTGAATAATG ATTGCTCAGT ACACGCAAGC GGGAATGGAA ATGCTTCTAC AGAGAGGAAT
2820





GGGGTCTCTT TTAGTGTTCA GAATGGAGAT GTGTGCCTTC ACGATTTCAC TGGAAAACAG
2880





CACATGTTTA ACGAGAAGGA AGATTCCTGC AATGGGAAAG GCCGTATGGC TCTCAGAAGG
2940





ACTTCAAAGC GGGGAAGCTT ACACTTTATT GAGCAAATGT GA





SEQ ID NO: 14 Protein sequence


Protein Accession #: Eos sequence


1          11         21         31         41         51


|          |          |          |          |          |


MVFSVRQCGN VGRTEEVLLT FKIFLVIICL NVVLVTSLEE DTDNSSLSPP PDVTLSLLPS
60





NETEKTKITI VETFNASGVK PQRNICNLSS ICNDSAFFRG EIMFQYDKES TVPQNQHITN
120





GTLTGVLSLS ELKRSELNKT LQTLSETYFI MCATAEAQST LNCTFTIKLN NTMNACAVIA
180





ALERVKIRPM EHCCCSVRIP CPSSPEELEK LQCDLQDPIV CLADHPRGPP FSSSQSIPVV
240





PRATVLSQVP KATSFAEPPD YSPVTHNVPS PIGEIQPLSP QPSAPIASSP AIDMPPQSET
300





ISSPMPQTNV SGTPPPVKAS FSSPTVSAPA NVNTTSAPPV QTDIVNTSSI SDLENQVLQM
360





EKALSLGSLE PNLAGEMINQ VSRLLHSPPD MLAPLAQRLL KVVDDIGLQL NFSNTTISLT
420





SPSLALAVIR VNASSFNTTT FVAQDPANLQ VSLETQAPEN SIGTITLPSS LMNNLPANDM
480





ELASRVQFNF FETPALFQDP SLENLSLTSY VISNSVANLT VRNLTRNVTV TLKHINPSQD
540





ELTVRCVFWD LGRNGGRGGW SDNGCSVKDR RLNETICTCS NLTSFGVLLD LSRTSVLPAQ
600





MMALTFITYI GCGLSSIFLS VTLVTYIAFE KIRRDYPSKI LIQLCAALLL LNLVFLLDSW
660





IALYKNQGLC ISVAVFLNYF LLVSFTWNGL EAFHMYLALV KVFNTYIRKY ILKFCIVGWG
720





VPAVVVTIIL TISPDNYGLG SYGKFPNGSP DDFCWINNNA VFYITVVGYF CVIFLLNVSN
780





FIVVLVQLCR IKKKKQLGAQ RKTSIQDLRS IAGLTFLLGI TWGFAFFAWG PVNVTFMYLF
840





AIFNTLQGFF IFIFYCVAKE NVRKQWRRYL CCGKLRLAEN SDWSKTATNG LKKQTVNQGV
900





SESSNELQSS SNSTNSTTLL VNNDCSVHAS GNGNASTERN GVSFSVQNGD VCLHDFTGKQ
960





HMFNEKEDSC NGKGRMALRR TSKRGSLHFI EQM





SEQ ID NO: 15 DNA sequence


Nucleic Acid Accession #: Eos sequence


Coding sequence: 1..2904


1          11         21         31         41         51


|          |          |          |          |          |


ATGGTTTTCT CTGTCAGGCA GTGTGGCCAT GTTGGCAGAA CTGAAGAAGT TTTACTGACG
60





TTCAAGATAT TCCTTGTCAT CATTTGTCTT CATGTCGTTC TGGTAACATC CCTGGAAGAA
120





GATACTGATA ATTCCAGTTT GTCACCACCA CCTGATGTTA CTTTAAGCTT ACTCCCTTCA
180





AACGAAACAG AAAAAACTAA AATCACTATA GTAAAAACCT TCAATGCTTC AGGCGTCAAA
240





CCCCAGAGAA ATATCTGCAA TTTGTCATCT ATTTGCAATG ACTCAGCATT TTTTAGAGGT
300





GAGATCATGT TTCAATATGA TAAAGAAAGC ACTGTTCCCC AGAATCAACA TATAACGAAT
360





GGCACCTTAA CTGGAGTCCT GTCTCTAAGT GAATTAAACA CATTAAATTG TACATTCACA
420





ATAAAACTGA ATAATACAAT GAATGCATGT GCTGTAATAG CTGCTTTGGA AAGAGTAAAG
480





ATTCGACCAA TGGAACACTG CTGCTGTTCT GTCAGGATAC CCTGCCCTTC CTCCCCAGAA
540





GAGTTGGAAA AGCTTCAGTG TGACCTCCAG GATCCCATTG TCTGTCTTGC TGACCATCCA
600





CGTGGCCCAC CATTTTCTTC CAGCCAATCC ATCCCAGTGG TGCCTCGGGC CACTGTGCTT
660





TCCCAGGTCC CCAAAGCTAC CTCTTTTGCT GAGCCTCCAG ATTATTCACC TGTGACCCAC
720





AATGTTCCCT CTCCAATAGG GGAGATTCAA CCCCTTTCAC CCCAGCCTTC AGCTCCCATA
780





GCTTCCAGCC CTGCCATTGA CATGCCCCCA CAGTCTGAAA CCATCTCTTC CCCTATGCCC
840





CAAACCCATG TCTCCGGCAC CCCACCTCCT GTGAAAGCCT CATTTTCCTC TCCCACCGTG
900





TCTGCCCCTG CGAATGTCAA CACTACCAGC GCACCTCCTG TCCAGACAGA CATCGTCAAC
960





ACCAGCAGTA TTTCTGATCT TGAGAACCAA GTGTTGCAGA TGGAGAAGGC TCTGTCCTTG
1020





GGCAGCCTGG AGCCTAACCT CGCAGGACAA ATGATCAACC AAGTCAGCAG ACTCCTTCAT
1080





TCCCCGCCTG ACATGCTGGC CCCTCTGGCT CAAAGATTGC TGAAAGTAGT GGATGACATT
1140





GGCCTACAGC TGAACTTTTC AAACACGACT ATAAGTCTAA CCTCCCCTTC TTTGGCTCTG
1200





GCTGTGATCA GAGTGAATGC CAGTAGTTTC AACACAACTA CCTTTGTGGC CCAAGACCCT
1260





GCAAATCTTC AGGTTTCTCT GGAAACCCAA GCTCCTGAGA ACAGTATTGG CACAATTACT
1320





CTTCCTTCAT CGCTGATGAA TAATTTACCA GCTCATGACA TGGAGCTAGC TTCCAGGGTT
1380





CAGTTCAATT TTTTTGAAAC ACCTGCTTTG TTTCAGGATC CTTCCCTGGA GAACCTCTCT
1440





CTGATCAGCT ACGTCATATC ATCGAGTGTT GCAAACCTGA CCGTCAGGAA CTTGACAAGA
1500





AACGTGACAG TCACATTAAA GCACATCAAC CCGAGCCAGG ATGAGTTAAC AGTGAGATGT
1560





GTATTTTGGG ACTTGGGCAG AAATGGTGGC AGAGGAGGCT GGTCAGACAA TGGCTGCTCT
1620





GTCAAAGACA GGAGATTGAA TGAAACCATC TGTACCTGTA GCCATCTAAC AAGCTTCGGC
1680





GTTCTGCTGG ACCTATCTAG GACATCTGTG CTGCCTGCTC AAATGATGGC TCTGACGTTC
1740





ATTACATATA TTGGTTGTGG GCTTTCATCA ATTTTTCTGT CAGTGACTCT TGTAACCTAC
1800





ATAGCTTTTG AAAAGATCCG GAGGGATTAC CCTTCCAAAA TCCTCATCCA GCTGTGTGCT
1860





GCTCTGCTTC TGCTGAACCT GGTCTTCCTC CTGGACTCGT GGATTGCTCT GTATAAGATG
1920





CAAGGCCTCT GCATCTCAGT GGCTGTATTT CTTCATTATT TTCTCTTGGT CTCATTCACA
1980





TGGATGGGCC TAGAAGCATT CCATATGTAC CTGGCCCTTG TCAAAGTATT TAATACTTAC
2040





ATCCGAAAAT ACATCCTTAA ATTCTGCATT GTCGGTTGGG GGGTACCAGC TGTGGTTGTG
2100





ACCATCATCC TGACTATATC CCCAGATAAC TATGGGCTTG GATCCTATGG GAAATTCCCC
2160





AATGGTTCAC CGGATGACTT CTGCTGGATC AACAACAATG CAGTATTCTA CATTACGGTG
2220





GTGGGATATT TCTGTGTGAT ATTTTTGCTG AACGTCAGCA TGTTCATTGT GGTCCTGGTT
2280





CAGCTCTGTC GAATTAAAAA GAAGAAGCAA CTGGGAGCCC AGCGAAAAAC CAGTATTCAA
2340





GACCTCAGGA GTATCGCTGG CCTTACATTT TTACTGGGAA TAACTTGGGG CTTTGCCTTC
2400





TTTGCCTGGG GACCAGTTAA CGTGACCTTC ATGTATCTGT TTGCCATCTT TAATACCTTA
2460





CAAGGATTTT TCATATTCAT CTTTTACTGT GTGGCCAAAG AAAATGTCAG GAAGCAATGG
2520





AGGCGGTATC TTTGTTGTGG AAAGTTACGG CTGGCTGAAA ATTCTGACTG GAGTAAAACT
2580





GCTACTAATG GTTTAAAGAA GCAGACTGTA AACCAAGGAG TGTCCAGCTC TTCAAATTCC
2640





TTACAGTCAA GCAGTAACTC CACTAACTCC ACCACACTGC TAGTGAATAA TGATTGCTCA
2700





GTACACGCAA GCGGGAATGG AAATGCTTCT ACAGAGAGGA ATGGGGTCTC TTTTAGTGTT
2760





CAGAATGGAG ATGTGTGCCT TCACGATTTC ACTGGAAAAC AGCACATGTT TAACGAGAAG
2820





GAAGATTCCT GCAATGGGAA AGGCCGTATG GCTCTCAGAA GGACTTCAAA GCGGGGAAGC
2880





TTACACTTTA TTGAGCAAAT GTGA





SEQ ID NO: 16 Protein sequence


Protein Accession #: Eoe sequence


1          11         21         31         41         51


|          |          |          |          |          |


MVFSVRQCGH VGRTEEVLLT FKIFLVIICL HVVLVTSLEE DTDNSSLSPP PDVTLSLLPS
60





NETEKTKITI VKTFNASGVK PQRNICNLSS ICNDSAFFRG EIMFQYDEES TVPQNQHITN
120





GTLTGVLSLS ELNTLNCTFT IKLNNTMNAC AVIAALERVK IRPMEHCCCS VRIPCPSSPE
180





ELEKLQCDLQ DPIVCLADHP RGPPFSSSQS IPVVPRATVL SQVPKATSFA EPPDYSPVTH
240





NVPSPIGEIQ PLSPQPSAPI ASSPAIDMPP QSETISSPMP QTHVSGTPPP VKASFSSPTV
300





SAPANVNTTS APPVQTDIVN TSSISDLENQ VLQMEKALSL GSLEPNLAGE MINQVSRLLH
360





SPPDMLAPLA QRLLKVVDDI GLQLNFSNTT ISLTSPSLAL AVIRVNASSF NTTTFVAQDP
420





ANLQVSLETQ APENSIGTIT LPSSLMNNLP AHDMELASRV QFNFFETPAL EQDPELENLS
480





LISYVISSSV ANLTVRNLTR NVTVTLKHIN PSQDELTVRC VFWDLGRNGG RGGWSDNGCS
540





VKDRRLNETI CTCSNLTSFG VLLDLSRTSV LPAQMMALTF ITYIGCGLSS IFLSVTLVTY
600





IAFEKIRRDY PSKILIQLCA ALLLLNLVFL LDSWIALYKM QGLCISVAVF LHYFLLVSFT
660





WMGLEAFNMY LALVKVFNTY IRKYILKFCI VGWGVPAVVV TIILTISPDN YGLGSYGKFP
720





NGSPDDFCWI NNNAVFYITV VGYFCVIFLL NVSMFIVVLV QLCRIKKKKQ LGAQRKTSIQ
780





DLRSIAGLTF LLGITWGFAF FAWGPVNVTF MYLFAIFNTL QGFFIFIFYC VAKENVRKQW
840





RRYLCCGKLR LAENSDWSKT ATNGLKKQTV NQGVSSSSNS LQSSSNSTNS TTLLVNNDCS
900





VHASGNGNAS TERNGVSFSV QNGDVCLHDF TGKQNNFNEK EDSCNGKGRM ALRRTSKRGS
960





LNFIEQM





SEQ ID NO: 17 DNA sequence


Nucleic Acid Accession #: Eos sequence


Coding sequence: 1..2811


1          11         21         31         41         51


|          |          |          |          |          |


ATGCTTTTCT CTGTCAGCCA GTGTGGCCAT GTTCGCAGAA CTGAAGAAGT TTTACTGACG
60





TTCAAGATAT TCCTTGTCAT CATTTGTCTT CATGTCGTTC TGGTAACATC CCTGGAAGAA
120





GATACTGATA ATTCCAGTTT GTCACCACCA CCTGAGGTTG AAACAACAAG CCTCAATGAT
180





GTTACTTTAA GCTTACTCCC TTCAAACGAA ACAGGCGTCA AACCCCAGAG AAATATCTGC
240





AATTTGTCAT CTATTTGCAA TGACTCACCA TTTTTTAGAG GTGAGATCAT GTTTCAATAT
300





GATAAAGAAA GCACTGTTCC CCAGAATCAA CATATAACGA ATGGCACCTT AACTGGAGTC
360





CTGTCTCTAA GTGAATTAAA ACGCTGAGAG CTCAACAAAA CCCTGCAAAC CCTAAGTGAG
420





ACTTACTTTA TAATGTGTGC TACACCAGAG GCCCAAAGCA CATTAAATTG TACATTCACA
480





ATAAAACTGA ATAATACAAT GAATGCATGT GCTGTAATAG CTGGTTTGGA AAGAGTAAAG
540





ATTCGACCAA TGGAACACTG CTGCTGTTCT GTCAGGATAC CCTGCCCTTC CTCCCCAGAA
600





GAGTTGGAAA AGCTTCAGTG TGACGTGCAG GATCCCATTG TCTGTCTTGC TGACCATCCA
660





CGTGGCCCAC CATTTTCTTC CAGCCAATCC ATCCCAGTGG TGCCTCGGGC CACTGTGCTT
720





TCCCAGGTCC CCAAAGCTAC CTCTTTTGCT GAGCCTCCAG ATTATTCACC TGTGACCCAC
780





AATGTTCCCT CTCCAATAGG GGAGATTCAA CCCCTTTCAC CCCAGCCTTC AGCTCCCATA
840





GCTTCCAGCC CTGCCATTGA CATGCCCCCA CAGTCTGAAA CGATCTCTTC CCCTATGCCC
900





CAAACCCATG TCTCCGGCAC CCCACCTCCT GTGAAAGCCT CATTTTCCTC TCCCACCGTG
960





TCTGCCCCTG CGAATGTCAA CACTACCAGC GCACCTCCTG TCCAGACAGA CATCGTCAAC
1020





ACCAGCAGTA TTTCTGATCT TGAGAACCAA GTGTTGCAGA TGGAGAAGGC TCTGTCCTTG
1080





GGCAGCCTGG AGCCTAACCT CGCAGGAGAA ATGATCAACC AAGTCAGCAG ACTCCTTCAT
1140





TCCCCGCCTG ACATGCTGGC CCCTCTGGCT CAAAGATTGC TGAAAGTAGT GGATGACATT
1200





GGCCTACAGC TGAACTTTTC AAACACGACT ATAAGTCTAA CCTCCCCTTC TTTGGCTCTG
1260





GCTGTGATCA GAGTGAATGC CAGTAGTTTC AACACAACTA CCTTTGTGGC CCAAGACCCT
1320





GCAAATCTTC AGGTTTCTCT GGAAACCCAA GCTGCTGAGA ACACTATTGG CACAATTACT
1380





CTTCCTTCAT CGCTGATGAA TAATTTACCA GCTCATGACA TGGAGCTAGC TTCCAGGGTT
1440





CAGTTCAATT TTTTTGAAAC ACCTGCTTTG TTTCAGGATC CTTCCCTGGA GAACCTCTCT
1500





CTGATCAGCT ACGTCATATC ATCGAGTGTT GCAAACCTGA CCGTCAGGAA CTTGACAAGA
1560





AACGTGACAG TCACATTAAA GCACATCAAC CCGAGCCAGG ATGAGTTAAC AGTGAGATGT
1620





GTATTTTGGG ACTTGGGCAG AAATGGTGGC AGAGGAGGCT GGTCAGACAA TGGCTGCTCT
1680





GTCAAAGACA GGAGATTGAA TGAAACCATC TGTACCTGTA GCCATCTAAC AAGCTTCGGC
1740





GTTCTGCTGG ACCTATCTAG GACATCTGTG CTGCCTGCTC AAATGATGGC TCTGACGTTC
1800





ATTACATATA TTGGTTGTGG GCTTTCATCA ATTTTTCTGT CAGTGACTCT TGTAACCTAC
1860





ATAGCTTTTG AAAAGATCCG GAGGGATTAC CCTTCCAAAA TCCTCATCCA GCTGTGTGCT
1920





GCTCTGCTTC TGCTGAACCT GGTCTTCCTC CTGGACTCGT GGATTGCTCT GTATAAGATG
1980





CAAGGCCTCT GCATCTCAGT GGCTGTATTT CTTCATTATT TTCTCTTGGT CTCATTCACA
2040





TGGATGGGCC TAGAAGCATT CCATATGTAC CTGGCCCTTG TCAAAGTATT TAATACTTAC
2100





ATCCGAAAAT ACATCCTTAA ATTCTGCATT GTCGGTTGGG GGGTACCAGC TGTGGTTGTG
2160





ACCATCATCC TGACTATATC CCCAGATAAC TATGGGCTTG GATCCTATGG GAAATTCCCC
2220





AATGGTTCAC CGGATGACTT CTGCTGGATC AACAACAATG CAGTATTCTA CATTACGGTG
2280





GTGGGATATT TCTGTGTGAT ATTTTTGCTG AACGTCAGCA TGTTCATTGT GGTCCTGGTT
2340





CAGCTCTGTC GAATTAAAAA GAAGAAGCAA CTGGGAGCCC AGCGAAAAAC CAGTATTCAA
2400





GACCTCAGGA GTATCGCTGG CCTTACATTT TTACTGGGAA TAACTTGGGG CTTTGCCTTC
2460





TTTGCCTGGG GACCAGTTAA CGTGACCTTC ATGTATCTGT TTGCCATCTT TAATACCTTA
2520





CAAGGATTTT TCATATTCAT CTTTTACTGT GTGGCCAAAG AAAATGTCAG GAAGCAATGG
2580





AGGCGGTATG TTTGTTGTGG AAAGTTACGG CTGGCTGAAA ATTCTGGAAA TGCTTCTACA
2640





GAGAGGAATG GGGTCTCTTT TAGTGTTCAG AATGGAGATG TGTGCCTTCA CGATTTCACT
2700





GGAAAACAGC ACATGTTTAA CGAGAAGGAA GATTCCTGCA ATGGGAAAGG CCGTATGGCT
2760





CTCAGAAGGA CTTCAAAGCG GGGAAGCTTA CACTTTATTG AGCAAATGTG A





SEQ ID NO: 18 Protein sequence


Protein Accession #: Eos sequence


1          11         21         31         41         51


|          |          |          |          |          |


MVFSVRQCGH VGRTEEVLLT FKIFLVIICL HVVLVTSLEE DTDNSSLSPP PEVETTSLND
60





VTLSLLPSNE TGVKPQRNIC NLSSICNDSA FFRGEIMFQY DKESTVPQNQ NITNGTLTGV
120





LSLSELKRSE LNKTLQTLSE TYFIMCATAE AQSTLNCTFT IKLNNTMNAC AVIAALERVK
180





IRPMEHCCCS VRIPCPSSPE ELEKLQCDLQ DPIVCLADHP RGPPFSSSQS IPVVPRATVL
240





SQVPKATSFA EPPDYSPVTN NVPSPIGEIQ PLSPQPSAPI ASSPAIDMPP QSETISSPMP
300





QTHVSQTPPP VKASPSSPTV SAPANVNTTS APPVQTDIVN TSSISDLENQ VLQMEKALSL
360





GSLEPNLAGE MINQVSRLLH SPPDMLAPLA QRLLKVVDDI GLQLNFSNTT ISLTSPSLAL
420





AVIRVNASSF NTTTPVAQDP ANLQVSLETQ APENSIGTIT LPSSLMNNLP ANDMELASRV
480





QFNFFETPAL FQDPSLENLS LISYVISSSV ANLTVRNLTR NVTVTLKHIN PSQDELTVRC
540





VFWDLGRNGG RGGWSDNGCS VKDRRLNETI CTCSHLTSFG VLLDLSRTSV LPAQMMALTF
600





ITYIGCGLSE IFLSVTLVTY IAFEKIRRDY PSKILIQLCA ALLLLNLVFL LDSWIALYKM
660





QGLCISVAVF LNYFLLVSFT WMGLEAFHMY LALVKVFNTY IRKYILKFCI VGWGVPAVVV
720





TIILTISPDN YGLGSYGKFP NGSPDDFCWI NNNAVFYITV VGYFCVIFLL NVSMFIVVLV
780





QLCRIKKKKQ LGAQRKTSIQ DLRSIAGLTF LLGITWGFAF FAWGPVNVTF MYLFAIFNTL
840





QGFFIFIFYC VAKENVRKQW RRYLCCGKLR LAENSGNAST ERNGVSFSVQ NGDVCLHDFT
900





GKQHMFNEKE DSCNGKGRMA LRRTSKRGSL HFIEQM





SEQ ID NO: 19 DNA sequence


Nucleic Acid Accession #: Eos sequence


Coding sequence: 1..3045


1          11         21         31         41         51


|          |          |          |          |          |


ATGGTTTTCT CTGTCAGGCA GTGTGGCCAT GTTGGCAGAA CTGAACAAGT TTTACTCACG
60





TTCAAGATAT TCCTTGTCAT CATTTGTCTT CATGTCGTTC TCGTAACATC CCTGGAAGAA
120





GATACTGATA ATTCCAGTTT GTCACCACCA CCTGCTAAAT TATCTGTTGT CAGTTTTGCC
180





CCCTCCTCCA ATGAGGTTGA AACAACAAGC CTCAATGATG TTACTTTAAG CTTACTCCCT
240





TCAAACGAAA CAGAAAAAAC TAAAATCACT ATAGTAAAAA CCTTCAATCC TTCAGGCGTC
300





AAACCCCAGA GAAATATCTG CAATTTGTCA TCTATTTGCA ATGACTCAGC ATTTTTTAGA
360





GGTGAGATCA TGTTTCAATA TGATAAAGAA AGCACTGTTG CCCAGAATCA ACATATAACG
420





AATGGCACCT TAACTGGAGT CCTGTCTCTA AGTGAATTAA AACGCTCAGA GCTCAACAAA
480





ACCCTGCAAA CCCTAAGTGA GACTTACTTT ATAATGTGTG CTACAGCAGA GGCCCAAAGC
540





ACATTAAATT GTACATTCAC AATAAAACTG AATAATACAA TGAATGCATG TGCTGCAATA
600





GCCGCTTTGG AAAGAGTAAA GATTCGACCA ATGGAACACT GCTGCTGTTC TGTCAGGATA
660





CCCTGCCCTT CCTCCCCAGA AGAGTTGGGA AAGCTTCAGT GTGACCTGCA GGATCCCATT
720





GTCTGTCTTG CTGACCATCC ACGTGGCCCA CCATTTTCTT CCAGCCAATC CATCCCAGTG
780





GTGCCTCGGG CCACTGTGCT TTCCCAGGTC CCCAAAGCTA CCTCTTTTGC TGAGCCTCCA
840





GATTATTCAC CTGTGACCCA CAATGTTCCC TCTCCAATAG GGGAGATTCA ACCCCTTTCA
900





CCCCAGCCTT CAGCTCCCAT AGCTTCCAGC CCTGCCATTG ACATGCCCCC ACAGTCTGAA
960





ACGATCTCTT CCCCTATGCC CCAAACCCAT GTCTCCGGCA CCCCACCTCC TGTGAAAGCC
1020





TCATTTTCCT CTCCCACCGT GTCTGCCCCT GCGAATGTCA ACACTACCAG CGCACCTCCT
1080





GTCCAGACAG ACATCGTCAA CACCAGCAGT ATTTCTGATC TTGAGAACCA AGTGTTGCAG
1140





ATGGAGAAGG CTCTGTCCTT GGGCAGCCTG GAGCCTAACC TCGCAGGAGA AATGATCAAC
1200





CAAGTCACCA GACTCCTTCA TTCCCCGCCT GACATGCTGG CCCCTCTGGC TCAAAGATTG
1260





CTGAAAGTAG TGGATGACAT TGGCCTACAG CTGAACTTTT CAAACACGAC TATAAGTCTA
1320





ACCTCCCCTT CTTTGGCTCT GGCTGTGATC AGAGTGAATG CCAGTAGTTT CAACACAACT
1380





ACCTTTGTGG CCCAAGACCC TGCAAATCTT CAGGTTTCTC TGGAAACCCA AGCTCCTGAG
1440





AACAGTATTG GCACAATTAC TCTTCCTTCA TCGCTGATGA ATAATTTACC AGCTCATGAC
1500





ATGGAGCTAG CTTCCAGGGT TCAGTTCAAT TTTTTTGAAA CACCTGCTTT GTTTCAGGAT
1560





CCTTCCCTGG AGAACCTCTC TCTGATCAGC TACGTCATAT CATCGAGTGT TGCAAACCTG
1620





ACCGTCAGGA ACTTGACAAG AAACGTGACA GTCACATTAA AGCACATCAA CCCGAGCCAG
1680





GATGAGTTAA CACTGAGATG TGTATTTTGG GACTTGGGCA GAAATGGTGG CAGAGGAGGC
1740





TGGTCAGACA ATGGCTGCTC TGTCAAAGAC AGGAGATTGA ATGAAACCAT CTGTACCTGT
1800





AGCCATCTAA CAAGCTTCGG CGTTCTGCTG GACCTATCTA GGACATCTGT GCTGCCTGCT
1860





CAAATGATGG CTCTGACGTT CATTACATAT ATTGGTTGTC GGCTTTCATC AATTTTTCTG
1920





TCAGTGACTC TTGTAACCTA CATACCTTTT GAAAAGATCC GGAGGGATTA CCCTTCCAAA
1980





ATCCTCATCC AGCTGTGTGC TGCTCTGCTT CTGCTGAACC TGGTCTTCCT CCTGGACTCG
2040





TGGATTGCTC TGTATAAGAT GCAAGGCCTC TGCATCTCAG TGGCTGTATT TCTTCATTAT
2100





TTTCTCTTGG TCTCATTCAC ATGGATGGGC CTAGAAGCAT TCCATATGTA CCTGGCCCTT
2160





GTCAAAGTAT TTAATACTTA CATCCGAAAA TACATCCTTA AATTCTGCAT TGTCGGTTGG
2220





GGGGTACCAG CTGTGGTTGT GACCATCATC CTGACTATAT CCCCAGATAA CTATCGGCTT
2280





GGATCCTATG GGAAATTCCC CAATGGTTCA CCGGATGACT TCTGCTGGAT CAACAACAAT
2340





CCAGTATTCT ACATTACGGT GGTGGGATAT TTCTGTGTCA TATTTTTGCT GAACGTCAGC
2400





ATGTTCATTG TGGTCCTGGT TCAGCTCTGT CGAATTAAAA AGAAGAAGCA ACTGGGAGCC
2460





CAGCGAAAAA CCAGTATTCA AGACCTCAGG AGTATCGCTG GCCTTACATT TTTACTGGGA
2520





ATAACTTGGG GCTTTGCCTT CTTTGCCTGG GGACCAGTTA ACGTGACCTT CATGTATCTG
2580





TTTGCCATCT TTAATACCTT ACAAGGATTT TTCATATTCA TCTTTTACTG TGTGGCCAAA
2640





GAAAATGTCA GGAAGCAATG GACGCGGTAT CTTTGTTGTC GAAAGTTACG GCTGGCTGAA
2700





AATTCTGACT GGAGTAAAAC TGCTACTAAT GGTTTAAAGA ACCAGACTGT AAACCAACGA
2760





GTGTCCACCT CTTCAAATTC CTTACAGTCA AGCAGTAACT CCACTAACTC CACCACACTG
2820





CTAGTGAATA ATGATTGCTC AGTACACGCA AGCGGGAATG GAAATGCTTC TACAGAGAGG
2880





AATGGGGTCT CTTTTAGTGT TCAGAATGGA GATGTGTGCC TTCACGATTT CACTGGAAAA
2940





CAGCACATGT TTAACGAGAA GGAAGATTCC TGCAATGGGA AAGGCCCTAT GGCTCTCAGA
3000





AGGACTTCAA AGCGGGGAAG CTTACACTTT ATTGAGCAAA TGTGA





SEQ ID NO: 20 Protein sequence


Protein Accession #: Eos sequence


1          11         21         31         41         51


|          |          |          |          |          |


MVFNVRQCGH VGRTEEVLLT FKIFLVIICL HVVLVTSLEE DTDNNSLSPP PAKLSVVSFA
60





PSNNEVETTS LNDVTLSLLP SNETEKTKIT IVKTFNASGV KPQRNICNLS SICNDSAFFR
120





GEIMFQYDKE STVPQNQHIT NGTLTGVLSL SELKRSELNK TLQTLNNTYF IMCATAEAQS
190





TLNCFPTIKL NNTMNACAAI AALERVKIRP MEHCCCSVRI PCPSSPEELG KLQCDLQDPI
240





VCLADHPRGP PFSSSQSIPV VPRATVLSQV PKATSFAEPP DYSPVTHNVP SPIGEIQPLS
300





PQPSAPIASS PAIDMPPQSE TISSPMPQTH VSGTPPPVKA SFSSPTVSAP ANVNTTSAPP
360





VQTDIVNTSS ISDLENQVLQ MEKALSLGSL EPNLAGEMIN QVSRLLHSPP DMLAPLAQRL
420





LKVVDDIGLQ LNFSNTTISL TSPSLALAVI RVNASSFNTT TFVAQDPANL QVSLETQAPE
480





NSIGTITLPS SLMNNLPAHD MELASNVQFN FFETPALFQD PSLENLSLIS YVISSSVANL
540





TVRNLTRNVT VTLKHINPSQ DELTVRCVFN DLGRNGGRGG WSDNGCSVKD RRLNETICTC
600





SHLTSPGVLL DLSRTSVLPA QMMALTFITY IGCGLSSIFL SVTLVTYIAF EKIRRDYPSK
660





ILIQLCAALL LLNLVFLLDS WIALYKMQGL CISVAVFLHY FLLVSFTWMG LEAFHMYLAL
720





VKVFNTYIRK YILKFCIVGW GVPAVVVTII LTISPDNYGL GSYGKFPNGS PDDFCWINNN
780





AVFYITVVGY FCVIFLLNVS MFIVVLVQLC RIKKKKQLGA QRKTSIQDLR SIAGLTFLLG
840





ITWGFAFFAW GPVNVTFMYL FAIFNTLQGF FIFIFYCVAK ENVRKQWRRY LCCGKLRLAE
900





NSDWSKTATN GLKKQTVNQG VSSSSNSLQN SSNSTNSTTL LVNNDCSVHA SGNGNASTER
960





NGVSFNVQNG DVCLHDFTGK QHMFNEKEDS CNGKGRMALR RTSKRGSLNF IEQM





SEQ ID NO: 21 DNA sequence


Nucleic Acid Accession #: NM_005756 1


Coding sequence: 37..3117


1          11         21         31         41         51


|          |          |          |          |          |


AGCCAGCCCG AGGACGCGAC CGGCAGGTGT GCACAGAGGT TCTCCACTTT GTTTTCTGAA
60





CTCGCGGTCA GGATGGTTTT CTCTGTCAGG CAGTGTGGCC ATGTTGGCAG AACTGAAGAA
120





GTTTTACTGA CGTTCAAGAT ATTCCTTGTC ATCATTTGTC TTCATGTCGT TCTGGTAACA
180





TCCCTGGAAG AAGATACTDA TAATTCCAGT TTGTCACCAC CACCTGCTAA ATTATCTGTT
240





GTCAGTTTTG CCCCCTCCTC CAATGAGCTT GAAACAACAA GCCTCAATGA TGTTACTTTA
300





AGCTTACTCC CTTCAAACGA AACAGAAAAA ACTAAAATCA CTATAGTAAA AACCTTCAAT
360





GCTTCAGGCG TCAAACCCCA GAGAAATATC TGCAATTTGT CATCTATTTG CAATGACTCA
420





GCATTTTTTA GAGGTGAGAT CATGTTTCAA TATGATAAAG AAAGCACTGT TCCCCAGAAT
480





CAACATATAA CGAATGGCAC CTTAACTGGA GTCCTGTCTC TAAGTGAATT AAAACGCTCA
540





GAGCTCAACA AAACCCTGCA AACCCTAAGT GAGACTTACT TTATAATGTG TGCTACAGCA
600





GAGGCCCAAA GCACATTAAA TTGTACATTC ACAATAAAAC TGAATAATAC AATGAATGCA
660





TGTGCTGCAA TAGCCGCTTT GGAAAGAGTA AAGATTCGAC CAATGGAACA CTGCTGCTGT
720





TCTGTCAGGA TACCCTGCCC TTCCTCCCCA GAAGAGTTGG GAAAGCTTCA GTGTGACCTG
780





CAGGATCCCA TTGTCTGTCT TGCTGACCAT CCACGTGGCC CACCATTTTC TTCCAGCCAA
840





TCCATCCCAG TGGTGCCTCG GGCCACTGTG CTTTCCCAGG TCCCCAAAGC TACCTCTTTT
900





GCTGAGCCTC CAGATTATTC ACCTGTGACC CACAATGTTC CCTCTCCAAT AGGGGAGATT
960





CAACCCCTTT CACCCCAGCC TTCAGCTCCC ATAGCTTCCA GCCCTGCCAT TGACATGCCC
1020





CCACAGTCTG AAACGATCTC TTCCCCTATG CCCCAAACCC ATGTCTCCGG CACCCCACCT
1080





CCTGTGAAAG CCTCATTTTC CTCTCCCACC GTGTCTGCCC CTGCGAATGT CAACACTACC
1140





AGCGCACCTC CTGTCCAGAC AGACATCGTC AACACCAGCA GTATTTCTGA TCTTGAGAAC
1200





CAAGTGTTGC AGATGGAGAA GGCTCTGTCC TTGGGCAGCC TGGAGCCTAA CCTCGCAGGA
1260





GAAATGATCA ACCAAGTCAG CAGACTCCTT CATTCCCCGC CTGACATGCT GGCCCCTCTG
1320





GCTCAAAGAT TGCTGAAAGT AGTGGATGAC ATTGGCCTAC AGCTGAACTT TTCAAACACG
1380





ACTATAAGTC TAACCTCCCC TTCTTTGGCT CTGGCTGTGA TCAGAGTGAA TGCCAGTAGT
1440





TTCAACACAA CTACCTTTGT GGCCCAAGAC CCTGCAAATC TTCAGGTTTC TCTGGAAACC
1500





CAAGCTCCTG AGAACAGTAT TGGCACAATT ACTCTTCCTT CATCGCTGAT GAATAATTTA
1560





CCAGCTCATG ACATGGAGCT AGCTTCCAGG GTTCAGTTCA ATTTTTTTGA AACACCTGCT
1620





TTGTTTCAGG ATCCTTCCCT GGAGAACCTC TCTCTGATCA GCTACGTCAT ATCATCGAGT
1680





GTTGCAAACC TGACCGTCAG GAACTTGACA AGAAACGTGA CAGTCACATT AAAGCACATC
1740





AACCCGAGCC AGGATGAGTT AACAGTGAGA TGTGTATTTT GGGACTTGGG CAGAAATGGT
1600





GGCAGAGGAG GCTGGTCAGA CAATGGCTGC TCTGTCAAAG ACAGGAGATT GAATGAAACC
1860





ATCTGTACCT GTAGCCATCT AACAAGCTTC GGCGTTCTGC TGGACCTATC TAGGACATCT
1920





GTGCTGCCTG CTCAAATGAT GGCTCTGACG TTCATTACAT ATATTGGTTG TGGGCTTTCA
1980





TCAATTTTTC TGTCAGTGAC TCTTGTAACC TACATAGCTT TTGAAAAGAT CCGGAGGGAT
2040





TACCCTTCCA AAATCCTCAT CCAGCTGTGT GCTGCTCTGC TTCTGCTGAA CCTGGTCTTC
2100





CTCCTGGACT CGTGGATTGC TCTGTATAAG ATGCAAGGCC TCTGCATCTC AGTGGCTGTA
2160





TTTCTTCATT ATTTTCTCTT GGTCTCATTC ACATGGATGG GCCTAGAAGC ATTCCATATG
2220





TACCTGGCCC TTGTCAAAGT ATTTAATACT TACATCCGAA AATACATCCT TAAATTCTGC
2280





ATTGTCGGTT GGGGGGTACC AGCTGTGGTT GTGACCATCA TCCTGACTAT ATCCCCAGAT
2340





AACTATGGGC TTGGATCCTA TGGGAAATTC CCCAATGGTT CACCGGATGA CTTCTGCTGG
2400





ATCAACAACA ATGCAGTATT CTACATTACG GTGGTGGGAT ATTTCTGTGT GATATTTTTG
2460





CTGAACGTCA GCATGTTCAT TGTGGTCCTG GTTCAGCTCT GTCGAATTAA AAAGAAGAAG
2520





CAACTGGGAG CCCAGCGAAA AACCAGTATT CAAGACCTCA GGAGTATCGC TGGCCTTACA
2580





TTTTTACTGG GAATAACTTG GGGCTTTGCC TTCTTTGCCT GGGGACCAGT TAACGTGACC
2640





TTCATGTATC TGTTTGCCAT CTTTAATACC TTACAAGGAT TTTTCATATT CATCTTTTAC
2700





TGTGTGGCCA AAGAAAATGT CAGGAAGCAA TGGAGGCGGT ATCTTTGTTG TGGAAAGTTA
2760





CGGCTGGCTG AAAATTCTGA CTGGAGTAAA ACTGCTACTA ATGGTTTAAA GAAGCAGACT
2820





GTAAACCAAG GAGTGTCCAG CTCTTCAAAT TCCTTACAGT CAAGCAGTAA CTCCACTAAC
2880





TCCACCACAC TGCTAGTGAA TAATGATTGC TCAGTACACG CAAGCGGGAA TGGAAATGCT
2940





TCTACAGAGA GGAATGGGGT CTCTTTTAGT GTTCAGAATG GAGATGTGTG CCTTCACGAT
3000





TTCACTGGAA AACAGCACAT GTTTAACGAG AAGGAAGATT CCTGCAATGG GAAAGGCCGT
3060





ATGGCTCTCA GAAGGACTTC AAAGCGGGGA AGCTTACACT TTATTGAGCA AATGTGATTC
3120





CTTTCTTCTA AAATCAAAGC ATGATGCTTG ACAGTGTGAA ATGTCCAATT TTACCTTTTA
3180





CACAATGTGA GATGTATGAA AATCAACTCA TTTTATTCTC GGCAACATCT GGAGAAGCAT
3240





AAGCTAATTA AGGGCGATGA TTATTATTAC AAGAAGAAAC CAAGACATTA CACCATGGTT
3300





TTTAGACATT TCTGATTTGG TTTCTTATCT TTCATTTTAT AAGAAGGTTG GTTTTAAACA
3360





ATACACTAAG AATGACTCCT ATAAAGAAAA CAAAAAAAGG TAGTGAACTT TCAGCTACCT
3420





TTTAAAGAGG CTAAGTTATC TTTGATAACA TCATATAAAG CAACTGTTGA CTTCAGCCTG
3480





TTGGTGAGTT TAGTTGTGCA TGCCTTTGTT GTATATAAGC TAAATTCTAG TGACCCATGT
3540





GTCAAAAATC TTACTTCTAC ATTTTTTTGT ATTTATTTTC TACTGTGTAA ATGTATTCCT
3600





TTGTAGAATC ATGGTTGTTT TGTCTCACGT GATAATTCAG AAAATCCTTG CTCGTTCCGC
3660





AAATCCTAAA GCTCCTTTTG GAGATGATAT AGGATGTGAA ATACAGAAAC CTCAGTGAAA
3720





TCAAGAAATA ATGATCCCAG CCAGACTGAG AAAATGTAAG CAGACAGTGC CACAGTTAGC
3780





TCATACAGTG CCTTTGAGCA AGTTAGGAAA AGATGCCCCC ACTGGGCAGA CACAGCCCTA
3840





TGGGTCATGG TTTGACAAAC AGAGTGAGAG ACCATATTTT AGCCCCACTC ACCCTCTTGG
3900





GTGCACGACC TGTACAGCCA AACACAGCAT CCAATATGAA TACCCATCCC CTGACCGCAT
3960





CCCCAGTAGT CAGATTATAG AATCTGCACC AAGATGTTTA GCTTTATACC TTGGCCACAG
4020





AGAGGGATGA ACTGTCATCC AGACCATGTG TCAGGAAAAT TGTGAACGTA GATGAGGTAC
4080





ATACACTGCC GCTTCTCAAA TCCCCAGAGC CTTTAGGAAC AGGAGAGTAG ACTAGGATTC
4140





CTTCTCTTAA AAAGGTACAT ATATATGGAA AAAAATCATA TTGCCGTTCT TTAAAAGGCA
4200





ACTGCATGGT ACATTGTTGA TTGTTATGAC TGGTACACTC TGGCCCAGCC AGAGCTATAA
4260





TTGTTTTTTA AATGTGTCTT GAAGAATGCA CAGTGACAAG GGGAGTAGCT ATTGGGAACA
4320





GGGAACTGTC CTACACTGCT ATTGTTGCTA CATGTATCGA GCCTTGATTG CTCCTAGTTA
4380





TATACAGGGT CTATCTTGCT TCCTACCTAC ATCTGCTTGA GCAGTGCCTC AAGTACATCC
4440





TTATTAGGAA CATTTCAAAC CCCTTTTAGT TAAGTCTTTC ACTAAGGTTC TCTTGCATAT
4500





ATTTCAAGTG AATGTTGGAT CTCAGACTAA CCATAGTAAT AATACACATT TCTGTGAGTG
4560





CTGACTTGTC TTTGCAATAT TTCTTTTCTG ATTTATTTAA TTTTCTTGTA TTTATATGTT
4620





AAAATCAAAA ATGTTAAAAT CAATGAAATA AATTTGCAGT TAAGA





SEQ ID NO: 22 Protein sequence


Protein Accession #: NP_005747.1


1          11         21         31         41         51


|          |          |          |          |          |


MVFSVRQCGH VGRTEEVLLT FKIPLVIICL HVVLVTSLEE DTDNSSLSPP PAKLSVVSFA
60





PSSNEVETTS LNDVTLSLLP SNETGVKPQR NICNLSSICN DSAFERGEIM PQYDKESTVP
120





QNQHITNGTL TGVLSLSELK RSELNKTLQT LSETYFIMCA TAEAQSTLNC TFTIKLNNTM
180





NACAVIAALE RVKIRPMEHC CCSVRIPCPS SPEELEKLQC DLQDPIVCLA DHPRGPPFSS
240





SQSIPVVPRA TVLSQVPKAT SFAEPPDYSP VTHNVPSPIG EIQPLSPQPS APIASSPAID
300





MPPQSETISS PMPQTHVSGT PPPVKASFSS PTVSAPANVN TTSAPPVQTD IVNTSSISDL
360





ENQVLQMEKA LSLGSLEPNL AGEMINQVER LLNSPPDMLA PLAQRLLKVV DDIGLQLNFS
420





NTTISLTSPS LALAVIRVNA SSFNTTTFVA QDPANLQVSL ETQAPENSIG TTTLPSSLMN
480





NLPAHDMELA SRVQFNFFET PALFQDPSLE NLSLISYVIS SSVANLTVRN LTRNVTVTLK
540





HINPSQDELT VRCVFWDLGR NGGRGGWSDN GCSVKDRRLN ETICTCSHLT SFGVLLDLSR
600





TSVLPAQMMA LTFITYIGCG LSSIFLSVTL VTYIAFEKIR RDYPSKILIQ LCAALLLLNL
660





VFLLDSWIAL YKMQGLCISV AVFLHYFLLV SFTWMGLEAF HMYLALVKVF NTYIRKYILK
720





FCIVGWGVPA VVVTIILTIS PDNYGLGSYG KFPNGSPDDF CWINNNAVFY ITVVGYFCVI
780





FLLNVSMFIV VLVQLCRIKK KKQLGAQRKT SIQDLRSIAG LTFLLGITWG FAFFAWGPVN
840





VTPMYLFAIF NTLQGFFIFI FYCVAKENVR KQWRRYLCCG KLRLAENSDW SKTATNGLKK
900





QTVNQGVSSS SNSLQSSSNS TNSTTLLVNN DCSVNASGNG NASTERNGVS FSVQNGDVCL
960





NDFTGKQHMF NEKEDSCNGK GRMALRRTSK RGSLHFIEQM





SEQ ID NO: 23 DNA sequence


Nucleic Acid Accession #: NM_001565.1


Codinq sequence: 67..363


1          11         21         31         41         51


|          |          |          |          |          |


GAGACATTCC TCAATTGCTT AGACATATTC TGAGCCTACA GCAGAGGAAC CTCCAGTCTC
60





AGCACCATGA ATCAAACTGC GATTCTGATT TGCTGCCTTA TCTTTCTGAC TCTAAGTGGC
120





ATTCAAGGAG TACCTCTCTC TAGAACCGTA CGCTGTACCT GCATCAGCAT TAGTAATCAA
180





CCTGTTAATC CAAGGTCTTT AGAAAAACTT GAAATTATTC CTGCAAGCCA ATTTTGTCCA
240





CGTGTTGAGA TCATTGCTAC AATGAAAAAG AAGGGTGAGA AGAGATGTCT GAATCCAGAA
300





TCGAAGGCCA TCAAGAATTT ACTGAAAGCA GTTAGCAAGG AAATGTCTAA AAGATCTCCT
360





TAAAACCAGA GGGGAGCAAA ATCGATGCAG TGCTTCCAAG GATGGACCAC ACAGAGGCTG
420





CCTCTCCCAT CACTTCCCTA CATGGAGTAT ATGTCAAGCC ATAATTGTTC TTAGTTTGCA
480





GTTACACTAA AAGGTGACCA ATGATGGTCA CCAAATCAGC TGCTACTACT CCTGTAGGAA
540





GGTTAATGTT CATCATCCTA AGCTATTCAG TAATAACTCT ACCCTGGCAC TATAATGTAA
600





GCTCTACTGA GGTGCTATGT TCTTAGTGGA TGTTCTGACC CTGCTTCAAA TATTTCCCTC
660





ACCTTTCCCA TCTTCCAAGG GTACTAAGGA ATCTTTCTGC TTTGGGGTTT ATCAGAATTC
720





TCAGAATCTC AAATAACTAA AAGGTATGCA ATCAAATCTG CTTTTTAAAG AATGCTCTTT
780





ACTTCATGGA CTTCCACTGC CATCCTCCCA AGGGGCCCAA ATTCTTTCAG TGGCTACCTA
840





CATACAATTC CAAACACATA CAGGAAGGTA GAAATATCTG AAAATGTATG TGTAAGTATT
900





CTTATTTAAT GAAAGACTGT ACAAAGTATA AGTCTTAGAT GTATATATTT CCTATATTGT
960





TTTCAGTGTA CATGGAATAA CATGTAATTA AGTACTATGT ATCAATGAGT AACAGGAAAA
1020





TTTTAAAAAT ACAGATAGAT ATATGCTCTG CATGTTACAT AAGATAAATG TGCTGAATGG
1080





TTTTCAAATA AAAATGAGGT ACTCTCCTGG AAATATTAAG





SEQ ID NO: 24 Protein sequence


Protein Accession #: NP_001556.1


1          11         21         31         41         51


|          |          |          |          |          |


MNQTAILICC LIFLTLSGIQ GVPLSRTVRC TCISISNQPV NPRSLEKLEI IPASQFCPRV
60





EIIATMKKKG EKRCLNPESK AIKNLLKAVS KEMSKRSP





SEQ ID NO: 25 DNA sequence


Nucleic Acid Accession #: XM_030559


Coding sequence: 1..1119


1         11         21         31         41         51


|          |          |          |          |          |


ATGAACCGCA GCCACCGGCA CGGGGCGGGC AGCGGCTGCC TGGGCACTAT GGAGGTGAAG
60





AGCAAGTTTG GAGCTGAATT TCGTCGGTTT TCGCTGGAAA GATCAAAACC TGGAAAATTT
120





GAGGAGTTTT ATGGATTACT ACAACATGTT CATAAGATCC CCAATGTTGA CGTTTTGGTA
180





GGCTATGCAG ACATCCATGG AGACTTACTA CCTATAAATA ATGATGATAA TTATCACAAA
240





GCTGTTTCAA CGGCCAATCC ACTGCTTAGG ATATTTATAC AAAAGAAGGA AGAAGCAGAC
300





TACAGTGCCT TTGGTACAGA CACGCTAATA AAGAAGAAGA ATGTTTTAAC CAACGTATTG
360





CGTCCTGACA ACCATAGAAA AAAGCCACAT ATAGTCATTA GTATGCCCCA AGACTTTAGA
420





CCTGTGTCTT CTATTATAGA CGTGGATATT CTCCCAGAAA CGCATCGTAG GGTACGTCTT
480





TACAAATACG GCACGGAGAA ACCCCTAGGA TTCTACATCC GGGATGGCTC CAGTGTCAGG
540





GTAACACCAC ATGGCTTAGA AAAGGTTCCA GGGATCTTTA TATCCAGGCT TGTCCCAGGA
600





GGTCTGGCTC AAAGTACAGG ACTATTAGCT GTTAATGATG AAGTTTTAGA AGTTAATGGC
660





ATAGAAGTTT CAGGGAAGAG CCTTGATCAA GTAACAGACA TGATGATTGC AAATAGCCGT
720





AACCTCATCA TAACAGTGAG ACCGGCAAAC CAGAGGAATA ATGTTGTGAG GAACAGTCGG
780





ACTTCTGGCA GTTCCGGTCA GTCTACTGAT AACAGCCTTC TTGGCTACCC ACAGCAGATT
840





GAACCAAGCT TTGAGCCAGA GGATGAAGAC AGCGAAGAAG ATGACATTAT CATTGAAGAC
900





AATGGAGTGC CACAGCAGAT TCCAAAAGCT GTTCCTAATA CTGAGAGCCT GGAGTCATTA
960





ACACAGATAG AGCTAAGCTT TGAGTCTGGA CAGAATGGCT TTATTCCCTC TAATGAAGTG
1020





AGCTTAGCAG CCATAGCAAG CAGCTCAAAC ACGGAATTTG AAACACATGC TCCAGATCAA
1080





AAACTCTTAG AAGAAGATGG AACAATCATA ACATTATGA





SEQ ID NO: 26 Protein sequence


Protein Accession #: XP_030559


1          11         21         31         41         51


|          |          |          |          |          |


MNRSHRHGAG SGCLGTMEVK SKPGAEFRRF SLERSKPGKF EEFYGLLQHV HKIPNVDVLV
60





GYADIHGDLL PINNDDNYNK AVSTANPLLR IFIQKKEEAD YSAFGTDTLI KKKNVLTNVL
120





RPDNHRKKPH IVISMPQDFR PVSSIIDVDI LPETHRRVRL YKYGTEKPLG FYIRDGSSVR
180





VTPHGLEKVF GIFISRLVPG GLAQETGLLA VNDEVLEVNG IEVSGKSLDQ VTDMMIANSR
240





NLIITVRPAN QRNNVVRNSR TSGSSDQSTD NSLLGYPQQI EPSFEPEDED SEEDDIIIED
300





NGVPQQIPKA VPNTESLESL TQIELSFESG QNGFIPSNEV SLAAIASSSN TEFETNAPDQ
360





KLLEEDGTII TL





SEQ ID NO: 27 DNA sequence


Nucleic Acid Accession #: NM_003667.1


Coding sequence: 1. .2651


1         11         21         31         41         51


|          |          |          |          |          |


ATGGACACCT CCCGGCTCGG TGTGCTGCTG TCCTTGCCTG TGCTGCTGCA GCTGGCGACC
60





GGGGGCAGCT CTCCCAGGTC TGGTGTGTTG CTGAGGGGCT GCCCCACACA CTGTCATTGC
120





GAGCCCGACG GCAGGATGTT GCTCAGGGTG GACTGCTCCG ACCTGGGGCT CTCGGAGCTG
180





CCTTCCAACC TCAGCGTCTT CACCTCCTAC CTAGACCTCA GTATGAACAA CATCAGTCAG
240





CTGCTCCCGA ATCCCCTGCC CAGTCTCCGC TTCCTGGAGG AGTTACGTCT TGCGGGAAAC
300





GCTCTGACAT ACATTCCCAA GGGAGCATTC ACTGGCCTTT ACAGTCTTAA AGTTCTTATG
360





CTGCAGAATA ATCAGCTAAG ACACGTACCC ACAGAAGCTC TGCAGAATTT GCGAAGCCTT
420





CAATCCCTGC GTCTGGATGC TAACCACATC AGCTATGTGC CCCCAAGCTG TTTCAGTGGC
480





CTGCATTCCC TGAGGCACCT GTGGCTGGAT GACAATGCGT TAACAGAAAT CCCCGTCCAG
540





GCTTTTAGAA GTTTATCGGC ATTGCAAGCC ATGACCTTGG CCCTGAACAA AATACACCAC
600





ATACCAGACT ATGCCTTTGG AAACCTCTCC AGCTTGGTAG TTCTACATCT CCATAACAAT
660





AGAATCCACT CCCTGGGAAA GAAATGCTTT GATGGGCTCC ACAGCCTAGA GACTTTAGAT
720





TTAAATTACA ATAACCTTGA TGAATTCCCC ACTGCAATTA GGACACTCTC CAACCTTAAA
780





GAACTACATT TCTATGACAA TCCCATCCAA TTTGTTGGGA GATCTGCTTT TCAACATTTA
840





CCTGAACTAA GAACACTGAC TCTGAATGGT GCCTCACAAA TAACTGAATT TCCTGATTTA
900





ACTGGAACTG CAAACCTGGA GAGTCTGACT TTAACTDGAG CACAGATCTC ATCTCTTCCT
960





CAAACCGTCT GCAATCAGTT ACCTAATCTC CAAGTGCTAG ATCTGTCTTA CAACCTATTA
1020





GAAGATTTAC CCAGTTTTTC AGTCTGCCAA AAGCTTCAGA AAATTGACCT AAGACATAAT
1080





GAAATCTACG AAATTAAAGT TGACACTTTC CAGCAGTTDC TTAGCCTCCG ATCGCTGAAT
1140





TTGGCTTGGA ACAAAATTGC TATTATTCAC CCCAATGCAT TTTCCACTTT GCCATCCCTA
1200





ATAAAGCTGG ACCTATCGTC CAACCTCCTG TCGTCTTTTC CTATAACTGG GTTACATGGT
1260





TTAACTCACT TAAAATTAAC AGGAAATCAT GCCTTACAGA GCTTGATATC ATCTGAAAAC
1320





TTTCCAGAAC TCAAGGTTAT AGAAATGCCT TATGCTTACC AGTGCTDTGC ATTTGGAGTG
1380





TGTGAGAATG CCTATAAGAT TTCTAATCAA TGGAATAAAG GTGACAACAG CAGTATGGAC
1440





GACCTTCATA AGAAAGATGC TGGAATGTTT CAGGCTCAAG ATGAACGTGA CCTTGAAGAT
1500





TTCCTGCTTG ACTTTGAGGA AGACCTGAAA GCCCTTCATT CAGTGCAGTG TTCACCTTCC
1560





CCAGGCCCCT TCAAACCCTG TGAACACCTG CTTGATGGCT GGCTGATCAG AATTGGAGTG
1620





TGGACCATAG CAGTTCTGGC ACTTACTTGT AATGCTTTGG TGACTTCAAC AGTTTTCAGA
1680





TCCCCTCTGT ACATTTCCCC CATTAAACTG TTAATTGGGG TCATCGCAGC AGTGAACATG
1740





CTCACGGGAG TCTCCAGTGC CGTGCTGGCT GGTGTGGATG CGTTCACTTT TGGCAGCTTT
1800





GCACGACATG GTGCCTGGTG GGAGAATGGG GTTGGTTGCC ATGTCATTGG TTTTTTGTCC
1860





ATTTTTGCTT CAGAATCATC TGTTTTCCTG CTTACTCTGG CAGCCCTGGA GCGTGGGTTC
1920





TCTGTGAAAT ATTCTGCAAA ATTTGAAACG AAAGCTCCAT TTTCTAGCCT GAAAGTAATC
1980





ATTTTGCTCT GTGCCCTGCT GGCCTTGACC ATGGCCGCAG TTCCCCTGCT GGGTGGCAGC
2040





AAGTATGGCG CCTCCCCTCT CTGCCTGCCT TTGCCTTTTG GGGAGCCCAG CACCATGGGC
2100





TACATGGTCG CTCTCATCTT GCTCAATTCC CTTTGCTTCC TCATGATGAC CATTGCCTAC
2160





ACCAAGCTCT ACTGCAATTT GGACAAGGGA GACCTGGAGA ATATTTGGGA CTGCTCTATG
2220





GTAAAACACA TTGCCCTGTT GCTCTTCACC AACTGCATCC TAAACTGCCC TGTGGCTTTC
2280





TTGTCCTTCT CCTCTTTAAT AAACCTTACA TTTATCAGTC CTGAAGTAAT TAAGTTTATC
2340





CTTCTGGTGG TAGTCCCACT TCCTGCATGT CTCAATCCCC TTCTCTACAT CTTGTTCAAT
2400





CCTCACTTTA AGGAGGATCT GGTGAGCCTG AGAAAGCAAA CCTACGTCTG GACAAGATCA
2460





AAACACCCAA GCTTGATGTC AATTAACTCT GATGATGTCG AAAAACAGTC CTGTGACTCA
2520





ACTCAAGCCT TGGTAACCTT TACCAGCTCC AGCATCACTT ATGACCTGCC TCCCAGTTCC
2580





GTGCCATCAC CAGCTTATCC AGTGACTGAG AGCTGCCATC TTTCCTCTGT GGCATTTGTC
2640





CCATGTCTTA A





SEQ ID NO: 28 Protein sequence:


Protein Accession #: NP_003658.1


1          11         21         31         41         51


|          |          |          |          |          |


MDTSRLGVLL SLPVLLQLAT GGSSPRSDVL LRGCPTHCHC EPDGRMLLRV DCSDLGLSEL
60





PSNLSVFTSY LDLSMNNISQ LLPNPLPSLR FLEELRLAGN ALTYIPKGAF TGLYSLKVLM
120





LQNNQLRNVP TEALQNLRSL QSLRLDANHI SYVPPSCFSG LNSLRHLWLD DNALTEIPVQ
180





AFRSLSALQA MTLALNKIHH IPDYAFGNLS SLVVLHLHNN RIHSLGKKCF DGLHSLETLD
240





LNYNNLDEFP TAIRTLSNLK ELNFYDNPIQ FVGRSAFQHL PELRTLTLNG ASQITEFPDL
300





TGTANLESLT LTGAQISSLP QTVCNQLPNL QVLDLSYNLL EDLPSFSVCQ KLQRIDLRHN
360





EIYEIKVDTF QQLLSLRSLN LAWNKIAIIH PNAFSTLPSL IKLDLSSNLL SSFPITGLHG
420





LTHLKLTGNH ALQSLISSEN FPELKVIEMP YAYQCCAFGV CENAYKISNQ WNKGDNSSMD
480





DLHKKDAGMF QAQDERDLED FLLDFEEDLK ALNSVQCSPS PGPFKPCEHL LDGWLIRIGV
540





WTIAVLALTC NALVTSTVFR SPLYISPIKL LIGVIAAVNM LTGVSSAVLA GVDAFTFGSF
600





ARHGAWWENG VGCHVIGFLS IFASESSVFL LTLAALERGF SVKYSAKFET KAPFSSLKVI
660





TLLCALLALT MAAVPLLGGS KYGASPLCLP LPFGEPSTMG YMVALILLNS LCFLMMTIAY
720





TKLYCNLDKG DLENIWDCSN VKHIALLLFT NCILNCPVAF LSFSSLINLT FISPEVIKFI
780





LLVVVPLPAC LNPLLYILFN PHFKEDLVSL RKQTYVWTRS KHPSLMSINS DDVEKQSCDS
840





TQALVTFTSS SITYDLPPSS VPSPAYPVTE SCNLSSVAFV PCL





SEQ ID NO: 29 DNA sequence


Nucleic Acid Accession #. NM_002497.1


Coding sequence: 135. 1472


1         11         21         31         41         51


|          |          |          |          |          |


GGCACGAGTA GGGGTGGCGG GTCACTGCTG CTCGGGCGCT TCTCCATCCA GGTCCCTCGA
60





GTTCCTGGTC CCTGCAGCTC CCCACTTGGC GCGCAACCTG CGTGAGGCAG CGCGACTCTG
120





CCGACTGGCC GGCCATGCCT TCCCGGGCTG AGGACTATCA AGTGTTGTAC ACCATTGGCA
180





CAGGCTCCTA CGGCCGCTGC CAGAACATCC GGAGGAAGAG TGATGGCAAC ATATTAGTTT
240





GGAAACAACT TGACTATGGC TCCATGACAG AAGCTGAGAA ACAGATGCTT GTTTCTGAAG
300





TGAATTTGCT TCGTGAACTG AAACATCCAA ACATCGTTCG TTACTATGAT CGGATTATTG
360





ACCGGACCAA TACAACACTG TACATTGTAA TGGAATATTG TGAAGGAGGG GATGTGGCTA
420





GTGTAATTAC AAAGGGAACC AAGGAAAGGC AATACTTAGA TGAAGAGTTT GTTCTTCGAG
480





TGATGACTCA GTTGACTCTG GCCCTGAAGG AATGCCACAG ACGAAGTGAT GGTGGTGATA
540





CCGTATTGCA TCGGGATCTT AAACCAGCCA ATGTTTTCCT GGATGGCAAG CAAAACGTCA
600





AGCTTGGAGA CTTTGGGCTA GCTAGAATAT TAAACCATGA CACGAGTTTT GCAAAAACAT
660





TTGTTGGCAC ACCTTATTAC ATGTCTCCTG AACAAATGAA TCGCATGTCC TACAATGAGA
720





AATCAGATAT CTGGTCATTG GGCTGCTTGC TGTATGAGTT ATGTGCATTA ATGCCTCCAT
780





TTACAGGTTT TAGCCAGAAA GAACTCGCTG GGAAAATCAG AGAAGGCAAA TTCAGGCGAA
840





TTCCATACCG TTACTCTGAT GAATTGAATG AAATTATTAC GAGGATGTTA AACTTAAAGG
900





ATTACCATCG ACCTTCTGTT GAAGAAATTC TTGAGAACCC TTTAATAGCA GATTTGGTTG
960





CAGACGACCA AAGAAGAAAT CTTGAGAGAA GAGGGCGACA ATTAGGAGAG CCAGAAAAAT
1020





CGCACGATTC CAGCCCTGTA TTGAGTGAGC TGAAACTGAA GGAAATTCAG TTACAGGAGC
1080





GAGAGCGAGC TCTCAAAGCA AGAGAAGAAA GATTGGAGCA GAAAGAACAG GAGCTTTGTG
1140





TTCGTGAGAG ACTAGCAGAG GACAAACTGG CTAGAGCAGA AAATCTGTTG AAGAACTACA
1200





GCTTGCTAAA GGAACGGAAG TTCCTGTCTC TGGCAAGTAA TCCAGAACTT CTTAATCTTC
1260





CATCCTCAGT AATTAAGAAG AAAGTTCATT TCAGTGGGGA AAGTAAAGAG AACATCATGA
1320





GGAGTGAGAA TTCTGAGAGT CAGCTCACAT CTAAGTCCAA GTGCAAGGAC CTGAAGAAAA
1380





GGCTTCACGC TGCCCAGCTG CGGGCTCAAG CCCTGTCAGA TATTGAGAAA AATTACCAAC
1440





TGAAAAGCAG ACAGATCCTG GGCATGCGCT AGCCAGGTAG AGAGACACAG AGCTGTGTAC
1500





AGGATGTAAT ATTACCAACC TTTAAAGACT GATATTCAAA TGCTGTACTG TTGAATACTT
1500





GGCCCCATGA GCCATGCCTT TCTGTATAGT ACACATGATA TTTCGGAATT GGTTTTACTG
1620





TTCTTCAGCA ACTATTGTAC AAAATGTTCA CATTTAATTT TTCTTTCTTC TTTTAAGAAC
1680





ATATTATAAA AAGAATACTT TCTTGGTTGG GCTTTTAATC CTGTGTGTGA TTACTAGTAG
1740





GAACATGAGA TGTGACATTC TAAATCTTGG GAGAAAAAAT AATATTAGGA AAAAAATATT
1600





TATGCAGGAA GAGTAGCACT CACTGAATAG TTTTAAATGA CTGAGTGGTA TGCTTACAAT
1860





TGTCATGTCT AGATTTAAAT TTTAAGTCTG AGATTTTAAA TGTTTTTGAG CTTAGAAAAC
1920





CCAGTTAGAT GCAATTTGGT CATTAATACC ATGACATCTT GCTTATAAAT ATTCCATTGC
1960





TCTGTAGTTC AAATCTGTTA GCTTTGTGAA AATTCATCAC TGTGATGTTT CTATTCTTTT
2040





TTTTTTTCTG TTTAACAGAA TATGAGCTGT CTGTCATTTA CCTACTTCTT TCCCACTAAA
2100





TAAAAGAATT CTTCAGTTA





SEQ ID NO: 30 Protein sequence:


Protein Accession #: NP_002488.1


1          11         21         31         41         51


|          |          |          |          |          |


MPSRAEDYEV LYTIGTGSYG RCQKIRRKSD GKILVWKELD YGSMTEAEKQ MLVSEVNLLR
60





ELKHPNIVRY YDRIIDRTNT TLYIVNEYCE GGDLASVITK GTKERQYLDE EFVLRVMTQL
120





TLALKECNRR SDGGHTVLHR DLKPANVFLD GKQNVKLGDF GLARILNHDT SFAKTFVGTP
180





YYMSPEQMNR MSYNEKSDIW SLGCLLYELC ALMPPFTAFS QKELAGKIRE GKFRRIPYRY
240





SDELNEIITR MLNLKDYHRP SVEEILENPL IAGLVADEQR RNLERRGRQL GEPEKSQDSS
300





PVLSELKLKE IQLQERERAL KAREERLEQK EQELCVRERL AEDKLARAEN LLKNYSLLKE
360





RKFLSLASNP ELLNLPSSVI KKKVHFSGES KENIMRSENS ESQLTSKSKC KDLKKRLHAA
420





QLRAQALSDI EKNYQLKSRQ ILGMR





SEQ ID NO: 31 DNA sequence


Nucleic Acid Accession #: NM020242


Coding sequence: 72..4240


1         11         21         31         41         51


|          |          |          |          |          |


CAGTCGCGCG CGGTGCAGTC GGGAGGTGGA GGCACCGGCT GCATTGTTTT CGGGATCGAG
60





GGGTGAGGGC GCTATGGCAC CCGGCTGCAA AACTGAGTTA CGCAGCGTGA CAAATGGTCA
120





GTCTAACCAA CCAAGTAATG AAGGTGATGC CATCAAAGTT TTTGTGCGAA TTCGTCCTCC
180





TGCAGAAAGA TCTGGGTCAG CTGATGGAGA GCAGAACTTA TGCTTATCTG TGCTGTCCTC
240





CACGAGTCTC CGGCTGCACT CCAACCCTGA GCCCAAGACC TTCACGTTTG ATCATGTTGC
300





AGATGTGGAT ACCACTCAGG AATCTGTATT TGCAACTGTC GCTAAAAGCA TTGTGGAGTC
360





TTGCATGAGC GGTTATAATG GTACCATCTT TGCATATGGA CAGACTGGCT CAGGGAAGAC
420





ATTTACTATG ATGGGACCAT CTGAATCTGA TAATTTTTCT CATAACCTGA GAGGAGTAAT
480





CCCACGAAGT TTTGAATATT TGTTTTCCTT AATTGATCGT GAAAAAGAAA AGGCTGGAGC
540





TGGAAAGAGT TTCCTTTGTA AGTGTTCCTT TATTGAAATC TACAACGAGC AGATATATGA
600





TCTACTGGAC TCTGCATCGG CTGGACTGTA CTTAAGGGAG CATATCAAGA AGGGAGTCTT
660





TGTTGTTGGT GCGGTGGAGC AGGTGGTAAC CTCAGCTGCT GAAGCCTATC AGGTGCTGTC
720





TGGAGGATGG AGGAATAGAC GTGTGGCATC AACATCAATG AACAGAGAAT CGTCTAGGTC
780





TCATGCCGTC TTTACAATTA CAATAGAGTC AATGGAGAAA AGTAATGAGA TTGTGAATAT
840





ACGGACCTCC CTACTCAACC TGGTGGATTT AGCAGGATCT GAAAGGCAAA AAGATACCCA
900





TGCAGAAGGG ATGAGATTGA AGGAAGCAGG TAACATAAAT CGATCATTGA GCTGCCTGGG
960





CCAAGTGATT ACAGCACTTG TCGACGTGGG TAATGGAAAA CAGAGACATG TTTGCTACAG
1020





AGACTCCAAA CTTACCTTCT TACTACGGGA TTCCCTTGGA GGTAATGCCA AAACAGCCAT
1080





AATTGCAAAT GTTCATCCTG GATCCAGGTG TTTTGGGGAA ACCCTATCAA CACTTAACTT
1140





TGCTCAAAGA GCCAAGCTGA TTAAAAACAA GGCAGTAGTA AATGAAGACA CCCAAGGAAA
1200





TGTGAGCCAG CTCCCGGCTG AAGTGAAGAG GCTCAAAGAA CAACTGGCGG AGCTTGCTTC
2260





AGGACAGACA CCACCAGAAA GCTTCCTGAC CAGAGACAAA AAGAAGACTA ACTATATGGA
1320





GTATTTCCAG GAAGCAATGT TATTCTTTAA GAAATCTGAA CAGGAAAAGA AGTCTCTGAT
1380





AGAAAAAGTT ACCCAATTAG AAGACCTCAC CCTCAAAAAG GAAAAATTTA TTCAATCTAA
1440





TAAAATGATT GTGAAATTCC GAGAGGATCA AATAATACGC TTGGAAAAGC TCCACAAGGA
1800





ATCCCGGGGA GGTTTTCTGC CTGAGGAGCA GGATCGTTTG CTCTCAGAAT TAAGGAATGA
1560





GATTCAAACT CTGCGAGAAC AAATAGAGCA CCACCCCAGA GTTGCAAAGT ATGCTATGGA
1620





AAATCATTCC CTCAGGGAGG AGAATAGAAG ACTGAGATTA TTAGAGCCTG TGAAAAGAGC
1680





TCAAGAAATG GATGCCCAGA CCATTGCAAA ACTAGAAAAA GCTTTCTCTG AAATAAGTGG
1740





CATGGAGAAA AGTGACAAAA ATCAGCAAGG ATTTTCACCT AAAGCTCAGA AAGAGCCATG
1800





TTTGTTTGCA AACACTGACA AGTTAAAAGC ACAACTCCTG CAAATTCAGA CAGAGCTGAA
1860





TAATTCAAAG CAAGAATATG AAGAATTCAA AGAACTTACT AGGAAAAGGC AGCTAGAATT
1920





GGAATCAGAG CTTCAGTCTT TGCAAAAAGC GAACCTTAAT CTTGAAAACC TTTTGGAAGC
1980





AACAAAAGCC TGCAAGCGGC AAGAAGTTTC TCAGCTGAAT AAAATTCATG CTGAAACACT
2040





TAAGATTATA ACTACACCAA CCAAGGCCTA CCAACTTCAT TCCCGACCAG TACCAAAATT
2100





AAGCCCTGAA ATGGGAAGCT TTGGCTCTCT ATACACTCAG AATTCTAGCA TATTAGATAA
2160





TGATATATTA AATGAGCCAG TTCCTCCTGA GATGAATGAA CAAGCTTTTG AGGCCATTTC
2220





TGAAGAGCTT AGAACAGTGC AGGAACAAAT GAGTGCTCTT CAAGCCAAAC TGGATGAAGA
2280





AGAGCATAAA AACCTAAAGC TTCAGCAGCA TGTTGACAAA CTGGAACATC ATTCTACCCA
2340





AATGCAGGAG CTTTTCTCAT CAGAAAGAAT TGATTGGACC AAACAGCAGG AAGAGCTTCT
2400





CTCACAGTTG AATGTCCTTG AAAAGCAGCT TCAAGAGACT CAAACTAAAA ATGACTTTTT
2460





GAAAAGTGAG GTACATGACC TGCGAGTAGT CCTTCATTCT GCTGACAAGG AGCTTTCTTC
2520





AGTGAAATTG GAATATAGTT CATTCAAAAC GAATCAGGAG AAAGAATTCA ACAAACTTTC
2580





TGAAAGACAC ATGCATGTAC AGCTTCAATT AGATAATCTC AGGTTAGAAA ACGAAAAGCT
2640





GCTTGAGAGC AAAGCCTGCC TACAGGATTC CTATGACAAC TTACAAGAAA TAATGAAATT
2700





TGAGATTGAC CAACTTTCAA GAAACCTCCA AAACTTCAAA AAAGAAAATG AAACTCTGAA
2760





ATCTGATCTG AATAATTTGA TGGAGCTTCT TGAGGCAGAA AAAGAACGCA ATAACAAATT
2820





ATCATTACAG TTTGAAGAAG ATAAAGAAAA CAGTTCTAAA GAAATCTTAA AAGTTCTTGA
2880





GGCTGTACGT CAGGAGAAAC AGAAAGAGAC GGCCAAGTGT GAGCAGCAGA TGGCAAAAGT
2940





ACAGAAACTA GAAGAGAGCT TGCTTGCTAC TGAAAAAGTG ATCAGTTCCC TGGAAAAGTC
3000





TAGAGATTCT GATAAGAAAG TTGTAGCTGA CCTCATGAAC CAGATCCAGG AGCTAAGAAC
3060





ATCGGTCTGT GAGAAAACAG AAACTATAGA CACCCTGAAA CAAGAACTGA AGGACATAAA
3120





TTGCAAATAC AACTCTGCTT TGGTTGACAG AGAAGAGAGC AGAGTGTTGA TCAAGAAGCA
3180





GGAAGTGGAT ATTCTGGATC TGAAAGAAAC CCTTAGGCTG AGAATACTTT CTGAGGACAT
3240





AGAGAGGGAT ATGCTCTGTG AGGACCTGGC TCATGCCACT GAGCAGCTGA ACATGCTCAC
3300





AGAGGCCTCA AAAAAACACT CGGGGCTGCT GCAGTCTGCC CAGGAAGAAC TGACCAAGAA
3360





GGAAGCCCTG ATTCAGGAAC TTCAGCACAA GCTAAACCAA AAGAAAGAGG AAGTAGAACA
3420





GAAGAAGAAT GAATATAACT TCAAAATGAG GCAACTAGAA CATGTGATGG ATTCTGCTGC
3480





TGAGGATCCC CAGAGTCCTA AGACACCACC TCACTTTCAA ACACATTTGG CAAAACTCCT
3540





GGAAACACAA GAACAAGAGA TAGAAGATGG AAGAGCCTCT AAGACTTCTT TGGAACACCT
3600





TGTAACAAAG CTAAATGAAG ACAGAGAAGT CAAAAATGCT GAAATCCTCA GAATGAAGGA
3660





GCAGTTGCGT GAAATGGAAA ACCTACGCCT GGAAAGTCAG CAGTTAATAG AGAAAAACTG
3720





GCTCCTGCAA GGTCAGCTGG ATGATATTAA AAGACAAAAG GAAAACAGTG ATCAGAATCA
3780





TCCAGATAAT CAACAGCTGA AGAATGAACA AGAAGAAAGT ATCAAAGAAA GACTTGCAAA
3840





AAGTAAAATA GTTGAAGAAA TGCTGAAAAT GAAAGCAGAC CTAGAAGAAG TCCAAAGTGC
3900





CCTTTACAAC AAAGAGATGG AATGCCTTAG AATGACTGAT GAAGTCGAAC GAACCCAAAC
3960





TTTGGAGTCT AAAGCATTCC AGGAAAAAGA ACAACTGAGA TCAAAGCTCG AAGAAATGTA
4020





TGAAGAAAGA GAGAGAACAT CCCAGGAGAT GGAAATGTTA AGGAAGCAGG TGGAGTGTCT
4080





TGCTGAGGAA AATGGAAAGT TGGTAGGTCA CCAAAATTTG CATCAGAAGA TTCAGTACGT
4140





AGTGCGACTA AAGAAGGAAA ATGTCAGGCT TGCTGAGGAG ACAGAAAAGT TGCGTGCCGA
4200





AAATGTATTT TTAAAAGAAA AGAAAAGAAG TGAATCTTGA GGATTCCGGT CAGCTACCTA
4260





GGCATCACCT TGTTTGAACA TGTTTCTTCT CTTTTACAAG TAAGACCTAC TCCTGGCCAC
4320





TTAGGAGAGC TGAATTTATG GACCTTAATT ATTAAATGTT TATAAGGTGG TGGTAACCAC
4380





CTCAAGTTTC TGATGAACAT TCTGCATCCA TATACACCCT GTGACAGTCA GCAGTCTGCT
4440





ATTAAGTGGC CTACTTCAAG GCTTTGAATC AACTTAAGGG AAAACCTTTT GTCTTTGTAA
4500





AAATAAAAGC CTGTAGCTAA GGTTTACAGT GGACATTAGC CAGATCATTT TCTTCTTAGA
4560





TTATGCCATA ATCTCCTTTG ATTCTTATGG AAGTTCTAAC AATATATCGT GGTTCCAACA
4620





CCTGCAGTGA GTTTAATGAC TGACTTAGTA GCAGGTACAA GAAGCAAACT TGTTAATATA
4680





GATTATTTTT GTATTCTTAC TTTAGGTATT TTACTTGAGC ATTTTCCATG ACTGTAAATA
4740





AAGCCATTTT TTAAGATAAA AAAAAAAAAA AAAAA





SEQ ID NO. 32 Protein sequence


Protein Accession #: NP_064627


1          11         21         31         41         51


|          |          |          |          |          |


MAPGCKTELR SVTNGQSNQP SNEGDAIKVF VRIRPPAERS GSADGEQNLC LSVLSSTSLR
60





LHSNPEPKTF TFDHVADVDT TQESVFATVA KSIVESCMSG YNGTIFAYGQ TGSGKTFTMM
120





GPSESDNFSH NLRGVIPRSF EYLFSLIDRE KEKAGAGKSF LCKCSFIEIY NEQIYDLLDS
180





ASAGLYLREH IKKGVFVVGA VEQVVTSAAE AYQVLSGGWR NRRVASTSMN RESSRSHAVF
240





TITIESMEKS NEIVNIRTSL LNLVDLAGSE RQKDTHAEGM RLKEAGNINR SLSCLGQVIT
300





ALVDVGNGKQ RHVCYRDSKL TFLLRDSLGG NAKTAIIANV HPGSRCFGET LSTLNFAQRA
360





KLIKNKAVVN EDTQGNVSQL QAEVKRLKEQ LAELASGQTP PESFLTRDKK KTNYMEYFQE
420





AMLFFKKSEQ EKKSLIEKVT QLEDLTLKKE KFIQSNKMIV KFREDQIIRL EKLHKESRGG
480





FLPEEQDRLL SELRNEIQTL REQIEHHPRV AKYAMENHSL REENRELELL EPVKRAQEMD
540





AQTIAKLEKA FSEISGMEKS DKNQQGFSPK AQKEPCLFAN TEKLKAQLLQ IQTELNNSKQ
600





EYEEFKELTR KRQLELESEL QSLQKANLNL ENLLEATKAC KRQEVSQLNK IHAETLKIIT
660





TPTKAYQLHS RPVPKLSPEM GSFGSLYTQN SSILDNDILN EPVPPEMNEQ AFEAISEELR
720





TVQEQMSALQ AKLDEEEHKN LKLQQHVDKL EHHSTQMQEL FSSERIDWTK QQEELLSQLN
780





VLEKQLQETQ TKNDFLKSEV HDLRVVLHSA DKELSSVKLE YSSFKTNQEK EFNKLSERHM
840





HVQLQLDNLR LENEKLLESK ACLQDSYDNL QEIMKFEIDQ LSRNLQNPKK ENETLKSDLN
900





NLMELLEAEK ERNNKLSLQF ENDREESSKE ILKVLEAVRQ ESQKETAKCE QQMAKVQKLE
960





ESLLATEKVI SSLEKSRDSD KKVVADLMNQ IQELRTSVCE KTETIDTLKQ ELKDINCKYN
1020





SALVDREESR VLIKKQEVDI LDLKETLRLR ILSEDIERDM LCEDLAHATE QLNMLTEASK
1080





KHSGLLQSAQ EELTEKEALI QELQHKLNQK KEEVEQKKNE YNFKMRQLEH VMDSAAEDPQ
1140





SPKTPPHFQT HLAKLLETQE QEIEDGRASK TSLEHLVTKL NEDREVKNAE ILRMKEQLRE
1200





MENLRLESQQ LIEKNWLLQG QLDDIKRQKE NSDQNHPDNQ QLKNEQEESI KERLAKSKIV
1260





EEMLKMKADL ERVQSALYNK EMECLRMTDE VERTQTLESK AFQEKEQLRS KLEEMYEERE
1320





RTSQEMEMLR KQVECLAEEN GKLVGHQNLH QKIQYVVRLK KENVRLAEET EKLRAENVFL
1380





KEKKRSES





SEQ ID NO. 33 DNA sequence


Nucleic Acid Accession 8: BC000633.1


Coding sequence: 1. .2574


1          11         21         31         41         51


|          |          |          |          |          |


ATGGAATCCG AGGATTTAAG TGGCAGAGAA TTGACAATTG ATTCCATAAT GAACAAAGTG
60





AGAGACATTA AAAATAAGTT TAAAAATGAA GACCTTACTG ATGAACTAAG CTTGAATAAA
120





ATTTCTGCTG ATACTACAGA TAACTCGGGA ACTGTTAACC AAATTATGAT GATGGCAAAC
180





AACCCAGAGG ACTGGTTGAG TTTGTTGCTC AAACTAGAGA AAAACAGTGT TCCGCTAAGT
240





GATGCTCTTT TAAATAAATT GATTGGTCGT TACAGTCAAG CAATTGAAGC GCTTCCCCCA
300





GATAAATATG GCCAAAATGA GAGTTTTGCT AGAATTCAAG TGAGATTTGC TGAATTAAAA
360





GCTATTCAAG AGCCAGATGA TGCACGTGAC TACTTTCAAA TGGCCAGAGC AAACTGCAAG
420





AAATTTGCTT TTGTTCATAT ATCTTTTGCA CAATTTGAAC TGTCACAAGG TAATGTCAAA
480





AAAAGTAAAC AACTTCTTCA AAAAGCTGTA GAACGTGGAG CACTACCACT AGAAATGCTG
540





GAAATTGCCC TGCGGAATTT AAACCTCCAA AAAAAGCAGC TGCTTTCAGA GGAGGAAAAG
600





AAGAATTTAT CAGCATCTAC GGTATTAACT GCCCAAGAAT CATTTTCCGG TTCACTTGGG
660





CATTTACAGA ATAGGAACAA CAGTTGTGAT TCCAGAGGAC AGACTACTAA AGCCAGGTTT
720





TTATATGGAG AGAACATGCC ACCACAAGAT GCAGAAATAG GTTACCGGAA TTCATTGAGA
780





CAAACTAACA AAACTAAACA GTCATGCCCA TTTGGAAGAG TCCCAGTTAA CCTTCTAAAT
840





AGCCCAGATT GTGATGTGAA GACAGATGAT TCAGTTGTAC CTTGTTTTAT GAAAAGACAA
900





ACCTCTAGAT CAGAATGCCG AGATTTGGTT GTGCCTGGAT CTAAACCAAG TGGAAATGAT
960





TCCTGTGAAT TAAGAAATTT AAAGTCTGTT CAAAATAGTC ATTTCAAGGA ACCTCTGGTG
1020





TCAGATGAAA AGAGTTCTGA ACTTATTATT ACTGATTCAA TAACCCTGAA GAATAAAACG
1080





GAATCAAGTC TTCTAGCTAA ATTAGAAGAA ACTAAAGAGT ATCAAGAACC AGAGGTTCCA
1140





GAGAGTAACC AGAAACAGTG GCAATCTAAG AGAAAGTCAG AGTGTATTAA CCAGAATCCT
1200





GCTGCATCTT CAAATCACTG GCAGATTCCG GAGTTAGCCC GAAAAGTTAA TACAGAGCAG
1260





AAACATACCA CTTTTGAGCA ACCTGTCTTT TCAGTTTCAA AACAGTCACC ACCAATATCA
1320





ACATCTAAAT GGTTTGACCC AAAATCTATT TGTAAGACAC CAAGCAGCAA TACCTTGGAT
1380





GATTACATGA GCTGTTTTAG AACTCCAGTT GTAAAGAATG ACTTTCCACC TGCTTGTCAG
1440





TTGTCAACAC CTTATGGCCA ACCTGCCTGT TTCCAGCAGC AACAGCATCA AATACTTGCC
1500





ACTCCACTTC AAAATTTACA GGTTTTAGCA TCTTCTTCAG CAAATGAATG CATTTCGGTT
1560





AAAGGAAGAA TTTATTCCAT TTTAAAGCAG ATAGGAAGTG GAGGTTCAAG CAAGGTATTT
1620





CAGGTGTTAA ATGAAAAGAA ACAGATATAT GCTATAAAAT ATGTGAACTT AGAAGAAGCA
1680





GATAACCAAA CTCTTGATAG TTACCGGAAC GAAATAGCTT ATTTGAATAA ACTACAACAA
1740





CACAGTGATA AGATCATCCG ACTTTATGAT TATGAAATCA CGGACCACTA CATCTACATG
1800





GTAATGGAGT GTGGAAATAT TGATCTTAAT AGTTGGCTTA AAAAGAAAAA ATCCATTGAT
1860





CCATGGGAAC GCAAGAGTTA CTGGAAAAAT ATGTTAGAGG CAGTTCACAC AATCCATCAA
1920





CATGGCATTG TTCACAGTGA TCTTAAACCA GCTAACTTTC TGATAGTTGA TGGAATGCTA
1980





AAGCTAATTG ATTTTGGGAT TGCAAACCAA ATGCAACCAG ATACAACAAG TGTTGTTAAA
2040





GATTCTCAGG TTGGCACAGT TAATTATATG CCACCAGAAG CAATCAAAGA TATGTCTTCC
2100





TCCAGAGAGA ATGGGAAATC TAAGTCAAAG ATAAGCCCCA AAAGTGATGT TTGGTCCTTA
2160





GGATGTATTT TGTACTATAT GACTTACGGG AAAACACCAT TTCAGCAGAT AATTAATCAG
2220





ATTTCTAAAT TACATGCCAT AATTGATCCT AATCATGAAA TTGAATTTCC CGATATTCCA
2280





GAGAAAGATC TTCAAGATGT GTTAAAGTGT TGTTTAAAAA GGGACCCAAA ACAGAGGATA
2340





TCCATTCCTG AGCTCCTGGC TCATCCCTAT GTTCAAATTC AAACTCATCC AGTTAACCAA
2400





ATGGCCAAGG GAACCACTGA AGAAATGAAA TATGTTCTGG GCCAACTTGT TGGTCTGAAT
2460





TCTCCTAACT CCATTTTGAA AGCTGCTAAA ACTTTATATG AACACTATAG TGGTGGTGAA
2520





AGTCATAATT CTTCATCCTC CAAGACTTTT GAAAAAAAAA GGQGGAAAAAA ATGA





SEQ ID NO: 34 Protein sequence


Protein Accession #: AAH00633.1


1          11         21         31         41         51


|          |          |          |          |          |


MESEDLSGRE LTIDSIMNKV RDIKNKFKNE DLTDELSLNK ISADTTDNSG TVNQIMNMAN
60





NPEDWLSLLL KLEKNSVPLS DALLNKLIGR YSQAIEALPP DKYGQNESFA RIQVRFAELK
120





AIQEPDDARD YFQMARANCK KFAFVHISFA QFELSQGNVK KSKQLLQKAV ERGAVPLEML
180





EIALRNLNLQ KKQLLSEEEK KNLSASTVLT AQESFSGSLG HLQNRNNSCD SRGQTTKARF
240





LYGENMPPQD AEIGYRNSLR QTNKTKQSCP FGRVPVNLLN SPDCDVKTDD SVVPCFMKRQ
300





TSRSECRDLV VPGSKPSGND SCELRNLKSV QNSHFKEPLV SDEKSSELII TDSITLKNET
360





ESSLLAKLEE TKEYQEPEVP ESNQKQWQSK RKSECINQNP AASSNHWQIP ELARKVNTEQ
420





KHTTFEQPVF SVSKQSPPIS TSKWFDPKSI CKTPSSNTLD DYMSCFRTPV VKNDFPPACQ
480





LSTPYGQPAC FQQQQHQILA TPLQNLQVLA SSSANECISV KGRIYSILKQ IGSGGSSKVF
540





QVLNEKEQIY AIKYVNLEEA DNQTLDSYRN EIAYLNKLQQ HSDKIIRLYD YEITDQYIYM
600





VMECGNIDLN SWLKKKKSID PWERKSYWKN MLEAVNTIHQ HGIVHSDLKP ANFLIVDGML
660





KLIDFGIANQ MQPDTTSVVK DSQVGTVNYM PPEAIKDMSS SRENGKSKSK ISPKSDVWSL
720





GCILYYMTYG KTPFQQIINQ ISKLHAIIDP NHEIEFPDIP EKDLQDVLKC CLKRDPKQRI
780





SIPELLAHPY VQIQTHPVNQ MAKGTTEEMK YVLGQLVGLN SPNSILKAAK TLYEHYSGGE
840





SNNSSSSKTF EKKRGKK





SEQ ID NO. 35 DNA sequence


Nucleic Acid Accession #: NM_005823.2


Coding sequence: 85. .1953


1          11         21         31         41         51


|          |          |          |          |          |


TCGCCACTCC CGTCTGCTGT GACGCGCGGA CAGAGACCTA CCGGTGGACC CACGCTGCCT
60





CCCTCCCTGG GATCTACACA GACCATGGCC TTGCCAACGG CTCGACCCCT GTTGGGGTCC
120





TGTGGGACCC CCGCCCTCGG CAGCCTCCTG TTCCTGCTCT TCAGCCTCGG ATGGGTGCAG
180





CCCTCGAGGA CGCTGGCTGG AGAGACAGGG CAGGAGGCTG CACCCCTGGA CGGAGTCCTG
240





GCCAACCCAC CTAACATTTC CAGCCTCTCC CCTCGCCAAC TCCTTGGCTT CCCGTGTGCG
300





GAGGTGTCCG GCCTGAGCAC GGAGCGTGTC CGGGAGCTGG CTGTGGCCTT GGCACAGAAG
360





AATGTCAAGC TCTCAACAGA GCAGCTGCGC TGTCTGGCTC ACCGGCTCTC TGAGCCCCCC
420





GAGGACCTGG ACGCCCTCCC ATTGGACCTG CTGCTATTCC TCAACCCAGA TGCGTTCTCG
480





GGGCCCCAGG CCTGCACCCG TTTCTTCTCC CGCATCACGA AGGCCAATGT GGACCTGCTC
540





CCGAGGGGGG CTCCCGAGCG ACAGCGGCTG CTGCCTGCGG CTCTGGCCTG CTGGGGTGTG
600





CGGGGGTCTC TGCTGAGCGA GGCTGATGTG CGGGCTCTGG GAGGCCTGGC TTGCGACCTG
660





CCTGGGCGCT TTGTGGGCGA GTCGGCCGAA GTGCTGCTAC CCCGGCTGGT GAGCTGCCCG
720





GGACCCCTGG ACCAGGACCA GCAGGAGGCA GCCAGGGCGG CTCTGCAGGG CGGGGGACCC
780





CCCTACGGCC CCCCGTCGAC ATGGTCTGTC TCCACGATGG ACGCTCTGCG GGGCCTGCTG
840





CCCGTGCTGG GCCAGCCCAT CATCCGCAGC ATCCCGCAGG GCATCGTGGC CGCGTGGCGG
900





CAACGCTCCT CTCGGGACCC ATCCTGGCGG CAGCCTGAAC GGACCATCCT CCGGCCGCGG
960





TTCCGGCGGG AAGTGGAGAA GACAGCCTGT CCTTCAGGCA AGAAGGCCCG CGAGATAGAC
1020





GAGAGCCTCA TCTTCTACAA GAAGTGGGAG CTGGAAGCCT GCGTGGATGC GGCCCTGCTG
2080





GCCACCCAGA TGGACCGCGT GAACGCCATC CCCTTCACCT ACGAGCAGCT GGACGTCCTA
1140





AAGCATAAAC TGGATGAGCT CTACCCACAA GGTTACCCCG AGTCTGTGAT CCAGCACCTG
1200





GGCTACCTCT TCCTCAAGAT GAGCCCTGAG GACATTCGCA AGTGGAATGT GACGTCCCTG
1260





GAGACCCTGA AGGCTTTGCT TGAAGTCAAC AAAGGGCACG AAATGAGTCC TCAGGTGGCC
1320





ACCCTGATCG ACCGCTTTGT GAAGGGAAGG GGCCAGCTAG ACAAAGACAC CCTAGACACC
1380





CTGACCGCCT TCTACCCTGG GTACCTGTGC TCCCTCAGCC CCGAGGAGCT GAGCTCCGTG
1440





CCCCCCAGCA GCATCTGGGC GGTCAGGCCC CAGGACCTGG ACACGTGTGA CCCAAGGCAG
1500





CTGGACGTCC TCTATCCCAA GGCCCGCCTT GCTTTCCAGA ACATGAACGG GTCCGAATAC
1560





TTCGTGAAGA TCCAGTCCTT CCTGGGTGGG GCCCCCACGG AGGATTTGAA GGCGCTCAGT
1620





CAGCAGAATG TGAGCATGGA CTTGGCCACG TTCATGAAGC TGCGGACGGA TGCGGTGCTG
1080





CCGTTGACTG TGGCTGAGGT GCAGAAACTT CTGGGACCCC ACGTGGAGGG CCTGAAGGCG
1740





GAGGAGCGGC ACCGCCCGGT GCGGGACTGG ATGCTACCGC ACCGGCAGGA CGACCTGGAC
1800





ACGCTGGGGC TGGGGCTACA GGGCGGCATC CCCAACGGCT ACCTGGTCCT AGACCTCAGC
1860





GTGCAAGAGG CCCTCTCGGG GACGCCCTGC CTCCTAGGAC CTGGACCTGT TCTCACCGTC
1920





CTGGCACTGC TCCTAGCCTC CACCCTGGCC TGAGGGCCCC ACTCCCTTGC TGGCCCCAGC
1980





CCTGCTGGGG ATCCCCGCCT GGCCAGGAGC AGGCACGGGT GATCCCCGTT CCACCCCAAG
2040





AGAACTCGCG CTCAGTAAAC GGGAACATGC CCCCTGCAGA CACGT





SEQ ID NO: 36 Protein sequence


Protein Accession #: NP_005814.1


1          11         21         31         41         51


|          |         |          |          |          |


MALPTARPLL GSCGTPALGS LLFLLFSLGW VQPSRTLAGE TGQEAAPLDG VLANPPNISS
60





LSPRQLLGFP CAEVSGLSTE RVRELAVALA QKNVKLSTEQ LRCLAHRLSE PPEDLDALPL
120





DLLLFLNPDA FSGPQACTRF FSRITKANVD LLPRGAPERQ RLLPAALACW GVRGSLLSEA
180





DVRALGGLAC DLPGRFVAES AEVLLPRLVS CPGPLDQDQQ EAARAALQGG GPPYGPPSTW
240





SVSTMDALRG LLPVLGQPII RSIPQGIVAA WRQRSSRDPS WRQPERTILR PEFEREVEET
300





ACPSGKKARE IDESLIFYKK WELEACVDAA LLATQMDRVN AIPFTYEQLD VLKHKLDELY
360





PQGYPESVIQ HLGYLFLKNS PEDIRKWNVT SLETKEALLE VNKGHEMSPQ VATLIDRFVK
420





GRGQLDKDTL DTLTAFYPGY LCSLSPEELS SVPPSSIWAV RPQDLDTCDP RQLDVLYPKA
480





RLAFQNMNGS EYFVKIQSFL GGAPTEDLKA LSQQNVSMDL ATFMKLRTDA VLPLTVAEVQ
540





KLLGPNVEGL KAEERHRPVR DWILRQRQDD LDTLGLGLQG GIPNGYLVLD LSVQEALSGT
600





PCLLGPGPVL TVLALLLAST LA





SEQ ID NO: 37 DNA sequence


Nucleic Acid Accession #: NM_013404.1


Coding sequence: 89. .1975


1         11         21         31         41         51


|          |          |          |          |          |


TGGCCGGCCA CTCCCGTCTG CTGTGACGCG CGGACAGAGA GCTACCGGTG GACCCACGGT
60





GCCTCCCTCC CTGGGATCTA CACAGACCAT GGCCTTGCAA CGGCTCGACC CCTGTTGGTC
120





CTGTGGGGAC CGCCCTGGCA GCCTCCTGTT CCTGCTCTTC AGCCTCGGAT GGGTGCATCC
180





CGCGAGGACC CTGGCTGAGG AGACAGGGAC GGAGTCTGCC CCCCTGGGGG GAGTCCTGAC
240





AACCCCCCAT AACATTTCCA GCCTCTCCCC TCGCCAACTC CTTGGCTTCC CGTGTGCGGA
300





GGTGTCCGGC CTGAGCACGG AGCGTGTCCG GGAGCTGGCT GTGGCCTTGG CACAGAAGAA
360





TGTCAAGCTC TCAACAGAGC AGCTGCGCTG TCTGGCTCAC CGGCTCTCTG AGCCCCCCGA
420





GGACCTGGAC GCCCTCCCAT TGGACCTGCT GCTATTCCTC AACCCAGATG CGTTCTCGGG
480





GCCCCAGGCC TGCACCCGTT TCTTCTCCCG CATCACGAAG GCCAATGTGG ACCTGCTCCC
540





GAGGGGGGCT CCCGAGCGAC AGCGGCTGCT GCCTGCGGCT CTGGCCTGCT GGGGTGTGCG
600





GGGGTCTCTG CTGAGCGAGG CTGATGTGCG GGCTCTGGGA GGCCTGGCTT GCGACCTGCC
660





TGGGCGCTTT GTGGCCGAGT CGGCCGAAGT GCTGCTACCC CGGCTGGTGA GCTGCCCGGG
720





ACCCCTGGAC CAGGACCAGC AGGAGGCAGC CAGGGCGGCT CTGCAGGGCG GGGGACCCCC
780





CTACGGCCCC CCGTCGACAT GGTCTGTCTC CACGATGGAC GCTCTGCGGG GCCTGCTGCC
840





CGTGCTGGGC CAGCCCATCA TCCGCAGCAT CCCGCAGGGC ATCGTGGCCG CGTGGCGGCA
900





ACGCTCCTCT CGGGACCCAT CCTGGCGGCA GCCTGAACGG ACCATCCTCC GGCCGCGGTT
960





CCGGCGGGAA GTGGAGAAGA CAGCCTGTCC TTCAGGCAAG AAGGCCCGCG AGATAGACGA
1020





GAGCCTCATC TTCTACAAGA AGTGGGAGCT GGAAGCCTGC GTGGATGCGG CCCTGCTGGC
1080





CACCCAGATG GACCGCGTGA ACGCCATCCC CTTCACCTAC GAGCAGCTGG ACGTCCTAAA
1140





GCATAAACTG GATGAGCTCT ACCCACAAGG TTACCCCGAG TCTGTGATCC AGCACCTGGG
1200





CTACCTCTTC CTCAAGATGA GCCCTGAGGA CATTCGCAAG TGGAATGTGA CGTCCCTGGA
1260





GACCCTGAAG GCTTTGCTTG AAGTCGACAA AGGGCACGAA ATGAGTCCTC AGGCTCCTCG
1320





GCGGCCCCTC CCACAGGTGG CCACCCTGAT CGACCGCTTT GTGAAGGGAA GGGGCCAGCT
1380





AGACAAAGAC ACCCTAGACA CCCTGACCGC CTTCTACCCT GGGTACCTGT GCTCCCTCAG
1440





CCCCCAGGAG CTGAGCTCCG TGCCCCCCAG CAGCATCTGG GCGGTCAGGC CCCAGGACCT
1500





GGACACGTGT GACCCAAGGC AGCTGGACGT CCTCTATCCC AAGGCCCGCC TTGCTTTCCA
1560





GAACATGAAC GGGTCCGAAT ACTTCGTGAA GATCCAGTCC TTCCTGGGTG GGGCCCCCAC
1020





GGAGGATTTG AAGGCGCTCA GTCAGCAGAA TGTGAGCATG GACTTGGCCA CGTTCATGAA
1680





GCTGCGGACG GATGCCGTGC TGCCGTTGAC TGTGGCTGAG GTGCAGAAAC TTCTGGGACC
1740





CCACGTGGAG GGCCTGAAGG CGGAGGAGCG GCACCGCCCG GTGCGGGACT GGATCCTACG
1800





GCAGCGGCAG GACGACCTGG ACACGCTGGG GCTGGGGCTA CAGGGGGGCA TCCCCAACGG
1860





CTACCTGGTC CTAGACCTCA GCGTGCAAGA GACCCTCTCG GGGACGCCCT GCCTCCTAGG
1920





ACCTGGACCT GTTCTCACCG TCCTGGCACT GCTCCTAGCC TCCACCCTGG CCTGAGGGCC
1960





CCACTCCCTT GCTGGCCCCA GCCCTGCTGG GGATCCCCGC CTGGCCAGGA GCAGGCACGG
2040





GTGATCCCCG TTCCACCCCA AGAGAACTCG CGCTCAGTAA ACGGGAACAT GCCCCCTGCA
2100





GACACGT





SEQ ID NO. 38 Protein sequence


Protein Accession #. NP_037536.1


1          11         21         31         41         51


|          |          |          |          |          |


MALQRLDPCW SCGDRPGSLL FLLFSLGWVH PARTLAGETG TESAPLGGVL TTPNNISSLS
60





PRQLLGFPCA EVSGLSTERV RELAVALAQK NVKLSTEQLR CLAHRLSEPP EDLDALPLDL
120





LLFLNPDAPS GPQACTRFFS RITKANVDLL PRGAPERQRL LPAALACWGV RGSLLSEADV
180





RALGGLACDL PGRFVAESAE VLLPRLVSCP GPLDQDQQEA ARAALQGGGP PYGPPSTWSV
240





STMDALRGLL PVLGQPIIRS IPQGIVAAWR QRSSRDPSWR QPERTILRPR FEREVEETAC
300





PSGKKAREID ESLIFYKKWE LEACVDAALL ATQMDRVNAI PFTYEQLDVL KHKLDELYPQ
360





GYPESVIQHL GYLFLKMSPE DIRKWNVTSL ETLKALLEVD KGHEMSPQAP RRPLPQVATL
420





IDRFVKGRGQ LDKDTLDTLT AFYPGYLCSL SPEELSSVPP SSIWAVRPQD LDTCDPRQLD
480





VLYPKARLAF QNMNGSEYPV KIQSFLGGAP TEDLKALSQQ NVSMDLATFM KLRTDAVLPL
540





TVAEVQKLLG PHVEGLKAEE RHRPVRDWIL RQRQDDLDTL GLGLQGGIPN GYLVLDLSVQ
600





ETLSGTPCLL GPGPVLTVLA LLLASTLA





SEQ ID NO. 39 DNA sequence


Nucleic Acid Accession #: NN_001508.1


Coding sequence: 1. .1362


1         11         21         31         41         51


|          |          |          |          |          |


ATGGCTTCAC CCAGCCTCCC GGGCAGTGAC TGCTCCCAAA TCATTGATCA CAGTCATGTC
60





CCCGAGTTTG AGGTGGCCAC CTGGATCAAA ATCACCCTTA TTCTGGTGTA CCTGATCATC
120





TTCGTGATGG GCCTTCTGGG GAACAGCGTC ACCATTCGGG TCACCCAGGT GCTGCAGAAG
180





AAAGGATACT TGCAGAAGGA GGTGACAGAC CACATGGTGA GTTTGGCTTG CTCGGACATC
240





TTGGTGTTCC TCATCGGCAT GCCCATGGAG TTCTACAGCA TCATCTGGAA TCCCCTGACC
300





ACGTCCAGCT ACACCCTGTC CTGCAAGCTG CACACTTTCC TCTTCGAGGC CTGCAGCTAC
360





GCTACGCTGC TGCACGTGCT GACGCTCAGC TTTGAGCGCT ACATCGCCAT CTGTCACCCC
420





TTCAGGTACA AGGCTGTGTC GGGACCTTGC CAGGTGAAGC TGCTGATTGG CTTCGTCTGG
480





GTCACCTCCG CCCTGGTGGC ACTGCCCTTG CTGTTTGCCA TGGGTACTGA GTACCCCCTG
540





GTGAACGTGC CCAGCCACCG GGGTCTCACT TGCAACCGCT CCAGCACCCG CCACCACGAG
600





CAGCCCGAGA CCTCCAATAT GTCCATCTGT ACCAACCTCT CCAGCCGCTG GACCGTGTTC
660





CAGTCCAGCA TCTTCGGCGC CTTCGTGGTC TACCTCGTGG TCCTGCTCTC CGTAGCCTTC
720





ATGTGCTGGA ACATGATGCA GGTGCTCATG AAAAGCCAGA AGGGCTCGCT GGCCGGGGGC
780





ACGCGGCCTC CGCAGCTGAG GAAGTCCGAG AGCGAAGAGA GCAGGACCGC CAGGAGGCAG
840





ACCATCATCT TCCTGAGGCT GATTGTTGTG ACATTGGCCG TATGCTGGAT GCCCAACCAG
900





ATTCGGAGGA TCATGGCTGC GGCCAAACCC AAGCACGACT GGACGAGGTC CTACTTCCGG
960





GCGTACATGA TCCTCCTCCC CTTCTCGGAG ACGTTTTTCT ACCTCAGCTC GGTCATCAAC
1020





CCGCTCCTGT ACACGGTGTC CTCGCAGCAG TTTCGGCGGG TGTTCGTGCA GGTGCTGTGC
1080





TGCCGCCTGT CGCTGCAGCA CGCCAACCAC GAGAAGCGCC TGCGCGTACA TGCGCACTCC
1140





ACCACCGACA GCGCCCGCTT TGTGCAGCGC CCGTTGCTCT TCGCGTCCCG GCGCCAGTCC
1200





TCTGCAAGGA GAACTGAGAA GATTTTCTTA AGCACTTTTC AGAGCGAGGC CGAGCCCCAG
1260





TCTAAGTCCC AGTCATTGAG TCTCGAGTCA CTAGAGCCCA ACTCAGGCGC GAAACCAGCC
1320





AATTCTGCTG CAGAGAATGG TTTTCAGGAG CATGAAGTTT GA





SEQ ID NO: 40 Protein sequence


Protein Accession #: NP_001499.1


1          11         21         31         41         51


|          |          |          |          |          |


MASPSLPGSD CSQIIDNSHV PEFEVATWIK ITLILVYLII FVMGLLGNSV TIRVTQVLQK
60





KGYLQKEVTD HMVSLACSDI LVFLIGMPME FYSIIWNPLT TSSYTLSCKL NTFLFEACSY
120





ATLLHVLTLS FERYIAICHP FRYKAVSGPC QVKLLIGFVW VTSALVALPL LFANGTEYPL
180





VNVPSNRGLT CNRSSTRHHE QPETSNMSIC TNLSSRWTVP QSSIFGAFVV YLVVLLSVAF
240





MCWNMMQVLM KSQKGSLAGG TRPPQLRKSE SEESRTARRQ TIIFLRLIVV TLAVCWMPNQ
300





IRRIMAAAKP KHDWTRSYFR AYMILLPFSE TFFYLSSVIN PLLYTVSSQQ FRRVFVQVLC
360





CRLSLQHANH EKRLRVHAHS TTDSARFVQR PLLFASRRQS SARRTEKIFL STFQSEAEPQ
420





SKSQSLSLES LEPNSGAKPA NSAAENGFQE HEV





SEQ ID NO: 41 DNA sequence


Nucleic Acid Accession #: NM_022358


Coding sequence: 65. .1057


1          11         21         31         41         51


|          |          |          |          |          |


GGAGCGCGCG GTCCGGGCAC ACGGAGCAGG TTGGGACCGC GGCGGGTACC GGGGCCGGGG
60





CCCCATGCGG AGGCCGAGCG TGCGCGCGGC CGGGCTGGTC CTGTGCACCC TGTGTTACCT
120





GCTGGTGGGC GCTGCTGTCT TCGACGCGCT CGAGTCCGAG GCGGAAAGCG GCCGCCAGCG
180





ACTGCTGGTC CAGAAGCGGG GCGCTCTCCG GAGGAACTTC GGCTTCTCGG CCGAGGACTA
240





CCGCGAGCTG GAGCGCCTGG CGCTCCAGGC TGAGCCCCAC CGCGCCGGCC GCCAGTGGAA
300





GTTCCCCGGC TCCTTCTACT TCGCCATCAC CGTCATCACT ACCATCGGGT ACGGCCACGC
360





CGCGCCGGGT ACGGACTCCG GCAAGGTCTT CTGCATGTTC TACGCGCTCC TGGGCATCCC
420





GCTGACGCTG GTCACTTTCC AGAGCCTGGG CGAACGGCTG AACGCGGTGG TGCGGCGCCT
480





CCTGTTGGCG GCCAAGTGCT GCCTGGGCCT GCGGTGGACG TGCGTGTCCA CGGAGAACCT
540





GGTGGTGGCC GGGCTGCTGG CGTGTGCCGC CACCCTGGCC CTCGGGGCCG TCGCCTTCTC
600





GCACTTCGAG GGCTGGACCT TCTTCCACGC CTACTACTAC TGCTTCATCA CCCTCACCAC
660





CATCGGCTTC GGCGACTTCG TGGCACTGCA GAGCGGCGAG GCGCTGCAGA GGAAGCTCCC
720





CTACGTGGCC TTCAGCTTCC TCTACATCCT CCTGGGGCTC ACGGTCATTG GCGCCTTCCT
780





CAACCTGGTG GTCCTGCGCT TCCTCGTTGC CAGCGCCGAC TGGCCCGAGC GCGCTGCCCG
840





CCCCCCCAGC CCGCGCCCCC CGGGGGCGCC CGAGAGCCGT GGCCTCTGGC TGCCCCGCCG
900





CCCGGCCCGC TCCGTGGGCT CCGCCTCTGT CTTCTGCCAC GTGCACAAGC TGGAGAGGTG
960





CGCCCGCGAC AACCTGGGCT TTTCGCCCCC CTCGAGCCCG GGGGTCGTGC GTGGCGGGCA
1020





GGCTCCCAGG CCTGGGGCCC GGTGGAAGTC CATCTGACAA CCCCACCCAG GCCAGGGTCG
1080





AATCTGGAAT GGGAGGGTCT GGCTTCAGCT ATCAGGGCAC CCTCCCCAGG GATTGGAAAC
1140





GGATGACGOG CCTCTAGGCG GTCTTCTGCC ACGAGCAGTT TCTCATTACT GTCTGTGGCT
1200





AAGTCCCCTC CCTCCTTTCC AAAAATATAT TACAGTCACA CCATAAAAAA AAAAAAAAAA
1260





SEQ ID NO: 42 Protein sequence


Protein Accession #: NP_071753


1          11         21         31         41         51


|          |          |          |          |          |


MRRPSVRAAG LVLCTLCYLL VGAAVFDALE SEAESGRQRL LVQKRGALRR KFGFSAEDYR
60





ELERLALQAE PHRAGRQWKF PCSFYFAITV ITTIGYGHAA PGTDSGKVFC MFYALLGIPL
120





TLVTFQSLGE RLNAVVRRLL LAAKCCLGLR WTCVSTENLV VAGLLACAAT LALGAVAFSH
180





FEGWTFFHAY YYCFITLTTI GFGDFVALQS GEALQRKLPY VAFSFLYILL GLTVIGAFLN
240





LVVLRFLVAS ADWPERAARP PSPRPPGAPE SRGLWLPRRP ARSVGSASVF CHVHKLERCA
300





RDNLGFSPPS SPGVVRGGQA PRPGARWKSI





SEQ ID NO: 43 DNA sequence


Nucleic Acid Accession #: NM_000869.1


Coding sequence: 220. .1656


1          11         21         31         41         51


|          |          |          |          |          |


GGAAACATGA TCCAGCTGAA GGACTGATTG CAGGAAAACT TGGCAGCTCC CCAACCTTGG
60





TGGCCCAGGG AGTGTGAGGC TGCAGCCTCA GAAGGTGTGA GCAGTGGCCA CGAGAGGCAG
120





GCTGGCTGGG ACATGAGGTT GGCAGAGGGC AGGCAAGCTG GCCCTTGGTG GGCCTCGCCC
180





TGAGCACTCG GAGGCACTCC TATGCTTGGA AAGCTCGCTA TGCTGCTGTG GGTCCAGCAG
240





GCGCTGCTCG CCTTGCTCCT CCCCACACTC CTGGCACAGG GAGAAGCCAG GAGGAGCCGA
300





AACACCACCA GGCCCGCTCT GCTGAGGCTG TCGGATTACC TTTTGACCAA CTACAGGAAG
360





GGTGTGCGCC CCGTGAGGGA CTGGAGGAAG CCAACCACCG TATCCATTGA CGTCATTGTC
420





TATGCCATCC TCAACGTGGA TGAGAAGAAT CAGGTGCTGA CCACCTACAT CTGGTACCGG
480





CAGTACTGGA CTGATGAGTT TCTCCAGTGG AACCCTGAGG ACTTTGACAA CATCACCAAG
540





TTGTCCATCC CCACGGACAG CATCTGGGTC CCGGACATTC TCATCAATGA GTTCGTGGAT
600





GTGGGGAAGT CTCCAAATAT CCCGTACGTG TATATTCGGC ATCAAGGCGA AGTTCAGAAC
660





TACAAGCCCC TTCAGGTGGT GACTGCCTGT AGCCTCGACA TCTACAACTT CCCCTTCGAT
720





GTCCAGAACT GCTCGCTGAC CTTCACCAGT TGGCTGCACA CCATCCAGGA CATCAACATC
780





TCTTTGTGGC GCTTGCCAGA AAAGGTGAAA TCCGACAGGA GTGTCTTCAT GAACCAGGGA
840





GAGTGGGAGT TGCTGGGGGT GCTGCCCTAC TTTCGGGAGT TCAGCATGGA AAGCAGTAAC
900





TACTATGCAG AAATGAAGTT CTATGTGGTC ATCCGCCGGC GGCCCCTCTT CTATGTGGTC
960





AGCCTGCTAC TGCCCAGCAT CTTCCTCATG GTCATGGACA TCGTGGGCTT CTACCTGCCC
1020





CCCAACAGTG GCGAGAGGGT CTCTTTCAAG ATTACACTCC TCCTGGGCTA CTCGGTCTTC
1080





CTGATCATCG TTTCTGACAC GCTGCCGGCC ACTGCCATCG GCACTCCTCT CATTGGTGTC
1140





TACTTTGTGG TGTGCATGGC TCTGCTGGTG ATAAGTTTGG CCGAGACCAT CTTCATTGTG
1200





CGGCTGGTGC ACAAGCAAGA CCTGCAGCAG CCCGTGCCTG CTTGGCTGCG TCACCTGGTT
1260





CTGGAGAGAA TCGCCTGGCT ACTTTGCCTG AGGGAGCAGT CAACTTCCCA GAGGCCCCCA
1320





GCCACCTCCC AAGCCACCAA GACTGATGAC TGCTCAGCCA TGGGAAACCA CTGCAGCCAC
1380





ATGGGAGGAC CCCAGGACTT CGAGAAGAGC CCGAGGGACA GATGTAGCCC TCCCCCACCA
1440





CCTCGGGAGG CCTCGCTGGC GGTGTGTGGG CTGCTGCAGG AGCTGTCCTC CATCCGGCAA
1500





TTCCTGGAAA AGCGGGATGA GATCCGAGAG GTGGCCCGAG ACTGGCTGCG CGTGGGCTCC
1560





GTGCTGGACA AGCTGCTATT CCACATTTAC CTGCTAGCGG TGCTGGCCTA CAGCATCACC
1620





CTGGTTATGC TCTGGTCCAT CTGGCAGTAC GCTTGAGTGG GTACAGCCCA GTGGAGGAGG
1680





GGGTACAGTC CTGGTTAGGT GOGGACAGAG GATTTCTGCT TAGGCCCCTC AGGACCCAGG
1740





GAATGCCAGG GACATTTTCA AGACACAGAC AAAGTCCCGT GCCCTGTTTC CAATGCCAAT
1800





TCATCTCAGC AATCACAAGC CAAGGTCTGA ACCCTTCCAC CAAAAACTGG GTGTTCAAGG
1860





CCCTTACACC CTTGTCCCAC CCCCAGCAGC TCACCATGGC TTTAAAACAT GCTCTCTTAG
1920





ATCAGGAGAA ACTCGGGCAC TCCCTAAGTC CACTCTAGTT GTGGACTTTT CCCCATTGAC
1980





CCTCACCTGA ATAAGGGACT TTGGAATTCT GCTTCTCTTT CACAACTTTG CTTTTAGGTT
2040





GAAGGCAAAA CCAACTCTCT ACTACACAGG CCTGATAACT CTGTACGAGG CTTCTCTAAC
2100





CCCTAGTGTC TTTTTTTTCT TCACCTCACT TGTGGCAGCT TCCCTGAACA CTCATCCCCC
2160





ATCAGATGAT GGGAGTGGGA AGAATAAAAT GCAGTGAAAC CC





SEQ ID NO: 44 Protein sequence


Protein Accession #: NP_000860.1


1          11         21         31         41         51


|          |          |          |          |          |


MLLWVQQALL ALLLPTLLAQ GEARRSRNTT RPALLRLSDY LLTNYRKGVR PVRDWRKPTT
60





VSIDVIVYAI LNVDEKNQVL TTYIWYRQYW TDEFLQWNPE DFDNITKLSI PTDSIWVPDI
120





LINEFVDVGK SPNIPYVYIR NQGEVQNYKP LQVVTACSLD IYNFPFDVQN CSLTFTSWLN
180





TIQDINISLW RLPEKVKSDR SVFMNQGEWE LLGVLPYFRE FSMESSNYYA EMKFYVVIRR
240





RPLFYVVSLL LPSIFLMVMD IVGFYLPPNS GERVSFKITL LLGYSVFLII VSDTLPATAI
300





GTPLIGVYFV VCMALLVISL AETIFIVRLV HKQDLQQPVP AWLRHLVLER IAWLLCLREQ
360





STSQRPPATS QATKTDDCSA MGNHCSHMGG PQDFEKSPRD RCSPPPPPRE ASLAVCGLLQ
420





ELSEIRQFLE KRDEIREVAR DWLRVGSVLD KLLFHIYLLA VLAYSITLVM LWSIWQYA





SEQ ID NO: 45 DNA sequence


Nucleic Acid Accession #: NM_015507


Coding sequence: 241. .1902


1         11         21         31         41         51


|          |          |          |          |          |


CCGCACAGGA GCCTCCGCCA GGCTACCCAG GGCGCCCCCA GCCCCTCCCC AGGCCGCGAG
60





CGCCCCTGCC GCGGTGCCTG GCCTCCCCTC GCAGACTGCA GGGACAGCAC CCGGTAACTG
120





CGAGTGGAGC GGAGGACCCG AGCGGCTGAG GAGAGAGGAG GCGGCCGCTT AGCTGCTACG
180





GGGTCCGGCC GGCGCCCTCC CGAGGGGGGC TCAGGAGGAG GAAGGAGGAC CCGTGCGAGA
240





ATGCCTCTGC CCTGGAGCCT TGCGCTCCCG CTGCTCCTCT CCTGGGTGGC AGGTCGTTTC
300





GGGAACGCGG CCAGTGCAAG GCATCACGGG TTGTTAGCAT CGGCACGTCA GCCTGGGGTC
360





TGTCACTATG GAACTAAACT GGCCTGCTGC TACGGCTGGA GAAGAAACAG CAAGGGAGTC
420





TGTGAAGCTA CATGCGAACC TGGATGTAAG TTTGGTGAGT GCGTGGGACC AAACAAATGC
480





AGATGCTTTC CAGGATACAC CGGGAAAACC TGCAGTCAAG ATGTGAATGA GTGTGGAATG
540





AAACCCCGGC CATGCCAACA CAGATGTGTC AATACACACC GAAGCTACAA GTGCTTTTGC
600





CTCAGTGGCC ACATGCTCAT GCCAGATGCT ACGTGTGTGA ACTCTAGGAC ATGTGCCATG
660





ATAAACTGTC AGTACAGCTG TGAAGACACA GAAGAAGGGC CACAGTGCCT GTGTCCATCC
720





TCAGGACTCC GCCTGGCCCC AAATGGAAGA GACTGTCTAG ATATTGATGA ATGTGCCTCT
780





GGTAAAGTCA TCTGTCCCTA CAATCGAAGA TGTGTGAACA CATTTGGAAG CTACTACTGC
840





AAATGTCACA TTGGTTTCGA ACTGCAATAT ATCAGTGGAC GATATGACTG TATAGATATA
900





AATGAATGTA CTATGGATAG CCATACGTGC AGCCACCATG CCAATTGCTT CAATACCCAA
960





GGGTCCTTCA AGTGTAAATG CAACCAGGGA TATAAAGGCA ATGGACTTCG GTGTTCTGCT
1020





ATCCCTGAAA ATTCTGTGAA GGAAGTCCTC AGAGCACCTG GTACCATCAA AGACAGAATC
1080





AAGAAGTTGC TTGCTCACAA AAACAGCATG AAAAAGAAGG CAAAAATTAA AAATGTTACC
1140





CCAGAACCCA CCAGGACTCC TACCCCTAAG GTGAACTTGC AGCCCTTCAA CTATGAAGAG
1200





ATAGTTTCCA GAGGCGGGAA CTCTCATGGA GGTAAAAAAG GGAATGAAGA GAAAATGAAA
1260





GAGGGGCTTG AGGATGAGAA AAGAGAAGAG AAAGCCCTGA AGAATGACAT AGAGGAGCGA
1320





AGCCTGCGAG GAGATGTGTT TTTCCCTAAG GTGAATGAAG CAGGTGAATT CGGCCTGATT
1380





CTGGTCCAAA GGAAAGCGCT AACTTCCAAA CTGGAACATA AAGATTTAAA TATCTCGGTT
1440





GACTGCAGCT TCAATCATGG GATCTGTGAC TGGAAACAGG ATAGAGAAGA TGATTTTGAC
1500





TGGAATCCTG CTGATCGAGA TAATGCTATT GGCTTCTATA TGGCAGTTCC GGCCTTGGCA
1560





GGTCACAAGA AAGACATTGG CCGATTGAAA CTTCTCCTAC CTGACCTGCA ACCCCAAAGC
1620





AACTTCTGTT TGCTCTTTGA TTACCGGCTG GCCGGAGACA AAGTCGGGAA ACTTCGAGTG
1680





TTTGTGAAAA ACAGTAACAA TGCCCTGGCA TGGGAGAAGA CCACGAGTGA GGATGAAAAG
1740





TGGAAGACAG GGAAAATTCA GTTGTATCAA GGAACTGATG CTACCAAAAG CATCATTTTT
1800





GAAGCAGAAC GTGGCAAGGG CAAAACCGGC GAAATCGCAG TGGATGGCGT CTTGCTTGTT
1860





TCAGGCTTAT GTCCAGATAG CCTTTTATCT GTGGATGACT GAATGTTACT ATCTTTATAT
1920





TTGACTTTGT ATGTCAGTTC CCTGGTTTTT TTGATATTGC ATCATAGGAC CTCTGGCATT
1980





TTAGAATTAC TAGCTGAAAA ATTGTAATGT ACCAACAGAA ATATTATTGT AAGATGCCTT
2040





TCTTGTATAA GATATGCCAA TATTTGCTTT AAATATCATA TCACTGTATC TTCTCAGTCA
2100





TTTCTGAATC TTTCCACATT ATATTATAAA ATATGGAAAT GTCAGTTTAT CTCCCCTCCT
2160





CAGTATATCT GATTTGTATA AGTAAGTTGA TGAGCTTCTC TCTACAACAT TTCTAGAAAA
2220





TAGAAAAAAA AGCACAGAGA AATGTTTAAC TGTTTGACTC TTATGATACT TCTTGGAAAC
2280





TATGACATCA ARGATAGACT TTTGCCTAAG TGGCTTAGCT GGGTCTTTCA TAGCCAAACT
2340





TGTATATTTA AATTCTTTGT AATAATAATA TCCAAATCAT CAAAAAAAAA AAAAAAAA





SEQ ID NO: 46 Protein sequence


Protein Accession #: NP_056322


1          11         21         31         41         51


|          |          |          |          |          |


MPLPWSLALP LLLSWVAGGF GNAASARHHG LLASARQPGV CHYGTKLACC YGWRRNSKGV
60





CEATCEPGCK FGECVGPNKC RCFPGYTGKT CSQDVNECGM KPRPCQHRCV NTHGSYKCFC
120





LSGHMLMPDA TCVNSRTCAM INCQYSCEDT EEGPQCLCPS SGLRLAPNGR DCLDIDECAS
180





GKVICPYNRR CVNTFGSYYC KCHIGFELQY ISGRYDCIDI NECTMDSHTC SHHANCFNTQ
240





GSFKCKCKQG YKGNGLRCSA IPENSVKEVL RAPGTIKDRI KKLLAHKNSM KKKAKIKNVT
300





PEPTRTPTPK VNLQPFNYEE IVSRGGNSHG GKKGNEEKMK EGLEDEKREE KALKNDIEER
360





SLRGDVFFPK VNEAGEFGLI LVQRKALTSK LEHKDLNISV DCSFNHGICD WKQDREDDFD
420





WNPADRDNAI GFYMAVPALA GHKKDIGRLK LLLPDLQPQS NFCLLFDYRL AGDKVGKLRV
480





FVKNSNNALA WEKTTSEDEK WKTGKIQLYQ GTDATKSIIF EAERGKGKTG EIAVDGVLLV
540





SGLCPDSLLS VDD





SEQ ID NO: 47 DNA sequence


Nucleic Acid Accession #: NM_005046


Coding sequence: 16. .777


1          11         21         31         41         51


|          |          |          |          |          |


GGATTTCCGG GCTCCATGGC AAGATCCCTT CTCCTGCCCC TGCAGATCCT ACTGCTATCC
60





TTAGCCTTGG AAACTGCAGG AGAAGAAGCC CAGGGTGACA AGATTATTGA TGGCGCCCCA
120





TGTGCAAGAG GCTCCCACCC ATGGCAGGTG GCCCTGCTCA GTGGCAATCA GCTCCACTGC
180





GGAGGCGTCC TGGTCAATGA GCGCTGGGTG CTCACTGCCG CCCACTGCAA GATGAATGAG
240





TACACCGTGC ACCTGGGCAG TGATACGCTG GGCCACAGGA GAGCTCAGAG GATCAAGGCC
300





TCGAAGTCAT TCCGCCACCC CGGCTACTCC ACACAGACCC ATGTTAATGA CCTCATGCTC
360





GTGAAGCTCA ATAGCCAGGC CAGGCTGTCA TCCATGGTGA AGAAAGTCAG GCTGCCCTCC
420





CGCTGCGAAC CCCCTGGAAC CACCTGTACT GTCTCCGGCT GGGGCACTAC CACGAGCCCA
480





GATGTGACGT TTCCCTCTGA CCTCATGTGC GTGGATGTCA AGCTCATCTC CCCCCAGGAC
540





TGCACGAAGG TTTACAAGGA CTTACTGGAA AATTCCATGC TGTGCGCTGG CATCCCCGAC
600





TCCAAGAAAA ACGCCTGCAA TGGTGACTCA GGGGGACCGT TGGTGTGCAG AGGTACGCTG
660





CAAGGTCTGG TGTCCTGGGG AACTTTCCCT TGCGGCCAAC CCAATGACCC AGGAGTCTAC
720





ACTCAAGTGT GCAAGTTCAC CAAGTGGATA AATGACACCA TGAAAAAGCA TCGCTAACGC
780





CACACTGAGT TAATTAACTG TGTGCTTCCA ACAGAAAATG CACAGGAGTG AGGACGCCGA
840





TGACCTATGA AGTCAAATTT GACTTTACCT TTCCTCAAAG ATATATTTAA ACCTCATGCC
900





CTGTTGATAA ACCAATCAAA TTGGTAAAGA CCTAAAACCA AAACAAATAA AGAAACACAA
960





AACCCTCAA





SEQ ID NO: 48 Protein sequence


Protein Accession #: NP_005037


1          11         21         31         41         51


|          |          |          |          |          |


MARSLLLPLQ ILLLSLALET AGEEAQGDKI IDGAPCARGS NPWQVALLSG NQLNCGGVLV
60





NESWVLTAAH CKMNEYTVHL GSDTLGDRRA QRIKASKSFR NPGYSTQTHV NDLMLVKLNS
120





QARLSSMVKK VRLPSRCEPP GTTCTVSGWG TTTSPDVTEP SDLMCVDVKL ISPQDCTKVY
180





KDLLENSMLC AGIPDSKKNA CNGDSGGPLV CRGTLQGLVS WGTFPCGQPN DPGVYTQVCK
240





FTKWINDTMK KHE





SEQ ID NO: 49 DNA sequence


Nucleic Acid Accession #: NM_003466.1


Coding sequence: 11 1363


1          11         21         31         41         51


|          |          |          |          |          |


GAATTCGGCG ATGCCICACA ACTCCATCAG ATCTGGCCAT GGAGGGCTGA ACCAGCTGGG
60





AGGGGCCTTT GTGAATGGCA GACCTCTGCC GGAAGTGGTC CGCCACCGCA TCGTAGACCT
120





GGCCCACCAG GGTGTAAGGC CCTGCGACAT CTCTCGCCAG CTCCGCGTCA GCCATGGTTG
180





CGTCAGCAAG ATCCTTGGCA GGTACTACGA GACTGGCAGC ATCCGGCCTG GAGTGATAGG
240





GGGCTCCAAG CCCAAGGTGG CCACCCCCAA GGTGGTGGAG AAGATTGGGG ACTACAAACG
300





CCAGAACCCT ACCATGTTTG CCTGGGAGAT CCGAGACCGG CTCCTGGCTG AGGGCGTCTG
360





TGACAATGAC ACTGTGCCCA GTGTCAGCTC CATTAATAGA ATCATCCGGA CCAAAGTGCA
420





GCAACCATTC AACCTCCCTA TGGACAGCTG CGTGGCCACC AAGTCCCTGA GTCCCGGACA
480





CACGCTGATC CCCAGCTCAG CTGTAACTCC CCCGGAGTCA CCCCAGTCGG ATTCCCTGGG
540





CTCCACCTAC TCCATCAATG GGCTCCTGGG CATCGCTCAG CCTGGCAGCG ACAAGAGGAA
600





AATGGATGAC AGTGATCAGG ATAGCTGCCG ACTAAGCATT GACTCACAGA GCACCACCAG
660





CGGACCCCGA AAGCACCTTC GCACGGATGC CTTCAGCCAG CACCACCTCG AGCCGCTCGA
720





GTGCCCATTT GAGCGGCAGC ACTACCCAGA GGCCTATGCC TCCCCCAGCC ACACCAAAGG
780





CGAGCAGGGC CTCTACCCGC TGCCCTTGCT CAACAGCACC CTGGACGACG GGAAGGCCAC
840





CCTGACCCCT TCCAACACGC CACTGGGGCG CAACCTCTCG ACTCACCAGA CCTACCCCGT
900





GGTGGCAGAT CCTCACTCAC CCTTCGCCAT AAAGCAGGAA ACCCCCGAGG TGTCCAGTTC
960





TAGCTCCACC CCTTCCTCTT TATCTAGCTC CGCCTTTTTG GATCTGCAGC AAGTCGGCTC
1020





CGGGGTCCCG CCCTTCAATG CCTTTCCCCA TGCTGCCTCC GTGTACGGGC AGTTCACGGG
1080





CCAGGCCCTC CTCTCAGGGC GAGAGATGGT GGGGCCCACG CTGCCCGGAT ACCCACCCCA
1140





CATCCCCACC ACCGGACAGG GCAGCTATGC CTCCTCTGCC ATCGCAGGCA TGGTGGGAGG
1200





AAGTGAATAC TCTGGCAATG CCTATGGCCA CACCCCCTAC TCCTCCTACA GCGAGGCCTG
1260





GCGCTTCCCC AACTCCAGCT TGCTGAGTTC CCCATATTAT TACAGTTCCA CATCAAGGCC
1320





GAGTGCACCG CCCACCACTG CCACGGCCTT TGACCATCTG TAGTTGAAGC TT





SEQ ID NO: 50 Protein sequence


Protein Accession #: NP_003457


1          11         21         31         41         51


|          |          |          |          |          |


MPHNSIRSGH GGLNGLGGAF VNGRPLPEVV RQRIVDLAHQ GVRPCDISRQ LRVSNGCVSK
60





ILGRYYETGS IRPGVIGGSK PKVATPEVVE KIGDYKRQNP TMFAWEIRDR LLAEGVCDND
120





TVPSVSSINR IIRTKVQQPF NLPMGSCVAT KSLSPGHTLI PSSAVTPPES PQSDSLGSTY
180





SINGLLGIAQ PGSDKRKMDD SDQDSCRLSI DSQSSSSGPR KHLRTDAFSQ HHLEPLECPF
240





ERQNYPEAYA SPSHTKGEQG LYPLPLLNST LDDGKATLTP SNTPLGRNLS TNQTYPVVAD
300





PNSPPAIKQE TPEVSSSSST PSSLSSSAFL DLQQVGSGVP PFNAFPHAAS VYGQFTGQAL
360





LSGREMVGPT LPGYPPHIPT SGQGSYASSA IAGMVAGSEY SGNAYGHTPY SSYSEAWRFP
420





NSSLLSSPYY YSSTSRPSAP PTTATAFDHL





SEQ ID NO: 51 DNA sequence


Nucleic Acid Accession #: NM_013962


Coding sequence: 161. 1357


1          11         21         31         41         51


|          |          |          |          |          |


TTCAGAAGGA GGAGAGACAC CGGGCCCAGG GCACCCTCGC GGGCGGGCGG ACCCAAGCAG
60





TGAGGGCCTG CAGCCGGCCG GCCAGGGCAG CGGCAGGCGC GGCCCGGACC TACGGGAGGA
120





AGCCCCGAGC CCTCGGCGGG CTGCGAGCGA CTCCCCGGCG ATGCCTCACA ACTCCATCAG
180





ATCTGGCCAT GGAGGGCTGA ACCAGCTGGG AGOGGCCTTT GTGAATGGCA GACCTCTGCC
240





GGAAGTGGTC CGCCAGCGCA TCGTAGACCT GGCCCACCAG GGTGTAAGGC CCTGCGACAT
300





CTCTCGCCAG CTCCGCGTCA GCCATGGCTG CGTCAGCAAG ATCCTTGGCA GGTACTACGA
360





GACTGGCAGG ATCCGGCCTG GAGTGATAGG GGGCTCCAAG CCCAAGGTGG CCACCCCCAA
420





GGTGGTGGAG AAGATTGGGG ACTACAAACG CCAGAACCCT ACCATGTTTG CCTGGGAGAT
480





CCGAGACCGG CTCCTGGCTG AGGGCGTCTG TGACAATGAC ACTGTGCCCA GTGTCAGCTC
540





CATTAATAGA ATCATCCGGA CCAAAGTGCA GCAACCATTC AACCTCCCTA TGGACAGCTG
600





CGTGGCCACC AAGTCCCTGA GTCCCGGACA CACGCTGATC CCCAGCTCAG CTGTAACTCC
660





CCCGGAGTCA CCCCAGTCGG ATTCCCTGGG CTCCACCTAC TCCATCAATG GGCTCCTGGG
720





CATCGCTCAG CCTGGCAGCG ACAAGAGGAA AATGGATGAC AGTGATCAGG ATAGCTGCCG
780





ACTAAGCATT GACTCACAGA GCAGCAGCAG CGGACCCCGA AAGCACCTTC GCACGGATGC
840





CTTCAGCCAG CACCACCTCG AGCCGCTCGA GTGCCCATTT GAGCGGCAGC ACTACCCAGA
900





GGCCTATGCC TCCCCCAGCC ACACCAAAGG CGACCAGGGC CTCTACCCGC TGCCCTTGCT
960





CAACAGCACC CTGGACGACG GGAAGGCCAC CCTGACCCCT TCCAACACGC CACTGGGGCG
1020





CAACCTCTCG ACTCACCAGA CCTACCCCGT GGTGGCAGCT CCGCCCTTTT GGATCTGCAG
1080





CAAGTCGGCT CCGGGGTCCC GCCCTTCAAT GCCTTTCCCC ATGCTGCCTC CGTGTACGGG
1140





CAGTTCACGG GCCAGGCCCT CCTCTCAGGG CGAGAGATGG TGGGGCCCAC GCTGCCCGGA
1200





TACCCACCCC ACATGCCCAC CAGCGGACAG GGCAGCTATG CCTCCTCTGC CATCGCAGGC
1260





ATGGTGGCAG GAAGTGAATA CTCTGGCAAT GCCTATGGCC ACACCCCCTA CTCCTCCTAC
1320





AGCGAGGCCT GGGGCTTCCC CAACTCCAGC TTGCTGAGTT CCCCATATTA TTACAGTTCC
1380





ACATCAAGGC CGAGTGCACC GCCCACCACT GCCACGGCCT TTGACCATCT GTAGTTGCCA
1440





TGGGGACAGT G





SEQ ID NO: 52 Protein sequence


Protein Accession #: NP_039246


1          11         21         31         41         51


|          |          |          |          |          |


MPHNSIRSGH GGLNQLGGAF VNGRPLPEVV RQRIVDLAHQ GVRPCDISRQ LRVSHGCVSK
60





ILGRYYETGS IRPGVIGGSK PKVATPKVVE KIGDYKRQNP TMFAWEIRDR LLAEGVCDND
120





TVPSVSSINR IIRTKVQQPF NLPMDSCVAT KSLSPGHTLI PSSAVTPPES PQSDSLGSTY
160





SINGLLGIAQ PGSDKRKMDD SDQDSCRLSI DSQSSSSGPR KHLRTDAPSQ HHLEPLECPF
240





ERQHYPEAYA SPSHTKGEQG LYPLPLLNST LDDGKATLTP SNTPLGRNLS TNQTYPVVAA
300





PPFWICSKSA PGSRPSMPFP MLPPCTGSSR ARPSSQGERW WGPRCPDTHP TSPPADRAAM
360





PPLPSQAWWQ EVNTLAMPMA TPPTPPTARP GASPTPAC





SEQ ID NO: 53 DNA sequence


Nucleic Acid Accession #: NN_012427


Coding sequence: 43. .924


1          11         21         31         41         51


|          |          |          |          |          |


CTTGTGGTTC CTCTCTACTT GGGGAAATCA GGTGCAGCGG CCATGGCTAC AGCAAGACCC
60





CCCTGGATGT GGGTGCTCTG TGCTCTGATC ACAGCCTTGC TTCTGGGGGT CACAGAGCAT
120





GTTCTCGCCA ACAATGATGT TTCCTGTGAC CACCCCTCTA ACACCGTGCC CTCTGGGAGC
180





AACCAGGACC TGGGAGCTGG GGCCGGGGAA GACGCCCGGT CGGATGACAG CAGCAGCCGC
240





ATCATCAATG GATCCGACTG CGATATGCAC ACCCAGCCGT GGCAGGCCGC GCTGTTGCTA
300





AGGCCCAACC AGCTCTACTG CGGGGCGGTG TTGGTGCATC CACAGTGGCT GCTCACGGCC
360





GCCCACTGCA GGAAGAAAGT TTTCAGAGTC CGTCTCGGCC ACTACTCCCT GTCACCAGTT
420





TATGAATCTG GGCAGCAGAT GTTCCAGGGG GTCAAATCCA TCCCCCACCC TGGCTACTCC
480





CACCCTGGCC ACTCTAACGA CCTCATGCTC ATCAAACTGA ACAGAAGAAT TCGTCCCACT
540





AAAGATGTCA GACCCATCAA CGTCTCCTCT CATTGTCCCT CTGCTGGGAC AAAGTGCTTG
600





GTGTCTGGCT GGGGGACAAC CAAGAGCCCC CAAGTGCACT TCCCTAAGGT CCTCCAGTGC
660





TTGAATATCA GCGTGCTAAG TCAGAAAAGG TGCGAGGATG CTTACCCGAG ACAGATAGAT
720





GACACCATGT TCTGCGCCGG TGACAAAGCA GGTAGAGACT CCTGCCAGGG TGATTCTGGG
780





GGGCCTGTGG TCTGCAATGG CTCCCTGCAG GGACTCGTGT CCTGGGGAGA TTACCCTTGT
640





GCCCGGCCCA ACAGACCGGG TGTCTACACG AACCTCTGCA AGTTCACCAA GTGGATCCAG
900





GAAACCATCC AGGCCAACTC CTGAGTCATC CCAGGACTCA GCACACCGGC ATCCCCACCT
960





GCTGCAGGGA CAGCCCTGAC ACTCCTTTCA GACCCTCATT CCTTCCCAGA GATGTTGAGA
1020





ATGTTCATCT CTCCAGCCCC TGACCCCATG TCTCCTGGAC TCAGGGTCTG CTTCCCCCAC
1080





ATTGGGCTGA CCGTGTCTCT CTAGTTGAAC CCTGGGAACA ATTTCCAAAA CTGTCCAGGG
1140





CGGGGGTTGC GTCTCAATCT CCCTGGGGCA CTTTCATCCT CAAGCTCAGG GCCCATCCCT
1200





TCTCTGCAGC TCTGACCCAA ATTTAGTCCC AGAAATAAAC TGAGAAGTGG AAAAAAAAAA





SEQ ID NO: 54 Protein sequence


Protein Accession #: NP_036559


1          11         21         31         41         51


|          |          |          |          |          |


MATARPPWMW VLCALITALL LGVTENVLAN NDVSCDHPSN TVPSGSNQDL GAGAGEDARS
60





DDSSSRIING SDCDMNTQPW QAALLLRPNQ LYCGAVLVHP QWLLTAAHCR KKVFRVRLGH
120





YSLSPVYESG QQMFQGVKSI PHPGYSHPGH SNDLMLIKLN RRIRPTKDVR PINVSSHCPS
180





AGTKCLVSGW GTTKSPQVHF PKVLQCLNIS VLSQKRCEDA YPRQIDDTMF CAGDKAGRDS
240





CQGDSGGPVV CNGSLQGLVS WGDYPCARPN RPGVYTNLCK FTKWIQETIQ ANS





SEQ ID NO: 55 DNA sequence


Nucleic Acid Accession #: NM_002214


Coding sequence: 681. .2990


1          11         21         31         41         51


|          |          |          |          |          |


CCCAGAGCCG CCTCCCCCTG TTGCTGGCAT CCCGAGCTTC CTCCCTTGCC AGCCAGGACG
60





CTGCCGACTT GTCTTTGCCC GCTGCTCCGC AGACGGGGCT GCAAAGCTGC AACTAATGGT
120





GTTGGCCTCC CTGCCCACCT GTGGAAGCAA CTGCGCTGAT TGATGCGCCA CAGACTTTTT
180





TCCCCTCGAC CTCGCCGGCG TACCCTCCCA CAGATCCAGC ATCACCCAGT GAATGTACAT
240





TAGGGTGGTT TCCCCCCCAG CTTCGGGCTT TGTTTGGGTT TCATTGTGTT TGGCTCTTCG
300





CTAAGCTGAT TTATGCAGCA GAAGCCCCAC CGGCTGGAGA GAAACAAAAG CTCTTTTCTT
360





TGTCCCGGAG CAGGCTGCGG AGCCCTTGCA GAGCCCTCTC TCCAGTCGCC GCCGGGCCCT
420





TGGCCGTCGA AGGAGGTGCT TCTCGCGGAG ACCGCGGGAC CCGCCGTGCC GAGCCGGGAG
480





GGCCGTAGGG GCCCTGAGAT GCCGAGCGGT GCCCGGGCCC GCTTACCTGC ACCGCTTGCT
540





CCGAGCCGCG GGGTCCGCCT GCTAGGCCTG CGGAAAACGT CCTAGCGACA CTCGCCCGCG
600





GGCCCCGAGG TCGCCCGGGA GGCCGAGCCC GCGTCCGGAA GGCAGCCAGG CGGCGGGCGC
660





GGGGCGGGCT GTTTTGCATT ATGTGCGGCT CGGCCCTGGC TTTTTTTACC GCTGCATTTG
720





TCTGCCTGCA AAACGACCGG CGAGGTCCCG CCTCGTTCCT CTGGGCAGCC TGGGTGTTTT
780





CACTTGTTCT TGGACTGGGC CAAGGTGAAG ACAATAGATG TGCATCTTCA AATGCAGCAT
840





CCTGTGCCAG GTGCCTTGCG CTGGGTCCAG AATGTGGATG GTGTGTTCAA GAGGATTTCA
900





TTTCAGGPGG ATCAAGAAGT GAACGTTGTG ATATTGTTTC CAATTTAATA AGCAAAGGCT
960





GCTCAGTTGA TTCAATAGAA TACCCATCTG TGCATGTTAT AATACCCACT GAAAATGAAA
1020





TTAATACCCA GGTGACACCA GGAGAAGTGT CTATCCAGCT GCGTCCAGGA GCCGAAGCTA
1080





ATTTTATGCT GAAAGTTCAT CCTCTGAAGA AATATCCTGT GGATCTTTAT TATCTTGTTG
1140





ATGTCTCAGC ATCAATGCAC AATAATATAG AAAAATTAAA TTCCGTTGGA AACGATTTAT
1200





CTAGAAAAAT GGCATTTTTC TCCCGTGACT TTCGTCTTGG ATTTGGCTCA TACGTTGATA
1260





AAACAGTTTC ACCATACATT AGCATCCACC CCGAAAGGAT TCATAATCAA TGCAGTGACT
1320





ACAATTTAGA CTGCATGCCT CCCCATGGAT ACATCCATGT GCTGTCTTTG ACAGAGAACA
1380





TCACTGAGTT TGAGAAAGCA GTTCATAGAC AGAAGATCTC TGGAAACATA GATACACCAG
1440





AAGGAGGTTT TGACGCCATG CTTCAGGCAG CTGTCTGTGA AAGTCATATC GGATGGCGAA
1500





AAGAGGCTAA AAGATTGCTG CTGGTGATGA CAGATCAGAC GTCTCATCTC GCTCTTGATA
1560





GCAAATTGGC AGGCATAGTG CTGCCCAATG ACGGAAACTC TCATCTGAAA AACAACGTCT
1620





ACGTCAAATC GACAACCATG GAACACCCCT CACTAGGCCA ACTTTCAGAG AAATTAATAG
2660





ACAACAACAT TAATGTCATC TTTGCAGTTC AAGGAAAACA ATTTCATTGG TATAAGGATC
1740





TTCTACCCCT CTTGCCAGGC ACCATTGCTG GTGAAATAGA ATCAAAGGCT GGAAACCTCA
1800





ATAATTTGGT AGTGGAAGCC TATCAGAAGC TCATTTCAGA ACTGAAAGTT CAGGTGGAAA
1860





ACCAGGTACA AGGCATCTAT TTTAACATTA CCGCCATCTG TCCAGATGGG TCCAGAAAGC
1920





CAGGCATGGA AGGATGCAGA AACGTGACGA GCAATGATGA AGTTCTTTTC AATGTAACAG
1980





TTACAATGAA AAAATGTGAT GTCACAGGAG CAAAAAACTA TGCAATAATC AAACCTATTG
2040





GTTTTAATGA AACCGCTAAA ATTCATATAC ACAGAAACTG CAGCTGTCAG TGTGAGGACA
2100





ACAGAGGACC TAAAGGAAAG TGTGTAGATG AAACTTTTCT AGATTCCAAG TGTTTCCAGT
2160





GTCATGAGAA TAAATGTCAT TTTGATGAAG ATCAGTTTTC TTCTGAGAGT TGCAAGTCAC
2220





ACAAGGATCA GCCTGTTTGC AGTGGTCGAG GAGTTTGTGT TTGTGGGAAA TGTTCATGTC
2280





ACAAAATTAA GCTTGGAAAA GTGTATGGAA AATACTGTGA AAAGGATGAC TTTTCTTGTC
2340





CATATCACCA TGGAAATCTG TGTCCTGGGC ATGGAGAGTG TGAAGCAGGC AGATGCCAAT
2400





GCTTCAGTGG CTGGGAAGGT GATCCATGCC AGTCCCCTTC AGCAGCAGCC CAGCACTGTG
2460





TCAATTCAAA GGGCCAAGTG TGCAGTGGAA GAGGCACGTG TGTGTGTGGA AGGTGTGAGT
2520





GCACCGATCC CAGGAGCATC GGCCGCTTCT GTGAACACTG CCCCACCTGT TATACACCGT
2580





GCAAGGAAAA CTGGAATTGT ATGCAATGCC TTCACCCTCA CAATTTGTCT CAGGCTATAC
2640





TTGATCAGTG CAAAACCTCA TGTGCTCTCA TGGAACAACA GCATTATGTC GACCAAACTT
2700





CAGAATGTTT CTCCAGCCCA AGCTACTTGA GAATATTTTT CATCATTTTC ATAGTTACAT
2760





TCTTGATTGG GTTGCTTAAA GTCCTGATCA TTAGACAGGT GATACTACAA TGGAATAGTA
2820





ATAAAATTAA GTCCTCATCA GATTACAGAG TGTCAGCCTC AAAAAAGGAT AAGTTGATTC
2880





TGCAAAGTGT TTGCACAAGA GCAGTCACCT ACCGACGTGA GAAGCCTGAA GAAATAAAAA
2940





TGGATATCAG CAAATTAAAT GCTCATGAAA CTTTCAGGTG CAACTTCTAA AAAAAGATTT
3000





TTAAACACTT AATGGGAAAC TGGAATTGTP AATAATTGCT CCTAAAGATT ATAATTTTAA
3060





AAGTCACAGG AGGAGACAAA TTGCTCACGG TGATGCCACT TGCTGGTTGT ACACTCGAAC
3120





GAAGACTGAC AAGTATCCTC ATCATGATGT GACTCACATA GCTGCTGACT TTTTCAGAGA
3180





AAAATGTGTC TTACTACTGT TTGAGACTAG TGTCGTTGTA GCACTTTACT GTAATATATA
3240





ACTTATTTAG ATCAGCATAG AATGTAGATC CTCTGAAGAG CACTGATTAC ACTTTACAGG
3300





TACCTGTTAT CCCTACGCTT CCCAGAGAGA ACAATGCTGT GAGAGAGTTT AGCATTGTGT
3360





CACTACAAGG GTACAGTAAT CCCTGCACTG GACATGTGAG GAAAAAAATA ATCTGGCAAG
3420





TATATTCTAA GGTTGCCAAA CACTTCAACA GTTGGTGGTT GAATAGACAA GAACAGCTAG
3480





ATGAATAAAT GATTCGTGTT TCACTCTTTC AAGAGGTGAA CAGATACAAC CTTAATCTTA
3540





AAAGATTATT GCTTTTTAAA GTGTGTAGTT TTATGCATGT GTGTTTATGG TTTGCTTATT
3600





TTTGCAAGAT GGATACTAAT TCCAGCATTC TCTCCTCTTT GCCTTTATGT TTTGTTTTCT
3660





TTTTTACAGG ATAAGTTTAT GTATGTCACA GATGACTGGA TTAATTAAGT GCTAAGTTAC
3720





TACTGCCATA AAAAACTAAT AATACAATGT CACTTTATCA GAATACTAGT TTTAAAAGCT
3780





GAATGTTAA





SEQ ID NO: 56 Protean sequence


Protein Accession #: NP_002205


1          11         21         31         41         51


|          |          |          |          |          |


MCGSALAFFT AAFVCLQNDR RGPASFLWAA WVFSLVLGLG QGEDNRCASS NAASCARCLA
60





LGPECGWCVQ EDFISGGSRS ERCDIVSNLI SKGCSVDSIE YPSVHVIIPT ENEINTQVTP
120





GEVSIQLRPG AEANFMLKVH PLKKYPVDLY YLVDVSASMH NNIEKLNSVG NDLSRKMAFF
180





SRDFRLGFGS YVDKTVSPYI SIHPERIHNQ CSDYNLDCMP PHGYIHVLSL TENITEFEKA
240





VHRQKISGNI DTPEGGFDAM LQAAVCESHI GWRKEAKRLL LVMTDQTSHL ALDSKLAGIV
300





VPNDGNCHLK NNVYVKSTTM EHPSLGQLSE KLIDNNINVI FAVQGKQFHW YKDLLPLLPG
360





TIAGEIESKA ANLNNLVVEA YQKLISEVKV QVENQVQGIY FNITAICPDG SRKPGMEGCR
420





NVTSNDEVLF NVTVTMKKCD VTGGKNYAII KPIGFNETAK IHIHRNCSCQ CEDNRGPKGK
480





CVDETPLDSK CFQCDENKCH FDEDQFSSES CKSHKDQPVC SGRGVCVCGK CSCHKIKLGK
540





VYGKYCEKDD FSCPYHHGNL CAGHGECEAG RCQCFSGWEG DRCQCPSAAA QHCVNSKGQV
600





CSGRGTCVCG RCECTDPRSI GRFCEHCPTC YTACKENWNC MQCLHPHNLS QAILDQCKTS
660





CALMEQQHYV DQTSECFSSP SYLRIFFIIF IVTFLIGLLK VLIIRQVILQ WNSNKIKSSS
720





DYRVSASKKD KLILQSVCTR AVTYRREKPE EIKMDISKLN AHETFRCNF





SEQ ID NO: 57 DNA sequence


Nucleic Acid Accession #: NM_001719


Coding sequence: 123. 1418


1          11         21         31         41         51


|          |          |          |          |          |


GGGCGCAGCG GGGCCCGTCT GCAGCAAGTG ACCGACGGGG GGGAGGGCCG CCTGCCCCCT
60





CTGCCACCTG GGGGGGTGCG GGCCCGGAGC CCGGAGCCCG GGTACCGCGT AGAGCCGGCG
120





CGATGCACGT GCGCTCACTG CGAGCTGCGG CGCCGCACAG CTTCGTGGCG CTCTGGGCAC
180





CCCTGTTCCT GCTGCGCTCC GCCCTGGCCG ACTTCAGCCT GGACAACGAG GTGCACTCGA
240





GCTTCATCCA CCGGCGCCTC CGCAGCCAGG ACCGGCGGGA GATGCAGCGC GAGATCCTCT
300





CCATTTTGGG CTTGCCCCAC CGCCCGCGCC CGCACCTCCA GGGCAAGCAC AACTCGGCAC
360





CCATGTTCAT GCTGGACCTG TACAACGCCA TGGCGGTGGA GGAGGGCGGC GGGCCCGGCG
420





GCCAGGGCTT CTCCTACCCC TACAAGGCCG TCTTCAGTAC CCAGGGCCCC CCTCTGGCCA
480





GCCTGCAAGA TAGCCATTTC CTCACCGACG CCGACATGGT CATGAGCTTC GTCAACCTCG
540





TGGAACATGA CAAGGAATTC TTCCACCCAC GCTACCACCA TCGAGAGTTC CGGTTTGATC
600





TTTCCAAGAT CCCAGAAGGG GAAGCTGTCA CGGCAGCCGA ATTCCGGATC TACAAGGACT
660





ACATCCGGGA ACGCTTCGAC AATGAGACGT TCCGGATCAG CGTTTATCAG GTGCTCCAGG
720





AGCACTTGGG CAGGGAATCG GATCTCTTCC TGCTCGACAG CCGTACCCTC TGGGCCTCGG
780





AGGAGGGCTG GCTGGTGTTT GACATCACAG CCACCAGCAA CCACTGGGTG GTCAATCCGC
840





GGCACAACCT GGGCCTGCAG CTCTCGGTGG AGACGCTGGA TGGGCAGAGC ATCAACCCCA
900





AGTTGGCGGG CCTGATTGGG CGGCACGGGC CCCAGAACAA GCAGCCCTTC ATGGTGGCTT
960





TCTTCAAGGC CACGGAGGTC CACTTCCGCA GCATCCGGTC CACGGGGAGC AAACAGCGCA
1020





GCCAGAACCG CTCCAAGACG CCCAAGAACC AGGAAGCCCT GCGGATGGCC AACGTGGCAG
1080





AGAACAGCAG CAGGGACCAG AGGCAGGCCT GTAAGAAGCA CGAGCTGTAT GTCAGCTTCC
1140





GAGACCTGGG CTGGCAGGAC TGCATCATCG CGCCTGAAGG CTACGCCGCC TACTACTGTG
1200





AGGGGGAGTG TGCCTTCCCT CTGAACTCCT ACATGAACGC CACCAACCAC GCCATCGTGC
1260





AGACGCTGGT CCACTTCATC AACCCGGAAA CGGTGCCCAA GCCCTGCTGT GCGCCCACGC
1320





AGCTCAATGC CATCTCCGTC CTCTACTTCG ATGACAGCTC CAACGTCATC CTGAAGAAAT
1380





ACAGAAACAT GGTGGTCCGG GCCTGTGGCT GCCACTAGCT CCTCCGAGAA TTCAGACCCT
1440





TTGGGGCCAA GTTTTTCTGG ATCCTCCATT GCTCGCCTTG GCCAGGAACC AGCAGACCAA
1500





CTGCCTTTTG TGAGACCTTC CCCTCCCTAT CCCCAACTTT AAAGGTGTGA GAGTATTAGG
1560





AAACATGAGC AGCATATGGC TTTTGATCAG TTTTTCAGTG GCAGCATCCA ATGAACAAGA
1620





TCCTACAAGC TGTGCAGGCA AAACCTAGCA GGAAAAAAAA ACAACGCATA AAGAAAAATG
1680





GCCGGGCCAG GTCATTGGCT GGGAAGTCTC AGCCATGCAC GGACTCGTTT CCAGAGGTAA
1740





TTATGAGCGC CTACCAGCCA GGCCACCCAG CCGTGGGAGG AAGGGGGCGT GGCAAGGGGT
1800





GGGCACATTG GTGTCTGTGC GAAAGGAAAA TTGACCCGGA AGTTCCTGTA ATAAATGTCA
1860





CAATAAAACG AATGAATG





SEQ ID NO: 58 Protein sequence


Protein Accession #: NP_001710


1          11         21         31         41         51


|          |          |          |          |          |


MNVRSLRAAA PHSFVALWAP LFLLESALAD FSLDNEVNSS FIHRRLRSQE RREMQREILS
60





ILGLPHRPRP HLQGKHNSAP MFMLDLYNAM AVEEGGGPGG QGFSYPYKAV FSTQGPPLAS
120





LQDSHFLTDA DMVMSFVNLV EHDKEFFHPR YHHREFRFDL SKIPEGEAVT AAEFRIYKDY
180





IREREDNETF RISVYQVLQE HLGRESDLFL LDSRTLWASE EGWLVFDITA TSNHWVVNPR
240





HNLGLQLSVE TLDGQSINPK LAGLIGRHGP QNKQPFMVAF FKATEVHFRS IRSTGSKQRS
300





QNRSKTPKNQ EALRMANVAE NSSSDQRQAC KKHELYVSFR DLGWQDWIIA PEGYAAYYCE
360





GECAFPLNSY MNATNHAIVQ TLVHFINPET VPKPCCAPTQ LNAISVLYFD DSSNVILKKY
420





RNMVVRACGC H





SEQ ID NO: 59 DNA sequence


Nucleic Acid Accession #: NM_002821


Codinq sequence: 150. 3362


1          11         21         31         41         51


|          |          |          |          |          |


AACTCCCGCC TCGGGACGCC TCGGGGTCGG GCTCCGGCTG CGGCTGCTGC TGCGGCGCCC
60





GCGCTCCGGT GCGTCCGCCT CCTGTGCCCG CCGCGGAGCA GTCTGCGGCC CGCCGTGCGC
120





CCTCAGCTCC TTTTCCTGAG CCCGCCGCGA TGGGAGCTGC GCGGGGATCC CCGGCCAGAC
180





CCCGCCGGTT GCCTCTGCTC AGCGTCCTGC TGCTGCCGCT GCTGGGCGGT ACCCAGACAG
240





CCATTGTCTT CATCAAGCAG CCGTCCTCCC AGGATGCACT GCAGGGGCGC CGGGCGCTGC
300





TTCGCTGTGA GGTTGAGGCT CCGGGCCCGG TACATGTGTA CTGGCTGCTC GATGGGGCCC
360





CTGTCCAGGA CACGGAGCGG CGTTTCGCCC AGGGCAGCAG CCTGAGCTTT GCAGCTGTGG
420





ACCGGCTGCA GGACTCTGGC ACCTTCCAGT GTGTGGCTCG GGATGATGTC ACTGGAGAAG
480





AAGCCCGCAG TGCCAACGCC TCCTTCAACA TCAAATGGAT TGAGGCAGGT CCTGTGGTCC
540





TGAAGCATCC AGCCTCGGAA GCTGAGATCC AGCCACAGAC CCAGGTCACA CTTCGTTGCC
600





ACATTGATGG GCACCCTCGG CCCACCTACC AATGGTTCCG AGATGGGACC CCCCTTTCTG
660





ATGGTCAGAG CAACCACACA GTCAGCAGCA AGGAGCGGAA CCTGACGCTC CGGCCAGCTG
720





GTCCTGAGCA TAGTGGGCTG TATTCCTGCT GCGCCCACAG TGCTTTTGGC CAGGCTTGCA
780





GCAGCCAGAA CTTCACCTTG AGCATTGCTG ATGAAAGCTT TGCCAGGGTG GTGCTGGCAC
840





CCCAGGACGT GGTAGTAGCG AGGTATGAGG AGGCCATGTT CCATTGCCAG TTCTCAGCCC
900





AGCCACCCCC GAGCCTGCAG TGGCTCTTTG AGGATGAGAC TCCCATCACT AACCGCAGTC
960





GCCCCCCACA CCTCCGCAGA GCCACAGTGT TTGCCAACGG GTCTCTGCTG CTGACCCAGG
1020





TCCGGCCACG CAATGCAGGG ATCTACCGCT GCATTGGCCA GGGGCAGAGG GGCCCACCCA
1080





TCATCCTGGA AGCCACACTT CACCTAGCAG AGATTGAAGA CATGCCGCTA TTTGAGCCAC
1140





GGGTGTTTAC AGCTGGCAGC GAGGACCGTG TGACCTGCCT TCCCCCCAAG GGTCTGCCAG
1200





AGCCCAGCGT GTGGTGGGAG CACGCGGGAG TCCGGCTGCC CACCCATGGC AGGGTCTACC
1260





AGAAGGGCCA CGAGCTGGTG TTGGCCAATA TTGCTGAAAG TGATGCTGGT GTCTACACCT
1320





GCCACGCGGC CAACCTGGCT GGTCAGCGGA GACAGGATGT CAACATCACT GTGGCCACTG
2380





TGCCCTCCTG GCTGAAGAAG CCCCAAGACA GCCAGCTGGA GGAGGGCAAA CCCGGCTACT
1440





TGGATTGCCT GACCCAGGCC ACACCAAAAC CTACAGTTGT CTGGTACAGA AACCAGATGC
1500





TCATCTCAGA GGACTCACGG TTCGAGGTCT TCAAGAATGG GACCTTGCGC ATCAACAGCG
1560





TGGAGGTGTA TGATGGGACA TGGTACCGTT GTATGAGCAG CACCCCAGCC GGCAGCATCG
1620





AGGCGCAAGC CCGTGTCCAA GTGCTGGAAA AGCTCAAGTT CACACCACCA CCCCAGCCAC
1680





AGCAGTGCAT GGAGTTTGAC AAGGAGGCCA CGGTGCCCTG TTCAGCCACA CGCCGAGAGA
1740





AGCCCACTAT TAACTGGGAA CGGGCAGATG GGAGCAGCCT CCCAGAGTGG GTGACAGACA
1800





ACGCTGGGAC CCTGCATTTT CCCCGGGTCA CTCGAGATGA CGCTGGCAAC TACACTTGCA
1860





TTGCCTCCAA CGGGCCGCAG GGCCAGATTC GTGCCCATGT CCAGCTCACT GTGGCAGTTT
1920





TTATCACCTT CAAAGTGGAA CCAGAGCGTA CGACTGTGTA CCAGGGCCAC ACAGCCCTAC
1980





TGCAGTGCGA CGCCCAGGGG GACCCCAAGC CGCTGATTCA GTGGAAAGGC AAGGACCGCA
2040





TCCTGGACCC CACCAAGCTG GGACCGAGGA TGCACATCTT CCAGAATGGC TCCCTGGTGA
2100





TCCATGACGT GGCCCCTGAG GACTCAGGCC GCTACACCTG CATTGCAGGC AACAGCTGCA
2160





ACATCAAGCA CACGGAGGCC CCCCTCTATG TCGTGGACAA GCCTGTGCCG GAGGAGTCGG
2220





AGGGCCCTGG CAGCCCTCCC CCCTACAAGA TGATCCAGAC CATTGGGTTG TCGGTGGGTG
2280





CCGCTGTGGC CTACATCATT GCCGTGCTGG GCCTCATGTT CTACTGCAAG AAGCGCTGCA
2340





AAGCCAAGCG GCTGCAGAAG CAGCCCGAGG GCGAGGAGCC AGAGATGGAA TGCCTCAACG
2400





GAGGGCCTTT GCAGAACGGG CAGCCCTCAG CAGAGATCCA AGAAGAAGTG GCCTTGACCA
2460





GCTTGGGCTC CGGCCCCGCG GCCACCAACA AACGCCACAG CACAAGTGAT AAGATGCACT
2520





TCCCACGGTC TAGCCTGCAG CCCATCACCA CGCTGGGGAA GAGTGAGTTT GGGGAGGTGT
2560





TCCTGGCAAA GGCTCAGGGC TTGGAGGAGG GAGTGGCAGA GACCCTGGTA CTTGTGAAGA
2640





GCCTGCAGAC GAAGGATGAG CAGCAGCAGC TGGACTTCCG GAGGGAGTTG GAGATGTTTG
2700





GGAAGCTGAA CCACGCCAAC GTGGTGCGGC TCCTGGGGCT GTGCCGGGAG GCTGAGCCCC
2760





ACTACATGGT GCTGGAATAT GTGGATCTGG GAGACCTCAA GCAGTTCCTG AGGATTTCCA
2820





AGAGCAAGGA TGAAAAATTG AAGTCACAGC CCCTCAGCAC CAAGCAGAAG GTGGCCCTAT
2880





GCACCCAGGT AGCCCTGGGC ATGGAGCACC TGTCCAACAA CCGCTTTGTG CATAAGGACT
2940





TGGCTGCGCG TAACTGCCTG GTCAGTGCCC AGAGACAAGT GAAGGTGTCT GCCCTGGGCC
3000





TCAGCAAGGA TGTGTACAAC AGTGAGTACT ACCACTTCCG CCAGGCCTGG GTGCCGCTGC
3060





GCTGGATGTC CCCCGAGGCC ATCCTGGAGG GTGACTTCTC TACCAAGTCT GATGTCTGGG
3120





CCTTCGGTGT GCTGATGTGG GAAGTGTTTA CACATGGAGA GATGCCCCAT GGTGGGCAGG
3180





CAGATGATGA AGTACTGGCA GATTTGCAGG CTGGGAAGGC TAGACTTCCT CAGCCCGAGG
3240





GCTGCCCTTC CAAACTCTAT CGGCTGATGC AGCGCTGCTG GGCCCTCAGC CCCAAGGACC
3300





GGCCCTCCTT CAGTGAGATT GCCAGCGCCC TGGGAGACAG CACCGTGGAC AGCAAGCCGT
3360





GAGGAGGGAG CCCGCTCAGG ATGGCCTGGG CAGGGGAGGA CATCTCTAGA GGGAAGCTCA
3420





CAGCATGATG GGCAAGATCC CTGTCCTCCT GGGCCCTGAG GTGCCCTAGT GCAACAGGCA
3480





TTGCTGAGGT CTGAGCAGGG CCTGGCCTTT CCTCCTCTTC CTCACCCTCA TCCTTTGGGA
3540





GGCTGACTTG GACCCAAACT GGGCGACTAG GGCTTTGAGC TGGGCAGTTT CCCCTGCCAC
3600





CTCTTCCTCT ATCAGGGACA GTGTGGGTGC CACAGGTAAC CCCAATTTCT GGCCTTCAAC
3660





TTCTCCCCTT GACCGGGTCC AACTCTGCCA CTCATCTGCC AACTTTGCCT GGGGAGGGCT
3720





AGGCTTGGGA TGAGCTGGGT TTGTGGGGAG TTCCTTAATA TTCTCAAGTT CTGGGCACAC
3780





AGGGTTAATG AGTCTCTTGC CCACTGGTCC ACTTGGGGGT CTAGACCAGG ATTATAGAGG
3840





ACACAGCAAG TGAGTCCTCC CCACTCTGGG CTTGTGCACA CTGACCCAGA CCCACGTCTT
3900





CCCCACCCTT CTCTCCTTTC CTCATCCTAA GTGCCTGGCA GATGAAGGAG TTTTCAGGAG
3960





CTTTTGACAC TATATAAACC GCCCTTTTTG TATGCACCAC GGGCGGCTTT TATATGTAAT
4020





TGCAGCGTGG GGTGGGTGGG CATGGGAGGT AGGGGTGGGG CCTGGAGATG AGGAGGGTGG
4080





GCCATCCTTA CCCCACACTT TTATTGTTGT CGTTTTTTGT TTGTTTTGTT TTTTTGTTTT
4140





TGTTTTTGTT TTTACACTCG CTGCTCTCAA TAAATAAGCC TTTTTTA





SEQ ID NO: 60 Protein sequence


Protein Accession #: NP_002812


1          11         21         31         41         51


|          |          |          |          |          |


MGAARGSPAR PRRLPLLSVL LLPLLGGTQT AIVPIKQPSS QDALQGRRAL LRGEVEAPGP
60





VHVYWLLDGA PVQDTERRFA QGSSLSFAAV DRLQDSGTFQ CVARDDVTGE EARSANASFN
120





IKWIEAGPVV LKHPASEAEI QPQTQVTLRC HIDGHPRPTY QWFRDGTPLS DGQSNHTVSS
180





KERNLTLRPA GPEHSGLYSC CAHSAFGQAC SSQNFTLSIA DESFARVVLA PQDVVVARYE
240





EAMPHCQFSA QPPPSLQWLF EDETPITNRS RPPHLRRATV FANGSLLLTQ VRPRNAGIYR
300





CIGQGQRGPP IILEATLHLA EIEDMPLFEP RVFTAGSEER VTCLPPKGLP EPSVWWEHAG
360





VRLPTHGRVY QKGHELVLAN IAESDAGVYT CHAANLAGQR RQDVNITVAT VPSWLKKPQD
420





SQLEEGKPGY LDCLTQATPK PTVVWYRNQM LISEDSRFEV FKNGTLRINS VEVYDGTWYR
480





CMSSTPAGSI EAQARVQVLE KLKFTPPPQP QQCMEFDKEA TVPCSATGRE KPTIEWERAD
540





GSSLPEWVTD NAGTLHFARV TRDDAGNYTC IASNGPQGQI RAHVQLTVAV FITFKVEPER
600





TTVYQGHTAL LQCEAQGDPK PLIQWKGKDR ILDPTKLGPR NHIFQNGSLV IHDVAPEDSG
660





RYTCIAGNSC NIKHTEAPLY VVDKPVPEES EGPGSPPPYK MIQTIGLSVG AAVAYIIAVL
720





GLMFYCKKRC KAKRLQKQPE GEEPEMECLN GGPLQNGQPS AEIQEEVALT SLGSGPAATN
780





KRHSTSDKMH FPRSSLQPIT TLGKSEFGEV FLAKAQGLEE GVAETLVLVK SLQTKDEQQQ
840





LDFRRELEMP GKLNHANVVE LLGLCREAEP HYMVLEYVDL GDLKQFLRIS KSKDEKLKSQ
900





PLSTKQKVAL CTQVALGMEK LSNNRFVHKD LAARNCLVSA QRQVKVSALG LSKDVYNSEY
960





YHFRQAWVPL RWMSPEAILE GDFSTKSDVW AFGVLMWEVF THGEMPNGGQ ADDEVLADLQ
1020





AGKARLPQPE GCPSKLYRLM QRCWALSPKD RPSFSEIASA LGDSTVDSKP





SEQ ID NO: 61 DNA sequence


Nucleic Acid Accession #: NN_006103


Coding sequence: 29. .406


1          11         21         31         41         51


|          |          |          |          |          |


CACCTGCACC CCGCCCGGGC ATAGCACCAT GCCTGCTTGT CGCCTAGGCC CGCTAGCCGC
60





CGCCCTCCTC CTCAGCCTGC TGCTGTTCGG CTTCACCCTA GTCTCAGGCA CAGGAGCAGA
120





GAAGACTGGC GTGTGCCCCG AGCTCCAGGC TGACCAGAAC TGCACGCAAG AGTGCGTCTC
180





GGACAGCGAA TGCGCCGACA ACCTCAAGTG CTGCAGCGCG GGCTGTGCCA CCTTCTGCCT
240





TCTCTGCCCA AATGATAAGG AGGGTTCCTG CCGCCAGGTG AACATTAACT TTCCCCAGCT
300





CGGCCTCTGT CGGGACCAGT GCCAGGTGGA CAGCCAGTGT CCTGGCCAGA TGAAATGCTG
360





CCGCAATGGC TGTGGGAAGG TGTCCTGTGT CACTCCCAAT TTCTGAGGTC CAGCCACCAC
420





CAGGCTGAGC AGTGAGGAGA GAAAGTTTCT GCCTGGCCCT GCATCTGGTT CCAGCCCACC
480





TGCCCTCCCC TTTTTCGGGA CTCTGTATTC CCTCTTCCGC TGACCACAGC TTCTCCCTTT
540





CCCAACCAAT AAAGTAACCA CTTTCAGCAA AAAAAAAAAA AAAA





SEQ ID NO 62 Protein sequence


Protein Accession #: NP_006094


1          11         21         31         41         51


|          |          |          |          |          |


MPACRLGPLA AALLLSLLLF GFTLVSGTGA EKTGVCPELQ ADQNCTQECV SDSECADNLK
60





CCSAGCATFC LLCPNDKEGS CPQVNINFPQ LGLCRDQCQV DSQCPGQMKC CRNGCGKVSC
120





VTPNF





SEQ ID NO: 63 DNA sequence


Nucleic Acid Accession #. NN_001203


Coding sequence: 274. .1782


1          11         21         31         41         51


|          |          |          |          |          |


CGCGGGGCGC GGACTGGGGG GGGCCTCGCG GGACGCGGGC AGTGCGGAGA CCGCGGCGCT
60





GAGGACGCGG GAGGCGGGAG CGCACGCGCG GGGTGGAGTT CAGCCTACTC TTTCTTAGAT
120





GTGAAAGGAA AGGAAGATCA TTTCATGCCT TGTTGATAAA GGTTCAGACT TCTGCTGATT
180





CATAACCATT TGGCTCTGAG CTATGACAAG AGAGGAAACA AAAAGTTAAA CTTACAAGCC
240





TGCCATAAGT GAGAAGCAAA CTTCCTTGAT AACATGCTTT TGCGAAGTGC AGGAAAATTA
300





AATGTGGGCA CCAAGAAAGA GGATGGTGAG AGTACAGCCC CCACCCCCCG TCCAAAGGTC
360





TTGCGTTGTA AATGCCACCA CCATTGTCCA GAAGACTCAG TCAACAATAT TTGCAGCACA
420





GACGGATATT GTTTCACGAT GATAGAAGAG GATGACTCTG GGTTGCCTGT GGTCACTTCT
480





GGTTGCGTAG GACTAGAAGG CTCAGATTTT CAGTGTCGGG ACACICGCAT TCCTCATCAA
540





AGAAGATCAA TTGAATGCTG CACAGAAAGG AACGAATGTA ATAAAGACCT ACACCCTACA
600





CTGCCTCCAT TGAAAAACAG AGATTTTGTT GATGGACCTA TACACCACAG GGCTTTACTT
660





ATATCTGTGA CTGTCTGTAG TTTGCTCTTG GTCCTTATCA TATTATTTTG TTACTTCCGG
720





TATAAAAGAC AAGAAACCAG ACCTCGATAC AGCATTGGGT TAGAACAGGA TGAAACTTAC
780





ATTCCTCCTG GAGAATCCCT GAGAGACTTA ATTGAGCAGT CTCAGAGCTC AGGAAGTGGA
840





TCAGGCCTCC CTCTGCTGGT CCAAAGGACT ATAGCTAAGC AGATTCAGAT GGTGAAACAG
900





ATTGGAAAAG GTCGCTATGG GGAAGTTTGG ATGGGAAAGT GGCGTGGCGA AAAGGTAGCT
960





GTGAAAGTGT TCTTCACCAC AGAGGAAGCC AGCTGGTTCA GAGAGACAGA AATATATCAG
1020





ACAGTGTTGA TGAGGCATGA AAACATTTTG GGTTTCATTG CIGGAGATAT CAAAGGGACA
1080





GGGTCCTGGA CCCAGTTGTA CCTAATCACA GACTATCATG AAAATGGTTC CCTTTATGAT
1140





TATCTGAAGT CCACCACCCT AGACGCTAAA TCAATGCTGA AGTTAGCCTA CTCTTCTGTC
1200





AGTGGCTTAT GTCATTTACA CACAGAAATC TTTAGTACTC AAGGCAAACC AGCAATTGCC
1260





CATCGAGATC TGAAAAGTAA AAACATTCTG GTGAAGAAAA ATGGAACTTG CTGTATTGCT
1320





CACCTGGGCC TGGCTGTTAA ATTTATTAGT GATACAAATG AAGTTGACAT ACCACCTAAC
1380





ACTCGAGTTG GCACCAAACG CTATATGCCT CCAGAAGTGT TGGAGGAGAG CTTGAACAGA
1440





AATCACTTCC AGTCTTACAT CATGGCTGAC ATGTATAGTT TTGGCCTCAT CCTTTGGGAG
1600





GTTGCTAGGA GATGTGTATC AGGAGGTATA GTGGAAGAAT ACCAGCTTCC TTATCATGAC
1560





CTAGTGCCCA GTGACCCCTC TTATGAGGAC ATGAGGGAGA TTGTGTGCAT CAAGAAGTTA
1620





CGCCCCTCAT TCCCAAACCG GTGGAGCAGT GATGAGTGTC TAAGGCAGAT GGGAAAACTC
1680





ATGACAGAAT GCTGGGCTCA CAATCCTGCA TCAAGGCTGA CAGCCCTGCG GGTTAAGAAA
1740





ACACTTGCCA AAATGTCAGA GTGCCAGGAC ATTAAACTCT GATAGGAGAG GAAAAGTAAG
1800





CATCTCTGCA GAAAGCCAAC AGGTACTCTT CTGTTTGTGG GCAGAGCAAA AGACATCAAA
1860





TAAGCATCCA CAGTACAAGC CTTGAACATC GTCCTGCTTC CCAGTGGGTT CAGACCTCAC
1920





CTTTCAGGGA GCGACCTGGG CAAAGACAGA GAAGCTCCCA GAAGGAGAGA TTGATCCGTG
1980





TCTGTTTGTA GGCGGAGAAA CCGTTGGGTA ACTTGTTCAA GATATGATGC AT





SEQ ID NO: 64 Protein sequence


Protein Accession #: NP_001194


1          11         21         31         41         51


|          |          |          |          |          |


MLLESAGKLN VGTKKEDGES TAPTPRPKVL RCKCHHHCPE DSVNNICSTD GYCFTMIEED
60





DSGLPVVTSG CLGLEGSDFQ CRDTPIPHQR RSIECCTERN ECNKDLNPTL PPLKNRDFVD
120





GPIHHRALLI SVTVCSLLLV LIILFCYFRY KRQETRPRYS IGLEQDETYI PPGESLRDLI
180





EQSQSSGSGS GLPLLVQRTI AEQIQMVKQI GKGRYGEVWM GKWRGEKVAV KVFFTTEEAS
240





WFRETEIYQT VLMRHENILG FIAADIKGTG SWTQLYLITD YHENGSLYDY LKSTTLDAKS
300





MLELAYSSVS GLCHLHTEIF STQGKPAIAH RDLKSKNILV KKNGTCCIAD LGLAVKFISD
360





TNEVDIPPNT RVGTKRYMPP EVLDESLNRN HFQSYIMADM YSFGLILWEV ARRCVSGGIV
420





EEYQLPYHDL VPSDPSYEDM REIVCIKKLR PSFPNRWSSD ECLRQMGKLM TECWAHNPAS
480





RLTALRVKET LAENSESQDI KL





SEQ ID NO 65 DNA sequence


Nucleic Acid Accession #: NN_006475.1


Coding sequence 28. .2538


1          11         21         31         41         51


|          |          |          |          |          |


AACAGAACTG CAACGGAGAG ACTCAAGATG ATTCCCTTTT TACCCATGTT TTCTCTACTA
60





TTGCTGCTTA TTGTTAACCC TATAAACGCC AACAATCATT ATGACAAGAT CTTGGCTCAT
120





AGTCGTATCA GGGGTCGGGA CCAAGGCCCA AATGTCTGTG CCCTTCAACA GATTTTGGGC
180





ACCAAAAAGA AATACTTCAG CACTTGTAAG AACTGGTATA AAAAGTCCAT CTGTGGACAG
240





AAAACGACTG TTTTATATGA ATGTTGCCCT GGTTATATCA GAATGGAAGG AATGAAAGGC
300





TGCCCAGCAG TTTTGCCCAT TGACCATGTT TATGGCACTC TGGGCATCGT GGGAGCCACC
360





ACAACGCAGC GCTATTCTGA CGCCTCAAAA CTGAGGGAGG AGATCGAGGG AAAGGGATCC
420





TTCACTTACT TTGCACCGAG TAATGAGGCT TGGGACAACT TGGATTCTGA TATCCGTAGA
480





GGTTTGGAGA GCAACGTGAA TGTTGAATTA CTGAATGCTT TACATAGTCA CATGATTAAT
540





AAGAGAATGT TGACCAAGGA CTTAAAAAAT GGCATGATTA TTCCTTCAAT GTATAACAAT
600





TTGGGGCTTT TCATTAACCA TTATCCTAAT GGGGTTGTCA CTGTTAATTG TGCTCGAATC
660





ATCCATGGGA ACCAGATTGC AACAAATGGT GTTGTCCATG TCATTGACCG TGTGCTTACA
720





CAAATTGGTA CCTCAATTCA AGACTTCATT GAAGCAGAAG ATGACCTTTC ATCTTTTAGA
780





GCAGCTGCCA TCACATCGGA CATATTGGAG GCCCTTGGAA GAGACGGTCA CTTCACACTC
840





TTTGCTCCCA CCAATGAGGC TTTTGAGAAA CTTCCACGAG GTGTCCTAGA AAGGTTCATG
900





GGAGACAAAG TGGCTTCCGA AGCTCTTATG AAGTACCACA TCTTAAATAC TCTCCAGTGT
960





TCTGAGTCTA TTATGGGAGG AGCAGTCTTT GAGACGCTGG AAGGAAATAC AATTGAGATA
1020





GGATGTGACG GTGACAGTAT AACAGTAAAT GGAATCAAAA TGGTGAACAA AAAGGATATT
1080





GTGACAAATA ATGGTGTGAT CCATTTGATT GATCACGTCC TAATTCCTGA TTCTGCCAAA
1140





CAAGTTATTG AGCTGGCTGG AAAACAGCAA ACCACCTTCA CGGATCTTGT GGCCCAATTA
1200





GGCTTGtCAT CTGCTCTGAG GCCAGATGGA GAATACACTT TGCTGGCACC TGTGAATAAT
1260





GCATTTTCTG ATGATACTCT CAGCATGGTT CACCGCCTCC TTAAATTAAT TCTGCAGAAT
1320





CACATATTGA AAGTAAAAGT TGGCCTTAAT GAGCTTTACA ACGGGCAAAT ACTGGAAACC
1380





ATCGGAGGCA AACAGCTCAG AGTCTTCGTA TATCCTACAG CTGTCTGCAT TGAAAATTCA
1440





TGCATGGAGA AAGGGAGTAA GCAACGGAGA AACGGTGCGA TTCACATATT CCGCGAGATC
1500





ATCAAGCCAG CAGAGAAATC CCTCCATGAA AAGTTAAAAC AAGATAAGCG CTTTAGCACC
1560





TTCCTCAGCC TACTTGAAGC TGCAGACTTG AAAGAGCTCC TGACACAACC TGGAGACTGG
1620





ACATTATTTG TGCCAACCAA TGATGCTTTT AAGGGAATGA CTAGTGAAGA AAAAGAAATT
1680





CTGATACGGC ACAAAAATGC TCTTCAAAAC ATCATTCTTT ATCACCTGAC ACCAGGAGTT
1740





TTCATTGGAA AAGGATTTGA ACCTGGTGTT ACTAACATTT TAAAGACCAC ACAAGGAAGC
1800





AAAATCTTTC TGAAAGAAGT AAATCATACA CTTCTGGTGA ATGAATTGAA ATCAAAAGAA
1860





TCTGACATCA TGACAACAAA TGGTGTAATT CATGTTGTAG ATAAACTCCT CTATCCAGCA
1920





GACACACCTG TTGGAAATGA TCAACTGCTG GAAATACTTA ATAAATTAAT CAAATACATC
1980





CAAATTAAGT TTGTTCGTGG TAGCACCTTC AAAGAAATCC CCGTGACTGT CTATACAACT
2040





AAAATTATAA CCAAAGTTGT GGAACCAAAA ATTAAAGTGA TTGAAGGCAG TCTTCAGCCT
2100





ATTATCAAAA CTGAAGGACC CACACTAACA AAAGTCAAAA TTGAAGGTGA ACCTGAATTC
2160





AGACTGATTA AAGAAGGTCA AACAATAACT GAAGTGATCC ATGGAGAGCC AATTATTAAA
2220





AAATACACCA AAATCATTGA TGGAGTGCCT GTGGAAATAA CTGAAAAAGA GACACGAGAA
2280





GAACGAATCA TTACAGGTCC TGAAATAAAA TACACTAGGA TTTCTACTGG AGGTGGAGAA
2340





ACAGAAGAAA CTCTGAAGAA ATTGTTACAA GAAGAGGTCA CCAAGGTCAC CAAATTCATT
2400





GAAGGTGGTG ATGGTCATTT ATTTGAAGAT GAAGAAATTA AAAGACTGCT TCAGGGAGAC
2460





ACACCCGTGA GGAAGTTGCA AGCCAACAAA AAAGTTCAAG GTTCTAGAAG ACGATTAAGG
2520





GAAGGTCGTT CTCAGTGAAA ATCCAAAAAC CAGAAAAAAA TGTTTATACA ACCCTAAGTC
2580





AATAACCTGA CCTTAGAAAA TTGTGAGAGC CAAGTTGACT TCAGGAACTG AAACATCAGC
2640





ACAAAGAAGC AATCATCAAA TAATTCTGAA CACAAATTTA ATATTTTTTT TTCTGAATGA
2700





GAAACATGAG GGAAATTGTG GACTTAGCCT CCTGTGGTAA AGGAATTGAA GAAAATATAA
2760





CACCTTACAC CCTTTTTCAT CTTGACATTA AAAGTTCTGG CTAACTTTGG AATCCATTAG
2820





AGAAAAATCC TTGTCACCAG ATTCATTACA ATTCAAATCG AAGAGTTGTG AACTGTTATC
2880





CCATTGAAAA GACCGAGCCT TGTATGTATG TTATGGATAC ATAAAATGCA CGCAAGCCAT
2940





TATCTCTCCA TGGGAAGCTA AGTTATAAAA ATAGGTGCTT GGTGTACAAA ACTTTTTATA
3000





TCAAAAGGCT TTGCACATTT CTATATGAGT GGGTTTACTG GTAAATTATG TTATTTTTTA
3060





CAACTAATTT TGTACTCTCA GAATGTTTGT CATATGCTTC TTGCAATGCA TATTTTTTAA
3120





TCTCAAACGT TTCAATAAAA CCATTTTTCA GATATAAAGA GAATTACTTC AAATTGAGTA
3180





ATTCAGAAAA ACTCAAGATT TAAGTTAAAA AGTGGTTTGG ACTTGGGAA





SEQ ID NO 66 protein sequence


Protein Accession #: NP_006466.1


1          11         21         31         41         51


|          |          |          |          |          |


MIPFLPMFSL LLLLIVNPIN ANNHYDKILA HSRIRGRDQG PNVCALQQIL GTKKKYFSTC
60





KNWYKKSICG QKTTVLYECC PGYMRMEGMK GCPAVLPIDH VYGTLGIVGA TTTQRYSDAS
120





KLREEIEGKG SFTYFAPSNE AWDNLDSDIR RGLESNVNVE LLNALHSHMI NKRMLTKDLK
180





NGMIIPSMYN NLGLFINHYP NGVVTVNCAR IIHGNQIATN GVVHVIDRVL TQIGTSIQDF
240





IEAEDDLSSF RAAAITSDTL EALGRDGHFT LFAPTNEAFE KLPRGVLERF MGDEVASEAL
300





MKYHILNTLQ CSESIMGGAV FETLEGETIE IGCDGDSITV NGIKMVNKKD IVTNNGVIHL
360





IDQVLIPDSA KQVIELAGKQ QTTFTDLVAQ LGLASALRPD GEYTLLAPVN NAFSDDTLSM
420





VGRLLELILQ NHILKVRVGL NELYNGQILE TIGGKQLRVF VYRTAVCIEN SCMEKGSKQG
480





RNGAIHIFRE IIKPAERSLH EKLRQDRRFS TFLSLLEAAD LKELLTQPGD WTLFVPTNDA
540





FKGMTSEEKE ILIRDKNALQ NIILYHLTPG VFIGKGPEPG VTNILKTTQG SKIFLKEVED
600





TLLVNELKSK ESDIMTTNGV IHVVDKLLYP ADTPVGNDQL LEILNKLIKY IQIKFVRGST
660





FKEIPVTVYT TKIITKVVEP KIKVIEGSLQ PIIKTEGPTL TKVKIEGEPE FRLIKEGETI
720





TEVIHGEPII KKYTKIIDGV PVEITEKETR EERIITGPEI KYTRISTGGG ETEETLKKLL
780





QEEVTKVTKF IEGGEGELFE DEEIKRLLQG DTPVRKLQAN KKVQGSRRRL REGESG





SEQ ID NO: 67 DNA sequence


Nucleic Acid Accession #: EOS sequence


Coding sequence: 1-927


1          11         21         31         41         51


|          |          |          |          |          |


ATGCCTGGGG GGTGCTCCCG GGGCCCCGCC GCCGGGGACG GGCGTCTGCG GCTGGCGCGA
60





CTAGCGCTGG TACTCCTGGG CTGGGTCTCC TCGTCTTCTC CCACCTCCTC GGCATCCTCC
120





TTCTCCTCCT CGGCGCCGTT CCTGGCTTCC GCCGTGTCCG CCCAGCCCCC GCTGCCGGAC
180





CAGTGCCCCG CGCTGTGCGA GTGCTCCGAG GCAGCGCGCA CAGTCAAGTG CGTTAACCGC
240





AATCTGACCG AGGTGCCCAC GGACCTGCCC GCCTACGTGC GCAACCTCTT CCTTACCGGC
300





AACCAGCTGG CCAGCAACCA CTTCCTTTAC CTGCCGCGGG ATGTGCTGGC CCAACTGCCC
360





AGCCTCAGGC ACCTGGACTT AAGTAATAAT TCGCTGGTGA GCCTGACCTA CGTGTCCTTC
420





CGCAACCTGA CACATCTAGA AAGCCTCCAC CTGGAGGACA ATGCCCTCAA GGTCCTTCAC
480





AATGGCACCC TGGCTGAGTT GCAAGGTCTA CCCCACATTA GGGTTTTCCT GGACAACAAT
540





CCCTGGGTCT GCGACTGCCA CATGGCAGAC ATGGTGACCT GGCTCAAGGA AACAGAGGTA
600





GTGCAGGGCA AAGACCGGCT CACCTGTGCA TATCCGGAAA AAATGAGGAA TCGGGTCCTC
660





TTGGAACTCA ACAGTGCTGA CCTGGACTGT GACCCGATTC TTCCCCCATC CCTGCAAACC
720





TCTTATGTCT TCCTGGGTAT TGTTTTAGCC CTGATAGGCG CTATTTTCCT CCTGGTTTTG
780





TATTTGAACC GCAAGGGGAT AAAAAAGTGG ATGCATAACA TCAGAGATGC CTGCAGGGAT
840





CACATGGAAG GGTATCATTA CAGATATGAA ATCAATGCGG ACCCCAGATT AACAAACCTC
900





AGTTCTAACT CGGATGTCCT CGAGTGA





SEQ ID NO: 68 Protein sequence


Protein Accession #: EOS sequence


1          11         21         31         41         51


|          |          |          |          |          |


MPGGCSRGPA AGDGRLRLAR LALVLLGWVS SSSPTSSASS FSSSAPFLAS AVSAQPPLPD
60





QCPALCECSE AARTVKCVNR NLTEVPTDLP AYVRNLFLTG NQLASNHFLY LPRDVLAQLP
120





SLRHLDLSNN SLVSLTYVSF RNLTHLESLH LEDNALKVLN NGTLAELQGL PHIRVFLDNN
180





PWVCDCHMAD MVTWLKETEV VQGKDRLTCA YPEKMRNRVL LELNSADLDC DPILPPSLQT
240





SYVFLGIVLA LIGAIFLLVL YLNRKGIKKW MHNIRDACRD HMEGYHYRYE INADPRLTNL
300





SSNSDVLE





SEQ ID NO: 69 DNA sequence


Nucleic Acid Accession #: NM_000095.1


Coding sequence 26..2299


1          11         21         31         41         51


|          |          |          |          |          |


CAGGACGCAG CTCCCCGCCA CCGCCATGGT CCCCGACACC GCCTGCGTTC TTCTGCTCAC
60





CCTGGCTGCC CTCGGCGCGT CCGGACAGGG CCAGADCCCG TTGGGCTCAG ACCTGGGCCC
120





GCAGATGCTT CGGGAACTGC ACGAAACCAA CGCGGCGCTG CAGGACGTGC GGGACTGGCT
180





GCGGCAGCAG GTCAGGGAGA TCACGTTCCT GAAAAACACG GTGATGGAGT GTGACGCGTG
240





CGGGATGCAG CAGTCAGTAC GCACCGGCCT ACCCAGCGTG CGGCCCCTGC TCCACTGCGC
300





GCCCGGCTTC TGCTTCCCCG GCGTGGCCTG CATCCAGACG GAGAGCGGCG GCCGCTGCGG
360





CCCCTGCCCC GCGGGCTTCA CGGGCAACGG CTCGCACTGC ACCGACCTCA ACGAGTGCAA
420





CGCCCACCCC TGCTTCCCCC GAGTCCGCTG TATCAACACC AGCCCGGGGT TCCGCTGCGA
480





GGCTTGCCCG CCGGGGTACA GCGGCCCCAC CCACCAGGGC GTGGGGCTGG CTTTCGCCAA
540





GGCCAACAAG CAGGTTTGCA CGGACATCAA CGAGTGTGAG ACCGGGCAAC ATAACTGCGT
600





CCCCAACTCC GTGTGCATCA ACACCCGGGG CTCCTTCCAG TGCGGCCCGT GCCAGCCCGG
650





CTTCGTGGGC GACCAGGCGT CCGGCTGCCA GCGCGGCGCA CAGCGCTTCT GCCCCGACGG
720





CTCGCCCAGC GAGTGCCACG AGCATGCAGA CTGCGTCCTA GAGCGCGATG GCTCGCGGTC
780





GTGCGTGTGT CGCGTTGGCT GGGCCGGCAA CGGGATCCTC TGTGGTCGCG ACACTGACCT
840





AGACGGCTTC CCGGACGAGA AGCTGCGCTG CCCGGAGCCG CAGTGCCGTA AGGACAACTG
900





CGTGACTGTG CCCAACTCAG GGCAGGAGGA TGTGGACCGC GATGGCATCG GAGACGCCTG
960





CGATCCGGAT GCCGACGGGG ACGGGGTCCC CAATGAAAAG GACAACTGCC CGCTGGTGCG
1020





GAACCCAGAC CAGCGCAACA CGGACGAGGA CAAGTGGGGC GATGCGTGCG ACAACTGCCG
1080





GTCCCAGAAG AACGACGACC AAAAGGACAC AGACCAGGAC GGCCGGGGCG ATGCGTGCGA
1140





CGACGACATC GACGGCGACC GGATCCGCAA CCAGGCCGAC AACTGCCCTA GCGTACCCAA
1200





CTCAGACCAG AACGACAGTG ATGGCGATGG TATAGGGGAT GCCTGTGACA ACTGTCCCCA
1260





GAAGAGCAAC CCGGATCAGG CGGATGTGGA CCACGACTTT GrGGGAGATG CTTGTGACAG
1320





CGATCAAGAC CAGGATGGAG ACGGACATCA GGACTCTCGG GACAACTGTC CCACGGTGCC
1380





TAACAGTGCC CAGGAGGACT CAGACCACGA TGGCCAGGGT GATGCCTGCG ACGACGACGA
1440





CGACAATGAC GGAGTCCCTG ACAGTCGGGA CAACTGCCGC CTGGTGCCTA ACCCCGGCCA
1500





GGAGGACGCG GACAGGGACG GCGTGGGCGA CGTGTGCCAG GACGACTTTG ATGCAGACAA
1580





GGTGGTAGAC AAGATCGACG TGTGTCCGGA GAACGCTGAA GTCACGCTCA CCGACTTCAG
1620





GGCCTTCCAG ACAGTCGTGC TGGACCCGGA GGGTGACGCG CAGATTGACC CCAACTGGGT
1680





CGTGCTCAAC CAGGGAAGGG AGATCGTGCA GACAATGAAC AGCGACCCAG GCCTGGCTGT
1740





GGGTTACACT GCCTTCAATG GCGTGGACTT CGAGGGCACG TTCCATGTGA ACACGGTCAC
1800





GGATGACGAC TATGCGGGCT TCATCTTTGG CTACCAGGAC AGCTCCAGCT TCTACGTGGT
1860





CATGTGGAAG CAGATGGAGC AAACGTATTG GCAGGCGAAC CCCTTCCGTG CTGTGGCCGA
1920





GCCTGGCATC CAACTCAAGG CTGTGAAGTC PTCCACAGGC CCCGGGGAAC AGCTGCGGAA
1980





CGCTCTGTGG CATACAGGAG ACACAGAGTC CCAGGTGCGG CTGCTGTGGA AGGACCCGCG
2040





AAACGTGGGT TGGAAGGACA AGAAGTCCTA TCGTTGGTTC CTGCAGCACC GGCCCCAAGT
2100





GGGCTACATc AGGGTGCGAT TCTATGAGGG CCCTGAGCTG GTGGCCGACA GCAACGTGGT
2160





CTTGGACACA ACCATGCGGG GTGGCCGCCT CGGGGTCTTC TGCTTCTCCC AGGAGAACAT
2220





CATCTGGGCC AACCTGCGTT ACCGCTGCAA TGACACCATC CCAGAGGACT ATGAGACCCA
2280





TCAGCTGCGG CAAGCCTAGG GACCAGGGTG AGGACCCGCC GGATGACAGC CACCCTCACC
2340





GCGGCTGGAT GGGGGCTCTG CACCCAGCCC AAGGGGTGGC CGTCCTGAGG GGGAAGTGAG
2400





AAGGGCTCAG AGAGGACAAA ATAAAGTGTG TGTGCAGGG





SEQ ID NO: 70 Protein sequence


Protein Accession # NP_000086.1


1          11         21         31         41         51


|          |          |          |          |          |


MVPDTACVLL LTLAALGASG QGQSPLGSDL GPQMLRELQE TNAALQDVRD WLRQQVREIT
60





FLKNTVMECD ACGMQQSVRT GLPSVRPLLH CAPGFCFPGV ACIGTESGGR CGPCPAGFTG
120





NGSHCTDVNE CNAHPCFPRV RCINTSPGFR CEACPPGYSG PTHQGVGLAF AKANKQVCTD
180





INECETGQHN CVPNSVCINT RGSFQCGPCQ PGFVGDQASG CQRGAQRFCP DGSPSECHEH
240





ADCVLERGDS RSCVCRVGWA GNGILCGRDT DLDGFPDEKL RCPEPQCRKD NCVTVPNSGQ
300





EGVDRDGIGD ACDPDADGDG VPNEKDNCPL VRNPDQRNTD EGKWGDACDN CRSQKNDDQK
360





DTDQDGRGDA CDDDIDGDRI RNQADNCPRV PNSDQKDSDG DGIGDACDNC PQKSNPDQAD
420





VDHDFVGDAC DSDQDQDGDG NQDSRDNCPT VPNSAQEDSD HDGQGDACDD DDDNDGVPDS
480





RDNCRLVPNP GQEDADRDGV GDVCQDDFDA DKVVDKIDVC PENAEVTLTD FRARQTVVLD
540





PEGDAQIDPN WVVLNQGREI VQTMNSDPGL AVGYTAFNGV DFEGTFHVNT VTDDDYAGFI
600





FGYQDSSSFY VVMWKQMEQT YWQANPFRAV AEPGIQLKAV KSSTGPGEQL RNALWHTGDT
660





ESQVRLLWKD PRNVGWRDKK SYRWFLQHRP QVGYIRVRFY EGPELVADSN VVLDTTMRGG
720





RLGVFCFSQE NIIWANLRYR CNDTIPEGYE THQLRQA





SEQ ID NO: 71 DNA sequence


Nucleic Acid Accession #: NN_024626


Coding sequence: 71. 919


1          11         21         31         41         51


|          |          |          |          |          |


GAGTCACCAA GGAAGGCAGC GGCAGCTCCA CTCAGCCAGT ACCCAGATAC GCTGGGAACC
60





TTCCCCAGCC ATGGCTTCCC TGGGGCAGAT CCTCTTCTCG AGCATAATTA GCATCATCAT
120





TATTCTGGCT GGAGCAATTG CACTCATCAT TGGCTTTCCT ATTTCAGGGA GACACTCCAT
160





CACAGTCACT ACTGTCGCCT CAGCTGGGAA CATIGGGCAG GATGGAATCC TGAGCTGCAC
240





TTTTGAACCT GACATCAAAC TTTCTGATAT CGTGATACAA TGGCTGAAGG AAGGTGTTTT
300





AGGCTTGGTC CATGAGTTCA AAGAAGGCAA AGATGAGCTG TCGGAGCAGG ATGAAATGTT
360





CAGAGGCCGG ACAUCACTGT TTGCTGATCA AGTGATAGTT GGCAATGCCT CTTTGCGGCT
420





GAAAAACGTG CAACTCACAG ATGCTGGCAC CTACAAATGT TATATCATCA CTTCTAAAGG
480





CAAGGGGAAT GCTAACCTTG AGTATAAAAC TGGAGCCTTC AGCATGCCGG AAGTGAATGT
540





GGACTATAAT GCCAGCTCAG AGACCTTGCG GTGTGAGGCT CCCCGATGGT TCCCCCAGCC
600





CACAGTGGTC TGGGCATCCC AAGTTGACCA GGGAGCCAAC TTCTCGGAAG TCTCCAATAC
660





CAGCTTTGAG CTGAACTCTG AGAATGTGAC CATGAAGGTT GTGTCTGTGC TCTACAATGT
720





TACGATCAAC AACACATACT CCTGTATGAT TGAAAATGAC ATTGCCAAAG CAACAGGGGA
780





TATCAAAGTG ACAGAATCGG AGATCAAAAG GCGGAGTCAC CTACAGCTGC TAAACTCAAA
840





GGCTTCTCTG TGTGTCTCTT CTTTCTTTGC CATCAGCTGG GCACTTCTGC CTCTCAGCCC
900





TTACCTGATG CTAAAATAAT GTGCCTCGGC CACAAAAAAG CATGCAAAGT CATTGTTACA
960





ACAGGGATCT ACAGAACTAT TTCACCACCA GATATGACCT AGTTTTATAT TTCTGGGAGG
1020





AAATGAATTC ATATCTAGAA GTCTGGAGTG AGCAAACAAG AGCAAGAAAC AAAAAGAAGC
1080





CAAAAGCAGA AGGCTCCAAT ATGAACAAGA TAAATCTATC TTCAAAGACA TATTAGAAGT
1140





TGGGAAAATA ATTCATGTGA ACTAGAGTCA ACTGTGTCAG GGCTAAGAAA CCCTGGTTTT
1200





GAGTAGAAAA GGGCCTGGAA AGAGGGGAGC CAACAAATCT GTCTGCTTCC TCACATTAGT
1260





CATTGGCAAA TAAGCATTCT GTCTCTTTGG CTGCTGCCTC AGCACAGAGA GCCAGAACTC
1320





TATCGGGCAC CAGGATAACA TCTCTCAGTG AACAGAGTTG ACAAGGCCTA TGGGAAATGC
1380





CTGATGGGAT TATCTTCAGC TTGTTGAGCT TCTAAGTTTC TTTCCCTTCA TTCTACCCTG
1440





CAAGCCAAGT TCTGTAAGAG AAATGCCTGA GTTCTAGCTC AGGTTTTCTT ACTCTGAATT
1500





TAGATCTCCA GACCCTGCCT GGCCACAATT CAAATTAAGG CAACAAACAT ATACCTTCCA
1560





TGAAGCACAC ACAGACTTTT GAAAGCAAGG ACAATGACTG CTTGAATTGA GGCCTTGAGG
1620





AATGAAGCTT TGAAGGAAAA GAATACTTTG TTTCCAGCCC CCTTCCCACA CTCTTCATGT
1680





GTTAACCACT GCCTTCCTGG ACCTTGGAGC CACGCTGACT GTATTACATG TTGTTATAGA
1740





AAACTGATTT TAGAGTTCTG ATCGTTCAAG AGAATGATTA AATATACATT TCCTAAAAAA
1800





AAAAAAAAAA A





SEQ ID NO. 72 Protein sequence


Protein Accession #: NP_078902


1          11         21         31         41         51


|          |          |          |          |          |


MASLGQILFW SIISIIIILA GAIALIIGFG ISGRHSITVT TVASAGNIGE DGILSCTFEP
60





DIKLSDIVIQ WLKEGVLGLV HEFKEGKDEL SEQDEMFRGR TAVFADQVIV GNASLRLKNV
120





QLTDAGTYKC YIITSKGKGN ANLEYKTGAF SMPEVNVDYN ASSETLRCEA PRWFPQPTVV
180





WASQVDQGAN FSEVSNTSFE LNSENVTMKV VSVLYNVTIN NTYSCMIEND IAKATGDIKV
240





TESEIKRRSH LQLLNSKASL CVSSFFAISW ALLPLSPYLM LK





SEQ ID NO: 73 DNA sequence


Nucleic Acid Accession #: XM_057014


Coding sequence: 143. .874


1         11         21         31         41         51


|          |          |          |          |          |


GGGAGGGAGA GAGGCGCGCG GGTGAAAGGC GCATTGATGC AGCCTGCGGC GGCCTCGGAG
60





CGCGGCGGAG CCAGACGCTG ACCACGTTCC TCTCCTCGGT CTCCTCCGCC TCCAGCTCCG
120





CGCTGCCCGG CAGCCGGGAG CCATGCGACC CCAGGGCCCC GCCGCCTCCC CGCAGCGGCT
180





CCGCGGCCTC CTGCTGCTCC TGCTGCTGCA GCTGCCCGCG CCGTCGAGCG CCTCTGAGAT
240





CCCCAAGGGG AAGCAAAAGG CGCAGCTCCG GCAGAGGGAG GTGGTGGACC TGTATAATGG
300





AATGTGCTTA CAAGGGCCAG CAGGAGTGCC TGGTCGAGAC GGGAGCCCTG GGGCCAATGG
360





CATTCCGGGT ACACCTGGGA TCCCAGGTCG GGATGGATTC AAAGGAGAAA AGGGGGAATG
420





TCTGAGGGAA AGCTTTGAGG AGTCCTGGAC ACCCAACTAC AAGCAGTGTT CATGGAGTTC
480





ATTGAATTAT GGCATAGATC TTGGGAAAAT TGCGGAGTGT ACATTTACAA AGATGCGTTC
540





AAATAGTGCT CTAAGAGTTT TGTTCAGTGG CTCACTTCGG CTAAAATGCA GAAATGCATG
600





CTGTCAGCGT TGGTATTTCA CATTCAATGG AGCTGAATGT TCAGGACCTC TTCCCATTGA
660





AGCTATAATT TATTTGGACC AAGGAAGCCC TGAAATGAAT TCAACAATTA ATATTCATCG
720





CACTTCTTCT GTGGAAGGAC TTTGTGAAGG AATTGGTGCT GGATTAGTGG ATGTTGCTAT
780





CTGGGTTGGC ACTTGTTCAG ATTACCCAAA AGGAGATGCT TCTACTGGAT GGAATTCAGT
840





TTCTCGCATC ATTATTGAAG AACTACCAAA ATAAATGCTT TAATTTTCAT TTGCTACCTC
900





TTTTTTTATT ATGCCTTGGA ATGGTTCACT TAAATGACAT TTTAAATAAG TTTATGTATA
980





CATCTGAATG AAAAGCAAAG CTAAATATGT TTACAGACCA AAGTGTGATT TCACACTGTT
1020





TTTAAATCTA GCATTATTCA TTTTGCTTCA ATCAAAAGTG GTTTCAATAT TTTTTTTAGT
1080





TGGTTAGAAT ACTTTCTTCA TAGTCACATT CTCTCAACCT ATAATTTGGA ATATTGTTGT
1140





GGTCTTTTGT TTTTTCTCTT AGTATAGCAT TTTTAAAAAA ATATAAAAGC TACCAATCTT
1200





TGTACAATTT GTAAATGTTA AGAATTTTTT TTATATCTGT TAAATAAAAA TTATTTCCAA
1260





CAACCTTAAA AAAAAAAAAA AAAA





SEQ ID NO: 74 Protein sequence


Protein Accession #: XP_057014


1          11         21         31         41         51


|          |          |          |          |          |


MRPQGPAASP QRLRGLLLLL LLQLPAPSSA SEIPKGKQKA QLRQREVVDL YNGMCLQGPA
60





GVPGRDGSPG ANGIPGTPGI PGRDGFKGEK GECLEESFEE SWTPNYKQCS WSSLNYGIDL
120





GKIAECTFTK MRSNSALRVL FSGSLRLKCR NACCQRWYFT FNGAECSGPL PIEAIIYLDQ
180





GSPEMNSTIN IHRTSSVEGL CEGIGAGLVD VAIWVGTCSD YPKGDASTGW NSVSRIIIEE
240





LPK





SEQ ID NO: 75 DNA sequence


Nucleic Acid Accession #: BC010423


Coding sequence: 248. .1780


1          11         21         31         41         51


|          |          |          |          |          |


CACACCGTGG GAAGCAGCTC TGGGGGACCT CGCACCTCCC GATCACGGCT TCTTGGCGGT
60





ACCTACGGCT GGGTGTGTAG AACGGGGCCG GGGCTGGGGC TGGGTCCCCT AGTGGAGACC
120





CAAGTGCGAG AGGCAAGAAC TCTGCAGCTT CCTGCCTTCT GGGTCAGTTC CTTATTCAAG
180





TCTGCAGCCG GCTCCCAGGG AGATCTCGGT GGAACTTCAG AAACGCTGGG CAGTCTGCCT
240





TTCAACCATG CCCCTGTCCC TGGGAGCCGA GATGTGGGGG CCTGAGGCCT GGCTGCTGCT
300





GCTGCTACTG CTGGCATCAT TTACAGGCCG GTGCCCCGCG GGTGAGCTGG AGACCTCAGA
360





CGTGGTAACT GTGGTGCTGG GCCAGGACGC AAAACTGCCC TGCTTCTACC GAGGGGACTC
420





CGGCGAGCAA GTGGGGCAAG TGGCATGGGC TCGGGTGGAC GCGGGCGAAG GCGCCCAGGA
480





ACTACCGCTA CTGCACTCCA AATACGGGCT TCATGTGAGC CCGGCTTACG AGGGCCGCGT
540





GGAGCAGCCG CCGCCCCCAC GCAACCCCCT GGACGGCTCA GTGCTCCTGC GCAACGCAGT
600





GCAGGCGGAT GAGGGCGAGT ACGAGTGCCG GGTCAGCACC TTCCCCGCCG GCAGCTTCCA
660





GGCGCGGCTG CGGCTCCGAG TGCTGGTGCC TCCCCTGCCC TCACTGAATC CTGGTCCAGC
720





ACTAGAAGAG GGCCAGGGCC TGACCCTGGC AGCCTCCTGC ACAGCTGAGG GCAGCCCAGC
780





CCCCAGCGTG ACCTGGGACA CGGAGGTCAA AGGCACAACG TCCAGCCGTT CCTTCAAGCA
840





CTCCCGCTCT GCTGCCGTCA CCTCAGAGTT CCACTTGGTG CCTAGCCGCA GCATGAATGG
900





GCAGCCACTG ACTTGTGTGG TGTCCCATCC TGGCCTGCTC CAGGACCAAA GGATCACCCA
960





CATCCTCCAC GTGTCCTTCC TTGCTGAGGC CTCTGTGAGG GGCCTTGAAG ACCAAAATCT
1020





GTGGCACATT GGCAGAGAAG GAGCTATGCT CAAGTGCCTG AGTGAAGGGC AGCCCCCTCC
1080





CTCATACAAC TGGACACGGC TGGATGGGCC TCTGCCCAGT GGGGTACGAG TGGATGGGGA
1140





CACTTTGGGC TTTCCCCCAC TGACCACTGA GCACAGCGGC ATCTACGTCT GCCATGTCAG
1200





CAATGAGTTC TCCTCAAGGG ATTCTCAGGT CACTGTGGAT GTTCTTGACC CCCAGGAAGA
1260





CTCTGGGAAG CAGGTGGACC TAGTGTCAGC CTCGGTGGTG GTGGTGGGTG TGATCGCCGC
1320





ACTCTTGTTC TGCCTTCTGG TGGTGGTGGT GGTGCTCATG TCCCGATACC ATCGGCGCAA
1380





GGCCCACCAG ATGACCCAGA AATATGAGGA GGAGCTGACC CTGACCAGGG AGAACTCCAT
1440





CCGGAGGCTG CATTCCCATC ACACGGACCC CAGGAGCCAG CCGGAGGAGA GTGTAGGGCT
1500





GAGAGCCGAG GGCCACCCTG ATAGTCTCAA GGACAACAGT AGCTGCTCTG TGATGAGTGA
1560





AGAGCCCGAG GGCCGCAGTT ACTCCACGCT GACCACGGTG AGGGAGATAG AAACACAGAC
1620





TGAACTGCTG TCTCCAGGCT CTGGGCGGGC CGAGGAGGAG GAAGATCAGG ATGAAGGCAT
1680





CAAACAGGCC ATGAACCATT TTGTTCAGGA GAATGGGACC CTACGGGCCA AGCCCACGGG
1740





CAATGGCATC TACATCAATG GGCGGGGACA CCTGGTCTGA CCCAGGCCTG CCTCCCTTCC
1800





CTAGGCCTGG CTCCTTCTGT TGACATGGGA GATTTTAGCT CATCTTGGGG GCCTCCTTAA
1860





ACACCCCCAT TTCTTGCGGA AGATGCTCCC CATCCCACTG ACTGCTTGAC CTTTACCTCC
1920





AACCCTTCTG TTCATCGGGA GGGCTCCACC AATTGAGTCT CTCCCACCAT GCATGCAGGT
1980





CACTGTGTGT GTGCATGTGT GCCTGTGTGA GTGTTGACTG ACTGTGTGTG TGTGGAGGGG
2040





TGACTGTCCG TGGAGGGGTG ACTGTGTCCG TGGTGTGTAT TATGCTGTCA TATCAGAGTC
2100





AAGTGAACTG TGGTGTATGT GCCACGGGAT TTGAGTGGTT GCGTGGGCAA CACTGTCAGG
2160





GTTTGGCGTG TGTGTCATGT GGCTGTGTGT GACCTCTGCC TGAAAAAGCA GGTATTTTCT
2220





CAGACCCCAG AGCAGTATTA ATGATGCAGA GGTTGGAGGA GAGAGGTGGA GACTGTGGCT
2280





CAGACCCAGG TGTGCGGGCA TAGCTGGAGC TGGAATCTGC CTCCGGTGTG AGGGAACCTG
2340





TCTCCTACCA CTTCGGAGCC ATGGGGGCAA GTGTGAAGCA GCCAGTCCCT GGGTCAGCCA
2400





GAGGCTTGAA CTGTTACAGA AGCCCTCTGC CCTCTGGTGG CCTCTGGGCC TGCTGCATGT
2460





ACATATTTTC TGTAAATATA CATGCGCCGG GAGCTTCTTG CAGGAATACT GCTCCGAATC
2520





ACTTTTAATT TTTTTCTTTT TTTTTTCTTG CCCTTTCCAT TAGTTGTATT TTTTATTTAT
2580





TTTTATTTTT ATTTTTTTTT AGAGTTTGAG TCCAGCCTGG ACGATATAGC CAGACCCTGT
2640





CTGTAAAAAA ACCAAAACCC AAAAAAAAAA AAAAAAAAAA





SEQ ID NO: 76 Protein sequence


Protein Accession #: AAH10423


1          11         21         31         41         51


|          |          |          |          |          |


MPLSLGAEMW GPEAWLLLLL LLASFTGRCP AGELETSDVV TVVLGQDAKL PCFYRGDSGE
60





QVGQVAWARV DAGEGAQELA LLHSKYGLHV SPAYEGRVEQ PPPPRNPLDG SVLLRNAVQA
120





DEGEYECRVS TFPAGSFQAR LRLRVLVPPL PSLNPGPALE EGQGLTLAAS CTAEGSPAPS
180





VTWDTEVKGT TSSRSFKHSR SAAVTSEFHL VPSRSMNGQP LTCVVSHPGL LQDQRITHIL
240





HVSFLAEASV RGLEDQNLWH IGREGAMLKC LSEGQPPPSY NWTRLDGPLP SGVRVDGDTL
300





GFPPLTTEHS GIYVCHVSNE FSSRDSQVTV DVLDPQEDSG KQVDLVSASV VVVGVIAALL
360





FCLLVVVVVL MSRYHRRKAQ QMTQKYEEEL TLTRENSIRR LHSHHTDPRS QPEESVGLRA
420





EGHPDSLKDN SSCSVMSEEP EGRSYSTLTT VREIETQTEL LSPGSGRAEE EEDQDEGIKQ
480





AMNHFVQENG TLRAKPTGNG IYINGRGHLV





SEQ ID NO: 77 DNA sequence


Nucleic Acid Accession #: NM_003474.2


Coding sequence 37. .3036


1          11         21         31         41         51


|          |          |          |          |          |


CACTAACGCT CTTCCTAGTC CCCGGGCCAA CTCGGACAGT TTGCTCATTT ATTGCAACGG
60





TCAAGGCTGG CTTGTGCCAG AACGGCGCGC GCGCGACGCA CGCACACACA CGGGGGGAAA
120





CTTTTTTAAA AATGAAAGGC TAGAAGAGCT CAGCGGCGGC GCGGGCCGTG CGCGAGGGCT
180





CCGGAGCTGA CTCGCCGAGG CAGGAAATCC CTCCGGTCGC GACGCCCGGC CCCGCTCGGC
240





GCCCGCGTGG GATGGTGCAG CGCTCGCCGC CGGGCCCGAG AGCTGCTGCA CTGAAGGCCG
300





GCGACGATGG CAGCGCGCCC GCTGCCCGTG TCCCCCGCCC GCGCCCTCCT GCTCGCCCTG
360





GCCGGTGCTC TGCTCGCGCC CTGCGAGGCC CGAGGGGTGA GCTTATGGAA CGAAGGAAGA
420





GCTGATGAAG TTGTCAGTGC CTCTGTTCGG AGTGGGGACC TCTGGATCCC AGTGAAGAGC
480





TTCGACTCCA AGAATCATCC AGAAGTGCTG AATATTCGAC TACAACGGGA AAGCAAAGAA
540





CTGATCATAA ATCTGGAAAG AAATGAAGGT CTCATTGCCA GCACTTTCAC GGAAACCCAC
600





TATCTGCAAG ACGGTACTGA TGTCTCCCTC GCTCGAAATT ACACGGTAAT TCTGGGTCAC
660





TGTTACTACC ATGGACATGT ACGGGGATAT TCTGATTCAG CAGTCAGTCT CAGCACGTGT
720





TCTGGTCTCA GGGGACTTAT TGTGTTTGAA AATGAAAGCT ATGTCTTAGA ACCAATGAAA
700





AGTGCAACCA ACAGATACAA ACTCTTCCCA GCGAAGAAGC TGAAAAGCGT CCGGGGATCA
840





TGTGGATCAC ATCACAACAC ACCAAACCTC GCTGCAAAGA ATGTGTTTCC ACCACCCTCT
900





CAGACATGGG CAAGAAGGCA TAAAAGAGAG ACCCTCAAGG CAACTAAGTA TGTGGAGCTG
960





GTGATCGTGG CAGACAACCG AGAGTTTCAG AGGCAAGGAA AAGATCTGGA AAAAGTTAAG
1020





CAGCGATTAA TAGAGATTGC TAATCACGTT GACAAGTTTT ACAGACCACT GAACATTCGG
1080





ATCGTGTTGG TAGGCGTGGA AGTGTGGAAT GACATGGACA AATGCTCTGT AAGTCAGGAC
1140





CCATTCACCA GCCTCCATGA ATTTCTGGAC TGGAGGAAGA TGAAGCTTCT ACCTCGCAAA
1200





TCCCATGACA ATGCGCAGCT TGTCAGTCGG GTTTATTTCC AAGGGACCAC CATCGGCATG
1260





GCCCCAATCA TGAGCATGTG CACCGCACAC CAGTCTGGGG GAATTGTCAT GGACCATTCA
1320





GACAATCCCC TTGGTGCAGC CGTGACCCTG GCACATGACC TGCGCCACAA TTTCGGGATG
1300





AATCATGACA CACTGGACAG GGGCTGTAGC TGTCAAATGG CCGTTGAGAA AGGAGGCTGC
1440





ATCATGAACG CTTCCACCGG GTACCCATTT CCCATGGTGT TCACCACTTG CAGCAGGAAG
1500





GACTTGGAGA CCAGCCTGGA GAAAGGAATG GGGGTGTGCC TGTTTAACCT CCCCCAAGTC
1560





AGGGAGTCTT TCGGGGGCCA GAAGTGTGGG AACAGATTTG TGGAAGAAGG AGACCACTGT
1620





GACTGTGGGG AGCCAGAGGA ATGTATGAAT CGCTGCTGCA ATGCCACCAC CTGTACCCTG
1680





AAGCCGGACG CTGTGTGCGC ACATGGGCTG TGCTGTGAAG ACTGCCAGCT GAAGCCTGCA
1740





GGAACAGCGT GCAGGGACTC CAGCAACTCC TGTGACCTCC CAGAGTTCTG CACAGGGGCC
1800





AGCCCTCACT GCCCAGCCAA CGTGTACCTG CACGATGGGC ACTCATGTCA GGATGTGGAC
1860





GGCTACTGCT ACAATGGCAT CTGCCAGACT CACGAGCAGC AGTGTGTCAC ACTCTGGGGA
1920





CCAGGTGCTA AACCTGCCCC TGGGATCTGC TTTGAGAGAG TCAATTCTGC AGGTGATCCT
1980





TATGGCAACT GTGGCAAAGT CTCGAAGAGT TCCTTTGCCA AATGCGAGAT GAGAGATGCT
2040





AAATGTGGAA AAATCCAGTG TCAAGGAGGT GCCAGCCGGC CAGTCATTGG TACCAATGCC
2100





GTTTCCATAG AAACAAACAT CCCCCTGCAG CAAGGAGGCC GGATTCTGTG CCGGGGGACC
2160





CACGTGTACT TGGGCGATGA CATGCCGGAC CCAGGGCTTG TGCTTGCAGG CACAAAGTGT
2220





GCAGATGGAA AAATCTGCCT GAATCGTCAA TGTCAAAATA TTAGTGTCTT TGGGGTTCAC
2280





GAGTGTGCAA TGCAGTGCCA CGGCAGAGGG GTGTGCAACA ACAGGAAGAA CTGCCACTGC
2340





GAGGCCCACT GGGCACCTCC CTTCTGTGAC AAGTTTGGCT TTGGAGGAAG CACAGACAGC
2400





GGCCCCATCC GGCAAGCAGA TAACCAAGGT TTAACCATAG GAATTCTGGT CACCATCCTG
2460





TGTCTTCTTG CTGCCGGATT TGTGGTTTAT CTCAAAAGGA AGACCTTGAT ACGACTGCTG
2520





TTTACAAATA AGAAGACCAC CATTGAAAAA CTAAGGTGTG TGCGCCCTTC CCGGCCACCC
2580





CGTGGCTTCC AACCCTGTCA GGCTCACCTC GGCCACCTTG GAAAAGGCCT GATGAGGAAG
2640





CCGCCAGATT CCTACCCACC GAAGGACAAT CCCAGGAGAT TGCTGCAGTG TCAGAATCTT
2700





GACATCAGCA GACCCCTCAA CGGCCTGAAT GTCCCTCAGC CCCAGTCAAC TCAGCGAGTG
2760





CTTCCTCCCC TCCACCGGGC CCCACGTGCA CCTAGCGTCC CTGCCAGACC CCTGCCAGCC
2820





AAGCCTGCAC TTAGGCAGGC CCAGGGGACC TGTAAGCCAA ACCCCCCTCA GAAGCCTCTG
2880





CCTGCAGATC CTCTGGCCAG AACAACTCGG CTCACTCATG CCTTGGCCAG GACCCCAGGA
2940





CAATGGGAGA CTCGGCTCCG CCTGGCACCC CTCAGACCTG CTCCACAATA TCCACACCAA
3000





GTGCCCAGAT CCACCCACAC CGCCTATATT AAGTGAGAAG CCGACACCTT TTTTCAACAG
3060





TGAAGACAGA AGTTTGCACT ATCTTTCAGC TCCAGTTGGA GTTTTTTGTA CCAACTTTTA
3120





GGATTTTTTT TAATGTTTAA AACATCATTA CTATAAGAAC TTTGAGCTAC TGCCGTCAGT
3180





GCTGTGCTGT GCTATGGTGC TCTGTCTACT TGCACAGGTA CTTGTAAATT ATTAATTTAT
3240





GCAGAATGTT GATTACAGTG CAGTGCGCTG TAGTAGGCAT TTTTACCATC ACTGAGTTTT
3300





CCATGGCAGG AAGGCTTGTT GTGCTTTTAG TATTTTAGTG AACTTGAAAT ATCCTGCTTG
3360





ATGGGATTCT GGACAGGATG TGTTTGCTTT CTGATCAAGG CCTTATTGGA AAGCAGTCCC
3420





CCAACTACCC CCAGCTGTGC TTATGGTACC AGATGCAGCT CAAGAGATCC CAAGTAGAAT
3480





CTCAGTTGAT TTTCTGGATT CCCCATCTCA GGCCAGAGCC AAGGGGCTTC AGGTCCAGGC
3540





TGTGTTTGGC TTTCAGGGAG GCCCTGTGCC CCTTGACAAC TGGCAGGCAG GCTCCCAGGG
3600





ACACCTGGGA GAAATCTGGC TTCTGGCCAG GAAGCTTTGG TGAGAACCTG GGTTGCAGAC
3660





AGGAATCTTA AGGTGTAGCC ACACCAGGAT AGAGACTGGA ACACTAGACA AGCCAGAACT
3720





TGACCCTGAG CTGACCAGCC GTGAGCATGT TTGGAAGGGG TCTGTAGTGT CACTCAAGGC
3780





GGTGCTTGAT AGAAATGCCA AGCACTTCTT TTTCTCGCTG TCCTTTCTAG AGCACTGCCA
3840





CCAGTAGGTT ATTTAGCTTG GGAAAGGTGG TGTTTCTGTA AGAAACCTAC TGCCCAGGCA
3900





CTGCAAACCG CCACCTCCCT ATACTGCTTG GAGCTGAGCA AATCACCACA AACTGTAATA
3960





CAATGATCCT GTATTCAGAC AGATGAGGAC TTTCCATGGG ACCACAACTA TTTTCAGATG
4020





TGAACCATTA ACCAGATCTA GTCAATCAAG TCTGTTTACT GCAAGGTTCA ACTTATTAAC
4080





AATTAGGCAG ACTCTTTATG CTTGCAAAAA CTACAACCAA TGGAATGTGA TGTTCATGGG
4140





TATAGTTCAT GTCTGCTATC ATTATTCGTA GATATTGGAC AAAGAACCTT CTCTATGGGG
4200





CATCCTCTTT TTCCAACTTG GCTGCAGGAA TCTTTAAAAG ATGCTTTTAA CAGAGTCTGA
4260





ACCTATTTCT TAAACACTTG CAACCTACCT GTTGAGCATC ACAGAATGTG ATAAGGAAAT
4320





CAACTTGCTT ATCAACTTCC TAAATATTAT GAGATGTGGC TTGGGCAGCA TCCCCTTGAA
4380





CTCTTCACTC TTCAAATGCC TGACTAGGGA GCCATGTTTC ACAAGGTCTT TAAAGTGACT
4440





AATGGCATGA GAAATACAAA AATACTCAGA TAAGGTAAAA TGCCATGATG CCTCTGTCTT
4500





CTGGACTGGT TTTCACATTA GAAGACAATT GACAACAGTT ACATAATTCA CTCTGAGTGT
4560





TTTATGAGAA AGCCTTCTTT TGGGGTCAAC AGTTTTCCTA TGCTTTGAAA CAGAAAAATA
4620





TGTACCAAGA ATCTTGGTTT GCCTTCCAGA AAACAAAACT GCATTTCACT TTCCCGGTGT
4680





TCCCCACTGT ATCTAGGCAA CATAGTATTC ATGACTATGG ATAAACTAAA CACGTGACAC
4740





AAACACACAC AAAAGGGAAC CCAGCTCTAA TACATTCCAA CTCGTATAGC ATGCATCTGT
4800





TTATTCTATA GTTATTAAGT TCTTTAAAAT GTAAAGCCAT GCTGGAAAAT AATACTGCTG
4860





AGATACATAC AGAATTACTG TAACTGATTA CACTTGGTAA TTGTACTAAA GCCAAACATA
4920





TATATACTAT TAAAAAGGTT TACAGAATTT TATGGTGCAT TACGTGGGCA TTGTCTTTTT
4980





AGATGCCCAA ATCCTTAGAT CTGGCATGTT AGCCCTTCCT CCAATTATAA GAGGATATGA
5040





ACCAAAAAAA AAAAAAAAAA AA





SEQ ID NO. 78 Protein sequence


Protein Accession #t: NP_003465


1          11         21         31         41         51


|          |          |          |          |          |


MAARPLPVSP ARALLLALAG ALLAPCEARG VSLWNEGRAD EVVSASVRSG DLWIPVKSFD
60





SKNHPEVLNI RLQRESKELI INLERNEGLI ASSFTETHYL QDGTDVSLAR NYTVILGHCY
120





YHGHVRGYSD SAVSLSTCSG LRGLIVFENE SYVLEPMKSA TNRYKLFPAK KLKSVRGSCG
180





SHHNTPNLAA KNVFPPPSQT WARRHKRETL KATKYVELVI VADNREFQRQ GKDLEKVKQR
240





LIEIANHVDK FYRPLNIRIV LVGVEVWNDM DKCSVSQDPF TSLHEFLDWR KMKLLPRKSH
300





DNAQLVSGVY FQGTTIGMAP IMSMCTADQS GGIVMDHSDN PLGAAVTLAH ELGHNFGMNH
360





DTLDRGCSCQ MAVEKGGCIM NASTGYPFPM VFSSCSRKDL ETSLEKGMGV CLFNLPEVRE
420





SFGGQKCGNR FVEEGEECDC GEPEECMNRC CNATTCTLKP DAVCAHGLCC EDCQLKPAGT
480





ACRDSSNSCD LPEFCTGASP HCPANVYLHD GHSCQDVDGY CYNGICQTHE QQCVTLWGPG
540





AKPAPGICFE RVNSAGDPYG NCGKVSKSSF AKCEMRDAKC GKIQCQGGAS RPVIGTNAVS
600





IETNIPLQQG GRILCRGTHV YLGDDMPDPG LVLAGTKCAD GKICLNRQCQ NISVFGVHEC
660





AMQCHGRGVC NNRKNCHCEA HWAPPFCDKF GFGGSTDSGP IRQADNQGLT IGILVTILCL
720





LAAGFVVYLK RKTLIRLLFT NKKTTIEKLR CVRPSRPPRG FQPCQAHLGN LGKGLMRKPP
780





DSYPPKDNPR RLLQCQNVDI SRPLNGLNVP QPQSTQRVLP PLHRAPRAPS VPARPLPAKP
840





ALRQAQGTCK PNPPQKPLPA DPLARTTRLT HALARTPGQW ETGLRLAPLR PAPQYPHQVP
900





RSTNTAYIK





SEQ ID NO: 79 DNA sequence


Nucleic Acid Accession #: NN_003714


Coding sequence: 135. .1043


1          11         21         31         41         51


|          |          |          |          |          |


GAGGAGGAGG GAAAAGGCGA GCAAAAAGGA AGAGTGGGAG GAGGAGGGGA AGCGGCGAAG
60





GAGGAAGAGG AGGAGGAGGA AGAGGGGAGC ACAAAGGATC CAGGTCTCCC GACGGGAGGT
120





TAATACCAAG AACCATGTGT GCCGAGCGGC TGGGCCAGIT CATGACCCTG GCTTTGGTGT
180





TGGCCACCTT TGACCCGGCG CGGGGGACCG ACGCCACCAA CCCACCCGAG GGTCCCCAAG
240





ACAGGAGCTC CCAGCAGAAA GGCCGCCTGT CCCTGCAGAA TACAGCGGAG ATCCAGCACT
300





GTTTGGTCAA CGCTGGCGAT GTGGGGTGTG GCGTGTTTGA ATGTTTCGAG AACAACTCTT
360





GTGAGATTCG GGGCTTACAT GGGATTTGCA TGACTTTTCT GCACAACGCT GGAAAATTTG
420





ATGCCCAGGG CAAGTCATTC ATCAAAGACG CCTTGAAATG TAAGGCCCAC GCTCTGCGGC
480





ACAGGTTCGG CTGCATAAGC CGGAAGTGCC CGGCCATCAG GGAAATGGTG TCCCAGTTGC
540





AGCGGGAATG CTACCTCAAG CACGACCTGT GCGCGGCTGC CCAGGAGAAC ACCCGGGTGA
600





TAGTGGAGAT GATCCATTTC AAGGACTTGC TGCTGCACGA ACCCTACGTG GACCTCGTGA
660





ACTTGCTGCT GACCTGTGGG GAGGAGGTGA AGGAGGCCAT CACCCACAGC GTGCAGGTTC
720





AGTGTGAGCA GAACTGGGGA AGCCTGTGCT CCATCTTGAG CTTCTGCACC TCGGCCATCC
780





AGAAGCCTCC CACGGCGCCC CCCGAGCGCC AGCCCCAGGT GGACAGAACC AAGCTCTCCA
840





GGGCCCACCA CGGGGAAGCA GGACATCACC TCCCAGAGCC CAGGACTAGG GAGACTGGCC
900





GAGGTGCCAA GGGTGAGCGA GGTAGCAAGA GCCACCCAAA CGCCCATGCC CGAGGCAGAG
960





TCGGGGGCCT TGGGGCTCAG GGACCTTCCG GAAGCAGCGA GTGGGAAGAC GAACAGTCTG
1020





AGTATTCTGA TATCCGGAGG TGAAATGAAA GGCCTGGCCA CGAAATCTTT CCTCCACGCC
1080





GTCCATTTTC TTATCTATGG ACATTCCAAA ACATTTACCA TTAGAGAGGG GGGATGTCAC
1140





ACGCAGGATT CTGTGGGGAC TGTGGACTTC ATCGAGGTGT GTGTTCGCGG AACGGACAGG
1200





TGAGATGGAG ACCCCTGGGG CCGTGGGGTC TCAGGGGTGC CTGGTGAATT CTGCACTTAC
1260





ACGTACTCAA GGGAGCGCGC CCGCGTTATC CTCGTACCTT TGTCTTCTTT CCATCTGTGG
1320





AGTCAGTGGG TGTCGGCCGC TCTGTTGTGG GGGAGGTGAA CCAGGGAGGG GCAGGGCAAG
1380





GCAGGGCCCC CAGAGCTGGG CCACACAGTG GGTGCTGGGC CTCGCCCCGA AGCTTCTGGT
1440





GCAGCAGCCT CTGGTGCTGT CTCCGCGGAA GTCAGGGCGG CTGGATTCCA GGACAGGAGT
1500





GAATGTAAAA ATAAATATCG CTTAGAATGC AGGAGAAGGG TGGAGAGGAG GCAGGGGCCG
1560





AGGGGGTGCT TGGTGCCAAA CTGAAATTCA GTTTCTTGTG TGGGGCCTTG CGGTTCAGAG
1620





CTCTTGGCGA GGGTGGAGGG AGGAGTGTCA TTTCTATGTG TAATTTCTGA GCCATTGTAC
1680





TGTCTGGGCT GGGGGGGACA CTGTCCAAGG GAGTGGCCCC TATGAGTTTA TATTTTAACC
1740





ACTGCTTCAA ATCTCGATTT CACTTTTTTT ATTTATCCAG TTATATCTAC ATATCTGTCA
1800





TCTAAATAAA TGGCTTTCAA ACAAAGCAAC TGGGTCATTA AAACCAGCTC AAAGGCGGTT
1860





TAAAAAAAAA AAAACCAGCC CATCCTTTGA GGCTGATTTT TCTTTTTTTT AAGTTCTATT
1920





TTAAAAGCTA TCAAACAGCG ACATAGCCAT ACATCTGACT GCCTGACATG GACTCCTGCC
1980





CACTTGGGGG AAACCTTATA CCCAGAGGAA AATACACACC TGGGGAGTAC ATTTGACAPA
2040





TTTCCCTTAG GATTTCGTTA TCTCACCTTG ACCCTCAGCC AAGATTGGTA AAGCTGCGTC
2100





CTGGCGATTC CAGGAGACCC AGCTGGAAAC CTGGCTTCTC CATGTGAGGG GATGGGAAAG
2160





GAAAGAAGAG AATGAAGACT ACTTAGTAAT TCCCATCAGG AAATGCTGAC CTTTTACATA
2220





AAATCAAGGA GACTGCTGAA AATCTCTAAG GGACAGGATT TTCCAGATCC TAATTGGAAA
2280





TTTAGCAATA AGGAGAGGAG TCCAAGGGGA CAAATAAAGG CAGAGAGAGA GAGAGAGAGA
2340





GGGAGAGGAA GAAAAGAGAG AGAGAAAAGA GCCTCGTGCC





SEQ ID NO. 80 Protein sequence


Protein Accession #: NP_003705


1          11         21         31         41         51


|          |          |          |          |          |


MCAERLGQPM TLALVLATFD PARGTDATNP PEGPQDRSSQ QKGRLSLQNT AEIQHCLVNA
60





GDVGCGVFEC FENNSCEIRG LHGICMTFLH NAGKFDAQGK SFIKDALKCK AHALRHRFGC
120





ISRKCPAIRE MVSQLQRECY LKHDLCAAAQ ENTRVIVEMI NFKDLLLHEP YVDLVNLLLT
180





CGEEVKEAIT NSVQVQCEQN WGSLCSILSF CTSAIQKPPT APPERQPQVD RTKLSRAHHG
240





EAGHHLPEPS SRETGRGAKG ERGSKSHPNA HARGRVGGLG AQGPSGSSEW EDEQSEYSDI
300





RN





SEQ ID NO: 81 DNA sequence


Nucleic Acid Accession #: CAT cluster


1          11         21         31         41         51


|          |          |          |          |          |


AATCATGTTT TTGGAATAAA AATGGTAAAT CTTTTTTTTT TTTTTTTTTT GTTAGTAATG
60





GAAGTATTCT ATTATTTTTA ATTTTATCTA TGTACAGACA AGAGCTATAT GCGAAAGTAG
120





CTATTACAGA CCCATTATAG TTTCATCATT TATAACCAGC GTTCGTAGTA AAGCAACAGA
180





AATACATCTT CAATGCAGAC TTGCTCCCAG CATCTCTTTC CTTTCATCCT TGACCATATT
240





GCATCCTGGA CAGCAACAAG ACATCCTCAG CCCACCACCC CTTCCCCTCC AATGTCGACT
300





GAGTGTTCGG TCAACTGATA AGCAGTGCAG ACTCTTCATT TTGCTTTGTT GGTGCCTTCG
360





AGGCATGTGA GGGCACAGCC TCAAATTCCA GAGACCTTGC CTTCAGGATT TGAGCTGCGC
420





AAAGATGTGA AAGAAGACCT TTAGCCACTC AGTGTTATCA AAAGCAATCA CCAAAGAAGT
480





TTTTGCATCT GGCATTGTGT TGGGACGTCC ATCAGCAGTA CCGTACSGTC TCTTTACTGG
540





ACAAGTATTT ACACCTTGTT AACAGCAGTG TACACCCGGT GGAAAACTCC TATCTAATGC
600





CATGGCAGAA TTGTAAACAT TTCCTCCTTC ACCAAATTTC TGGATCGAAT AAACATGTAC
660





CCTTAAACTT TATTGGCTTC TCCGGTCTT GCCACTGCGGG GCCCAAAAAC TTTCAGAAGT
720





AGGAATCCTG TGGCATCTGC TAATGGTGAT TGGAAGAAAG AGTAGAGGTG ACAGTATCTA
780





TCGCTCCAGT ACCAGAACTA TTACGAAATG TTCCAGCTGC GATTTCACAG CAATCCCCCC
840





TGACCCCTCG ACGTGGTTCT CCTATTTCAG TCACCCTGTG CCC





SEQ ID NO: 82 DNA sequence


Nucleic Acid Accession #. XM_061091.1


Coding sequence: 1. .2481


1          11         21         31         41         51


|          |          |          |          |          |


ATGCCAAATA CTTCAGGAAC AACCAGGATT GAAATTTCGC TTCTCCAACA GCCCCCCGGG
60





CACCGACCGC TGGTCGCCGC TCTCCTTCCC CTCAGTCCCA GCCCCGACTT GGCTCTGGCG
120





CCCGGGTACC CGCCAGTGCC GGCTGCCGAT GACCCATTCA CGCTCCCCAT GATTGGAGGT
180





CAGATGCATG GTGAGAAGGT AGATCTCTGG AGCCTTGGTG TTCTTTCCTA TGAATTTTTA
240





GTTGGGAAGC CTCCTTTTGA GGCAAACGAA GTCCATGTAA GCAAAGAAAC CATCGGGAAG
300





ATTTCAGCTC CCAGCAAAAT GATGTGGTGC TCGGCTGCAG TCCACATCAT GTTTCTGTTA
360





CATGGGTCTA ACAGCGTCGG GAAAGGGAGC TTTGAAAGGT CCAAGCACTT TGCCATCACA
420





GTCTGTGACG GTCTGGACAT CAGCCCCGAG AGGGTCAGAG TGGGAGCATT CCAGTTCAGT
480





TCCACTCCTC ATCTGGAATT CCCCTTGGAT TCATTTTCAA CCCAACAGGA AGTGAAGGCA
540





AGAATCAAGA GGATGGTTTT CAAAGGAGGC CGCACGGAGA CGGAACTTGC TCTGAAATAC
600





CTTCTGCACA GAGGGTTGCC TGGAGGCAGA AATGCTTCTG TGCCCCAGAT CCTCATCATC
660





GTCACTGATG GGAAGTCCCA GGGGGATGTG GCACTGCCAT CCAAGCAGCT GAAGGAAAGG
720





GGTGTCACTG TGTTTGCTGT GGGGGTCAGG TTTCCCAGGT GGGAGGAGCT GCATGCACTG
780





GCCAGCGAGC CTAGAGGGCA GCACGTGCTG TTGGCTGAGC AGGTGGAGGA TGCCACCAAC
840





GGCCTCTTCA GCACCCTCAG CAGCTCGGCC ATCTGCTCCA GCGCCACGCC AGCTGGGAGC
900





CCCGAGCTTG TCTTCATGGA GCGGTTAATG GGCATCTCTC TGATAGGCCC CTGTGACTCG
960





CAGCCCTGCC AGAATGGAGG CACATGTGTT CCAGAAGGAC TGGACCGCTA CCAGTGCCTC
1020





TGCCCGCTGG CCTTTGGAGG GGAGGCTAAC TGTGCCCTGA AGCTGAGCCT GGAATGCAGG
1080





GTCGACCTCC TCTTCCTGCT GGACAGCTCT GCGGGCACCA CTCTGGACGG CTTCCTGCGG
1140





GCCAAAGTCT TCGTGAAGCG GTTTGTGCGG GCCGTGCTGA GCGAGGACTC TCGGGCCCGA
1200





GTGGGTGTGG CCACATACAG CAGGGAGCTG CTGGTGGCGG TGCCTGTGGG GGACTACCAG
1260





GATGTGCCTG ACCTGGTCTG GAGCCTCGAT GGCATTCCCT TCCGTGGTGG CCCCACCCTG
1320





ACGGGCAGTG CCTTGCGGCA GGCCGCAGAG CGTGGCTTCG GGAGCGCCAC CAGGACAGGC
1380





CAGGACCGGC CACGTAGAGT GGTGGTTTTG CTCACTGAGT CACACTCCGA GGATGAGGTT
1440





GCGGGCCCAG CGCGTCACGC AAGGGCGCGA GAGCTGCTCC TGCTGGGTGT AGGCAGTGAG
1500





GCCGTGCGGG CAGAGCTGGA GGAGATCACA GGCAGCCCAA AGCATGTGAT GGTCTACTCG
1560





GATCCTCAGG ATCTGTTCAA CCAAATCCCT GAGCTGCAGG GGAAGCTGTG CAGCCGGCAG
1620





CGGCCAGGGT GCCGGACACA AGCCCTGGAC CTCGTCTTCA TGTTGGACAC CTCTGCCTCA
1680





GTAGGGCCCG AGAATTTTGC TCAGATGCAG AGCTTTGTGA GAAGCTGTGC CCTCCAGTTT
1740





GAGGTGAACC CTGACGTGAC ACAGGTCGGC CTGGTGGTGT ATGGCAGCCA GGTGCAGACT
1800





GCCTTCGGGC TGGACACCAA ACCCACCCGG GCTGCGATGC TGCGGGCCAT TAGCCAGGCC
1860





CCCTACCTAG GTGGGGTGGG CTCAGCCGGC ACCGCCCTGC TGCACATCTA TGACAAACTG
1920





ATGACCGTCC AGAGGGGTGC CCGGCCTGGT GTCCCCAAAG CTGTGGTGGT GCTCACAGGC
1980





GGGAGAGGCG CAGAGGATGC AGCCGTTCCT GCCCAGAAGC TGAGGAACAA TGGCATCTCT
2040





GTCTTGGTCG TGGGCGTGGG GCCTGTCCTA AGTGAGGGTC TGCGGAGGCT TGCAGGTCCC
2100





CGGGATTCCC TGATCCACGT GGCAGCTTAC GCCGACCTGC GGTACCACCA GGACGTGCTC
2160





ATTGAGTGGC TGTGTGGAGA AGCCAAGCAG CCAGTCAACC TCTGCAAACC CAGCCCGTGC
2220





ATGAATGAGG GCAGCTGCGT CCTGCAGAAT GGGAGCTACC GCTGCAAGTG TCGGGATGGC
2280





TGGGAGGGCC CCCACTGCGA GAACCGTGAG TGGAGCTCTT GCTCTGTATG TGTGAGCCAG
2340





GGATGGATTC TTGAGACGCC CCTGAGGCAC ATGGCTCCCG TGCAGGAGGG CAGCAGCCGT
2400





ACCCCTCCCA GCAACTACAG AGAAGGCCTG GGCACTGAAA TGGTGCCTAC CTTCTGGAAT
2460





GTCTGTGCCC CAGGTCCTTA G





SEQ ID NO: 83 Protein sequence


Protein Accession #: XP_061091.1


1          11         21         31         41         51


|          |          |          |          |          |


MPNTSGTTRI EIWLLQEPPG HRALVAALLP VSPSPELALA PGYPPVPAAD DRFTLPMIGG
60





QMHCEKVDLW SLCVLCYEFL VGKPPFEANE VHVSKETIGK ISAASKMNWC SAAVDIMFLL
120





DGSNSVGKGS FERSKNFAIT VCDGLDISPE RVRVGAFQFS STPHLEFPLD SFSTQQEVKA
180





RIKRMVFKGG RTETELALKY LLHRGLPGGR NASVPQILII VTDGKSQGDV ALPSKQLKER
240





GVTVFAVGVR FPRWEELHAL ASEPRGQHVL LAEQVEDATN GLFETLSSSA ICSSATPAGS
300





PELVFMERLM GISLIGPCDS QPCQNGGTCV PEGLDGYQCL CPLAFGGEAN CALKLSLECR
360





VDLLFLLDSS AGTTLDGFLR AKVFVKRFVR AVLSEDSRAR VGVATYSREL LVAVPVCEYQ
420





DVPDLVWSLD GIPFRGGPTL TGSALRQAAE RGFGSATRTG QDRPRRVVVL LTESHSEDEV
480





AGPARHARAR ELLLLGVGSE AVRAELEEIT GSPKHVMVYS DPQDLFNQIP ELQCKLCSRQ
540





RPGCRTQALD LVFNLDTSAS VGPENFAQMQ SPVRSCALQF EVNPDVTQVG LVVYGSQVQT
600





AFGLDTEPTR AAMLRAISQA PYLGGVGSAG TALLHIYDKV MTVQRGARPG VPKAVVVLTG
660





GRGAEDAAVP AQKLRNNGIS VLVVGVGPVL SEGLRRLAGP RDSLIHVAAY ADLRYHQDVL
720





IEWLCGEAKQ PVNLCKPSPC MNEGSCVLQN GSYRCKCRDG WEGPHCENRE WSSCSVCVSQ
780





GWILETPLRH MAPVQEGSSR TPPSNYREGL GTEMVPTFWN VCAPGP





SEQ ID NO: 84 DNA sequence


Nucleic Acid Accession #: Eos sequence


Coding sequence: 1. .2424


1          11         21         31         41         51


|          |          |          |          |          |


ATGCCCCCTT TCCTGTTGCT GGAGGCCGTC TGTGTTTTCC TGTTTTCCAG AGTGCCCCCA
60





TCTCTCCCTC TCCAGGAACT CCATGTAAGC AAAGAAACCA TCGGGAAGAT TTCAGCTGCC
120





AGCAAAATGA TGTGGTCCTC GGCTGCACTG GACATCATGT TTCTGTTAGA TGGGTCTAAC
180





AGCGTCGGGA AAGGGAGCTT TGAAAGGTCC AAGCACTTTG CCATCACAGT CTGTGACGGT
240





CTGGACATCA GCCCCGAGAG GGTCAGAGTC GGAGGATTGC AGTTCAGTTC CACTCCTCAT
300





CTGGAATTCC CCTTGGATTC ATTTTCAACC CAACAGGAAG TGAAGGCAAG AATCAAGAGG
360





ATGGTTTTCA AAGGAGGGCG CACCGAGACG GAACTTGCTC TGAAATACCT TCTGCACAGA
420





GGGTTGCCIG GAGGCAGAAA TGCTTCTGTG CCCCAGATCC TCATCATCGT CACTGATGGG
480





AAGTCCCAGG GGGATGTGGC ACTGCCATCC AAGCAGCTGA AGGAAAGGGG TGTCACTGTG
540





TTTGCTGTGG GGGTCAGGTT TCCCAGGTGG GAGGAGCTGC ATGCACTGGC CACCGAGGCT
600





AGAGGGCAGC ACGTGCTGTT GGCTGAGCAG GTGGAGGATG CCACCAACGG CCTCTTCAGC
660





ACCCTCAGCA GCTCGGCCAT CTGCTCCAGC GCCACGCCAG ACTGCAGGGT CGAGGCTCAC
720





CCCTGTGAGC ACAGGACGCT GGAGATGGTC CGGGAGTTCG CTGGCAATGC CCCATGCTGG
780





AGAGGATCGC GGCGGACCCT TGCGGTGCTG GCTGCACACT GTCCCTTCTA CAGCTGGAAG
840





AGAGTGTTCC TAACCCACCC TGCCACCTGC TACAGGACCA CCTGCCCAGG CCCCTGTGAC
900





TCGCAGCCCT GCCAGAATGG AGGCACATGT GTTCCAGAAG GACTGGACGG CTACCAGTGC
960





CTCTGCCCGC TGGCCTTTGG AGGGGAGGCT AACTGTGCCC TGAAGCTGAG CCTGGAATGC
1020





AGGGTCGACC TCCTCTTCCT GCTGGACAGC TCTGCGGGCA CCACTCTGGA CGGCTTCCTG
1080





CGGGCCAAAG TCTTCGTGAA GCGGTTTGTG CGGGCCGTGC TGAGCGAGGA CTCTCGGGCC
1140





CGAGTGGGTG TGGCCACATA CACCAGGGAG CTGCTGGTGG CGGTGCCTGT GGGGGAGTAC
1200





CAGGATGTGC CTGACCTGGT CTGGAGCCTC GATGGCATTC CCTTCCGTGG TGGCCCCACC
1260





CTGACGGGCA GTGCCTTGCG GCAGGCGGCA GAGCGTGGCT TCGGGAGCGC CACCAGGACA
1320





GGCCAGGACC GGCCACGTAG AGTGGTGGTT TTGCTCACTG AGTCACACTC CGAGGATGAG
1380





GTTGCGGGCC CAGCGCGTCA CGCAAGGGCG CGAGAGCTGC TCCTGCTGGG TGTAGGCAGT
1440





GAGGCCGTGC GGGCAGAGCT GGAGGAGATC ACAGGCAGCC CAAAGCATGT GATGGTCTAC
1500





TCGGATCCTC AGGATCTGTT CAACCAAATC CCTGAGCTGC AGGGGAAGCT GTGCAGCCGG
1560





CAGCGGCCAG GGTGCCGGAC ACAAGCCCTG GACCTCGTCT TCATGTTGGA CACCTCTGCC
1620





TCAGTAGGGC CCGAGAATTT TGCTCAGATG CAGAGCTTTG TGAGAAGCTG TGCCCTCCAG
1680





TTTGAGGTGA ACCCTGACGT GACACAGGTC GGCCTGGTGG TGTATGGCAG CCAGGTGCAG
1740





ACTGCCTTCG GGCTGGACAC CAAACCCACC CGGGCTGCGA TGCTGCGGGC CATTAGCCAG
1800





GCCCCCTACC TAGGTGGGGT GGGCTCAGCC GGCACCGCCC TGCTGCACAT CTATGACAAA
1860





GTGATGACCG TCCAGAGGGG TGCCCGGCCT GGTGTCCCCA AAGCTGTGGT GGTGCTCACA
1920





GGCGGGAGAG GCGCAGAGGA TGCAGCCGTT CCTGCCCAGA AGCTGAGGAA CAATGGCATC
1980





TCTGTCTTGG TCGTGGGCGT GGGGCCTGTC CTAAGTGAGG GTCTGCGGAG GCTTGCAGGT
2040





CCCCGGGATT CCCTGATCCA CGTGGCAGCT TACGCCGACC TGCCGTACCA CCAGGACGTG
2100





CTCATTGAGT GGCTGTGTGG AGAAGCCAAG CAGCCAGTCA ACCTCTGCAA ACCCAGCCCG
2160





TGCATGAATG AGGGCAGCTG CGTCCTGCAG AATGGGAGCT ACCGCTGCAA GTGTCGGGAT
2220





GGCTGGGAGG GCCCCCACTG CGAGAACCGT GAGTGGAGCT CTTGCTCTGT ATGTGTGAGC
2280





CAGGGATGGA TTCTTGAGAC GCCCCTGAGG CACATGGCTC CCGTGCAGGA GGGCAGCAGC
2340





CGTACCCCTC CCAGCAACTA CAGAGAAGGC CTGGGCACTG AAATGGTGCC TACCTTCTGG
2400





AATGTCTGTG CCCCAGGTCC TTAG





SEQ ID NO: 85 Protein sequence


Protein Accession #: Eos sequence


1          11         21         31         41         51


|          |          |          |          |          |


MPPFLLLEAV CVFLFSRVPP SLPLQEVNVS KETIGKISAA SKNNWCSAAV DIMFLLDGSN
60





SVGKGSFERS KNFAITVCDG LDISPERVRV GAPQPSSTPN LEFPLDSFST QQEVKARIKR
120





MVFKGGRTET ELALKYLLNR GLPGGRNASV PQILIIVTDG RSQGDVALPS KQLKERGVTV
180





PAVGVRFPRW RELNALASEP RGQNVLLAEQ VEDATNGLFS TLSSSAICSS ATPDCRVEAN
240





PCENRTLEMV REFAGNAPCW RGSRRTLAVL AAHCPPYSWK RVPLTNPATC YRTTCPGPCD
300





SQPCQNGGTC VPEGLDGYQC LCPLAFGGEA NCALKLSLEC RVDLLPLLDS SAGTTLDGFL
360





RAKVFVKRFV 8AVLSEDSRA RVGVATYSRE LLVAVPVGEY QDVPDLVWSL DGIPFRGGPT
420





LTGSALRQAA EROFOSATET GQDRPRRVVV LLTESNSEDE VAGPARHARA RELLLLGVGS
480





EAVRAELEEI TGSPKNVNVY SDPQDLFNQI PELQGKLCSR QRPGCRTQAL DLVFMLDTSA
540





SVGPENPAQN QSFVRSCALQ FEVNPDVTQV GLVVYGSQVQ TAFGLDTKPT RAANLRAISQ
600





APYLGOVOSA GTALLNIYDK VMTVQRGARP GVPKAVVVLT GGRGAEDAAV PAQKLRNNGI
660





SVLVVGVGPV LSEGLRRLAG PRDSLINVAA YADLRYNQDV LIEWLCGEAK QPVNLCKPSP
720





CMNEGSCVLQ NGSYRCKCRD GWEGPNCENR EWSSCSVCVS QGWILETPLR HMAPVQEGSS
780





RTPPSNYREG LGTENVPTFW NVCAPGP





SEQ ID NO: 86 DNA sequence


Nucleic Acid Accession #: Eos sequence


Coding sequence: 89. .2356


1          11         21         31         41         51


|          |          |          |          |          |


GCCCCCTGGC CCGAGCCGCG CCCGGGTCTG TGAGTAGAGC CGCCCGGGCA CCGAGCGCTG
60





GTCGCCGCTC TCCTTCCGTT ATATCAACAT GCCCCCTTTC CTGTTGCTGG AAGCCGTCTG
120





TGTTTTCCTG TTTTCCAGAG TGCCCCCATC TCTCCCTCTC CAGGAAGTCC ATGTAAGCAA
180





AGAAACCATC GGGAAGATTT CAGCTGCCAG CAAAATGATG TGGTGCTCGG CTGCAGTGGA
240





CATCATGTTT CTGTTAGATG GGTCTAACAG CGTCGGGAAA GGGAGCTTTG AAAGGTCCAA
300





GCACTTTGCC ATCACAGTCT GTGACGGTCT GGACATCAGC CCCGAGAGGG TCAGAGTGGG
360





AGCATTCCAG TTCAGTTCCA CTCCTCATCT GGAATTCCCC TTGGATTCAT TTTCAACCCA
420





ACAGGAAGTG AAGGCAAGAA TCAAGAGGAT GGTTTTCAAA GGAGGGCGCA CGGAGACGGA
480





ACTTGCTCTG AAATACCTTC TGCACAGAGG GTTGCCTGGA GGCAGAAATG CTTCTGTGCC
540





CCAGATCCTC ATCATCGTCA CTGATGGGAA GTCCCAGGGG GATGTGGCAC TGCCATCCAA
600





GCAGCTGAAG GAAAGGGGTG TCACTGTGTT TGCTGTGGGG GTCACGTTTC CCAGGTGGGA
660





GGAGCTGCAT GCACTGGCCA GCGAGCCTAG AGGGCAGCAC GTGCTCTTGG CTGAGCAGGT
720





GGAGGATGCC ACCAACGGCC TCTTCACCAC CCTCAGCAGC TCGGCCATCT GCTCCAGCGC
780





CACGCCAGAC TGCAGGGTCG AGGCTCACCC CTGTGAGCAC AGGACGCTGG AGATGGTCCG
840





GGAGTTCGCT GGCAATGCCC CATGCTGGAG AGGATCGCGG CGGACCCTTG CGGTGCTGGC
900





TGCACACTGT CCCTTCTACA GCTGGAAGAG AGTGTTCCTA ACCCACCCTG CCACCTGCTA
960





CAGGACCACC TGCCCAGGCC CCTGTGACTC GCAGCCCTGC CAGAATGGAG GCACATGTGT
1020





TCCAGAAGGA CTGGACGGCT ACCAGTGCCT CTGCCCGCTG GCCTTTGGAG GGGAGGCTAA
1080





CTGTGCCCTG AAGCTGAGCC TGGAATGCAG GGTCGACCTC CTCTTCCTGC TGGACAGCTC
1140





TGCGGGCACC ACTGTGGACG GCTTCCTGCG GGCCAAAGTC TTCGTGAAGC GGTTTGTGCG
1200





GGCCGTGCTG ACCGAGGACT CTCGGGCCCG AGTGGGTGTG GCCACATACA GCAGGGAGGT
1260





GCTGGTGGCG GTGCCTGTGG GGGAGTACCA GGATGTGCCT GACCTGGTCT GGAGCCTCGA
1320





TGGCATTCCC TTCCGTGGTG GCCCCACCCT GACGGGCAGT GCCTTGCGGC AGGCGGCAGA
1380





GCGTGGCTTC GGGAGCGCCA CCAGGACAGG CCAGGACCGG CCACGTAGAG TGGTGGTTTT
1440





GCTCACTGAG TCACACTCCG AGGATGAGGT TGCGGGCCCA GCGCGTCACG CAAGGGCGCG
1500





AGAGCTGCTC CTGCTGGGTG TAGGCAGTGA GGCCGTGCGG GCAGAGCTGG AGGAGATCAC
1560





AGGCAGCCCA AAGCATGTGA TGGTCTACTC GGATCCTCAG GATCTGTTCA ACCAAATCCC
1620





TGAGCTGCAG GGGAAGCTGT GCAGCCGGCA GCGGCCAGGG TGCCGGACAC AAGCCCTGGA
1680





CCTCGTCTTC ATGTTGGACA CCTCTGCCTC AGTAGGGCCC GAGAATTTTG CTCAGATGCA
1740





GAGCTTTGTG AGAAGCTGTG CCCTCCAGTT TGAGGTGAAC CCTGACGTGA CACAGGTCGG
1800





CCTGGTGGTG TATGGCAGCC AGGTGCAGAC TGCCTTCGGG CTGGACACCA AACCCACCCG
1860





GGCTGCGATG CTGCGGGCCA TTAGCCAGGC CCCCTACCTA GGTGGGGTGG GCTCAGCCGG
1920





CACCGCCCTG CTGCACATCT ATGACAAAGT GATGACCGTC CAGAGGGGTG CCCGGCCTGG
1980





TGTCCCCAAA GCTGTGGTGG TGCTCACAGG CGGGAGAGGC GCAGAGGATG CAGCCGTTCC
2040





TGCCCAGAAG CTGAGGAACA ATGGCATCTC TGTCTTGGTC GTGGGCGTGG GGCCTGTCCT
2100





AAGTGAGGGT CTGCGGAGGC TTGCAGGTCC CCGGGATTCC CTGATCCACG TGGCAGCTTA
2160





CGCCGACCTG CGGTACCACC AGGACGTGCT CATTGAGTGG CTGTGTGGAG AAGCCAAGCA
2220





GCCAGTCAAC CTCTGCAAAC CCAGCCCGTG CATGAATGAG GGCAGCTGCG TCCTGCAGAA
2280





TGGGAGCTAC CGCTGCAAGT GTCGGGATGG CTGGGAGGGC CCCCACTGCG AGAACCGATT
2340





CTTGAGACGC CCCTGAGGCA CATGGCTCCC GTGCAGGAGG GCAGCAGCCG TACCCCTCCC
2400





AGCAACTACA GAGAAGGCCT GGGCACTGAA ATGGTGCCTA CCTTCTGGAA TGTCTGTGCC
2460





CCAGGTCCTT AGAATGTCTG CTTCCCGCCG TGGCCAGGAC CACTATTCTC ACTGAGGGAG
2520





GAGGATGTCC CAACTGCAGC CATGCTGCTT AGAGACAAGA AAGCAGCTGA TGTCACCCAC
2580





AAACGATGTT GTTGAAAAGT TTTGATGTGT AAGTAAATAC CCACTTTCTG TACCTGCTGT
2640





GCCTTGTTGA GGCTATGTCA TCTGCCACCT TTCCCTTGAG GATAAACAAG GGGTCCTGAA
2700





GACTTAAATT TAGCGGCCTG ACGTTCCTTT GCACACAATC AATGCTCGCC AGAATGTTGT
2760





TGACACAGTA ATGCCCAGCA GAGGCCTTTA CTAGAGCATC CTTTGGACGG





SEQ ID NO: 87 Protein sequence


Protein Accession #: Eos sequence


1          11         21         31         41         51


|          |          |          |          |          |


MPPFLLLEAV CVFLFSRVPP SLPLQEVHVS KETIGKISAA SKNMNCSAAV DIMFLLDGSN
60





SVGKGSFERS KHFAITVCDG LDISPERVRV GAFQFSSTPH LEFPLDSFST QQEVKARIKR
120





MVFKGGRTET ELALKYLLHR GLPGGRNASV PQILIIVTDG KSQGDVALPS KQLKERGVTV
180





FAVGVRFPRW EELHALASEP RGQHVLLAEQ VEDATNGLFS TLSSSAICSS ATPDCRVEAH
240





PCEHRTLEMV REFAGNAPCW RGSRRTLAVL AAHCPFYSWK RVFLTHPATC YRTTCPGPCD
300





SQPCQNGGTC VPEGLDGYQC LCPLAFGGEA NCALKLSLEC RVDLLFLLDS SAGTTLDGPL
360





RAKVFVKRFV RAVLSEDSRA RVGVATYSRE LLVAVPVGEY QDVPDLVWSL DGIPFRGGPT
420





LTGSALRQAA ERGFGSATRT GQDRPRRVVV LLTESHSEDE VAGPARHARA RELLLLGVGS
480





EAVRAELEEI TGSPKHVMVY SDPODLENQI PELQGKLCSR QRPGCRTQAL DLVFMLDTSA
540





SVGPENFAQM QSFVRSCALQ FEVNPDVTQV GLVVYGSQVQ TAFGLDTKPT RAAMLRAISQ
600





APYLGGVGSA GTALLHIYDK VMTVQRGARP GVPKAVVVLT GGRGAEDAAV PAQKLRNNGI
660





SVLVVGVGPV LSEGLRRLAG PRDSLIHVAA YADLRYHQDV LIEWLCGEAK QPVNLCKPSP
720





CMNEGSCVLQ NGSYRCKCRD GWEGPHCENR FLRRP





SEQ ID NO: 88 DNA sequence


Nucleic Acid Accession #: NM_019894


Coding sequence: 1. .1314


1          11         21         31         41         51


|          |          |          |          |          |


ATGTTACAGG ATCCTGACAG TGATCAACCT CTGAACAGCC TCGATGTCAA ACCCCTGCGC
  60





AAACCCCGTA TCCCCATGGA GACCTTCAGA AAGGTGGGGA TCCCCATCAT CATAGCACTA
120





CTGAGCCTGG CGAGTATCAT CATTGTGGTT GTCCTCATCA AGGTGATTCT GGATAAATAC
180





TACTTCCTCT GCGGGCAGCC TCTCCACTTC ATCCCGAGGA AGCAGCTGTG TGACGGAGAG
240





CTGGACTGTC CCTTGGGGGA GGACGAGGAG CACTGTGTCA AGAGCTTCCC CGAAGGGCCT
300





GCAGTGGCAG TCCGCCTCTC CAAGGACCGA TCCACACTGC AGGTGCTGGA CTCGGCCACA
360





GGGAACTGGT TCTCTGCCTG TTTCGACAAC TTCACAGAAG CTCTCGCTGA GACAGCCTGT
420





AGGCAGATGG GCTACAGCAG CAAACCCACT TTCAGAGCTG TGGAGATTGG CCCAGACCAG
480





GATCTGGATG TTGTTGAAAT CACAGAAAAC AGCCAGGAGC TTCGCATGCG GAACTCAAGT
540





GGGCCCTGTC TCTCAGGCTC CCTGGTCTCC CTGCACTGTC TTGCCTGTGG GAAGAGCCTG
600





AAGACCCCCC GTGTGGTGGG TGGGGAGGAG GCCTCTGTGG ATTCTTGGCC TTGGCAGGTC
660





AGCATCCAGT ACGACAAACA GCACGTCTGT GGAGGGAGCA TCCTGGACCC CCACTGGGTC
720





CTCACGGCAG CCCACTGCTT CAGGAAACAT ACCGATGTGT TCAACTGGAA GGTGCGGGCA
780





GGCTCAGACA AACTGGGCAC CTTCCCATCC CTGGCTGTGG CCAAGATCAT CATCATTGAA
840





TTCAACCCCA TCTACCCCAA AGACAATGAC ATCGCCCTCA TGAAGCTGCA GTTCCCACTC
900





ACTTTCTCAG GCACAGTCAG CCCCATCTGT CTGCCCTTCT TTGATGAGGA GCTCACTCCA
960





GCCACCGCAC TCTCCATCAT TGCATGGCGC TTTACGAAGC AGAATGGAGG GAAGATGTCT
1020





GACATACTGC TGCAGGCGTG AGTCCAGGTC ATTGACACCA CACGGTGCAA TGCAGACCAT
1080





SCGTACCAGG GGGAAGTCAC CGAGAAGATG ATGTGTGCAG GCATCCCGGA AGGGGGTGTG
1140





GACACCTGCC AGGGTGACAG TGGTGGGCCC CTGATGTACC AATCTGACCA GTGGCATGTG
1200





GTGGGCATCG TTAGCTGGGG CTATGGCTGC GGGGGCCCGA GCACCCCAGG AGTATACACC
1260





AACGTCTCAG CCTATCTCAA CTGGATCTAC AATGTCTGGA AGGCTGAGCT GTAA





SEQ ID NO: 89 Protein sequence


Protein Accession #: NP_063947.1


1          11         21         31         41         51


|          |          |          |          |          |


MLQDPDSDQP LNSLDVKPLR KPRIPMETFR EVGIPIIIAL LSLASIIIVV VLIKVILDKY
60





YFLCGQPLHF IPRKQLCDGE LDCPLGEDEE NCVKSFPEGP AVAVRLSKDR STLQVLDSAT
120





GNWFSACFDN FTEALAETAC RQMGYSSKPT FRAVEIGPDQ DLDVVEITEN SQELRMRNSS
180





GPCLSGSLVS LHCLACGKSL KTPRVVGGEE ASVDSWPWQV SIQYDKQHVC GGSILDPHWV
240





LTAAHCFRKH TDVFNWKVRA GSGKLGSFPS LAVAKIIIIE FNPMYPKDND IALMKLQFPL
300





TFSGTVRPIC LPFFDEELTP ATPLWIIGWG FTKQNGGKMS DILLQASVQV IDSTRCNADD
360





AYQGEVTEKM MCAGIPEGGV GTCQGDSGGP LMYQSDQWHV VGIVSWGYGC GGPSTPGVYT
420





KVSAYLNWIY NVWKAEL





SEQ ID NO: 90 DNA sequence


Nucleic Acid Accession #: NM_002776.1


Coding sequence: 82..912


1          11         21         31         41         51


|          |          |          |          |          |


ACCACCGCCA GACCACAGGC AGGGCAGAGG CACGTCTGGG TCCCCTCCCT CCTTCCTATC
60





GGCGACTCCC AGATCCTGGC CATGAGAGCT CCGCACCTCC ACCTCTCCGC CGCCTCTCGC
120





GCCCGGGCTC TGGCGAAGCT GCTGCCGCTG CTGATGGCGC AACTCTGGGC CGCAGAGGCG
180





GCGCTGCTCC CCCAAAACGA CACGCGCTTG GACCCCGAAG CCTATGGCGC CCCGTGCGCG
240





CGCGGCTCGC AGCCCTGGCA GGTCTCGCTC TTCAACGGCC TCTCGTTCCA CTGCGCGGGT
300





GTCCTGGTGG ACCAGAGTTG GGTGCTGACG GCCGCGCACT GCGGAAACAA GCCACTGTGG
360





GCTCGAGTAG GGGATGATCA CCTGCTGCTT CTTCAGGGCG AGCAGCTCCG CCGGACGACT
420





CGCTCTGTTG TCCATCCCAA GTACCACCAG GGCTCAGGCC CCATCCTGCC AAGGCGAACG
480





GATGAGCACG ATCTCATGTT GCTAAAGCTG CCCAGGCCCG TAGTGCCGGG GCCCCGCGTC
540





CGGGCCCTGC AGCTTCCCTA CCGCTGTGCT CAGCCCGGAG ACCAGTGCCA GGTTGCTGGC
600





TGGGCCACCA CGGCCGCCCG GAGAGTGAAG TACAACAAGG GCCTGACCTG CTCCAGCATC
660





ACTATCCTGA GCCCTAAAGA GTGTGAGGTC TTCTACCCTG GCGTGGTCAC CAACAACATG
720





ATATGTGCTG GACTGGACCG GGGCCAGGAC CCTTGCCAGA GTGACTCTGG AGGCCCCCTG
780





GTCTGTGACG AGACCCTCCA AGGCATCCTC TCGTGGGGTG TTTACCCCTG TGGCTCTGCC
840





CAGCATCCAG CTGTCTACAC CCAGATCTGC AAATACATGT CCTGGATCAA TAAAGTCATA
900





CGCTCCAACT GATCCAGATG CTACGCTCCA GCTGATCCAG ATGTTATGCT CCTGCTGATC
960





CAGATGCCCA GAGGCTCCAT CGTCCATCCT CTTCCTCCCC AGTCGGCTGA ACTCTCCCCT
1020





TGTCTGCACT GTTCAAACCT CTGCCGCCCT CCACACCTCT AAACATCTCC CCTCTCACCT
1080





CATTCCCCCA CCTATCCCCA TTCTCTGCCT GTACTGAAGC TGAAATGCAG GAAGTGGTGG
1140





CAAAGGTTTA TTCCAGAGAA GCCAGGAAGC CGGTCATCAC CCAGCCTCTG AGAGCAGTTA
1200





CTGGGGTCAC CCAACCTGAC TTCCTCTGCC ACTCCCCGCT GTGTGACTTT GGGCAAGCCA
1260





AGTGCCCTCT CTGAACCTCA GTTTCCTCAT CTGCAAAATG GGAACAATGA CGTGCCTACC
1320





TCTtAGACAT GTTGTGAGGA GACTATGATA TAACATGTGT ATGTAAATCT TCATGTGATT
1380





GTCATGTAAG GCTTAACACA GTGGGTGGTG AGTTCTGACT AAAGGTTACC TGTTGTCGTG
1440





AAAAAAAAAA AAAA





SEQ ID NO: 91 Protein sequence


Protein Accession #: NP_002767.1


1          11         21         31         41         51


|          |          |          |          |          |


MRAPNLNLSA ASGARALAKL LPLLMAQLWA AEAALLPQND TRLDPEAYGA PCARGSQPWQ
60





VSLFNGLSFN CAGVLVGQSW VLTAANCGNK PLWARVGDDN LLLLQGEQLR RTTRSVVNPK
120





YHQGSGPILP RRTDENDLML LKLARPVVPG PRVRALQLPY RCAQPGDQCQ VAGWGTTAAR
180





RVKYNKGLTC SSITILSPKE CEVFYPGVVT NNNICAGLDR GQDPCQSDSG GPLVCDETLQ
240





GILSNGVYPC GSAQNPAVYT QICKYMSWIN KVIRSN





SEQ ID NO: 92 DNA sequence


Nucleic Acid Accession #: NM_032044.1


Coding sequence: 182-658


1          11         21         31         41         51


|          |          |          |          |          |


AAGATATAAA AGCTCCAGAA ACGTTGACTG GGACCACTGG AGACACTGAA GAAGGCAGGG
60





GCCCTTAGAG TCTTGGTTGC CAAACAGATT TGCAGATCAA GGAGAACCCA GGAGTTTCAA
120





AGAAGCGCTA GTAAGGTCTC TGAGATCCTT GCACTAGCTA CATCCTCAGG GTAGGAGGAA
180





GATGGCTTCC AGAAGCATGC GGCTGCTCCT ATTGCTGAGC TGCCTGGCCA AAACAGGAGT
240





CCTGGGTGAT ATCATCATGA GACCCAGCTG TGCTCCTGGA TGGTTTTACC ACAAGTCCAA
300





TTGCTATGGT TACTTCAGGA AGCTGAGGAA CTGGTCTGAT GCCGAGCTCG AGTGTCAGTC
360





TTACGGAAAC GGAGCCCACC TGGCATCTAT CCTGAGTTTA AAGGAAGCCA GCACCATAGC
420





AGAGTACATA AGTGGCTATC AGAGAAGCCA GCCGATATGG ATTGGCCTGC ACGACCCACA
480





GAAGAGGCAG CAGTGGCAGT GGATTGATGG GGCCATGTAT CTGTACAGAT CCTGGTCTGG
540





CAAGTCCATG GGTGGGAACA AGCACTGTGC TGAGATGAGC TCCAATAACA ACTTTTTAAC
600





TTGGAGCAGC AACGAATGCA ACAAGCGCCA ACACTTCCTG TGCAAGTACC GACCATAGAG
660





CAAGAATCAA GATTCTGCTA ACTCCTGCAC AGCCCCGTCC TCTTCCTTTC TGCTAGCCTG
720





GCTAAATCTG CTCATTATTT CAGAGGGGAA ACCTAGCAAA CTAAGAGTGA TAAGGGCCCT
780





ACTACACTGG CTTTTTTAGG CTTAGAGACA GAAACTTTAG CATTGGCCCA GTAGTGGCTT
840





CTAGCTCTAA ATGTTTGCCC CGCCATCCCT TTCCACAGTA TCCTTCTTCC CTCCTCCCCT
900





GTCTCTGGCT GTCTCCAGCA GTCTAGAAGA GTGCATCTCC AGCCTATGAA ACAGCTGGGT
960





CTTTGGCCAT AAGAAGTAAA GATTTGAAGA CAGAAGGAAG AAACTCAGGA GTAAGCTTCT
1020





AGACCCCTTC AGCTTCTACA CCCTTCTGCC CTCTCTCCAT TGCCTGCACC CCACCCCAGC
1080





CACTCAACTC CTGCTTGTTT TTCCTTTGGC CATAGGAAGG TTTACCAGTA GAATCCTTGC
1140





TAGGTTGATG TGGGCCATAC ATTCCTTTAA TAAACCATTG TGTACATAAG AAAAAAAAAA





SEQ ID NO: 93 Protein sequence


Protein Accession #: NP_114433.1


1          11         21         31         41         51


|          |          |          |          |          |


MASRSMRLLL LLSCLAKTGV LGDIIMRPSC APGWFYHKSN CYGYFRKLRN WSDAELECQS
60





YGNGAHLASI LSLKEASTIA EYISGYQRSQ PIWIGLHDPQ KRQQWQWIDG AMYLYRSWSG
120





KSMGGNKHCA EMSSNNNFLT WSSNECNKRQ HFLCKYRP





SEQ ID NO. 94 DNA sequence


Nucleic Acid Accession #: XM_051860


Coding sequence. 1..4086


1         11         21         31         41         51


|          |          |          |          |          |


GAGCTAGCGC TCAAGCAGAG CCCAGCGCCG TGCTATCGGA CAGAGCCTGG CGAGCGCAAG
60





CGGCGCGGGG AGCCAGCGGG GCTGAGCGCG GCCAGGGTCT GAACCCAGAT TTCCCACACT
120





AGCTACCACT CCGCTTGCCC ACGCCCCGCC AGCTCGCGGC GCCTGGCGGT CAGCGACCAC
180





ACGTCCGGGG CCGCTGCGCT CCTGGCCCGC GAGGCGTGAC ACTGTCTCGG CTACAGACCC
240





AGAGGGAGCA CACTGCCAGG ATGGGAGCTG CTGGGAGGCA GGACTTCCTC TTCAACCCCA
300





TCCTGACCAT CAGCTGGCTC ACTCTGACCT GCTTCCCTGG GGCCACATCC ACAGTGGCTG
360





CTGGGTGCCC TGACCAGAGC CCTGAGTTGC AACCCTGGAA CCCTGGCCAT GACCAAGACC
420





ACCATGTGCA TATCGGCCAG GGCAAGACAC TGCTGCTCAC CTCTTCTGCC ACGGTCTATT
460





CCATCCACAT CTCAGAGGGA GGCAAGCTGG TCATTAAAGA CCACGACGAG CCGATTGTTT
540





TGCGAACCCG GCACATCCTG ATTGACAACG GAGGAGAGCT GCATCCTGGG AGTGCCCTCT
600





GCCCTTTCCA GGGCAATTTC ACCATCATTT TGTATGGAAG GGCTGATGAA GGTATTCAGC
660





CGGATCCTTA CTATGGTCTG AACTACATTG GGGTTGGTAA AGGAGGCGCT CTTGAGTTGC
720





ATGGACAGAA AAAGCTCTCC TGGACATTTC TGAACAAGAC CCTTCACCCA CGTGGCATGG
780





CAGAAGGAGG CTATTTTTTT GAAAGGAGCT GGGGCCACCG TGGAGTTATT GTTCATGTCA
840





TCGACCCCAA ATCAGGCACA GTCATCCATT CTGACCGGTT TGACACCTAT AGATCCAAGA
900





AAGAGAGTGA ACGTCTGGTC CAGTATTTGA ACGCGGTGCC CGATGGCAGG ATCCTTTCTG
960





TTGCAGTGAA TGATGAAGGT TCTCGAAATC TGGATGACAT GGCCAGGAAG GCGATGACCA
1020





AATTGGGAAG CAAACACTTC CTGCACCTTG GATTTAGACA CCCTTGGAGT TTTCTAACTG
1080





TGAAAGGAAA TCCATCATCT TCAGTGGAAG ACCATATTGA ATATCATGGA CATCGAGGCT
1140





CTGCTGCTGC CCGGGTATTC AAATTGTTCC AGACAGAGCA TGGCGAATAT TTCAATGTTT
1200





CTTTGTCCAG TGAGTGGGTT CAAGACGTGG AGTGGACGGA GTGGTTCGAT CATGATAAAG
1260





TATCTCAGAC TAAAGGTGGG GAGAAAATTT CAGACCTCTG GAAAGCTCAC CCAGGAAAAA
1320





TATGCAATCG TCCCATTGAT ATACAGGCCA CTACAATGGA TGGAGTTAAC CTCAGCACCG
1380





AGGTTGTCTA CAAAAAAGGC CAGGATTATA GGTTTGCTTG CTACCACCGG GGCAGAGCCT
1440





GCCGGAGCTA CCGTGTACGG TTCCTCTGTG GGAAGCCTGT GAGGCCCAAA CTCACAGTCA
1500





CCATTGACAC CAATGTGAAC AGCACCATTC TGAACTTGGA GGATAATGTA CACTCATGGA
1560





AACCTGGAGA TACCCTGGTC ATTGCCAGTA CTGATTACTC CATGTACCAG GCAGAAGAGT
1620





TCCAGGTGCT TCCCTGCAGA TCCTGCGCCC CCAACCAGGT CAAAGTGGCA GGGAAACCAA
1680





TGTACCTCCA CATCGGGGAG GAGATAGACG GCGTGGACAT GCGGGCGGAG GTTGGGCTTC
1740





TGAGCCGCAA CATCATAGTG ATGGGGGAGA TGGACGACAA ATGCTACCCC TACAGAAACC
1800





ACATCTGCAA TTTCTTTGAC TTCGATACCT TTGGGGGCCA CATCAAGTTT GCTCTGGGAT
1860





TTAAGGCAGC ACACTTGGAG GGCACGGAGC TGAAGCATAT GGGACACCAG CTGGTGGGTC
1920





AGTACCCGAT TCACTTCCAC CTGGCCGGTG ATGTAGACGA AAGGGGAGGT TATGACCCAC
1980





CCACATACAT CAGGGACCTC TCCATCCATC ATACATTCTC TCGCTGCGTC ACAGTCCATG
2040





GCTCCAATGG CTTGTTGATC AAGGACGTTG TGGGCTATAA CTCTTTGGGC CACTGCTTCT
2100





TCACGGAAGA TGGGCCGGAG GAACGCAACA CTTTTGACCA CTGTCTTGGC CTCCTTGTCA
2160





AGTCTGGAAC CCTCCTCCCC TCGGACCGTG ACAGCAAGAT GTGCAAGATG ATCACAGAGG
2220





ACTCCTACCC CGGGTACATC CCCAAGCCCA GGCAAGACTG CAATGCTGTG TCCACCTTCT
2280





GGATGGCCAA TCCCAACAAC AACCTCATCA ACTGTGCCGC TGCAGGATCT GAGGAAACTG
2340





GATTTTGGTT TATTTTTCAC CACGTACCAA CGGGCCCCTC CGTGGGAATG TACTCCCCAG
2400





GTTATTCAGA GCACATTCCA CTGGGAAAAT TCTATAACAA CCGAGCACAT TCCAACTACC
2460





GGGCTGGCAT GATCATAGAC AACGGAGTCA AAACCACCGA GGCCTCTGCC AAGGACAAGC
2520





GGCCGTTCCT CTCAATCATC TCTGCCAGAT ACAGCCCTCA CCAGGACGCC GACCCGCTGA
2580





AGCCCCGGGA GCCGGCCATC ATCAGACACT TCATTGCCTA CAAGAACCAG GACCACGGGG
2640





CCTGGCTGCG CGGCGGGGAT GTGTGGCTGG ACAGCTGCCG GTTTGCTGAC AATGGCATTG
2700





GCCTGACCCT GGCCAGTGGT GGAACCTTCC CGTATGACGA CGGCTCCAAG CAAGAGATAA
2760





AGAACAGCTT GTTTGTTGGC GAGAGTGGCA ACGTGGGGAC GGAAATGATG GACAATAGGA
2820





TCTGGGGCCC TGGCGGCTTG GACCATAGCG GAAGGACCCT CCCTATAGGC CAGAATTTTC
2880





CAATTAGAGG AATTCAGTTA TATGATGGCC CCATCAACAT CCAAAACTGC ACTTTCCGAA
2940





AGTTTGTGGC CCTGGAGGGC CGGCACACCA GCGCCCTGGC CTTCCGCCTG AATAATGCCT
3000





GGCAGAGCTG CCCCCATAAC AACGTGACCG GCATTGCCTT TGAGGACGTT CCGATTACTT
3060





CCAGAGTGTT CTTCGGAGAG CCTGGGCCCT GGTTCAACCA GCTGGACATG GATGGGGATA
3120





AGACATCTGT GTTCCATGAC GTCGACGGCT CCGTGTCCGA GTACCCTGGC TCCTACCTCA
3180





CGAAGAATGA CAACTGGCTG GTCCGGCACC CAGACTGCAT CAATGTTCCC GACTGGAGAG
3240





GGGCCATTTG CAGTGGGTGC TATGCACAGA TGTACATTCA AGCCTACAAG ACCAGTAACC
3300





TGCGAATGAA GATCATCAAG AATGACTTCC CCAGCCACCC TCTTTACCTG GAGGGGGCGC
3360





TCACCAGGAG CACCCATTAC CAGCAATACC AACCGGTTGT CACCCTGCAG AAGGGCTACA
3420





CCATCCACTG GGACCAGACG GCCCCCGCCG AACTCGCCAT CTGGCTCATC AACTTCAACA
3480





AGGGCGACTG CATGCGAGTG GGCCTCTGCT ACCCGCGAGG CACCACATTC TCCATCCTGT
3540





CGGATGTTCA CAATCGCCTG CTGAAGCAAA CGTCCAAGAC GGGCGTCTTC GTGAGGACCT
3600





TGCAGATGGA CAAAGTGGAC CAGAGCTACC CTGGCAGGAG CCACTACTAC TGGGACGAGG
3660





ACTCAGGGCT GTTGTTCCTG AAGCTGAAAG CTCAGAACGA GAGAGAGAAG TTTGCTTTCT
3720





GCTCCATGAA AGGCTGTGAC AGGATAAAGA TTAAAGCTCT GATTCCAAAG AACGCAGGCG
3780





TCAGTGACTG CACAGCCACA GCTTACCCCA AGTTCACCGA GAGGGCTGTC GTAGACGTGC
3840





CGATGCCCAA GAAGCTCTTT GGTTCTCAGC TGAAAACAAA GGACCATTTC TTGGAGGTGA
3900





AGATGGAGAG TTCCAAGCAG CACTTCTTCC ACCTCTGGAA CGACTTCGCT TACATTGAAG
3960





TGGATGGGAA GAAGTACCCC AGTTCGGAGG ATGCCAICCA GGTGGTGGTG ATTGACGGGA
4020





ACCAAGGGCG CCTGGTGAGC CACACGAGCT TCACCAACTC CATTCTGCAA GGCATACCAT
4080





GGCAGCTTTT CAACTATGTG GCGACCATCC CTGACAATTC CATACTCCTT ATGGCATCAA
4140





AGGGAAGATA CGTCTCCACA GGCCCATGGA CCAGAGTCCT CGAAAAGCTT GCGGCAGACA
4200





GGGGTCTCAA GTTGAAAGAC CAAATGGCAT TCGTTGGCTT CAAAGGCAGC TTCCGGCCCA
4260





TCTGGGTGAC ACTGCACACT CAGGATCACA AAGCCAAAAT CTTCCAAGTT GTCCCCATCC
4320





CTGTGGTGAA GAAGAAGAAG TTGTCAGGAC AGCTGCCGCC CGGTGCCACC TCGTCCTAGA
4380





CTATGACGGT GACTCTTGGC ACCACACCAG TGGGGGATGG CTGGGTCCCC CAGCCCCTGC
4440





CAGCAGCTGC CTGGGAAGGC CGTGTTTCAG CCCTGATGGG CCAAGGGAAG GCTATCAGAG
4500





ACCCTGGTGC TCCCACCTGC CCCTACTCAA GTGTCTACCT GGAGCCCCTG GGGCGGTGCT
4560





GGCCAATGCT GGAAACATTC ACTTTCCTGC AGCCTCTTGG GTGCTTCTCT CCTATCTGTG
4620





CCTCTTCAGT GGGGGTTTGG GGACCATATC AGGAGACCTG GGTTGTGCTG ACAGCAAAGA
4680





TCCACTTTGG CAGGAGCCCT GACCCAGCTA GGAGGTAGTC TGGAGGGCTG GTCATTCACA
4740





GATCCCCATG GTCTTCAGCA GACAAGTGAG GGTGGTAAAT GTAGGAGAAA GAGCCTTGGC
4800





CTTAAGGAAA TCTTTACTCC TGTAAGCAAG AGCCAACCTC ACAGGATTAG GAGCTGGGGT
4860





AGAACTGGCT ATCCTTGGGG AAGAGGCAAG CCCTGCCTCT GGCCGTGTCC ACCTTTCAGG
4920





AGACTTTGAG TGGCAGGTTT GGACTTGGAC TAGATGACTC TCAAAGGCCC TTTTAGTTCT
4980





GAGATTCCAG AAATCTGCTG CATTTCACAT GGTACCTGGA ACCCAACAGT TCATGGATAT
5040





CCACTGATAT CCATGATGCT GGGTGCCCCA GCGCACACGG GATGGAGAGG TGAGAACTAA
5100





TGCCTAGCTT GAGGGGTCTG CAGTCCAGTA GGGCAGGCAG TCAGGTCCAT GTGCACTGCA
5160





ATGCCAGGTG GAGAAATCAC AGAGAGGTAA AATGGAGGCC AGTGCCATTT CAGAGGGGAC
5220





GCTCAGGAAG GCTTCTTGCT TACAGGAATG AAGGCTGGGG GCATTTTGCT GGGGGGAGAT
5280





GAGGCAGCCT CTGGAATGGC TCAGGGATTC AGCCCTCCCT GCCGCTGCCT GCTGAAGCTG
5340





GTGACTACGG GGTCGCCCTT TGCTCACGTC TCTCTGGCCC ACTCATGATG GAGAAGTGTG
5400





GTCAGAGGGG AGCAATGGGC TTTGCTGCTT ATGAGCACAG AGGAATTCAG TCCCCAGGCA
5460





GCCCTGCCTC TGACTCCAAG AGGGTGAAGT CCACAGAAGT GAGCTCCTGC CTTAGGGCCT
5520





CATTTGCTCT TCATCCAGGG AACTGAGCAC AGGGGGCCIC CAGGAGACCC TAGATGTGCT
5580





CGTACTCCCT CGGCCTGGGA TTTCAGAGCT GGAAATATAG AAAATATCTA GCCCAAAGCC
5640





TTCATTTTAA CAGATGGGGA AAGTGAGCCC CCAAGATGGG AAAGAACCAC ACAGCTAAGG
5700





GAGGGCCTGG GGAGCCCCAC CCTAGCCCTT GCTGCCACAC CACATTGCCT CAACAACCGG
5760





CCCCAGAGTG CCCAGGCACT CCTGAGGTAG CTTCTGGAAA TGGGGACAAG TCCCCTCGAA
5820





GGAAAGGAAA TGACTAGACT AGAATGACAG CTAGCAGATC TCTTCCCTCC TGCTCCCAGC
5880





GCACACAAAC CCGCCCTCCC CTTGGTGTTG GCGGTCCCTG TGGCCTTCAC TTTGTTCACT
5940





ACCTGTCAGC CCAGCCTGGG TGCACAGTAG CTGCAACTCC CCATTGGTGC TACCTGGCTC
6000





TCCTGTCTCT GCAGCTCTAC AGGTGAGGCC CACCAGAGGG AGTAGGGCTC GCCATGTTTC
6060





TGGTGAGCCA ATTTGGCTGA TCTTGGGTGT CTGAACAGCT ATTGGGTCCA CCCCAGTCCC
6120





TTTCAGCTGC TGCTTAATGC CCTGCTCTCT CCCTGGCCCA CCTTATAGAG AGCCCAAAGA
6180





GCTCCTGTAA GAGGGAGAAC TCTATCTGTG GTTTATAATC TTGCACGAGG CACCAGAGTC
6240





TCCCTGGGTC TTGTGATGAA CTACATTTAT CCCCTTTCCT GCCCCAACCA CAAACTCTTT
6300





CCTTCAAAGA GGGCCTGCCT GGCTCCCTCC ACCCAACTGC ACCCATGAGA CTCGGTCCAA
6360





GAGTCCATTC CCCAGGTGGG AGCCAACTGT CAGGGAGGTC TTTCCCACCA AACATCTTTC
6420





AGCTGCTGGG AGGTGACCAT AGGGCTCTGC TTTTAAAGAT ATGGCTGCTT CAAAGGCCAG
6480





AGTCACAGGA AGGACTTCTT CCAGGGAGAT TAGTGGTGAT GGAGAGGAGA GTTAAAATGA
6540





CCTCATGTCC TTCTTGTCCA CGGTTTTGTT GAGTTTTCAC TCTTCTAATG CAAGGGTCTC
6600





ACACTGTGAA CCACTTAGGA TGTGATCACT TTCAGGTGGC CAGGAATGTT GAATGTCTTT
6660





GGCTCAGTTC ATTTAAAAAA GATATCTATT TGAAAGTTCT CAGAGTTGTA CATATGTTTC
6720





ACAGTACAGG ATCTGTACAT AAAAGTTTCT TTCCTAAACC ATTCACCAAG AGCCAATATC
6780





TAGGCATTTT CTTGGTAGCA CAAATTTTCT TATTGCTTAG AAAATTGTCC TCCTTGTTAT
6840





TTCTGTTTGT AAGACTTAAG TGAGTTAGGT CTTTAAGGAA AGCAACGCTC CTCTGAAATG
6900





CTTGTCTTTT TTCTGTTGCC GAAATAGCTG GTCCTTTTTC GGGAGTTAGA TGTATAGAGT
6960





GTTTGTATGT AAACATTTCT TGTAGGCATC ACCATGAACA AAGATATATT TTCTATTTAT
7020





TTATTATATG TGCACTTCAA GAAGTCACTG TCAGAGAAAT AAAGAATTGT CTTAAATGTC





SEQ ID NO: 95 Protein sequence


Protein Accession #: XP_051860.2


1          11         21         31         41         51


|          |          |          |          |          |


MGAAGRGDFL FKAMLTISWL TLTCFPGATS TVAAGCPDQS PELQPWNPGH DQDHHVHIGQ
60





GKTLLLTSSA TVYSIHISEG GKLVIKDHDE PTVLRTRHIL IDNGGELHAG SALCPFQGNF
120





TIILYGRADE GIQPGPYYGL KYIGVGKGGA LELHGQKKLS WTFLNKTLHP GGMAEGGYFF
180





ERSWGHRGVI VHVIDPKSGT VIHSDRFDTY RSKKESERLV QYLNAVPDGR ILSVAVNDEG
240





SRNLDDMARK AMTKLGSKHF LHLGFRHPWS FLTVKGNPSS SVEDHIEYHG HRGSAAARVF
300





KLFQTEHGEY FNVSLSSEWV QGVEWTEWFD HDKVSQTKGG EKISDLWKAH PGKICNRPID
360





IQATTMDGVN LSTEVVYKKG QDYRFACYDR GRACRSYRVR FLCGKPVRPK LTVTIDTNVN
420





STILNLEDNV QSWKPGDTLV IASTDYSMYQ AEEFQVLPCR SCAPNQVKVA GKPMYLHIGE
480





EIDGVDMRAE VGLLSRNIIV MGEMEDKCYP YRNHICNFFD FDTFGGHIKF ALGFKAAHLE
540





GTELKHMGQQ LVGQYPIHFH LAGDVDERGG YDPPTYIRDL SIHHTFSRCV TVHGSNGLLI
600





KDVVGYNSLG HCFFTEDGPE ERNTPDHCLG LLVKSGTLLP SDRDSKMCKM ITEDSYPGYI
660





PKPRQDCNAV STFWMANPNN NLINCAAAGS EETGFWFIFH HVPTGPSVGM YSPGYSEHIP
720





LGKFYNNRAH SNYRAGMIID NGVKTTEASA KDKRPFLSII SARYSPHQDA DPLKPREPAI
780





IRHFIAYKNQ DHGAWLRGGD VWLDSCRFAD NGIGLTLASG GTFPYDDGSK QEIKNSLFVG
840





ESGNVGTEMM DNRIWGPGGL DHSGRTLPIG QNFPIRGIQL YDGPINIQNC TFRKFVALEG
900





RHTSALAFRL NNAWQSCPHN NVTGIAFEDV PITSRVFFGE PGPWFNQLDM DGDKTSVFHD
860





VDGSVSEYPG SYLTKNDNWL VRHPDCINVP DWRGAICSGC YAQMYIQAYK TSNLRMKIIK
1020





NDFPSNPLYL EGALTRSTHY QQYQPVVTLQ KGYTIHWQGT APAELAIWLI NFNKGDWIRV
1080





GLCYPRGTTF SILSDVHNRL LKQTSKTGVF VRTLQMDKVE QSYPGRSHYY WDEDSGLLFL
1140





KLKAQNEREK FAFCSMKGCE RIKIKALIPK NAGVSDCTAT AYPKFTERAV VDVPMPKKLF
1200





GSQLKTKDHF LEVKMESSKQ NFFHLWNDFA YIEVDGKKYP SSEDGIQVVV IDGNQGRVVS
1260





HTSFRNSILQ GIPWQLFNYV ATIPDNSIVL MASKGRYVSR GPWTRVLEKL GADRGLKLKE
1320





QMAFVGFKGS FRPIWVTLDT EDNKAKIFQV VPIPVVKKKK L





SEQ ID NO: 96 DNA sequence


Nucleic Acid Accession #: NM_020436 and AK001666


Coding sequence: 63-3224


1          11         21         31         41         51


|          |          |          |          |          |


CAGGAATTTG TGGCGGAGAG GGCAAATAAC TGCGGCTCTC CCGGCGCCCC GATGCTCGCA
60





CCATGTCGAG GCGCAAGCAG GCGAAACCCC AGCACATCAA CTCGGAGGAG GACCAGGGCG
120





AGCAGCAGCC GCAGCAGCAG ACCCCGGAGT TTGCAGATGC GGCCCCAGCG GCGCCCGCGG
180





CGGGGGAGCT GGGTGCTCCA GTGAACCACC CAGGGAATGA CGAGGTGGCG AGTGAGGATG
240





AAGCCACAGT AAAGCGGCTT CGTCGGGAGG AGACGCACGT CTGTGAGAAA TGCTGTGCGG
300





AGTTCTTCAG CATCTCTGAG TTCCTGGAAC ATAAGAAAAA TTGCACTAAA AATCCACCTG
360





TCCTCATCAT GAATGACAGC GAGGGGCCTG TGCCTTCAGA AGACTTCTCC GGAGCTGTAC
420





TGAGCCACCA GCCCACCAGT CCCGGCAGTA AGGACTGTCA CAGGGAGAAT CGCGGCAGCT
480





CAGAGGACAT GAAGGAGAAG CCGGATGCGG AGTCTGTGGT GTACCTAAAG ACAGAGACAG
540





CCCTGCCACC CACCCCCCAG GACATAAGCT ATTTAGCCAA AGGCAAAGTG GCCAACACTA
600





ATGTGACCTT GCAGGCACTA CGGGGCACCA AGGTGGCGGT GAATCAGCGG AGCGCGGATG
660





CACTCCCTGC CCCCGTGCCT GGTGCCAACA GCATCCCGTG GGTCCTCGAG CAGATCTTGT
720





GTCTGCAGCA GCAGCAGCTA CAGCAGATCC AGCTCACCGA GCAGATCCGC ATCCAGGTGA
780





ACATGTGGGC CTCCCACGCC CTCCACTCAA GCGGGGCAGG GGCCGACACT CTGAAGACCT
840





TGGGCAGCCA CATGTCTCAG CAGGTTTCTG CAGCTGTGGC TTTGCTCAGC CAGAAAGCTG
900





GAAGCCAAGG TCTGTCTCTG GATGCCTTGA AACAAGCCAA GCTACCTCAC GCCAACATCC
960





CTTCTGCCAC CAGCTCCCTG TCCCCAGGGC TGGCACCCTT CACTCTGAAG CCGGATGGGA
1020





CCCGGGTGCT CCCGAACGTC ATGTCCCGCC TCCCGAGCGC TTTGCTTCCT CAGGCCCCGG
1080





GCTCGGTGCT CTTCCAGAGC CCTTTCTCCA CTGTGGCGCT AGACACATCC AAGAAAGGGA
1140





AGGGGAAGCC ACCGAACATC TCCGCGGTGG ATGTCAAACC CAAAGACGAG GCGGCCCTCT
1200





ACAAGCACAA GTGTAAGTAC TGTAGCAAGG TTTTTGGGAC TGATAGCTCC TTGCAGATCC
1260





ACCTCCGCTC CCACACTGGA GAGAGACCCT TCGTGTGCTC TGTCTGTGGT CATCGCTTCA
1320





CCACCAAGGG CAACCTCAAG GTGCACTTTC ACCGACATCC CCAGGTGAAG GCAAACCCCC
1380





AGCTGTTTGC CGAGTTCCAG GACAAAGTGG CGGCCGGCAA TGGCATCCCC TATGCACTCT
1440





CTGTACCTGA CCCCATAGAT GAACCGAGTC TTTCTTTAGA CAGCAAACCT GTCCTTGTAA
1500





CCACCTCTGT AGGGCTACCT CAGAATCTTT CTTCGGGGAC TAATCCCAAG GACCTCACGG
1560





GTGGCTCCTT GCCCGGTGAC CTGCAGCCTG GGCCTTCTCC AGAAAGTGAG GGTGGACCCA
1620





CACTCCCTGG GGTGGGACCA AACTATAATT CCCCAAGGGC TGGTGGCTTC CAAGGGAGTG
1680





GGACCCCTGA GCCAGGGTCA GAGACCCTGA AATTGCAGCA GTTGGTGGAG AACATTGACA
1740





AGGCCACCAC TGATCCCAAC GAATGTCTCA TTTGCCACCG AGTCTTAAGC TGTCAGAGCT
1800





CCCTCAAGAT GCATTATCGC ACCCACACCG GGGAGAGACC GTTCCAGTGT AAGATCTGTG
1860





GCCGAGCCTT TTCTACCAAA GGTAACCTGA AGACACACCT TGGGGTTCAC CGAACCAACA
1920





CATCCATTAA GACGCAGCAT TCGTGCCCCA TCTGCCAGAA GAAGTTCACT AATGCCGTGA
1980





TGCTGCAGCA ACATATTCGG ATGCACATGG GCGGTCAGAT TCCCAACACG CCCCTGCCAG
2040





AGAATCCCTG TGACTTTACG GGTTCTGAGC CAATGACCGT GGGTGAGAAC GGCAGCACCG
2100





GCGCTATCTG CCATGATGAT GTCATCGAAA GCATCGATGT AGAGGAAGTC AGCTCCCAGG
2160





AGGCTCCCAG CAGCTCCTCC AAGGTCCCCA CGCCTCTTCC CAGCATCCAC TCGGCATCAC
2220





CCACGCTAGG GTTTGCCATG ATGGCTTCCT TAGATGCCCC AGGGAAAGTG GGTCCTGCCC
2200





CTTTTAACCT GCAGCGCCAG GGCAGCAGAG AAAACGGTTC CGTGGAGAGC GATGGCTTGA
2340





CCAACGACTC ATCCTCGCTG ATGGGAGACC AGGAGTATCA GAGCCGAAGC CCAGATATCC
2400





TGGAAACCAC ATCCTTCCAG GCACTCTCCC CGGCCAATAG TCAAGCCGAA AGCATCAAGT
2460





CAAAGTCTCC CGATGCTGGG AGCAAAGCAG AGAGCTCCGA GAACAGCCGC ACTGAGATGG
2520





AAGGTCGGAG CAGTCTCCCT TCCACGTTTA TCCGAGCCCC GCCGACCTAT GTCAAGGTTG
2580





AAGTTCCTGG CACATTTGTG GGACCCTCGA CATTGTCCCC AGGGATGACC CCTTTGTTAG
2640





CAGCCCAGCC ACGCCGACAG GCCAAGCAAC ATGGCTGCAC ACGGTGTGGG AAGAACTTCT
2700





CGTCTGCTAG CGCTCTTCAG ATCCACGAGC GGACTCACAC TGGAGAGAAG CCTTTTGTGT
2760





GCAACATTTG TGGGCGAGCT TTTACCACCA AAGGCAACTT AAAGGTTCAC TACATGACAC
2820





ACGGGGCGAA CAATAACTCA GCCCGCCGTG GAAGGAAGTT GGCCATCGAG AACACCATGG
2880





CTCTGTTAGG TACGGACGGA AAAAGAGTCT CAGAAATCTT TCCCAAGGAA ATCCTGGCCC
2940





CTTCAGTGAA TGTGGACCCT GTTGTGTGGA ACCAGTACAC CAGCATGCTC AATGGCGGTC
3000





TGGCCGTGAA GACCAATGAG ATCTCTGTGA TCCAGAGTGG GGGGGTTCCT ACCCTCCCGG
3060





TTTCCTTGGG GGCCACCTCC GTTGTGAATA ACGCCACTGT CTCCAAGATG GATGGCTCCC
3120





AGTCGGGTAT CAGTGCAGAT GTGGAAAAAC CAAGTGCTAC TGACGGCGTT CCCAAACACC
3180





AGTTTCCTCA CTTCCTGGAA GAAAACAAGA TTGCGGTCAG CTAAGGGAGA ACTTGCGTGG
3240





AAGGAGCAAT GCAGACACAG TGAAATCTCT AGAATCTGCT TTGTTTTGTA AGAACTCATC
3300





TCCTCCTGTT TTCTTTTTCT TACTGATATG CAAATGATGT TTACTACGTT GGTTGTGACC
3360





ACAACCTCAG GCAAGTGCTA CAATCACGAT TGTTGCTATG CTGCTTTGCA AAAAGTTG





SEQ ID NO: 97 protein sequence


Protein Accession #: NP_065169.1


1          11         21         31         41         51


|          |          |          |          |          |


MSRRKQAKPQ HINSEEDQGE QQPQQQTPEF ADAAPAAPAA GELGAPVNHP GNGEVASEDE
60





ATVKRLRREE THVCEKCCAE FFSISEFLEN KKNCTKNPPV LIMNDSEGPV PSEDFSGAVL
120





SHQPTSPGSK DCHRENGGSS EDMKEKPDAE SVVYLKTETA LPPTPQDISY LAKGKVANTN
190





VTLQALRGTK VAVNQRSADA LPAPVPGANS IPWVLEQILC LQQQQLQQIQ LTEQIRIQVN
240





MWASHALNSS GAGADTLKTL GSHMSQQVSA AVALLSQKAG SQGLSLDALK QAKLPHANIP
300





SATSSLSPGL APFTLKPDGT RVLPNVMSRL PSALLPQAPG SVLFQSPFST VALDTSKKGK
360





GKPPNISAVD VKPKDEAALY KHKCKYCSKV FGTDSSLQIH LRSHTGERPF VCSVCGHRFT
420





TKGNLKVNFH RHPQVKANPQ LFAEFQDKVA AGNGIPYALS VPDPIDEPSL SLDSKPVLVT
480





TSVGLPQNLS SGTNPKDLTG GSLPGDLQPG PSPESEGGPT LPGVGPNYNS PRAGGFGGSG
540





TPEPGSETLK LQQLVENIDK ATTDPNECLI CNRVLSCQSS LKMHYRTHTG ERPEGCKICG
600





RAFSTKGNLK THLGVHRTNT SIKTQHSCPI CQKKFTNAVM LQQHIRMHMG GQIPNTPLPE
660





NPCDFTGSEP MTVGENGSTG AICHDDVIES IDVEEVSSQE APSSSSKVPT PLPSHISASP
720





TLGFAMMASL DAPGEVGPAP FNLQRQGSRE NGSVESDGLT NDSSSLMGDQ EYQSRSPDIL
780





ETTSFQALSP ANSQAESIKS KSPDAGSKAE SSENSRTEME GRSSLPSTFI RAPPTYVKVE
840





VPGTFVGPST LSPGMTPLLA AQPRRQAKQH GCTRCGKNFS SASALQIHER THTGEKPFVC
900





NICGRAFTTK GNLKVHYMTH GANNNSARRG RKLAIENTMA LLGTDGKRVS ETEPEEILAP
960





SVNVDPVVWN QYTSMLNGGL AVKTNEISVI QSGGVPTLPV SLGATSVVNN ATVSKMDGSQ
1020





SGISADVEKP SATDGVPKHQ FPHFLEENKI AVS





SEQ ID NO: 98 DNA sequence


Nucleic Acid Accession #: NM_000612.2


Coding sequence 553. .1095


1          11         21         31         41         51


|          |          |          |          |          |


TTCTCCCGCA ACCTTCCCTT CCCTCCCTCC CGTCCCCCCC AGCTCCTAGC CTCCGACTCC
60





CTCCCCCCCT CACGCCCGCC CTCTCGCCTT CGCCGAACCA AAGTGGATTA ATTACACGCT
120





TTCTGTTTCT CTCCGTGCTG TTCTCTCCCG CTGTGCGCCT GCCCGCCTCT CGCTGTCCTC
180





TCTCCCCCTC GCCCTCTCTT CGGCCCCCCC CTTTCACGTT CACTCTGTCT CTCCCACTAT
240





CTCTGCCCCC CTCTATCCTT GATACAACAG CTGACCTCAT TTCCCGATAC CTTTTCCCCC
300





CCGAAAAGTA CAACATCTGG CCCGCCCCAG CCCGAAGACA GCCCGTCCTC CCTGGACAAT
360





CAGACGAATT CTCCCCCCCC CCCCAAAAAA AAAAGCCATC CCCCCGCTCT GCCCCGTCGC
420





AcATTCGGCC CCCGCGACTC GGCCAGAGCG GCGCTGGCAG AGGAGTGTCC GGCAGGAGGG
480





CCAACGCCCG CTGTTCGGTT TGCGACACGC ACCAGGGAGG TGGGCGGCAG CGTCGCCGGC
540





TTCCAGACAC CAATGGGAAT CCCAATGGGG AAGTCGATGC TGGTGCTTCT CACCTTCTTG
600





GCCTTCGCCT CGTGCTGCAT TGCTGCTTAC CGCCCCAGTG AGACCCTGTG CGGCGGGGAG
660





CTGGTGGACA CCCTCCAGTT CGTCTGTGGG GACCGCGGCT TCTACTTCAG CAGGCCCGCA
720





AGCCGTGTGA GCCGTCGCAG CCGTGGCATC GTTGAGGAGT GCTGTTTCCG CAGCTGTGAC
780





CTGGCCCTCC TGGAGACGTA CTGTGCTACC CCCGCCAAGT CCGAGAGGGA CGTGTCGACC
840





CCTCCGACCG TGCTTCCGGA CAACTTCCCC AGATACCCCG TGGGCAAGTT CTTCCAATAT
900





GACACCTGGA AGCAGTCCAC CCAGCGCCTG CGCAGGGGCC TGCCTGCCCT CCTGCGTGCC
960





CGCCGGGGTC ACGTGCTCGC CAAGGAGCTC GAGGCGTTCA GGGAGGCCAA ACGTCACCGT
1020





CCCCTGATTG CTCTACCCAC CCAAGACCCC GCCCACGGGG GCGCCCCCCC AGAGATGGCC
1080





AGCAATCGGA AGTGAGCAAA ACTGCCGCAA GTCTGCAGCC CGGCGCCACC ATCCTGCAGC
1140





CTCCTCCTGA CCACGGACGT TTCCATCAGG TTCCATCCCG AAAATCTCTC GGTTCCACGT
1200





CCCCCTGGGG CTTCTCCTGA CCCAGTCCCC GTGCCCCGCC TCCCCGAAAC AGGCTACTCT
1260





CCTCGGCCCC CTCCATCGGG CTGAGGAAGC ACAGCAGCAT CTTCAAACAT GTACAAAATC
1320





GATTGGCTTT AAACACCCTT CACATACCCT CCCCCC





SEQ ID NO: 99 Protein sequence


Protein Accession #: NP_000603.1


1          11         21         31         41         51


|          |          |          |          |          |


MGIPMGKSML VLLTFLAFAS CCIAAYRPSE TLCGGELVDT LQFVCGDRGF YFSRPASRVS
60





RRSRGIVEEC CFRSCDLALL ETYCATPAKS ERDVSTPPTV LPDNFPRYPV GEFEQYGTWK
120





QSTQRLRRGL PALLEARRGH VLAKELEAFR EAKRHRPLIA LPTQDPAHGG APPEMASNEK





SEQ ID NO. 100 DNA sequence


Nucleic Acid Accession #: NM_004217.1


Coding sequence: 58. .1092


1         11         21         31         41         51


|          |          |          |          |          |


GGCCGGGAGA GTAGCAGTGC CTTGGACCCC AGCTCTCCTC CCCCTTTCTC TCTAAGGATG
60





GCCCAGAAGG AGAACTCCTA CCCCTGGCCC TACGGCCGAC AGACGGCTCC ATCTGGCCTG
120





AGCACCCTGC CCCAGCGAGT CCTCCGGAAA GAGCCTGTCA CCCCATCTGC ACTTGTCCTC
180





ATGAGCCGCT CCAATGTCCA GCCCACAGCT GCCCCTGGCC AGAAGGTGAT GGAGAATAGC
240





AGTGGGACAC CCGACATCTT AACGCGGCAC TTCACAATTG ATGACTTTGA GATTGGGCGT
300





CCTCTGGGCA AAGGCAAGTT TGGAAACGTG TACTTGGCTC GGGAGAAGAA AAGCCATTTC
360





ATCGTGGCGC TCAAGGTCCT CTTCAAGTCC CAGATAGAGA AGGAGGGCGT GGAGCATCAG
420





CTGCGCAGAG AGATCGAAAT CCAGGCCCAC CTGCACCATC CCAACATCCT GCGTCTCTAC
480





AACTATTTTT ATGACCGGAG GAGGATCTAC TTGATTCTAG AGTATGCCCC CGGCGGGGAG
540





CTCTACAAGG AGCTGCAGAA GAGCTGCACA TTTGACGAGC AGCGAACAGC CACGATCATG
600





GAGGAGTTGG CAGATGCTCT AATGTACTGC CATGGGAAGA AGGTGATTCA CAGAGACATA
660





AAGCCAGAAA ATCTGCTCTT AGGGCTCAAG GGAGAGCTGA AGATTGCTGA CTTCGGCTGG
720





TCTGTGCATG CGCCCTCCCT GAGGAGGAAG ACAATGTGTG GCACCCTGGA CTACCTGCCC
780





CCAGAGATGA TTGAGGGGCG CATGCACAAT GAGAAGGTGG ATCTGTGGTG CATTGGAGTG
840





CTTTGCTATG AGCTGCTGGT GGGGAACCCA CCCTTTGAGA GTGCATCACA CAACGAGACC
900





TATCGCCGCA TCGTCAAGGT GGACCTAAAG TTCCCCGCTT CTGTGCCCAC GGGAGCCCAG
960





GACCTCATCT CCAAACTGCT CAGGCATAAC CCCTCGGAAC GGCTGCCCCT GGCCCAGGTC
1020





TCAGCCCACC CTTGGGTCCG GGCCAACTCT CGGAGGGTGC TGCCTCCCTC TGCCCTTCAA
1080





TCTGTCGCCT GATGGTCCCT GTCATTCACT CGGGTGCGTG TGTTTGTATG TCTGTGTATG
1140





TATAGGGGAA AGAAGGGATC CCTAACTGTT CCCTTATCTG TTTTCTACCT CCTCCTTTGT
1200





TTAATAAAGG CTGAAGCTTT TTGT





SEQ ID NO: 101 Protein sequence


Protein Accession #: NP_004208


1          11         21         31         41         51


|          |          |          |          |          |


MAQKENSYPW PYGRQTAPSG LSTLPQRVLR KEPVTPSALV LMSRSNVQPT AAPGQKVMEN
60





SSGTPDILTR HFTIDDFEIG RPLGKGKFGN VYLAREKESH FIVALKVLFK SQIEKEGVEH
120





QLRREIEIQA HLHHPNILRL YNYFYDRRRI YLILEYAPRG ELYKELQKSC TFDEQRTATI
180





MEELADALMY CHGKKVIHRD IKPENLLLGL KGELKIADFG WSVHAPSLRR KTMCGTLDYL
240





PPEMIEGRMH NEKVDLWCIG VLCYELLVGN PPFESASHNE TYRRIVKVDL KFPASVPTGA
300





QDLISKLLRH NPSERLPLAQ VSAHPWVRAN SRRVLPPSAL QSVA





SEQ ID NO: 102 DNA sequence


Nucleic Acid Accession #. AK025790


Coding sequence 56. .1642


1         11         21         31         41         51


|          |          |          |          |          |


AGTATCCCAG GAGGAGCAAG TGGCACGTCT TCGGACCTAG GCTGCCCCTG CCGTCATGTC
60





GCAAGGGATC CTTTCTCCGC CAGCGGGCTT GCTGTCCGAT GACGATGTCG TAGTTTCTCC
120





CATGTTTGAG TCCACAGCTG CAGATTTGGG GTCTGTGGTA CGCAAGAACC TGCTATCAGA
180





CTGCTCTGTC GTCTCTACCT CCCTAGAGGA CAACCAGCAG GTTCCATCTG AGGACAGTAT
240





GGAGAAGGTG AAAGTATACT TGAGGGTTAG GCCCTTCTTA CCTTCAGAGT TGGAACGACA
300





GGAAGATCAG GGTTGTGTCC GTATTGAGAA TGTGGAGACC CTTGTTCTAC AAGCACCCAA
360





GGACTCTTTT GCCCTGAAGA GCAATGAACG GGGAATTGGC CAAGCCACAC ACAGGTTCAC
420





CTTTTCCCAG ATCTTTGGGC CAGAAGTGGG ACAGGCATCC TTCTTCAACC TAACTGTGAA
480





GGAGATGGTA AAGGATGTAC TCAAAGGGCA GAACTGGCTC ATCTATACAT ATGGAGTCAC
540





TAACTCAGGG AAAACCCACA CGATTCAAGG TACCATCAAG GATGGAGGGA TTCTCCCCCG
600





GTCCCTGGCG CTGATCTTCA ATAGCCTCCA AGGCCAACTT CATCCAACAC CTGATCTGAA
660





GCCCTTGCTC TCCAATCAGC TAATCTGGCT AGACAGCAAG CAGATCCGAC AGGAGGAAAT
720





GAAGAAGCTG TCCCTGCTAA ATGGAGGCCT CCAAGAGGAG GAGCTGTCCA CTTCCTTGAA
780





GAGGAGTGTC TACATCGAAA GTCGGATAGG TACCAGCACC AGCTTCGACA GTGGCATTGC
840





TGGGCTCTCT TCTATCAGTC AGTGTACCAG CAGTAGCCAG CTGGATGAAA CAAGTCATCG
900





ATGGGCACAG CCAGACACTC CCCCACTACC TGTCCCGGCA AACATTCGCT TCTCCATCTG
960





GATCTCATTC TTTGAGATCT ACAACGAACT GCTTTATGAC CTATTAGAAC CGCCTAGCCA
1020





ACAGCGCAAG AGGCAGACTT TGCGGCTATG CGAGGATCAA AATGGCAATC CCTATGTGAA
1080





AGATCTCAAC TGGATTCATG TGCAAGATGC TGACGACGCC TGGAAGCTCC TAAAAGTGGG
1140





TCGTAAGAAC CAGAGCTTTG CCAGcACCCA CCTcAACCAC AACTCCAGCC GCAGTCACAG
1200





CATCTTCTCA ATCAGGATCC TAGACCTTCA GGGGGAAGGA GATATAGTCC CCAAGATCAG
1260





CGAGCTGTCA CTCTGTGATC TGGCTGGCTC AGAGCGCTGC AAACATCAGA AGAGTGGTGA
1320





ACGGTTGAAG GAAGCAGGAA ACATTAACAC CTCTCTACAC ACCCTGGGCC GCTGTATTGC
1380





TGCCCTTCGT CAAAACCAGC AGAACCGGTC AAAGCAGAAC CTGGTTCCCT TCCGTGACAG
1440





CAAGTTGACT CGAGTGTTCC AAGGTTTCTT CACAGGCCGA GGCCGTTCCT GCATGATTGT
1500





CAATGTGAAT CCCTGTGCAT CTACCTATGA TGAAACTCTT CATGTGGCCA AGTTCTCAGC
1560





CATTGCTAGC CAGGTGACTT GTGCATGCCC CACCTATGCA ACTGGGATTC CCATCCCTGC
1620





ACTCGTTCAT CAAGGAACAT AGTCTTCAGG TATCCCCCAG CTTAGAGAAA GGGGCTAAGG
1680





CAGACACAGG CCTTCATGAT GATATTGAAA ATGAAGCTGA CATCTCCATG TATGGCAAAG
1740





AGGAGCTCCT ACAAGTTGTG GAAGCCATGA AGACACTGCT TTTGAAGGAA CGACAGGAAA
1800





AGCTACAGCT GGAGATGCAT CTCCGAGATG AAATTTGCAA TGAGATGGTA GAACAGATGC
1860





AACAGCGGGA ACAGTGGTGC AGTGAACATT TGGACACCCA AAAGGAACTA TTGGAGGAAA
1920





TGTATGAAGA AAAACTAAAT ATCCTCAAGG AGTCACTGAC AAGTTTTTAC CAAGAAGAGA
1980





TTCAGGAGCG GGATGAAAAG ATTGAAGAGC TAGAAGCTCT CTTGCAGGAA GCCAGACAAC
2040





AGTCAGTGGC CCATCAGCAA TCAGGGTCTG AATTGGCCCT ACGGCGGTCA CAAAGGTTGG
2100





CAGCTTCTGC CTCCACCCAG CAGCTTCAGG AGGTTAAAGC TAAATTACAG CAGTGCAAAG
2160





CAGAGCTAAA CTCTACCACT GAAGAGTTGC ATAAGTATCA GAAAATGTTA GAACCACCAC
2220





CCTCAGCCAA GCCCTTCACC ATTGATGTGG ACAAGAAGTT AGAAGAGGGC CAGAAGAATA
2280





TAAGGCTGTT GCGGACAGAG CTTCAGAAAC TTGGTGAGTC TCTCCAATCA GCAGAGAGAG
2340





CTTGTTGCCA CAGCACTGGG GCAGGAAAAC TTCGTCAAGC CTTGACCACT TGTGATGACA
2400





TCTTAATCAA ACAGGACCAG ACTCTGGCTG AACTGCAGAA CAACATGGTG CTAGTGAAAC
2460





TGGACCTTCG GAAGAAGGCA GCATGTATTG CTGAGCAGTA TCATACTGTG TTGAAACTCC
2520





AAGGCCAGGT TTCTGCCAAA AAGCGCCTTG GTACCAACCA GGAAAATCAG CAACCAAACC
2580





AACAACCACC AGGGAAGAAA CCATTCCTTC GAAATTTACT TCCCCGAACA CCAACCTGCC
2640





AAAGCTCAAC AGACTGCAGC CCTTATGCCC GGATCCTACG CTCACGGCGT TCCCCTTTAC
2700





TCAAATCTGG GCCTTTTGGC AAAAAGTACT AAGGCTGTGG GGAAAGAGAA GAGCAGTCAT
2760





GGCCCTGAGG TGGGTCAGCT ACTCTCCTGA AGAAATAGGT CTCTTTTATG CTTTACCATA
2820





TATCAGGAAT TATATCCAGG ATGCAATACT CAGACACTAG CTTTTTTCTC ACTTTTGTAT
2880





TATAACCACC TATGTAATCT CATGTTGTTG TTTTTTTTTA TTTACTTATA TGATTTCTAT
2940





GCACACAAAA ACAGTTATAT TAAAGATATT ATTGTTCACA TTTTTTATTG AATTCCAAAT
3000





GTAGCAAAAT CATTAAAACA AATTATAAAA GGGACAGAAA AA





SEQ ID NO: 103 Protein sequence


Protein Accession #: NP_005724.1


1          11         21         31         41         51


|          |          |          |          |          |


MSQGILSPPA GLLSDDDVVV SPMFESTAAD LGSVVRKNLL SDCSVVSTSL EDKQQVPSED
60





SMEKVKVYLR VRPLLPSELE RQEDQGCVRI ENVETLVLQA PKDSFALKSN ERGIGQATHR
120





FTFSQIFGPE VGQASFFNLT VKEMVKDVLK GQNWLIYTYG VTNSGKTHTI QGTIKGGGIL
180





PRSLALIFNS LQGQLHPTPD LKPLLSNEVI WLDSKQIRQE EMKKLSLLNG GLQEEELSTS
240





LKRSVYIESR IGTSTSFDSG IAGLSSISQC TSSSQLDETS HRWAQPDTAP LPVPANIRFS
300





IWISFFEIYN ELLYDLLEPP SQQRKRQTLR LCEDQNGNPY VKDLNWINVQ DAEEAWKLLK
360





VGRKNQSFAS TNLNQNSSRS HSIFSIRILH LQGEGDIVPK ISELSLCDLA GSERCKDQKS
420





GERLKEAGNI NTSLHTLGRC IAALRQNQQN RSKQNLVPFR DSKLTRVFQG FFTGRGRSCM
480





IVNVNPCAST YDETLHVAKF SAIASQVTCA CPTYATGIPI PALVHQGT





SEQ ID NO: 104 DNA sequence


Nucleic Acid Accession #: NM_006952.1


Coding sequence: 11. .793


1          11         21         31         41         51


|          |          |          |          |          |


AATCCCGACA ATGGCGAAAC ACAACTCAAC TGTTCGTTGC TTCCAGGGCC TCCTGATTTT
60





TGGAAATGTG ATTATTGGTT GTTCCCGCAT TGCCCTGACT GCGGAGTGCA TCTTCTTTGT
120





ATCTCACCAA CACAGCCTCT ACCCACTGCT TGAAGCCACC GACAACCATG ACATCTATGG
180





GGCTGCCTGG ATCGGCATAT TTGTGGGCAT CTGCCTCTTC TCCCTCTCTG TTCTAGGCAT
240





TGTAGGCATC ATGAACTCCA GCAGGAAAAT TCTTCTGGCG TATTTCATTC TGATCTTTAT
300





AGTATATGCC TTTGAAGTCG CATCTTCTAT CACAGCAGCA ACACAACGAG ACTTTTTCAC
360





ACCCAACCTC TTCCTGAAGC ACATGCTAGA GAGGTACCAA AACAACAGCC CTCCAAACAA
420





TCATGACCAG TGGAAAAACA ATGGAGTCAC CAAAACCTGG GACAGGCTCA TGCTCCAGGA
480





CAATTGCTGT GGCGTAAATG CTCCATCAGA CTGGCAAAAA TACACATCTG CCTTCCGGAC
540





TGAGAATAAT GATGCTGACT ATCCCTGGCC TCGTCAATGC TGTGTTATGA ACAATCTTAA
600





AGAACCTCTC AACCTGGACG CTTGTAAACT AGGCGTGCCT GGTTTTTATC ACAATCACGG
660





CTGCTATGAA CTGATCTCTG GTCCAATGAA CCGACACGCC TGGGGGGTTG CCTCGTTTGC
720





ATTTGCCATT CTCTGCTGGA CTTTTTGGGT TCTCCTGGGT ACCATGTTCT ACTCGAGCAG
780





AATTGAATAT TAAGAA





SEQ ID NO: 105 Protein sequence


Protein Accession #. NP_008883.1


1          11         21         31         41         51


|          |          |          |          |          |


MAKDNSTVRC FQGLLIPCNV IIGCCGIALT AECIFFVSDQ HSLYPLLEAT DNDDIYGAAW
60





IGIFVGICLF CLSVLGIVGI MKSSRKILLA YFILMFIVYA FEVASCITAA TQRDFFTPNL
120





FLKQMLERYQ NNSPPNNDDQ WKNNGVTKTW DRLMLQDNCC GVNGPSDWGK YTSAFRTENN
180





DADYPWPRQC CVMNNLKEPL NLEACKLGVP GFYHNQGCYE LISCPMNRHA WGVAMFGPAI
240





LCWTFWVLLG TMFYWSRIEY





SEQ ID NO: 106 DNA sequence


Nucleic Acid Accession #: NM_002740.1


Coding sequence: 178. .1968


1          11         21         31         41         51


|          |          |          |          |          |


CCGCGGTTCC GGCTGCTCCG GCCAGGGGAC CCTTGGGTCG GCGCTGCGGG CGAGGTGGGC
60





ADGTAGGTGG GCGGACGGCC GCGGTTCTCC CGCAAGCGCA GGCGGCGGAG TCCCCCACCG
120





CGCCCGAAGC GCCCCCCGCA CCCCCGGCCT CCAGCGTTGA GGGGGGGGAG TGAGGAGATG
180





CCGACCCAGA GGGACAGCAG CACCATGTCC CACACGGTCG CAGGCGCCGG CAGCGGGGAC
240





CATTCCCACC AGGTCCGGGT GAAAGCCT ACTACCGCGGGG ATATCATGAT AACACATTTT
300





GAACCTTCCA TCTCCTTTGA GGGCCTTTGC AATGAGGTTC GAGACATGTG TTCTTTTGAC
360





AACGAACAGC TCTTCACCAT GAAATGGATA GATGAGGAAG GAGACCCGTG TACAGTATCA
420





TCTCAGTTGG AGTTAGAAGA AGCCTTTAGA CTTTATGAGC TAAACAAGGA TTCTGAACTC
480





TTGATTCATG TGTTCCCTTG TGTACCAGAA CGTCCTGGGA TGCCTTGTCC AGGAGAAGAT
540





AAATCCATCT ACCGTAGAGG TGCACGCCGC TGGAGAAAGC TTTATTGTGC CAATGGCCAC
600





ACTTTCCAAG CCAAGCGTTT CAACAGGCGT GCTCACTGTG CCATCTGCAC AGACCGAATA
660





TGGGGACTTG GACGCCAAGG ATATAAGTGC ATCAACTDCA AACTCTTGGT TCATAAGAAG
720





TGCCATAAAC TCGTCACAAT TGAATGTGGG CGGCATTCTT TGCCACAGGA ACCAGTGATG
780





CCCATGGATC AGTCATCCAT GCATTCTGAC CATGCACAGA CAGTAATTCC ATATAATCCT
840





TCAADTCATG AGAGTTTGGA TCAAGTTGGT GAAGAAAAAG AGGCAATGAA CACCAGGGAA
900





AGTGGCAAAG CTTCATCCAG TCTAGGTCTT CAGGATTTTG ATTTGCTCCG GGTAATAGGA
960





AGAGGAAGTT ATGCCAAAGT ACTGTTGGTT CGATTAAAAA AAACAGATCG TATTTATGCA
1020





ATGAAAGTTG TGAAAAAAGA GCTTGTTAAT GATGATGAGG ATATTGATTG GGTACAGACA
1080





GAGAAGCATG TGTTTGAGCA GGCATCCAAT CATCCTTTCC TTGTTGGGCT GCATTCTTGC
1140





TTTCAGACAG AAAGCAGATT GTTCTTTGTT ATAGAGTATG TAAATGGAGG AGACCTAATG
1200





TTTCATATGC AGCGACAAAD AAAACTTCCT GAAGAACATG CCAGATTTTA CTCTGCAGAA
1260





ATCAGTCTAG CATTAAATTA TCTTCATGAG CGAGGGATAA TTTATAGAGA TTTGAAACTG
1320





GACAATGTAT TACTGGACTC TGAAGGCCAC ATTAAACTCA CTGACTACGG CATGTGTAAG
1380





GAAGGATTAC GGCCAGGAGA TACAACCAGC ACTTTCTGTG GTACTCCTAA TTACATTGCT
1440





CCTGAAATTT TAAGAGGAGA AGATTATGGT TTCAGTGTTG ACTGGTGGGC TCTTGGAGTG
1500





CTCATGTTTG AGATGATGGC AGGAAGGTCT CCATTTGATA TTGTTGGGAG CTCCGATAAC
1560





CCTGACCAGA ACACAGAGGA TTATCTCTTC CAAGTTATTT TGGAAAAACA AATTCGCATA
1620





CCACGTTCTC TGTCTGTAAA AGCTGCAAGT GTTCTGAAGA GTTTTCTTAA TAAGGACCCT
1080





AAGGAACGAT TGGGTTGTCA TCCTCAAACA GGATTTGCTG ATATTCAGGG ACACCCGTTC
1740





TTCCGAAATG TTGATTGGGA TATGATGGAG CAAAAACAGG TGGTACCTCC CTTTAAACCA
1800





AATATTTCTG GGGAATTTGG TTTGGACAAC TTTGATTCTC AGTTTACTAA TGAACCTGTC
1860





CAGCTCACTC CAGATGACGA TGACATTGTG AGGAAGATTG ATCAGTCTGA ATTTGAAGGT
1920





TTTGAGTATA TCAATCCTCT TTTGATGTCT GCAGAAGAAT GTGTCTGATC CTCATTTTTC
1980





AACCATGTAT TCTACTCATG TTGCCATTTA ATGCATGGAT AAACTTGCTG CAAGCCTGGA
2040





TACAATTAAC CATTTTATAT TTGCCACCTA CAAAAAAACA CCCAATATCT TCTCTTGTAG
2100





ACTATATGAA TCAATTATTA CATCTGTTTT ACTATGAAAA AAAAATTAAT ACTACTAGCT
2160





TCCAGACAAT CATGTCAAAA TTTAGTTGAA CTGGTTTTTC AGTTTTTAAA AGGCCTACAG
2220





ATGAGTAATG AAGTTACCTT TTTTGTTTAA AAAAAAAAAA G





SEQ ID NO: 107 Protein sequence


Protein Accession #: NP_002731.1


1          11         21         31         41         51


|          |          |          |          |          |


MSNTVAGGGS GDHSHQVRVK AYYRGDIMIT NFEPSISFEG LCNEVRDMCS FDNEQLFTMK
60





WIDEEGDPCT VSSQLELEEA FRLYELNKDS ELLIHVFPCV PERPGMPCPG EDKSIYRRGA
120





RRWRKLYCAN GHTFQAKRFN REAHCAICTD RIWGLGEQGY KCINCKLLVH KKCHKLVTIE
160





CGRHSLPQEP VMPMDQSSMH SDHAQTVIPY NPSSHESLDQ VGEEKEAMNT RESCKASSSL
240





GLQDFDLLRV IGRGSYAKVL LVRLKKTDRI YAMKVVKKEL VNDDEDIDWV QTEKHVFEQA
300





SNHPFLVGLH SCFQTESRLF FVIEYVNGGD LMFHMQRQRK LPEEHARFYS AEISLALNYL
360





HERGIIYRDL KLDNVLLDSE GHIKLTDYGM CKEGLRPGDT TSTFCGTPNY IAPEILRGED
420





YGFSVDWWAL GVLMFEMMAG RSPEDIVGSS DNPDQNTEDY LFQVILEKQI RIPRSLSVKA
480





ASVLKSFLNK DPRERLGCHP QTGFADIQGH PFFRNVDWDM MEQKQVVPPF KPNISGEFGL
540





DNFDSQFTNE PVQLTPDDDD IVRKIDQSEF EGFEYINPLL MSAEECV





SEQ ID NO: 108 DNA sequence


Nucleic Acid Accession #: NM_000349.1


Coding sequence: 127. .984


1          11         21         31         41         51


|          |          |          |          |          |


GGGACTCAGA GGCGAAGCTT GAGGGGCTCA GGAAGGACGA AGAACCACCC TTGAGAGAAG
60





AGGCAGCAGC AGCCGCGGCA GCAGCAGCGG CAGCGACCCC ACCACTGCCA CATTTGCCAG
120





GAAACAATGC TGCTACCGAC ATTCAAGCTG TGCGCTGGGA GCTCCTACAG ACACATGCGC
160





AACATGAAGG GGCTGAGGCA ACAGGCTGTG ATGGCCATCA GCCAGGAGCT GAACCGGACG
240





GCCCTGGGGG GCCCCACCCC TAGGACGTGG ATTAACCAGG TTCGGCGGCG GAGCTCTCTA
300





CTCCGTTCTC GGCTGGAAGA GACTCTCTAC AGTGACCAGG AGCTGGCCTA TCTCCAGCAG
360





GGGGAGGAGG CCATGCAGAA GGCCTTGGGC ATCCTTAGCA ACCAAGAGGG CTGGAAGAAG
420





GACAGTCAGC AGGACAATGG GGACAAAGTG ATGAGTAAAG TGGTCCCAGA TGTGGGCAAG
480





GTGTTCCGGC TGGAGGTCGT GGTGGACCAG CCCATGGAGA GGCTCTATGA AGAGCTCGTG
540





GAGGGCATGG AAGCAATGGG GGAGTGGAAC CCCAATGTCA AGGAGATCAA GGTCCTGCAG
600





AAGATCGGAA AAGATACATT CATTACTCAC GAGCTGGCTG CCGAGGCAGC AGGAAACCTG
660





GTGGGGCCCC GTGACTTTGT GACCGTGCGC TGTGCCAAGC GCCCAGGCTC CACCTGTGTG
720





CTGGCTGGCA TGGACACAGA CTTCGGGAAC ATGCCTGAGC AGAAGGGTGT CATCAGGGCG
780





GAGCACGGTC CCACTTGCAT GGTGCTTCAC CCGTTGGCTG GAAGTCCCTC TAAGACCAAA
840





CTTACGTGGC TACTCAGCAT CGACCTCAAG GGGTGGCTGC CCAAGAGCAT CATCAACCAG
900





GTCCTGTCCC AGACCCAGGT GGATTTTGCC AACCACCTGC GCAAGCGCCT GGAGTCCCAC
960





CCTGCCTCTG AAGCCAGGTG TTGAAGACCA GCCTGCTGTT CCCAACTGTG CCCAGCTGCA
1020





CTGGTACACA CGCTCATCAG GAGAATCCCT ACTGGAAGCC TGCAAGTCTA AGATCTCCAT
1080





CTGGTGACAG TGGGATGGGT GGGGTTCGTG TTTAGAGTAT GACACTAGGA TTCAGATTGG
1140





TGAAGTTTTT AGTACCAAGA AAACAGGGAT GAGGCTCTTG GATTAAAAGG TAACTTCATT
1200





CACTGATTAG CTATGACATG AGGGTTCAGG CCCCTAAAAT AATTGTAAAA CTTTTTTTCT
1260





GGGCCCTTAT GTACCCACCT AAAACCATCT TTAAAATGCT AGTGGCTGAT ATGGGTGTGG
1320





GGGATGCTAA CCACAGGGCC TGAGAAGTCT TGCTTTATGG GCTCAAGAAT GCCATGCGCT
1380





GGCACTACAT GTGCACAAAG CAGAATCTCA GAGGGTCTCC TGCAGCCCTC TGCTCCTCCC
1440





GGCCGCTGCA CAGCAACACC ACAGAACAAG CAGCACCCCA CAGTGGGTGC CTTCCAGAAA
1500





TATAGTCCAA GCTTTCTCTG TGGAAAAAGA CAAAACTCAT TACTAGACAT GTTTCCCTAT
1560





TGCTTTCATA GGCACCAGTC AGAATAAAGA ATCATAATTC ACACC





SEQ ID NO: 109 Protein sequence


Protein Accession #: NP_000340.1


1          11         21         31         41         51


|          |          |          |          |          |


MLLATFKLCA GSSYRHMRNM KGLRQQAVMA ISQELNRRAL GGPTPSTWIN QVRRRSSLLG
60





SELEETLYSD QELAYLQQGE EAMQKALGIL SNQEGWKKES QQDNGDKVMS KVVPDVGKVF
120





RLEVVVDQPM ERLYEELVER MEAMGEWNPN VKEIKVLQKI GKDTFITHEL AAEAAGNLVG
180





PRDFVSVRCA KRRGSTCVLA GMDTDFGNMP EQKGVIRAEH GPTCMVLHPL AGSPSKTKLT
240





WLLSIDLKGW LPKSIINQVL SQTQVDFANH LRKRLESHPA SEARC





SEQ ID NO: 110 DNA sequence


Nucleic Acid Accession #: EOS sequence


Coding sequence: 131-682


1          11         21         31         41         51


|          |          |          |          |          |


GCTGGGAGCC TGGGCCGGGA GCCGGGTGAG GGCGCCGAGA GGCTCGGTGG GCGCGGGCGG
60





CGAGATATGC CACACTTCTG CCTGCTGTTG GCAACCCTCC TGGACTAGGC TGCTCTTGTT
120





AATCACATGG ATGTTATATA AGAGTTCGGA CCGCCCAGCA CACAAGGTCA GCATGCTGCT
180





CCTCTGTCAC GCTCTCGCTA TAGCTGTTGT CCAGATCGTT ATCTTCTCAG AAAGCTGGGC
240





ATTTGCCAAG AACATCAACT TCTATAATGT GAGGCCTCCT CTCGACCCTA CACCATTTCC
300





AAATAGCTTC AAGTGCTTTA CTTGTGAAAA CGCAGGGGAT AATTATAACT GCAATCGATG
360





GGCAGAAGAC AAATGGTGTC CACAAAATAC ACAGTACTGT TTGACAGTTC ATCACTTCAC
420





CAGCCACGGA AGAAGCACAT CCATCACCAA AAAGTGTGCC TCCAGAAGTG AATGTCATTT
480





TGTCGGTTGC CACCACAGCC GAGATTCTGA ACATACGGAG TGTAGGTCTT GCTGTGAAGG
540





AATGATCTGC AATGTAGAAT TACCCACCAA TCACACTAAT GCAGTGTTTG CCGTAATGCA
600





CGCTCAGAGA ACATCTGGCA GCAGTGCCCC CACACTCTAC CTACCAGTGC TTGCCTGGGT
660





CTTTGTGCTT CCATTGCTGT GATGCCACCA TTCCTAGGAG AGGCAGAGAC CAGCCTCTAA
720





AGCACAAGCC AAAAACTGTG TGAACGGTGA ACTTTGGAGT GAAGATCAAT CTTGCACTTG
780





GTGAAGAGTG CACATTGGAC CTCAAGGCGA AAGCCAGTGG TTTGCTTGGA TAAAATGTTC
840





CCGCATGAGG CCACAGGACT GAGGATGGGA ATTTGGCAGG GCCTGAGAAG ATGGTCTGAC
900





TTCCAGGCTT CCTGGTCAAA GAGAGCTACG TTTGGGCAGT TCTGCAGAGA GGATCCTGGC
960





AACTAGTCCC ACCTGACTAG GCCTTTAGCT GAAAGGATTT CTTGACCTCC TTGACTGCCT
1020





CAGAGGCTGC CAGGTCAAAC CCTCTTGTTT ATGTGATTAG CTCAGAGCAT CTCTATGAAA
1080





TCTAACCCTT CCCCTCATGA GAAAGCAGTT TTCCCCACCA ACAGCATAGT CAATGAGAAA
1140





GGCAACTGTA CGAAGAAAAC TTCCAGTGGA ACTAATATGA AATCTATTTG CAAATTATGG
1200





GGGGAAATAA AGCTTTTAAA TTATACAATG T





SEQ ID NO: 111 Protein sequence


Protein Accession #: AAM20908.1


1          11         21         31         41         51


|          |          |          |          |          |


MLYKSSDRPA HKVSMLLLCH ALAIAVVQIV IFSESWAFAK NINFYNVRPP LDPTPFPNSF
60





KCFTCENAGD NYNGNRWAED KWCPQNTQYC LTVHHFTSHG RSTSITKKCA SRSECHFVGC
120





HHSRDSEHTE CRSCCEGMIC NVELPTNHTN AVFAVMHAQR TSGSSAPTLY LPVLAWVFVL
180





PLL





SEQ ID NO: 112 DNA sequence


Nucleic Acid Accession #: Eos sequence


Coding sequence: 228-884


1         11         21         31         41         51


|          |          |          |          |          |


CGCCCGCCGG CCCCAGGCGG GTGCGCTGGG AGCCTGGGCC GGGAGCCGGG TGAGGGCGCC
60





GAGAGGCTCG GTGGGCGCGG CCGGCGAGGA CTCTGCTGGA GCACGACTTC AGAGTGTTTG
120





TTTTCAGCCT GCTTTTAAAG TCATTTGAAG AGAGCGGCTT TCAAGATATG CCACACTTCT
180





GCCTGCTGTT GGCAACCCTC CTGGACTAGG CTGCTCTTGT TAATCACATG GATGTTGCTG
240





ATTACTCTGA GTGCAAACCT TTTCACTGTT CCAGAGAGGA GCCTCACAAC CACATTCTCC
300





TTCTCAAGGT GTGGTGCTTA CTGCGCAGGC TGACCAGATA TAAGAGTTCG GACCGCCCAG
360





CACACAAGGT CACCATGCTG CTCCTCTGTC ACGCTCTCGC TATAGCTGTT GTCCAGATCG
420





TTATCTTCTC ACAAAGCTGG GCATTTGCCA AGAACATCAA CTTCTATAAT GTGAGGCCTC
480





CTCTCGACCC TACACCATTT CCAAATAGCT TCAAGTGCTT TACTTGTGAA AACGCAGGGG
540





ATAATTATAA CTGCAATCGA TGGGCAGAAG ACAAATGGTG TCCACAAAAT ACACACTACT
600





GTTTGACAGT TCATCACTTC ACCAGCCACG GAAGAAGCAC ATCCATCACC AAAAAGTGTG
660





CCTCCAGAAG TGAATGTCAT TTTGTCGGTT GCCACCACAG CCCAGATTCT GAACATACGG
720





AGTGTACGTC TTGCTGTGAA GGAATGATCT GCAATGTAGA ATTACCCACC AATCACACTA
780





ATGCAGTCTT TGCCGTAATG CACGCTCAGA GAACATCTGG CAGCAGTGCC CCCACACTCT
840





ACCTACCAGT GCTTGCCTGG GTCTTTGTGC TTCCATTGCT GTGATGCCAC CATTCCTAGG
900





AGAGGCAGAG ACCAGCCTGT AAAGCACAAG CCAAAAACTG TGTGAACGGT GAACTTTGGA
960





GTGAAGATCA ATCTTGCACT TGGTGAAGAG TGCACATTGG ACCTCAAGGC GAAAGCCAGT
1020





GGTTTGCTTG GATAAAATGT TCCCGCATGA GGCCACAGGA CTGAGGATGG GAATTTGGCA
1080





GGGCCTGAGA AGATGGTCTG ACTTCCAGGC TTCCTGGTCA AAGAGAGCTA CGTTTGGGCA
1140





GTTCTGCAGA GAGGATCCTG GCAACTAGTC CCACCTGACT AGGCCTTTAG CTGAAAGGAT
1200





TTCTTGACCT CCTTGACTGC CTCAGAGGCT GCCAGGTCAA ACCCTCTTGT TTATGTGATT
1260





AGCTCAGAGC ATCTCTATGA AATCTAACCC TTCCCCTCAT GAGAAAGCAG TTTTCCCCAC
1320





CAACAGCATA GTCAATGAGA AAGGCAACTG TACGAAGAAA ACTTCCAGTG GAACTAATAT
1380





GAAATCTATT TGCAAATTAT GGGGGGAAAT AAAGCTTTTA AATTATAAA





SEQ ID NO: 113 Protein sequence


Protein Accession #: Eos sequence


1          11         21         31         41         51


|          |          |          |          |          |


MDVADYSECK PFHCSREEPD NHILLLKVWC LLRRLTRYKS SDRPAHKVSM LLLCHALAIA
60





VVQIVIFSES WAFAKNINFY NVRPPLDPTP FPNSFKCFTC ENAGDNYNCN RWAEDKWCPQ
120





NTQYCLTVHH FTSHGRSTSI TKKCASRSEC HFVGCHHSRD SEHTECRSCC EGMICNVELP
180





TNNTNAVFAV MHAQRTSGSS APTLYLPVLA WVFVLPLL





SEQ ID NO: 114 DNA sequence


Nucleic Acid Accession #: EOS sequence


Coding sequence: 402-1025


1          11         21         31         41         51


|          |          |          |          |          |


ACTTCCTGAG CCGGGCTGGC TGGGTGGGAA CAGGCTCCTT GCCGCCTCCC CAGCGCTGGC
60





CACTACCACA CTGCCGCCCG CCTGGGCCTC CTTTCAACCT CGTGGTGGAG CCCTGCGGTT
120





TCCCAGCGGA GCCGGGCCCG GGGCTGCTCC CTCGCGGGCG AGGCTCACCT GTCCCGGCCC
180





GGCCCCCTCC CGCGCCCCAG GTGGTTCAGG GCAGGGAGGA GCCGCGCCCC GCCCCGCGCG
240





GTAGCAGCCA ACGCCGGCCC CAGGCGGGTG CGCTGGGAGC CTGGGCCGGG AGCCGGGTGA
300





GGGCGCCGAG AGGCTCGGTG GGCGCGGGCG GCGAGATATG CCACACTTCT GCCTGCTGTT
360





GGCAACCCTC CTGGACTAGG CTGCTCTTGT TAATCACATG GATGTTGCTG ATTACTCTGA
420





GTGCAAACCT TTTCACTGTT CCAGAGAGGA GCCTGACAAC CACATTCTCC TTCTCAAGAT
480





ATAAGAGTTC GGACCGCCCA GCACACAAGG TCAGCATGCT GCTCCTCTGT CACGCTCTCG
540





CTATAGCTGT TGTCCAGATC GTTATCTTCT CAGAAAGCTG GGCATTTGCC AAGAACATCA
600





ACTTCTATAA TGTGAGGCCT CCTCTCGACC CTACACCATT TCCAAATAGC TTCAAGTGCT
660





TTACTTGTGA AAACGCAGGG GATAATTATA ACTGCAATCG ATGGGCAGAA GACAAATGGT
720





GTCCACAAAA TACACACTAC TGTTTGACAG TTCATCACTT CACCAGCCAC GGAAGAAGCA
780





CATCCATCAC CAAAAAGTGT GCCTCCAGAA GTGAATGTCA TTTTGTCGGT TGCCACCACA
840





GCCGAGATTC TGAACATACG GAGTGTAGGT CTTGCTGTGA AGGAATGATC TGCAATGTAG
900





AATTACCCAC CAATCACACT AATGCAGTGT TTGCCGTAAT GCACGCTCAG AGAACATCTG
960





GCAGCAGTGC CCCCACACTC TACCTACCAG TGCTTGCCTG GGTCTTTGTG CTTCCATTGC
1020





TGTGATGCCA CCATTCCTAG GAGAGGCAGA GACCAGCCTC TAAAGCACAA GCCAAAAACT
1080





GTGTGAACGG TGAACTTTGG AGTGAAGATC AATCTTGCAC TTGGTGAAGA GTGCACATTG
1140





GACCTCAAGG CGAAAGCCAG TGGTTTGCTT GGATAAAATG TTCCCGCATG AGGCCACAGG
1200





ACTGAGGATG GGAATTTGGC AGGGCCTGAG AAGATGGTCT GACTTCCAGG CTTCCTGGTC
1260





AAAGAGAGCT ACGTTTGGGC AGTTCTGCAG AGAGGATCCT GGCAACTAGT CCCACCTGAC
1320





TAGGCCTTTA GCTGAAAGGA TTTCTTGACC TCCTTGACTG CCTCAGAGGC TGCCAGGTCA
1380





AACCCTCTTG TTTATGTGAT TAGCTCAGAG CATCTCTATG AAATCTAACC CTTCCCCTCA
1440





TGAGAAAGCA GTTTTCCCCA CCAACAGCAT AGTCAATGAG AAAGGCAACT GTACGAAGAA
1500





AACTTCCAGT GGAACTAATA TGAAATCTAT TTGCAAATTA TGGGGGGAAA TAAAGCTTTT
1560





AAATTATACA ATGT





SEQ ID NO: 115 Protein sequence


Protein Accession #: EOS sequence


1          11         21         31         41         51


|          |          |          |          |          |


MLLITLSANL FTVPERSLTT TFSFSRYKSS DRPAHKVSML LLCHALAIAV VQIVTFSESW
60





AFAKNINFYN VRPPLDPTPF PNSFKCFTCE NAGDNYNCNR WAEDKWCPQN TQYCLTVHHF
120





TSHGRSTSIT KKCASRSECH FVGCHHSRDS EHTECRSCCE GMICNVELPT NHTNAVFAVM
180





HAQRTSGSSA PTLYLPVLAW VFVLP





SEQ ID NO: 116 DNA sequence


Nucleic Acid Accession #: Eos sequence


Coding sequence: 1-1059


1          11         21         31         41         51


|          |          |          |          |          |


ATGGTATGGC AGCAAGATTA TGCAACCAGG AGAGAGCACC ATGGCTGCCG TCTGGAATTC
60





TGCCGTGTAT CTGCAGGGTG CCCTTGCCTA AGCCCCTTGA CCTCTTTGGT TATAGTTTCC
120





TCATGTGCTG AGAGAGGTGA GGAAGCTGCA GAAGAAGACT TTGAAACTAG CAGAGGTGGG
180





TTCATGAGGA TGAAGGAAAG AAGCCATGCC CATAACATAA AAGTGCAAGG TGAAGCAGGA
240





GGTGCTGATG AAGAAGCTGC AGCAAGTGAT CCAGAAGATC TAGCTAAGAT CATTGATGAA
300





GATGTGAAAG GCATTGTACA GAAGAAGATG AGAATCACAG TAAACCAAAC AAAGGAAATG
360





CAGAAGAGAT ATTTTCAGCT GAATATTGGA AATGTAAAAT GCCACACGTT GGATGAGATG
420





ATTATCCGAG CTCAGACTTG GGAAATAGTC ATGCTTCTGG ACCAAGTGCC AGGTCCTGGC
480





CCTACACAAC AGGTAGATGG TTGGATATAT TTGGATAATG GAGCTTTCCA AACAGAAGCA
540





AAACACAAAC CCACTGATGT AAAATATAAA GAAACTGAAC CAGTGTGTCT TTTCACCATA
600





GATATAAGAG TTCGGACCGC CCAGCACACA AGAATAAAAC AGAAAGTCTC CATTACTTCT
660





ATGGCTACAC CATTTCCAAA TAGCTTCAAG TGCTTTACTT GTGAAAACGC AGGGGATAAT
720





TATAACTGCA ATCGATGGGC AGAAGACAAA TGGTGTCCAC AAAATACACA GTACTGTTTG
780





ACAGTTCATC ACTTCACCAG CCACGGAAGA AGCACATCCA TCACCAAAAA GTGTGCCTCC
840





AGAAGTGAAT GTCATTTTGT CGGTTGCCAC CACAGCCGAG ATTCTGAACA TACGGAGTGT
900





AGGTCTTGCT GTGAAGGAAT GATCTGCAAT GTAGAATTAC CCACCAATCA CACTAATGCA
960





GTGTTTGCCG TAATGCACGC TCAGAGAACA TCTGGCAGCA GTGCCCCCAC ACTCTACCTA
1020





CCAGTGCTTG CCTGGGTCTT TGTGCTTCCA TTGCTGTGAT GCCACCATTC CTAGGAGAGG
1080





CAGAGACCAG CCTCTAAAGC ACAAGCCAAA AACTGTGTGA ACGGTGAACT TTGGAGTGAA
1140





GATCAATCTT GCACTTGGTG AAGAGTGCAC ATTGGACCTC AAGGCGAAAG CCAGTGGTTT
1200





GCTTGGATAA AATGTTCCCG CATGAGGCCA CAGGACTGAG GATGGGAATT TGGCAGGGCC
1260





TGAGAAGATG GTCTGACTTC CAGGCTTCCT GGTCAAAGAG AGCTACGTTT GGGCAGTTCT
1320





GCAGAGAGGA TCCTGGCAAC TAGTCCCACC TGACTAGGCC TTTAGCTGAA AGGATTTCTT
1380





GACCTCCTTG ACTGCCTCAG AGGCTGCCAG GTCAAACCCT CTTGTTTATG TGATTAGCTC
1440





AGAGCATCTC TATGAAATCT AACCCTTCCC CTCATGAGAA AGCAGTTTTC CCCACCAACA
1500





GCATAGTCAA TGAGAAAGGC AACTGTACGA AGAAAACTTC CAGTGGAACT AATATGAAAT
1560





CTATTTGCAA ATTATGGGGG GAAATAAAGC TTTTAAATTA TACAATGTAA A





SEQ ID NO: 117 Protein sequence


Protein Accession #: Eos sequence


1          11         21         31         41         51


|          |          |          |          |          |


MVNQQDYGTR REHHGCRLEF CRVSAGCPCL SPLTSLVIVS SSAERGEEAA EEDFETSRGG
60





FMRMKERSHA HNIKVQGEAG GADEEAAASD PEDLAKIIDE DVKGIVQKKM RITVNQTKEM
120





QKRYFQLNIG NVKCHTLDEM IIRAQTWEIV MLLDQVPGPD PTQQVDGWIY LDNGAFQTEA
180





KHKPTDVKYK ETEPVCLFTI DIRVRTAQHT RIKQKVSITS MATPFPNSFK CFTCENAGDN
240





YNCNRWAEDK WCPQNTQYCL TVHHFTSHGR STSITKKCAS RSECHFVGCN HSRDSEHTEC
300





RSCCEGMICN VELPTNHTNA VFAVMHAQRT SGSSAPTLYL PVLAWVFVLP LL





SEQ ID NO: 118 DNA sequence


Nucleic Acid Accession #: XM_036659.6


Coding sequence: 528-1688


1          11         21         31         41         51


|          |          |          |          |          |


AGTAGGGAGG TGGGCAGGAG CCAGTGATGA CGGAATGGCA ATCACATTTG ACCTCTGATC
60





TGTTTATTTC CTCCTCCTTG ACGTCTCCAT ATAAATGTTA CACGGGCATC CCCACACTCG
120





GATACGCACC CACAGTGGCT GATTCGGGGG TAACCGTGTC ATTTGCTTGC AACACTGGCA
180





CCTCTGCCCT GCACCCCDGG AGTGAGCAGT GAGTGAGGCT CGGGTCTGGG CGCTGGCTCC
240





GAATCTTCGG GCTGGGAGAG ACTCCACCAT CTGGGGGCGG CCTGGGGDAG CAGCCTTAGT
300





GTCTTCCTGC TGATGCAATC CGCTAGGTCG CGAGTCTCCG CCDCGAGAGG GCCGGTCTGC
360





AATCCAGCCC GCCACGTGTA CTCGCCGCCG CCTCGGGCAC TGCCCCAGGT CTTGCTGCAG
420





CCDGGACCGC GCTCTGCAGC CGCAGACCCG GTCCACACGG CCAGGGGCTA CGACCCTTGG
480





GATCTGCCCT CCGCTCAGCT CGAGCTTCCC TCGTGGCCGA CGGAACAATG AAGGATTGCA
540





GTAACGGATG CTCCGCAGAG TGTACCGGAG AAGGAGGATC AAAAGAGGTG GTGGGGACTT
600





TTAAGGCTAA AGACCTAATA GTCACACCAG CTACCATTTT AAAGGAAAAA CCAGACCCCA
660





ATAATCTGGT TTTTGGAACT GTGTTCACGG ATCATATGCT GACGGTGGAG TGGTCCTCAG
720





AGTTTGGATG GGAGAAACcT CATATCAAGC CTCTTCAGAA CCTGTCATTG CACCCTGGCT
780





CATCAGCTTT GCACTATGCA GTGGAATTAT TTGAAGGATT GAAGGCATTT CGAGGAGTAG
840





ATAATAAAAT TCGACTGTTT CAGCCAAACC TCAACATGGA TAGAATGTAT CGCTCTGCTG
900





TGAGGGCAAC TCTGCCGGTA TTTGACAAAG AAGAGCTCTT AGAGTGTATT CAACAGCTTG
960





TGAAATTGGA TCAAGAATGG GTCCCATATT CAACATCTGC TAGTCTGTAT ATTCGTCCTA
1020





CATTCATTGG AACTGAGCCT TCTCTTGGAG TCAAGAAGCC TACCAAAGCC CTGCTCTTTG
1080





TACTCTTGAG CCCAGTGGGA CCTTATTTTT CAAGTGGAAC CTTTAATCCA GTGTCCCTGT
1140





GGGCCAATCC CAAGTATGTA AGAGCCTGGA AAGGTGGAAC TGGGGACTGC AAGATGGGAG
1200





GGAATTACGG CTCATCTCTT TTTGCCCAAT GTGAAGCAGT AGATAATGGG TGTCAGCAGG
1260





TCCTGTGGCT CTATGGAGAG GACCATCAGA TCACTGAAGT GGGAACTATG AATCTTTTTC
1320





TTTACTGGAT AAATGAAGAT GGAGAAGAAG AACTGGCAAC TCCTCCACTA GATGGCATCA
1380





TTCTTCCAGG AGTGACAAGG CGGTGCATTC TGGACCTGGC ACATGACTGG GGTGAATTTA
1440





AGGTGTCAGA GAGATACCTC ACCATGGATG ACTTGACAAC AGCCCTGGAG CGGAACAGAG
1500





TGAGACAGAT GTTTGGCTCT GGTACAGCCT GTGTTGTTTG CCCAGTTTCT CATATACTGT
1560





ACAAAGGCCA CACAATACAC ATTCCAACTA TCCACAATGG TCCTAAGCTG CCAACCCGCA
1620





TCTTGACCAA ATTAACTGAT ATGCACTATG GAAGACAAGA GAGCGACTGG ACAATTCTGC
1680





TATCCTGAAT GGAAAATAGA GGATACAATG GAAAATACAC GATACCAACT GTATGCTACT
1740





GGGACAGACT GTTGCATTTG AATTGTGATA GATTTCTTTG CCTACCTGTG CATAATGTAG
1800





TTTGTAGTAT CAATGTCTTA CAAGAGTGAT TGTTTCTTCA TCCCAGAGAA AATGAATTGC
1860





AATCATCAAA TGGTGTTTCA TAACTTGGTA GTAGTAACTT ACCTTACCTT ACCTAGAAAA
1920





ACATTAATGT AAGCCATATA ACATGGGATT TTCCTCAATG ATTTTAGTGC CTCCTTTTGT
1980





ACTTCACTCA GATACTAAAT AGTAGTTTAT TCTTTAATAT AAGTTACATT CTGCTCCTCA
2040





AACAAATGCA ATTTTTTGTC TGTGTTTGAA AGCTAATTTC AGAAAATTTC ATAGGTTACA
2100





TTTCCTGCAG CCTATCTTTA TCCACAGAAA GTGTTTTCTT TTTTTTAAAT CAAGACTTTT
2160





AAAACTGGAT TTCCTCCCAT CACTGTTTTT TGAAGGTCCT CCAAGTCCGT GTTAAGGTAA
2220





ATATCTGTTT TCTTCCTGAT GTCACAGCCT GAGCATACTC TGTGCATTAG GAAGACCTGA
2280





GTGCATTTCC CACCATTGTC CTTTCCACAT TATGTTGTAG CTGGCTGGCT GTGAGGGGAC
2340





TACAAGACTG AGGGTCTTGT GGGTTATAGA TCTTTGTATC CCCCATGGCT GACATATAGT
2400





AGGTACTCAG TAAATGGTTT TATAATGAAT CAGTGAACAT TTTGCTTCTA TAGAAGTGTA
2460





CCTTCTTTGT TTCTATATTA TGAAACCTCT TTATTAGAAT TTGTGATTGA TTCTGACAGT
2520





GTATAGATTT ACCTTATATT GTCTTTATTT TCCATGAGCT ACTAAGTCAT TAGAGATACT
2580





CTGAAGCATA GTTAGTTTAG GAAATCACTT CATATTGATT GTATTAGAAT TATCTTGGAA
2640





TTGAAGATAT ATCCCTAGAG CAGGGGACCC CAACCCCCAG GCCATGGGCC ACACAGCAGG
2700





AAGAGGTGAG TGGTGGGCCA TTGAGGAGCT TCATCTGTAT TTATGGCTAC TTCCCATCAC
2760





TCGAATTACC ACCTGAACTC CACCTCTTGT CAGCTCAGTG GCACCATTAG ATTCTCATAG
2820





GAGCACAAAT CCTATTGTGA ACTCTGCATG CAAGGGATCT AGGCTATGCG CTCCTTATGA
2880





GAATCTAATG CTTGATGACC TGAGGTGTAA CAGTTTCATC CTGAAACCAC CCTTCACCCT
2940





GCAGTCTGTG GAAAAATTGT CTTCCACAAA ACTGGTCCCT GGTGCCAAAA ATGTTGGGGA
3000





CCACTGCTCT AGAGAGAGGT CATGATATCA TACCAACCAA ATGGAAATGA CAAATGTTTT
3060





ATGTCAAGTG TTAATTGCAG AAATAAATCT TTTTTTTTTT TTTTTGGTAG AAAACAAAGA
3120





GGCATACTCT GATTTTTATA CTCTGTTTTT GCAGGTGCTC TTTTCTTTGA ATGGAGATTT
3180





GATGAGCAAG TGGTTAGGAT GCAGGGAGAG CTACTATGGG TGATATTTTC CTTGTTTAGG
3240





AGCTGTGAGT TAAAATTGTA TCCTTTGTGG TTTATCTAAG GAAAGTCAAA TCTTGACAGA
3300





AAACATTTTT CCTTGGAAGG TCAACTCTCA GACATTGTAT TTTGGTTTCC CTCAGTCCTC
3360





ATAACTTCCT TCTTGCTGAA CATATTTTAT TCTCTTTTCA GAGAAGGAAA ATAAAAAGGA
3420





TTCTAAAAGT TTGATGCATT GGAAAAATTT CCTTGAGGCA TTTAGCAACA CATAGAAAAT
3480





GGGCTTTGAT TCTTTTCCAA AACTTTTAGC CATAGGGTCT TTTATAGACA GGGATAGTAA
3540





AATGAAAATT GAGAAATATA AGATGAAAAG GAATGATAAA AATATCTTTT AGGGGGCTTT
3600





TAATTGGTGA TCTGAAATCT TGGGAGAAGC TGTTCTTTTC AGGCCTGAGG TGCTCTTGAC
3660





TGTCGCCTGC GCACTGTGTA CCCCGAGCAA CATTCTAAGG GTGTGCTTTC GCCTTGGCTA
3720





ACTCCTTTGA CCTCATTCTT CATATACTAG TCTAGGAAAA AGTTGCAGGT AATTTAAACT
3780





GTCTAGTGGT ACATAGTAAC TAAATTTCTA TTCCTATGAG AAATGAGAAT TATTTATTTG
3840





CCATCAACAC ATTTTATACT TTGCATCTCC AAATTTATTG TGGCGAGACT TGTCCATTGT
3900





GAAAGTTAGA GAACATTATG TTTGTATCAT TTCTTTCATA AAACCTCAAG AGCATTTTTA
3960





AGCCCTTTTC ATCAGACCCA GTGAAAACTA AGGATAGATG TTTAAAAACT GGAGGTCTCC
4020





TGATAAGGAG AACACAATCC ACCATTGTCA TTTAAGTAAT AAGACAGGAA ATTGACCTTG
4080





ACGCTTTCTT GTTAAATAGA TTTAACAGGA ACATCTGCAC ATCTTTTTTC CTTGTGCACT
4140





ATTTGTTTAA TTGCAGTGGA TTAATACAGC AAGAGTGCCA CATTATAACT AGGCAATTAT
4200





CCATTCTTCA AGACTTAGTT ATTGTCACAC TAATTGATCG TTTAAGGCAT AAGATGGTCT
4260





AGCATTAGGA ACATGTGAAG CTAATCTGCT CAAAAAGATC AACAAATTAA TATTGTTGCT
4320





GATATTTGCA TAATTGGCTG CAATTATTTA ATGTTTAATT GGGTTGATCA AATGAGATTC
4380





AGCAATTCAC AAGTGCATTA ATATAAACAG AACTGGTGGC ACTTAAAATG ATAATGATTA
4440





ACTTATATTG CATGTTCTCT TCCTTTCACT TTTTTCAGTT TCTACATTTC AGACCGAGCT
4500





TGTCAGCTTT TTTGAAAACA CATCAGTAGA AACCAAGATT TTAAAATGAA GTGTCAAGAC
4560





AAAGGCAAAA CCTGAGCAGT TCCTAAAAAG ATTTGCTGTT AGAAATTTTC TTTGTGGCAG
4620





TCATTTATTA AGGATTCAAC TCGTGATACA CCAAAAGAAG AGTTGACTTC AGAGATGTGT
4680





TCCATGCTCT CTAGCACAGG AATGAATAAA TTTATAACAC CTGCTTTAGC CTTTGTTTTC
4740





AAAAGCACAA AGGAAAAGTG AAAGGGAAAG AGAAACAAGT GACTGAGAAG TCTTGTTAAG
4800





GAATCAGGTT TTTTCTACCT GGTAAACATT CTCTATTCTT TTCTCAAAAG ATTGCTGTAA
4860





GAAAAAATGT AAGAC





SEQ ID NO: 119 Protein sequence


Protein Accession #: XP_038659.2


1          11         21         31         41         51


|          |          |          |          |          |


MKDCSNGCSA ECTGEGGSKE VVGTFKAKDL IVTPATILKE KPDPNNLVFG TVFTDHNLTV
60





EWSSEFGWEK PHIKPLQNLS LHPGSSALHY AVELFEGLKA FRGVDNKIRL FQPNLNMDRM
120





YRSAVRATLP VFDKEELLEC IQQLVKLDQE WVPYSTSASL YIRPTFIGTE PSLGVKKPTK
180





ALLFVLLSPV GPYFSSGTFN PVSLWANPKY VRAWKGGTGD CKMGGNYGSS LFAQCEAVDN
240





GCQQVLWLYG EDNQITEVGT MNLFLYWINE DGEEELATPP LDGIILPGVT RRCILDLAHQ
300





WGEFKVSERY LTMDDLTTAL EGNRVREMPG SGTACVVCPV SDILYKGETI HIPTMENGPK
360





LASRILGKLT DIQYGREESG WTIVLS





SEQ ID NO: 120 DNA sequence


Nucleic Acid Accession #: NM_005377


Coding sequence: 121..1194


1          11         21         31         41         51


|          |          |          |          |          |


ACAGAGGGCG GGTCGCGCGC TCGGTGGCCG TTGTGCGCGT GTGTGGAGTG CCCTGCTGCC
60





CCCAGCTGGA GGGGAACTAG TCTGCTCCAG GTGGCAAGCT GCGTGAGCAA GCAAGCCAAC
120





ATGGACCGCG ACTCGTACCA TCACTATTTC TACGACTATG ACGGCGGGGA GGATTTCTAC
180





CGCTCCACGA CGCCCAGCGA GGACATCTGG AAGAAATTCG AGTTGGTGCC GCCGCCCTGG
240





ACTTGGGTCC GCAGCCGGGA ACCCAGCCCT CACCTTTGGT CTCCTGGAAC GTGGCCGGTA
300





GGGTGCGCTG GGGACGAGAC GGAATCCCAG GACTACTGGA AAGCTTGGGA CGCGAACTAC
360





GCCTCCCTCA TCCGCCGTGA CTGCATGTGG AGCGGCTTCT CCACCCAGGA GCCGCTGGAG
420





AGAGCGGTGA GTGACCTGCT TGCCGTTGGC GCGCCCTCGG GATACTCGCC CAAGGAGTTC
480





GCCACCCCCG ACTACACTCC CGAGCTCGAA GCCGGCAACC TAGCGCCCAT CTTCCCCTGT
540





TTGTTGGGCG AGCCCAAGAT CCAGGCCTGC TCCAGGTCTG AGAGCCCAAG CGACTCCGAG
600





GGTGAAGAAA TCGACGTGAC AGTAAAGAAG AGGCAGTCTT TGAGTACGCG GAAGCCAGTC
660





ATCATCGCGG TGCGTGCAGA CCTTCTGGAT CCCCGCATGA ATCTCTTCCA CATCTCCATC
720





CACCAGCAAC AGCACAACTA TGCTGCCCCT TTTCCTCCAG AAAGCTGCTT CCAAGAAGGG
780





GCTCCAAAGA GGATGCCCCC AAAAGAGGCT CTAGAGAGAG AAGCTCCAGG GGGAAAGGAT
840





CATAAGGAAG ATGAAGAGAT TGTGAGCCTC CCACCTGTAG AAAGTGAGGC TGCCCAGTCC
900





TGCCAGCCCA AACCCATCCA TTATGATACT GAGAATTGGA CCAAGAAGAA GTACCACAGC
960





TACCTGGAGC GCAAGAGACG GAATGATCAA CGTTCGCGGT TCTTGGCCCT GAUGGACCAG
1020





GTACCCGCCC TGGCCAGCTG CTCTAGGGTT TCCAAAGTAA TGATCCTAGT CAAGGCCACG
1080





GAATACTTAC ATGAACTGGC GGAAGCCGAG GAGAGGATGG CTACGGAGAA AAGGCAGCTC
1140





GAATGCCAGC GACGGCAATT GCAGAAAAGA ATTGAGTACC TCAGTAGCTA CTGACCAAAA
1200





AGCCTGACCA TTCTGTCTTA AAAAGACACA AGTTTTCTTT TTGATCTCCC TCTCCCCTTT
1260





AGTAACTTGT ACATTTTTGT TACACCAGGA CACTCTGGAC AGTAGATTGC AGAATCGATT
1320





GCAGCCAGTG CACAAACAAT ATAAAGGCTT GCATTCTTGG AAACTTTGAA ACCCAGCTCT
1380





CTCTCTTCCC TGACTTATGG GAGTGCTTTG TGTTTTCTGG CACCTTTGGC TTCTCAGCAG
1440





GCAGCTGACT GAGGAGACTT GGGGTCTTCC TGGCTCACTA TCTCCAAAGA AAAGGCTGAC
1500





AGATGGTATG CAACAGGTGG TGGATGTTGT TGGGGGCTCC AGCCTGGAGG AAATCTCACA
1560





CTCTACATGA ACTTTAGGCT AGGAAAGGAT GTCTCTGGGG TGATGCAAGG ACAGCTGGGT
1620





GTGGACGCTC TCCTGCGGCT CCATTTTTTT CCAGGAGACA CACAAGCTGC CTTGGGTGAA
1680





AACAAGCTCA GAGACTTGAT CAACGTGGAC CATTACCTCA CTGTCAGACA CTACAGCTAG
1740





CTGAGGAGTT GGAAACCTTA CATATATGTA TATATATATG TATGTATATA TGTATATATG
1800





TATATATATA TGTATGTATA TATGTATATA TGTATATATA TATGTATGTA TATATGTATA
1660





TATGTATATA TATATGTATG TATATATGTA TATATTATGA TGTTGGCTGA CCCCCTTCCT
1920





CCCACTCTCA ATGCTGTGAC TCAGAACATT TAAGAGAACT TCGTCTGTAA GTAATTTGTC
1980





TTAAAGCCCT CTGGGCTCTC TTCTCTGAGT GAGGGAACTT TCTGTCTTCA CAAGGGACTT
2040





TGTCTCATTC TGCCTCTGTT ATGCAATGGG TTCTACAGCA CCCTTTCCCG CAGGTTAGAA
2100





ATATTTCCCT AAGACACAGG GAAATGGGTC TTAGCCTGGG GCCTGGGGAA AGTTCCCAAG
2160





CCCTGGCTCA TGAACTCAAT CCCTGCCCAG GTGTTTTCTG AGGGGCCCTT GAGGCCAATC
2220





TTTTCTCAAG ACAGTGTGAG GCACCTTAGA AGGGAGAACT GTAACACTTT CTCTTTCGCA
2280





CCTGCCTCTC ATCTCAATCC TTGACTGATG AATTTGAAGT TCTACTAGAA CCATGAAAAC
2340





TTGTTCCTTT CGTGCATCTC CAAGGAGCTT GCTGGCTCTG CAGCCACGCT TGGGCCCTCG
2400





CACCAGCCTG CAATGAATCA GATGTCTGTC ACAGAATCTG GGCCTCTCTG AAGTTTTCTG
2460





GAGAGCTGTT GGGACTCATC CAGTGCTCCA CAACGTGGAC TTGCCTCCTG GTGTGTTTTA
2520





AAGGATCCTC CAGGAGCTCT GCTTAGCCAA TCATCATGAT GGATTTTTTT TTTTTTTTTT
2580





GAGACGGAGT CTCAACTCTT GTCGCCCAGG CTGGAGGTTA ATGGCATGAT CTCGGCTCAC
2640





TGCAACCTCT GCCTCCCGGG TTCAAGCGAT TCTCCTGCCT GAGCCTTCCG AGTAGCTGGG
2700





ATCGCAGGCG CCTGCCACCA CGCCTAGCTA ATTTCTGTAT TTTTAGTAGA GATGGGGTTT
2760





CACCACATTG GCCAGGCTGG TCTTGACCTC CTGACCTAGG TGATCCACTG CCTCCATGAT
2620





AGATTTTGCC CCAGCTGGAC TCTGCAGCTCC ACGTGGAAT CCAGGTGCCT GCCTCCAGTC
2880





TGGGAAAGTC ACCAACCCGC AGCTTGTCATG TGGGTAACT TCTGAACCCT AAGCC





SEQ ID NO: 121 Protein sequence


Protein Accession #: NP_005368


1          11         21         31         41         51


|          |          |          |          |          |


MDRDSYHHYF YDYGGGEDFY RSTTPSEDIW KKFELVPPPW TWVRSREPSP QLWSPGTWPV
60





GCAGDETESQ DYWEAWDANY ASLIRRDCNW SGFSTQEPLE HAVSDLLAVG APSGYSPKEF
120





ATPDYTPELE AGNLAPIFPC LLGEPKIQAC SRSESPSDSE GEEIDVTVKK RQSLSTRKPV
180





IIAVRADLLD PRMNLFHISI HQQQHNYAAP FPPESCFQEG APKRMPPKEA LEREAPGGKD
240





DKEDEEIVSL PPVESEAAQS CQPKPIHYDT ENWTKKKYNS YLERKRRNDQ RSRFLALRDE
300





VPALASCSRV SKVMILVKAT EYLHELAEAE ERMATEKRQL ECQRRQLQKR IEYLSSY





SEQ ID NO: 122 DNA sequence


Nucleic Acid Accession #: AB006625.2


Coding sequence: 356..4750


1          11         21         31         41         51


|          |          |          |          |          |


GAGGTTTGGG AGGCGCGGGA GATGTCCACC CTGGGCTGGT GGCGCCGCCG GGCGCCGGGC
60





GCCATGAGGG TGCGCTAGGC GGCTGTTCGT GCCCGAGGCT GCGCAGCACT GAGGTGAGCT
120





TTGCCTTCTT GATCTTCCGT CCTTCTTGGA GACGACTGGC GAGAGGAAGA GGGACTAGGT
180





CCAAACGCTA GGTGGCTGGG TCCAGCCGGA GACCCGCACC AAGGAGGAGA TCATCGAGCT
240





CTTGGTCCTT GAGCAGTACC TGACCATCAT CCCTGAAAAG CTCAAGCCTT GGGTGCGAGC
300





AAAAAAGCCG GAGAACTGTG AGAAGCTCGT CACTCTGCTG GAGAATTACA AGGAGATGTA
360





CCAACCAGAA GACGACAACA ACAGTGACGT GACCAGCGAC GACGACATGA CCCGGAACAG
420





AAGAGAGTCC TCACCACCTC ACTCAGTCCA TTCTTTCAGT GGTGACCGGG ACTGGGACCG
480





GAGGGGCAGA AGCAGAGACA TGGAGCCACG AGACCGCTGG TCCCACACCA GGAACCCAAG
540





AAGCAGGATG CCTCCGCGGG ATCTTTCCCT TCCTGTGGTG GCGAAAACAA GCTTTGAAAT
600





GGACAGAGAG GACGACAGGG ACTCCAGGGC TTATGAGTCC CGATCTCAGG ATGCTGAATC
660





ATACCAAAAT GTGGTGGACC TCGCTGAGGA CAGGAAACCT CACAACACAA TCCAGGACAA
720





CATGGAAAAC TACAGGAAGC TGCTCTCCCT CGGAGTGCAG CTTGCTGAAG ACGATGGCCA
780





CTCCCACATG ACGCAGGGCC ACTCATCAAG ATCCAAGAGA AGTGCCTACC CAAGCACCAG
840





TCGAGGTCTA AAAACTATGC CTGAAGCCAA AAAATCAACC CACCGGCGGG CGATTTCTGA
900





AGATGAATCT TCCCACGGAG TGATAATGGA AAAATTCATC AAGCATGTGT CACGCAGTTC
960





CAAATCCCCA ACAGCAAGGG AGTCAAGCGA CCGGTCACAG AGATTCCCCA GAATGTCAGA
1020





TGATAACTGG AAGGACATTT CATTGAACAA GAGGGAGTCA GTGATCCAGC AGCGGGTTTA
1080





TGAAGGGAAT GCATTTAGGG GAGGCTTTAG CTTTAATTCA ACCCTTGTTT CCAGAAAGAG
1140





AGTTCTTGAA AGAAAGAGGC GCTATCATTT TGACACACAT GGGAAGCGCT CCATTCACGA
1200





TCAAAAAGGC TGTCCCAGGA ACAAGCCCTT TGAATGTGGT AGTGAGATGA GAAAACCCAT
1260





GAGCGTGAGC ACCCTGAGCA CCCTCAGCTC CCCCTCCTTT ACCGAGTCAC AGCCAATTCA
1320





TTTTGGGGCA ATGCCATATC TATGTGATGA GTGTGGGAGG TCGTTCAGTG TCATCTCAGA
1380





ATTTGTTGAG CACCAGATCA TGCATACTAG AGAGAACCTC TATGAGTATG GTGAGTCCTT
1440





TATCCACAGT GTGGCTGTCA GTGAAGTTCA GAAAAGTCAG GTTGCAGGGA AACGTTTTGA
1500





ATGTAAGGAC TGTGGAGAGA CCTTCAATAA GAGTGCCGCC TTGGCTGAAC ATCGGAAGAT
1560





TCATGCTAGA GGTTATCTTG TGGAATGTAA CAATCAGGAA TGTGAGGAAG CCTTCATGCC
1620





TAGCCCCACC TTTAGTGAGC TTCAGAAAAT ATATGCCAAA GACAAATTCT ACGAGTGCAG
1680





GGTGTGTAAG GAAACCTTCC TTCATACTTC TGCCCTGATT GACCACCAGA AAATCCACTT
1740





TGGGGATGAC AAAGATAATG AGCGTCAACA TGAACGTGAA CGTGAACGTG AGCGCGGGGA
1800





AACCTTTAGG CCCAGCCCAG CCCTTAATGA GTTTCAGAAA ATGTATGGTA AAGAGAAAAT
1860





GTACGAATGT AAGGTGTGTG GGCACACTTT CCTTCATAGC TCATCCCTGA AAGAACATCA
1920





GAAAATCCAT ACTAGAGGGA ACCCATTTGA AAACAAGGGT AAAGTGTGTG AGGAAACCTT
1980





TATTCCTGGT CAGTCCCTTA AAAGGCGTCA GAAAACTTAC AATAAGGAGA AGCTCTGTGA
2040





CTTTACAGAT GGCCGGGATG CCTTCATGCA AAGCTCAGAC CTCAGTGAGC ATCAGAAAAT
2100





TCATTCTCGA AAGAACCTCT TTGAAGGCAG AGGGTATGAG AAATCTGTCA TTCATAGTGG
2160





GCCATTCACT GAATCTCAGA AGAGTCATAC TATAACAAGA CCTCTTGAAA GTGATGAGGA
2220





CGAAAAGGCG TTCACCATTA GCTCTAACCC CTATGAAAAC CAGAAGATTC CCACTAAGGA
2280





AAATGTCTAC GACGCAAAAT CATATGAGAG GTCTGTTATT CATAGCTTAG CCTCTGTGGA
2340





AGCTCAGAAA AGTCACAGTG TAGCAGGGCC CAGTAAACCA AAAGTAATGG CAGAGTCTAC
2400





CATTCAGAGC TTCGATGCTA TCAACCATCA GAGAGTTCGT GCTGGAGGGA ACACCTCTGA
2460





AGGAAGGGAA TACAGTAGGT CTGTTATCCA TAGCTTAGTG GCTTCCAAAC CTCCAAGAAG
2520





TCACAATGGA AATGAATTGG TGCAATCTAA TGAGAAGGGA GAATCCTCCA TTTATATCTC
2580





AGACCTTAAT GATAAGCGAC AGAAGATTCC TGCCAGAGAG AACCCTTGTG AAGGGGGCAC
2640





TAAGAATCGC AACTATGAAG ACTCTGTCAT ACAGAGTGTA TTCCGTGCCA AACCTCAGAA
2700





AAGTGTTCCT GGAGAGGGAT CTGGTGAGTT TAAGAAGGAT GGCGAATTCT CTGTTCCCAG
2760





CTCAAATGTC CGTGAATACC ACAACGCTCG TGCTAAAAAG AAATACATTG AGCATAGGAG
2820





CAATGAGACC TCTGTAATTC ACTCTCTGCC TTTTGGTGAA CAAACATTTC GCCCTCGAGG
2860





GATGCTCTAT GAATGTCAGG AGTGTGGGGA GTGCTTTGCT CATAGCTCTG ACCTCACTGA
2940





GCACCAGAAG ATTCATGATA GGGAGAAGCC CTCTGGAAGC AGAAACTATG AATGGTCTGT
3000





CATTCGCAGC TTGGCCCCTA CTGACCCTCA AACAAGTTAC GCCCAAGAGC AGTATGCTAA
3060





AGAGCAAGCG CGGAACAAAT GTAAGGACTT CAGACAATTT TTTGCTACCA GCGAAGACCT
3120





CAACACAAAC CAGAAAATCT ATGACCAAGA GAAGTCTCAT GGCCAGGACT CTCAAGGCGA
3180





GAATACTGAT GGGGAGGAGA CCCACAGCGA GGAGACCCAT GGTCAGGAGA CAATTGAAGA
3240





CCCTGTCATT CAAGGCTCAG ACATGGAAGA CCCTCAGAAG GATGACCCTG ATGACAAAAT
3300





CTATGAATGT GAGGACTGTG GCCTGGGCTT TGTGGATCTC ACAGACCTCA CAGACCATCA
3360





GAAAGTCCAC AGCAGGAAGT GCCTGGTTGA CAGTCGGGAG TACACACATT CTGTAATTCA
3420





CACCCATTCC ATCAGCGAGT ATCAGAGAGA TTACACTGGA GAGCAGCTGT ATGAATGTCC
3480





AAAGTGTGGG GAATCTTTTA TTCATAGCTC ATTCCTTTTC GAGCATCAGA GAATCCATGA
3540





ACAAGACCAG TTGTATTCCA TGAAGGGGTG TGATGATGGT TTTATTGCCC TCTTGCCCAT
3600





GAAGCCACGG AGGAATCGTG CTGCAGAGAG GAATCCTGCT CTTGCTGGGT CGGCCATTCG
3660





ATGCCTTTTG TGTGGACAAG GCTTCATTCA TAGCTCTGCC CTTAATGAGC ATATGAGACT
3720





TCATAGGGAA GATGATTTAC TGGAGCAGAG CCAGATGGCT GAGGAAGCTA TCATTCCAGG
3780





CTTAGCCCTC ACTGAGTTTC AGAGAAGTCA GACCGAAGAG AGACTCTTTG AATGTGCAGT
3840





CTGTGGAGAA TCTTTCGTCA ACCCAGCAGA ACTTGCAGAT CACGTAACTG TTCATAAGAA
3900





TGAGCCCTAT GAGTACGGGT CCTCCTATAC TCACACCTCA TTTCTTACTG AGCCCCTCAA
3960





AGGAGCTATA CCATTCTATG AATGCAAGGA TTGTGGTAAG TCCTTTATTC ATAGCACAGT
4020





CCTCACTAAA CATAAGGAGC TTCATCTGGA AGAAGAAGAA GAAGATGAAG CAGCAGCAGC
4080





TGCAGCAGCA GCAGCCCAGG AAGTTGAAGC CAATGTCCAT GTTCCACAAG TAGTTCTGAG
4140





GATTCAGGGC TTAAACGTAG AGGCTGCTGA GCCAGAAGTG GAGGCTGCCG AGCCAGAAGT
4200





GGAGGCTGCT GAGCCAGAAG TGGAGGCTGC TGAGCCAAAC QGAGAGGCTG AAGGGCCAGA
4260





TGGAGAGGCT GCAGAGCCCA TTGGAGAGGC TGGACAGCCA AATGGAGAGG CCGAGCAGCC
4320





AAATGGGGAT GCTGATGAGC CAGATGGTGC AGGTATTGAA GACCCAGAAG AAAGAGCTGA
4380





AGAGCCAGAG GGAAAAGCTG AAGAGCCAGA GGGAGATGCC GACGAGCCTG ACGGTGTGGG
4440





AATTGAAGAC CCAGAAGAAG GTGAAGATCA AGAGATTCAG GTAGAAGAAC CATACTATGA
4500





CTGCCATGAA TGCACAGAAA CCTTCACTTC CAGCACAGCA TTCAGTGAAC ACCTGAAAAC
4560





TCATGCCAGC ATGATCATAT TTGAGCCTGC AAATGCCTTT GGGGAGTGCT CAGGCTACAT
4620





CGAACGTGCC AGCACCAGCA CAGGTGGTGC CAATCAAGCT GATGAGAAGT ACTTCAAATG
4680





TGACGTCTGT GGGCAGCTCT TCAATGACCG CCTGTCCCTC GCCAGACACC AGAATACCCA
4740





CACTGGCTGA GGGCATGGGG TAAAGGTTAG AAAACCTTCA CCTAGGACTT GACCCTTACC
4800





AAACCACAGA GAATCCAAAC CAATCCATGA TAATGTCAGT AGGAGACTTA ACCTTAGTGT
4860





GTTACACACC TGACTTAACA TCTCTAAACT CAGATTGAAA AGAGACCGAA TGTGCAGATT
4920





CCACAGTCTT AAGCTTTCCC CTTCAGATGT CAGTGTCTGC ATGTGGGAAA GCCATAGCAC
4980





ACATCTTACC TTTCCAAGTA ATCAGATTGA GAAAACCCTA TGAGTATTCC AGACTACAGA
5040





GTTTGCCCAA ATCAACTGTA AATGACACTT GTGTAACGTA TATATAGTGT TTCATGAGGT
5100





GTATATAAAA TAGCAAATTA TGACAGAACA GTGATCACAT ATATTTGGAT TTATATGATA
5160





TACAGTTACA GTTTACTCTG CAGAGGTACC TTACCTGGTA TTCTTTGAAT TTTTTTTTTT
5220





TTTGGAGGAG GAAGAGAGCA ACAAATTTGA TTATATTTTT AAGTGTCTTA GATCCTGAGA
5280





AAGATTTATT GTGCATTATT TGAACCCTGT CAATATCTTT TTGAGTAATT GTTTTGTTTC
5340





TTACCCTTAA ATAGTCTTGT GAAGCTGTAG GCATGATAGA TAACATGGCT TTTACTCCTT
5400





ACTGTTTGAA AAGATAAGTA CTTTAGCTTC TTTCTGCAGC CATTTCATCT GCACCAACAC
5460





TTTGGAACCT AATACTGTGT AAGGCTTTAC AATATACGGA TTGGCTTTTT GTGACCCAGA
5520





TTGATTGGTT GCCACATGTT ATGTTTGTTG AAGTGGTTCT CATGCAAAAA TATTACACAT
5580





TTGTGTTCTG GGTTTTTTTT TTTTTTTAAC CAACTCAATA TGTGTTTGAT GATAGTGAAT
5640





TGATAAAACC CGAAGCTTTT CCCTGTAAAT CTTACATCTT TGCCTTTAAA GAATGGGTTA
5700





CAACCATCAC TAGATCACAG TAGTGCCTAA TGAAGGTTGA GAACCGTAGG AGAGGCTCTC
5760





ATGCTGTAAA TAATGTTGCA GGCTAATAAC CTTTCATCAC TTCCTTTGTG CGCTTCCTGC
5820





CTTAAGTGAC AAGTAGCAAC ATGGCTTGGG TCCCCTGTGC ACCATGAGGT TATGCTGCCA
5880





CAAGTCAGTT TGCACCGTAG GTGCCCAGGA GCTAGTATCC TTAGATCTTT CTATCCCTAA
5940





CTTAATTCTC TTCGTTATTT ATCTGACCCT CTAACTCCAT GTCTAACTTG CATT





SEQ ID NO: 123 Protein sequence


Protein Accession #. BAA22956.2


1          11         21         31         41         51


|          |          |          |          |          |


VQTLGGWVQP ETRTKEEIIE LLVLEQYLTI IPEKLEPWVR AKKPENCEKL VTLLENYKEN
60





YQPEDDNNSD VTSDDDMTRN RRESSPPHSV HSFSGDRDWD RRGRSRDMEP RDRWSHTRNP
120





RSRMPPRDLS LPVVAKTSFE MDREDDRDSR AYESRSQDAE SYQNVVDLAE DRKPHNTIQD
180





NMENYRKLLS LGVQLAEDDG HSHMTQGHSS RSKRSAYPST SRGLKTMPEA KKSTHRRGIC
240





EDESSHGVIM EKFIKDVSRS SKSGRARESS DRSQRFPRMS DDNWKDISLN KRESVIQQRV
300





YEGNAFRGGF RFNSTLVSRK RVLERKRRYH FDTDGKGSIH DQKGCPRKKP FECGSEMRKA
360





MSVSSLSSLS SPSFTESQPI DFGAMPYVCD ECGRSFSVIS EFVEHQIMHT RENLYEYGES
420





FIHSVAVSEV QKSQVGGKRF ECKDCGETFN ESAALAEHRK IHARGYLVEC KNQECEEAFM
480





PSPTFSELQK IYGKDKFYEC RVCKETFLHS SALIEHQKIH FGDDKDNERE HERERERERG
540





ETFRPSPALN EFQKMYGKEK MYECKVCGET FLHSSSLKEH QKIHTRGNPF ENKGKVCEET
600





FIPGQSLKRR QKTYNKEKLC DFTDGRDAFM QSSELSEHQK IHSRKNLFEG RGYEKSVIHS
660





GPFTESQESH TITRPLESDE DEKAFTISSN PYENQKIPTK ENVYEAKSYE RSVIHSLASV
720





EAQKSNSVAG PSKPKVMAES TIQSFDAINH QRVRAGGNTS EGREYSRSVI HSLVASKPPR
780





SHNGNELVES NEKGESSIYI SDLNDKRQKI PARENPCEGG SKNRNYEDSV IQSVFRAKPQ
840





KSVPGEGSGE FKKDGEFSVP SSNVREYQKA RAKKKYIENR SNETSVIHSL PFGEQTFRPR
900





GMLYECQECG ECFAHSSDLT EHQKIHDREK PSGSRNYEWS VIRSLAPTDP QTSYAQEQYA
960





KEQARNECKO FRQFFATSED LNTNQKIYDQ EKSHGESEQG ENTDGEETHS EETHGQETIE
1020





DPVIQGSDME DPQKDDPDDK IYECEDCGLG FVDLTDLTDH QKVNSRKCLV DSREYTNSVI
1080





HTHSISEYQR DYTGEQLYEC PECGESFIHS SELFEHQRIH EQDQLYSMKG CDDGFIALLP
1140





MKPRRNRAAE KNPALAGSAI RCLLCGQGFI HSSALNEHMR LHREDDLLEQ SQMAEEAIIP
1200





GLALTEFQRS QTEERLFECA VCGESFVNPA ELADNVTVNK NEPYEYGSSY THTSFLTEPL
1260





KGAIPFYRCK DCGKSFIHST VLTKHKELHL EEEEEDEAAA AAAAAAQEVE ANVHVPQVVL
1320





RIQGLNVEAA EPEVEAAEPE VEAAEPEVEA AEPNGEAEGP DGEAAEPIGE AGQPNGEAEQ
1380





PNGDADEPDG AGIEDPEERA EEPEGKAEEP EGDADEPDGV GIEDPEEGED QEIQVEEPYY
1440





DCHECTETFT SSTAFSEHLK THASMIIFEP ANAFGECSGY IERASTSTGG ANQADEKYFE
1500





CDVCGQLFND RLSLARHQNT HTG





SEQ ID NO: 124 DNA sequence


Nucleic Acid Accession #: NM_007196


Coding sequence: 180..1962


1          11         21         31         41         51


|          |          |          |          |          |


GTTCCCAGAA GCTCCCCAGG CTCTAGTGCA GGAGGAGAAG GAGGAGGAGG AGGAGGTGGA
60





GATTCCCAGT TAAAAGGCTC CAGAATCGTG TACCAGGCAG AGAACTGAAG TACTGGGGCC
120





TCCTCCACTG GGTCCGAATC AGTAGGTGAC CCCGCCCCTG GATTCTGGAA GACCTCACCA
180





TGGGACGCCC CCGACCTCGT GCGGCCAAGA CGTGGATGTT CCTGCTCTTG CTGGGGGGAG
240





CCTGGGCAGG ACACTCCAGG GCACAGGAGG ACAAGGTGCT GGGGGGTCAT GAGTCCCAAC
300





CCCATTCGCA GCCTTGGCAG GCGGCCTTGT TCCAGGGCCA GCAACTACTC TGTGGCGGTG
360





TCCTTGTAGG TGGCAACTGG GTCCTTACAG CTGCCCACTG TAAAAAACCG AAATACACAG
420





TACGCCTGGG AGACCACAGG CTACAGAATA AAGATGGCCC AGAGCAAGAA ATACCTGTGG
480





TTCAGTCCAT CCCACACCCC TGCTACAACA GCAGCGATGT GGAGGACCAC AACCATGATC
540





TGATGCTTCT TCAACTGCGT GACCAGGCAT CCCTGGGGTC CAAAGTGAAG CCCATCAGCC
600





TGGCAGATCA TTGCACCCAG CCTGGCCAGA AGTGCACCGT CTCAGGCTGG GGCACTGTCA
660





CCAGTCCCCG AGAGAATTTT CCTGACACTC TCAACTGTGC AGAAGTAAAA ATCTTTCCCC
720





AGAAGAAGTG TGAGGATGCT TACCCGGGGC AGATCACAGA TGGCATGGTC TGTGCAGGCA
780





GCAGCAAAGG GGCTGACACG TGCCAGGGCG ATTCTGGAGG CCCCCTGGTG TGTGATGGTG
840





CACTCCAGGG CATCACATCC TGGGGCTCAG ACCCCTGTGG GAGGTCCGAC AAACCTGGCG
900





TCTATACCAA CATCTGCCGC TACCTGGACT GGATCAAGAA GATCATAGGC AGCAAGGGCT
960





GATTCTAGGA TAAGCACTAG ATCTCCCTTA ATAAACTCAC AACTCTC





SEQ ID NO: 125 Protein sequence


Protein Accession #: NP_009127


1          11         21         31         41         51


|          |          |          |          |          |


MGRPRPRAAK TWMFLLLLGG AWAGHSRAQE DKVLGGHECQ PHSQPWQAAL FQGQQLLCGG
60





VLVGGNWVLT AAHCKKPKYT VRLGDHSLQN KDGPEQEIPV VQSIPHPCYN SSDVEDHNHD
120





LMLLQLRDQA SLGSKVKPIS LADHCTQPGQ KCTVSGWGTV TSPRENFPDT LNCAEVKIFP
180





QKKCEDAYPG QITDGMVCAG SSKGADTCQG DSGGPLVCDG ALQGITSWGS DPCGRSDKPG
240





VYTNICRYLD WIKKIIGSKG





SEQ ID NO: 126 DNA sequence


Nucleic Acid Accession #: SN_014791.1


Coding sequence: 171..2126


1          11         21         31         41         51


|          |          |          |          |          |


TTGGCGGGCG GAAGCGGCCA CAACCCGGCG ATCGAAAAGA TTCTTAGGAA CGCCGTACCA
60





GCCGCGTCTC TCAGGACAGC AGGCCCCTGT CCTTCTGTCG GGCGCCGCTC AGCCGTGCCC
120





TCCGCCCCTC AGGTTCTTTT TCTAATTCCA AATAAACTTG CAAGAGGACT ATGAAAGATT
180





ATGATGAACT TCTCAAATAT TATGAATTAC ATGAAACTAT TGGGACAGGT GGCTTTGCAA
240





AGGTCAAACT TGCCTGCCAT ATCCTTACTG GAGAGATGGT AGCTATAAAA ATCATGGATA
300





AAAACACACT AGGGAGTGAT TTGCCCCGGA TCAAAACGGA GATTGAGGCC TTGAAGAACC
360





TGAGACATCA GCATATATGT CAACTCTACC ATGTGCTAGA GACAGCCAAC AAAATATTCA
420





TGGTTCTTGA GTACTGCCCT GGAGGAGAGC TGTTTGACTA TATAATTTCC CAGGATCGCC
480





TGTCAGAAGA GGAGACGCGG GTTGTCTTCC GTCAGATAGT ATCTGCTGTT GCTTATGTGC
540





ACAGCCAGGG CTATGCTCAC AGGGACCTCA AGCCAGAAAA TTTGCTGTTT GATGAATATC
600





ATAAATTAAA GCTGATTGAC TTTGGTCTCT GTGCAAAACC CAAGGGTAAC AAGGATTACC
660





ATCTACAGAC ATGCTGTGGG AGTCTGGCTT ATGCAGCACC TGAGTTAATA CAAGGCAAAT
720





CATATCTTGG ATCAGAGGCA GATGTTTGGA GCATGGGCAT ACTGTTATAT GTTCTTATGT
780





GTGGATTTCT ACCATTTGAT GATGATAATG TAATGGCTTT ATACAAGAAG ATTATGAGAG
840





GAAAATATGA TGTTCCCAAG TGGCTCTCTC CCAGTAGCAT TCTGCTTCTT CAACAAATGC
900





TGCAGGTCCA CCCAAAGAAA CGGATTTCTA TGAAAAATCT ATTGAACCAT CCCTGGATCA
960





TGCAAGATTA CAACTATCCT GTTGAGTGGC AAAGCAAGAA TCCTTTTATT CACCTCGATG
1020





ATGATTGCGT AACAGAACTT TCTGTACATC ACAGAAACAA CAGGCAAACA ATGGAGGATT
1080





TAATTTCACT GTGGCAGTAT GATCACCTCA CGGCTACCTA TCTTCTGCTT CTAGCCAAGA
1140





AGGCTCCCGG AAAACCAGTT CGTTTAACGC TTTCTTCTTT CTCCTGTGGA CAAGCCAGTG
1200





CTACCCCATT CACAGACATC AAGTCAAATA ATTGGAGTCT GGAAGATGTG ACCGCAAGTG
1260





ATAAAAATTA TGTGGCGGGA TTAATAGACT ATGATTGGTG TGAAGATGAT TTATCAACAG
1320





GTGCTGCTAC TCCCCGAACA TCACAGTTTA CCAAGTACTG GACAGAATCA AATGGGGTGG
1380





AATCTAAATC ATTAACTCCA GCCTTATGCA GAACACCTGC AAATAAATTA AACAACAAAG
1440





AAAATGTATA TACTCCTAAG TCTGCTGTAA AGAATGAAGA GTACTTTATG TTTCCTCAGC
1500





CAAAGACTCC AGTTAATAAG AACCAGCATA AGAGACAAAT ACTCACTACG CCAAATCGTT
1560





ACACTACACC CTCAAAAGCT AGAAACCAGT GCCTGAAAGA AACTCCAATT AAAATACCAG
1620





TAAATTCAAC AGGAACAGAC AAGTTAATGA CAGGTGTCAT TAGCCCTGAG AGGCGGTGCC
1680





GCTCAGTGGA ATTGGATCTC AACCAAGCAC ATATGGAGGA GACTCCAAAA AGAAAGGGAG
1740





CCAAAGTGTT TGGGAGCCTT GAAAGCGGGT TGGATAAGGT TATCACTGTG CTCACCAGGA
1800





GCAAAAGGAA GGGTTCTGCC AGAGACGGGC CCAGAAGACT AAAGCTTCAC TATAATGTGA
1860





CTACAACTAG ATTAGTGAAT CCAGATCAAC TGTTGAATGA AATAATGTCT ATTCTTCCAA
1920





AGAAGCATGT TGACTTTGTA CAAAAGGGTT ATACACTGAA GTGTCAAACA CAGTCAGATT
1980





TTGGGAAAGT GACAATGCAA TTTGAATTAG AAGTGTGCCA GCTTCAAAAA CCCGATCTGG
2040





TGGGTATCAG GACGCAGCGG CTTAAGGGCG ATGCCTGCGT TTACAAAAGA TTAGTGCAAG
2100





ACATCCTATC TAGCTGCAAG GTATAATTGA TGGATTCTTC CATCCTGCCG GATGAGTGTG
2160





GGTGTGATAC AGCCTACATA AAGACTGTTA TGATCGCTTT GATTTTAAAG TTCATTGGAA
2220





CTACCAACTT GTTTCTAAAG AGCTATCTTA AGACCAATAT CTCTTTGTTT TTAAACAAAA
2280





GATATTATTT TGTGTATGAA TCTAAATCAA GCCCATCTGT CATTATGTTA CTGTCTTTTT
2340





TAATCATGTG GTTTTGTATA TTAATAATTG TTGACTTTCT TAGATTCACT TCCATATGTG
2400





AATGTAAGCT CTTAACTATG TCTCTTTGTA ATGTGTAATT TCTTTCTGAA ATAAAACCAT
2460





TTGTGAATAT





SEQ ID NO. 127 Protein sequence


Protein Accession #: NP_055606.1


1          11         21         31         41         51


|          |          |          |          |          |


MKDYDELLKY YELHETIGTG GFAKVKLACH ILTGEMVAIK IMDKNTLGSD LPRIKTEIEA
60





LKNLRHQHIC QLYHVLETAN KIFMVLEYCP GGELFDYIIS QDRLSEEETR VVFRQIVSAV
120





AYVHSQGYAH RDLKPENLLF DEYNKLELID FGLCAKPKGN KDYHLQTCCG SLAYAAPELI
180





QGKSYLGSEA DVWSMGILLY VLMCGFLPFD DDNVMALYKK IMRGKYDVPK WLSPSSILLL
240





QQMLQVDPKK RISMKNLLNH PWIMQDYNYP VEWQSKNPFI HLDDDCVTEL SVHHRNNRQT
300





MEDLISLWQY DHLTATYLLL LAKKARGKPV RLRLSSFSCG QASATPFTDI KSNNWSLEDV
360





TASDKNYVAG LIDYDWCEDD LSTGAATPRT SQFTKYWTES NGVESKSLTP ALCRTPANKL
420





KNKENVYTPK SAVENKEYFE FPEPKTPVNK NQNKRETLTT PNRYTTPSKA RNQCLKETPI
480





KIPVNSTGTD KLMTGVISPE RRCRSVELDL NQANMEETPK RKGAKVPGSL ERGLDKVITV
540





LTRSKRKGSA RDGPRRLKLN YNVTTTRLVN PDQLLNEIMS ILPKKNVDFV QKGYTLKCQT
600





QSDFGKVTMQ FELEVCQLQK PDVVGIRRQR LEGGANVYKE LVEDILSSCK V





SEQ ID NO: 128 DNA sequence


Nucleic Acid Accession #: EOS sequence


Coding sequence: 169-1323


1          11         21         31         41         51


|          |          |          |          |          |


GGGATCCTTT CTGGAATGGA GGTCTTATGA GCTGCTATTG AACACGGCAG AGCCTGTTGG
60





TGACCTGCAC ACAGGAGCCC TCCAGTCAGT ACTGATTGAA TTACTCAAGG CTGCCTCTCT
120





GCAAAGTTGA GCACTACAGG ACGTCGGGAC TGGGCATTTC CTTCCAACAT GGCCGCCACT
180





GCCTCTCCGC AGCCACTCGC CACTGAGGAT GCCGATTCTG AGAATAGCAG CTTCTATTAC
240





TATGACTACC TGGATGAAGT GGCCTTCATG CTCTGCAGGA AGGATGCAGT GGTGTCCTTT
300





GGCAAAGTCT TCCTCCCAGT CTTCTATAGC CTGATTTTTG TGTTGGGCCT CAGCGGGAAC
360





CTCCTTCTTC TCATGGTCTT GCTCCGTTAC GTGCCTCGCA GGCGGATGGT TGAGATCTAT
420





CTGCTGAATC TGGCCATCTC CAACCTTCTG TTTCTGGTGA CACTGCCCTT CTGGGGCATC
480





TCCGTGGCCT GGCATTGGGT CTTCGGGAGT TTCTTGTGCA AGATGGTGAG CACTCTTTAT
540





ACTATTAACT TTTACAGTGG CATCTTTTTC ATTAGCTGCA TGAGCCTGGA CAAGTACCTG
600





GAGATCGTTC ATGCTCAGCC CTACCACAGG CTGAGGACCC GGGCCAAGAG CCTGCTCCTT
660





GCTACCATAG TATGGGCTGT GTCCCTGGCC GTCTCCATCC CTGATATGGT CTTTGTACAG
720





ACACATGAAA ATCCCAAGGG TGTGTGGAAC TGCCACGCAG ATTTCGGCGG GCATGGGACC
780





ATTTGGAAGC TCTTCCTCCG CTTCCAGCAG AACCTCCTAG GGTTTCTCCT TCCACTCCTT
840





GCCATGATCT TCTTCTACTC CCGTATTGGT TGTGTCTTGG TGAGGCTGAG GCCCGCAGGC
900





CAGGGCCGGG CTTTAAAAAT AGCTGCAGCC TTGGTGGTGG CCTTCTTCGT GCTATGGTTC
960





CCATACAATC TCACCTTGTT TCTGCATACG CTGTTGGACC TGCAAGTATT CGGGAACTGT
1020





GAGGTCAGCC AGCATCTAGA CTACGCACTC CAGGTAACAG AGAGCATCGC CTTCCTTCAC
1080





TGCTGCTTTT CCCCCATCCT GTATGCCTTC TCCAGTCACC GCTTCCGCCA GTACCTGAAG
1140





GCTTTCCTGG CTCCCGTGCT TGGATGGCAC CTGGCACCTG GCACTGCCCA GGCCTCATTA
1200





TCCAGCTGTT CTGAGAGCAG CATACTTACT GCCCAAGAGG AAATGACTGG CATGAATGAC
1260





CTTGGAGAGA GGCAGTCTGA GAACTACCCT AACAAGGAGG ATGTGGGGAA TAAATCAGCC
1320





TGAGTGACCA AATTTTGGTC TGGTGGGAAC AGATGGGAAC CAGCTCAATT GGGTGTCCAC
1380





TCAAAGTGCT CTCTCCAGGG GCCTCAGTGA CTGTGTTGCT AAACCCAGTG GTCAGTTCTC
1440





AGTTCTCAGC CATCAGCAGC ATTTGCTCGC CCCGCCTTCT TCCTCCACTT TCTTCACTTG
1500





CTTCCAGGAT ACCACGCTTT CTTTTCTGAA TTGCTACAAT CTTTCTTCCT TCCTTCCTTG
1560





CTTCCTTCCT TCCTTCCTTC CCTCTCTCCC TCCCTCCCTC CCTCGCTTCT TCCCTTCCTC
1620





CTTTCCTCCC TTCCTACTTT CCTTCCTTCC TTCTGACAGG GTCTTGCTCT ATTGCTCTGT
1660





CACCCAGGCT GGAATGCAGT GGCCAGATCT CCGCTCACTG TAGCCTCCTC CCCCTGGGTT
1740





GAAGCAATTC TCATGCCTCA GCCTCCCAAG TAGCCAGGAC TATAGGCACC TGCCACCATG
1800





CCTGGCTAAT TTTTGTATTT TTTTTCTTTC TTTCTTTCTT TTCTTTTTTT TTTTTTTTTG
1860





AGACGGAGTC TCACTCTTGT TGCCCAGGCT GGACAACAAT GGCGCGATCT CGGCTCACTG
1920





CAACCTCCAC CTCCCGGATT CAAGCGATTC TCCTGCCTCA GCCTCCTGAG TAGCTGGAAC
1980





TACATGCGCG TGCCACCACG CACAGCTAAT TTTTATAATT TTACTAGAGA TGGGGTTTCA
2040





CTGCGTTGGC CAGGATGATC TCGATCTCTT GACCTTGGGA TCCACCCGCC TTGGCCTCCC
2100





AAAGTGCTGG GATTACAGGT GTGAGCCACC ATGCCTGGCC CTAATTTTTG TGTTTTTATT
2160





AGAAACAGAG TTTCACCATG TTGGCCAGGC TGGAGAATTG CTGTAATAGT TTTCCAACT
G 2220





GCCCCTGTCC TTCCTCTCTC TTGCTCTCCT CCCATCTCAT CTGCACCTAG CAGCCAGAGT
2280





GATCCTGATA CTCTCGGCCT TTACTTCCGC CTCCCTCAGA GCAGCAGCCT GTCAAAACAC
2340





CAGATTACAA CAAATTTAGT TTAAAGGTCT CAATTAGCGT TATTGGCAAT TCTAGAATCA
2400





GGCAACAGAC TCATTGAATC AGGAACAGAT TCACTCCATA AAATACAGAG AGTGCTGCAA
2460





TGAGCTGGGT AGAAGAGGTT AGTTTTATAG ACAGGAAGGG GCTGTCAAAG GCAGAAAGAA
2520





ATGAAGAACA AAAAAAAAGA TTGATTTTTT TTTTTTTGAG ACAGGATCTC ACTCTGTCAT
2580





CCAGGCTGAA GTCCAATCCC ACAATCATGG CTCACTGCAG CCACCACCTC CTGAGCTCAA
2640





GTGATCCTCC CATCTAAGCC CCCAAGTAGC TAGGACTACA GGAGCACACC ACCACACCTG
2700





GCTAATTTTT GTATTTTTTG TGGAGACAGG GTCTCAGTAT GTTACCCAGG TTGGACTGGA
2760





AACCCTTGGC TCAAGCAATT TGCCTGCCTC AGCCTCCCAA ACTGCTGGGA TTACAGGCGT
2820





GAGCCACTGC ACAGGGCCAG ATTCATCATT TCAAAGTTAC TTTCTATATG CGGCCGGAAC
2880





AGGGTGGTTG ACATCAGTTT TCTTCAGGTT ACTTTTTAAT AATGATTAAA ACGGGGAACT
2940





TCATTATCAT GAGCATGGTT ACTGTCTGCA TTATTACGCC AACTGAAACT GTCATGTTTG
3000





GGAATTTGGC TGTTAACTCT GTCTCCAGGA GTCTCAAAGG TCAGATAACA ACTTAGTTTT
3060





GGTTTGAGGA CATGGAACTT TAATACGACA GATTCCATTT TGGTTTGGTC TGGTCAGCTG
3120





GGACCTAGTG CAGGAGGTTA GTCCAAAACA ATGGCCTTCC ATAGTTTTTA CTTAACAAGC
3180





CCAACTCCTT ACGGTAATCC TTTAAGGCCT ATGTGATCTG CCCTCACCCT GGCTACACTC
3240





TTTGCCCTTA TGTCCACCAG CCTCCAGTGC TCCAGACACA ACTGATCTCA AATACTCCTG
3300





ACACATCCCC CTGGGGATTC CTCTTCCTGG ATTGCTCTCC TCTCAGCTGT CTGCTTGGCT
3360





CACTCTCTCA CCTTCTGAGG TCTTAGCTCA GATACCACCT TTCACTCACC TGTCCAACCT
3420





ATTTAACACA AACTGGCCCA TCTCTGACGC TCCTGATCTT CCTGATGCTC TATTTTTAAA
3480





TTTTTTCAAT AGTGCTTATT TCTTTCAGAC ATTGTATATG TTTCTCCTAT TTGTGATGTT
3540





CAGTGGCTAC TGTCCCCACC CACATTGTCC CAGGTGAATT CCACAAGGTA GGGATCTTGG
3800





TTAGGCTCAC TGCTGTACCC AACCCCCTAA CACAGGGCCT GGTGTGTAGG TTTTCAGAAA
3880





GTATCTGTAA AATGCATGGG TGGAGGAGGG AGCATTTTCC TTCTGGCACT GCTGGGGAAA
3720





AAGAACCTAA GGCCCTCCAC TCACCAGGGT TCCACATTCT CTGTAGTCCA GCTGGGAAAT
3780





GCTATTAAAA GGACCATTCT CGTAGCCTTG ATGGTGGACC CAGCATCTGG CAATCAGGAG
3840





GGCCTTGAAG TACTCTGCCT AGGGAATGTC CCAGGACCAT ATACAGTCTG CAGAAGGAGG
3900





CAGTGAACAC ACTTGGCCTA GGCCCCATCT CAGGAGCCTT CACATCTCCC TGGGACCTGC
3960





ACAATCAAGT CCAAAATCTT TGTCTGATGT CAAGGCTAGG GCTTTTGCAA ATAGGATCCC
4020





ATACATCTTC CAGCCCTCAT ACTCCTCCAC TCCCTTTTCA TTTCCTGAAC ATTCCAACTT
4080





CTATGCCTTT GCTCTTGTGG GCTCCCTCAT GTAATTAGGA TAATTTCCAG CCAGGTATTC
4140





CCTCACCCTT GTTTTACAAC TGAATCCCAC TTTCTCTGGG ACTCCACTGC TTGGTCACTC
4200





TGCCCTGTGC TTTGAGAGGA GGTTGGGTGG AGCATGGGAC ATGGGCCATT TACTGCCTTC
4260





ACATTTCCCT GGTCACGGTG ATTTTTTTAG GGGTGGGCAC ATGACCTAGG TAGAGCCAAT
4320





GAAGTGCAAT ATCACTAGAA CATGTGAGAA GAGAGGCATG AAACCGAAGC TGAGAGGGTT
4380





TGAGATCTGG AGCTACTCCT TCCTCCACCC AAACTTCAGA AGGTGAAGGA GATAGTGCAT
4440





GTGAGTGAGC AGATCCCGAG GGCACTGTTT GAGCCTCAGA ATCAAAGCAC TTCTGAAGCT
4500





AGTCCCAATC TTGGATTCGA CAGTTACAAG AACCAATAAA TTCCTTTCCT TGTGG





SEQ ID NO: 129 Protein sequence


Protein Accession #: NP_001287.2


1          11         21         31         41         51


|          |          |          |          |          |


MAATASPQPL ATEDADSENS SFYYYDYLDE VAFMLCRKDA VVSFGKVFLP VFYSLIFVLG
60





LSGNLLLLMV LLRYVPRRRM VEIYLLNLAI SNLLFLVTLP PWGTSVAWHW VFGSPLCKMV
120





STLYTINFYS GIFFISCMSL DKYLEIVHAQ PYHRLRTRAK SLLLATIVWA VSLAVSIPDM
180





VFVQTHENPK GVWNCHADFG GHGTIWKLFL RFQQNLLGFL LPLLAMIFFY SRIGCVLVRL
240





RPAGQGRALK IAAALVVAFF VLWFPYNLTL FLHTLLDLQV FGNCEVSQHL DYALQVTESI
300





AFLHCCFSPI LYAFSSHRFR QYLKAFLAAV LGWNLAPGTA QASLSSCSES SILTAQEEMT
360





GMNDLGERQS ENYPNKEDVG NKSA





SEQ ID NO: 130 DNA sequence


Nucleic Acid Accession #: NM_002774


Coding sequence: 246. 980


1          11         21         31         41         51


|          |          |          |          |          |


AGGCGGACAA AGCCCGATTG TTCCTGGGCC CTTTCCCCAT CGCGCCTGGG CCTGCTCCCC
60





AGCCCGGGGC AGGGGCGGGG GCCAGTGTGG TGACACACGC TGTAGCTGTC TCCCCGGCTG
120





GCTGGCTCGC TCTCTCCTGG GGACACAGAG GTCGGCAGGC AGCACACAGA GGGACCTACG
180





GGCAGCTGTT CCTTCCCCCG ACTCAAGAAT CCCCGGAGGC CCGGAGGCCT GCAGCAGGAG
240





CGGCCATGAA GAAGCTGATG GTGGTGCTGA GTCTGATTGC TGCAGCCTGG GCAGAGGAGC
300





AGAATAAGTT GGTGCATGGC GGACCCTGCG ACAAGACATC TCACCCCTAC CAAGCTGCCC
360





TCTACACCTC GGGCCACTTG CTCTGTGGTG GGGTCCTTAT CCATCCACTG TGGGTCCTCA
420





CAGCTGCCCA CTGCAAAAAA CCGAATCTTC AGGTCTTCCT GGGGAAGCAT AACCTTCGGC
480





AAAGGGAGAG TTCCCAGGAG CAGAGTTCTG TTGTCCGGGC TGTGATCCAC CCTGACTATG
540





ATGCCGCCAG CCATGACCAG GACATCATGC TGTTGCGCCT GGCACGCCCA GCCAAACTCT
600





CTGAACTCAT CCAGCCCCTT CCCCTGGAGA GGGACTGCTC AGCCAACACC ACCAGCTGCC
660





ACATCCTGGG CTGGGGCAAG ACAGCAGATG GTGATTTCCC TGACACCATC CAGTGTGCAT
720





ACATCCACCT GGTGTCCCGT GAGGAGTGTG AGCATGCCTA CCCTGGCCAG ATCACCCAGA
780





ACATGTTGTG TGCTGGGGAT GAGAAGTACG GGAAGGATTC CTGCCAGGGT GATTCTGGGG
840





GTCCGCTGGT ATGTGGAGAC CACCTCCGAG GCCTTGTGTC ATGGGGTAAC ATCCCCTGTG
900





GATCAAAGGA GAAGCCAGGA CTCTACACCA ACGTCTGCAG ATACACGAAC TGGATCCAAA
960





AAACCATTCA GGCCAAGTGA CCCTGACATG TGACATCTAC CTCCCGACCT ACCACCCCAC
1020





TGGCTGDTTC CAGAACGTCT CTCACCTAGA CCTTGCCTCC CCTCCTCTCC TGCCCAGCTC
1080





TGACCCTGAT GCTTAATAAA CGCAGCGACG TGAGGGTCCT GATTCTCCCT GGTTTTACCC
1140





CAGCTCCATC CTTGCATCAC TGGGGAGGAC GTGATGAGTG AGGACTTGGG TCCTCCGTCT
1200





TACCCCCACC ACTAAGAGAA TACAGGAAAA TCCCTTCTAG GCATCTCCTC TCCCCAACCC
1260





TTCCACACGT TTGATTTCTT CCTGCAGAGG CCCAGCCACG TGTCTGGAAT CCCAGCTCCG
1320





CTGCTTACTG TCGGTGTCCC CTTGGGATGT ACCTTTCTTC ACTGCAGATT TCTCACCTGT
1380





AAGATGAAGA TAAGGATGAT ACAGTCTCCA TCAGGCAGTG GCTGTTGGAA AGATTTAAGA
1440





TTTCACACCT ATGACATACA TGGGATAGCA CCTGCGCCGC CATGCACTCA ATAAACAATG
1500





TATTTT





SEQ ID NO: 131 Protein sequence


Protein Accession #: NP_002765


1          11         21         31         41         51


|          |          |          |          |          |


MKKLMVVLSL IAAAWAEEQN KLVHGGPCDK TSHPYQAALY TSGHLLCGGV LIHPLWVLTA
60





AHCKKPNLQV FLGKHNLRQR ESSQEQSSVV RAVIHPDYDA ASHDQDIMLL RLARPAKLSE
120





LIQPLPLERD CSANTTSCHI LGWGKTADGD FPDTIQCAYI HLVSREECEH AYPGQITQNM
180





LCAGDEKYGK DSCQGDSGGP LVCGDNLRGL VSWGNIPCGS KEKPGVYTNV CRYTNWIQKT
240





IQAK





SEQ ID NO: 132 DNA sequence


Nucleic Acid Accession #: AY038071 1


Coding sequence: 1..1685


1         11         21         31         41         51


|          |          |          |          |          |


ATGAGCAATC AGTACCACGA GGAGGGCTGC TCCGAGACGC CCGAGTGCAA AAGTAAATCT
60





CCAACTTTGC TCTCCTCCTA CTGCATCGAC AGCATCCTGG GCCGGAGGAG CCCGTGCAAA
120





ATGCGGTTGC TGGGAGCCGC GCAGAGCTTG CCTGCTCCGC TGACCAGCCG CGCCGACCCG
180





GAAAAGGCCG TGCAAGGCTC CCCTAAGAGC AGCAGCGCCC CGTTCGAGGC CGAGCTGCAC
240





CTGCCGCCCA AGCTGCGGCG CCTGTACGGC CCGGGCGGGG GCCGCCTCCT TCACGGTGCG
300





GCAGCGGCGG CGGCGGCGGC GGCGGCGGCG GCGGCAGCGG CCGCCACGGC CACGGCGGGT
360





CCACGCGGGG AGGCCCCTCC GCCGCCACCG CCAACCCCGC GGCCCGGGGA ACGGCCGGAC
420





GGCGCAGGGG CCGCCGCGGC AGCCGCGGCC GCGGCCGCCG CGGCCTGGGA CACCCTCAAG
480





ATCAGCCAGG CGCCCCAGGT GAGCATCAGC CGCAGCAAGT CGTACCGCGA GAACGGGGCG
540





CCCTTCGTGC CGCCGCCGCC CGCGCTGGAC GAGCTGGGCG GCCCGGGGGG CGTCACGCAC
600





CCGGAGGAGC GCCTCGGCGT GGCCCGCGGC CCGGGCAGCG CCCCGGCTGC GGGTGGTGGC
660





ACCGGCACCG AGGACGACGA GGAGGAGCTG CTGGAGGACG AAGAAGATGA GGACGAGGAA
720





GAGGAACTGC TGGAGGACGA CGAGGAGGAG CTGCTGGAGG ACGACGCCCG CGCGCTGCTC
780





AAGGAGCCCC GGCGCTGTCC TGTGGCCGCC ACTGGCGCCC TGGCCGCAGC AGCTGCCGCT
840





GCAGTGGCCA CAGAGGGCCG GGAGCTGTCA CCCAAGGAGC AGCTGCTGCT GCACCCGGAA
900





GACGCTGAGG GCAAGGACGG CGAGGACAGC GTGTGCCTCT CTGCGGGCAG CGACTCGGAG
960





GAGGGGCTGC TGAAACGCAA ACAGAGGCGC TACCGCACCA CGTTCACCAG CTACCAGCTG
1020





GAGGAACTGG AGCGGGCCTT CCAGAAGACG CACTACCCGG ACGTCTTCAC CAGGGAGGAA
1080





CTGGCCATGA GGCTGGACTT GACCGAGGCC CGAGTCCAGG TCTGGTTCCA GAACCGTCGG
1140





GCCAAGTGGC GCAAGCGGGA GAAGGCAGGC GCGCAGACCC ACCCCCCTGG GCTGCCCTTC
1200





CCGGGGCCGC TCTCCGCCAC CCACCCGCTC AGCCCCTACC TGGACGCCAG CCCCTTCCCT
1260





CCGCACCACC CGGCGCTCGA CTCCGCTTGG ACTGCCGCTG CCGCCGCCGC CGCCGCCGCC
1320





TTCCCGAGCC TACCTCCGCC TCCGGGCTCG GCCAGCCTGC CGCCCAGCGG GGCGCCGCTG
1380





GGCCTGAGCA CTTTCCTCGG AGCGGCAGTG TTCCGACACC CAGCTTTCAT CAGCCCGGCA
1440





TTCGGCAGGC TCTTTTCCAC AATGGCCCCC CTGACCAGCG CGTCGACCGC GGCCGCGCTC
1500





CTGAGACAGC CCACACCCGC CGTGGACGCC GCAGTGGCAT CGGGCCCCCT GGCCGACCCG
1560





GCCACGGCGG CCGCAGACAG ACGCGCCTCT AGCATAGCCG CGCTGAGGCT CAAGGCCAAG
1620





GAGCACGCGG CGCAGCTCAC GCAGCTCAAC ATCCTGCCGG GCACCACCAC GGGCAAGGAG
1680





GTGTGC





SEQ ID NO: 133 protein sequence


Protein Accession #: AAK93901.1


1          11         21         31         41         51


|          |          |          |          |          |


MSNQYQEEGC SERPECKSKS PTLLSSYCID SILGRRSPCK MRLLGAAQSL PAPLTSRADP
60





EKAVQGSPKS SSAPFEAELH LPPKLRRLYG PGGGRLLQGA AAAAAAAAAA AAAAATATAG
120





PRGEAPPPPP PTARPGERPD GAGAAAAAAA AAAAAWDTLK ISQAPQVSIS RSKSYRENGA
180





PFVPPPPALD ELGGPGGVTH PEERLGVAGG PGSAPAAGGG TGTEDDEEEL LEDEEDEDEE
240





EELLEDDEEE LLEDDANALL KEPRRCPVAA TGAVAAAAAA AVATEGGELS PKEELLLHPE
300





DAEGEDGEDS VCLSAGSDSE EGLLERKQRR YRTTFTSYQL EELERAFQET HYPDVFTREE
360





LAMRLDLTEA RVQVNFQNRR AKEREREKAG AQTNPPGLPF PGPLSATNPL SPYLGASPFP
420





PHHPALDSAW TAAAAAAAAA FPSLPPPPGS ASLPPSGAPL GLSTFLGAAV FRNPAFISPA
480





FGRLFSTMAP LTSASTAAAL LRQPTPAVEG AVASGALADP ATAAADRRAS SIAALRLKAK
540





EHAAQLTQLN ILPGTSTGKE VC





SEQ ID NO: 134 DNA sequence


Nucleic Acid Accession #: CAT cluster


1         11         21         31         41         51


|          |          |          |          |          |


TTTTTTTTTT TTTTTTTAAA GCAGATCATC TCTCCAAATC ATCACTTCTA TCAAGCCTAT
60





TGCTTGAGCA GTGTTATAGC ACTCAGCCCT CACGGCAAAG ATAAGTCTTC ACCATTCTCA
120





CACGTAGCAC ACACATATTC AGCCATATCA TGCTCAATGG GAATACAGGA CTTTGTAGAA
180





ACAGAACTGA TTCCTGCAGA ATATCCTGAG ATACTTATCA AGCTGTTAAA GGAGACATCA
240





GTCTTTTGTC TGTATTGCCC TTGACACCTC CTCAAGGAAA GTATCTAGAA ATTCTTTGTC
300





TTCTGAAGAA CCCTCACACC TCTTAGGTCT AATGTAGGTT AAGTGCCCTG CAGATCTCCC
360





TAGAATAGAA AAGCACCTTG AAAACTGTAG TCTGACTTAA TACACACAAA TATAATGAAA
420





GCACTAATTC ATAAGATCCT GTTATTTGAA GGAAAAAGCA GCAAAAGGCA CAAGCTTCAC
480





ATATTGGTCT TGCACAGGAA AAAGCTGGAA TTCTACC





SEQ ID NO: 135 DNA sequence


Nucleic Acid Accession #: NM_006799


Coding sequence. 19..963


1          11         21         31         41         51


|          |          |          |          |          |


GCCGGGGGAG AGGAGGCCAT GGGCGCGCGC GGGGCGCTGC TGCTGGCGCT GCTGCTGGCT
60





CGGGCTGGAC TCAGGAAGCC GGAGTCGCAG GAGGCGGCGC CGTTATCAGG ACCATGCGGC
120





CGACGGGTCA TCACGTCGCG CATCGTGGGT GGAGAGGACG CCGAACTCGG GCGTTGGCCG
180





TGGCAGGGGA GCCTGCGCCT GTGGGATTCC CACGTATGCG GAGTGAGCCT GCTCAGCCAC
240





CGCTGGGCAC TCACGGCGGC GCACTGCTTT GAAACCTATA GTGACCTTAG TGATCCCTCC
300





GGGTGGATGG TCCAGTTTGG CCAGCTGACT TCCATGCCAT CCTTCTGGAG CCTGCAGGCC
360





TACTACACCC GTTACTTCGT ATCGAATATC TATCTGAGCC CTCGCTACCT GGGGAATTCA
420





CCCTATGACA TTGCCTTGGT GAAGCTGTCT GCACCTGTCA CCTACACTAA ACACATCCAG
460





CCCATCTGTC TCCAGGCCTC CACATTTGAG TTTGAGAACC GGACAGACTG CTGGGTGACT
540





GGCTGGGGGT ACATCAAAGA GGATGAGGCA CTGCCATCTC CCCACACCCT CCAGGAAGTT
600





CAGGTCGCCA TCATAAACAA CTCTATGTGC AACCACCTCT TCCTCAAGTA CAGTTTCCGC
660





AAGGACATCT TTGGAGACAT GGTTTGTGCT GGCAATGCCC AAGGCGGGAA GGATGCCTGC
720





TTCGGTGACT CAGGTGGACC CTTGGCCTGT AACAAGAATG GACTGTGGTA TCAGATTGGA
780





GTCGTGAGCT GGGGAGTGGG CTGTGGTCGG CCCAATCGGC CCGGTGTCTA CACCAATATC
840





AGCCACCACT TTGAGTGGAT CCAGAAGCTG ATGGCCCAGA GTGGCATGTC CCAGCCAGAC
900





CCCTCCTGGC CGCTACTCTT TTTCCCTCTT CTCTGGGCTC TCCCACTCCT GGGGCCGGTC
960





TGAGCCTACC TGAGCCCATG CAGCCTGGGG CCACTGCCAA GTCAGGCCCT GGTTCTCTTC
1020





TGTCTTGTTT GGTAATAAAC ACATTCCAGT TGATGCCTTG CAGGGCATTC TTCAAAA





SEQ ID NO: 136 Protein sequence


Protein Accession #: NP_006790


1          11         21         31         41         51


|          |          |          |          |          |


MGARGALLLA LLLARAGLRK PESQEAAPLS GPCGRRVITS RIVGGEDAEL GRWPWQGSLR
60





LWDSHVCGVS LLSHRWALTA AHCFETYSDL SDPSGWMVQF GQLTSNPSFW SLQAYYTRYF
120





VSNIYLSPRY LGNSPYDIAL VKLSAPVTYT KHIQPICLQA STEEFENRTD CWVTGWGYIK
180





EDEALPSPHT LQEVQVAIIN NSMCNHLFLK YSFRKDIFGD MVCAGNAQGG KDACFGDSGG
240





PLACNKNGLW YQIGVVSWGV GCGRPNRPGV YTNISHHFEW IQKLMAQSGM SQPDPSWPLL
300





FFPLLWALPL LGPV





SEQ ID NO: 137 DNA sequence


Nucleic Acid Accession #: Eos sequence


Coding sequence: 1..939


1          11         21         31         41         51


|          |          |          |          |          |


ATGGGCGCGC GCGGGGCGCT GCTGCTGGCG CTGCTGCTGG CTCGGGCTGG ACTCAGGAAG
60





CCGGAGTCGC AGGAGGCGGC GCCCTTATCA GGACCATGCG GCCGACGGGT CATCACGTCG
120





CGCATCGTGG GTGGAGAGGA CGCCGAACTC GGGCGTTGGC CGTGGCAGGG GAGCCTGCGC
180





CTGTGGGATT CCCACGTATG CGGAGTGAGC CTGCTCAGCC ACCGCTGGGC ACTCACGGCG
240





GCGCACTGCT TTGAAACTGA CCTTAGTGAT CCCTCCGGGT GGATGGTCCA GTTTGGCCAG
300





CTGACTTCCA TGCCATCCTT CTGGAGCCTG CAGGCCTACT ACACCCGTTA CTTCGTATCG
360





AATATCTATC TGAGCCCTCG CTACCTGGGG AATTCACCCT ATGACATTGC CTTGGTGAAG
420





CTGTCTGCAC CTGTCACCTA CACTAAACAC ATCCAGCCCA TCTGTCTCCA GGCCTCCACA
480





TTTGAGTTTG AGAACCGGAC AGACTGCTGG GTGACTGGCT GGGGGTACAT CAAAGAGGAT
540





GAGGCACTGC CATCTCCCCA CACCCTCCAG GAAGTTCAGG TCGCCATCAT AAACAACTCT
600





ATGTGCAACC ACCTCTTCCT CAAGTACAGT TTCCGCAAGG ACATCTTTGG AGACATGGTT
660





TGTGCTGGCA ATGCCCAAGG CGGGAAGGAT GCCTGCTTCG GTGACTCAGG TGGACCCTTG
720





GCCTGTAACA AGAATGGACT GTGGTATCAG ATTGGAGTCG TGAGCTGGGG AGTGGGCTGT
780





GGTCGGCCCA ATCGGCCCGG TGTCTACACC AATATCAGCC ACCACTTTGA GTGGATCCAG
840





AAGCTGATGG CCCAGAGTGG CATGTCCCAG CCAGACCCCT CCTGGCCACT ACTCTTTTTC
900





CCTCTTCTCT GGGCTCTCCC ACTCCTGGGG CCGGTCTGA





SEQ ID NO: 138 Protein sequence


Protein Accession #: Eos sequence


1          11         21         31         41         51


|          |          |          |          |          |


MGARGALLLA LLLARAGLRK PESQEAAPLS GPCGRRVITS RIVGGEDAEL GRWPWQGSLR
60





LWDSHVCGVS LLSHRWALTA AHCFETDLSD PSGWNVQFGQ LTSMPSFWSL QAYYTRYFVS
120





NIYLSPRYLG NSPYDIALVK LSAPVTYTKH IQPICLQAST FEFENRTDCW VTGWGYIKED
180





EALPSPHTLQ EVQVAIINNS MCNHLFLKYS FRKDIFGDMV CAGNAQGGKD ACFGDSGGPL
240





ACNKNGLWYQ IGVVSWGVGC GRPNRPGVYT NISHHFEWIQ KLMAQSGMSQ PDPSWPLLFF
300





PLLWALPLLG PV





SEQ ID NO: 139 DNA sequence


Nucleic Acid Accession #: NM_014344


Coding sequence: 131..1444


1          11         21         31         41         51


|          |          |          |          |          |


GCGGCCGCGA TGGGGCCGAA GCGCCCGAAG CCCCCCAGCC CACAAACTGC CGCGCCGGCG
60





TCGCCGCCGG CACCCCCGTG CCTGGGCTCG CCTTGAAGCG GCGGCGGCGC ACCGGCACAG
120





CCGCGGGAGC ATGGGCAGGA GGATGCGGGG CGCCGCCGCG ACCGCGGGGC TCTGGCTGCT
180





GGCGCTGGGC TCGCTGCTGG CGCTGTGGGG AGGGCTCCTG CCGCCGCGGA CCGAGCTGCC
240





CGCCTCCCGG CCGCCCGAAG ACCGACTCCC ACGGCGCCCG GCCCGGAGCG GCGGCCCCGC
300





GCCCGCGCCT CGCTTCCCTC TGCCCCCGCC CCTGGCGTGG GACGCCCGCG GCGGCTCCCT
360





GAAAACTTTC CGGGCGCTGC TCACCCTGGC GGCCGGGCCG GACGGCCCGC CCCGGCAGTC
420





CCGGAGCGAG CCCAGGTGGC ACGTGTCAGC CAGGCAGCCC CGGCCGGAGG AGAGCGCCGC
480





GGTGCACGGG GGCGTCTTCT GGAGCCGCGG CCTGGAGGAG CAGGTGCCCC CGGGCTTTTC
540





GGAGGCCCAG GCGGCGGCGT GGCTGGAGGC GGCTCGCGGC GCCCGGATGG TGGCCCTGGA
000





GCGCGGGGGT TGCGGGCGCA GCTCCAACCG ACTGGCCCGT TTTGCCGACG GCACCCGCGC
660





CTGCGTGCGC TACGGCATCA ACCCGGAGCA GATTCAGGGC GAGGCCCTGT CTTACTATCT
720





GGCGCGCCTG CTGGGCCTCC AGCGCCACGT GCCGCCGCTG GCACTGGCTC GGGTGGAGGC
780





TCGGGGCGCG CAGTGGGCGC AGGTGCAGGA GGAGCTGCGC GCTGCGCACT GGACCGAGGG
840





CAGCGTGGTG AGCCTGACAC GCTGGCTGCC CAACCTCACG GACGTGGTGG TGCCCGCGCC
900





CTGGCGCTCG GAGGACGGCC GTCTGCGCCC CCTCCGGGAT GCCGGGGGTG AGCTGGCCAA
960





CCTCAGCCAG GCGGAGCTGG TGGACCTAGT ACAATGGACC GACTTAATCC TTTTCGACTA
1020





CCTGACGGCC AACTTCGACC GGCTCGTAAG CAACCTCTTC AGCCTGCAGT GGGACCCGCG
1080





CGTCATGCAG CGTGCCACCA GCAACCTGCA CCGCGGTCCG GGCGGGGCGC TGGTCTTTCT
1140





GGACAATGAG GCGGGCTTGG TGCACGGCTA CCGGGTAGCA GGCATGTGGG ACAAGTATAA
1200





CGAGCCGCTG TTGCAGTCAG TGTGCGTGTT CCGCGAGCGG ACCGCGCGGC GCGTCCTGGA
1260





GCTGCACCGC GGACAGGACG CCGCGGCCCG GCTGCTGCGC CTCTACCGGC GCCACGAGCC
1320





TCGCTTCCCC GAGCTGGCCG CCCTTGCAGA CCCCCACGCT CAGCTGCTAC AGCGCCGCCT
1380





CGACTTCCTC GCCAAGCACA TTTTGCACTG TAAGGCCAAG TACGGCCGCC GGTCTGGGAC
1440





TTAGTGTCAC CGGGAGGAAA AGAGAGAGAT CTGGGGCTGG GGTATGGATG ATGGGGGGAA
1500





GGGCGGTCGC CTCTGCCACT GTCAGGGACC AGCCGGCCAA CGCCCACCCG CAAAGGTGTC
1560





TAAAAACTTC AGCTTTTCAC CCACCTGCCC CTTTCTTTCA ATCCCACGCT GTTTCCTTTC
1620





AAAGTTCTGG GAGGACGAAC TCACCGAGGC GAGAAGTGTA ACATTCTCTC CACCCAGCTT
1680





ATAAAAGGAT TCTTTACTGT GCCAGCACGG GGATTGGATC CGAAGAAACT GGCTACTGGG
1740





GTTTGGCCCC CGAGTGGCCG TCCCTGTGGG AGATGCACCC CATTCTTGGG CCCCCCTCAT
1800





TCCCTTTCCG AAAAAGGAAA ACTTGCGTTT GAGCCGTTGA GCTAATTCTG CAATTTTCTA
1860





CCAAACAGAG CGCTGGTGGC CCCGGAGCAG GGCTGTGACA TTGGCTGGTG GAGCCCCTTC
1920





CTGTGTTCTC CCTTTGTTCC AGCGCCGCGA TGGTGAGATC ACTGTTCCAA GCAGGGGGAC
1980





GGCTCGCGAT AGGACAAAGA GAGCAGGACC TCCAGACTCT GGGGAGCCCT GCAGACCTTG
2040





ACAATTTGCC TGACTCATTC CTGACCTCTT GTCATTTTGG CCTGAAGGCT ACAAATTCAG
2100





GGTCAGCTGT ATGCACTAAG TCAAATAATG AATTTCTTCC TCCCTCTCGC AACCGACCAA
2160





AATTTTGACA ACGATGATGT TCACCAGAAG GAAAAAAAAA TCAGTTTTAT GCACTTTATT
2220





TTGTTTTGAT TTTCATTTTT TATTAAGAAA AAATTTTATT TTACAGAATT TACCTTCTCT
2280





GTATATATGT GCATAAAGTG TGGTGTAAAT ATACTAAACA AACTTATATT TCAATAAAAG
2340





GGAGTTTAAA ATTTAAAAAA AAAAAAA





SEQ ID NO: 140 protein sequence


Protein Accession #: NP_055159


1          11         21         31         41         51


|          |          |          |          |          |


MGRRNRGAAA TAGLWLLALG SLLALWGGLL PPRTELPASR PPEDRLPRRP ARSGGPAPAP
60





RFPLPPPLAW GARGGSLKTF RALLTLAAGA DGPPRQSRSE PRWNVSARQP EPEESAAVNG
120





GVFWSRGLEE QVPPGFSEAQ AAAWLEAARG ARMVALERGG CGRSSNRLAR FADGTRACVR
180





YGINPEQIQG EALSYYLARL LGLQRNVPPL ALARVEARGA QWAQVQEELR AANWTEGSVV
240





SLTRNLPNLT DVVVPAPWRS EDGELEPLED AGGELANLSQ AELVDLVQWT GLILFGYLTA
300





NFGRLVSNLF SLQWDPRVMQ NATSNLNRGP GGALVELGNE AGLVNGYRVA GMWDKYNEPL
360





LQSVCVFRER TARRVLELNR GQGAAARLLR LYRRNEPRFP ELAALADPHA QLLQRRLGFL
420





AKNILNCEAK YGRRSGT





SEQ ID NO: 141 DNA sequence


Nucleic Acid Accession #: Eos sequence


Coding sequence: 11..574


1          11         21         31         41         51


|          |          |          |          |          |


GTCCGCCAAG ATGCCTGCCC CAGTCCCTCT GCTGTCTGCA GCCCAGCCTT CACCCTCTTG
60





CATGGGGAAA TCGTCTACAG ACTTCTGCCC ATGGCTGTAT GTACGCACGG ACAGAGCTAG
120





CAATGACCCT GCTGGCAGGT ATGATAGGAA GCCTCTTCTG TCACAGGATT CATTCCCAGA
180





CAATGACCCC AAATGCCTGT CCCTGCTCCC CCCACCCCCC AACATCAAAA TAGCCGAGAA
240





AAATGCCCTT CTCGGAGCCA AATGTGTGGT GATGCCTTAC AATCAGAAAT TCCTACAGTG
300





GCCTGAGGCT TCCACCACTA AACGCAAAGC TGTAGATACC TATTGCTTGG ATTATAAGCC
360





TTCCAAGGGA AGAAGGTGGG CTGCAAGAGC ACCAAGCACC AGAATCACAT ATGGGACTAT
420





CACCAAAGAG AGAGACTACT GCGCGGAAGA CCAGACTATC GAGAGCTGGA GAGAAGAAGG
480





TTTCCCAGTG GGCTTGAAGC TTGCTGTGCT TGGTATTTTC ATCATTGTGG TGTTTGTCTA
540





CCTGACTGTG GAAAATAAGT CGCTGTTTGG TTAAGTAATT TAGG





SEQ ID NO: 142 Protein sequence


Protein Accession #: Eos sequence


1          11         21         31         41         51


|          |          |          |          |          |


MPAPVPLLSA AQPSPSCNGK SSTDFCPWLY VRTDRASNDP AGRYDRKPLL SQDSFPDNDP
60





KCLSLLPPPP NIKIAEKNAL LGAKCVVMPY NQKFLQWPEA STTKRKAVDT YCLDYKPSKG
120





RRWAARAPST RITYGTITKE EDYCAEDQTI ESWREEGFPV GLKLAVLGIF IIVVFVYLTV
180





ENKSLFG





SEQ ID NO: 143 DNA sequence


Nucleic Acid Accession #: XM_050184 6


Coding sequence: 39..365


1          11         21         31         41         51


|          |          |          |          |          |


GATTCTACCA TCAGAAAAGA GGCCAAACTT CTATCATCAT GGTGGATGTG AAGTGTCTGA
60





GTGACTGTAA ATTGCAGAAC CAACTTGAGA AGCTTGGATT TTCACCTGGC CCAATACTAC
120





CTTCCACCAG AAAGTTGTAT GAAAAAAAGT TAGTACAGTT GTTGGTCTCA CCTCCCTGTG
180





CACCACCTGT GATGAATGGA CCCAGAGAGC TGGATGGAGC GCAGGACAGT GATGACAGCG
240





AAGGTGGGCT GCAAGAGCAC CAAGCACCAG AATCACATAT GGGACTATCA CCAAAGAGAG
300





AGACTACTGC GCGGAAGACC AGACTATCGA GAGCTGGAGA GAAGAAGGTT TCCCAGTGGG
360





CTTGAAGCTT GCTGTGCTTG GTATTTTCAT CATTGTGGTG TTTGTCTACC TGACTGTGGA
420





AAATAAGTCG CTGTTTGGTT AAGTAATTTA GGAGCAAAGC AATGCTCCAA GCGAGGCCTC
480





CTGCTTCAGG AAAGAACCAA AACACTACCC TGAAGGGCCA GCCTAGCCTG CAGCCCTCCC
540





TTGCAGGGAG CCTTCCCTTG CACTGTGCTG CTCTCACAGA TCGGTGTCTG GGCTCAGCCA
600





GGTGGAAGGA ACCTGCCTAA CCAGGCACCT GTGTTAAGAG CATGATGGTT AGGAAATCCC
660





CCAAGTCATG TCAACTCTCA TTAAAGGTGC TTCCATATTT GAGCAGGCGT CAAAC





SEQ ID NO: 144 Protein sequence


Protein Accession #: XP_050184.1


1          11         21         31         41         51


|          |          |          |          |          |


MVDVKCLSDC KLQNQLEKLG FSPGPILPST RKLYEKKLVQ LLVSPPCAPP VMNGPRELDG
60





AQGEDGSEGG LGEHQAPESH MGLSPKRETT ARKTRLSRAG EKKVSQWA





SEQ ID NO: 145 DNA sequence


Nucleic Acid Accession #: NM_002204.1


Coding sequence: 74. 3229


1          11         21         31         41         51


|          |          |          |          |          |


AGGTGAACAG GTCCTCACGC CCAGCTCCGC CCCCTCACGC GCTCTCGCCG GGACCCCGCT
60





TCCGCTGGCA GCCATGGGCC CCGGCCCCAG CCGCGCGCCC CGCGCCCCAC GCCTGATGCT
120





CTGTGCGCTC GCCTTGATGG TGGCGGCCGG CGGCTGCGTC GTCTCCGCCT TCAACCTGGA
180





TACCCGATTC CTGGTAGTGA AGGAGGCCGG GAACCCGGGC AGCCTCTTCG GCTACTCGGT
240





CGCCCTCCAT CGGCAGACAG AGCGGCAGCA GCGCTACCTG CTCCTGGCTG GTCCCCCCCG
300





GGAGCTCGCT GTGCCCGATG GCTACACCAA CCGGACTGGT GCTGTGTACC TGTGCCCACT
360





CACTGCCCAC AAGGATGACT GTGAGCGGAT GAACATCACA GTGAAAAATG ACCCTGGCCA
420





TCACATTATT GAGGACATGT GGCTTGGAGT GACTGTGGCC AGCCAGGGCC CTGCAGGCAG
480





AGTTCTGGTC TGTGCCCACC GCTACACCCA GGTGCTGTGG TCAGGGTCAG AAGACCAGCG
540





GCGCATGGTG GGCAAGTGCT ACGTGCGAGG CAATGACCTA GAGCTGGACT CCAGTGATGA
600





CTGGCAGACC TACCACAACG AGATGTGCAA TAGCAACACA GACTACCTGG AGACGGGCAT
660





GTGCCAGCTG GGCACCAGCG GTGGCTTCAC CCAGAACACT GTGTACTTCG GCGCCCCCGG
720





TGCCTACAAC TGGAAAGGAA ACAGCTACAT GATTCAGCGC AAGGAGTGGG ACTTATCTGA
780





GTATAGTTAC AAGGACCCAG AGGACCAAGG AAACCTCTAT ATTGGGTACA CGATGCAGGT
840





AGGCAGCTTC ATCCTGCACC CCAAAAACAT CACCATTGTG ACAGGTGCCC CACGGCACCG
900





ACATATGGGC GCGCTGTTCT TGCTGAGCCA GGAGGCAGGC GGAGACCTGC GGAGGAGGCA
960





GGTGCTGGAG GGCTCGCAGG TGGGCGCCTA TTTTGGCAGC GCAATTGCCC TGGCAGACCT
1020





GAACAATGAT GGGTGGCAGG ACCTCCTGGT GGGCGCCCCC TACTACTTCG AGAGGAAAGA
1080





GGAAGTAGGG GGTGCCATCT ATGTCTTCAT GAACCAGGCG GGAACCTCCT TCCCTGCTCA
1140





CCCCTCACTC CTTCTTCATG GCCCCAGTGG CTCTGCCTTT GGTTTATCTG TGGCCAGCAT
1200





TGGTGACATC AACCAGGATG GATTTCAGGA TATTGCTGTG GGAGCTCCGT TTGAAGGCTT
1260





GGGCAAAGTG TACATCTATC ACAGTAGCTC TAAGGGGCTC CTTAGACAGC CCCAGCAGGT
1320





AATCCATGGA GAGAAGCTGG GACTGCCTGG GTTGGCCACC TTCGGCTATT CCCTCAGTGG
1380





GCAGATGGAT GTGGATGAGA ACTTCTACCC AGACCTTCTA GTGGGAAGCC TGTCAGACCA
1440





CATTGTGCTG CTGCGGGCCC GGCCAGTCAT CAACATCGTC CACAAGACCT TGGTGCCCAG
1500





GCCAGCTGTG CTGGACCCTG CACTTTGCAC GGCCACCTCT TGTGTGCAAG TGGAGCTGTG
1560





CTTTGCTTAC AACCAGAGTG CCGGGAACCC CAACTACAGG CGAAACATCA CCCTGGCCTA
1620





CACTCTGGAG GCTGACAGGG ACCGCCGGCC GCCCCGGCTC CGCTTTGCCG GCAGTGAGTC
1680





CGCTGTCTTC CACGGCTTCT TCTCCATGCC CGAGATGCGC TGCCAGAAGC TGGAGCTGCT
1740





CCTGATGGAC AACCTCCGTG ACAAACTCCG CCCCATCATC ATCTCCATGA ACTACTCTTT
1800





ACCTTTGCGG ATGCCCGATC GCCCCCGGCT GGCGCTGCGG TCCCTGGACG CCTACCCGAT
1860





CCTCAACCAG GCACAGGCTC TGGAGAACCA CACTGAGGTC CAGTTCCAGA AGGACTGCGG
1920





GCCTGACAAC AAGTGTGAGA GCAACTTGCA CATGCGGGCA GCCTTCGTGT CAGAGCAGCA
1980





GCAGAAGCTG AGCAGGCTCC AGTACAGCAG AGACGTCCGG AAATTGCTCC TGAGCATCAA
2040





CGTGACGAAC ACCCGGACCT CGGAGCGCTC CGGGGAGGAC GCCCACGAGG CGCTGCTCAC
2100





CCTGGTGGTG CCTCCCGCCC TGCTGCTGTC CTCAGTGCGC CCCCCCGGGG CCTGCCAAGC
2160





TAATGAGACC ATCTTTTGCG AGCTGGGGAA CCCCTTCAAA CGGAACCAGA GGATGGAGCT
2220





GCTCATCGCC TTTGAGGTCA TCGGGGTGAC CCTGCACACA AGGGACCTTC AGGTGCAGCT
2280





GCAGCTCTCC ACGTCGAGTC ACCAGGACAA CCTGTGGCCC ATGATCCTCA CTCTGCTGGT
2340





GGACTATACA CTCCAGACCT CGCTTAGCAT GGTAAATCAC CGGCTACAAA GCTTCTTTGG
2400





GGGGACAGTG ATGGGTGAGT CTGGCATGAA AACTGTGGAG GATGTAGGAA GCCCCCTCAA
2460





GTATGAATTC CAGGTGGGCC CAATGGGGGA GGGGCTGGTG GGCCTGGGGA CCCTGGTCCT
2520





AGGTCTGGAG TGGCCCTACG AAGTCAGCAA TGGCAAGTGG CTGCTGTATC CCACGGAGAT
2580





CACCGTCCAT GGCAATGGGT CCTGGCCCTG CCGACCACCT GGAGACCTTA TCAACCCTCT
2640





CAACCTCACT CTTTCTGACC GTGGGGACAG GCCATCATCC CCACAGCGCA GGCGCCGACA
2700





GCTGGATCCA GGGGGAGGGC AGGGCCCCCC ACCTGTCACT CTGGCTGCTG CCAAAAAAGC
2760





CAAGTCTGAG ACTGTGCTGA CCTGTGCCAC AGGGCGTGCC CACTGTGTGT GGCTAGAGTG
2820





CCCCATCCCT GATGCCCCCG TTGTCACCAA CGTGACTGTG AAGGCACGAG TGTGGAACAG
2880





CACCTTCATC GAGGATTACA GAGACTTTGA CCGAGTCCGG GTAAATGGCT GGGCTACCCT
2940





ATTCCTCCGA ACCAGCATCC CCACCATCAA CATGGAGAAC AAGACCACGT GGTTCTCTGT
3000





GGACATTGAC TCGGAGCTGG TGGAGGAGCT GCCGGCCGAA ATCGAGCTGT GGCTGGTGCT
3060





GGTGGCCGTG GGTGCAGGGC TGCTGCTGCT GGGGCTGATC ATCCTCCTGC TGTGGAAGTG
3120





CGGCTTCTTC AAGCGAGCCC GCACTCGCGC CCTGTATGAA GCTAAGAGGC AGAAGGCGGA
3180





GATGAAGAGC CAGCCGTCAG AGACAGAGAG GCTGACCGAC GACTACTGAG GGGGCAGCCC
3240





CCCGCCCCCG GCCCACCTGG TGTGACTTCT TTAAGCGGAC CCGCTATTAT CAGATCATGC
3300





CCAAGTACCA CGCAGTGCGG ATCCGGGAGG AGGAGCGCTA CCCACCTCCA GGGAGCACCC
3360





TGCCCACCAA GAAGCACTGG GTGACCAGCT GGCAGACTCC GGACCAATAC TACTGACGTC
3420





CTCCCTGATC CCACCCCCTC CTCCCCCAGT GTCCCCTTTC TTCCTATTTA TCATAAGTTA
3480





TGCCTCTGAC AGTCCACAGG GGCCACCACC TTTGGCTGGT AGCAGCAGGC TCAGGCACAT
3540





ACACCTCGTC AAGAGCATGC ACATGCTGTC TGGCCCTGGG GATCTTCCCA CAGGAGGGCC
3600





AGCGCTGTGG ACCTTACAAC GCCGAGTGCA CTGCATTCCT GTGCCCTAGA TGCACGTGGG
3660





GCCCACTGCT CGTGGACTGT GCTGGTGCAT CACGGATGGT GCATGGGCTC GCCGTGTCTC
3720





AGCCTCTGCC AGCGCCAGCG CCAAAACAAG CCAAAGAGCC TCCCACCAGA GCCGGGAGGA
3780





AAAGGCCCCT GCAATGTGGT GACACCTCCC CTTTCACACC TGGATCCATC TTGAGAGCCA
3840





CAGTCACTGG ATTGACTTTG CTGTCAAAAC TACTGACAGG GAGCAGCCCC CGGGCCGCTG
3900





GCTGGTGGGC CCCCAATTGA CACCCATGCC AGAGAGGTGG GGATCCTGCC TAAGGTTGTC
3960





TACGGGGGCA CTTGGAGGAC CTGGCGTGCT CAGACCCAAC AGCAAAGGAA CTAGAAAGAA
4020





GGACCCAGAA GGCTTGCTTT CCTGCATCTC TGTGAACCCT CTCTCCTTGG CCACAGACTG
4080





AACTCGCAGG GAGTGCAGCA GGAAGGAACA AAGACAGGCA AACGGCAACG TAGCCTGGGC
4140





TCACTGTGCT GGGGCATGGC GGGATCCTCC ACAGAGAGGA GGGGACCAAT TCTGGACAGA
4200





CAGATGTTGG GAGGATACAG AGGAGATGCC ACTTCTCACT CACCACTACC AGCCAGCCTC
4260





CAGAAGGCCC CAGAGAGACC CTGCAAGACC ACGGAGGGAG CCGACACTTG AATGTAGTAA
4320





TAGGCAGGGG GCCCTGCCAC CCCATCCAGC CAGACCCCAG CTGAACCATG CGTCAGGGGC
4380





CTAGAGGTGG AGTTCTTAGC TATCCTTGGC TTTCTGTGCC AGCCTGGCTC TGCCCCTCCC
4440





CCATGGGCTG TGTCCTAAGG CCCATTTGAG AAGCTGAGGC TAGTTCCAAA AACCTCTCCT
4500





GACCCCTGCC TGTTGGCAGC CCACTCCCCA GCCCCAGCCC CTTCCATGGT ACTGTAGCAG
4560





GGGAATTCCC TCCCCCTCCT TGTGCCTTCT TTGTATATAG GCTTCTCACC GCGACCAATA
4620





AACAGCTCCC AGTTTGT





SEQ ID NO: 146 Protein sequence


Protein Accession #: NP_002195.1


1          11         21         31         41         51


|          |          |          |          |          |


MGPGPSRAPR APRLMLCALA LMVAAGGCVV SAFNLDTRFL VVKEAGNPGS LFGYSVALHR
60





QTERQQRYLL LAGAPRELAV PDGYTNRTGA VYLCPLTAHK DDCERMNITV KNDPGHHIIE
120





DMWLGVTVAS QGPAGRVLVC AHRYTQVLWS GSEDQRRMVG KCYVRGNDLE LDSSDDWQTY
180





HNEMCNSNTD YLETGMCQLG TSGGFTQNTV YFGAPGAYNW KGNSYMIQNK EWDLSEYSYK
240





DPEDQGNLYI GYTMGVGSFI LHPKNITIVT GAPRHRHMGA VFLLSQEAGG DLRRRQVLEG
300





SQVGAYFGSA IALADLNNDG WQDLLVGAPY YFERKEEVGG AIYVFMNQAG TSFPAHPSLL
360





LHGPSGSAFG LEVASIGDIN QDGFQDIAVG APFEGLGKVY IYNSSSKGLL RQPQQVIHGE
420





KLGLPGLATF GYSLSGQMDV DENFYPDLLV GSLSDHIVLL RARPVINIVH KTLVPRPAVL
480





DPALCTATSC VQVELCFAYN QSAGNPNYRR NITLAYTLEA DRGREPPELK FAGSESAVFN
540





GFFSMPEMRC QKLELLLNDN LRDKLRPIII SMNYSLPLRM PGRGRLGLNE LDAYPILNQA
600





QALENNTEVQ FQKECGPDNK CESNLQMRAA FVSEQQQKLS RLQYSRDVRK LLLSINVTNT
660





RTSNRSGEDA NEALLTLVVP PALLLSSVRP PGACQANETI FCELGNPFKR NQRMELLIAF
720





EVIGVTLNTR DLQVQLQLST SSNQDNLWPM ILTLLVDYTL QTSLSMVNNR LQSFFGGTVM
780





GESGMKTVED VGSPLKYEFQ VGPNGEGLVG LGTLVLGLEW PYEVSNGKWL LYPTEITVNG
840





NGSWPCRPPG DLINPLNLTL SDPGDRPSSP QRRRRQLDPG GGQGPPPVTL AAAKKAKSET
900





VLTCATGRAH CVWLECPIPD APVVTNVTV KARVWNSTFIE DYNDFDRVRV NGWATLELET
960





SIPTINMENK TTWFSVDIDS ELVEELPAFI ELWLVLVAVG AGLLLLGLII LLLWKCGFFK
1020





NARTRALYEA KRQKAEMKSQ PSETERLTDD Y





SEQ ID NO: 147 DNA sequence


Nucleic Acid Accession #: NM_005501.1


Coding sequence: 74..3274


1          11         21         31         41         51


|          |          |          |          |          |


AGGTGAACAG GTCCTCACGC CCAGCTCCGC CCCCTCACGC GCTCTCGCCG GGACCCCGCT
60





TCCGCTGGCA GCCATGGGCC CCGGCCCCAG CCGCGCGCCC CGCGCCCCAC GCCTGATGCT
120





CTGTGCGCTC GCCTTGATGG TGGCGGCCGG CGGCTGCGTC GTCTCCGCCT TCAACCTGGA
180





TACCCGATTC CTGGTAGTGA AGGAGGCCGG GAACCCGGGC AGCCTCTTCG GCTACTCGGT
240





CGCCCTCCAT CGGCAGACAG AGCGGCAGCA GCGCTACCTG CTCCTGGCTG GTGCCCCCCG
300





GGAGCTCGCT GTGCCCGATG GCTACACCAA CCGGACTGGT GCTGTGTACC TGTGCCCACT
360





CACTGCCCAC AAGGATGACT GTGAGCGGAT GAACATCACA GTGAAAAATG ACCCTGGCCA
420





TCACATTATT GAGGACATGT GGCTTGGAGT GACTGTGGCC AGCCAGGGCC CTGCAGGCAG
480





AGTTCTGGTC TGTGCCCACC GCTACACCCA GGTGCTGTGG TCAGGGTCAG AAGACCAGCG
540





GCGCATGGTG GGCAAGTGCT ACGTGCGAGG CAATGACCTA GAGCTGGACT CCAGTGATGA
600





CTGGCAGACC TACCACAACG AGATGTGCAA TAGCAACACA GACTACCTGG AGACGGGCAT
660





GTGCCAGCTG GGCACCAGCG GTGGCTTCAC CCAGAACACT GTGTACTTCG GCGCCCCCGG
720





TGCCTACAAC TGGAAAGGAA ACAGCTACAT GATTCAGCGC AAGGAGTGGG ACTTATCTGA
780





GTATAGTTAC AAGGACCCAG AGGACCAAGG AAACCTCTAT ATTGGGTACA CGATGCAGGT
840





AGGCAGCTTC ATCCTGCACC CCAAAAACAT CACCATTGTG ACAGGTGCCC CACGGCACCG
900





ACATATGGGC GCGGTGTTCT TGCTGAGCCA GGAGGCAGGC GGAGACCTGC GGAGGAGGCA
960





GGTGCTGGAG GGCTCGCAGG TGGGCGCCTA TTTTGGCAGC GCAATTGCCC TGGCAGACCT
1020





GAACAATGAT GGGTGGCAGG ACCTCCTGGT GGGCGCCCCC TACTACTTCG AGAGGAAAGA
1080





CGAAGTAGGG GGTGCCATCT ATGTCTTCAT GAACCAGGCG GGAACCTCCT TCCCTGCTCA
1140





CCCCTCACTC CTTCTTCATG GCCCCAGTGG CTCTGCCTTT GGTTTATCTG TGGCCAGCAT
1200





TGGTGACATC AACCAGGATG GATTTCAGGA TATTGCTGTG GGAGCTCCGT TTGAAGGCTT
1260





GCGCAAAGTG TACATCTATC ACAGTAGCTC TAAGGGGCTC CTTAGACAGC CCCAGCAGGT
1320





AATCCATGGA GAGAAGCTGG GACTGCCTGG GTTGGCCACC TTCGGCTATT CCCTCAGTGG
1380





GCAGATGCAT GTGGATGAGA ACTTCTACCC AGACCTTCTA GTGGGAAGCC TGTCAGACCA
1440





CATTGTGCTG CTGCGGGCCC GGCCAGTCAT CAACATCGTC CACAAGACCT TGGTGCCCAG
1500





GCCAGCTGTG CTGGACCCTG CACTTTGCAC GGCCACCTCT TGTGTGCAAG TGGAGCTGTG
1560





CTTTGCTTAC AACCAGAGTG CCGGGAACCC CAACTACAGG CCAAACATCA CCCTGGCCTA
1620





CACTCTGGAG GCTGACAGGG ACCGCCGGCC GCCCCGGCTC CGCTTTGCCG GCAGTGAGTC
1680





CGCTGTCTTC CACGGCTTCT TCTCCATGCC CGAGATGCGC TGCCAGAAGC TGGAGCTGCT
1740





CCTGATGGAC AACCTCCGTG ACAAACTCCG CCCCATCATC ATCTCCATGA ACTACTCTTT
1800





ACCTTTGCGG ATGCCCGATC GCCCCCGGCT GGGGCTGCGG TCCCTGGACG CCTACCCGAT
1860





CCTCAACCAG GCACAGGCTC TGGAGAACCA CACTGAGGTC CAGTTCCAGA AGGAGTGCGG
1920





GCCTGACAAC AAGTGTGAGA GCAACTTGCA GATGCGGGCA GCCTTCGTGT CAGAGCAGCA
1980





GCAGAAGCTG AGCAGGCTCC AGTACAGCAG AGACGTCCGG AAATTGCTCC TGAGCATCAA
2040





CGTGACGAAC ACGCGGACGT CGGAGCGCTC CGGGGAGGAC GCCCACGAGG CGCTGCTCAC
2100





CCTGGTGGTG CCTCCCGCCC TGCTGCTGTC CTCAGTGCGC CCCCCCGGGG CCTGCCAAGC
2160





TAATGAGACC ATCTTTTGCG AGCTGGCGAA CCCCTTCAAA CGGAACCAGA GGATGGAGCT
2220





GCTCATCGCC TTTGAGGTCA TCGGGGTGAC CCTGCACACA AGGGACCTTC AGCTGCAGCT
2280





GCAGGTCTCC ACGTCGAGTC ACCAGGACAA CCTGTGGCCC ATGATCCTCA CTCTGCTGGT
2340





GGACTATACA CTCCAGACCT CGCTTAGCAT CGTAAATCAC CGGCTACAAA GCTTCTTTGG
2400





GGGGACAGIG ATGGGTGAGT CTGGCATGAA AACTGTGGAG GATGTAGGAA GCCCCCTCAA
2460





GTATGAATTC CAGGTGGGCC CAATGGGGGA GGGGCTGGTG GGCCTGGGGA CCCTGGTCCT
2520





AGGTCTGGAG TGGCCCTACG AAGTCAGCAA TGGCAAGTGG CTGCTGTATC CCACGGAGAT
2580





CACCGTCCAT GGCAATCGCT CCTGGCCCTG CCGACCACCT GGAGACCTTA TCAACCCTCT
2640





CAACCTCACT CTTTCTGACC CTGGGGACAG GCCATCATCC CCACAGCGCA GGCGCCGACA
2700





GCTGGATGCA GGGGGAGGCC ACGGCCCCCC ACCTGTCACT CTGGCTCCTG CCAAAAAAGC
2760





CAAGTCTGAG ACTGTGCTGA CCTGTGCCAC AGGGCGTGCC CACTGTGTCT GGCTAGACTG
2820





CCCCATCCCT GATGCCCCCG TTGTCACCAA CGTGACTGTS AAGGCACGAG TGTGGAACAG
2880





CACCTTCATC GAGGATTACA GAGACTTTGA CCGAGTCCGG GTAAATGGCT GGGCTACCCT
2940





ATTCCTCCGA ACCACCATCC CCACCATCAA CATGGAGAAC AAGACCACGT GGTTCTCTGT
3000





GGACATTGAC TCGGAGCTGG TGGAGGAGCT GCCGGCCGAA ATCGAGCTGT GGCTGGTGCT
3060





GGTGGCCGTG GGTGCAGGGC TGCTGCTGCT GGGGCTGATC ATCCTCCTGC TGTGGAAGTG
3120





TGACTTCTTT AAGCGGACCC GCTATTATCA GATCATGCCC AAGTACCACG CAGTGCGGAT
3180





CGGGGAGGAG GAGCGCTACC CACCTCCAGG GAGCACCCTG CCCACCAAGA AGCACTGGGT
3240





GACCAGCTGG CAGACTCGGG ACCAATACTA CTGACGTCCT CCCTGATCCC ACCCCCTCCT
3300





CCCCCAGTGT CCCCTTTCTT CCTATTTATC ATAAGTTATG CCTCTGACAG TCCACAGGGG
3360





CCACCACCTT TGGCTGGTAG CAGCAGGCTC AGGCACATAC ACCTCGTCAA GAGCATGCAC
3420





ATGCTGTCTG GCCCTGGGGA TCTTCCCACA GGAGGGCCAG CGCTGTGGAC CTTACAACGC
3480





CGAGTGCACT GCATTCCTGT GCCCTAGATG CACGTGGGGC CCACTGCTCG TGGACTGTGC
3540





TGGTGCATCA CGGATGGTGC ATGGGCTCGC CGTGTCTCAG CCTCTGCCAG CGCCAGCGCC
3600





AAAACAAGCC AAAGAGCCTC CCACCAGAGC CGGGAGGAAA AGGCCCCTGC AATGTGGTGA
3660





CACCTCCCCT TTCACACCTG GATCCATCTT GAGAGCCACA GTCACTGGAT TGACTTTGCT
3720





GTCAAAACTA CTGACAGGGA GCAGCCCCCG GGCCGCTGGC TGGTGGGCCC CCAATTGACA
3780





CCCATGCCAG AGAGGTGGGG ATCCTGCCTA AGGTTGTCTA CGCGGGCACT TGGAGGACCT
3840





GGCGTGCTCA GACCCAACAG CAAAGGAACT AGAAAGAAGG ACCCAGAAGG CTTGCTTTCC
3900





TGCATCTCTG TGAAGCCTCT CTCCTTGGCC ACAGACTGAA CTCGCAGGGA GTGCAGCAGG
3960





AAGGAACAAA GACAGGCAAA CGGCAACGTA GCCTGGGCTC ACTGTGCTGG GGCATGGCGG
4020





GATCCTCCAC AGAGAGGAGG GGACCAATTC TGGACAGACA GATGTTGGGA GGATACAGAG
4080





GAGATGCCAC TTCTCACTCA CCACTACCAG CCAGCCTCCA GAAGGCCCCA GAGAGACCCT
4140





GCAAGACCAC GGAGGGAGGC GACACTTGAA TGTAGTAATA GGCAGGGGGC CCTGCCACCC
4200





CATCCAGCCA GACCCCAGCT GAACCATGCG TCAGGGGCCT AGAGGTGGAG TTCTTAGCTA
4260





TCCTTGGCTT TCTGTGCCAG CCTGGCTCTG CCCCTCCCCC ATGGGCTGTG TCCTAAGGCC
4320





CATTTGAGAA GCTGAGGCTA GTTCCAAAAA CCTCTCCTGA CCCCTGCCTG TTGGCAGCCC
4380





ACTCCCCAGC CCCAGCCCCT TCCATGGTAC TGTAGGAGGG GAATTCCCTC CCCCTCCTTG
4440





TGCCTTCTTT GTATATAGGC TTCTCACCGC GACCAATAAA CAGCTCCCAG TTTGT





SEQ ID NO. 148 Protein sequence


Protein Accession #. NP_005492.1


1          11         21         31         41         51


|          |          |          |          |          |


MGPGPSRAPR APRLMLCALA LMVAAGGCVV SAFNLDTRFL VVKEAGNPGS LFGYSVALHR
60





QTERQQRYLL LAGAPRELAV PDGYTNRTGA VYLCPLTAHK DDCERNNITV KNDPGHHIIE
120





DMWLGVTVAS QGPAGRVLVC AHRYTQVLWS GSEDQRRMVG KCYVRGNDLE LGSSGDWGTY
180





HNEMCNSNTD YLETGMCQLG TSGGFTQNTV YFGAPGAYNW KGNSYMIQRK EWGLSEYSYK
240





DPEDGGNLYI GYTNQVGSFI LHPKNITIVT GAPRHRHMGA VFLLSGEAGG DLRRRQVLEG
300





SQVGAYFGSA IALADLNNDG WQDLLVGAPY YFERKEEVGG AIYVFMNQAG TSFPAHPSLL
360





LHGPSGSAFG LSVASIGDIH QDGFQDIAVG APFEGLGKVY IYHSSSKGLL RQPQQVIHGE
420





KLGLPGLATF GYSLSGQMDV DENFYPDLLV GSLSDHIVLL RARPVINIVH KTLVPRPAVL
480





DPALCTATSC VQVELCFAYN QSAGNPNYRR NITLAYTLEA DRDREPPRLR FAGSESAVFH
540





GFFSMPEMRC QKLELLLMDN LEDELEPIII SMNYSLPLRM PDRPRLGLRS LDAYPILNQA
600





QALENHTEVQ FQKECGPDNK CESNLQMRAA FVSEQQQKLS RLQYSRDVRK LLLSINVTNT
860





RTSERSGEDA HEALLTLVVP PALLLSSVRP PGACQANETI FCELGNPFKR NQRMELLIAF
720





EVIGVTLHTR DLQVQLQLST SSHQDNLWPM ILTLLVDYTL QTSLSMVNHR LQSFFGGTVM
780





GESGMKTVED VGSPLKYEFQ VGPMGEGLVG LGTLVLGLEW PYEVSNGKWL LYPTEITVHG
840





NGSWPCRPPG DLINPLNLTL SDPGDRPSSP QRRRRQLDPG GGQGPPPVTL AAAKKAKSET
900





VLTCATGRAH CVWLECPIPD APVVTNVTVK ARVWNSTFIE DYRDFDRVRV NGWATLFLRT
960





SIPTINMENK TTWFSVDIDS ELVEELPAEI ELWLVLVAVG AGLLLLGLII LLLWKCDFPK
1020





RTRYYGIMPK YHAVRIREEE RYPPPGSTLP TKKHWVTSWG TRDQYY





SEQ ID NO: 149 DNA sequence


Nucleic Acid Accession #: NM_006424.1


Coding sequence: 64..2136


1          11         21         31         41         51


|          |          |          |          |          |


CGGGCCAGGT TTCCAGGCTC GGCCGCCGCC TCCATCCCAG CACCTGCGGA GGGACCGCTG
60





ACCATGGCTC CCTGGCCTGA ATTGGGACAT GCCCAGGCCA ACCCCGATAA GTACCTCGAA
120





GGGGCCGCAG GTCAGCAGCC CACTGCCCCT GATAAAAGCA AAGAGACCAA CAAAACAGAT
180





AACACTGAGG CACCTGTAAC CAAGATTGAA CTTCTGCCGT CCTACTCCAC GGCTACACTG
240





ATAGATGAGC CCACTGAGGT GGATGACGCC TGGAACCTAC CCACTCTTCA GGACTCGGGG
300





ATCAAGTGGT CAGAGAGAGA CACCAAAGGG AAGATTCTCT GTTTGTTCCA AGGGATTGGG
360





AGATTGATTT TACTTCTCGG ATTTCTCTAG TTTTTCGTGT GCTCCCTGGA TATTCTTAGT
420





AGCGCCTTCC AGCTGGTTGG AGGAAAAATG GCAGGACACT TCTTCAGCAA CAGCTCTATT
460





ATGTCCAACC CTTTGTTGGG GCTGGTGATC GGGGTGCTGG TGACCGTCTT GGTGCAGAGC
540





TCCAGCACCT CAACGTCCAT CGTTGTCAGC ATGGTGTCCT CTTCATTGCT CACTGTTCGG
600





GCTGCCATCC CCATTATCAT GGGGGCCAAC ATTGGAACGT CAATCACCAA CACTATTGTT
660





GCGCTCATGC AGGTGGGAGA TCGGAGTGAG TTCAGAAGAG CTTTTGCAGG AGCCACTGTC
720





CATGACTTCT TCAACTGGCT GTCCGTGTTG GTGCTCTTGC CCGTGGAGGT GGCCACCCAT
760





TACCTCGAGA TCATAACCCA GCTTATAGTG GAGAGCTTCC ACTTCAAGAA TGGAGAAGAT
840





GCCCCAGATC TTCTGAAAGT CATCACTAAG CCCTTCACAA AGCTCATTGT CCAGCTGGAT
900





AAAAAAGTTA TCAGCCAAAT TGCAATGAAC GATGAAAAAG CGAAAAACAA GAGTCTTGTC
960





AAGATTTGGT GCAAAACTTT TACCAACAAG ACCCAGATTA ACGTCACTGT TCCCTCGACT
1020





GCTAACTGCA CCTCCCCTTC CCTCTGTTGG ACGGATGGGA TCCAAAACTG GACCATGAAG
1080





AATGTGACCT ACAAGGAGAA CATCGCCAAA TGCCACCATA TCTTTGTGAA TTTCCACCTC
1140





CCGGATCTTG CTGTGGGCAC CATCTTGCTC ATACTCTCCC TGCTGGTCCT CTGTGGTTGC
1200





CTGATCATGA TTGTCAAGAT CCTGGGCTCT GTGCTCAAGG GGCAGGTCGC CACTGTCATC
1260





AAGAAGACCA TCAACACTGA TTTCCCCTTT CCCTTTGCAT GGTTGACTGG CTACCTGGCC
1320





ATCCTCGTCG GGCCAGGCAT GACCTTCATC GTACAGAGCA GCTCTGTGTT CACGTCGGCC
1360





TTGACCCCCC TGATTGGAAT CGGCGTGATA ACCATTGAGA GGGCTTATCC ACTCACGCTG
1440





GGCTCCAACA TCGGCACCAC CACCACCGCC ATCCTGGCCG CCTTAGCCAG CCCTGGCAAT
1500





GCATTGAGGA GTTCACTCCA GATCGCCCTG TGCCACTTTT TCTTCAACAT CTCCGGCATC
1560





TTGCTGTGGT ACCCGATCCC GTTCACTCGC CTGCCCATCC GCATGGCCAA GGGGCTGGGC
1620





AACATCTCTG CCAAGTATCG CTGGTTCGCC GTCTTCTACC TGATCATCTT CTTCTTCCTG
1660





ATCCCGCTGA CGGTGTTTGG CCTCTCGCTG GCCGGCTGGC GGGTGCTGGT TGGTGTCGGG
1740





GTTCCCGTCG TCTTCATCAT CATCCTGGTA CTGTGCCTCC GACTCCTGCA GTCTCGCTGC
1600





CCACGCGTCC TGCCGAAGAA ACTCCAGAAC TGGAACTTCC TGCCGCTGTG GATGCGCTCG
1860





CTGAAGCCCT GGGATGCCGT CGTCTCCAAG TTCACCGGCT GCTTCCAGAT GCGCTGCTGC
1920





TACTGCTGCC GCGTGTGCTG CCGCGCGTGC TGCTTGCTGT GTGGCTGCCC CAAGTGCTGC
1980





CGCTGCAGCA AGTGCTGCGA GGACTTGGAG GAGGCGCAGG AGGGGGAGGA TGTCCCTGTC
2040





AAGGCTCCTG AGACCTTTGA TAACATAACC ATTAGCAGAG AGGCTCAGGG TGAGGTCCCT
2100





GCCTCGGACT CAAAGACCGA ATGCACGGCC TTGTAGGGGA CGCCCCAGAT TGTCAGGGAT
2160





GGGGGGATGG TCCTTGAGTT TTGCATGCTC TCCTCCCTCC CACTTCTGCA CCCTTTCACC
2220





ACCTCGAGGA GATTTGCTCC CCATTAGCGA ATGAAATTGA TGCAGTCCTA AAAAAAAAAA





SEQ ID NO: 150 Protein sequence


Protein Accession #: NP_006415 1


1          11         21         31         41         51


|          |          |          |          |          |


MAPWPELGDA QPNPDKYLEG AAGQQPTAPD ESKETNETDN TEAPVTKIEL LPSYSTATLI
60





DEPTEVDDPW NLPTLQDSGI KWSERDTKGK ILCFFQGIGR LILLLGFLYF FVCSLDILSS
120





AFQLVGGKMA GQFFSNSSIM SNPLLGLVIG VLVTVLVQSS STSTSIVVSM VSSSLLTVRA
180





AIPIIMGANI GTSITNTIVA LMQVGDRSEF RRAFAGATVH DFFNWLSVLV LLPVEVATHY
240





LEITTQLIVE SFHFKNGEDA PDLLKVITKP FTKLIVQLDK KVISQIAMND EKAKNKSLVK
300





IWCKTFTNKT QINVTVPSTA NCTSPSLCWT DGIQNWTMKN VTYKENIAKC QHIFVNFHLP
360





DLAVGTILLI LSLLVLCGCL IMIVKILGSV LKGQVATVIK KTINTDFPFP FAWLTGYLAI
420





LVGAGMTFIV QSSSVFTSAL TPLIGIGVIT IENAYPLTLG SNIGTTTTAI LAALASPGNA
480





LRSSLQIALC HFFFNISGIL LWYPIPFTRL PIRMAKGLGN ISAKYRWFAV FYLIIFFFLI
540





PLTVFGLSLA GWRVLVGVGV PVVFIIILVL CLRLLQSNCP RVLPKKLQNW NFLPLWMRSL
600





KPWDAVVSKF TGCFQMRCCY CCRVCCRACC LLCGCPKCCR CSKCCEDLEE AQEGQDVPVK
660





APETFDNITI SREAQGEVPA SDSETECTAL





SEQ ID NO: 181 DNA sequence


Nucleic Acid Accession #: XE_030559


Coding sequence: 1..1119


1          11         21         31         41         51


|          |          |          |          |          |


ATGAACCGCA GCCACCGGCA CGGGGCGGGC AGCGGCTGCC TGGGCACTAT GGAGGTGAAG
60





AGCAAGTTTG GAGCTGAATT TCGTCGGTTT TCGCTGGAAA GATCAAAACC TGGAAAATTT
120





GAGGAGTTTT ATGGATTACT ACAACATGTT CATAAGATCC CCAATGTTGA CGTTTTGGTA
180





GGCTATGCAG ACATCCATGG AGACTTACTA CCTATAAATA ATGATGATAA TTATCACAAA
240





GCTGTTTCAA CGGCCAATCC ACTGCTTAGG ATATTTATAC AAAAGAAGGA AGAAGCAGAC
300





TACAGTGCCT TTGGTACAGA CACGCTAATA AAGAAGAAGA ATGTTTTAAC CAACGTATTG
360





CGTCCTGACA ACCATAGAAA AAAGCCACAT ATAGTCATTA GTATGCCCCA AGACTTTAGA
420





CCTGTGTCTT CTATTATAGA CGTGGATATT CTCCCAGAAA CGCATCGTAG GGTACGTCTT
480





TACAAATACG GCACGGAGAA ACCCCTAGGA TTCTACATCC GGGATGGCTC CAGTGTCAGG
540





GTAACACCAC ATGGCTTAGA AAAGGTTCCA GGGATCTTTA TATCCAGGCT TGTCCCAGGA
600





GGTCTGGCTC AAAGTACAGG ACTATTAGCT GTTAATGATG AAGTTTTAGA AGTTAATGGC
660





ATAGAAGTTT CAGGGAAGAG CCTTGATCAA GTAACAGACA TGATGATTGC AAATAGCCGT
720





AACCTCATCA TAACAGTGAG ACCGGCAAAC CAGAGGARTA ATGTTGTGAG GAACAGTCGG
780





ACTTCTGGCA GTTCCGGTCA GTCTACTGAT AACAGCCTTC TTGGCTACCC ACAGCAGATT
840





GAACCAAGCT TTGAGCCAGA GGATGAAGAC AGCGAAGAAG ATGACATTAT CATTGAAGAC
900





AATGGAGTGC CACAGCAGAT TCCAAAAGCT GTTCCTAATA CTGAGAGCCT GGAGTCATTA
960





ACACAGATAG AGCTAAGCTT TGAGTCTGGA CAGAATGGCT TTATTCCCTC TAATGAAGTG
1020





AGCTTAGCAG CCATAGCAAG CAGCTCAAAC ACGGAATTTG AAACACATGC TCCAGATCAA
1080





AAACTCTTAG AAGAAGATGG AACAATCATA ACATTATGA





SEQ ID NO. 152 Protein sequence


Protein Accession #: XP_030559


1          11         21         31         41         51


|          |          |          |          |          |


MNRSHRHGAG SGCLGTMEVK SKFGAEFRRF SLERSKPGKF EEFYGLLQHV HKIPNVDVLV
60





GYADIHGDLL PINNDDNYHK AVSTANPLLR IFIQKKEEAD YSAFGTDTLI KKKNVLTNVL
120





RPDNHRKKPH IVISMPQDFR PVSSIIDVDI LPETHRRVRL YKYGTEKPLG FYIRDGSSVR
180





VTPHGLEKVP GIFISRLVPG GLAQSTGLLA VNDEVLEVNG IEVSGKSLDQ VTDMNIANSR
240





NLIITVRPAN QRNNVVRNSR TSGSSGQSTD NSLLGYPQQI EPSFEPEDED SEEDDIIIED
300





NGVPQQIPKA VPNTESLESL TQIELSFESG QNGFIPSNEV SLAAIASSSN TEFETHAPDQ
360





KLLEEDGTIT TL





SEQ ID NO. 153 DNA sequence


Nucleic Acid Accession #: NM_003064.2


Coding sequence 23..421


1          11         21         31         41         51


|          |          |          |          |          |


CAGAGTCACT CCTGCCTTCA CCATGAAGTC CAGCGGCCTC TTCCCCTTCC TGGTGCTGCT
60





TGCCCTGGGA ACTCTGGCAC CTTGGGCTGT GGAAGGCTCT GGAAAGTCCT TCAAAGCTGG
120





AGTCTGTCCT CCTAAGAAAT CTGCCCAGTG CCTTAGATAC AAGAAACCTG AGTGCCAGAG
190





TGACTGGCAG TGTCCAGGGA AGAAGAGATG TTGTCCTGAC ACTTGTGGCA TCAAATGCCT
240





GGATCCTGTT GACACCCCAA ACCCAACAAG GAGGAAGCCT GGGAAGTGCC CAGTGACTTA
300





TGGCCAATGT TTGATGCTTA ACCCCCCCAA TTTCTGTGAG ATGGATGGCC AGTGCAAGCG
360





TGACTTGAAG TGTTGCATGG GCATGTGTGG GAAATCCTGC GTTTCCCCTG TGAAAGCTTG
420





ATTCCTGCCA TATGGAGGAG GCTCTGGAGT CCTGCTCTGT GTGGTCCAGG TCCTTTCCAC
480





CCTGAGACTT GGCTCCACCA CTGATATCCT CCTTTGGGGA AAGGCTTGGC ACACAGCAGG
540





CTTTCAAGAA GTGCCAGTTG ATCAATGAAT AAATAAACGA GCCTATTTCT CTTTGCAC





SEQ ID NO: 154 Protein sequence


Protein Accession #: NP_003055.1


1          11         21         31         41         51


|          |          |          |          |          |


MKSSGLFPFL VLLALGTLAP WAVEGSGKSF KAGVCPPKKS AQCLRYKEPE CQSDWQCPGK
60





KRCCPDTCGI KCLDPVDTPN PTRRKPGKCP VTYGQCLMLN PPNFCEMDGQ CKRDLKCCMG
120





MCGKSCVSPV KA





SEQ ID NO: 155 DNA sequence


Nucleic Acid Accession #: NM_001306.1


Coding sequence: 199..861


1          11         21         31         41         51


|          |          |          |          |          |


AATTCGGCAC GAGGGCAGGT GCAGGCGCAC GCGGCGAGAG CGTATGGAGC CGAGCCGTTA
60





GCGCGCGCCG TCGGTGAGTC AGTCCGTCCG TCCGTCCGTC CGTCGGGGCG CCGCAGCTCC
120





CGCCAGGCCC AGCGGCCCCG GCCCCTCGTC TCCCCGCACC CGGAGCCACC CGGTGGAGCG
180





GGCCTTGCCG CGGCAGCCAT GTCCATGGGC CTGGAGATCA CGGGCACCGC GCTGGCCGTG
240





CTGGGGTGGC TGGGCACCAT CGTGTGCTGC GCGTTGCCCA TGTGGCGCGT GTCGGCCTTC
300





ATCGGCAGCA ACATCATCAC GTCGCAGAAC ATCTGGGAGG GCCTGTGGAT GAACTGCGTG
360





GTGCAGAGCA CCGGCCAGAT GCAGTGCAAG GTGTACGACT CGCTGCTGGC ACTGCCACAG
420





GACCTTCAGG CGGCCCGCGC CCTCATCGTG GTGGCCATCC TGCTGGCCGC CTTCGGGCTG
480





CTAGTGGCGC TGGTGGGCGC CCAGTGCACC AACTGCGTGC AGGACGACAC GGCCAAGGCC
540





AAGATCACCA TCGTGGCAGG CGTGCTGTTC CTTCTCGCCG CCCTGCTCAC CCTCGTGCCG
600





GTGTCCTGGT CGGCCAACAC CATTATCCGG GACTTCTACA ACCCCGTGGT GCCCGAGGCG
660





CAGAAGCGCG AGATGGGCGC GGGCCTGTAC GTGGGCTGGG CGGCCGCGGC GCTGCAGCTG
720





CTGGGGGGCG CGCTGCTCTG CTGCTCGTGT CCCCCACGCG AGAAGAAGTA CACGGCCACC
780





AAGGTCGTCT ACTCCGCGCC GCGCTCCACC GGCCCGGGAG CCAGCCTGGG CACAGGCTAC
640





GACCGCAAGG ACTACGTCTA AGGGACAGAC GCAGGGAGAC CCCACCACCA CCACCACCAC
900





CAACACCACC ACCACCACCG CGAGCTGGAG CGCGCACCAG GCCATCCAGC GTGCAGCCTT
960





GCCTCGGAGG CCAGCCCACC CCCAGAAGCC AGGAAGCCCC CGCGCTGGAC TGGGGCAGCT
1020





TCCCCAGCAG CCACGGCTTT GCGGGCCGGG CAGTCGACTT CGGGGCCCAG GGACCAACCT
1080





GCATGGACTG TGAAACCTCA CCCTTCTGGA GCACGGGGCC TGGGTGACCG CCAATACTTG
1140





ACCACCCCGT CGAGCCCCAT CGGGCCGCTG CCCCCATGTC GCGCTGGGCA GGGACCGGCA
1200





GCCCTGGAAG GGGCACTTGA TATTTTTCAA TAAAAGCCTC TCGTTTTAGC





SEQ ID NO: 156 Protein sequence


Protein Accession #: NP_001297.1


1          11         21         31         41         51


|          |          |          |          |          |


MSMGLEITGT ALAVLGWLGT IVCCALPMWR VSAFIGSNII TSQNIWEGLW MNCVVQSTGQ
60





MQCKVYDSLL ALPQDLQAAR ALIVVAILLA AFGLLVALVG AQCTNCVQDD TAKAKITIVA
120





GVLFLLAALL TLVPVSWSAN TIIRDFYNPV VPEAQKREMG AGLYVGWAAA ALQLLGGALL
180





CCSCPPREKK YTATKVVYSA PRSTGPGASL GTGYDRKDYV





SEQ ID NO: 157 DNA sequence


Nucleic Acid Accession #: NN_005564


Coding sequence: 1..597


1          11         21         31         41         51


|          |          |          |          |          |


ATGCCCCTAG GTCTCCTGTG GCTGGGCCTA GCCCTGTTGG GGGCTCTGCA TGCCCAGGCC
60





CAGGACTCCA CCTCAGACCT GATCCCAGCC CCACCTCTGA GCAAGGTCCC TCTGCAGCAG
120





AACTTCCAGG ACAACCAATT CCAGGGGAAG TGGTATGTGG TAGGCCTGGC AGGGAATGCA
180





ATTCTCAGAG AAGACAAAGA CCCGCAAAAG ATGTATGCCA CCATCTATGA GCTGAAAGAA
240





GACAAGAGCT ACAATGTCAC CTCCGTCCTG TTTAGGAAAA AGAAGTGTGA CTACTGGATC
300





AGGACTTTTG TTCCAGGTTG CCAGCCCGGC GAGTTCACGC TGGGCAACAT TAAGAGTTAC
360





CCTGGATTAA CGAGTTACCT CGTCCGAGTG GTGAGCACCA ACTACAACCA GCATGCTATG
420





GTGTTCTTCA AGAAAGTTTC TCAAAACAGG GAGTACTTCA AGATCACCCT CTACGGGAGA
480





ACCAAGGAGC TGACTTCGGA ACTAAAGGAG AACTTCATCC GCTTCTCCAA ATATCTGGGC
540





CTCCCTGAAA ACCACATCGT CTTCCCTGTC CCAATCGACC AGTGTATCGA CGGCTGA





SEQ ID NO: 158 Protein sequence


Protein Accession #: NP_005555


1          11         21         31         41         51


|          |          |          |          |          |


MPLGLLNLGL ALLGALHAQA QOSTEDLIPA PPLSKVPLQQ NFQDNQFQGK WYVVGLAGNA
60





ILEEDEOPQK MYATIYELKE DKSYNVTSVL FEKEECDYWI RTFVPGCQPG EFTLGNIKSY
120





PGLTSYLVRV VSTNYNQHAN VFFKKVSQNR EYFKITLYGR TKELTSELKE NFIRFSKYLG
180





LPENHIVFPV PIDQCIDG





SEQ ID NO. 159 DNA sequence


Nucleic Acid Accession #: NM_006853.1


Coding sequence. 26 .874


1          11         21         31         41         51


|          |          |          |          |          |


AGGAATCTGC GCTCGGGTTC CGCAGATGCA GAGGTTGACG TGGCTGCCGG ACTGGAAGTC
60





ATCGGGCAGA GGTCTCACAG CAGCCAAGGA ACCTGGGGCC CGCTCCTCCC CCCTCCAGGC
120





CATGAGGATT CTGCAGTTAA TCCTGCTTGC TCTGGCAACA GGGCTTGTAG GGGGAGAGAC
180





CAGGATCATC AAGGGGTTCG AGTGCAAGCC TCACTCCCAG CCCTGGCAGG CAGCCCTGTT
240





CGAGAAGACG CGGCTACTCT GTGGGGCGAC GCTCATCGCC CCCAGATGGC TCCTGACAGC
300





AGCCCACTGC CTCAAGCCCC GCTACATAGT TCACCTGGGG CAGCACAACC TCCAGAAGGA
360





GGAGGGCTGT GAGCAGACCC GGACAGCCAC TGAGTCCTTC CCCCACCCCG GCTTCAACAA
420





CAGCCTCCCC AACAAAGACC ACCGCAATGA CATCATGCTG GTGAAGATGG CATCGCCAGT
480





CTCCATCACC TGGGCTGTGC GACCCCTCAC CCTCTCCTCA CGCTGTGTCA CTGCTGGCAC
540





CAGCTGCCTC ATTTCCGGCT GGGGCACCAC GTCCAGCCCC CAGTTACGCC TGCCTCACAC
600





CTTGCGATGC GCCAACATCA CCATCATTGA GCACCAGAAG TGTGAGAACG CCTACCCCGG
660





CAACATCACA DACACCATGG TGTGTGCCAG CGTGCAGGAA GGGGDCAAGG ACTCCTGCCA
720





GGGTGACTCC GGGGGCCCTC TGGTCTGTAA CCAGTCTCTT CAAGGCATTA TCTCCTGGGG
780





CCAGGATCCG TGTGCGATCA CCCGAAAGCC TGGTGTCTAC ACGAAAGTCT GCAAATATGT
840





GGACTGGATC CADGAGACCA TGAAGAACAA TTAGACTGGA CCCACCCACC ACAGCCCATC
900





ACCCTCCATT TCCACTTGGT GTTTGGTTCC TGTTCACTCT GTTAATAAGA AACCCTAAGC
960





CAAGACCCTC TACGAACATT CTTTGGGCCT CCTGGACTAC AGGAGATGCT GTCACTTAAT
1020





AATCAACCTG GGGTTCGAAA TCAGTGAGAC CTGGATTCAA ATTCTGCCTT GAAATATTGT
1080





GACTCTGGGA ATGACAACAC CTGGTTTGTT CTCTGTTGTA TCCCCAGCCC CAAAGACAGC
1140





TCCTGGCCAT ATATCAAGGT TTCAATAAAT ATTTGCTAAA TGAGTG





SEQ ID NO: 160 Protein sequence


Protein Accession #: NP_006844.1


1          11         21         31         41         51


|          |          |          |          |          |


MRILQLILLA LATGLVGGET RIIKOFECEP HSQPWQAALF EKTRLLCGAT LIAPRWLLTA
60





ANCLKPRYIV HLGQHNLQKE EGCEQTRTAT ESFPHPGFNN SLPNKDHRND IMLVKMASPV
120





SITWAVRPLT LSSRCVTAGT SCLISGWGST SSPQLNLPHT LRCANITIIE HQKCENAYPG
180





NITDTMVCAS VQEGGKDSCQ GDSGGPLVCN QSLQGIISWG QDPCAITRKP GVYTKVCKYV
240





DWIQETMKNN










[0405] It is understood that the examples described above in no way serve to limit the true scope of this invention, but rather are presented for illustrative purposes. All publications, sequences of accession numbers, and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference.


Claims
  • 1. A method of detecting an ovarian cancer-associated transcript in a cell from a patient, the method comprising contacting a biological sample from the patient with a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-20.
  • 2. The method of claim 1, wherein the biological sample comprises isolated nucleic acids.
  • 3. The method of claim 2, wherein the nucleic acids are mRNA.
  • 4. The method of claim 2, further comprising the step of amplifying nucleic acids before the step of contacting the biological sample with the polynucleotide.
  • 5. The method of claim 1, wherein the polynucleotide comprises a sequence as shown in Tables 1-20.
  • 6. The method of claim 1, wherein the polynucleotide is immobilized on a solid surface.
  • 7. The method of claim 1, wherein the patient is undergoing a therapeutic regimen to treat ovarian cancer.
  • 8. The method of claim 1, wherein the patient is suspected of having ovarian cancer.
  • 9. An isolated nucleic acid molecule consisting of a polynucleotide sequence as shown in Tables 1-20.
  • 10. The nucleic acid molecule of claim 9, which is labeled.
  • 11. An expression vector comprising the nucleic acid of claim 9.
  • 12. A host cell comprising the expression vector of claim 11.
  • 13. An isolated polypeptide which is encoded by a nucleic acid molecule having polynucleotide sequence as shown in Tables 1-20.
  • 14. An antibody that specifically binds a polypeptide of claim 13.
  • 15. The antibody of claim 14, further conjugated to an effector component.
  • 16. The antibody of claim 15, wherein the effector component is a fluorescent label.
  • 17. The antibody of claim 15, wherein the effector component is a radioisotope or a cytotoxic chemical.
  • 18. The antibody of claim 15, which is an antibody fragment.
  • 19. The antibody of claim 15, which is a humanized antibody
  • 20. A method of detecting an ovarian cancer cell in a biological sample from a patient, the method comprising contacting the biological sample with an antibody of claim 14.
  • 21. The method of claim 20, wherein the antibody is further conjugated to an effector component.
  • 22. The method of claim 21, wherein the effector component is a fluorescent label.
  • 23. A method for identifying a compound that modulates an ovarian cancer-associated polypeptide, the method comprising the steps of: (i) contacting the compound with an ovarian cancer-associated polypeptide, the polypeptide encoded by a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-20; and (ii) determining the functional effect of the compound upon the polypeptide.
  • 24. A drug screening assay comprising the steps of (i) administering a test compound to a mammal having ovarian cancer or a cell isolated therefrom; (ii) comparing the level of gene expression of a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-20 in a treated cell or mammal with the level of gene expression of the polynucleotide in a control cell or mammal, wherein a test compound that modulates the level of expression of the polynucleotide is a candidate for the treatment of ovarian cancer.
CROSS-REFERENCES TO RELATED APPLICATIONS.

[0001] This application is related to U.S. Ser. No. U.S. Ser. No. 60/299,234, filed Jun. 18, 2001; U.S. Ser. No. 60/315,287, filed Aug. 27, 2001; U.S. Ser. No. 60/350,666, filed Nov. 13, 2001; and U.S. Ser. No. 60/372,246, filed Apr. 12, 2002, each of which is incorporated herein by reference for all purposes.

Provisional Applications (4)
Number Date Country
60372246 Apr 2002 US
60350666 Nov 2001 US
60315287 Aug 2001 US
60299234 Jun 2001 US